2. Induced Disease Models Products Antibody-drug Conjugate/ADC Related Cell Cycle/DNA Damage Epigenetics PI3K/Akt/mTOR Autophagy Apoptosis Anti-infection Others
  3. Cardiovascular System Disease Models ADC Payload Antibiotic Bacterial Topoisomerase AMPK HIV Autophagy Mitophagy Apoptosis HBV Fluorescent Dye
  4. Heart Disease Models
  5. Doxorubicin

Doxorubicin (Hydroxydaunorubicin), a cytotoxic anthracycline antibiotic, is an anti-cancer chemotherapy agent. Doxorubicin is a potent human DNA topoisomerase I and topoisomerase II inhibitor with IC50s of 0.8 μM and 2.67 μM, respectively. Doxorubicin reduces basal phosphorylation of AMPK and its downstream target acetyl-CoA carboxylase. Doxorubicin induces apoptosis and autophagy.

The free form of the compound is prone to instability, it is advisable to consider the stable salt form (Doxorubicin hydrochloride) that retains the same biological activity.

For research use only. We do not sell to patients.

CAS No. : 23214-92-8

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Other In-stock Forms of Doxorubicin:

Other Forms of Doxorubicin:

Doxorubicin Related Antibodies

Top Publications Citing Use of Products

650 Publications Citing Use of MCE Doxorubicin

IF
In Vivo Efficacy Study
IHC
Cell Proliferation/Viability Assay
WB

    Doxorubicin purchased from MedChemExpress. Usage Cited in: Mol Cancer. 2024 May 9;23(1):83.  [Abstract]

    Exhausted T-cells (NExT) loaded with Doxorubicin (5–50 nM; 48 h) significantly reduces the viability of SUM159 cells.

    Doxorubicin purchased from MedChemExpress. Usage Cited in: Bioact Mater. 2024 May 11:38:384-398.  [Abstract]

    Doxorubicin hydrochloride (10 μM; 3-5 days) significantly reduces the viability of lung cancer organoid-2 (LCO-2) and LCO-3, while showing no significant effect on LCO-1 viability.

    Doxorubicin purchased from MedChemExpress. Usage Cited in: J Clin Invest. 2024 Mar 7;134(10):e172716.  [Abstract]

    The given cell lines were treated with 250 nM osimertinib (Osim), 1.25 μM Etoposide (VP-16), 125 nM Doxorubicin (DXR), 5 nM Paclitaxel, 10 μM Cisplatin, 25 μM Carboplatin, 25 nM Gemcitabine, 20 nM 5-Fluorouracil (5-FU), 25 μM Cyclophosphamide, 25 μM Capecitabine, or 10 nM Vincristine alone or in combination for 3 days. Cell numbers were then measured using the SRB assay.

    Doxorubicin purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2023 Nov:120:155074.  [Abstract]

    SUDHL-4, OCI-Ly3 cells were treated with different concentrations of FKB (Flavokawain B; HY-N2132; 1.25–20 µg/ml) or Doxorubicin (HY-15142A; 10 µM) for 24 and 48 h. Cell viability (OD value at 490 nm) was measured using the MTS assay. *p < 0.05, #p < 0.01, †p < 0.001, and ‡p < 0.0001 versus control at corresponding time points.

    Doxorubicin purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2023 Nov:120:155074.  [Abstract]

    Raji, and Jeko-1 cells were treated with different concentrations of FKB (Flavokawain B; HY-N2132; 1.25–20 µg/ml) or Doxorubicin (HY-15142A; 10 µM) for 24 and 48 h. Cell viability (OD value at 490 nm) was measured using the MTS assay. *p < 0.05, #p < 0.01, †p < 0.001, and ‡p < 0.0001 versus control at corresponding time points.

    Doxorubicin purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2023 Nov:120:155074.  [Abstract]

    FKB (Flavokawain B; HY-N2132) decelerates lymphoma growth of SUDHL-4 cells in a xenograft animal model in vivo. BALB/c nude mice were subcutaneously inoculated with 5 × 106 SUDHL-4 cells on day 0. Mice were randomly divided into four groups (n = 5 per group) and treatment with vehicle or the corresponding drugs (FKB (HY-N2132; 0.75, 1.5 mg/kg; every four days; IP), or Doxorubicin (HY-15142A; 5 mg/kg; once a week; IP)) was initiated on day 3. The tumor volume was recorded at indicated days. *p < 0.05 and #p < 0.01 versus the control. Tumors were weighed and photographed after removing from each mouse at the end of the experiment (on day 29). *p < 0.05, #p < 0.01, and †p < 0.001 versus the control.

    Doxorubicin purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2023 Nov:120:155074.  [Abstract]

    SUDHL-4 and OCI-Ly3 cells were treated with FKA (Flavokawain A; HY-N2420; 1.25-20 µg/mL) or Doxorubicin (HY-15142A; 10 µM) for 24 and 48 h. Cell viability was measured using the MTS assay. *P < 0.05, #P < 0.01, †P < 0.001, and ‡P < 0.0001 versus control at corresponding time points.SUDHL-4 (A), OCI-Ly3 (B), Raji (C), and Jeko-1 (D) cells were treated with FKA (1.25-20 µg/mL) or doxorubicin (10 µM) for 24 and 48 h. Cell viability was measured using the MTS assay. *P < 0.05, #P < 0.01, †P < 0.001, and ‡P < 0.0001 versus control at corresponding time points.

    Doxorubicin purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2023 Nov:120:155074.  [Abstract]

    Raji and Jeko-1 cells were treated with FKA (Flavokawain A; HY-N2420; 1.25-20 µg/mL) or Doxorubicin (HY-15142A; 10 µM) for 24 and 48 h. Cell viability was measured using the MTS assay. *P < 0.05, #P < 0.01, †P < 0.001, and ‡P < 0.0001 versus control at corresponding time points.SUDHL-4 (A), OCI-Ly3 (B), Raji (C), and Jeko-1 (D) cells were treated with FKA (1.25-20 µg/mL) or doxorubicin (10 µM) for 24 and 48 h. Cell viability was measured using the MTS assay. *P < 0.05, #P < 0.01, †P < 0.001, and ‡P < 0.0001 versus control at corresponding time points.

    Doxorubicin purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2023 Nov:120:155074.  [Abstract]

    SUDHL-4 and OCI-Ly3 cells were treated with FKC (Flavokawain C; HY-N2445; 1.25-20 µg/mL) or Doxorubicin (HY-15142A; 10 µM) for 24 and 48 h. Cell viability was measured using the MTS assay. *P < 0.05, #P < 0.01, †P < 0.001, and ‡P < 0.0001 versus control at corresponding time points.SUDHL-4 (A), OCI-Ly3 (B), Raji (C), and Jeko-1 (D) cells were treated with FKA (1.25-20 µg/mL) or doxorubicin (10 µM) for 24 and 48 h. Cell viability was measured using the MTS assay. *P < 0.05, #P < 0.01, †P < 0.001, and ‡P < 0.0001 versus control at corresponding time points.

    Doxorubicin purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2023 Nov:120:155074.  [Abstract]

    Raji and Jeko-1 cells were treated with FKC (Flavokawain C; HY-N2445; 1.25-20 µg/mL) or Doxorubicin (HY-15142A; 10 µM) for 24 and 48 h. Cell viability was measured using the MTS assay. *P < 0.05, #P < 0.01, †P < 0.001, and ‡P < 0.0001 versus control at corresponding time points.SUDHL-4 (A), OCI-Ly3 (B), Raji (C), and Jeko-1 (D) cells were treated with FKA (1.25-20 µg/mL) or doxorubicin (10 µM) for 24 and 48 h. Cell viability was measured using the MTS assay. *P < 0.05, #P < 0.01, †P < 0.001, and ‡P < 0.0001 versus control at corresponding time points.

    Doxorubicin purchased from MedChemExpress. Usage Cited in: Adv Funct Mater. 23 October 2021.

    Cell viability after incubated with free DOX under normoxia and hypoxia at various DOX (Doxorubicin) (0.65-20 μg/mL) concentrations for 24 h determined by MTT assay.

    Doxorubicin purchased from MedChemExpress. Usage Cited in: Nat Cell Biol. 2020 Sep;22(9):1056-1063.  [Abstract]

    UFMylation of endogenous p53 was analysed by western blot in HCT116 p53+/+ cells depleted of UFL1 or DDRGK1 upon DNA damage induced by doxorubicin (doxo; 1 µM; 24 h) or etoposide (eto; 25 µg ml−1; 12 h).

    Doxorubicin purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2019 Nov 25;10(12):887.  [Abstract]

    Doxorubicin or CPT-11 significantly promoted KRT8 expression in chordoma cells in vitro. Representative images of immunofluorescence staining of KRT8 of CM318 and UCH1 cell line.

    Doxorubicin purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2019 Nov 25;10(12):887.  [Abstract]

    Doxorubicin or CPT-11 significantly promoted KRT8 expression in chordoma cells in vitro. Western blotting analysis and quantification of KRT8 protein expression (normalized to GAPDH expression).

    Doxorubicin purchased from MedChemExpress. Usage Cited in: Free Radic Biol Med. 2019 Jan:130:557-567.  [Abstract]

    Representative pictures of Live/Dead staining of effects of 7,8-DHF on high dose of Dox-induced cell death and MMP reduction of H9c2 cells.

    Doxorubicin purchased from MedChemExpress. Usage Cited in: J Cell Mol Med. 2019 Sep;23(9):6034-6047.  [Abstract]

    Effects of YWPC (50 mg/L for 24 h) on DOX (5 μM for 24 h)-induces dissipation of mitochondrial membrane potential measured in H9C2 cells loaded with JC-1 using fluorescence microscopy.

    Doxorubicin purchased from MedChemExpress. Usage Cited in: Nat Commun. 2018 Oct 8;9(1):4139.  [Abstract]

    One hour after treated with UV or 2 h after treated with MMS, Camptothecin (CPT) (10 μM), or Doxorubicin (DOX; 0.5 μM), HEK293T cells expressing HA-SUMO2 and His-RhoB are subjected to sumoylation assay to detect the SUMO2 conjugation of RhoB.

    Doxorubicin purchased from MedChemExpress. Usage Cited in: J Clin Invest. 2018 Jan 2;128(1):483-499.  [Abstract]

    Immunoblotting for EZH2 in lysates of immortalized mouse podocytes after treatment with Adriamycin (300 ng/mL) for 48 hours (n=6).

    Doxorubicin purchased from MedChemExpress. Usage Cited in: J Exp Clin Cancer Res. 2018 Sep 19;37(1):232.  [Abstract]

    Immunoblotting shows that both P-gp protein expression is significantly decreased in 24 h after US exposure in MCF-7/ADR and HEPG2/ADM cells.

    Doxorubicin purchased from MedChemExpress. Usage Cited in: Nanoscale Res Lett. 2018 Nov 3;13(1):350.  [Abstract]

    Fluorescence microscopy of images of fixed 4T1-luc2-GFP breast cancer cells treated with Doxorubicin (DOX) after 48-h exposure. Scale bars indicate 100 μm. Blue nuclear stain: DAPI; green (transfected cell line): GFP; red (intrinsic molecular fluorescence): DOX

    Doxorubicin purchased from MedChemExpress. Usage Cited in: Cell Signal. 2017 Aug:36:108-116.  [Abstract]

    PAQR3 affects DNA damage repair. AGS cells are treated with different doses of VP-16 (for 24 h), CDDP (for 24 h) and Doxorubicin (for 10 h) as indicated, followed by immunoblotting with the antibodies.

    Doxorubicin purchased from MedChemExpress. Usage Cited in: Cell Physiol Biochem. 2017;42(3):965-973.  [Abstract]

    U937 cells are treated with Thapsigargin (TG, 1 μM), NSC 125973 (PTX, 5nM) as well as Doxorubincin (DOX, 1 μM) for 12 hours and the indicated proteins are detected by Western blot.

    Doxorubicin purchased from MedChemExpress. Usage Cited in: Nat Med. 2016 May;22(5):547-56.  [Abstract]

    Immunofluorescent staining for α-actinin (ACTN2) and cardiac troponin T (TNNT2) to demonstrate sarcomeric organization in hiPSC–CMs derived from patients who do not experience Doxorubicin–induced cardiotoxicity (DOX) versus those who do experience Doxorubicin-induced cardiotoxicity (DOXTOX) after 24 h treatment with Doxorubicin. Scale bar, 20 µm.

    View All ADC Payload Isoform Specific Products:

    View All Isoforms
    Auristatin Calicheamicins Camptothecins Daunorubicins/Doxorubicins Duocarmycins Maytansinoids Pyrrolobenzodiazepines Traditional Cytotoxic Agents

    View All Antibiotic Isoform Specific Products:

    View All Isoforms
    Aminoglycoside Glycopeptide Lipopeptide Macrolide Oxazolidinone Quinolone Tetracycline β-lactam

    View All Topoisomerase Isoform Specific Products:

    View All Isoforms
    Topoisomerase Topo I Topo II DNA gyrase

    View All AMPK Isoform Specific Products:

    View All Isoforms
    NUAK1 NUAK2 AMPK AMPK α1β1γ1 AMPK α2β1γ1 AMPK α1β2γ1 AMPK α2β2γ1 BRSK1 BRSK2 HUNK AMPKα

    View All HIV Isoform Specific Products:

    View All Isoforms
    HIV HIV-1 HIV-2

    • Biological Activity

    • Purity & Documentation

    • References

    • Customer Review

    Description

    Doxorubicin (Hydroxydaunorubicin), a cytotoxic anthracycline antibiotic, is an anti-cancer chemotherapy agent. Doxorubicin is a potent human DNA topoisomerase I and topoisomerase II inhibitor with IC50s of 0.8 μM and 2.67 μM, respectively. Doxorubicin reduces basal phosphorylation of AMPK and its downstream target acetyl-CoA carboxylase. Doxorubicin induces apoptosis and autophagy[1][2][3].

    IC50 & Target[1][2][3][7]

    Topoisomerase I

    0.8 μM (IC50)

    Topoisomerase II

    2.67 μM (IC50)

    Daunorubicins/Doxorubicins

     

    HIV-1

     

    Cellular Effect
    Cell Line Type Value Description References
    143B IC50
    0.1 μM
    Compound: DOX
    Cytotoxicity against human 143B cells measured after 72 hrs by Celltiter-Glo assay
    Cytotoxicity against human 143B cells measured after 72 hrs by Celltiter-Glo assay
    		[PMID: 31820976]
    16HBE14o- GI50
    0.18 μM
    Compound: Adriamycin
    Growth inhibition of human 16HBE cells by sulforhodamine B assay
    Growth inhibition of human 16HBE cells by sulforhodamine B assay
    		[PMID: 24650643]
    184B5 GI50
    1.15 μM
    Compound: Doxorubicin
    Cytotoxicity against human 184B5 cells assessed as growth inhibition after 72 hrs by MTT assay
    Cytotoxicity against human 184B5 cells assessed as growth inhibition after 72 hrs by MTT assay
    		[PMID: 29670691]
    184B5 GI50
    1.2 μM
    Compound: Doxorubicin
    Antiproliferative activity against human 184B5 cells after 72 hrs by MTT assay
    Antiproliferative activity against human 184B5 cells after 72 hrs by MTT assay
    		[PMID: 30071406]
    1A9 EC50
    0.1 μM
    Compound: doxorubicin
    Cytotoxicity against human 1A9 cells after 72 hrs
    Cytotoxicity against human 1A9 cells after 72 hrs
    		[PMID: 17378530]
    1A9 ED50
    0.02 μM
    Compound: DOX
    Cytotoxicity against human 1A9 cells
    Cytotoxicity against human 1A9 cells
    		[PMID: 17591444]
    4T1 IC50
    0.065 μM
    Compound: Doxorubicin
    Cytotoxicity against mouse 4T1 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    Cytotoxicity against mouse 4T1 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    		[PMID: 37216812]
    4T1 IC50
    0.481 μM
    Compound: Doxorubicin
    Cytotoxicity activity against mouse 4T1 cells assessed as cell growth inhibition after 48 hrs by MTT assay
    Cytotoxicity activity against mouse 4T1 cells assessed as cell growth inhibition after 48 hrs by MTT assay
    		[PMID: 30433783]
    4T1 IC50
    0.99 μM
    Compound: Doxorubicin
    Cytotoxicity against mouse 4T1 cells assessed as decrease in cell viability after 24 hrs by MTT assay
    Cytotoxicity against mouse 4T1 cells assessed as decrease in cell viability after 24 hrs by MTT assay
    		[PMID: 27496212]
    4T1 IC50
    1.63 μM
    Compound: DOX
    Cytotoxicity against mouse 4T1 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
    Cytotoxicity against mouse 4T1 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
    		[PMID: 37421890]
    4T1 IC50
    90 nM
    Compound: Doxorubicin
    Cytotoxicity against mouse 4T1 cells assessed as cell growth inhibition incubated for 72 hrs by CCK8 assay
    Cytotoxicity against mouse 4T1 cells assessed as cell growth inhibition incubated for 72 hrs by CCK8 assay
    		[PMID: 35213166]
    5-8F IC50
    0.34 μM
    Compound: DOX
    Antiproliferative activity against human 5-8F cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay
    Antiproliferative activity against human 5-8F cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay
    		[PMID: 36709571]
    5637 IC50
    0.02 μM
    Compound: Doxorubicin
    Antitumor activity was evaluated against human bladder carcinoma cell line 5637.
    Antitumor activity was evaluated against human bladder carcinoma cell line 5637.
    		[PMID: 10411476]
    5637 IC50
    0.02 μM
    Compound: Doxorubicin
    Antitumor activity against human bladder carcinoma 5637 cells.
    Antitumor activity against human bladder carcinoma 5637 cells.
    		[PMID: 12431049]
    5637 IC50
    0.02 μM
    Compound: doxo
    Antiproliferative activity against human 5637 cell line by MTT assay
    Antiproliferative activity against human 5637 cell line by MTT assay
    		[PMID: 16913700]
    5637 IC50
    0.02 μM
    Compound: doxorubicin
    Antitumor activity against human bladder carcinoma 5637 cells
    Antitumor activity against human bladder carcinoma 5637 cells
    		[PMID: 12431048]
    5637 IC50
    0.98 μM
    Compound: DOX
    Antiproliferative activity against human 5637 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay
    Antiproliferative activity against human 5637 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay
    		[PMID: 38079530]
    769-P IC50
    0.45 μM
    Compound: Doxorubicin
    Anticancer activity against human 769-P cells by MTT assay
    Anticancer activity against human 769-P cells by MTT assay
    		[PMID: 31404864]
    786-0 GI50
    0.025 μg/mL
    Compound: DOX; Doxo
    Antiproliferative activity against human 786-0 cells after 48 hrs by SRB assay
    Antiproliferative activity against human 786-0 cells after 48 hrs by SRB assay
    		[PMID: 26859070]
    786-0 GI50
    0.02 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human 786-0 cells by sulforhodamine B assay
    Cytotoxicity against human 786-0 cells by sulforhodamine B assay
    		[PMID: 26913941]
    786-0 GI50
    0.04 μg/mL
    Compound: DOX
    Growth inhibition of human 786-0 cells after 48 hrs by sulforhodamine B assay
    Growth inhibition of human 786-0 cells after 48 hrs by sulforhodamine B assay
    		[PMID: 21041092]
    786-0 GI50
    0.11 μM
    Compound: Dox
    Growth inhibition of human 786-0 cells after 48 hrs by sulforhodamine B dye-based spectrophotometric assay
    Growth inhibition of human 786-0 cells after 48 hrs by sulforhodamine B dye-based spectrophotometric assay
    		[PMID: 28505535]
    786-0 GI50
    0.13 μM
    Compound: Doxorubicin
    Growth inhibition of human 786-0 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human 786-0 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28329730]
    786-0 GI50
    0.13 μM
    Compound: Doxorubicin
    Growth inhibition of human 786-0 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human 786-0 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 29102177]
    786-0 GI50
    0.13 μM
    Compound: Doxorubicin hydrochloride, NSC 123127
    Cytotoxicity against human 786-0 cells after 48 hrs by SRB assay
    Cytotoxicity against human 786-0 cells after 48 hrs by SRB assay
    		[PMID: 23871905]
    786-0 GI50
    0.15 μM
    Compound: DOXO
    Antiproliferative activity against human 786-0 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    Antiproliferative activity against human 786-0 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    		[PMID: 31247374]
    786-0 GI50
    0.15 μg/mL
    Compound: DOX
    Antiproliferative activity against human 786-0 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    Antiproliferative activity against human 786-0 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    		[PMID: 25062010]
    786-0 GI50
    0.15 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human 786-0 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    Cytotoxicity against human 786-0 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    		[PMID: 26561866]
    786-0 GI50
    0.16 μM
    Compound: Doxorubicin
    Growth inhibition of human 786-0 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human 786-0 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 33477019]
    786-0 GI50
    0.18 μg/mL
    Compound: Doxorubicin
    Growth inhibition of human 786-0 cells after 48 hrs by sulforhodamine B assay
    Growth inhibition of human 786-0 cells after 48 hrs by sulforhodamine B assay
    		[PMID: 22410248]
    786-0 GI50
    < 0.046 μM
    Compound: Dox
    Antiproliferative activity against human 786-0 cells assessed as growth inhibition after 48 hrs by SRB assay
    Antiproliferative activity against human 786-0 cells assessed as growth inhibition after 48 hrs by SRB assay
    		[PMID: 26454648]
    786-0 IC50
    0.13 μM
    Compound: Doxorubicin
    Cytotoxicity against human 786-O cells assessed as growth inhibition by MTS assay
    Cytotoxicity against human 786-O cells assessed as growth inhibition by MTS assay
    		[PMID: 24824796]
    A 172 IC50
    0.13 μM
    Compound: DOX
    Antiproliferative activity against human A-172 cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay
    Antiproliferative activity against human A-172 cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay
    		[PMID: 34968902]
    A 172 IC50
    0.2 μM
    Compound: Dox
    Cytotoxicity against human A172 cells after 72 hrs by MTT assay
    Cytotoxicity against human A172 cells after 72 hrs by MTT assay
    		[PMID: 30659997]
    A-375 EC50
    0.009 μM
    Compound: Dox
    Induction of senescence-like phenotype in human A-375 cells assessed as increase in morphological changes after 72 hrs by staining based imaging assay
    Induction of senescence-like phenotype in human A-375 cells assessed as increase in morphological changes after 72 hrs by staining based imaging assay
    		[PMID: 33268144]
    A-375 EC50
    0.009 μM
    Compound: Doxorubicin
    Induction of senescence in human A-375 cells treated for 3 days by Hoechst staining based imaging analysis
    Induction of senescence in human A-375 cells treated for 3 days by Hoechst staining based imaging analysis
    		[PMID: 33859796]
    A-375 IC50
    0.008 μM
    Compound: Doxorubicin
    Antiproliferative activity in human A-375 cells assessed as reduction of cell number
    Antiproliferative activity in human A-375 cells assessed as reduction of cell number
    		[PMID: 33859796]
    A-375 IC50
    0.01 μM
    Compound: Doxorubicin
    Antiproliferative activity against human A375 cells assessed as inhibition of cell proliferation incubated for 72 hrs by conventional ATP quantification method
    Antiproliferative activity against human A375 cells assessed as inhibition of cell proliferation incubated for 72 hrs by conventional ATP quantification method
    		[PMID: 25937235]
    A-375 IC50
    0.01 μM
    Compound: doxorubicin
    Cytotoxicity against human A375 cells after 24 hrs by MTT assay
    Cytotoxicity against human A375 cells after 24 hrs by MTT assay
    		[PMID: 17400463]
    A-375 IC50
    0.01 μM
    Compound: doxorubicin
    Cytotoxicity against human A375 cells after 24 hrs by MTT assay
    Cytotoxicity against human A375 cells after 24 hrs by MTT assay
    		[PMID: 18281125]
    A-375 IC50
    0.011 μM
    Compound: Dox
    Antiproliferative activity against human A-375 cells assessed as cell growth inhibition
    Antiproliferative activity against human A-375 cells assessed as cell growth inhibition
    		[PMID: 33268144]
    A-375 IC50
    0.024 μM
    Compound: Doxorubicin
    Cytotoxicity activity against human A375 cells assessed as cell growth inhibition after 48 hrs by MTT assay
    Cytotoxicity activity against human A375 cells assessed as cell growth inhibition after 48 hrs by MTT assay
    		[PMID: 30433783]
    A-375 IC50
    0.07 μM
    Compound: Adriamycin
    In vitro antitumor activity against A375 (melanoma) human tumor cell lines.
    In vitro antitumor activity against A375 (melanoma) human tumor cell lines.
    		10.1016/0960-894X(96)00167-9
    A-375 IC50
    0.13 μM
    Compound: DOX
    Antiproliferative activity against human A375 cells after 72 hrs by MTT assay
    Antiproliferative activity against human A375 cells after 72 hrs by MTT assay
    		[PMID: 21496972]
    A-375 IC50
    0.19 μM
    Compound: ADM; DOX
    Antiproliferative activity against human A375 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Antiproliferative activity against human A375 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    		[PMID: 31491611]
    A-375 IC50
    0.26 μM
    Compound: DOX
    Cytotoxicity against human A-375 cells expressing high level of topoisomerase I/II measured after 72 hrs by MTT assay
    Cytotoxicity against human A-375 cells expressing high level of topoisomerase I/II measured after 72 hrs by MTT assay
    		[PMID: 35612499]
    A-375 IC50
    0.33 μM
    Compound: DOX
    Antiproliferative activity against human A-375 cells assessed as inhibition of cell viability incubated for 72 hrs by MTT assay
    Antiproliferative activity against human A-375 cells assessed as inhibition of cell viability incubated for 72 hrs by MTT assay
    		[PMID: 35818137]
    A-375 IC50
    0.37 μM
    Compound: DOX
    Antiproliferative activity against human A375 cells after 72 hrs by CCK-8 assay
    Antiproliferative activity against human A375 cells after 72 hrs by CCK-8 assay
    		[PMID: 29597166]
    A-375 IC50
    0.4 μM
    Compound: Doxorubicin
    Cytotoxicity against human A375 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human A375 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 29789258]
    A-375 IC50
    0.4 μM
    Compound: Doxorubicin
    Cytotoxicity against human A-375 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Blue cell viability assay
    Cytotoxicity against human A-375 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Blue cell viability assay
    		[PMID: 35271771]
    A-375 IC50
    0.75 μM
    Compound: ADM
    Cytotoxicity against human A375 cells after 72 hrs by sulforhodamine B assay
    Cytotoxicity against human A375 cells after 72 hrs by sulforhodamine B assay
    		[PMID: 23639650]
    A-375 IC50
    1 μM
    Compound: ADM
    Cytotoxicity against human A375 cells after 72 hrs by MTT assay
    Cytotoxicity against human A375 cells after 72 hrs by MTT assay
    		[PMID: 25874331]
    A-375 IC50
    1 μM
    Compound: ADM
    Cytotoxicity against human A375 cells after 72 hrs by MTT assay
    Cytotoxicity against human A375 cells after 72 hrs by MTT assay
    		[PMID: 26280921]
    A-375 IC50
    1.2 μM
    Compound: Doxorubicin
    Anticancer activity against human A375 cells by MTT assay
    Anticancer activity against human A375 cells by MTT assay
    		10.1039/C4MD00219A
    A-375 IC50
    1.8 μg/mL
    Compound: doxorubicin
    Cytotoxicity against human A375 cells after 24 hrs by MTT assay
    Cytotoxicity against human A375 cells after 24 hrs by MTT assay
    		[PMID: 12608856]
    A-375 IC50
    2.1 μM
    Compound: Doxorubicin
    Cytotoxicity against human A-375 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Cytotoxicity against human A-375 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    		[PMID: 32975117]
    A-375 IC50
    5.51 μM
    Compound: Doxorubicin
    Anticancer activity against human A375 cells after 48 hrs by MTT assay
    Anticancer activity against human A375 cells after 48 hrs by MTT assay
    		[PMID: 22136907]
    A-375 IC50
    6.35 μM
    Compound: Dox
    Antiproliferative activity against human A375 cells for 24 hrs by MTT assay
    Antiproliferative activity against human A375 cells for 24 hrs by MTT assay
    		[PMID: 24929289]
    A-375 IC50
    7.01 μM
    Compound: Doxorubicin
    Cytotoxicity against human A375 spheroid cells assessed as reduction in spheroid cell viability after 48 hrs by MTT assay
    Cytotoxicity against human A375 spheroid cells assessed as reduction in spheroid cell viability after 48 hrs by MTT assay
    		[PMID: 30433783]
    A-375 IC50
    7.2 μM
    Compound: Doxo
    Cytotoxicity against human A375 cells after 48 hrs by MTT assay
    Cytotoxicity against human A375 cells after 48 hrs by MTT assay
    		[PMID: 25563891]
    A-431 EC50
    0.7 μM
    Compound: Doxorubicin
    Antiproliferative activity against human A-431 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay
    Antiproliferative activity against human A-431 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay
    		[PMID: 35567964]
    A-431 ED50
    1.2 x 10-2 μg/mL
    Compound: Adriamycin
    Cytotoxicity against human A431 cells by MTT assay
    Cytotoxicity against human A431 cells by MTT assay
    		[PMID: 7714533]
    A-431 GI50
    0.0012 μM
    Compound: Doxorubicin
    Antiproliferative activity against human A431 cells by SRB assay
    Antiproliferative activity against human A431 cells by SRB assay
    		[PMID: 19394218]
    A-431 GI50
    0.18 μM
    Compound: Doxorubicin
    Growth inhibition of human A431 cells after 2 days by SRB assay
    Growth inhibition of human A431 cells after 2 days by SRB assay
    		[PMID: 22000924]
    A-431 GI50
    0.18 μM
    Compound: Doxorubicine
    Growth inhibition of human A431 cells after 2 days by sulforhodamine B assay
    Growth inhibition of human A431 cells after 2 days by sulforhodamine B assay
    		[PMID: 20045222]
    A-431 IC50
    0.03 μM
    Compound: Dox
    Anticancer activity against human A431 cells after 48 hrs by MTT assay
    Anticancer activity against human A431 cells after 48 hrs by MTT assay
    		[PMID: 22209733]
    A-431 IC50
    0.05 μM
    Compound: adriamycin
    Growth inhibition of human A431 cells by MTT assay
    Growth inhibition of human A431 cells by MTT assay
    		[PMID: 17049252]
    A-431 IC50
    0.16 μM
    Compound: DOX
    Cytotoxicity against human A431 cells measured after 72 hrs by Celltiter-Glo assay
    Cytotoxicity against human A431 cells measured after 72 hrs by Celltiter-Glo assay
    		[PMID: 31820976]
    A-431 IC50
    0.19 μM
    Compound: Doxorubicin
    Cytotoxicity against human A431 cells after 72 hrs by MTT assay
    Cytotoxicity against human A431 cells after 72 hrs by MTT assay
    		[PMID: 18692939]
    A-431 IC50
    0.21 μg/mL
    Compound: Adriamycin
    Inhibitory concentration required against A 431 human epidermoid carcinoma cell line
    Inhibitory concentration required against A 431 human epidermoid carcinoma cell line
    		[PMID: 11354370]
    A-431 IC50
    0.37 μM
    Compound: Doxorubicin
    Cytotoxicity against human A431 cells after 48 hrs by MTT assay
    Cytotoxicity against human A431 cells after 48 hrs by MTT assay
    		[PMID: 20846862]
    A-431 IC50
    1.35 nM
    Compound: DOX
    Cytotoxicity against human A431 cells by SRB assay
    Cytotoxicity against human A431 cells by SRB assay
    		[PMID: 24890652]
    A-431 IC50
    1.35 nM
    Compound: DOX
    Cytotoxicity against human A431 cells over-expressing EGFR
    Cytotoxicity against human A431 cells over-expressing EGFR
    		[PMID: 30098869]
    A-431 IC50
    1.35 nM
    Compound: Doxorubicin
    Cytotoxicity against human A431 cells
    Cytotoxicity against human A431 cells
    		[PMID: 27894589]
    A-431 IC50
    1.43 μM
    Compound: Doxorubicin
    Antiproliferative activity against human A431 cells assessed as reduction in cell viability after 24 hrs by MTT assay
    Antiproliferative activity against human A431 cells assessed as reduction in cell viability after 24 hrs by MTT assay
    		[PMID: 31546197]
    A-431 IC50
    1.43 μM
    Compound: Doxorubicin
    Antiproliferative activity against human A-431 cells
    Antiproliferative activity against human A-431 cells
    		[PMID: 31945642]
    A-431 IC50
    117 ng/mL
    Compound: Adriamycin
    Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of A431 human epidermal carcinoma cell line
    Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of A431 human epidermal carcinoma cell line
    		[PMID: 12113817]
    A-431 IC50
    42.37 μM
    Compound: Dox
    Anticancer activity against human A431 cells
    Anticancer activity against human A431 cells
    		[PMID: 31330449]
    A204 IC50
    0.00648 μM
    Compound: Doxorubicin
    Antiproliferative activity against human A204 cells assessed as inhibition of cell growth incubated for 7 days by CellTiterGlo assay
    Antiproliferative activity against human A204 cells assessed as inhibition of cell growth incubated for 7 days by CellTiterGlo assay
    		[PMID: 30540463]
    A2058 CC50
    1.79 μM
    Compound: Doxorubicin
    Cytotoxicity against human A2058 cells after 72 hrs by MTT assay
    Cytotoxicity against human A2058 cells after 72 hrs by MTT assay
    		[PMID: 29792325]
    A2058 EC50
    6.5 μM
    Compound: 12
    Dark toxicity in human A2058 cells assessed as decrease in cell viability after 24 hrs by MTT assay
    Dark toxicity in human A2058 cells assessed as decrease in cell viability after 24 hrs by MTT assay
    		[PMID: 29172528]
    A2058 IC50
    < 0.11 μM
    Compound: Doxorubicin
    Cytotoxicity against human A2058 cells assessed as reduction in cell viability
    Cytotoxicity against human A2058 cells assessed as reduction in cell viability
    		[PMID: 32005414]
    A2780 EC50
    0.01 μM
    Compound: DR
    Cytotoxicity against human A2780 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
    Cytotoxicity against human A2780 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
    		[PMID: 32956968]
    A2780 EC50
    0.01 μM
    Compound: Doxorubicin
    Cytotoxicity against human A2780 cells assessed as reduction in cell viability measured after 72 hrs by SRB assay
    Cytotoxicity against human A2780 cells assessed as reduction in cell viability measured after 72 hrs by SRB assay
    		[PMID: 33049606]
    A2780 EC50
    0.02 μM
    Compound: Dox
    Cytotoxicity against human A2780 cells incubated for 72 hrs by SRB assay
    Cytotoxicity against human A2780 cells incubated for 72 hrs by SRB assay
    		[PMID: 36780832]
    A2780 GI50
    0.16 μM
    Compound: ADR
    Growth inhibition of human A2780 cells
    Growth inhibition of human A2780 cells
    		10.1039/C1MD00072A
    A2780 GI50
    0.16 μM
    Compound: ADR
    Cytotoxicity against human A2780 cells after 48 hrs by sulforhodamine B assay
    Cytotoxicity against human A2780 cells after 48 hrs by sulforhodamine B assay
    		[PMID: 18657979]
    A2780 GI50
    0.16 μM
    Compound: ADR
    Growth inhibition of human A2780 cells after 48 hrs by SRB assay
    Growth inhibition of human A2780 cells after 48 hrs by SRB assay
    		[PMID: 20031423]
    A2780 GI50
    0.16 μM
    Compound: ADR
    Cytotoxicity against human A2780 cells after 24 hrs by WST-1 assay
    Cytotoxicity against human A2780 cells after 24 hrs by WST-1 assay
    		[PMID: 20732817]
    A2780 GI50
    0.16 μM
    Compound: ADR
    Anticancer activity against human A2780 cells by SRB method
    Anticancer activity against human A2780 cells by SRB method
    		[PMID: 21676506]
    A2780 GI50
    0.16 μM
    Compound: ADR
    Growth inhibition of human A2780 cells by SRB assay
    Growth inhibition of human A2780 cells by SRB assay
    		[PMID: 22361684]
    A2780 GI50
    0.16 μM
    Compound: ADR
    Growth inhibition of human A2780 cells after 48 hrs by sulforhodamine B assay
    Growth inhibition of human A2780 cells after 48 hrs by sulforhodamine B assay
    		[PMID: 22364746]
    A2780 GI50
    0.16 μM
    Compound: ADR
    Growth inhibition of human A2780 cells after 48 hrs by sulforhodamine B assay
    Growth inhibition of human A2780 cells after 48 hrs by sulforhodamine B assay
    		[PMID: 23849207]
    A2780 GI50
    0.17 μM
    Compound: ADR, Adriamycin
    Growth inhibition of human A2780 cells by SRB method
    Growth inhibition of human A2780 cells by SRB method
    		[PMID: 18207392]
    A2780 GI50
    0.17 μM
    Compound: adriamycin
    Cytotoxicity against human A2780 cells after 24 hrs by SRB method
    Cytotoxicity against human A2780 cells after 24 hrs by SRB method
    		[PMID: 18262426]
    A2780 GI50
    19.4 nM
    Compound: 33
    Antiproliferative activity against human A2780 cells assessed as growth inhibition incubated for 72 hrs by MTT assay
    Antiproliferative activity against human A2780 cells assessed as growth inhibition incubated for 72 hrs by MTT assay
    		[PMID: 36584238]
    A2780 GI50
    < 0.1 μM
    Compound: ADR
    Cytotoxicity against human A2780 cells after 48 hrs by SRB assay
    Cytotoxicity against human A2780 cells after 48 hrs by SRB assay
    		[PMID: 20673627]
    A2780 GI50
    < 0.1 μM
    Compound: ADR
    Cytotoxicity against human A2780 cells after 48 hrs by sulforhodamine B assay
    Cytotoxicity against human A2780 cells after 48 hrs by sulforhodamine B assay
    		[PMID: 21737288]
    A2780 GI50
    < 0.1 μM
    Compound: ADR
    Anticancer activity against human A2780 cells by SRB method
    Anticancer activity against human A2780 cells by SRB method
    		[PMID: 22104151]
    A2780 IC50
    0.007 μM
    Compound: Doxorubicin
    Inhibitory concentration against A2780 ovarian carcinoma cell line
    Inhibitory concentration against A2780 ovarian carcinoma cell line
    		[PMID: 15715481]
    A2780 IC50
    0.007 μM
    Compound: doxorubicin
    Cytotoxicity against cisplatin-resistant human A2780 cells
    Cytotoxicity against cisplatin-resistant human A2780 cells
    		[PMID: 17375902]
    A2780 IC50
    0.007 μM
    Compound: doxorubicin
    Cytotoxicity against human A2780 cells
    Cytotoxicity against human A2780 cells
    		[PMID: 17375902]
    A2780 IC50
    0.0096 μM
    Compound: Doxirubicin
    Concentration required to inhibit A2780-cell growth by 50%
    Concentration required to inhibit A2780-cell growth by 50%
    		[PMID: 9703471]
    A2780 IC50
    0.0096 μM
    Compound: Doxorubicin
    In vitro cytotoxicity was tested against human Ovarian carcinoma A2780 cell line
    In vitro cytotoxicity was tested against human Ovarian carcinoma A2780 cell line
    		[PMID: 10411474]
    A2780 IC50
    0.0096 μM
    Compound: Dx
    The compound was tested for cytotoxic activity against A2780 cell line(human ovarian carcinoma )
    The compound was tested for cytotoxic activity against A2780 cell line(human ovarian carcinoma )
    		[PMID: 11123989]
    A2780 IC50
    0.01 μM
    Compound: DOX
    Cytotoxicity against human A2780 cells incubated for 72 hrs by SRB assay
    Cytotoxicity against human A2780 cells incubated for 72 hrs by SRB assay
    		[PMID: 38996651]
    A2780 IC50
    0.01 μM
    Compound: DX
    Cytotoxicity against human A2780 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
    Cytotoxicity against human A2780 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
    		[PMID: 32422522]
    A2780 IC50
    0.017 μM
    Compound: Doxorubicin
    In vitro cytotoxicity was tested against human Ovarian carcinoma A2780 cisplatin resistant cell line
    In vitro cytotoxicity was tested against human Ovarian carcinoma A2780 cisplatin resistant cell line
    		[PMID: 10411474]
    A2780 IC50
    0.02 μM
    Compound: doxorubicin
    Antiproliferative activity against human A2780 cells after 3 days by MTT assay
    Antiproliferative activity against human A2780 cells after 3 days by MTT assay
    		[PMID: 19093883]
    A2780 IC50
    0.044 μM
    Compound: Doxorubicin
    Cytotoxicity against human A2780 cells assessed as intracellular ATP level after 72 hrs by luminometry
    Cytotoxicity against human A2780 cells assessed as intracellular ATP level after 72 hrs by luminometry
    		[PMID: 21354800]
    A2780 IC50
    0.05 μM
    Compound: Doxorubicin
    Cytotoxicity against human A2780 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Cytotoxicity against human A2780 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    		[PMID: 33823396]
    A2780 IC50
    0.1 μM
    Compound: adriamycin
    Cytotoxicity against human A2780 cells by MTT assay
    Cytotoxicity against human A2780 cells by MTT assay
    		[PMID: 17190442]
    A2780 IC50
    0.123 μM
    Compound: Dox
    Cytotoxicity against human A2780 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay
    Cytotoxicity against human A2780 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay
    		[PMID: 30599418]
    A2780 IC50
    0.18 μM
    Compound: ADM; DOX
    Antiproliferative activity against human A2780 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Antiproliferative activity against human A2780 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    		[PMID: 31491611]
    A2780 IC50
    0.27 μM
    Compound: DOX
    Cytotoxicity against human A2780 cells after 48 hrs by MTT assay
    Cytotoxicity against human A2780 cells after 48 hrs by MTT assay
    		[PMID: 26386603]
    A2780 IC50
    0.29 μM
    Compound: Doxorubicin
    Inhibitory concentration against A2780 ovarian carcinoma resistant to doxorubicin
    Inhibitory concentration against A2780 ovarian carcinoma resistant to doxorubicin
    		[PMID: 15715481]
    A2780 IC50
    0.29 μM
    Compound: doxorubicin
    Cytotoxicity against doxorubicin-resistant human A2780 cells
    Cytotoxicity against doxorubicin-resistant human A2780 cells
    		[PMID: 17375902]
    A2780 IC50
    0.33 μM
    Compound: Adriamycin
    Cytotoxicity against human A2780 cells by MTT assay
    Cytotoxicity against human A2780 cells by MTT assay
    		[PMID: 22070654]
    A2780 IC50
    0.5 μM
    Compound: ADR
    Cytotoxicity against human A2780 cells by sulforhodamine B assay
    Cytotoxicity against human A2780 cells by sulforhodamine B assay
    		[PMID: 17822905]
    A2780 IC50
    0.5 μM
    Compound: ADR
    Cytotoxicity against human A2780 cells by SRB assay
    Cytotoxicity against human A2780 cells by SRB assay
    		[PMID: 18656370]
    A2780 IC50
    0.6 μM
    Compound: Adriamycin
    Cytotoxicity against human A2780 cells assessed as growth inhibition after 48 hrs by MTT assay
    Cytotoxicity against human A2780 cells assessed as growth inhibition after 48 hrs by MTT assay
    		[PMID: 26356746]
    A2780 IC50
    0.6 μM
    Compound: Doxorubicin
    Antiproliferative activity against human A2780 cells assessed as cell viability incubated for 48 hrs by MTS assay
    Antiproliferative activity against human A2780 cells assessed as cell viability incubated for 48 hrs by MTS assay
    		[PMID: 33348171]
    A2780 IC50
    0.71 μM
    Compound: DOX
    Antiproliferative activity against human A2780 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Antiproliferative activity against human A2780 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    		[PMID: 32996316]
    A2780 IC50
    0.98 μM
    Compound: DOX
    Cytotoxicity against human A2780 cells assessed as cell viability after 48 hrs by MTT assay
    Cytotoxicity against human A2780 cells assessed as cell viability after 48 hrs by MTT assay
    		[PMID: 27149641]
    A2780 IC50
    1.2 nM
    Compound: Doxorubicin
    Cytotoxicity against human A2780 cells
    Cytotoxicity against human A2780 cells
    		[PMID: 21774499]
    A2780 IC50
    1.3 μM
    Compound: Doxorubicin
    Cytotoxicity against human A2780 cells after 24 hrs by MTT assay
    Cytotoxicity against human A2780 cells after 24 hrs by MTT assay
    		[PMID: 26252628]
    A2780 IC50
    1.9 μM
    Compound: DOX
    Antiproliferative activity against taxol-resistant human A2780 cells after 48 hrs by SRB method
    Antiproliferative activity against taxol-resistant human A2780 cells after 48 hrs by SRB method
    		[PMID: 25061803]
    A2780 IC50
    12.1 ng/mL
    Compound: ADR
    Cytotoxicity against human cancer cell lines A2780 (ovarian)
    Cytotoxicity against human cancer cell lines A2780 (ovarian)
    		[PMID: 11311062]
    A2780 IC50
    13 nM
    Compound: ADM
    Cytotoxicity againt human A2780 cells
    Cytotoxicity againt human A2780 cells
    		[PMID: 17239597]
    A2780 IC50
    19.9 nM
    Compound: Doxorubicin
    In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780
    In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780
    		[PMID: 10479282]
    A2780 IC50
    23 nM
    Compound: doxorubicin
    Cytotoxicity against human A2780 cells after 72 hrs by MTT assay
    Cytotoxicity against human A2780 cells after 72 hrs by MTT assay
    		[PMID: 23886686]
    A2780 IC50
    3 nM
    Compound: doxorubicin
    Inhibition of cisplatin-resistant A2780 cell growth
    Inhibition of cisplatin-resistant A2780 cell growth
    		[PMID: 17125254]
    A2780 IC50
    357 nM
    Compound: doxorubicin
    Cytotoxicity against A2780-DX5, Doxorubicin-resistant Ovarian carcinoma cell line
    Cytotoxicity against A2780-DX5, Doxorubicin-resistant Ovarian carcinoma cell line
    		[PMID: 8831755]
    A2780 IC50
    466 nM
    Compound: Doxorubicin
    In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/Dx(RI)
    In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/Dx(RI)
    		[PMID: 10479282]
    A2780 IC50
    5 nM
    Compound: doxorubicin
    Cytotoxicity against A2780-WT, human ovarian carcinoma cell line
    Cytotoxicity against A2780-WT, human ovarian carcinoma cell line
    		[PMID: 8831755]
    A2780 IC50
    5.12 μM
    Compound: Doxorubicin
    Cytotoxicity against human A2780 cells assessed as inhibition in cell growth incubated for 72 hrs by MTT assay
    Cytotoxicity against human A2780 cells assessed as inhibition in cell growth incubated for 72 hrs by MTT assay
    		[PMID: 37567059]
    A2780 IC50
    5.7 nM
    Compound: Adriamycin
    Growth inhibition of human A2780 cells
    Growth inhibition of human A2780 cells
    		[PMID: 17490878]
    A2780 IC50
    56 nM
    Compound: doxorubicin
    Cytotoxicity against A2780-CP3, cisplatin-resistant Ovarian carcinoma cell line
    Cytotoxicity against A2780-CP3, cisplatin-resistant Ovarian carcinoma cell line
    		[PMID: 8831755]
    A2780 IC50
    61 nM
    Compound: doxorubicin
    Inhibition of Doxorubicin-resistant A2780 cell growth
    Inhibition of Doxorubicin-resistant A2780 cell growth
    		[PMID: 17125254]
    A2780 IC50
    63 nM
    Compound: doxorubicin
    Cytotoxicity against A2780-C25, oxaliplatin-resistant Ovarian carcinoma cell line
    Cytotoxicity against A2780-C25, oxaliplatin-resistant Ovarian carcinoma cell line
    		[PMID: 8831755]
    A2780 IC50
    7.5 nM
    Compound: doxorubicin
    Inhibition of A2780 cell growth
    Inhibition of A2780 cell growth
    		[PMID: 17125254]
    A2780 IC50
    8.5 nM
    Compound: Dox
    Cytotoxicity against human A2780 cells incubated for 72 hrs by SRB assay
    Cytotoxicity against human A2780 cells incubated for 72 hrs by SRB assay
    		[PMID: 37480713]
    A2780 ADR GI50
    802 μM
    Compound: 33
    Antiproliferative activity against human A2780 ADR cells expressing ABCB1 assessed as growth inhibition incubated for 72 hrs by MTT assay
    Antiproliferative activity against human A2780 ADR cells expressing ABCB1 assessed as growth inhibition incubated for 72 hrs by MTT assay
    		[PMID: 36584238]
    A2780 ADR IC50
    194 nM
    Compound: Doxorubicin
    Cytotoxicity against human A2780/ADR cells
    Cytotoxicity against human A2780/ADR cells
    		[PMID: 21774499]
    A2780 ADR IC50
    298 nM
    Compound: Adriamycin
    Growth inhibition of multidrug-resistant human 2780AD cells
    Growth inhibition of multidrug-resistant human 2780AD cells
    		[PMID: 17490878]
    A2780 ADR IC50
    909 nM
    Compound: ADM
    Cytotoxicity againt multidrug-resistant human 2780AD cells
    Cytotoxicity againt multidrug-resistant human 2780AD cells
    		[PMID: 17239597]
    A2780cis IC50
    0.099 μM
    Compound: DOX
    Cytotoxicity against human A2780cis cells incubated for 72 hrs by SRB assay
    Cytotoxicity against human A2780cis cells incubated for 72 hrs by SRB assay
    		[PMID: 38996651]
    A2780cis IC50
    80.4 nM
    Compound: Dox
    Cytotoxicity against human A2780cis cell incubated for 72 hrs by SRB assay
    Cytotoxicity against human A2780cis cell incubated for 72 hrs by SRB assay
    		[PMID: 37480713]
    A2780cisR IC50
    0.006 μM
    Compound: Doxorubicin
    Inhibitory concentration against A2780 ovarian carcinoma resistant to cisplatin
    Inhibitory concentration against A2780 ovarian carcinoma resistant to cisplatin
    		[PMID: 15715481]
    A2780cisR IC50
    0.017 μM
    Compound: Dx
    The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma )
    The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma )
    		[PMID: 11123989]
    A2780cisR IC50
    5 nM
    Compound: Doxorubicin
    Cytotoxicity against human A2780cis cells
    Cytotoxicity against human A2780cis cells
    		[PMID: 21774499]
    A498 ED50
    0.00046 μg/mL
    Compound: Adriamycin
    In vitro cytotoxic activity against A-498 (human kidney carcinoma) cell line
    In vitro cytotoxic activity against A-498 (human kidney carcinoma) cell line
    		[PMID: 11551759]
    A498 ED50
    0.00226 μg/mL
    Compound: Adriamycin
    Cytotoxicity against human kidney carcinoma A-498cell lines
    Cytotoxicity against human kidney carcinoma A-498cell lines
    		10.1016/0960-894X(95)00182-S
    A498 ED50
    0.00286 μg/mL
    Compound: adriamycin
    Cytotoxicity against human A498 cells after 7 days by MTT assay
    Cytotoxicity against human A498 cells after 7 days by MTT assay
    		[PMID: 11087592]
    A498 ED50
    0.0156 μg/mL
    Compound: adriamycin
    Cytotoxicity against human A-498 cells after 7 days by MTT assay
    Cytotoxicity against human A-498 cells after 7 days by MTT assay
    		[PMID: 10514307]
    A498 ED50
    0.0335 μg/mL
    Compound: Adriamycin
    Cytotoxic activity was tested against human A-498 (Kidney carcinoma) cell line
    Cytotoxic activity was tested against human A-498 (Kidney carcinoma) cell line
    		10.1016/0960-894X(95)00309-H
    A498 ED50
    0.0663 μg/mL
    Compound: Adriamycin
    Cytotoxicity concentration against human kidney carcinoma A-498 cell line
    Cytotoxicity concentration against human kidney carcinoma A-498 cell line
    		[PMID: 8627602]
    A498 ED50
    1.1 x 10-3 μg/mL
    Compound: adriamycin
    Cytotoxicity against human A498 cells after 7 days by MTT assay
    Cytotoxicity against human A498 cells after 7 days by MTT assay
    		10.1021/np970510f
    A498 ED50
    1.13 x 10-1 μg/mL
    Compound: Adriamycin
    Cytotoxicity against human A498 cells after 7 days by MTT assay
    Cytotoxicity against human A498 cells after 7 days by MTT assay
    		[PMID: 9322367]
    A498 ED50
    1.22 x 10-2 μg/mL
    Compound: adriamycin
    Cytotoxicity against human A498 cells after 7 days by MTT assay
    Cytotoxicity against human A498 cells after 7 days by MTT assay
    		[PMID: 9134750]
    A498 ED50
    1.58 x 10-2 μg/mL
    Compound: adriamycin
    Cytotoxicity against human A498 cells after 7 days by MTT assay
    Cytotoxicity against human A498 cells after 7 days by MTT assay
    		[PMID: 9584396]
    A498 ED50
    1.78 x 10-3 μg/mL
    Compound: Adriamycin
    Cytotoxicity against human A498 cells after 7 days by MTT assay
    Cytotoxicity against human A498 cells after 7 days by MTT assay
    		[PMID: 8946743]
    A498 ED50
    1.87 μg/mL
    Compound: Adriamycin
    Cytotoxicity on kidney carcinoma (A-498) cell line
    Cytotoxicity on kidney carcinoma (A-498) cell line
    		[PMID: 8632402]
    A498 ED50
    1.9 x 10-2 μg/mL
    Compound: adriamycin
    Cytotoxicity against human A-498 cells by MTT assay
    Cytotoxicity against human A-498 cells by MTT assay
    		[PMID: 9917277]
    A498 ED50
    1.9 x 10-3 μg/mL
    Compound: Adr
    Cytotoxicity against human A498 cells
    Cytotoxicity against human A498 cells
    		[PMID: 8778247]
    A498 ED50
    1.9 x 10-3 μg/mL
    Compound: adriamycin
    Cytotoxicity against human A498 cells after 7 days by MTT assay
    Cytotoxicity against human A498 cells after 7 days by MTT assay
    		[PMID: 10395501]
    A498 ED50
    1.97 x 10-3 μg/mL
    Compound: Adriamycin
    Cytotoxicity against human A498 cells after 7 days by MTT assay
    Cytotoxicity against human A498 cells after 7 days by MTT assay
    		[PMID: 7494147]
    A498 ED50
    1.98 x 10-3 μg/mL
    Compound: adriamycin
    Cytotoxicity against human A498 cells after 7 days by MTT assay
    Cytotoxicity against human A498 cells after 7 days by MTT assay
    		[PMID: 9599253]
    A498 ED50
    1 x 10-2 μg/mL
    Compound: Adriamycin
    Cytotoxicity against human A498 cells after 7 days by MTT assay
    Cytotoxicity against human A498 cells after 7 days by MTT assay
    		[PMID: 9214729]
    A498 ED50
    1 x 10-2 μg/mL
    Compound: adriamycin
    Cytotoxicity against human A498 cells after 7 days by MTT assay
    Cytotoxicity against human A498 cells after 7 days by MTT assay
    		[PMID: 8882434]
    A498 ED50
    2.26 x 10-3 μg/mL
    Compound: adriamycin
    Cytotoxicity against human A498 cells after 7 days by MTT assay
    Cytotoxicity against human A498 cells after 7 days by MTT assay
    		[PMID: 11325235]
    A498 ED50
    2.49 x 10-2 μg/mL
    Compound: adriamycin
    Cytotoxicity against human A498 cells
    Cytotoxicity against human A498 cells
    		[PMID: 8991957]
    A498 ED50
    2.86 x 10-3 μg/mL
    Compound: adriamycin
    Cytotoxicity against human A-498 cells after 7 days by MTT assay
    Cytotoxicity against human A-498 cells after 7 days by MTT assay
    		[PMID: 15730242]
    A498 ED50
    3.2 x 10-3 μg/mL
    Compound: Adriamycin
    Cytotoxicity against human A498 cells by MTT assay
    Cytotoxicity against human A498 cells by MTT assay
    		[PMID: 7714533]
    A498 ED50
    3.5 nM
    Compound: Adriamycin
    In vitro cytotoxicity against Renal A-498 human tumors following a 6 day exposure.
    In vitro cytotoxicity against Renal A-498 human tumors following a 6 day exposure.
    		[PMID: 10498214]
    A498 ED50
    3.66 x 10-4 μg/mL
    Compound: adriamycin
    Cytotoxicity against human A498 cells after 7 days by MTT assay
    Cytotoxicity against human A498 cells after 7 days by MTT assay
    		[PMID: 8676130]
    A498 ED50
    4.24 x 10-3 μg/mL
    Compound: adr
    Cytotoxicity against human A498 cells after 7 days by MTT assay
    Cytotoxicity against human A498 cells after 7 days by MTT assay
    		[PMID: 9461654]
    A498 ED50
    4.62 x 10-2 μg/mL
    Compound: Adriamycin
    Cytotoxicity against human A498 cells
    Cytotoxicity against human A498 cells
    		[PMID: 8946744]
    A498 ED50
    6.2 x 10-3 μg/mL
    Compound: adriamycin
    Cytotoxicity against human A498 cells after 7 days by MTT assay
    Cytotoxicity against human A498 cells after 7 days by MTT assay
    		[PMID: 9599260]
    A498 ED50
    6.49 x 10-3 μg/mL
    Compound: adriamycin
    Cytotoxicity against human A498 cells after 7 days by MTT assay
    Cytotoxicity against human A498 cells after 7 days by MTT assay
    		[PMID: 8904848]
    A498 GI50
    0.0064 μg/mL
    Compound: Doxorubicin
    Antitumor cytotoxic activity against A-498 cell line was determined
    Antitumor cytotoxic activity against A-498 cell line was determined
    		[PMID: 11551772]
    A498 GI50
    0.1 μM
    Compound: Doxorubicin
    Growth inhibition of human A498 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human A498 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28329730]
    A498 GI50
    0.1 μM
    Compound: Doxorubicin
    Growth inhibition of human A498 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human A498 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 29102177]
    A498 GI50
    0.1 μM
    Compound: Doxorubicin hydrochloride, NSC 123127
    Cytotoxicity against human A498 cells after 48 hrs by SRB assay
    Cytotoxicity against human A498 cells after 48 hrs by SRB assay
    		[PMID: 23871905]
    A498 GI50
    < 10 μg/mL
    Compound: ADR
    Cytotoxicity against human A498 cells
    Cytotoxicity against human A498 cells
    		[PMID: 21802797]
    A498 IC50
    0.035 μM
    Compound: adriamycin
    Antitumor activity against human A498 cells by methylene blue staining method
    Antitumor activity against human A498 cells by methylene blue staining method
    		[PMID: 17656091]
    A498 IC50
    1.1 μM
    Compound: Doxorubicin
    Antiproliferative activity against human A498 cells after 48 hrs by SRB assay
    Antiproliferative activity against human A498 cells after 48 hrs by SRB assay
    		[PMID: 30503942]
    A498 IC50
    4.9 x 10-3 μg/mL
    Compound: Adriamycin
    Cytotoxicity against human A498 cells by MTT assay
    Cytotoxicity against human A498 cells by MTT assay
    		[PMID: 9644064]
    A498 IC50
    52.8 nM
    Compound: Doxorubicin
    Cytotoxicity against human kidney carcinoma cell lines A4982LM
    Cytotoxicity against human kidney carcinoma cell lines A4982LM
    		[PMID: 12392727]
    A498 IC50
    6.1 μM
    Compound: DOX
    Antiproliferative activity against human A498 cells after 72 hrs by MTT assay
    Antiproliferative activity against human A498 cells after 72 hrs by MTT assay
    		[PMID: 30429098]
    A549 CC50
    0.03 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells assessed as reduction in cell viability measured for 48 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as reduction in cell viability measured for 48 hrs by MTT assay
    		[PMID: 38056297]
    A549 CC50
    10.5 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells after 72 hrs by MTT assay
    Cytotoxicity against human A549 cells after 72 hrs by MTT assay
    		[PMID: 29792325]
    A549 CC50
    2 μM
    Compound: Dox
    Cytotoxicity against human A549 cells incubated for 72 hrs by MTT assay
    Cytotoxicity against human A549 cells incubated for 72 hrs by MTT assay
    		[PMID: 39079310]
    A549 EC50
    0.01 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells
    Cytotoxicity against human A549 cells
    		[PMID: 18990572]
    A549 EC50
    0.9 μM
    Compound: doxorubicin
    Cytotoxicity against human A549 cells after 72 hrs
    Cytotoxicity against human A549 cells after 72 hrs
    		[PMID: 17378530]
    A549 ED50
    0.0001 μg/mL
    Compound: Adriamycin
    Tested in vitro for cytotoxicity against A-549 lung cancer cells
    Tested in vitro for cytotoxicity against A-549 lung cancer cells
    		[PMID: 8027979]
    A549 ED50
    0.00015 μg/mL
    Compound: ADRIAMYCIN
    Compound was tested for cytotoxic activity against human lung carcinoma (A-549)
    Compound was tested for cytotoxic activity against human lung carcinoma (A-549)
    		10.1016/0960-894X(94)80019-7
    A549 ED50
    0.00021 μg/mL
    Compound: Adriamycin
    In vitro cytotoxic activity against A-549 (human lung carcinoma) cell line
    In vitro cytotoxic activity against A-549 (human lung carcinoma) cell line
    		[PMID: 11551759]
    A549 ED50
    0.001 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells by sulforhodamine B method
    Cytotoxicity against human A549 cells by sulforhodamine B method
    		[PMID: 12193011]
    A549 ED50
    0.001 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells after 48 hrs by sulforhodamine B assay
    Cytotoxicity against human A549 cells after 48 hrs by sulforhodamine B assay
    		[PMID: 19783438]
    A549 ED50
    0.00399 μg/mL
    Compound: Adriamycin
    Cytotoxicity against human lung carcinoma A-549 cell lines
    Cytotoxicity against human lung carcinoma A-549 cell lines
    		10.1016/0960-894X(95)00182-S
    A549 ED50
    0.0043 μg/mL
    Compound: adriamycin
    Cytotoxicity against human A549 cells after 7 days by MTT assay
    Cytotoxicity against human A549 cells after 7 days by MTT assay
    		[PMID: 10514307]
    A549 ED50
    0.00622 μg/mL
    Compound: adriamycin
    Cytotoxicity against human A549 cells after 7 days by MTT assay
    Cytotoxicity against human A549 cells after 7 days by MTT assay
    		[PMID: 11087592]
    A549 ED50
    0.007 μM
    Compound: doxorubicin
    Cytotoxicity against human A549 cells by SRB assay
    Cytotoxicity against human A549 cells by SRB assay
    		[PMID: 18314958]
    A549 ED50
    0.00844 μg/mL
    Compound: Adriamycin
    Compound was tested for its cytotoxic activity in MTT assay against A-549 cell line (human lung carcinoma)
    Compound was tested for its cytotoxic activity in MTT assay against A-549 cell line (human lung carcinoma)
    		10.1016/0960-894X(95)00004-D
    A549 ED50
    0.012 μg/mL
    Compound: doxorubicin
    Cytotoxicity against human A549 cells by SRB method
    Cytotoxicity against human A549 cells by SRB method
    		[PMID: 16252909]
    A549 ED50
    0.01 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells
    Cytotoxicity against human A549 cells
    		[PMID: 15104487]
    A549 ED50
    0.01 μg/mL
    Compound: doxorubicin
    Cytotoxicity against human A549 cells after 48 hrs by SRB assay
    Cytotoxicity against human A549 cells after 48 hrs by SRB assay
    		[PMID: 15921415]
    A549 ED50
    0.01 μg/mL
    Compound: doxorubicin
    Cytotoxicity against human A549 cells
    Cytotoxicity against human A549 cells
    		[PMID: 16441084]
    A549 ED50
    0.01 μg/mL
    Compound: doxorubicin
    Cytotoxicity against human A549 cell line
    Cytotoxicity against human A549 cell line
    		[PMID: 17253840]
    A549 ED50
    0.0262 μg/mL
    Compound: Adriamycin
    Cytotoxicity concentration against human lung carcinoma A-549 cell line
    Cytotoxicity concentration against human lung carcinoma A-549 cell line
    		[PMID: 8627602]
    A549 ED50
    0.029 μM
    Compound: Adriamycin
    Cytotoxic concentration required to inhibit 50% cell growth in A-549 lung carcinoma cell lines
    Cytotoxic concentration required to inhibit 50% cell growth in A-549 lung carcinoma cell lines
    		[PMID: 1875350]
    A549 ED50
    0.02 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells after 48 hrs by SRB assay
    Cytotoxicity against human A549 cells after 48 hrs by SRB assay
    		[PMID: 11325244]
    A549 ED50
    0.02 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells
    Cytotoxicity against human A549 cells
    		[PMID: 11520227]
    A549 ED50
    0.02 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells
    Cytotoxicity against human A549 cells
    		[PMID: 12350153]
    A549 ED50
    0.02 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells
    Cytotoxicity against human A549 cells
    		[PMID: 12662097]
    A549 ED50
    0.02 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells
    Cytotoxicity against human A549 cells
    		[PMID: 14640527]
    A549 ED50
    0.02 μg/mL
    Compound: doxorubicin
    Cytotoxicity against human A549 cells
    Cytotoxicity against human A549 cells
    		[PMID: 11678655]
    A549 ED50
    0.02 μg/mL
    Compound: doxorubicin
    Cytotoxicity against human A549 cells after 48 hrs by SRB assay
    Cytotoxicity against human A549 cells after 48 hrs by SRB assay
    		[PMID: 15730260]
    A549 ED50
    0.0346 μg/mL
    Compound: Adriamycin
    Cytotoxic activity was tested against human prostate cell line A-549 (lung carcinoma)
    Cytotoxic activity was tested against human prostate cell line A-549 (lung carcinoma)
    		10.1016/0960-894X(95)00309-H
    A549 ED50
    0.03 μg/mL
    Compound: Adriamycin
    Cytotoxicity against human A549 cells after 24 hrs by SRB assay
    Cytotoxicity against human A549 cells after 24 hrs by SRB assay
    		[PMID: 20850305]
    A549 ED50
    0.03 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells
    Cytotoxicity against human A549 cells
    		[PMID: 12662102]
    A549 ED50
    0.03 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells
    Cytotoxicity against human A549 cells
    		[PMID: 15270579]
    A549 ED50
    0.03 μg/mL
    Compound: doxorubicin
    Cytotoxicity against human A549 cells
    Cytotoxicity against human A549 cells
    		[PMID: 12762820]
    A549 ED50
    0.04 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells
    Cytotoxicity against human A549 cells
    		[PMID: 14640526]
    A549 ED50
    0.04 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells
    Cytotoxicity against human A549 cells
    		[PMID: 15497935]
    A549 ED50
    0.04 μg/mL
    Compound: doxorubicin
    Cytotoxicity against human A549 cells
    Cytotoxicity against human A549 cells
    		[PMID: 14640517]
    A549 ED50
    0.04 μg/mL
    Compound: doxorubicin
    Cytotoxicity against human A549 cells
    Cytotoxicity against human A549 cells
    		[PMID: 16643027]
    A549 ED50
    0.05 μg/mL
    Compound: adriamycin
    Cytotoxicity against human A549 cells by SRB assay
    Cytotoxicity against human A549 cells by SRB assay
    		10.1021/np960188t
    A549 ED50
    0.07 μg/mL
    Compound: doxorubicin
    Cytotoxicity against human A549 cells
    Cytotoxicity against human A549 cells
    		[PMID: 15104515]
    A549 ED50
    0.08 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells
    Cytotoxicity against human A549 cells
    		[PMID: 17190456]
    A549 ED50
    0.11 μg/mL
    Compound: doxorubicin
    Cytotoxicity against human A549 cells
    Cytotoxicity against human A549 cells
    		[PMID: 15787431]
    A549 ED50
    0.12 μg/mL
    Compound: doxorubicin
    Cytotoxicity against human A549 cells by SRB assay
    Cytotoxicity against human A549 cells by SRB assay
    		[PMID: 9392887]
    A549 ED50
    0.18 μM
    Compound: DOX
    Cytotoxicity against human A549 cells
    Cytotoxicity against human A549 cells
    		[PMID: 17591444]
    A549 ED50
    0.1 μg/mL
    Compound: doxorubicin
    Cytotoxicity against human A549 cells
    Cytotoxicity against human A549 cells
    		[PMID: 10217707]
    A549 ED50
    0.1 μg/mL
    Compound: doxorubicin
    Cytotoxicity against human A549 cells after 3 days by MTT assay
    Cytotoxicity against human A549 cells after 3 days by MTT assay
    		[PMID: 16252910]
    A549 ED50
    0.21 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells by MTT assay
    Cytotoxicity against human A549 cells by MTT assay
    		[PMID: 17315955]
    A549 ED50
    1.01 x 10-2 μg/mL
    Compound: Adriamycin
    Cytotoxicity against human A549 cells after 7 days by MTT assay
    Cytotoxicity against human A549 cells after 7 days by MTT assay
    		[PMID: 7673926]
    A549 ED50
    1.01 x 10-3 μg/mL
    Compound: adriamycin
    Cytotoxicity against human A549 cells after 7 days by MTT assay
    Cytotoxicity against human A549 cells after 7 days by MTT assay
    		[PMID: 8676130]
    A549 ED50
    1.01 μg/mL
    Compound: Adriamycin
    The compound was evaluated for antiproliferative activity against A549 cell line
    The compound was evaluated for antiproliferative activity against A549 cell line
    		[PMID: 11055343]
    A549 ED50
    1.1 x 10-3 μg/mL
    Compound: Adriamycin
    Cytotoxicity against human A549 cells after 7 days by MTT assay
    Cytotoxicity against human A549 cells after 7 days by MTT assay
    		[PMID: 7714532]
    A549 ED50
    1.1 x 10-3 μg/mL
    Compound: adriamycin
    Cytotoxicity against human A549 cells after 7 days
    Cytotoxicity against human A549 cells after 7 days
    		[PMID: 8021648]
    A549 ED50
    1.13 x 10-3 μg/mL
    Compound: adriamycin
    Cytotoxicity against human A549 cells after 7 days by MTT assay
    Cytotoxicity against human A549 cells after 7 days by MTT assay
    		[PMID: 11325235]
    A549 ED50
    1.3 x 10-3 μg/mL
    Compound: adriamycin
    Cytotoxicity against human A549 cells after 7 days by MTT assay
    Cytotoxicity against human A549 cells after 7 days by MTT assay
    		[PMID: 10395501]
    A549 ED50
    1.48 x 10-3 μg/mL
    Compound: adriamycin
    Cytotoxicity against human A549 cells after 7 days
    Cytotoxicity against human A549 cells after 7 days
    		[PMID: 1593281]
    A549 ED50
    1.48 x 10-3 μg/mL
    Compound: adriamycin
    Cytotoxicity against human A549 cells after 7 days
    Cytotoxicity against human A549 cells after 7 days
    		[PMID: 8201311]
    A549 ED50
    1.57 x 10-3 μg/mL
    Compound: Adr
    Cytotoxicity against human A549 cells
    Cytotoxicity against human A549 cells
    		[PMID: 8778247]
    A549 ED50
    1.7 x 10-2 μg/mL
    Compound: adriamycin
    Cytotoxicity against human A549 cells by MTT assay
    Cytotoxicity against human A549 cells by MTT assay
    		[PMID: 9917277]
    A549 ED50
    1.78 x 10-3 μg/mL
    Compound: Adriamycin
    Cytotoxicity against human A549 cells after 7 days by MTT assay
    Cytotoxicity against human A549 cells after 7 days by MTT assay
    		[PMID: 8946743]
    A549 ED50
    1.8 x 10-3 μg/mL
    Compound: Adriamycin
    Cytotoxicity against human A549 cells
    Cytotoxicity against human A549 cells
    		[PMID: 1602301]
    A549 ED50
    1.91 x 10-2 μg/mL
    Compound: adriamycin
    Cytotoxicity against human A549 cells after 7 days by MTT assay
    Cytotoxicity against human A549 cells after 7 days by MTT assay
    		[PMID: 9599260]
    A549 ED50
    1.98 x 10-4 μg/mL
    Compound: Adriamycin
    Cytotoxicity against human A549 cells
    Cytotoxicity against human A549 cells
    		[PMID: 8350089]
    A549 ED50
    152 μM
    Compound: doxorubicin
    Antitumor activity against human A549 cells after 24 hrs by MTT assay
    Antitumor activity against human A549 cells after 24 hrs by MTT assay
    		[PMID: 17482824]
    A549 ED50
    2.08 x 10-4 μg/mL
    Compound: adriamycin
    Cytotoxicity against human A549 cells
    Cytotoxicity against human A549 cells
    		[PMID: 8377016]
    A549 ED50
    2.37 x 10-4 μg/mL
    Compound: Adriamycin
    Cytotoxicity against human A549 cells
    Cytotoxicity against human A549 cells
    		[PMID: 1479382]
    A549 ED50
    2.43 x 10-2 μg/mL
    Compound: adriamycin
    Cytotoxicity against human A549 cells after 7 days by MTT assay
    Cytotoxicity against human A549 cells after 7 days by MTT assay
    		[PMID: 8904848]
    A549 ED50
    2.84 x 10-2 μg/mL
    Compound: adriamycin
    Cytotoxicity against human A549 cells
    Cytotoxicity against human A549 cells
    		[PMID: 8991957]
    A549 ED50
    2.9 μM
    Compound: Adriamycin
    Compound was evaluated for cytotoxicity against human A-549 non-small cell lung cancer cell line.
    Compound was evaluated for cytotoxicity against human A-549 non-small cell lung cancer cell line.
    		[PMID: 1613753]
    A549 ED50
    2.92 x 10-2 μg/mL
    Compound: adriamycin
    Cytotoxicity against human A549 cells
    Cytotoxicity against human A549 cells
    		[PMID: 1665173]
    A549 ED50
    2.94 x 10-3 μg/mL
    Compound: Adriamycin
    Cytotoxicity against human A549 cells after 7 days by MTT assay
    Cytotoxicity against human A549 cells after 7 days by MTT assay
    		[PMID: 7673936]
    A549 ED50
    2.94 x 10-3 μg/mL
    Compound: adriamycin
    Cytotoxicity against human A549 cells after 7 days by MTT assay
    Cytotoxicity against human A549 cells after 7 days by MTT assay
    		[PMID: 9584396]
    A549 ED50
    2 x 10-3 μg/mL
    Compound: adriamycin
    Cytotoxicity against human A549 cells after 7 days by MTT assay
    Cytotoxicity against human A549 cells after 7 days by MTT assay
    		[PMID: 8882437]
    A549 ED50
    3.1 x 10-4 μg/mL
    Compound: Adriamycin
    Cytotoxicity against human A549 cells by MTT assay
    Cytotoxicity against human A549 cells by MTT assay
    		[PMID: 7714533]
    A549 ED50
    3.41 x 10-3 μg/mL
    Compound: Adriamycin
    Cytotoxicity against human A549 cells after 7 days by MTT assay
    Cytotoxicity against human A549 cells after 7 days by MTT assay
    		[PMID: 7494147]
    A549 ED50
    3.56 x 10-3 μg/mL
    Compound: Adriamycin
    Cytotoxicity against human A549 cells after 7 days by MTT assay
    Cytotoxicity against human A549 cells after 7 days by MTT assay
    		[PMID: 7494150]
    A549 ED50
    3.56 x 10-3 μg/mL
    Compound: Adriamycin
    Cytotoxicity against human A549 cells after 7 days by MTT assay
    Cytotoxicity against human A549 cells after 7 days by MTT assay
    		[PMID: 7673935]
    A549 ED50
    3.67 x 10-3 μg/mL
    Compound: adriamycin
    Cytotoxicity against human A549 cells after 7 days by MTT assay
    Cytotoxicity against human A549 cells after 7 days by MTT assay
    		[PMID: 9599253]
    A549 ED50
    3.93 x 10-3 μg/mL
    Compound: Adriamycin
    Cytotoxicity against human A549 cells after 7 days by MTT assay
    Cytotoxicity against human A549 cells after 7 days by MTT assay
    		[PMID: 9322367]
    A549 ED50
    3 x 10-2 μg/mL
    Compound: adriyamicin
    Cytotoxicity against human A549 cells
    Cytotoxicity against human A549 cells
    		[PMID: 8991955]
    A549 ED50
    4.09 x 10-4 μg/mL
    Compound: adriamycin
    Cytotoxicity against human A549 cells
    Cytotoxicity against human A549 cells
    		[PMID: 1294696]
    A549 ED50
    4.16 μg/mL
    Compound: Adriamycin
    Cytotoxicity on lung carcinoma (A-549) cell line
    Cytotoxicity on lung carcinoma (A-549) cell line
    		[PMID: 8632402]
    A549 ED50
    4.28 x 10-3 μg/mL
    Compound: Adriamycin
    Cytotoxicity against human A549 cells
    Cytotoxicity against human A549 cells
    		[PMID: 8946744]
    A549 ED50
    4.47 x 10-3 μg/mL
    Compound: adriamycin
    Cytotoxicity against human A549 cells after 7 days by MTT assay
    Cytotoxicity against human A549 cells after 7 days by MTT assay
    		10.1021/np970510f
    A549 ED50
    4.99 x 10-3 μg/mL
    Compound: adr
    Cytotoxicity against human A549 cells after 7 days by MTT assay
    Cytotoxicity against human A549 cells after 7 days by MTT assay
    		[PMID: 9461654]
    A549 ED50
    4.99 x 10-3 μg/mL
    Compound: adriamycin
    Cytotoxicity against human A549 cells after 7 days by MTT assay
    Cytotoxicity against human A549 cells after 7 days by MTT assay
    		[PMID: 9014350]
    A549 ED50
    5.04 x 10-4 μg/mL
    Compound: Adriamycin
    Cytotoxicity against human A549 cells after 7 days
    Cytotoxicity against human A549 cells after 7 days
    		[PMID: 1453182]
    A549 ED50
    5.06 x 10-3 μg/mL
    Compound: adriamycin
    Cytotoxicity against human A549 cells after 7 days by MTT assay
    Cytotoxicity against human A549 cells after 7 days by MTT assay
    		[PMID: 8882434]
    A549 ED50
    5.3 x 10-3 μg/mL
    Compound: Adriamycin
    Cytotoxicity against human A549 cells after 7 days by MTT assay
    Cytotoxicity against human A549 cells after 7 days by MTT assay
    		[PMID: 9214729]
    A549 ED50
    59.5 nM
    Compound: doxorubicin
    Cytotoxicity against human A549 cells by MTT assay
    Cytotoxicity against human A549 cells by MTT assay
    		[PMID: 17655260]
    A549 ED50
    6.2 nM
    Compound: Adriamycin
    In vitro cytotoxicity against Lung A-549 human tumors following a 6 day exposure.
    In vitro cytotoxicity against Lung A-549 human tumors following a 6 day exposure.
    		[PMID: 10498214]
    A549 ED50
    6.22 x 10-3 μg/mL
    Compound: adriamycin
    Cytotoxicity against human A549 cells after 7 days by MTT assay
    Cytotoxicity against human A549 cells after 7 days by MTT assay
    		[PMID: 15730242]
    A549 ED50
    6.84 x 10-3 μg/mL
    Compound: adriamycin
    Cytotoxicity against human A549 cells
    Cytotoxicity against human A549 cells
    		[PMID: 1791471]
    A549 ED50
    6.96 x 10-3 μg/mL
    Compound: Adriamycin
    Cytotoxicity against human A549 cells
    Cytotoxicity against human A549 cells
    		[PMID: 2348205]
    A549 ED50
    8.9 x 10-1 μg/mL
    Compound: Adriamycin
    Cytotoxicity against human A549 cells
    Cytotoxicity against human A549 cells
    		[PMID: 10479316]
    A549 ED50
    9.2 x 10-3 μg/mL
    Compound: adriamycin
    Cytotoxicity against human A549 cells after 7 hrs by MTT assay
    Cytotoxicity against human A549 cells after 7 hrs by MTT assay
    		[PMID: 7623031]
    A549 GI50
    0.003 μM
    Compound: Doxorubicin
    Antiproliferative activity against human A549 cells by SRB assay
    Antiproliferative activity against human A549 cells by SRB assay
    		[PMID: 19394218]
    A549 GI50
    0.007 μM
    Compound: Adriamycin
    Cytotoxicity against human A549 cells by MTT assay
    Cytotoxicity against human A549 cells by MTT assay
    		[PMID: 19405508]
    A549 GI50
    0.016 μM
    Compound: Doxorubicin
    Cytostatic activity against human A549 cells after 5 days by SRB assay
    Cytostatic activity against human A549 cells after 5 days by SRB assay
    		[PMID: 21711054]
    A549 GI50
    0.04 μg/mL
    Compound: adriamycin
    Cytotoxicity against human A549 cells by MTT assay
    Cytotoxicity against human A549 cells by MTT assay
    		[PMID: 11000028]
    A549 GI50
    0.06 μM
    Compound: Doxorubicin
    Growth inhibition of human A549/ATCC cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human A549/ATCC cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28329730]
    A549 GI50
    0.06 μM
    Compound: Doxorubicin
    Growth inhibition of human A549/ATCC cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human A549/ATCC cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 29102177]
    A549 GI50
    0.06 μM
    Compound: Doxorubicin hydrochloride, NSC 123127
    Cytotoxicity against human A549/ATCC cells after 48 hrs by SRB assay
    Cytotoxicity against human A549/ATCC cells after 48 hrs by SRB assay
    		[PMID: 23871905]
    A549 GI50
    0.062 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells after 72 hrs by SRB assay
    Cytotoxicity against human A549 cells after 72 hrs by SRB assay
    		[PMID: 20014800]
    A549 GI50
    0.07 μM
    Compound: Adriamycin
    In vitro antiproliferative activity against human A-549 NSCL cell line
    In vitro antiproliferative activity against human A-549 NSCL cell line
    		[PMID: 14971893]
    A549 GI50
    0.07 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells after 48 hrs by sulforhodamine B assay
    Cytotoxicity against human A549 cells after 48 hrs by sulforhodamine B assay
    		[PMID: 24158013]
    A549 GI50
    0.092 μg/mL
    Compound: Doxorubicin
    Antitumor cytotoxic activity against A-549 cell line was determined
    Antitumor cytotoxic activity against A-549 cell line was determined
    		[PMID: 11551772]
    A549 GI50
    0.1 μM
    Compound: doxorubicin
    Cytotoxicity against human A549 cells by SRB assay
    Cytotoxicity against human A549 cells by SRB assay
    		[PMID: 17512741]
    A549 GI50
    0.1 μM
    Compound: doxorubicin
    Cytotoxicity against human A549 cells by SRB assay
    Cytotoxicity against human A549 cells by SRB assay
    		[PMID: 19007287]
    A549 GI50
    0.15 μM
    Compound: ADR
    Cytotoxicity against human A549 cells after 48 hrs by SRB assay
    Cytotoxicity against human A549 cells after 48 hrs by SRB assay
    		[PMID: 20673627]
    A549 GI50
    0.16 μM
    Compound: Doxorubicin
    Growth inhibition of human A549 cells after 72 hrs by SRB assay
    Growth inhibition of human A549 cells after 72 hrs by SRB assay
    		[PMID: 18585035]
    A549 GI50
    0.2 μM
    Compound: Doxorubicin
    Cytotoxic activity against human A549 cells
    Cytotoxic activity against human A549 cells
    		[PMID: 28256841]
    A549 GI50
    0.2 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells after 48 hrs by sulforhodamine B assay
    Cytotoxicity against human A549 cells after 48 hrs by sulforhodamine B assay
    		[PMID: 29112820]
    A549 GI50
    0.27 μM
    Compound: Doxorubicin
    Antiproliferative activity against human A549 assessed as growth inhibition after 48 hrs by SRB assay
    Antiproliferative activity against human A549 assessed as growth inhibition after 48 hrs by SRB assay
    		[PMID: 21875046]
    A549 GI50
    0.6 μM
    Compound: Dox
    Cytotoxicity against human A549 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
    		[PMID: 34634616]
    A549 GI50
    0.66 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells after 72 hrs by SRB assay
    Cytotoxicity against human A549 cells after 72 hrs by SRB assay
    		[PMID: 21885166]
    A549 GI50
    0.97 μM
    Compound: Dox
    Anticancer activity against human A549 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    Anticancer activity against human A549 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    		[PMID: 35533562]
    A549 GI50
    1.1 μM
    Compound: Dox
    Antiproliferative activity against human A549 cells incubated for 72 hrs and measured by MTT assay
    Antiproliferative activity against human A549 cells incubated for 72 hrs and measured by MTT assay
    		[PMID: 35973342]
    A549 GI50
    1.15 μM
    Compound: Doxorubicin
    Antiproliferative activity against human A549 cells assessed as growth inhibition by MTT assay
    Antiproliferative activity against human A549 cells assessed as growth inhibition by MTT assay
    		[PMID: 39026636]
    A549 GI50
    1.21 μM
    Compound: Doxorubicin
    Antiproliferative activity against human A549 cells assessed as growth inhibition incubated for 48 hrs by MTT assay
    Antiproliferative activity against human A549 cells assessed as growth inhibition incubated for 48 hrs by MTT assay
    		[PMID: 31128433]
    A549 GI50
    1.9 μM
    Compound: Doxorubicin
    Anti-proliferative activity against human A549 cells incubated for 48 hrs by SRB assay
    Anti-proliferative activity against human A549 cells incubated for 48 hrs by SRB assay
    		[PMID: 26163220]
    A549 GI50
    13.01 μM
    Compound: ADR
    Anticancer activity against human A549 cells by SRB method
    Anticancer activity against human A549 cells by SRB method
    		[PMID: 22104151]
    A549 GI50
    47.6 nM
    Compound: 33
    Antiproliferative activity against human A549 cells expressing MCT1 assessed as growth inhibition incubated for 72 hrs by MTT assay
    Antiproliferative activity against human A549 cells expressing MCT1 assessed as growth inhibition incubated for 72 hrs by MTT assay
    		[PMID: 36584238]
    A549 GI50
    608 nM
    Compound: DOX
    Antiproliferative activity against human A549 cells assessed as growth inhibition incubated for 3 days
    Antiproliferative activity against human A549 cells assessed as growth inhibition incubated for 3 days
    		[PMID: 38599298]
    A549 GI50
    7.25 μM
    Compound: ADR
    Growth inhibition of human A549 cells
    Growth inhibition of human A549 cells
    		10.1039/C1MD00072A
    A549 GI50
    7.25 μM
    Compound: ADR
    Cytotoxicity against human A549 cells after 48 hrs by sulforhodamine B assay
    Cytotoxicity against human A549 cells after 48 hrs by sulforhodamine B assay
    		[PMID: 18657979]
    A549 GI50
    7.25 μM
    Compound: ADR
    Growth inhibition of human A549 cells after 48 hrs by SRB assay
    Growth inhibition of human A549 cells after 48 hrs by SRB assay
    		[PMID: 20031423]
    A549 GI50
    7.25 μM
    Compound: ADR
    Cytotoxicity against human A549 cells after 24 hrs by WST-1 assay
    Cytotoxicity against human A549 cells after 24 hrs by WST-1 assay
    		[PMID: 20732817]
    A549 GI50
    7.25 μM
    Compound: ADR
    Anticancer activity against human A549 cells by SRB method
    Anticancer activity against human A549 cells by SRB method
    		[PMID: 21676506]
    A549 GI50
    7.25 μM
    Compound: ADR
    Growth inhibition of human A549 cells by SRB assay
    Growth inhibition of human A549 cells by SRB assay
    		[PMID: 22361684]
    A549 GI50
    7.25 μM
    Compound: ADR
    Growth inhibition of human A549 cells after 48 hrs by sulforhodamine B assay
    Growth inhibition of human A549 cells after 48 hrs by sulforhodamine B assay
    		[PMID: 22364746]
    A549 GI50
    7.25 μM
    Compound: ADR
    Growth inhibition of human A549 cells after 48 hrs by sulforhodamine B assay
    Growth inhibition of human A549 cells after 48 hrs by sulforhodamine B assay
    		[PMID: 23849207]
    A549 GI50
    7.25 μM
    Compound: ADR, Adriamycin
    Growth inhibition of human A549 cells by SRB method
    Growth inhibition of human A549 cells by SRB method
    		[PMID: 18207392]
    A549 GI50
    7.25 μM
    Compound: adriamycin
    Cytotoxicity against human A549 cells after 24 hrs by SRB method
    Cytotoxicity against human A549 cells after 24 hrs by SRB method
    		[PMID: 18262426]
    A549 GI50
    8.14 μM
    Compound: Doxo
    Cytotoxicity against human A549 cells after 48 hrs by MTT assay
    Cytotoxicity against human A549 cells after 48 hrs by MTT assay
    		[PMID: 26513642]
    A549 GI50
    < 0.01 μM
    Compound: Doxorubicin
    Growth inhibition of human A549 cells after 48 hrs by SRB assay
    Growth inhibition of human A549 cells after 48 hrs by SRB assay
    		10.1039/C6MD00097E
    A549 GI50
    < 0.01 μM
    Compound: Doxorubicin
    Antiproliferative activity against human A549 cells after 48 hrs by SRB assay
    Antiproliferative activity against human A549 cells after 48 hrs by SRB assay
    		[PMID: 25827522]
    A549 GI50
    < 0.01 μM
    Compound: Doxorubicin
    Growth inhibition of human A549 cells after 48 hrs by SRB assay
    Growth inhibition of human A549 cells after 48 hrs by SRB assay
    		[PMID: 26067381]
    A549 GI50
    < 0.01 μM
    Compound: Doxorubicin
    Antiproliferative activity against human A549 cells after 48 hrs by SRB assay
    Antiproliferative activity against human A549 cells after 48 hrs by SRB assay
    		[PMID: 26994690]
    A549 GI50
    < 0.01 μM
    Compound: Doxorubicin
    Growth inhibition in human A549 cells after 48 hrs by SRB assay
    Growth inhibition in human A549 cells after 48 hrs by SRB assay
    		[PMID: 31546197]
    A549 GI50
    < 0.1 μM
    Compound: ADR
    Cytotoxicity against human A549 cells after 48 hrs by sulforhodamine B assay
    Cytotoxicity against human A549 cells after 48 hrs by sulforhodamine B assay
    		[PMID: 21737288]
    A549 GI50
    < 1 μM
    Compound: DOX
    Antiproliferative activity against human A549 cells by MTT assay
    Antiproliferative activity against human A549 cells by MTT assay
    		[PMID: 31990554]
    A549 GI50
    < 10 μM
    Compound: Doxorubicin
    Antiproliferative activity against human A549 cells assessed as cell growth inhibition by SRB assay
    Antiproliferative activity against human A549 cells assessed as cell growth inhibition by SRB assay
    		[PMID: 37875056]
    A549 GI50
    < 10 μg/mL
    Compound: ADR
    Cytotoxicity against human A549 cells
    Cytotoxicity against human A549 cells
    		[PMID: 21802797]
    A549 IC50
    0.001 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells by SRB assay
    Cytotoxicity against human A549 cells by SRB assay
    		[PMID: 22951040]
    A549 IC50
    0.0014 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells by sulforhodamine B bioassay
    Cytotoxicity against human A549 cells by sulforhodamine B bioassay
    		[PMID: 25098650]
    A549 IC50
    0.002 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells after 48 hrs by SRB assay
    Cytotoxicity against human A549 cells after 48 hrs by SRB assay
    		[PMID: 22483395]
    A549 IC50
    0.002 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells assessed as cell growth inhibition after 48 hrs by SRB assay
    Cytotoxicity against human A549 cells assessed as cell growth inhibition after 48 hrs by SRB assay
    		[PMID: 25466198]
    A549 IC50
    0.002 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by SRB assay
    Cytotoxicity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by SRB assay
    		[PMID: 25981688]
    A549 IC50
    0.002 μg/mL
    Compound: dox, doxorubicin
    Cytotoxicity against human A549 cells
    Cytotoxicity against human A549 cells
    		[PMID: 17618015]
    A549 IC50
    0.0031 μg/mL
    Compound: Doxorubicin
    In vitro inhibitory activity against A549 tumor cell culture
    In vitro inhibitory activity against A549 tumor cell culture
    		10.1016/S0960-894X(97)00191-1
    A549 IC50
    0.004 μM
    Compound: Doxorubicin
    Inhibitory activity against A549 cell line using MTT assay(Wild type p53)
    Inhibitory activity against A549 cell line using MTT assay(Wild type p53)
    		[PMID: 10780913]
    A549 IC50
    0.007 μM
    Compound: doxorubicin
    Cytotoxicity against human A549 cells by SRB assay
    Cytotoxicity against human A549 cells by SRB assay
    		[PMID: 19435339]
    A549 IC50
    0.009 μM
    Compound: Doxorubicin
    Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    		[PMID: 27010926]
    A549 IC50
    0.01 μM
    Compound: Adriamycin
    Cytotoxic activity against A-549 (Human lung carcinoma) cell line
    Cytotoxic activity against A-549 (Human lung carcinoma) cell line
    		[PMID: 15225700]
    A549 IC50
    0.01 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells by SRB assay
    Cytotoxicity against human A549 cells by SRB assay
    		[PMID: 20719504]
    A549 IC50
    0.015 μM
    Compound: DOX
    Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 27668963]
    A549 IC50
    0.01 μg/mL
    Compound: Adriamycin
    Antiproliferative activity against PLCgamma1 expressing human A549 cells
    Antiproliferative activity against PLCgamma1 expressing human A549 cells
    		[PMID: 10869194]
    A549 IC50
    0.01 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells by sulforhodamine B assay
    Cytotoxicity against human A549 cells by sulforhodamine B assay
    		[PMID: 21684168]
    A549 IC50
    0.02 μM
    Compound: 2
    Compound was evaluated for the cytotoxicity against A-549 tumor cell line after 3 days of incubation
    Compound was evaluated for the cytotoxicity against A-549 tumor cell line after 3 days of incubation
    		10.1016/S0960-894X(97)10122-6
    A549 IC50
    0.02 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells assessed as growth inhibition by SRB assay
    Cytotoxicity against human A549 cells assessed as growth inhibition by SRB assay
    		[PMID: 23634786]
    A549 IC50
    0.02 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells by sulforhodamine B assay
    Cytotoxicity against human A549 cells by sulforhodamine B assay
    		[PMID: 23815260]
    A549 IC50
    0.02 μM
    Compound: Doxorubicin
    Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation incubated for 72 hrs by conventional ATP quantification method
    Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation incubated for 72 hrs by conventional ATP quantification method
    		[PMID: 25937235]
    A549 IC50
    0.021 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells by SRB assay
    Cytotoxicity against human A549 cells by SRB assay
    		[PMID: 20594848]
    A549 IC50
    0.021 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells assessed as reduction in cell proliferation measured after 48 hrs by SRB assay
    Cytotoxicity against human A549 cells assessed as reduction in cell proliferation measured after 48 hrs by SRB assay
    		[PMID: 27856237]
    A549 IC50
    0.022 μM
    Compound: doxorubicin
    Cytotoxicity against human A549 cells after 3 days by SRB assay
    Cytotoxicity against human A549 cells after 3 days by SRB assay
    		[PMID: 18321715]
    A549 IC50
    0.023 μM
    Compound: DOX
    Cytotoxicity against human A549 cells incubated for 72 hrs by SRB assay
    Cytotoxicity against human A549 cells incubated for 72 hrs by SRB assay
    		[PMID: 38996651]
    A549 IC50
    0.025 μM
    Compound: adriamycin
    Cytotoxicity against human A549 cells after 72 hrs by SRB assay
    Cytotoxicity against human A549 cells after 72 hrs by SRB assay
    		[PMID: 19028425]
    A549 IC50
    0.025 μg/mL
    Compound: ADR
    Cytotoxicity against human A549 cells after 72 hrs by MTT assay
    Cytotoxicity against human A549 cells after 72 hrs by MTT assay
    		[PMID: 18590312]
    A549 IC50
    0.02 μg/mL
    Compound: doxorubicin
    Growth inhibition of A 549 cell line by MTT reduction for 7 days of incubation time
    Growth inhibition of A 549 cell line by MTT reduction for 7 days of incubation time
    		[PMID: 8496904]
    A549 IC50
    0.03 μM
    Compound: Doxorubicin
    Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation incubated for 72 hrs by conventional ATP quantification method
    Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation incubated for 72 hrs by conventional ATP quantification method
    		[PMID: 25937235]
    A549 IC50
    0.031 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells after 24 hrs by SRB method
    Cytotoxicity against human A549 cells after 24 hrs by SRB method
    		[PMID: 18429610]
    A549 IC50
    0.04 μM
    Compound: DOX
    Cytotoxicity against human A549 cells assessed as inhibition of cell growth measured after 96 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as inhibition of cell growth measured after 96 hrs by MTT assay
    		[PMID: 35255689]
    A549 IC50
    0.04 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 29275232]
    A549 IC50
    0.049 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells by SRB assay
    Cytotoxicity against human A549 cells by SRB assay
    		[PMID: 23544451]
    A549 IC50
    0.04 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells after 72 hrs by WST-8 assay
    Cytotoxicity against human A549 cells after 72 hrs by WST-8 assay
    		[PMID: 25534608]
    A549 IC50
    0.04 μg/mL
    Compound: adriamycin
    Cytotoxicity against human A549 cells by SRB assay
    Cytotoxicity against human A549 cells by SRB assay
    		[PMID: 15921426]
    A549 IC50
    0.04 μg/mL
    Compound: doxorubicin
    Anticancer activity against human A549 cells after 72 hrs by sulforhodamine B assay
    Anticancer activity against human A549 cells after 72 hrs by sulforhodamine B assay
    		[PMID: 19342127]
    A549 IC50
    0.053 μg/mL
    Compound: adriamycin
    Growth inhibition of A549 (human lung carcinoma) cell line.
    Growth inhibition of A549 (human lung carcinoma) cell line.
    		[PMID: 2002477]
    A549 IC50
    0.056 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells assessed as reduction in cell viability by CellTiter Glo luminescent assay
    Cytotoxicity against human A549 cells assessed as reduction in cell viability by CellTiter Glo luminescent assay
    		[PMID: 32755677]
    A549 IC50
    0.057 μg/mL
    Compound: Doxorubicin
    Antiproliferative activity against human A549 cells assessed as inhibition of cell viability by MTT assay
    Antiproliferative activity against human A549 cells assessed as inhibition of cell viability by MTT assay
    		[PMID: 32223924]
    A549 IC50
    0.059 μM
    Compound: Doxorubicin
    Anticancer activity against human A549 cells harboring KRAS mutant assessed as inhibition of cell growth
    Anticancer activity against human A549 cells harboring KRAS mutant assessed as inhibition of cell growth
    		[PMID: 38199330]
    A549 IC50
    0.05 μg/mL
    Compound: Doxorubicin
    Cytotoxic activity against A549 cell line (non-small cell lung carcinoma)
    Cytotoxic activity against A549 cell line (non-small cell lung carcinoma)
    		[PMID: 15922597]
    A549 IC50
    0.05 μg/mL
    Compound: doxorubicin
    Growth inhibition of A 549 cell line by MTT reduction for 3 days of incubation time
    Growth inhibition of A 549 cell line by MTT reduction for 3 days of incubation time
    		[PMID: 8496904]
    A549 IC50
    0.064 μM
    Compound: Doxorubicin
    Inhibitory concentration against A549 lung carcinoma cell line
    Inhibitory concentration against A549 lung carcinoma cell line
    		[PMID: 15715481]
    A549 IC50
    0.074 μM
    Compound: DOX
    Cytotoxicity against human A549 cells assessed as cell growth inhibition after 48 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as cell growth inhibition after 48 hrs by MTT assay
    		[PMID: 31999451]
    A549 IC50
    0.075 μM
    Compound: Doxorubicin
    Anticancer activity against human A549 cells by sulforhodamine B assay
    Anticancer activity against human A549 cells by sulforhodamine B assay
    		[PMID: 19819696]
    A549 IC50
    0.08 μM
    Compound: DOX
    Antiproliferative activity against human A549 cells after 72 hrs by SRB assay
    Antiproliferative activity against human A549 cells after 72 hrs by SRB assay
    		[PMID: 30106296]
    A549 IC50
    0.08 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells after 72 hrs by MTT assay
    Cytotoxicity against human A549 cells after 72 hrs by MTT assay
    		[PMID: 19361894]
    A549 IC50
    0.09 μM
    Compound: Dox
    Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay
    Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay
    		[PMID: 34116381]
    A549 IC50
    0.09 μM
    Compound: Doxorubicin
    Cytotoxicity against Homo sapiens (human) A549 cells after 72 hr by MTT assay
    Cytotoxicity against Homo sapiens (human) A549 cells after 72 hr by MTT assay
    		10.1007/s00044-010-9517-9
    A549 IC50
    0.09 μM
    Compound: Doxorubicin
    Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
    Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
    		[PMID: 27060757]
    A549 IC50
    0.092 μM
    Compound: Doxorubicin
    Antiproliferative activity against human A549 cells incubated for 72 hrs by sulforhodamine B assay
    Antiproliferative activity against human A549 cells incubated for 72 hrs by sulforhodamine B assay
    		[PMID: 32432867]
    A549 IC50
    0.1 μM
    Compound: DOX
    Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction)
    Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction)
    		10.1016/S0960-894X(01)81264-6
    A549 IC50
    0.1 μM
    Compound: Doxorubicin
    Antiproliferative activity against human A549 cells after 72 hrs by SRB assay
    Antiproliferative activity against human A549 cells after 72 hrs by SRB assay
    		[PMID: 18063366]
    A549 IC50
    0.1 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells after 72 hrs by CCK8 assay
    Cytotoxicity against human A549 cells after 72 hrs by CCK8 assay
    		[PMID: 28398051]
    A549 IC50
    0.1 μM
    Compound: doxorubicin
    Cytotoxicity against human A549 cells after 24 hrs by MTT assay
    Cytotoxicity against human A549 cells after 24 hrs by MTT assay
    		[PMID: 24050254]
    A549 IC50
    0.11 μM
    Compound: DOX
    Cytotoxicity against human A549 cells measured after 72 hrs by Celltiter-Glo assay
    Cytotoxicity against human A549 cells measured after 72 hrs by Celltiter-Glo assay
    		[PMID: 31820976]
    A549 IC50
    0.118 μM
    Compound: Doxorubicin
    Anticancer activity against human A549 cells after 48 hrs by SRB assay
    Anticancer activity against human A549 cells after 48 hrs by SRB assay
    		[PMID: 17070967]
    A549 IC50
    0.12 μM
    Compound: Adriamycin
    In vitro antitumor activity against A549 (lung) human tumor cell lines.
    In vitro antitumor activity against A549 (lung) human tumor cell lines.
    		10.1016/0960-894X(96)00167-9
    A549 IC50
    0.12 μM
    Compound: Doxorubicin
    Antiproliferative activity against human A549 cells after 72 hrs by MTT assay
    Antiproliferative activity against human A549 cells after 72 hrs by MTT assay
    		[PMID: 27886545]
    A549 IC50
    0.12 μM
    Compound: doxorubicin
    Cytotoxicity against human A549 cells after 48 hrs
    Cytotoxicity against human A549 cells after 48 hrs
    		[PMID: 17673337]
    A549 IC50
    0.124 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells after 72 hrs by MTT assay
    Cytotoxicity against human A549 cells after 72 hrs by MTT assay
    		[PMID: 25462279]
    A549 IC50
    0.124 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells by SRB assay
    Cytotoxicity against human A549 cells by SRB assay
    		[PMID: 28139925]
    A549 IC50
    0.13 μM
    Compound: DOX
    Antiproliferative activity against human A549 cells after 48 hrs by SRB assay
    Antiproliferative activity against human A549 cells after 48 hrs by SRB assay
    		[PMID: 30106296]
    A549 IC50
    0.13 μM
    Compound: Doxorubicin
    Cytotoxicity activity against human A549 cells incubated for 48 hrs by SRB assay
    Cytotoxicity activity against human A549 cells incubated for 48 hrs by SRB assay
    		[PMID: 34119830]
    A549 IC50
    0.132 μM
    Compound: Dox
    Cytotoxicity against human A549 cells incubated for 72 hrs by MTT assay
    Cytotoxicity against human A549 cells incubated for 72 hrs by MTT assay
    		[PMID: 39149093]
    A549 IC50
    0.14 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells assessed as growth inhibition incubated for 72 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as growth inhibition incubated for 72 hrs by MTT assay
    		[PMID: 26280922]
    A549 IC50
    0.14 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells by MTT assay
    Cytotoxicity against human A549 cells by MTT assay
    		[PMID: 26873414]
    A549 IC50
    0.14 μM
    Compound: Doxorubicin
    Anticancer activity against human A549 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    Anticancer activity against human A549 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    		[PMID: 35694689]
    A549 IC50
    0.15 μM
    Compound: doxorubicin
    Cytotoxicity against human A549 cells by SRB assay
    Cytotoxicity against human A549 cells by SRB assay
    		[PMID: 17194596]
    A549 IC50
    0.16 μM
    Compound: Adriamycin
    Cytotoxicity against human A549 cells after 24 hrs by SRB assay
    Cytotoxicity against human A549 cells after 24 hrs by SRB assay
    		[PMID: 24370114]
    A549 IC50
    0.16 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells by SRB assay
    Cytotoxicity against human A549 cells by SRB assay
    		[PMID: 20176479]
    A549 IC50
    0.17 μM
    Compound: Adriamycin
    Cytotoxicity against human A549 cells after 72 hrs by SRB assay
    Cytotoxicity against human A549 cells after 72 hrs by SRB assay
    		[PMID: 20593838]
    A549 IC50
    0.17 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
    		[PMID: 30902399]
    A549 IC50
    0.17 μM
    Compound: doxorubicin
    Cytotoxicity against human A549 cells after 6 days by MTT method
    Cytotoxicity against human A549 cells after 6 days by MTT method
    		[PMID: 16309317]
    A549 IC50
    0.18 μM
    Compound: doxorubicin
    Cytotoxicity against human A549 cells by SRB microtiter plate assay
    Cytotoxicity against human A549 cells by SRB microtiter plate assay
    		[PMID: 17585747]
    A549 IC50
    0.19 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells after 24 hrs by XTT assay
    Cytotoxicity against human A549 cells after 24 hrs by XTT assay
    		[PMID: 27227682]
    A549 IC50
    0.19 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells after 3 days by MTT assay
    Cytotoxicity against human A549 cells after 3 days by MTT assay
    		[PMID: 15387653]
    A549 IC50
    0.1 μg/mL
    Compound: doxorubicin
    Cytotoxicity against human A549 cells after 2 days by sulforhodamine B assay
    Cytotoxicity against human A549 cells after 2 days by sulforhodamine B assay
    		[PMID: 17067159]
    A549 IC50
    0.2 μM
    Compound: adriamycin
    Cytotoxicity against human A549 cells by MTT assay
    Cytotoxicity against human A549 cells by MTT assay
    		[PMID: 17190442]
    A549 IC50
    0.21 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells after 24 hrs by MTS assay
    Cytotoxicity against human A549 cells after 24 hrs by MTS assay
    		[PMID: 30289713]
    A549 IC50
    0.22 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells after 96 hrs by MTT assay
    Cytotoxicity against human A549 cells after 96 hrs by MTT assay
    		[PMID: 24852278]
    A549 IC50
    0.22 μM
    Compound: Doxorubicin
    Antiproliferative activity against human A549 cells by MTT reduction assay
    Antiproliferative activity against human A549 cells by MTT reduction assay
    		[PMID: 33421712]
    A549 IC50
    0.223 μM
    Compound: Doxorubicin
    Antiproliferative activity against human A549 cells incubated for 24 hrs by MTT assay
    Antiproliferative activity against human A549 cells incubated for 24 hrs by MTT assay
    		[PMID: 29409753]
    A549 IC50
    0.23 μM
    Compound: Doxo
    Cytotoxicity against human A549 cells assessed as inhibition of cell proliferation after 24 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as inhibition of cell proliferation after 24 hrs by MTT assay
    		[PMID: 27036521]
    A549 IC50
    0.23 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    		[PMID: 37216812]
    A549 IC50
    0.24 μM
    Compound: Doxorubicin
    Antiproliferative activity against human A549 cells incubated for 48 hrs by WST8 assay
    Antiproliferative activity against human A549 cells incubated for 48 hrs by WST8 assay
    		[PMID: 31679979]
    A549 IC50
    0.24 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
    		[PMID: 37951135]
    A549 IC50
    0.258 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells after 48 hrs by MTT assay
    Cytotoxicity against human A549 cells after 48 hrs by MTT assay
    		[PMID: 25019480]
    A549 IC50
    0.26 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells
    Cytotoxicity against human A549 cells
    		[PMID: 23511021]
    A549 IC50
    0.27 μg/mL
    Compound: Doxorubicin
    Cytotoxic activity against human A549 cells by MTT assay
    Cytotoxic activity against human A549 cells by MTT assay
    		[PMID: 28366267]
    A549 IC50
    0.29 μM
    Compound: DOX
    Antiproliferative activity against cis-platinum-resistant human A549 cells after 48 hrs by SRB method
    Antiproliferative activity against cis-platinum-resistant human A549 cells after 48 hrs by SRB method
    		[PMID: 25061803]
    A549 IC50
    0.29 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells after 72 hrs by XTT assay
    Cytotoxicity against human A549 cells after 72 hrs by XTT assay
    		[PMID: 19647439]
    A549 IC50
    0.2 μg/mL
    Compound: Adriamycin
    Inhibitory concentration required against A 549 lung cancer cell line
    Inhibitory concentration required against A 549 lung cancer cell line
    		[PMID: 11354370]
    A549 IC50
    0.2 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells by MTT colorimetric method
    Cytotoxicity against human A549 cells by MTT colorimetric method
    		[PMID: 17125220]
    A549 IC50
    0.2 μg/mL
    Compound: doxorubicin
    Cytotoxicity against human A549 cells by MTT assay
    Cytotoxicity against human A549 cells by MTT assay
    		[PMID: 18973388]
    A549 IC50
    0.3 μM
    Compound: Doxorubicin
    In vitro cytotoxicity against human A549 (lung cancer) cell line.
    In vitro cytotoxicity against human A549 (lung cancer) cell line.
    		[PMID: 15177438]
    A549 IC50
    0.32 μM
    Compound: DOX
    Antiproliferative activity against human A549 cells assessed as inhibition of cell growth after 48 hrs by MTT assay
    Antiproliferative activity against human A549 cells assessed as inhibition of cell growth after 48 hrs by MTT assay
    		[PMID: 25737400]
    A549 IC50
    0.32 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells
    Cytotoxicity against human A549 cells
    		[PMID: 20036537]
    A549 IC50
    0.33 μM
    Compound: Doxorubicin
    Antiproliferative activity against human A549 cells after 72 hrs by sulforhodamine B assay
    Antiproliferative activity against human A549 cells after 72 hrs by sulforhodamine B assay
    		[PMID: 26496013]
    A549 IC50
    0.33 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells after 48 hrs by SRB assay
    Cytotoxicity against human A549 cells after 48 hrs by SRB assay
    		[PMID: 20732814]
    A549 IC50
    0.34 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    		[PMID: 30389295]
    A549 IC50
    0.34 μM
    Compound: doxorubicin
    Cytotoxicity against human A549 cells by MTT assay
    Cytotoxicity against human A549 cells by MTT assay
    		[PMID: 21174408]
    A549 IC50
    0.35 μM
    Compound: ADR
    Cytotoxicity against human A549 cells
    Cytotoxicity against human A549 cells
    		[PMID: 24128115]
    A549 IC50
    0.35 μM
    Compound: Doxorubicin
    Anticancer activity against human A549 cells assessed as inhibition of cell growth measured after 72 hrs by SRB assay
    Anticancer activity against human A549 cells assessed as inhibition of cell growth measured after 72 hrs by SRB assay
    		[PMID: 33940466]
    A549 IC50
    0.35 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells after 3 days by MTT assay
    Cytotoxicity against human A549 cells after 3 days by MTT assay
    		[PMID: 19691312]
    A549 IC50
    0.36 μM
    Compound: Doxorubicin
    Anticancer activity against human A549 cells after 48 hrs by MTT assay
    Anticancer activity against human A549 cells after 48 hrs by MTT assay
    		[PMID: 21641694]
    A549 IC50
    0.36 μM
    Compound: Doxorubucin
    Cytotoxicity against human A549 cells by MTT assay
    Cytotoxicity against human A549 cells by MTT assay
    		[PMID: 20718475]
    A549 IC50
    0.36 μM
    Compound: doxorubicin
    Cytotoxicity against human A549 cells after 72 hrs by MTT colorimetric method
    Cytotoxicity against human A549 cells after 72 hrs by MTT colorimetric method
    		[PMID: 17622129]
    A549 IC50
    0.37 μM
    Compound: DOX
    Cytotoxicity against human A549 cells expressing high level of topoisomerase I/II measured after 72 hrs by MTT assay
    Cytotoxicity against human A549 cells expressing high level of topoisomerase I/II measured after 72 hrs by MTT assay
    		[PMID: 35612499]
    A549 IC50
    0.37 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells after 48 hrs by MTT assay
    Cytotoxicity against human A549 cells after 48 hrs by MTT assay
    		[PMID: 26397393]
    A549 IC50
    0.38 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against Homo sapiens (human) A549 cells assessed as survival after 3 days by crystal violet staining
    Cytotoxicity against Homo sapiens (human) A549 cells assessed as survival after 3 days by crystal violet staining
    		10.1007/s00044-012-0025-y
    A549 IC50
    0.39 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against Homo sapiens (human) A549 cells after 3 days by MTT assay
    Cytotoxicity against Homo sapiens (human) A549 cells after 3 days by MTT assay
    		10.1007/s00044-011-9903-y
    A549 IC50
    0.4 μM
    Compound: Doxo
    Cytotoxicity against human A549 cells after 72 hrs by MTT assay
    Cytotoxicity against human A549 cells after 72 hrs by MTT assay
    		[PMID: 20334960]
    A549 IC50
    0.4 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells after 3 days by MTT assay
    Cytotoxicity against human A549 cells after 3 days by MTT assay
    		[PMID: 18547115]
    A549 IC50
    0.4 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells by Alamar Blue assay
    Cytotoxicity against human A549 cells by Alamar Blue assay
    		[PMID: 27536968]
    A549 IC50
    0.4 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells after 72 hrs by MTT assay
    Cytotoxicity against human A549 cells after 72 hrs by MTT assay
    		[PMID: 28927795]
    A549 IC50
    0.4 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells after 72 hrs by CCK8 assay
    Cytotoxicity against human A549 cells after 72 hrs by CCK8 assay
    		[PMID: 30869892]
    A549 IC50
    0.4 μM
    Compound: doxorubicin
    Cytotoxicity against human A549 cells after 4 days by MTT assay
    Cytotoxicity against human A549 cells after 4 days by MTT assay
    		[PMID: 19824618]
    A549 IC50
    0.41 μM
    Compound: Adriamycin
    Cytotoxicity against human A549 cells by MTT assay
    Cytotoxicity against human A549 cells by MTT assay
    		[PMID: 23548547]
    A549 IC50
    0.411 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells after 72 hrs by SRB assay
    Cytotoxicity against human A549 cells after 72 hrs by SRB assay
    		[PMID: 24231309]
    A549 IC50
    0.414 μM
    Compound: Adriamycin
    Cytotoxicity against human A549 cells by SRB assay
    Cytotoxicity against human A549 cells by SRB assay
    		[PMID: 25497963]
    A549 IC50
    0.42 μM
    Compound: DOX
    Antiproliferative activity against human A549 cells assessed as inhibition of cell viability incubated for 72 hrs by MTT assay
    Antiproliferative activity against human A549 cells assessed as inhibition of cell viability incubated for 72 hrs by MTT assay
    		[PMID: 35818137]
    A549 IC50
    0.42 μg/mL
    Compound: doxo
    Cytotoxicity against human A549 cells by MTT method
    Cytotoxicity against human A549 cells by MTT method
    		[PMID: 17417907]
    A549 IC50
    0.43 μM
    Compound: DOX
    Antiproliferative activity against human A549 cells after 72 hrs by CCK-8 assay
    Antiproliferative activity against human A549 cells after 72 hrs by CCK-8 assay
    		[PMID: 29597166]
    A549 IC50
    0.44 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells after 48 hrs by MTT assay
    Cytotoxicity against human A549 cells after 48 hrs by MTT assay
    		[PMID: 24836071]
    A549 IC50
    0.44 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    		[PMID: 25078311]
    A549 IC50
    0.44 μM
    Compound: doxorubicin
    Cytotoxicity against human A549 cells after 48 hrs by MTT assay
    Cytotoxicity against human A549 cells after 48 hrs by MTT assay
    		10.1007/s00044-013-0777-z
    A549 IC50
    0.45 μM
    Compound: Doxorubicin
    Antiproliferative activity against human A549 cells assessed as cell viability after 48 hrs by SRB assay
    Antiproliferative activity against human A549 cells assessed as cell viability after 48 hrs by SRB assay
    		[PMID: 26947606]
    A549 IC50
    0.459 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells after 2 days by MTT assay
    Cytotoxicity against human A549 cells after 2 days by MTT assay
    		[PMID: 23932340]
    A549 IC50
    0.459 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells by MTT assay
    Cytotoxicity against human A549 cells by MTT assay
    		[PMID: 24287557]
    A549 IC50
    0.46 μM
    Compound: Doxorubicin
    In vitro cytotoxicity against human A549 cells assessed as growth inhibition by MTT assay
    In vitro cytotoxicity against human A549 cells assessed as growth inhibition by MTT assay
    		[PMID: 24742385]
    A549 IC50
    0.47 μM
    Compound: Doxorubicin
    Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    		[PMID: 31704206]
    A549 IC50
    0.477 μM
    Compound: Dox
    Cytotoxicity against human A549 cells by MTT assay
    Cytotoxicity against human A549 cells by MTT assay
    		[PMID: 21983438]
    A549 IC50
    0.477 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells after 48 hrs by sulforhodamine B assay
    Cytotoxicity against human A549 cells after 48 hrs by sulforhodamine B assay
    		10.1039/C0MD00219D
    A549 IC50
    0.477 μM
    Compound: Doxorubicin
    Anticancer activity against human A549 cells by MTT assay
    Anticancer activity against human A549 cells by MTT assay
    		[PMID: 21570750]
    A549 IC50
    0.48 μM
    Compound: DOX
    Antiproliferative activity against human A549 cells after 24 hrs by SRB assay
    Antiproliferative activity against human A549 cells after 24 hrs by SRB assay
    		[PMID: 30106296]
    A549 IC50
    0.48 μM
    Compound: DOX
    Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by CCK8 assay
    Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by CCK8 assay
    		[PMID: 30576904]
    A549 IC50
    0.48 μM
    Compound: DOX
    Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK8 assay
    Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK8 assay
    		[PMID: 31671309]
    A549 IC50
    0.48 μM
    Compound: Doxorubicin
    Antiproliferative activity against human A549 cells after 48 hrs by CCK-8 assay
    Antiproliferative activity against human A549 cells after 48 hrs by CCK-8 assay
    		[PMID: 30253344]
    A549 IC50
    0.4 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells by MTT assay
    Cytotoxicity against human A549 cells by MTT assay
    		[PMID: 16724859]
    A549 IC50
    0.5 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells assessed as growth inhibition by SRB assay
    Cytotoxicity against human A549 cells assessed as growth inhibition by SRB assay
    		[PMID: 23664877]
    A549 IC50
    0.5 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 27015002]
    A549 IC50
    0.5 μM
    Compound: Doxorubicin
    Antiproliferative activity against human A549 cells measured after 48 hrs by MTT assay
    Antiproliferative activity against human A549 cells measured after 48 hrs by MTT assay
    		[PMID: 31148449]
    A549 IC50
    0.51 μM
    Compound: Adriamycin
    Cytotoxicity against human A549 cells assessed as growth inhibition after 48 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as growth inhibition after 48 hrs by MTT assay
    		[PMID: 26356746]
    A549 IC50
    0.51 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells after 48 hrs by MTT assay
    Cytotoxicity against human A549 cells after 48 hrs by MTT assay
    		[PMID: 21708464]
    A549 IC50
    0.52 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells after 48 hrs by sulforhodamine B assay
    Cytotoxicity against human A549 cells after 48 hrs by sulforhodamine B assay
    		[PMID: 21071221]
    A549 IC50
    0.52 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells by MTT assay
    Cytotoxicity against human A549 cells by MTT assay
    		[PMID: 18590313]
    A549 IC50
    0.53 μM
    Compound: DOX
    Antiproliferative activity against human A549 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay
    Antiproliferative activity against human A549 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay
    		[PMID: 37602711]
    A549 IC50
    0.53 μM
    Compound: Doxorubicin
    Cytotoxicity in human A549 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    Cytotoxicity in human A549 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    		[PMID: 28923382]
    A549 IC50
    0.54 μM
    Compound: Adriamycin
    Cytotoxicity against human A549 cells by MTT assay
    Cytotoxicity against human A549 cells by MTT assay
    		[PMID: 23434227]
    A549 IC50
    0.54 μg/mL
    Compound: Doxorubicin
    Anticancer activity against human A549 cells by MTT assay
    Anticancer activity against human A549 cells by MTT assay
    		[PMID: 31404864]
    A549 IC50
    0.55 μM
    Compound: Dox
    Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 30615450]
    A549 IC50
    0.55 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells by Alamar blue assay
    Cytotoxicity against human A549 cells by Alamar blue assay
    		[PMID: 27256910]
    A549 IC50
    0.55 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells after 72 hrs by alamar blue assay
    Cytotoxicity against human A549 cells after 72 hrs by alamar blue assay
    		[PMID: 28159416]
    A549 IC50
    0.55 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells after 24 hrs by MTT assay
    Cytotoxicity against human A549 cells after 24 hrs by MTT assay
    		[PMID: 30654238]
    A549 IC50
    0.56 μM
    Compound: ADM
    Cytotoxicity against human A549 cells after 72 hrs by sulforhodamine B assay
    Cytotoxicity against human A549 cells after 72 hrs by sulforhodamine B assay
    		[PMID: 23639650]
    A549 IC50
    0.57 μM
    Compound: Dox
    Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    		[PMID: 37956506]
    A549 IC50
    0.58 μM
    Compound: DOX
    Cytotoxicity against human A549 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay
    		[PMID: 31820976]
    A549 IC50
    0.59 μM
    Compound: DOX
    Antiproliferative activity against human A549 cells assessed as cell growth inhibition after 72 hrs by MTT assay
    Antiproliferative activity against human A549 cells assessed as cell growth inhibition after 72 hrs by MTT assay
    		[PMID: 33276990]
    A549 IC50
    0.59 μM
    Compound: Doxo
    Cytotoxicity against human A549 cells after 3 days by MTT assay
    Cytotoxicity against human A549 cells after 3 days by MTT assay
    		[PMID: 21800859]
    A549 IC50
    0.5 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
    		[PMID: 35526504]
    A549 IC50
    0.6 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells by MTT assay
    Cytotoxicity against human A549 cells by MTT assay
    		[PMID: 25172418]
    A549 IC50
    0.6 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    		[PMID: 29702447]
    A549 IC50
    0.6 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells by MTT assay
    Cytotoxicity against human A549 cells by MTT assay
    		[PMID: 29975532]
    A549 IC50
    0.6 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by CCK-8 assay
    Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by CCK-8 assay
    		[PMID: 36693198]
    A549 IC50
    0.63 μM
    Compound: DOX
    Antiproliferative activity against human A549 cells after 72 hrs by CCK-8 assay
    Antiproliferative activity against human A549 cells after 72 hrs by CCK-8 assay
    		[PMID: 29614418]
    A549 IC50
    0.63 μM
    Compound: Dox
    Cytotoxicity activity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity activity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 30031974]
    A549 IC50
    0.63 μM
    Compound: Doxorubicin
    Antiproliferative activity against human A549 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay
    Antiproliferative activity against human A549 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay
    		[PMID: 31884407]
    A549 IC50
    0.63 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells by MTT assay
    Cytotoxicity against human A549 cells by MTT assay
    		[PMID: 21106454]
    A549 IC50
    0.665 μg/mL
    Compound: E; DOX
    Antiproliferative activity against human A549 cells measured after 48 hrs by MTT assay
    Antiproliferative activity against human A549 cells measured after 48 hrs by MTT assay
    		[PMID: 35963130]
    A549 IC50
    0.69 μM
    Compound: ADM
    Cytotoxicity against human A549 cells assessed as inhibition of cell growth after 72 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as inhibition of cell growth after 72 hrs by MTT assay
    		[PMID: 25089733]
    A549 IC50
    0.69 μM
    Compound: adriamycin
    Cytotoxicity against human A549 cells assessed as cell growth inhibition after 72 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as cell growth inhibition after 72 hrs by MTT assay
    		[PMID: 26295905]
    A549 IC50
    0.7 μM
    Compound: Dox
    Cytotoxicity against human A549 cells after 48 hrs by MTT assay
    Cytotoxicity against human A549 cells after 48 hrs by MTT assay
    		[PMID: 28865276]
    A549 IC50
    0.7 μM
    Compound: Doxorubicin
    Cytotoxicity against Homo sapiens (human) A549 cells by MTT assay
    Cytotoxicity against Homo sapiens (human) A549 cells by MTT assay
    		10.1007/s00044-012-0370-x
    A549 IC50
    0.7 μM
    Compound: Doxorubicin
    Cytotoxicity against Homo sapiens (human) A549 cells assessed as inhibition of cell growth after 3 days by MTT assay
    Cytotoxicity against Homo sapiens (human) A549 cells assessed as inhibition of cell growth after 3 days by MTT assay
    		10.1007/s00044-012-0402-6
    A549 IC50
    0.7 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells by MTT assay
    Cytotoxicity against human A549 cells by MTT assay
    		[PMID: 24300737]
    A549 IC50
    0.7 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells assessed as reduction in cell viability after 24 hrs by CCK8 assay
    Cytotoxicity against human A549 cells assessed as reduction in cell viability after 24 hrs by CCK8 assay
    		[PMID: 32324401]
    A549 IC50
    0.7 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells assessed as number of viable cells measured after 48 hrs by MTT based colorimetric assay
    Cytotoxicity against human A549 cells assessed as number of viable cells measured after 48 hrs by MTT based colorimetric assay
    		[PMID: 36970146]
    A549 IC50
    0.7 μM
    Compound: Doxorubicine
    Cytotoxicity against human A549 cells by MTT assay
    Cytotoxicity against human A549 cells by MTT assay
    		[PMID: 22014995]
    A549 IC50
    0.72 μM
    Compound: Adriamycin
    Cytotoxicity against human A549 cells by MTT assay
    Cytotoxicity against human A549 cells by MTT assay
    		[PMID: 22070654]
    A549 IC50
    0.72 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells after 72 hrs by MTT assay
    Cytotoxicity against human A549 cells after 72 hrs by MTT assay
    		[PMID: 19406535]
    A549 IC50
    0.73 μM
    Compound: Doxo
    Cytotoxicity against human A549 cells assessed as cell viability after 48 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as cell viability after 48 hrs by MTT assay
    		10.1039/C2MD20302B
    A549 IC50
    0.73 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells assessed as cell viability after 72 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as cell viability after 72 hrs by MTT assay
    		[PMID: 23992864]
    A549 IC50
    0.74 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells assessed as reduction in cell viability after 46 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as reduction in cell viability after 46 hrs by MTT assay
    		[PMID: 29138027]
    A549 IC50
    0.74 μM
    Compound: doxorubicin
    Cytotoxicity against human A549 cells assessed as growth inhibition after 48 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as growth inhibition after 48 hrs by MTT assay
    		[PMID: 23806110]
    A549 IC50
    0.75 μM
    Compound: adriamycin
    Cytotoxicity against human A549 cells after 48 hrs
    Cytotoxicity against human A549 cells after 48 hrs
    		[PMID: 17583953]
    A549 IC50
    0.76 μM
    Compound: Dox
    Cytotoxicity against human A549 cells assessed as inhibition of cell growth after 48 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as inhibition of cell growth after 48 hrs by MTT assay
    		[PMID: 27397495]
    A549 IC50
    0.766 μM
    Compound: Dox
    Cytotoxicity against human A549 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay
    		[PMID: 30599418]
    A549 IC50
    0.79 μg/mL
    Compound: doxorubicin
    Cytotoxicity against human A549 cells after 3 days by MTT assay
    Cytotoxicity against human A549 cells after 3 days by MTT assay
    		[PMID: 16252914]
    A549 IC50
    0.8 μM
    Compound: ADM
    Cytotoxic activity against human A549 cells by SRB method
    Cytotoxic activity against human A549 cells by SRB method
    		[PMID: 25611519]
    A549 IC50
    0.8 μM
    Compound: ADM
    Cytotoxicity against human A549 cells by SRB method
    Cytotoxicity against human A549 cells by SRB method
    		[PMID: 29144133]
    A549 IC50
    0.8 μM
    Compound: Dox
    Cytotoxicity against human A549 cells assessed as growth inhibition after 24 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as growth inhibition after 24 hrs by MTT assay
    		[PMID: 24507927]
    A549 IC50
    0.8 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells after 72 hrs by MTT assay
    Cytotoxicity against human A549 cells after 72 hrs by MTT assay
    		[PMID: 21035234]
    A549 IC50
    0.8 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells assessed as growth inhibition after 24 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as growth inhibition after 24 hrs by MTT assay
    		[PMID: 24780595]
    A549 IC50
    0.8 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells by MTT assay
    Cytotoxicity against human A549 cells by MTT assay
    		[PMID: 25241926]
    A549 IC50
    0.8 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells after 24 hrs by MTT assay
    Cytotoxicity against human A549 cells after 24 hrs by MTT assay
    		[PMID: 26252628]
    A549 IC50
    0.8 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 26551342]
    A549 IC50
    0.8 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells assessed as reduction in cell viability by MTT assay
    Cytotoxicity against human A549 cells assessed as reduction in cell viability by MTT assay
    		[PMID: 26646219]
    A549 IC50
    0.8 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells assessed as reduction in cell viability by MTT assay
    Cytotoxicity against human A549 cells assessed as reduction in cell viability by MTT assay
    		[PMID: 26774921]
    A549 IC50
    0.8 μM
    Compound: Doxorubicin
    Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
    Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
    		[PMID: 30679134]
    A549 IC50
    0.8 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells assessed as cell growth inhibition
    Cytotoxicity against human A549 cells assessed as cell growth inhibition
    		[PMID: 36092140]
    A549 IC50
    0.82 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells assessed as reduction in cell viability by MTT assay
    Cytotoxicity against human A549 cells assessed as reduction in cell viability by MTT assay
    		[PMID: 31404864]
    A549 IC50
    0.837 μM
    Compound: doxorubicin
    Cytotoxicity against human A549 cells after 72 hrs by MTT assay
    Cytotoxicity against human A549 cells after 72 hrs by MTT assay
    		[PMID: 19860383]
    A549 IC50
    0.84 μM
    Compound: Doxorubicin
    Antitumor activity against Homo sapiens (human) A549 cells assessed as cell growth inhibition after 48 hr by MTT assay
    Antitumor activity against Homo sapiens (human) A549 cells assessed as cell growth inhibition after 48 hr by MTT assay
    		10.1007/s00044-013-0497-4
    A549 IC50
    0.84 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells after 72 hrs by MTT assay
    Cytotoxicity against human A549 cells after 72 hrs by MTT assay
    		[PMID: 19689125]
    A549 IC50
    0.86 μM
    Compound: DOX
    Cytotoxicity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 assay
    Cytotoxicity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 assay
    		[PMID: 38039790]
    A549 IC50
    0.86 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells by WST-8 assay
    Cytotoxicity against human A549 cells by WST-8 assay
    		[PMID: 29295796]
    A549 IC50
    0.86 μM
    Compound: doxorubicin
    Cytotoxicity against human A549 cells after 3 days by MTT assay
    Cytotoxicity against human A549 cells after 3 days by MTT assay
    		[PMID: 18419154]
    A549 IC50
    0.87 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells after 72 hrs by MTT assay
    Cytotoxicity against human A549 cells after 72 hrs by MTT assay
    		[PMID: 25419616]
    A549 IC50
    0.89 μM
    Compound: Doxorubicin
    Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
    Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
    		[PMID: 28554092]
    A549 IC50
    0.89 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells assessed as reduction in cell viability after 4 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as reduction in cell viability after 4 hrs by MTT assay
    		[PMID: 30773423]
    A549 IC50
    0.9 μM
    Compound: DOX
    Cytotoxicity against human A549 cells assessed as reduction in cell viability by MTT assay
    Cytotoxicity against human A549 cells assessed as reduction in cell viability by MTT assay
    		[PMID: 34323485]
    A549 IC50
    0.9 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells by MTT assay
    Cytotoxicity against human A549 cells by MTT assay
    		10.1039/C3MD00166K
    A549 IC50
    0.91 μM
    Compound: Dox
    Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
    Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
    		[PMID: 35339100]
    A549 IC50
    0.95 μM
    Compound: DOX
    Cytotoxicity against human A549 cells assessed as growth inhibition after 72 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as growth inhibition after 72 hrs by MTT assay
    		[PMID: 27016707]
    A549 IC50
    0.95 μM
    Compound: DOX
    Antiproliferative activity against human A549 cells assessed as reduction in cell growth measured after 72 hrs by CCK8 assay
    Antiproliferative activity against human A549 cells assessed as reduction in cell growth measured after 72 hrs by CCK8 assay
    		[PMID: 31784322]
    A549 IC50
    0.95 μM
    Compound: DOXO
    Cytotoxicity against human A549 cells assessed as cell viability after 48 hrs by alamar blue assay
    Cytotoxicity against human A549 cells assessed as cell viability after 48 hrs by alamar blue assay
    		[PMID: 21797280]
    A549 IC50
    0.95 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells after 48 hrs by Alamar blue assay
    Cytotoxicity against human A549 cells after 48 hrs by Alamar blue assay
    		[PMID: 20931970]
    A549 IC50
    0.96 μM
    Compound: Doxorubicin
    Anticancer activity against human A549 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay
    Anticancer activity against human A549 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay
    		[PMID: 32438251]
    A549 IC50
    0.97 μM
    Compound: Doxorubicin
    Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay.
    Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay.
    		[PMID: 14643344]
    A549 IC50
    0.97 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells
    Cytotoxicity against human A549 cells
    		[PMID: 21095131]
    A549 IC50
    0.97 μM
    Compound: Doxorubicin
    Cytotoxicity activity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Cytotoxicity activity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    		[PMID: 32531682]
    A549 IC50
    0.97 μM
    Compound: doxorubicin
    Cytotoxicity against human A549 cells by SRB assay
    Cytotoxicity against human A549 cells by SRB assay
    		[PMID: 17827007]
    A549 IC50
    0.98 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells by MTT assay
    Cytotoxicity against human A549 cells by MTT assay
    		[PMID: 25747499]
    A549 IC50
    1 μM
    Compound: DOX
    Antiproliferative activity against human A549 cells assessed as growth inhibition after 48 hrs by MTT assay
    Antiproliferative activity against human A549 cells assessed as growth inhibition after 48 hrs by MTT assay
    		[PMID: 22044164]
    A549 IC50
    1 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells by MTT assay
    Cytotoxicity against human A549 cells by MTT assay
    		[PMID: 21996519]
    A549 IC50
    1 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells by MTT assay
    Cytotoxicity against human A549 cells by MTT assay
    		[PMID: 23079527]
    A549 IC50
    1 μM
    Compound: Doxorubicin
    Antiproliferative activity against human A549 cells after 24 hrs by BrdU incorporation assay
    Antiproliferative activity against human A549 cells after 24 hrs by BrdU incorporation assay
    		[PMID: 27555286]
    A549 IC50
    1 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells assessed as reduction in cell viability by MTT assay
    Cytotoxicity against human A549 cells assessed as reduction in cell viability by MTT assay
    		[PMID: 32915576]
    A549 IC50
    1.01 μM
    Compound: Doxorubicin
    Anticancer activity against human A549 cells assessed as growth inhibition incubated for 48 hrs by MTT assay
    Anticancer activity against human A549 cells assessed as growth inhibition incubated for 48 hrs by MTT assay
    		[PMID: 34363936]
    A549 IC50
    1.02 μM
    Compound: Dox
    Anticancer activity against human A549 cells after 48 hrs by MTT assay
    Anticancer activity against human A549 cells after 48 hrs by MTT assay
    		[PMID: 22209733]
    A549 IC50
    1.05 μM
    Compound: DOX
    Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay
    Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay
    		[PMID: 35341920]
    A549 IC50
    1.06 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells assessed as cell growth inhibition after 48 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as cell growth inhibition after 48 hrs by MTT assay
    		[PMID: 26708114]
    A549 IC50
    1.06 μM
    Compound: Doxorubicin
    Antiproliferative activity against human A549 cells assessed as reduction in cell viability measured after 72 hrs by MTS assay
    Antiproliferative activity against human A549 cells assessed as reduction in cell viability measured after 72 hrs by MTS assay
    		[PMID: 31962262]
    A549 IC50
    1.07 μM
    Compound: DOX
    Cytotoxicity against human A549 cells after 48 hrs by MTT assay
    Cytotoxicity against human A549 cells after 48 hrs by MTT assay
    		[PMID: 31057738]
    A549 IC50
    1.1 μM
    Compound: Doxorubicin
    Anticancer activity against human A549 cells by MTT assay
    Anticancer activity against human A549 cells by MTT assay
    		10.1039/C4MD00219A
    A549 IC50
    1.11 μM
    Compound: DOX
    Cytotoxicity against human A549 cells after 48 hrs by SRB method
    Cytotoxicity against human A549 cells after 48 hrs by SRB method
    		[PMID: 25933593]
    A549 IC50
    1.15 μM
    Compound: ADM
    Antiproliferative activity against human A549 cells overexpressing NQO1 assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    Antiproliferative activity against human A549 cells overexpressing NQO1 assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    		[PMID: 35803175]
    A549 IC50
    1.18 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells after 72 hrs by MTT assay
    Cytotoxicity against human A549 cells after 72 hrs by MTT assay
    		[PMID: 22472043]
    A549 IC50
    1.2 μM
    Compound: Doxorubicin
    Antiproliferative activity against human A549 cells measured after 48 hrs in presence of NQO1 inhibitor dicoumarol by MTT assay
    Antiproliferative activity against human A549 cells measured after 48 hrs in presence of NQO1 inhibitor dicoumarol by MTT assay
    		[PMID: 32682198]
    A549 IC50
    1.2 μM
    Compound: doxorubicin
    Cytotoxicity against human A549 cells by SRB protein staining method
    Cytotoxicity against human A549 cells by SRB protein staining method
    		[PMID: 25781655]
    A549 IC50
    1.21 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells by MTT assay
    Cytotoxicity against human A549 cells by MTT assay
    		[PMID: 23764302]
    A549 IC50
    1.21 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells by MTT assay
    Cytotoxicity against human A549 cells by MTT assay
    		[PMID: 23911578]
    A549 IC50
    1.21 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells by MTT assay
    Cytotoxicity against human A549 cells by MTT assay
    		[PMID: 24113366]
    A549 IC50
    1.21 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells by MTT assay
    Cytotoxicity against human A549 cells by MTT assay
    		[PMID: 25172420]
    A549 IC50
    1.21 μM
    Compound: Doxorubicin
    Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay
    Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay
    		[PMID: 31108261]
    A549 IC50
    1.28 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells assessed as growth inhibition after 72 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as growth inhibition after 72 hrs by MTT assay
    		[PMID: 25703298]
    A549 IC50
    1.2 μg/mL
    Compound: Adriamycin
    Cytotoxicity against human A549 cells by MTT assay
    Cytotoxicity against human A549 cells by MTT assay
    		[PMID: 17918910]
    A549 IC50
    1.3 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells after 24 hrs by WST assay
    Cytotoxicity against human A549 cells after 24 hrs by WST assay
    		[PMID: 25881821]
    A549 IC50
    1.303 μM
    Compound: Doxorubicin
    Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
    Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
    		[PMID: 29501940]
    A549 IC50
    1.32 μM
    Compound: Doxorubicin
    Antiproliferative activity against human A549 cells measured after 48 hrs by MTT assay
    Antiproliferative activity against human A549 cells measured after 48 hrs by MTT assay
    		[PMID: 32682198]
    A549 IC50
    1.4 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells by SRB assay
    Cytotoxicity against human A549 cells by SRB assay
    		[PMID: 29035560]
    A549 IC50
    1.43 μM
    Compound: Doxorubicin
    Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 24 hrs by MTT assay
    Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 24 hrs by MTT assay
    		[PMID: 31546197]
    A549 IC50
    1.445 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    		[PMID: 28462842]
    A549 IC50
    1.495 μM
    Compound: Doxorubicin
    Cytotoxicity activity against human A549 cells assessed as cell growth inhibition after 48 hrs by MTT assay
    Cytotoxicity activity against human A549 cells assessed as cell growth inhibition after 48 hrs by MTT assay
    		[PMID: 30433783]
    A549 IC50
    1.4 μg/mL
    Compound: doxorubicin
    Cytotoxicity against human A549 cells by MTT assay
    Cytotoxicity against human A549 cells by MTT assay
    		[PMID: 22413887]
    A549 IC50
    1.5 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells after 72 hrs by MTT assay
    Cytotoxicity against human A549 cells after 72 hrs by MTT assay
    		[PMID: 25453799]
    A549 IC50
    1.5 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells incubated for 48 hrs by MTT assay
    Cytotoxicity against human A549 cells incubated for 48 hrs by MTT assay
    		[PMID: 33421712]
    A549 IC50
    1.58 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells after 48 hrs by MTT assay
    Cytotoxicity against human A549 cells after 48 hrs by MTT assay
    		[PMID: 26264845]
    A549 IC50
    1.58 μM
    Compound: Doxorubicin
    Anticancer activity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Anticancer activity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    		[PMID: 26330077]
    A549 IC50
    1.6 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 48 hrs by SRB assay
    Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 48 hrs by SRB assay
    		[PMID: 28818768]
    A549 IC50
    1.65 μM
    Compound: Doxorubicin
    Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
    Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
    		[PMID: 24418772]
    A549 IC50
    1.68 μM
    Compound: II
    Cytotoxicity against human A549 cells after 48 hrs by MTT assay
    Cytotoxicity against human A549 cells after 48 hrs by MTT assay
    		[PMID: 29289881]
    A549 IC50
    1.7 μM
    Compound: Doxorubicin
    Growth inhibition of human A549 cells by MTT assay
    Growth inhibition of human A549 cells by MTT assay
    		[PMID: 28916158]
    A549 IC50
    1.778 μM
    Compound: Doxorubicin
    Anti-proliferative activity against human A549 cells measured after 48 hrs by MTT assay
    Anti-proliferative activity against human A549 cells measured after 48 hrs by MTT assay
    		[PMID: 27744185]
    A549 IC50
    1.78 μM
    Compound: Doxorubicin
    Cytotoxic activity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Cytotoxic activity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    		[PMID: 25966052]
    A549 IC50
    1.79 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    		[PMID: 35339645]
    A549 IC50
    1.8 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells
    Cytotoxicity against human A549 cells
    		[PMID: 33421712]
    A549 IC50
    1.83 μM
    Compound: doxorubicin
    Cytotoxicity against human A549 cells
    Cytotoxicity against human A549 cells
    		[PMID: 25581396]
    A549 IC50
    1.86 μM
    Compound: Doxo
    Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
    Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
    		[PMID: 29129513]
    A549 IC50
    1.88 μM
    Compound: Dox
    Cytotoxicity against human A549 cells after 24 hrs by MTT assay
    Cytotoxicity against human A549 cells after 24 hrs by MTT assay
    		10.1007/s00044-013-0584-6
    A549 IC50
    1.9 μM
    Compound: DOX
    Antiproliferative activity against human A549 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
    Antiproliferative activity against human A549 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
    		[PMID: 32631552]
    A549 IC50
    1.9 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells after 72 hrs by MTT assay
    Cytotoxicity against human A549 cells after 72 hrs by MTT assay
    		[PMID: 19394829]
    A549 IC50
    1.9 μM
    Compound: Doxorubicin
    Antiproliferative activity against human A549 cells after 72 hrs by MTT assay
    Antiproliferative activity against human A549 cells after 72 hrs by MTT assay
    		[PMID: 19632833]
    A549 IC50
    1.9 μM
    Compound: Doxorubicin
    Antiproliferative activity against human A549 cells assessed as cell viability after 72 hrs by MTT assay
    Antiproliferative activity against human A549 cells assessed as cell viability after 72 hrs by MTT assay
    		[PMID: 24012378]
    A549 IC50
    1.9 μM
    Compound: Doxorubicin
    Anticancer activity against human A549 cells after 48 hrs by MTT assay
    Anticancer activity against human A549 cells after 48 hrs by MTT assay
    		[PMID: 25615796]
    A549 IC50
    1.92 μM
    Compound: ADR
    Cytotoxicity against human A549 cells
    Cytotoxicity against human A549 cells
    		[PMID: 17723301]
    A549 IC50
    1.945 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    		[PMID: 28482219]
    A549 IC50
    1.986 μM
    Compound: Doxorubicin
    Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
    Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
    		[PMID: 26301558]
    A549 IC50
    1.99 μM
    Compound: Doxorubicin
    Cytotoxicity against human lung carcinoma A549 cell line using MTT assay
    Cytotoxicity against human lung carcinoma A549 cell line using MTT assay
    		[PMID: 9873387]
    A549 IC50
    10.2 μM
    Compound: Doxorubicin
    Antiproliferative activity against human A549 cells after 72 hrs by MTT assay
    Antiproliferative activity against human A549 cells after 72 hrs by MTT assay
    		[PMID: 28886509]
    A549 IC50
    10.28 μM
    Compound: Dox
    Cytotoxicity against human A549 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay
    		[PMID: 35635947]
    A549 IC50
    10.3 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    		[PMID: 37484570]
    A549 IC50
    10.55 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells after 24 hrs by MTT assay
    Cytotoxicity against human A549 cells after 24 hrs by MTT assay
    		10.1039/C3MD00013C
    A549 IC50
    10.76 μM
    Compound: Dox
    Cytotoxicity against human A549 cells assessed as cell viability measured after 24 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as cell viability measured after 24 hrs by MTT assay
    		[PMID: 33183865]
    A549 IC50
    10.83 μM
    Compound: DOX
    Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay
    Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay
    		[PMID: 36463726]
    A549 IC50
    11 μM
    Compound: Doxorubicin
    Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
    Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
    		[PMID: 28919340]
    A549 IC50
    11.62 μM
    Compound: Dox
    Cytotoxicity against human A549 cells assessed as decrease in cell viability treated for 2 hrs measured after 48 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as decrease in cell viability treated for 2 hrs measured after 48 hrs by MTT assay
    		[PMID: 28129977]
    A549 IC50
    13.6 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells assessed as reduction in cell viability after 24 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as reduction in cell viability after 24 hrs by MTT assay
    		[PMID: 24681979]
    A549 IC50
    14 μM
    Compound: Doxo
    Cytotoxicity against human A549 cells after 48 hrs by alamar blue assay
    Cytotoxicity against human A549 cells after 48 hrs by alamar blue assay
    		[PMID: 25468043]
    A549 IC50
    14.7 nM
    Compound: Doxorubicin
    Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 24 hrs by SRB assay
    Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 24 hrs by SRB assay
    		[PMID: 31655432]
    A549 IC50
    140 nM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells assessed as cell growth inhibition incubated for 72 hrs by CCK8 assay
    Cytotoxicity against human A549 cells assessed as cell growth inhibition incubated for 72 hrs by CCK8 assay
    		[PMID: 35213166]
    A549 IC50
    149 nM
    Compound: DX
    Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation incubated for 72 hrs by SRB assay
    Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation incubated for 72 hrs by SRB assay
    		[PMID: 34592435]
    A549 IC50
    15.07 μM
    Compound: Doxorubicin
    Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
    Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
    		10.1039/C2MD20023F
    A549 IC50
    15.07 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells after 48 hrs by MTT assay
    Cytotoxicity against human A549 cells after 48 hrs by MTT assay
    		[PMID: 22386528]
    A549 IC50
    17 μM
    Compound: Doxorubicin
    Anticancer activity against human A549 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
    Anticancer activity against human A549 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
    		[PMID: 34838335]
    A549 IC50
    172 nM
    Compound: DX
    Antiproliferative activity against human A549 cells assessed as inhibition of cell growth measured after 72 hrs by SRB assay
    Antiproliferative activity against human A549 cells assessed as inhibition of cell growth measured after 72 hrs by SRB assay
    		[PMID: 33611191]
    A549 IC50
    18.56 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells assessed as decrease in cell viability after 48 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as decrease in cell viability after 48 hrs by MTT assay
    		[PMID: 28262524]
    A549 IC50
    190 nM
    Compound: DX
    Antiproliferative activity against human A549 cells assessed as inhibition of proliferation after 72 hrs by SRB assay
    Antiproliferative activity against human A549 cells assessed as inhibition of proliferation after 72 hrs by SRB assay
    		[PMID: 34116158]
    A549 IC50
    2.04 μM
    Compound: DOX
    Cytotoxicity against against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 30340899]
    A549 IC50
    2.1 μM
    Compound: Dox
    Antiproliferative activity against human A549 cells assessed as reduction in cell viability by MTT assay
    Antiproliferative activity against human A549 cells assessed as reduction in cell viability by MTT assay
    		[PMID: 31765156]
    A549 IC50
    2.1 μM
    Compound: Doxo (I)
    Antiproliferative activity against human A549 cells by MTT assay
    Antiproliferative activity against human A549 cells by MTT assay
    		10.1039/C4MD00228H
    A549 IC50
    2.1 μM
    Compound: Doxorubicin
    Antiproliferative activity against human A549 cells assessed as cell growth inhibition by MTT assay
    Antiproliferative activity against human A549 cells assessed as cell growth inhibition by MTT assay
    		[PMID: 34838335]
    A549 IC50
    2.12 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells after 48 hrs by MTT assay
    Cytotoxicity against human A549 cells after 48 hrs by MTT assay
    		[PMID: 25462233]
    A549 IC50
    2.12 μM
    Compound: Doxorubicin
    Antiproliferative activity against human A549 cells assessed as cell viability after 24 hrs by MTT assay
    Antiproliferative activity against human A549 cells assessed as cell viability after 24 hrs by MTT assay
    		[PMID: 26874744]
    A549 IC50
    2.17 μM
    Compound: DOX
    Cytotoxicity against human A549 cells assessed as cell viability after 48 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as cell viability after 48 hrs by MTT assay
    		[PMID: 27149641]
    A549 IC50
    2.18 μM
    Compound: Doxorubicin
    Anticancer activity against human A549 cells after 48 hrs by MTT assay
    Anticancer activity against human A549 cells after 48 hrs by MTT assay
    		[PMID: 22136907]
    A549 IC50
    2.2 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells by MTT assay
    Cytotoxicity against human A549 cells by MTT assay
    		[PMID: 21425785]
    A549 IC50
    2.2 μM
    Compound: adriamycin
    Cytotoxicity against human A549 cells by rapid colorimetric assay
    Cytotoxicity against human A549 cells by rapid colorimetric assay
    		[PMID: 19585998]
    A549 IC50
    2.2 x 10-3 μg/mL
    Compound: Adriamycin
    Cytotoxicity against human A549 cells by MTT assay
    Cytotoxicity against human A549 cells by MTT assay
    		[PMID: 9644064]
    A549 IC50
    2.23 μM
    Compound: DOX
    Antiproliferative activity against human A549 cells by MTT assay
    Antiproliferative activity against human A549 cells by MTT assay
    		[PMID: 20171108]
    A549 IC50
    2.3 μM
    Compound: DOX
    Inhibition of topoisomerase 2 in human A549 cells assessed as reduction in cell growth measured after 72 hrs by MTT assay
    Inhibition of topoisomerase 2 in human A549 cells assessed as reduction in cell growth measured after 72 hrs by MTT assay
    		[PMID: 30846253]
    A549 IC50
    2.3 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 29789258]
    A549 IC50
    2.31 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay
    		[PMID: 33352388]
    A549 IC50
    2.34 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells after 48 hrs by MTT assay
    Cytotoxicity against human A549 cells after 48 hrs by MTT assay
    		[PMID: 26948541]
    A549 IC50
    2.48 μM
    Compound: Doxorubicin
    Antiproliferative activity against human A549 cells after 24 hrs by MTT assay
    Antiproliferative activity against human A549 cells after 24 hrs by MTT assay
    		10.1039/C5MD00581G
    A549 IC50
    2.54 μM
    Compound: DOX
    Cytotoxicity against human A549 cells assessed as inhibition of cell viability incubated for 48 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as inhibition of cell viability incubated for 48 hrs by MTT assay
    		[PMID: 38169372]
    A549 IC50
    2.58 μM
    Compound: Doxorubicin
    Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    		[PMID: 31883489]
    A549 IC50
    2.6 x 10-7 M
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells after 72 hrs by XTT assay
    Cytotoxicity against human A549 cells after 72 hrs by XTT assay
    		[PMID: 20619940]
    A549 IC50
    2.6 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells after 24 hrs by MTT assay
    Cytotoxicity against human A549 cells after 24 hrs by MTT assay
    		[PMID: 25300819]
    A549 IC50
    2.67 μM
    Compound: DOX
    Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs
    Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs
    		[PMID: 32736079]
    A549 IC50
    2.7 nM
    Compound: Doxorubicin
    Cytotoxicity against Renal cell lines A549 was determined
    Cytotoxicity against Renal cell lines A549 was determined
    		[PMID: 12392727]
    A549 IC50
    2.7 μM
    Compound: Adriamycin
    Cytotoxicity against human A549 cells by MTT colorimetric method
    Cytotoxicity against human A549 cells by MTT colorimetric method
    		[PMID: 23043498]
    A549 IC50
    2.8 μM
    Compound: Adriamycin
    Growth inhibition of human A549 cells by MTT assay
    Growth inhibition of human A549 cells by MTT assay
    		[PMID: 21721519]
    A549 IC50
    2.8 μM
    Compound: Adriamycin
    Cytotoxicity against human A549 cells by MTT assay
    Cytotoxicity against human A549 cells by MTT assay
    		[PMID: 22647719]
    A549 IC50
    2.81 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells assessed as cell viability after 48 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as cell viability after 48 hrs by MTT assay
    		[PMID: 27015609]
    A549 IC50
    2.905 μM
    Compound: DOX
    Growth inhibition of human A549 cells after 48 hrs by MTT assay
    Growth inhibition of human A549 cells after 48 hrs by MTT assay
    		[PMID: 29509413]
    A549 IC50
    21.18 μM
    Compound: DOX
    Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by sulphorhodamine-B assay
    Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by sulphorhodamine-B assay
    		[PMID: 38810335]
    A549 IC50
    21.5 nM
    Compound: Dox
    Cytotoxicity against human A549 cells incubated for 72 hrs by SRB assay
    Cytotoxicity against human A549 cells incubated for 72 hrs by SRB assay
    		[PMID: 37480713]
    A549 IC50
    22 nM
    Compound: Doxorubicin
    Tested against A549 lung carcinoma in the sulforhodamine B assay.
    Tested against A549 lung carcinoma in the sulforhodamine B assay.
    		[PMID: 8648600]
    A549 IC50
    22 nM
    Compound: dixorubicin
    Activity against A549 cancer cell line.
    Activity against A549 cancer cell line.
    		[PMID: 8960558]
    A549 IC50
    22 nM
    Compound: doxorubicin
    Tested for inhibitory activity against human tumor cell line A549 (a non small, drug resistant cell line that does not produce P-glycoprotein) of lung carcinoma using sulforhodamine B assay.
    Tested for inhibitory activity against human tumor cell line A549 (a non small, drug resistant cell line that does not produce P-glycoprotein) of lung carcinoma using sulforhodamine B assay.
    		[PMID: 10956214]
    A549 IC50
    228.2 nM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells assessed as growth inhibition after 72 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as growth inhibition after 72 hrs by MTT assay
    		[PMID: 29886322]
    A549 IC50
    24.27 μM
    Compound: DOX
    Cytotoxicity against Homo sapiens (human) A549 cells assessed as growth inhibition after 48 hr by MTT assay
    Cytotoxicity against Homo sapiens (human) A549 cells assessed as growth inhibition after 48 hr by MTT assay
    		10.1007/s00044-012-0018-x
    A549 IC50
    258 nM
    Compound: DOX; DX
    Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 120 hrs by MTT assay
    Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 120 hrs by MTT assay
    		[PMID: 31653441]
    A549 IC50
    258 nM
    Compound: Doxorubicin
    Antiproliferative activity against human A549 cells incubated for 72 hrs by SRB assay
    Antiproliferative activity against human A549 cells incubated for 72 hrs by SRB assay
    		[PMID: 33465696]
    A549 IC50
    26.81 μM
    Compound: DOX
    Cytotoxicity against human A549 cells after 72 hrs by sulforhodamine B assay
    Cytotoxicity against human A549 cells after 72 hrs by sulforhodamine B assay
    		[PMID: 25912674]
    A549 IC50
    3 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells assessed as reduction in cell viability by DAPI staining based assay
    Cytotoxicity against human A549 cells assessed as reduction in cell viability by DAPI staining based assay
    		[PMID: 33461146]
    A549 IC50
    3.03 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells assessed as cell viability after 48 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as cell viability after 48 hrs by MTT assay
    		[PMID: 25594739]
    A549 IC50
    3.08 μM
    Compound: DOX
    Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    		[PMID: 32996316]
    A549 IC50
    3.118 μg/mL
    Compound: ADM
    Cytotoxicity against human A549 cells by MTT assay
    Cytotoxicity against human A549 cells by MTT assay
    		[PMID: 25862199]
    A549 IC50
    3.13 μM
    Compound: Dox
    Antiproliferative activity against human A549 cells after 72 hrs by cell titer glo assay
    Antiproliferative activity against human A549 cells after 72 hrs by cell titer glo assay
    		[PMID: 24161704]
    A549 IC50
    3.13 μM
    Compound: Doxo
    Cytotoxicity against human A549 cells after 48 hrs by MTT assay
    Cytotoxicity against human A549 cells after 48 hrs by MTT assay
    		[PMID: 25563891]
    A549 IC50
    3.14 μM
    Compound: DOX
    Cytotoxicity against human A549/CDDP cells assessed as growth inhibition after 48 hrs by MTT assay
    Cytotoxicity against human A549/CDDP cells assessed as growth inhibition after 48 hrs by MTT assay
    		[PMID: 27149641]
    A549 IC50
    3.16 μM
    Compound: Doxorubicin
    Antiproliferative activity against human A549 cells after 72 hrs by MTT assay
    Antiproliferative activity against human A549 cells after 72 hrs by MTT assay
    		[PMID: 30500683]
    A549 IC50
    3.19 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells by MTT assay
    Cytotoxicity against human A549 cells by MTT assay
    		[PMID: 33148490]
    A549 IC50
    3.24 μM
    Compound: DOX
    Antiproliferative activity against human A549 cells assessed as cell growth inhibition by MTT assay
    Antiproliferative activity against human A549 cells assessed as cell growth inhibition by MTT assay
    		[PMID: 32631524]
    A549 IC50
    3.28 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells after 24 hrs by MTT assay
    Cytotoxicity against human A549 cells after 24 hrs by MTT assay
    		[PMID: 22542958]
    A549 IC50
    3.2 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells by MTT assay
    Cytotoxicity against human A549 cells by MTT assay
    		10.1039/C4MD00566J
    A549 IC50
    3.3 μM
    Compound: Dox
    Cytotoxicity against human A549 cells assessed as inhibition of cell viability after 48 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as inhibition of cell viability after 48 hrs by MTT assay
    		[PMID: 27055942]
    A549 IC50
    3.3 μM
    Compound: Doxorubicin
    Antiproliferative activity against human A549 cells by MTT assay
    Antiproliferative activity against human A549 cells by MTT assay
    		[PMID: 31546197]
    A549 IC50
    3.35 μM
    Compound: DOX
    Antineoplastic activity against human A549 cells measured after 36 hrs by MTT assay
    Antineoplastic activity against human A549 cells measured after 36 hrs by MTT assay
    		[PMID: 30746067]
    A549 IC50
    3.4 μM
    Compound: DOX
    Antiproliferative activity against human A549 cells after 72 hrs by MTT assay
    Antiproliferative activity against human A549 cells after 72 hrs by MTT assay
    		[PMID: 30398868]
    A549 IC50
    3.4 μM
    Compound: Doxorubicin
    Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
    Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
    		[PMID: 25453802]
    A549 IC50
    3.41 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells by CCK8 assay
    Cytotoxicity against human A549 cells by CCK8 assay
    		[PMID: 29452840]
    A549 IC50
    3.6 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells after 94 hrs by MTT assay
    Cytotoxicity against human A549 cells after 94 hrs by MTT assay
    		[PMID: 21868138]
    A549 IC50
    3.69 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells after 48 hrs by MTT assay
    Cytotoxicity against human A549 cells after 48 hrs by MTT assay
    		[PMID: 22472043]
    A549 IC50
    3.76 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells assessed as reduction in cell viability
    Cytotoxicity against human A549 cells assessed as reduction in cell viability
    		[PMID: 32005414]
    A549 IC50
    3.97 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells assessed as reduction in cell viability after 24 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as reduction in cell viability after 24 hrs by MTT assay
    		[PMID: 31404864]
    A549 IC50
    3.98 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells after 24 hrs by MTT assay
    Cytotoxicity against human A549 cells after 24 hrs by MTT assay
    		10.1007/s00044-013-0784-0
    A549 IC50
    4 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells after 48 hrs by MTT assay
    Cytotoxicity against human A549 cells after 48 hrs by MTT assay
    		[PMID: 23792352]
    A549 IC50
    4 μM
    Compound: doxorubicin
    Cytotoxicity against human A549 cells after 48 hrs by MTT assay
    Cytotoxicity against human A549 cells after 48 hrs by MTT assay
    		[PMID: 23748152]
    A549 IC50
    4.11 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells after 48 hrs by SRB assay
    Cytotoxicity against human A549 cells after 48 hrs by SRB assay
    		[PMID: 24095746]
    A549 IC50
    4.36 μM
    Compound: Doxorubicin
    Antiproliferative activity against human A549 cells after 48 hrs by SRB assay
    Antiproliferative activity against human A549 cells after 48 hrs by SRB assay
    		[PMID: 30503942]
    A549 IC50
    4.4 μM
    Compound: Doxorubicin
    Antiproliferative activity against human A549 cells incubated for 48 hrs by MTT assay
    Antiproliferative activity against human A549 cells incubated for 48 hrs by MTT assay
    		[PMID: 38442524]
    A549 IC50
    4.91 μM
    Compound: DOX
    Cytotoxicity against human A549 cells assessed as cell growth inhibition after 72 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as cell growth inhibition after 72 hrs by MTT assay
    		[PMID: 26720155]
    A549 IC50
    4.91 μM
    Compound: DOX
    Antiproliferative activity against human A549 cells after 72 hrs by MTT assay
    Antiproliferative activity against human A549 cells after 72 hrs by MTT assay
    		[PMID: 28135634]
    A549 IC50
    4.91 μM
    Compound: DOX
    Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 28427016]
    A549 IC50
    4.91 μM
    Compound: DOX
    Cytotoxicity against human A549 cells assessed as inhibition of cell growth after 72 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as inhibition of cell growth after 72 hrs by MTT assay
    		[PMID: 30746062]
    A549 IC50
    4.91 μM
    Compound: DOX
    Antiproliferative activity against human A549 cells assessed as reduction in cell viability measured after 6 days by MTT assay
    Antiproliferative activity against human A549 cells assessed as reduction in cell viability measured after 6 days by MTT assay
    		[PMID: 32653698]
    A549 IC50
    4.91 μM
    Compound: DOX
    Antiproliferative activity against human A549 cells by MTT colorimetric assay
    Antiproliferative activity against human A549 cells by MTT colorimetric assay
    		[PMID: 38527380]
    A549 IC50
    4.91 μM
    Compound: DOX
    Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    		[PMID: 39067378]
    A549 IC50
    4.91 μM
    Compound: Dox
    Cytotoxicity against human A549 cells assessed as cell growth inhibition after 72 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as cell growth inhibition after 72 hrs by MTT assay
    		[PMID: 27231128]
    A549 IC50
    4.985 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells incubated for 72 hrs by MTT assay
    Cytotoxicity against human A549 cells incubated for 72 hrs by MTT assay
    		[PMID: 38894896]
    A549 IC50
    4 x 10-4 μg/mL
    Compound: adriamycin
    Cytotoxicity against human A549 cells
    Cytotoxicity against human A549 cells
    		[PMID: 8991944]
    A549 IC50
    426 nM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by XTT assay
    Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by XTT assay
    		[PMID: 29190084]
    A549 IC50
    459 nM
    Compound: DOX
    Antiproliferative activity against human A549 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
    Antiproliferative activity against human A549 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
    		[PMID: 30878835]
    A549 IC50
    5 μM
    Compound: Doxorubicin
    Antiproliferative activity against human A549 cells by MTT assay
    Antiproliferative activity against human A549 cells by MTT assay
    		[PMID: 29072457]
    A549 IC50
    5.13 μM
    Compound: Doxorubicin
    Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay
    Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay
    		[PMID: 35367708]
    A549 IC50
    5.1 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
    Cytotoxicity against human A549 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
    		[PMID: 27894044]
    A549 IC50
    5.3 μM
    Compound: DOX
    Cytotoxicity against human A549 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay
    		[PMID: 31589431]
    A549 IC50
    5.32 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells measured after 48 hrs by MTT assay
    Cytotoxicity against human A549 cells measured after 48 hrs by MTT assay
    		[PMID: 27476117]
    A549 IC50
    5.5 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells assessed as reduction in cell viability preincubated for 24 hrs measured after 4 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as reduction in cell viability preincubated for 24 hrs measured after 4 hrs by MTT assay
    		[PMID: 34223162]
    A549 IC50
    5.5 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells incubated for 24 hrs by MTT assay
    Cytotoxicity against human A549 cells incubated for 24 hrs by MTT assay
    		[PMID: 36621136]
    A549 IC50
    5.58 nM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells assessed as cell viability after 5 days by cell viability analyzer
    Cytotoxicity against human A549 cells assessed as cell viability after 5 days by cell viability analyzer
    		[PMID: 26291039]
    A549 IC50
    5.93 μM
    Compound: Doxorubicin
    Antiproliferative activity against human A549 cells assessed as inhibition of cell growth after 72 hrs by MTT assay
    Antiproliferative activity against human A549 cells assessed as inhibition of cell growth after 72 hrs by MTT assay
    		[PMID: 32311607]
    A549 IC50
    6.13 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells assessed as cell viability by SRB assay
    Cytotoxicity against human A549 cells assessed as cell viability by SRB assay
    		[PMID: 26022842]
    A549 IC50
    6.22 μM
    Compound: Doxo
    Cytotoxicity against human A549 cells measured after 24 hrs by MTT assay
    Cytotoxicity against human A549 cells measured after 24 hrs by MTT assay
    		[PMID: 31104996]
    A549 IC50
    6.61 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells after 24 hrs by MTT assay
    Cytotoxicity against human A549 cells after 24 hrs by MTT assay
    		[PMID: 22182926]
    A549 IC50
    6.94 μM
    Compound: DOX
    Antiproliferative activity against human A549 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay
    Antiproliferative activity against human A549 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay
    		[PMID: 38079530]
    A549 IC50
    69.33 μM
    Compound: Doxorubicin
    Anticancer activity against human A549 cells by MTT assay
    Anticancer activity against human A549 cells by MTT assay
    		[PMID: 25743216]
    A549 IC50
    7.1 μM
    Compound: DX
    Cytotoxicity against human A549 cells after 48 hrs by sulforhodamine B assay
    Cytotoxicity against human A549 cells after 48 hrs by sulforhodamine B assay
    		10.1039/C5MD00513B
    A549 IC50
    7.47 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells after 48 hrs by MTT assay
    Cytotoxicity against human A549 cells after 48 hrs by MTT assay
    		[PMID: 24607876]
    A549 IC50
    7.52 μM
    Compound: Dox
    Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
    Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
    		[PMID: 26494582]
    A549 IC50
    7.86 μM
    Compound: Doxorubicin
    Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
    Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
    		[PMID: 30108986]
    A549 IC50
    7.88 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells after 72 hrs by MTT assay
    Cytotoxicity against human A549 cells after 72 hrs by MTT assay
    		[PMID: 18440233]
    A549 IC50
    740 nM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells after 48 hrs by MTT assay
    Cytotoxicity against human A549 cells after 48 hrs by MTT assay
    		[PMID: 30172625]
    A549 IC50
    8.05 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells assessed as growth inhibition after 48 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as growth inhibition after 48 hrs by MTT assay
    		[PMID: 25140752]
    A549 IC50
    8.4 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells
    Cytotoxicity against human A549 cells
    		[PMID: 24793880]
    A549 IC50
    8.5 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells by MTT assay
    Cytotoxicity against human A549 cells by MTT assay
    		[PMID: 33766771]
    A549 IC50
    8.5 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells incubated for 48 hrs by SRB assay
    Cytotoxicity against human A549 cells incubated for 48 hrs by SRB assay
    		[PMID: 26048808]
    A549 IC50
    8.73 μM
    Compound: Doxorubicin
    Anticancer activity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    Anticancer activity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    		[PMID: 36439979]
    A549 IC50
    9.2 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells after 48 hrs by MTT assay
    Cytotoxicity against human A549 cells after 48 hrs by MTT assay
    		[PMID: 20846862]
    A549 IC50
    9.4 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells measured after 24 to 72 hrs by MTT assay
    Cytotoxicity against human A549 cells measured after 24 to 72 hrs by MTT assay
    		[PMID: 37482018]
    A549 IC50
    9.5 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
    		[PMID: 35526504]
    A549 IC50
    9.7 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells assessed as cell viability after 48 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as cell viability after 48 hrs by MTT assay
    		[PMID: 25655719]
    A549 IC50
    90 μM
    Compound: Doxorubicin
    Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 72 hrs by CellTiter Glo assay
    Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 72 hrs by CellTiter Glo assay
    		[PMID: 33016067]
    A549 IC50
    < 0.1 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells after 72 hrs by MTT assay
    Cytotoxicity against human A549 cells after 72 hrs by MTT assay
    		[PMID: 22330634]
    A549 IC50
    < 1 μM
    Compound: Doxorubicin
    Cytotoxicity against Homo sapiens (human) A549 cells after 48 hr by MTT assay
    Cytotoxicity against Homo sapiens (human) A549 cells after 48 hr by MTT assay
    		10.1007/s00044-011-9884-x
    A549 IC50
    < 1 μM
    Compound: doxorubicin
    Cytotoxicity against human A549 cells by SRB assay
    Cytotoxicity against human A549 cells by SRB assay
    		[PMID: 33847126]
    A549 IC50
    > 100 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
    		[PMID: 33340938]
    A549 IC50
    > 200 μM
    Compound: Doxorubicin
    Inhibition topoisomerase 1 in human A549 cells assessed as conversion of supercoiled pBR322 DNA to relaxed form
    Inhibition topoisomerase 1 in human A549 cells assessed as conversion of supercoiled pBR322 DNA to relaxed form
    		[PMID: 11430001]
    A549/CDDP IC50
    4.59 μM
    Compound: DOX
    Growth inhibition of human A549/CDDP cells after 48 hrs by MTT assay
    Growth inhibition of human A549/CDDP cells after 48 hrs by MTT assay
    		[PMID: 29509413]
    A549/TR IC50
    1.6 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549/Taxol cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Cytotoxicity against human A549/Taxol cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    		[PMID: 37672645]
    A673 EC50
    0.39 μM
    Compound: Doxorubicin
    Induction of apoptosis in human A673 cells assessed as caspase-3 activation after 24 hrs by luminescence assay
    Induction of apoptosis in human A673 cells assessed as caspase-3 activation after 24 hrs by luminescence assay
    		[PMID: 23600925]
    A673 IC50
    0.1 μM
    Compound: DOX
    Cytotoxicity against human A673 cells measured after 72 hrs by Celltiter-Glo assay
    Cytotoxicity against human A673 cells measured after 72 hrs by Celltiter-Glo assay
    		[PMID: 31820976]
    A673 IC50
    0.17 μM
    Compound: Doxorubicin
    Cytotoxicity against human A673 cells after 72 hrs by resazurin/resorufin-based fluorescence assay
    Cytotoxicity against human A673 cells after 72 hrs by resazurin/resorufin-based fluorescence assay
    		[PMID: 23600925]
    A704 IC50
    2 μM
    Compound: Doxorubicin
    Cytotoxicity against human A704 cells after 72 hrs by MTT assay
    Cytotoxicity against human A704 cells after 72 hrs by MTT assay
    		[PMID: 19406535]
    ACHN ED50
    0.3 μg/mL
    Compound: Adriamycin
    Cytotoxicity against human ACHN cells
    Cytotoxicity against human ACHN cells
    		[PMID: 10346965]
    ACHN GI50
    0.08 μM
    Compound: ADR
    Cytotoxicity against human ACHN cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay
    Cytotoxicity against human ACHN cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay
    		[PMID: 28870801]
    ACHN GI50
    0.08 μM
    Compound: ADR
    Cytotoxicity against human ACHN cells assessed as growth inhibition after 72 hrs by SRB assay
    Cytotoxicity against human ACHN cells assessed as growth inhibition after 72 hrs by SRB assay
    		[PMID: 30253887]
    ACHN GI50
    0.08 μM
    Compound: Doxorubicin
    Growth inhibition of human ACHN cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human ACHN cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28329730]
    ACHN GI50
    0.08 μM
    Compound: Doxorubicin
    Growth inhibition of human ACHN cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human ACHN cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 29102177]
    ACHN GI50
    0.08 μM
    Compound: Doxorubicin hydrochloride, NSC 123127
    Cytotoxicity against human ACHN cells after 48 hrs by SRB assay
    Cytotoxicity against human ACHN cells after 48 hrs by SRB assay
    		[PMID: 23871905]
    ACHN GI50
    0.088 μM
    Compound: ADR
    Anticancer activity against human ACNH cells assessed as growth inhibition incubated for 48 hrs by sulforhodamine B method
    Anticancer activity against human ACNH cells assessed as growth inhibition incubated for 48 hrs by sulforhodamine B method
    		[PMID: 34500188]
    ACHN GI50
    0.0995 μM
    Compound: ADR
    Cytotoxicity against human ACHN cells after 72 hrs by sulforhodamine B assay
    Cytotoxicity against human ACHN cells after 72 hrs by sulforhodamine B assay
    		[PMID: 27096046]
    ACHN GI50
    0.182 μM
    Compound: doxorubicin
    Cytotoxicity against human ACHN cells
    Cytotoxicity against human ACHN cells
    		[PMID: 20579876]
    ACHN GI50
    0.2 μM
    Compound: ADR
    Cytotoxicity against human ACHN cells assessed as growth inhibition after 72 hrs by sulforhodamine B assay
    Cytotoxicity against human ACHN cells assessed as growth inhibition after 72 hrs by sulforhodamine B assay
    		[PMID: 25953156]
    ACHN GI50
    0.22 μM
    Compound: Doxorubicin
    Anticancer activity against human ACHN cells by SRB assay
    Anticancer activity against human ACHN cells by SRB assay
    		[PMID: 20732810]
    ACHN GI50
    0.41 μM
    Compound: Doxorubicin
    Cytotoxicity against human ACHN cells by SRB assay
    Cytotoxicity against human ACHN cells by SRB assay
    		[PMID: 19596579]
    ACHN GI50
    1.63 μM
    Compound: ADR
    Antiproliferative activity against human ACHN cells by SRB assay
    Antiproliferative activity against human ACHN cells by SRB assay
    		[PMID: 22738641]
    ACHN GI50
    1.63 μM
    Compound: ADR
    Antiproliferative activity against human ACHN cells by SRB method
    Antiproliferative activity against human ACHN cells by SRB method
    		[PMID: 24835787]
    ACHN GI50
    2 μM
    Compound: Doxorubicin
    Cytotoxicity against human ACHN cells after 48 hrs by sulforhodamine B assay
    Cytotoxicity against human ACHN cells after 48 hrs by sulforhodamine B assay
    		[PMID: 23964644]
    ACHN IC50
    0.001 μM
    Compound: doxo
    Antiproliferative activity against human ACHN cell line by MTT assay
    Antiproliferative activity against human ACHN cell line by MTT assay
    		[PMID: 16913700]
    ACHN IC50
    0.02 μM
    Compound: Doxorubicin
    Cytotoxicity against human ACHN cells assessed as reduction in cell viability after 72 hrs by CellTiter96 AQueous one solution cell proliferation assay
    Cytotoxicity against human ACHN cells assessed as reduction in cell viability after 72 hrs by CellTiter96 AQueous one solution cell proliferation assay
    		[PMID: 28617598]
    ACHN IC50
    0.02 μM
    Compound: Doxorubicin
    Antiproliferative activity against human ACHN cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay
    Antiproliferative activity against human ACHN cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay
    		[PMID: 34851111]
    ACHN IC50
    0.04 μM
    Compound: Doxo
    Antiproliferative activity against human ACHN cells assessed as cell viability measured after 4 days by MTT assay
    Antiproliferative activity against human ACHN cells assessed as cell viability measured after 4 days by MTT assay
    		[PMID: 31869654]
    ACHN IC50
    0.04 μM
    Compound: Doxorubicin
    Antitumor activity against human renal adenocarcinoma ACHN cells.
    Antitumor activity against human renal adenocarcinoma ACHN cells.
    		[PMID: 12431049]
    ACHN IC50
    0.04 μM
    Compound: Doxorubicin
    Antiproliferative activity against human ACHN cells after 96 hrs by MTT assay
    Antiproliferative activity against human ACHN cells after 96 hrs by MTT assay
    		[PMID: 19053767]
    ACHN IC50
    0.04 μM
    Compound: doxorubicin
    Antitumor activity against human renal adenocarcinoma ACHN cells
    Antitumor activity against human renal adenocarcinoma ACHN cells
    		[PMID: 12431048]
    ACHN IC50
    0.14 μg/mL
    Compound: Adriamycin
    Inhibitory concentration required against ACHN renal cancer cell line
    Inhibitory concentration required against ACHN renal cancer cell line
    		[PMID: 11354370]
    ACHN IC50
    0.4 μM
    Compound: Doxorubicin
    Antitumor activity was evaluated against human renal adenocarcinoma cell line ACHN.
    Antitumor activity was evaluated against human renal adenocarcinoma cell line ACHN.
    		[PMID: 10411476]
    ACHN IC50
    0.7 μM
    Compound: Doxorubicin
    Compound was tested for its effect on the proliferation of ACHN human kidney adenocarcinoma
    Compound was tested for its effect on the proliferation of ACHN human kidney adenocarcinoma
    		10.1016/0960-894X(96)00216-8
    ACHN IC50
    0.79 μM
    Compound: Doxorubicin
    Anticancer activity against human ACHN cells after 48 hrs by MTT assay
    Anticancer activity against human ACHN cells after 48 hrs by MTT assay
    		[PMID: 22136907]
    ACHN IC50
    14.2 μM
    Compound: doxorubicin
    Cytotoxicity against multidrug-resistant human ACHN cells after 72 hrs by fluorometric microculture cytotoxicity assay
    Cytotoxicity against multidrug-resistant human ACHN cells after 72 hrs by fluorometric microculture cytotoxicity assay
    		[PMID: 16562840]
    ACHN IC50
    14.2 μM
    Compound: doxorubicin
    Cytotoxicity against ACHN cells
    Cytotoxicity against ACHN cells
    		[PMID: 17442577]
    ACHN IC50
    2.08 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human ACHN cells by MTT assay
    Cytotoxicity against human ACHN cells by MTT assay
    		10.1039/C4MD00566J
    AGS GI50
    0.01 μM
    Compound: Doxorubicin
    Antiproliferative activity against human AGS assessed as growth inhibition after 48 hrs by SRB assay
    Antiproliferative activity against human AGS assessed as growth inhibition after 48 hrs by SRB assay
    		[PMID: 21875046]
    AGS GI50
    0.02 μM
    Compound: Doxorubicin
    Growth inhibition of Homo sapiens (human) AGS cells after 48 hr by MTT assay
    Growth inhibition of Homo sapiens (human) AGS cells after 48 hr by MTT assay
    		10.1007/s00044-012-0232-6
    AGS IC50
    0.31 μM
    Compound: adriamycin
    Cytotoxicity against human AGS cells by MTT assay
    Cytotoxicity against human AGS cells by MTT assay
    		[PMID: 17125240]
    AGS IC50
    1.2 μM
    Compound: doxorubicin
    Cytotoxicity against human AGS cells assessed as growth inhibition after 48 hrs by MTT assay
    Cytotoxicity against human AGS cells assessed as growth inhibition after 48 hrs by MTT assay
    		[PMID: 23806110]
    AGS IC50
    10.9 μM
    Compound: ADR
    Cytotoxicity against human AGS cells after 48 hrs by MTT assay
    Cytotoxicity against human AGS cells after 48 hrs by MTT assay
    		10.1039/C2MD20270K
    AN3-CA EC50
    30 nM
    Compound: Doxorubicin
    Antiproliferative activity against human AN3-CA cells assessed as reduction in cell viability incubated for 5 days by celltiter-glo assay
    Antiproliferative activity against human AN3-CA cells assessed as reduction in cell viability incubated for 5 days by celltiter-glo assay
    		[PMID: 30996949]
    ARPE-19 IC50
    0.76 μM
    Compound: Doxorubicin
    Cytotoxicity against human ARPE19 cells after 48 hrs by Alamar blue assay
    Cytotoxicity against human ARPE19 cells after 48 hrs by Alamar blue assay
    		[PMID: 20931970]
    ASPC1 IC50
    0.86 μM
    Compound: Doxorubicin
    Cytotoxicity against human AsPC1 cells deficit of P53 gene incubated for 72 hrs by MTS assay
    Cytotoxicity against human AsPC1 cells deficit of P53 gene incubated for 72 hrs by MTS assay
    		[PMID: 31158748]
    ASPC1 IC50
    1.87 μM
    Compound: Adriamycin
    Cytotoxicity against human AsPC1 cells assessed as inhibition of cell proliferation after 48 hrs by XTT assay
    Cytotoxicity against human AsPC1 cells assessed as inhibition of cell proliferation after 48 hrs by XTT assay
    		[PMID: 24717154]
    ASPC1 IC50
    < 1 μM
    Compound: ADM
    Cytotoxicity against human ASPC1 cells by SRB method
    Cytotoxicity against human ASPC1 cells by SRB method
    		[PMID: 37807846]
    ASPC1 IC50
    < 1 μM
    Compound: Doxorubicin
    Cytotoxicity against human ASPC1 cells by SRB assay
    Cytotoxicity against human ASPC1 cells by SRB assay
    		[PMID: 33371684]
    ASPC1 IC50
    < 1 μM
    Compound: Doxorubicin
    Cytotoxicity against human ASPC1 cells assessed as reduction in cell growth by MTT assay
    Cytotoxicity against human ASPC1 cells assessed as reduction in cell growth by MTT assay
    		[PMID: 36734533]
    ASPC1 IC50
    < 1 μM
    Compound: Doxorubicin
    Cytotoxicity against human ASPC1 cells assessed as inhibition of cell growth by SRB assay
    Cytotoxicity against human ASPC1 cells assessed as inhibition of cell growth by SRB assay
    		[PMID: 38064664]
    AT3B-1 IC50
    167.5 μM
    Compound: 1, Dox
    Tumor killing activity in AT3B1 drug-resistant cell line by MTT assay
    Tumor killing activity in AT3B1 drug-resistant cell line by MTT assay
    		[PMID: 16168650]
    AT3B-1 IC50
    42.4 μM
    Compound: 1, Dox
    Inhibition of tumor killing activity in AT3B1 drug-resistant cell line with 10 uM verapamil (P-gp inhibitor)
    Inhibition of tumor killing activity in AT3B1 drug-resistant cell line with 10 uM verapamil (P-gp inhibitor)
    		[PMID: 16168650]
    B16 IC50
    0.001 μg/mL
    Compound: 1 (doxorubicin)
    In vitro inhibitory activity against mouse melanoma cell line (B16) using CV coloration
    In vitro inhibitory activity against mouse melanoma cell line (B16) using CV coloration
    		[PMID: 15013011]
    B16 IC50
    0.03 μM
    Compound: Doxorubicin
    Anticancer activity against mouse B16 cells after 48 hrs by MTT assay
    Anticancer activity against mouse B16 cells after 48 hrs by MTT assay
    		[PMID: 22668451]
    B16 IC50
    0.03 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against mouse B16 cells after 72 hrs by MTT assay
    Cytotoxicity against mouse B16 cells after 72 hrs by MTT assay
    		[PMID: 18586355]
    B16 IC50
    0.03 μg/mL
    Compound: doxorubicin
    Cytotoxicity against mouse B16 cells after 72 hrs by MTT assay
    Cytotoxicity against mouse B16 cells after 72 hrs by MTT assay
    		[PMID: 15787450]
    B16 IC50
    0.03 μg/mL
    Compound: doxorubicin
    Cytotoxicity against mouse B16 cells after 72 hrs by MTT assay
    Cytotoxicity against mouse B16 cells after 72 hrs by MTT assay
    		[PMID: 17827021]
    B16 IC50
    0.09 μg/mL
    Compound: Adriamycin
    In vitro inhibition of B16 (human colon) tumor cell growth.
    In vitro inhibition of B16 (human colon) tumor cell growth.
    		[PMID: 12161130]
    B16 IC50
    0.1 μM
    Compound: doxorubicin
    Cytotoxicity against murine B16 cells by MTT assay
    Cytotoxicity against murine B16 cells by MTT assay
    		[PMID: 17256903]
    B16 IC50
    0.11 μg/mL
    Compound: Adriamycin
    Inhibitory concentration against B16 murine melanoma cell line
    Inhibitory concentration against B16 murine melanoma cell line
    		[PMID: 11354370]
    B16 IC50
    0.14 μM
    Compound: DOX
    Antiproliferative activity against mouse B16 cells after 72 hrs by MTT assay
    Antiproliferative activity against mouse B16 cells after 72 hrs by MTT assay
    		[PMID: 21496972]
    B16 IC50
    0.18 μM
    Compound: ADM
    Antiproliferative activity against mouse B16 cells after 72 hrs by MTT assay
    Antiproliferative activity against mouse B16 cells after 72 hrs by MTT assay
    		[PMID: 25529742]
    B16 IC50
    0.18 μM
    Compound: ADM
    Antiproliferative activity against mouse B16 cells assessed as growth inhibition after 72 hrs by MTT assay
    Antiproliferative activity against mouse B16 cells assessed as growth inhibition after 72 hrs by MTT assay
    		[PMID: 25984840]
    B16 IC50
    0.18 μM
    Compound: Doxorubicin
    Antiproliferative activity against mouse B16 cells after 72 hrs MTT assay
    Antiproliferative activity against mouse B16 cells after 72 hrs MTT assay
    		[PMID: 25247772]
    B16 IC50
    0.2 μM
    Compound: Dox
    Cytotoxicity against mouse B16 cells after 72 hrs by MTT assay
    Cytotoxicity against mouse B16 cells after 72 hrs by MTT assay
    		[PMID: 30659997]
    B16 IC50
    0.43 μM
    Compound: Doxorubicin
    Cytotoxicity against mouse B16 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    Cytotoxicity against mouse B16 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    		[PMID: 26934105]
    B16 IC50
    0.54 μg/mL
    Compound: Adriamycin
    In vitro cytotoxicity against B16 tumor cell lines.
    In vitro cytotoxicity against B16 tumor cell lines.
    		[PMID: 9871531]
    B16 IC50
    1.7 μM
    Compound: Doxorubicin
    Cytotoxicity against mouse B16 cells after 48 hrs by MTT assay
    Cytotoxicity against mouse B16 cells after 48 hrs by MTT assay
    		[PMID: 22304344]
    B16 IC50
    17.67 μM
    Compound: doxorubicin
    Cytotoxicity against mouse B16 cells assessed as inhibition of cell viability after 24 hrs by MTT assay
    Cytotoxicity against mouse B16 cells assessed as inhibition of cell viability after 24 hrs by MTT assay
    		[PMID: 26200396]
    B16 IC50
    2.78 μM
    Compound: Doxorubicin
    Cytotoxicity against mouse B16 cells assessed as cell viability after 48 hrs by MTT assay
    Cytotoxicity against mouse B16 cells assessed as cell viability after 48 hrs by MTT assay
    		[PMID: 25594739]
    B16 IC50
    21.5 μM
    Compound: Doxorubicin
    Antiproliferative activity against mouse B16 cells after 48 hrs by MTT assay
    Antiproliferative activity against mouse B16 cells after 48 hrs by MTT assay
    		[PMID: 21620529]
    B16 IC50
    3.16 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against mouse B16 cells by MTT assay
    Cytotoxicity against mouse B16 cells by MTT assay
    		10.1039/C4MD00566J
    B16 IC50
    670 nM
    Compound: Doxorubicin
    Cytotoxicity against mouse B16 cells after 48 hrs by MTT assay
    Cytotoxicity against mouse B16 cells after 48 hrs by MTT assay
    		[PMID: 30172625]
    B16 IC50
    7.6 nM
    Compound: Adriamycin
    Inhibition of murine B16 melanoma cell proliferation measured by the MTT assay
    Inhibition of murine B16 melanoma cell proliferation measured by the MTT assay
    		[PMID: 10377224]
    B16 IC50
    90 ng/mL
    Compound: Adriamycin
    Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of B16 murine melanoma cell line
    Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of B16 murine melanoma cell line
    		[PMID: 12113817]
    B16 IC50
    < 0.001 μg/mL
    Compound: 1 (doxorubicin)
    In vitro cytotoxic concentration against mouse melanoma cell line (B16) using MTT coloration
    In vitro cytotoxic concentration against mouse melanoma cell line (B16) using MTT coloration
    		[PMID: 15013011]
    B16 IC50
    < 0.1 μM
    Compound: Doxorubicin
    Cytotoxicity against mouse B16 cells after 72 hrs by MTT assay
    Cytotoxicity against mouse B16 cells after 72 hrs by MTT assay
    		[PMID: 22330634]
    B16-BL6 IC50
    3.07 μM
    Compound: Doxorubicin
    Cytotoxicity against mouse B16-BL6 cells after 72 hrs by MTT assay
    Cytotoxicity against mouse B16-BL6 cells after 72 hrs by MTT assay
    		[PMID: 19689125]
    B16-BL6 IC50
    8.05 μM
    Compound: Doxorubicin
    Cytotoxicity against mouse B16-BL6 cells after 72 hrs by MTT assay
    Cytotoxicity against mouse B16-BL6 cells after 72 hrs by MTT assay
    		[PMID: 18440233]
    B16-F1 IC50
    0.23 μM
    Compound: Doxorubicin
    Antiproliferative activity against mouse B16-F1 cells after 72 hrs by MTT reduction assay
    Antiproliferative activity against mouse B16-F1 cells after 72 hrs by MTT reduction assay
    		[PMID: 28551177]
    B16-F10 IC50
    0.0031 μg/mL
    Compound: Doxorubicin
    In vitro inhibitory activity against B16F10 tumor cells
    In vitro inhibitory activity against B16F10 tumor cells
    		10.1016/S0960-894X(97)00191-1
    B16-F10 IC50
    0.016 μM
    Compound: DOX
    Cytotoxicity against mouse B16/F10 cells measured after 72 hrs by Celltiter-Glo assay
    Cytotoxicity against mouse B16/F10 cells measured after 72 hrs by Celltiter-Glo assay
    		[PMID: 31820976]
    B16-F10 IC50
    0.072 μM
    Compound: Doxorubicin
    Cytotoxicity against mouse B16F10 cells after 48 hrs by CCK8 assay
    Cytotoxicity against mouse B16F10 cells after 48 hrs by CCK8 assay
    		[PMID: 23777898]
    B16-F10 IC50
    0.12 μM
    Compound: Adriamycin
    Cytotoxicity against mouse B16F10 cells assessed as inhibition of cell proliferation after 48 hrs by XTT assay
    Cytotoxicity against mouse B16F10 cells assessed as inhibition of cell proliferation after 48 hrs by XTT assay
    		[PMID: 24717154]
    B16-F10 IC50
    0.19 μM
    Compound: ADM
    Antiproliferative activity against mouse B16F10 cells after 72 hrs by MTT assay
    Antiproliferative activity against mouse B16F10 cells after 72 hrs by MTT assay
    		[PMID: 30344912]
    B16-F10 IC50
    0.346 μM
    Compound: Doxorubicin
    Cytotoxicity activity against mouse B16F10 cells assessed as cell growth inhibition after 48 hrs by MTT assay
    Cytotoxicity activity against mouse B16F10 cells assessed as cell growth inhibition after 48 hrs by MTT assay
    		[PMID: 30433783]
    B16-F10 IC50
    0.663 μM
    Compound: Dox
    Cytotoxicity against mouse B16F10 cells assessed as cell killing effect after 72 hrs by MTT assay
    Cytotoxicity against mouse B16F10 cells assessed as cell killing effect after 72 hrs by MTT assay
    		[PMID: 26005543]
    B16-F10 IC50
    2.3 μM
    Compound: Doxorubicin
    Cytotoxicity against mouse B16-F10 cells assessed as reduction in cell viability incubated for 72 hrs by Alamar blue assay
    Cytotoxicity against mouse B16-F10 cells assessed as reduction in cell viability incubated for 72 hrs by Alamar blue assay
    		[PMID: 27300257]
    B16-F10 IC50
    3.28 μM
    Compound: Doxorubicin
    Anticancer activity against mouse B16-F10 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
    Anticancer activity against mouse B16-F10 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
    		[PMID: 34124677]
    B16-F10 IC50
    4.23 μM
    Compound: Doxorubicin
    Cytotoxicity against mouse B16F10 cells after 72 hrs by alamar blue assay
    Cytotoxicity against mouse B16F10 cells after 72 hrs by alamar blue assay
    		[PMID: 24969014]
    B16-F10 IC50
    4.33 μM
    Compound: Doxorubicin
    Cytotoxicity against mouse B16F10 spheroid cells assessed as reduction in spheroid cell viability after 48 hrs by MTT assay
    Cytotoxicity against mouse B16F10 spheroid cells assessed as reduction in spheroid cell viability after 48 hrs by MTT assay
    		[PMID: 30433783]
    B16-F10-luc2 IC50
    0.04 μM
    Compound: 1
    Cytotoxicity against mouse B16-F10-Luc2 cells expressing EGFR measured after 72 hrs in absence of cetuximab by resazurin assay
    Cytotoxicity against mouse B16-F10-Luc2 cells expressing EGFR measured after 72 hrs in absence of cetuximab by resazurin assay
    		[PMID: 34411983]
    B16-F10-luc2 IC50
    0.04 μM
    Compound: 1
    Cytotoxicity against mouse B16-F10-Luc2 cells expressing human EGFR measured after 72 hrs by resazurin assay
    Cytotoxicity against mouse B16-F10-Luc2 cells expressing human EGFR measured after 72 hrs by resazurin assay
    		[PMID: 34411983]
    B16-F10-luc2 IC50
    0.09 μM
    Compound: 1
    Cytotoxicity against mouse B16-F10-Luc2 cells expressing EGFR measured after 72 hrs in presence of 3.3 uM cetuximab by resazurin assay
    Cytotoxicity against mouse B16-F10-Luc2 cells expressing EGFR measured after 72 hrs in presence of 3.3 uM cetuximab by resazurin assay
    		[PMID: 34411983]
    B16-F10-luc2 IC50
    0.11 μM
    Compound: 1
    Cytotoxicity against mouse B16-F10-Luc2 cells measured after 72 hrs by resazurin assay
    Cytotoxicity against mouse B16-F10-Luc2 cells measured after 72 hrs by resazurin assay
    		[PMID: 34411983]
    BALB/3T3 GI50
    0.6 μM
    Compound: Dox
    Cytotoxicity against mouse BALB/3T3 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
    Cytotoxicity against mouse BALB/3T3 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
    		[PMID: 34634616]
    BALB/3T3 GI50
    0.62 μM
    Compound: Dox
    Antiproliferative activity against mouse BALB/3T3 cells incubated for 72 hrs and measured by MTT assay
    Antiproliferative activity against mouse BALB/3T3 cells incubated for 72 hrs and measured by MTT assay
    		[PMID: 35973342]
    BALB/3T3 IC50
    0.092 μM
    Compound: Doxorubicin
    Cytotoxicity against mouse BALB/3T3 cells incubated for 72 hrs by sulforhodamine B assay
    Cytotoxicity against mouse BALB/3T3 cells incubated for 72 hrs by sulforhodamine B assay
    		[PMID: 32432867]
    BALB/3T3 IC50
    0.11 μM
    Compound: Doxorubicin
    Cytotoxicity against mouse BALB/3T3 cells after 72 hrs by SRB assay
    Cytotoxicity against mouse BALB/3T3 cells after 72 hrs by SRB assay
    		[PMID: 26639764]
    BALB/3T3 IC50
    0.18 μM
    Compound: doxorubicin
    Antiproliferative activity against mouse BALB/3T3 cells assessed as growth inhibition after 72 hrs by SRB method
    Antiproliferative activity against mouse BALB/3T3 cells assessed as growth inhibition after 72 hrs by SRB method
    		[PMID: 25644674]
    BALB/3T3 IC50
    0.31 μM
    Compound: Doxorubicin
    Antiproliferative activity against mouse BALB/3T3 cells after 72 hrs
    Antiproliferative activity against mouse BALB/3T3 cells after 72 hrs
    		[PMID: 26163197]
    BALB/3T3 IC50
    0.5 μM
    Compound: Doxorubicin
    Antiproliferative activity mouse BALB/3T3 cells
    Antiproliferative activity mouse BALB/3T3 cells
    		[PMID: 24631190]
    BALB/3T3 IC50
    0.53 μM
    Compound: Doxorubicin
    Cytotoxicity against mouse BALB/3T3 cells
    Cytotoxicity against mouse BALB/3T3 cells
    		[PMID: 26338363]
    BALB/3T3 IC50
    1.08 μM
    Compound: Doxorubicin
    Cytotoxicity against mouse BALB/3T3 cells assessed as cell viability after 1 hr by sulforhodamine B assay
    Cytotoxicity against mouse BALB/3T3 cells assessed as cell viability after 1 hr by sulforhodamine B assay
    		[PMID: 26496013]
    BALB/3T3 IC50
    1.91 μM
    Compound: Doxorubicin
    Cytotoxicity against mouse BALB/3T3 cells incubated for 72 hrs by MTT assay
    Cytotoxicity against mouse BALB/3T3 cells incubated for 72 hrs by MTT assay
    		[PMID: 23079523]
    BALB/3T3 IC50
    166 nM
    Compound: DOX; DX
    Antiproliferative activity against mouse BALB/3T3 cells assessed as reduction in cell viability incubated for 120 hrs by MTT assay
    Antiproliferative activity against mouse BALB/3T3 cells assessed as reduction in cell viability incubated for 120 hrs by MTT assay
    		[PMID: 31653441]
    BALB/3T3 IC50
    166 nM
    Compound: Doxorubicin
    Antiproliferative activity against mouse BALB/3T3 cells incubated for 72 hrs by SRB assay
    Antiproliferative activity against mouse BALB/3T3 cells incubated for 72 hrs by SRB assay
    		[PMID: 33465696]
    BALB/3T3 IC50
    200 nM
    Compound: DX
    Antiproliferative activity against mouse BALB/3T3 cells assessed as inhibition of proliferation after 72 hrs by SRB assay
    Antiproliferative activity against mouse BALB/3T3 cells assessed as inhibition of proliferation after 72 hrs by SRB assay
    		[PMID: 34116158]
    BALB/3T3 IC50
    315 nM
    Compound: DX
    Cytotoxicity against mouse BALB/3T3 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
    Cytotoxicity against mouse BALB/3T3 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
    		[PMID: 34592435]
    BALB/3T3 IC50
    32.3 nM
    Compound: DX
    Cytotoxicity against mouse BALB/3T3 cells assessed as inhibition of cell growth measured after 72 hrs by SRB assay
    Cytotoxicity against mouse BALB/3T3 cells assessed as inhibition of cell growth measured after 72 hrs by SRB assay
    		[PMID: 33611191]
    BC IC50
    0.17 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human BC cells by colorimetric method
    Cytotoxicity against human BC cells by colorimetric method
    		[PMID: 16989536]
    BC IC50
    0.3 μM
    Compound: Doxorubicin
    Cytotoxicity against human BC cells by SRB assay
    Cytotoxicity against human BC cells by SRB assay
    		[PMID: 20038128]
    BC IC50
    0.5 μM
    Compound: doxorubicin
    Cytotoxicity against human BC cells
    Cytotoxicity against human BC cells
    		[PMID: 16919455]
    BC IC50
    2.88 x 10-4 M
    Compound: doxorubicin
    Cytotoxicity against human BC cells by SRB assay
    Cytotoxicity against human BC cells by SRB assay
    		[PMID: 16933890]
    BEAS-2B GI50
    0.1 μM
    Compound: Doxorubicin
    Antiproliferative activity against human BEAS2B cells after 72 hrs by MTT assay
    Antiproliferative activity against human BEAS2B cells after 72 hrs by MTT assay
    		[PMID: 30071406]
    BEAS-2B GI50
    0.13 μM
    Compound: Doxorubicin
    Cytotoxicity against human BEAS2B cells assessed as growth inhibition after 72 hrs by MTT assay
    Cytotoxicity against human BEAS2B cells assessed as growth inhibition after 72 hrs by MTT assay
    		[PMID: 29670691]
    BEAS-2B IC50
    0.8 μM
    Compound: Doxorubicin
    Cytotoxicity against human BEAS-2B cells assessed as cell growth inhibition
    Cytotoxicity against human BEAS-2B cells assessed as cell growth inhibition
    		[PMID: 36092140]
    BEAS-2B IC50
    18.6 μM
    Compound: Doxorubicin
    Cytotoxicity against human BEAS2B cells assessed as reduction in cell viability after 70 hrs by alamar blue assay
    Cytotoxicity against human BEAS2B cells assessed as reduction in cell viability after 70 hrs by alamar blue assay
    		[PMID: 29471119]
    BEAS-2B IC50
    2.4 μM
    Compound: Doxorubicin
    Antiproliferative activity against human BEAS2B cells after 70 hrs by alamar blue assay
    Antiproliferative activity against human BEAS2B cells after 70 hrs by alamar blue assay
    		[PMID: 29471119]
    BEAS-2B IC50
    42 μM
    Compound: DOX
    Cytotoxicity against human BEAS-2B cells assessed as inhibition of cell viability incubated for 48 hrs by MTT assay
    Cytotoxicity against human BEAS-2B cells assessed as inhibition of cell viability incubated for 48 hrs by MTT assay
    		[PMID: 38169372]
    BGC-823 IC50
    0.35 μM
    Compound: adriamycin
    Cytotoxicity against human BGC823 cells after 48 hrs
    Cytotoxicity against human BGC823 cells after 48 hrs
    		[PMID: 17583953]
    BGC-823 IC50
    0.405 μM
    Compound: ADR
    Antiproliferative activity against human BGC823 cells after 72 hrs by sulforhodamine B assay
    Antiproliferative activity against human BGC823 cells after 72 hrs by sulforhodamine B assay
    		[PMID: 30241010]
    BGC-823 IC50
    0.66 μM
    Compound: DOX
    Antiproliferative activity against human BGC-823 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay
    Antiproliferative activity against human BGC-823 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay
    		[PMID: 35341920]
    BGC-823 IC50
    0.9 μM
    Compound: Doxorubicin
    Cytotoxicity against human BGC823 cells after 72 hrs by MTT assay
    Cytotoxicity against human BGC823 cells after 72 hrs by MTT assay
    		[PMID: 22749279]
    BGC-823 IC50
    1 μM
    Compound: adriamycin
    Cytotoxicity against human BGC-823 cells by MTT assay
    Cytotoxicity against human BGC-823 cells by MTT assay
    		[PMID: 17190442]
    BGC-823 IC50
    1.33 μM
    Compound: Adriamycin
    Cytotoxicity against human BGC823 cells by MTT assay
    Cytotoxicity against human BGC823 cells by MTT assay
    		[PMID: 23434227]
    BGC-823 IC50
    1.48 μM
    Compound: Adriamycin
    Cytotoxicity against human BGC823 cells by MTT assay
    Cytotoxicity against human BGC823 cells by MTT assay
    		[PMID: 24182355]
    BGC-823 IC50
    2.6 μM
    Compound: ADM
    Antiproliferative against human BGC823 cells assessed as growth inhibition after 72 hrs by MTT assay
    Antiproliferative against human BGC823 cells assessed as growth inhibition after 72 hrs by MTT assay
    		10.1039/C1MD00038A
    BGC-823 IC50
    38.2 μM
    Compound: 21
    Antitumor activity against human BGC-823 cells assessed as cell growth inhibition
    Antitumor activity against human BGC-823 cells assessed as cell growth inhibition
    		[PMID: 36858050]
    BGC-823 IC50
    4.8 μM
    Compound: Doxorubicin
    Antitumor activity against human BGC823 cells after 48 hrs by SRB assay
    Antitumor activity against human BGC823 cells after 48 hrs by SRB assay
    		[PMID: 20884091]
    BGC-823 IC50
    9.8 μM
    Compound: Doxorubicin
    Cytotoxicity against human BGC-823 cells measured after 24 to 72 hrs by MTT assay
    Cytotoxicity against human BGC-823 cells measured after 24 to 72 hrs by MTT assay
    		[PMID: 37482018]
    BJ GI50
    8.91 μM
    Compound: Doxorubicin
    Cytotoxicity against human BJ cells assessed as cell growth inhibition
    Cytotoxicity against human BJ cells assessed as cell growth inhibition
    		[PMID: 36584305]
    BJ IC50
    0.39 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human BJ cells incubated for 24 hrs by MTT assay
    Cytotoxicity against human BJ cells incubated for 24 hrs by MTT assay
    		[PMID: 38505856]
    BJ IC50
    0.78 μg/mL
    Compound: DOX
    Cytotoxicity against human BJ cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    Cytotoxicity against human BJ cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    		[PMID: 36958177]
    BJ IC50
    17.62 μM
    Compound: DOX
    Cytotoxicity against human BJ cells
    Cytotoxicity against human BJ cells
    		[PMID: 30015070]
    BJ IC50
    2.33 μM
    Compound: DOXO
    Cytotoxicity against human BJ cells assessed as cell viability after 48 hrs by alamar blue assay
    Cytotoxicity against human BJ cells assessed as cell viability after 48 hrs by alamar blue assay
    		[PMID: 21797280]
    BJ IC50
    2.33 μM
    Compound: Doxorubicin
    Cytotoxicity against human BJ cells after 48 hrs by Alamar blue assay
    Cytotoxicity against human BJ cells after 48 hrs by Alamar blue assay
    		[PMID: 20931970]
    BJ IC50
    2.7 μM
    Compound: Doxorubicin
    Cytotoxicity against human BJ cells after 48 hrs by Alamar Blue assay
    Cytotoxicity against human BJ cells after 48 hrs by Alamar Blue assay
    		[PMID: 19473028]
    BMDM IC50
    4.6 μM
    Compound: Adriamycin
    Cytotoxicity against mouse BMDM cells after 72 hrs by MTT assay
    Cytotoxicity against mouse BMDM cells after 72 hrs by MTT assay
    		[PMID: 22616554]
    BT-474 EC50
    623 nM
    Compound: Doxorubicin
    Antiproliferative activity against human BT-474 cells assessed as reduction in cell viability incubated for 5 days by celltiter-glo assay
    Antiproliferative activity against human BT-474 cells assessed as reduction in cell viability incubated for 5 days by celltiter-glo assay
    		[PMID: 30996949]
    BT-474 IC50
    0.041 μM
    Compound: DOX
    Antiproliferative activity against human BT474 cells after 48 hrs by CellTiter-Glo assay
    Antiproliferative activity against human BT474 cells after 48 hrs by CellTiter-Glo assay
    		[PMID: 27769032]
    BT-474 IC50
    0.053 μM
    Compound: DOX
    Antiproliferative activity against human BT474 cells after 24 hrs by CellTiter-Glo assay
    Antiproliferative activity against human BT474 cells after 24 hrs by CellTiter-Glo assay
    		[PMID: 27769032]
    BT-474 IC50
    0.07 μM
    Compound: Dox
    Cytotoxicity against human BT474 cells after 3 days by MTT assay
    Cytotoxicity against human BT474 cells after 3 days by MTT assay
    		[PMID: 21741833]
    BT-474 IC50
    0.18 μM
    Compound: DOX
    Antiproliferative activity against human BT474 spheroids after 3 days by CellTiter-Glo assay
    Antiproliferative activity against human BT474 spheroids after 3 days by CellTiter-Glo assay
    		[PMID: 27769032]
    BT-474 IC50
    0.3 μM
    Compound: Doxorubicin
    Cytotoxicity against human BT474 cells assessed as reduction in cell survival after 48 hrs by MTT assay
    Cytotoxicity against human BT474 cells assessed as reduction in cell survival after 48 hrs by MTT assay
    		[PMID: 28494255]
    BT-474 IC50
    1.9 μM
    Compound: DOX
    Cytotoxicity against human BT474 cells measured after 72 hrs by Celltiter-Glo assay
    Cytotoxicity against human BT474 cells measured after 72 hrs by Celltiter-Glo assay
    		[PMID: 31820976]
    BT-474 IC50
    8.92 μg/mL
    Compound: doxorubicin
    Cytotoxicity against human BT474 cells after 3 days by MTT assay
    Cytotoxicity against human BT474 cells after 3 days by MTT assay
    		[PMID: 19456120]
    BT-549 GI50
    0.01 μM
    Compound: Doxorubicin
    Cytostatic activity against human BT549 cells after 5 days by SRB assay
    Cytostatic activity against human BT549 cells after 5 days by SRB assay
    		[PMID: 21711054]
    BT-549 GI50
    0.23 μM
    Compound: Doxorubicin
    Growth inhibition of human BT549 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human BT549 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28329730]
    BT-549 GI50
    0.23 μM
    Compound: Doxorubicin
    Growth inhibition of human BT549 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human BT549 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 29102177]
    BT-549 GI50
    0.23 μM
    Compound: Doxorubicin hydrochloride, NSC 123127
    Cytotoxicity against human BT549 cells after 48 hrs by SRB assay
    Cytotoxicity against human BT549 cells after 48 hrs by SRB assay
    		[PMID: 23871905]
    BT-549 IC50
    0.008 μg/mL
    Compound: doxorubicin
    Cytotoxicity against human BT549 cells after 2 to 7 days by neutral red assay
    Cytotoxicity against human BT549 cells after 2 to 7 days by neutral red assay
    		[PMID: 8984156]
    BT-549 IC50
    0.009 μM
    Compound: Doxorubicin
    Antiproliferative activity against human BT-549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Antiproliferative activity against human BT-549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    		[PMID: 27010926]
    BT-549 IC50
    0.01 μM
    Compound: Doxorubicin
    Cytotoxicity against human BT549 cells assessed as growth inhibition after 72 hrs by SRB assay
    Cytotoxicity against human BT549 cells assessed as growth inhibition after 72 hrs by SRB assay
    		[PMID: 30457333]
    BT-549 IC50
    0.045 μM
    Compound: Doxorubicin
    Cytotoxicity against human BT549 cells after 48 hrs by neutral red dye based assay
    Cytotoxicity against human BT549 cells after 48 hrs by neutral red dye based assay
    		[PMID: 29317147]
    BT-549 IC50
    0.11 μM
    Compound: Doxorubicin
    Cytotoxicity against human BT549 cells after 72 hrs by resazurin/resorufin-based fluorescence assay
    Cytotoxicity against human BT549 cells after 72 hrs by resazurin/resorufin-based fluorescence assay
    		[PMID: 23600925]
    BT-549 IC50
    0.17 μM
    Compound: Doxorubicin
    Cytotoxicity against human BT549 cells after 48 hrs by neutral red assay relative to control
    Cytotoxicity against human BT549 cells after 48 hrs by neutral red assay relative to control
    		[PMID: 25975638]
    BT-549 IC50
    0.6 μg/mL
    Compound: doxorubicin
    Cytotoxicity against human BT549 cells by neutral red assay
    Cytotoxicity against human BT549 cells by neutral red assay
    		[PMID: 17976995]
    BT-549 IC50
    0.8 μg/mL
    Compound: doxorubicin
    Cytotoxicity against human BT549 cells after 48 hrs by Neutral Red dye
    Cytotoxicity against human BT549 cells after 48 hrs by Neutral Red dye
    		[PMID: 20550123]
    BT-549 IC50
    1.2 μM
    Compound: Doxorubicin
    Cytotoxicity against human BT549 cells after 48 hrs by Neutral red assay
    Cytotoxicity against human BT549 cells after 48 hrs by Neutral red assay
    		[PMID: 19658408]
    BT-549 IC50
    1.35 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human BT549 cells assessed as cell growth inhibition after 48 hrs by neutral red dye based assay
    Cytotoxicity against human BT549 cells assessed as cell growth inhibition after 48 hrs by neutral red dye based assay
    		[PMID: 27769668]
    BT-549 IC50
    1.3 μg/mL
    Compound: doxorubicin
    Cytotoxicity against human BT549 cells after 48 hrs by neutral red dye staining
    Cytotoxicity against human BT549 cells after 48 hrs by neutral red dye staining
    		[PMID: 19928902]
    BT-549 IC50
    1.6 μM
    Compound: Doxorubicin
    Cytotoxicity against human BT549 cells assessed as cell growth inhibition after 48 hrs by neutral red assay
    Cytotoxicity against human BT549 cells assessed as cell growth inhibition after 48 hrs by neutral red assay
    		[PMID: 26005918]
    BT-549 IC50
    1.96 μM
    Compound: doxorubicin
    Cytotoxicity against human BT549 cells after 48 hrs by neutral red assay
    Cytotoxicity against human BT549 cells after 48 hrs by neutral red assay
    		[PMID: 19879765]
    BT-549 IC50
    1 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human BT549 cells after 48 hrs by neutral red staining
    Cytotoxicity against human BT549 cells after 48 hrs by neutral red staining
    		[PMID: 15165136]
    BT-549 IC50
    1 μg/mL
    Compound: doxorubicin
    Cytotoxicity against human BT549 cells
    Cytotoxicity against human BT549 cells
    		[PMID: 12880315]
    BT-549 IC50
    2.6 μM
    Compound: doxorubicin
    Cytotoxicity against human BT549 cells assessed as viable cells by neutral red dye method
    Cytotoxicity against human BT549 cells assessed as viable cells by neutral red dye method
    		[PMID: 22530813]
    BT-549 IC50
    3.6 μM
    Compound: Doxorubicin
    Cytotoxicity against human BT549 cells assessed as reduction in cell viability after 48 hrs by neutral red dye-based assay
    Cytotoxicity against human BT549 cells assessed as reduction in cell viability after 48 hrs by neutral red dye-based assay
    		[PMID: 27618204]
    BT-549 IC50
    3.7 μM
    Compound: doxorubicin
    Cytotoxicity against human BT549 cells assessed as growth inhibition measured after 48 hrs by XTT assay
    Cytotoxicity against human BT549 cells assessed as growth inhibition measured after 48 hrs by XTT assay
    		[PMID: 23547843]
    BT-549 IC50
    < 0.55 μM
    Compound: Doxorubicin
    Cytotoxicity against Homo sapiens (human) BT549 cells by neutral red staining
    Cytotoxicity against Homo sapiens (human) BT549 cells by neutral red staining
    		10.1007/s00044-011-9587-3
    BT-549 IC50
    < 0.55 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human BT549 cells after 48 hrs by neutral red assay
    Cytotoxicity against human BT549 cells after 48 hrs by neutral red assay
    		[PMID: 19105653]
    BT-549 IC50
    < 1.1 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human BT549 cells after 2 to 7 days by neutral red assay
    Cytotoxicity against human BT549 cells after 2 to 7 days by neutral red assay
    		[PMID: 11374943]
    BXPC-3 IC50
    0.02 μM
    Compound: Doxorubicin
    Antiproliferative activity against human BxPC3 cells assessed as inhibition of cell proliferation incubated for 72 hrs by conventional ATP quantification method
    Antiproliferative activity against human BxPC3 cells assessed as inhibition of cell proliferation incubated for 72 hrs by conventional ATP quantification method
    		[PMID: 25937235]
    BXPC-3 IC50
    0.4 μM
    Compound: DOX, Doxorubicin
    Antiproliferative activity against human BxPC3 cells after 72 hrs by MTT assay
    Antiproliferative activity against human BxPC3 cells after 72 hrs by MTT assay
    		[PMID: 24095089]
    BXPC-3 IC50
    0.56 μM
    Compound: Doxorubicin
    Antiproliferative activity against human BxPC3 cells after 48 hrs by MTT assay
    Antiproliferative activity against human BxPC3 cells after 48 hrs by MTT assay
    		[PMID: 28554092]
    BXPC-3 IC50
    1.78 μM
    Compound: Doxorubicin
    Antiproliferative activity against human BxPC3 cells assessed as growth inhibition incubated for 48 hrs by MTT assay
    Antiproliferative activity against human BxPC3 cells assessed as growth inhibition incubated for 48 hrs by MTT assay
    		[PMID: 26253231]
    BXPC-3 IC50
    13 μM
    Compound: Doxorubicin
    Cytotoxicity against human BxPC3 cells after 48 hrs by MTT assay
    Cytotoxicity against human BxPC3 cells after 48 hrs by MTT assay
    		[PMID: 27173802]
    BXPC-3 IC50
    13.56 μM
    Compound: Doxorubicin
    Cytotoxicity against human BxPC3 cells after 48 hrs by MTT assay
    Cytotoxicity against human BxPC3 cells after 48 hrs by MTT assay
    		[PMID: 29573910]
    BXPC-3 IC50
    14.3 μM
    Compound: Doxorubicin
    Cytotoxicity against human BxPC3 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Cytotoxicity against human BxPC3 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    		[PMID: 28254167]
    BXPC-3 IC50
    9.12 μM
    Compound: Doxorubicin
    Growth inhibition of human BxPC3 cells after 48 hrs by MTT assay
    Growth inhibition of human BxPC3 cells after 48 hrs by MTT assay
    		[PMID: 30072225]
    Bcap37 IC50
    1.12 μM
    Compound: AMD
    Cytotoxicity against human Bcap37 cells after 48 hrs by MTT assay
    Cytotoxicity against human Bcap37 cells after 48 hrs by MTT assay
    		[PMID: 26900656]
    Bcap37 IC50
    1.19 μM
    Compound: AMD
    Antiproliferative activity against human Bcap37 cells after 48 hrs by MTT assay
    Antiproliferative activity against human Bcap37 cells after 48 hrs by MTT assay
    		[PMID: 26807545]
    Bcap37 IC50
    1.2 μM
    Compound: ADM
    Cytotoxicity against human Bcap37 cells after 72 hrs by MTT assay
    Cytotoxicity against human Bcap37 cells after 72 hrs by MTT assay
    		[PMID: 25874331]
    Bcap37 IC50
    1.2 μM
    Compound: ADM
    Cytotoxicity against human Bcap37 cells after 72 hrs by MTT assay
    Cytotoxicity against human Bcap37 cells after 72 hrs by MTT assay
    		[PMID: 26280921]
    Bcap37 IC50
    1.28 μM
    Compound: ADM
    Antiproliferative activity against human Bcap37 cells after 72 hrs by MTT assay
    Antiproliferative activity against human Bcap37 cells after 72 hrs by MTT assay
    		[PMID: 23124210]
    Bcap37 IC50
    1.9 μM
    Compound: ADM
    Cytotoxicity against human Bcap37 cells after 72 hrs by MTT assay
    Cytotoxicity against human Bcap37 cells after 72 hrs by MTT assay
    		10.1007/s00044-013-0854-3
    Bcap37 IC50
    2 μM
    Compound: ADM
    Antiproliferative against human Bcap37 cells assessed as growth inhibition after 72 hrs by MTT assay
    Antiproliferative against human Bcap37 cells assessed as growth inhibition after 72 hrs by MTT assay
    		10.1039/C1MD00038A
    Bcap37 IC50
    2.87 μM
    Compound: ADM
    Cytotoxicity against human Bcap37 cells after 38 hrs by MTT assay
    Cytotoxicity against human Bcap37 cells after 38 hrs by MTT assay
    		[PMID: 25965778]
    BeWo IC50
    1.07 μM
    Compound: Doxorubicin
    Antitumor activity against human Bewo cells assessed as inhibition of cell growth by MTT assay
    Antitumor activity against human Bewo cells assessed as inhibition of cell growth by MTT assay
    		[PMID: 25160837]
    BeWo IC50
    6.24 μg/mL
    Compound: (20) adriamycin
    In vitro cytotoxicity of compound against Bewo, human choriocarcinoma was defined by microculture tetrazolium assay
    In vitro cytotoxicity of compound against Bewo, human choriocarcinoma was defined by microculture tetrazolium assay
    		[PMID: 12620075]
    Bel-7402 GI50
    < 1 μM
    Compound: DOX
    Antiproliferative activity against human Bel7402 cells by MTT assay
    Antiproliferative activity against human Bel7402 cells by MTT assay
    		[PMID: 31990554]
    Bel-7402 IC50
    0.01 μg/mL
    Compound: ADR
    Cytotoxicity against human Bel7402 cells after 72 hrs by MTT assay
    Cytotoxicity against human Bel7402 cells after 72 hrs by MTT assay
    		[PMID: 18590312]
    Bel-7402 IC50
    0.01 μg/mL
    Compound: ADR
    Cytotoxicity against human Bel7402 cells after 72 hrs by SRB assay
    Cytotoxicity against human Bel7402 cells after 72 hrs by SRB assay
    		[PMID: 18590312]
    Bel-7402 IC50
    0.021 μM
    Compound: adriamycin
    Cytotoxicity against human Bel7402 cells after 72 hrs by SRB assay
    Cytotoxicity against human Bel7402 cells after 72 hrs by SRB assay
    		[PMID: 19028425]
    Bel-7402 IC50
    0.049 μM
    Compound: Doxorubicin
    Cytotoxicity against human Bel7402 cells after 48 hrs by MTT assay
    Cytotoxicity against human Bel7402 cells after 48 hrs by MTT assay
    		[PMID: 20846862]
    Bel-7402 IC50
    0.067 μM
    Compound: ADR
    Cytotoxicity against human Bel7402 cells after 72 hrs by sulforhodamine B assay
    Cytotoxicity against human Bel7402 cells after 72 hrs by sulforhodamine B assay
    		[PMID: 20949916]
    Bel-7402 IC50
    0.12 μM
    Compound: Adriamycin
    Cytotoxicity against human Bel7402 cells after 72 hrs by SRB assay
    Cytotoxicity against human Bel7402 cells after 72 hrs by SRB assay
    		[PMID: 20593838]
    Bel-7402 IC50
    0.22 μM
    Compound: ADM
    Antiproliferative activity against human Bel7402 cells after 72 hrs by MTT assay
    Antiproliferative activity against human Bel7402 cells after 72 hrs by MTT assay
    		[PMID: 25529742]
    Bel-7402 IC50
    0.22 μM
    Compound: ADM
    Antiproliferative activity against human Bel7402 cells assessed as growth inhibition after 72 hrs by MTT assay
    Antiproliferative activity against human Bel7402 cells assessed as growth inhibition after 72 hrs by MTT assay
    		[PMID: 25984840]
    Bel-7402 IC50
    0.22 μM
    Compound: Doxorubicin
    Antiproliferative activity against human Bel7402 cells after 72 hrs MTT assay
    Antiproliferative activity against human Bel7402 cells after 72 hrs MTT assay
    		[PMID: 25247772]
    Bel-7402 IC50
    0.43 μM
    Compound: DOX
    Cytotoxicity against human Bel-7402 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 assay
    Cytotoxicity against human Bel-7402 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 assay
    		[PMID: 38039790]
    Bel-7402 IC50
    0.53 μM
    Compound: Adriamycin
    Cytotoxicity against human Bel7402 cells by MTT assay
    Cytotoxicity against human Bel7402 cells by MTT assay
    		[PMID: 22070654]
    Bel-7402 IC50
    0.58 μM
    Compound: Doxorubicin
    Antiproliferative activity human Bel7402 cells after 20 hrs by MTT assay
    Antiproliferative activity human Bel7402 cells after 20 hrs by MTT assay
    		[PMID: 20149494]
    Bel-7402 IC50
    0.6 μM
    Compound: ADM
    Cytotoxic activity against human Bel7402 cells by MTT method
    Cytotoxic activity against human Bel7402 cells by MTT method
    		[PMID: 25611519]
    Bel-7402 IC50
    0.9 μM
    Compound: ADM
    Antiproliferative activity against human Bel7402 cells after 24 hrs by MTT assay
    Antiproliferative activity against human Bel7402 cells after 24 hrs by MTT assay
    		[PMID: 20932754]
    Bel-7402 IC50
    1 μM
    Compound: adriamycin
    Cytotoxicity against human Bel-7402 cells by MTT assay
    Cytotoxicity against human Bel-7402 cells by MTT assay
    		[PMID: 17190442]
    Bel-7402 IC50
    1.36 μM
    Compound: DOX
    Cytotoxicity against human Bel7402 cells after 48 hrs by MTT assay
    Cytotoxicity against human Bel7402 cells after 48 hrs by MTT assay
    		[PMID: 26386603]
    Bel-7402 IC50
    5 μM
    Compound: Doxorubicin
    Antitumor activity against human Bel7402 cells after 48 hrs by SRB assay
    Antitumor activity against human Bel7402 cells after 48 hrs by SRB assay
    		[PMID: 20884091]
    Bel-7402 IC50
    578.2 nM
    Compound: Doxorubicin
    Antiproliferative against human Bel7402 cells assessed as cell viability after 96 hrs by MTT assay
    Antiproliferative against human Bel7402 cells assessed as cell viability after 96 hrs by MTT assay
    		[PMID: 24211639]
    Bel-7402 IC50
    < 1 μM
    Compound: doxorubicin
    Cytotoxicity against human Bel-7402 cells by SRB assay
    Cytotoxicity against human Bel-7402 cells by SRB assay
    		[PMID: 33847126]
    Bel-7402 IC50
    > 1 μM
    Compound: Doxorubicin
    Antiproliferative activity against human Bel-7402 cells by MTT assay
    Antiproliferative activity against human Bel-7402 cells by MTT assay
    		[PMID: 36089748]
    Breast cancer cell line IC50
    0.9 μg/mL
    Compound: DOX
    Tested for anticancer activity against human breast cancer
    Tested for anticancer activity against human breast cancer
    		[PMID: 11514168]
    C-33-A IC50
    0.28 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human C33A cells after 48 hrs by SRB assay
    Cytotoxicity against human C33A cells after 48 hrs by SRB assay
    		[PMID: 20732814]
    C-33-A IC50
    0.82 μM
    Compound: Doxorubicin
    Cytotoxicity against human C33A cells after 48 hrs by sulforhodamine B assay
    Cytotoxicity against human C33A cells after 48 hrs by sulforhodamine B assay
    		[PMID: 21071221]
    C3H IC50
    0.04 μM
    Compound: Doxorubicin
    Cytotoxicity against mouse C3H cells after 72 hrs by MTS assay
    Cytotoxicity against mouse C3H cells after 72 hrs by MTS assay
    		[PMID: 26810263]
    C6 IC50
    0.1 μM
    Compound: Dox
    Cytotoxicity against rat C6 cells after 72 hrs by MTT assay
    Cytotoxicity against rat C6 cells after 72 hrs by MTT assay
    		[PMID: 30659997]
    C6 IC50
    0.5 μM
    Compound: Dox
    Cytotoxicity against rat C6 cells after 72 hrs by sulforhodamine B assay
    Cytotoxicity against rat C6 cells after 72 hrs by sulforhodamine B assay
    		[PMID: 28504888]
    C6 IC50
    25.64 μM
    Compound: Dox
    Cytotoxicity against rat C6 cells assessed as cell viability measured after 24 hrs by MTT assay
    Cytotoxicity against rat C6 cells assessed as cell viability measured after 24 hrs by MTT assay
    		[PMID: 33183865]
    C8166 IC50
    0.02 μM
    Compound: Doxorubicin
    Antitumor activity against CD4+ human acute T-lymphoblastic C8166 leukemia cells.
    Antitumor activity against CD4+ human acute T-lymphoblastic C8166 leukemia cells.
    		[PMID: 12431049]
    C8166 IC50
    0.02 μM
    Compound: doxo
    Antiproliferative activity against human C8166 cell line by MTT assay
    Antiproliferative activity against human C8166 cell line by MTT assay
    		[PMID: 16913700]
    C8166 IC50
    0.02 μM
    Compound: doxorubicin
    Antitumor activity against CD+ human acute T-lymphoblastic leukemia C8166 cells
    Antitumor activity against CD+ human acute T-lymphoblastic leukemia C8166 cells
    		[PMID: 12431048]
    C8166 IC50
    0.05 μM
    Compound: Doxorubicin
    Compound was tested for its effect on the proliferation of C8166 cells expressing the TAT gene of HTLV-1.
    Compound was tested for its effect on the proliferation of C8166 cells expressing the TAT gene of HTLV-1.
    		10.1016/0960-894X(96)00216-8
    CAKI-1 GI50
    0.95 μM
    Compound: Doxorubicin
    Growth inhibition of human Caki1 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human Caki1 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 29102177]
    CAKI-1 GI50
    0.95 μM
    Compound: Doxorubicin hydrochloride, NSC 123127
    Cytotoxicity against human Caki1 cells after 48 hrs by SRB assay
    Cytotoxicity against human Caki1 cells after 48 hrs by SRB assay
    		[PMID: 23871905]
    CAL-27 IC50
    0.18 μM
    Compound: DOX
    Antiproliferative activity against human CAL-27 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay
    Antiproliferative activity against human CAL-27 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay
    		[PMID: 36709571]
    CAL-27 IC50
    0.4 μM
    Compound: Doxorubicin
    Cytotoxicity against human CAL-27 cells assessed as cell growth inhibition
    Cytotoxicity against human CAL-27 cells assessed as cell growth inhibition
    		[PMID: 36092140]
    CAL-27 IC50
    1.56 μM
    Compound: AMD
    Anticancer activity against human CAL-27 cells assessed as inhibition of cell growth
    Anticancer activity against human CAL-27 cells assessed as inhibition of cell growth
    		[PMID: 28888820]
    CAPAN-1 IC50
    1.7 μM
    Compound: Dox
    Antiproliferative activity against human CAPAN-1 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay
    Antiproliferative activity against human CAPAN-1 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay
    		[PMID: 32428792]
    CAPAN-1 IC50
    1.7 μM
    Compound: Doxorubicin
    Cytotoxicity against human Capan1 cells assessed as reduction in cell viability
    Cytotoxicity against human Capan1 cells assessed as reduction in cell viability
    		[PMID: 30660827]
    CAPAN-1 IC50
    1.7 μM
    Compound: Doxorubicin
    Cytotoxicity in human CAPAN-1 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Cytotoxicity in human CAPAN-1 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    		[PMID: 34082225]
    CAPAN-1 IC50
    1.71 μM
    Compound: Dox
    Antiproliferative activity against human CAPAN-1 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    Antiproliferative activity against human CAPAN-1 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    		[PMID: 38176358]
    CAPAN-1 IC50
    1.8 μM
    Compound: Doxorubicin
    Cytotoxicity against human Capan1 cells assessed as reduction in cell viability by MTT assay
    Cytotoxicity against human Capan1 cells assessed as reduction in cell viability by MTT assay
    		[PMID: 30660827]
    CCD 19Lu IC50
    2 μg/mL
    Compound: Adriamycin (ADM)
    Tested for the cytostatic activity as inhibitory concentration against CCD-19Lu (human normal pulmonary) cells
    Tested for the cytostatic activity as inhibitory concentration against CCD-19Lu (human normal pulmonary) cells
    		10.1016/S0960-894X(97)00071-1
    CCD-18Co IC50
    0.269 μM
    Compound: DOX
    Cytotoxicity against human CCD-18Co cells incubated for 72 hrs by SRB assay
    Cytotoxicity against human CCD-18Co cells incubated for 72 hrs by SRB assay
    		[PMID: 38996651]
    CCD-18Co IC50
    757.1 nM
    Compound: Dox
    Cytotoxicity against human CCD-18Co cells incubated for 72 hrs by SRB assay
    Cytotoxicity against human CCD-18Co cells incubated for 72 hrs by SRB assay
    		[PMID: 37480713]
    CCD-841CoN IC50
    1.5 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human CCD-841CoN cells assessed as cell growth inhibition measured after 24 hrs by MTT assay
    Cytotoxicity against human CCD-841CoN cells assessed as cell growth inhibition measured after 24 hrs by MTT assay
    		[PMID: 35526504]
    CCRF S-180 IC50
    29.2 μM
    Compound: Doxorubicin
    Antiproliferative activity against mouse S180 cells after 48 hrs by MTT assay
    Antiproliferative activity against mouse S180 cells after 48 hrs by MTT assay
    		[PMID: 21620529]
    CCRF S-180 IC50
    9.25 μM
    Compound: Doxorubicin
    Antiproliferative activity against mouse S180 cells assessed as cell viability after 48 hrs by MTT assay
    Antiproliferative activity against mouse S180 cells assessed as cell viability after 48 hrs by MTT assay
    		[PMID: 25648297]
    CCRF-CEM CC50
    0.02 μM
    Compound: Doxorubicin
    Cytotoxicity against human CCRF-CEM cells after 96 hrs by MTT assay
    Cytotoxicity against human CCRF-CEM cells after 96 hrs by MTT assay
    		[PMID: 26119992]
    CCRF-CEM EC50
    0.009 μM
    Compound: Doxorubicin
    Cytotoxicity against human CCRF-CEM cells assessed as reduction in cell viability after 72 hrs by resazurin dye based assay
    Cytotoxicity against human CCRF-CEM cells assessed as reduction in cell viability after 72 hrs by resazurin dye based assay
    		[PMID: 29937978]
    CCRF-CEM EC50
    0.015 μM
    Compound: Doxorubicin
    Cytotoxicity against human CCRF-CEM cells assessed as reduction in cell viability after 72 hrs by resazurin dye based assay
    Cytotoxicity against human CCRF-CEM cells assessed as reduction in cell viability after 72 hrs by resazurin dye based assay
    		[PMID: 29887512]
    CCRF-CEM EC50
    0.02 μM
    Compound: Doxorubicin
    Cytotoxicity against human CCRF-CEM cells after 96 hrs by MTT assay
    Cytotoxicity against human CCRF-CEM cells after 96 hrs by MTT assay
    		[PMID: 26320088]
    CCRF-CEM EC50
    0.4654 μM
    Compound: doxorubicin
    Cytotoxicity against human CCRF-CEM cells after 48 hrs by cell titer-blue assay
    Cytotoxicity against human CCRF-CEM cells after 48 hrs by cell titer-blue assay
    		[PMID: 19743858]
    CCRF-CEM EC50
    3.078 μM
    Compound: doxorubicin
    Cytotoxicity against human CCRF-CEM/C2 cells after 48 hrs by cell titer-blue assay
    Cytotoxicity against human CCRF-CEM/C2 cells after 48 hrs by cell titer-blue assay
    		[PMID: 19743858]
    CCRF-CEM GI50
    0.02 μM
    Compound: Doxorubicin
    Growth inhibition of human CCRF-CEM cells after 2 days by MTT assay
    Growth inhibition of human CCRF-CEM cells after 2 days by MTT assay
    		[PMID: 20570145]
    CCRF-CEM GI50
    0.08 μM
    Compound: Doxorubicin
    Growth inhibition of human CCRF-CEM cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human CCRF-CEM cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28329730]
    CCRF-CEM GI50
    0.08 μM
    Compound: Doxorubicin
    Growth inhibition of human CCRF-CEM cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human CCRF-CEM cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 29102177]
    CCRF-CEM GI50
    0.08 μM
    Compound: Doxorubicin hydrochloride, NSC 123127
    Cytotoxicity against human CCRF-CEM cells after 48 hrs by SRB assay
    Cytotoxicity against human CCRF-CEM cells after 48 hrs by SRB assay
    		[PMID: 23871905]
    CCRF-CEM GI50
    3 x 10-2 μM
    Compound: Doxorubicin
    Antiproliferative activity against human CCRF-CEM cells after 72 hrs by MTT assay
    Antiproliferative activity against human CCRF-CEM cells after 72 hrs by MTT assay
    		[PMID: 30071406]
    CCRF-CEM GI50
    3.3 x 10-2 μM
    Compound: Doxorubicin
    Cytotoxicity against human CCRF-CEM cells assessed as growth inhibition after 72 hrs by MTT assay
    Cytotoxicity against human CCRF-CEM cells assessed as growth inhibition after 72 hrs by MTT assay
    		[PMID: 29670691]
    CCRF-CEM IC50
    0.003 μM
    Compound: Doxorubicin
    Cytotoxicity against human CCRF-CEM cells assessed as cell viability after 72 hrs by resazurin assay
    Cytotoxicity against human CCRF-CEM cells assessed as cell viability after 72 hrs by resazurin assay
    		[PMID: 26260339]
    CCRF-CEM IC50
    0.003 μM
    Compound: Doxorubicin
    Cytotoxicity against human CCRF-CEM cells assessed as reduction in cell viability after 72 hrs by resazurin reduction assay
    Cytotoxicity against human CCRF-CEM cells assessed as reduction in cell viability after 72 hrs by resazurin reduction assay
    		[PMID: 28456567]
    CCRF-CEM IC50
    0.009 μM
    Compound: Doxorubicin
    Cytotoxicity against human CCRF-CEM cells by resazurin assay
    Cytotoxicity against human CCRF-CEM cells by resazurin assay
    		[PMID: 24561670]
    CCRF-CEM IC50
    0.009 μM
    Compound: Doxorubicin
    Antiproliferative activity against human CCRF-CEM cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Antiproliferative activity against human CCRF-CEM cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    		[PMID: 27010926]
    CCRF-CEM IC50
    0.01 μM
    Compound: Doxorubicin
    Antiproliferative activity against human CCRF-CEM cells after 72 hrs by MTT assay
    Antiproliferative activity against human CCRF-CEM cells after 72 hrs by MTT assay
    		[PMID: 27808511]
    CCRF-CEM IC50
    0.017 μM
    Compound: Doxorubicin
    Growth inhibition of human CCRF-CEM cells by resazurin assay
    Growth inhibition of human CCRF-CEM cells by resazurin assay
    		[PMID: 28121440]
    CCRF-CEM IC50
    0.017 μM
    Compound: Doxorubicin
    Antileukemic activity against human CCRF-CEM cells after 24 to 48 hrs by resazurin dye based fluorescence assay
    Antileukemic activity against human CCRF-CEM cells after 24 to 48 hrs by resazurin dye based fluorescence assay
    		[PMID: 29560715]
    CCRF-CEM IC50
    0.017 μM
    Compound: Doxorubicin
    Cytotoxicity against human CCRF-CEM cells
    Cytotoxicity against human CCRF-CEM cells
    		[PMID: 36972793]
    CCRF-CEM IC50
    0.01 μg/mL
    Compound: Adriamycin (ADM)
    Tested for the cytostatic activity as inhibitory concentration against CCRF-CEM human leukemia cells
    Tested for the cytostatic activity as inhibitory concentration against CCRF-CEM human leukemia cells
    		10.1016/S0960-894X(97)00071-1
    CCRF-CEM IC50
    0.02 μM
    Compound: Doxo
    Antiproliferative activity against human CCRF-CEM cells assessed as cell viability measured after 4 days by MTT assay
    Antiproliferative activity against human CCRF-CEM cells assessed as cell viability measured after 4 days by MTT assay
    		[PMID: 31869654]
    CCRF-CEM IC50
    0.02 μM
    Compound: Doxorubicin
    Cytotoxicity tested in vitro against T-lymphoid leukemic cell line
    Cytotoxicity tested in vitro against T-lymphoid leukemic cell line
    		10.1016/S0960-894X(01)80594-1
    CCRF-CEM IC50
    0.02 μM
    Compound: Doxorubicin
    Antiproliferative activity against human CCRF-CEM cells after 96 hrs by MTT assay
    Antiproliferative activity against human CCRF-CEM cells after 96 hrs by MTT assay
    		[PMID: 19053767]
    CCRF-CEM IC50
    0.02 μM
    Compound: Doxorubicin
    Cytotoxicity against human CCRF-CEM cells assessed as reduction in cell viability after 72 hrs by resazurin dye-based fluorescence assay
    Cytotoxicity against human CCRF-CEM cells assessed as reduction in cell viability after 72 hrs by resazurin dye-based fluorescence assay
    		[PMID: 32663024]
    CCRF-CEM IC50
    0.02 μM
    Compound: Doxorubicin
    Cytotoxicity against human CCRF-CEM cells assessed as reduction in cell viability after 72 hrs by RRA assay
    Cytotoxicity against human CCRF-CEM cells assessed as reduction in cell viability after 72 hrs by RRA assay
    		[PMID: 33508467]
    CCRF-CEM IC50
    0.02 μM
    Compound: doxorubicin
    Antitumor activity against human acute T-lymphoblastic leukemia CCRF-CEM cells
    Antitumor activity against human acute T-lymphoblastic leukemia CCRF-CEM cells
    		[PMID: 12431048]
    CCRF-CEM IC50
    0.02 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human CEM cells after 72 hrs by MTT assay
    Cytotoxicity against human CEM cells after 72 hrs by MTT assay
    		[PMID: 18586355]
    CCRF-CEM IC50
    0.02 μg/mL
    Compound: doxorubicin
    Cytotoxicity against human CEM cells after 72 hrs by MTT assay
    Cytotoxicity against human CEM cells after 72 hrs by MTT assay
    		[PMID: 15787450]
    CCRF-CEM IC50
    0.03 μM
    Compound: Doxorubicin
    Antitumor activity against human acute T-lymphoblastic CCRF-CEM leukemia cells.
    Antitumor activity against human acute T-lymphoblastic CCRF-CEM leukemia cells.
    		[PMID: 12431049]
    CCRF-CEM IC50
    0.03 μM
    Compound: doxo
    Antiproliferative activity against human CCRF-CEM cell line by MTT assay
    Antiproliferative activity against human CCRF-CEM cell line by MTT assay
    		[PMID: 16913700]
    CCRF-CEM IC50
    0.037 μM
    Compound: Doxorubicin
    Cytotoxicity against human CCRF-CEM cells by CCK-8 assay
    Cytotoxicity against human CCRF-CEM cells by CCK-8 assay
    		[PMID: 22884578]
    CCRF-CEM IC50
    0.052 μM
    Compound: Doxorubicin
    Antiproliferative activity against human CCRF-CEM cells after 48 hrs by MTT assay
    Antiproliferative activity against human CCRF-CEM cells after 48 hrs by MTT assay
    		[PMID: 27060757]
    CCRF-CEM IC50
    0.06 μM
    Compound: 1; Dox
    Antiproliferative activity against human CEM cells after 72 hrs by MTT assay
    Antiproliferative activity against human CEM cells after 72 hrs by MTT assay
    		[PMID: 26633734]
    CCRF-CEM IC50
    0.06 μM
    Compound: Dox
    Cytotoxicity against human CEM cells after 72 hrs by MTT assay
    Cytotoxicity against human CEM cells after 72 hrs by MTT assay
    		[PMID: 21144624]
    CCRF-CEM IC50
    0.06 μM
    Compound: adriamycin
    Cytotoxicity against drug-sensitive CCRF-CEM cells after 72 hrs
    Cytotoxicity against drug-sensitive CCRF-CEM cells after 72 hrs
    		[PMID: 17323939]
    CCRF-CEM IC50
    0.08 μM
    Compound: Doxorubicin
    Compound was tested for its effect on the proliferation of CCRF-CEM human lymphoblastic T-leukemia cell line
    Compound was tested for its effect on the proliferation of CCRF-CEM human lymphoblastic T-leukemia cell line
    		10.1016/0960-894X(96)00216-8
    CCRF-CEM IC50
    0.09 μM
    Compound: Doxorubicin
    Cytotoxicity against human CCRF-CEM cells after 72 hrs by MTT assay
    Cytotoxicity against human CCRF-CEM cells after 72 hrs by MTT assay
    		[PMID: 19394829]
    CCRF-CEM IC50
    0.09 μM
    Compound: Doxorubicin
    Antiproliferative activity against human CCRF-CEM cells assessed as cell viability after 72 hrs by MTT assay
    Antiproliferative activity against human CCRF-CEM cells assessed as cell viability after 72 hrs by MTT assay
    		[PMID: 24012378]
    CCRF-CEM IC50
    0.09 μM
    Compound: Doxorubicin
    Cytotoxicity against human CCRF-CEM cells assessed as reduction in cell viability incubated for 6 hrs by SRB assay
    Cytotoxicity against human CCRF-CEM cells assessed as reduction in cell viability incubated for 6 hrs by SRB assay
    		[PMID: 36691388]
    CCRF-CEM IC50
    0.1 mM
    Compound: Dox
    Antiproliferative activity against human CEM cells after 72 hrs by MTT assay
    Antiproliferative activity against human CEM cells after 72 hrs by MTT assay
    		[PMID: 29459273]
    CCRF-CEM IC50
    0.1 μM
    Compound: 2
    Antiproliferative activity against human CEM cells assessed as growth inhibition after 72 hrs by MTT assay
    Antiproliferative activity against human CEM cells assessed as growth inhibition after 72 hrs by MTT assay
    		[PMID: 33974416]
    CCRF-CEM IC50
    0.1 μM
    Compound: 5
    Antiproliferative activity against human CEM cells after 72 hrs by MTT assay
    Antiproliferative activity against human CEM cells after 72 hrs by MTT assay
    		[PMID: 29137865]
    CCRF-CEM IC50
    0.1 μM
    Compound: Dox
    Antiproliferative activity in human CEM cells after 72 hrs by MTT assay
    Antiproliferative activity in human CEM cells after 72 hrs by MTT assay
    		[PMID: 30268824]
    CCRF-CEM IC50
    0.1 μM
    Compound: Doxorubicin
    Antitumor activity was evaluated against leukemia cell line CCRF-CEM(human acute T lymphoblastic leukemia).
    Antitumor activity was evaluated against leukemia cell line CCRF-CEM(human acute T lymphoblastic leukemia).
    		[PMID: 10411476]
    CCRF-CEM IC50
    0.1 μM
    Compound: Doxorubicin
    Cytotoxicity against CCRF-CEM lymphocytic leukemia cell line
    Cytotoxicity against CCRF-CEM lymphocytic leukemia cell line
    		[PMID: 10476861]
    CCRF-CEM IC50
    0.11 μM
    Compound: doxorubicin
    Cytotoxicity against human CCRF-CEM cells assessed as cell viability after 48 hrs by celltiter-blue assay
    Cytotoxicity against human CCRF-CEM cells assessed as cell viability after 48 hrs by celltiter-blue assay
    		[PMID: 22582991]
    CCRF-CEM IC50
    0.17 μM
    Compound: Doxorubicin
    Cytotoxicity against human CCRF-CEM cells after 48 hrs by MTT assay
    Cytotoxicity against human CCRF-CEM cells after 48 hrs by MTT assay
    		[PMID: 32496057]
    CCRF-CEM IC50
    0.39 μM
    Compound: Doxorubicin
    Cytostatic activity against human CEM/0 after 72 hrs by cell counting
    Cytostatic activity against human CEM/0 after 72 hrs by cell counting
    		[PMID: 22555152]
    CCRF-CEM IC50
    0.5 μM
    Compound: Doxo
    Cytotoxicity against human CCRF-CEM cells assessed as cell viability after 24 hrs by MTT assay
    Cytotoxicity against human CCRF-CEM cells assessed as cell viability after 24 hrs by MTT assay
    		[PMID: 24484281]
    CCRF-CEM IC50
    0.5 μM
    Compound: doxorubicin
    Cytotoxicity against human CCRF-CEM cells assessed as cell viability after 24 hrs by MTT assay
    Cytotoxicity against human CCRF-CEM cells assessed as cell viability after 24 hrs by MTT assay
    		[PMID: 25993619]
    CCRF-CEM IC50
    1.05 μM
    Compound: DOX
    Antiproliferative activity against human CCRF-CEM cells after 48 hrs by resazurin dye-based fluorescence assay
    Antiproliferative activity against human CCRF-CEM cells after 48 hrs by resazurin dye-based fluorescence assay
    		[PMID: 29665526]
    CCRF-CEM IC50
    1.05 μM
    Compound: Dox
    Cytotoxicity against human CCRF-CEM cells after 48 hrs by resazurin assay
    Cytotoxicity against human CCRF-CEM cells after 48 hrs by resazurin assay
    		[PMID: 29107422]
    CCRF-CEM IC50
    2.14 μM
    Compound: doxorubicin
    Cytotoxicity against human CCRF-CEM cells by XTT assay
    Cytotoxicity against human CCRF-CEM cells by XTT assay
    		[PMID: 22663190]
    CCRF-CEM IC50
    3.14 μM
    Compound: Doxorubicin
    Cytotoxicity against human CEM cells after 48 hrs
    Cytotoxicity against human CEM cells after 48 hrs
    		[PMID: 20873721]
    CCRF-CEM IC50
    3.14 μM
    Compound: Doxorubicin
    Cytotoxicity against human CEM cells after 48 hrs by alamar blue assay
    Cytotoxicity against human CEM cells after 48 hrs by alamar blue assay
    		[PMID: 22272829]
    CCRF-CEM IC50
    36.9 nM
    Compound: doxorubicin
    Cytotoxicity against human CCRF-CEM by XTT assay
    Cytotoxicity against human CCRF-CEM by XTT assay
    		[PMID: 20527917]
    CCRF-CEM IC50
    45 nM
    Compound: Dox
    Inhibition of cell proliferation of human CCRF-CEM cells after 96 hrs by CellTiter assay
    Inhibition of cell proliferation of human CCRF-CEM cells after 96 hrs by CellTiter assay
    		[PMID: 22276998]
    CCRF-CEM IC50
    55.91 μM
    Compound: Dox
    Antiproliferative activity against human CCRF-CM cells assessed as inhibition of cell proliferation incubated for 72 hrs by CellTiter-Glo assay
    Antiproliferative activity against human CCRF-CM cells assessed as inhibition of cell proliferation incubated for 72 hrs by CellTiter-Glo assay
    		[PMID: 27687968]
    CCRF-SB CC50
    0.03 μM
    Compound: Doxorubicin
    Cytotoxicity against human CCRF-SB cells after 96 hrs by MTT assay
    Cytotoxicity against human CCRF-SB cells after 96 hrs by MTT assay
    		[PMID: 26119992]
    CCRF-SB EC50
    0.01 μM
    Compound: Doxorubicin
    Cytotoxicity against human CCRF-SB cells after 96 hrs by MTT assay
    Cytotoxicity against human CCRF-SB cells after 96 hrs by MTT assay
    		[PMID: 26320088]
    CCRF-SB IC50
    0.01 μM
    Compound: Doxorubicin
    Antitumor activity was evaluated against leukemia cell line CCRF-SB(human acute B lymphoblastic leukemia).
    Antitumor activity was evaluated against leukemia cell line CCRF-SB(human acute B lymphoblastic leukemia).
    		[PMID: 10411476]
    CCRF-SB IC50
    0.02 μM
    Compound: Doxorubicin
    Antitumor activity against human acute B-lymphoblastic CCRF-SB leukemia cells.
    Antitumor activity against human acute B-lymphoblastic CCRF-SB leukemia cells.
    		[PMID: 12431049]
    CCRF-SB IC50
    0.02 μM
    Compound: doxo
    Antiproliferative activity against human CCRF-SB cell line by MTT assay
    Antiproliferative activity against human CCRF-SB cell line by MTT assay
    		[PMID: 16913700]
    CCRF-SB IC50
    0.03 μM
    Compound: Doxo
    Antiproliferative activity against human CCRF-SB cells assessed as cell viability measured after 4 days by MTT assay
    Antiproliferative activity against human CCRF-SB cells assessed as cell viability measured after 4 days by MTT assay
    		[PMID: 31869654]
    CCRF-SB IC50
    0.03 μM
    Compound: Doxorubicin
    Antiproliferative activity against human CCRF-SB cells after 96 hrs by MTT assay
    Antiproliferative activity against human CCRF-SB cells after 96 hrs by MTT assay
    		[PMID: 19053767]
    CCRF-SB IC50
    0.03 μM
    Compound: doxorubicin
    Antitumor activity against human acute B-lymphoblastic leukemia CCRF-SB cells
    Antitumor activity against human acute B-lymphoblastic leukemia CCRF-SB cells
    		[PMID: 12431048]
    CCRF-SB IC50
    0.05 μM
    Compound: Doxorubicin
    Compound was tested for its effect on the proliferation of CCRF-SB human lymphoblastic B-leukemia cell line.
    Compound was tested for its effect on the proliferation of CCRF-SB human lymphoblastic B-leukemia cell line.
    		10.1016/0960-894X(96)00216-8
    CEM-VM1 IC50
    0.55 μM
    Compound: adriamycin
    Cytotoxicity against teniposide-resistant CEM/VM1 cells after 72 hrs
    Cytotoxicity against teniposide-resistant CEM/VM1 cells after 72 hrs
    		[PMID: 17323939]
    CEM/VLB100 IC50
    3.71 μM
    Compound: adriamycin
    Cytotoxicity against vinblastine-resistant CEM/VLB100 cells after 72 hrs
    Cytotoxicity against vinblastine-resistant CEM/VLB100 cells after 72 hrs
    		[PMID: 17323939]
    CH1 IC50
    0.0063 μM
    Compound: Doxirubicin
    Concentration required to inhibit CH1-cell growth by 50%
    Concentration required to inhibit CH1-cell growth by 50%
    		[PMID: 9703471]
    CH1 IC50
    0.0063 μM
    Compound: Doxorubicin
    In vitro cytotoxicity was tested against human Ovarian carcinoma CH1 cell line
    In vitro cytotoxicity was tested against human Ovarian carcinoma CH1 cell line
    		[PMID: 10411474]
    CH1 IC50
    0.0063 μM
    Compound: Dx
    The compound was tested for cytotoxic activity against CH1 cell line(human ovarian carcinoma )
    The compound was tested for cytotoxic activity against CH1 cell line(human ovarian carcinoma )
    		[PMID: 11123989]
    CH1 IC50
    0.45 μM
    Compound: Doxorubicin
    In vitro cytotoxicity was tested against human Ovarian carcinoma CH1 cisplatin resistant cell line
    In vitro cytotoxicity was tested against human Ovarian carcinoma CH1 cisplatin resistant cell line
    		[PMID: 10411474]
    CHO CC50
    0.6 μM
    Compound: Doxorubicin
    Cytotoxicity against CHO cells assessed as cell viability after 24 hrs by MTT assay
    Cytotoxicity against CHO cells assessed as cell viability after 24 hrs by MTT assay
    		[PMID: 25791675]
    CHO CC50
    4.65 μM
    Compound: Doxorubicin
    Cytotoxicity against CHO cells assessed as reduction in cell viability after 24 hrs by MTT assay
    Cytotoxicity against CHO cells assessed as reduction in cell viability after 24 hrs by MTT assay
    		[PMID: 32088496]
    CHO IC50
    0.01 μg/mL
    Compound: adriamycin
    Cytotoxicity against CHO cells
    Cytotoxicity against CHO cells
    		[PMID: 9249977]
    CHO IC50
    0.08 μM
    Compound: Adriamycin
    Cytotoxicity against CHO cells after 72 hrs by MTT assay
    Cytotoxicity against CHO cells after 72 hrs by MTT assay
    		[PMID: 21721528]
    CHO IC50
    0.11 μg/mL
    Compound: adriamycin
    Cytotoxicity against MDR1 gene transfected CHO cells
    Cytotoxicity against MDR1 gene transfected CHO cells
    		[PMID: 9249977]
    CHO IC50
    3.6 μM
    Compound: Doxorubicin
    Cytotoxicity against Chinese hamster CHO cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    Cytotoxicity against Chinese hamster CHO cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    		[PMID: 34782182]
    CHO IC50
    9.7 μM
    Compound: Adriamycin
    Cytotoxicity against CHO cells selected at 1 ug/mL colchicine after 72 hrs by MTT assay
    Cytotoxicity against CHO cells selected at 1 ug/mL colchicine after 72 hrs by MTT assay
    		[PMID: 21721528]
    CHO IC50
    60000 x 10-5 M
    Compound: DOX
    Compound was tested for the drug concentration that inhibited cell growth by 50% compared to untreated control cultures of CHO /DOX cell line
    Compound was tested for the drug concentration that inhibited cell growth by 50% compared to untreated control cultures of CHO /DOX cell line
    		[PMID: 9526570]
    CHO IC50
    600 x 10-5 M
    Compound: DOX
    Drug concentration that inhibit cell growth by 50% compared to untreated control cultures of CHO cells (for 6 days at 37 degree Celsius)
    Drug concentration that inhibit cell growth by 50% compared to untreated control cultures of CHO cells (for 6 days at 37 degree Celsius)
    		[PMID: 9526570]
    CHO IC50
    600 x 10-10 M
    Compound: Doxorubicin
    The compound was tested in vitro for growth inhibition of Chinese Hamster Ovary(CHO) cells
    The compound was tested in vitro for growth inhibition of Chinese Hamster Ovary(CHO) cells
    		[PMID: 1354750]
    CHO IC50
    60000 x 10-10 M
    Compound: Doxorubicin
    The compound was tested in vitro for growth inhibition of subline (CHO/DOX) with acquired resistance to doxorubicin
    The compound was tested in vitro for growth inhibition of subline (CHO/DOX) with acquired resistance to doxorubicin
    		[PMID: 1354750]
    CHO-K1 IC50
    0.4 μM
    Compound: Doxorubicin
    Antitumor activity was evaluated against Chinese hamster ovary carcinoma cell line CHO-K1.
    Antitumor activity was evaluated against Chinese hamster ovary carcinoma cell line CHO-K1.
    		[PMID: 10411476]
    CHO-K1 IC50
    1.2 μM
    Compound: Doxorubicin
    Compound was tested for its effect on the proliferation of CHO-K1 hamster ovarian cancer cell line.
    Compound was tested for its effect on the proliferation of CHO-K1 hamster ovarian cancer cell line.
    		10.1016/0960-894X(96)00216-8
    CHO-K1 IC50
    4.2 μM
    Compound: Doxorubicin
    Cytotoxicity against CHOK1 cells assessed as decrease in cell viability after 48 hrs by MTT assay
    Cytotoxicity against CHOK1 cells assessed as decrease in cell viability after 48 hrs by MTT assay
    		[PMID: 27843113]
    CNE IC50
    0.22 μM
    Compound: DOX
    Antiproliferative activity against human CNE cells after 72 hrs by CCK-8 assay
    Antiproliferative activity against human CNE cells after 72 hrs by CCK-8 assay
    		[PMID: 29614418]
    CNE-2 IC50
    2.12 μM
    Compound: AMD
    Anticancer activity against human CNE-2 cells assessed as inhibition of cell growth
    Anticancer activity against human CNE-2 cells assessed as inhibition of cell growth
    		[PMID: 28888820]
    CNE-2 IC50
    3.52 μM
    Compound: Doxorubicin
    Cytotoxicity against human CNE2 cells by CCK8 assay
    Cytotoxicity against human CNE2 cells by CCK8 assay
    		[PMID: 29452840]
    CNS cell GI50
    94 μM
    Compound: doxorubicin
    Cytotoxicity against human CNS cells after 48 hrs by SRB assay
    Cytotoxicity against human CNS cells after 48 hrs by SRB assay
    		[PMID: 19070942]
    COLO 201 IC50
    0.8 μM
    Compound: Doxorubicin
    Growth inhibition of human Colo-201 cells by MTT assay
    Growth inhibition of human Colo-201 cells by MTT assay
    		[PMID: 33901643]
    COLO 205 GI50
    0.14 μM
    Compound: ADR
    Growth inhibition of human COLO205 cells
    Growth inhibition of human COLO205 cells
    		10.1039/C1MD00072A
    COLO 205 GI50
    0.14 μM
    Compound: ADR
    Cytotoxicity against human Colo205 cells after 48 hrs by sulforhodamine B assay
    Cytotoxicity against human Colo205 cells after 48 hrs by sulforhodamine B assay
    		[PMID: 18657979]
    COLO 205 GI50
    0.14 μM
    Compound: ADR
    Growth inhibition of human COLO205 cells after 48 hrs by SRB assay
    Growth inhibition of human COLO205 cells after 48 hrs by SRB assay
    		[PMID: 20031423]
    COLO 205 GI50
    0.14 μM
    Compound: ADR
    Cytotoxicity against human COLO205 cells after 24 hrs by WST-1 assay
    Cytotoxicity against human COLO205 cells after 24 hrs by WST-1 assay
    		[PMID: 20732817]
    COLO 205 GI50
    0.14 μM
    Compound: ADR
    Anticancer activity against human COLO205 cells by SRB method
    Anticancer activity against human COLO205 cells by SRB method
    		[PMID: 21676506]
    COLO 205 GI50
    0.14 μM
    Compound: ADR
    Growth inhibition of human COLO205 cells by SRB assay
    Growth inhibition of human COLO205 cells by SRB assay
    		[PMID: 22361684]
    COLO 205 GI50
    0.14 μM
    Compound: ADR
    Growth inhibition of human COLO205 cells after 48 hrs by sulforhodamine B assay
    Growth inhibition of human COLO205 cells after 48 hrs by sulforhodamine B assay
    		[PMID: 22364746]
    COLO 205 GI50
    0.14 μM
    Compound: ADR
    Growth inhibition of human COLO205 cells after 48 hrs by sulforhodamine B assay
    Growth inhibition of human COLO205 cells after 48 hrs by sulforhodamine B assay
    		[PMID: 23849207]
    COLO 205 GI50
    0.14 μM
    Compound: adriamycin
    Cytotoxicity against human Colo205 cells after 24 hrs by SRB method
    Cytotoxicity against human Colo205 cells after 24 hrs by SRB method
    		[PMID: 18262426]
    COLO 205 GI50
    0.15 μM
    Compound: ADR, Adriamycin
    Growth inhibition of human Colo205 cells by SRB method
    Growth inhibition of human Colo205 cells by SRB method
    		[PMID: 18207392]
    COLO 205 GI50
    0.18 μM
    Compound: Doxorubicin
    Growth inhibition of human COLO205 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human COLO205 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28329730]
    COLO 205 GI50
    0.18 μM
    Compound: Doxorubicin
    Growth inhibition of human COLO205 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human COLO205 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 29102177]
    COLO 205 GI50
    0.18 μM
    Compound: Doxorubicin hydrochloride, NSC 123127
    Cytotoxicity against human COLO205 cells after 48 hrs by SRB assay
    Cytotoxicity against human COLO205 cells after 48 hrs by SRB assay
    		[PMID: 23871905]
    COLO 205 GI50
    14.7 μM
    Compound: ADR
    Anticancer activity against human COLO205 cells by SRB method
    Anticancer activity against human COLO205 cells by SRB method
    		[PMID: 22104151]
    COLO 205 GI50
    < 0.1 μM
    Compound: ADR
    Cytotoxicity against human COLO205 cells after 48 hrs by SRB assay
    Cytotoxicity against human COLO205 cells after 48 hrs by SRB assay
    		[PMID: 20673627]
    COLO 205 GI50
    < 0.1 μM
    Compound: ADR
    Cytotoxicity against human COLO205 cells after 48 hrs by sulforhodamine B assay
    Cytotoxicity against human COLO205 cells after 48 hrs by sulforhodamine B assay
    		[PMID: 21737288]
    COLO 205 IC50
    0.02 μM
    Compound: Doxorubicin
    Antiproliferative activity against human COLO205 cells assessed as inhibition of cell proliferation incubated for 72 hrs by conventional ATP quantification method
    Antiproliferative activity against human COLO205 cells assessed as inhibition of cell proliferation incubated for 72 hrs by conventional ATP quantification method
    		[PMID: 25937235]
    COLO 205 IC50
    0.11 μg/mL
    Compound: Adriamycin
    Inhibitory concentration required against COLO 205 colon cancer cell line
    Inhibitory concentration required against COLO 205 colon cancer cell line
    		[PMID: 11354370]
    COLO 205 IC50
    0.26 μM
    Compound: adriamycin
    Cytotoxicity against human COLO205 cells after 72 hrs by MTT assay
    Cytotoxicity against human COLO205 cells after 72 hrs by MTT assay
    		[PMID: 17107806]
    COLO 205 IC50
    0.37 μM
    Compound: Doxo
    Cytotoxicity against human COLO205 cells assessed as cell viability after 48 hrs by MTT assay
    Cytotoxicity against human COLO205 cells assessed as cell viability after 48 hrs by MTT assay
    		10.1039/C2MD20302B
    COLO 205 IC50
    0.4 μM
    Compound: Doxorubicin
    Anticancer activity against human COLO205 cells by MTT assay
    Anticancer activity against human COLO205 cells by MTT assay
    		[PMID: 21570750]
    COLO 205 IC50
    0.5 μM
    Compound: Doxorubicin
    Cytotoxicity against human COLO205 cells by MTT assay
    Cytotoxicity against human COLO205 cells by MTT assay
    		[PMID: 24300737]
    COLO 205 IC50
    0.52 μM
    Compound: DOX
    Antiproliferative activity against human COLO205 cells after 72 hrs by Sulforhodamine B-stain assay
    Antiproliferative activity against human COLO205 cells after 72 hrs by Sulforhodamine B-stain assay
    		[PMID: 27484508]
    COLO 205 IC50
    0.7 μM
    Compound: Dox
    Cytotoxicity against human COLO205 cells assessed as growth inhibition after 24 hrs by MTT assay
    Cytotoxicity against human COLO205 cells assessed as growth inhibition after 24 hrs by MTT assay
    		[PMID: 24507927]
    COLO 205 IC50
    0.7 μM
    Compound: Doxorubicin
    Cytotoxicity against human COLO205 cells assessed as growth inhibition after 24 hrs by MTT assay
    Cytotoxicity against human COLO205 cells assessed as growth inhibition after 24 hrs by MTT assay
    		[PMID: 24780595]
    COLO 205 IC50
    1.43 μM
    Compound: Doxorubicin
    Antiproliferative activity against human COLO205 cells assessed as reduction in cell viability after 24 hrs by MTT assay
    Antiproliferative activity against human COLO205 cells assessed as reduction in cell viability after 24 hrs by MTT assay
    		[PMID: 31546197]
    COLO 205 IC50
    1.43 μM
    Compound: Doxorubicin
    Antiproliferative activity against human COLO 205 cells
    Antiproliferative activity against human COLO 205 cells
    		[PMID: 31945642]
    COLO 205 IC50
    1.5 μM
    Compound: Doxorubicin
    Antitumor activity against human COLO205 cells after 24 to 48 hrs by MTT assay
    Antitumor activity against human COLO205 cells after 24 to 48 hrs by MTT assay
    		[PMID: 21553829]
    COLO 205 IC50
    1.69 μM
    Compound: Dox
    Anticancer activity against human COLO205 cells after 48 hrs by MTT assay
    Anticancer activity against human COLO205 cells after 48 hrs by MTT assay
    		[PMID: 22209733]
    COLO 205 IC50
    2 μM
    Compound: ADR
    Cytotoxicity against human Colo205 cells by sulforhodamine B assay
    Cytotoxicity against human Colo205 cells by sulforhodamine B assay
    		[PMID: 17822905]
    COLO 205 IC50
    2 μM
    Compound: ADR
    Cytotoxicity against human Colo205 cells by SRB assay
    Cytotoxicity against human Colo205 cells by SRB assay
    		[PMID: 18656370]
    COLO 205 IC50
    2.1 μM
    Compound: Doxorubicin
    Antiproliferative activity against human COLO 205 cells assessed as cell growth inhibition by MTT assay
    Antiproliferative activity against human COLO 205 cells assessed as cell growth inhibition by MTT assay
    		[PMID: 34838335]
    COLO 205 IC50
    2.5 μM
    Compound: Doxorubicin
    Cytotoxicity against human COLO 205 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay
    Cytotoxicity against human COLO 205 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay
    		[PMID: 35293752]
    COLO 205 IC50
    3.8 μM
    Compound: DOX
    Cytotoxicity against human COLO205 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay
    Cytotoxicity against human COLO205 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay
    		[PMID: 31589431]
    COLO 320 IC50
    7.4 μM
    Compound: Doxorubicin
    Cytotoxicity against human COLO 320 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay
    Cytotoxicity against human COLO 320 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay
    		[PMID: 35293752]
    COR-L23 IC50
    20.1 nM
    Compound: Doxorubicin
    Cytotoxicity measured using the COR-L23 parental (COR-L23/P) human non small cell lung carcinoma cell line
    Cytotoxicity measured using the COR-L23 parental (COR-L23/P) human non small cell lung carcinoma cell line
    		[PMID: 11806724]
    COR-L23 IC50
    319.3 nM
    Compound: Doxorubicin
    Cytotoxicity measured with the drug resistant human non small cell lung carcinoma cell line COR-L23 (COR-L23/R) which over expresses multidrug resistance associated with protein(MRP)
    Cytotoxicity measured with the drug resistant human non small cell lung carcinoma cell line COR-L23 (COR-L23/R) which over expresses multidrug resistance associated with protein(MRP)
    		[PMID: 11806724]
    COS-7 IC50
    2.05 μM
    Compound: Doxorubicin
    Cytotoxicity against African green monkey COS7 cells assessed as reduction in cell viability by MTT assay
    Cytotoxicity against African green monkey COS7 cells assessed as reduction in cell viability by MTT assay
    		[PMID: 31404864]
    COS-7 IC50
    3.04 μM
    Compound: Doxorubicin
    Growth inhibition of African green monkey COS7 cells by MTT assay
    Growth inhibition of African green monkey COS7 cells by MTT assay
    		[PMID: 28147307]
    CWR22R IC50
    0.02 μM
    Compound: Doxorubicin
    Cytotoxicity against human 22Rv1 cells assessed as reduction in cell viability after 72 hrs by CellTiter96 AQueous one solution cell proliferation assay
    Cytotoxicity against human 22Rv1 cells assessed as reduction in cell viability after 72 hrs by CellTiter96 AQueous one solution cell proliferation assay
    		[PMID: 28617598]
    CWR22R IC50
    0.02 μM
    Compound: Doxorubicin
    Antiproliferative activity against human 22Rv1 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay
    Antiproliferative activity against human 22Rv1 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay
    		[PMID: 34851111]
    CWR22R IC50
    6.32 μM
    Compound: Doxorubicin
    Growth inhibition of human 22Rv1 cells after 48 hrs by MTT assay
    Growth inhibition of human 22Rv1 cells after 48 hrs by MTT assay
    		[PMID: 30072225]
    Ca9-22 CC50
    0.7 μM
    Compound: DXR
    Cytotoxicity against human Ca9-22 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Cytotoxicity against human Ca9-22 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    		[PMID: 31532650]
    Ca9-22 IC50
    0.09 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human sCa9-22 cells by MTT assay
    Cytotoxicity against human sCa9-22 cells by MTT assay
    		[PMID: 18590313]
    Ca9-22 IC50
    0.14 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human Ca9-22 cells after 3 days by MTT assay
    Cytotoxicity against human Ca9-22 cells after 3 days by MTT assay
    		[PMID: 19691312]
    Ca9-22 IC50
    0.14 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human Ca9-22 cells
    Cytotoxicity against human Ca9-22 cells
    		[PMID: 20036537]
    Ca9-22 IC50
    0.1 μg/mL
    Compound: doxorubicin
    Cytotoxicity against human Ca9-22 cells by MTT assay
    Cytotoxicity against human Ca9-22 cells by MTT assay
    		[PMID: 18973388]
    Ca9-22 IC50
    0.26 μM
    Compound: Doxo
    Cytotoxicity against human Ca9-22 cells after 3 days by MTT assay
    Cytotoxicity against human Ca9-22 cells after 3 days by MTT assay
    		[PMID: 21800859]
    Ca9-22 IC50
    0.31 μg/mL
    Compound: doxorubicin
    Cytotoxicity against human Ca9-22 cells by MTT assay
    Cytotoxicity against human Ca9-22 cells by MTT assay
    		[PMID: 22413887]
    Ca9-22 IC50
    1.3 μM
    Compound: Doxo
    Cytotoxicity against human Ca9-22 cells after 72 hrs by MTT assay
    Cytotoxicity against human Ca9-22 cells after 72 hrs by MTT assay
    		[PMID: 20334960]
    Ca9-22 IC50
    14.47 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human Ca9-22 cells by MTT assay
    Cytotoxicity against human Ca9-22 cells by MTT assay
    		[PMID: 21106454]
    Caco-2 GI50
    0.32 μM
    Compound: Doxorubicin
    Antiproliferative activity against human Caco2 cells after 2 days by sulforhodamine B assay
    Antiproliferative activity against human Caco2 cells after 2 days by sulforhodamine B assay
    		[PMID: 24184076]
    Caco-2 IC50
    0.024 μM
    Compound: DOX
    Antiproliferative activity against human Caco-2 cells assessed as inhibition of cell growth incubated for 48 hrs by CellTiter 96 Aqueous One Solution Cell Proliferation Assay
    Antiproliferative activity against human Caco-2 cells assessed as inhibition of cell growth incubated for 48 hrs by CellTiter 96 Aqueous One Solution Cell Proliferation Assay
    		[PMID: 38626522]
    Caco-2 IC50
    0.02 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human Caco2 cells after 72 hrs by WST-8 assay
    Cytotoxicity against human Caco2 cells after 72 hrs by WST-8 assay
    		[PMID: 25534608]
    Caco-2 IC50
    0.03 μM
    Compound: Doxorubicin
    Cytotoxicity against human Caco2 cells assessed as cell growth inhibition
    Cytotoxicity against human Caco2 cells assessed as cell growth inhibition
    		[PMID: 26934105]
    Caco-2 IC50
    0.05 μM
    Compound: Doxorubicin
    Cytotoxicity against human Caco-2 cells assessed as reduction in cell viability after 48 hrs
    Cytotoxicity against human Caco-2 cells assessed as reduction in cell viability after 48 hrs
    		[PMID: 34601029]
    Caco-2 IC50
    0.05 μM
    Compound: Doxorubicine
    Cytotoxicity against human CaCo-2 cells assessed as reduction in cell viability incubated for 48 hrs by Hoechst-33342 staining based cell counting method (Rvb > 25 microM)
    Cytotoxicity against human CaCo-2 cells assessed as reduction in cell viability incubated for 48 hrs by Hoechst-33342 staining based cell counting method (Rvb > 25 microM)
    		[PMID: 33422908]
    Caco-2 IC50
    0.09 μM
    Compound: Doxorubicin
    Antiproliferative activity against human Caco2 cells after 48 hrs by Hoechst 33342 staining-based assay
    Antiproliferative activity against human Caco2 cells after 48 hrs by Hoechst 33342 staining-based assay
    		[PMID: 30655216]
    Caco-2 IC50
    0.17 μM
    Compound: Doxorubicin
    Toxicity in human Caco-2 cells assessed as reduction in cell number after 48 hrs by Hoechst 33342 staining based assay
    Toxicity in human Caco-2 cells assessed as reduction in cell number after 48 hrs by Hoechst 33342 staining based assay
    		[PMID: 31753515]
    Caco-2 IC50
    0.35 μM
    Compound: Doxorubicin
    Antiproliferative activity against human Caco2 cells after 24 and 72 hrs by MTT assay
    Antiproliferative activity against human Caco2 cells after 24 and 72 hrs by MTT assay
    		[PMID: 24941130]
    Caco-2 IC50
    0.6 μM
    Compound: Doxorubicin
    Antitumor activity against human differentiated Caco2 cells after 24 to 48 hrs by MTT assay
    Antitumor activity against human differentiated Caco2 cells after 24 to 48 hrs by MTT assay
    		[PMID: 21553829]
    Caco-2 IC50
    0.73 μM
    Compound: Doxorubicin
    Antiproliferative activity against human Caco2 cells after 48 hrs by neutral red assay
    Antiproliferative activity against human Caco2 cells after 48 hrs by neutral red assay
    		[PMID: 29885574]
    Caco-2 IC50
    0.96 μM
    Compound: Doxorubicin
    Cytotoxicity against human Caco2 cells assessed as growth inhibition after 72 hrs by MTT assay
    Cytotoxicity against human Caco2 cells assessed as growth inhibition after 72 hrs by MTT assay
    		[PMID: 26874404]
    Caco-2 IC50
    1 μM
    Compound: Doxorubicin
    Antiproliferative activity against human Caco2 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Antiproliferative activity against human Caco2 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    		[PMID: 31546197]
    Caco-2 IC50
    1 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human Caco-2 cells after 24 hrs
    Cytotoxicity against human Caco-2 cells after 24 hrs
    		[PMID: 20207452]
    Caco-2 IC50
    2.7 μM
    Compound: Adriamycin
    Cytotoxicity against human Caco2 cells by MTT assay
    Cytotoxicity against human Caco2 cells by MTT assay
    		[PMID: 22946634]
    Caco-2 IC50
    21 μM
    Compound: 21
    Cytotoxicity against human Caco2 cells assessed as reduction in cell viability after 24 hrs by MTT assay
    Cytotoxicity against human Caco2 cells assessed as reduction in cell viability after 24 hrs by MTT assay
    		[PMID: 32435401]
    Caco-2 IC50
    26.79 μM
    Compound: DOX
    Antiproliferative activity against human Caco2 cells by MTT assay
    Antiproliferative activity against human Caco2 cells by MTT assay
    		[PMID: 30216848]
    Caco-2 IC50
    3 μM
    Compound: Doxorubicin
    Antiproliferative activity against human Caco2 cells assessed as cell viability after 24 hrs by MTT assay
    Antiproliferative activity against human Caco2 cells assessed as cell viability after 24 hrs by MTT assay
    		[PMID: 26874744]
    Caco-2 IC50
    3.83 μM
    Compound: Dox
    Antiproliferative activity against human Caco2 cells by MTT assay
    Antiproliferative activity against human Caco2 cells by MTT assay
    		[PMID: 28802125]
    Caco-2 IC50
    48.1 nM
    Compound: DOX
    Anticancer activity against human Caco-2 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Anticancer activity against human Caco-2 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 33901898]
    Caco-2 IC50
    5 μM
    Compound: Doxorubicin
    Cytotoxicity against human Caco2 cells after 72 hrs by MTT assay
    Cytotoxicity against human Caco2 cells after 72 hrs by MTT assay
    		[PMID: 24099994]
    Caco-2 IC50
    5.13 μM
    Compound: Doxorubicin
    Antiproliferative activity against human Caco2 cells after 72 hrs by ELISA
    Antiproliferative activity against human Caco2 cells after 72 hrs by ELISA
    		[PMID: 31404864]
    Caco-2 IC50
    6.7 μM
    Compound: Doxorubicin
    Antitumor activity against human undifferentiated Caco2 cells after 24 to 48 hrs by MTT assay
    Antitumor activity against human undifferentiated Caco2 cells after 24 to 48 hrs by MTT assay
    		[PMID: 21553829]
    Caco-2 IC50
    63.3 μM
    Compound: Doxorubicin
    Cytotoxicity against human Caco2 cells assessed as cell viability after 24 hrs by MTT assay
    Cytotoxicity against human Caco2 cells assessed as cell viability after 24 hrs by MTT assay
    		[PMID: 28463785]
    Caco-2 IC50
    64.2 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human Caco2 cells assessed as cell growth inhibition measured after 24 by MTT assay
    Cytotoxicity against human Caco2 cells assessed as cell growth inhibition measured after 24 by MTT assay
    		[PMID: 35526504]
    Caco-2 IC50
    9.4 μM
    Compound: Doxorubicin
    Cytotoxicity against human Caco2 cells assessed as decrease in cell viability after 48 hrs by MTT assay
    Cytotoxicity against human Caco2 cells assessed as decrease in cell viability after 48 hrs by MTT assay
    		[PMID: 27843113]
    Calu-1 GI50
    < 1 x 10-2 μM
    Compound: Doxorubicin
    Cytotoxicity against human HTB-54 cells assessed as growth inhibition after 72 hrs by MTT assay
    Cytotoxicity against human HTB-54 cells assessed as growth inhibition after 72 hrs by MTT assay
    		[PMID: 29670691]
    Calu-1 GI50
    < 1 x 10-2 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HTB-54 cells after 72 hrs by MTT assay
    Antiproliferative activity against human HTB-54 cells after 72 hrs by MTT assay
    		[PMID: 30071406]
    Calu-1 IC50
    1.1 μM
    Compound: Doxorubicin
    Cytotoxicity against HTB-54 lung carcinoma cell line
    Cytotoxicity against HTB-54 lung carcinoma cell line
    		[PMID: 10476861]
    Calu-3 IC50
    0.11 μM
    Compound: DOX
    Antiproliferative activity against human Calu3 cells after 48 hrs by CellTiter-Glo assay
    Antiproliferative activity against human Calu3 cells after 48 hrs by CellTiter-Glo assay
    		[PMID: 27769032]
    Calu-3 IC50
    0.27 μM
    Compound: DOX
    Antiproliferative activity against human Calu3 cells after 24 hrs by CellTiter-Glo assay
    Antiproliferative activity against human Calu3 cells after 24 hrs by CellTiter-Glo assay
    		[PMID: 27769032]
    Cancer cell lines GI50
    0.065 μM
    Compound: Doxorubicin
    Growth inhibition of human colon cancer cells after 72 hrs by sulforhodamine B assay
    Growth inhibition of human colon cancer cells after 72 hrs by sulforhodamine B assay
    		[PMID: 20884089]
    Cancer cell lines GI50
    0.065 μM
    Compound: Doxorubicin
    Growth inhibition of human gastric cancer cells after 72 hrs by sulforhodamine B assay
    Growth inhibition of human gastric cancer cells after 72 hrs by sulforhodamine B assay
    		[PMID: 20884089]
    Cancer cell lines GI50
    0.065 μM
    Compound: Doxorubicin
    Growth inhibition of human lung cancer cells after 72 hrs by sulforhodamine B assay
    Growth inhibition of human lung cancer cells after 72 hrs by sulforhodamine B assay
    		[PMID: 20884089]
    Cancer cell lines GI50
    0.4 μM
    Compound: Adriamycin
    Cytotoxicity against human lung cancer cells
    Cytotoxicity against human lung cancer cells
    		[PMID: 11473418]
    Cancer cell lines GI50
    1.69 μM
    Compound: Adriamycin
    Cytotoxicity against human CNS cancer cells
    Cytotoxicity against human CNS cancer cells
    		[PMID: 11473418]
    Cancer cell lines GI50
    1.82 μM
    Compound: Adriamycin
    Cytotoxicity against human breast cancer cells
    Cytotoxicity against human breast cancer cells
    		[PMID: 11473418]
    Cancer cell lines GI50
    2.55 μM
    Compound: Adriamycin
    Cytotoxicity against human colon cancer cells
    Cytotoxicity against human colon cancer cells
    		[PMID: 11473418]
    Cancer cell lines GI50
    4.35 μM
    Compound: Adriamycin
    Cytotoxicity against human ovarian cancer cells
    Cytotoxicity against human ovarian cancer cells
    		[PMID: 11473418]
    Cancer cell lines GI50
    5.82 μM
    Compound: Adriamycin
    Cytotoxicity against human stomach cancer cells
    Cytotoxicity against human stomach cancer cells
    		[PMID: 11473418]
    Cancer cell lines IC50
    1.95 nM
    Compound: Doxorubicin
    Cytotoxicity against Breast cancer cell lines MDA-231 was determined
    Cytotoxicity against Breast cancer cell lines MDA-231 was determined
    		[PMID: 12392727]
    Cancer cell lines IC50
    129 ng/mL
    Compound: ADR
    Cytotoxicity against human cancer cell lines SBC-3 /ADR of lung (adriamycin resistant)
    Cytotoxicity against human cancer cell lines SBC-3 /ADR of lung (adriamycin resistant)
    		[PMID: 11311062]
    Cancer cell lines IC50
    8.7 nM
    Compound: Doxorubicin
    Cytotoxicity against Lung cancer cell lines PACA2 was determined
    Cytotoxicity against Lung cancer cell lines PACA2 was determined
    		[PMID: 12392727]
    Col2 IC50
    0.52 μM
    Compound: Doxorubicin
    In vitro cytotoxicity against human Col2 (colon cancer) cell line.
    In vitro cytotoxicity against human Col2 (colon cancer) cell line.
    		[PMID: 15177438]
    DLD-1 ED50
    0.1 μg/mL
    Compound: doxorubicin
    Cytotoxicity against human DLD1 cells after 3 days by MTT assay
    Cytotoxicity against human DLD1 cells after 3 days by MTT assay
    		[PMID: 16252910]
    DLD-1 ED50
    0.57 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human DLD1 cells by MTT assay
    Cytotoxicity against human DLD1 cells by MTT assay
    		[PMID: 15104488]
    DLD-1 IC50
    0.1 μM
    Compound: adriamycin
    Antitumor activity against human DLD1 cells by methylene blue staining method
    Antitumor activity against human DLD1 cells by methylene blue staining method
    		[PMID: 17656091]
    DLD-1 IC50
    0.32 μg/mL
    Compound: Adriamycin
    Inhibitory concentration required against DLD-1 colon cancer cell line
    Inhibitory concentration required against DLD-1 colon cancer cell line
    		[PMID: 11354370]
    DLD-1 IC50
    0.84 μM
    Compound: Dox
    Cytotoxicity against human DLD1 cells after 48 hrs by MTT assay
    Cytotoxicity against human DLD1 cells after 48 hrs by MTT assay
    		[PMID: 25247771]
    DLD-1 IC50
    10.2 μM
    Compound: Doxorubicin
    Anticancer activity against human DLD-1 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay
    Anticancer activity against human DLD-1 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay
    		[PMID: 30772606]
    DLD-1 IC50
    136 ng/mL
    Compound: ADR
    Cytotoxicity against human cancer cell lines DLD-1 of colon.
    Cytotoxicity against human cancer cell lines DLD-1 of colon.
    		[PMID: 11311062]
    DLD-1 IC50
    145 nM
    Compound: Doxorubicin
    Cytotoxicity against human DLD1 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
    Cytotoxicity against human DLD1 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
    		[PMID: 30429975]
    DLD-1 IC50
    163.01 μM
    Compound: Doxorubicin
    Cytotoxicity against human DLD1 cells assessed as reduction in cell viability
    Cytotoxicity against human DLD1 cells assessed as reduction in cell viability
    		[PMID: 31404864]
    DLD-1 IC50
    2.6 μM
    Compound: Doxorubicin
    Cytotoxicity against human DLD1 cells by Alamar Blue assay
    Cytotoxicity against human DLD1 cells by Alamar Blue assay
    		[PMID: 27536968]
    DLD-1 IC50
    2.78 μM
    Compound: Doxorubicin
    Cytotoxicity against human DLD1 cells by Alamar blue assay
    Cytotoxicity against human DLD1 cells by Alamar blue assay
    		[PMID: 27256910]
    DLD-1 IC50
    2.78 μM
    Compound: Doxorubicin
    Cytotoxicity against human DLD1 cells after 72 hrs by alamar blue assay
    Cytotoxicity against human DLD1 cells after 72 hrs by alamar blue assay
    		[PMID: 28159416]
    DLD-1 IC50
    510.6 nM
    Compound: Doxorubicin
    Antiproliferative activity against human DLD1 cells assessed as reduction in cell viability
    Antiproliferative activity against human DLD1 cells assessed as reduction in cell viability
    		[PMID: 31655432]
    DU-145 EC50
    0.2 μM
    Compound: Doxorubicin
    Cytotoxicity against human DU145 cells after 96 hrs by MTT assay
    Cytotoxicity against human DU145 cells after 96 hrs by MTT assay
    		[PMID: 26320088]
    DU-145 EC50
    40 nM
    Compound: Doxorubicin
    Antiproliferative activity against AR-positive human DU-145 cells assessed as reduction in cell viability measured after 72 hrs by MTS assay
    Antiproliferative activity against AR-positive human DU-145 cells assessed as reduction in cell viability measured after 72 hrs by MTS assay
    		[PMID: 36577036]
    DU-145 ED50
    0.15 μM
    Compound: DOX
    Cytotoxicity against human DU145 cells
    Cytotoxicity against human DU145 cells
    		[PMID: 17591444]
    DU-145 GI50
    0.02 μM
    Compound: Adriamycin
    In vitro antiproliferative activity against human DU-145 prostate cell line
    In vitro antiproliferative activity against human DU-145 prostate cell line
    		[PMID: 14971893]
    DU-145 GI50
    0.06 μM
    Compound: Doxorubicin
    Growth inhibition of human DU145 cells after 72 hrs by SRB assay
    Growth inhibition of human DU145 cells after 72 hrs by SRB assay
    		[PMID: 18585035]
    DU-145 GI50
    0.1081 μM
    Compound: Doxorubicin
    Cytotoxicity against human DU145 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay
    Cytotoxicity against human DU145 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay
    		[PMID: 31534659]
    DU-145 GI50
    0.11 μM
    Compound: Doxorubicin
    Growth inhibition of human DU145 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human DU145 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28329730]
    DU-145 GI50
    0.11 μM
    Compound: Doxorubicin
    Growth inhibition of human DU145 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human DU145 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 29102177]
    DU-145 GI50
    0.11 μM
    Compound: Doxorubicin hydrochloride, NSC 123127
    Cytotoxicity against human DU145 cells after 48 hrs by SRB assay
    Cytotoxicity against human DU145 cells after 48 hrs by SRB assay
    		[PMID: 23871905]
    DU-145 GI50
    0.134 μM
    Compound: Doxorubicin
    Cytotoxicity against human DU145 cells assessed as growth inhibition measured after 48 hrs by SRB assay
    Cytotoxicity against human DU145 cells assessed as growth inhibition measured after 48 hrs by SRB assay
    		[PMID: 31059248]
    DU-145 GI50
    0.35 μM
    Compound: Doxorubicin
    Growth inhibition of human DU145 cells after 2 days by MTT assay
    Growth inhibition of human DU145 cells after 2 days by MTT assay
    		[PMID: 20138760]
    DU-145 GI50
    0.95 μM
    Compound: Doxorubicin
    Anti-proliferative activity against human DU145 cells incubated for 48 hrs by SRB assay
    Anti-proliferative activity against human DU145 cells incubated for 48 hrs by SRB assay
    		[PMID: 26163220]
    DU-145 GI50
    < 0.01 μM
    Compound: Doxorubicin
    Growth inhibition of human DU145 cells after 48 hrs by SRB assay
    Growth inhibition of human DU145 cells after 48 hrs by SRB assay
    		10.1039/C6MD00097E
    DU-145 GI50
    < 0.01 μM
    Compound: Doxorubicin
    Growth inhibition in human DU145 cells after 48 hrs by SRB assay
    Growth inhibition in human DU145 cells after 48 hrs by SRB assay
    		[PMID: 31546197]
    DU-145 GI50
    < 0.1 μM
    Compound: ADR
    Cytotoxicity against 10'5 CFU/mL human DU145 cells after 48 hrs by SRB assay
    Cytotoxicity against 10'5 CFU/mL human DU145 cells after 48 hrs by SRB assay
    		[PMID: 21794959]
    DU-145 IC50
    0.01 μM
    Compound: Doxorubicin
    Cytotoxicity against human DU145 cells assessed as cell survival after 24 hrs by XTT assay
    Cytotoxicity against human DU145 cells assessed as cell survival after 24 hrs by XTT assay
    		[PMID: 25059501]
    DU-145 IC50
    0.02 μM
    Compound: Doxorubicin
    Antiproliferative activity against human DU145 cells assessed as inhibition of cell proliferation incubated for 72 hrs by conventional ATP quantification method
    Antiproliferative activity against human DU145 cells assessed as inhibition of cell proliferation incubated for 72 hrs by conventional ATP quantification method
    		[PMID: 25937235]
    DU-145 IC50
    0.03 μM
    Compound: doxorubicin
    Antitumor activity against human prostate carcinoma DU145 cells
    Antitumor activity against human prostate carcinoma DU145 cells
    		[PMID: 12431048]
    DU-145 IC50
    0.051 μM
    Compound: DOX
    Cytotoxicity against human DU145 cells measured after 72 hrs by Celltiter-Glo assay
    Cytotoxicity against human DU145 cells measured after 72 hrs by Celltiter-Glo assay
    		[PMID: 31820976]
    DU-145 IC50
    0.07 μM
    Compound: DOX
    Antiproliferative activity against human DU145 cells after 72 hrs by Sulforhodamine B-stain assay
    Antiproliferative activity against human DU145 cells after 72 hrs by Sulforhodamine B-stain assay
    		[PMID: 27484508]
    DU-145 IC50
    0.072 μM
    Compound: DOX
    Cytotoxicity against human DU-145 cells incubated for 48 hrs by MTT assay
    Cytotoxicity against human DU-145 cells incubated for 48 hrs by MTT assay
    		[PMID: 38185054]
    DU-145 IC50
    0.1 μM
    Compound: Doxorubicin
    Cytotoxicity against human DU145 cells after 72 hrs by MTT assay
    Cytotoxicity against human DU145 cells after 72 hrs by MTT assay
    		[PMID: 19361894]
    DU-145 IC50
    0.1 μM
    Compound: Doxorubicin
    Cytotoxicity against human hormone nonresponsive DU-145 cells assessed as reduction in cell proliferation by MTT assay
    Cytotoxicity against human hormone nonresponsive DU-145 cells assessed as reduction in cell proliferation by MTT assay
    		[PMID: 38414352]
    DU-145 IC50
    0.12 μM
    Compound: Doxorubicin
    Antiproliferative activity against human DU145 cells assessed as cell viability incubated for 72 hrs by MTT assay
    Antiproliferative activity against human DU145 cells assessed as cell viability incubated for 72 hrs by MTT assay
    		[PMID: 25799376]
    DU-145 IC50
    0.13 μM
    Compound: doxorubicin
    Cytotoxicity against human DU145 cells by SRB microtiter plate assay
    Cytotoxicity against human DU145 cells by SRB microtiter plate assay
    		[PMID: 17585747]
    DU-145 IC50
    0.153 μM
    Compound: Dox
    Cytotoxicity against human DU145 cells assessed as decrease in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human DU145 cells assessed as decrease in cell viability after 72 hrs by MTT assay
    		[PMID: 30108718]
    DU-145 IC50
    0.2 μM
    Compound: DOX
    Cytotoxicity against human DU145 cells after 48 hrs by MTT assay
    Cytotoxicity against human DU145 cells after 48 hrs by MTT assay
    		[PMID: 23218718]
    DU-145 IC50
    0.2 μM
    Compound: DOX, Doxorubicin
    Antiproliferative activity against human DU145 cells after 72 hrs by MTT assay
    Antiproliferative activity against human DU145 cells after 72 hrs by MTT assay
    		[PMID: 24095089]
    DU-145 IC50
    0.3 μM
    Compound: Doxorubicin
    Cytotoxicity against human DU-145 cells assessed as number of viable cells measured after 48 hrs by MTT based colorimetric assay
    Cytotoxicity against human DU-145 cells assessed as number of viable cells measured after 48 hrs by MTT based colorimetric assay
    		[PMID: 36970146]
    DU-145 IC50
    0.363 μM
    Compound: Doxorubicin
    Cytotoxicity against human DU145 cells after 24 hrs by MTT assay
    Cytotoxicity against human DU145 cells after 24 hrs by MTT assay
    		[PMID: 30654238]
    DU-145 IC50
    0.4 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human DU145 cells assessed as reduction in cell viability after 48 hrs by SRB assay
    Cytotoxicity against human DU145 cells assessed as reduction in cell viability after 48 hrs by SRB assay
    		[PMID: 30660827]
    DU-145 IC50
    0.5 μM
    Compound: Doxorubicin
    Cytotoxicity against human DU145 cells assessed as cell viability after 48 hrs by MTT assay
    Cytotoxicity against human DU145 cells assessed as cell viability after 48 hrs by MTT assay
    		[PMID: 25655719]
    DU-145 IC50
    0.52 μM
    Compound: adriamycin
    Cytotoxicity against human DU145 cells measured on day 4 by CCK8 assay
    Cytotoxicity against human DU145 cells measured on day 4 by CCK8 assay
    		[PMID: 25936262]
    DU-145 IC50
    0.53 μM
    Compound: Doxorubicin
    Cytotoxicity against human DU145 cells assessed as cell viability after 72 hrs by MTT assay
    Cytotoxicity against human DU145 cells assessed as cell viability after 72 hrs by MTT assay
    		[PMID: 24530030]
    DU-145 IC50
    0.534 μM
    Compound: 1
    Cytotoxicity in human DU-145 cells assessed as reduction in cell viability incubated for 2 hrs by Cell-titer-blue assay
    Cytotoxicity in human DU-145 cells assessed as reduction in cell viability incubated for 2 hrs by Cell-titer-blue assay
    		[PMID: 33064004]
    DU-145 IC50
    0.58 μM
    Compound: Doxo
    Cytotoxicity against human DU145 cells after 48 hrs by MTT assay
    Cytotoxicity against human DU145 cells after 48 hrs by MTT assay
    		[PMID: 21885273]
    DU-145 IC50
    0.6 μM
    Compound: Doxorubicin
    Cytotoxicity against human DU145 cells by MTT assay
    Cytotoxicity against human DU145 cells by MTT assay
    		[PMID: 24300737]
    DU-145 IC50
    0.6 μM
    Compound: Doxorubicin
    Cytotoxicity against human DU145 cells by MTT assay
    Cytotoxicity against human DU145 cells by MTT assay
    		[PMID: 25172418]
    DU-145 IC50
    0.6 μM
    Compound: Doxorubicin
    Cytotoxicity against human DU145 cells by MTT assay
    Cytotoxicity against human DU145 cells by MTT assay
    		[PMID: 26586599]
    DU-145 IC50
    0.7 μM
    Compound: Doxorubicin
    Cytotoxicity against human DU145 cells assessed as reduction in cell viability by MTT assay
    Cytotoxicity against human DU145 cells assessed as reduction in cell viability by MTT assay
    		[PMID: 26646219]
    DU-145 IC50
    0.7 μM
    Compound: Doxorubicin
    Cytotoxicity against human DU145 cells assessed as reduction in cell viability by MTT assay
    Cytotoxicity against human DU145 cells assessed as reduction in cell viability by MTT assay
    		[PMID: 26774921]
    DU-145 IC50
    0.7 μM
    Compound: Doxorubicin
    Cytotoxicity against human DU145 cells assessed as cell growth inhibition by MTT assay
    Cytotoxicity against human DU145 cells assessed as cell growth inhibition by MTT assay
    		[PMID: 27187861]
    DU-145 IC50
    0.7 μM
    Compound: Doxorubicin
    Cytotoxicity against human DU145 cells incubated for 24 hrs by MTT asasy
    Cytotoxicity against human DU145 cells incubated for 24 hrs by MTT asasy
    		[PMID: 28615134]
    DU-145 IC50
    0.8 μM
    Compound: Doxorubicin
    Cytotoxicity against human DU145 cells by MTT assay
    Cytotoxicity against human DU145 cells by MTT assay
    		[PMID: 25241926]
    DU-145 IC50
    0.86 μM
    Compound: Adriamycin
    Cytotoxicity against human DU145 cells after 2 days
    Cytotoxicity against human DU145 cells after 2 days
    		[PMID: 22318164]
    DU-145 IC50
    0.86 μM
    Compound: Adriamycin
    Cytotoxicity against human DU145 cells after 2 days by CCK-8 assay
    Cytotoxicity against human DU145 cells after 2 days by CCK-8 assay
    		[PMID: 25481396]
    DU-145 IC50
    0.895 μM
    Compound: Doxorubicin
    Cytotoxicity against human DU145 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Cytotoxicity against human DU145 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    		[PMID: 28462842]
    DU-145 IC50
    0.95 μM
    Compound: Adriamycin
    Cytotoxicity against human DU145 cells after 2 days by CCK8 assay
    Cytotoxicity against human DU145 cells after 2 days by CCK8 assay
    		[PMID: 26361737]
    DU-145 IC50
    1 μM
    Compound: Adriamycin
    Cytotoxicity against human DU145 cells after 2 days
    Cytotoxicity against human DU145 cells after 2 days
    		[PMID: 21601964]
    DU-145 IC50
    1.08 μM
    Compound: Doxorubicin
    Cytotoxicity against human DU145 cells after 48 hrs by MTT assay
    Cytotoxicity against human DU145 cells after 48 hrs by MTT assay
    		[PMID: 26948541]
    DU-145 IC50
    1.1 μM
    Compound: Adriamycin
    Cytotoxicity against human DU145 cells after 2 days by cell counting kit-8 analysis
    Cytotoxicity against human DU145 cells after 2 days by cell counting kit-8 analysis
    		[PMID: 22503656]
    DU-145 IC50
    1.1 μM
    Compound: Doxorubicin
    Cytotoxicity against human DU-145 cells assessed as inhibition of cell growth incubated for 72 hrs by XTT assay
    Cytotoxicity against human DU-145 cells assessed as inhibition of cell growth incubated for 72 hrs by XTT assay
    		[PMID: 33540356]
    DU-145 IC50
    1.3 μM
    Compound: Doxorubicin
    Anticancer activity against human DU145 cells after 48 hrs by MTT assay
    Anticancer activity against human DU145 cells after 48 hrs by MTT assay
    		[PMID: 25615796]
    DU-145 IC50
    1.38 μM
    Compound: Doxorubicin
    Cytotoxicity against human DU145 cells after 48 hrs by MTT assay
    Cytotoxicity against human DU145 cells after 48 hrs by MTT assay
    		[PMID: 26264845]
    DU-145 IC50
    1.4 μM
    Compound: Doxorubicin
    Anticancer activity against human DU-145 cells assessed as growth inhibition incubated for 48 hrs by MTT assay
    Anticancer activity against human DU-145 cells assessed as growth inhibition incubated for 48 hrs by MTT assay
    		[PMID: 34363936]
    DU-145 IC50
    1.41 μM
    Compound: Doxorubicin
    Cytotoxicity against human DU145 cells assessed as cell viability after 48 hrs by MTT assay
    Cytotoxicity against human DU145 cells assessed as cell viability after 48 hrs by MTT assay
    		[PMID: 27015609]
    DU-145 IC50
    1.428 μM
    Compound: Doxorubicin
    Anti-proliferative activity against human DU145 cells measured after 48 hrs by MTT assay
    Anti-proliferative activity against human DU145 cells measured after 48 hrs by MTT assay
    		[PMID: 27744185]
    DU-145 IC50
    1.57 μM
    Compound: ADR
    Cytotoxicity against human DU145 cells after 72 hrs by MTT assay
    Cytotoxicity against human DU145 cells after 72 hrs by MTT assay
    		[PMID: 22819942]
    DU-145 IC50
    1.57 μM
    Compound: adriamycin
    Cytotoxicity against human DU145 cells
    Cytotoxicity against human DU145 cells
    		[PMID: 18178085]
    DU-145 IC50
    1.6 μM
    Compound: Doxorubicin
    Cytotoxicity against human DU145 cells assessed as decrease in cell viability after 24 hrs by MTT assay
    Cytotoxicity against human DU145 cells assessed as decrease in cell viability after 24 hrs by MTT assay
    		[PMID: 27496212]
    DU-145 IC50
    1.622 μM
    Compound: Doxorubicin
    Cytotoxicity against human DU145 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Cytotoxicity against human DU145 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    		[PMID: 28482219]
    DU-145 IC50
    1.64 μM
    Compound: DOX
    Anticancer activity against human DU-145 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay
    Anticancer activity against human DU-145 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay
    		[PMID: 38784465]
    DU-145 IC50
    1.75 μM
    Compound: Adriamycin
    Cytotoxicity against human DU145 cells by MTT assay
    Cytotoxicity against human DU145 cells by MTT assay
    		[PMID: 21115246]
    DU-145 IC50
    1.8 μM
    Compound: Doxorubicin
    Cytotoxicity against human DU-145 cells incubated for 48 hrs by MTT assay
    Cytotoxicity against human DU-145 cells incubated for 48 hrs by MTT assay
    		[PMID: 33421712]
    DU-145 IC50
    1.807 μM
    Compound: Doxorubicin
    Antiproliferative activity against human DU145 cells after 48 hrs by MTT assay
    Antiproliferative activity against human DU145 cells after 48 hrs by MTT assay
    		[PMID: 29501940]
    DU-145 IC50
    1.82 μM
    Compound: Doxorubicin
    Cytotoxicity against human DU145 cells assessed as cell growth inhibition after 48 hrs by MTT assay
    Cytotoxicity against human DU145 cells assessed as cell growth inhibition after 48 hrs by MTT assay
    		[PMID: 26708114]
    DU-145 IC50
    1.86 μM
    Compound: II
    Cytotoxicity against human DU145 cells after 48 hrs by MTT assay
    Cytotoxicity against human DU145 cells after 48 hrs by MTT assay
    		[PMID: 29289881]
    DU-145 IC50
    1.9 μM
    Compound: Adriamycin
    Cytotoxicity against human DU145 cells after 4 days by MTT assay
    Cytotoxicity against human DU145 cells after 4 days by MTT assay
    		[PMID: 21704436]
    DU-145 IC50
    1.909 μM
    Compound: Doxorubicin
    Antiproliferative activity against human DU145 cells after 48 hrs by MTT assay
    Antiproliferative activity against human DU145 cells after 48 hrs by MTT assay
    		[PMID: 26301558]
    DU-145 IC50
    1.91 μM
    Compound: Doxorubicin
    Cytotoxicity in human DU145 cells incubated for 48 hrs by MTT assay
    Cytotoxicity in human DU145 cells incubated for 48 hrs by MTT assay
    		[PMID: 28923381]
    DU-145 IC50
    1.94 μM
    Compound: Doxorubicin
    Anticancer activity against human DU145 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Anticancer activity against human DU145 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    		[PMID: 26330077]
    DU-145 IC50
    10.86 μM
    Compound: Doxorubicin
    Cytotoxicity against human DU145 cells after 48 hrs by MTT assay
    Cytotoxicity against human DU145 cells after 48 hrs by MTT assay
    		[PMID: 22818039]
    DU-145 IC50
    12.3 μM
    Compound: Doxorubicin
    Cytotoxicity against human DU145 cells after 48 hrs by MTT assay
    Cytotoxicity against human DU145 cells after 48 hrs by MTT assay
    		[PMID: 21429743]
    DU-145 IC50
    12.4 μM
    Compound: Doxorubicin
    Cytotoxicity against human DU-145 cells assessed as cell death measured by MTT assay
    Cytotoxicity against human DU-145 cells assessed as cell death measured by MTT assay
    		[PMID: 39137365]
    DU-145 IC50
    13.24 μM
    Compound: Doxorubicin
    Cytotoxicity against human DU145 cells after 24 hrs by MTT assay
    Cytotoxicity against human DU145 cells after 24 hrs by MTT assay
    		[PMID: 22687747]
    DU-145 IC50
    15.65 μM
    Compound: Doxorubicin
    Cytotoxicity against human DU145 cells
    Cytotoxicity against human DU145 cells
    		[PMID: 22123320]
    DU-145 IC50
    17.67 μM
    Compound: Doxorubicin
    Anticancer activity against human DU145 cells by MTT assay
    Anticancer activity against human DU145 cells by MTT assay
    		[PMID: 25743216]
    DU-145 IC50
    2.13 μM
    Compound: Doxo
    Antiproliferative activity against human DU145 cells after 48 hrs by MTT assay
    Antiproliferative activity against human DU145 cells after 48 hrs by MTT assay
    		[PMID: 29129513]
    DU-145 IC50
    2.4 μM
    Compound: Doxorubicin
    Anticancer activity against human DU145 cells by MTT assay
    Anticancer activity against human DU145 cells by MTT assay
    		10.1039/C4MD00219A
    DU-145 IC50
    2.4 μM
    Compound: Doxorubicin
    Cytotoxicity against human DU145 cells assessed as reduction in cell viability measured after 48 hrs by SRB assay
    Cytotoxicity against human DU145 cells assessed as reduction in cell viability measured after 48 hrs by SRB assay
    		[PMID: 28818768]
    DU-145 IC50
    2.45 μM
    Compound: Doxo (I)
    Antiproliferative activity against human DU145 cells by MTT assay
    Antiproliferative activity against human DU145 cells by MTT assay
    		10.1039/C4MD00228H
    DU-145 IC50
    2.49 μM
    Compound: Doxorubicin
    Anticancer activity against human DU145 cells assessed as cell viability after 48 hrs by MTT assay
    Anticancer activity against human DU145 cells assessed as cell viability after 48 hrs by MTT assay
    		[PMID: 26542964]
    DU-145 IC50
    2.54 μM
    Compound: DOX
    Antiproliferative activity against human DU145 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
    Antiproliferative activity against human DU145 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
    		[PMID: 32631552]
    DU-145 IC50
    2.68 μM
    Compound: Adriamycin
    Cytotoxicity against human DU145 cells after 2 days by CCK-8 assay
    Cytotoxicity against human DU145 cells after 2 days by CCK-8 assay
    		[PMID: 24013413]
    DU-145 IC50
    23.48 μM
    Compound: Adriamycin
    Cytotoxicity against human DU145 cells after 24 hrs by MTT assay
    Cytotoxicity against human DU145 cells after 24 hrs by MTT assay
    		[PMID: 22276650]
    DU-145 IC50
    3.11 μM
    Compound: DOX
    Cytotoxicity against human DU145 cells after 48 hrs by SRB method
    Cytotoxicity against human DU145 cells after 48 hrs by SRB method
    		[PMID: 25933593]
    DU-145 IC50
    3.11 μM
    Compound: Doxorubicin
    Antiproliferative activity against human DU-145 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Antiproliferative activity against human DU-145 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    		[PMID: 31883489]
    DU-145 IC50
    3.27 μM
    Compound: Doxorubicin
    Cytotoxicity against human DU145 cells after 72 hrs by XTT assay
    Cytotoxicity against human DU145 cells after 72 hrs by XTT assay
    		10.1007/s00044-013-0558-8
    DU-145 IC50
    3.9 nM
    Compound: doxorubicin
    Anticancer activity against human DU145 cells after 72 hrs by XTT assay
    Anticancer activity against human DU145 cells after 72 hrs by XTT assay
    		[PMID: 18829316]
    DU-145 IC50
    4.06 μM
    Compound: Doxorubicin
    Cytotoxicity against human DU145 cells after 48 hrs by MTT assay
    Cytotoxicity against human DU145 cells after 48 hrs by MTT assay
    		[PMID: 25462233]
    DU-145 IC50
    4.75 μM
    Compound: Doxorubicin
    Antiproliferative activity against human DU145 cells after 48 hrs by MTT assay
    Antiproliferative activity against human DU145 cells after 48 hrs by MTT assay
    		[PMID: 26907155]
    DU-145 IC50
    4.8 μM
    Compound: DOX
    Cytotoxicity against human DU145 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay
    Cytotoxicity against human DU145 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay
    		[PMID: 31589431]
    DU-145 IC50
    4.88 μM
    Compound: Dox
    Cytotoxicity against human DU145 cells after 2 days
    Cytotoxicity against human DU145 cells after 2 days
    		[PMID: 24904965]
    DU-145 IC50
    5.3 μM
    Compound: Doxorubicin
    Cytotoxicity against human DU145 cells assessed as cell viability after 48 hrs by MTT assay
    Cytotoxicity against human DU145 cells assessed as cell viability after 48 hrs by MTT assay
    		[PMID: 25594739]
    DU-145 IC50
    5.4 μM
    Compound: DX
    Cytotoxicity against human DU145 cells after 48 hrs by sulforhodamine B assay
    Cytotoxicity against human DU145 cells after 48 hrs by sulforhodamine B assay
    		10.1039/C5MD00513B
    DU-145 IC50
    5.53 μM
    Compound: Doxorubicin
    Antiproliferative activity against human DU-145 cells incubated for 72 hrs by microplate reader analysis
    Antiproliferative activity against human DU-145 cells incubated for 72 hrs by microplate reader analysis
    		[PMID: 37418826]
    DU-145 IC50
    5.8 μM
    Compound: DXR
    Cytotoxicity against human androgen-independent DU145 cells by MTT assay
    Cytotoxicity against human androgen-independent DU145 cells by MTT assay
    		[PMID: 22326399]
    DU-145 IC50
    52.8 nM
    Compound: Doxorubicin
    In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line DU145
    In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line DU145
    		[PMID: 10479282]
    DU-145 IC50
    6 μM
    Compound: doxorubicin
    Cytotoxicity against human DU145 cells after 48 hrs by MTT assay
    Cytotoxicity against human DU145 cells after 48 hrs by MTT assay
    		[PMID: 23748152]
    DU-145 IC50
    6.24 μM
    Compound: Doxo
    Cytotoxicity against human DU145 cells after 24 hrs by MTT assay
    Cytotoxicity against human DU145 cells after 24 hrs by MTT assay
    		[PMID: 21885273]
    DU-145 IC50
    6.7 μM
    Compound: Doxorubicin
    Cytotoxicity against human DU145 cells
    Cytotoxicity against human DU145 cells
    		[PMID: 24793880]
    DU-145 IC50
    8.19 μM
    Compound: Doxorubicin
    Cytotoxicity against human DU145 cells after 48 hrs by MTT assay
    Cytotoxicity against human DU145 cells after 48 hrs by MTT assay
    		[PMID: 24607876]
    DU-145 IC50
    91.2 μM
    Compound: Doxorubicin
    Antiproliferative activity against human DU-145 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    Antiproliferative activity against human DU-145 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    		[PMID: 39038494]
    DU-145 IC50
    < 0.1 μM
    Compound: DOX
    Cytotoxicity against human DU-145 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 assay
    Cytotoxicity against human DU-145 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 assay
    		[PMID: 38039790]
    DU-145 IC50
    < 2.94 μM
    Compound: Doxorubicin
    Inhibition of proliferation of human DU145 cells after 72 hrs by XTT assay
    Inhibition of proliferation of human DU145 cells after 72 hrs by XTT assay
    		[PMID: 20810194]
    DU-145 IC50
    > 30 μM
    Compound: Doxorubicin
    Cytotoxicity against human DU-145 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay
    Cytotoxicity against human DU-145 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay
    		[PMID: 37369169]
    Daoy GI50
    0.016 μM
    Compound: Doxorubicin
    Antiproliferative activity against human DaOY cells assessed as growth inhibition after 72 hrs by MTT assay
    Antiproliferative activity against human DaOY cells assessed as growth inhibition after 72 hrs by MTT assay
    		[PMID: 30360625]
    Daoy IC50
    0.0629 μM
    Compound: Doxorubicin
    Antiproliferative activity against human Daoy cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
    Antiproliferative activity against human Daoy cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
    		[PMID: 34325324]
    Daoy IC50
    8.8 nM
    Compound: 5; Dox
    Cytotoxicity against human DaOY cells assessed as reduction in cell viability incubated for 72 hrs by AlamarBlue cell viability assay
    Cytotoxicity against human DaOY cells assessed as reduction in cell viability incubated for 72 hrs by AlamarBlue cell viability assay
    		[PMID: 31347843]
    Daudi IC50
    0.127 μM
    Compound: Dox
    Antiproliferative activity against human Daudi cells after 72 hrs by MTT assay
    Antiproliferative activity against human Daudi cells after 72 hrs by MTT assay
    		[PMID: 25998504]
    Daudi IC50
    0.3 μM
    Compound: adriamycin
    Cytotoxicity against human Daudi cells under deem light after 96 hrs by MTT assay
    Cytotoxicity against human Daudi cells under deem light after 96 hrs by MTT assay
    		[PMID: 17993275]
    Detroit 562 IC50
    1.26 μM
    Compound: Doxorubicin
    Cytotoxicity against human Detroit 562 cells assessed as reduction in cell viability after 4 hrs by MTT assay
    Cytotoxicity against human Detroit 562 cells assessed as reduction in cell viability after 4 hrs by MTT assay
    		[PMID: 30773423]
    DuPro EC50
    1.8 μM
    Compound: 58
    In vitro effective concentration against DuPRO cancer cell line
    In vitro effective concentration against DuPRO cancer cell line
    		[PMID: 14667208]
    DuPro EC50
    1.8 μM
    Compound: doxorubicin
    Concentration required to kill 50% of tumor cells in PSA nonproducing DuPRO human prostate cancer cell line
    Concentration required to kill 50% of tumor cells in PSA nonproducing DuPRO human prostate cancer cell line
    		[PMID: 11708923]
    EA.hy 926 IC50
    4.2 μM
    Compound: Doxorubicin
    Cytotoxicity against human EAhy926 cells assessed as decrease in cell viability after 48 hrs by MTT assay
    Cytotoxicity against human EAhy926 cells assessed as decrease in cell viability after 48 hrs by MTT assay
    		[PMID: 27843113]
    EBC-1 IC50
    305.1 nM
    Compound: Doxorubicin
    Antiproliferative activity against human EBC1 cells after 72 hrs by MTT assay
    Antiproliferative activity against human EBC1 cells after 72 hrs by MTT assay
    		[PMID: 28412159]
    EKVX GI50
    0.41 μM
    Compound: Doxorubicin
    Growth inhibition of human EKVX cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human EKVX cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28329730]
    EKVX GI50
    0.41 μM
    Compound: Doxorubicin
    Growth inhibition of human EKVX cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human EKVX cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 29102177]
    EKVX GI50
    0.41 μM
    Compound: Doxorubicin hydrochloride, NSC 123127
    Cytotoxicity against human EKVX cells after 48 hrs by SRB assay
    Cytotoxicity against human EKVX cells after 48 hrs by SRB assay
    		[PMID: 23871905]
    EKVX IC50
    5.73 μM
    Compound: Dox
    Antiproliferative activity against human EKVX cells assessed as inhibition of cell viability by MTT assay
    Antiproliferative activity against human EKVX cells assessed as inhibition of cell viability by MTT assay
    		[PMID: 37922829]
    EL4 IC50
    0.67 μg/mL
    Compound: (20) adriamycin
    In vitro cytotoxicity of compound against EL4, mouse thymoma was defined by microculture tetrazolium assay
    In vitro cytotoxicity of compound against EL4, mouse thymoma was defined by microculture tetrazolium assay
    		[PMID: 12620075]
    EMT6 ED50
    0.012 μM
    Compound: Adriamycin
    Compound is measured for surviving fractions of EMT6 tumor cells treated in culture with (0.50 uM) concentration for 1 hr under aerobic condition.
    Compound is measured for surviving fractions of EMT6 tumor cells treated in culture with (0.50 uM) concentration for 1 hr under aerobic condition.
    		[PMID: 7452674]
    EMT6 ED50
    < 0.0001 μM
    Compound: Adriamycin
    Compound is measured for surviving fractions of EMT6 tumor cells treated in culture with (0.50 uM) concentration for 1 hr under hypoxic condition.
    Compound is measured for surviving fractions of EMT6 tumor cells treated in culture with (0.50 uM) concentration for 1 hr under hypoxic condition.
    		[PMID: 7452674]
    EOL1 IC50
    0.00126 μM
    Compound: Doxorubicin
    Antiproliferative activity against human EOL1 cells assessed as inhibition of cell growth incubated for 7 days by CellTiterGlo assay
    Antiproliferative activity against human EOL1 cells assessed as inhibition of cell growth incubated for 7 days by CellTiterGlo assay
    		[PMID: 30540463]
    Ehrlich IC50
    0.259 μM
    Compound: Doxorubicin
    Anticancer activity against EAC cell assessed as cell growth inhibition measured after 24 to 72 hrs by MTT assay
    Anticancer activity against EAC cell assessed as cell growth inhibition measured after 24 to 72 hrs by MTT assay
    		[PMID: 36577217]
    Ehrlich IC50
    0.35 μM
    Compound: Doxorubicin
    Cytotoxicity against mouse EAC after 3 days by MTT assay
    Cytotoxicity against mouse EAC after 3 days by MTT assay
    		[PMID: 8350087]
    Ehrlich IC50
    35 μg/mL
    Compound: doxorubicin
    Antitumor activity against mouse Ehrlich ascites carcinoma cells
    Antitumor activity against mouse Ehrlich ascites carcinoma cells
    		[PMID: 17962022]
    Ehrlich IC50
    37.4 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against mouse EAC cells assessed as cell growth inhibition measured after 2 hrs by trypan blue exclusion assay
    Cytotoxicity against mouse EAC cells assessed as cell growth inhibition measured after 2 hrs by trypan blue exclusion assay
    		[PMID: 27894044]
    Ehrlich IC50
    37.5 μg/mL
    Compound: Doxorubicin
    Antitumor activity against mouse EAC cells assessed as non viable cells after 2 hrs by trypan blue exclusion test
    Antitumor activity against mouse EAC cells assessed as non viable cells after 2 hrs by trypan blue exclusion test
    		[PMID: 20149941]
    Ehrlich IC50
    38 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against mouse EAC assessed as non-viable cells after 2 hrs by trypan blue exclusion test
    Cytotoxicity against mouse EAC assessed as non-viable cells after 2 hrs by trypan blue exclusion test
    		[PMID: 21112675]
    Ehrlich IC50
    38 μg/mL
    Compound: doxorubicin
    Cytotoxicity against mouse EAC cells after 2 hrs by trypan blue exclusion
    Cytotoxicity against mouse EAC cells after 2 hrs by trypan blue exclusion
    		[PMID: 19944497]
    Ehrlich IC50
    4.18 μM
    Compound: doxorubicin
    Cytotoxicity against mouse EAC after 24 hrs by MTT assay
    Cytotoxicity against mouse EAC after 24 hrs by MTT assay
    		[PMID: 19128861]
    Ehrlich IC50
    5.22 μM
    Compound: Doxorubicin
    Cytotoxicity against mouse EAC cells after 24 hrs by MTT assay
    Cytotoxicity against mouse EAC cells after 24 hrs by MTT assay
    		[PMID: 22542958]
    Ehrlich IC50
    52 μg/mL
    Compound: Doxorubicin
    Antitumor activity against mouse EAC after 2 hrs by trypan blue exclusion assay
    Antitumor activity against mouse EAC after 2 hrs by trypan blue exclusion assay
    		[PMID: 19853327]
    Ehrlich IC50
    68.13 μM
    Compound: Doxorubicin
    Cytotoxicity against mouse EAC cells
    Cytotoxicity against mouse EAC cells
    		[PMID: 19879135]
    Ehrlich IC50
    68.13 μg/mL
    Compound: Doxorubicin
    Anticancer activity against mouse EAC cells assessed as reduction in cell viability
    Anticancer activity against mouse EAC cells assessed as reduction in cell viability
    		[PMID: 33276991]
    Ehrlich IC50
    69.9 μM
    Compound: Doxorubicin
    Cytotoxicity against mouse EAC cells after 2 hrs by trypan blue exclusion assay
    Cytotoxicity against mouse EAC cells after 2 hrs by trypan blue exclusion assay
    		[PMID: 20413187]
    Ehrlich IC50
    > 10 μM
    Compound: doxorubicin
    Cytotoxicity against mouse EAC cells after 24 hrs by MTT assay
    Cytotoxicity against mouse EAC cells after 24 hrs by MTT assay
    		[PMID: 17400463]
    Ehrlich IC50
    > 10 μM
    Compound: doxorubicin
    Cytotoxicity against mouse Ehrlich ascites carcinoma cells after 24 hrs by MTT assay
    Cytotoxicity against mouse Ehrlich ascites carcinoma cells after 24 hrs by MTT assay
    		[PMID: 18281125]
    Epithelial cell IC50
    9.787 nM
    Compound: Doxorubicin
    Cytotoxicity against albino rat epithelial rat by MTT assay
    Cytotoxicity against albino rat epithelial rat by MTT assay
    		[PMID: 34116327]
    Erythrocyte EC50
    > 200 μg/mL
    Compound: Dox
    Hemolytic toxicity in mouse erythrocytes assessed as induction of cell membrane disruption incubated for 30 mins by hemoglobin release based spectrophotometry
    Hemolytic toxicity in mouse erythrocytes assessed as induction of cell membrane disruption incubated for 30 mins by hemoglobin release based spectrophotometry
    		[PMID: 25147145]
    Erythrocyte EC50
    > 50 μg/mL
    Compound: DOXO
    Toxicity in mouse erythrocytes assessed as hemolytic activity after 30 mins by spectrophotometry
    Toxicity in mouse erythrocytes assessed as hemolytic activity after 30 mins by spectrophotometry
    		[PMID: 19947600]
    F460pv8/eto IC50
    0.02 μM
    Compound: Doxorubicin
    Inhibitory activity against F460pv8/eto cell line using MTT assay
    Inhibitory activity against F460pv8/eto cell line using MTT assay
    		[PMID: 10780913]
    FHC IC50
    17.586 μM
    Compound: Dox
    Cytotoxicity against human FHCs assessed as inhibition of cell viability by MTT assay
    Cytotoxicity against human FHCs assessed as inhibition of cell viability by MTT assay
    		[PMID: 37922829]
    FaDu IC50
    0.16 μM
    Compound: DOX
    Antiproliferative activity against human FaDu cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay
    Antiproliferative activity against human FaDu cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay
    		[PMID: 36709571]
    FaDu IC50
    0.68 μM
    Compound: Doxorubicin
    Cytotoxicity against human FADU cells assessed as reduction in cell viability after 4 hrs by MTT assay
    Cytotoxicity against human FADU cells assessed as reduction in cell viability after 4 hrs by MTT assay
    		[PMID: 30773423]
    FaDu IC50
    14 μM
    Compound: Dox
    Cytotoxicity against human FaDu cells by SRB assay
    Cytotoxicity against human FaDu cells by SRB assay
    		[PMID: 38516606]
    Fibroblast IC50
    0.005 μM
    Compound: Doxorubicin
    Antiproliferative activity against human fibroblast cells after 48 hrs by Hoechst 33342 staining-based assay
    Antiproliferative activity against human fibroblast cells after 48 hrs by Hoechst 33342 staining-based assay
    		[PMID: 30655216]
    Fibroblast IC50
    0.015 μM
    Compound: Doxorubicine
    Cytotoxicity against human Fibroblast cells assessed as reduction in cell viability incubated for 48 hrs by Hoechst-33342 staining based cell counting method (Rvb > 25 microM)
    Cytotoxicity against human Fibroblast cells assessed as reduction in cell viability incubated for 48 hrs by Hoechst-33342 staining based cell counting method (Rvb > 25 microM)
    		[PMID: 33422908]
    Fibroblast IC50
    0.02 μM
    Compound: Doxorubicin
    Cytotoxicity against human skin fibroblast cells assessed as reduction in cell viability after 48 hrs
    Cytotoxicity against human skin fibroblast cells assessed as reduction in cell viability after 48 hrs
    		[PMID: 34601029]
    Fibroblast IC50
    0.03 μM
    Compound: Doxorubicin
    Toxicity in human skin fibroblasts assessed as reduction in cell number after 48 hrs by Hoechst 33342 staining based assay
    Toxicity in human skin fibroblasts assessed as reduction in cell number after 48 hrs by Hoechst 33342 staining based assay
    		[PMID: 31753515]
    Fibroblast IC50
    0.04 μM
    Compound: Doxorubicin
    Cytotoxicity against human Fibroblasts assessed as cell growth inhibition
    Cytotoxicity against human Fibroblasts assessed as cell growth inhibition
    		[PMID: 26934105]
    Fibroblast IC50
    0.2 μM
    Compound: Doxorubicin
    Cytotoxicity in human Fibroblast cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Cytotoxicity in human Fibroblast cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    		[PMID: 34082225]
    Fibroblast IC50
    1.3 x 10-11 μM
    Compound: Doxo
    Cytotoxicity against human gingival fibroblast cells after 48 hrs by alamar blue assay
    Cytotoxicity against human gingival fibroblast cells after 48 hrs by alamar blue assay
    		[PMID: 25468043]
    Fibroblast IC50
    67 μM
    Compound: Doxorubicin
    Cytotoxicity against fibroblast (unknown origin) cells assessed as reduction in cell viability incubated for 6 hrs by SRB assay
    Cytotoxicity against fibroblast (unknown origin) cells assessed as reduction in cell viability incubated for 6 hrs by SRB assay
    		[PMID: 36691388]
    Fibroblast IC50
    7.86 μM
    Compound: Doxorubicin
    Antiproliferative activity against human dermal fibroblast cells after 72 hrs
    Antiproliferative activity against human dermal fibroblast cells after 72 hrs
    		[PMID: 25127463]
    Flp-In-293 IC50
    < 40 μM
    Compound: Doxorubicin
    Antiproliferative activity against human Flp-In-293 cells expressing ABCB1 assessed as cell growth inhibition incubated for 72 hrs by SRB assay
    Antiproliferative activity against human Flp-In-293 cells expressing ABCB1 assessed as cell growth inhibition incubated for 72 hrs by SRB assay
    		[PMID: 35751979]
    G-361 GI50
    < 1 x 10-7 M
    Compound: ADR
    Cytotoxicity against Homo sapiens (human) G361 cells by SRB assay
    Cytotoxicity against Homo sapiens (human) G361 cells by SRB assay
    		10.1007/s00044-012-0084-0
    G-361 IC50
    0.09 μM
    Compound: Doxo
    Antiproliferative activity against human G-361 cells assessed as cell viability measured after 4 days by MTT assay
    Antiproliferative activity against human G-361 cells assessed as cell viability measured after 4 days by MTT assay
    		[PMID: 31869654]
    G-361 IC50
    0.09 μM
    Compound: Doxorubicin
    Antitumor activity against human skin melanoma G361 cells.
    Antitumor activity against human skin melanoma G361 cells.
    		[PMID: 12431049]
    G-361 IC50
    0.09 μM
    Compound: doxo
    Antiproliferative activity against human G361 cell line by MTT assay
    Antiproliferative activity against human G361 cell line by MTT assay
    		[PMID: 16913700]
    G-361 IC50
    0.09 μM
    Compound: doxorubicin
    Antitumor activity against human skin melanoma G-361 cells
    Antitumor activity against human skin melanoma G-361 cells
    		[PMID: 12431048]
    G-361 IC50
    2.44 μM
    Compound: Doxorubicin
    Antiproliferative activity against human G-361 cells
    Antiproliferative activity against human G-361 cells
    		[PMID: 34655985]
    GCT IC50
    137 nM
    Compound: Dox
    Antiproliferative activity against human GCT cells assessed as inhibition of cell growth measured after 72 hrs by Celltiter-glo proliferation assay
    Antiproliferative activity against human GCT cells assessed as inhibition of cell growth measured after 72 hrs by Celltiter-glo proliferation assay
    		[PMID: 36001933]
    GES1 IC50
    0.53 μM
    Compound: ADM
    Cytotoxicity against human GES-1 cells after 48 hrs by MTT assay
    Cytotoxicity against human GES-1 cells after 48 hrs by MTT assay
    		[PMID: 25462264]
    GOTO IC50
    4.73 x 10-3 μM
    Compound: Doxorubicin
    Cytotoxicity against human GOTO cells by MTT assay
    Cytotoxicity against human GOTO cells by MTT assay
    		[PMID: 19345581]
    GOTO IC50
    4.73 x 10-3 μM
    Compound: Doxorubicin
    Cytotoxicity against human GOTO cells after 3 days by MTT assay
    Cytotoxicity against human GOTO cells after 3 days by MTT assay
    		[PMID: 20356655]
    H22 IC50
    36.51 μM
    Compound: Doxorubicin
    Antiproliferative activity against mouse H22 cells after 48 hrs by MTT assay
    Antiproliferative activity against mouse H22 cells after 48 hrs by MTT assay
    		[PMID: 21620529]
    H69AR IC50
    < 1 μM
    Compound: ADM
    Cytotoxicity against human NCI-H69AR cells by SRB method
    Cytotoxicity against human NCI-H69AR cells by SRB method
    		[PMID: 37807846]
    H69AR IC50
    < 1 μM
    Compound: Doxorubicin
    Cytotoxicity against human NCI-H69AR cells assessed as reduction in cell growth by MTT assay
    Cytotoxicity against human NCI-H69AR cells assessed as reduction in cell growth by MTT assay
    		[PMID: 36734533]
    H69AR IC50
    < 1 μM
    Compound: Doxorubicin
    Cytotoxicity against human NCI-H69AR cells assessed as inhibition of cell growth by SRB assay
    Cytotoxicity against human NCI-H69AR cells assessed as inhibition of cell growth by SRB assay
    		[PMID: 38064664]
    H9c2 IC50
    0.39 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against rat H9c2 cells incubated for 24 hrs by MTT assay
    Cytotoxicity against rat H9c2 cells incubated for 24 hrs by MTT assay
    		[PMID: 38505856]
    H9c2 IC50
    3.9 μM
    Compound: Doxorubicin
    Cytotoxicity against rat H9c2 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    Cytotoxicity against rat H9c2 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    		[PMID: 37216812]
    HBL-100 IC50
    0.08 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HBL100 cells after 70 hrs by alamar blue assay
    Antiproliferative activity against human HBL100 cells after 70 hrs by alamar blue assay
    		[PMID: 29471119]
    HBL-100 IC50
    0.24 μM
    Compound: Doxorubicin
    Cytotoxicity against human HBL100 cells after 72 hrs by MTT assay
    Cytotoxicity against human HBL100 cells after 72 hrs by MTT assay
    		[PMID: 19361894]
    HBL-100 IC50
    8.5 μM
    Compound: Doxorubicin
    Cytotoxicity against human HBL100 cells assessed as reduction in cell viability after 70 hrs by alamar blue assay
    Cytotoxicity against human HBL100 cells assessed as reduction in cell viability after 70 hrs by alamar blue assay
    		[PMID: 29471119]
    HCC 2998 GI50
    0.26 μM
    Compound: Doxorubicin
    Growth inhibition of human HCC2998 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human HCC2998 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28329730]
    HCC 2998 GI50
    0.26 μM
    Compound: Doxorubicin
    Growth inhibition of human HCC2998 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human HCC2998 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 29102177]
    HCC 2998 GI50
    0.26 μM
    Compound: Doxorubicin hydrochloride, NSC 123127
    Cytotoxicity against human HCC2998 cells after 48 hrs by SRB assay
    Cytotoxicity against human HCC2998 cells after 48 hrs by SRB assay
    		[PMID: 23871905]
    HCC 2998 IC50
    0.17 μg/mL
    Compound: Adriamycin
    Inhibitory concentration required against HCC2998 colon cancer cell line
    Inhibitory concentration required against HCC2998 colon cancer cell line
    		[PMID: 11354370]
    HCC1806 IC50
    0.34 μM
    Compound: DOX
    Anti-proliferative activity against human HCC1806 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    Anti-proliferative activity against human HCC1806 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    		[PMID: 38776807]
    HCC1937 IC50
    0.44 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HCC1937 cells after 48 hrs by SRB assay
    Antiproliferative activity against human HCC1937 cells after 48 hrs by SRB assay
    		[PMID: 29407962]
    HCC1937 IC50
    1.08 μM
    Compound: Doxorubicin
    Cytotoxicity against human HCC1937 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    Cytotoxicity against human HCC1937 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    		[PMID: 37216812]
    HCC1954 IC50
    0.045 μM
    Compound: DOX
    Cytotoxicity against human HCC1954 cells measured after 72 hrs by Celltiter-Glo assay
    Cytotoxicity against human HCC1954 cells measured after 72 hrs by Celltiter-Glo assay
    		[PMID: 31820976]
    HCC70 IC50
    0.05 μM
    Compound: Doxorubicin
    Cytotoxicity against human HCC70 cells assessed as growth inhibition after 72 hrs by SRB assay
    Cytotoxicity against human HCC70 cells assessed as growth inhibition after 72 hrs by SRB assay
    		[PMID: 30457333]
    HCT-116 CC50
    1.3 μM
    Compound: Dox
    Cytotoxicity against human HCT-116 cells incubated for 72 hrs by MTT assay
    Cytotoxicity against human HCT-116 cells incubated for 72 hrs by MTT assay
    		[PMID: 39079310]
    HCT-116 EC50
    0.16 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay
    Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay
    		[PMID: 35567964]
    HCT-116 EC50
    0.29 μM
    Compound: Doxorubicin
    Induction of apoptosis in human HCT116 cells assessed as caspase activation after 48 hrs
    Induction of apoptosis in human HCT116 cells assessed as caspase activation after 48 hrs
    		[PMID: 19282188]
    HCT-116 EC50
    41 nM
    Compound: Dox
    Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth incubated for 72 hrs by MTS assay
    Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth incubated for 72 hrs by MTS assay
    		[PMID: 37982711]
    HCT-116 ED50
    0.17 μg/mL
    Compound: doxorubicin
    Cytotoxicity against human HCT116 cells
    Cytotoxicity against human HCT116 cells
    		[PMID: 15787431]
    HCT-116 GI50
    0.011 μM
    Compound: Doxorubicin
    Cytostatic activity against human HCT116 cells after 5 days by SRB assay
    Cytostatic activity against human HCT116 cells after 5 days by SRB assay
    		[PMID: 21711054]
    HCT-116 GI50
    0.023 μM
    Compound: Doxorubicin
    Tested for in vitro concentration required to inhibit growth by 50% against HCT116 human colon cancer cell line
    Tested for in vitro concentration required to inhibit growth by 50% against HCT116 human colon cancer cell line
    		[PMID: 11755363]
    HCT-116 GI50
    0.08 μM
    Compound: Doxorubicin
    Growth inhibition of human HCT116 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human HCT116 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28329730]
    HCT-116 GI50
    0.08 μM
    Compound: Doxorubicin
    Growth inhibition of human HCT116 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human HCT116 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 29102177]
    HCT-116 GI50
    0.08 μM
    Compound: Doxorubicin hydrochloride, NSC 123127
    Cytotoxicity against human HCT116 cells after 48 hrs by SRB assay
    Cytotoxicity against human HCT116 cells after 48 hrs by SRB assay
    		[PMID: 23871905]
    HCT-116 GI50
    0.13 μM
    Compound: Doxorubicine
    Growth inhibition of human HCT116 cells after 2 days by sulforhodamine B assay
    Growth inhibition of human HCT116 cells after 2 days by sulforhodamine B assay
    		[PMID: 20045222]
    HCT-116 GI50
    0.15 μM
    Compound: Adriamycin
    Growth inhibition of human HCT116 cells by sulforhodamine B assay
    Growth inhibition of human HCT116 cells by sulforhodamine B assay
    		[PMID: 24650643]
    HCT-116 GI50
    0.15 μM
    Compound: Adriamycin
    Antiproliferative activity against human HCT116 cells assessed as growth inhibition after 72 hrs by MTT assay
    Antiproliferative activity against human HCT116 cells assessed as growth inhibition after 72 hrs by MTT assay
    		[PMID: 24686011]
    HCT-116 GI50
    0.4 μM
    Compound: Doxorubicin
    Growth inhibition of human HCT116 cells after 2 days by MTT assay
    Growth inhibition of human HCT116 cells after 2 days by MTT assay
    		[PMID: 20570145]
    HCT-116 GI50
    0.5 μM
    Compound: Dox
    Antiproliferative activity against p53-deficient human HCT-116 cells incubated for 72 hrs and measured by MTT assay
    Antiproliferative activity against p53-deficient human HCT-116 cells incubated for 72 hrs and measured by MTT assay
    		[PMID: 35973342]
    HCT-116 GI50
    0.57 μM
    Compound: Dox
    Anticancer activity against human HCT-116 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    Anticancer activity against human HCT-116 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    		[PMID: 35533562]
    HCT-116 GI50
    0.6 μM
    Compound: Dox
    Cytotoxicity against human HCT-116 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
    Cytotoxicity against human HCT-116 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
    		[PMID: 34634616]
    HCT-116 GI50
    0.76 μM
    Compound: Dox
    Antiproliferative activity against human HCT-116 cells incubated for 72 hrs and measured by MTT assay
    Antiproliferative activity against human HCT-116 cells incubated for 72 hrs and measured by MTT assay
    		[PMID: 35973342]
    HCT-116 GI50
    21.4 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability after 72 hrs by MTS-PMS assay
    Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability after 72 hrs by MTS-PMS assay
    		[PMID: 27614919]
    HCT-116 GI50
    70 nM
    Compound: Doxorubicin
    Antiproliferative activity against human HCT116 cells assessed as growth inhibition after 24 to 72 hrs by MTS assay
    Antiproliferative activity against human HCT116 cells assessed as growth inhibition after 24 to 72 hrs by MTS assay
    		10.1039/C0MD00179A
    HCT-116 GI50
    77 nM
    Compound: DOX
    Antiproliferative activity against human HCT-116 cells assessed as growth inhibition incubated for 3 days
    Antiproliferative activity against human HCT-116 cells assessed as growth inhibition incubated for 3 days
    		[PMID: 38599298]
    HCT-116 GI50
    < 1 μM
    Compound: DOX
    Antiproliferative activity against human HCT116 cells by MTT assay
    Antiproliferative activity against human HCT116 cells by MTT assay
    		[PMID: 31990554]
    HCT-116 IC50
    0.007 μM
    Compound: DOX
    Cytotoxicity against human HCT116 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human HCT116 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 27668963]
    HCT-116 IC50
    0.007 μg
    Compound: Doxorubicin
    Cytotoxicity against human HCT116 cells assessed as decrease in cell viability after 48 hrs by SRB assay
    Cytotoxicity against human HCT116 cells assessed as decrease in cell viability after 48 hrs by SRB assay
    		[PMID: 27393950]
    HCT-116 IC50
    0.01 μM
    Compound: DOX
    Antiproliferative activity against human HCT116 cells measured after 72 hrs by MTT assay
    Antiproliferative activity against human HCT116 cells measured after 72 hrs by MTT assay
    		[PMID: 31431364]
    HCT-116 IC50
    0.01 μM
    Compound: Doxorubicin
    Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability
    Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability
    		[PMID: 35183880]
    HCT-116 IC50
    0.02 μM
    Compound: Doxorubicin
    Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay
    Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay
    		10.1039/C4MD00371C
    HCT-116 IC50
    0.02 μM
    Compound: Doxorubicin
    Cytotoxicity against human HCT116 cells assessed as cell viability after 72 hrs by MTT assay
    Cytotoxicity against human HCT116 cells assessed as cell viability after 72 hrs by MTT assay
    		[PMID: 24530030]
    HCT-116 IC50
    0.02 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HCT116 cells assessed as inhibition of cell proliferation incubated for 72 hrs by conventional ATP quantification method
    Antiproliferative activity against human HCT116 cells assessed as inhibition of cell proliferation incubated for 72 hrs by conventional ATP quantification method
    		[PMID: 25937235]
    HCT-116 IC50
    0.023 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay
    Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay
    		[PMID: 31264855]
    HCT-116 IC50
    0.037 μM
    Compound: adriamycin
    Antitumor activity against human HCT116 cells by methylene blue staining method
    Antitumor activity against human HCT116 cells by methylene blue staining method
    		[PMID: 17656091]
    HCT-116 IC50
    0.04 μM
    Compound: Doxorubicin
    Cytotoxicity against human HCT-116 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    Cytotoxicity against human HCT-116 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    		[PMID: 38284153]
    HCT-116 IC50
    0.05 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HCT116 cells after 48 hrs by Hoechst 33342 staining-based assay
    Antiproliferative activity against human HCT116 cells after 48 hrs by Hoechst 33342 staining-based assay
    		[PMID: 30655216]
    HCT-116 IC50
    0.05 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability
    Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability
    		[PMID: 31945642]
    HCT-116 IC50
    0.05 μM
    Compound: Doxorubicine
    Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability incubated for 48 hrs by Hoechst-33342 staining based cell counting method (Rvb > 25 microM)
    Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability incubated for 48 hrs by Hoechst-33342 staining based cell counting method (Rvb > 25 microM)
    		[PMID: 33422908]
    HCT-116 IC50
    0.069 μM
    Compound: Doxorubicin
    Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay
    Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay
    		[PMID: 25462279]
    HCT-116 IC50
    0.07 μM
    Compound: Doxorubicin
    Cytotoxicity against human HCT116 cells after 48 hrs by MTT assay
    Cytotoxicity against human HCT116 cells after 48 hrs by MTT assay
    		[PMID: 20846862]
    HCT-116 IC50
    0.07 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay
    Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay
    		[PMID: 24780599]
    HCT-116 IC50
    0.07 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay
    Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay
    		[PMID: 27060757]
    HCT-116 IC50
    0.07 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay
    Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay
    		[PMID: 27448912]
    HCT-116 IC50
    0.08 μM
    Compound: Doxorubicin
    Cytotoxicity against human HCT116 cells assessed as cell growth inhibition
    Cytotoxicity against human HCT116 cells assessed as cell growth inhibition
    		[PMID: 26934105]
    HCT-116 IC50
    0.08 μM
    Compound: Doxorubicin
    Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability after 48 hrs
    Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability after 48 hrs
    		[PMID: 34601029]
    HCT-116 IC50
    0.09 μM
    Compound: Doxorubicin
    Cytotoxicity against human HCT116 cells after 24 hrs by MTT assay
    Cytotoxicity against human HCT116 cells after 24 hrs by MTT assay
    		[PMID: 21215623]
    HCT-116 IC50
    0.09 μM
    Compound: Doxorubicin
    Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability by CellTiter Glo luminescent assay
    Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability by CellTiter Glo luminescent assay
    		[PMID: 32755677]
    HCT-116 IC50
    0.1 mM
    Compound: Dox
    Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay
    Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay
    		[PMID: 29459273]
    HCT-116 IC50
    0.1 μM
    Compound: 1; Dox
    Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay
    Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay
    		[PMID: 26890118]
    HCT-116 IC50
    0.1 μM
    Compound: 5
    Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay
    Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay
    		[PMID: 29137865]
    HCT-116 IC50
    0.1 μM
    Compound: DOX
    Cytotoxicity against human HCT116 cells assessed as growth inhibition after 72 hrs by MTT assay
    Cytotoxicity against human HCT116 cells assessed as growth inhibition after 72 hrs by MTT assay
    		[PMID: 27016707]
    HCT-116 IC50
    0.1 μM
    Compound: DOX
    Antiproliferative activity against human HCT116 cells assessed as reduction in cell growth measured after 72 hrs by CCK8 assay
    Antiproliferative activity against human HCT116 cells assessed as reduction in cell growth measured after 72 hrs by CCK8 assay
    		[PMID: 31784322]
    HCT-116 IC50
    0.1 μM
    Compound: DOX
    Cytotoxicity against human HCT116 cells measured after 72 hrs by Celltiter-Glo assay
    Cytotoxicity against human HCT116 cells measured after 72 hrs by Celltiter-Glo assay
    		[PMID: 31820976]
    HCT-116 IC50
    0.1 μM
    Compound: Dox
    Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay
    Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay
    		[PMID: 30659997]
    HCT-116 IC50
    0.1 μM
    Compound: Doxorubicin
    Intrinsic cytotoxic activity against wild type HCT116 cell line
    Intrinsic cytotoxic activity against wild type HCT116 cell line
    		[PMID: 15546712]
    HCT-116 IC50
    0.1 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HCT116 cells assessed as inhibition of cell proliferation incubated for 72 hrs by conventional ATP quantification method
    Antiproliferative activity against human HCT116 cells assessed as inhibition of cell proliferation incubated for 72 hrs by conventional ATP quantification method
    		[PMID: 25937235]
    HCT-116 IC50
    0.1 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HCT116 cells after 72 hrs by MTT reduction assay
    Antiproliferative activity against human HCT116 cells after 72 hrs by MTT reduction assay
    		[PMID: 28551177]
    HCT-116 IC50
    0.1 μM
    Compound: Doxorubicin
    Cytotoxicity in human HCT-116 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Cytotoxicity in human HCT-116 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    		[PMID: 34082225]
    HCT-116 IC50
    0.11 μM
    Compound: 1; Dox
    Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay
    Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay
    		[PMID: 26633734]
    HCT-116 IC50
    0.11 μM
    Compound: Dox
    Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay
    Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay
    		[PMID: 21144624]
    HCT-116 IC50
    0.11 μM
    Compound: Doxorubicin
    Cytotoxicity against human HCT116 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
    Cytotoxicity against human HCT116 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
    		[PMID: 31836446]
    HCT-116 IC50
    0.11 μg/mL
    Compound: Adriamycin
    In vitro inhibition of HCT116 (human colon) tumor cell growth.
    In vitro inhibition of HCT116 (human colon) tumor cell growth.
    		[PMID: 12161130]
    HCT-116 IC50
    0.12 μM
    Compound: Doxorubicin
    Toxicity in human HCT-116 cells assessed as reduction in cell number after 48 hrs by Hoechst 33342 staining based assay
    Toxicity in human HCT-116 cells assessed as reduction in cell number after 48 hrs by Hoechst 33342 staining based assay
    		[PMID: 31753515]
    HCT-116 IC50
    0.15 μM
    Compound: DOX
    Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay
    Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay
    		[PMID: 37602711]
    HCT-116 IC50
    0.15 μM
    Compound: DOXO
    Cytotoxicity against human HCT116 cells assessed as cell viability after 72 hrs by MTT assay
    Cytotoxicity against human HCT116 cells assessed as cell viability after 72 hrs by MTT assay
    		[PMID: 26142490]
    HCT-116 IC50
    0.15 μM
    Compound: Doxorubicin
    Cytotoxicity against human HCT116 cells expressing NQO1 assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human HCT116 cells expressing NQO1 assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 27341379]
    HCT-116 IC50
    0.16 μM
    Compound: Dx
    Cytotoxicity against human HCT116 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
    Cytotoxicity against human HCT116 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
    		[PMID: 21444205]
    HCT-116 IC50
    0.17 μg/mL
    Compound: Adriamycin
    Inhibitory concentration against HCT 116 human colon cancer cell line
    Inhibitory concentration against HCT 116 human colon cancer cell line
    		[PMID: 11354370]
    HCT-116 IC50
    0.18 μM
    Compound: Dox
    Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay
    Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay
    		[PMID: 25998504]
    HCT-116 IC50
    0.18 μM
    Compound: Doxorubicin
    Cytotoxicity against human HCT116 cells assessed as growth inhibition incubated for 72 hrs by MTT assay
    Cytotoxicity against human HCT116 cells assessed as growth inhibition incubated for 72 hrs by MTT assay
    		[PMID: 26280922]
    HCT-116 IC50
    0.18 μM
    Compound: Doxorubicin
    Anticancer activity against human HCT-116 cells
    Anticancer activity against human HCT-116 cells
    		[PMID: 31926469]
    HCT-116 IC50
    0.2 μM
    Compound: ADM
    Cytotoxic activity against human HCT116 cells by SRB method
    Cytotoxic activity against human HCT116 cells by SRB method
    		[PMID: 25611519]
    HCT-116 IC50
    0.2 μM
    Compound: ADM
    Cytotoxicity against human HCT116 cells by SRB method
    Cytotoxicity against human HCT116 cells by SRB method
    		[PMID: 29144133]
    HCT-116 IC50
    0.2 μM
    Compound: Dox
    Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay
    Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay
    		[PMID: 32428792]
    HCT-116 IC50
    0.2 μM
    Compound: Doxorubicin
    Cytotoxicity against human HCT116 cells by SRB assay
    Cytotoxicity against human HCT116 cells by SRB assay
    		[PMID: 26561719]
    HCT-116 IC50
    0.2 μM
    Compound: Doxorubicin
    Cytotoxic activity against human HCT116 cells incubated for 48 hrs by MTT assay
    Cytotoxic activity against human HCT116 cells incubated for 48 hrs by MTT assay
    		[PMID: 28055219]
    HCT-116 IC50
    0.2 μM
    Compound: Doxorubicin
    Cytotoxicity against human HCT-116 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay
    Cytotoxicity against human HCT-116 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay
    		[PMID: 36044031]
    HCT-116 IC50
    0.21 μM
    Compound: Adriamycin
    Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay
    Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay
    		[PMID: 24370114]
    HCT-116 IC50
    0.21 μM
    Compound: DOX
    Cytotoxicity against human HCT116 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human HCT116 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 29660689]
    HCT-116 IC50
    0.21 μM
    Compound: DOXO
    Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay
    Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay
    		[PMID: 28818447]
    HCT-116 IC50
    0.21 μM
    Compound: Dox
    Anticancer activity against human HCT116 cells
    Anticancer activity against human HCT116 cells
    		[PMID: 31306817]
    HCT-116 IC50
    0.21 μM
    Compound: Dox
    Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 33479619]
    HCT-116 IC50
    0.21 μM
    Compound: Doxorubicin
    Cytotoxicity against human HCT-116 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    Cytotoxicity against human HCT-116 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    		[PMID: 34778772]
    HCT-116 IC50
    0.211 μM
    Compound: DOX
    Cytotoxicity against human HCT-116 cells incubated for 48 hrs by MTT assay
    Cytotoxicity against human HCT-116 cells incubated for 48 hrs by MTT assay
    		[PMID: 38185054]
    HCT-116 IC50
    0.22 μM
    Compound: Doxorubicin
    Cytotoxicity against human HCT116 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
    Cytotoxicity against human HCT116 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
    		[PMID: 31836446]
    HCT-116 IC50
    0.221 μM
    Compound: Dox
    Cytotoxicity against human HCT116 cells assessed as decrease in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human HCT116 cells assessed as decrease in cell viability after 72 hrs by MTT assay
    		[PMID: 30108718]
    HCT-116 IC50
    0.23 μM
    Compound: Doxorubicin
    Cytotoxicity against human HCT116 cells assessed as growth inhibition by MTT assay
    Cytotoxicity against human HCT116 cells assessed as growth inhibition by MTT assay
    		[PMID: 24398294]
    HCT-116 IC50
    0.24 μM
    Compound: Doxorubicin
    Cytotoxicity against human HCT116 cells after 48 hrs by neutral red dye based assay
    Cytotoxicity against human HCT116 cells after 48 hrs by neutral red dye based assay
    		[PMID: 29317147]
    HCT-116 IC50
    0.25 μM
    Compound: Doxorubicin
    Cytotoxicity against human HCT116 cells after 48 hrs by WST8 assay
    Cytotoxicity against human HCT116 cells after 48 hrs by WST8 assay
    		[PMID: 25163667]
    HCT-116 IC50
    0.25 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HCT116 cells incubated for 48 hrs by WST8 assay
    Antiproliferative activity against human HCT116 cells incubated for 48 hrs by WST8 assay
    		[PMID: 31679979]
    HCT-116 IC50
    0.27 μM
    Compound: DOX
    Cytotoxicity against human HCT116 cells assessed as cell growth inhibition after 48 hrs by MTT assay
    Cytotoxicity against human HCT116 cells assessed as cell growth inhibition after 48 hrs by MTT assay
    		[PMID: 31999451]
    HCT-116 IC50
    0.286 μg/mL
    Compound: DOX
    Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay
    Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay
    		[PMID: 20722446]
    HCT-116 IC50
    0.29 μM
    Compound: DOX
    Antiproliferative activity against doxorubicin sensitive human HCT-116 cells measured after 72 hrs by MTT assay
    Antiproliferative activity against doxorubicin sensitive human HCT-116 cells measured after 72 hrs by MTT assay
    		[PMID: 35612499]
    HCT-116 IC50
    0.3 μM
    Compound: Dox
    Antiproliferative activity against human HCT-116 assessed as growth inhibition measured after 72 hrs by MTT assay
    Antiproliferative activity against human HCT-116 assessed as growth inhibition measured after 72 hrs by MTT assay
    		[PMID: 34902732]
    HCT-116 IC50
    0.3 μM
    Compound: Dox
    Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    		[PMID: 38176358]
    HCT-116 IC50
    0.3 μM
    Compound: Doxorubicin
    Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay
    Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay
    		[PMID: 22749279]
    HCT-116 IC50
    0.3 μM
    Compound: Doxorubicin
    Cytotoxicity against human HCT116 cells assessed as cell growth inhibition after 72 hrs by alamar blue assay
    Cytotoxicity against human HCT116 cells assessed as cell growth inhibition after 72 hrs by alamar blue assay
    		[PMID: 31403289]
    HCT-116 IC50
    0.31 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay
    Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay
    		[PMID: 27886545]
    HCT-116 IC50
    0.31 μM
    Compound: Doxorubicin
    Cytotoxicity against human HCT116 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Cytotoxicity against human HCT116 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    		[PMID: 28327308]
    HCT-116 IC50
    0.33 μM
    Compound: Doxorubicin
    Cytotoxicity against human HCT116 cells assessed as effect on cell viability measured after 48 hrs by MTT assay
    Cytotoxicity against human HCT116 cells assessed as effect on cell viability measured after 48 hrs by MTT assay
    		[PMID: 27521588]
    HCT-116 IC50
    0.34 μM
    Compound: DOX
    Cytotoxicity against human HCT-116 cells expressing high level of topoisomerase I/II measured after 72 hrs by MTT assay
    Cytotoxicity against human HCT-116 cells expressing high level of topoisomerase I/II measured after 72 hrs by MTT assay
    		[PMID: 35612499]
    HCT-116 IC50
    0.34 μM
    Compound: DOXO
    Antiproliferative activity against p53 expressing human HCT116 cells after 96 hrs by MTS assay
    Antiproliferative activity against p53 expressing human HCT116 cells after 96 hrs by MTS assay
    		[PMID: 26890119]
    HCT-116 IC50
    0.34 μM
    Compound: Dox
    Cytotoxicity against human HCT116 cells after 48 hrs by MTT assay
    Cytotoxicity against human HCT116 cells after 48 hrs by MTT assay
    		[PMID: 25247771]
    HCT-116 IC50
    0.34 μM
    Compound: Doxorubicin
    Cytotoxicity against human HCT116 cells expressing wild type p53 incubated for 72 hrs by MTS assay
    Cytotoxicity against human HCT116 cells expressing wild type p53 incubated for 72 hrs by MTS assay
    		[PMID: 31158748]
    HCT-116 IC50
    0.34 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HCT 116 cells assessed as reduction in cell viability measured after 72 hrs by MTS assay
    Antiproliferative activity against human HCT 116 cells assessed as reduction in cell viability measured after 72 hrs by MTS assay
    		[PMID: 31962262]
    HCT-116 IC50
    0.34 μM
    Compound: Doxorubicin
    Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability measured after 72 hrs by MTS assay
    Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability measured after 72 hrs by MTS assay
    		[PMID: 33261897]
    HCT-116 IC50
    0.36 μM
    Compound: Doxorubicin
    Cytotoxicity against human HCT116 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay
    Cytotoxicity against human HCT116 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay
    		[PMID: 27080182]
    HCT-116 IC50
    0.38 μM
    Compound: DOXO
    Antiproliferative activity against p53 deficient human HCT116 cells after 96 hrs by MTS assay
    Antiproliferative activity against p53 deficient human HCT116 cells after 96 hrs by MTS assay
    		[PMID: 26890119]
    HCT-116 IC50
    0.38 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HCT116 cells assessed as cell viability after 48 hrs by SRB assay
    Antiproliferative activity against human HCT116 cells assessed as cell viability after 48 hrs by SRB assay
    		[PMID: 26947606]
    HCT-116 IC50
    0.38 μM
    Compound: Doxorubicin
    Cytotoxicity against human HCT116 cells deficient in p53 incubated for 72 hrs by MTS assay
    Cytotoxicity against human HCT116 cells deficient in p53 incubated for 72 hrs by MTS assay
    		[PMID: 31158748]
    HCT-116 IC50
    0.39 μM
    Compound: Doxorubicin
    Cytotoxicity against human HCT-116 cells
    Cytotoxicity against human HCT-116 cells
    		[PMID: 34332400]
    HCT-116 IC50
    0.4 μM
    Compound: DOX
    Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay
    Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay
    		[PMID: 30429098]
    HCT-116 IC50
    0.4 μM
    Compound: Dox
    Cytotoxicity against human HCT116 cells by MTT assay
    Cytotoxicity against human HCT116 cells by MTT assay
    		[PMID: 21983438]
    HCT-116 IC50
    0.4 μM
    Compound: Doxorubicin
    Cytotoxicity against human HCT116 cells after 48 hrs by sulforhodamine B assay
    Cytotoxicity against human HCT116 cells after 48 hrs by sulforhodamine B assay
    		10.1039/C0MD00219D
    HCT-116 IC50
    0.41 μM
    Compound: Doxorubicin
    Cytotoxicity against human HCT-116 cells
    Cytotoxicity against human HCT-116 cells
    		[PMID: 34655985]
    HCT-116 IC50
    0.41 μM
    Compound: adriamycin
    Cytotoxicity against human HCT116 cells by MTT assay
    Cytotoxicity against human HCT116 cells by MTT assay
    		[PMID: 17125240]
    HCT-116 IC50
    0.467 μM
    Compound: Doxorubicin
    Anticancer activity against human HCT-116 cells assessed as reduction in cell viability incubated for 24 hrs by MTT colorimetric assay
    Anticancer activity against human HCT-116 cells assessed as reduction in cell viability incubated for 24 hrs by MTT colorimetric assay
    		[PMID: 35694689]
    HCT-116 IC50
    0.477 μM
    Compound: Doxorubicin
    Cytotoxicity against human HCT116 cells assessed as growth inhibition after 72 hrs by MTT assay
    Cytotoxicity against human HCT116 cells assessed as growth inhibition after 72 hrs by MTT assay
    		[PMID: 25703298]
    HCT-116 IC50
    0.48 μM
    Compound: Doxorubicin
    Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay
    Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay
    		[PMID: 30783501]
    HCT-116 IC50
    0.48 μM
    Compound: Doxorubicin
    Cytotoxicity against human HCT-116 p53+/+ cells assessed as reduction in cell viability after 72 hrs by RRA assay
    Cytotoxicity against human HCT-116 p53+/+ cells assessed as reduction in cell viability after 72 hrs by RRA assay
    		[PMID: 33508467]
    HCT-116 IC50
    0.49 μM
    Compound: Dox
    Cytotoxicity against human HCT-116 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay
    Cytotoxicity against human HCT-116 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay
    		[PMID: 36395650]
    HCT-116 IC50
    0.5 mM
    Compound: Dox
    Antiproliferative activity against p53 knockout human HCT116 cells after 72 hrs by MTT assay
    Antiproliferative activity against p53 knockout human HCT116 cells after 72 hrs by MTT assay
    		[PMID: 29459273]
    HCT-116 IC50
    0.5 μM
    Compound: 1; Dox
    Antiproliferative activity against p53 knockout human HCT116 cells after 72 hrs by MTT assay
    Antiproliferative activity against p53 knockout human HCT116 cells after 72 hrs by MTT assay
    		[PMID: 26890118]
    HCT-116 IC50
    0.5 μM
    Compound: 5
    Antiproliferative activity against p53 deficient human HCT116 cells after 72 hrs by MTT assay
    Antiproliferative activity against p53 deficient human HCT116 cells after 72 hrs by MTT assay
    		[PMID: 29137865]
    HCT-116 IC50
    0.5 μM
    Compound: Adriamycin
    Cytotoxicity against human HCT116 cells assessed as growth inhibition after 48 hrs by sulphorhodamine B assay
    Cytotoxicity against human HCT116 cells assessed as growth inhibition after 48 hrs by sulphorhodamine B assay
    		[PMID: 26222449]
    HCT-116 IC50
    0.5 μM
    Compound: Doxorubicin
    Cytotoxicity against human HCT116 cells assessed as reduction in cell survival after 48 hrs by MTT assay
    Cytotoxicity against human HCT116 cells assessed as reduction in cell survival after 48 hrs by MTT assay
    		[PMID: 28494255]
    HCT-116 IC50
    0.5 μM
    Compound: Doxorubicin
    Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
    Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
    		[PMID: 33668008]
    HCT-116 IC50
    0.5 μM
    Compound: Doxorubicin
    Cytotoxicity against human HCT-116 cells assessed as cell growth inhibition incubated for 24 to 72 hrs by MTT assay
    Cytotoxicity against human HCT-116 cells assessed as cell growth inhibition incubated for 24 to 72 hrs by MTT assay
    		[PMID: 37989057]
    HCT-116 IC50
    0.52 μM
    Compound: Dox
    Cytotoxicity against human p53 knockout HCT116 cells after 72 hrs by MTT assay
    Cytotoxicity against human p53 knockout HCT116 cells after 72 hrs by MTT assay
    		[PMID: 21144624]
    HCT-116 IC50
    0.55 μM
    Compound: Dox
    Antiproliferative activity against human HCT-116 cells by MTT assay
    Antiproliferative activity against human HCT-116 cells by MTT assay
    		[PMID: 38387333]
    HCT-116 IC50
    0.55 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    		[PMID: 31546197]
    HCT-116 IC50
    0.579 μM
    Compound: 1
    Cytotoxicity in human HCT-116 cells assessed as reduction in cell viability incubated for 2 hrs by Cell-titer-blue assay
    Cytotoxicity in human HCT-116 cells assessed as reduction in cell viability incubated for 2 hrs by Cell-titer-blue assay
    		[PMID: 33064004]
    HCT-116 IC50
    0.58 μM
    Compound: Dox
    Cytotoxicity against human HCT-116 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    Cytotoxicity against human HCT-116 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    		[PMID: 37001390]
    HCT-116 IC50
    0.6 μM
    Compound: Dox
    Cytotoxicity against p53 knockout human HCT116 cells after 72 hrs by MTT assay
    Cytotoxicity against p53 knockout human HCT116 cells after 72 hrs by MTT assay
    		[PMID: 30659997]
    HCT-116 IC50
    0.6 μM
    Compound: Doxorubicin
    Cytotoxicity against p53 knock out human HCT-116 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Cytotoxicity against p53 knock out human HCT-116 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    		[PMID: 34082225]
    HCT-116 IC50
    0.62 μM
    Compound: doxorubicin
    Cytotoxicity against human HCT116 cells by SRB assay
    Cytotoxicity against human HCT116 cells by SRB assay
    		[PMID: 17194596]
    HCT-116 IC50
    0.63 μM
    Compound: Doxorubicin
    Cytotoxicity against human HCT116 cells after 48 hrs by sulforhodamine B assay
    Cytotoxicity against human HCT116 cells after 48 hrs by sulforhodamine B assay
    		[PMID: 23291120]
    HCT-116 IC50
    0.65 μg/mL
    Compound: Dox
    Cytotoxicity against human HCT116 cells after 48 hrs by sulforhodamine B assay
    Cytotoxicity against human HCT116 cells after 48 hrs by sulforhodamine B assay
    		[PMID: 20399544]
    HCT-116 IC50
    0.7 μM
    Compound: Dox
    Antiproliferative activity against human HCT-116 cells with inactivated p53 gene assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay
    Antiproliferative activity against human HCT-116 cells with inactivated p53 gene assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay
    		[PMID: 32428792]
    HCT-116 IC50
    0.7 μM
    Compound: Doxorubicin
    Cytotoxicity against human HCT-116 cells assessed as cell growth inhibition
    Cytotoxicity against human HCT-116 cells assessed as cell growth inhibition
    		[PMID: 38630559]
    HCT-116 IC50
    0.72 μM
    Compound: Dox
    Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    		[PMID: 37956506]
    HCT-116 IC50
    0.74 μM
    Compound: Doxorubicin
    Cytotoxicity against human HCT116 cells assessed as growth inhibition after 72 hrs by MTT assay
    Cytotoxicity against human HCT116 cells assessed as growth inhibition after 72 hrs by MTT assay
    		[PMID: 26874404]
    HCT-116 IC50
    0.79 μM
    Compound: DOX
    Antiproliferative activity against human HCT116 cells after 72 hrs by CCK-8 assay
    Antiproliferative activity against human HCT116 cells after 72 hrs by CCK-8 assay
    		[PMID: 29597166]
    HCT-116 IC50
    0.8 μM
    Compound: Dox
    Antiproliferative activity against human HCT-116p53KO subline assessed as growth inhibition measured after 72 hrs by MTT assay
    Antiproliferative activity against human HCT-116p53KO subline assessed as growth inhibition measured after 72 hrs by MTT assay
    		[PMID: 34902732]
    HCT-116 IC50
    0.87 μM
    Compound: DOX
    Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay
    Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay
    		[PMID: 35341920]
    HCT-116 IC50
    0.96 μM
    Compound: Doxorubicin
    Cytotoxicity against human HCT-116 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
    Cytotoxicity against human HCT-116 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
    		[PMID: 37951135]
    HCT-116 IC50
    1.01 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay
    Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay
    		[PMID: 28554092]
    HCT-116 IC50
    1.01 μM
    Compound: Doxorubicin
    Cytotoxicity in human HCT116 cells incubated for 48 hrs by MTT assay
    Cytotoxicity in human HCT116 cells incubated for 48 hrs by MTT assay
    		[PMID: 28923381]
    HCT-116 IC50
    1.1 μM
    Compound: DOX
    Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability by MTT assay
    Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability by MTT assay
    		[PMID: 34323485]
    HCT-116 IC50
    1.1 μM
    Compound: adriamycin
    Cytotoxicity against human HCT116 cells
    Cytotoxicity against human HCT116 cells
    		[PMID: 18178085]
    HCT-116 IC50
    1.19 μM
    Compound: Dox
    Anticancer activity against Homo sapiens (human) HCT116 cells assessed as growth inhibition after 48 hr by SRB assay
    Anticancer activity against Homo sapiens (human) HCT116 cells assessed as growth inhibition after 48 hr by SRB assay
    		10.1007/s00044-012-0057-3
    HCT-116 IC50
    1.23 μM
    Compound: Doxorubicin
    Antiproliferative activity against p53-deficient human HCT116 cells after 48 hrs by MTT assay
    Antiproliferative activity against p53-deficient human HCT116 cells after 48 hrs by MTT assay
    		[PMID: 28554092]
    HCT-116 IC50
    1.38 μM
    Compound: Adriamycin
    Cytotoxicity against human HCT116 cells by MTT assay
    Cytotoxicity against human HCT116 cells by MTT assay
    		[PMID: 24182355]
    HCT-116 IC50
    1.3 μg/mL
    Compound: Doxorubicin, Adriablastina
    Cytotoxicity against human HCT116 cells after 48 hrs by sulforhodamine B method
    Cytotoxicity against human HCT116 cells after 48 hrs by sulforhodamine B method
    		[PMID: 21664013]
    HCT-116 IC50
    1.4 μM
    Compound: 1, DOX
    Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay
    Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay
    		[PMID: 25244612]
    HCT-116 IC50
    1.4 μM
    Compound: I
    Antiproliferative activity against human HCT116 cells expressing wild-type p53 after 72 hrs by MTT test
    Antiproliferative activity against human HCT116 cells expressing wild-type p53 after 72 hrs by MTT test
    		[PMID: 17276690]
    HCT-116 IC50
    1.6 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human HCT-116 cells by MTT assay
    Cytotoxicity against human HCT-116 cells by MTT assay
    		[PMID: 36325400]
    HCT-116 IC50
    1.78 μM
    Compound: Doxorubicin
    Cytotoxicity against human HCT-116 p53-/- cells assessed as reduction in cell viability after 72 hrs by RRA assay
    Cytotoxicity against human HCT-116 p53-/- cells assessed as reduction in cell viability after 72 hrs by RRA assay
    		[PMID: 33508467]
    HCT-116 IC50
    1.878 μM
    Compound: Dox
    Antiproliferative activity against human HCT-116 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    Antiproliferative activity against human HCT-116 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    		[PMID: 36240546]
    HCT-116 IC50
    1.8 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human HCT-116 cells assessed as cell growth inhibition
    Cytotoxicity against human HCT-116 cells assessed as cell growth inhibition
    		[PMID: 35526504]
    HCT-116 IC50
    1.96 μM
    Compound: DOX
    Antiproliferative activity against human HCT116 cells harboring PI3Kalpha H1047R mutant after 72 hrs by CCK8 assay
    Antiproliferative activity against human HCT116 cells harboring PI3Kalpha H1047R mutant after 72 hrs by CCK8 assay
    		[PMID: 30071408]
    HCT-116 IC50
    1.96 μM
    Compound: DOX
    Antiproliferative activity against human HCT116 cells after 72 hrs by CCK-8 assay
    Antiproliferative activity against human HCT116 cells after 72 hrs by CCK-8 assay
    		[PMID: 30245395]
    HCT-116 IC50
    1.96 μM
    Compound: DOX
    Cytotoxicity against against human HCT116 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against against human HCT116 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 30340899]
    HCT-116 IC50
    100 nM
    Compound: Doxorubicin
    In vitro cytotoxicity expressed as concentration that inhibits 50% of HCT(human colon carcinoma)116 cell proliferation
    In vitro cytotoxicity expressed as concentration that inhibits 50% of HCT(human colon carcinoma)116 cell proliferation
    		[PMID: 11606141]
    HCT-116 IC50
    110 ng/mL
    Compound: Adriamycin
    Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of HCT116 human colon carcinoma cell line
    Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of HCT116 human colon carcinoma cell line
    		[PMID: 12113817]
    HCT-116 IC50
    15.82 μM
    Compound: Doxorubicin
    Anticancer activity against human HCT-116 cells assessed as cell growth inhibition
    Anticancer activity against human HCT-116 cells assessed as cell growth inhibition
    		[PMID: 32771798]
    HCT-116 IC50
    19.7 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HCT-116 cells assessed as cell viability incubated for 48 hrs by MTT assay
    Antiproliferative activity against human HCT-116 cells assessed as cell viability incubated for 48 hrs by MTT assay
    		[PMID: 32771798]
    HCT-116 IC50
    19.9 nM
    Compound: Doxorubicin
    Cytotoxicity against human HCT116 cells after 72 hrs by cell counting Kit-8 assay
    Cytotoxicity against human HCT116 cells after 72 hrs by cell counting Kit-8 assay
    		[PMID: 25499433]
    HCT-116 IC50
    2.05 μM
    Compound: DOX
    Antiproliferative activity against doxorubicin resistant human HCT-116 cells measured after 72 hrs by MTT assay
    Antiproliferative activity against doxorubicin resistant human HCT-116 cells measured after 72 hrs by MTT assay
    		[PMID: 35612499]
    HCT-116 IC50
    2.2 μM
    Compound: Doxorubicin
    Cytotoxicity against human HCT116 cells after 24 hrs by WST assay
    Cytotoxicity against human HCT116 cells after 24 hrs by WST assay
    		[PMID: 25881821]
    HCT-116 IC50
    2.38 μM
    Compound: Doxorubicin
    Cytotoxicity against human HCT116 cells by WST-8 assay
    Cytotoxicity against human HCT116 cells by WST-8 assay
    		[PMID: 29295796]
    HCT-116 IC50
    2.4 μM
    Compound: Doxorubicin
    Anticancer activity against human HCT-116 cells by MTT assay
    Anticancer activity against human HCT-116 cells by MTT assay
    		[PMID: 33421712]
    HCT-116 IC50
    2.4 μM
    Compound: Doxorubicin
    Cytotoxicity against human HCT-116 cells
    Cytotoxicity against human HCT-116 cells
    		[PMID: 33421712]
    HCT-116 IC50
    2.56 μM
    Compound: doxorubicin
    Cytotoxicity against human HCT116 cells after 96 hrs by MTT assay
    Cytotoxicity against human HCT116 cells after 96 hrs by MTT assay
    		10.1007/s00044-013-0795-x
    HCT-116 IC50
    2.6 μM
    Compound: Doxorubicin
    Cytotoxicity against human HCT116 cells after 96 hrs by MTT assay
    Cytotoxicity against human HCT116 cells after 96 hrs by MTT assay
    		[PMID: 31200236]
    HCT-116 IC50
    2.601 μM
    Compound: Doxorubicin
    Anticancer activity against human HCT116 cells
    Anticancer activity against human HCT116 cells
    		[PMID: 31404864]
    HCT-116 IC50
    2.61 μM
    Compound: Doxorubicin
    Anticancer activity against human HCT-116 cells assessed as reduction in cell viability
    Anticancer activity against human HCT-116 cells assessed as reduction in cell viability
    		[PMID: 35694689]
    HCT-116 IC50
    22 nM
    Compound: Doxorubicine
    Cytotoxicity against human HCT116 cells after 72 hrs by MTS assay
    Cytotoxicity against human HCT116 cells after 72 hrs by MTS assay
    		[PMID: 21142180]
    HCT-116 IC50
    22 nM
    Compound: doxorubicine
    Cytotoxicity against human HCT116 cells incubated for 72 hrs by MTS assay
    Cytotoxicity against human HCT116 cells incubated for 72 hrs by MTS assay
    		[PMID: 23072299]
    HCT-116 IC50
    3.29 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth incubated for 48 hrs
    Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth incubated for 48 hrs
    		[PMID: 34530384]
    HCT-116 IC50
    3.36 μg/mL
    Compound: Doxorubicin
    Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay
    Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay
    		[PMID: 34973507]
    HCT-116 IC50
    3.3 μg/mL
    Compound: Doxorubicin
    Antiproliferative activity against human HCT116 cells after 24 hrs by MTS assay
    Antiproliferative activity against human HCT116 cells after 24 hrs by MTS assay
    		[PMID: 20813435]
    HCT-116 IC50
    3.42 μM
    Compound: Dox
    Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell viability by MTT assay
    Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell viability by MTT assay
    		[PMID: 37922829]
    HCT-116 IC50
    3.7 μM
    Compound: Dox
    Cytotoxicity against human HCT116 cells assessed as cell viability after 24 hrs by crystal violet staining assay
    Cytotoxicity against human HCT116 cells assessed as cell viability after 24 hrs by crystal violet staining assay
    		[PMID: 26706352]
    HCT-116 IC50
    3.73 μg/mL
    Compound: Doxorubicin
    Antitumor activity against human HCT116 cells
    Antitumor activity against human HCT116 cells
    		[PMID: 20739102]
    HCT-116 IC50
    3.73 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human HCT116 cells after 48 hrs by sulforhodamine B assay
    Cytotoxicity against human HCT116 cells after 48 hrs by sulforhodamine B assay
    		[PMID: 21723735]
    HCT-116 IC50
    366 nM
    Compound: DOX
    Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
    Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
    		[PMID: 30878835]
    HCT-116 IC50
    4.17 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HCT-116 cells measured after 24 hrs by MTT assay
    Antiproliferative activity against human HCT-116 cells measured after 24 hrs by MTT assay
    		[PMID: 37875056]
    HCT-116 IC50
    4.4 μM
    Compound: 1, DOX
    Antiproliferative activity against p53-deficient human HCT116 cells after 72 hrs by MTT assay
    Antiproliferative activity against p53-deficient human HCT116 cells after 72 hrs by MTT assay
    		[PMID: 25244612]
    HCT-116 IC50
    4.4 μM
    Compound: I
    Antiproliferative activity against human p53 deficient HCT116 p53-/- cells after 72 hrs by MTT test
    Antiproliferative activity against human p53 deficient HCT116 p53-/- cells after 72 hrs by MTT test
    		[PMID: 17276690]
    HCT-116 IC50
    4.8 μM
    Compound: Doxorubicin
    Anticancer activity against human HCT116 cells measured after 48 hrs by SRB assay
    Anticancer activity against human HCT116 cells measured after 48 hrs by SRB assay
    		[PMID: 27112448]
    HCT-116 IC50
    49.5 μM
    Compound: Doxorubicin
    Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Blue cell viability assay
    Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Blue cell viability assay
    		[PMID: 35271771]
    HCT-116 IC50
    5.1 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    		[PMID: 34530384]
    HCT-116 IC50
    5.23 μM
    Compound: DOX
    Cytotoxicity against human HCT116 cells after 24 hrs by MTT assay
    Cytotoxicity against human HCT116 cells after 24 hrs by MTT assay
    		[PMID: 30015070]
    HCT-116 IC50
    5.23 μM
    Compound: DOX
    Antiproliferative activity against human HCT116 cells by MTT assay
    Antiproliferative activity against human HCT116 cells by MTT assay
    		[PMID: 30216848]
    HCT-116 IC50
    5.23 μM
    Compound: DOX
    Anticancer activity against human HCT116 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay
    Anticancer activity against human HCT116 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay
    		[PMID: 32085964]
    HCT-116 IC50
    5.23 μM
    Compound: DOX
    Antiproliferative activity against human HCT-116 cells after 72 hrs by MTT assay
    Antiproliferative activity against human HCT-116 cells after 72 hrs by MTT assay
    		[PMID: 35964425]
    HCT-116 IC50
    5.23 μM
    Compound: DOX
    Cytotoxicity against human HCT-116 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay
    Cytotoxicity against human HCT-116 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay
    		[PMID: 36242988]
    HCT-116 IC50
    5.23 μM
    Compound: DOX
    Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay
    Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay
    		[PMID: 37054758]
    HCT-116 IC50
    5.23 μM
    Compound: Dox
    Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    		[PMID: 32527460]
    HCT-116 IC50
    5.23 μM
    Compound: Dox
    Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    		[PMID: 34126285]
    HCT-116 IC50
    5.23 μM
    Compound: Doxorubicin
    Antitumor activity against human HCT-116 cells assessed as inhibition of cell viability by MTT assay
    Antitumor activity against human HCT-116 cells assessed as inhibition of cell viability by MTT assay
    		[PMID: 33065442]
    HCT-116 IC50
    5.95 μM
    Compound: Doxorubicin
    Cytotoxicity against human HCT116 cells after 24 to 96 hrs by MTS assay
    Cytotoxicity against human HCT116 cells after 24 to 96 hrs by MTS assay
    		[PMID: 20303768]
    HCT-116 IC50
    56.6 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability after 72 hrs by CellTiter Glo assay
    Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability after 72 hrs by CellTiter Glo assay
    		[PMID: 33016067]
    HCT-116 IC50
    57.77 nM
    Compound: Doxorubicin
    Antiproliferative activity against human HCT-116 cells assessed as cell growth inhibition measured after 72 hrs by crystal violet staining based assay
    Antiproliferative activity against human HCT-116 cells assessed as cell growth inhibition measured after 72 hrs by crystal violet staining based assay
    		[PMID: 34795858]
    HCT-116 IC50
    5 mM
    Compound: Adriamycin
    Cytotoxicity against human HCT116 cells after 48 hrs by MTT assay
    Cytotoxicity against human HCT116 cells after 48 hrs by MTT assay
    		[PMID: 22440624]
    HCT-116 IC50
    5 mM
    Compound: Adriamycin
    Cytotoxicity against human HCT116 cells after 24 hrs by MTT assay
    Cytotoxicity against human HCT116 cells after 24 hrs by MTT assay
    		[PMID: 23685942]
    HCT-116 IC50
    6 nM
    Compound: doxorubicin
    Cytotoxicity against human HCT116 cells after 72 hrs by MTS assay
    Cytotoxicity against human HCT116 cells after 72 hrs by MTS assay
    		[PMID: 19655762]
    HCT-116 IC50
    6.3 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human HCT116 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
    Cytotoxicity against human HCT116 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
    		[PMID: 27894044]
    HCT-116 IC50
    6.86 μM
    Compound: DOX
    Cytotoxicity against human HCT116 cells after 48 hrs by SRB assay
    Cytotoxicity against human HCT116 cells after 48 hrs by SRB assay
    		[PMID: 22444025]
    HCT-116 IC50
    6.86 μM
    Compound: Doxorubicin
    Antitumor activity against Homo sapiens (human) HCT116 cells assessed as cell growth inhibition after 48 hr by MTT assay
    Antitumor activity against Homo sapiens (human) HCT116 cells assessed as cell growth inhibition after 48 hr by MTT assay
    		10.1007/s00044-013-0497-4
    HCT-116 IC50
    6.86 μM
    Compound: Doxorubicin
    Cytotoxicity against human HCT116 cells after 48 hrs by sulforhodamine B assay
    Cytotoxicity against human HCT116 cells after 48 hrs by sulforhodamine B assay
    		[PMID: 22119131]
    HCT-116 IC50
    6.86 μM
    Compound: Doxorubicin
    Cytotoxicity against human HCT116 cells after 48 hrs by sulforhodamine B assay
    Cytotoxicity against human HCT116 cells after 48 hrs by sulforhodamine B assay
    		[PMID: 22119132]
    HCT-116 IC50
    7.03 μM
    Compound: Doxorubicin
    Anticancer activity against human HCT-116 cells assessed as cell growth inhibition measured after 24 hrs by SRB assay
    Anticancer activity against human HCT-116 cells assessed as cell growth inhibition measured after 24 hrs by SRB assay
    		[PMID: 36481599]
    HCT-116 IC50
    7.41 μM
    Compound: Dox
    Cytotoxicity against human HCT-116 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay
    Cytotoxicity against human HCT-116 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay
    		[PMID: 35635947]
    HCT-116 IC50
    7.7 μM
    Compound: adriamycin
    Cytotoxicity against human HCT116 cells after 4 days by MTT assay
    Cytotoxicity against human HCT116 cells after 4 days by MTT assay
    		[PMID: 17194586]
    HCT-116 IC50
    73.6 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    		[PMID: 39038494]
    HCT-116 IC50
    761.45 nM
    Compound: Doxorubicin
    Anticancer activity against human HCT-116 cells overexpressing MMP9/MAO-A by MTT assay
    Anticancer activity against human HCT-116 cells overexpressing MMP9/MAO-A by MTT assay
    		[PMID: 34116327]
    HCT-116 IC50
    78 nM
    Compound: Doxorubicin
    Cytotoxicity against CD133 positive human HCT116 cells
    Cytotoxicity against CD133 positive human HCT116 cells
    		[PMID: 29468872]
    HCT-116 IC50
    8.07 μM
    Compound: Cpd I
    Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay
    Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay
    		[PMID: 33360576]
    HCT-116 IC50
    8.07 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth measured after 48 hrs by CCK-8 assay
    Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth measured after 48 hrs by CCK-8 assay
    		[PMID: 38669910]
    HCT-116 IC50
    8.07 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HCT-116 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay
    Antiproliferative activity against human HCT-116 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay
    		[PMID: 38669910]
    HCT-116 IC50
    8.29 μM
    Compound: Doxorubicin
    Cytotoxicity against human HCT116 cells after 24 hrs by SRB assay
    Cytotoxicity against human HCT116 cells after 24 hrs by SRB assay
    		[PMID: 30096580]
    HCT-116 IC50
    8.29 μM
    Compound: Doxorubicin
    Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability by SRB assay
    Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability by SRB assay
    		[PMID: 32361329]
    HCT-116 IC50
    8.7 μM
    Compound: ADR
    Cytotoxicity against human HCT116 cells after 48 hrs by MTT assay
    Cytotoxicity against human HCT116 cells after 48 hrs by MTT assay
    		10.1039/C2MD20270K
    HCT-116 IC50
    8.7 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay
    Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay
    		[PMID: 30660827]
    HCT-116 IC50
    8.8 nM
    Compound: Doxorubicin
    Cytotoxicity against human HCT116 cells assessed as reduction in cell viability by SRB assay
    Cytotoxicity against human HCT116 cells assessed as reduction in cell viability by SRB assay
    		[PMID: 30660827]
    HCT-116 IC50
    80 nM
    Compound: Doxorubicin
    Cytotoxicity against human HCT-116 cells assessed as cell growth inhibition incubated for 72 hrs by CCK8 assay
    Cytotoxicity against human HCT-116 cells assessed as cell growth inhibition incubated for 72 hrs by CCK8 assay
    		[PMID: 35213166]
    HCT-116 IC50
    810 nM
    Compound: DX
    Cytotoxicity against human HCT116 cancer cell line was determined after 144 hr
    Cytotoxicity against human HCT116 cancer cell line was determined after 144 hr
    		[PMID: 15456268]
    HCT-116 IC50
    9.4 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    		[PMID: 31323616]
    HCT-116 IC50
    9.63 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    		[PMID: 33214036]
    HCT-116 IC50
    9.63 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability
    Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability
    		[PMID: 38669910]
    HCT-116 IC50
    9.74 μM
    Compound: Doxorubicin
    Cytotoxicity against human HCT116 cells after 24 hrs by MTT assay
    Cytotoxicity against human HCT116 cells after 24 hrs by MTT assay
    		[PMID: 28489373]
    HCT-116 IC50
    < 1 μM
    Compound: doxorubicin
    Cytotoxicity against human HCT-116 cells by SRB assay
    Cytotoxicity against human HCT-116 cells by SRB assay
    		[PMID: 33847126]
    HCT-116 IC50
    > 8 μM
    Compound: Doxorubicin
    Cytotoxicity against human HCT116 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay
    Cytotoxicity against human HCT116 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay
    		[PMID: 31836446]
    HCT-116/VM46 IC50
    0.01 μM
    Compound: Doxorubicin
    Cytotoxicity against human HCT-116/VM46 cells assessed as reversal of multi drug resistance at 1 uM
    Cytotoxicity against human HCT-116/VM46 cells assessed as reversal of multi drug resistance at 1 uM
    		[PMID: 33276991]
    HCT-15 EC50
    0.03 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human HCT15 cells
    Cytotoxicity against human HCT15 cells
    		[PMID: 18990572]
    HCT-15 ED50
    0.006 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human HCT15 cells by sulforhodamine B method
    Cytotoxicity against human HCT15 cells by sulforhodamine B method
    		[PMID: 12193011]
    HCT-15 ED50
    0.02 μg/mL
    Compound: doxorubicin
    Cytotoxicity against human HCT15 cell line
    Cytotoxicity against human HCT15 cell line
    		[PMID: 17253840]
    HCT-15 ED50
    0.03 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human HCT15 cells
    Cytotoxicity against human HCT15 cells
    		[PMID: 12662097]
    HCT-15 ED50
    0.04 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human HCT15 cells after 48 hrs by SRB assay
    Cytotoxicity against human HCT15 cells after 48 hrs by SRB assay
    		[PMID: 11325244]
    HCT-15 ED50
    0.04 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human HCT15 cells
    Cytotoxicity against human HCT15 cells
    		[PMID: 11520227]
    HCT-15 ED50
    0.04 μg/mL
    Compound: doxorubicin
    Cytotoxicity against human HCT15 cells
    Cytotoxicity against human HCT15 cells
    		[PMID: 11678655]
    HCT-15 ED50
    0.05 μg/mL
    Compound: doxorubicin
    Cytotoxicity against human HCT15 cells after 48 hrs by SRB assay
    Cytotoxicity against human HCT15 cells after 48 hrs by SRB assay
    		[PMID: 15921415]
    HCT-15 ED50
    0.05 μg/mL
    Compound: doxorubicin
    Cytotoxicity against human HCT15 cells
    Cytotoxicity against human HCT15 cells
    		[PMID: 16441084]
    HCT-15 ED50
    0.06 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human HCT15 cells
    Cytotoxicity against human HCT15 cells
    		[PMID: 12350153]
    HCT-15 ED50
    0.06 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human HCT15 cells
    Cytotoxicity against human HCT15 cells
    		[PMID: 15104487]
    HCT-15 ED50
    0.06 μg/mL
    Compound: doxorubicin
    Cytotoxicity against human HCT15 cells
    Cytotoxicity against human HCT15 cells
    		[PMID: 16643027]
    HCT-15 ED50
    0.071 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human HCT15 cells after 48 hrs by sulforhodamine B assay
    Cytotoxicity against human HCT15 cells after 48 hrs by sulforhodamine B assay
    		[PMID: 19783438]
    HCT-15 ED50
    0.07 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human HCT15 cells
    Cytotoxicity against human HCT15 cells
    		[PMID: 12662102]
    HCT-15 ED50
    0.09 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human HCT15 cells
    Cytotoxicity against human HCT15 cells
    		[PMID: 14640526]
    HCT-15 ED50
    0.12 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human HCT15 cells
    Cytotoxicity against human HCT15 cells
    		[PMID: 15270579]
    HCT-15 ED50
    0.13 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human HCT-15 cells
    Cytotoxicity against human HCT-15 cells
    		[PMID: 17190456]
    HCT-15 ED50
    0.164 μM
    Compound: doxorubicin
    Cytotoxicity against human HCT15 cells by SRB assay
    Cytotoxicity against human HCT15 cells by SRB assay
    		[PMID: 18314958]
    HCT-15 ED50
    0.17 μg/mL
    Compound: doxorubicin
    Cytotoxicity against human HCT15 cells
    Cytotoxicity against human HCT15 cells
    		[PMID: 15104515]
    HCT-15 ED50
    0.18 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human HCT15 cells
    Cytotoxicity against human HCT15 cells
    		[PMID: 15497935]
    HCT-15 ED50
    0.24 μg/mL
    Compound: doxorubicin
    Cytotoxicity against human HCT15 cells
    Cytotoxicity against human HCT15 cells
    		[PMID: 14640517]
    HCT-15 ED50
    0.29 μg/mL
    Compound: doxorubicin
    Cytotoxicity against human HCT15 cells
    Cytotoxicity against human HCT15 cells
    		[PMID: 12762820]
    HCT-15 ED50
    0.35 μg/mL
    Compound: doxorubicin
    Cytotoxicity against human HCT15 cells by SRB method
    Cytotoxicity against human HCT15 cells by SRB method
    		[PMID: 16252909]
    HCT-15 ED50
    0.6 μg/mL
    Compound: Adriamycin
    Cytotoxicity against human HCT-15 cells
    Cytotoxicity against human HCT-15 cells
    		[PMID: 10346965]
    HCT-15 ED50
    0.79 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human HCT15 cells
    Cytotoxicity against human HCT15 cells
    		[PMID: 14640527]
    HCT-15 ED50
    0.9 μg/mL
    Compound: doxorubicin
    Cytotoxicity against human HCT-15 cells
    Cytotoxicity against human HCT-15 cells
    		[PMID: 10217707]
    HCT-15 ED50
    1.8 μg/mL
    Compound: adriamycin
    Cytotoxicity against human HCT15 cells by SRB assay
    Cytotoxicity against human HCT15 cells by SRB assay
    		10.1021/np960188t
    HCT-15 ED50
    2.4 μg/mL
    Compound: doxorubicin
    Cytotoxicity against human HCT15 cells by SRB assay
    Cytotoxicity against human HCT15 cells by SRB assay
    		[PMID: 9392887]
    HCT-15 GI50
    0.071 μg/mL
    Compound: Doxorubicin
    Antitumor cytotoxic activity against HCT-15 cell line was determined
    Antitumor cytotoxic activity against HCT-15 cell line was determined
    		[PMID: 11551772]
    HCT-15 GI50
    0.076 μM
    Compound: ADR
    Anticancer activity against human HCT-15 cells assessed as growth inhibition incubated for 48 hrs by sulforhodamine B method
    Anticancer activity against human HCT-15 cells assessed as growth inhibition incubated for 48 hrs by sulforhodamine B method
    		[PMID: 34500188]
    HCT-15 GI50
    0.077 μM
    Compound: ADR
    Cytotoxicity against human HCT15 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay
    Cytotoxicity against human HCT15 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay
    		[PMID: 28870801]
    HCT-15 GI50
    0.077 μM
    Compound: ADR
    Cytotoxicity against human HCT15 cells assessed as growth inhibition after 72 hrs by SRB assay
    Cytotoxicity against human HCT15 cells assessed as growth inhibition after 72 hrs by SRB assay
    		[PMID: 30253887]
    HCT-15 GI50
    0.0854 μM
    Compound: ADR
    Cytotoxicity against human HCT15 cells after 72 hrs by sulforhodamine B assay
    Cytotoxicity against human HCT15 cells after 72 hrs by sulforhodamine B assay
    		[PMID: 27096046]
    HCT-15 GI50
    0.19 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HCT15 cells by SRB assay
    Antiproliferative activity against human HCT15 cells by SRB assay
    		[PMID: 19394218]
    HCT-15 GI50
    0.45 μM
    Compound: ADR
    Cytotoxicity against human HCT15 cells assessed as growth inhibition after 72 hrs by sulforhodamine B assay
    Cytotoxicity against human HCT15 cells assessed as growth inhibition after 72 hrs by sulforhodamine B assay
    		[PMID: 25953156]
    HCT-15 GI50
    1.34 μM
    Compound: ADR
    Antiproliferative activity against human HCT15 cells by SRB assay
    Antiproliferative activity against human HCT15 cells by SRB assay
    		[PMID: 22738641]
    HCT-15 GI50
    1.34 μM
    Compound: ADR
    Antiproliferative activity against human HCT15 cells by SRB method
    Antiproliferative activity against human HCT15 cells by SRB method
    		[PMID: 24835787]
    HCT-15 GI50
    1.4 μM
    Compound: Doxorubicin
    Cytotoxicity against human HCT15 cells after 48 hrs by sulforhodamine B assay
    Cytotoxicity against human HCT15 cells after 48 hrs by sulforhodamine B assay
    		[PMID: 23964644]
    HCT-15 GI50
    1.64 μM
    Compound: Doxorubicin
    Cytotoxicity against human HCT15 cells by SRB assay
    Cytotoxicity against human HCT15 cells by SRB assay
    		[PMID: 19596579]
    HCT-15 GI50
    2.177 μM
    Compound: doxorubicin
    Cytotoxicity against human HCT15 cells
    Cytotoxicity against human HCT15 cells
    		[PMID: 20579876]
    HCT-15 GI50
    6.46 μM
    Compound: Doxorubicin
    Growth inhibition of human HCT15 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human HCT15 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28329730]
    HCT-15 GI50
    6.46 μM
    Compound: Doxorubicin
    Growth inhibition of human HCT15 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human HCT15 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 29102177]
    HCT-15 GI50
    6.46 μM
    Compound: Doxorubicin hydrochloride, NSC 123127
    Cytotoxicity against human HCT15 cells after 48 hrs by SRB assay
    Cytotoxicity against human HCT15 cells after 48 hrs by SRB assay
    		[PMID: 23871905]
    HCT-15 GI50
    7.92 μM
    Compound: Doxorubicin
    Antiproliferative activity against multidrug resistant human HCT15/CLO2 cells by SRB assay
    Antiproliferative activity against multidrug resistant human HCT15/CLO2 cells by SRB assay
    		[PMID: 19394218]
    HCT-15 GI50
    < 10 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human HCT15 cells after 48 hrs by SRB assay
    Cytotoxicity against human HCT15 cells after 48 hrs by SRB assay
    		10.1039/C5MD00224A
    HCT-15 IC50
    0.009 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HCT-15 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Antiproliferative activity against human HCT-15 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    		[PMID: 27010926]
    HCT-15 IC50
    0.01 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human HCT15 cells by MTT assay
    Cytotoxicity against human HCT15 cells by MTT assay
    		[PMID: 17764956]
    HCT-15 IC50
    0.025 μM
    Compound: 1 (Doxorubicin)
    In vitro cytotoxic activity against human colon cancer cell line HCT15 after 72 hr of drug exposure determined by the SRB assay
    In vitro cytotoxic activity against human colon cancer cell line HCT15 after 72 hr of drug exposure determined by the SRB assay
    		[PMID: 14980672]
    HCT-15 IC50
    0.028 μM
    Compound: Doxorubicin
    Cytotoxicity against human HCT15 cells by SRB assay
    Cytotoxicity against human HCT15 cells by SRB assay
    		[PMID: 20719504]
    HCT-15 IC50
    0.02 μg/mL
    Compound: doxorubicin
    Anticancer activity against human HCT15 cells after 72 hrs by sulforhodamine B assay
    Anticancer activity against human HCT15 cells after 72 hrs by sulforhodamine B assay
    		[PMID: 19342127]
    HCT-15 IC50
    0.035 μM
    Compound: Doxorubicin
    Cytotoxicity against human HCT15 cells after 48 hrs by SRB assay
    Cytotoxicity against human HCT15 cells after 48 hrs by SRB assay
    		[PMID: 22483395]
    HCT-15 IC50
    0.037 μM
    Compound: Doxorubicin
    Anticancer activity against human HCT15 cells by sulforhodamine B assay
    Anticancer activity against human HCT15 cells by sulforhodamine B assay
    		[PMID: 19819696]
    HCT-15 IC50
    0.038 μM
    Compound: Doxorubicin
    Cytotoxicity against human HCT15 cells by SRB assay
    Cytotoxicity against human HCT15 cells by SRB assay
    		[PMID: 20594848]
    HCT-15 IC50
    0.05 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human HCT15 cells by sulforhodamine B assay
    Cytotoxicity against human HCT15 cells by sulforhodamine B assay
    		[PMID: 21684168]
    HCT-15 IC50
    0.082 μM
    Compound: Doxorubicin
    Cytotoxicity against human HCT15 cells by SRB assay
    Cytotoxicity against human HCT15 cells by SRB assay
    		[PMID: 22951040]
    HCT-15 IC50
    0.08 μg/mL
    Compound: adriamycin
    Cytotoxicity against human HCT15 cells by SRB assay
    Cytotoxicity against human HCT15 cells by SRB assay
    		[PMID: 15921426]
    HCT-15 IC50
    0.09 μM
    Compound: Doxorubicin
    Cytotoxicity against human HCT15 cells assessed as cell death after 48 hrs by MTT assay
    Cytotoxicity against human HCT15 cells assessed as cell death after 48 hrs by MTT assay
    		[PMID: 24215890]
    HCT-15 IC50
    0.1 μM
    Compound: Doxorubicin
    In vitro cytotoxic activity against HCT15 (colon cancer) cell lines by using SRB assay
    In vitro cytotoxic activity against HCT15 (colon cancer) cell lines by using SRB assay
    		[PMID: 9873661]
    HCT-15 IC50
    0.1077 μM
    Compound: Doxorubicin
    Cytotoxicity against human HCT15 cells by sulforhodamine B bioassay
    Cytotoxicity against human HCT15 cells by sulforhodamine B bioassay
    		[PMID: 25098650]
    HCT-15 IC50
    0.109 μM
    Compound: Doxorubicin
    Cytotoxicity against human HCT15 cells assessed as inhibition of cell growth incubated for 48 hrs by SRB assay
    Cytotoxicity against human HCT15 cells assessed as inhibition of cell growth incubated for 48 hrs by SRB assay
    		[PMID: 25981688]
    HCT-15 IC50
    0.129 μM
    Compound: Doxorubicin
    Cytotoxicity against human HCT15 cells assessed as cell growth inhibition after 48 hrs by SRB assay
    Cytotoxicity against human HCT15 cells assessed as cell growth inhibition after 48 hrs by SRB assay
    		[PMID: 25466198]
    HCT-15 IC50
    0.13 μM
    Compound: Doxorubicin
    Cytotoxicity against human HCT15 cells assessed as growth inhibition by SRB assay
    Cytotoxicity against human HCT15 cells assessed as growth inhibition by SRB assay
    		[PMID: 23634786]
    HCT-15 IC50
    0.13 μM
    Compound: Doxorubicin
    Cytotoxicity against human HCT15 cells by sulforhodamine B assay
    Cytotoxicity against human HCT15 cells by sulforhodamine B assay
    		[PMID: 23815260]
    HCT-15 IC50
    0.164 μM
    Compound: doxorubicin
    Cytotoxicity against human HCT15 cells by SRB assay
    Cytotoxicity against human HCT15 cells by SRB assay
    		[PMID: 19435339]
    HCT-15 IC50
    0.2 μM
    Compound: Doxorubicin
    Cytotoxicity against human HCT15 cells assessed as cell growth inhibition after 48 hrs by SRB assay
    Cytotoxicity against human HCT15 cells assessed as cell growth inhibition after 48 hrs by SRB assay
    		[PMID: 28641156]
    HCT-15 IC50
    0.225 μM
    Compound: Doxorubicin
    Anticancer activity against human HCT15 cells after 48 hrs by SRB assay
    Anticancer activity against human HCT15 cells after 48 hrs by SRB assay
    		[PMID: 17070967]
    HCT-15 IC50
    0.23 μM
    Compound: Doxorubicine
    Inhibitory activity against HCT-15 colon cell line using sulforhodamine B (SRB) protein assay
    Inhibitory activity against HCT-15 colon cell line using sulforhodamine B (SRB) protein assay
    		[PMID: 12039588]
    HCT-15 IC50
    0.23 μM
    Compound: doxorubicin
    Cytotoxicity against human HCT15 cells
    Cytotoxicity against human HCT15 cells
    		[PMID: 12608854]
    HCT-15 IC50
    0.251 μM
    Compound: doxorubicin
    Cytotoxicity against human HCT15 cells after 3 days by SRB assay
    Cytotoxicity against human HCT15 cells after 3 days by SRB assay
    		[PMID: 18321715]
    HCT-15 IC50
    0.27 μM
    Compound: doxorubicin
    Cytotoxicity against human HCT15 cells after 48 hrs
    Cytotoxicity against human HCT15 cells after 48 hrs
    		[PMID: 17673337]
    HCT-15 IC50
    0.28 μg/mL
    Compound: Doxorubicin
    Cytotoxic activity against HCT15 cell line (human colon solid tumor cell line)
    Cytotoxic activity against HCT15 cell line (human colon solid tumor cell line)
    		[PMID: 15922597]
    HCT-15 IC50
    0.53 μg/mL
    Compound: Adriamycin
    Inhibitory concentration required against HCT 15 colon cancer cell line
    Inhibitory concentration required against HCT 15 colon cancer cell line
    		[PMID: 11354370]
    HCT-15 IC50
    0.6 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HCT15 cells after 72 hrs by SRB assay
    Antiproliferative activity against human HCT15 cells after 72 hrs by SRB assay
    		[PMID: 18063366]
    HCT-15 IC50
    0.7 μg/mL
    Compound: Adriamycin
    Antiproliferative activity against PLCgamma1 expressing human HCT15 cells
    Antiproliferative activity against PLCgamma1 expressing human HCT15 cells
    		[PMID: 10869194]
    HCT-15 IC50
    0.8 μM
    Compound: Doxorubicin
    Cytotoxicity against human HCT-15 cells assessed as cell growth inhibition
    Cytotoxicity against human HCT-15 cells assessed as cell growth inhibition
    		[PMID: 36092140]
    HCT-15 IC50
    0.82 μM
    Compound: Doxorubicin
    Cytotoxicity against human HCT15 cells by SRB assay
    Cytotoxicity against human HCT15 cells by SRB assay
    		[PMID: 20176479]
    HCT-15 IC50
    0.872 μM
    Compound: Doxorubicin
    Cytotoxicity against human HCT15 cells assessed as reduction in cell proliferation measured after 48 hrs by SRB assay
    Cytotoxicity against human HCT15 cells assessed as reduction in cell proliferation measured after 48 hrs by SRB assay
    		[PMID: 27856237]
    HCT-15 IC50
    1.03 μM
    Compound: Adriamycin
    Cytotoxicity against human HCT15 cells after 2 days by cell counting kit-8 analysis
    Cytotoxicity against human HCT15 cells after 2 days by cell counting kit-8 analysis
    		[PMID: 22503656]
    HCT-15 IC50
    1.08 μM
    Compound: Adriamycin
    Cytotoxicity against human HCT15 cells after 2 days by CCK-8 assay
    Cytotoxicity against human HCT15 cells after 2 days by CCK-8 assay
    		[PMID: 25481396]
    HCT-15 IC50
    1.08 μM
    Compound: Adriamycin
    Cytotoxicity against human HCT15 cells after 2 days by CCK8 assay
    Cytotoxicity against human HCT15 cells after 2 days by CCK8 assay
    		[PMID: 26361737]
    HCT-15 IC50
    1.13 μM
    Compound: DOX
    Antiproliferative activity against human HCT15 cells after 72 hrs by sulforhodamine B assay
    Antiproliferative activity against human HCT15 cells after 72 hrs by sulforhodamine B assay
    		[PMID: 25981689]
    HCT-15 IC50
    1.2 μM
    Compound: Adriamycin
    Cytotoxicity against human HCT15 cells after 2 days
    Cytotoxicity against human HCT15 cells after 2 days
    		[PMID: 21601964]
    HCT-15 IC50
    1.23 μM
    Compound: adriamycin
    Cytotoxicity against human HCT15 cells measured on day 4 by CCK8 assay
    Cytotoxicity against human HCT15 cells measured on day 4 by CCK8 assay
    		[PMID: 25936262]
    HCT-15 IC50
    1.25 μM
    Compound: Adriamycin
    Cytotoxicity against human HCT15 cells by MTT assay
    Cytotoxicity against human HCT15 cells by MTT assay
    		[PMID: 21115246]
    HCT-15 IC50
    1.28 μM
    Compound: Adriamycin
    Cytotoxicity against human HCT15 cells after 2 days
    Cytotoxicity against human HCT15 cells after 2 days
    		[PMID: 22318164]
    HCT-15 IC50
    1.38 μM
    Compound: Adriamycin
    Cytotoxicity against human HCT15 cells after 2 days by CCK-8 assay
    Cytotoxicity against human HCT15 cells after 2 days by CCK-8 assay
    		[PMID: 24013413]
    HCT-15 IC50
    1.67 μM
    Compound: Doxorubicin
    Cytotoxic activity against HCT 15 human colon tumor cell line, using sulforhodamine B (SRB) assay.
    Cytotoxic activity against HCT 15 human colon tumor cell line, using sulforhodamine B (SRB) assay.
    		[PMID: 14643344]
    HCT-15 IC50
    1.67 μM
    Compound: Doxorubicin
    Cytotoxicity against human HCT15 cells
    Cytotoxicity against human HCT15 cells
    		[PMID: 21095131]
    HCT-15 IC50
    1.67 μM
    Compound: doxorubicin
    Cytotoxicity against human HCT15 cells by SRB assay
    Cytotoxicity against human HCT15 cells by SRB assay
    		[PMID: 17827007]
    HCT-15 IC50
    1.76 μM
    Compound: ADR
    Cytotoxicity against human HCT15 cells after 72 hrs by MTT assay
    Cytotoxicity against human HCT15 cells after 72 hrs by MTT assay
    		[PMID: 22819942]
    HCT-15 IC50
    153.95 nM
    Compound: Doxoruibicin
    Cytotoxicity against human HCT15 cells
    Cytotoxicity against human HCT15 cells
    		[PMID: 21324692]
    HCT-15 IC50
    153.95 nM
    Compound: doxorubicin
    Antiproliferative activity against human HCT15 cells assessed as growth inhibition
    Antiproliferative activity against human HCT15 cells assessed as growth inhibition
    		[PMID: 21324686]
    HCT-15 IC50
    16.4 nM
    Compound: Doxorubicin
    Antiproliferative activity against human HCT15 cells assessed as reduction in cell viability incubated for 24 hrs by SRB assay
    Antiproliferative activity against human HCT15 cells assessed as reduction in cell viability incubated for 24 hrs by SRB assay
    		[PMID: 31655432]
    HCT-15 IC50
    2.2 μM
    Compound: DOX
    Antiproliferative activity against human HCT15 cells after 72 hrs by MTT assay
    Antiproliferative activity against human HCT15 cells after 72 hrs by MTT assay
    		[PMID: 30429098]
    HCT-15 IC50
    3.33 μM
    Compound: DOX
    Cytotoxicity against human HCT15 cells measured after 2 days by MTT assay
    Cytotoxicity against human HCT15 cells measured after 2 days by MTT assay
    		[PMID: 26334499]
    HCT-15 IC50
    3.53 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HCT-15 cells incubated for 72 hrs by microplate reader analysis
    Antiproliferative activity against human HCT-15 cells incubated for 72 hrs by microplate reader analysis
    		[PMID: 37418826]
    HCT-15 IC50
    3.76 μM
    Compound: Dox
    Cytotoxicity against human HCT15 cells after 2 days
    Cytotoxicity against human HCT15 cells after 2 days
    		[PMID: 24904965]
    HCT-15 IC50
    5 nM
    Compound: Adriamycin
    Cytotoxicity against human HCT15 cells after 48 hrs by SRB assay
    Cytotoxicity against human HCT15 cells after 48 hrs by SRB assay
    		[PMID: 22858298]
    HCT-15 IC50
    50 nM
    Compound: Doxorubicin
    In vitro cytotoxicity expressed as concentration that inhibits 50% of HCT 15 (colon) sensitive variant cell proliferation
    In vitro cytotoxicity expressed as concentration that inhibits 50% of HCT 15 (colon) sensitive variant cell proliferation
    		[PMID: 11606141]
    HCT-15 IC50
    80 nM
    Compound: Doxorubicin
    In vitro cytotoxicity expressed as concentration that inhibits 50% of HCT 15 (colon) resistant variant cell proliferation
    In vitro cytotoxicity expressed as concentration that inhibits 50% of HCT 15 (colon) resistant variant cell proliferation
    		[PMID: 11606141]
    HCT-15 IC50
    81 nM
    Compound: doxorubicin
    Cytotoxicity against human HCT15 cells after 72 hrs by MTS assay
    Cytotoxicity against human HCT15 cells after 72 hrs by MTS assay
    		[PMID: 19655762]
    HCT-15 IC50
    > 1000 nM
    Compound: Doxorubicin
    Cytotoxicity against human HCT15 cells after 72 hrs by MTT assay
    Cytotoxicity against human HCT15 cells after 72 hrs by MTT assay
    		[PMID: 20690624]
    HCT-29 IC50
    2.5 μM
    Compound: Adriamycin
    Cytotoxicity against human HCT29 cells after 4 days by MTT assay
    Cytotoxicity against human HCT29 cells after 4 days by MTT assay
    		[PMID: 21704436]
    HCT-8 ED50
    1.2 μM
    Compound: DOX
    Cytotoxicity against human HCT8 cells
    Cytotoxicity against human HCT8 cells
    		[PMID: 17591444]
    HCT-8 IC50
    0.01 μg/mL
    Compound: Dox
    Cytotoxicity against Homo sapiens (human) HCT8 cells after 72 hr by MTT assay
    Cytotoxicity against Homo sapiens (human) HCT8 cells after 72 hr by MTT assay
    		10.1007/s00044-011-9894-8
    HCT-8 IC50
    0.02 μM
    Compound: D
    Antineoplastic activity against human HCT8 cells after 72 hrs by MTT assay
    Antineoplastic activity against human HCT8 cells after 72 hrs by MTT assay
    		[PMID: 22000949]
    HCT-8 IC50
    0.02 μM
    Compound: Dox
    Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay
    Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay
    		[PMID: 25147145]
    HCT-8 IC50
    0.02 μM
    Compound: Doxorubicin
    Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay
    Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay
    		[PMID: 19406535]
    HCT-8 IC50
    0.02 μM
    Compound: Doxorubicin
    Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay
    Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay
    		[PMID: 20971532]
    HCT-8 IC50
    0.02 μM
    Compound: doxorubicin
    Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay
    Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay
    		[PMID: 21381705]
    HCT-8 IC50
    0.03 μM
    Compound: Dox
    Cytotoxicity against human HCT8 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human HCT8 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 31306817]
    HCT-8 IC50
    0.03 μM
    Compound: Doxorubicin
    Cytotoxicity against HCT8 cells
    Cytotoxicity against HCT8 cells
    		[PMID: 17175071]
    HCT-8 IC50
    0.04 μg/mL
    Compound: Dox
    Anticancer activity against Homo sapiens (human) HCT8 cells assessed as inhibition of cell survival after 72 hr by MTT assay
    Anticancer activity against Homo sapiens (human) HCT8 cells assessed as inhibition of cell survival after 72 hr by MTT assay
    		10.1007/s00044-012-0236-2
    HCT-8 IC50
    0.04 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay
    Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay
    		[PMID: 18586355]
    HCT-8 IC50
    0.04 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay
    Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay
    		[PMID: 19084293]
    HCT-8 IC50
    0.04 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human HCT8 cells after 3 days by MTT assay
    Cytotoxicity against human HCT8 cells after 3 days by MTT assay
    		[PMID: 19159272]
    HCT-8 IC50
    0.04 μg/mL
    Compound: doxorubicin
    Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay
    Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay
    		[PMID: 15787450]
    HCT-8 IC50
    0.04 μg/mL
    Compound: doxorubicin
    Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay
    Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay
    		[PMID: 17827021]
    HCT-8 IC50
    0.05 μM
    Compound: Doxorubicin
    Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay
    Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay
    		[PMID: 27363939]
    HCT-8 IC50
    0.06 μM
    Compound: DOXO
    Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay
    Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay
    		[PMID: 19947600]
    HCT-8 IC50
    0.06 μM
    Compound: Doxorubicin
    Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay
    Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay
    		[PMID: 21115213]
    HCT-8 IC50
    0.06 μg/mL
    Compound: Doxo
    Cytotoxicity against human HCT8 cells for 72 hrs by MTT assay
    Cytotoxicity against human HCT8 cells for 72 hrs by MTT assay
    		[PMID: 21334795]
    HCT-8 IC50
    0.09 μM
    Compound: Doxorubicin
    Cytotoxicity against human HCT8 cells after 69 hrs by MTT assay
    Cytotoxicity against human HCT8 cells after 69 hrs by MTT assay
    		[PMID: 19780590]
    HCT-8 IC50
    0.1 μM
    Compound: Doxorubicin
    Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay
    Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay
    		[PMID: 22250891]
    HCT-8 IC50
    0.1 μM
    Compound: Doxorubicin
    Cytotoxicity against human HCT8 cells by colorimetric method
    Cytotoxicity against human HCT8 cells by colorimetric method
    		[PMID: 24387625]
    HCT-8 IC50
    0.13 μM
    Compound: Doxorubicin
    Cytotoxicity against human HCT8 cells assessed as cell viability after 72 hrs by MTT assay
    Cytotoxicity against human HCT8 cells assessed as cell viability after 72 hrs by MTT assay
    		[PMID: 24530030]
    HCT-8 IC50
    0.19 μM
    Compound: DOXO
    Cytotoxicity against human HCT8 cells assessed as cell viability after 72 hrs by MTT assay
    Cytotoxicity against human HCT8 cells assessed as cell viability after 72 hrs by MTT assay
    		[PMID: 26142490]
    HCT-8 IC50
    0.42 μM
    Compound: Adriamycin
    Cytotoxicity against human HCT8 cells by MTT assay
    Cytotoxicity against human HCT8 cells by MTT assay
    		[PMID: 22070654]
    HCT-8 IC50
    0.8 μM
    Compound: adriamycin
    Cytotoxicity against human HCT8 cells by MTT assay
    Cytotoxicity against human HCT8 cells by MTT assay
    		[PMID: 17190442]
    HCT-8 IC50
    1.17 μM
    Compound: DOX
    Cytotoxicity against human HCT8 cells assessed as cell viability after 48 hrs by MTT assay
    Cytotoxicity against human HCT8 cells assessed as cell viability after 48 hrs by MTT assay
    		[PMID: 27149641]
    HCT-8 IC50
    1.5 μM
    Compound: doxorubicine
    Cytotoxic activity against human HCT8 cells after 69 hrs by MTT assay
    Cytotoxic activity against human HCT8 cells after 69 hrs by MTT assay
    		[PMID: 19788290]
    HCT-8 IC50
    19.6 μM
    Compound: Dox
    Cytotoxicity against human HCT8 cells under hypoxic condition after 24 hrs by crystal violet method
    Cytotoxicity against human HCT8 cells under hypoxic condition after 24 hrs by crystal violet method
    		[PMID: 25375258]
    HCT-8 IC50
    2.4 μM
    Compound: Dox
    Cytotoxicity against human HCT8 cells under normoxic condition after 24 hrs by crystal violet method
    Cytotoxicity against human HCT8 cells under normoxic condition after 24 hrs by crystal violet method
    		[PMID: 25375258]
    HCT-8 IC50
    3.4 μM
    Compound: DOX
    Antiproliferative activity against vincristine-resistant human HCT8 cells after 48 hrs by SRB method
    Antiproliferative activity against vincristine-resistant human HCT8 cells after 48 hrs by SRB method
    		[PMID: 25061803]
    HCT-8 IC50
    7.2 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HCT8 cells after 48 hrs by MTT assay
    Antiproliferative activity against human HCT8 cells after 48 hrs by MTT assay
    		[PMID: 30660827]
    HEK-293T CC50
    1.13 μM
    Compound: Doxorubicin
    Cytotoxicity against HEK293T cells after 48 hrs by MTT assay
    Cytotoxicity against HEK293T cells after 48 hrs by MTT assay
    		[PMID: 30103191]
    HEK-293T IC50
    0.038 μM
    Compound: DOX
    Antiproliferative activity against HEK293T cells assessed as inhibition of cell growth incubated for 48 hrs by CellTiter 96 Aqueous One Solution Cell Proliferation Assay
    Antiproliferative activity against HEK293T cells assessed as inhibition of cell growth incubated for 48 hrs by CellTiter 96 Aqueous One Solution Cell Proliferation Assay
    		[PMID: 38626522]
    HEK-293T IC50
    0.75 μM
    Compound: DOX
    Cytotoxicity against human HEK293T cells measured after 72 hrs by MTT assay
    Cytotoxicity against human HEK293T cells measured after 72 hrs by MTT assay
    		[PMID: 35612499]
    HEK-293T IC50
    0.75 μM
    Compound: Doxorubicin
    Cytotoxicity against human HEK293T cells after 48 hrs by MTT assay in presence of 10% FBS
    Cytotoxicity against human HEK293T cells after 48 hrs by MTT assay in presence of 10% FBS
    		[PMID: 26298501]
    HEK-293T IC50
    0.84 μM
    Compound: Doxorubicin
    Cytotoxicity against human HEK293T cells after 48 hrs by MTT assay in absence of 10% FBS
    Cytotoxicity against human HEK293T cells after 48 hrs by MTT assay in absence of 10% FBS
    		[PMID: 26298501]
    HEK-293T IC50
    1.051 μM
    Compound: Dox
    Cytotoxicity in HEK293T cells assessed as reduction in cell viability incubated for 24 hrs under hypoxic condition by MTT assay
    Cytotoxicity in HEK293T cells assessed as reduction in cell viability incubated for 24 hrs under hypoxic condition by MTT assay
    		[PMID: 31542715]
    HEK-293T IC50
    1.13 μM
    Compound: Doxorubicin
    Cytotoxicity against HEK293T cells after 48 hrs by MTT assay
    Cytotoxicity against HEK293T cells after 48 hrs by MTT assay
    		[PMID: 30170925]
    HEK-293T IC50
    1.2 μM
    Compound: Dox
    Cytotoxicity against HEK293T cells assessed as inhibition of cell viability after 48 hrs by MTT assay
    Cytotoxicity against HEK293T cells assessed as inhibition of cell viability after 48 hrs by MTT assay
    		[PMID: 27055942]
    HEK-293T IC50
    2.4 μM
    Compound: Doxorubicin
    Antiproliferative activity against HEK293T cells incubated for 48 hrs by MTT assay
    Antiproliferative activity against HEK293T cells incubated for 48 hrs by MTT assay
    		[PMID: 38442524]
    HEK-293T IC50
    3.1 μM
    Compound: Doxorubicin
    Cytotoxicity against human HEK293T cells after 48 hrs by MTT assay
    Cytotoxicity against human HEK293T cells after 48 hrs by MTT assay
    		[PMID: 27173802]
    HEK-293T IC50
    3.59 μM
    Compound: Doxorubicin
    Cytotoxicity against human HEK293T cells after 48 hrs by MTT assay
    Cytotoxicity against human HEK293T cells after 48 hrs by MTT assay
    		[PMID: 29573910]
    HEK-293T IC50
    3.77 μM
    Compound: Doxorubicin
    Cytotoxicity against HEK293T cells assessed as reduction in cell viability after 24 hrs by MTT assay
    Cytotoxicity against HEK293T cells assessed as reduction in cell viability after 24 hrs by MTT assay
    		[PMID: 31404864]
    HEK-293T IC50
    3.77 μM
    Compound: Doxorubicin
    Cytotoxicity against human HEK293T cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay
    Cytotoxicity against human HEK293T cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay
    		[PMID: 35367708]
    HEK293 CC50
    0.4 μM
    Compound: Dox
    Cytotoxicity against HEK293 cells incubated for 72 hrs by MTT assay
    Cytotoxicity against HEK293 cells incubated for 72 hrs by MTT assay
    		[PMID: 39079310]
    HEK293 GI50
    0.8 μM
    Compound: Dox
    Antiproliferative activity against human HEK293 cells incubated for 72 hrs and measured by MTT assay
    Antiproliferative activity against human HEK293 cells incubated for 72 hrs and measured by MTT assay
    		[PMID: 35973342]
    HEK293 GI50
    9.69 μM
    Compound: Doxorubicin
    Cytotoxicity against HEK293 cells assessed as cell growth inhibition
    Cytotoxicity against HEK293 cells assessed as cell growth inhibition
    		[PMID: 36584305]
    HEK293 IC50
    0.01 μM
    Compound: Adriamycin
    Cytotoxicity against human HEK293 cells after 72 hrs by MTT assay
    Cytotoxicity against human HEK293 cells after 72 hrs by MTT assay
    		[PMID: 21721528]
    HEK293 IC50
    0.018 μM
    Compound: DOX
    Antiproliferative activity against human HEK293 cells measured after 72 hrs by MTT assay
    Antiproliferative activity against human HEK293 cells measured after 72 hrs by MTT assay
    		[PMID: 31431364]
    HEK293 IC50
    0.02 μM
    Compound: DOX
    Cytotoxicity against HEK293 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against HEK293 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 30340899]
    HEK293 IC50
    0.04 μM
    Compound: ADM
    Cytotoxic activity against human HEK293 cells by SRB method
    Cytotoxic activity against human HEK293 cells by SRB method
    		[PMID: 25611519]
    HEK293 IC50
    0.064 μM
    Compound: Doxorubicin
    Cytotoxicity against HEK293 cells after 24 hrs by SRB method
    Cytotoxicity against HEK293 cells after 24 hrs by SRB method
    		[PMID: 18429610]
    HEK293 IC50
    0.106 μM
    Compound: Dox
    Cytotoxicity against HEK-293 cells assessed as reduction in cell viability incubated for 96 hrs by MTT method
    Cytotoxicity against HEK-293 cells assessed as reduction in cell viability incubated for 96 hrs by MTT method
    		[PMID: 34236840]
    HEK293 IC50
    0.36 μM
    Compound: DX
    Cytotoxicity against HEK293 cells assessed as reduction in cell viability after 72 hrs by MTS assay
    Cytotoxicity against HEK293 cells assessed as reduction in cell viability after 72 hrs by MTS assay
    		[PMID: 29681486]
    HEK293 IC50
    0.42 μM
    Compound: Adriamycin
    Cytotoxicity against human HEK293 cells transfected with plasmid expressing MDR1 after 72 hrs by MTT assay
    Cytotoxicity against human HEK293 cells transfected with plasmid expressing MDR1 after 72 hrs by MTT assay
    		[PMID: 21721528]
    HEK293 IC50
    0.46 μM
    Compound: DX
    Toxicity against HEK293 cells assessed as reduction in cell viability after 48 hrs by EZ4U label based assay
    Toxicity against HEK293 cells assessed as reduction in cell viability after 48 hrs by EZ4U label based assay
    		[PMID: 26052884]
    HEK293 IC50
    0.46 μM
    Compound: DX
    Antiproliferative activity against human HEK293 cells assessed as cell viability after 48 hrs by formazan EZ4U dye based assay
    Antiproliferative activity against human HEK293 cells assessed as cell viability after 48 hrs by formazan EZ4U dye based assay
    		[PMID: 26690914]
    HEK293 IC50
    0.46 μM
    Compound: DX
    Cytotoxicity against HEK293 cells assessed as decrease in cell viability after 48 hrs by formazan dye-based EZ4U assay
    Cytotoxicity against HEK293 cells assessed as decrease in cell viability after 48 hrs by formazan dye-based EZ4U assay
    		[PMID: 30108984]
    HEK293 IC50
    0.46 μM
    Compound: Dox
    Cytotoxicity against HEK293 cells assessed as reduction in cell viability after 48 hrs by EZ4U Non-radioactive cell proliferation assay
    Cytotoxicity against HEK293 cells assessed as reduction in cell viability after 48 hrs by EZ4U Non-radioactive cell proliferation assay
    		[PMID: 28372935]
    HEK293 IC50
    0.46 μM
    Compound: doxorubicin
    Antiproliferative activity against HEK293 cells at 0.01 to 250 uM after 48 hrs by formazan based EZ4U assay
    Antiproliferative activity against HEK293 cells at 0.01 to 250 uM after 48 hrs by formazan based EZ4U assay
    		[PMID: 25868743]
    HEK293 IC50
    0.69 μM
    Compound: Doxorubicin
    Cytotoxicity against human HEK293 cells after 24 hrs by MTT assay
    Cytotoxicity against human HEK293 cells after 24 hrs by MTT assay
    		[PMID: 25300819]
    HEK293 IC50
    0.7 μM
    Compound: Doxorubicin
    Antiproliferative activity against HEK293 cells after 72 hrs by XTT assay
    Antiproliferative activity against HEK293 cells after 72 hrs by XTT assay
    		10.1039/C1MD00234A
    HEK293 IC50
    0.9 μM
    Compound: doxorubicin
    Cytotoxicity against transformed human HEK293 cells after 24 to 48 hrs by MTT assay
    Cytotoxicity against transformed human HEK293 cells after 24 to 48 hrs by MTT assay
    		[PMID: 21058726]
    HEK293 IC50
    1 μM
    Compound: ADR
    Cytotoxicity against human HEK293 cells after 72 hrs by MTT assay
    Cytotoxicity against human HEK293 cells after 72 hrs by MTT assay
    		[PMID: 22819942]
    HEK293 IC50
    1.006 μM
    Compound: Doxorubicin
    Cytotoxicity against HEK293 cells after 24 hrs by MTT assay
    Cytotoxicity against HEK293 cells after 24 hrs by MTT assay
    		10.1007/s00044-013-0784-0
    HEK293 IC50
    1.06 μM
    Compound: Adriamycin
    Antiproliferative activity against human HEK293 cells after 48 hrs by MTT assay
    Antiproliferative activity against human HEK293 cells after 48 hrs by MTT assay
    		[PMID: 24582982]
    HEK293 IC50
    1.2 μM
    Compound: DOX
    Antiproliferative activity against human HEK293 cells after 72 hrs by MTT assay
    Antiproliferative activity against human HEK293 cells after 72 hrs by MTT assay
    		[PMID: 30429098]
    HEK293 IC50
    1.34 μM
    Compound: Adriamycin
    Cytotoxicity against human HEK293 cells after 2 days by cell counting kit-8 analysis
    Cytotoxicity against human HEK293 cells after 2 days by cell counting kit-8 analysis
    		[PMID: 22503656]
    HEK293 IC50
    1.43 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HEK293 cells
    Antiproliferative activity against human HEK293 cells
    		[PMID: 31945642]
    HEK293 IC50
    1.65 μM
    Compound: Doxorubicin
    Cytotoxicity against human HEK293 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
    Cytotoxicity against human HEK293 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
    		[PMID: 34124677]
    HEK293 IC50
    10 μM
    Compound: Doxorubicin
    Cytotoxicity against HEK293 cells assessed as reduction in cell viability measured after 48 hrs by SRB assay
    Cytotoxicity against HEK293 cells assessed as reduction in cell viability measured after 48 hrs by SRB assay
    		[PMID: 28818768]
    HEK293 IC50
    11.34 mM
    Compound: DOX
    Growth inhibition of human HEK293 cells assessed as cell viability incubated for 48 hrs by MTT assay
    Growth inhibition of human HEK293 cells assessed as cell viability incubated for 48 hrs by MTT assay
    		[PMID: 31648875]
    HEK293 IC50
    142.8 μM
    Compound: 12
    Antiproliferative activity against HEK293 cells after 48 hrs by MTT assay
    Antiproliferative activity against HEK293 cells after 48 hrs by MTT assay
    		[PMID: 29852328]
    HEK293 IC50
    148.4 μM
    Compound: 21
    Cytotoxicity against human HEK293 cells after 48 hrs by MTT assay
    Cytotoxicity against human HEK293 cells after 48 hrs by MTT assay
    		[PMID: 29289880]
    HEK293 IC50
    16.7 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human HEK293 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay
    Cytotoxicity against human HEK293 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay
    		[PMID: 35526504]
    HEK293 IC50
    160 μM
    Compound: Doxorubicin
    Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake by scintillation counting
    Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake by scintillation counting
    		[PMID: 22541068]
    HEK293 IC50
    1 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human HEK293 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
    Cytotoxicity against human HEK293 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
    		[PMID: 35526504]
    HEK293 IC50
    2.1 μM
    Compound: Doxorubicin
    Cytotoxicity in human HEK293 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    Cytotoxicity in human HEK293 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    		[PMID: 28923382]
    HEK293 IC50
    240 μM
    Compound: Doxorubicin
    Inhibition of human liver OATP2B1 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E3S uptake incubated for 5 mins by scintillation counting
    Inhibition of human liver OATP2B1 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E3S uptake incubated for 5 mins by scintillation counting
    		[PMID: 22541068]
    HEK293 IC50
    3.07 μM
    Compound: Adriamycin
    Cytotoxicity against HEK293 cells after 2 days by CCK-8 assay
    Cytotoxicity against HEK293 cells after 2 days by CCK-8 assay
    		[PMID: 24013413]
    HEK293 IC50
    3.13 μM
    Compound: Doxorubicin
    Cytotoxicity against HEK293 cells assessed as decrease in cell viability after 48 hrs by MTT assay
    Cytotoxicity against HEK293 cells assessed as decrease in cell viability after 48 hrs by MTT assay
    		[PMID: 27816268]
    HEK293 IC50
    3.9 μM
    Compound: Doxorubicin
    Growth inhibition of HEK293 cells after 48 hrs by MTT assay
    Growth inhibition of HEK293 cells after 48 hrs by MTT assay
    		[PMID: 30072225]
    HEK293 IC50
    41 μM
    Compound: Doxorubicin
    Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake incubated for 5 mins by scintillation counting
    Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake incubated for 5 mins by scintillation counting
    		[PMID: 22541068]
    HEK293 IC50
    44.4 μM
    Compound: DOX
    Antiproliferative activity against HEK293 cells after 48 hrs by MTT assay
    Antiproliferative activity against HEK293 cells after 48 hrs by MTT assay
    		[PMID: 27108400]
    HEK293 IC50
    455 nM
    Compound: DX
    Cytotoxicity against HEK293 cells assessed as reduction of cell viability after 48 hrs by formazan dye-based EZ4U test
    Cytotoxicity against HEK293 cells assessed as reduction of cell viability after 48 hrs by formazan dye-based EZ4U test
    		[PMID: 24996140]
    HEK293 IC50
    5.68 μM
    Compound: DOX
    Cytotoxicity against human HEK293 cells assessed as reduction in cell viability after 48 hrs by CCK8 assay
    Cytotoxicity against human HEK293 cells assessed as reduction in cell viability after 48 hrs by CCK8 assay
    		[PMID: 30576904]
    HEK293 IC50
    5.68 μM
    Compound: DOX
    Antiproliferative activity against HEK293 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK8 assay
    Antiproliferative activity against HEK293 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK8 assay
    		[PMID: 31671309]
    HEK293 IC50
    6.1 μM
    Compound: Doxorubicin
    Cytotoxicity against human HEK293 cells assessed as inhibition of cell growth after overnight incubation by MTT assay
    Cytotoxicity against human HEK293 cells assessed as inhibition of cell growth after overnight incubation by MTT assay
    		[PMID: 32165076]
    HEK293 IC50
    6.1 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human HEK293 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
    Cytotoxicity against human HEK293 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
    		[PMID: 35526504]
    HEK293 IC50
    7.2 μM
    Compound: Doxorubicin
    Cytotoxicity against human HEK293 cells assessed as decrease in cell viability after 24 hrs by MTT assay
    Cytotoxicity against human HEK293 cells assessed as decrease in cell viability after 24 hrs by MTT assay
    		[PMID: 27496212]
    HEK293 IC50
    7.41 μM
    Compound: Doxorubicin
    Cytotoxicity against HEK293 cells after 48 hrs by MTT assay
    Cytotoxicity against HEK293 cells after 48 hrs by MTT assay
    		[PMID: 24607876]
    HEK293 IC50
    7.92 μM
    Compound: Doxorubicin
    Cytotoxicity against HEK293 cells assessed as reduction in cell viability
    Cytotoxicity against HEK293 cells assessed as reduction in cell viability
    		[PMID: 32738998]
    HEK293 IC50
    89.27 μM
    Compound: Doxorubicin
    Cytotoxicity against human HEK293 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    Cytotoxicity against human HEK293 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    		[PMID: 38665840]
    HEK293 IC50
    > 100 μM
    Compound: Doxorubicin
    Cytotoxicity against HEK293 cells by MTT assay
    Cytotoxicity against HEK293 cells by MTT assay
    		[PMID: 24287557]
    HEK293 IC50
    > 200 μM
    Compound: Doxorubicin
    In vitro cytotoxicity against HEK293 cells assessed as growth inhibition by MTT assay
    In vitro cytotoxicity against HEK293 cells assessed as growth inhibition by MTT assay
    		[PMID: 24742385]
    HEK293 IC50
    > 200 μM
    Compound: Doxorubicin
    Cytotoxicity against HEK293 cells assessed as reduction in cell viability after 4 hrs by MTT assay
    Cytotoxicity against HEK293 cells assessed as reduction in cell viability after 4 hrs by MTT assay
    		[PMID: 30773423]
    HEL IC50
    0.05 μM
    Compound: Doxorubicin
    Cytotoxicity against HEL cells assessed as reduction in cell viability incubated for 72 hrs by WST assay
    Cytotoxicity against HEL cells assessed as reduction in cell viability incubated for 72 hrs by WST assay
    		[PMID: 37672645]
    HEL IC50
    0.42 μM
    Compound: Doxorubicin
    Antiproliferative activity against HEL cells after 72 hrs by MTT assay
    Antiproliferative activity against HEL cells after 72 hrs by MTT assay
    		[PMID: 30500683]
    HEL IC50
    2.13 μM
    Compound: Doxorubicin
    Cytotoxicity against HEL cells after 48 hrs by MTT assay
    Cytotoxicity against HEL cells after 48 hrs by MTT assay
    		[PMID: 28390228]
    HEL 299 IC50
    1.7 μM
    Compound: Doxorubicin
    Compound was tested for its effect on the proliferation of HELL-299 human diploid embryonal lung cell line.
    Compound was tested for its effect on the proliferation of HELL-299 human diploid embryonal lung cell line.
    		10.1016/0960-894X(96)00216-8
    HEp-2 IC50
    0.04 μM
    Compound: DOX
    Antitumor activity against human Hep2 cells after 72 hrs by MTT assay
    Antitumor activity against human Hep2 cells after 72 hrs by MTT assay
    		[PMID: 17935309]
    HEp-2 IC50
    0.04 μM
    Compound: Doxorubicin
    Antitumor activity against Hep-2 larynx carcinoma cells.
    Antitumor activity against Hep-2 larynx carcinoma cells.
    		[PMID: 12431049]
    HEp-2 IC50
    0.04 μM
    Compound: doxo
    Antiproliferative activity against human Hep2 cell line by MTT assay
    Antiproliferative activity against human Hep2 cell line by MTT assay
    		[PMID: 16913700]
    HEp-2 IC50
    0.04 μM
    Compound: doxorubicin
    Antitumor activity against larynx carcinoma Hep-2 cells
    Antitumor activity against larynx carcinoma Hep-2 cells
    		[PMID: 12431048]
    HEp-2 IC50
    0.059 μM
    Compound: Doxorubicin
    Inhibitory concentration against Hep-2 epidermal carcinoma cell line
    Inhibitory concentration against Hep-2 epidermal carcinoma cell line
    		[PMID: 15715481]
    HEp-2 IC50
    0.42 μM
    Compound: doxorubicin
    Cytotoxicity against human Hep2 cells after 24 hrs by MTT assay
    Cytotoxicity against human Hep2 cells after 24 hrs by MTT assay
    		[PMID: 17400463]
    HEp-2 IC50
    0.42 μM
    Compound: doxorubicin
    Cytotoxicity against human Hep2 cells after 24 hrs by MTT assay
    Cytotoxicity against human Hep2 cells after 24 hrs by MTT assay
    		[PMID: 18281125]
    HEp-2 IC50
    0.4 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human Hep2 cells after 24 hrs
    Cytotoxicity against human Hep2 cells after 24 hrs
    		[PMID: 20207452]
    HEp-2 IC50
    0.51 μM
    Compound: Doxorubicin
    Antiproliferative activity against human Hep2 cells after 48 hrs by neutral red assay
    Antiproliferative activity against human Hep2 cells after 48 hrs by neutral red assay
    		[PMID: 29885574]
    HEp-2 IC50
    1.21 μM
    Compound: Doxorubicin
    Cytotoxicity against human Hep2 cells assessed as inhibition of cell viability after 72 hrs by MTT assay
    Cytotoxicity against human Hep2 cells assessed as inhibition of cell viability after 72 hrs by MTT assay
    		[PMID: 29329071]
    HEp-2 IC50
    1.29 μM
    Compound: Doxorubicin
    Cytotoxicity against human Hep2 cells after 72 hrs by MTT assay
    Cytotoxicity against human Hep2 cells after 72 hrs by MTT assay
    		[PMID: 27116711]
    HEp-2 IC50
    1.3 μM
    Compound: Doxorubicin
    Growth inhibition of human Hep2 cells after 72 hrs by MTT assay
    Growth inhibition of human Hep2 cells after 72 hrs by MTT assay
    		[PMID: 28189083]
    HEp-2 IC50
    1.5 μM
    Compound: Adriamycin
    Cytotoxicity against human Hep2 cells by neutral red method
    Cytotoxicity against human Hep2 cells by neutral red method
    		[PMID: 26291474]
    HEp-2 IC50
    1.78 μM
    Compound: DOX
    Cytotoxicity against against human Hep2 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against against human Hep2 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 30340899]
    HEp-2 IC50
    6.32 μM
    Compound: Doxorubicin
    Antiproliferative activity against human Hep2 after 24 hrs by MTT assay
    Antiproliferative activity against human Hep2 after 24 hrs by MTT assay
    		[PMID: 30826188]
    HEp-2 IC50
    8.54 μM
    Compound: DOX
    Antiproliferative activity against human HEp-2 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay
    Antiproliferative activity against human HEp-2 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay
    		[PMID: 37054758]
    HEp-2 IC50
    8.7 μM
    Compound: Doxorubicin
    Cytotoxicity against Homo sapiens (human) Hep2 cells by MTT assay
    Cytotoxicity against Homo sapiens (human) Hep2 cells by MTT assay
    		10.1007/s00044-012-0370-x
    HEp-2 IC50
    8.7 μM
    Compound: Doxorubicine
    Cytotoxicity against human Hep2 cells by MTT assay
    Cytotoxicity against human Hep2 cells by MTT assay
    		[PMID: 22014995]
    HFF CC50
    0.03 μM
    Compound: Doxorubicin
    Cytotoxicity against human HFF cells after 72 hrs by MTT assay
    Cytotoxicity against human HFF cells after 72 hrs by MTT assay
    		[PMID: 21741131]
    HFF EC50
    150 nM
    Compound: Doxorubicin
    Cytotoxicity against HFF cells assessed as reduction in cell viability measured after 72 hrs by MTS assay
    Cytotoxicity against HFF cells assessed as reduction in cell viability measured after 72 hrs by MTS assay
    		[PMID: 36577036]
    HFF IC50
    0.15 μM
    Compound: Doxorubicin
    Cytotoxicity against HFF cells assessed as reduction in cell viability after 72 hrs by CellTiter96 AQueous one solution cell proliferation assay
    Cytotoxicity against HFF cells assessed as reduction in cell viability after 72 hrs by CellTiter96 AQueous one solution cell proliferation assay
    		[PMID: 28617598]
    HFF IC50
    0.15 μM
    Compound: Doxorubicin
    Cytotoxicity against human HFF cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Cytotoxicity against human HFF cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    		[PMID: 34851111]
    HFF IC50
    1.4 μM
    Compound: Doxorubicin
    Cytotoxicity against human HFF cells assessed as reduction in cell proliferation by MTT assay
    Cytotoxicity against human HFF cells assessed as reduction in cell proliferation by MTT assay
    		[PMID: 38414352]
    HFF-1 CC50
    0.53 μM
    Compound: Doxorubicin
    Cytotoxicity against human HFF-1 cells assessed as reduction in cell viability incubated for 120 hrs by MTS assay
    Cytotoxicity against human HFF-1 cells assessed as reduction in cell viability incubated for 120 hrs by MTS assay
    		[PMID: 32590115]
    HFF-1 GI50
    > 400 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HFF1 cells after 2 days by sulforhodamine B assay
    Antiproliferative activity against human HFF1 cells after 2 days by sulforhodamine B assay
    		[PMID: 24184076]
    HFF-1 IC50
    > 100 μM
    Compound: 21
    Cytotoxicity against human HFF1 cells assessed as reduction in cell viability after 24 hrs by MTT assay
    Cytotoxicity against human HFF1 cells assessed as reduction in cell viability after 24 hrs by MTT assay
    		[PMID: 32435401]
    HGC-27 IC50
    37.4 μM
    Compound: Doxorubicin
    Cytotoxicity against HGC27 cells after 24 hrs by MTT assay
    Cytotoxicity against HGC27 cells after 24 hrs by MTT assay
    		10.1039/C5MD00515A
    HL-60 CC50
    0.47 μM
    Compound: Doxorubicin
    Concentration for 50% cytotoxicity towards malignant cells expressed in HL-60 neoplastic cell line
    Concentration for 50% cytotoxicity towards malignant cells expressed in HL-60 neoplastic cell line
    		[PMID: 15745812]
    HL-60 EC50
    1.508 μM
    Compound: doxorubicin
    Cytotoxicity against human HL60 cells after 48 hrs by cell titer-blue assay
    Cytotoxicity against human HL60 cells after 48 hrs by cell titer-blue assay
    		[PMID: 19743858]
    HL-60 EC50
    2.5 μM
    Compound: Doxorubicin
    Cytotoxicity against human HL60 cells assessed as reduction in cell viability after 24 hrs by MTT assay relative to control
    Cytotoxicity against human HL60 cells assessed as reduction in cell viability after 24 hrs by MTT assay relative to control
    		[PMID: 21882827]
    HL-60 GI50
    0.0087 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HL-60 cells assessed as reduction in cell viability measured after 72 hrs
    Antiproliferative activity against human HL-60 cells assessed as reduction in cell viability measured after 72 hrs
    		[PMID: 31945642]
    HL-60 GI50
    0.018 μM
    Compound: adriamycin
    Antiproliferative activity against human HL60 cells by trypan blue assay
    Antiproliferative activity against human HL60 cells by trypan blue assay
    		[PMID: 18357994]
    HL-60 GI50
    1.45 mM
    Compound: Doxorubicin
    Photocytotoxicity against human HL60 cells irradiated with 2.5 J cm^-2 ultraviolet radiation after 72 hrs by MTT assay
    Photocytotoxicity against human HL60 cells irradiated with 2.5 J cm^-2 ultraviolet radiation after 72 hrs by MTT assay
    		[PMID: 18023182]
    HL-60 GI50
    2.36 mM
    Compound: Doxorubicin
    Photocytotoxicity against human HL60 cells irradiated with 1.25 J cm^-2 ultraviolet radiation after 72 hrs by MTT assay
    Photocytotoxicity against human HL60 cells irradiated with 1.25 J cm^-2 ultraviolet radiation after 72 hrs by MTT assay
    		[PMID: 18023182]
    HL-60 GI50
    28 nM
    Compound: Doxorubicin
    Growth inhibition of human HL60 cells after 48 hrs by sulforhodamine B assay
    Growth inhibition of human HL60 cells after 48 hrs by sulforhodamine B assay
    		[PMID: 23623253]
    HL-60 GI50
    28 nM
    Compound: Doxorubicin
    Cytotoxicity against human HL60 cells after 48 hrs by SRB assay
    Cytotoxicity against human HL60 cells after 48 hrs by SRB assay
    		[PMID: 24113365]
    HL-60 IC50
    0.003 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human HL60 cells by MTT assay
    Cytotoxicity against human HL60 cells by MTT assay
    		[PMID: 18590313]
    HL-60 IC50
    0.0072 μM
    Compound: Adriamycin (ADM)
    Tested for the cytostatic activity as inhibitory concentration against leukemia HL-60 cells
    Tested for the cytostatic activity as inhibitory concentration against leukemia HL-60 cells
    		10.1016/S0960-894X(97)00071-1
    HL-60 IC50
    0.0072 μM
    Compound: adriamycin
    Cytotoxicity against human HL60 cells after 72 hrs by MTT assay
    Cytotoxicity against human HL60 cells after 72 hrs by MTT assay
    		[PMID: 11170674]
    HL-60 IC50
    0.009 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HL-60 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Antiproliferative activity against human HL-60 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    		[PMID: 27010926]
    HL-60 IC50
    0.01 μM
    Compound: DOX
    Cytotoxicity against human HL60 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human HL60 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 28531811]
    HL-60 IC50
    0.01 μM
    Compound: Doxorubicin
    Cytotoxicity against human HL60 cells after 72 hrs by MTT assay
    Cytotoxicity against human HL60 cells after 72 hrs by MTT assay
    		[PMID: 23827179]
    HL-60 IC50
    0.01 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HL60 cells after 72 hrs by MTT assay
    Antiproliferative activity against human HL60 cells after 72 hrs by MTT assay
    		[PMID: 27808511]
    HL-60 IC50
    0.01 μM
    Compound: Doxorubicin
    Cytotoxicity against human HL-60 cells assessed as reduction in cell viability by CellTiter Glo luminescent assay
    Cytotoxicity against human HL-60 cells assessed as reduction in cell viability by CellTiter Glo luminescent assay
    		[PMID: 32755677]
    HL-60 IC50
    0.011 μM
    Compound: Doxorubicin
    Growth inhibition of human HL-60 cells assessed as reduction cell viability incubated for 72 hrs by MTT assay
    Growth inhibition of human HL-60 cells assessed as reduction cell viability incubated for 72 hrs by MTT assay
    		[PMID: 39145689]
    HL-60 IC50
    0.013 μM
    Compound: adriamycin
    Cytotoxicity against HL60 cells after 72 hrs by dye exclusion assay
    Cytotoxicity against HL60 cells after 72 hrs by dye exclusion assay
    		[PMID: 17069934]
    HL-60 IC50
    0.016 μM
    Compound: Adriamycin
    Cytotoxicity against human HL60 cells by SRB assay
    Cytotoxicity against human HL60 cells by SRB assay
    		[PMID: 19341288]
    HL-60 IC50
    0.017 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HL60 cells after 72 hrs by MTT reduction assay
    Antiproliferative activity against human HL60 cells after 72 hrs by MTT reduction assay
    		[PMID: 28551177]
    HL-60 IC50
    0.018 μM
    Compound: Doxorubicin
    Anticancer activity against human HL60 cells by MTT assay
    Anticancer activity against human HL60 cells by MTT assay
    		[PMID: 19136263]
    HL-60 IC50
    0.02 μM
    Compound: Adriamycin
    Cytotoxicity against human HL60 cells after 72 hrs by MTT assay
    Cytotoxicity against human HL60 cells after 72 hrs by MTT assay
    		[PMID: 24370114]
    HL-60 IC50
    0.02 μM
    Compound: DOX
    Cytotoxicity against human HL60 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human HL60 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 29660689]
    HL-60 IC50
    0.02 μM
    Compound: Doxorubicin
    Cytotoxicity against Homo sapiens (human) HL60 cells after 48 hr by trypan blue assay
    Cytotoxicity against Homo sapiens (human) HL60 cells after 48 hr by trypan blue assay
    		10.1007/s00044-009-9222-8
    HL-60 IC50
    0.02 μM
    Compound: Doxorubicin
    Cytotoxicity against human HL60 cells after 72 hrs by MTT assay
    Cytotoxicity against human HL60 cells after 72 hrs by MTT assay
    		[PMID: 17227762]
    HL-60 IC50
    0.02 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HL60 cells assessed as inhibition of cell proliferation incubated for 72 hrs by conventional ATP quantification method
    Antiproliferative activity against human HL60 cells assessed as inhibition of cell proliferation incubated for 72 hrs by conventional ATP quantification method
    		[PMID: 25937235]
    HL-60 IC50
    0.02 μM
    Compound: Doxorubicin
    Cytotoxicity against human HL60 cells assessed as growth inhibition incubated for 72 hrs by CCK8 assay
    Cytotoxicity against human HL60 cells assessed as growth inhibition incubated for 72 hrs by CCK8 assay
    		[PMID: 26280922]
    HL-60 IC50
    0.02 μM
    Compound: Doxorubicin
    Cytotoxicity against human HL60 cells after 72 hrs by MTT assay
    Cytotoxicity against human HL60 cells after 72 hrs by MTT assay
    		[PMID: 27116711]
    HL-60 IC50
    0.02 μM
    Compound: Doxorubicin
    Cytotoxicity against human HL60 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
    Cytotoxicity against human HL60 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
    		[PMID: 31836446]
    HL-60 IC50
    0.02 μM
    Compound: Doxorubicin
    Cytotoxicity against human HL-60 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    Cytotoxicity against human HL-60 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    		[PMID: 34778772]
    HL-60 IC50
    0.027 μM
    Compound: Doxorubicin
    Cytotoxicity against human HL60 cells after 72 hrs by XTT assay
    Cytotoxicity against human HL60 cells after 72 hrs by XTT assay
    		[PMID: 19647439]
    HL-60 IC50
    0.028 μg/mL
    Compound: (Doxorubicin) DOX
    Cytotoxicity tested against drug sensitive HL60/S cell line
    Cytotoxicity tested against drug sensitive HL60/S cell line
    		[PMID: 10612603]
    HL-60 IC50
    0.02 μg/mL
    Compound: Dox
    Cytotoxicity against Homo sapiens (human) HL60 cells after 72 hr by MTT assay
    Cytotoxicity against Homo sapiens (human) HL60 cells after 72 hr by MTT assay
    		10.1007/s00044-011-9894-8
    HL-60 IC50
    0.02 μg/mL
    Compound: Dox
    Anticancer activity against Homo sapiens (human) HL60 cells assessed as inhibition of cell survival after 72 hr by MTT assay
    Anticancer activity against Homo sapiens (human) HL60 cells assessed as inhibition of cell survival after 72 hr by MTT assay
    		10.1007/s00044-012-0236-2
    HL-60 IC50
    0.02 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human HL60 cells by MTT assay
    Cytotoxicity against human HL60 cells by MTT assay
    		[PMID: 17764956]
    HL-60 IC50
    0.02 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human HL60 cells after 72 hrs by MTT assay
    Cytotoxicity against human HL60 cells after 72 hrs by MTT assay
    		[PMID: 18586355]
    HL-60 IC50
    0.02 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human HL60 cells after 72 hrs by MTT assay
    Cytotoxicity against human HL60 cells after 72 hrs by MTT assay
    		[PMID: 19084293]
    HL-60 IC50
    0.02 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human HL60 cells after 3 days by MTT assay
    Cytotoxicity against human HL60 cells after 3 days by MTT assay
    		[PMID: 19159272]
    HL-60 IC50
    0.02 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human HL60 cells after 72 hrs by MTT assay
    Cytotoxicity against human HL60 cells after 72 hrs by MTT assay
    		[PMID: 20537433]
    HL-60 IC50
    0.02 μg/mL
    Compound: doxorubicin
    Cytotoxicity against human HL60 cells after 72 hrs by MTT assay
    Cytotoxicity against human HL60 cells after 72 hrs by MTT assay
    		[PMID: 15787450]
    HL-60 IC50
    0.02 μg/mL
    Compound: doxorubicin
    Cytotoxicity against human HL60 cells after 72 hrs by MTT assay
    Cytotoxicity against human HL60 cells after 72 hrs by MTT assay
    		[PMID: 17827021]
    HL-60 IC50
    0.03 μM
    Compound: DOXO
    Cytotoxicity against human HL60 cells after 72 hrs by MTT assay
    Cytotoxicity against human HL60 cells after 72 hrs by MTT assay
    		[PMID: 19947600]
    HL-60 IC50
    0.03 μM
    Compound: Dox
    Cytotoxicity against human HL60 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human HL60 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 31306817]
    HL-60 IC50
    0.03 μM
    Compound: Doxorubicin
    Cytotoxicity against human HL60 cells after 72 hrs by MTT assay
    Cytotoxicity against human HL60 cells after 72 hrs by MTT assay
    		10.1039/C4MD00371C
    HL-60 IC50
    0.03 μM
    Compound: Doxorubicin
    Cytotoxicity against HL60 cells
    Cytotoxicity against HL60 cells
    		[PMID: 17175071]
    HL-60 IC50
    0.03 μM
    Compound: Doxorubicin
    Cytotoxicity against human HL60 cells assessed as LDH release after 72 hrs
    Cytotoxicity against human HL60 cells assessed as LDH release after 72 hrs
    		[PMID: 17227762]
    HL-60 IC50
    0.03 μM
    Compound: Doxorubicin
    Cytotoxicity against human HL60 cells after 72 hrs by MTT assay
    Cytotoxicity against human HL60 cells after 72 hrs by MTT assay
    		[PMID: 21115213]
    HL-60 IC50
    0.03 μM
    Compound: Doxorubicin
    Cytotoxicity against human HL60 cells assessed as cell viability after 72 hrs by MTT assay
    Cytotoxicity against human HL60 cells assessed as cell viability after 72 hrs by MTT assay
    		[PMID: 24530030]
    HL-60 IC50
    0.03 μM
    Compound: Doxorubicin
    Cytotoxicity against human HL60 cells after 72 hrs by MTT assay
    Cytotoxicity against human HL60 cells after 72 hrs by MTT assay
    		[PMID: 27363939]
    HL-60 IC50
    0.031 μM
    Compound: Doxorubicin
    Cytotoxicity against human HL60 cells by MTT assay
    Cytotoxicity against human HL60 cells by MTT assay
    		[PMID: 28139925]
    HL-60 IC50
    0.037 μM
    Compound: Doxorubicin
    Cytotoxicity against human HL60 cells assessed as growth inhibition by MTT assay
    Cytotoxicity against human HL60 cells assessed as growth inhibition by MTT assay
    		[PMID: 24398294]
    HL-60 IC50
    0.03 μg/mL
    Compound: DOX
    Cytotoxicity against human HL60 cells after 72 hrs by MTT assay
    Cytotoxicity against human HL60 cells after 72 hrs by MTT assay
    		[PMID: 24589485]
    HL-60 IC50
    0.03 μg/mL
    Compound: Doxo
    Cytotoxicity against human HL60 cells for 72 hrs by MTT assay
    Cytotoxicity against human HL60 cells for 72 hrs by MTT assay
    		[PMID: 21334795]
    HL-60 IC50
    0.04 μM
    Compound: Adriamycin
    Cytotoxicity against human HL60 cells after 72 hrs by MTT assay
    Cytotoxicity against human HL60 cells after 72 hrs by MTT assay
    		[PMID: 20593838]
    HL-60 IC50
    0.04 μM
    Compound: D
    Antineoplastic activity against human HL60 cells after 72 hrs by MTT assay
    Antineoplastic activity against human HL60 cells after 72 hrs by MTT assay
    		[PMID: 22000949]
    HL-60 IC50
    0.04 μM
    Compound: Dox
    Cytotoxicity against human HL60 cells after 72 hrs by MTT assay
    Cytotoxicity against human HL60 cells after 72 hrs by MTT assay
    		[PMID: 25147145]
    HL-60 IC50
    0.04 μM
    Compound: Dox
    Cytotoxicity against human HL60 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Cytotoxicity against human HL60 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    		[PMID: 32551011]
    HL-60 IC50
    0.04 μM
    Compound: Doxorubicin
    Cytotoxicity against human HL60 cells after 72 hrs by MTT assay
    Cytotoxicity against human HL60 cells after 72 hrs by MTT assay
    		[PMID: 19406535]
    HL-60 IC50
    0.04 μM
    Compound: Doxorubicin
    Cytotoxicity against human HL60 cells after 72 hrs by MTT assay
    Cytotoxicity against human HL60 cells after 72 hrs by MTT assay
    		[PMID: 20971532]
    HL-60 IC50
    0.04 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HL60 cells
    Antiproliferative activity against human HL60 cells
    		[PMID: 24631190]
    HL-60 IC50
    0.04 μM
    Compound: Doxorubicin
    Cytotoxicity against human HL60 cells assessed as cell growth inhibition after 72 hrs by alamar blue assay
    Cytotoxicity against human HL60 cells assessed as cell growth inhibition after 72 hrs by alamar blue assay
    		[PMID: 31403289]
    HL-60 IC50
    0.04 μM
    Compound: doxorubicin
    Cytotoxicity against human HL60 cells by SRB assay
    Cytotoxicity against human HL60 cells by SRB assay
    		[PMID: 17194596]
    HL-60 IC50
    0.04 μM
    Compound: doxorubicin
    Cytotoxicity against human HL60 cells after 72 hrs by MTT assay
    Cytotoxicity against human HL60 cells after 72 hrs by MTT assay
    		[PMID: 21381705]
    HL-60 IC50
    0.04 μM
    Compound: doxorubicin
    Cytotoxicity against human HL60 cells assessed as cell viability after 48 hrs by celltiter-blue assay
    Cytotoxicity against human HL60 cells assessed as cell viability after 48 hrs by celltiter-blue assay
    		[PMID: 22582991]
    HL-60 IC50
    0.04 μM
    Compound: doxorubicin
    Antiproliferative activity against human HL60 cells assessed as growth inhibition after 72 hrs by MTT assay
    Antiproliferative activity against human HL60 cells assessed as growth inhibition after 72 hrs by MTT assay
    		[PMID: 25644674]
    HL-60 IC50
    0.044 μM
    Compound: doxorubicin
    Cytotoxicity against human HL60 cells after 3 days by SRB assay
    Cytotoxicity against human HL60 cells after 3 days by SRB assay
    		[PMID: 18321715]
    HL-60 IC50
    0.05 μM
    Compound: DOX
    Cytotoxicity against human HL60 cells after 18 hrs by annexin-V labeling-based flow cytometry
    Cytotoxicity against human HL60 cells after 18 hrs by annexin-V labeling-based flow cytometry
    		[PMID: 22985027]
    HL-60 IC50
    0.05 μM
    Compound: DOX
    Cytotoxicity against human HL60 cells after 72 hrs by MTT assay
    Cytotoxicity against human HL60 cells after 72 hrs by MTT assay
    		[PMID: 29970309]
    HL-60 IC50
    0.05 μM
    Compound: Doxorubicin
    Cytotoxicity against human HL60 cells after 69 hrs by MTT assay
    Cytotoxicity against human HL60 cells after 69 hrs by MTT assay
    		[PMID: 19780590]
    HL-60 IC50
    0.05 μM
    Compound: Doxorubicin
    Cytotoxicity against human HL60 cells by colorimetric method
    Cytotoxicity against human HL60 cells by colorimetric method
    		[PMID: 24387625]
    HL-60 IC50
    0.051 μM
    Compound: Dox
    Antiproliferative activity against human HL60 cells after 72 hrs by MTT assay
    Antiproliferative activity against human HL60 cells after 72 hrs by MTT assay
    		[PMID: 27089210]
    HL-60 IC50
    0.058 μM
    Compound: doxorubicin
    Cytotoxicity against human HL60 cells by MTT method
    Cytotoxicity against human HL60 cells by MTT method
    		[PMID: 25781655]
    HL-60 IC50
    0.06 μM
    Compound: DOXO
    Cytotoxicity against human HL60 cells assessed as cell viability after 72 hrs by MTT assay
    Cytotoxicity against human HL60 cells assessed as cell viability after 72 hrs by MTT assay
    		[PMID: 26142490]
    HL-60 IC50
    0.06 μM
    Compound: Dox
    Cytotoxicity against human HL-60 assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Cytotoxicity against human HL-60 assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    		[PMID: 33065435]
    HL-60 IC50
    0.06 μM
    Compound: Doxorubicin
    Cytotoxicity against human HL60 cells incubated for 72 hrs by MTT assay
    Cytotoxicity against human HL60 cells incubated for 72 hrs by MTT assay
    		[PMID: 23079523]
    HL-60 IC50
    0.06 μM
    Compound: Doxorubicin
    Cytotoxicity against NQO1-deficient human HL60 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against NQO1-deficient human HL60 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 27341379]
    HL-60 IC50
    0.07 μM
    Compound: DOX
    Cytotoxicity against human HL60 cells after 72 hrs by MTT assay
    Cytotoxicity against human HL60 cells after 72 hrs by MTT assay
    		[PMID: 24095093]
    HL-60 IC50
    0.07 μM
    Compound: doxorubicine
    Cytotoxic activity against human HL60 cells after 69 hrs by MTT assay
    Cytotoxic activity against human HL60 cells after 69 hrs by MTT assay
    		[PMID: 19788290]
    HL-60 IC50
    0.082 μM
    Compound: Doxorubicin
    Cytotoxicity against human HL60 cells assessed as growth inhibition by MTT assay
    Cytotoxicity against human HL60 cells assessed as growth inhibition by MTT assay
    		[PMID: 23664877]
    HL-60 IC50
    0.09 μM
    Compound: ADR
    Cytotoxicity against human HL60 cells
    Cytotoxicity against human HL60 cells
    		[PMID: 24128115]
    HL-60 IC50
    0.09 %
    Compound: Doxorubicin
    Cytotoxicity against human HL-60 cells assessed as reduction in cell viability
    Cytotoxicity against human HL-60 cells assessed as reduction in cell viability
    		[PMID: 35183880]
    HL-60 IC50
    0.1 μM
    Compound: Dox
    Cytotoxicity against human HL60 cells after 72 hrs by MTT assay
    Cytotoxicity against human HL60 cells after 72 hrs by MTT assay
    		[PMID: 30659997]
    HL-60 IC50
    0.1 μM
    Compound: Doxrubicin
    Growth inhibition of human HL60 cells after 3 days
    Growth inhibition of human HL60 cells after 3 days
    		[PMID: 18375126]
    HL-60 IC50
    0.11 μM
    Compound: Dox
    Cytotoxicity against human HL-60 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
    Cytotoxicity against human HL-60 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
    		[PMID: 33852973]
    HL-60 IC50
    0.11 μM
    Compound: Doxorubicin
    Cytotoxicity against human HL60 cells assessed as inhibition of metabolic activity after 48 hrs by MTT assay
    Cytotoxicity against human HL60 cells assessed as inhibition of metabolic activity after 48 hrs by MTT assay
    		[PMID: 27187858]
    HL-60 IC50
    0.12 μM
    Compound: Adriamycin
    Cytotoxicity against human HL60 cells by MTT assay
    Cytotoxicity against human HL60 cells by MTT assay
    		[PMID: 23548547]
    HL-60 IC50
    0.12 μM
    Compound: DXR
    Cytotoxicity against human HL-60 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay
    Cytotoxicity against human HL-60 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay
    		[PMID: 34808062]
    HL-60 IC50
    0.123 μM
    Compound: Adriamycin
    Cytotoxicity against human HL60 cells by SRB assay
    Cytotoxicity against human HL60 cells by SRB assay
    		[PMID: 25497963]
    HL-60 IC50
    0.14 μM
    Compound: Doxorubicin
    Cytotoxicity against human HL60 cells after 24 hrs by MTT assay
    Cytotoxicity against human HL60 cells after 24 hrs by MTT assay
    		[PMID: 25353976]
    HL-60 IC50
    0.16 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against Homo sapiens (human) HL60 cells
    Cytotoxicity against Homo sapiens (human) HL60 cells
    		10.1007/s00044-011-9882-z
    HL-60 IC50
    0.17 μM
    Compound: ADM
    Antiproliferative activity against human HL60 cells after 72 hrs by MTT assay
    Antiproliferative activity against human HL60 cells after 72 hrs by MTT assay
    		[PMID: 25529742]
    HL-60 IC50
    0.17 μM
    Compound: ADM
    Antiproliferative activity against human HL60 cells assessed as growth inhibition after 72 hrs by MTT assay
    Antiproliferative activity against human HL60 cells assessed as growth inhibition after 72 hrs by MTT assay
    		[PMID: 25984840]
    HL-60 IC50
    0.17 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HL60 cells after 72 hrs MTT assay
    Antiproliferative activity against human HL60 cells after 72 hrs MTT assay
    		[PMID: 25247772]
    HL-60 IC50
    0.19 μM
    Compound: Doxorubicin
    Cytotoxicity against human HL60 cells assessed as inhibition of cell viability after 72 hrs by MTT assay
    Cytotoxicity against human HL60 cells assessed as inhibition of cell viability after 72 hrs by MTT assay
    		[PMID: 29329071]
    HL-60 IC50
    0.2 μM
    Compound: ADM
    Cytotoxicity against human HL60 cells by MTT method
    Cytotoxicity against human HL60 cells by MTT method
    		[PMID: 29144133]
    HL-60 IC50
    0.2 μM
    Compound: DOX
    Cytotoxicity against human HL60 cells measured after 72 hrs by Celltiter-Glo assay
    Cytotoxicity against human HL60 cells measured after 72 hrs by Celltiter-Glo assay
    		[PMID: 31820976]
    HL-60 IC50
    0.2 μM
    Compound: Dox
    Antiproliferative activity against human HL-60 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay
    Antiproliferative activity against human HL-60 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay
    		[PMID: 32428792]
    HL-60 IC50
    0.2 μM
    Compound: Dox
    Cytotoxicity against human HL-60 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human HL-60 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 33479619]
    HL-60 IC50
    0.2 μM
    Compound: Doxorubicin
    Growth inhibition of human HL60 cells after 72 hrs by MTT assay
    Growth inhibition of human HL60 cells after 72 hrs by MTT assay
    		[PMID: 28189083]
    HL-60 IC50
    0.2 μM
    Compound: Doxorubicin
    Cytotoxicity against human HL60 cells after 72 hrs by CCK8 assay
    Cytotoxicity against human HL60 cells after 72 hrs by CCK8 assay
    		[PMID: 30869892]
    HL-60 IC50
    0.2 μM
    Compound: Doxorubicin
    Cytotoxicity in human HL-60 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Cytotoxicity in human HL-60 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    		[PMID: 34082225]
    HL-60 IC50
    0.2 μM
    Compound: Doxorubicin
    Cytotoxicity against human HL-60 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
    Cytotoxicity against human HL-60 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
    		[PMID: 35526504]
    HL-60 IC50
    0.2 μM
    Compound: doxorubicin
    Cytotoxicity against human HL60 cells assessed as growth inhibition measured after 48 hrs by XTT assay
    Cytotoxicity against human HL60 cells assessed as growth inhibition measured after 48 hrs by XTT assay
    		[PMID: 23547843]
    HL-60 IC50
    0.2 μM
    Compound: doxorubicin
    Cytotoxicity against human HL60 cells after 72 hrs by MTS assay
    Cytotoxicity against human HL60 cells after 72 hrs by MTS assay
    		[PMID: 25490132]
    HL-60 IC50
    0.22 μM
    Compound: Dox
    Antiproliferative activity against human HL-60 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    Antiproliferative activity against human HL-60 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    		[PMID: 38176358]
    HL-60 IC50
    0.3 μM
    Compound: Doxorubicin
    Cytotoxicity against human HL60 cells assessed as cell growth inhibition after 48 hrs by MTT assay
    Cytotoxicity against human HL60 cells assessed as cell growth inhibition after 48 hrs by MTT assay
    		[PMID: 27371926]
    HL-60 IC50
    0.31 μM
    Compound: Doxorubicin
    Cytotoxicity against human HL60 cells assessed as cell viability after 72 hrs by MTT assay
    Cytotoxicity against human HL60 cells assessed as cell viability after 72 hrs by MTT assay
    		[PMID: 23992864]
    HL-60 IC50
    0.33 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HL60 cells after 24 and 72 hrs by MTT assay
    Antiproliferative activity against human HL60 cells after 24 and 72 hrs by MTT assay
    		[PMID: 24941130]
    HL-60 IC50
    0.4 μM
    Compound: DOX
    Antiproliferative activity against human HL60 cells after 72 hrs by Sulforhodamine B-stain assay
    Antiproliferative activity against human HL60 cells after 72 hrs by Sulforhodamine B-stain assay
    		[PMID: 27484508]
    HL-60 IC50
    0.42 μM
    Compound: Doxorubicin
    Antitumor activity against human HL60 cells assessed as inhibition of cell growth by MTT assay
    Antitumor activity against human HL60 cells assessed as inhibition of cell growth by MTT assay
    		[PMID: 25160837]
    HL-60 IC50
    0.457 μg/mL
    Compound: DOX
    Cytotoxicity against human HL60 cells after 72 hrs by MTT assay
    Cytotoxicity against human HL60 cells after 72 hrs by MTT assay
    		[PMID: 20722446]
    HL-60 IC50
    0.51 μM
    Compound: doxorubicin
    Inhibitory concentration against HL60 cells
    Inhibitory concentration against HL60 cells
    		[PMID: 14971909]
    HL-60 IC50
    0.532 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HL60 cells after 48 hrs by EZ-Cytox cell viability assay
    Antiproliferative activity against human HL60 cells after 48 hrs by EZ-Cytox cell viability assay
    		[PMID: 28406643]
    HL-60 IC50
    0.55 μM
    Compound: 49
    Cytotoxicity against human HL60 cells by MTT assay
    Cytotoxicity against human HL60 cells by MTT assay
    		[PMID: 23932070]
    HL-60 IC50
    0.7 μM
    Compound: Adriamycin
    Cytotoxicity against human HL60 cells after 2 days
    Cytotoxicity against human HL60 cells after 2 days
    		[PMID: 21601964]
    HL-60 IC50
    0.7 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HL-60 cells assessed as reduction in cell growth after 24 hrs by MTS assay
    Antiproliferative activity against human HL-60 cells assessed as reduction in cell growth after 24 hrs by MTS assay
    		[PMID: 25300820]
    HL-60 IC50
    0.72 μM
    Compound: adriamycin
    Cytotoxicity against human HL60 cells
    Cytotoxicity against human HL60 cells
    		[PMID: 18178085]
    HL-60 IC50
    0.8 μM
    Compound: Adriamycin
    Cytotoxicity against human HL60 cells after 4 days by MTT assay
    Cytotoxicity against human HL60 cells after 4 days by MTT assay
    		[PMID: 21704436]
    HL-60 IC50
    0.8 μM
    Compound: Doxorubicin
    Cytotoxicity against human HL-60 cells assessed as reduction in cell viability incubated for 72 hrs by Alamar blue assay
    Cytotoxicity against human HL-60 cells assessed as reduction in cell viability incubated for 72 hrs by Alamar blue assay
    		[PMID: 27300257]
    HL-60 IC50
    0.9 μM
    Compound: ADM
    Cytotoxicity against human HL60 cells after 72 hrs by MTT assay
    Cytotoxicity against human HL60 cells after 72 hrs by MTT assay
    		[PMID: 23639650]
    HL-60 IC50
    0.91 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HL60 cells after 48 hrs by MTT assay
    Antiproliferative activity against human HL60 cells after 48 hrs by MTT assay
    		[PMID: 28919340]
    HL-60 IC50
    0.92 μM
    Compound: DOX
    Cytotoxicity against human HL-60 cells after 72 hrs by MTT assay
    Cytotoxicity against human HL-60 cells after 72 hrs by MTT assay
    		[PMID: 18783950]
    HL-60 IC50
    0.92 μM
    Compound: DOX
    Antiproliferative activity against human HL60 cells after 72 hrs by MTT assay
    Antiproliferative activity against human HL60 cells after 72 hrs by MTT assay
    		[PMID: 20359789]
    HL-60 IC50
    0.92 μM
    Compound: DOX
    Antiproliferative activity against human HL60 cells after 72 hrs by MTT assay
    Antiproliferative activity against human HL60 cells after 72 hrs by MTT assay
    		[PMID: 24021462]
    HL-60 IC50
    0.92 μM
    Compound: DOX
    Cytotoxicity against human HL60 cells after 72 hrs by MTT assay
    Cytotoxicity against human HL60 cells after 72 hrs by MTT assay
    		[PMID: 25259516]
    HL-60 IC50
    0.92 μM
    Compound: DOX
    Cytotoxicity against human HL60 cells assessed as cell growth inhibition after 72 hrs by MTT assay
    Cytotoxicity against human HL60 cells assessed as cell growth inhibition after 72 hrs by MTT assay
    		[PMID: 26720155]
    HL-60 IC50
    0.92 μM
    Compound: DOX
    Antiproliferative activity against human HL60 cells after 72 hrs by MTT assay
    Antiproliferative activity against human HL60 cells after 72 hrs by MTT assay
    		[PMID: 28135634]
    HL-60 IC50
    0.92 μM
    Compound: DOX
    Cytotoxicity against human HL60 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human HL60 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 28427016]
    HL-60 IC50
    0.92 μM
    Compound: DOX
    Cytotoxicity against human HL60 cells assessed as inhibition of cell growth after 72 hrs by MTT assay
    Cytotoxicity against human HL60 cells assessed as inhibition of cell growth after 72 hrs by MTT assay
    		[PMID: 30746062]
    HL-60 IC50
    0.92 μM
    Compound: DOX
    Antiproliferative activity against human HL60 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay
    Antiproliferative activity against human HL60 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay
    		[PMID: 31557614]
    HL-60 IC50
    0.92 μM
    Compound: DOX
    Antiproliferative activity against human HL-60 cells assessed as reduction in cell viability measured after 6 days by MTT assay
    Antiproliferative activity against human HL-60 cells assessed as reduction in cell viability measured after 6 days by MTT assay
    		[PMID: 32653698]
    HL-60 IC50
    0.92 μM
    Compound: DOX
    Antiproliferative activity against human HL-60 cells by MTT colorimetric assay
    Antiproliferative activity against human HL-60 cells by MTT colorimetric assay
    		[PMID: 38527380]
    HL-60 IC50
    0.92 μM
    Compound: DOX
    Antiproliferative activity against human HL-60 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    Antiproliferative activity against human HL-60 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    		[PMID: 39067378]
    HL-60 IC50
    0.92 μM
    Compound: Dox
    Cytotoxicity against human HL60 cells assessed as cell growth inhibition after 72 hrs by MTT assay
    Cytotoxicity against human HL60 cells assessed as cell growth inhibition after 72 hrs by MTT assay
    		[PMID: 27231128]
    HL-60 IC50
    1.13 x 10-3 μM
    Compound: Doxorubicin
    Cytotoxicity against human HL60 cells by MTT assay
    Cytotoxicity against human HL60 cells by MTT assay
    		[PMID: 19345581]
    HL-60 IC50
    1.13 x 10-3 μM
    Compound: Doxorubicin
    Cytotoxicity against human HL60 cells after 3 days by MTT assay
    Cytotoxicity against human HL60 cells after 3 days by MTT assay
    		[PMID: 20356655]
    HL-60 IC50
    1.2 μM
    Compound: Doxorubicin
    Cytotoxicity against human HL60 cells assessed as reduction in cell viability by MTT assay
    Cytotoxicity against human HL60 cells assessed as reduction in cell viability by MTT assay
    		[PMID: 30660827]
    HL-60 IC50
    1.2 μM
    Compound: Doxorubicin
    Cytotoxicity against human HL-60 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Cytotoxicity against human HL-60 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    		[PMID: 32975117]
    HL-60 IC50
    1.53 μM
    Compound: Doxorubicin
    Cytotoxicity against human HL60 cells after 72 hrs by alamar blue assay
    Cytotoxicity against human HL60 cells after 72 hrs by alamar blue assay
    		[PMID: 24969014]
    HL-60 IC50
    1.6 μM
    Compound: Dox
    Cytotoxicity against human HL60 cells after 24 hrs by MTT assay
    Cytotoxicity against human HL60 cells after 24 hrs by MTT assay
    		[PMID: 29398445]
    HL-60 IC50
    1.73 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HL60 cells after 24 hrs by MTT assay
    Antiproliferative activity against human HL60 cells after 24 hrs by MTT assay
    		10.1039/C5MD00581G
    HL-60 IC50
    1.88 μg/mL
    Compound: (Doxorubicin) DOX
    Cytotoxicity tested against HL60/Vinc cell line
    Cytotoxicity tested against HL60/Vinc cell line
    		[PMID: 10612603]
    HL-60 IC50
    13 nM
    Compound: doxorubicin
    Cytotoxicity against human HL60 cells after 72 hrs by MTS assay
    Cytotoxicity against human HL60 cells after 72 hrs by MTS assay
    		[PMID: 19655762]
    HL-60 IC50
    2.05 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HL-60 cells assessed as reduction in cell viability by MTT assay
    Antiproliferative activity against human HL-60 cells assessed as reduction in cell viability by MTT assay
    		[PMID: 34715305]
    HL-60 IC50
    2.97 μg/mL
    Compound: (Doxorubicin) DOX
    Cytotoxicity against drug resistant HL60/ADR cell line
    Cytotoxicity against drug resistant HL60/ADR cell line
    		[PMID: 10612603]
    HL-60 IC50
    3.137 μM
    Compound: Doxorubicin
    Cytotoxicity against human HL60 cells after 94 hrs by MTT assay
    Cytotoxicity against human HL60 cells after 94 hrs by MTT assay
    		[PMID: 21868138]
    HL-60 IC50
    3.5 μM
    Compound: Doxorubicin
    Cytotoxicity against human HL60 cells assessed as reduction in cell viability
    Cytotoxicity against human HL60 cells assessed as reduction in cell viability
    		[PMID: 30660827]
    HL-60 IC50
    3.6 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HL60 cells after 24 to 72 hrs by MTT assay
    Antiproliferative activity against human HL60 cells after 24 to 72 hrs by MTT assay
    		[PMID: 30660827]
    HL-60 IC50
    30 nM
    Compound: Doxorubicine
    Cytotoxicity against human HL60 cells after 72 hrs by MTS assay
    Cytotoxicity against human HL60 cells after 72 hrs by MTS assay
    		[PMID: 21142180]
    HL-60 IC50
    30 nM
    Compound: doxorubicine
    Cytotoxicity against human HL60 cells incubated for 72 hrs by MTS assay
    Cytotoxicity against human HL60 cells incubated for 72 hrs by MTS assay
    		[PMID: 23072299]
    HL-60 IC50
    46 nM
    Compound: Doxorubicin
    Cytotoxicity against human HL60 cells incubated for 72 hrs by MTT assay
    Cytotoxicity against human HL60 cells incubated for 72 hrs by MTT assay
    		[PMID: 32040324]
    HL-60 IC50
    5.5 μM
    Compound: DOX
    Antiproliferative activity against human HL60 cells after 48 hrs by MTT assay
    Antiproliferative activity against human HL60 cells after 48 hrs by MTT assay
    		[PMID: 27108400]
    HL-60 IC50
    53.3 μM
    Compound: Doxorubicin
    Antitumor activity against human HL60 cells after 48 hrs by MTT assay
    Antitumor activity against human HL60 cells after 48 hrs by MTT assay
    		[PMID: 20884091]
    HL-60 IC50
    7.2 nM
    Compound: ADRIAMYCIN
    Compound was tested for its anticancer activity against HL-60 cells.
    Compound was tested for its anticancer activity against HL-60 cells.
    		10.1016/S0960-894X(96)00486-6
    HL-60 IC50
    7.8 nM
    Compound: Doxorubicin
    Compound was tested in vitro for cytotoxicity against HL60 human leukemia cell line (72 hr exposure to compound)
    Compound was tested in vitro for cytotoxicity against HL60 human leukemia cell line (72 hr exposure to compound)
    		[PMID: 10479282]
    HL-60 IC50
    8.91 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HL60 cells after 48 hrs by MTT assay
    Antiproliferative activity against human HL60 cells after 48 hrs by MTT assay
    		[PMID: 29547830]
    HL-60 IC50
    81 nM
    Compound: Doxorubicin
    Cytotoxicity against human HL60 cells after 72 hrs by MTT assay
    Cytotoxicity against human HL60 cells after 72 hrs by MTT assay
    		[PMID: 20690624]
    HL-60 IC50
    990 nM
    Compound: Doxorubicine
    Cytotoxicity against human HL60R cells after 72 hrs by MTS assay
    Cytotoxicity against human HL60R cells after 72 hrs by MTS assay
    		[PMID: 21142180]
    HL-60 IC50
    < 0.125 μM
    Compound: Dox
    Cytotoxicity against human HL-60 cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay
    Cytotoxicity against human HL-60 cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay
    		[PMID: 33713977]
    HL-60 IC50
    < 0.125 μM
    Compound: Dox
    Cytotoxicity against human HL-60 cells by MTT assay
    Cytotoxicity against human HL-60 cells by MTT assay
    		[PMID: 36057236]
    HL-60 IC50
    < 0.125 μM
    Compound: Dox
    Cytotoxicity against human HL-60 cells assessed as inhibition of cell growth by MTT assay
    Cytotoxicity against human HL-60 cells assessed as inhibition of cell growth by MTT assay
    		[PMID: 36336315]
    HL-60 IC50
    < 0.63 μM
    Compound: Doxorubicin
    Growth inhibition of human HL60 cells after 48 hrs by MTT assay
    Growth inhibition of human HL60 cells after 48 hrs by MTT assay
    		[PMID: 28073673]
    HL-60 IC50
    < 1 μM
    Compound: doxorubicin
    Cytotoxicity against human HL-60 cells by MTT assay
    Cytotoxicity against human HL-60 cells by MTT assay
    		[PMID: 33847126]
    HL-60(TB) GI50
    0.12 μM
    Compound: Doxorubicin
    Growth inhibition of human HL-60(TB) cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human HL-60(TB) cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28329730]
    HL-60(TB) GI50
    0.12 μM
    Compound: Doxorubicin
    Growth inhibition of human HL-60(TB) cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human HL-60(TB) cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 29102177]
    HL-60(TB) GI50
    0.12 μM
    Compound: Doxorubicin hydrochloride, NSC 123127
    Cytotoxicity against human HL-60(TB) cells after 48 hrs by SRB assay
    Cytotoxicity against human HL-60(TB) cells after 48 hrs by SRB assay
    		[PMID: 23871905]
    HL60/ADR IC50
    2 μM
    Compound: adriamycin
    Cytotoxicity against adriamycin-resistant HL60/ADR cells expressing MRP1 after 72 hrs by dye exclusion assay
    Cytotoxicity against adriamycin-resistant HL60/ADR cells expressing MRP1 after 72 hrs by dye exclusion assay
    		[PMID: 17069934]
    HL60/ADR IC50
    8.8 μM
    Compound: Dox
    Antiproliferative activity against human HL60/ADR cells after 72 hrs by MTT assay
    Antiproliferative activity against human HL60/ADR cells after 72 hrs by MTT assay
    		[PMID: 27089210]
    HL60/MX2 EC50
    8.046 μM
    Compound: doxorubicin
    Cytotoxicity against human HL60/MX2 cells after 48 hrs by cell titer-blue assay
    Cytotoxicity against human HL60/MX2 cells after 48 hrs by cell titer-blue assay
    		[PMID: 19743858]
    HMEC GI50
    276 nM
    Compound: Doxorubicin
    Antiproliferative activity against HMEC assessed as growth inhibition after 24 to 72 hrs by MTS assay
    Antiproliferative activity against HMEC assessed as growth inhibition after 24 to 72 hrs by MTS assay
    		10.1039/C0MD00179A
    HMEC-1 IC50
    0.06 μM
    Compound: Adriamycin
    Cytotoxicity against human HMEC1 cells after 72 hrs by MTT assay
    Cytotoxicity against human HMEC1 cells after 72 hrs by MTT assay
    		[PMID: 22616554]
    HMEC-1 IC50
    0.1 μM
    Compound: 2
    Cytotoxicity against human HMEC-1 cells assessed as growth inhibition after 72 hrs by MTT assay
    Cytotoxicity against human HMEC-1 cells assessed as growth inhibition after 72 hrs by MTT assay
    		[PMID: 33974416]
    HMEC-1 IC50
    0.36 μM
    Compound: Doxorubicin
    Cytotoxicity against HMEC1 cells after 48 hrs by Alamar blue assay
    Cytotoxicity against HMEC1 cells after 48 hrs by Alamar blue assay
    		[PMID: 20931970]
    HMEC-1 IC50
    0.5 μM
    Compound: Doxorubicin
    Cytotoxicity against human HMEC-1 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
    Cytotoxicity against human HMEC-1 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
    		[PMID: 37951135]
    HMLE IC50
    0.01 μM
    Compound: Doxorubicin
    Antiproliferative activity against human shGFP-fused HMLE cells after 72 hrs by MTT assay
    Antiproliferative activity against human shGFP-fused HMLE cells after 72 hrs by MTT assay
    		[PMID: 27448912]
    HOP-62 GI50
    0.07 μM
    Compound: Doxorubicin
    Growth inhibition of human HOP62 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human HOP62 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28329730]
    HOP-62 GI50
    0.07 μM
    Compound: Doxorubicin
    Growth inhibition of human HOP62 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human HOP62 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 29102177]
    HOP-62 GI50
    0.07 μM
    Compound: Doxorubicin hydrochloride, NSC 123127
    Cytotoxicity against human HOP62 cells after 48 hrs by SRB assay
    Cytotoxicity against human HOP62 cells after 48 hrs by SRB assay
    		[PMID: 23871905]
    HOP-62 GI50
    0.14 μM
    Compound: ADR
    Growth inhibition of human HOP62 cells
    Growth inhibition of human HOP62 cells
    		10.1039/C1MD00072A
    HOP-62 GI50
    0.14 μM
    Compound: ADR
    Cytotoxicity against human HOP62 cells after 48 hrs by sulforhodamine B assay
    Cytotoxicity against human HOP62 cells after 48 hrs by sulforhodamine B assay
    		[PMID: 18657979]
    HOP-62 GI50
    0.14 μM
    Compound: ADR
    Growth inhibition of human HOP62 cells after 48 hrs by SRB assay
    Growth inhibition of human HOP62 cells after 48 hrs by SRB assay
    		[PMID: 20031423]
    HOP-62 GI50
    0.14 μM
    Compound: ADR
    Cytotoxicity against human HOP62 cells after 48 hrs by SRB assay
    Cytotoxicity against human HOP62 cells after 48 hrs by SRB assay
    		[PMID: 20673627]
    HOP-62 GI50
    0.14 μM
    Compound: ADR
    Cytotoxicity against human HOP62 cells after 24 hrs by WST-1 assay
    Cytotoxicity against human HOP62 cells after 24 hrs by WST-1 assay
    		[PMID: 20732817]
    HOP-62 GI50
    0.14 μM
    Compound: ADR
    Anticancer activity against human HOP62 cells by SRB method
    Anticancer activity against human HOP62 cells by SRB method
    		[PMID: 21676506]
    HOP-62 GI50
    0.14 μM
    Compound: ADR
    Growth inhibition of human HOP62 cells by SRB assay
    Growth inhibition of human HOP62 cells by SRB assay
    		[PMID: 22361684]
    HOP-62 GI50
    0.14 μM
    Compound: ADR
    Growth inhibition of human HOP62 cells after 48 hrs by sulforhodamine B assay
    Growth inhibition of human HOP62 cells after 48 hrs by sulforhodamine B assay
    		[PMID: 22364746]
    HOP-62 GI50
    0.14 μM
    Compound: ADR
    Growth inhibition of human HOP62 cells after 48 hrs by sulforhodamine B assay
    Growth inhibition of human HOP62 cells after 48 hrs by sulforhodamine B assay
    		[PMID: 23849207]
    HOP-62 GI50
    0.15 μM
    Compound: ADR
    Cytotoxicity against human HOP62 cells after 48 hrs by sulforhodamine B assay
    Cytotoxicity against human HOP62 cells after 48 hrs by sulforhodamine B assay
    		[PMID: 21737288]
    HOP-62 GI50
    < 0.1 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HOP-62 cells assessed as cell growth inhibition
    Antiproliferative activity against human HOP-62 cells assessed as cell growth inhibition
    		[PMID: 32961322]
    HOP-62 IC50
    0.004 μM
    Compound: Doxorubicin
    In vitro cytotoxic activity against HOP62 (lung cancer) cell lines by using SRB assay
    In vitro cytotoxic activity against HOP62 (lung cancer) cell lines by using SRB assay
    		[PMID: 9873661]
    HOP-62 IC50
    0.02 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HOP62 cells assessed as inhibition of cell proliferation incubated for 72 hrs by conventional ATP quantification method
    Antiproliferative activity against human HOP62 cells assessed as inhibition of cell proliferation incubated for 72 hrs by conventional ATP quantification method
    		[PMID: 25937235]
    HOP-62 IC50
    1 μM
    Compound: ADR
    Cytotoxicity against human Hop62 cells by sulforhodamine B assay
    Cytotoxicity against human Hop62 cells by sulforhodamine B assay
    		[PMID: 17822905]
    HOP-62 IC50
    1 μM
    Compound: ADR
    Cytotoxicity against human Hop62 cells by SRB assay
    Cytotoxicity against human Hop62 cells by SRB assay
    		[PMID: 18656370]
    HOP-92 GI50
    0.1 μM
    Compound: Doxorubicin
    Growth inhibition of human HOP92 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human HOP92 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28329730]
    HOP-92 GI50
    0.1 μM
    Compound: Doxorubicin
    Growth inhibition of human HOP92 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human HOP92 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 29102177]
    HOP-92 GI50
    0.1 μM
    Compound: Doxorubicin hydrochloride, NSC 123127
    Cytotoxicity against human HOP92 cells after 48 hrs by SRB assay
    Cytotoxicity against human HOP92 cells after 48 hrs by SRB assay
    		[PMID: 23871905]
    HOS IC50
    0.03 μM
    Compound: DOX
    Cytotoxicity against human HOS cells incubated for 48 hrs by MTT assay
    Cytotoxicity against human HOS cells incubated for 48 hrs by MTT assay
    		[PMID: 38185054]
    HOS-TE85 IC50
    0.59 μM
    Compound: Doxorubicin
    Cytotoxicity against human MNNG-HOS cells after 72 hrs by resazurin/resorufin-based fluorescence assay
    Cytotoxicity against human MNNG-HOS cells after 72 hrs by resazurin/resorufin-based fluorescence assay
    		[PMID: 23600925]
    HSC-2 CC50
    0.2 μM
    Compound: DXR
    Cytotoxicity against human HSC2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Cytotoxicity against human HSC2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    		[PMID: 31532650]
    HSC-2 CC50
    0.2 μM
    Compound: DXR
    Cytotoxicity against human HSC-2 cells incubated for 48 hrs by MTT assay
    Cytotoxicity against human HSC-2 cells incubated for 48 hrs by MTT assay
    		[PMID: 33744685]
    HSC-2 CC50
    0.68 μM
    Compound: Doxorubicin
    Concentration for 50% cytotoxicity towards malignant cells expressed in HSC-2 neoplastic cell line
    Concentration for 50% cytotoxicity towards malignant cells expressed in HSC-2 neoplastic cell line
    		[PMID: 15745812]
    HSC-2 IC50
    2.5 μg/mL
    Compound: doxorubicin
    Cytotoxicity against human HSC2 cells after 24 hrs by MTT assay
    Cytotoxicity against human HSC2 cells after 24 hrs by MTT assay
    		[PMID: 12608856]
    HSC-3 CC50
    2.9 μM
    Compound: Doxorubicin
    Concentration for 50% cytotoxicity towards malignant cells expressed in HSC-3 neoplastic cell line
    Concentration for 50% cytotoxicity towards malignant cells expressed in HSC-3 neoplastic cell line
    		[PMID: 15745812]
    HSC-4 CC50
    0.1 μM
    Compound: DXR
    Cytotoxicity against human HSC4 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Cytotoxicity against human HSC4 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    		[PMID: 31532650]
    HT-1080 IC50
    0.0058 μM
    Compound: Doxorubicin
    Cytotoxicity against human HT1080 cells after 72 hrs by MTT assay
    Cytotoxicity against human HT1080 cells after 72 hrs by MTT assay
    		[PMID: 29705708]
    HT-1080 IC50
    0.017 μM
    Compound: Doxorubicin
    Cytotoxic activity in human HT1080 cells assessed as reduction in cell viability incubated for 3 days by MTT assay
    Cytotoxic activity in human HT1080 cells assessed as reduction in cell viability incubated for 3 days by MTT assay
    		[PMID: 28395220]
    HT-1080 IC50
    0.02 μM
    Compound: Doxorubicin
    Cytotoxicity against Homo sapiens (human) HT1080 cells assessed as growth inhibition after 72 hr by MTT assay
    Cytotoxicity against Homo sapiens (human) HT1080 cells assessed as growth inhibition after 72 hr by MTT assay
    		10.1007/s00044-012-0428-9
    HT-1080 IC50
    0.022 μM
    Compound: doxorubicin
    Cytotoxicity against human HT1080 cells by MTT assay
    Cytotoxicity against human HT1080 cells by MTT assay
    		[PMID: 17141923]
    HT-1080 IC50
    0.022 μM
    Compound: doxorubicin
    Cytotoxicity against human HT1080 cells after 3 days by SRB assay
    Cytotoxicity against human HT1080 cells after 3 days by SRB assay
    		[PMID: 18321715]
    HT-1080 IC50
    0.06 μM
    Compound: doxorubicin
    Cytotoxicity against human HT1080 cells by SRB assay
    Cytotoxicity against human HT1080 cells by SRB assay
    		[PMID: 17194596]
    HT-1080 IC50
    0.1 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HT1080 cells after 72 hrs by MTT assay
    Antiproliferative activity against human HT1080 cells after 72 hrs by MTT assay
    		[PMID: 19632833]
    HT-1080 IC50
    0.17 μg/mL
    Compound: 1 (doxorubicin)
    In vitro inhibitory activity against human fibrosarcoma cell line (HT1080) using CV coloration
    In vitro inhibitory activity against human fibrosarcoma cell line (HT1080) using CV coloration
    		[PMID: 15013011]
    HT-1080 IC50
    0.31 μg/mL
    Compound: 1 (doxorubicin)
    In vitro cytotoxic concentration against human fibrosarcoma cell line (HT1080) using MTT coloration
    In vitro cytotoxic concentration against human fibrosarcoma cell line (HT1080) using MTT coloration
    		[PMID: 15013011]
    HT-1080 IC50
    0.41 μM
    Compound: Doxorubicin
    Cytotoxicity against human HT1080 cells after 72 hrs by MTT assay
    Cytotoxicity against human HT1080 cells after 72 hrs by MTT assay
    		[PMID: 19689125]
    HT-1080 IC50
    0.53 μM
    Compound: Doxorubicin
    Cytotoxicity against human HT1080 cells after 72 hrs by MTT assay
    Cytotoxicity against human HT1080 cells after 72 hrs by MTT assay
    		[PMID: 19919052]
    HT-1080 IC50
    0.93 μM
    Compound: DOX
    Cytotoxicity against human HT-1080 cells assessed as reduction in cell viability incubated for 48 hrs
    Cytotoxicity against human HT-1080 cells assessed as reduction in cell viability incubated for 48 hrs
    		[PMID: 32736079]
    HT-1080 IC50
    15.4 μM
    Compound: Doxorubicin
    Cytotoxicity against human HT1080 cells assessed as reduction in cell viability after 24 hrs by MTT assay
    Cytotoxicity against human HT1080 cells assessed as reduction in cell viability after 24 hrs by MTT assay
    		[PMID: 24681979]
    HT-1080 IC50
    19.22 μM
    Compound: Doxorubicin
    Anticancer activity against human HT1080 cells after 48 hrs by SRB assay
    Anticancer activity against human HT1080 cells after 48 hrs by SRB assay
    		[PMID: 24077528]
    HT-1080 IC50
    24 nM
    Compound: Dox
    Antiproliferative activity against human HT-1080 cells assessed as inhibition of cell growth measured after 72 hrs by Celltiter-glo proliferation assay
    Antiproliferative activity against human HT-1080 cells assessed as inhibition of cell growth measured after 72 hrs by Celltiter-glo proliferation assay
    		[PMID: 36001933]
    HT-1080 IC50
    59 nM
    Compound: doxorubicin
    Antiproliferative activity against human HT1080 cells after 72 hrs by MTT assay
    Antiproliferative activity against human HT1080 cells after 72 hrs by MTT assay
    		[PMID: 14640513]
    HT-1080 IC50
    9.32 μM
    Compound: Doxorubicin
    Cytotoxicity against human HT1080 cells after 72 hrs by MTT assay
    Cytotoxicity against human HT1080 cells after 72 hrs by MTT assay
    		[PMID: 18440233]
    HT-29 EC50
    0.9 μM
    Compound: Dox
    Cytotoxicity against human HT-29 cells incubated for 72 hrs by SRB assay
    Cytotoxicity against human HT-29 cells incubated for 72 hrs by SRB assay
    		[PMID: 36780832]
    HT-29 EC50
    0.9 μM
    Compound: Doxorubicin
    Cytotoxicity against human HT-29 cells assessed as reduction in cell viability measured after 72 hrs by SRB assay
    Cytotoxicity against human HT-29 cells assessed as reduction in cell viability measured after 72 hrs by SRB assay
    		[PMID: 33049606]
    HT-29 EC50
    2.5 μM
    Compound: Doxorubicin
    Compound was tested in vitro to inhibit 50% colon carcinoma HT-29 cell growth after 72 h
    Compound was tested in vitro to inhibit 50% colon carcinoma HT-29 cell growth after 72 h
    		10.1016/S0960-894X(96)00243-0
    HT-29 EC50
    > 30 μM
    Compound: DR
    Cytotoxicity against human HT-29 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
    Cytotoxicity against human HT-29 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
    		[PMID: 32956968]
    HT-29 ED50
    0.00015 μg/mL
    Compound: Adriamycin
    Tested in vitro for cytotoxicity against H-29 colon cancer cells
    Tested in vitro for cytotoxicity against H-29 colon cancer cells
    		[PMID: 8027979]
    HT-29 ED50
    0.00055 μg/mL
    Compound: ADRIAMYCIN
    Compound was tested for cytotoxic activity against human colon adenocarcinoma (HT-29)
    Compound was tested for cytotoxic activity against human colon adenocarcinoma (HT-29)
    		10.1016/0960-894X(94)80019-7
    HT-29 ED50
    0.0013 μg/mL
    Compound: Adriamycin
    In vitro cytotoxic activity against HT-29 (human colon adenocarcinoma) cell line
    In vitro cytotoxic activity against HT-29 (human colon adenocarcinoma) cell line
    		[PMID: 11551759]
    HT-29 ED50
    0.0168 μg/mL
    Compound: adriamycin
    Cytotoxicity against human HT-29 cells after 7 days by MTT assay
    Cytotoxicity against human HT-29 cells after 7 days by MTT assay
    		[PMID: 10514307]
    HT-29 ED50
    0.0243 μg/mL
    Compound: Adriamycin
    Cytotoxicity against human colon adenocarcinoma HT-29 cell lines
    Cytotoxicity against human colon adenocarcinoma HT-29 cell lines
    		10.1016/0960-894X(95)00182-S
    HT-29 ED50
    0.0261 μg/mL
    Compound: Adriamycin
    Compound was tested for its cytotoxic activity in MTT assay against HT-29 cell line (human colon adenocarcinoma)
    Compound was tested for its cytotoxic activity in MTT assay against HT-29 cell line (human colon adenocarcinoma)
    		10.1016/0960-894X(95)00004-D
    HT-29 ED50
    0.0287 μg/mL
    Compound: adriamycin
    Cytotoxicity against human HT29 cells after 7 days by MTT assay
    Cytotoxicity against human HT29 cells after 7 days by MTT assay
    		[PMID: 11087592]
    HT-29 ED50
    0.0494 μg/mL
    Compound: Adriamycin
    Cytotoxicity concentration against human colon adrenocarcinoma HT-29 cell line
    Cytotoxicity concentration against human colon adrenocarcinoma HT-29 cell line
    		[PMID: 8627602]
    HT-29 ED50
    0.055 μM
    Compound: Adriamycin
    Cytotoxic concentration required to inhibit 50% cell growth in HT-29 colon adenocarcinoma cell lines
    Cytotoxic concentration required to inhibit 50% cell growth in HT-29 colon adenocarcinoma cell lines
    		[PMID: 1875350]
    HT-29 ED50
    0.0896 μg/mL
    Compound: Adriamycin
    Cytotoxic activity was tested against human HT-29 (colon adenocarcinoma) cell line
    Cytotoxic activity was tested against human HT-29 (colon adenocarcinoma) cell line
    		10.1016/0960-894X(95)00309-H
    HT-29 ED50
    1.12 x 10-4 μg/mL
    Compound: adriamycin
    Cytotoxicity against human HT-29 cells
    Cytotoxicity against human HT-29 cells
    		[PMID: 1294696]
    HT-29 ED50
    1.16 x 10-2 μg/mL
    Compound: Adriamycin
    Cytotoxicity against human HT-29 cells after 7 days by MTT assay
    Cytotoxicity against human HT-29 cells after 7 days by MTT assay
    		[PMID: 7494147]
    HT-29 ED50
    1.2 x 10-2 μg/mL
    Compound: Adriamycin
    Cytotoxicity against human HT-29 cells
    Cytotoxicity against human HT-29 cells
    		[PMID: 1602301]
    HT-29 ED50
    1.28 x 10-2 μg/mL
    Compound: adriamycin
    Cytotoxicity against human HT-29 cells after 7 days by MTT assay
    Cytotoxicity against human HT-29 cells after 7 days by MTT assay
    		[PMID: 11325235]
    HT-29 ED50
    1.3 x 10-3 μg/mL
    Compound: adriamycin
    Cytotoxicity against human HT-29 cells
    Cytotoxicity against human HT-29 cells
    		[PMID: 8377016]
    HT-29 ED50
    1.62 x 10-2 μg/mL
    Compound: adriamycin
    Cytotoxicity against human HT-29 cells after 7 days by MTT assay
    Cytotoxicity against human HT-29 cells after 7 days by MTT assay
    		10.1021/np970510f
    HT-29 ED50
    1.93 x 10-2 μg/mL
    Compound: Adr
    Cytotoxicity against human HT29 cells
    Cytotoxicity against human HT29 cells
    		[PMID: 8778247]
    HT-29 ED50
    1 x 10-2 μg/mL
    Compound: adriamycin
    Cytotoxicity against human HT29 cells after 7 days by MTT assay
    Cytotoxicity against human HT29 cells after 7 days by MTT assay
    		[PMID: 10395501]
    HT-29 ED50
    2.62 x 10-2 μg/mL
    Compound: adriamycin
    Cytotoxicity against human HT-29 cells after 7 days by MTT assay
    Cytotoxicity against human HT-29 cells after 7 days by MTT assay
    		[PMID: 8676130]
    HT-29 ED50
    2.7 x 10-3 μg/mL
    Compound: Adriamycin
    Cytotoxicity against human HT-29 cells after 7 days by MTT assay
    Cytotoxicity against human HT-29 cells after 7 days by MTT assay
    		[PMID: 7714532]
    HT-29 ED50
    2.75 x 10-2 μg/mL
    Compound: Adriamycin
    Cytotoxicity against human HT-29 cells after 7 days by MTT assay
    Cytotoxicity against human HT-29 cells after 7 days by MTT assay
    		[PMID: 7673926]
    HT-29 ED50
    2.78 x 10-2 μg/mL
    Compound: adriamycin
    Cytotoxicity against human HT-29 cells after 7 days by MTT assay
    Cytotoxicity against human HT-29 cells after 7 days by MTT assay
    		[PMID: 9599260]
    HT-29 ED50
    2.79 x 10-3 μg/mL
    Compound: adriamycin
    Cytotoxicity against human HT-29 cells after 7 days
    Cytotoxicity against human HT-29 cells after 7 days
    		[PMID: 8021648]
    HT-29 ED50
    2.87 x 10-2 μg/mL
    Compound: adriamycin
    Cytotoxicity against human HT-29 cells after 7 days by MTT assay
    Cytotoxicity against human HT-29 cells after 7 days by MTT assay
    		[PMID: 15730242]
    HT-29 ED50
    2 x 10-2 μg/mL
    Compound: Adriamycin
    Cytotoxicity against human HT-29 cells after 7 days by MTT assay
    Cytotoxicity against human HT-29 cells after 7 days by MTT assay
    		[PMID: 9214729]
    HT-29 ED50
    274 μM
    Compound: doxorubicin
    Antitumor activity against human HT29 cells after 24 hrs by MTT assay
    Antitumor activity against human HT29 cells after 24 hrs by MTT assay
    		[PMID: 17482824]
    HT-29 ED50
    3.01 x 10-2 μg/mL
    Compound: Adriamycin
    Cytotoxicity against human HT-29 cells
    Cytotoxicity against human HT-29 cells
    		[PMID: 2348205]
    HT-29 ED50
    3.01 x 10-2 μg/mL
    Compound: Adriamycin
    Cytotoxicity against human HT-29 cells after 7 days by MTT assay
    Cytotoxicity against human HT-29 cells after 7 days by MTT assay
    		[PMID: 7494150]
    HT-29 ED50
    3.01 x 10-2 μg/mL
    Compound: Adriamycin
    Cytotoxicity against human HT-29 cells after 7 days by MTT assay
    Cytotoxicity against human HT-29 cells after 7 days by MTT assay
    		[PMID: 7673935]
    HT-29 ED50
    3.1 x 10-2 μg/mL
    Compound: adriamycin
    Cytotoxicity against human HT-29 cells by MTT assay
    Cytotoxicity against human HT-29 cells by MTT assay
    		[PMID: 9917277]
    HT-29 ED50
    3.32 x 10-4 μg/mL
    Compound: Adriamycin
    Cytotoxicity against human HT-29 cells
    Cytotoxicity against human HT-29 cells
    		[PMID: 8350089]
    HT-29 ED50
    3.44 x 10-2 μg/mL
    Compound: adriamycin
    Cytotoxicity against human HT-29 cells
    Cytotoxicity against human HT-29 cells
    		[PMID: 1665173]
    HT-29 ED50
    3.46 x 10-2 μg/mL
    Compound: adriamycin
    Cytotoxicity against human HT29 cells after 7 days by MTT assay
    Cytotoxicity against human HT29 cells after 7 days by MTT assay
    		[PMID: 8904848]
    HT-29 ED50
    3.48 x 10-2 μg/mL
    Compound: Adriamycin
    Cytotoxicity against human HT-29 cells after 7 days by MTT assay
    Cytotoxicity against human HT-29 cells after 7 days by MTT assay
    		[PMID: 7673936]
    HT-29 ED50
    3.51 x 10-2 μg/mL
    Compound: adr
    Cytotoxicity against human HT-29 cells after 7 days by MTT assay
    Cytotoxicity against human HT-29 cells after 7 days by MTT assay
    		[PMID: 9461654]
    HT-29 ED50
    3.57 x 10-2 μg/mL
    Compound: adriamycin
    Cytotoxicity against human HT-29 cells after 7 days by MTT assay
    Cytotoxicity against human HT-29 cells after 7 days by MTT assay
    		[PMID: 9014350]
    HT-29 ED50
    3.7 μg/mL
    Compound: Adriamycin
    Cytotoxicity against human HT-29 cells
    Cytotoxicity against human HT-29 cells
    		[PMID: 10479316]
    HT-29 ED50
    3.81 x 10-2 μg/mL
    Compound: adriamycin
    Cytotoxicity against human HT-29 cells after 7 days by MTT assay
    Cytotoxicity against human HT-29 cells after 7 days by MTT assay
    		[PMID: 9584396]
    HT-29 ED50
    3.92 x 10-2 μg/mL
    Compound: adriamycin
    Cytotoxicity against human HT-29 cells after 7 hrs by MTT assay
    Cytotoxicity against human HT-29 cells after 7 hrs by MTT assay
    		[PMID: 7623031]
    HT-29 ED50
    3.9 μg/mL
    Compound: Adriamycin
    Cytotoxicity on adenocarcinoma (HT-29 colon) cell line
    Cytotoxicity on adenocarcinoma (HT-29 colon) cell line
    		[PMID: 8632402]
    HT-29 ED50
    37 nM
    Compound: Adriamycin
    In vitro cytotoxicity against Colon HT-29 human tumors following a 6 day exposure.
    In vitro cytotoxicity against Colon HT-29 human tumors following a 6 day exposure.
    		[PMID: 10498214]
    HT-29 ED50
    4.16 x 10-2 μg/mL
    Compound: adriamycin
    Cytotoxicity against human HT29 cells
    Cytotoxicity against human HT29 cells
    		[PMID: 8991957]
    HT-29 ED50
    4.16 x 10-3 μg/mL
    Compound: adriamycin
    Cytotoxicity against human HT-29 cells
    Cytotoxicity against human HT-29 cells
    		[PMID: 1791471]
    HT-29 ED50
    4.28 x 10-3 μg/mL
    Compound: Adriamycin
    Cytotoxicity against human HT29 cells after 7 days by MTT assay
    Cytotoxicity against human HT29 cells after 7 days by MTT assay
    		[PMID: 8946743]
    HT-29 ED50
    4.37 x 10-2 μg/mL
    Compound: adriamycin
    Cytotoxicity against human HT29 cells after 7 days by MTT assay
    Cytotoxicity against human HT29 cells after 7 days by MTT assay
    		[PMID: 8882434]
    HT-29 ED50
    4.45 x 10-3 μg/mL
    Compound: Adriamycin
    Cytotoxicity against human HT-29 cells after 7 days
    Cytotoxicity against human HT-29 cells after 7 days
    		[PMID: 1453182]
    HT-29 ED50
    4.83 x 10-3 μg/mL
    Compound: Adriamycin
    Cytotoxicity against human HT-29 cells
    Cytotoxicity against human HT-29 cells
    		[PMID: 1479382]
    HT-29 ED50
    4.98 x 10-2 μg/mL
    Compound: Adriamycin
    Cytotoxicity against human HT29 cells
    Cytotoxicity against human HT29 cells
    		[PMID: 8946744]
    HT-29 ED50
    4 x 10-2 μg/mL
    Compound: adriamycin
    Cytotoxicity against human HT29 cells after 7 days by MTT assay
    Cytotoxicity against human HT29 cells after 7 days by MTT assay
    		[PMID: 8882437]
    HT-29 ED50
    5.5 μM
    Compound: Adriamycin
    Cytotoxicity against human HT-29 colon cell line.
    Cytotoxicity against human HT-29 colon cell line.
    		[PMID: 1613753]
    HT-29 ED50
    5.6 x 10-4 μg/mL
    Compound: Adriamycin
    Cytotoxicity against human HT-29 cells by MTT assay
    Cytotoxicity against human HT-29 cells by MTT assay
    		[PMID: 7714533]
    HT-29 ED50
    6.69 x 10-3 μg/mL
    Compound: adriamycin
    Cytotoxicity against human HT-29 cells after 7 days
    Cytotoxicity against human HT-29 cells after 7 days
    		[PMID: 1593281]
    HT-29 ED50
    6.69 x 10-3 μg/mL
    Compound: adriamycin
    Cytotoxicity against human HT-29 cells after 7 days
    Cytotoxicity against human HT-29 cells after 7 days
    		[PMID: 8201311]
    HT-29 ED50
    7.25 x 10-1 μg/mL
    Compound: Adriamycin
    Cytotoxicity against human HT29 cells after 7 days by MTT assay
    Cytotoxicity against human HT29 cells after 7 days by MTT assay
    		[PMID: 9322367]
    HT-29 ED50
    7 x 10-3 μg/mL
    Compound: adriyamicin
    Cytotoxicity against human HT29 cells
    Cytotoxicity against human HT29 cells
    		[PMID: 8991955]
    HT-29 ED50
    9.66 x 10-3 μg/mL
    Compound: adriamycin
    Cytotoxicity against human HT-29 cells after 7 days by MTT assay
    Cytotoxicity against human HT-29 cells after 7 days by MTT assay
    		[PMID: 9599253]
    HT-29 GI50
    0.0046 μg/mL
    Compound: Doxorubicin
    Antitumor cytotoxic activity against HT-29 cell line was determined
    Antitumor cytotoxic activity against HT-29 cell line was determined
    		[PMID: 11551772]
    HT-29 GI50
    0.05 μM
    Compound: Dox
    Growth inhibition of human HT-29 cells by MTT assay
    Growth inhibition of human HT-29 cells by MTT assay
    		[PMID: 31330449]
    HT-29 GI50
    0.056 μM
    Compound: Doxorubicin
    Tested for in vitro concentration required to inhibit growth by 50% against HT-29 human colon cancer cell line
    Tested for in vitro concentration required to inhibit growth by 50% against HT-29 human colon cancer cell line
    		[PMID: 11755363]
    HT-29 GI50
    0.06 μM
    Compound: Adriamycin
    Cytotoxicity against human HT-29 cells by MTT assay
    Cytotoxicity against human HT-29 cells by MTT assay
    		[PMID: 19405508]
    HT-29 GI50
    0.066 μM
    Compound: Doxorubicin
    Cytotoxicity against human HT-29 cells after 72 hrs by SRB assay
    Cytotoxicity against human HT-29 cells after 72 hrs by SRB assay
    		[PMID: 20014800]
    HT-29 GI50
    0.06 μg/mL
    Compound: adriamycin
    Cytotoxicity against human HT29 cells by MTT assay
    Cytotoxicity against human HT29 cells by MTT assay
    		[PMID: 11000028]
    HT-29 GI50
    0.07 μg/mL
    Compound: DOX
    Growth inhibition of human HT-29 cells after 48 hrs by sulforhodamine B assay
    Growth inhibition of human HT-29 cells after 48 hrs by sulforhodamine B assay
    		[PMID: 21041092]
    HT-29 GI50
    0.1 μM
    Compound: Doxorubicin
    Cytotoxicity against human HT-29 cells after 48 hrs by sulforhodamine B assay
    Cytotoxicity against human HT-29 cells after 48 hrs by sulforhodamine B assay
    		[PMID: 24158013]
    HT-29 GI50
    0.1 μM
    Compound: Doxorubicin
    Cytotoxicity against human HT-29 cells assessed as growth inhibition after 72 hrs by MTT assay
    Cytotoxicity against human HT-29 cells assessed as growth inhibition after 72 hrs by MTT assay
    		[PMID: 29670691]
    HT-29 GI50
    0.1 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HT-29 cells after 72 hrs by MTT assay
    Antiproliferative activity against human HT-29 cells after 72 hrs by MTT assay
    		[PMID: 30071406]
    HT-29 GI50
    0.1 μM
    Compound: doxorubicin
    Cytotoxicity against human HT29 cells by SRB assay
    Cytotoxicity against human HT29 cells by SRB assay
    		[PMID: 17512741]
    HT-29 GI50
    0.1 μM
    Compound: doxorubicin
    Cytotoxicity against human HT-29 cells by SRB assay
    Cytotoxicity against human HT-29 cells by SRB assay
    		[PMID: 19007287]
    HT-29 GI50
    0.12 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HT-29 assessed as growth inhibition after 48 hrs by SRB assay
    Antiproliferative activity against human HT-29 assessed as growth inhibition after 48 hrs by SRB assay
    		[PMID: 21875046]
    HT-29 GI50
    0.12 μM
    Compound: Doxorubicin
    Growth inhibition of human HT-29 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human HT-29 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28329730]
    HT-29 GI50
    0.12 μM
    Compound: Doxorubicin
    Growth inhibition of human HT-29 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human HT-29 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 29102177]
    HT-29 GI50
    0.12 μM
    Compound: Doxorubicin hydrochloride, NSC 123127
    Cytotoxicity against human HT-29 cells after 48 hrs by SRB assay
    Cytotoxicity against human HT-29 cells after 48 hrs by SRB assay
    		[PMID: 23871905]
    HT-29 GI50
    0.13 μg/mL
    Compound: DOX; Doxo
    Antiproliferative activity against human HT-29 cells after 48 hrs by SRB assay
    Antiproliferative activity against human HT-29 cells after 48 hrs by SRB assay
    		[PMID: 26859070]
    HT-29 GI50
    0.18 μM
    Compound: Doxorubicin
    Cytotoxicity against human HT-29 cells by sulforhodamine B assay
    Cytotoxicity against human HT-29 cells by sulforhodamine B assay
    		[PMID: 20413188]
    HT-29 GI50
    0.2 μM
    Compound: Doxorubicin
    Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay
    Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay
    		[PMID: 21115210]
    HT-29 GI50
    0.2 μM
    Compound: Doxorubicin
    Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay
    Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay
    		[PMID: 23831811]
    HT-29 GI50
    0.21 μM
    Compound: Doxorubicin
    Growth inhibition of human HT29 cells after 72 hrs by SRB assay
    Growth inhibition of human HT29 cells after 72 hrs by SRB assay
    		[PMID: 18585035]
    HT-29 GI50
    0.23 μM
    Compound: Dox
    Growth inhibition of human HT-29 cells after 48 hrs by sulforhodamine B dye-based spectrophotometric assay
    Growth inhibition of human HT-29 cells after 48 hrs by sulforhodamine B dye-based spectrophotometric assay
    		[PMID: 28505535]
    HT-29 GI50
    0.26 μM
    Compound: Doxorubicin
    Anticancer activity against human HT-29 cells assessed as cell growth inhibition measured after 48 hrs by sulforhodamine B assay
    Anticancer activity against human HT-29 cells assessed as cell growth inhibition measured after 48 hrs by sulforhodamine B assay
    		[PMID: 33214037]
    HT-29 GI50
    0.27 μg/mL
    Compound: Doxorubicin
    Growth inhibition of human HT-29 cells after 48 hrs by sulforhodamine B assay
    Growth inhibition of human HT-29 cells after 48 hrs by sulforhodamine B assay
    		[PMID: 22410248]
    HT-29 GI50
    0.27 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human HT-29 cells by sulforhodamine B assay
    Cytotoxicity against human HT-29 cells by sulforhodamine B assay
    		[PMID: 26913941]
    HT-29 GI50
    0.28 μM
    Compound: Doxorubicin
    Growth inhibition of human HT-29 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human HT-29 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 33477019]
    HT-29 GI50
    0.3 μM
    Compound: Dox
    Antiproliferative activity against human HT-29 cells assessed as growth inhibition after 48 hrs by SRB assay
    Antiproliferative activity against human HT-29 cells assessed as growth inhibition after 48 hrs by SRB assay
    		[PMID: 26454648]
    HT-29 GI50
    0.3 μM
    Compound: Doxorubicin
    Cytotoxic activity against human HT-29 cells
    Cytotoxic activity against human HT-29 cells
    		[PMID: 28256841]
    HT-29 GI50
    0.3 μM
    Compound: Doxorubicin
    Cytotoxicity against human HT-29 cells after 48 hrs by sulforhodamine B assay
    Cytotoxicity against human HT-29 cells after 48 hrs by sulforhodamine B assay
    		[PMID: 29112820]
    HT-29 GI50
    0.85 μM
    Compound: Doxorubicin
    Growth inhibition of human HT-29 cells after 2 days by MTT assay
    Growth inhibition of human HT-29 cells after 2 days by MTT assay
    		[PMID: 20138760]
    HT-29 GI50
    0.85 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human HT-29 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    Cytotoxicity against human HT-29 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    		[PMID: 26561866]
    HT-29 GI50
    1.01 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HT-29 cells assessed as growth inhibition incubated for 48 hrs by MTT assay
    Antiproliferative activity against human HT-29 cells assessed as growth inhibition incubated for 48 hrs by MTT assay
    		[PMID: 31128433]
    HT-29 GI50
    1.13 μM
    Compound: Doxorubicin
    Cytotoxicity against human HT-29 cells after 72 hrs by SRB assay
    Cytotoxicity against human HT-29 cells after 72 hrs by SRB assay
    		[PMID: 21885166]
    HT-29 GI50
    1.15 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HT-29 cells assessed as growth inhibition by MTT assay
    Antiproliferative activity against human HT-29 cells assessed as growth inhibition by MTT assay
    		[PMID: 39026636]
    HT-29 GI50
    2.58 μM
    Compound: DOXO
    Antiproliferative activity against human HT-29 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    Antiproliferative activity against human HT-29 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    		[PMID: 31247374]
    HT-29 GI50
    3.1 μM
    Compound: Adriamycin
    In vitro antiproliferative activity against human HT-29 colon cell line
    In vitro antiproliferative activity against human HT-29 colon cell line
    		[PMID: 14971893]
    HT-29 IC50
    0.002 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HT-29 cells after 96 hrs by MTT assay
    Antiproliferative activity against human HT-29 cells after 96 hrs by MTT assay
    		[PMID: 19053767]
    HT-29 IC50
    0.0031 μg/mL
    Compound: Doxorubicin
    In vitro inhibitory activity against HT-29 tumor cells
    In vitro inhibitory activity against HT-29 tumor cells
    		10.1016/S0960-894X(97)00191-1
    HT-29 IC50
    0.015 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 31546197]
    HT-29 IC50
    0.018 μM
    Compound: adriamycin
    Cytotoxicity against human HT-29 cells after 72 hrs by SRB assay
    Cytotoxicity against human HT-29 cells after 72 hrs by SRB assay
    		[PMID: 19028425]
    HT-29 IC50
    0.02 μM
    Compound: 2
    Compound was evaluated for the cytotoxicity against HT-29 tumor cell line after 3 days of incubation
    Compound was evaluated for the cytotoxicity against HT-29 tumor cell line after 3 days of incubation
    		10.1016/S0960-894X(97)10122-6
    HT-29 IC50
    0.026 μM
    Compound: DX
    Concentration required to inhibit cell growth by 50% in vitro against Human colon adenocarcinoma cell line
    Concentration required to inhibit cell growth by 50% in vitro against Human colon adenocarcinoma cell line
    		[PMID: 11563932]
    HT-29 IC50
    0.026 μM
    Compound: Doxorubicin
    In vitro cytotoxicity was tested against human colon adenocarcinoma HT-29 cell line
    In vitro cytotoxicity was tested against human colon adenocarcinoma HT-29 cell line
    		[PMID: 10411474]
    HT-29 IC50
    0.026 μM
    Compound: Dx
    The compound was tested for cytotoxic activity against HT-29 cell line(human colon adeno carcinoma)
    The compound was tested for cytotoxic activity against HT-29 cell line(human colon adeno carcinoma)
    		[PMID: 11123989]
    HT-29 IC50
    0.02 μg/mL
    Compound: doxorubicin
    Growth inhibition of HT 29 cell line by MTT reduction for 7 days of incubation time
    Growth inhibition of HT 29 cell line by MTT reduction for 7 days of incubation time
    		[PMID: 8496904]
    HT-29 IC50
    0.05 μM
    Compound: Doxorubicin
    Antitumor activity was evaluated against human colon adenocarcinoma cell line HT-29.
    Antitumor activity was evaluated against human colon adenocarcinoma cell line HT-29.
    		[PMID: 10411476]
    HT-29 IC50
    0.05 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability
    Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability
    		[PMID: 31945642]
    HT-29 IC50
    0.05 μg/mL
    Compound: dox, doxorubicin
    Cytotoxicity against human HT29 cells
    Cytotoxicity against human HT29 cells
    		[PMID: 17618015]
    HT-29 IC50
    0.06 μM
    Compound: Doxorubicin
    Cytotoxicity against human HT-29 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    Cytotoxicity against human HT-29 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    		[PMID: 38284153]
    HT-29 IC50
    0.06 μg/mL
    Compound: doxorubicin
    Growth inhibition of HT 29 cell line by MTT reduction for 3 days of incubation time
    Growth inhibition of HT 29 cell line by MTT reduction for 3 days of incubation time
    		[PMID: 8496904]
    HT-29 IC50
    0.07 μM
    Compound: Doxorubicin
    Cytotoxicity against Homo sapiens (human) HT-29 cells after 72 hr by MTT assay
    Cytotoxicity against Homo sapiens (human) HT-29 cells after 72 hr by MTT assay
    		10.1007/s00044-010-9517-9
    HT-29 IC50
    0.082 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    		[PMID: 31883489]
    HT-29 IC50
    0.086 μM
    Compound: DOX
    Cytotoxicity against human HT-29 cells incubated for 72 hrs by SRB assay
    Cytotoxicity against human HT-29 cells incubated for 72 hrs by SRB assay
    		[PMID: 38996651]
    HT-29 IC50
    0.09 μM
    Compound: Adriamycin
    Cytotoxic activity of compound against HT-29 (Human colon carcinoma) cell line
    Cytotoxic activity of compound against HT-29 (Human colon carcinoma) cell line
    		[PMID: 15225700]
    HT-29 IC50
    0.092 μM
    Compound: ADR
    Cytotoxicity against human HT-29 cells after 72 hrs by sulforhodamine B assay
    Cytotoxicity against human HT-29 cells after 72 hrs by sulforhodamine B assay
    		[PMID: 20949916]
    HT-29 IC50
    0.1 μM
    Compound: Dox
    Antiproliferative activity against human HT-29 cells after 48 hrs by MTT assay
    Antiproliferative activity against human HT-29 cells after 48 hrs by MTT assay
    		[PMID: 26494582]
    HT-29 IC50
    0.11 μg/mL
    Compound: adriamycin
    Growth inhibition of HT-29 (human colon adenocarcinoma) cell line.
    Growth inhibition of HT-29 (human colon adenocarcinoma) cell line.
    		[PMID: 2002477]
    HT-29 IC50
    0.12 μM
    Compound: DOX
    Compound was tested for cytotoxicity on HT-29 colon cancer cell line using a proliferation assay (MTT reduction)
    Compound was tested for cytotoxicity on HT-29 colon cancer cell line using a proliferation assay (MTT reduction)
    		10.1016/S0960-894X(01)81264-6
    HT-29 IC50
    0.12 μM
    Compound: Doxorubicin
    Cytotoxicity against human HT-29 cells assessed as reduction in cell viability incubated for 6 hrs by SRB assay
    Cytotoxicity against human HT-29 cells assessed as reduction in cell viability incubated for 6 hrs by SRB assay
    		[PMID: 36691388]
    HT-29 IC50
    0.15 μM
    Compound: DOX
    Antiproliferative activity against human HT-29 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay
    Antiproliferative activity against human HT-29 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay
    		[PMID: 31557614]
    HT-29 IC50
    0.15 μM
    Compound: Doxo
    Antiproliferative activity against human HT-29 cells assessed as cell viability measured after 4 days by MTT assay
    Antiproliferative activity against human HT-29 cells assessed as cell viability measured after 4 days by MTT assay
    		[PMID: 31869654]
    HT-29 IC50
    0.15 μM
    Compound: Doxorubicin
    Antitumor activity against human colon adenocarcinoma HT-29 cells.
    Antitumor activity against human colon adenocarcinoma HT-29 cells.
    		[PMID: 12431049]
    HT-29 IC50
    0.15 μM
    Compound: Doxorubicin
    Cytotoxicity against human HT-29 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
    Cytotoxicity against human HT-29 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
    		[PMID: 33340938]
    HT-29 IC50
    0.15 μM
    Compound: Doxorubicin
    Cytotoxicity against human HT-29 cells assessed as inhibition of cell growth after 48 hrs by SRB assay
    Cytotoxicity against human HT-29 cells assessed as inhibition of cell growth after 48 hrs by SRB assay
    		[PMID: 34077833]
    HT-29 IC50
    0.15 μM
    Compound: doxo
    Antiproliferative activity against human HT29 cell line by MTT assay
    Antiproliferative activity against human HT29 cell line by MTT assay
    		[PMID: 16913700]
    HT-29 IC50
    0.15 μM
    Compound: doxorubicin
    Antitumor activity against human colon adenocarcinoma HT-29 cells
    Antitumor activity against human colon adenocarcinoma HT-29 cells
    		[PMID: 12431048]
    HT-29 IC50
    0.153 μM
    Compound: Dx
    Antiproliferative activity against HT29 cells by MTT assay after 72 hrs
    Antiproliferative activity against HT29 cells by MTT assay after 72 hrs
    		[PMID: 16824751]
    HT-29 IC50
    0.164 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HT-29 cells assessed as inhibition of cell proliferation after 3 days by MTS assay
    Antiproliferative activity against human HT-29 cells assessed as inhibition of cell proliferation after 3 days by MTS assay
    		10.1039/C1MD00155H
    HT-29 IC50
    0.18 μM
    Compound: doxorubicin
    Compound was tested for cytotoxicity against colon adenocarcinoma
    Compound was tested for cytotoxicity against colon adenocarcinoma
    		[PMID: 8182705]
    HT-29 IC50
    0.1 μg/mL
    Compound: (20) adriamycin
    In vitro cytotoxicity of compound against HT29, human colorectal adenocarcinoma was defined by microculture tetrazolium assay
    In vitro cytotoxicity of compound against HT29, human colorectal adenocarcinoma was defined by microculture tetrazolium assay
    		[PMID: 12620075]
    HT-29 IC50
    0.21 μg/mL
    Compound: Adriamycin
    Inhibitory concentration required against HT 29 colon cancer cell line
    Inhibitory concentration required against HT 29 colon cancer cell line
    		[PMID: 11354370]
    HT-29 IC50
    0.24 μM
    Compound: DOX
    Cytotoxicity against human HT-29 cells after 96 hrs under normoxic condition by MTT assay
    Cytotoxicity against human HT-29 cells after 96 hrs under normoxic condition by MTT assay
    		[PMID: 29649740]
    HT-29 IC50
    0.24 μM
    Compound: Doxorubicin
    Cytotoxicity against human HT-29 cells after 72 hrs by XTT assay
    Cytotoxicity against human HT-29 cells after 72 hrs by XTT assay
    		[PMID: 19647439]
    HT-29 IC50
    0.25 μM
    Compound: DOX
    Cytotoxicity against human HT-29 cells after 96 hrs under hypoxic condition by MTT assay
    Cytotoxicity against human HT-29 cells after 96 hrs under hypoxic condition by MTT assay
    		[PMID: 29649740]
    HT-29 IC50
    0.259 μM
    Compound: Doxorubicin
    Anticancer activity against human HT-29 cell assessed as cell growth inhibition measured after 24 to 72 hrs by MTT assay
    Anticancer activity against human HT-29 cell assessed as cell growth inhibition measured after 24 to 72 hrs by MTT assay
    		[PMID: 36577217]
    HT-29 IC50
    0.26 μM
    Compound: Doxorubicin
    Cytotoxicity against human HT-29 cells after 48 hrs by MTT assay
    Cytotoxicity against human HT-29 cells after 48 hrs by MTT assay
    		[PMID: 26963142]
    HT-29 IC50
    0.28 μM
    Compound: Doxorubicin
    Inhibitory concentration that reduced the viability of HT 29 cell population by 50%.
    Inhibitory concentration that reduced the viability of HT 29 cell population by 50%.
    		[PMID: 9003520]
    HT-29 IC50
    0.3 μM
    Compound: Doxorubicin
    Cytotoxicity against human HT-29 cells assessed as growth inhibition by MTT assay
    Cytotoxicity against human HT-29 cells assessed as growth inhibition by MTT assay
    		[PMID: 25765907]
    HT-29 IC50
    0.3 μM
    Compound: Doxorubicin
    Growth inhibition of human HT-29 cells incubated for 48 hrs by MTT assay
    Growth inhibition of human HT-29 cells incubated for 48 hrs by MTT assay
    		[PMID: 27080187]
    HT-29 IC50
    0.31 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HT-29 cells after 24 and 72 hrs by MTT assay
    Antiproliferative activity against human HT-29 cells after 24 and 72 hrs by MTT assay
    		[PMID: 24941130]
    HT-29 IC50
    0.32 μM
    Compound: DOX
    Cytotoxicity against human HT-29 cells assessed as growth inhibition after 48 hrs by MTT assay
    Cytotoxicity against human HT-29 cells assessed as growth inhibition after 48 hrs by MTT assay
    		[PMID: 24148837]
    HT-29 IC50
    0.32 μM
    Compound: Doxorubicin
    Cytotoxicity against human HT-29 cells expressing estrogen receptor after 48 hrs by MTT assay
    Cytotoxicity against human HT-29 cells expressing estrogen receptor after 48 hrs by MTT assay
    		10.1039/C2MD20327H
    HT-29 IC50
    0.32 μM
    Compound: Doxorubicin
    Cytotoxicity against human HT-29 cells after 1 hr by SRB assay
    Cytotoxicity against human HT-29 cells after 1 hr by SRB assay
    		[PMID: 22770744]
    HT-29 IC50
    0.32 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HT-29 cells after 48 hrs by MTT assay
    Antiproliferative activity against human HT-29 cells after 48 hrs by MTT assay
    		[PMID: 30108986]
    HT-29 IC50
    0.32 μM
    Compound: Doxorubicin (Dx)
    In vitro cytotoxicity against colorectal adenocarcinoma HT-29 cells
    In vitro cytotoxicity against colorectal adenocarcinoma HT-29 cells
    		[PMID: 16169719]
    HT-29 IC50
    0.33 μM
    Compound: Adriamycin
    Cytotoxicity against human HT-29 cells by SRB assay
    Cytotoxicity against human HT-29 cells by SRB assay
    		[PMID: 19341288]
    HT-29 IC50
    0.34 μM
    Compound: Doxorubicin
    Cytotoxicity against human HT-29 cells by MTT assay
    Cytotoxicity against human HT-29 cells by MTT assay
    		[PMID: 30719909]
    HT-29 IC50
    0.34 μM
    Compound: Doxorubicin
    Cytotoxicity in human HT-29 cells incubated for 72 hrs by MTT assay
    Cytotoxicity in human HT-29 cells incubated for 72 hrs by MTT assay
    		[PMID: 30978023]
    HT-29 IC50
    0.34 μM
    Compound: Doxorubicin
    Compound was tested for its antitumor activity against HT-29 colon carcinoma cell line
    Compound was tested for its antitumor activity against HT-29 colon carcinoma cell line
    		[PMID: 9873394]
    HT-29 IC50
    0.35 μM
    Compound: Doxorubicin
    Cytotoxicity against Homo sapiens (human) HT-29 cells assessed as growth inhibition after 72 hr by MTT assay
    Cytotoxicity against Homo sapiens (human) HT-29 cells assessed as growth inhibition after 72 hr by MTT assay
    		10.1007/s00044-012-0428-9
    HT-29 IC50
    0.35 μM
    Compound: doxorubicin
    Cytotoxicity against human HT29 cells by MTT assay
    Cytotoxicity against human HT29 cells by MTT assay
    		[PMID: 17141923]
    HT-29 IC50
    0.36 μM
    Compound: DOX
    Antiproliferative activity against human HT-29 cells after 72 hrs by Sulforhodamine B-stain assay
    Antiproliferative activity against human HT-29 cells after 72 hrs by Sulforhodamine B-stain assay
    		[PMID: 27484508]
    HT-29 IC50
    0.4 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HT-29 cells by MTT assay
    Antiproliferative activity against human HT-29 cells by MTT assay
    		[PMID: 29072457]
    HT-29 IC50
    0.4 μM
    Compound: Doxorubicin
    Anticancer activity against human HT-29 cells assessed as inhibition of cell growth measured after 72 hrs by SRB assay
    Anticancer activity against human HT-29 cells assessed as inhibition of cell growth measured after 72 hrs by SRB assay
    		[PMID: 33940466]
    HT-29 IC50
    0.44 μM
    Compound: DOX
    Cytotoxicity against human HT-29 cells after 48 hrs by sulforhodamine B assay
    Cytotoxicity against human HT-29 cells after 48 hrs by sulforhodamine B assay
    		[PMID: 23810282]
    HT-29 IC50
    0.48 μM
    Compound: adriamycin
    Cytotoxicity against human HT29 cell line
    Cytotoxicity against human HT29 cell line
    		[PMID: 17228871]
    HT-29 IC50
    0.59 μM
    Compound: Doxorubicin
    Cytotoxicity activity against human HT-29 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity activity against human HT-29 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 32627543]
    HT-29 IC50
    0.5 μg/mL
    Compound: adriamycin
    Compound was evaluated for the growth inhibition of HT-29 colon cell line.
    Compound was evaluated for the growth inhibition of HT-29 colon cell line.
    		[PMID: 9873640]
    HT-29 IC50
    0.6 μM
    Compound: Dox
    Cytotoxicity against human HT-29 cells after 24 hrs by MTS assay
    Cytotoxicity against human HT-29 cells after 24 hrs by MTS assay
    		[PMID: 21094049]
    HT-29 IC50
    0.68 μM
    Compound: Doxorubicin
    Cytotoxicity against human HT-29 cells after 48 hrs by MTT assay
    Cytotoxicity against human HT-29 cells after 48 hrs by MTT assay
    		[PMID: 26398312]
    HT-29 IC50
    0.69 μM
    Compound: Doxorubicin
    Cytotoxicity against human HT-29 cells assessed as inhibition of cell viability after 72 hrs by MTT assay
    Cytotoxicity against human HT-29 cells assessed as inhibition of cell viability after 72 hrs by MTT assay
    		[PMID: 29329071]
    HT-29 IC50
    0.7 μM
    Compound: Doxorubicin
    Cytotoxicity against HT-29 colon carcinoma cell line
    Cytotoxicity against HT-29 colon carcinoma cell line
    		[PMID: 10476861]
    HT-29 IC50
    0.82 μM
    Compound: Doxorubicin
    Cytotoxicity against human HT-29 cells after 2 days by MTT assay
    Cytotoxicity against human HT-29 cells after 2 days by MTT assay
    		[PMID: 21353544]
    HT-29 IC50
    0.82 μM
    Compound: Doxorubicin
    Cytotoxicity against human HT-29 cells assessed as reduction in cell viability by MTT assay
    Cytotoxicity against human HT-29 cells assessed as reduction in cell viability by MTT assay
    		[PMID: 31404864]
    HT-29 IC50
    0.87 μM
    Compound: Doxorubicin
    Cytotoxicity against human HT-29 cells by Alamar blue assay
    Cytotoxicity against human HT-29 cells by Alamar blue assay
    		[PMID: 27256910]
    HT-29 IC50
    0.87 μM
    Compound: Doxorubicin
    Cytotoxicity against human HT-29 cells after 72 hrs by alamar blue assay
    Cytotoxicity against human HT-29 cells after 72 hrs by alamar blue assay
    		[PMID: 28159416]
    HT-29 IC50
    0.89 μM
    Compound: doxorubicin
    Antiproliferative activity against human HT-29 cells assessed as growth inhibition after 72 hrs by SRB method
    Antiproliferative activity against human HT-29 cells assessed as growth inhibition after 72 hrs by SRB method
    		[PMID: 25644674]
    HT-29 IC50
    0.9 μM
    Compound: DX
    Cytotoxicity against human HT29 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
    Cytotoxicity against human HT29 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
    		[PMID: 32422522]
    HT-29 IC50
    0.9 μM
    Compound: Doxorubicin
    Cytotoxicity against human HT-29 cells assessed as reduction in cell viability by MTT assay
    Cytotoxicity against human HT-29 cells assessed as reduction in cell viability by MTT assay
    		[PMID: 31820973]
    HT-29 IC50
    0.93 μM
    Compound: Doxorubicin
    Anticancer activity against human HT-29 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Anticancer activity against human HT-29 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    		[PMID: 26330077]
    HT-29 IC50
    1 μM
    Compound: DOX
    Antiproliferative activity against human HT-29 cells assessed as growth inhibition after 48 hrs by MTT assay
    Antiproliferative activity against human HT-29 cells assessed as growth inhibition after 48 hrs by MTT assay
    		[PMID: 22044164]
    HT-29 IC50
    1.01 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HT-29 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay
    Antiproliferative activity against human HT-29 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay
    		[PMID: 31108261]
    HT-29 IC50
    1.06 μM
    Compound: Doxorubicin
    Anticancer activity against human HT-29 cells after 48 hrs by MTT assay
    Anticancer activity against human HT-29 cells after 48 hrs by MTT assay
    		[PMID: 22136907]
    HT-29 IC50
    1.1 μM
    Compound: Doxorubicin
    Compound was tested for its effect on the proliferation of HT-29 human colon adenocarcinoma.
    Compound was tested for its effect on the proliferation of HT-29 human colon adenocarcinoma.
    		10.1016/0960-894X(96)00216-8
    HT-29 IC50
    1.1 μM
    Compound: Doxorubicin
    Antitumor activity against human HT-29 cells after 24 to 48 hrs by MTT assay
    Antitumor activity against human HT-29 cells after 24 to 48 hrs by MTT assay
    		[PMID: 21553829]
    HT-29 IC50
    1.13 μM
    Compound: ADM
    Antiproliferative activity against human HT-29 cells overexpressing NQO1 assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    Antiproliferative activity against human HT-29 cells overexpressing NQO1 assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    		[PMID: 35803175]
    HT-29 IC50
    1.13 μM
    Compound: Doxorubicin
    Cytotoxicity against human HT-29 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay
    Cytotoxicity against human HT-29 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay
    		[PMID: 33352388]
    HT-29 IC50
    1.15 μM
    Compound: Doxorubicin
    Cytotoxicity against human HT-29 cells after 48 hrs by Alamar Blue assay
    Cytotoxicity against human HT-29 cells after 48 hrs by Alamar Blue assay
    		[PMID: 19473028]
    HT-29 IC50
    1.16 μM
    Compound: Doxorubicin
    Cytotoxicity against human HT-29 cells assessed as cell growth inhibition after 48 hrs by MTT assay
    Cytotoxicity against human HT-29 cells assessed as cell growth inhibition after 48 hrs by MTT assay
    		[PMID: 26708114]
    HT-29 IC50
    1.23 μM
    Compound: Doxorubicin
    Cytotoxicity against human HT-29 cells after 48 hrs by Alamar blue assay
    Cytotoxicity against human HT-29 cells after 48 hrs by Alamar blue assay
    		[PMID: 20931970]
    HT-29 IC50
    1.3 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HT-29 cells after 72 hrs by MTT assay
    Antiproliferative activity against human HT-29 cells after 72 hrs by MTT assay
    		[PMID: 19632833]
    HT-29 IC50
    1.4 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HT-29 cells assessed as reduction in cell growth incubated for 24 hrs by MTT assay
    Antiproliferative activity against human HT-29 cells assessed as reduction in cell growth incubated for 24 hrs by MTT assay
    		[PMID: 33744686]
    HT-29 IC50
    1.41 μM
    Compound: II
    Cytotoxicity against human HT-29 cells after 48 hrs by MTT assay
    Cytotoxicity against human HT-29 cells after 48 hrs by MTT assay
    		[PMID: 29289881]
    HT-29 IC50
    1.48 μM
    Compound: Doxorubicin
    Cytotoxicity activity against human HT-29 cells assessed as reduction in cell growth measured after 72 hrs by MTT assay
    Cytotoxicity activity against human HT-29 cells assessed as reduction in cell growth measured after 72 hrs by MTT assay
    		[PMID: 32531682]
    HT-29 IC50
    1.5 μM
    Compound: Doxorubicin
    Cytotoxicity against human HT-29 cells assessed as inhibition in cell growth incubated for 72 hrs by MTT assay
    Cytotoxicity against human HT-29 cells assessed as inhibition in cell growth incubated for 72 hrs by MTT assay
    		[PMID: 37567059]
    HT-29 IC50
    1.57 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    		[PMID: 33477020]
    HT-29 IC50
    1.64 μM
    Compound: Doxorubicin
    Cytotoxicity against human HT29 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Cytotoxicity against human HT29 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    		[PMID: 33823396]
    HT-29 IC50
    1.6 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human HT-29 cells assessed as cell growth inhibition
    Cytotoxicity against human HT-29 cells assessed as cell growth inhibition
    		[PMID: 35526504]
    HT-29 IC50
    1.7 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HT-29 cells after 48 hrs by MTT assay
    Antiproliferative activity against human HT-29 cells after 48 hrs by MTT assay
    		10.1039/C5MD00163C
    HT-29 IC50
    1.7 μM
    Compound: Doxorubicin
    Cytotoxicity against human HT-29 cells after 24 hrs by MTT assay
    Cytotoxicity against human HT-29 cells after 24 hrs by MTT assay
    		[PMID: 26252628]
    HT-29 IC50
    1.76 μM
    Compound: DOX
    Cytotoxicity against human HT-29 cells after 48 hrs by MTT assay
    Cytotoxicity against human HT-29 cells after 48 hrs by MTT assay
    		[PMID: 24487188]
    HT-29 IC50
    1.76 μM
    Compound: Dox
    Cytotoxicity against human HT-29 cells after 24 hrs by MTT assay
    Cytotoxicity against human HT-29 cells after 24 hrs by MTT assay
    		10.1007/s00044-013-0584-6
    HT-29 IC50
    1.76 μM
    Compound: Doxorubicin
    Cytotoxicity against human HT-29 cells assessed as inhibition of cell viability after 48 hrs by MTT assay
    Cytotoxicity against human HT-29 cells assessed as inhibition of cell viability after 48 hrs by MTT assay
    		[PMID: 24953027]
    HT-29 IC50
    107.8 nM
    Compound: Dox
    Cytotoxicity against human HT-29 cells incubated for 72 hrs by SRB assay
    Cytotoxicity against human HT-29 cells incubated for 72 hrs by SRB assay
    		[PMID: 37480713]
    HT-29 IC50
    12.94 μM
    Compound: Dox
    Antiproliferative activity against human HT-29 cells assessed as inhibition of cell proliferation incubated for 72 hrs by CellTiter-Glo assay
    Antiproliferative activity against human HT-29 cells assessed as inhibition of cell proliferation incubated for 72 hrs by CellTiter-Glo assay
    		[PMID: 27687968]
    HT-29 IC50
    16 μM
    Compound: Doxorubicin
    Cytotoxicity against human HT-29 cells assessed as reduction in cell viability after 24 hrs by MTT assay
    Cytotoxicity against human HT-29 cells assessed as reduction in cell viability after 24 hrs by MTT assay
    		[PMID: 24681979]
    HT-29 IC50
    16.32 μM
    Compound: Dox
    Cytotoxicity against human HT-29 cells assessed as cell viability measured after 24 hrs by MTT assay
    Cytotoxicity against human HT-29 cells assessed as cell viability measured after 24 hrs by MTT assay
    		[PMID: 33183865]
    HT-29 IC50
    19.3 μM
    Compound: Doxorubicin
    Anticancer activity against human HT-29 cells after 48 hrs by MTT assay
    Anticancer activity against human HT-29 cells after 48 hrs by MTT assay
    		[PMID: 22668451]
    HT-29 IC50
    2.05 μM
    Compound: doxorubicin
    Cytotoxicity against human HT-29 cells after 48 hrs by MTT assay
    Cytotoxicity against human HT-29 cells after 48 hrs by MTT assay
    		[PMID: 20405844]
    HT-29 IC50
    2.24 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HT-29 cells after 48 hrs by MTT assay
    Antiproliferative activity against human HT-29 cells after 48 hrs by MTT assay
    		[PMID: 31200236]
    HT-29 IC50
    2.37 μM
    Compound: Doxorubicin
    Cytotoxicity against HT29 cell line
    Cytotoxicity against HT29 cell line
    		[PMID: 16777412]
    HT-29 IC50
    2.75 μM
    Compound: Dox
    Antiproliferative activity against human HT-29 cells after 72 hrs by cell titer glo assay
    Antiproliferative activity against human HT-29 cells after 72 hrs by cell titer glo assay
    		[PMID: 24161704]
    HT-29 IC50
    2.8 x 10-7 M
    Compound: Doxorubucin
    Cytotoxicity against human HT-29 cells after 72 hrs by XTT assay
    Cytotoxicity against human HT-29 cells after 72 hrs by XTT assay
    		[PMID: 20538470]
    HT-29 IC50
    231.2 nM
    Compound: Doxorubicin
    In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line HT-29/Mx(RI)
    In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line HT-29/Mx(RI)
    		[PMID: 10479282]
    HT-29 IC50
    26 nM
    Compound: Doxorubicin (Dx)
    In vitro cytotoxic potency against HT-29 (human colon adenocarcinoma) cell line.
    In vitro cytotoxic potency against HT-29 (human colon adenocarcinoma) cell line.
    		[PMID: 11806721]
    HT-29 IC50
    3 x 10-7 M
    Compound: Doxorubicin
    Cytotoxicity against human HT-29 cells after 72 hrs by XTT assay
    Cytotoxicity against human HT-29 cells after 72 hrs by XTT assay
    		[PMID: 20619940]
    HT-29 IC50
    330 nM
    Compound: Doxorubicin
    Human tumor cell cytotoxicity assay was performed using MTT (HT-29 cell line )
    Human tumor cell cytotoxicity assay was performed using MTT (HT-29 cell line )
    		[PMID: 8576914]
    HT-29 IC50
    331 nM
    Compound: Doxorubicin
    Cytotoxicity was determined in vitro in HT-29 cells(colon) of human tumor cell lines by using MTT assay
    Cytotoxicity was determined in vitro in HT-29 cells(colon) of human tumor cell lines by using MTT assay
    		[PMID: 7853331]
    HT-29 IC50
    37 nM
    Compound: Adriamycin
    Antiproliferative activity against human HT-29 cells after 96 hrs by MTT assay
    Antiproliferative activity against human HT-29 cells after 96 hrs by MTT assay
    		[PMID: 2778449]
    HT-29 IC50
    5.1 x 10-4 μg/mL
    Compound: adriamycin
    Cytotoxicity against human HT29 cells
    Cytotoxicity against human HT29 cells
    		[PMID: 8991944]
    HT-29 IC50
    5.3 x 10-3 μg/mL
    Compound: Adriamycin
    Cytotoxicity against human HT-29 cells by MTT assay
    Cytotoxicity against human HT-29 cells by MTT assay
    		[PMID: 9644064]
    HT-29 IC50
    5.38 μM
    Compound: Dox
    Cytotoxicity in human HT-29 cells assessed as reduction in cell viability incubated for 24 hrs under hypoxic condition by MTT assay
    Cytotoxicity in human HT-29 cells assessed as reduction in cell viability incubated for 24 hrs under hypoxic condition by MTT assay
    		[PMID: 31542715]
    HT-29 IC50
    5.92 μM
    Compound: DOX
    Antiproliferative activity against human HT29 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Antiproliferative activity against human HT29 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    		[PMID: 32996316]
    HT-29 IC50
    56.4 nM
    Compound: Doxorubicin
    In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line HT-29
    In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line HT-29
    		[PMID: 10479282]
    HT-29 IC50
    6.04 μM
    Compound: Doxorubicin
    Cytotoxicity against human HT-29 cells after 48 hrs by alamar blue assay
    Cytotoxicity against human HT-29 cells after 48 hrs by alamar blue assay
    		[PMID: 22272829]
    HT-29 IC50
    6.4 μM
    Compound: Doxorubicin
    Cytotoxicity against human HT-29 cells after 48 hrs
    Cytotoxicity against human HT-29 cells after 48 hrs
    		[PMID: 20873721]
    HT-29 IC50
    61.8 nM
    Compound: Doxorubicin
    Cytotoxicity against Colon cancer cell lines HT-29 was determined
    Cytotoxicity against Colon cancer cell lines HT-29 was determined
    		[PMID: 12392727]
    HT-29 IC50
    7.4 μM
    Compound: Doxorubicin
    Cytotoxicity against human HT-29 cells assessed as decrease in cell viability after 48 hrs by MTT assay
    Cytotoxicity against human HT-29 cells assessed as decrease in cell viability after 48 hrs by MTT assay
    		[PMID: 27843113]
    HT-29 IC50
    7.7 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HT-29 cells after 72 hrs by SRB assay
    Antiproliferative activity against human HT-29 cells after 72 hrs by SRB assay
    		[PMID: 25462265]
    HT-29 IC50
    7.7 μM
    Compound: Doxorubicin
    Cytotoxicity against human HT-29 cells by sulforhodamine B assay
    Cytotoxicity against human HT-29 cells by sulforhodamine B assay
    		[PMID: 31401008]
    HT-29 IC50
    7.86 μM
    Compound: DOX
    Antiproliferative activity against human HT-29 cells assessed as inhibition of cell growth after 48 hrs by MTT assay
    Antiproliferative activity against human HT-29 cells assessed as inhibition of cell growth after 48 hrs by MTT assay
    		[PMID: 25737400]
    HT1197 IC50
    0.03 μg/mL
    Compound: Adriamycin
    Antiproliferative activity against PLCgamma1 expressing human HT1197 cells
    Antiproliferative activity against PLCgamma1 expressing human HT1197 cells
    		[PMID: 10869194]
    HUVEC GI50
    0.0268 μM
    Compound: Doxorubicin
    Cytotoxicity against HUVEC cells after 48 hrs by SRB assay
    Cytotoxicity against HUVEC cells after 48 hrs by SRB assay
    		[PMID: 26462052]
    HUVEC GI50
    0.1 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against HUVEC
    Cytotoxicity against HUVEC
    		[PMID: 25372601]
    HUVEC GI50
    0.1 μg/mL
    Compound: doxorubicin
    Antiproliferative activity against HUVEC after 72 hrs by resazurin dye reduction assay
    Antiproliferative activity against HUVEC after 72 hrs by resazurin dye reduction assay
    		[PMID: 20153202]
    HUVEC GI50
    109 nM
    Compound: Doxorubicin
    Antiproliferative activity against HUVEC assessed as growth inhibition after 24 to 72 hrs by MTS assay
    Antiproliferative activity against HUVEC assessed as growth inhibition after 24 to 72 hrs by MTS assay
    		10.1039/C0MD00179A
    HUVEC IC50
    0.0807 μM
    Compound: Doxorubicin
    Cytotoxicity against HUVEC assessed as cell viability after 48 hrs by MTT assay
    Cytotoxicity against HUVEC assessed as cell viability after 48 hrs by MTT assay
    		[PMID: 24012378]
    HUVEC IC50
    0.1 μM
    Compound: Doxorubicin
    Cytotoxicity against human HUVEC cells assessed as inhibition of cell growth after 48 hrs by SRB assay
    Cytotoxicity against human HUVEC cells assessed as inhibition of cell growth after 48 hrs by SRB assay
    		[PMID: 34077833]
    HUVEC IC50
    0.15 μM
    Compound: Doxorubicin
    Antiproliferative activity against HUVEC after 70 hrs by alamar blue assay
    Antiproliferative activity against HUVEC after 70 hrs by alamar blue assay
    		[PMID: 29471119]
    HUVEC IC50
    0.4 μM
    Compound: Doxorubicin
    Cytotoxicity against HUVEC cells after 48 hrs by WST8 assay
    Cytotoxicity against HUVEC cells after 48 hrs by WST8 assay
    		[PMID: 25163667]
    HUVEC IC50
    0.48 μM
    Compound: Doxorubicin
    Cytotoxicity against HUVEC assessed as reduction in cell viability after 70 hrs by alamar blue assay
    Cytotoxicity against HUVEC assessed as reduction in cell viability after 70 hrs by alamar blue assay
    		[PMID: 29471119]
    HUVEC IC50
    1.1 μM
    Compound: Dox
    Cytotoxicity against human HUVEC cells after 48 hrs by MTT assay
    Cytotoxicity against human HUVEC cells after 48 hrs by MTT assay
    		[PMID: 24028446]
    HUVEC IC50
    1.4 μM
    Compound: DXR
    Cytotoxicity against HUVEC cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay
    Cytotoxicity against HUVEC cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay
    		[PMID: 34808062]
    HUVEC IC50
    1.4 μM
    Compound: Doxorubicin
    Cytotoxicity against HUVEC assessed as inhibition of metabolic activity after 48 hrs by MTT assay
    Cytotoxicity against HUVEC assessed as inhibition of metabolic activity after 48 hrs by MTT assay
    		[PMID: 27187858]
    HUVEC IC50
    23.34 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human HUVEC cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay
    Cytotoxicity against human HUVEC cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay
    		[PMID: 34973507]
    HUVEC IC50
    3.8 μM
    Compound: Dox
    Cytotoxicity against human HUVEC cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
    Cytotoxicity against human HUVEC cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
    		[PMID: 33852973]
    HUVEC IC50
    30.3 nM
    Compound: Doxorubicin
    Antiproliferative activity against human HUVEC cells after 96 hrs by MTT assay
    Antiproliferative activity against human HUVEC cells after 96 hrs by MTT assay
    		[PMID: 21296467]
    HUVEC IC50
    4.4 μM
    Compound: DOX
    Cytotoxicity against HUVEC measured after 36 hrs by MTT assay
    Cytotoxicity against HUVEC measured after 36 hrs by MTT assay
    		[PMID: 30746067]
    HUVEC IC50
    6.3 μM
    Compound: Doxorubicin
    Cytotoxicity against human HUVEC after 24 hrs by MTT assay
    Cytotoxicity against human HUVEC after 24 hrs by MTT assay
    		[PMID: 26252628]
    HUVEC IC50
    79.6 μM
    Compound: Doxorubicin
    Cytotoxicity against HUVEC assessed as reduction in cell viability by MTT assay
    Cytotoxicity against HUVEC assessed as reduction in cell viability by MTT assay
    		[PMID: 26774921]
    HUVEC IC50
    8.65 μM
    Compound: DOX
    Cytotoxicity against HUVEC assessed as reduction in cell viability after 48 hrs by MTT assay
    Cytotoxicity against HUVEC assessed as reduction in cell viability after 48 hrs by MTT assay
    		[PMID: 28355069]
    HaCaT GI50
    0.11 μg/mL
    Compound: DOX
    Antiproliferative activity against human HaCaT cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    Antiproliferative activity against human HaCaT cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    		[PMID: 25062010]
    HaCaT GI50
    0.2 μM
    Compound: Dox
    Growth inhibition of human HaCaT cells after 48 hrs by sulforhodamine B dye-based spectrophotometric assay
    Growth inhibition of human HaCaT cells after 48 hrs by sulforhodamine B dye-based spectrophotometric assay
    		[PMID: 28505535]
    HaCaT GI50
    0.64 μM
    Compound: Dox
    Cytotoxicity against human HaCaT cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    Cytotoxicity against human HaCaT cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    		[PMID: 35533562]
    HaCaT GI50
    0.9 μM
    Compound: Dox
    Cytotoxicity against human HaCaT cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
    Cytotoxicity against human HaCaT cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
    		[PMID: 34634616]
    HaCaT GI50
    0.9 μM
    Compound: Dox
    Antiproliferative activity against human HaCaT cells incubated for 72 hrs and measured by MTT assay
    Antiproliferative activity against human HaCaT cells incubated for 72 hrs and measured by MTT assay
    		[PMID: 35973342]
    HaCaT GI50
    < 0.025 μg/mL
    Compound: DOX; Doxo
    Cytotoxicity against human HaCaT cells after 48 hrs by SRB assay
    Cytotoxicity against human HaCaT cells after 48 hrs by SRB assay
    		[PMID: 26859070]
    HaCaT GI50
    < 0.046 μM
    Compound: Dox
    Antiproliferative activity against human HaCaT cells assessed as growth inhibition after 48 hrs by SRB assay
    Antiproliferative activity against human HaCaT cells assessed as growth inhibition after 48 hrs by SRB assay
    		[PMID: 26454648]
    HaCaT GI50
    < 0.046 μM
    Compound: Doxorubicin
    Cytotoxicity against human HaCaT cells assessed as cell growth inhibition measured after 48 hrs by sulforhodamine B assay
    Cytotoxicity against human HaCaT cells assessed as cell growth inhibition measured after 48 hrs by sulforhodamine B assay
    		[PMID: 33214037]
    HaCaT IC50
    0.01 μM
    Compound: Doxorubicin
    Cytotoxicity against human HaCaT cells assessed as reduction in cell viability incubated for 4 days by CellTiter 96 aqueous one solution assay
    Cytotoxicity against human HaCaT cells assessed as reduction in cell viability incubated for 4 days by CellTiter 96 aqueous one solution assay
    		[PMID: 31596585]
    HaCaT IC50
    0.03 μM
    Compound: Dox
    Cytotoxicity against human HaCaT cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human HaCaT cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 30615450]
    HaCaT IC50
    0.03 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HaCaT cells after 48 hrs by Hoechst 33342 staining-based assay
    Antiproliferative activity against human HaCaT cells after 48 hrs by Hoechst 33342 staining-based assay
    		[PMID: 30655216]
    HaCaT IC50
    0.23 μM
    Compound: Doxorubicin
    Cytotoxicity against human HaCaT cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
    Cytotoxicity against human HaCaT cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
    		[PMID: 31753514]
    HaCaT IC50
    0.235 μM
    Compound: Doxorubicin
    Cytotoxicity against human HaCaT cells assessed as growth inhibition measured after 72 hrs by MTT assay
    Cytotoxicity against human HaCaT cells assessed as growth inhibition measured after 72 hrs by MTT assay
    		[PMID: 31383628]
    HaCaT IC50
    0.29 μM
    Compound: DOX
    Cytotoxicity against human HaCaT cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Cytotoxicity against human HaCaT cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    		[PMID: 31678743]
    HaCaT IC50
    0.52 μM
    Compound: Doxorubicin
    Cytotoxicity against human HaCaT cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Cytotoxicity against human HaCaT cells assessed as reduction in cell viability after 48 hrs by MTT assay
    		[PMID: 30389295]
    HaCaT IC50
    0.53 μM
    Compound: Doxorubicin
    Cytotoxicity against human HaCaT cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    Cytotoxicity against human HaCaT cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    		[PMID: 26934105]
    HaCaT IC50
    0.86 μM
    Compound: Dox
    Antiproliferative activity against human HaCaT cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay
    Antiproliferative activity against human HaCaT cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay
    		[PMID: 36809707]
    HaCaT IC50
    1.09 μM
    Compound: Dox
    Cytotoxicity activity against human HaCaT cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity activity against human HaCaT cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 30031974]
    HaCaT IC50
    3.26 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human HaCaT cells assessed as cell shrinkage after 24 hrs by SRB assay
    Cytotoxicity against human HaCaT cells assessed as cell shrinkage after 24 hrs by SRB assay
    		[PMID: 24269165]
    HaCaT IC50
    4.56 μM
    Compound: Dox
    Cytotoxicity against human HaCaT cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    Cytotoxicity against human HaCaT cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    		[PMID: 37001390]
    HaCaT IC50
    50 μM
    Compound: Doxorubicin
    Cytotoxicity against human HaCaT cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Blue cell viability assay
    Cytotoxicity against human HaCaT cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Blue cell viability assay
    		[PMID: 35271771]
    HeLa CC50
    0.66 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
    Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
    		[PMID: 30103191]
    HeLa CC50
    2 μM
    Compound: doxorubicin
    Cytotoxicity against human HeLa cells
    Cytotoxicity against human HeLa cells
    		[PMID: 19188072]
    HeLa CC50
    2 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells
    Cytotoxicity against human HeLa cells
    		[PMID: 25372601]
    HeLa CC50
    2 μg/mL
    Compound: doxorubicin
    Cytotoxicity against human HeLa cells after 72 hrs by methylene blue staining
    Cytotoxicity against human HeLa cells after 72 hrs by methylene blue staining
    		[PMID: 20153202]
    HeLa EC50
    2.5 μM
    Compound: Doxorubicin
    Cytotoxicity against Homo sapiens (human) HeLa cells after 48 hr by MTT assay
    Cytotoxicity against Homo sapiens (human) HeLa cells after 48 hr by MTT assay
    		10.1007/s00044-012-0294-5
    HeLa EC50
    4.3 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells assessed as reduction in cell population to midpoint between values of non-treated control and lowest population by MTT assay
    Cytotoxicity against human HeLa cells assessed as reduction in cell population to midpoint between values of non-treated control and lowest population by MTT assay
    		[PMID: 37839713]
    HeLa ED50
    0.14 μg/mL
    Compound: doxorubicin
    Cytotoxicity against human HeLa cells by methylene blue staining method
    Cytotoxicity against human HeLa cells by methylene blue staining method
    		[PMID: 15921421]
    HeLa ED50
    0.1 μg/mL
    Compound: doxorubicin
    Cytotoxicity against human HeLa cells after 3 days by MTT assay
    Cytotoxicity against human HeLa cells after 3 days by MTT assay
    		[PMID: 16252910]
    HeLa ED50
    0.22 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells by MTT assay
    Cytotoxicity against human HeLa cells by MTT assay
    		[PMID: 15104488]
    HeLa GI50
    0.01 μM
    Compound: Adriamycin
    In vitro antiproliferative activity against human HeLa cervix cell line
    In vitro antiproliferative activity against human HeLa cervix cell line
    		[PMID: 14971893]
    HeLa GI50
    0.01 μM
    Compound: Adriamycin
    In vitro antiproliferative activity against human HeLa-APL cervix cell line
    In vitro antiproliferative activity against human HeLa-APL cervix cell line
    		[PMID: 14971893]
    HeLa GI50
    0.023 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HeLa cells by SRB assay
    Antiproliferative activity against human HeLa cells by SRB assay
    		[PMID: 31546197]
    HeLa GI50
    0.031 μM
    Compound: Doxorubicin
    Growth inhibition of human HeLa cells after 48 hrs by SRB assay
    Growth inhibition of human HeLa cells after 48 hrs by SRB assay
    		[PMID: 26067381]
    HeLa GI50
    0.05 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
    Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
    		[PMID: 27889456]
    HeLa GI50
    0.05 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells assessed as inhibition of cell growth
    Cytotoxicity against human HeLa cells assessed as inhibition of cell growth
    		[PMID: 33148490]
    HeLa GI50
    0.073 μM
    Compound: Doxorubicin
    Growth inhibition of human HeLa cells after 48 hrs by SRB assay
    Growth inhibition of human HeLa cells after 48 hrs by SRB assay
    		[PMID: 25264072]
    HeLa GI50
    0.073 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HeLa cells assessed as reduction in net protein increase after 48 hrs by SRB assay
    Antiproliferative activity against human HeLa cells assessed as reduction in net protein increase after 48 hrs by SRB assay
    		[PMID: 25462234]
    HeLa GI50
    0.073 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HeLa cells assessed as growth inhibition after 48 hrs by SRB assay
    Antiproliferative activity against human HeLa cells assessed as growth inhibition after 48 hrs by SRB assay
    		[PMID: 27209232]
    HeLa GI50
    0.083 μM
    Compound: Doxorubicin
    Growth inhibition of human HeLa cells after 48 hrs by SRB assay
    Growth inhibition of human HeLa cells after 48 hrs by SRB assay
    		[PMID: 27964883]
    HeLa GI50
    0.09 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HeLa cells after 48 hrs by SRB assay
    Antiproliferative activity against human HeLa cells after 48 hrs by SRB assay
    		[PMID: 26994690]
    HeLa GI50
    0.093 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HeLa cells assessed as growth inhibition after 72 hrs by MTT assay
    Antiproliferative activity against human HeLa cells assessed as growth inhibition after 72 hrs by MTT assay
    		[PMID: 30360625]
    HeLa GI50
    0.3 μM
    Compound: Dox
    Cytotoxicity against human HeLa cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
    Cytotoxicity against human HeLa cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
    		[PMID: 34634616]
    HeLa GI50
    0.33 μM
    Compound: Doxorubicin
    Growth inhibition of Homo sapiens (human) HeLa cells after 48 hr by MTT assay
    Growth inhibition of Homo sapiens (human) HeLa cells after 48 hr by MTT assay
    		10.1007/s00044-012-0232-6
    HeLa GI50
    0.7 μM
    Compound: Dox
    Anticancer activity against human HeLa cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    Anticancer activity against human HeLa cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    		[PMID: 35533562]
    HeLa GI50
    0.76 μM
    Compound: Dox
    Antiproliferative activity against human HeLa cells incubated for 72 hrs and measured by MTT assay
    Antiproliferative activity against human HeLa cells incubated for 72 hrs and measured by MTT assay
    		[PMID: 35973342]
    HeLa GI50
    10.7 μM
    Compound: DOX
    Growth inhibition of human HeLa cells after 48 hrs by SRB assay
    Growth inhibition of human HeLa cells after 48 hrs by SRB assay
    		[PMID: 28433679]
    HeLa GI50
    6.7 μM
    Compound: DOX
    Cytotoxicity against human HeLa cells after 48 hrs by SRB assay
    Cytotoxicity against human HeLa cells after 48 hrs by SRB assay
    		[PMID: 29316526]
    HeLa GI50
    7.51 μM
    Compound: Doxo
    Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
    Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
    		[PMID: 26513642]
    HeLa GI50
    < 0.01 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HeLa cells after 48 hrs by SRB assay
    Antiproliferative activity against human HeLa cells after 48 hrs by SRB assay
    		[PMID: 25827522]
    HeLa GI50
    < 0.1 μM
    Compound: ADR
    Cytotoxicity against human HeLa cells by SRB assay
    Cytotoxicity against human HeLa cells by SRB assay
    		10.1007/s00044-013-0855-2
    HeLa GI50
    < 10 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HeLa cells assessed as cell growth inhibition by SRB assay
    Antiproliferative activity against human HeLa cells assessed as cell growth inhibition by SRB assay
    		[PMID: 37875056]
    HeLa IC50
    0.005 μg
    Compound: doxurubicin
    Compound was tested in vitro for cytotoxicity against HeLa cells.
    Compound was tested in vitro for cytotoxicity against HeLa cells.
    		[PMID: 8709115]
    HeLa IC50
    0.008 mM
    Compound: DOX
    Cytotoxicity against human HeLa cells after 3 days by MTT assay
    Cytotoxicity against human HeLa cells after 3 days by MTT assay
    		[PMID: 22520152]
    HeLa IC50
    0.01 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells assessed as cell survival after 24 hrs by XTT assay
    Cytotoxicity against human HeLa cells assessed as cell survival after 24 hrs by XTT assay
    		[PMID: 25059501]
    HeLa IC50
    0.016 μM
    Compound: DOX
    Antitumor activity against Homo sapiens (human) HeLa cells assessed as inhibition of cell proliferation after 48 hr by SRB assay
    Antitumor activity against Homo sapiens (human) HeLa cells assessed as inhibition of cell proliferation after 48 hr by SRB assay
    		10.1007/s00044-012-0051-9
    HeLa IC50
    0.028 μM
    Compound: adriamycin
    In vitro antiproliferative activity against Hela S3 cells.
    In vitro antiproliferative activity against Hela S3 cells.
    		[PMID: 8151613]
    HeLa IC50
    0.03 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells assessed as reduction in cell growth after 72 hrs by cell titer glo assay
    Cytotoxicity against human HeLa cells assessed as reduction in cell growth after 72 hrs by cell titer glo assay
    		[PMID: 27080175]
    HeLa IC50
    0.03 μM
    Compound: adriamycin
    Inhibition of 10e-2 uM estradiol induced human cancer cell HeLa S3 proliferation
    Inhibition of 10e-2 uM estradiol induced human cancer cell HeLa S3 proliferation
    		[PMID: 8784443]
    HeLa IC50
    0.04 μM
    Compound: DOX
    Antitumor activity against human HeLa cells after 72 hrs by MTT assay
    Antitumor activity against human HeLa cells after 72 hrs by MTT assay
    		[PMID: 17935309]
    HeLa IC50
    0.04 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells by MTT assay
    Cytotoxicity against human HeLa cells by MTT assay
    		[PMID: 19278239]
    HeLa IC50
    0.04 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
    Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
    		[PMID: 20207049]
    HeLa IC50
    0.05 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay
    Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay
    		[PMID: 28257197]
    HeLa IC50
    0.051 μg/mL
    Compound: Doxorubicin
    Antiproliferative activity against human HeLa cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay
    Antiproliferative activity against human HeLa cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay
    		[PMID: 34973507]
    HeLa IC50
    0.053 μM
    Compound: Doxorubicin
    Cytotoxicity against Homo sapiens (human) HeLa cells after 96 hr by MTT assay
    Cytotoxicity against Homo sapiens (human) HeLa cells after 96 hr by MTT assay
    		10.1007/s00044-010-9340-3
    HeLa IC50
    0.06 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay
    Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay
    		[PMID: 22555152]
    HeLa IC50
    0.065 μM
    Compound: DOX
    Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
    Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
    		[PMID: 25259516]
    HeLa IC50
    0.065 μM
    Compound: DOX
    Antiproliferative activity against human HeLa cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay
    Antiproliferative activity against human HeLa cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay
    		[PMID: 31557614]
    HeLa IC50
    0.066 μg/mL
    Compound: adriamycin
    Cytotoxicity against human HeLa cells
    Cytotoxicity against human HeLa cells
    		[PMID: 12762806]
    HeLa IC50
    0.07 μM
    Compound: DOX
    Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
    Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
    		[PMID: 18783950]
    HeLa IC50
    0.07 μM
    Compound: DOX
    Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay
    Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay
    		[PMID: 20359789]
    HeLa IC50
    0.07 μM
    Compound: DOX
    Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay
    Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay
    		[PMID: 24021462]
    HeLa IC50
    0.07 μM
    Compound: DOX
    Cytotoxicity against human HeLa cells assessed as cell growth inhibition after 72 hrs by MTT assay
    Cytotoxicity against human HeLa cells assessed as cell growth inhibition after 72 hrs by MTT assay
    		[PMID: 26720155]
    HeLa IC50
    0.07 μM
    Compound: DOX
    Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay
    Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay
    		[PMID: 28135634]
    HeLa IC50
    0.07 μM
    Compound: DOX
    Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 28427016]
    HeLa IC50
    0.07 μM
    Compound: DOX
    Cytotoxicity against human HeLa cells assessed as inhibition of cell growth after 72 hrs by MTT assay
    Cytotoxicity against human HeLa cells assessed as inhibition of cell growth after 72 hrs by MTT assay
    		[PMID: 30746062]
    HeLa IC50
    0.07 μM
    Compound: DOX
    Antiproliferative activity against human HeLa cells assessed as reduction in cell viability measured after 6 days by MTT assay
    Antiproliferative activity against human HeLa cells assessed as reduction in cell viability measured after 6 days by MTT assay
    		[PMID: 32653698]
    HeLa IC50
    0.07 μM
    Compound: DOX
    Antiproliferative activity against human HeLa cells by MTT colorimetric assay
    Antiproliferative activity against human HeLa cells by MTT colorimetric assay
    		[PMID: 38527380]
    HeLa IC50
    0.07 μM
    Compound: DOX
    Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    		[PMID: 39067378]
    HeLa IC50
    0.07 μM
    Compound: Dox
    Cytotoxicity against human HeLa cells assessed as cell growth inhibition after 72 hrs by MTT assay
    Cytotoxicity against human HeLa cells assessed as cell growth inhibition after 72 hrs by MTT assay
    		[PMID: 27231128]
    HeLa IC50
    0.07 μM
    Compound: Doxorubicin
    Antitumor activity against HeLa cervical carcinoma cells.
    Antitumor activity against HeLa cervical carcinoma cells.
    		[PMID: 12431049]
    HeLa IC50
    0.07 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HeLa cells after 96 hrs by MTT assay
    Antiproliferative activity against human HeLa cells after 96 hrs by MTT assay
    		[PMID: 19053767]
    HeLa IC50
    0.07 μM
    Compound: Doxorubicin
    Cytotoxicity against human Hela cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
    Cytotoxicity against human Hela cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
    		[PMID: 33340938]
    HeLa IC50
    0.07 μM
    Compound: doxo
    Antiproliferative activity against human HeLa cells by MTT assay
    Antiproliferative activity against human HeLa cells by MTT assay
    		[PMID: 16913700]
    HeLa IC50
    0.07 μM
    Compound: doxorubicin
    Antitumor activity against cervix carcinoma Hela cells
    Antitumor activity against cervix carcinoma Hela cells
    		[PMID: 12431048]
    HeLa IC50
    0.09 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 48 hrs by CCK-8 assay
    Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 48 hrs by CCK-8 assay
    		[PMID: 36693198]
    HeLa IC50
    0.1 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 72 hrs by MTT method
    Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 72 hrs by MTT method
    		[PMID: 25932671]
    HeLa IC50
    0.1 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HeLa cells assessed as cell viability after 48 hrs by SRB assay
    Antiproliferative activity against human HeLa cells assessed as cell viability after 48 hrs by SRB assay
    		[PMID: 26947606]
    HeLa IC50
    0.1 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells after 72 hrs by CCK8 assay
    Cytotoxicity against human HeLa cells after 72 hrs by CCK8 assay
    		[PMID: 28398051]
    HeLa IC50
    0.11 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 48 hrs by MTT assay
    		[PMID: 30389295]
    HeLa IC50
    0.13 μM
    Compound: DOX
    Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay
    Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay
    		[PMID: 21496972]
    HeLa IC50
    0.14 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells after 24 hrs by XTT assay
    Cytotoxicity against human HeLa cells after 24 hrs by XTT assay
    		[PMID: 27227682]
    HeLa IC50
    0.14 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells assessed as reduction in cell viability by MTT assay
    Cytotoxicity against human HeLa cells assessed as reduction in cell viability by MTT assay
    		[PMID: 31820973]
    HeLa IC50
    0.154 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
    Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
    		[PMID: 25462279]
    HeLa IC50
    0.16 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
    Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
    		[PMID: 18692939]
    HeLa IC50
    0.163 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
    Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
    		[PMID: 21158422]
    HeLa IC50
    0.19 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells after 72 hrs by XTT assay
    Cytotoxicity against human HeLa cells after 72 hrs by XTT assay
    		[PMID: 19647439]
    HeLa IC50
    0.19 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
    Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
    		[PMID: 22414612]
    HeLa IC50
    0.2 mM
    Compound: Dox
    Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay
    Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay
    		[PMID: 29459273]
    HeLa IC50
    0.2 μM
    Compound: 1; Dox
    Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay
    Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay
    		[PMID: 26633734]
    HeLa IC50
    0.2 μM
    Compound: 2
    Antiproliferative activity against human HeLa cells assessed as growth inhibition after 72 hrs by MTT assay
    Antiproliferative activity against human HeLa cells assessed as growth inhibition after 72 hrs by MTT assay
    		[PMID: 33974416]
    HeLa IC50
    0.2 μM
    Compound: 5
    Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay
    Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay
    		[PMID: 29137865]
    HeLa IC50
    0.2 μM
    Compound: Dox
    Antiproliferative activity in human HeLa cells after 72 hrs by MTT assay
    Antiproliferative activity in human HeLa cells after 72 hrs by MTT assay
    		[PMID: 30268824]
    HeLa IC50
    0.2 μM
    Compound: Dox
    Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
    Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
    		[PMID: 30659997]
    HeLa IC50
    0.2 μM
    Compound: Doxo
    Antiproliferative activity against human HeLa cells assessed as cell viability measured after 4 days by MTT assay
    Antiproliferative activity against human HeLa cells assessed as cell viability measured after 4 days by MTT assay
    		[PMID: 31869654]
    HeLa IC50
    0.2 μM
    Compound: Doxorubicin
    Antitumor activity was evaluated against human cervix carcinoma cell line HeLa.
    Antitumor activity was evaluated against human cervix carcinoma cell line HeLa.
    		[PMID: 10411476]
    HeLa IC50
    0.2 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
    Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
    		[PMID: 19394829]
    HeLa IC50
    0.2 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HeLa cells assessed as cell viability after 72 hrs by MTT assay
    Antiproliferative activity against human HeLa cells assessed as cell viability after 72 hrs by MTT assay
    		[PMID: 24012378]
    HeLa IC50
    0.2 μM
    Compound: Doxorubicin
    Cytotoxicity in human HeLa cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Cytotoxicity in human HeLa cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    		[PMID: 34082225]
    HeLa IC50
    0.21 μM
    Compound: ADM
    Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay
    Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay
    		[PMID: 25529742]
    HeLa IC50
    0.21 μM
    Compound: ADM
    Antiproliferative activity against human HeLa cells assessed as growth inhibition after 72 hrs by MTT assay
    Antiproliferative activity against human HeLa cells assessed as growth inhibition after 72 hrs by MTT assay
    		[PMID: 25984840]
    HeLa IC50
    0.21 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HeLa cells after 72 hrs MTT assay
    Antiproliferative activity against human HeLa cells after 72 hrs MTT assay
    		[PMID: 25247772]
    HeLa IC50
    0.22 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells after 48 hrs by WST8 assay
    Cytotoxicity against human HeLa cells after 48 hrs by WST8 assay
    		[PMID: 25163667]
    HeLa IC50
    0.221 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HeLa cells after 72 hrs by MTT reduction assay
    Antiproliferative activity against human HeLa cells after 72 hrs by MTT reduction assay
    		[PMID: 28551177]
    HeLa IC50
    0.23 μM
    Compound: Doxorubicin
    Anticancer activity against human HeLa cells after 48 hrs by MTT assay
    Anticancer activity against human HeLa cells after 48 hrs by MTT assay
    		[PMID: 21641694]
    HeLa IC50
    0.24 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells incubated for 72 hrs by MTT assay
    Cytotoxicity against human HeLa cells incubated for 72 hrs by MTT assay
    		[PMID: 32040324]
    HeLa IC50
    0.24 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
    Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
    		[PMID: 21708464]
    HeLa IC50
    0.256 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells at 50 uM by MTT reduction assay
    Cytotoxicity against human HeLa cells at 50 uM by MTT reduction assay
    		[PMID: 33276991]
    HeLa IC50
    0.27 μM
    Compound: DX
    Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 48 hrs by CCK-8 method
    Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 48 hrs by CCK-8 method
    		[PMID: 38039788]
    HeLa IC50
    0.29 μM
    Compound: Doxorubicin
    Growth inhibition of human HeLa cells assessed as reduction cell viability incubated for 72 hrs by MTT assay
    Growth inhibition of human HeLa cells assessed as reduction cell viability incubated for 72 hrs by MTT assay
    		[PMID: 39145689]
    HeLa IC50
    0.3 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells after 44 hrs by SRB assay
    Cytotoxicity against human HeLa cells after 44 hrs by SRB assay
    		10.1007/s00044-013-0788-9
    HeLa IC50
    0.3 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells assessed as growth inhibition after 48 hrs by MTT assay
    Cytotoxicity against human HeLa cells assessed as growth inhibition after 48 hrs by MTT assay
    		[PMID: 26972921]
    HeLa IC50
    0.32 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    		[PMID: 28358196]
    HeLa IC50
    0.33 μM
    Compound: Adriamycin
    Concentration required to inhibit growth of human cervical carcinoma (HeLa) cell line
    Concentration required to inhibit growth of human cervical carcinoma (HeLa) cell line
    		[PMID: 15317455]
    HeLa IC50
    0.33 μM
    Compound: DOX
    Antiproliferative activity against human HeLa cells by MTT assay
    Antiproliferative activity against human HeLa cells by MTT assay
    		[PMID: 20171108]
    HeLa IC50
    0.33 μM
    Compound: Doxorubicin
    Antitumor activity against human HeLa cells assessed as inhibition of cell growth by MTT assay
    Antitumor activity against human HeLa cells assessed as inhibition of cell growth by MTT assay
    		[PMID: 25160837]
    HeLa IC50
    0.337 μM
    Compound: Dox
    Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay
    Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay
    		[PMID: 25998504]
    HeLa IC50
    0.339 μg/mL
    Compound: (Doxorubicin) DOX
    Cytotoxicity tested against Hela C1 cells
    Cytotoxicity tested against Hela C1 cells
    		[PMID: 10612603]
    HeLa IC50
    0.34 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HeLa cells after 24 and 72 hrs by MTT assay
    Antiproliferative activity against human HeLa cells after 24 and 72 hrs by MTT assay
    		[PMID: 24941130]
    HeLa IC50
    0.36 μM
    Compound: DOX
    Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
    Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
    		[PMID: 24487188]
    HeLa IC50
    0.36 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells assessed as inhibition of cell viability after 48 hrs by MTT assay
    Cytotoxicity against human HeLa cells assessed as inhibition of cell viability after 48 hrs by MTT assay
    		[PMID: 24953027]
    HeLa IC50
    0.36 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
    Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
    		[PMID: 25453799]
    HeLa IC50
    0.36 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 4 hrs by MTT assay
    Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 4 hrs by MTT assay
    		[PMID: 30773423]
    HeLa IC50
    0.37 μM
    Compound: Doxorubicin
    Anticancer activity against human HeLa cells incubated for 24 hrs by MTT assay
    Anticancer activity against human HeLa cells incubated for 24 hrs by MTT assay
    		[PMID: 28579122]
    HeLa IC50
    0.374 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells
    Cytotoxicity against human HeLa cells
    		[PMID: 34124673]
    HeLa IC50
    0.4 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HeLa cells incubated for 48 hrs by WST8 assay
    Antiproliferative activity against human HeLa cells incubated for 48 hrs by WST8 assay
    		[PMID: 31679979]
    HeLa IC50
    0.41 μM
    Compound: adriamycin
    Cytotoxicity against human HeLa cells after 1 to 11 days by MTT assay
    Cytotoxicity against human HeLa cells after 1 to 11 days by MTT assay
    		[PMID: 19072548]
    HeLa IC50
    0.429 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HeLa cells assessed as reduction in cell viability measured at 48 hrs by MTT assay
    Antiproliferative activity against human HeLa cells assessed as reduction in cell viability measured at 48 hrs by MTT assay
    		[PMID: 36652792]
    HeLa IC50
    0.43 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells after 48 hrs by MTT assay in presence of 10% FBS
    Cytotoxicity against human HeLa cells after 48 hrs by MTT assay in presence of 10% FBS
    		[PMID: 26298501]
    HeLa IC50
    0.45 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells by MTT assay
    Cytotoxicity against human HeLa cells by MTT assay
    		[PMID: 23911578]
    HeLa IC50
    0.45 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells by MTT assay
    Cytotoxicity against human HeLa cells by MTT assay
    		[PMID: 25172420]
    HeLa IC50
    0.45 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells after 48 hrs by MTT assay in absence of 10% FBS
    Cytotoxicity against human HeLa cells after 48 hrs by MTT assay in absence of 10% FBS
    		[PMID: 26298501]
    HeLa IC50
    0.451 μM
    Compound: DOXO
    Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay
    Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay
    		[PMID: 29685681]
    HeLa IC50
    0.451 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells by MTT assay
    Cytotoxicity against human HeLa cells by MTT assay
    		[PMID: 23764302]
    HeLa IC50
    0.451 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells by MTT assay
    Cytotoxicity against human HeLa cells by MTT assay
    		[PMID: 24113366]
    HeLa IC50
    0.47 μM
    Compound: ADM
    Cytotoxicity against human HeLa cells assessed as inhibition of cell growth after 72 hrs by MTT assay
    Cytotoxicity against human HeLa cells assessed as inhibition of cell growth after 72 hrs by MTT assay
    		[PMID: 25089733]
    HeLa IC50
    0.47 μM
    Compound: adriamycin
    Cytotoxicity against human HeLa cells assessed as cell growth inhibition after 72 hrs by MTT assay
    Cytotoxicity against human HeLa cells assessed as cell growth inhibition after 72 hrs by MTT assay
    		[PMID: 26295905]
    HeLa IC50
    0.48 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 46 hrs by MTT assay
    Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 46 hrs by MTT assay
    		[PMID: 29138027]
    HeLa IC50
    0.5 μM
    Compound: ADM
    Cytotoxic activity against human HeLa cells by MTT method
    Cytotoxic activity against human HeLa cells by MTT method
    		[PMID: 25611519]
    HeLa IC50
    0.5 μM
    Compound: ADM
    Cytotoxicity against human HeLa cells by SRB method
    Cytotoxicity against human HeLa cells by SRB method
    		[PMID: 29144133]
    HeLa IC50
    0.5 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 48 hrs by MTT assay
    		[PMID: 29702447]
    HeLa IC50
    0.5 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 24 hrs by CCK8 assay
    Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 24 hrs by CCK8 assay
    		[PMID: 32324401]
    HeLa IC50
    0.5 μM
    Compound: doxorubicin
    Cytotoxicity against human HeLa cells after 72 hrs by MTS assay
    Cytotoxicity against human HeLa cells after 72 hrs by MTS assay
    		[PMID: 25490132]
    HeLa IC50
    0.509 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells assessed as growth inhibition after 2 days by MTT assay
    Cytotoxicity against human HeLa cells assessed as growth inhibition after 2 days by MTT assay
    		[PMID: 23932340]
    HeLa IC50
    0.509 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells by MTT assay
    Cytotoxicity against human HeLa cells by MTT assay
    		[PMID: 24287557]
    HeLa IC50
    0.51 μM
    Compound: Doxorubicin
    In vitro cytotoxicity against human HeLa cells assessed as growth inhibition by MTT assay
    In vitro cytotoxicity against human HeLa cells assessed as growth inhibition by MTT assay
    		[PMID: 24742385]
    HeLa IC50
    0.51 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells assessed as growth inhibition after 48 hrs by MTT assay
    Cytotoxicity against human HeLa cells assessed as growth inhibition after 48 hrs by MTT assay
    		[PMID: 26381063]
    HeLa IC50
    0.52 μM
    Compound: DOX
    Cytotoxicity against human HeLa cells measured after 2 days by MTT assay
    Cytotoxicity against human HeLa cells measured after 2 days by MTT assay
    		[PMID: 26334499]
    HeLa IC50
    0.54 μg/mL
    Compound: Doxorubicin
    Anticancer activity against human HeLa cells by MTT assay
    Anticancer activity against human HeLa cells by MTT assay
    		[PMID: 31404864]
    HeLa IC50
    0.55 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HeLa cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Antiproliferative activity against human HeLa cells assessed as reduction in cell viability after 48 hrs by MTT assay
    		[PMID: 31546197]
    HeLa IC50
    0.59 μM
    Compound: DOX
    Antiproliferative activity against human HeLa cells assessed as inhibition of cell proliferation measured after 48 hrs by CCK-8 assay
    Antiproliferative activity against human HeLa cells assessed as inhibition of cell proliferation measured after 48 hrs by CCK-8 assay
    		[PMID: 34978808]
    HeLa IC50
    0.6 μM
    Compound: DOX
    Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
    Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
    		[PMID: 26386603]
    HeLa IC50
    0.6 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
    Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
    		[PMID: 22749279]
    HeLa IC50
    0.6 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells by MTT assay
    Cytotoxicity against human HeLa cells by MTT assay
    		[PMID: 25241926]
    HeLa IC50
    0.6 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells assessed as cell growth inhibition by MTT assay
    Cytotoxicity against human HeLa cells assessed as cell growth inhibition by MTT assay
    		[PMID: 27187861]
    HeLa IC50
    0.6 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay
    Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay
    		[PMID: 30679134]
    HeLa IC50
    0.606 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay
    Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay
    		[PMID: 28406643]
    HeLa IC50
    0.62 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
    Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
    		[PMID: 19689125]
    HeLa IC50
    0.66 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
    Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
    		[PMID: 30170925]
    HeLa IC50
    0.68 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
    Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
    		[PMID: 18440233]
    HeLa IC50
    0.69 μM
    Compound: Doxorubicin
    Cytotoxicity against p53 repressed human HeLa cells asessed as reduction in cell viability incubated for 24 hrs by MTT assay
    Cytotoxicity against p53 repressed human HeLa cells asessed as reduction in cell viability incubated for 24 hrs by MTT assay
    		[PMID: 31324563]
    HeLa IC50
    0.7 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells by MTT assay
    Cytotoxicity against human HeLa cells by MTT assay
    		[PMID: 25172418]
    HeLa IC50
    0.7 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells incubated for 24 hrs by MTT asasy
    Cytotoxicity against human HeLa cells incubated for 24 hrs by MTT asasy
    		[PMID: 28615134]
    HeLa IC50
    0.71 μM
    Compound: Doxorubicin
    Cytotoxicity against Homo sapiens (human) HeLa cells by MTT assay
    Cytotoxicity against Homo sapiens (human) HeLa cells by MTT assay
    		10.1007/s00044-012-0370-x
    HeLa IC50
    0.71 μM
    Compound: Doxorubicine
    Cytotoxicity against human HeLa cells by MTT assay
    Cytotoxicity against human HeLa cells by MTT assay
    		[PMID: 22014995]
    HeLa IC50
    0.73 μM
    Compound: doxorubicin
    Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
    Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
    		[PMID: 19819703]
    HeLa IC50
    0.78 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay
    Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay
    		[PMID: 27060757]
    HeLa IC50
    0.8 μM
    Compound: Dox
    Antiproliferative activity against human HeLa cells assessed as reduction in cell viability by MTT assay
    Antiproliferative activity against human HeLa cells assessed as reduction in cell viability by MTT assay
    		[PMID: 31765156]
    HeLa IC50
    0.8 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells after 24 hrs by MTT assay
    Cytotoxicity against human HeLa cells after 24 hrs by MTT assay
    		[PMID: 30654238]
    HeLa IC50
    0.82 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells assessed as reduction in cell viability by MTT assay
    Cytotoxicity against human HeLa cells assessed as reduction in cell viability by MTT assay
    		[PMID: 31404864]
    HeLa IC50
    0.834 μM
    Compound: DOX
    Cytotoxicity against human HeLa cells assessed as cell growth inhibition after 48 hrs by MTT assay
    Cytotoxicity against human HeLa cells assessed as cell growth inhibition after 48 hrs by MTT assay
    		[PMID: 26638041]
    HeLa IC50
    0.85 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells assessed as cell viability after 72 hrs by MTT assay
    Cytotoxicity against human HeLa cells assessed as cell viability after 72 hrs by MTT assay
    		[PMID: 23992864]
    HeLa IC50
    0.88 μM
    Compound: adriamycin
    Cytotoxicity against human HeLa cells measured on day 4 by CCK8 assay
    Cytotoxicity against human HeLa cells measured on day 4 by CCK8 assay
    		[PMID: 25936262]
    HeLa IC50
    0.8 μg/mL
    Compound: Adriamycin
    Cytotoxicity against human HeLa cells by MTT assay
    Cytotoxicity against human HeLa cells by MTT assay
    		[PMID: 17918910]
    HeLa IC50
    0.9 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
    Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
    		[PMID: 25462233]
    HeLa IC50
    0.9 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HeLa cells measured after 72 hrs by MTT assay
    Antiproliferative activity against human HeLa cells measured after 72 hrs by MTT assay
    		[PMID: 39021085]
    HeLa IC50
    0.93 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HeLa cells after 24 hrs by MTT assay
    Antiproliferative activity against human HeLa cells after 24 hrs by MTT assay
    		10.1039/C5MD00581G
    HeLa IC50
    0.97 μM
    Compound: Adriamycin
    Cytotoxicity against human HeLa cells by MTT assay
    Cytotoxicity against human HeLa cells by MTT assay
    		[PMID: 24182355]
    HeLa IC50
    0.988 μg/mL
    Compound: (Doxorubicin) DOX
    Cytotoxicity tested against Hela T5 cells
    Cytotoxicity tested against Hela T5 cells
    		[PMID: 10612603]
    HeLa IC50
    1 x 10-8 M
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells assessed as growth inhibition after 72 hrs by XTT assay
    Cytotoxicity against human HeLa cells assessed as growth inhibition after 72 hrs by XTT assay
    		[PMID: 23470139]
    HeLa IC50
    1 μM
    Compound: Adriamycin
    Cytotoxicity against human HeLa cells after 2 days
    Cytotoxicity against human HeLa cells after 2 days
    		[PMID: 21601964]
    HeLa IC50
    1 μM
    Compound: Adriamycin
    Cytotoxicity against human HeLa cells after 2 days by CCK-8 assay
    Cytotoxicity against human HeLa cells after 2 days by CCK-8 assay
    		[PMID: 25481396]
    HeLa IC50
    1 μM
    Compound: Adriamycin
    Cytotoxicity against human HeLa cells by neutral red method
    Cytotoxicity against human HeLa cells by neutral red method
    		[PMID: 26291474]
    HeLa IC50
    1 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay
    Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay
    		[PMID: 19632833]
    HeLa IC50
    1 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells incubated for 48 hrs by MTT assay
    Cytotoxicity against human HeLa cells incubated for 48 hrs by MTT assay
    		[PMID: 33421712]
    HeLa IC50
    1.009 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells after 24 hrs by SRB method
    Cytotoxicity against human HeLa cells after 24 hrs by SRB method
    		[PMID: 18429610]
    HeLa IC50
    1.02 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells by CCK8 assay
    Cytotoxicity against human HeLa cells by CCK8 assay
    		[PMID: 29452840]
    HeLa IC50
    1.07 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    		[PMID: 32866757]
    HeLa IC50
    1.089 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 48 hrs by MTT assay
    		[PMID: 28482219]
    HeLa IC50
    1.107 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HeLa cells assessed as reduction in cell viability incubated for 3 days by MTT assay
    Antiproliferative activity against human HeLa cells assessed as reduction in cell viability incubated for 3 days by MTT assay
    		[PMID: 32707525]
    HeLa IC50
    1.1073 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HeLa cells by MTT assay
    Antiproliferative activity against human HeLa cells by MTT assay
    		[PMID: 31404864]
    HeLa IC50
    1.12 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells after 24 hrs by MTT assay
    Cytotoxicity against human HeLa cells after 24 hrs by MTT assay
    		10.1039/C3MD00013C
    HeLa IC50
    1.12 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells after 24 hrs by MTT assay
    Cytotoxicity against human HeLa cells after 24 hrs by MTT assay
    		[PMID: 22182926]
    HeLa IC50
    1.17 μM
    Compound: DOX
    Cytotoxicity against human HeLa cells assessed as growth inhibition after 48 hrs by MTT assay
    Cytotoxicity against human HeLa cells assessed as growth inhibition after 48 hrs by MTT assay
    		[PMID: 24148837]
    HeLa IC50
    1.17 μM
    Compound: DOX
    Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay
    Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay
    		[PMID: 25619894]
    HeLa IC50
    1.17 μM
    Compound: DOX
    Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth after 48 hrs by MTT assay
    Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth after 48 hrs by MTT assay
    		[PMID: 25737400]
    HeLa IC50
    1.17 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells expressing estrogen receptor after 48 hrs by MTT assay
    Cytotoxicity against human HeLa cells expressing estrogen receptor after 48 hrs by MTT assay
    		10.1039/C2MD20327H
    HeLa IC50
    1.17 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells after 1 hr by SRB assay
    Cytotoxicity against human HeLa cells after 1 hr by SRB assay
    		[PMID: 22770744]
    HeLa IC50
    1.17 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay
    Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay
    		[PMID: 30108986]
    HeLa IC50
    1.2 μM
    Compound: DOX
    Antiproliferative activity against human HeLa cells after 72 hrs by Sulforhodamine B-stain assay
    Antiproliferative activity against human HeLa cells after 72 hrs by Sulforhodamine B-stain assay
    		[PMID: 27484508]
    HeLa IC50
    1.2 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
    Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
    		[PMID: 26398312]
    HeLa IC50
    1.2 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay
    Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay
    		[PMID: 28886509]
    HeLa IC50
    1.2 μM
    Compound: Doxorubicin
    Anticancer activity against human HeLa cells measured after 48 hrs by MTT assay
    Anticancer activity against human HeLa cells measured after 48 hrs by MTT assay
    		[PMID: 33421712]
    HeLa IC50
    1.2 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells by MTT assay
    Cytotoxicity against human HeLa cells by MTT assay
    		[PMID: 33766771]
    HeLa IC50
    1.21 μM
    Compound: Dox
    Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 30615450]
    HeLa IC50
    1.258 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay
    Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay
    		[PMID: 26301558]
    HeLa IC50
    1.28 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells by MTT assay
    Cytotoxicity against human HeLa cells by MTT assay
    		10.1039/C4MD00566J
    HeLa IC50
    1.3 μM
    Compound: Doxorubicin
    Cytotoxic activity against human HeLa cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Cytotoxic activity against human HeLa cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    		[PMID: 25966052]
    HeLa IC50
    1.31 μM
    Compound: Adriamycin
    Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay
    Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay
    		[PMID: 24582982]
    HeLa IC50
    1.43 μM
    Compound: DOX
    Cytotoxicity against human HeLa cells after 48 hrs by SRB method
    Cytotoxicity against human HeLa cells after 48 hrs by SRB method
    		[PMID: 25933593]
    HeLa IC50
    1.44 μM
    Compound: doxo
    Antiproliferative activity against human HeLa cells assessed as decrease in cell viability measured after 72 hrs by MTT assay
    Antiproliferative activity against human HeLa cells assessed as decrease in cell viability measured after 72 hrs by MTT assay
    		[PMID: 30763817]
    HeLa IC50
    1.45 μM
    Compound: Adriamycin
    Cytotoxicity against human HeLa cells after 2 days
    Cytotoxicity against human HeLa cells after 2 days
    		[PMID: 22318164]
    HeLa IC50
    1.5 μM
    Compound: DOX
    Antiproliferative activity against human HeLa cells assessed as growth inhibition after 48 hrs by MTT assay
    Antiproliferative activity against human HeLa cells assessed as growth inhibition after 48 hrs by MTT assay
    		[PMID: 22044164]
    HeLa IC50
    1.5 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay
    Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay
    		[PMID: 24941129]
    HeLa IC50
    1.51 μM
    Compound: Doxorubicin
    Anticancer activity against human HeLa cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Anticancer activity against human HeLa cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    		[PMID: 26330077]
    HeLa IC50
    1.59 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
    Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
    		[PMID: 26948541]
    HeLa IC50
    1.6 x 10-2 μM
    Compound: adriamycin
    Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
    Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
    		[PMID: 19285863]
    HeLa IC50
    1.64 μM
    Compound: Adriamycin
    Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
    Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
    		[PMID: 21534590]
    HeLa IC50
    1.68 μM
    Compound: Dox
    Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay
    Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay
    		[PMID: 26494582]
    HeLa IC50
    1.68 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HeLa cells incubated for 72 hrs by microplate reader analysis
    Antiproliferative activity against human HeLa cells incubated for 72 hrs by microplate reader analysis
    		[PMID: 37418826]
    HeLa IC50
    1.69 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay
    Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay
    		[PMID: 30500683]
    HeLa IC50
    1.7 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HeLa cells
    Antiproliferative activity against human HeLa cells
    		[PMID: 31557608]
    HeLa IC50
    1.73 μM
    Compound: Doxo
    Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay
    Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay
    		[PMID: 29129513]
    HeLa IC50
    1.78 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells assessed as cell growth inhibition after 48 hrs by MTT assay
    Cytotoxicity against human HeLa cells assessed as cell growth inhibition after 48 hrs by MTT assay
    		[PMID: 26708114]
    HeLa IC50
    1.8 μM
    Compound: Doxorubicin
    Anticancer activity against human HeLa cells by MTT assay
    Anticancer activity against human HeLa cells by MTT assay
    		[PMID: 33421712]
    HeLa IC50
    1.8 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells incubated for 24 hrs by MTT reduction assay
    Cytotoxicity against human HeLa cells incubated for 24 hrs by MTT reduction assay
    		[PMID: 33421712]
    HeLa IC50
    1.81 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HeLa cells incubated for 24 hrs by MTT assay
    Antiproliferative activity against human HeLa cells incubated for 24 hrs by MTT assay
    		[PMID: 29409753]
    HeLa IC50
    1.82 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay
    Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay
    		[PMID: 29172084]
    HeLa IC50
    1.862 μM
    Compound: Doxorubicin
    Anti-proliferative activity against human HeLa cells measured after 48 hrs by MTT assay
    Anti-proliferative activity against human HeLa cells measured after 48 hrs by MTT assay
    		[PMID: 27744185]
    HeLa IC50
    1.9 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells
    Cytotoxicity against human HeLa cells
    		[PMID: 33421712]
    HeLa IC50
    1.91 μM
    Compound: II
    Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
    Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
    		[PMID: 29289881]
    HeLa IC50
    1.94 μM
    Compound: DOX
    Antiproliferative activity against human HeLa cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
    Antiproliferative activity against human HeLa cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
    		[PMID: 32631552]
    HeLa IC50
    1.96 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells assessed as inhibition of cell growth and measured after 72 hrs resazurin reduction assay
    Cytotoxicity against human HeLa cells assessed as inhibition of cell growth and measured after 72 hrs resazurin reduction assay
    		[PMID: 36126331]
    HeLa IC50
    1.995 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay
    Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay
    		[PMID: 29501940]
    HeLa IC50
    10.78 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells assessed as cell viability by SRB assay
    Cytotoxicity against human HeLa cells assessed as cell viability by SRB assay
    		[PMID: 26022842]
    HeLa IC50
    10.89 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells
    Cytotoxicity against human HeLa cells
    		[PMID: 24793880]
    HeLa IC50
    11.5 μM
    Compound: Doxo
    Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay
    Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay
    		[PMID: 27597408]
    HeLa IC50
    11.5 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells measured after 24 to 72 hrs by MTT assay
    Cytotoxicity against human HeLa cells measured after 24 to 72 hrs by MTT assay
    		[PMID: 37482018]
    HeLa IC50
    11 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
    Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
    		[PMID: 11473441]
    HeLa IC50
    13.5 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    		[PMID: 37484570]
    HeLa IC50
    13 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
    Cytotoxicity against human HeLa cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
    		[PMID: 35526504]
    HeLa IC50
    14 μM
    Compound: DOX
    Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
    Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
    		[PMID: 31015907]
    HeLa IC50
    19.3 μM
    Compound: Doxorubicin
    Anticancer activity against human HeLa cells assessed as cell growth inhibition
    Anticancer activity against human HeLa cells assessed as cell growth inhibition
    		[PMID: 36577217]
    HeLa IC50
    2 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 48 hrs by MTT assay
    		[PMID: 31938458]
    HeLa IC50
    2 μM
    Compound: adriamycin
    Cytotoxicity against human HeLa cells under deem light after 96 hrs by MTT assay
    Cytotoxicity against human HeLa cells under deem light after 96 hrs by MTT assay
    		[PMID: 17993275]
    HeLa IC50
    2.02 μM
    Compound: Dox
    Cytotoxicity against human HeLa Cells
    Cytotoxicity against human HeLa Cells
    		[PMID: 31129455]
    HeLa IC50
    2.05 μM
    Compound: Doxorubicin
    Growth inhibition of human HeLa cells by MTT assay
    Growth inhibition of human HeLa cells by MTT assay
    		[PMID: 28147307]
    HeLa IC50
    2.089 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 48 hrs by MTT assay
    		[PMID: 28462842]
    HeLa IC50
    2.09 μM
    Compound: DOX
    Cytotoxicity against human HeLa cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay
    Cytotoxicity against human HeLa cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay
    		[PMID: 34700239]
    HeLa IC50
    2.1 μM
    Compound: Doxorubicin
    Anticancer activity against human HeLa cells assessed as growth inhibition incubated for 48 hrs by MTT assay
    Anticancer activity against human HeLa cells assessed as growth inhibition incubated for 48 hrs by MTT assay
    		[PMID: 34363936]
    HeLa IC50
    2.2 μM
    Compound: DOX
    Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
    Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
    		[PMID: 23218718]
    HeLa IC50
    2.23 μM
    Compound: DOX
    Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 24 hrs by MTT assay
    Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 24 hrs by MTT assay
    		[PMID: 29421568]
    HeLa IC50
    2.29 μM
    Compound: Doxorubicin
    Anticancer activity against human HeLa cells after 48 hrs by MTT assay
    Anticancer activity against human HeLa cells after 48 hrs by MTT assay
    		[PMID: 25615796]
    HeLa IC50
    2.3 μM
    Compound: DOX
    Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 48 hrs by Alamar blue staining based fluorescence assay
    Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 48 hrs by Alamar blue staining based fluorescence assay
    		[PMID: 28291684]
    HeLa IC50
    2.33 μM
    Compound: DOX
    Anticancer activity against human HeLa cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay
    Anticancer activity against human HeLa cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay
    		[PMID: 38784465]
    HeLa IC50
    2.45 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells treated for 72 hrs by MTT assay
    Cytotoxicity against human HeLa cells treated for 72 hrs by MTT assay
    		[PMID: 35344904]
    HeLa IC50
    2.57 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells assessed as cell viability after 48 hrs by MTT assay
    Cytotoxicity against human HeLa cells assessed as cell viability after 48 hrs by MTT assay
    		[PMID: 27015609]
    HeLa IC50
    2.63 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
    Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
    		[PMID: 26264845]
    HeLa IC50
    2.684 μg/mL
    Compound: ADM
    Cytotoxicity against human HeLa cells by MTT assay
    Cytotoxicity against human HeLa cells by MTT assay
    		[PMID: 25862199]
    HeLa IC50
    2.78 μM
    Compound: DOX
    Antiproliferative activity against human HeLa cells assessed as cell growth inhibition by MTT assay
    Antiproliferative activity against human HeLa cells assessed as cell growth inhibition by MTT assay
    		[PMID: 32631524]
    HeLa IC50
    2.9 x 10-7 M
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells after 72 hrs by XTT assay
    Cytotoxicity against human HeLa cells after 72 hrs by XTT assay
    		[PMID: 20619940]
    HeLa IC50
    20.93 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
    Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
    		[PMID: 22818039]
    HeLa IC50
    20.95 μM
    Compound: Dox
    Antiproliferative activity against human HeLa cells incubated for 48 hrs by MTT assay
    Antiproliferative activity against human HeLa cells incubated for 48 hrs by MTT assay
    		[PMID: 38990190]
    HeLa IC50
    21.9 μM
    Compound: DXR
    Cytotoxicity against human HeLa cells assessed as cell growth inhibition after 24 hrs by XTT assay
    Cytotoxicity against human HeLa cells assessed as cell growth inhibition after 24 hrs by XTT assay
    		[PMID: 26649907]
    HeLa IC50
    3 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells assessed as reduction in cell viability by DAPI staining based assay
    Cytotoxicity against human HeLa cells assessed as reduction in cell viability by DAPI staining based assay
    		[PMID: 33461146]
    HeLa IC50
    3.09 μM
    Compound: adriamycin
    Cytotoxicity against human HeLa cells
    Cytotoxicity against human HeLa cells
    		[PMID: 18178085]
    HeLa IC50
    3.24 μM
    Compound: DOX
    Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth incubated for 48 hrs by sulphorhodamine-B assay
    Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth incubated for 48 hrs by sulphorhodamine-B assay
    		[PMID: 38810335]
    HeLa IC50
    3.24 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa after 24 hrs by MTT assay
    Cytotoxicity against human HeLa after 24 hrs by MTT assay
    		[PMID: 20056520]
    HeLa IC50
    3.24 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells after 24 hrs by MTT assay
    Cytotoxicity against human HeLa cells after 24 hrs by MTT assay
    		[PMID: 23835482]
    HeLa IC50
    3.24 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells after 24 hrs incubation by MTT assay
    Cytotoxicity against human HeLa cells after 24 hrs incubation by MTT assay
    		[PMID: 24856067]
    HeLa IC50
    3.24 μM
    Compound: doxorubicin
    Cytotoxicity against human HeLa cells after 24 hrs by MTT assay
    Cytotoxicity against human HeLa cells after 24 hrs by MTT assay
    		[PMID: 19128861]
    HeLa IC50
    3.3 μM
    Compound: DOX
    Inhibition of topoisomerase 2 in human HeLa cells assessed as reduction in cell growth measured after 72 hrs by MTT assay
    Inhibition of topoisomerase 2 in human HeLa cells assessed as reduction in cell growth measured after 72 hrs by MTT assay
    		[PMID: 30846253]
    HeLa IC50
    3.3 μM
    Compound: adriamycin
    Cytotoxicity against human HeLa cells after 4 days by MTT assay
    Cytotoxicity against human HeLa cells after 4 days by MTT assay
    		[PMID: 17194586]
    HeLa IC50
    3.33 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HeLa cells assessed as reduction in cell viability measured at 24 hrs by MTT assay
    Antiproliferative activity against human HeLa cells assessed as reduction in cell viability measured at 24 hrs by MTT assay
    		[PMID: 36652792]
    HeLa IC50
    3.55 μM
    Compound: DOX
    Antineoplastic activity against human HeLa cells measured after 36 hrs by MTT assay
    Antineoplastic activity against human HeLa cells measured after 36 hrs by MTT assay
    		[PMID: 30746067]
    HeLa IC50
    3.57 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells assessed as cell viability after 48 hrs by MTT assay
    Cytotoxicity against human HeLa cells assessed as cell viability after 48 hrs by MTT assay
    		[PMID: 25594739]
    HeLa IC50
    3.64 μg/mL
    Compound: DOX
    Antitumor activity against human HeLa cells after 48 hrs by MTT assay
    Antitumor activity against human HeLa cells after 48 hrs by MTT assay
    		[PMID: 20599299]
    HeLa IC50
    3.7 μM
    Compound: Adriamycin
    Cytotoxicity against human HeLa cells after 4 days by MTT assay
    Cytotoxicity against human HeLa cells after 4 days by MTT assay
    		[PMID: 21704436]
    HeLa IC50
    3.9 μM
    Compound: doxorubicin
    Cytotoxicity against human HeLa cells assessed as growth inhibition measured after 48 hrs by XTT assay
    Cytotoxicity against human HeLa cells assessed as growth inhibition measured after 48 hrs by XTT assay
    		[PMID: 23547843]
    HeLa IC50
    3.92 μM
    Compound: Doxorubicin
    Anticancer activity against human HeLa cells assessed as cell viability after 48 hrs by MTT assay
    Anticancer activity against human HeLa cells assessed as cell viability after 48 hrs by MTT assay
    		[PMID: 26542964]
    HeLa IC50
    3.97 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 24 hrs by MTT assay
    Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 24 hrs by MTT assay
    		[PMID: 31404864]
    HeLa IC50
    3.99 μM
    Compound: AMD
    Antiproliferative activity against human HeLa cells measured after 48 hrs by MTT assay
    Antiproliferative activity against human HeLa cells measured after 48 hrs by MTT assay
    		[PMID: 27639364]
    HeLa IC50
    30.21 μM
    Compound: Doxorubicin
    Anticancer activity against human HeLa cells after 48 hrs by SRB assay
    Anticancer activity against human HeLa cells after 48 hrs by SRB assay
    		[PMID: 24077528]
    HeLa IC50
    37 nM
    Compound: doxorubicin
    Cytotoxicity against human HeLa cells after 48 hrs by WST8 assay
    Cytotoxicity against human HeLa cells after 48 hrs by WST8 assay
    		[PMID: 20180542]
    HeLa IC50
    4 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 48 hrs by neutral red dye-based assay
    Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 48 hrs by neutral red dye-based assay
    		[PMID: 27618204]
    HeLa IC50
    4.1 μM
    Compound: doxorubicin
    Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
    Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
    		[PMID: 23748152]
    HeLa IC50
    4.16 nM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells assessed as cell viability after 5 days by cell viability analyzer
    Cytotoxicity against human HeLa cells assessed as cell viability after 5 days by cell viability analyzer
    		[PMID: 26291039]
    HeLa IC50
    4.17 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HeLa cells measured after 24 hrs by MTT assay
    Antiproliferative activity against human HeLa cells measured after 24 hrs by MTT assay
    		[PMID: 37875056]
    HeLa IC50
    4.19 μg/mL
    Compound: Doxorubicin
    Antitumor activity against human HeLa cells
    Antitumor activity against human HeLa cells
    		[PMID: 20739102]
    HeLa IC50
    4.25 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells
    Cytotoxicity against human HeLa cells
    		[PMID: 32932211]
    HeLa IC50
    4.61 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay
    Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay
    		[PMID: 35367708]
    HeLa IC50
    4.8 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 48 hrs by MTT assay
    		[PMID: 28254167]
    HeLa IC50
    5 nM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells
    Cytotoxicity against human HeLa cells
    		[PMID: 31926469]
    HeLa IC50
    5 μM
    Compound: ADM
    Cytotoxicity against human HeLa cells
    Cytotoxicity against human HeLa cells
    		[PMID: 22283451]
    HeLa IC50
    5 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
    Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
    		[PMID: 27173802]
    HeLa IC50
    5.1 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells assessed as reduction in cell population to half by MTT assay
    Cytotoxicity against human HeLa cells assessed as reduction in cell population to half by MTT assay
    		[PMID: 37839713]
    HeLa IC50
    5.17 μM
    Compound: Doxorubicin
    Antitumor activity against human HeLa cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay
    Antitumor activity against human HeLa cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay
    		[PMID: 30138804]
    HeLa IC50
    5.2 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells after 24 hrs by MTT assay
    Cytotoxicity against human HeLa cells after 24 hrs by MTT assay
    		[PMID: 26252628]
    HeLa IC50
    5.2 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells after 24 hrs by MTT assay
    Cytotoxicity against human HeLa cells after 24 hrs by MTT assay
    		[PMID: 27769619]
    HeLa IC50
    5.23 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
    Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
    		[PMID: 29573910]
    HeLa IC50
    5.3 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
    Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
    		[PMID: 22304344]
    HeLa IC50
    5.3 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HeLa cells incubated for 48 hrs by MTT assay
    Antiproliferative activity against human HeLa cells incubated for 48 hrs by MTT assay
    		[PMID: 38442524]
    HeLa IC50
    5.57 μM
    Compound: DOX
    Antiproliferative activity against human HeLa cells by MTT assay
    Antiproliferative activity against human HeLa cells by MTT assay
    		[PMID: 30216848]
    HeLa IC50
    5.57 μM
    Compound: DOX
    Anticancer activity against human HeLa cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay
    Anticancer activity against human HeLa cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay
    		[PMID: 32085964]
    HeLa IC50
    5.57 μM
    Compound: DOX
    Antiproliferative activity against human HeLa cells assessed as reduction in cell growth
    Antiproliferative activity against human HeLa cells assessed as reduction in cell growth
    		[PMID: 33388654]
    HeLa IC50
    5.57 μM
    Compound: DOX
    Cytotoxicity against human HeLa cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay
    Cytotoxicity against human HeLa cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay
    		[PMID: 36242988]
    HeLa IC50
    5.57 μM
    Compound: DOX
    Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay
    Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay
    		[PMID: 37054758]
    HeLa IC50
    5.57 μM
    Compound: Dox
    Antiproliferative activity against human HeLa cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Antiproliferative activity against human HeLa cells assessed as reduction in cell viability after 48 hrs by MTT assay
    		[PMID: 32527460]
    HeLa IC50
    5.57 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells assessed as decrease in cell viability after 48 hrs by MTT assay
    Cytotoxicity against human HeLa cells assessed as decrease in cell viability after 48 hrs by MTT assay
    		[PMID: 29702448]
    HeLa IC50
    5.57 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HeLa after 24 hrs by MTT assay
    Antiproliferative activity against human HeLa after 24 hrs by MTT assay
    		[PMID: 30826188]
    HeLa IC50
    5.7 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells assessed as reduction in cell viability preincubated for 24 hrs measured after 4 hrs by MTT assay
    Cytotoxicity against human HeLa cells assessed as reduction in cell viability preincubated for 24 hrs measured after 4 hrs by MTT assay
    		[PMID: 34223162]
    HeLa IC50
    50 μM
    Compound: Doxorubicin
    TP_TRANSPORTER: inhibition of E217betaG uptake (E217betaG: 0.05 uM) in membrane vesicle from MRP1-expressing HeLa cells
    TP_TRANSPORTER: inhibition of E217betaG uptake (E217betaG: 0.05 uM) in membrane vesicle from MRP1-expressing HeLa cells
    		[PMID: 8621644]
    HeLa IC50
    55 nM
    Compound: doxorubicin
    Cytotoxicity against human HeLa cells after 120 hrs by WST8 assay
    Cytotoxicity against human HeLa cells after 120 hrs by WST8 assay
    		[PMID: 20180542]
    HeLa IC50
    57.8 μM
    Compound: DOX
    Antitumor activity against human HeLa cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    Antitumor activity against human HeLa cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    		[PMID: 35859879]
    HeLa IC50
    5 mM
    Compound: Adriamycin
    Cytotoxicity against human HeLa cells after 24 hrs by MTT assay
    Cytotoxicity against human HeLa cells after 24 hrs by MTT assay
    		[PMID: 23685942]
    HeLa IC50
    6 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay
    Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay
    		[PMID: 25453802]
    HeLa IC50
    6.3 μM
    Compound: ADR
    Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
    Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
    		10.1039/C2MD20270K
    HeLa IC50
    6.3 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay
    Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay
    		[PMID: 30660827]
    HeLa IC50
    6.94 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
    Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
    		[PMID: 24607876]
    HeLa IC50
    7.01 μM
    Compound: Doxo
    Cytotoxicity against human HeLa cells measured after 24 hrs by MTT assay
    Cytotoxicity against human HeLa cells measured after 24 hrs by MTT assay
    		[PMID: 31104996]
    HeLa IC50
    7.04 μM
    Compound: DOX
    Anticancer activity against human HeLa cells assessed as inhibition of tumor cell proliferation after 48 hrs by MTT assay
    Anticancer activity against human HeLa cells assessed as inhibition of tumor cell proliferation after 48 hrs by MTT assay
    		[PMID: 25064350]
    HeLa IC50
    7.18 μM
    Compound: Dox
    Cytotoxicity against human HeLa cells assessed as decrease in cell viability treated for 2 hrs measured after 48 hrs by MTT assay
    Cytotoxicity against human HeLa cells assessed as decrease in cell viability treated for 2 hrs measured after 48 hrs by MTT assay
    		[PMID: 28129977]
    HeLa IC50
    7.2 μM
    Compound: DX
    Cytotoxicity against human HeLa cells after 48 hrs by sulforhodamine B assay
    Cytotoxicity against human HeLa cells after 48 hrs by sulforhodamine B assay
    		10.1039/C5MD00513B
    HeLa IC50
    7.4 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells assessed as cell growth inhibition measured after 24 hrs by MTT assay
    Cytotoxicity against human HeLa cells assessed as cell growth inhibition measured after 24 hrs by MTT assay
    		[PMID: 35526504]
    HeLa IC50
    7.71 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells after 48 hrs by SRB assay
    Cytotoxicity against human HeLa cells after 48 hrs by SRB assay
    		[PMID: 23994327]
    HeLa IC50
    7.9 μM
    Compound: DOX
    Cytotoxicity against human HeLa cells assessed as cell growth inhibition measured after 24 hrs by MTT assay
    Cytotoxicity against human HeLa cells assessed as cell growth inhibition measured after 24 hrs by MTT assay
    		[PMID: 31589431]
    HeLa IC50
    71 nM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 96 hrs by MTT assay
    Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 96 hrs by MTT assay
    		[PMID: 28600080]
    HeLa IC50
    780 nM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
    Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
    		[PMID: 30172625]
    HeLa IC50
    8.1 μM
    Compound: Doxorubicin
    Anticancer activity against human HeLa cells assessed as inhibition of cell proliferation measured after 24 hrs by MTT based microplate ELISA reader analysis
    Anticancer activity against human HeLa cells assessed as inhibition of cell proliferation measured after 24 hrs by MTT based microplate ELISA reader analysis
    		[PMID: 34438126]
    HeLa IC50
    8.3 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 24 hrs by trypan blue-based hemacytometer counting analysis
    Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 24 hrs by trypan blue-based hemacytometer counting analysis
    		[PMID: 28756265]
    HeLa IC50
    8.66 μM
    Compound: DOX
    Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay
    Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay
    		[PMID: 30398868]
    HeLa IC50
    8.72 μg/mL
    Compound: DOX
    Cytotoxicity against human HeLa cells after 48 hrs by SRB assay
    Cytotoxicity against human HeLa cells after 48 hrs by SRB assay
    		[PMID: 19932530]
    HeLa IC50
    8.87 μM
    Compound: DOX
    Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay
    Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay
    		[PMID: 35964425]
    HeLa IC50
    8.96 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells by WST-8 assay
    Cytotoxicity against human HeLa cells by WST-8 assay
    		[PMID: 29295796]
    HeLa IC50
    9.03 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells by MTT assay
    Cytotoxicity against human HeLa cells by MTT assay
    		[PMID: 26873414]
    HeLa IC50
    9.76 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HeLa cells assessed as reduction in cell viability by MTT assay
    Antiproliferative activity against human HeLa cells assessed as reduction in cell viability by MTT assay
    		[PMID: 37859725]
    HeLa IC50
    90 nM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    		[PMID: 35059132]
    HeLa IC50
    < 0.01 μM
    Compound: DOX
    Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth incubated for 48 hrs by CellTiter 96 Aqueous One Solution Cell Proliferation Assay
    Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth incubated for 48 hrs by CellTiter 96 Aqueous One Solution Cell Proliferation Assay
    		[PMID: 38626522]
    HeLa IC50
    < 1 μM
    Compound: Doxorubicin
    Cytotoxicity against Homo sapiens (human) HeLa cells after 48 hr by MTT assay
    Cytotoxicity against Homo sapiens (human) HeLa cells after 48 hr by MTT assay
    		10.1007/s00044-011-9884-x
    HeLa IC50
    < 1 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells by MTT assay
    Cytotoxicity against human HeLa cells by MTT assay
    		[PMID: 21996519]
    HeLa IC50
    < 1 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells by MTT assay
    Cytotoxicity against human HeLa cells by MTT assay
    		[PMID: 23079527]
    HeLa IC50
    > 1 μM
    Compound: Doxorubicin
    Cytotoxicity against oleic acid-induced human HeLa cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    Cytotoxicity against oleic acid-induced human HeLa cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    		[PMID: 35059132]
    HeLa IC50
    > 200 μM
    Compound: Doxorubicin
    Inhibition topoisomerase 1 in human HeLa cells assessed as conversion of supercoiled pBR322 DNA to relaxed form
    Inhibition topoisomerase 1 in human HeLa cells assessed as conversion of supercoiled pBR322 DNA to relaxed form
    		[PMID: 11430001]
    HeLa S3 IC50
    0.03 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLaS3 cells after 48 hrs by MTT assay
    Cytotoxicity against human HeLaS3 cells after 48 hrs by MTT assay
    		[PMID: 26963142]
    HeLa S3 IC50
    0.03 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLaS3 cells by MTT assay
    Cytotoxicity against human HeLaS3 cells by MTT assay
    		[PMID: 30719909]
    HeLa S3 IC50
    0.12 μM
    Compound: Doxorubicin
    Cytotoxicity in human HeLaS3 cells incubated for 72 hrs by MTT assay
    Cytotoxicity in human HeLaS3 cells incubated for 72 hrs by MTT assay
    		[PMID: 30978023]
    HeLa S3 IC50
    0.15 μM
    Compound: Doxorubicin
    Cytotoxicity activity against human HeLa S3 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity activity against human HeLa S3 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 32627543]
    HeLa S3 IC50
    < 0.1 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HeLaS3 cells by MTT assay
    Antiproliferative activity against human HeLaS3 cells by MTT assay
    		[PMID: 29072457]
    HeLa S3 IC50
    < 40 μM
    Compound: Doxorubicin
    Antiproliferative activity against drug-sensitive human HeLaS3 cells assessed as cell growth inhibition incubated for 72 hrs by SRB assay
    Antiproliferative activity against drug-sensitive human HeLaS3 cells assessed as cell growth inhibition incubated for 72 hrs by SRB assay
    		[PMID: 35751979]
    Hep 3B2 EC50
    5.6 μM
    Compound: doxorubicin
    Cytotoxicity against human Hep3B cells deficient in p53 gene by MTT assay
    Cytotoxicity against human Hep3B cells deficient in p53 gene by MTT assay
    		[PMID: 20455578]
    Hep 3B2 IC50
    0.025 μM
    Compound: DOX
    Antiproliferative activity against human Hep3B cells assessed as inhibition of cell growth incubated for 48 hrs by CellTiter 96 Aqueous One Solution Cell Proliferation Assay
    Antiproliferative activity against human Hep3B cells assessed as inhibition of cell growth incubated for 48 hrs by CellTiter 96 Aqueous One Solution Cell Proliferation Assay
    		[PMID: 38626522]
    Hep 3B2 IC50
    0.06 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human Hep3B cells
    Cytotoxicity against human Hep3B cells
    		[PMID: 17970595]
    Hep 3B2 IC50
    0.14 μM
    Compound: Doxorubucin
    Cytotoxicity against human Hep3B cells by MTT assay
    Cytotoxicity against human Hep3B cells by MTT assay
    		[PMID: 20718475]
    Hep 3B2 IC50
    0.24 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human Hep3B cells
    Cytotoxicity against human Hep3B cells
    		[PMID: 23511021]
    Hep 3B2 IC50
    0.26 μM
    Compound: Doxorubicin
    Anticancer activity against human Hep3B cells measured after 48 hrs
    Anticancer activity against human Hep3B cells measured after 48 hrs
    		[PMID: 38665827]
    Hep 3B2 IC50
    0.27 μM
    Compound: Doxorubicin
    Cytotoxicity against human Hep3B cells
    Cytotoxicity against human Hep3B cells
    		[PMID: 34655985]
    Hep 3B2 IC50
    0.27 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human Hep3B cells by MTT assay
    Cytotoxicity against human Hep3B cells by MTT assay
    		[PMID: 18590313]
    Hep 3B2 IC50
    0.29 μM
    Compound: DOX
    Cytotoxicity against human Hep3B cells measured after 48 hrs by MTT assay
    Cytotoxicity against human Hep3B cells measured after 48 hrs by MTT assay
    		[PMID: 23290052]
    Hep 3B2 IC50
    0.2 μg/mL
    Compound: doxorubicin
    Cytotoxicity against human Hep3B cells by MTT assay
    Cytotoxicity against human Hep3B cells by MTT assay
    		[PMID: 18973388]
    Hep 3B2 IC50
    0.31 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human Hep3B cells after 3 days by MTT assay
    Cytotoxicity against human Hep3B cells after 3 days by MTT assay
    		[PMID: 15387653]
    Hep 3B2 IC50
    0.41 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human Hep3B cells after 3 days by MTT assay
    Cytotoxicity against human Hep3B cells after 3 days by MTT assay
    		[PMID: 19691312]
    Hep 3B2 IC50
    0.42 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human Hep3B cells by MTT assay
    Cytotoxicity against human Hep3B cells by MTT assay
    		[PMID: 21106454]
    Hep 3B2 IC50
    0.45 μg/mL
    Compound: doxo
    Cytotoxicity against human Hep3B cells by MTT method
    Cytotoxicity against human Hep3B cells by MTT method
    		[PMID: 17417907]
    Hep 3B2 IC50
    0.48 μM
    Compound: Doxorubicin
    Cytotoxicity against human Hep3B cells after 3 days by MTT assay
    Cytotoxicity against human Hep3B cells after 3 days by MTT assay
    		[PMID: 18547115]
    Hep 3B2 IC50
    0.56 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human Hep3B cells
    Cytotoxicity against human Hep3B cells
    		[PMID: 20036537]
    Hep 3B2 IC50
    0.59 μM
    Compound: doxorubicin
    Cytotoxicity against human Hep3B cells after 3 days by MTT assay
    Cytotoxicity against human Hep3B cells after 3 days by MTT assay
    		[PMID: 18419154]
    Hep 3B2 IC50
    0.6 μM
    Compound: Doxo
    Cytotoxicity against human Hep3B cells after 72 hrs by MTT assay
    Cytotoxicity against human Hep3B cells after 72 hrs by MTT assay
    		[PMID: 20334960]
    Hep 3B2 IC50
    0.62 μM
    Compound: doxorubicin
    Cytotoxicity against human Hep3B cells after 72 hrs by MTT colorimetric method
    Cytotoxicity against human Hep3B cells after 72 hrs by MTT colorimetric method
    		[PMID: 17622129]
    Hep 3B2 IC50
    0.7 μM
    Compound: Doxorubicin
    Cytotoxicity against human Hep3B cells by MTT assay
    Cytotoxicity against human Hep3B cells by MTT assay
    		[PMID: 21425785]
    Hep 3B2 IC50
    1.02 μM
    Compound: Doxorubicin
    Cytotoxicity against human Hep3B cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
    Cytotoxicity against human Hep3B cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
    		[PMID: 34838335]
    Hep 3B2 IC50
    1.03 μM
    Compound: Doxo
    Cytotoxicity against human Hep3B cells after 3 days by MTT assay
    Cytotoxicity against human Hep3B cells after 3 days by MTT assay
    		[PMID: 21800859]
    Hep 3B2 IC50
    1.15 μM
    Compound: Dox
    Cytotoxicity against human Hep3B cells by MTT assay
    Cytotoxicity against human Hep3B cells by MTT assay
    		[PMID: 28262527]
    Hep 3B2 IC50
    1.31 μg/mL
    Compound: doxorubicin
    Cytotoxicity against human Hep3B cells by MTT assay
    Cytotoxicity against human Hep3B cells by MTT assay
    		[PMID: 22413887]
    Hep 3B2 IC50
    1.57 μM
    Compound: Doxo
    Cytotoxicity against human Hep3B cells
    Cytotoxicity against human Hep3B cells
    		[PMID: 21784631]
    Hep 3B2 IC50
    1.8 μM
    Compound: Doxorubicin
    Cytotoxicity against human Hep3B cells assessed as reduction in cell viability by MTT assay
    Cytotoxicity against human Hep3B cells assessed as reduction in cell viability by MTT assay
    		[PMID: 30660827]
    Hep 3B2 IC50
    13.25 μM
    Compound: Dox
    Antiproliferative activity against human Hep3B cells for 24 hrs by MTT assay
    Antiproliferative activity against human Hep3B cells for 24 hrs by MTT assay
    		[PMID: 24929289]
    Hep 3B2 IC50
    16 μM
    Compound: DOX
    Cytotoxicity against human Hep3B cells measured after 72 hrs by Celltiter-Glo assay
    Cytotoxicity against human Hep3B cells measured after 72 hrs by Celltiter-Glo assay
    		[PMID: 31820976]
    Hep 3B2 IC50
    2.4 μM
    Compound: Doxorubicin
    Growth inhibition of human Hep3B cells by MTT assay
    Growth inhibition of human Hep3B cells by MTT assay
    		[PMID: 28916158]
    Hep 3B2 IC50
    2.6 μM
    Compound: Doxorubicin
    Cytotoxicity against human Hep3B cells assessed as reduction in cell viability
    Cytotoxicity against human Hep3B cells assessed as reduction in cell viability
    		[PMID: 30660827]
    Hep 3B2 IC50
    4.5 μM
    Compound: Dox
    Cytotoxicity against human Hep3B cells after 48 hrs by MTT assay
    Cytotoxicity against human Hep3B cells after 48 hrs by MTT assay
    		[PMID: 28865276]
    Hep 3B2 IC50
    7.21 μM
    Compound: Doxorubicin
    Antiproliferative activity against human Hep3B cells assessed as growth inhibition
    Antiproliferative activity against human Hep3B cells assessed as growth inhibition
    		[PMID: 33744442]
    HepG2 CC50
    0.02 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells incubated for 72 hrs by MTT assay
    Cytotoxicity against human HepG2 cells incubated for 72 hrs by MTT assay
    		[PMID: 25282267]
    HepG2 CC50
    0.06 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 24 hrs by MTT assay
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 24 hrs by MTT assay
    		[PMID: 32088496]
    HepG2 CC50
    0.2 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
    Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
    		[PMID: 21741131]
    HepG2 CC50
    0.2 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
    Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
    		[PMID: 21852132]
    HepG2 CC50
    0.2 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
    Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
    		[PMID: 22608675]
    HepG2 CC50
    0.2 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
    Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
    		[PMID: 22889559]
    HepG2 CC50
    0.2 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
    Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
    		[PMID: 24080103]
    HepG2 CC50
    0.2 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    		[PMID: 25559208]
    HepG2 CC50
    0.2 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells assessed as cell viability after 72 hrs by MTT assay
    Cytotoxicity against human HepG2 cells assessed as cell viability after 72 hrs by MTT assay
    		[PMID: 25791675]
    HepG2 CC50
    0.2 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
    Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
    		[PMID: 25846065]
    HepG2 CC50
    0.2 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells measured after 72 hrs by MTT assay
    Cytotoxicity against human HepG2 cells measured after 72 hrs by MTT assay
    		[PMID: 27155463]
    HepG2 CC50
    0.2 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 27654395]
    HepG2 CC50
    0.2 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells assessed as decrease in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human HepG2 cells assessed as decrease in cell viability after 72 hrs by MTT assay
    		[PMID: 29885575]
    HepG2 CC50
    0.2 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 30092366]
    HepG2 CC50
    0.2 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
    Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
    		[PMID: 30655943]
    HepG2 CC50
    0.2 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells
    Cytotoxicity against human HepG2 cells
    		[PMID: 31926469]
    HepG2 CC50
    0.2 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    		[PMID: 32292551]
    HepG2 CC50
    0.2 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 32652409]
    HepG2 CC50
    0.2 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 32795774]
    HepG2 CC50
    0.2 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
    		[PMID: 34364164]
    HepG2 CC50
    0.2 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells incubated for 72 hrs by MTT assay
    Cytotoxicity against human HepG2 cells incubated for 72 hrs by MTT assay
    		[PMID: 38452406]
    HepG2 CC50
    0.2 μM
    Compound: Doxorubicine
    Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
    Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
    		[PMID: 24946216]
    HepG2 CC50
    0.77 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 120 hrs by MTS assay
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 120 hrs by MTS assay
    		[PMID: 32590115]
    HepG2 CC50
    1.8 μM
    Compound: Dox
    Cytotoxicity against human HepG2 cells incubated for 72 hrs by MTT assay
    Cytotoxicity against human HepG2 cells incubated for 72 hrs by MTT assay
    		[PMID: 39079310]
    HepG2 CC50
    1.95 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
    Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
    		[PMID: 29792325]
    HepG2 CC50
    11.2 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HepG2 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
    		[PMID: 37944413]
    HepG2 EC50
    0.3 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells after 96 hrs by MTT assay
    Cytotoxicity against human HepG2 cells after 96 hrs by MTT assay
    		[PMID: 26320088]
    HepG2 EC50
    0.67 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay
    Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay
    		[PMID: 35567964]
    HepG2 EC50
    6.1 μM
    Compound: doxorubicin
    Cytotoxicity against human HepG2 cells expressing wild type p53 gene by MTT assay
    Cytotoxicity against human HepG2 cells expressing wild type p53 gene by MTT assay
    		[PMID: 20455578]
    HepG2 EC50
    > 10 μM
    Compound: doxorubicin
    Cytotoxicity against doxorubicin resistant human HepG2 cells expressing wild type p53 gene by MTT assay
    Cytotoxicity against doxorubicin resistant human HepG2 cells expressing wild type p53 gene by MTT assay
    		[PMID: 20455578]
    HepG2 ED50
    102 μM
    Compound: doxorubicin
    Antitumor activity against human HepG2 cells after 24 hrs by MTT assay
    Antitumor activity against human HepG2 cells after 24 hrs by MTT assay
    		[PMID: 17482824]
    HepG2 GI50
    0.01 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
    Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
    		[PMID: 27889456]
    HepG2 GI50
    0.04 μM
    Compound: Dox
    Growth inhibition of human HepG2 cells by MTT assay
    Growth inhibition of human HepG2 cells by MTT assay
    		[PMID: 31330449]
    HepG2 GI50
    0.19 μM
    Compound: DOX
    Cytotoxicity against human HepG2 cells assessed as growth inhibition after 72 hrs by MTT assay
    Cytotoxicity against human HepG2 cells assessed as growth inhibition after 72 hrs by MTT assay
    		[PMID: 29705710]
    HepG2 GI50
    0.19 μM
    Compound: DOX
    Growth inhibition of human HepG2 cells after 72 hrs by MTT assay
    Growth inhibition of human HepG2 cells after 72 hrs by MTT assay
    		[PMID: 30336023]
    HepG2 GI50
    0.25 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    Cytotoxicity against human HepG2 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    		[PMID: 26561866]
    HepG2 GI50
    0.7 μM
    Compound: Dox
    Cytotoxicity against human HepG2 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
    Cytotoxicity against human HepG2 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
    		[PMID: 34634616]
    HepG2 GI50
    1.4 μM
    Compound: Doxorubicin
    Anti-proliferative activity against human HepG2 cells incubated for 48 hrs by SRB assay
    Anti-proliferative activity against human HepG2 cells incubated for 48 hrs by SRB assay
    		[PMID: 26163220]
    HepG2 GI50
    10.7 μM
    Compound: DOX
    Cytotoxicity against human HepG2 cells after 48 hrs by SRB assay
    Cytotoxicity against human HepG2 cells after 48 hrs by SRB assay
    		[PMID: 29316526]
    HepG2 GI50
    35.3 μM
    Compound: DOX
    Growth inhibition of human HepG2 cells after 48 hrs by SRB assay
    Growth inhibition of human HepG2 cells after 48 hrs by SRB assay
    		[PMID: 28433679]
    HepG2 GI50
    4.45 μM
    Compound: Doxo
    Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
    Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
    		[PMID: 26513642]
    HepG2 IC50
    0.007 μg
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells assessed as decrease in cell viability after 48 hrs by SRB assay
    Cytotoxicity against human HepG2 cells assessed as decrease in cell viability after 48 hrs by SRB assay
    		[PMID: 27393950]
    HepG2 IC50
    0.009 mM
    Compound: DOX
    Cytotoxicity against human HepG2 cells after 3 days by MTT assay
    Cytotoxicity against human HepG2 cells after 3 days by MTT assay
    		[PMID: 22520152]
    HepG2 IC50
    0.01 μM
    Compound: DOX
    Cytotoxicity against human HepG2 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    Cytotoxicity against human HepG2 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    		[PMID: 30826510]
    HepG2 IC50
    0.017 g/L
    Compound: Doxorubicin
    Cytotoxicity against Homo sapiens (human) HepG2 cells after 24 hr by MTT assay
    Cytotoxicity against Homo sapiens (human) HepG2 cells after 24 hr by MTT assay
    		10.1007/s00044-010-9433-z
    HepG2 IC50
    0.02 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay
    		[PMID: 27886545]
    HepG2 IC50
    0.04 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells assessed as cell growth inhibition after 72 hrs by alamar blue assay
    Cytotoxicity against human HepG2 cells assessed as cell growth inhibition after 72 hrs by alamar blue assay
    		[PMID: 31403289]
    HepG2 IC50
    0.05 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay
    		[PMID: 22555152]
    HepG2 IC50
    0.06 μM
    Compound: Adriamycin
    Cytotoxicity against human HepG2 cells by SRB method
    Cytotoxicity against human HepG2 cells by SRB method
    		[PMID: 18181575]
    HepG2 IC50
    0.06 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    		[PMID: 34782182]
    HepG2 IC50
    0.069 μM
    Compound: DOX
    Cytotoxicity against human HepG2 cells assessed as cell growth inhibition after 48 hrs by MTT assay
    Cytotoxicity against human HepG2 cells assessed as cell growth inhibition after 48 hrs by MTT assay
    		[PMID: 31999451]
    HepG2 IC50
    0.08 μM
    Compound: Dox
    Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay
    Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay
    		[PMID: 23802716]
    HepG2 IC50
    0.1 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells after 72 hrs by CCK8 assay
    Cytotoxicity against human HepG2 cells after 72 hrs by CCK8 assay
    		[PMID: 28398051]
    HepG2 IC50
    0.1 μM
    Compound: doxorubicin
    Growth inhibition of human HepG2 cells after 72 hrs by MTT assay
    Growth inhibition of human HepG2 cells after 72 hrs by MTT assay
    		[PMID: 18313307]
    HepG2 IC50
    0.12 μM
    Compound: Doxorubicin
    Antitumor activity against human hepatocellular carcinoma HepG-2 cells.
    Antitumor activity against human hepatocellular carcinoma HepG-2 cells.
    		[PMID: 12431049]
    HepG2 IC50
    0.12 μM
    Compound: doxorubicin
    Antitumor activity against human hepatocellular carcinoma HepG2 cells
    Antitumor activity against human hepatocellular carcinoma HepG2 cells
    		[PMID: 12431048]
    HepG2 IC50
    0.16 μM
    Compound: ADM; DOX
    Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    		[PMID: 31491611]
    HepG2 IC50
    0.16 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells after 3 days by MTT assay
    Cytotoxicity against human HepG2 cells after 3 days by MTT assay
    		[PMID: 19691312]
    HepG2 IC50
    0.17 μM
    Compound: doxorubicin
    Cytotoxicity against human HepG2 cells after 6 days by MTT method
    Cytotoxicity against human HepG2 cells after 6 days by MTT method
    		[PMID: 16309317]
    HepG2 IC50
    0.17 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells by MTT assay
    Cytotoxicity against human HepG2 cells by MTT assay
    		[PMID: 18590313]
    HepG2 IC50
    0.18 μg/mL
    Compound: doxorubicin
    Cytotoxicity against human HepG2 cells after 3 days by MTT assay
    Cytotoxicity against human HepG2 cells after 3 days by MTT assay
    		[PMID: 16252914]
    HepG2 IC50
    0.18 μg/mL
    Compound: doxorubicin
    Cytotoxicity against human HepG2 cells by MTT assay
    Cytotoxicity against human HepG2 cells by MTT assay
    		[PMID: 22413887]
    HepG2 IC50
    0.19 μM
    Compound: DOX
    Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay
    		[PMID: 21496972]
    HepG2 IC50
    0.19 μM
    Compound: DOX
    Cytotoxicity against human HepG2 cells measured after 48 hrs by MTT assay
    Cytotoxicity against human HepG2 cells measured after 48 hrs by MTT assay
    		[PMID: 23290052]
    HepG2 IC50
    0.19 μM
    Compound: Doxorubucin
    Cytotoxicity against human HepG2 cells by MTT assay
    Cytotoxicity against human HepG2 cells by MTT assay
    		[PMID: 20718475]
    HepG2 IC50
    0.19 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells after 3 days by MTT assay
    Cytotoxicity against human HepG2 cells after 3 days by MTT assay
    		[PMID: 15387653]
    HepG2 IC50
    0.2 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
    Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
    		[PMID: 19482476]
    HepG2 IC50
    0.2 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells assessed as cell viability after 72 hrs by MTT assay
    Cytotoxicity against human HepG2 cells assessed as cell viability after 72 hrs by MTT assay
    		[PMID: 24650715]
    HepG2 IC50
    0.2 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    		[PMID: 28277681]
    HepG2 IC50
    0.2 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells assessed as number of viable cells measured after 48 hrs by MTT based colorimetric assay
    Cytotoxicity against human HepG2 cells assessed as number of viable cells measured after 48 hrs by MTT based colorimetric assay
    		[PMID: 36970146]
    HepG2 IC50
    0.2 μM
    Compound: doxorubicin
    Cytotoxicity against human HepG2 cells by MTT assay
    Cytotoxicity against human HepG2 cells by MTT assay
    		[PMID: 17981462]
    HepG2 IC50
    0.2 μM
    Compound: doxorubicin
    Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
    Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
    		[PMID: 19926173]
    HepG2 IC50
    0.21 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
    		[PMID: 31836446]
    HepG2 IC50
    0.22 μg/mL
    Compound: Doxorubicin
    Cytotoxic activity against human HepG2 cells by MTT assay
    Cytotoxic activity against human HepG2 cells by MTT assay
    		[PMID: 28366267]
    HepG2 IC50
    0.23 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by fluorescein diacetate dye based fluorometric microculture assay
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by fluorescein diacetate dye based fluorometric microculture assay
    		[PMID: 28038943]
    HepG2 IC50
    0.23 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against Homo sapiens (human) HepG2 cells after 3 days by MTT assay
    Cytotoxicity against Homo sapiens (human) HepG2 cells after 3 days by MTT assay
    		10.1007/s00044-011-9903-y
    HepG2 IC50
    0.23 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against Homo sapiens (human) HepG2 cells assessed as survival after 3 days by crystal violet staining
    Cytotoxicity against Homo sapiens (human) HepG2 cells assessed as survival after 3 days by crystal violet staining
    		10.1007/s00044-012-0025-y
    HepG2 IC50
    0.23 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells by MTT assay
    Cytotoxicity against human HepG2 cells by MTT assay
    		[PMID: 21106454]
    HepG2 IC50
    0.26 μM
    Compound: Dox
    Cytotoxicity against human HepG2 cells after 3 days by MTT assay
    Cytotoxicity against human HepG2 cells after 3 days by MTT assay
    		[PMID: 21741833]
    HepG2 IC50
    0.29 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
    Cytotoxicity against human HepG2 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
    		[PMID: 37951135]
    HepG2 IC50
    0.29 μM
    Compound: doxorubicin
    Cytotoxicity against human HepG2 cells by MTT assay
    Cytotoxicity against human HepG2 cells by MTT assay
    		[PMID: 21174408]
    HepG2 IC50
    0.2 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human Hep G2 cells by MTT colorimetric method
    Cytotoxicity against human Hep G2 cells by MTT colorimetric method
    		[PMID: 17125220]
    HepG2 IC50
    0.2 μg/mL
    Compound: doxorubicin
    Cytotoxicity against human HepG2 cells by MTT assay
    Cytotoxicity against human HepG2 cells by MTT assay
    		[PMID: 18973388]
    HepG2 IC50
    0.3 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay
    		10.1039/C5MD00163C
    HepG2 IC50
    0.3 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay
    		[PMID: 19632833]
    HepG2 IC50
    0.3 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells by MTT assay
    Cytotoxicity against human HepG2 cells by MTT assay
    		[PMID: 29975532]
    HepG2 IC50
    0.3 μM
    Compound: doxorubicin
    Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay
    Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay
    		[PMID: 24050254]
    HepG2 IC50
    0.34 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells
    Cytotoxicity against human HepG2 cells
    		[PMID: 20036537]
    HepG2 IC50
    0.35 μM
    Compound: DOX
    Cytotoxicity against human HepG2 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 assay
    Cytotoxicity against human HepG2 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 assay
    		[PMID: 38039790]
    HepG2 IC50
    0.36 μM
    Compound: doxorubicin
    Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
    Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
    		[PMID: 25314138]
    HepG2 IC50
    0.37 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
    Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
    		[PMID: 20846862]
    HepG2 IC50
    0.37 μM
    Compound: doxorubicin
    Cytotoxicity against human HepG2 cells after 4 days by MTT assay
    Cytotoxicity against human HepG2 cells after 4 days by MTT assay
    		[PMID: 19824618]
    HepG2 IC50
    0.38 μM
    Compound: Doxorubicin
    Growth inhibition of human HepG2 cells incubated for 48 hrs by MTT assay
    Growth inhibition of human HepG2 cells incubated for 48 hrs by MTT assay
    		[PMID: 27080187]
    HepG2 IC50
    0.39 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HepG2 cells by MTT assay
    Antiproliferative activity against human HepG2 cells by MTT assay
    		[PMID: 36089748]
    HepG2 IC50
    0.392 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells assessed as cell viability incubated for 72 hrs by cellTiter 96 AQueous non-radioactive cell proliferation assay
    Cytotoxicity against human HepG2 cells assessed as cell viability incubated for 72 hrs by cellTiter 96 AQueous non-radioactive cell proliferation assay
    		[PMID: 28797771]
    HepG2 IC50
    0.3 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells by MTT assay
    Cytotoxicity against human HepG2 cells by MTT assay
    		[PMID: 16724859]
    HepG2 IC50
    0.4 μM
    Compound: Adriamycin
    Concentration required to inhibit growth of human hepatocellular carcinoma (HepG2) cell line
    Concentration required to inhibit growth of human hepatocellular carcinoma (HepG2) cell line
    		[PMID: 15317455]
    HepG2 IC50
    0.4 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells by MTT assay
    Cytotoxicity against human HepG2 cells by MTT assay
    		[PMID: 25747499]
    HepG2 IC50
    0.4 μM
    Compound: doxorubicin
    Cytotoxicity against human HepG2 cells after 72 hrs by MTS assay
    Cytotoxicity against human HepG2 cells after 72 hrs by MTS assay
    		[PMID: 25490132]
    HepG2 IC50
    0.41 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells assessed as cell viability after 72 hrs by MTT assay
    Cytotoxicity against human HepG2 cells assessed as cell viability after 72 hrs by MTT assay
    		[PMID: 23992864]
    HepG2 IC50
    0.41 μg/mL
    Compound: adriamycin
    Growth inhibition of HepG2 cells
    Growth inhibition of HepG2 cells
    		[PMID: 17547458]
    HepG2 IC50
    0.42 μM
    Compound: Doxorubicin
    Cytotoxicity against Homo sapiens (human) HepG2 cells assessed as inhibition of cell growth after 3 days by MTT assay
    Cytotoxicity against Homo sapiens (human) HepG2 cells assessed as inhibition of cell growth after 3 days by MTT assay
    		10.1007/s00044-012-0402-6
    HepG2 IC50
    0.42 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells
    Cytotoxicity against human HepG2 cells
    		[PMID: 19910192]
    HepG2 IC50
    0.42 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells after 72 hrs by alamar blue assay
    Cytotoxicity against human HepG2 cells after 72 hrs by alamar blue assay
    		[PMID: 24969014]
    HepG2 IC50
    0.425 μM
    Compound: DOX
    Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay
    Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay
    		[PMID: 35341920]
    HepG2 IC50
    0.45 μM
    Compound: Doxorubicin
    Anticancer activity against human HepG2 cells by MTT assay
    Anticancer activity against human HepG2 cells by MTT assay
    		[PMID: 31404864]
    HepG2 IC50
    0.46 μM
    Compound: DX
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by CCK-8 method
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by CCK-8 method
    		[PMID: 38039788]
    HepG2 IC50
    0.467 μM
    Compound: Doxorubicin
    Anticancer activity against human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by MTT colorimetric assay
    Anticancer activity against human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by MTT colorimetric assay
    		[PMID: 35694689]
    HepG2 IC50
    0.46 μg/mL
    Compound: doxo
    Cytotoxicity against human HepG2 cells by MTT method
    Cytotoxicity against human HepG2 cells by MTT method
    		[PMID: 17417907]
    HepG2 IC50
    0.48 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells after 96 hrs by MTT assay
    Cytotoxicity against human HepG2 cells after 96 hrs by MTT assay
    		[PMID: 24852278]
    HepG2 IC50
    0.48 μg/mL
    Compound: adriamycin
    Growth inhibition of human HepG2 cells
    Growth inhibition of human HepG2 cells
    		[PMID: 17358082]
    HepG2 IC50
    0.4 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells
    Cytotoxicity against human HepG2 cells
    		[PMID: 23511021]
    HepG2 IC50
    0.4 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells assessed as cell viability after 48 hrs by neutral red-based assay
    Cytotoxicity against human HepG2 cells assessed as cell viability after 48 hrs by neutral red-based assay
    		[PMID: 26469557]
    HepG2 IC50
    0.4 μg/mL
    Compound: Doxorubicin
    Antiproliferative activity against human HepG2 cells assessed as inhibition of cell viability by MTT assay
    Antiproliferative activity against human HepG2 cells assessed as inhibition of cell viability by MTT assay
    		[PMID: 32223924]
    HepG2 IC50
    0.5 μM
    Compound: Adriamycin
    Cytotoxicity against human HepG2 cells by MTT assay
    Cytotoxicity against human HepG2 cells by MTT assay
    		[PMID: 24182355]
    HepG2 IC50
    0.5 μM
    Compound: Doxo
    Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
    Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
    		[PMID: 20334960]
    HepG2 IC50
    0.5 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells by MTT assay
    Cytotoxicity against human HepG2 cells by MTT assay
    		10.1039/C3MD00166K
    HepG2 IC50
    0.5 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells by MTT assay
    Cytotoxicity against human HepG2 cells by MTT assay
    		[PMID: 21425785]
    HepG2 IC50
    0.5 μM
    Compound: Doxorubicin
    Anticancer activity against human HepG2 cells after 48 hrs by MTT assay
    Anticancer activity against human HepG2 cells after 48 hrs by MTT assay
    		[PMID: 21641694]
    HepG2 IC50
    0.5 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay
    Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay
    		[PMID: 25554367]
    HepG2 IC50
    0.5 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells by SRB assay
    Cytotoxicity against human HepG2 cells by SRB assay
    		[PMID: 29035560]
    HepG2 IC50
    0.5 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HepG2 cells measured after 48 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells measured after 48 hrs by MTT assay
    		[PMID: 31148449]
    HepG2 IC50
    0.5 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability at 200 uM incubated for 24 hrs by MTT assay
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability at 200 uM incubated for 24 hrs by MTT assay
    		[PMID: 31926469]
    HepG2 IC50
    0.5 μM
    Compound: doxorubicin
    Cytotoxicity against human HepG2 cells after 72 hrs by MTT colorimetric method
    Cytotoxicity against human HepG2 cells after 72 hrs by MTT colorimetric method
    		[PMID: 17622129]
    HepG2 IC50
    0.52 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    		[PMID: 30389295]
    HepG2 IC50
    0.54 μM
    Compound: Dox
    Cytotoxicity against human HepG2 cells by MTT assay
    Cytotoxicity against human HepG2 cells by MTT assay
    		[PMID: 28262527]
    HepG2 IC50
    0.54 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells assessed as cell growth inhibition after 48 hrs by MTT assay
    Cytotoxicity against human HepG2 cells assessed as cell growth inhibition after 48 hrs by MTT assay
    		[PMID: 27371926]
    HepG2 IC50
    0.55 μM
    Compound: DOX
    Hepatotoxicity in human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay
    Hepatotoxicity in human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay
    		[PMID: 36696766]
    HepG2 IC50
    0.55 μM
    Compound: DX
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTS assay
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTS assay
    		[PMID: 29681486]
    HepG2 IC50
    0.55 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    		[PMID: 31704206]
    HepG2 IC50
    0.57 μM
    Compound: Dox
    Cytotoxicity against human HepG2 Cells
    Cytotoxicity against human HepG2 Cells
    		[PMID: 31129455]
    HepG2 IC50
    0.57 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
    Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
    		[PMID: 25019480]
    HepG2 IC50
    0.57 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
    Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
    		[PMID: 26397393]
    HepG2 IC50
    0.58 μM
    Compound: DOX
    Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
    Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
    		[PMID: 26386603]
    HepG2 IC50
    0.59 μM
    Compound: doxorubicin
    Cytotoxicity against human HepG2 cells assessed as growth inhibition after 48 hrs by MTT assay
    Cytotoxicity against human HepG2 cells assessed as growth inhibition after 48 hrs by MTT assay
    		[PMID: 23806110]
    HepG2 IC50
    0.59 μg/mL
    Compound: Dox
    Cytotoxicity against human HepG2 cells after 48 hrs by sulforhodamine B assay
    Cytotoxicity against human HepG2 cells after 48 hrs by sulforhodamine B assay
    		[PMID: 20399544]
    HepG2 IC50
    0.6 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells by MTT assay
    Cytotoxicity against human HepG2 cells by MTT assay
    		[PMID: 24300737]
    HepG2 IC50
    0.62 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HepG2 cells after 48 hrs by neutral red assay
    Antiproliferative activity against human HepG2 cells after 48 hrs by neutral red assay
    		[PMID: 29885574]
    HepG2 IC50
    0.62 μM
    Compound: Doxorubicin
    Anticancer activity against human HepG2 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay
    Anticancer activity against human HepG2 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay
    		[PMID: 32438251]
    HepG2 IC50
    0.63 μM
    Compound: Doxo
    Cytotoxicity against human HepG2 cells after 3 days by MTT assay
    Cytotoxicity against human HepG2 cells after 3 days by MTT assay
    		[PMID: 21800859]
    HepG2 IC50
    0.64 μM
    Compound: doxorubicin
    Cytotoxicity against human HepG2 cells after 3 days by MTT assay
    Cytotoxicity against human HepG2 cells after 3 days by MTT assay
    		[PMID: 18419154]
    HepG2 IC50
    0.64 μg/mL
    Compound: Doxorubicin
    Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay
    Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay
    		[PMID: 34973507]
    HepG2 IC50
    0.66 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
    Cytotoxicity against human HepG2 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
    		[PMID: 34838335]
    HepG2 IC50
    0.67 μM
    Compound: DOX
    Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    		[PMID: 32996316]
    HepG2 IC50
    0.68 μM
    Compound: DOX
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 24 hrs by MTT assay
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 24 hrs by MTT assay
    		[PMID: 29421568]
    HepG2 IC50
    0.68 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells assessed as reduction in cell growth after 48 hrs by MTT assay
    Cytotoxicity against human HepG2 cells assessed as reduction in cell growth after 48 hrs by MTT assay
    		[PMID: 27422336]
    HepG2 IC50
    0.69 μM
    Compound: ADM
    Growth inhibition of human HepG2 cells after 48 hrs by WST8 assay
    Growth inhibition of human HepG2 cells after 48 hrs by WST8 assay
    		[PMID: 16499322]
    HepG2 IC50
    0.69 μM
    Compound: DOX
    Antiproliferative activity against human HepG2 cells assessed as cell growth inhibition after 72 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells assessed as cell growth inhibition after 72 hrs by MTT assay
    		[PMID: 33276990]
    HepG2 IC50
    0.6 μg/mL
    Compound: Doxorubicine
    Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay
    Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay
    		[PMID: 24177357]
    HepG2 IC50
    0.7 μM
    Compound: Dox
    Cytotoxicity against human HepG2 cells after 72 hrs by sulforhodamine B assay
    Cytotoxicity against human HepG2 cells after 72 hrs by sulforhodamine B assay
    		[PMID: 30132670]
    HepG2 IC50
    0.7 μM
    Compound: Dox
    Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability by MTT assay
    Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability by MTT assay
    		[PMID: 31765156]
    HepG2 IC50
    0.7 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
    Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
    		[PMID: 22749279]
    HepG2 IC50
    0.7 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by Alamar blue assay
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by Alamar blue assay
    		[PMID: 27300257]
    HepG2 IC50
    0.7 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells assessed as cell growth inhibition
    Cytotoxicity against human HepG2 cells assessed as cell growth inhibition
    		[PMID: 38630559]
    HepG2 IC50
    0.72 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells assessed as growth inhibition after 72 hrs by MTT assay
    Cytotoxicity against human HepG2 cells assessed as growth inhibition after 72 hrs by MTT assay
    		[PMID: 26874404]
    HepG2 IC50
    0.72 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay
    Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay
    		[PMID: 30654238]
    HepG2 IC50
    0.72 μM
    Compound: Doxorubicin
    Antitumor activity against human HepG2 cells
    Antitumor activity against human HepG2 cells
    		[PMID: 31926469]
    HepG2 IC50
    0.72 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability measured after 48 hrs by MTS assay
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability measured after 48 hrs by MTS assay
    		[PMID: 31926469]
    HepG2 IC50
    0.74 μM
    Compound: Dox
    Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay
    		[PMID: 35339100]
    HepG2 IC50
    0.74 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
    Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
    		[PMID: 25419616]
    HepG2 IC50
    0.77 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells assessed as cell survival after 48 hrs by MTT assay
    Cytotoxicity against human HepG2 cells assessed as cell survival after 48 hrs by MTT assay
    		[PMID: 25537271]
    HepG2 IC50
    0.79 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
    Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
    		[PMID: 24836071]
    HepG2 IC50
    0.79 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    		[PMID: 25078311]
    HepG2 IC50
    0.79 μM
    Compound: doxorubicin
    Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
    Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
    		10.1007/s00044-013-0777-z
    HepG2 IC50
    0.8 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells by MTT assay
    Cytotoxicity against human HepG2 cells by MTT assay
    		[PMID: 26586599]
    HepG2 IC50
    0.8 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 24 hrs by CCK8 assay
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 24 hrs by CCK8 assay
    		[PMID: 32324401]
    HepG2 IC50
    0.82 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells after 3 days by MTT assay
    Cytotoxicity against human HepG2 cells after 3 days by MTT assay
    		[PMID: 18547115]
    HepG2 IC50
    0.87 μM
    Compound: AMD
    Anticancer activity against human HepG2 cells assessed as cell survival after 48 hrs by MTT assay
    Anticancer activity against human HepG2 cells assessed as cell survival after 48 hrs by MTT assay
    		[PMID: 25812966]
    HepG2 IC50
    0.877 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells after 72 hrs by SRB assay
    Cytotoxicity against human HepG2 cells after 72 hrs by SRB assay
    		[PMID: 24231309]
    HepG2 IC50
    0.886 μM
    Compound: 92308101
    HARVARD: Inhibition of liver stage Plasmodium berghei infection in HepG2 cells
    HARVARD: Inhibition of liver stage Plasmodium berghei infection in HepG2 cells
    		[PMID: 22586124]
    HepG2 IC50
    0.9 μM
    Compound: Dox
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 28704759]
    HepG2 IC50
    0.919 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells by SRB assay
    Cytotoxicity against human HepG2 cells by SRB assay
    		[PMID: 34128674]
    HepG2 IC50
    0.95 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay
    Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay
    		10.1039/C3MD00013C
    HepG2 IC50
    0.954 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
    Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
    		[PMID: 20832916]
    HepG2 IC50
    0.99 μM
    Compound: Doxorubicin
    Anticancer activity against human HepG2 cells by SRB assay
    Anticancer activity against human HepG2 cells by SRB assay
    		[PMID: 34128674]
    HepG2 IC50
    0.9 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells after 48 hrs by neutral red
    Cytotoxicity against human HepG2 cells after 48 hrs by neutral red
    		[PMID: 23891181]
    HepG2 IC50
    1 μM
    Compound: DOX
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    		[PMID: 32371335]
    HepG2 IC50
    1 μM
    Compound: Dox
    Cytotoxicity against human HepG2 cells after 24 hrs by MTS assay
    Cytotoxicity against human HepG2 cells after 24 hrs by MTS assay
    		[PMID: 21094049]
    HepG2 IC50
    1 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay
    		[PMID: 28919340]
    HepG2 IC50
    1 μM
    Compound: Doxorubicin
    Cytotoxicity activity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity activity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 32627543]
    HepG2 IC50
    1 μM
    Compound: doxorubicin
    Cytotoxicity against human HepG2 cells after 48 hrs by neutral red assay
    Cytotoxicity against human HepG2 cells after 48 hrs by neutral red assay
    		[PMID: 24900509]
    HepG2 IC50
    1.01 μM
    Compound: DOX
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 24 hrs by MTT assay
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 24 hrs by MTT assay
    		[PMID: 29909338]
    HepG2 IC50
    1.02 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
    Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
    		[PMID: 23871222]
    HepG2 IC50
    1.05 μM
    Compound: Doxorubicin
    Anticancer activity against human HepG2 cells by MTT assay
    Anticancer activity against human HepG2 cells by MTT assay
    		[PMID: 25743216]
    HepG2 IC50
    1.07 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells by MTT assay
    Cytotoxicity against human HepG2 cells by MTT assay
    		[PMID: 30719909]
    HepG2 IC50
    1.08 μM
    Compound: Dox
    Anticancer activity against Homo sapiens (human) HepG2 cells assessed as growth inhibition after 48 hr by SRB assay
    Anticancer activity against Homo sapiens (human) HepG2 cells assessed as growth inhibition after 48 hr by SRB assay
    		10.1007/s00044-012-0057-3
    HepG2 IC50
    1.1 μM
    Compound: Doxorubicin
    Anticancer activity against human HepG2 cells assessed as cell viability after 48 hrs by MTT microcultured tetrazolium assay
    Anticancer activity against human HepG2 cells assessed as cell viability after 48 hrs by MTT microcultured tetrazolium assay
    		[PMID: 25096298]
    HepG2 IC50
    1.12 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    		[PMID: 32866757]
    HepG2 IC50
    1.13 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells by CCK8 assay
    Cytotoxicity against human HepG2 cells by CCK8 assay
    		[PMID: 29452840]
    HepG2 IC50
    1.15 μM
    Compound: Adriamycin
    Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay
    		[PMID: 24582982]
    HepG2 IC50
    1.18 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells after 3 days by microplate reader analysis
    Cytotoxicity against human HepG2 cells after 3 days by microplate reader analysis
    		[PMID: 32705864]
    HepG2 IC50
    1.2 μM
    Compound: ADM
    Cytotoxicity against human Hep G2 cells after 48 hrs by WST-8 assay
    Cytotoxicity against human Hep G2 cells after 48 hrs by WST-8 assay
    		[PMID: 15730243]
    HepG2 IC50
    1.2 μM
    Compound: ADM
    Cytotoxicity against human Hep G2 by WST-8 assay
    Cytotoxicity against human Hep G2 by WST-8 assay
    		[PMID: 16933868]
    HepG2 IC50
    1.2 μM
    Compound: Adriamycin
    Growth inhibition of human HepG2 cells
    Growth inhibition of human HepG2 cells
    		[PMID: 17490878]
    HepG2 IC50
    1.2 μM
    Compound: DOX
    Antineoplastic activity against human HepG2 cells measured after 36 hrs by MTT assay
    Antineoplastic activity against human HepG2 cells measured after 36 hrs by MTT assay
    		[PMID: 30746067]
    HepG2 IC50
    1.2 μM
    Compound: Doxorubicin
    Cytotoxicity against Homo sapiens (human) HepG2 cells after 48 hr by MTT assay
    Cytotoxicity against Homo sapiens (human) HepG2 cells after 48 hr by MTT assay
    		10.1007/s00044-011-9884-x
    HepG2 IC50
    1.2 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
    Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
    		[PMID: 27797185]
    HepG2 IC50
    1.2 μM
    Compound: adriamycin
    Cytotoxicity against human HepG2 cells by rapid colorimetric assay
    Cytotoxicity against human HepG2 cells by rapid colorimetric assay
    		[PMID: 19585998]
    HepG2 IC50
    1.21 μM
    Compound: DOX
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    		[PMID: 30771605]
    HepG2 IC50
    1.21 μg/mL
    Compound: Doxorubicin
    Anticancer activity against human cells HepG2 cells assessed as growth inhibition after 48 hrs by MTT assay
    Anticancer activity against human cells HepG2 cells assessed as growth inhibition after 48 hrs by MTT assay
    		[PMID: 25042338]
    HepG2 IC50
    1.22 μM
    Compound: ADM
    Cytotoxicity against human HepG2 cells assessed as inhibition of cell growth after 72 hrs by MTT assay
    Cytotoxicity against human HepG2 cells assessed as inhibition of cell growth after 72 hrs by MTT assay
    		[PMID: 25089733]
    HepG2 IC50
    1.22 μM
    Compound: adriamycin
    Cytotoxicity against human HepG2 cells assessed as cell growth inhibition after 72 hrs by MTT assay
    Cytotoxicity against human HepG2 cells assessed as cell growth inhibition after 72 hrs by MTT assay
    		[PMID: 26295905]
    HepG2 IC50
    1.29 μM
    Compound: Doxo
    Cytotoxicity against human HepG2 cells
    Cytotoxicity against human HepG2 cells
    		[PMID: 21784631]
    HepG2 IC50
    1.3 mM
    Compound: ADM
    Growth inhibition of human HepG2 cells
    Growth inhibition of human HepG2 cells
    		[PMID: 17595134]
    HepG2 IC50
    1.3 μM
    Compound: DOX
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability by MTT assay
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability by MTT assay
    		[PMID: 34323485]
    HepG2 IC50
    1.34 μM
    Compound: AMD
    Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
    Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
    		[PMID: 26900656]
    HepG2 IC50
    1.37 μM
    Compound: DOX
    Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
    Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
    		[PMID: 31057738]
    HepG2 IC50
    1.43 μM
    Compound: Doxorubicin
    Cytotoxicity in human HepG2 cells incubated for 72 hrs by MTT assay
    Cytotoxicity in human HepG2 cells incubated for 72 hrs by MTT assay
    		[PMID: 30978023]
    HepG2 IC50
    1.49 μM
    Compound: DOX
    Anticancer activity against human HepG2 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay
    Anticancer activity against human HepG2 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay
    		[PMID: 38784465]
    HepG2 IC50
    1.5 μM
    Compound: DOX
    Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay
    		[PMID: 28756264]
    HepG2 IC50
    1.51 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HepG2 cells measured after 48 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells measured after 48 hrs by MTT assay
    		[PMID: 32682198]
    HepG2 IC50
    1.54 μM
    Compound: DOXO
    Cytotoxicity against human HepG2 cells assessed as cell viability after 48 hrs by alamar blue assay
    Cytotoxicity against human HepG2 cells assessed as cell viability after 48 hrs by alamar blue assay
    		[PMID: 21797280]
    HepG2 IC50
    1.54 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells after 48 hrs by Alamar blue assay
    Cytotoxicity against human HepG2 cells after 48 hrs by Alamar blue assay
    		[PMID: 20931970]
    HepG2 IC50
    1.54 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
    Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
    		[PMID: 26963142]
    HepG2 IC50
    1.6 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells by MTT assay
    Cytotoxicity against human HepG2 cells by MTT assay
    		[PMID: 19583252]
    HepG2 IC50
    1.61 μM
    Compound: Doxorubicin
    Anticancer activity against human HepG2 cells after 48 hrs by MTT assay
    Anticancer activity against human HepG2 cells after 48 hrs by MTT assay
    		[PMID: 25615796]
    HepG2 IC50
    1.69 μM
    Compound: Dox
    Cytotoxicity against Homo sapiens (human) HepG2 cells assessed as reduction of cell survival after 48 hr by MTT assay
    Cytotoxicity against Homo sapiens (human) HepG2 cells assessed as reduction of cell survival after 48 hr by MTT assay
    		10.1007/s00044-012-0150-7
    HepG2 IC50
    1.6 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
    Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
    		[PMID: 21708464]
    HepG2 IC50
    1.7 x 10-1 μM
    Compound: doxorubicin
    Growth inhibition of human HepG2 cells after 72 hrs by SRB assay
    Growth inhibition of human HepG2 cells after 72 hrs by SRB assay
    		[PMID: 18512984]
    HepG2 IC50
    1.8 μM
    Compound: Doxorubicin
    Anticancer activity against human HepG2 cells assessed as growth inhibition incubated for 48 hrs by MTT assay
    Anticancer activity against human HepG2 cells assessed as growth inhibition incubated for 48 hrs by MTT assay
    		[PMID: 34363936]
    HepG2 IC50
    1.89 μM
    Compound: DOX
    Growth inhibition of human HepG2 cells after 48 hrs by MTT assay
    Growth inhibition of human HepG2 cells after 48 hrs by MTT assay
    		[PMID: 29509413]
    HepG2 IC50
    1.969 μM
    Compound: DOX
    Cytotoxicity against human HepG2 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay
    Cytotoxicity against human HepG2 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay
    		[PMID: 34700239]
    HepG2 IC50
    1.99 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HepG2 cells assessed as growth inhibition
    Antiproliferative activity against human HepG2 cells assessed as growth inhibition
    		[PMID: 33744442]
    HepG2 IC50
    10 nM
    Compound: Dox
    Anticancer activity against human HepG2 cells assessed as reduction in cell viability by MTT assay
    Anticancer activity against human HepG2 cells assessed as reduction in cell viability by MTT assay
    		[PMID: 31740054]
    HepG2 IC50
    10 μM
    Compound: Doxorubicin
    Antiproliferative activity against doxorubicin resistant human HepG2 cells for 24 hrs in presence of c-phycocyanin by MTT assay
    Antiproliferative activity against doxorubicin resistant human HepG2 cells for 24 hrs in presence of c-phycocyanin by MTT assay
    		[PMID: 34128674]
    HepG2 IC50
    10.15 μM
    Compound: Doxorubicin
    Cytotoxicity activity against human HepG2 cells by MTT assay
    Cytotoxicity activity against human HepG2 cells by MTT assay
    		[PMID: 26873414]
    HepG2 IC50
    10.4 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    		[PMID: 31323616]
    HepG2 IC50
    11.1 μM
    Compound: 92308101
    HARVARD: Cytotoxicity in HepG2 cell line
    HARVARD: Cytotoxicity in HepG2 cell line
    		[PMID: 22586124]
    HepG2 IC50
    11.6 μM
    Compound: Doxorubicin
    Anticancer activity against human HepG2 cells
    Anticancer activity against human HepG2 cells
    		[PMID: 31926469]
    HepG2 IC50
    12.5 μM
    Compound: Adriamycin
    Anticancer activity against human HepG2 cells assessed as cell viability after 24 hrs by MTT assay
    Anticancer activity against human HepG2 cells assessed as cell viability after 24 hrs by MTT assay
    		[PMID: 24974349]
    HepG2 IC50
    130 nM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells assessed as cell growth inhibition incubated for 72 hrs by CCK8 assay
    Cytotoxicity against human HepG2 cells assessed as cell growth inhibition incubated for 72 hrs by CCK8 assay
    		[PMID: 35213166]
    HepG2 IC50
    14.3 μM
    Compound: DOX
    Cytotoxicity against human HepG2 cells MTT assay
    Cytotoxicity against human HepG2 cells MTT assay
    		[PMID: 19329312]
    HepG2 IC50
    14.7 μM
    Compound: Dox
    Cytotoxicity against human HepG2 Cells by MTT/Trypan Blue Exclusion Assay
    Cytotoxicity against human HepG2 Cells by MTT/Trypan Blue Exclusion Assay
    		[PMID: 31129455]
    HepG2 IC50
    17.54 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay
    		[PMID: 21620529]
    HepG2 IC50
    18.03 μM
    Compound: Dox
    Cytotoxicity against human HepG2 cells assessed as cell viability measured after 24 hrs by MTT assay
    Cytotoxicity against human HepG2 cells assessed as cell viability measured after 24 hrs by MTT assay
    		[PMID: 33183865]
    HepG2 IC50
    18.7 μM
    Compound: 12
    Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay
    		[PMID: 29852328]
    HepG2 IC50
    19 nM
    Compound: Doxorubicin
    Antiproliferative activity against human HepG2 cells after 96 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells after 96 hrs by MTT assay
    		[PMID: 21296467]
    HepG2 IC50
    19 μg/mL
    Compound: doxorubicin
    Cytotoxicity against Homo sapiens (human) HepG2 cells after 24 hr by MTT assay
    Cytotoxicity against Homo sapiens (human) HepG2 cells after 24 hr by MTT assay
    		10.1007/s00044-010-9436-9
    HepG2 IC50
    2 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells after 48 hrs by Neutral Red assay
    Cytotoxicity against human HepG2 cells after 48 hrs by Neutral Red assay
    		10.1039/C3MD00097D
    HepG2 IC50
    2.03 μM
    Compound: ADM
    Antiproliferative activity against human HepG2 cells after 24 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells after 24 hrs by MTT assay
    		[PMID: 20932754]
    HepG2 IC50
    2.1 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay
    Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay
    		[PMID: 26821210]
    HepG2 IC50
    2.1 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    		[PMID: 29702447]
    HepG2 IC50
    2.17 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells after 94 hrs by MTT assay
    Cytotoxicity against human HepG2 cells after 94 hrs by MTT assay
    		[PMID: 21868138]
    HepG2 IC50
    2.21 μM
    Compound: ADM
    Cytotoxicity against human HepG2 cells
    Cytotoxicity against human HepG2 cells
    		[PMID: 16724842]
    HepG2 IC50
    2.3 μM
    Compound: Doxorubicin
    Hepatotoxicity in human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    Hepatotoxicity in human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    		[PMID: 33439019]
    HepG2 IC50
    2.32 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay
    		[PMID: 33352388]
    HepG2 IC50
    2.35 μM
    Compound: Doxorubicin
    Anticancer activity against human HepG2 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
    Anticancer activity against human HepG2 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
    		[PMID: 34124677]
    HepG2 IC50
    2.41 x 10-1 μg/mL
    Compound: Adriamycin
    Cytotoxicity against human HepG2 cells after 3 days
    Cytotoxicity against human HepG2 cells after 3 days
    		[PMID: 11975482]
    HepG2 IC50
    2.41 x 10-1 μg/mL
    Compound: adriamycin
    Cytotoxicity against human HepG2 cells after 12 days by methylene blue colorimetric method
    Cytotoxicity against human HepG2 cells after 12 days by methylene blue colorimetric method
    		[PMID: 11473425]
    HepG2 IC50
    2.5 nM
    Compound: Doxorubicin
    Inhibition of TRK in human HepG2 cells after 48 hrs by ELISA
    Inhibition of TRK in human HepG2 cells after 48 hrs by ELISA
    		[PMID: 24013411]
    HepG2 IC50
    2.511 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    		[PMID: 28462842]
    HepG2 IC50
    2.594 μM
    Compound: Doxorubicin
    Anti-proliferative activity against human HepG2 cells measured after 48 hrs by MTT assay
    Anti-proliferative activity against human HepG2 cells measured after 48 hrs by MTT assay
    		[PMID: 27744185]
    HepG2 IC50
    2.5 mM
    Compound: Adriamycin
    Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
    Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
    		[PMID: 22440624]
    HepG2 IC50
    2.5 mM
    Compound: Adriamycin
    Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay
    Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay
    		[PMID: 23685942]
    HepG2 IC50
    2.6 μM
    Compound: DOX
    Inhibition of topoisomerase 2 in human HepG2 cells assessed as reduction in cell growth measured after 72 hrs by MTT assay
    Inhibition of topoisomerase 2 in human HepG2 cells assessed as reduction in cell growth measured after 72 hrs by MTT assay
    		[PMID: 30846253]
    HepG2 IC50
    2.67 μM
    Compound: AMD
    Antiproliferative activity against human HepG2 cells measured after 48 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells measured after 48 hrs by MTT assay
    		[PMID: 27639364]
    HepG2 IC50
    2.68 μM
    Compound: doxorubicin
    Cytotoxicity against human HepG2 cells after 96 hrs by MTT assay
    Cytotoxicity against human HepG2 cells after 96 hrs by MTT assay
    		10.1007/s00044-013-0795-x
    HepG2 IC50
    2.7 μM
    Compound: Adriamycin
    Cytotoxicity against human HepG2 cells by MTT assay
    Cytotoxicity against human HepG2 cells by MTT assay
    		[PMID: 22946634]
    HepG2 IC50
    2.7 μM
    Compound: DOX
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability measured after 24 hrs by CCK8 assay
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability measured after 24 hrs by CCK8 assay
    		[PMID: 34450496]
    HepG2 IC50
    2.75 μM
    Compound: Doxorubicin
    Anticancer activity against human HepG2 cells assessed as inhibition of cell growth incubated for 3 days by MTT assay
    Anticancer activity against human HepG2 cells assessed as inhibition of cell growth incubated for 3 days by MTT assay
    		[PMID: 35007724]
    HepG2 IC50
    2.85 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells after 96 hrs by MTT assay
    Cytotoxicity against human HepG2 cells after 96 hrs by MTT assay
    		[PMID: 31200236]
    HepG2 IC50
    2.9 μM
    Compound: Dox
    Inhibition of human HepG2cells assessed as inhibition of cell growth after 72 hrs by SRB method
    Inhibition of human HepG2cells assessed as inhibition of cell growth after 72 hrs by SRB method
    		[PMID: 26071861]
    HepG2 IC50
    20.2 nM
    Compound: Doxorubicin
    Antiproliferative against human HepG2 cells assessed as cell viability after 96 hrs by MTT assay
    Antiproliferative against human HepG2 cells assessed as cell viability after 96 hrs by MTT assay
    		[PMID: 24211639]
    HepG2 IC50
    21.2 μM
    Compound: 21
    Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
    Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
    		[PMID: 29289880]
    HepG2 IC50
    22 nM
    Compound: DOX
    Anticancer activity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Anticancer activity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 33901898]
    HepG2 IC50
    23.22 μM
    Compound: doxorubicin
    Cytotoxicity against human HepG2 cells assessed as inhibition of cell viability after 24 hrs by MTT assay
    Cytotoxicity against human HepG2 cells assessed as inhibition of cell viability after 24 hrs by MTT assay
    		[PMID: 26200396]
    HepG2 IC50
    240 nM
    Compound: doxorubicin
    Cytotoxicity against human HepG2 cells after 72 hrs by MTS assay
    Cytotoxicity against human HepG2 cells after 72 hrs by MTS assay
    		[PMID: 19655762]
    HepG2 IC50
    26.6 μM
    Compound: Dox
    Antiproliferative activity against human HepG2 cells incubated for 48 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells incubated for 48 hrs by MTT assay
    		[PMID: 38990190]
    HepG2 IC50
    27.11 μM
    Compound: Doxorubicin
    Anticancer activity against human HepG2 cells after 48 hrs by SRB assay
    Anticancer activity against human HepG2 cells after 48 hrs by SRB assay
    		[PMID: 24077528]
    HepG2 IC50
    3 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability by DAPI staining based assay
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability by DAPI staining based assay
    		[PMID: 33461146]
    HepG2 IC50
    3.01 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells assessed as cell viability after 48 hrs by MTT assay
    Cytotoxicity against human HepG2 cells assessed as cell viability after 48 hrs by MTT assay
    		[PMID: 27015609]
    HepG2 IC50
    3.01 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    		[PMID: 31404864]
    HepG2 IC50
    3.1 μg/mL
    Compound: DOX
    Cytotoxicity against human HepG2 cells by SRB assay
    Cytotoxicity against human HepG2 cells by SRB assay
    		[PMID: 23831694]
    HepG2 IC50
    3.3 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells
    Cytotoxicity against human HepG2 cells
    		[PMID: 32386856]
    HepG2 IC50
    3.36 μg/mL
    Compound: doxorubicin
    Cytotoxicity against human HepG2 cells after 3 days by MTT assay
    Cytotoxicity against human HepG2 cells after 3 days by MTT assay
    		[PMID: 19456120]
    HepG2 IC50
    3.39 μM
    Compound: Doxo
    Cytotoxicity against human HepG2 cells assessed as inhibition of cell proliferation after 24 hrs by MTT assay
    Cytotoxicity against human HepG2 cells assessed as inhibition of cell proliferation after 24 hrs by MTT assay
    		[PMID: 27036521]
    HepG2 IC50
    3.45 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HepG2 cells after 72 hrs by SRB assay
    Antiproliferative activity against human HepG2 cells after 72 hrs by SRB assay
    		[PMID: 25462265]
    HepG2 IC50
    3.45 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells by sulforhodamine B assay
    Cytotoxicity against human HepG2 cells by sulforhodamine B assay
    		[PMID: 31401008]
    HepG2 IC50
    3.5 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells assessed as cell viability after 48 hrs by MTT assay
    Cytotoxicity against human HepG2 cells assessed as cell viability after 48 hrs by MTT assay
    		[PMID: 25655719]
    HepG2 IC50
    3.54 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells by MTT assay
    Cytotoxicity against human HepG2 cells by MTT assay
    		[PMID: 33148490]
    HepG2 IC50
    3.56 μM
    Compound: Dox
    Cytotoxicity against human HepG2 cells assessed as cell viability after 24 hrs by crystal violet staining assay
    Cytotoxicity against human HepG2 cells assessed as cell viability after 24 hrs by crystal violet staining assay
    		[PMID: 26706352]
    HepG2 IC50
    3.56 μg/mL
    Compound: Doxorubicin
    Antiproliferative activity against human HepG2 cells
    Antiproliferative activity against human HepG2 cells
    		[PMID: 34020340]
    HepG2 IC50
    3.73 μg/mL
    Compound: DOX
    Cytotoxicity against human HepG2 by sulforhodamie B colorimetric assay
    Cytotoxicity against human HepG2 by sulforhodamie B colorimetric assay
    		[PMID: 22178093]
    HepG2 IC50
    3.73 μg/mL
    Compound: DOX
    Cytotoxicity against human HepG2 cells after 72 hrs by sulforhodamine B assay
    Cytotoxicity against human HepG2 cells after 72 hrs by sulforhodamine B assay
    		[PMID: 22370339]
    HepG2 IC50
    3.73 μg/mL
    Compound: Doxorubicin
    Antitumor activity against human HepG2 cells
    Antitumor activity against human HepG2 cells
    		[PMID: 20739102]
    HepG2 IC50
    3.82 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
    Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
    		[PMID: 25462233]
    HepG2 IC50
    3.82 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HepG2 cells assessed as cell viability after 24 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells assessed as cell viability after 24 hrs by MTT assay
    		[PMID: 26874744]
    HepG2 IC50
    3.9 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells after 48 hrs by SRB assay
    Cytotoxicity against human HepG2 cells after 48 hrs by SRB assay
    		[PMID: 24095746]
    HepG2 IC50
    32 μM
    Compound: DOX
    Cytotoxicity against Homo sapiens (human) HepG2 cells after 48 hr by SRB assay
    Cytotoxicity against Homo sapiens (human) HepG2 cells after 48 hr by SRB assay
    		10.1007/s00044-011-9751-9
    HepG2 IC50
    32 μM
    Compound: DOX
    Cytotoxicity against human HepG2 cells assessed as cell viability after 48 hrs by SRB assay
    Cytotoxicity against human HepG2 cells assessed as cell viability after 48 hrs by SRB assay
    		[PMID: 27085944]
    HepG2 IC50
    32 μM
    Compound: Doxorubicin
    Anticancer activity against human HepG2 cells assessed as inhibition of cell proliferation at 100 uM measured after 24 hrs by MTT assay
    Anticancer activity against human HepG2 cells assessed as inhibition of cell proliferation at 100 uM measured after 24 hrs by MTT assay
    		[PMID: 31926469]
    HepG2 IC50
    334 μM
    Compound: doxorubicin
    Resistant ratio, IC50 for multidrug resistant human HepG2 cells to IC50 for human HepG2 cells
    Resistant ratio, IC50 for multidrug resistant human HepG2 cells to IC50 for human HepG2 cells
    		[PMID: 18313307]
    HepG2 IC50
    36.3 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells assessed as surviving fraction ratio after 48 hrs by SRB assay relative to control
    Cytotoxicity against human HepG2 cells assessed as surviving fraction ratio after 48 hrs by SRB assay relative to control
    		[PMID: 25618015]
    HepG2 IC50
    36.74 μM
    Compound: doxorubicin
    Growth inhibition of doxorubicin resistant human HepG2 cells after 72 hrs by MTT assay
    Growth inhibition of doxorubicin resistant human HepG2 cells after 72 hrs by MTT assay
    		[PMID: 18313307]
    HepG2 IC50
    4.1 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HepG2 cells after 48 hrs by SRB assay
    Antiproliferative activity against human HepG2 cells after 48 hrs by SRB assay
    		[PMID: 30503942]
    HepG2 IC50
    4.1 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HepG2 cells after 72 hrs by ELISA
    Antiproliferative activity against human HepG2 cells after 72 hrs by ELISA
    		[PMID: 31404864]
    HepG2 IC50
    4.17 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay
    Cytotoxicity against human HepG2 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay
    		[PMID: 35696863]
    HepG2 IC50
    4.17 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HepG2 cells measured after 24 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells measured after 24 hrs by MTT assay
    		[PMID: 37875056]
    HepG2 IC50
    4.23 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells assessed as cell viability after 72 hrs by MTT assay
    Cytotoxicity against human HepG2 cells assessed as cell viability after 72 hrs by MTT assay
    		[PMID: 28171832]
    HepG2 IC50
    4.2 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
    Cytotoxicity against human HepG2 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
    		[PMID: 27894044]
    HepG2 IC50
    4.3 μM
    Compound: DOX
    Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay
    		[PMID: 30398868]
    HepG2 IC50
    4.3 μM
    Compound: Doxorubicin
    Antitumor activity against human HepG2 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay
    Antitumor activity against human HepG2 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay
    		[PMID: 30138804]
    HepG2 IC50
    4.4 μM
    Compound: Dox
    Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
    Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
    		[PMID: 28865276]
    HepG2 IC50
    4.5 μM
    Compound: DOX
    Anticancer activity against human HepG2 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay
    Anticancer activity against human HepG2 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay
    		[PMID: 32085964]
    HepG2 IC50
    4.5 μM
    Compound: DOX
    Antiproliferative activity against human HepG2 cells assessed as reduction in cell growth
    Antiproliferative activity against human HepG2 cells assessed as reduction in cell growth
    		[PMID: 33388654]
    HepG2 IC50
    4.5 μM
    Compound: DOX
    Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay
    		[PMID: 35964425]
    HepG2 IC50
    4.5 μM
    Compound: DOX
    Cytotoxicity against human HepG2 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay
    Cytotoxicity against human HepG2 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay
    		[PMID: 36242988]
    HepG2 IC50
    4.5 μM
    Compound: DOX
    Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay
    		[PMID: 37054758]
    HepG2 IC50
    4.5 μM
    Compound: Dox
    Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    		[PMID: 34126285]
    HepG2 IC50
    4.5 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells assessed as decrease in cell viability after 48 hrs by MTT assay
    Cytotoxicity against human HepG2 cells assessed as decrease in cell viability after 48 hrs by MTT assay
    		[PMID: 29702448]
    HepG2 IC50
    4.5 μM
    Compound: Doxorubicin
    Antitumor activity against human HepG2 cells assessed as inhibition of cell viability by MTT assay
    Antitumor activity against human HepG2 cells assessed as inhibition of cell viability by MTT assay
    		[PMID: 33065442]
    HepG2 IC50
    4.5 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    Cytotoxicity against human HepG2 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    		[PMID: 35101650]
    HepG2 IC50
    4.5 x 10-1 μg/mL
    Compound: adriamycin
    Cytotoxicity against human HepG2 cells
    Cytotoxicity against human HepG2 cells
    		[PMID: 12608866]
    HepG2 IC50
    4.56 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by RRA assay
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by RRA assay
    		[PMID: 33508467]
    HepG2 IC50
    4.57 μg/mL
    Compound: DOX
    Antitumor activity against human HepG2 cells after 48 hrs by MTT assay
    Antitumor activity against human HepG2 cells after 48 hrs by MTT assay
    		[PMID: 20599299]
    HepG2 IC50
    4.6 μg/mL
    Compound: 1; Dox
    Growth inhibition of human HepG2 cell line assessed as reduction in cell viability by SRB colorimetric assay
    Growth inhibition of human HepG2 cell line assessed as reduction in cell viability by SRB colorimetric assay
    		[PMID: 37482023]
    HepG2 IC50
    4.89 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells after 72 hrs by XTT assay
    Cytotoxicity against human HepG2 cells after 72 hrs by XTT assay
    		10.1007/s00044-013-0558-8
    HepG2 IC50
    4.93 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay
    		[PMID: 28038941]
    HepG2 IC50
    4 mg/mL
    Compound: Doxorubicin
    Anticancer activity against human HepG2 cells after 48 hrs by SRB assay
    Anticancer activity against human HepG2 cells after 48 hrs by SRB assay
    		[PMID: 32631569]
    HepG2 IC50
    4 μg/mL
    Compound: Doxorubicin
    Antiproliferative activity against human HepG2 cells after 48 hrs by SRB assay
    Antiproliferative activity against human HepG2 cells after 48 hrs by SRB assay
    		[PMID: 27688190]
    HepG2 IC50
    4 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells
    Cytotoxicity against human HepG2 cells
    		[PMID: 31200236]
    HepG2 IC50
    5 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay
    Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay
    		[PMID: 22632935]
    HepG2 IC50
    5 μM
    Compound: Doxorubicin
    Anticancer activity against human HepG2 cells incubated for 24 hrs by MTT assay
    Anticancer activity against human HepG2 cells incubated for 24 hrs by MTT assay
    		[PMID: 28579122]
    HepG2 IC50
    5 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells assessed as inhibition of cell growth after 72 hrs by SRB assay
    Cytotoxicity against human HepG2 cells assessed as inhibition of cell growth after 72 hrs by SRB assay
    		[PMID: 28734245]
    HepG2 IC50
    5.23 μM
    Compound: Doxorubicin
    Anticancer activity against Homo sapiens (human) HepG2 cells after 48 hr by SRB assay
    Anticancer activity against Homo sapiens (human) HepG2 cells after 48 hr by SRB assay
    		10.1007/s00044-011-9653-x
    HepG2 IC50
    5.23 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells assessed as inhibition of cell proliferation after 24 hrs by SRB assay
    Cytotoxicity against human HepG2 cells assessed as inhibition of cell proliferation after 24 hrs by SRB assay
    		[PMID: 20850308]
    HepG2 IC50
    5.34 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells measured after 48 hrs by MTT assay
    Cytotoxicity against human HepG2 cells measured after 48 hrs by MTT assay
    		[PMID: 27476117]
    HepG2 IC50
    5.4 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    Cytotoxicity against human HepG2 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    		[PMID: 26317881]
    HepG2 IC50
    5.4 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HepG2 cells by MTT reduction assay
    Antiproliferative activity against human HepG2 cells by MTT reduction assay
    		[PMID: 33421712]
    HepG2 IC50
    5.43 μM
    Compound: DOX
    Antiproliferative activity against human HepG2 cells after 48 hrs by resazurin dye-based fluorescence assay
    Antiproliferative activity against human HepG2 cells after 48 hrs by resazurin dye-based fluorescence assay
    		[PMID: 29665526]
    HepG2 IC50
    5.57 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
    Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
    		[PMID: 22647723]
    HepG2 IC50
    5.59 μM
    Compound: Doxorubicin
    Anticancer activity against human HepG2 cells assessed as cell growth inhibition measured after 24 hrs by SRB assay
    Anticancer activity against human HepG2 cells assessed as cell growth inhibition measured after 24 hrs by SRB assay
    		[PMID: 36481599]
    HepG2 IC50
    5.5 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells after 48 hrs by sulforhodamine B assay
    Cytotoxicity against human HepG2 cells after 48 hrs by sulforhodamine B assay
    		[PMID: 21723735]
    HepG2 IC50
    5.7 μM
    Compound: DOX
    Cytotoxicity against human HepG2 cells after 48 hrs by SRB assay
    Cytotoxicity against human HepG2 cells after 48 hrs by SRB assay
    		[PMID: 22444025]
    HepG2 IC50
    5.7 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells measured after 48 hrs by SRB assay
    Cytotoxicity against human HepG2 cells measured after 48 hrs by SRB assay
    		[PMID: 27112448]
    HepG2 IC50
    6.11 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HepG2 cells incubated for 24 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells incubated for 24 hrs by MTT assay
    		[PMID: 29409753]
    HepG2 IC50
    6.91 μM
    Compound: DOX
    Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
    Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
    		[PMID: 27889629]
    HepG2 IC50
    6.91 μM
    Compound: DOX
    Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
    Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
    		[PMID: 30108853]
    HepG2 IC50
    60.29 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells assessed as growth inhibition by MTT assay
    Cytotoxicity against human HepG2 cells assessed as growth inhibition by MTT assay
    		[PMID: 33243532]
    HepG2 IC50
    630 nM
    Compound: DOX
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 25461322]
    HepG2 IC50
    69 μM
    Compound: Doxorubicin
    Cytotoxicity activity against human HepG2 cells after 24 hrs
    Cytotoxicity activity against human HepG2 cells after 24 hrs
    		[PMID: 20547797]
    HepG2 IC50
    693.1 nM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells assessed as growth inhibition after 72 hrs by MTT assay
    Cytotoxicity against human HepG2 cells assessed as growth inhibition after 72 hrs by MTT assay
    		[PMID: 29886322]
    HepG2 IC50
    7 μM
    Compound: ADM
    Cytotoxicity against human HepG2 cells
    Cytotoxicity against human HepG2 cells
    		[PMID: 22283451]
    HepG2 IC50
    7.1 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
    Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
    		[PMID: 22304344]
    HepG2 IC50
    7.3 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth after overnight incubation by MTT assay
    Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth after overnight incubation by MTT assay
    		[PMID: 32165076]
    HepG2 IC50
    7.3 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth after 48 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth after 48 hrs by MTT assay
    		[PMID: 33784602]
    HepG2 IC50
    7.34 μM
    Compound: Doxorubicin
    Antitumor activity against human HepG2 cells measured after 48 hrs by MTT assay
    Antitumor activity against human HepG2 cells measured after 48 hrs by MTT assay
    		[PMID: 37859719]
    HepG2 IC50
    7.36 μM
    Compound: Doxorubicin
    Antitumor activity against Homo sapiens (human) HepG2 cells assessed as cell growth inhibition after 48 hr by MTT assay
    Antitumor activity against Homo sapiens (human) HepG2 cells assessed as cell growth inhibition after 48 hr by MTT assay
    		10.1007/s00044-013-0497-4
    HepG2 IC50
    7.36 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells after 48 hrs by sulforhodamine B assay
    Cytotoxicity against human HepG2 cells after 48 hrs by sulforhodamine B assay
    		[PMID: 22119131]
    HepG2 IC50
    7.36 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells after 48 hrs by sulforhodamine B assay
    Cytotoxicity against human HepG2 cells after 48 hrs by sulforhodamine B assay
    		[PMID: 22119132]
    HepG2 IC50
    7.36 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells assessed as cell survival after 48 hrs by SRB assay
    Cytotoxicity against human HepG2 cells assessed as cell survival after 48 hrs by SRB assay
    		[PMID: 23708013]
    HepG2 IC50
    7.36 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells after 48 hrs by SRB assay
    Cytotoxicity against human HepG2 cells after 48 hrs by SRB assay
    		[PMID: 23994327]
    HepG2 IC50
    7.46 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells after 24 hrs by SRB assay
    Cytotoxicity against human HepG2 cells after 24 hrs by SRB assay
    		[PMID: 30096580]
    HepG2 IC50
    7.46 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability by SRB assay
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability by SRB assay
    		[PMID: 32361329]
    HepG2 IC50
    7.94 μM
    Compound: Cpd I
    Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay
    		[PMID: 33360576]
    HepG2 IC50
    7.94 μM
    Compound: Doxorubicin
    Anticancer activity against human HepG2 cells assessed as reduction in cell viability
    Anticancer activity against human HepG2 cells assessed as reduction in cell viability
    		[PMID: 35694689]
    HepG2 IC50
    7.94 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth measured after 48 hrs by CCK-8 assay
    Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth measured after 48 hrs by CCK-8 assay
    		[PMID: 38669910]
    HepG2 IC50
    7.94 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HepG2 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay
    		[PMID: 38669910]
    HepG2 IC50
    7.94 μg/mL
    Compound: Doxorubicin
    Antiproliferative activity against human HepG2 cells assessed as reduction in cell growth measured after 24 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells assessed as reduction in cell growth measured after 24 hrs by MTT assay
    		[PMID: 37453330]
    HepG2 IC50
    73.5 μM
    Compound: DOX
    Antitumor activity against human HepG2 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    Antitumor activity against human HepG2 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    		[PMID: 35859879]
    HepG2 IC50
    8 μM
    Compound: Doxorubicin
    Anticancer activity against human HepG2 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay
    Anticancer activity against human HepG2 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay
    		[PMID: 30772606]
    HepG2 IC50
    8.28 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    		[PMID: 33214036]
    HepG2 IC50
    8.28 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability
    Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability
    		[PMID: 38669910]
    HepG2 IC50
    8.9 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells measured after 24 hrs by MTT assay
    Cytotoxicity against human HepG2 cells measured after 24 hrs by MTT assay
    		[PMID: 34363937]
    HepG2 IC50
    80.9 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells by MTT assay
    Cytotoxicity against human HepG2 cells by MTT assay
    		[PMID: 36325400]
    HepG2 IC50
    80.9 μg/mL
    Compound: Doxorubicin
    Antitumor activity against human HepG2 xenografted BALB/c mouse assessed as reduction in tumor growth at 30 mg/kg, ip administered for once every 3 days measured after 15 days
    Antitumor activity against human HepG2 xenografted BALB/c mouse assessed as reduction in tumor growth at 30 mg/kg, ip administered for once every 3 days measured after 15 days
    		[PMID: 34147747]
    HepG2 IC50
    85.46 μM
    Compound: DOX
    Cytotoxicity against human adriamycin-resistant HepG2 cells measured after 48 hrs by MTT assay
    Cytotoxicity against human adriamycin-resistant HepG2 cells measured after 48 hrs by MTT assay
    		[PMID: 23290052]
    HepG2 IC50
    98.7 nM
    Compound: Doxorubicin
    Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay
    		[PMID: 28412159]
    HepG2 IC50
    < 0.01 μM
    Compound: DOX
    Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth incubated for 48 hrs by CellTiter 96 Aqueous One Solution Cell Proliferation Assay
    Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth incubated for 48 hrs by CellTiter 96 Aqueous One Solution Cell Proliferation Assay
    		[PMID: 38626522]
    HepG2 IC50
    < 0.11 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability
    		[PMID: 32005414]
    HepG2 IC50
    < 2.94 μM
    Compound: Doxorubicin
    Inhibition of proliferation of human HepG2 cells after 72 hrs by XTT assay
    Inhibition of proliferation of human HepG2 cells after 72 hrs by XTT assay
    		[PMID: 20810194]
    HepG2 IC50
    > 40 μg/mL
    Compound: doxorubicin
    Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay
    Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay
    		[PMID: 12608856]
    HepG2 IC50
    > 50 μM
    Compound: DOX
    Cytotoxicity against human doxorubicin-resistant HepG2 cells after 48 hrs by MTT assay
    Cytotoxicity against human doxorubicin-resistant HepG2 cells after 48 hrs by MTT assay
    		[PMID: 27889629]
    HepG2 IC50
    > 75 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells assessed as decrease in cell viability after 48 hrs by MTT assay
    Cytotoxicity against human HepG2 cells assessed as decrease in cell viability after 48 hrs by MTT assay
    		[PMID: 27843113]
    HepG2 2.2.15 IC50
    4.5 x 10-1 μg/mL
    Compound: Adriamycin
    Cytotoxicity against human HepG2(2.2.15) cells after 3 day
    Cytotoxicity against human HepG2(2.2.15) cells after 3 day
    		[PMID: 10654411]
    HepG2 2.2.15 IC50
    4.5 x 10-1 μg/mL
    Compound: Adriamycin
    Cytotoxicity against human HepG2(2.2.15) cells after 3 days
    Cytotoxicity against human HepG2(2.2.15) cells after 3 days
    		[PMID: 11975482]
    HepG2 2.2.15 IC50
    4.5 x 10-1 μg/mL
    Compound: adriamycin
    Cytotoxicity against human HepG2(2.2.15) cells after 12 days by methylene blue colorimetric method
    Cytotoxicity against human HepG2(2.2.15) cells after 12 days by methylene blue colorimetric method
    		[PMID: 11473425]
    HepG2 2.2.15 IC50
    4.5 x 10-1 μg/mL
    Compound: adriamycin
    Cytotoxicity against human HepG2(2.2.15) cells
    Cytotoxicity against human HepG2(2.2.15) cells
    		[PMID: 12608866]
    Hs-578T GI50
    0.33 μM
    Compound: Doxorubicin
    Growth inhibition of human Hs578T cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human Hs578T cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28329730]
    Hs-578T GI50
    0.33 μM
    Compound: Doxorubicin
    Growth inhibition of human Hs 578T cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human Hs 578T cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 29102177]
    Hs-578T GI50
    0.33 μM
    Compound: Doxorubicin hydrochloride, NSC 123127
    Cytotoxicity against human Hs578T cells after 48 hrs by SRB assay
    Cytotoxicity against human Hs578T cells after 48 hrs by SRB assay
    		[PMID: 23871905]
    Hs-578T IC50
    0.37 μM
    Compound: Doxorubicin
    Cytotoxicity against human Hs578T cells assessed as cell viability after 72 hrs by MTT assay
    Cytotoxicity against human Hs578T cells assessed as cell viability after 72 hrs by MTT assay
    		[PMID: 24530030]
    Hs-578T IC50
    0.52 μM
    Compound: Doxorubicin
    Anticancer activity against human Hs 578T cells after 72 hrs by sulforhodamine B assay
    Anticancer activity against human Hs 578T cells after 72 hrs by sulforhodamine B assay
    		[PMID: 30081238]
    Hs-578T IC50
    0.546 μM
    Compound: doxorubicin
    Cytotoxicity against human Hs578T cells after 72 hrs by CellTiter-Glo assay
    Cytotoxicity against human Hs578T cells after 72 hrs by CellTiter-Glo assay
    		[PMID: 22316168]
    Hs-578T IC50
    0.75 μM
    Compound: Dox
    Cytotoxicity against human Hs578T cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human Hs578T cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 31306817]
    Hs-578T IC50
    0.83 μM
    Compound: Dox
    Cytotoxicity against human Hs 578T cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human Hs 578T cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 31306817]
    Hs-578T IC50
    1.07 μM
    Compound: DOX
    Anti-proliferative activity against human Hs-578T cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    Anti-proliferative activity against human Hs-578T cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    		[PMID: 38776807]
    Hs-578T IC50
    1345.5 nM
    Compound: Dox
    Inhibition of human Hs-578T cell spheroids incubated for 7 days by luciferase based assay
    Inhibition of human Hs-578T cell spheroids incubated for 7 days by luciferase based assay
    		[PMID: 36780832]
    Hs-578T IC50
    98.32 μM
    Compound: doxorubicin
    Cytotoxicity against human Hs578T cells at 40 uM after 72 hrs by CellTiter-Glo assay relative to untreated control
    Cytotoxicity against human Hs578T cells at 40 uM after 72 hrs by CellTiter-Glo assay relative to untreated control
    		[PMID: 22316168]
    HuCC-A1 IC50
    0.239 μM
    Compound: Doxorubicin
    Cytotoxicity against human HuCCa1 cells after 48 hrs by MTT assay
    Cytotoxicity against human HuCCa1 cells after 48 hrs by MTT assay
    		[PMID: 25019480]
    HuCC-A1 IC50
    0.33 μg/mL
    Compound: Doxorubicin
    Cytotoxic activity against human HuCCa1 cells by MTT assay
    Cytotoxic activity against human HuCCa1 cells by MTT assay
    		[PMID: 28366267]
    HuCC-A1 IC50
    0.35 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against Homo sapiens (human) HuCCa1 cells assessed as survival after 3 days by crystal violet staining
    Cytotoxicity against Homo sapiens (human) HuCCa1 cells assessed as survival after 3 days by crystal violet staining
    		10.1007/s00044-012-0025-y
    HuCC-A1 IC50
    0.42 μM
    Compound: Doxorubicin
    Cytotoxicity against HuCCa1 cells after 48 hrs by MTT assay
    Cytotoxicity against HuCCa1 cells after 48 hrs by MTT assay
    		[PMID: 26397393]
    HuCC-A1 IC50
    0.45 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against Homo sapiens (human) HuCCa1 cells after 3 days by crystal violet staining
    Cytotoxicity against Homo sapiens (human) HuCCa1 cells after 3 days by crystal violet staining
    		10.1007/s00044-011-9903-y
    HuCC-A1 IC50
    0.64 μM
    Compound: Doxorubicin
    Cytotoxicity against Homo sapiens (human) HuCCa1 cells assessed as inhibition of cell growth after 3 days by crystal violet staining
    Cytotoxicity against Homo sapiens (human) HuCCa1 cells assessed as inhibition of cell growth after 3 days by crystal violet staining
    		10.1007/s00044-012-0402-6
    HuCC-A1 IC50
    0.64 μM
    Compound: doxorubicin
    Cytotoxicity against HuCCa1 cells after 4 days by MTT assay
    Cytotoxicity against HuCCa1 cells after 4 days by MTT assay
    		[PMID: 19824618]
    HuCC-A1 IC50
    0.67 μM
    Compound: doxorubicin
    Cytotoxicity against human HuCCA1 cells by MTT assay
    Cytotoxicity against human HuCCA1 cells by MTT assay
    		[PMID: 21174408]
    HuCC-A1 IC50
    0.83 μM
    Compound: Doxorubicin
    Cytotoxicity against human HuCCa1 cells after 48 hrs by MTT assay
    Cytotoxicity against human HuCCa1 cells after 48 hrs by MTT assay
    		[PMID: 24836071]
    HuCC-A1 IC50
    0.83 μM
    Compound: Doxorubicin
    Cytotoxicity against human HuCCa1 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Cytotoxicity against human HuCCa1 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    		[PMID: 25078311]
    HuCC-A1 IC50
    0.83 μM
    Compound: doxorubicin
    Cytotoxicity against human HuCCa1 cells after 48 hrs by MTT assay
    Cytotoxicity against human HuCCa1 cells after 48 hrs by MTT assay
    		10.1007/s00044-013-0777-z
    HuCC-A1 IC50
    1.1 μM
    Compound: Doxorubicin
    Cytotoxicity against human HuCCa1 cells by MTT assay
    Cytotoxicity against human HuCCa1 cells by MTT assay
    		10.1039/C3MD00166K
    HuCC-A1 IC50
    1.13 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HuCCa1 cells assessed as reduction in cell viability after 48 hrs by XTT assay
    Antiproliferative activity against human HuCCa1 cells assessed as reduction in cell viability after 48 hrs by XTT assay
    		[PMID: 31704206]
    HuCC-A1 IC50
    2.39 μM
    Compound: Doxorubicin
    Cytotoxicity against human HuCCa1 cells by MTT assay
    Cytotoxicity against human HuCCa1 cells by MTT assay
    		[PMID: 25747499]
    HuCCT-1 IC50
    0.048 μM
    Compound: DOX
    Cytotoxicity against human HuCCT1 cells measured after 72 hrs by Celltiter-Glo assay
    Cytotoxicity against human HuCCT1 cells measured after 72 hrs by Celltiter-Glo assay
    		[PMID: 31820976]
    HuTu80 IC50
    0.2 μM
    Compound: Doxorubicin
    Cytotoxicity against human HuTu80 cells assessed as number of viable cells measured after 48 hrs by MTT based colorimetric assay
    Cytotoxicity against human HuTu80 cells assessed as number of viable cells measured after 48 hrs by MTT based colorimetric assay
    		[PMID: 36970146]
    Huh-7 IC50
    0.02 μM
    Compound: Doxorubicin
    Cytotoxicity against human Huh-7 cells assessed as reduction in cell viability after 48 hrs
    Cytotoxicity against human Huh-7 cells assessed as reduction in cell viability after 48 hrs
    		[PMID: 34601029]
    Huh-7 IC50
    0.03 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HuH7 cells after 48 hrs by Hoechst 33342 staining-based assay
    Antiproliferative activity against human HuH7 cells after 48 hrs by Hoechst 33342 staining-based assay
    		[PMID: 30655216]
    Huh-7 IC50
    0.03 μM
    Compound: Doxorubicin
    Toxicity in human Huh-7 cells assessed as reduction in cell number after 48 hrs by Hoechst 33342 staining based assay
    Toxicity in human Huh-7 cells assessed as reduction in cell number after 48 hrs by Hoechst 33342 staining based assay
    		[PMID: 31753515]
    Huh-7 IC50
    0.036 μM
    Compound: Doxorubicine
    Cytotoxicity against human HuH-7 cells assessed as reduction in cell viability incubated for 48 hrs by Hoechst-33342 staining based cell counting method (Rvb > 25 microM)
    Cytotoxicity against human HuH-7 cells assessed as reduction in cell viability incubated for 48 hrs by Hoechst-33342 staining based cell counting method (Rvb > 25 microM)
    		[PMID: 33422908]
    Huh-7 IC50
    0.12 μM
    Compound: DOX
    Cytotoxicity against human Huh-7 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 assay
    Cytotoxicity against human Huh-7 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 assay
    		[PMID: 38039790]
    Huh-7 IC50
    0.22 μM
    Compound: Doxorubicin
    Cytotoxicity against human HuH7 cells after 48 hrs by WST8 assay
    Cytotoxicity against human HuH7 cells after 48 hrs by WST8 assay
    		[PMID: 25163667]
    Huh-7 IC50
    0.22 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HuH7 cells incubated for 48 hrs by WST8 assay
    Antiproliferative activity against human HuH7 cells incubated for 48 hrs by WST8 assay
    		[PMID: 31679979]
    Huh-7 IC50
    0.24 μM
    Compound: Doxorubicin
    Cytotoxicity against human HuH7 cells assessed as reduction in cell growth after 48 hrs by MTT assay
    Cytotoxicity against human HuH7 cells assessed as reduction in cell growth after 48 hrs by MTT assay
    		[PMID: 27422336]
    Huh-7 IC50
    0.36 μM
    Compound: Doxorubicin
    Cytotoxicity against human HuH7 cells assessed as cell viability after 72 hrs by WST-1 assay
    Cytotoxicity against human HuH7 cells assessed as cell viability after 72 hrs by WST-1 assay
    		[PMID: 26711144]
    Huh-7 IC50
    0.36 μM
    Compound: Doxorubicin
    Cytotoxicity against human HuH7 cells assessed as reduction in cell viability after 72 hrs by WST1 assay
    Cytotoxicity against human HuH7 cells assessed as reduction in cell viability after 72 hrs by WST1 assay
    		[PMID: 28189419]
    Huh-7 IC50
    0.36 μM
    Compound: doxorubicin
    Cytotoxicity against human HuH7 cells after 72 hrs by WST1 assay
    Cytotoxicity against human HuH7 cells after 72 hrs by WST1 assay
    		[PMID: 26083682]
    Huh-7 IC50
    0.4 μM
    Compound: Doxorubicin
    Cytotoxicity against human HuH7 cells assessed as reduction in cell viability after 72 hrs by WST-1 assay
    Cytotoxicity against human HuH7 cells assessed as reduction in cell viability after 72 hrs by WST-1 assay
    		[PMID: 27035556]
    Huh-7 IC50
    0.7 μM
    Compound: Doxorubicin
    Cytotoxicity against human HuH7 cells after 24 hrs by MTT assay
    Cytotoxicity against human HuH7 cells after 24 hrs by MTT assay
    		[PMID: 25554367]
    Huh-7 IC50
    1.11 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HuH7 cells assessed as growth inhibition incubated for 48 hrs by MTT assay
    Antiproliferative activity against human HuH7 cells assessed as growth inhibition incubated for 48 hrs by MTT assay
    		[PMID: 26253231]
    Huh-7 IC50
    5.43 μM
    Compound: Dox
    Cytotoxicity against human HuH7 cells after 48 hrs by resazurin assay
    Cytotoxicity against human HuH7 cells after 48 hrs by resazurin assay
    		[PMID: 29107422]
    Huh-7 IC50
    5.7 μM
    Compound: Doxorubicin
    Antitumor activity against human Huh7 cells measured after 48 hrs by MTT assay
    Antitumor activity against human Huh7 cells measured after 48 hrs by MTT assay
    		[PMID: 37859719]
    IEC-6 IC50
    2.6 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against rat IEC-6 cells by MTT assay
    Cytotoxicity against rat IEC-6 cells by MTT assay
    		10.1039/C4MD00566J
    IGROV-1 GI50
    0.17 μM
    Compound: Doxorubicin
    Growth inhibition of human IGROV1 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human IGROV1 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28329730]
    IGROV-1 GI50
    0.17 μM
    Compound: Doxorubicin
    Growth inhibition of human IGROV1 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human IGROV1 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 29102177]
    IGROV-1 GI50
    0.17 μM
    Compound: Doxorubicin hydrochloride, NSC 123127
    Cytotoxicity against human IGROV1 cells after 48 hrs by SRB assay
    Cytotoxicity against human IGROV1 cells after 48 hrs by SRB assay
    		[PMID: 23871905]
    IGROV-1 GI50
    2.4 μM
    Compound: Adriamycin
    In vitro antiproliferative activity against human IGROV-ET ovarian cell line
    In vitro antiproliferative activity against human IGROV-ET ovarian cell line
    		[PMID: 14971893]
    IGROV-1 GI50
    4.4 μM
    Compound: Adriamycin
    In vitro antiproliferative activity against human IGROV ovarian cell line
    In vitro antiproliferative activity against human IGROV ovarian cell line
    		[PMID: 14971893]
    IGROV-1 IC50
    4.36 μM
    Compound: Doxorubicin
    Antiproliferative activity against human IGROV1 cells after 48 hrs by MTT assay
    Antiproliferative activity against human IGROV1 cells after 48 hrs by MTT assay
    		[PMID: 29547830]
    IMR-32 GI50
    0.023 μM
    Compound: Doxorubicin
    Growth inhibition of human IMR32 cells after 48 hrs by SRB assay
    Growth inhibition of human IMR32 cells after 48 hrs by SRB assay
    		[PMID: 25264072]
    IMR-32 GI50
    0.023 μM
    Compound: Doxorubicin
    Antiproliferative activity against human IMR32 cells assessed as reduction in net protein increase after 48 hrs by SRB assay
    Antiproliferative activity against human IMR32 cells assessed as reduction in net protein increase after 48 hrs by SRB assay
    		[PMID: 25462234]
    IMR-32 GI50
    0.023 μM
    Compound: Doxorubicin
    Antiproliferative activity against human IMR32 cells assessed as growth inhibition after 48 hrs by SRB assay
    Antiproliferative activity against human IMR32 cells assessed as growth inhibition after 48 hrs by SRB assay
    		[PMID: 27209232]
    IMR-32 GI50
    0.023 μM
    Compound: Doxorubicin
    Antiproliferative activity against human IMR32 cells by SRB assay
    Antiproliferative activity against human IMR32 cells by SRB assay
    		[PMID: 31546197]
    IMR-32 GI50
    0.025 μM
    Compound: Doxorubicin
    Growth inhibition of human IMR32 cells after 48 hrs by SRB assay
    Growth inhibition of human IMR32 cells after 48 hrs by SRB assay
    		[PMID: 27964883]
    IMR-32 GI50
    < 0.01 μM
    Compound: Doxorubicin
    Growth inhibition of human IMR32 cells after 48 hrs by SRB assay
    Growth inhibition of human IMR32 cells after 48 hrs by SRB assay
    		10.1039/C6MD00097E
    IMR-32 GI50
    < 0.01 μM
    Compound: Doxorubicin
    Growth inhibition in human IMR32 cells after 48 hrs by SRB assay
    Growth inhibition in human IMR32 cells after 48 hrs by SRB assay
    		[PMID: 31546197]
    IMR-32 IC50
    0.0051 μM
    Compound: DX
    Antiproliferative activity against human IMR32 cells assessed as cell viability after 48 hrs by formazan EZ4U dye based assay
    Antiproliferative activity against human IMR32 cells assessed as cell viability after 48 hrs by formazan EZ4U dye based assay
    		[PMID: 26690914]
    IMR-32 IC50
    0.01 μM
    Compound: Doxorubicin
    Antitumor activity was evaluated against human neuroblastoma cell line IMR-32.
    Antitumor activity was evaluated against human neuroblastoma cell line IMR-32.
    		[PMID: 10411476]
    IMR-32 IC50
    0.01 μM
    Compound: doxorubicin
    Antitumor activity against human neuroblastoma IMR32 cells
    Antitumor activity against human neuroblastoma IMR32 cells
    		[PMID: 12431048]
    IMR-32 IC50
    0.043 μM
    Compound: Doxorubicin
    Cytotoxicity against human IMR-32 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Cytotoxicity against human IMR-32 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    		[PMID: 38056297]
    IMR-32 IC50
    0.05 μM
    Compound: DX
    Cytotoxicity against human IMR32 cells assessed as reduction in cell viability after 72 hrs by MTS assay
    Cytotoxicity against human IMR32 cells assessed as reduction in cell viability after 72 hrs by MTS assay
    		[PMID: 29681486]
    IMR-32 IC50
    0.08 μM
    Compound: Doxorubicin
    Antiproliferative activity against human IMR32 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Antiproliferative activity against human IMR32 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 31546197]
    IMR-32 IC50
    0.8 μg/mL
    Compound: Doxorubicine
    Cytotoxicity against human IMR32 cells after 24 hrs by MTT assay
    Cytotoxicity against human IMR32 cells after 24 hrs by MTT assay
    		[PMID: 24177357]
    IMR-32 IC50
    1.7 μM
    Compound: adriamycin
    Growth inhibition of human IMR32 cells after 48 hrs by sulforhodamine B assay
    Growth inhibition of human IMR32 cells after 48 hrs by sulforhodamine B assay
    		[PMID: 19939522]
    IMR-32 IC50
    2.3 μM
    Compound: Doxorubicin
    Cytotoxicity against human IMR32 cells assessed as reduction in cell viability measured after 48 hrs by SRB assay
    Cytotoxicity against human IMR32 cells assessed as reduction in cell viability measured after 48 hrs by SRB assay
    		[PMID: 28818768]
    IMR-32 IC50
    3.2 μM
    Compound: Doxorubicin
    Antiproliferative activity against human IMR32 cells after 48 hrs by SRB assay
    Antiproliferative activity against human IMR32 cells after 48 hrs by SRB assay
    		[PMID: 28419927]
    IMR-32 IC50
    44.4 μM
    Compound: Doxorubicin
    Anticancer activity against human IMR32 cells by MTT assay
    Anticancer activity against human IMR32 cells by MTT assay
    		[PMID: 25743216]
    IMR-32 IC50
    5.1 nM
    Compound: DX
    Cytotoxicity against human IMR32 cells assessed as cell viability after 48 hrs by formazan dye-based EZ4U test
    Cytotoxicity against human IMR32 cells assessed as cell viability after 48 hrs by formazan dye-based EZ4U test
    		[PMID: 24996140]
    IMR-32 IC50
    5.1 nM
    Compound: DX
    Antiproliferative activity against human IMR32 cells assessed as inhibition of cell viability after 48 hrs
    Antiproliferative activity against human IMR32 cells assessed as inhibition of cell viability after 48 hrs
    		[PMID: 26360048]
    IMR-32 IC50
    5.1 nM
    Compound: Dox
    Cytotoxicity against human IMR32 cells assessed as reduction in cell viability after 48 hrs by EZ4U Non-radioactive cell proliferation assay
    Cytotoxicity against human IMR32 cells assessed as reduction in cell viability after 48 hrs by EZ4U Non-radioactive cell proliferation assay
    		[PMID: 28372935]
    IMR-32 IC50
    8.49 μM
    Compound: Doxorubicin
    Cytotoxicity against human IMR32 cells after 48 hrs by SRB assay
    Cytotoxicity against human IMR32 cells after 48 hrs by SRB assay
    		[PMID: 28318941]
    IMR-90 EC50
    360 nM
    Compound: Dox
    Cytotoxicity against human IMR-90 cells assessed as inhibition of cell growth incubated for 72 hrs by MTS assay
    Cytotoxicity against human IMR-90 cells assessed as inhibition of cell growth incubated for 72 hrs by MTS assay
    		[PMID: 37982711]
    IMR-90 IC50
    0.59 μM
    Compound: Doxorubicin
    Cytotoxicity against human IMR90 cells after 24 hrs by MTT assay
    Cytotoxicity against human IMR90 cells after 24 hrs by MTT assay
    		[PMID: 21215623]
    IMR-90 IC50
    1 μM
    Compound: Doxorubicin
    Antiproliferative activity against human IMR90 cells after 72 hrs by MTT assay
    Antiproliferative activity against human IMR90 cells after 72 hrs by MTT assay
    		[PMID: 19632833]
    IMR-90 IC50
    21.3 μM
    Compound: Doxorubicin
    Cytotoxicity against human IMR90 cells assessed as reduction in cell viability by MTT assay
    Cytotoxicity against human IMR90 cells assessed as reduction in cell viability by MTT assay
    		[PMID: 26646219]
    Ishikawa IC50
    0.1 μM
    Compound: Dox
    Antiproliferative activity against human Ishikawa cells after 72 hrs by MTT assay
    Antiproliferative activity against human Ishikawa cells after 72 hrs by MTT assay
    		[PMID: 25998504]
    Ishikawa IC50
    9.02 μM
    Compound: DOX
    Anticancer activity against human Ishikawa cells assessed as inhibition of tumor cell proliferation after 48 hrs by MTT assay
    Anticancer activity against human Ishikawa cells assessed as inhibition of tumor cell proliferation after 48 hrs by MTT assay
    		[PMID: 25064350]
    J774 IC50
    79.4 nM
    Compound: DOX
    Inhibitory concentration required for cytotoxicity in J774.2 murine macrophage-like cells
    Inhibitory concentration required for cytotoxicity in J774.2 murine macrophage-like cells
    		10.1016/0960-894X(95)00300-I
    J774.1 CC50
    0.02 μM
    Compound: Doxorubicin
    Cytotoxicity against mouse J774.1 cells after 72 hrs by MTT assay
    Cytotoxicity against mouse J774.1 cells after 72 hrs by MTT assay
    		[PMID: 24080103]
    J774.1 IC50
    0.06 μM
    Compound: Doxorubicin
    Cytotoxicity against mouse J774A.1 cells after 72 hrs by MTT assay
    Cytotoxicity against mouse J774A.1 cells after 72 hrs by MTT assay
    		[PMID: 25846065]
    J774.2 IC50
    0.56 μM
    Compound: Dox
    Cytotoxicity against mouse J774.2 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    Cytotoxicity against mouse J774.2 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    		[PMID: 37001390]
    J774.2 IC50
    0.64 μM
    Compound: Dox
    Antiproliferative activity against J774.2 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay
    Antiproliferative activity against J774.2 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay
    		[PMID: 36809707]
    J774.2 IC50
    2752.5 nM
    Compound: DOX
    Inhibitory concentration required for cytotoxicity in DOX-resistant (DOX/R) cells
    Inhibitory concentration required for cytotoxicity in DOX-resistant (DOX/R) cells
    		10.1016/0960-894X(95)00300-I
    J774.2 IC50
    368.4 nM
    Compound: DOX
    Inhibitory concentration required for cytotoxicity in hydroxyrubicin-resistant (WP159/R) cells
    Inhibitory concentration required for cytotoxicity in hydroxyrubicin-resistant (WP159/R) cells
    		10.1016/0960-894X(95)00300-I
    J774.A1 CC50
    0.01 μM
    Compound: Doxorubicin
    Cytotoxicity against mouse J774A1 cells incubated for 72 hrs by MTT assay
    Cytotoxicity against mouse J774A1 cells incubated for 72 hrs by MTT assay
    		[PMID: 25282267]
    J774.A1 CC50
    0.02 μM
    Compound: Doxorubicin
    Cytotoxicity against mouse J774A1 cells after 72 hrs by MTT assay
    Cytotoxicity against mouse J774A1 cells after 72 hrs by MTT assay
    		[PMID: 22608675]
    J774.A1 IC50
    0.02 μM
    Compound: Doxorubicin
    Cytotoxic activity against mouse J774A1 cells after 72 hrs by MTT assay
    Cytotoxic activity against mouse J774A1 cells after 72 hrs by MTT assay
    		[PMID: 21555166]
    JIMT-1 IC50
    0.37 μM
    Compound: ADM
    Antiproliferative activity against human JIMT-1 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
    Antiproliferative activity against human JIMT-1 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
    		[PMID: 36332551]
    JIMT-1 IC50
    0.59 μM
    Compound: DX
    Antiproliferative activity against human JIMT1 cells after 72 hrs by SRB assay
    Antiproliferative activity against human JIMT1 cells after 72 hrs by SRB assay
    		[PMID: 30025346]
    JeKo-1 IC50
    0.18 μM
    Compound: Doxorubicin
    Cytotoxicity activity against human JeKo1 cells assessed as reduction in cell viability after 48 hrs by CCK-8 assay
    Cytotoxicity activity against human JeKo1 cells assessed as reduction in cell viability after 48 hrs by CCK-8 assay
    		[PMID: 29288944]
    Jurkat GI50
    0.21 μM
    Compound: doxorubicin
    Growth inhibition of Jurkat cell
    Growth inhibition of Jurkat cell
    		[PMID: 17181155]
    Jurkat GI50
    0.43 μM
    Compound: Dox
    Anticancer activity against human Jurkat cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    Anticancer activity against human Jurkat cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    		[PMID: 35533562]
    Jurkat GI50
    0.65 μM
    Compound: Dox
    Antiproliferative activity against human Jurkat cells incubated for 72 hrs and measured by MTT assay
    Antiproliferative activity against human Jurkat cells incubated for 72 hrs and measured by MTT assay
    		[PMID: 35973342]
    Jurkat GI50
    24 μM
    Compound: doxorubicin
    Growth inhibition of Jurkat cell overexpressing BclXL
    Growth inhibition of Jurkat cell overexpressing BclXL
    		[PMID: 17181155]
    Jurkat GI50
    26 μM
    Compound: doxorubicin
    Growth inhibition of Jurkat cell overexpressing Bcl2
    Growth inhibition of Jurkat cell overexpressing Bcl2
    		[PMID: 17181155]
    Jurkat GI50
    < 1 μM
    Compound: DOX
    Antiproliferative activity against human Jurkat cells by MTT assay
    Antiproliferative activity against human Jurkat cells by MTT assay
    		[PMID: 31990554]
    Jurkat IC50
    0.009 μM
    Compound: Doxorubicin
    Antiproliferative activity against human Jurkat cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Antiproliferative activity against human Jurkat cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    		[PMID: 27010926]
    Jurkat IC50
    0.012 μM
    Compound: DOX
    Cytotoxicity against human Jurkat cells assessed as cell growth inhibition after 48 hrs by MTT assay
    Cytotoxicity against human Jurkat cells assessed as cell growth inhibition after 48 hrs by MTT assay
    		[PMID: 26638041]
    Jurkat IC50
    0.02 μM
    Compound: DOX
    Cytotoxicity against human Jurkat cell viability after 72 hrs by MTT assay
    Cytotoxicity against human Jurkat cell viability after 72 hrs by MTT assay
    		[PMID: 29660689]
    Jurkat IC50
    0.03 μM
    Compound: DOX
    Cytotoxicity against human Jurkat cells after 72 hrs by MTT assay
    Cytotoxicity against human Jurkat cells after 72 hrs by MTT assay
    		[PMID: 18783950]
    Jurkat IC50
    0.03 μM
    Compound: DOX
    Antiproliferative activity against human Jurkat cells after 72 hrs by MTT assay
    Antiproliferative activity against human Jurkat cells after 72 hrs by MTT assay
    		[PMID: 20359789]
    Jurkat IC50
    0.03 μM
    Compound: DOX
    Antiproliferative activity against human Jurkat cells after 72 hrs by MTT assay
    Antiproliferative activity against human Jurkat cells after 72 hrs by MTT assay
    		[PMID: 24021462]
    Jurkat IC50
    0.03 μM
    Compound: DOX
    Cytotoxicity against human Jurkat cells after 72 hrs by MTT assay
    Cytotoxicity against human Jurkat cells after 72 hrs by MTT assay
    		[PMID: 25259516]
    Jurkat IC50
    0.03 μM
    Compound: DOX
    Cytotoxicity against human Jurkat T cells assessed as cell growth inhibition after 72 hrs by MTT assay
    Cytotoxicity against human Jurkat T cells assessed as cell growth inhibition after 72 hrs by MTT assay
    		[PMID: 26720155]
    Jurkat IC50
    0.03 μM
    Compound: DOX
    Antiproliferative activity against human Jurkat cells after 72 hrs by MTT assay
    Antiproliferative activity against human Jurkat cells after 72 hrs by MTT assay
    		[PMID: 28135634]
    Jurkat IC50
    0.03 μM
    Compound: DOX
    Cytotoxicity against human Jurkat cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human Jurkat cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 28427016]
    Jurkat IC50
    0.03 μM
    Compound: DOX
    Cytotoxicity against human Jurkat cells assessed as inhibition of cell growth after 72 hrs by MTT assay
    Cytotoxicity against human Jurkat cells assessed as inhibition of cell growth after 72 hrs by MTT assay
    		[PMID: 30746062]
    Jurkat IC50
    0.03 μM
    Compound: DOX
    Antiproliferative activity against human Jurkat cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay
    Antiproliferative activity against human Jurkat cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay
    		[PMID: 31557614]
    Jurkat IC50
    0.03 μM
    Compound: DOX
    Antiproliferative activity against human Jurkat cells assessed as reduction in cell viability measured after 6 days by MTT assay
    Antiproliferative activity against human Jurkat cells assessed as reduction in cell viability measured after 6 days by MTT assay
    		[PMID: 32653698]
    Jurkat IC50
    0.03 μM
    Compound: DOX
    Antiproliferative activity against human Jurkat cells by MTT colorimetric assay
    Antiproliferative activity against human Jurkat cells by MTT colorimetric assay
    		[PMID: 38527380]
    Jurkat IC50
    0.03 μM
    Compound: DOX
    Antiproliferative activity against human Jurkat cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    Antiproliferative activity against human Jurkat cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    		[PMID: 39067378]
    Jurkat IC50
    0.03 μM
    Compound: Dox
    Cytotoxicity against human Jurkat cells assessed as cell growth inhibition after 72 hrs by MTT assay
    Cytotoxicity against human Jurkat cells assessed as cell growth inhibition after 72 hrs by MTT assay
    		[PMID: 27231128]
    Jurkat IC50
    0.05 μM
    Compound: Doxorubicin
    Cytotoxicity against human Jurkat cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
    Cytotoxicity against human Jurkat cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
    		[PMID: 33668008]
    Jurkat IC50
    0.05 μM
    Compound: Doxorubicin
    Cytotoxicity against human Jurkat cells assessed as cell growth inhibition incubated for 24 to 72 hrs by MTT assay
    Cytotoxicity against human Jurkat cells assessed as cell growth inhibition incubated for 24 to 72 hrs by MTT assay
    		[PMID: 37989057]
    Jurkat IC50
    0.078 μM
    Compound: Doxorubicin
    Cytotoxicity against human Jurkat cells after 72 hrs by MTT assay
    Cytotoxicity against human Jurkat cells after 72 hrs by MTT assay
    		[PMID: 19394829]
    Jurkat IC50
    0.078 μM
    Compound: Doxorubicin
    Antiproliferative activity against human Jurkat cells assessed as cell viability after 72 hrs by MTT assay
    Antiproliferative activity against human Jurkat cells assessed as cell viability after 72 hrs by MTT assay
    		[PMID: 24012378]
    Jurkat IC50
    0.09 μM
    Compound: Doxorubicin
    Cytotoxicity against human Jurkat cells after 72 hrs by MTT assay
    Cytotoxicity against human Jurkat cells after 72 hrs by MTT assay
    		[PMID: 17227762]
    Jurkat IC50
    0.1 μM
    Compound: Dox
    Cytotoxicity against human Jurkat cells after 72 hrs by MTT assay
    Cytotoxicity against human Jurkat cells after 72 hrs by MTT assay
    		[PMID: 30659997]
    Jurkat IC50
    0.11 μM
    Compound: DOX
    Cytotoxicity against human Jurkat cells after 72 hrs by MTT assay
    Cytotoxicity against human Jurkat cells after 72 hrs by MTT assay
    		[PMID: 29970309]
    Jurkat IC50
    0.2 μM
    Compound: Doxorubicin
    Cytotoxicity against human Jurkat cells assessed as reduction in cell viability measured after 48 hrs MTT assay
    Cytotoxicity against human Jurkat cells assessed as reduction in cell viability measured after 48 hrs MTT assay
    		[PMID: 33668008]
    Jurkat IC50
    0.23 μM
    Compound: Doxorubicin
    Cytotoxicity against human Jurkat cells assessed as effect on cell viability measured after 48 hrs by MTT assay
    Cytotoxicity against human Jurkat cells assessed as effect on cell viability measured after 48 hrs by MTT assay
    		[PMID: 27521588]
    Jurkat IC50
    0.26 μM
    Compound: Doxorubicin
    Cytotoxicity against human Jurkat cells assessed as reduction in cell survival after 48 hrs by MTT assay
    Cytotoxicity against human Jurkat cells assessed as reduction in cell survival after 48 hrs by MTT assay
    		[PMID: 28494255]
    Jurkat IC50
    0.3 μM
    Compound: Doxorubicin
    Cytotoxicity against human Jurkat cells assessed as cell growth inhibition measured after 45 hrs
    Cytotoxicity against human Jurkat cells assessed as cell growth inhibition measured after 45 hrs
    		[PMID: 35526504]
    Jurkat IC50
    0.32 μM
    Compound: Doxorubicin
    Cytotoxicity against human Jurkat cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    Cytotoxicity against human Jurkat cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    		[PMID: 37216812]
    Jurkat IC50
    0.7 μM
    Compound: Doxorubicin
    Cytotoxicity against human Jurkat cells assessed as reduction in cell viability measured after 24 hrs MTT assay
    Cytotoxicity against human Jurkat cells assessed as reduction in cell viability measured after 24 hrs MTT assay
    		[PMID: 33668008]
    Jurkat IC50
    1 μM
    Compound: Doxorubicin
    Cytotoxicity against human Jurkat cells assessed as cell growth inhibition measured after 24 hrs
    Cytotoxicity against human Jurkat cells assessed as cell growth inhibition measured after 24 hrs
    		[PMID: 35526504]
    Jurkat IC50
    1.7 μM
    Compound: doxorubicin
    Inhibitory concentration against Jurkat cells
    Inhibitory concentration against Jurkat cells
    		[PMID: 14971909]
    Jurkat IC50
    1.8 μM
    Compound: Doxorubicin
    Cytotoxicity against human Jurkat cells assessed as cell growth inhibition measured after 18 hrs
    Cytotoxicity against human Jurkat cells assessed as cell growth inhibition measured after 18 hrs
    		[PMID: 35526504]
    Jurkat IC50
    2.35 μM
    Compound: doxo
    Antiproliferative activity against human Jurkat T cells assessed as decrease in cell viability measured after 24 to 72 hrs by MTT assay
    Antiproliferative activity against human Jurkat T cells assessed as decrease in cell viability measured after 24 to 72 hrs by MTT assay
    		[PMID: 30763817]
    Jurkat IC50
    37.5 nM
    Compound: Doxorubicin
    Antiproliferative activity against human Jurkat cells after 96 hrs by MTT assay
    Antiproliferative activity against human Jurkat cells after 96 hrs by MTT assay
    		[PMID: 21296467]
    Jurkat IC50
    45.87 μM
    Compound: Dox
    Anticancer activity against human Jurkat cells
    Anticancer activity against human Jurkat cells
    		[PMID: 31330449]
    Jurkat IC50
    9.6 nM
    Compound: Doxorubicin
    Concentration required to inhibit 50% growth of human Jurkat cells
    Concentration required to inhibit 50% growth of human Jurkat cells
    		[PMID: 10395479]
    Jurkat IC50
    9.6 nM
    Compound: Doxorubicin
    Inhibitory concentration to reduce cell number to 50% in a panel of cultured, wild type human Jurkat leukemia (JL C) cells.
    Inhibitory concentration to reduce cell number to 50% in a panel of cultured, wild type human Jurkat leukemia (JL C) cells.
    		[PMID: 11806725]
    Jurkat IC50
    9.6 nM
    Compound: Doxorubicin
    Growth inhibitory activity against human Jurkat leukemia cell line (JLC)
    Growth inhibitory activity against human Jurkat leukemia cell line (JLC)
    		[PMID: 12620081]
    Jurkat IC50
    9.6 nM
    Compound: doxorubicin
    Inhibitory concentration required to reduce human Jurkat leukemia (JLC sensitive, wild type) cell number to 50% of control cultures
    Inhibitory concentration required to reduce human Jurkat leukemia (JLC sensitive, wild type) cell number to 50% of control cultures
    		[PMID: 9191970]
    Jurkat E6.1 IC50
    1.03 μM
    Compound: Dox
    Cytotoxicity against human Jurkat E6-1 cells after 24 hrs by MTT assay
    Cytotoxicity against human Jurkat E6-1 cells after 24 hrs by MTT assay
    		[PMID: 29398445]
    K-562R IC50
    35 μM
    Compound: Dox
    Cytotoxicity against doxorubicin-resistant human K562R cells incubated for 72 hrs by CellTiter 96 aqueous one solution reagent based assay
    Cytotoxicity against doxorubicin-resistant human K562R cells incubated for 72 hrs by CellTiter 96 aqueous one solution reagent based assay
    		[PMID: 27753480]
    K562 ED50
    59.5 nM
    Compound: doxorubicin
    Cytotoxicity against human K562 cells by MTT assay
    Cytotoxicity against human K562 cells by MTT assay
    		[PMID: 17655260]
    K562 GI50
    0.03 μM
    Compound: Adriamycin
    In vitro antiproliferative activity against human K-562 cell line
    In vitro antiproliferative activity against human K-562 cell line
    		[PMID: 14971893]
    K562 GI50
    0.03 μM
    Compound: Doxorubicin
    Cytotoxicity against human K562 cells by sulforhodamine B assay
    Cytotoxicity against human K562 cells by sulforhodamine B assay
    		[PMID: 20413188]
    K562 GI50
    0.06 μM
    Compound: Doxorubicin
    Anticancer activity against human K562 cells assessed as cell growth inhibition measured after 48 hrs by sulforhodamine B assay
    Anticancer activity against human K562 cells assessed as cell growth inhibition measured after 48 hrs by sulforhodamine B assay
    		[PMID: 33214037]
    K562 GI50
    0.1 μM
    Compound: Doxorubicin
    Cytotoxicity against human K562 cells after 72 hrs by MTT assay
    Cytotoxicity against human K562 cells after 72 hrs by MTT assay
    		[PMID: 21115210]
    K562 GI50
    0.1 μM
    Compound: adriamycin
    Antitumor activity against human K562 cells after 48 hrs by sulforhodamine B protein assay
    Antitumor activity against human K562 cells after 48 hrs by sulforhodamine B protein assay
    		[PMID: 17448574]
    K562 GI50
    0.19 μM
    Compound: Doxorubicin
    Growth inhibition of human K562 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human K562 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28329730]
    K562 GI50
    0.19 μM
    Compound: Doxorubicin
    Growth inhibition of human K562 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human K562 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 29102177]
    K562 GI50
    0.19 μM
    Compound: Doxorubicin hydrochloride, NSC 123127
    Cytotoxicity against human K562 cells after 48 hrs by SRB assay
    Cytotoxicity against human K562 cells after 48 hrs by SRB assay
    		[PMID: 23871905]
    K562 GI50
    0.4 μg/mL
    Compound: DOX
    Growth inhibition of human K562 cells after 48 hrs by sulforhodamine B assay
    Growth inhibition of human K562 cells after 48 hrs by sulforhodamine B assay
    		[PMID: 21041092]
    K562 GI50
    0.7 μM
    Compound: Dox
    Antiproliferative activity against human K562 cells incubated for 72 hrs and measured by MTT assay
    Antiproliferative activity against human K562 cells incubated for 72 hrs and measured by MTT assay
    		[PMID: 35973342]
    K562 GI50
    0.93 μM
    Compound: Dox
    Growth inhibition of human K562 cells after 48 hrs by sulforhodamine B dye-based spectrophotometric assay
    Growth inhibition of human K562 cells after 48 hrs by sulforhodamine B dye-based spectrophotometric assay
    		[PMID: 28505535]
    K562 GI50
    1.11 μM
    Compound: DOXO
    Antiproliferative activity against human K562 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    Antiproliferative activity against human K562 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    		[PMID: 31247374]
    K562 GI50
    11.62 μM
    Compound: Doxorubicin
    Inhibition of P-gp in doxorubicin resistant human K562 cells assessed as reduction in cell viability measured after 48 hrs by SRB assay
    Inhibition of P-gp in doxorubicin resistant human K562 cells assessed as reduction in cell viability measured after 48 hrs by SRB assay
    		[PMID: 27908756]
    K562 GI50
    1 μM
    Compound: doxorubicin
    Antiproliferative activity against human K562 cells
    Antiproliferative activity against human K562 cells
    		[PMID: 19188072]
    K562 GI50
    1 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human K562 cells
    Cytotoxicity against human K562 cells
    		[PMID: 25372601]
    K562 GI50
    1 μg/mL
    Compound: doxorubicin
    Antiproliferative activity against human K562 cells after 72 hrs by resazurin dye reduction assay
    Antiproliferative activity against human K562 cells after 72 hrs by resazurin dye reduction assay
    		[PMID: 20153202]
    K562 GI50
    2 x 10-2 μM
    Compound: Doxorubicin
    Cytotoxicity against human K562 cells assessed as growth inhibition after 72 hrs by MTT assay
    Cytotoxicity against human K562 cells assessed as growth inhibition after 72 hrs by MTT assay
    		[PMID: 29670691]
    K562 GI50
    65 nM
    Compound: Doxorubicin
    Antiproliferative activity against human K562 cells measured after 48 hrs by Presto blue assay
    Antiproliferative activity against human K562 cells measured after 48 hrs by Presto blue assay
    		[PMID: 27908756]
    K562 GI50
    < 0.046 μM
    Compound: Dox
    Antiproliferative activity against human K562 cells assessed as growth inhibition after 48 hrs by SRB assay
    Antiproliferative activity against human K562 cells assessed as growth inhibition after 48 hrs by SRB assay
    		[PMID: 26454648]
    K562 GI50
    < 0.1 μM
    Compound: Doxorubicin
    Antiproliferative activity against human K562 cells assessed as cell growth inhibition
    Antiproliferative activity against human K562 cells assessed as cell growth inhibition
    		[PMID: 32961322]
    K562 GI50
    < 1 μM
    Compound: DOX
    Antiproliferative activity against human K562 cells by MTT assay
    Antiproliferative activity against human K562 cells by MTT assay
    		[PMID: 31990554]
    K562 GI50
    < 10 μM
    Compound: Doxorubicin
    Antiproliferative activity against human K562 cells assessed as cell growth inhibition by SRB assay
    Antiproliferative activity against human K562 cells assessed as cell growth inhibition by SRB assay
    		[PMID: 37875056]
    K562 GI50
    > 150 nM
    Compound: Doxorubicin
    Inhibition of P-gp in doxorubicin resistant human K562 cells assessed as reduction in cell viability measured after 48 hrs by Presto blue assay
    Inhibition of P-gp in doxorubicin resistant human K562 cells assessed as reduction in cell viability measured after 48 hrs by Presto blue assay
    		[PMID: 27908756]
    K562 IC50
    0.006 μM
    Compound: Dox
    Antiproliferative activity against human K562 cells after 72 hrs by MTT assay
    Antiproliferative activity against human K562 cells after 72 hrs by MTT assay
    		[PMID: 27423028]
    K562 IC50
    0.01 μM
    Compound: ADR
    Antiproliferative activity against human K562 cells after 48 hrs by hemocytometer
    Antiproliferative activity against human K562 cells after 48 hrs by hemocytometer
    		[PMID: 21705223]
    K562 IC50
    0.01 μM
    Compound: Adriamycin
    In vitro inhibitory concentration against human chronic myelogenous leukemia K562 cell growth
    In vitro inhibitory concentration against human chronic myelogenous leukemia K562 cell growth
    		[PMID: 12852768]
    K562 IC50
    0.01 μM
    Compound: Adriamycin
    Antiproliferative activity against human K562 cells after 48 hrs by hemocytometric analysis
    Antiproliferative activity against human K562 cells after 48 hrs by hemocytometric analysis
    		[PMID: 21563750]
    K562 IC50
    0.01 μM
    Compound: adriamycin
    Antiproliferative activity against human K562 cell line
    Antiproliferative activity against human K562 cell line
    		[PMID: 17181164]
    K562 IC50
    0.01 μM
    Compound: adriamycin
    Antiproliferative activity against human K562 cells after 48 hrs
    Antiproliferative activity against human K562 cells after 48 hrs
    		[PMID: 19220018]
    K562 IC50
    0.011 μg/mL
    Compound: ADR
    Cytotoxicity against human K562 cells after 72 hrs by MTT assay
    Cytotoxicity against human K562 cells after 72 hrs by MTT assay
    		[PMID: 18590312]
    K562 IC50
    0.011 μg/mL
    Compound: ADR
    Cytotoxicity against human K562 cells after 72 hrs by SRB assay
    Cytotoxicity against human K562 cells after 72 hrs by SRB assay
    		[PMID: 18590312]
    K562 IC50
    0.018 μM
    Compound: Doxorubicin
    Antiproliferative activity against human K562 cells after 72 hrs by MTT reduction assay
    Antiproliferative activity against human K562 cells after 72 hrs by MTT reduction assay
    		[PMID: 28551177]
    K562 IC50
    0.019 μM
    Compound: Doxorubicin
    Cytotoxicity against human K562 cells assessed as reduction in cell viability measured after 72 hrs by MTS assay
    Cytotoxicity against human K562 cells assessed as reduction in cell viability measured after 72 hrs by MTS assay
    		[PMID: 33261897]
    K562 IC50
    0.021 μM
    Compound: DOX
    Cytotoxicity against human K562 cells measured after 72 hrs by Celltiter-Glo assay
    Cytotoxicity against human K562 cells measured after 72 hrs by Celltiter-Glo assay
    		[PMID: 31820976]
    K562 IC50
    0.03 μM
    Compound: Doxo
    Cytotoxicity against human K562 cells after 72 hrs by MTT assay
    Cytotoxicity against human K562 cells after 72 hrs by MTT assay
    		[PMID: 23245571]
    K562 IC50
    0.032 μM
    Compound: DOX
    Cytotoxicity against human doxorubicin-sensitive K562 cells after 72 hrs by MTT assay
    Cytotoxicity against human doxorubicin-sensitive K562 cells after 72 hrs by MTT assay
    		[PMID: 19140665]
    K562 IC50
    0.033 μM
    Compound: Doxorubicin
    Cytotoxicity against human K562 cells after 72 hrs by MTS assay
    Cytotoxicity against human K562 cells after 72 hrs by MTS assay
    		[PMID: 20471276]
    K562 IC50
    0.035 μg/mL
    Compound: doxorubicin
    Cytotoxicity against human K562 cells after 2 to 7 days by neutral red assay
    Cytotoxicity against human K562 cells after 2 to 7 days by neutral red assay
    		[PMID: 8984156]
    K562 IC50
    0.047 μM
    Compound: Dox
    Cytotoxicity against human K562 cells incubated for 72 hrs by CellTiter 96 aqueous one solution reagent based assay
    Cytotoxicity against human K562 cells incubated for 72 hrs by CellTiter 96 aqueous one solution reagent based assay
    		[PMID: 27753480]
    K562 IC50
    0.06 μM
    Compound: Doxorubicin
    Cytotoxicity against human K562 cells after 72 hrs by flow cytometry
    Cytotoxicity against human K562 cells after 72 hrs by flow cytometry
    		[PMID: 19482476]
    K562 IC50
    0.06 μM
    Compound: doxorubicin
    Cytotoxicity against human K562 cells after 72 hrs by flow cytometry
    Cytotoxicity against human K562 cells after 72 hrs by flow cytometry
    		[PMID: 19926173]
    K562 IC50
    0.07 μM
    Compound: Doxorubicin
    Anticancer activity against human K562 cells incubated for 24 hrs by MTT assay
    Anticancer activity against human K562 cells incubated for 24 hrs by MTT assay
    		[PMID: 28579122]
    K562 IC50
    0.08 μM
    Compound: Doxorubicin
    Growth inhibition of human K562 cells after 72 hrs by MTS method
    Growth inhibition of human K562 cells after 72 hrs by MTS method
    		[PMID: 18258442]
    K562 IC50
    0.09 μM
    Compound: Adriamycin
    Cytotoxicity against human K562 cells by SRB method
    Cytotoxicity against human K562 cells by SRB method
    		[PMID: 18181575]
    K562 IC50
    0.1 mM
    Compound: Dox
    Antiproliferative activity against human K562 cells after 72 hrs by MTT assay
    Antiproliferative activity against human K562 cells after 72 hrs by MTT assay
    		[PMID: 29459273]
    K562 IC50
    0.1 μM
    Compound: 1; Dox
    Antiproliferative activity against human K562 cells after 72 hrs by MTT assay
    Antiproliferative activity against human K562 cells after 72 hrs by MTT assay
    		[PMID: 26890118]
    K562 IC50
    0.1 μM
    Compound: 5
    Antiproliferative activity against human K562 cells after 72 hrs by MTT assay
    Antiproliferative activity against human K562 cells after 72 hrs by MTT assay
    		[PMID: 29137865]
    K562 IC50
    0.1 μM
    Compound: Dox
    Cytotoxicity against human K562 cells after 72 hrs by MTT assay
    Cytotoxicity against human K562 cells after 72 hrs by MTT assay
    		[PMID: 30659997]
    K562 IC50
    0.1 μM
    Compound: Dox
    Antiproliferative activity against human K562 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay
    Antiproliferative activity against human K562 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay
    		[PMID: 32428792]
    K562 IC50
    0.1 μM
    Compound: Doxorubicin
    Cytotoxicity against human K562 cells after 72 hrs by MTT assay
    Cytotoxicity against human K562 cells after 72 hrs by MTT assay
    		[PMID: 19361894]
    K562 IC50
    0.1 μM
    Compound: Doxorubicin
    Cytotoxicity in human K562 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Cytotoxicity in human K562 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    		[PMID: 34082225]
    K562 IC50
    0.12 μM
    Compound: 1; Dox
    Antiproliferative activity against human K562 cells after 72 hrs by MTT assay
    Antiproliferative activity against human K562 cells after 72 hrs by MTT assay
    		[PMID: 26633734]
    K562 IC50
    0.12 μM
    Compound: Dox
    Cytotoxicity against human K562 cells after 72 hrs by MTT assay
    Cytotoxicity against human K562 cells after 72 hrs by MTT assay
    		[PMID: 21144624]
    K562 IC50
    0.12 μM
    Compound: doxorubicin
    Growth inhibitory concentration of compound was measured against human leukemia cell line (K562)
    Growth inhibitory concentration of compound was measured against human leukemia cell line (K562)
    		[PMID: 10698436]
    K562 IC50
    0.14 μM
    Compound: DOX
    Cytotoxicity against human K562 cells after 72 hrs by MTT assay
    Cytotoxicity against human K562 cells after 72 hrs by MTT assay
    		[PMID: 29970309]
    K562 IC50
    0.14 μM
    Compound: Doxorubicin
    Cytotoxicity against p53 null human K562 cells asessed as reduction in cell viability incubated for 24 hrs by MTT assay
    Cytotoxicity against p53 null human K562 cells asessed as reduction in cell viability incubated for 24 hrs by MTT assay
    		[PMID: 31324563]
    K562 IC50
    0.14 μM
    Compound: I
    Antiproliferative activity against human K562 cells after 72 hrs by MTT test
    Antiproliferative activity against human K562 cells after 72 hrs by MTT test
    		[PMID: 17276690]
    K562 IC50
    0.14 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human K562 cells after 72 hrs by MTT assay
    Cytotoxicity against human K562 cells after 72 hrs by MTT assay
    		[PMID: 18586355]
    K562 IC50
    0.157 μM
    Compound: Doxorubicin
    Cytotoxicity against human K562 cells at 50 uM by MTT reduction assay
    Cytotoxicity against human K562 cells at 50 uM by MTT reduction assay
    		[PMID: 33276991]
    K562 IC50
    0.17 μM
    Compound: Doxorubicin
    Cytotoxicity against human K562 cells after 48 hrs by MTT assay
    Cytotoxicity against human K562 cells after 48 hrs by MTT assay
    		[PMID: 22537362]
    K562 IC50
    0.17 μM
    Compound: doxorubicin
    Cytotoxicity against human K562 cells after 48 hrs by MTT assay
    Cytotoxicity against human K562 cells after 48 hrs by MTT assay
    		[PMID: 21087017]
    K562 IC50
    0.198 μM
    Compound: Doxorubicin
    Anticancer activity against human K562 cells by MTT assay
    Anticancer activity against human K562 cells by MTT assay
    		[PMID: 21570750]
    K562 IC50
    0.2 μM
    Compound: Doxorubicin
    Cytotoxicity against human K562 cells assessed as reduction in cell viability incubated for 72 hrs by MTT method
    Cytotoxicity against human K562 cells assessed as reduction in cell viability incubated for 72 hrs by MTT method
    		[PMID: 25932671]
    K562 IC50
    0.21 μM
    Compound: Doxorubicin
    Antiproliferative activity against human K562 cells incubated for 48 hrs by MTT assay
    Antiproliferative activity against human K562 cells incubated for 48 hrs by MTT assay
    		[PMID: 32035399]
    K562 IC50
    0.21 μM
    Compound: Doxorubicin
    Cytotoxicity against human K562 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
    Cytotoxicity against human K562 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
    		[PMID: 37951135]
    K562 IC50
    0.22 μM
    Compound: Doxorubicin
    Antiproliferative activity against human K562 cells measured after 72 hrs by CCK8 assay
    Antiproliferative activity against human K562 cells measured after 72 hrs by CCK8 assay
    		[PMID: 27484511]
    K562 IC50
    0.22 μM
    Compound: Doxorubicin
    Antiproliferative activity against human K562 cells incubated for 72 hrs by CCK8 assay
    Antiproliferative activity against human K562 cells incubated for 72 hrs by CCK8 assay
    		[PMID: 32992133]
    K562 IC50
    0.24 μM
    Compound: doxorubicin
    Growth inhibition of human K562 cells after 72 hrs by SRB assay
    Growth inhibition of human K562 cells after 72 hrs by SRB assay
    		[PMID: 18313307]
    K562 IC50
    0.25 μM
    Compound: Adriamycin
    Cytotoxicity against human K562 cells after 72 hrs by MTT assay
    Cytotoxicity against human K562 cells after 72 hrs by MTT assay
    		[PMID: 24370114]
    K562 IC50
    0.25 μM
    Compound: DOX
    Antiproliferative activity against human K562 cells after 72 hrs by MTT assay
    Antiproliferative activity against human K562 cells after 72 hrs by MTT assay
    		[PMID: 20359789]
    K562 IC50
    0.25 μM
    Compound: DOX
    Antiproliferative activity against human K562 cells after 72 hrs by MTT assay
    Antiproliferative activity against human K562 cells after 72 hrs by MTT assay
    		[PMID: 24021462]
    K562 IC50
    0.25 μM
    Compound: DOX
    Cytotoxicity against human K562 cells after 72 hrs by MTT assay
    Cytotoxicity against human K562 cells after 72 hrs by MTT assay
    		[PMID: 25259516]
    K562 IC50
    0.25 μM
    Compound: DOX
    Cytotoxicity against human K562 cells assessed as cell growth inhibition after 72 hrs by MTT assay
    Cytotoxicity against human K562 cells assessed as cell growth inhibition after 72 hrs by MTT assay
    		[PMID: 26720155]
    K562 IC50
    0.25 μM
    Compound: DOX
    Antiproliferative activity against human K562 cells after 72 hrs by MTT assay
    Antiproliferative activity against human K562 cells after 72 hrs by MTT assay
    		[PMID: 28135634]
    K562 IC50
    0.25 μM
    Compound: DOX
    Cytotoxicity against human K562 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human K562 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 28427016]
    K562 IC50
    0.25 μM
    Compound: DOX
    Cytotoxicity against human K562 cells assessed as inhibition of cell growth after 72 hrs by MTT assay
    Cytotoxicity against human K562 cells assessed as inhibition of cell growth after 72 hrs by MTT assay
    		[PMID: 30746062]
    K562 IC50
    0.25 μM
    Compound: DOX
    Antiproliferative activity against human K562 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay
    Antiproliferative activity against human K562 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay
    		[PMID: 31557614]
    K562 IC50
    0.25 μM
    Compound: DOX
    Antiproliferative activity against human K562 cells assessed as reduction in cell viability measured after 6 days by MTT assay
    Antiproliferative activity against human K562 cells assessed as reduction in cell viability measured after 6 days by MTT assay
    		[PMID: 32653698]
    K562 IC50
    0.25 μM
    Compound: DOX
    Antiproliferative activity against human K562 cells by MTT colorimetric assay
    Antiproliferative activity against human K562 cells by MTT colorimetric assay
    		[PMID: 38527380]
    K562 IC50
    0.25 μM
    Compound: DOX
    Antiproliferative activity against human K562 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    Antiproliferative activity against human K562 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    		[PMID: 39067378]
    K562 IC50
    0.25 μM
    Compound: Dox
    Cytotoxicity against human K562 cells assessed as cell growth inhibition after 72 hrs by MTT assay
    Cytotoxicity against human K562 cells assessed as cell growth inhibition after 72 hrs by MTT assay
    		[PMID: 27231128]
    K562 IC50
    0.25 μM
    Compound: Dox
    Antiproliferative activity against human K562 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    Antiproliferative activity against human K562 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    		[PMID: 38176358]
    K562 IC50
    0.26 μg/mL
    Compound: DOX
    Cytotoxicity against human K562 cells after 72 hrs by MTT assay
    Cytotoxicity against human K562 cells after 72 hrs by MTT assay
    		[PMID: 24589485]
    K562 IC50
    0.28 μM
    Compound: Adriamycin
    Cytotoxicity against human K-562 cells after 48 hrs by SRB assay
    Cytotoxicity against human K-562 cells after 48 hrs by SRB assay
    		[PMID: 17125233]
    K562 IC50
    0.28 μM
    Compound: Doxorubicin
    Cytotoxicity against human K562 cells by MTT assay
    Cytotoxicity against human K562 cells by MTT assay
    		[PMID: 23544451]
    K562 IC50
    0.28 μM
    Compound: Doxorubicin
    Cytotoxicity against human K562 cells assessed as growth inhibition after 72 hrs by MTT assay
    Cytotoxicity against human K562 cells assessed as growth inhibition after 72 hrs by MTT assay
    		[PMID: 27623548]
    K562 IC50
    0.28 μM
    Compound: Doxorubicine
    Iinhibitory activity against K562 leukemia cell line using sulforhodamine B (SRB) protein assay
    Iinhibitory activity against K562 leukemia cell line using sulforhodamine B (SRB) protein assay
    		[PMID: 12039588]
    K562 IC50
    0.28 μM
    Compound: doxorubicin
    Cytotoxicity against human K562 cells
    Cytotoxicity against human K562 cells
    		[PMID: 12608854]
    K562 IC50
    0.3 μM
    Compound: doxorubicin
    Growth inhibition of human K562 cells by MTS method
    Growth inhibition of human K562 cells by MTS method
    		[PMID: 19457675]
    K562 IC50
    0.32 μM
    Compound: adriamycin
    Cytotoxicity against human K562 cells by MTT assay
    Cytotoxicity against human K562 cells by MTT assay
    		[PMID: 19422203]
    K562 IC50
    0.325 μM
    Compound: 1
    Cytotoxicity against human K562 cells incubated for 2 hrs by cell titre blue viability assay
    Cytotoxicity against human K562 cells incubated for 2 hrs by cell titre blue viability assay
    		[PMID: 37561481]
    K562 IC50
    0.325 μM
    Compound: 1
    Cytotoxicity against human K562 cells incubated for 2 hrs followed by compound washout and measured after 72 hrs by Celltiter-blue viability assay
    Cytotoxicity against human K562 cells incubated for 2 hrs followed by compound washout and measured after 72 hrs by Celltiter-blue viability assay
    		[PMID: 39088428]
    K562 IC50
    0.33 μM
    Compound: DOX
    Cytotoxicity against human K562 cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay
    Cytotoxicity against human K562 cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay
    		[PMID: 31820976]
    K562 IC50
    0.36 μM
    Compound: Doxorubicin
    Cytotoxicity against human K562 cells expressing estrogen receptor after 48 hrs by MTT assay
    Cytotoxicity against human K562 cells expressing estrogen receptor after 48 hrs by MTT assay
    		10.1039/C2MD20327H
    K562 IC50
    0.361 μM
    Compound: 1
    Cytotoxicity in human K562 cells assessed as reduction in cell viability incubated for 2 hrs by Cell-titer-blue assay
    Cytotoxicity in human K562 cells assessed as reduction in cell viability incubated for 2 hrs by Cell-titer-blue assay
    		[PMID: 33064004]
    K562 IC50
    0.37 μM
    Compound: Dox
    Antiproliferative activity against human K562 cells by MTT assay
    Antiproliferative activity against human K562 cells by MTT assay
    		[PMID: 38387333]
    K562 IC50
    0.424 μM
    Compound: Dox
    Antiproliferative activity against human K562 cells after 48 hrs by MTT assay
    Antiproliferative activity against human K562 cells after 48 hrs by MTT assay
    		[PMID: 26494582]
    K562 IC50
    0.425 μM
    Compound: Adriamycin
    Cytotoxicity against human K562 cells after 48 hrs by MTT assay
    Cytotoxicity against human K562 cells after 48 hrs by MTT assay
    		[PMID: 21843940]
    K562 IC50
    0.43 μM
    Compound: ADR
    Cytotoxicity against human K562 cells after 72 hrs by sulforhodamine B and MTT assay
    Cytotoxicity against human K562 cells after 72 hrs by sulforhodamine B and MTT assay
    		[PMID: 22119124]
    K562 IC50
    0.43 μM
    Compound: ADR
    Cytotoxicity against human K562 cells after 72 hrs by MTS assay
    Cytotoxicity against human K562 cells after 72 hrs by MTS assay
    		[PMID: 22405646]
    K562 IC50
    0.43 μM
    Compound: ADR
    Antiproliferative activity against human K562 cells after 72 hrs by MTS assay
    Antiproliferative activity against human K562 cells after 72 hrs by MTS assay
    		[PMID: 22450134]
    K562 IC50
    0.44 μM
    Compound: doxorubicin
    Cytotoxicity against human K562 cells assessed as cell viability after 48 hrs by celltiter-blue assay
    Cytotoxicity against human K562 cells assessed as cell viability after 48 hrs by celltiter-blue assay
    		[PMID: 22582991]
    K562 IC50
    0.45 μM
    Compound: ADM
    Anticancer activity against human K562 cells after 48 hrs by MTT assay
    Anticancer activity against human K562 cells after 48 hrs by MTT assay
    		[PMID: 25462264]
    K562 IC50
    0.45 μg/mL
    Compound: doxorubicin
    Cytotoxicity against multidrug-resistant human K562 cells
    Cytotoxicity against multidrug-resistant human K562 cells
    		[PMID: 18052129]
    K562 IC50
    0.46 μM
    Compound: Doxorubicin
    Cytotoxicity against human K562 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
    Cytotoxicity against human K562 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
    		[PMID: 31836446]
    K562 IC50
    0.49 μM
    Compound: Dox
    Cytotoxicity against human K562 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human K562 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 33479619]
    K562 IC50
    0.5 μM
    Compound: Doxorubicin
    Antiproliferative activity against human K562 cells after 72 hrs by MTT assay
    Antiproliferative activity against human K562 cells after 72 hrs by MTT assay
    		[PMID: 27808511]
    K562 IC50
    0.51 μM
    Compound: DOX
    Antiproliferative activity against human K562 cells after 72 hrs by Sulforhodamine B-stain assay
    Antiproliferative activity against human K562 cells after 72 hrs by Sulforhodamine B-stain assay
    		[PMID: 27484508]
    K562 IC50
    0.51 μM
    Compound: DOX
    Cytotoxicity against human K562 cells assessed as cell growth inhibition after 48 hrs by MTT assay
    Cytotoxicity against human K562 cells assessed as cell growth inhibition after 48 hrs by MTT assay
    		[PMID: 31202598]
    K562 IC50
    0.528 μM
    Compound: 1
    Cytotoxicity against human K562 cells overexpressing ABCG2 incubated for 2 hrs followed by compound washout and measured after 72 hrs by Celltiter-blue viability assay
    Cytotoxicity against human K562 cells overexpressing ABCG2 incubated for 2 hrs followed by compound washout and measured after 72 hrs by Celltiter-blue viability assay
    		[PMID: 39088428]
    K562 IC50
    0.54 μg/mL
    Compound: Doxorubicin
    Anticancer activity against human K562 cells by MTT assay
    Anticancer activity against human K562 cells by MTT assay
    		[PMID: 31404864]
    K562 IC50
    0.55 μM
    Compound: Adriamycin
    Antiproliferative activity against human K562 cells after 48 hrs by MTT assay
    Antiproliferative activity against human K562 cells after 48 hrs by MTT assay
    		[PMID: 25686590]
    K562 IC50
    0.58 μM
    Compound: adriamycin
    Cytotoxicity against human K562 cells after 48 hrs
    Cytotoxicity against human K562 cells after 48 hrs
    		[PMID: 17583953]
    K562 IC50
    0.59 μM
    Compound: Dox
    Cytotoxicity against human K562 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    Cytotoxicity against human K562 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    		[PMID: 37001390]
    K562 IC50
    0.6 μM
    Compound: ADM
    Cytotoxicity against human K562 cells by MTT method
    Cytotoxicity against human K562 cells by MTT method
    		[PMID: 29144133]
    K562 IC50
    0.62 μM
    Compound: DOX
    Cytotoxicity against human K562 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Cytotoxicity against human K562 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    		[PMID: 28355069]
    K562 IC50
    0.62 μM
    Compound: Doxorubicin
    Antiproliferative activity tested as 50% inhibition of DNA synthesis in human K562 erythroleukemia cell line
    Antiproliferative activity tested as 50% inhibition of DNA synthesis in human K562 erythroleukemia cell line
    		[PMID: 11720862]
    K562 IC50
    0.65 μM
    Compound: Doxorubicin
    Antiproliferative activity against human K562 cells after 72 hrs by MTT assay
    Antiproliferative activity against human K562 cells after 72 hrs by MTT assay
    		[PMID: 30500683]
    K562 IC50
    0.7 μM
    Compound: Doxorubicin
    Cytotoxicity against human K562 cells assessed as reduction in cell viability incubated for 72 hrs by Alamar blue assay
    Cytotoxicity against human K562 cells assessed as reduction in cell viability incubated for 72 hrs by Alamar blue assay
    		[PMID: 27300257]
    K562 IC50
    0.8 μM
    Compound: 1, DOX
    Antiproliferative activity against human K562 cells after 72 hrs by MTT assay
    Antiproliferative activity against human K562 cells after 72 hrs by MTT assay
    		[PMID: 25244612]
    K562 IC50
    0.8 μM
    Compound: Doxorubicin
    Cytotoxicity against human K562 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human K562 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 27015002]
    K562 IC50
    0.89 μM
    Compound: Doxorubicin
    Antiproliferative activity against human K562 cells after 72 hrs by MTT assay
    Antiproliferative activity against human K562 cells after 72 hrs by MTT assay
    		[PMID: 29172084]
    K562 IC50
    0.94 μM
    Compound: Doxorubicin
    Cytotoxicity against human K562 cells by Alamar blue assay
    Cytotoxicity against human K562 cells by Alamar blue assay
    		[PMID: 27256910]
    K562 IC50
    0.94 μM
    Compound: Doxorubicin
    Cytotoxicity against human K562 cells after 72 hrs by alamar blue assay
    Cytotoxicity against human K562 cells after 72 hrs by alamar blue assay
    		[PMID: 28159416]
    K562 IC50
    1 μM
    Compound: Doxorubicin
    Cytotoxicity against K-562 myelocytic leukemia cell line
    Cytotoxicity against K-562 myelocytic leukemia cell line
    		[PMID: 10476861]
    K562 IC50
    1 μM
    Compound: Doxorubicin
    Antiproliferative activity against human K562 cells assessed as inhibition of cell survival after 48 hrs by MTT assay
    Antiproliferative activity against human K562 cells assessed as inhibition of cell survival after 48 hrs by MTT assay
    		[PMID: 27265687]
    K562 IC50
    1 μM
    Compound: adriamycin
    Cytotoxicity against human K562 cells under deem light after 96 hrs by MTT assay
    Cytotoxicity against human K562 cells under deem light after 96 hrs by MTT assay
    		[PMID: 17993275]
    K562 IC50
    1.1 μM
    Compound: Adriamycin
    Cytotoxicity against human K562 cells assessed as growth inhibition after 48 hrs by MTT assay
    Cytotoxicity against human K562 cells assessed as growth inhibition after 48 hrs by MTT assay
    		[PMID: 26356746]
    K562 IC50
    1.23 μM
    Compound: DOX
    Anticancer activity against human K562 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay
    Anticancer activity against human K562 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay
    		[PMID: 38784465]
    K562 IC50
    1.25 μM
    Compound: Doxorubicin
    Cytotoxicity against human K562 cells after 72 hrs by alamar blue assay
    Cytotoxicity against human K562 cells after 72 hrs by alamar blue assay
    		[PMID: 24969014]
    K562 IC50
    1.33 μM
    Compound: Adriamycin
    Cytotoxicity against human K562 cells by MTT assay
    Cytotoxicity against human K562 cells by MTT assay
    		[PMID: 21115246]
    K562 IC50
    1.38 μM
    Compound: Doxorubicin
    Cytotoxicity against human K562 cells assessed as inhibition of cell viability after 72 hrs by MTT assay
    Cytotoxicity against human K562 cells assessed as inhibition of cell viability after 72 hrs by MTT assay
    		[PMID: 29329071]
    K562 IC50
    1.4 μM
    Compound: Doxorubicin
    Cytotoxicity against human K562 cells after 48 hrs by MTT assay
    Cytotoxicity against human K562 cells after 48 hrs by MTT assay
    		[PMID: 32496057]
    K562 IC50
    1.41 μM
    Compound: Doxorubicin
    Cytotoxicity against human K562 cells after 72 hrs by MTT assay
    Cytotoxicity against human K562 cells after 72 hrs by MTT assay
    		[PMID: 22677031]
    K562 IC50
    1.41 μg/mL
    Compound: Adriamycin
    Cytotoxicity against human K562 cells by MTT assay
    Cytotoxicity against human K562 cells by MTT assay
    		[PMID: 17918910]
    K562 IC50
    1.42 μM
    Compound: Dox
    Antiproliferative activity against human K562 Cells
    Antiproliferative activity against human K562 Cells
    		[PMID: 31129455]
    K562 IC50
    1.43 μM
    Compound: Doxorubicin
    Antiproliferative activity against human K562 cells assessed as reduction in cell viability after 24 hrs by MTT assay
    Antiproliferative activity against human K562 cells assessed as reduction in cell viability after 24 hrs by MTT assay
    		[PMID: 31546197]
    K562 IC50
    1.43 μM
    Compound: Doxorubicin
    Antiproliferative activity against human K562 cells
    Antiproliferative activity against human K562 cells
    		[PMID: 31945642]
    K562 IC50
    1.46 μM
    Compound: doxorubicin
    Cytotoxicity against human K562 cells
    Cytotoxicity against human K562 cells
    		[PMID: 25581396]
    K562 IC50
    1.514 μM
    Compound: DOXO
    Antiproliferative activity against human K562 cells after 48 hrs by MTT assay
    Antiproliferative activity against human K562 cells after 48 hrs by MTT assay
    		[PMID: 29685681]
    K562 IC50
    1.58 μM
    Compound: DOX
    Cytotoxicity against human K562 cells assessed as reduction in cell viability after 24 hrs by MTT assay
    Cytotoxicity against human K562 cells assessed as reduction in cell viability after 24 hrs by MTT assay
    		[PMID: 29421568]
    K562 IC50
    1.587 μM
    Compound: 1
    Cytotoxicity against human K562 cells overexpressing ABCB1 incubated for 2 hrs followed by compound washout and measured after 72 hrs by Celltiter-blue viability assay
    Cytotoxicity against human K562 cells overexpressing ABCB1 incubated for 2 hrs followed by compound washout and measured after 72 hrs by Celltiter-blue viability assay
    		[PMID: 39088428]
    K562 IC50
    1.6 μM
    Compound: Doxorubicin
    Cytotoxicity against human K562 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human K562 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 26551342]
    K562 IC50
    1.67 μM
    Compound: D
    Antineoplastic activity against human K562 cells after 72 hrs by MTT assay
    Antineoplastic activity against human K562 cells after 72 hrs by MTT assay
    		[PMID: 22000949]
    K562 IC50
    1.77 μM
    Compound: Doxorubicin
    Cytotoxicity against human chronic myelogenous leukemia (K562) cell line using MTT assay
    Cytotoxicity against human chronic myelogenous leukemia (K562) cell line using MTT assay
    		[PMID: 9873387]
    K562 IC50
    10.9 μM
    Compound: Doxorubicin
    Cytotoxicity against human K562 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    Cytotoxicity against human K562 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    		[PMID: 26317881]
    K562 IC50
    101 μM
    Compound: doxorubicin
    Resistant ratio, IC50 for multidrug resistant human K562 cells to IC50 for human K562 cells
    Resistant ratio, IC50 for multidrug resistant human K562 cells to IC50 for human K562 cells
    		[PMID: 18313307]
    K562 IC50
    13.53 μM
    Compound: Doxo
    Antiproliferative activity against human K562 cells after 48 hrs by MTT assay
    Antiproliferative activity against human K562 cells after 48 hrs by MTT assay
    		[PMID: 27597408]
    K562 IC50
    13.6 μM
    Compound: Doxorubicin
    Cytotoxicity against human K562 cells by spectrophotometric analysis
    Cytotoxicity against human K562 cells by spectrophotometric analysis
    		[PMID: 22148280]
    K562 IC50
    14 nM
    Compound: Adriamycin
    Cytotoxicity against human K562 cells after 48 hrs by SRB assay
    Cytotoxicity against human K562 cells after 48 hrs by SRB assay
    		[PMID: 22858298]
    K562 IC50
    15.6 nM
    Compound: Doxorubicin
    Compound was tested in vitro for cytotoxicity against MDR cell line K562R (72 hr exposure to compound)
    Compound was tested in vitro for cytotoxicity against MDR cell line K562R (72 hr exposure to compound)
    		[PMID: 10479282]
    K562 IC50
    15000 nM
    Compound: ADR
    Antiproliferative activity measured against K562adr leukemia cells.
    Antiproliferative activity measured against K562adr leukemia cells.
    		[PMID: 9876111]
    K562 IC50
    16.31 μM
    Compound: Doxorubicin
    Antiproliferative activity against drug resistant human K562 cells incubated for 48 hrs by MTT assay
    Antiproliferative activity against drug resistant human K562 cells incubated for 48 hrs by MTT assay
    		[PMID: 32035399]
    K562 IC50
    17.23 μM
    Compound: Doxorubicin
    Antiproliferative activity against human K562 cells after 48 hrs by MTT assay
    Antiproliferative activity against human K562 cells after 48 hrs by MTT assay
    		[PMID: 21620529]
    K562 IC50
    2 μM
    Compound: Doxorubicin
    Antiproliferative activity against human K562 cells after 48 hrs by MTT assay
    Antiproliferative activity against human K562 cells after 48 hrs by MTT assay
    		[PMID: 30179747]
    K562 IC50
    2.05 μM
    Compound: Dox
    Antiproliferative activity against human K562 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay
    Antiproliferative activity against human K562 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay
    		[PMID: 36809707]
    K562 IC50
    2.3 μM
    Compound: Doxorubicin
    Anticancer activity against human K562 cells
    Anticancer activity against human K562 cells
    		[PMID: 31926469]
    K562 IC50
    2.3 μM
    Compound: Doxorubicin
    Antiproliferative activity against human K562 cells incubated for 48 hrs by MTT assay
    Antiproliferative activity against human K562 cells incubated for 48 hrs by MTT assay
    		[PMID: 38442524]
    K562 IC50
    2.41 μM
    Compound: Doxorubicin
    Cytotoxicity against human K562 cells after 48 hrs by MTT assay
    Cytotoxicity against human K562 cells after 48 hrs by MTT assay
    		[PMID: 28390228]
    K562 IC50
    2.5 μM
    Compound: Doxorubicin
    Cytotoxicity against human K562 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay
    Cytotoxicity against human K562 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay
    		[PMID: 35526504]
    K562 IC50
    2.5 μM
    Compound: adriamycin
    Cytotoxicity against human K562 cells by rapid colorimetric assay
    Cytotoxicity against human K562 cells by rapid colorimetric assay
    		[PMID: 19585998]
    K562 IC50
    2.84 μM
    Compound: DOX
    Cytotoxicity against human doxorubicin-resistant K562 cells expressing Pgp after 72 hrs by MTT assay
    Cytotoxicity against human doxorubicin-resistant K562 cells expressing Pgp after 72 hrs by MTT assay
    		[PMID: 19140665]
    K562 IC50
    2.84 μM
    Compound: Doxo
    Cytotoxicity against human doxorubicin-resistant K562 cells after 72 hrs by MTT assay
    Cytotoxicity against human doxorubicin-resistant K562 cells after 72 hrs by MTT assay
    		[PMID: 23245571]
    K562 IC50
    2.85 μM
    Compound: Adriamycin
    Cytotoxicity against human K562 cells after 2 days
    Cytotoxicity against human K562 cells after 2 days
    		[PMID: 22318164]
    K562 IC50
    2.96 μM
    Compound: Doxorubicin
    Antiproliferative activity against human K562 cells after 48 hrs by MTT assay
    Antiproliferative activity against human K562 cells after 48 hrs by MTT assay
    		[PMID: 28038941]
    K562 IC50
    220 nM
    Compound: Doxorubicin
    Cytotoxicity against human K562 cells incubated for 72 hrs by CCK8 assay
    Cytotoxicity against human K562 cells incubated for 72 hrs by CCK8 assay
    		[PMID: 32992133]
    K562 IC50
    24.14 μM
    Compound: doxorubicin
    Growth inhibition of doxorubicin-resistant human K562 cells after 72 hrs by SRB assay
    Growth inhibition of doxorubicin-resistant human K562 cells after 72 hrs by SRB assay
    		[PMID: 18313307]
    K562 IC50
    2474 nM
    Compound: Doxorubicin
    Compound was tested in vitro for cytotoxicity against MDR cell line K562R (RI) (72 hr exposure to compound)
    Compound was tested in vitro for cytotoxicity against MDR cell line K562R (RI) (72 hr exposure to compound)
    		[PMID: 10479282]
    K562 IC50
    3.79 μM
    Compound: Doxorubicin
    Cytotoxicity against human K562 cells after 24 hrs by MTT assay
    Cytotoxicity against human K562 cells after 24 hrs by MTT assay
    		[PMID: 22687747]
    K562 IC50
    4.49 μM
    Compound: Doxorubicin
    Cytotoxicity against Homo sapiens (human) K562 cells assessed as inhibition of cell proliferation after 24 hr by MTT assay
    Cytotoxicity against Homo sapiens (human) K562 cells assessed as inhibition of cell proliferation after 24 hr by MTT assay
    		10.1007/s00044-012-0436-9
    K562 IC50
    46.69 μM
    Compound: ADR
    Cytotoxicity against human K562 cells after 72 hrs by MTS assay
    Cytotoxicity against human K562 cells after 72 hrs by MTS assay
    		[PMID: 22429509]
    K562 IC50
    5.23 μM
    Compound: Doxorubicin
    Cytotoxicity against human K562 cells incubated for 72 hrs by Sulphorhodamine assay
    Cytotoxicity against human K562 cells incubated for 72 hrs by Sulphorhodamine assay
    		[PMID: 37146520]
    K562 IC50
    50 nM
    Compound: Doxorubicin
    In vitro cytotoxicity expressed as concentration that inhibits 50% of K562S (sensitive clone)cell proliferation
    In vitro cytotoxicity expressed as concentration that inhibits 50% of K562S (sensitive clone)cell proliferation
    		[PMID: 11606141]
    K562 IC50
    56.83 μM
    Compound: ADR
    Cytotoxicity against adriamycin-selected multi drug-resistant human K562 cells after 72 hrs by sulforhodamine B and MTT assay
    Cytotoxicity against adriamycin-selected multi drug-resistant human K562 cells after 72 hrs by sulforhodamine B and MTT assay
    		[PMID: 22119124]
    K562 IC50
    6.12 x 10-3 μM
    Compound: Doxorubicin
    Cytotoxicity against human K562 cells after 3 days by MTT assay
    Cytotoxicity against human K562 cells after 3 days by MTT assay
    		[PMID: 20356655]
    K562 IC50
    6.25 μM
    Compound: DOX
    Cytotoxicity against human K562 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human K562 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 28531811]
    K562 IC50
    6.66 x 10-3 μM
    Compound: Doxorubicin
    Cytotoxicity against human K562 cells by MTT assay
    Cytotoxicity against human K562 cells by MTT assay
    		[PMID: 19345581]
    K562 IC50
    7000 nM
    Compound: Doxorubicin
    In vitro cytotoxicity expressed as concentration that inhibits 50% of K562R (resistant clone) cell proliferation
    In vitro cytotoxicity expressed as concentration that inhibits 50% of K562R (resistant clone) cell proliferation
    		[PMID: 11606141]
    K562 IC50
    8.5 μM
    Compound: doxorubicin
    Cytotoxicity against human K562 cells assessed as viable cells after 72 hrs by MTS/PMS assay
    Cytotoxicity against human K562 cells assessed as viable cells after 72 hrs by MTS/PMS assay
    		[PMID: 20055495]
    K562 IC50
    < 1 μM
    Compound: ADM
    Cytotoxicity against human K562 cells by MTT method
    Cytotoxicity against human K562 cells by MTT method
    		[PMID: 37807846]
    K562 IC50
    < 1 μM
    Compound: Doxorubicin
    Cytotoxicity against human K562 cells by MTT assay
    Cytotoxicity against human K562 cells by MTT assay
    		[PMID: 33371684]
    K562 IC50
    < 1 μM
    Compound: Doxorubicin
    Cytotoxicity against human K562 cells assessed as reduction in cell growth by MTT assay
    Cytotoxicity against human K562 cells assessed as reduction in cell growth by MTT assay
    		[PMID: 36734533]
    K562 IC50
    < 1 μM
    Compound: Doxorubicin
    Cytotoxicity against human K562 cells assessed as inhibition of cell growth by MTT assay
    Cytotoxicity against human K562 cells assessed as inhibition of cell growth by MTT assay
    		[PMID: 38064664]
    K562 IC50
    < 1 μM
    Compound: doxorubicin
    Cytotoxicity against human K562 cells by MTT assay
    Cytotoxicity against human K562 cells by MTT assay
    		[PMID: 33847126]
    K562 IC50
    > 167.6 μM
    Compound: Doxorubicin
    Cytotoxicity against human K562 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Cytotoxicity against human K562 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    		[PMID: 32531682]
    K562-Lucena 1 IC50
    > 10 μM
    Compound: Doxorubicin
    Cytotoxicity against human K562-Lucena 1 cells after 48 hrs by MTT assay
    Cytotoxicity against human K562-Lucena 1 cells after 48 hrs by MTT assay
    		[PMID: 32496057]
    K562/A02 GI50
    14.28 μM
    Compound: Doxorubicin
    Cytotoxicity against human K562/A02 cells by SRB assay
    Cytotoxicity against human K562/A02 cells by SRB assay
    		[PMID: 32992133]
    K562/A02 IC50
    0.43 μM
    Compound: ADR
    Cytotoxicity against human K562/A02 cells overexpress P-gp after 72 hrs by MTS assay
    Cytotoxicity against human K562/A02 cells overexpress P-gp after 72 hrs by MTS assay
    		[PMID: 22429509]
    K562/A02 IC50
    17.84 μM
    Compound: Adriamycin
    Cytotoxicity against adriamycin-resistant human K562/A02 cells after 48 hrs by MTT assay
    Cytotoxicity against adriamycin-resistant human K562/A02 cells after 48 hrs by MTT assay
    		[PMID: 21843940]
    K562/A02 IC50
    46.69 μM
    Compound: ADR
    Cytotoxicity against human K562/A02 cells expressing p-glycoprotein after 72 hrs by MTS assay
    Cytotoxicity against human K562/A02 cells expressing p-glycoprotein after 72 hrs by MTS assay
    		[PMID: 22405646]
    K562/A02 IC50
    46.69 μM
    Compound: ADR
    Antiproliferative activity against multidrug-resistant human K562/A02 cells overexpressing p-glycoprotein after 72 hrs by MTS assay
    Antiproliferative activity against multidrug-resistant human K562/A02 cells overexpressing p-glycoprotein after 72 hrs by MTS assay
    		[PMID: 22450134]
    K562/A02 IC50
    5.961 μM
    Compound: Dox
    Antiproliferative activity against human K562/A02 cells after 72 hrs by MTT assay
    Antiproliferative activity against human K562/A02 cells after 72 hrs by MTT assay
    		[PMID: 27423028]
    K562/A02 IC50
    55.47 μM
    Compound: DOX
    Cytotoxicity against human K562/A02 cells overexpressing P-gp assessed as cell growth inhibition after 48 hrs by MTT assay
    Cytotoxicity against human K562/A02 cells overexpressing P-gp assessed as cell growth inhibition after 48 hrs by MTT assay
    		[PMID: 31202598]
    K562/A02 IC50
    89.8 μM
    Compound: DOX
    Cytotoxicity against human K562/A02 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Cytotoxicity against human K562/A02 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    		[PMID: 28355069]
    K562/Adr IC50
    15.27 μg/mL
    Compound: doxorubicin
    Cytotoxicity against doxorubicin-resistant human K562/Adr cells
    Cytotoxicity against doxorubicin-resistant human K562/Adr cells
    		[PMID: 18052129]
    K562/Adr IC50
    18.779 μM
    Compound: Doxorubicin
    Antiproliferative activity against human K562/ADR cells measured after 72 hrs by CCK8 assay
    Antiproliferative activity against human K562/ADR cells measured after 72 hrs by CCK8 assay
    		[PMID: 27484511]
    K562/Adr IC50
    18.799 μM
    Compound: Doxorubicin
    Antiproliferative activity against human K562/ADR cells incubated for 72 hrs by CCK8 assay
    Antiproliferative activity against human K562/ADR cells incubated for 72 hrs by CCK8 assay
    		[PMID: 32992133]
    K562/Adr IC50
    220 nM
    Compound: Doxorubicin
    Cytotoxicity against human K562/ADR cells incubated for 72 hrs by CCK8 assay
    Cytotoxicity against human K562/ADR cells incubated for 72 hrs by CCK8 assay
    		[PMID: 32992133]
    K562/Adr IC50
    67.6 μM
    Compound: ADM
    Anticancer activity against human K562/ADR cells after 48 hrs by MTT assay
    Anticancer activity against human K562/ADR cells after 48 hrs by MTT assay
    		[PMID: 25462264]
    KARPAS-299 IC50
    0.38 μM
    Compound: DOX
    Cytotoxicity against human KARPAS299 cells measured after 72 hrs by Celltiter-Glo assay
    Cytotoxicity against human KARPAS299 cells measured after 72 hrs by Celltiter-Glo assay
    		[PMID: 31820976]
    KB EC50
    0.25 μM
    Compound: Doxorubicin
    Cytotoxicity against human KB/HeLa cells after 48 hrs by resazurin dye assay
    Cytotoxicity against human KB/HeLa cells after 48 hrs by resazurin dye assay
    		[PMID: 23988351]
    KB EC50
    0.4 μM
    Compound: doxorubicin
    Cytotoxicity against human KB cells after 72 hrs
    Cytotoxicity against human KB cells after 72 hrs
    		[PMID: 17378530]
    KB ED50
    0.058 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human KB cells after 72 hrs by neutral red staining
    Cytotoxicity against human KB cells after 72 hrs by neutral red staining
    		[PMID: 11374944]
    KB ED50
    0.1 μM
    Compound: DOX
    Cytotoxicity against human KB cells
    Cytotoxicity against human KB cells
    		[PMID: 17591444]
    KB ED50
    0.15 μg/mL
    Compound: doxorubicin
    Cytotoxicity against human KB cells by methylene blue staining method
    Cytotoxicity against human KB cells by methylene blue staining method
    		[PMID: 15921421]
    KB ED50
    0.1 μg/mL
    Compound: doxorubicin
    Cytotoxicity against human KB cells after 3 days by MTT assay
    Cytotoxicity against human KB cells after 3 days by MTT assay
    		[PMID: 16252910]
    KB ED50
    0.25 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human KB cells by MTT assay
    Cytotoxicity against human KB cells by MTT assay
    		[PMID: 15104488]
    KB ED50
    0.3 μg/mL
    Compound: Doxourbicine
    Cytotoxicity against human KB cells by MTT assay
    Cytotoxicity against human KB cells by MTT assay
    		[PMID: 12502336]
    KB GI50
    0.11 μM
    Compound: ADR
    Cytotoxicity against human KB cells after 48 hrs by SRB assay
    Cytotoxicity against human KB cells after 48 hrs by SRB assay
    		[PMID: 20673627]
    KB GI50
    0.16 μM
    Compound: ADR
    Anticancer activity against human KB cells by SRB method
    Anticancer activity against human KB cells by SRB method
    		[PMID: 22104151]
    KB GI50
    0.17 μM
    Compound: ADR
    Growth inhibition of human KB cells
    Growth inhibition of human KB cells
    		10.1039/C1MD00072A
    KB GI50
    0.17 μM
    Compound: ADR
    Growth inhibition of human KB cells after 48 hrs by SRB assay
    Growth inhibition of human KB cells after 48 hrs by SRB assay
    		[PMID: 20031423]
    KB GI50
    0.17 μM
    Compound: ADR
    Cytotoxicity against human KB cells after 24 hrs by WST-1 assay
    Cytotoxicity against human KB cells after 24 hrs by WST-1 assay
    		[PMID: 20732817]
    KB GI50
    0.17 μM
    Compound: ADR
    Anticancer activity against human KB cells by SRB method
    Anticancer activity against human KB cells by SRB method
    		[PMID: 21676506]
    KB GI50
    0.17 μM
    Compound: ADR
    Growth inhibition of human KB cells by SRB assay
    Growth inhibition of human KB cells by SRB assay
    		[PMID: 22361684]
    KB GI50
    0.17 μM
    Compound: ADR
    Growth inhibition of human KB cells after 48 hrs by sulforhodamine B assay
    Growth inhibition of human KB cells after 48 hrs by sulforhodamine B assay
    		[PMID: 22364746]
    KB GI50
    0.17 μM
    Compound: ADR
    Growth inhibition of human KB cells after 48 hrs by sulforhodamine B assay
    Growth inhibition of human KB cells after 48 hrs by sulforhodamine B assay
    		[PMID: 23849207]
    KB GI50
    0.17 μM
    Compound: ADR, Adriamycin
    Growth inhibition of human KB cells by SRB method
    Growth inhibition of human KB cells by SRB method
    		[PMID: 18207392]
    KB GI50
    0.17 μM
    Compound: adriamycin
    Cytotoxicity against human KB cells after 24 hrs by SRB method
    Cytotoxicity against human KB cells after 24 hrs by SRB method
    		[PMID: 18262426]
    KB GI50
    1.72 μM
    Compound: ADR
    Cytotoxicity against human KB cells after 48 hrs by sulforhodamine B assay
    Cytotoxicity against human KB cells after 48 hrs by sulforhodamine B assay
    		[PMID: 18657979]
    KB GI50
    < 0.1 μM
    Compound: Doxorubicin
    Antiproliferative activity against human KB cells assessed as cell growth inhibition
    Antiproliferative activity against human KB cells assessed as cell growth inhibition
    		[PMID: 32961322]
    KB IC50
    0.007 μM
    Compound: Adriamycin
    Cytotoxicity against human KB cells
    Cytotoxicity against human KB cells
    		[PMID: 16872155]
    KB IC50
    0.009 μM
    Compound: Doxorubicin
    Antiproliferative activity against human KB cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Antiproliferative activity against human KB cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    		[PMID: 27010926]
    KB IC50
    0.01 μM
    Compound: Doxorubicin
    Cytotoxicity in human KB cells incubated for 72 hrs by MTT assay
    Cytotoxicity in human KB cells incubated for 72 hrs by MTT assay
    		[PMID: 30978023]
    KB IC50
    0.012 μM
    Compound: Doxorubicin
    Cytotoxicity against human KB cells after 48 hrs by MTT assay
    Cytotoxicity against human KB cells after 48 hrs by MTT assay
    		[PMID: 22537362]
    KB IC50
    0.012 μM
    Compound: doxorubicin
    Cytotoxicity against human KB cells after 48 hrs by MTT assay
    Cytotoxicity against human KB cells after 48 hrs by MTT assay
    		[PMID: 21087017]
    KB IC50
    0.015 μM
    Compound: Doxorubicin
    Inhibitory concentration that reduced the viability of KB cell population by 50%.
    Inhibitory concentration that reduced the viability of KB cell population by 50%.
    		[PMID: 9003520]
    KB IC50
    0.02 μM
    Compound: Doxorubicin
    Cytotoxicity against human KB cells
    Cytotoxicity against human KB cells
    		[PMID: 15387664]
    KB IC50
    0.02 μM
    Compound: Doxorubicin
    Cytotoxicity activity against human KB cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity activity against human KB cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 32627543]
    KB IC50
    0.02 μM
    Compound: Doxorubicin
    Cytotoxicity against human KB cells assessed as reduction in cell viability
    Cytotoxicity against human KB cells assessed as reduction in cell viability
    		[PMID: 33540356]
    KB IC50
    0.021 μM
    Compound: Doxorubicin
    Inhibitory concentration against KB epidermal carcinoma cell line
    Inhibitory concentration against KB epidermal carcinoma cell line
    		[PMID: 15715481]
    KB IC50
    0.024 μM
    Compound: Doxorubicin
    Cytotoxicity against human KB cells after 48 hrs by neutral red dye based assay
    Cytotoxicity against human KB cells after 48 hrs by neutral red dye based assay
    		[PMID: 29317147]
    KB IC50
    0.028 μM
    Compound: Doxorubicin
    Cytotoxicity against human KB cells after 44 hrs by SRB assay
    Cytotoxicity against human KB cells after 44 hrs by SRB assay
    		10.1007/s00044-013-0788-9
    KB IC50
    0.02 μg/mL
    Compound: adriamycin
    In vitro reduction in viability of KB cells by modified crystal violet assay.
    In vitro reduction in viability of KB cells by modified crystal violet assay.
    		[PMID: 8277498]
    KB IC50
    0.03 μM
    Compound: Adriamycin
    Concentration required to inhibit growth of human epidermoid carcinoma (KB) cell line
    Concentration required to inhibit growth of human epidermoid carcinoma (KB) cell line
    		[PMID: 15317455]
    KB IC50
    0.04 μM
    Compound: Doxorubicin
    Antiproliferative activity against drug-resistant tumor cell line KBwt.
    Antiproliferative activity against drug-resistant tumor cell line KBwt.
    		[PMID: 10411476]
    KB IC50
    0.06 μM
    Compound: Doxorubicin
    Antiproliferative activity against drug-resistant tumor cell line KBCamp.
    Antiproliferative activity against drug-resistant tumor cell line KBCamp.
    		[PMID: 10411476]
    KB IC50
    0.06 μM
    Compound: Doxorubicin
    Concentration required to reduce proliferation of KB human nasopharyngeal carcinoma (KBWT) cell line by 50% as determined by the MTT method
    Concentration required to reduce proliferation of KB human nasopharyngeal carcinoma (KBWT) cell line by 50% as determined by the MTT method
    		[PMID: 14761187]
    KB IC50
    0.06 μM
    Compound: doxorubicin
    Compound concentration required to reduce the cell proliferation of Wild type and Drug- resistant human nasopharyngeal carcinoma KB cells by 50%
    Compound concentration required to reduce the cell proliferation of Wild type and Drug- resistant human nasopharyngeal carcinoma KB cells by 50%
    		[PMID: 12431048]
    KB IC50
    0.09 μM
    Compound: Doxorubicin
    Cytotoxicity against human KB cells after 48 hrs by MTT assay
    Cytotoxicity against human KB cells after 48 hrs by MTT assay
    		[PMID: 26963142]
    KB IC50
    0.1 μM
    Compound: Adriblastine
    Cytotoxicity against human KB cells
    Cytotoxicity against human KB cells
    		[PMID: 15974615]
    KB IC50
    0.12 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human KB cells after 48 hrs by SRB assay
    Cytotoxicity against human KB cells after 48 hrs by SRB assay
    		[PMID: 20732814]
    KB IC50
    0.12 μg/mL
    Compound: doxorubicin
    Cytotoxicity against human KB cells by sulforhodamine B assay
    Cytotoxicity against human KB cells by sulforhodamine B assay
    		[PMID: 19555123]
    KB IC50
    0.12 μg/mL
    Compound: doxorubicin
    Cytotoxicity against human KB cells after 2 to 7 days by neutral red assay
    Cytotoxicity against human KB cells after 2 to 7 days by neutral red assay
    		[PMID: 8984156]
    KB IC50
    0.13 μM
    Compound: DOX
    Cytotoxicity against human KB cells after 48 hrs by MTT assay
    Cytotoxicity against human KB cells after 48 hrs by MTT assay
    		[PMID: 26386603]
    KB IC50
    0.13 μM
    Compound: Doxorubicin
    Cytotoxicity against human KB cells by MTT assay
    Cytotoxicity against human KB cells by MTT assay
    		[PMID: 30719909]
    KB IC50
    0.13 μg/mL
    Compound: doxorubicin
    Cytotoxicity against human KB cells by SRB assay
    Cytotoxicity against human KB cells by SRB assay
    		[PMID: 19778068]
    KB IC50
    0.141 μM
    Compound: Dox
    Antiproliferative activity against human KB cells after 72 hrs by MTT assay
    Antiproliferative activity against human KB cells after 72 hrs by MTT assay
    		[PMID: 27423028]
    KB IC50
    0.144 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human KB cells by resazurin microplate assay
    Cytotoxicity against human KB cells by resazurin microplate assay
    		[PMID: 19456117]
    KB IC50
    0.15 μM
    Compound: doxo
    Antiproliferative activity against human KB cell line by MTT assay
    Antiproliferative activity against human KB cell line by MTT assay
    		[PMID: 16913700]
    KB IC50
    0.17 μM
    Compound: ADR
    Cytotoxicity against human KB cells
    Cytotoxicity against human KB cells
    		[PMID: 17723301]
    KB IC50
    0.18 μM
    Compound: doxorubicin
    Cytotoxicity against human KB cells by SRB microtiter plate assay
    Cytotoxicity against human KB cells by SRB microtiter plate assay
    		[PMID: 17585747]
    KB IC50
    0.1 μg/mL
    Compound: doxorubicin
    Cytotoxicity against human KB cells after 2 days by sulforhodamine B assay
    Cytotoxicity against human KB cells after 2 days by sulforhodamine B assay
    		[PMID: 17067159]
    KB IC50
    0.2 μM
    Compound: Doxorubicin
    Cytotoxicity against human KB cells
    Cytotoxicity against human KB cells
    		[PMID: 11575949]
    KB IC50
    0.2 μM
    Compound: Doxorubicin
    Cytotoxicity against human KB cells assessed as reduction in cell viability by MTT assay
    Cytotoxicity against human KB cells assessed as reduction in cell viability by MTT assay
    		[PMID: 31820973]
    KB IC50
    0.22 μM
    Compound: DOX
    Antiproliferative activity against human KB cells after 72 hrs by SRB assay
    Antiproliferative activity against human KB cells after 72 hrs by SRB assay
    		[PMID: 30106296]
    KB IC50
    0.22 μM
    Compound: Doxorubicin
    Cytotoxicity against human KB cells after 48 hrs by sulforhodamine B assay
    Cytotoxicity against human KB cells after 48 hrs by sulforhodamine B assay
    		[PMID: 21071221]
    KB IC50
    0.22 μM
    Compound: Doxorubicin
    Cytotoxicity against human KB cells after 48 hrs by neutral red assay relative to control
    Cytotoxicity against human KB cells after 48 hrs by neutral red assay relative to control
    		[PMID: 25975638]
    KB IC50
    0.22 μM
    Compound: doxorubicin
    Growth inhibitory concentration of compound was measured against human nasopharyngeal carcinoma cell line (KB)
    Growth inhibitory concentration of compound was measured against human nasopharyngeal carcinoma cell line (KB)
    		[PMID: 10698436]
    KB IC50
    0.22 μg/mL
    Compound: doxorubicin
    Cytotoxicity against human KB cells
    Cytotoxicity against human KB cells
    		[PMID: 18052129]
    KB IC50
    0.23 nM
    Compound: Doxorubicin
    Antiproliferative activity against human KB cells after 72 hrs by methylene blue staining
    Antiproliferative activity against human KB cells after 72 hrs by methylene blue staining
    		[PMID: 21067930]
    KB IC50
    0.23 μg/mL
    Compound: doxorubicin
    Cytotoxicity against human KB cells
    Cytotoxicity against human KB cells
    		[PMID: 17567069]
    KB IC50
    0.24 μM
    Compound: Doxorubicin
    Cytotoxicity against human KB cells by SRB assay
    Cytotoxicity against human KB cells by SRB assay
    		[PMID: 20038128]
    KB IC50
    0.25 μg/mL
    Compound: doxorubicin
    Cytotoxicity against human KB cells by resazurin microplate assay
    Cytotoxicity against human KB cells by resazurin microplate assay
    		[PMID: 20329738]
    KB IC50
    0.27 μM
    Compound: adriamycin
    Cytotoxicity against human KB cells after 72 hrs
    Cytotoxicity against human KB cells after 72 hrs
    		[PMID: 15921436]
    KB IC50
    0.27 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human KB cells by colorimetric method
    Cytotoxicity against human KB cells by colorimetric method
    		[PMID: 16989536]
    KB IC50
    0.28 μM
    Compound: Doxorubicin
    Cytotoxicity against human KB cells by resazurin microplate assay
    Cytotoxicity against human KB cells by resazurin microplate assay
    		[PMID: 19739600]
    KB IC50
    0.3 μM
    Compound: Doxorubicin
    Antiproliferative activity against human KB cells after 72 hrs by MTT assay
    Antiproliferative activity against human KB cells after 72 hrs by MTT assay
    		[PMID: 19632833]
    KB IC50
    0.3 μM
    Compound: doxorubicin
    Cytotoxicity against human KB cells
    Cytotoxicity against human KB cells
    		[PMID: 16919455]
    KB IC50
    0.33 μM
    Compound: DOX
    Cytotoxicity against human KB cells after 48 hrs by MTT assay
    Cytotoxicity against human KB cells after 48 hrs by MTT assay
    		[PMID: 23218718]
    KB IC50
    0.33 μM
    Compound: doxorubicin
    Cytotoxicity against human KB cells
    Cytotoxicity against human KB cells
    		[PMID: 20815366]
    KB IC50
    0.33 μM
    Compound: doxorubicin
    Cytotoxicity against human KB cells by SRB assay
    Cytotoxicity against human KB cells by SRB assay
    		[PMID: 22004007]
    KB IC50
    0.34 μM
    Compound: DOX
    Antiproliferative activity against human KB cells after 48 hrs by SRB assay
    Antiproliferative activity against human KB cells after 48 hrs by SRB assay
    		[PMID: 30106296]
    KB IC50
    0.37 μM
    Compound: Doxorubicin
    Cytotoxicity against human KB cells by resazurin microplate assay
    Cytotoxicity against human KB cells by resazurin microplate assay
    		[PMID: 21090800]
    KB IC50
    0.38 μM
    Compound: doxorubicin
    Cytotoxicity against human KB cells by colorimetric method
    Cytotoxicity against human KB cells by colorimetric method
    		[PMID: 23795891]
    KB IC50
    0.4 μM
    Compound: Doxorubicin
    Antiproliferative activity against drug-resistant tumor cell line KBV20C.
    Antiproliferative activity against drug-resistant tumor cell line KBV20C.
    		[PMID: 10411476]
    KB IC50
    0.4 μM
    Compound: Doxorubicin
    Concentration required to reduce proliferation of KB subclones passaged in the presence of vincristine 0.02 uM (KB7D) cell line by 50% as determined by the MTT method
    Concentration required to reduce proliferation of KB subclones passaged in the presence of vincristine 0.02 uM (KB7D) cell line by 50% as determined by the MTT method
    		[PMID: 14761187]
    KB IC50
    0.4 μM
    Compound: Doxorubicin
    Cytotoxicity against human KB cells after 72 hrs by MTS assay
    Cytotoxicity against human KB cells after 72 hrs by MTS assay
    		[PMID: 23148652]
    KB IC50
    0.5 μM
    Compound: Doxorubicin
    Antiproliferative activity against drug-resistant tumor cell line KBMDR.
    Antiproliferative activity against drug-resistant tumor cell line KBMDR.
    		[PMID: 10411476]
    KB IC50
    0.55 μM
    Compound: doxorubicin
    Cytotoxicity against human KB cells by resazurin assay
    Cytotoxicity against human KB cells by resazurin assay
    		[PMID: 23806072]
    KB IC50
    0.56 μM
    Compound: Doxorubicin
    Cytotoxicity against human KB cells by SRB assay
    Cytotoxicity against human KB cells by SRB assay
    		[PMID: 23806014]
    KB IC50
    0.65 μM
    Compound: Doxorubicin
    Antiproliferative activity against drug-resistant tumor cell line KB7D.
    Antiproliferative activity against drug-resistant tumor cell line KB7D.
    		[PMID: 10411476]
    KB IC50
    0.82 μM
    Compound: DOX
    Antiproliferative activity against human KB cells after 24 hrs by SRB assay
    Antiproliferative activity against human KB cells after 24 hrs by SRB assay
    		[PMID: 30106296]
    KB IC50
    0.84 μM
    Compound: Doxorubicin
    Antiproliferative activity against human KB cells after 72 hrs by sulforhodamine B assay
    Antiproliferative activity against human KB cells after 72 hrs by sulforhodamine B assay
    		[PMID: 26496013]
    KB IC50
    0.9 μM
    Compound: Doxorubicin
    Cytotoxicity against human KB cells after 3 days by resazurin microplate assay
    Cytotoxicity against human KB cells after 3 days by resazurin microplate assay
    		[PMID: 22280818]
    KB IC50
    0.91 μM
    Compound: doxorubicin
    Antiproliferative activity against human KB cells assessed as reduction in cell growth incubated at 37 degC for 3 days by resazurin microplate assay
    Antiproliferative activity against human KB cells assessed as reduction in cell growth incubated at 37 degC for 3 days by resazurin microplate assay
    		[PMID: 25734623]
    KB IC50
    0.96 μM
    Compound: Doxorubicin
    Cytotoxicity against human KB cells after 3 days by resazurin microplate assay
    Cytotoxicity against human KB cells after 3 days by resazurin microplate assay
    		[PMID: 23313636]
    KB IC50
    0.97 μg/mL
    Compound: adriamycin
    Cytotoxicity against human KB cells
    Cytotoxicity against human KB cells
    		[PMID: 9249977]
    KB IC50
    0.9 μg/mL
    Compound: doxorubicin
    Cytotoxicity against human KB cells by neutral red assay
    Cytotoxicity against human KB cells by neutral red assay
    		[PMID: 17976995]
    KB IC50
    0.9 μg/mL
    Compound: doxorubicin
    Cytotoxicity against human KB cells after 48 hrs by neutral red dye staining
    Cytotoxicity against human KB cells after 48 hrs by neutral red dye staining
    		[PMID: 19928902]
    KB IC50
    1 nM
    Compound: doxorubicin
    Cytotoxicity against human KB cells after 72 hrs by MTS assay
    Cytotoxicity against human KB cells after 72 hrs by MTS assay
    		[PMID: 19655762]
    KB IC50
    1 μM
    Compound: Doxorubicin
    Cytotoxicity against human KB cells by sulforhodamine B assay
    Cytotoxicity against human KB cells by sulforhodamine B assay
    		[PMID: 26928423]
    KB IC50
    1.06 μM
    Compound: Doxorubicin
    Cytotoxicity against human KB cells assessed as reduction in cell viability by resazurin microplate assay
    Cytotoxicity against human KB cells assessed as reduction in cell viability by resazurin microplate assay
    		[PMID: 27311894]
    KB IC50
    1.19 μM
    Compound: Doxorubicin
    Cytotoxicity against human KB cells by resazurin microplate assay
    Cytotoxicity against human KB cells by resazurin microplate assay
    		[PMID: 27228159]
    KB IC50
    1.2 μM
    Compound: Doxorubicin
    Cytotoxicity against human KB cells assessed as reduction in cell viability by resazurin based fluorescence assay
    Cytotoxicity against human KB cells assessed as reduction in cell viability by resazurin based fluorescence assay
    		[PMID: 33852304]
    KB IC50
    1.35 μM
    Compound: Doxorubicin
    Cytotoxicity against human KB cells after 72 hrs by resazurin based fluorescence assay
    Cytotoxicity against human KB cells after 72 hrs by resazurin based fluorescence assay
    		[PMID: 28927795]
    KB IC50
    1.35 μg/mL
    Compound: doxorubicin
    Cytotoxicity against human KB cells after 48 hrs by Neutral Red dye
    Cytotoxicity against human KB cells after 48 hrs by Neutral Red dye
    		[PMID: 20550123]
    KB IC50
    1.4 μM
    Compound: Doxorubicin
    Cytotoxicity against human KB cells after 48 hrs by MTT assay
    Cytotoxicity against human KB cells after 48 hrs by MTT assay
    		[PMID: 26398312]
    KB IC50
    1.59 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human KB cells assessed as cell growth inhibition after 48 hrs by neutral red dye based assay
    Cytotoxicity against human KB cells assessed as cell growth inhibition after 48 hrs by neutral red dye based assay
    		[PMID: 27769668]
    KB IC50
    1.5 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human KB cells
    Cytotoxicity against human KB cells
    		[PMID: 8759170]
    KB IC50
    1.7 μM
    Compound: doxorubicin
    Cytotoxicity against human KB cells by resazurin reduction assay
    Cytotoxicity against human KB cells by resazurin reduction assay
    		[PMID: 22482432]
    KB IC50
    1.7 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human KB cells after 48 hrs by neutral red staining
    Cytotoxicity against human KB cells after 48 hrs by neutral red staining
    		[PMID: 15165136]
    KB IC50
    1.7 μg/mL
    Compound: doxorubicin
    Cytotoxicity against human KB cells
    Cytotoxicity against human KB cells
    		[PMID: 12880315]
    KB IC50
    1.8 μM
    Compound: Doxorubicin
    Concentration required to reduce proliferation of KB subclones passaged in the presence of doxorubicin 0.09 uM (KBMDR) cell line by 50% as determined by the MTT method
    Concentration required to reduce proliferation of KB subclones passaged in the presence of doxorubicin 0.09 uM (KBMDR) cell line by 50% as determined by the MTT method
    		[PMID: 14761187]
    KB IC50
    2.01 μM
    Compound: Dox
    Cytotoxicity against human KB cells after 3 days by MTT assay
    Cytotoxicity against human KB cells after 3 days by MTT assay
    		[PMID: 21741833]
    KB IC50
    2.04 μM
    Compound: doxorubicin
    Cytotoxicity against human KB cells after 48 hrs by neutral red assay
    Cytotoxicity against human KB cells after 48 hrs by neutral red assay
    		[PMID: 19879765]
    KB IC50
    2.19 x 10-4 M
    Compound: doxorubicin
    Cytotoxicity against human KB cells by SRB assay
    Cytotoxicity against human KB cells by SRB assay
    		[PMID: 16933890]
    KB IC50
    2.6 μM
    Compound: Doxorubicin
    Cytotoxicity against human KB cells assessed as cell growth inhibition after 48 hrs by neutral red assay
    Cytotoxicity against human KB cells assessed as cell growth inhibition after 48 hrs by neutral red assay
    		[PMID: 26005918]
    KB IC50
    2.6 μM
    Compound: doxorubicin
    Cytotoxicity against human KB cells assessed as viable cells by neutral red dye method
    Cytotoxicity against human KB cells assessed as viable cells by neutral red dye method
    		[PMID: 22530813]
    KB IC50
    2.7 μg/mL
    Compound: doxorubicin
    Cytotoxicity against multidrug-resistant human KB-VCR cells after 2 days by sulforhodamine B assay
    Cytotoxicity against multidrug-resistant human KB-VCR cells after 2 days by sulforhodamine B assay
    		[PMID: 17067159]
    KB IC50
    3 μM
    Compound: Doxorubicin
    Concentration required to reduce proliferation of KB subclones passaged in the presence of etoposide 7 uM (KB7D) cell line by 50% as determined by the MTT method
    Concentration required to reduce proliferation of KB subclones passaged in the presence of etoposide 7 uM (KB7D) cell line by 50% as determined by the MTT method
    		[PMID: 14761187]
    KB IC50
    3 μM
    Compound: Doxorubicin
    Cytotoxicity against human KB cells after 72 hrs by MTT assay
    Cytotoxicity against human KB cells after 72 hrs by MTT assay
    		[PMID: 19361894]
    KB IC50
    3.04 μM
    Compound: AMD
    Anticancer activity against human KB cells assessed as inhibition of cell growth
    Anticancer activity against human KB cells assessed as inhibition of cell growth
    		[PMID: 28888820]
    KB IC50
    3.8 μM
    Compound: Doxorubicin
    Cytotoxicity against human KB cells assessed as reduction in cell viability after 48 hrs by neutral red dye-based assay
    Cytotoxicity against human KB cells assessed as reduction in cell viability after 48 hrs by neutral red dye-based assay
    		[PMID: 27618204]
    KB IC50
    3.8 μM
    Compound: doxorubicin
    Cytotoxicity against human KB cells assessed as growth inhibition measured after 48 hrs by XTT assay
    Cytotoxicity against human KB cells assessed as growth inhibition measured after 48 hrs by XTT assay
    		[PMID: 23547843]
    KB IC50
    300 nM
    Compound: Doxorubicin
    Antiproliferative activity against human KB cells assessed as inhibition of cell viability after 72 hrs by MTT assay
    Antiproliferative activity against human KB cells assessed as inhibition of cell viability after 72 hrs by MTT assay
    		[PMID: 23360521]
    KB IC50
    4.3 μM
    Compound: Doxorubicin
    Cytotoxicity against human KB cells after 24 hrs by WST assay
    Cytotoxicity against human KB cells after 24 hrs by WST assay
    		[PMID: 25881821]
    KB IC50
    40 nM
    Compound: Doxorubicine
    Cytotoxicity against human KB cells after 72 hrs by MTS assay
    Cytotoxicity against human KB cells after 72 hrs by MTS assay
    		[PMID: 21142180]
    KB IC50
    40 nM
    Compound: doxorubicine
    Cytotoxicity against human KB cells incubated for 72 hrs by MTS assay
    Cytotoxicity against human KB cells incubated for 72 hrs by MTS assay
    		[PMID: 23072299]
    KB IC50
    5.8 μM
    Compound: Doxorubicin
    Antitumor activity against human KB cells after 48 hrs by SRB assay
    Antitumor activity against human KB cells after 48 hrs by SRB assay
    		[PMID: 20884091]
    KB IC50
    7.01 μM
    Compound: ADR (Adriamycin)
    In vitro cytotoxicity using human epidermoid carcinoma (KB-A1) cells
    In vitro cytotoxicity using human epidermoid carcinoma (KB-A1) cells
    		10.1016/0960-894X(96)00457-X
    KB IC50
    7.01 μM
    Compound: Adriamycin (ADR)
    In vitro cytotoxic activity was evaluated using the KB-3-1 resistant to adriamycin (ADR) subline KB-A1
    In vitro cytotoxic activity was evaluated using the KB-3-1 resistant to adriamycin (ADR) subline KB-A1
    		[PMID: 12443763]
    KB IC50
    < 0.55 μM
    Compound: Doxorubicin
    Cytotoxicity against Homo sapiens (human) KB cells by neutral red staining
    Cytotoxicity against Homo sapiens (human) KB cells by neutral red staining
    		10.1007/s00044-011-9587-3
    KB IC50
    < 0.55 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human KB cells after 48 hrs by neutral red assay
    Cytotoxicity against human KB cells after 48 hrs by neutral red assay
    		[PMID: 19105653]
    KB IC50
    < 1.1 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human KB cells after 2 to 7 days by neutral red assay
    Cytotoxicity against human KB cells after 2 to 7 days by neutral red assay
    		[PMID: 11374943]
    KB IC50
    > 400 μM
    Compound: Adriamycin
    Cytotoxicity against human KB cells by SRB method
    Cytotoxicity against human KB cells by SRB method
    		[PMID: 18181575]
    KB 3-1 GI50
    0.74 μM
    Compound: Dox
    Antiproliferative activity against human KB 3-1 cells incubated for 72 hrs and measured by MTT assay
    Antiproliferative activity against human KB 3-1 cells incubated for 72 hrs and measured by MTT assay
    		[PMID: 35973342]
    KB 3-1 GI50
    0.98 μM
    Compound: Dox
    Anticancer activity against human KB 3-1 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    Anticancer activity against human KB 3-1 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    		[PMID: 35533562]
    KB 3-1 GI50
    676.08 nM
    Compound: 21
    Cytotoxicity against human KB 3.1 cells after 72 hrs by MTT assay
    Cytotoxicity against human KB 3.1 cells after 72 hrs by MTT assay
    		[PMID: 24502276]
    KB 3-1 IC50
    0.0004 μM
    Compound: Doxorubicin
    Antiproliferative activity against human KB 3.1 cells after 72 hrs by MTT assay
    Antiproliferative activity against human KB 3.1 cells after 72 hrs by MTT assay
    		[PMID: 17949859]
    KB 3-1 IC50
    0.006 μM
    Compound: Doxorubicin
    Antiproliferative activity against human KB-3-1 cells assessed as cell growth inhibition
    Antiproliferative activity against human KB-3-1 cells assessed as cell growth inhibition
    		[PMID: 38733884]
    KB 3-1 IC50
    0.01 μM
    Compound: Doxorubicin
    Antiproliferative activity against human KB 3.1 cells after 24 hrs by MTT assay
    Antiproliferative activity against human KB 3.1 cells after 24 hrs by MTT assay
    		[PMID: 17949859]
    KB 3-1 IC50
    0.02 μM
    Compound: Adriamycin
    Cytotoxicity against human KB-3-1 cells after 72 hrs by MTT assay
    Cytotoxicity against human KB-3-1 cells after 72 hrs by MTT assay
    		[PMID: 21721528]
    KB 3-1 IC50
    0.021 μM
    Compound: ADR (Adriamycin)
    In vitro cytotoxicity using human epidermoid carcinoma (KB-3-1) cells
    In vitro cytotoxicity using human epidermoid carcinoma (KB-3-1) cells
    		10.1016/0960-894X(96)00457-X
    KB 3-1 IC50
    0.021 μM
    Compound: Adriamycin (ADR)
    In vitro cytotoxic activity was evaluated using the human epidermoid carcinoma cell line KB-3-1
    In vitro cytotoxic activity was evaluated using the human epidermoid carcinoma cell line KB-3-1
    		[PMID: 12443763]
    KB 3-1 IC50
    0.18 μM
    Compound: doxorubicin
    Growth inhibition of human KB3-1 cells after 72 hrs by MTT assay
    Growth inhibition of human KB3-1 cells after 72 hrs by MTT assay
    		[PMID: 18313307]
    KB 3-1 IC50
    0.37 μM
    Compound: Doxorubicin
    Cytotoxicity against human KB-3-1 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human KB-3-1 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 29501942]
    KB 3-1 IC50
    0.56 μM
    Compound: Dox
    Cytotoxicity against human KB 3-1 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    Cytotoxicity against human KB 3-1 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    		[PMID: 37001390]
    KB 3-1 IC50
    1.2 μM
    Compound: Doxorubicin
    Cytotoxicity against human KB3-1 cells after 72 hrs by MTT assay
    Cytotoxicity against human KB3-1 cells after 72 hrs by MTT assay
    		[PMID: 21035234]
    KB 3-1 IC50
    178 μM
    Compound: doxorubicin
    Resistant ratio, IC50 for multidrug resistant human KB3-1 cells to IC50 for human KB3-1 cells
    Resistant ratio, IC50 for multidrug resistant human KB3-1 cells to IC50 for human KB3-1 cells
    		[PMID: 18313307]
    KB-V1 GI50
    > 1000 nM
    Compound: 21
    Cytotoxicity against vinblastine-resistant human KBV1 cells after 72 hrs by MTT assay
    Cytotoxicity against vinblastine-resistant human KBV1 cells after 72 hrs by MTT assay
    		[PMID: 24502276]
    KB-V1 IC50
    31.98 μM
    Compound: doxorubicin
    Growth inhibition of human KB V1 cells after 72 hrs by MTT assay
    Growth inhibition of human KB V1 cells after 72 hrs by MTT assay
    		[PMID: 18313307]
    KB-V1 IC50
    4.7 μM
    Compound: Adriamycin
    Cytotoxicity against vinblastine-selected human KBV1 cells after 72 hrs by MTT assay
    Cytotoxicity against vinblastine-selected human KBV1 cells after 72 hrs by MTT assay
    		[PMID: 21721528]
    KCL-22 IC50
    1.8 μM
    Compound: Doxorubicin
    Antiproliferative activity against human KCL22 cells after 48 hrs by MTT assay
    Antiproliferative activity against human KCL22 cells after 48 hrs by MTT assay
    		[PMID: 24941129]
    KG-1a IC50
    0.65 μg/mL
    Compound: DOX
    Cytotoxicity against human KG1a cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Cytotoxicity against human KG1a cells assessed as reduction in cell viability after 48 hrs by MTT assay
    		[PMID: 29274817]
    KM12 ED50
    0.11 μg/mL
    Compound: adriamycin
    Cytotoxicity against human KM12 cells after 48 hrs by SRB assay
    Cytotoxicity against human KM12 cells after 48 hrs by SRB assay
    		10.1021/np50124a024
    KM12 GI50
    0.27 μM
    Compound: Doxorubicin
    Growth inhibition of human KM12 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human KM12 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28329730]
    KM12 GI50
    0.27 μM
    Compound: Doxorubicin
    Growth inhibition of human KM12 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human KM12 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 29102177]
    KM12 GI50
    0.27 μM
    Compound: Doxorubicin hydrochloride, NSC 123127
    Cytotoxicity against human KM12 cells after 48 hrs by SRB assay
    Cytotoxicity against human KM12 cells after 48 hrs by SRB assay
    		[PMID: 23871905]
    KM12 IC50
    0.02 μM
    Compound: Doxorubicin
    Antiproliferative activity against human KM12 cells assessed as inhibition of cell proliferation incubated for 72 hrs by conventional ATP quantification method
    Antiproliferative activity against human KM12 cells assessed as inhibition of cell proliferation incubated for 72 hrs by conventional ATP quantification method
    		[PMID: 25937235]
    KM12 IC50
    8.92 μM
    Compound: Dox
    Antiproliferative activity against human KM12 cells assessed as inhibition of cell viability by MTT assay
    Antiproliferative activity against human KM12 cells assessed as inhibition of cell viability by MTT assay
    		[PMID: 37922829]
    KU-19-19 EC50
    72 nM
    Compound: Doxorubicin
    Antiproliferative activity against human KU-19-19 cells assessed as reduction in cell viability incubated for 5 days by celltiter-glo assay
    Antiproliferative activity against human KU-19-19 cells assessed as reduction in cell viability incubated for 5 days by celltiter-glo assay
    		[PMID: 30996949]
    Kelly IC50
    0.18 μM
    Compound: Doxorubicin
    Antiproliferative activity against human Kelly cells after 72 hrs by CellTiter-Glo luminescent cell viability assay
    Antiproliferative activity against human Kelly cells after 72 hrs by CellTiter-Glo luminescent cell viability assay
    		[PMID: 28273560]
    Kelly IC50
    6.57 μM
    Compound: Doxorubicin
    Antiproliferative activity against human adriamycin-resistant Kelly cells after 72 hrs by CellTiter-Glo luminescent cell viability assay
    Antiproliferative activity against human adriamycin-resistant Kelly cells after 72 hrs by CellTiter-Glo luminescent cell viability assay
    		[PMID: 28273560]
    L02 IC50
    0.11 μM
    Compound: Doxorubicin
    Cytotoxicity against human LO2 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Cytotoxicity against human LO2 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    		[PMID: 29702447]
    L02 IC50
    0.14 μM
    Compound: ADM; DOX
    Cytotoxicity against human L02 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Cytotoxicity against human L02 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    		[PMID: 31491611]
    L02 IC50
    0.18 μM
    Compound: DOX
    Cytotoxicity against human L02 cells measured after 72 hrs by MTT assay
    Cytotoxicity against human L02 cells measured after 72 hrs by MTT assay
    		[PMID: 35612499]
    L02 IC50
    0.18 μM
    Compound: Dox
    Antiproliferative activity against human L02 cells after 48 hrs by MTT assay
    Antiproliferative activity against human L02 cells after 48 hrs by MTT assay
    		[PMID: 35339100]
    L02 IC50
    0.256 μM
    Compound: Dox
    Cytotoxicity against human L02 cells assessed as reduction in cell viability incubated for 96 hrs by MTT method
    Cytotoxicity against human L02 cells assessed as reduction in cell viability incubated for 96 hrs by MTT method
    		[PMID: 34236840]
    L02 IC50
    0.351 μM
    Compound: DOX
    Cytotoxicity against human HL7702 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay
    Cytotoxicity against human HL7702 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay
    		[PMID: 34700239]
    L02 IC50
    0.59 μM
    Compound: Doxorubicin
    Cytotoxicity against human L02 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
    Cytotoxicity against human L02 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
    		[PMID: 32438251]
    L02 IC50
    0.6 μM
    Compound: DOX
    Cytotoxicity against human L02 cells assessed as inhibition in cell growth measured after 48 hrs by MTT assay
    Cytotoxicity against human L02 cells assessed as inhibition in cell growth measured after 48 hrs by MTT assay
    		[PMID: 37602711]
    L02 IC50
    0.7 μM
    Compound: DOX
    Cytotoxicity against human LO2 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay
    Cytotoxicity against human LO2 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay
    		[PMID: 31820976]
    L02 IC50
    0.79 μM
    Compound: DOX
    Cytotoxicity against human HL7702 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 assay
    Cytotoxicity against human HL7702 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 assay
    		[PMID: 38039790]
    L02 IC50
    0.85 μM
    Compound: DOX
    Antiproliferative activity against human L02 cells after 72 hrs by CCK-8 assay
    Antiproliferative activity against human L02 cells after 72 hrs by CCK-8 assay
    		[PMID: 29597166]
    L02 IC50
    0.88 μM
    Compound: DOX
    Antiproliferative activity against human L02 cells after 72 hrs by CCK-8 assay
    Antiproliferative activity against human L02 cells after 72 hrs by CCK-8 assay
    		[PMID: 29614418]
    L02 IC50
    0.9 μM
    Compound: Doxorubicin
    Cytotoxicity against human L02 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human L02 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 29789258]
    L02 IC50
    0.94 μM
    Compound: Doxorubicin
    Cytotoxicity against human HL7702 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Cytotoxicity against human HL7702 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    		[PMID: 32866757]
    L02 IC50
    1.09 μM
    Compound: Doxorubicin
    Cytotoxicity against human L02 cells assessed as reduction in cell viability after 24 hrs by MTT assay
    Cytotoxicity against human L02 cells assessed as reduction in cell viability after 24 hrs by MTT assay
    		[PMID: 31404864]
    L02 IC50
    1.09 μM
    Compound: Doxorubicin
    Cytotoxicity against human L02 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay
    Cytotoxicity against human L02 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay
    		[PMID: 35367708]
    L02 IC50
    1.1 μM
    Compound: Doxorubicin
    Cytotoxicity against human LO2 cells assessed as reduction in cell viability after 24 hrs by CCK8 assay
    Cytotoxicity against human LO2 cells assessed as reduction in cell viability after 24 hrs by CCK8 assay
    		[PMID: 32324401]
    L02 IC50
    10.36 μM
    Compound: DOX
    Cytotoxicity against human LO2 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    Cytotoxicity against human LO2 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    		[PMID: 30771605]
    L02 IC50
    10.4 μM
    Compound: DOX
    Cytotoxicity against human HL-7702 cells after 48 hrs by MTT assay
    Cytotoxicity against human HL-7702 cells after 48 hrs by MTT assay
    		[PMID: 28756264]
    L02 IC50
    10.44 μM
    Compound: DOX
    Cytotoxicity against human HL-7702 cells after 48 hrs by MTT assay
    Cytotoxicity against human HL-7702 cells after 48 hrs by MTT assay
    		[PMID: 31057738]
    L02 IC50
    12.23 μM
    Compound: DOX
    Cytotoxicity against human HL-7702 cells after 48 hrs by MTT assay
    Cytotoxicity against human HL-7702 cells after 48 hrs by MTT assay
    		[PMID: 27889629]
    L02 IC50
    13.25 μM
    Compound: Doxorubicin
    Cytotoxicity against human L02 cells by CCK8 assay
    Cytotoxicity against human L02 cells by CCK8 assay
    		[PMID: 29452840]
    L02 IC50
    13.8 μM
    Compound: DOX
    Cytotoxicity against human L02 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    Cytotoxicity against human L02 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    		[PMID: 32371335]
    L02 IC50
    2.18 μM
    Compound: Doxorubicin
    Cytotoxicity against human L02 cells measured after 48 hrs by MTT assay
    Cytotoxicity against human L02 cells measured after 48 hrs by MTT assay
    		[PMID: 32682198]
    L02 IC50
    2.19 μM
    Compound: DOX
    Cytotoxicity against human L02 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay
    Cytotoxicity against human L02 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay
    		[PMID: 35341920]
    L02 IC50
    2.24 μM
    Compound: DOX
    Antiproliferative activity against human L02 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Antiproliferative activity against human L02 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    		[PMID: 32996316]
    L02 IC50
    3.5 μM
    Compound: DOX
    Cytotoxicity against human L02 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay
    Cytotoxicity against human L02 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay
    		[PMID: 30846253]
    L02 IC50
    3.6 μM
    Compound: DOX
    Antiproliferative activity against human L02 cells after 72 hrs by MTT assay
    Antiproliferative activity against human L02 cells after 72 hrs by MTT assay
    		[PMID: 30398868]
    L02 IC50
    53.3 nM
    Compound: Doxorubicin
    Cytotoxicity against human L02 cells assessed as growth inhibition after 72 hrs by MTT assay
    Cytotoxicity against human L02 cells assessed as growth inhibition after 72 hrs by MTT assay
    		[PMID: 29886322]
    L02 IC50
    6.93 μM
    Compound: DOX
    Cytotoxicity against human LO2 cells assessed as reduction in cell viability after 24 hrs by MTT assay
    Cytotoxicity against human LO2 cells assessed as reduction in cell viability after 24 hrs by MTT assay
    		[PMID: 29421568]
    L02 IC50
    6.93 μM
    Compound: Dox
    Cytotoxicity against human LO2 Cells
    Cytotoxicity against human LO2 Cells
    		[PMID: 31129455]
    L02 IC50
    7.87 μM
    Compound: DOX
    Cytotoxicity against human LO2 cells assessed as reduction in cell viability after 24 hrs by MTT assay
    Cytotoxicity against human LO2 cells assessed as reduction in cell viability after 24 hrs by MTT assay
    		[PMID: 29909338]
    L02 IC50
    8.6 μM
    Compound: Dox
    Cytotoxicity against human L02 cells assessed as reduction in cell viability by MTT assay
    Cytotoxicity against human L02 cells assessed as reduction in cell viability by MTT assay
    		[PMID: 31765156]
    L02 IC50
    < 1 μM
    Compound: ADM
    Cytotoxicity against human L02 cells by SRB method
    Cytotoxicity against human L02 cells by SRB method
    		[PMID: 37807846]
    L02 IC50
    < 1 μM
    Compound: Doxorubicin
    Cytotoxicity against human L02 cells by SRB assay
    Cytotoxicity against human L02 cells by SRB assay
    		[PMID: 33371684]
    L02 IC50
    < 1 μM
    Compound: Doxorubicin
    Cytotoxicity against human L02 cells assessed as reduction in cell growth by MTT assay
    Cytotoxicity against human L02 cells assessed as reduction in cell growth by MTT assay
    		[PMID: 36734533]
    L02 IC50
    < 1 μM
    Compound: doxorubicin
    Cytotoxicity against human L02 cells by SRB assay
    Cytotoxicity against human L02 cells by SRB assay
    		[PMID: 33847126]
    L02 IC50
    > 100 μM
    Compound: Doxorubicin
    Cytotoxicity against human L02 cells incubated for 48 hrs by MTT assay
    Cytotoxicity against human L02 cells incubated for 48 hrs by MTT assay
    		[PMID: 35367708]
    L02 IC50
    > 50 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human L02 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay
    Cytotoxicity against human L02 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay
    		[PMID: 34973507]
    L1210 ED50
    0.016 μg/mL
    Compound: Adriamycin
    The compound was evaluated for antiproliferative activity against L1210 cell line
    The compound was evaluated for antiproliferative activity against L1210 cell line
    		[PMID: 11055343]
    L1210 ED50
    0.58 μM
    Compound: 1
    Compound was evaluated for the inhibition of RNA synthesis in leukemia L1210 cells
    Compound was evaluated for the inhibition of RNA synthesis in leukemia L1210 cells
    		[PMID: 3761328]
    L1210 ED50
    0.58 μM
    Compound: 1
    Concentration of drug necessary to reduce by 50% the incorporation of tritiated uridine in the RNA of actively growing L1210 cells.
    Concentration of drug necessary to reduce by 50% the incorporation of tritiated uridine in the RNA of actively growing L1210 cells.
    		[PMID: 7086816]
    L1210 ED50
    0.58 μM
    Compound: 2
    Compound was evaluated for the 50% inhibition of the incorporation of [3H]- thymidine in the RNA (inhibition of synthesis in leukemia L1210 cells)
    Compound was evaluated for the 50% inhibition of the incorporation of [3H]- thymidine in the RNA (inhibition of synthesis in leukemia L1210 cells)
    		[PMID: 3761325]
    L1210 ED50
    0.58 μM
    Compound: 2
    Inhibition of RNA synthesis in mouse L1210 cells
    Inhibition of RNA synthesis in mouse L1210 cells
    		[PMID: 423182]
    L1210 ED50
    0.58 μM
    Compound: 2
    Inhibition of RNA synthesis in mouse L1210 cells
    Inhibition of RNA synthesis in mouse L1210 cells
    		[PMID: 490536]
    L1210 ED50
    0.58 μM
    Compound: Doxorubicin
    Compound was evaluated for drug concentration for 50% inhibition of actively growing L1210 cells in culture for the inhibition of incorporation of [3H]uridine in the RNA
    Compound was evaluated for drug concentration for 50% inhibition of actively growing L1210 cells in culture for the inhibition of incorporation of [3H]uridine in the RNA
    		[PMID: 3806572]
    L1210 ED50
    0.67 μM
    Compound: Adriamycin
    Inhibition of RNA synthesis in mouse L1210 cells after 3 hrs by [3H]uridine incorporation assay
    Inhibition of RNA synthesis in mouse L1210 cells after 3 hrs by [3H]uridine incorporation assay
    		[PMID: 915894]
    L1210 ED50
    0.7 μM
    Compound: 1
    Inhibition of RNA synthesis in mouse L1210 cells
    Inhibition of RNA synthesis in mouse L1210 cells
    		[PMID: 423181]
    L1210 ED50
    0.7 μM
    Compound: 2
    Inhibition of RNA synthesis in mouse L1210 cells assessed as inhibition of [3H]uridine incorporation
    Inhibition of RNA synthesis in mouse L1210 cells assessed as inhibition of [3H]uridine incorporation
    		[PMID: 490537]
    L1210 ED50
    0.8 μM
    Compound: Adriamycin
    Inhibition of DNA synthesis in mouse L1210 cells preincubated for 3 hrs followed by [3H]-thymidine addition measured after 1 hr by scintillation spectrometric analysis
    Inhibition of DNA synthesis in mouse L1210 cells preincubated for 3 hrs followed by [3H]-thymidine addition measured after 1 hr by scintillation spectrometric analysis
    		[PMID: 176359]
    L1210 ED50
    0.9 μM
    Compound: Adriamycin
    Inhibition of RNA synthesis in mouse L1210 cells preincubated for 3 hrs followed by [3H]-uridine addition measured after 1 hr by scintillation spectrometric analysis
    Inhibition of RNA synthesis in mouse L1210 cells preincubated for 3 hrs followed by [3H]-uridine addition measured after 1 hr by scintillation spectrometric analysis
    		[PMID: 176359]
    L1210 ED50
    1.5 μM
    Compound: 1
    Inhibition of DNA synthesis in mouse L1210 cells
    Inhibition of DNA synthesis in mouse L1210 cells
    		[PMID: 423181]
    L1210 ED50
    1.5 μM
    Compound: 1
    Concentration of drug necessary to reduce by 50% the incorporation of tritiated thymidine in the DNA of actively growing L1210 cells
    Concentration of drug necessary to reduce by 50% the incorporation of tritiated thymidine in the DNA of actively growing L1210 cells
    		[PMID: 7086816]
    L1210 ED50
    1.5 μM
    Compound: 2
    Inhibition of DNA synthesis in mouse L1210 cells
    Inhibition of DNA synthesis in mouse L1210 cells
    		[PMID: 423182]
    L1210 ED50
    1.5 μM
    Compound: 2
    Inhibition of DNA synthesis in mouse L1210 cells
    Inhibition of DNA synthesis in mouse L1210 cells
    		[PMID: 490536]
    L1210 ED50
    1.5 μM
    Compound: Adriamycin
    Inhibition of DNA synthesis in mouse L1210 cells after 3 hrs by [3H]thymidine incorporation assay
    Inhibition of DNA synthesis in mouse L1210 cells after 3 hrs by [3H]thymidine incorporation assay
    		[PMID: 915894]
    L1210 ED50
    1.6 μM
    Compound: 1
    Compound was evaluated for the inhibition of DNA synthesis in leukemia L1210 cells
    Compound was evaluated for the inhibition of DNA synthesis in leukemia L1210 cells
    		[PMID: 3761328]
    L1210 ED50
    1.6 μM
    Compound: 2
    Compound was evaluated for the 50% inhibition of the incorporation of [3H]- thymidine in the DNA (inhibition of synthesis in leukemia L1210 cells)
    Compound was evaluated for the 50% inhibition of the incorporation of [3H]- thymidine in the DNA (inhibition of synthesis in leukemia L1210 cells)
    		[PMID: 3761325]
    L1210 ED50
    1.6 μM
    Compound: Doxorubicin
    Compound was evaluated for drug concentration for 50% inhibition of actively growing L1210 cells in culture for the inhibition of incorporation of [3H]thymidine in the DNA
    Compound was evaluated for drug concentration for 50% inhibition of actively growing L1210 cells in culture for the inhibition of incorporation of [3H]thymidine in the DNA
    		[PMID: 3806572]
    L1210 ED50
    2 μM
    Compound: 2
    Inhibition of DNA synthesis in mouse L1210 cells assessed as inhibition of [3H]thymidine incorporation
    Inhibition of DNA synthesis in mouse L1210 cells assessed as inhibition of [3H]thymidine incorporation
    		[PMID: 490537]
    L1210 IC50
    0.025 μM
    Compound: Adriamycin
    Antiproliferative activity was evaluated against murine L1210 leukemia cell line
    Antiproliferative activity was evaluated against murine L1210 leukemia cell line
    		[PMID: 11128630]
    L1210 IC50
    0.025 μM
    Compound: Adriamycin
    Inhibitory concentration required against L1210 leukemia cells
    Inhibitory concentration required against L1210 leukemia cells
    		[PMID: 12182872]
    L1210 IC50
    0.025 μM
    Compound: Adriamycin (ADR)
    In vitro cytotoxic activity was evaluated using the murine leukemia L1210 cell line
    In vitro cytotoxic activity was evaluated using the murine leukemia L1210 cell line
    		[PMID: 12443763]
    L1210 IC50
    0.025 μM
    Compound: Doxorubicin
    In vitro inhibitory activity was tested against L1210 leukemia cells
    In vitro inhibitory activity was tested against L1210 leukemia cells
    		[PMID: 10890167]
    L1210 IC50
    0.029 μM
    Compound: adriamycin
    Cytotoxicity against mouse L1210 cell line
    Cytotoxicity against mouse L1210 cell line
    		[PMID: 17228871]
    L1210 IC50
    0.02 μg/mL
    Compound: doxorubicin
    Growth inhibition of L1210 murine leukemia cells after 1 hr exposure in stem cell assay
    Growth inhibition of L1210 murine leukemia cells after 1 hr exposure in stem cell assay
    		[PMID: 8496904]
    L1210 IC50
    0.03 μM
    Compound: doxorubicine
    Cytotoxicity against mouse L1210 cells after 48 hrs by MTT method
    Cytotoxicity against mouse L1210 cells after 48 hrs by MTT method
    		[PMID: 7561901]
    L1210 IC50
    0.032 μM
    Compound: Adriamycin
    Cytotoxicity against mouse L1210 cells
    Cytotoxicity against mouse L1210 cells
    		[PMID: 915894]
    L1210 IC50
    0.033 μM
    Compound: ADR (Adriamycin)
    In vitro cytotoxicity using murine leukemia L1210 cells from american type culture collection.
    In vitro cytotoxicity using murine leukemia L1210 cells from american type culture collection.
    		10.1016/0960-894X(96)00457-X
    L1210 IC50
    0.04 μM
    Compound: DOX
    Compound was tested for cytotoxicity on L1210 leukemia cell line using a proliferation assay (MTT reduction)
    Compound was tested for cytotoxicity on L1210 leukemia cell line using a proliferation assay (MTT reduction)
    		10.1016/S0960-894X(01)81264-6
    L1210 IC50
    0.048 μM
    Compound: Doxorubicin
    Inhibitory activity against L1210 cell growth
    Inhibitory activity against L1210 cell growth
    		[PMID: 1992140]
    L1210 IC50
    0.04 μg/mL
    Compound: doxorubicin
    Growth inhibition of L1210 murine leukemia cells after 1 hr exposure in untreated control culture
    Growth inhibition of L1210 murine leukemia cells after 1 hr exposure in untreated control culture
    		[PMID: 8496904]
    L1210 IC50
    0.05 μM
    Compound: doxorubicin
    Growth inhibitory concentration of compound was measured against murine leukemia cell line (L1210)
    Growth inhibitory concentration of compound was measured against murine leukemia cell line (L1210)
    		[PMID: 10698436]
    L1210 IC50
    0.05 μM
    Compound: doxorubicin
    Tested in vitro for inhibition after 48 hr exposure against murine leukemia cell line L1210
    Tested in vitro for inhibition after 48 hr exposure against murine leukemia cell line L1210
    		[PMID: 7996544]
    L1210 IC50
    0.06 μM
    Compound: doxorubicin
    Tested in vitro for inhibition after 48 hr exposure against murine leukemia cell line L1210/L-PAM resistant to melphalan (L-PAM)
    Tested in vitro for inhibition after 48 hr exposure against murine leukemia cell line L1210/L-PAM resistant to melphalan (L-PAM)
    		[PMID: 7996544]
    L1210 IC50
    0.08 μM
    Compound: Doxorubicin (Dx)
    In vitro cytotoxicity against murine leukemia cell line L1210
    In vitro cytotoxicity against murine leukemia cell line L1210
    		[PMID: 16169719]
    L1210 IC50
    0.09 μg/mL
    Compound: adriamycin
    Cytotoxicity against mouse L1210 cells
    Cytotoxicity against mouse L1210 cells
    		[PMID: 9249977]
    L1210 IC50
    0.15 μM
    Compound: Dox
    Antitumor activity against mouse L1210 cell line assessed as inhibition of [3H]thymidine incorporation
    Antitumor activity against mouse L1210 cell line assessed as inhibition of [3H]thymidine incorporation
    		[PMID: 16563756]
    L1210 IC50
    0.2 μM
    Compound: doxorubicin
    Ability to inhibit growth of L1210 leukemic cell lines was determined in an in vitro MTT assay.
    Ability to inhibit growth of L1210 leukemic cell lines was determined in an in vitro MTT assay.
    		[PMID: 1995877]
    L1210 IC50
    0.23 μM
    Compound: Doxorubicin
    Antitumor activity was evaluated against leukemia cell line L1210 (mouse leukemia).
    Antitumor activity was evaluated against leukemia cell line L1210 (mouse leukemia).
    		[PMID: 10411476]
    L1210 IC50
    0.2 μg/mL
    Compound: doxorubicin
    Cytotoxicity against mouse L1210 cells by MTT assay
    Cytotoxicity against mouse L1210 cells by MTT assay
    		[PMID: 9051915]
    L1210 IC50
    0.37 μM
    Compound: 1; Dox
    Antiproliferative activity against mouse L1210 cells after 48 hrs by MTT assay
    Antiproliferative activity against mouse L1210 cells after 48 hrs by MTT assay
    		[PMID: 26633734]
    L1210 IC50
    0.37 μM
    Compound: Dox
    Cytotoxicity against mouse L1210 cells after 48 hrs by MTT assay
    Cytotoxicity against mouse L1210 cells after 48 hrs by MTT assay
    		[PMID: 21144624]
    L1210 IC50
    0.4 mM
    Compound: Dox
    Antiproliferative activity against mouse L1210 cells after 48 hrs by MTT assay
    Antiproliferative activity against mouse L1210 cells after 48 hrs by MTT assay
    		[PMID: 29459273]
    L1210 IC50
    0.4 μM
    Compound: 1; Dox
    Antiproliferative activity against mouse L1210 cells after 48 hrs by MTT assay
    Antiproliferative activity against mouse L1210 cells after 48 hrs by MTT assay
    		[PMID: 26890118]
    L1210 IC50
    0.4 μM
    Compound: 2
    Antiproliferative activity against mouse L1210 cells assessed as growth inhibition after 72 hrs by MTT assay
    Antiproliferative activity against mouse L1210 cells assessed as growth inhibition after 72 hrs by MTT assay
    		[PMID: 33974416]
    L1210 IC50
    0.4 μM
    Compound: 5
    Antiproliferative activity against mouse L1210 cells after 72 hrs by MTT assay
    Antiproliferative activity against mouse L1210 cells after 72 hrs by MTT assay
    		[PMID: 29137865]
    L1210 IC50
    0.4 μM
    Compound: Dox
    Antiproliferative activity in mouse L1210 cells after 48 hrs by MTT assay
    Antiproliferative activity in mouse L1210 cells after 48 hrs by MTT assay
    		[PMID: 30268824]
    L1210 IC50
    0.9 μM
    Compound: Doxorubicin
    Compound was tested for its effect on the proliferation of L1210 murine leukemia cell line.
    Compound was tested for its effect on the proliferation of L1210 murine leukemia cell line.
    		10.1016/0960-894X(96)00216-8
    L1210 IC50
    0.9 μg/mL
    Compound: doxorubicin
    Growth inhibition of L1210/ADM murine leukemia cells after 3 hr exposure in MTT assay
    Growth inhibition of L1210/ADM murine leukemia cells after 3 hr exposure in MTT assay
    		[PMID: 8496904]
    L1210 IC50
    1.2 μM
    Compound: Doxorubicin
    Cytotoxicity against mouse L1210 cells assessed as reduction in cell viability by MTT assay
    Cytotoxicity against mouse L1210 cells assessed as reduction in cell viability by MTT assay
    		[PMID: 30660827]
    L1210 IC50
    1.6 μM
    Compound: Doxorubicin
    Cytotoxicity against mouse L1210 cells assessed as reduction in cell viability
    Cytotoxicity against mouse L1210 cells assessed as reduction in cell viability
    		[PMID: 30660827]
    L1210 IC50
    1.7 μM
    Compound: Doxorubicin
    Antiproliferative activity against mouse L1210 cells after 24 to 72 hrs by MTT assay
    Antiproliferative activity against mouse L1210 cells after 24 to 72 hrs by MTT assay
    		[PMID: 30660827]
    L1210 IC50
    179 nM
    Compound: Doxorubicin
    Compound was tested in vitro against L1210 leukemia cells
    Compound was tested in vitro against L1210 leukemia cells
    		[PMID: 12570384]
    L1210 IC50
    182 nM
    Compound: doxorubicin
    Antitumor activity against mouse L1210 cells assessed as inhibition of [3H]thymidine uptake after 48 hrs
    Antitumor activity against mouse L1210 cells assessed as inhibition of [3H]thymidine uptake after 48 hrs
    		[PMID: 18508273]
    L1210 IC50
    26 nM
    Compound: adriamycin
    In vitro cytotoxicity against L1210 (murine leukemia) cells.
    In vitro cytotoxicity against L1210 (murine leukemia) cells.
    		[PMID: 8057291]
    L1210 IC50
    28 ng/mL
    Compound: Doxorubicin
    Inhibitory activity against L1210 cell growth
    Inhibitory activity against L1210 cell growth
    		[PMID: 1992140]
    L1210 IC50
    34.3 nM
    Compound: Adriamycin
    Inhibition of murine L1210 leukemia cell proliferation measured by the MTT assay
    Inhibition of murine L1210 leukemia cell proliferation measured by the MTT assay
    		[PMID: 10377224]
    L1210 IC50
    35 nM
    Compound: Doxorubicin
    Anti-tumor activity against murine L1210 sensitive cell line by using MTT assay
    Anti-tumor activity against murine L1210 sensitive cell line by using MTT assay
    		[PMID: 7699715]
    L1210 IC50
    35 nM
    Compound: Doxorubicin
    Inhibitory activity against resistant murine leukemia L1210 cell lines.
    Inhibitory activity against resistant murine leukemia L1210 cell lines.
    		[PMID: 8648600]
    L1210 IC50
    35 nM
    Compound: Doxorubicin
    Inhibitory activity against sensitive L1210 cell lines
    Inhibitory activity against sensitive L1210 cell lines
    		[PMID: 8648600]
    L1210 IC50
    35 nM
    Compound: dixorubicin
    Antitumor activity against sensitive L1210 murine leukemia cell lines.
    Antitumor activity against sensitive L1210 murine leukemia cell lines.
    		[PMID: 8960558]
    L1210 IC50
    35 nM
    Compound: doxorubicin
    Tested for inhibitory activity against murine cell line L12110, a strain sensitive to doxorubicin using MTT assay.
    Tested for inhibitory activity against murine cell line L12110, a strain sensitive to doxorubicin using MTT assay.
    		[PMID: 10956214]
    L1210 IC50
    37.84 nM
    Compound: doxorubicin
    Cytotoxicity was determined after 48 hr of continuous exposure against L1210 murine leukemia cells
    Cytotoxicity was determined after 48 hr of continuous exposure against L1210 murine leukemia cells
    		[PMID: 15115402]
    L1210 IC50
    3884 nM
    Compound: Doxorubicin
    Antitumor activity against murine L1210 resistant cell line by using MTT assay
    Antitumor activity against murine L1210 resistant cell line by using MTT assay
    		[PMID: 7699715]
    L1210 IC50
    3884 nM
    Compound: dixorubicin
    Antitumor activity against murine leukemia L1210 cell line.
    Antitumor activity against murine leukemia L1210 cell line.
    		[PMID: 8960558]
    L1210 IC50
    3884 nM
    Compound: doxorubicin
    Tested for inhibitory activity against murine cell line L12110, a strain resistant to doxorubicin using MTT assay.
    Tested for inhibitory activity against murine cell line L12110, a strain resistant to doxorubicin using MTT assay.
    		[PMID: 10956214]
    L1210 IC50
    39.56 nM
    Compound: doxorubicin
    Cytotoxicity was determined after 48 hr of continuous exposure against L1210 murine leukemia cells,(cells resistant to melphalan (L-PAM)
    Cytotoxicity was determined after 48 hr of continuous exposure against L1210 murine leukemia cells,(cells resistant to melphalan (L-PAM)
    		[PMID: 15115402]
    L1210 IC50
    4.2 μM
    Compound: Doxorubicin
    Antiproliferative activity against mouse L1210 cells by MTT assay
    Antiproliferative activity against mouse L1210 cells by MTT assay
    		[PMID: 30660827]
    L1210 IC50
    61 nM
    Compound: Doxorubicin
    An average for IC50 values in the two solid tumor cell lines and sensitive L1210 leukemia cell line.
    An average for IC50 values in the two solid tumor cell lines and sensitive L1210 leukemia cell line.
    		[PMID: 8648600]
    L1210 IC50
    < 0.1 μg/mL
    Compound: doxorubicin
    Cytotoxicity against mouse L1210 cells assessed as cell viability by trypan blue assay
    Cytotoxicity against mouse L1210 cells assessed as cell viability by trypan blue assay
    		[PMID: 9051915]
    L1210 IC50
    6.9 x 10-8 M
    Compound: 2 (Doxorubicin)
    Tested in vitro against murine L1210 leukemia.
    Tested in vitro against murine L1210 leukemia.
    		[PMID: 3806589]
    L1210 IC50
    6.9 x 10-8 M
    Compound: doxorubicin
    In vitro for its inhibitory activity against murine L1210 leukemia
    In vitro for its inhibitory activity against murine L1210 leukemia
    		[PMID: 3397990]
    L1210 (1565) IC50
    0.022 μM
    Compound: Adriamycin
    Cytotoxic activity against L-1210 parental cell line
    Cytotoxic activity against L-1210 parental cell line
    		10.1016/0960-894X(95)00067-4
    L1210 (1565) IC50
    0.315 μM
    Compound: Adriamycin
    cytotoxic activity against adriamycin (ADR) resistant L-1210 cell line
    cytotoxic activity against adriamycin (ADR) resistant L-1210 cell line
    		10.1016/0960-894X(95)00067-4
    L132 IC50
    0.01 μM
    Compound: Doxorubicin
    Cytotoxicity against human L132 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Cytotoxicity against human L132 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    		[PMID: 31883489]
    L2987 IC50
    0.3 μM
    Compound: DOX 1a
    In vitro inhibitory concentration of the unconjugated compound against human L2987 lung carcinoma cell line
    In vitro inhibitory concentration of the unconjugated compound against human L2987 lung carcinoma cell line
    		[PMID: 12798317]
    L5178Y IC50
    0.07 μM
    Compound: Doxorubicin
    Antiproliferative activity against mouse L5178Y cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Antiproliferative activity against mouse L5178Y cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    		[PMID: 38665830]
    L5178Y IC50
    0.28 μM
    Compound: DOXO
    Antiproliferative activity against parental mouse L5178Y cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    Antiproliferative activity against parental mouse L5178Y cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    		[PMID: 36179403]
    L5178Y IC50
    0.7 μM
    Compound: DOXO
    Cytotoxicity against parental mouse L5178Y cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay
    Cytotoxicity against parental mouse L5178Y cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay
    		[PMID: 36179403]
    L5178Y IC50
    1.75 μM
    Compound: DOXO
    Antiproliferative activity against multidrug resistant mouse L5178Y cells expressing ABCB1 assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    Antiproliferative activity against multidrug resistant mouse L5178Y cells expressing ABCB1 assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    		[PMID: 36179403]
    L5178Y IC50
    2.14 μM
    Compound: DOXO
    Cytotoxicity against multidrug resistant mouse L5178Y cells expressing ABCB1 assessed as inhibition of cell growth incubated for 24 hrs by MTT assay
    Cytotoxicity against multidrug resistant mouse L5178Y cells expressing ABCB1 assessed as inhibition of cell growth incubated for 24 hrs by MTT assay
    		[PMID: 36179403]
    L5178Y IC50
    4.6 μM
    Compound: Doxorubicin
    Cytotoxicity against mouse L5178Y cells by MTT assay
    Cytotoxicity against mouse L5178Y cells by MTT assay
    		[PMID: 30015071]
    L5178Y IC50
    6.82 μM
    Compound: Doxorubicin
    Reversal of multidrug resistance in multidrug resistant mouse L5178Y cells transfected with human ABCB1 assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Reversal of multidrug resistance in multidrug resistant mouse L5178Y cells transfected with human ABCB1 assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    		[PMID: 38665830]
    L929 GI50
    1.2 μM
    Compound: doxorubicin
    Antiproliferative activity against mouse L929 cells
    Antiproliferative activity against mouse L929 cells
    		[PMID: 19188072]
    L929 IC50
    0.16 μM
    Compound: Doxorubicin
    Cytotoxicity against mouse L929 cells assessed as cell viability after 72 hrs by MTT assay
    Cytotoxicity against mouse L929 cells assessed as cell viability after 72 hrs by MTT assay
    		[PMID: 24530030]
    L929 IC50
    0.22 μM
    Compound: DOXO
    Antiproliferative activity against mouse L929 cells after 72 hrs by MTT assay
    Antiproliferative activity against mouse L929 cells after 72 hrs by MTT assay
    		[PMID: 28818447]
    L929 IC50
    0.23 μM
    Compound: DOXO
    Cytotoxicity against mouse L929 cells assessed as cell viability after 72 hrs by MTT assay
    Cytotoxicity against mouse L929 cells assessed as cell viability after 72 hrs by MTT assay
    		[PMID: 26142490]
    L929 IC50
    0.23 μM
    Compound: Doxorubicin
    Cytotoxicity against NQO1-deficient mouse L929 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against NQO1-deficient mouse L929 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 27341379]
    L929 IC50
    0.66 μM
    Compound: Doxorubicin
    Cytotoxicity against mouse L929 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
    Cytotoxicity against mouse L929 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
    		[PMID: 31836446]
    L929 IC50
    1.72 μM
    Compound: DOX
    Cytotoxicity against mouse L929 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against mouse L929 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 29660689]
    L929 IC50
    1.72 μM
    Compound: Doxorubicin
    Cytotoxicity against mouse L929 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    Cytotoxicity against mouse L929 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    		[PMID: 34778772]
    L929 IC50
    161 nM
    Compound: Doxorubicin
    Antiproliferative activity against mouse L929 cells assessed as inhibition of cell viability after 72 hrs by XTT assay
    Antiproliferative activity against mouse L929 cells assessed as inhibition of cell viability after 72 hrs by XTT assay
    		[PMID: 23360521]
    L929 IC50
    20 μM
    Compound: Dox
    Cytotoxicity against mouse L929 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against mouse L929 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 33479619]
    L929 IC50
    325.9 μM
    Compound: DOX
    Cytotoxicity against mouse L929 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay
    Cytotoxicity against mouse L929 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay
    		[PMID: 35859879]
    L929 IC50
    7.5 μM
    Compound: Doxorubicin
    Cytotoxicity against mouse L929 cells by MTT assay
    Cytotoxicity against mouse L929 cells by MTT assay
    		[PMID: 33766771]
    L929 IC50
    > 100 μM
    Compound: Dox
    Antiproliferative activity against mouse L929 cells incubated for 48 hrs by MTT assay
    Antiproliferative activity against mouse L929 cells incubated for 48 hrs by MTT assay
    		[PMID: 38990190]
    LAMA-84 IC50
    0.74 μM
    Compound: DOXO
    Cytotoxicity against human LAMA-84 cells assessed as cell viability after 48 hrs by alamar blue assay
    Cytotoxicity against human LAMA-84 cells assessed as cell viability after 48 hrs by alamar blue assay
    		[PMID: 21797280]
    LAMA-84 IC50
    0.74 μM
    Compound: Doxorubicin
    Cytotoxicity against human LAMA-84 cells after 48 hrs by Alamar blue assay
    Cytotoxicity against human LAMA-84 cells after 48 hrs by Alamar blue assay
    		[PMID: 20931970]
    LAMA-84 IC50
    0.76 μM
    Compound: Doxorubicin
    Cytotoxicity against human LAMA-84 cells after 48 hrs by Alamar Blue assay
    Cytotoxicity against human LAMA-84 cells after 48 hrs by Alamar Blue assay
    		[PMID: 19473028]
    LLC-PK1 IC50
    0.2 μM
    Compound: Adriamycin
    Cytotoxicity against pig LLC-PK1 cells transfected with empty vector after 72 hrs by MTT assay
    Cytotoxicity against pig LLC-PK1 cells transfected with empty vector after 72 hrs by MTT assay
    		[PMID: 21721528]
    LLC-PK1 IC50
    0.4 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against pig LLC-PK1 cells assessed as reduction in cell viability incubated for 48 hrs by neutral red based assay
    Cytotoxicity against pig LLC-PK1 cells assessed as reduction in cell viability incubated for 48 hrs by neutral red based assay
    		[PMID: 26371504]
    LLC-PK1 IC50
    0.5 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against pig LLC-PK1 cells assessed as cell viability after 48 hrs by neutral red-based assay
    Cytotoxicity against pig LLC-PK1 cells assessed as cell viability after 48 hrs by neutral red-based assay
    		[PMID: 26469557]
    LLC-PK1 IC50
    0.65 μg/mL
    Compound: DOX
    Cytotoxicity against LLC-PK1 cells by neutral red method
    Cytotoxicity against LLC-PK1 cells by neutral red method
    		[PMID: 17181171]
    LLC-PK1 IC50
    0.65 μg/mL
    Compound: doxorubicin
    Cytotoxicity against LLC-PK1 cells by neutral red assay
    Cytotoxicity against LLC-PK1 cells by neutral red assay
    		[PMID: 17070063]
    LLC-PK1 IC50
    0.75 μM
    Compound: Doxorubicin
    Cytotoxicity against Sus scrofa (pig) LLC-PK1 cells by neutral red staining
    Cytotoxicity against Sus scrofa (pig) LLC-PK1 cells by neutral red staining
    		10.1007/s00044-011-9587-3
    LLC-PK1 IC50
    1.3 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against pig LLC-PK1 cells assessed as reduction in viable cells measured after 48 hrs by neutral red dye-based method
    Cytotoxicity against pig LLC-PK1 cells assessed as reduction in viable cells measured after 48 hrs by neutral red dye-based method
    		[PMID: 27584935]
    LLC-PK1 IC50
    1.6 μM
    Compound: doxorubicin
    Cytotoxicity against pig LLC-PK1 cells assessed as growth inhibition measured after 48 hrs by XTT assay
    Cytotoxicity against pig LLC-PK1 cells assessed as growth inhibition measured after 48 hrs by XTT assay
    		[PMID: 23547843]
    LLC-PK1 IC50
    17 μM
    Compound: Doxorubicin
    Cytotoxicity against pig LLC-PK1 cells assessed as reduction in cell viability after 48 hrs by neutral red dye-based assay
    Cytotoxicity against pig LLC-PK1 cells assessed as reduction in cell viability after 48 hrs by neutral red dye-based assay
    		[PMID: 27618204]
    LLC-PK1 IC50
    19.72 μM
    Compound: Adriamycin
    Cytotoxicity against pig LLC-PK1 cells after 72 hrs by MTT assay
    Cytotoxicity against pig LLC-PK1 cells after 72 hrs by MTT assay
    		[PMID: 21721528]
    LLC-PK1 IC50
    2.6 μM
    Compound: Doxorubicin
    Cytotoxicity against pig LLC-PK1 cells assessed as cell growth inhibition after 48 hrs by neutral red assay
    Cytotoxicity against pig LLC-PK1 cells assessed as cell growth inhibition after 48 hrs by neutral red assay
    		[PMID: 26005918]
    LLC-PK1 IC50
    < 0.55 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against pig LLC-PK1 cells after 48 hrs by neutral red assay
    Cytotoxicity against pig LLC-PK1 cells after 48 hrs by neutral red assay
    		[PMID: 19105653]
    LLC-PK1 IC50
    < 1 μM
    Compound: Doxorubicin
    Cytotoxicity against a pig LLC-PK1 cells after 48 hrs by Neutral Red assay
    Cytotoxicity against a pig LLC-PK1 cells after 48 hrs by Neutral Red assay
    		10.1039/C3MD00097D
    LN-18 IC50
    68.9 μM
    Compound: DOX
    Antiproliferative activity against human LN18 cells after 48 hrs by MTT assay
    Antiproliferative activity against human LN18 cells after 48 hrs by MTT assay
    		[PMID: 27108400]
    LN-229 IC50
    0.17 μM
    Compound: DOX
    Antiproliferative activity against human LN-229 cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay
    Antiproliferative activity against human LN-229 cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay
    		[PMID: 34968902]
    LN-229 IC50
    1.82 μM
    Compound: Dox
    Antiproliferative activity against human LN-229 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    Antiproliferative activity against human LN-229 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    		[PMID: 38176358]
    LN-229 IC50
    2.25 μM
    Compound: Doxorubicin
    Antiproliferative activity against human LN229 cells assessed as growth inhibition incubated for 48 hrs by MTT assay
    Antiproliferative activity against human LN229 cells assessed as growth inhibition incubated for 48 hrs by MTT assay
    		[PMID: 26253231]
    LN-229 IC50
    2 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human LN-229 cells assessed as cell growth inhibition measured after 48 hrs
    Cytotoxicity against human LN-229 cells assessed as cell growth inhibition measured after 48 hrs
    		[PMID: 35526504]
    LNCaP CC50
    106.6 nM
    Compound: Dox
    Cytotoxicity against PSMA-positive human LNCAP cells by MTT assay
    Cytotoxicity against PSMA-positive human LNCAP cells by MTT assay
    		[PMID: 30904185]
    LNCaP EC50
    0.7 μM
    Compound: 58
    In vitro effective concentration against LNCaP prostate cancer cell line
    In vitro effective concentration against LNCaP prostate cancer cell line
    		[PMID: 14667208]
    LNCaP EC50
    0.7 μM
    Compound: doxorubicin
    Concentration required to kill 50% of tumor cells in PSA producing LNCaP human prostate cancer cell line
    Concentration required to kill 50% of tumor cells in PSA producing LNCaP human prostate cancer cell line
    		[PMID: 11708923]
    LNCaP EC50
    110 nM
    Compound: Doxorubicin
    Antiproliferative activity against androgen-sensitive human LNCaP cells assessed as reduction in cell viability measured after 72 hrs by MTS assay
    Antiproliferative activity against androgen-sensitive human LNCaP cells assessed as reduction in cell viability measured after 72 hrs by MTS assay
    		[PMID: 36577036]
    LNCaP ED50
    0.04 μM
    Compound: DOX
    Cytotoxicity against human LN-Cap cells
    Cytotoxicity against human LN-Cap cells
    		[PMID: 17591444]
    LNCaP GI50
    0.02 μM
    Compound: Adriamycin
    In vitro antiproliferative activity against human LN-caP prostate cell line
    In vitro antiproliferative activity against human LN-caP prostate cell line
    		[PMID: 14971893]
    LNCaP GI50
    45.3 nM
    Compound: DOX
    Growth inhibition of human LNCaP cells after 72 hrs by MTT assay
    Growth inhibition of human LNCaP cells after 72 hrs by MTT assay
    		[PMID: 17181166]
    LNCaP GI50
    45.3 nM
    Compound: Doxorubicin
    Cytotoxicity against human LNCaP cells assessed as inhibition of cell growth measured for 72 hrs by MTT assay
    Cytotoxicity against human LNCaP cells assessed as inhibition of cell growth measured for 72 hrs by MTT assay
    		[PMID: 31945642]
    LNCaP IC50
    0.02 μM
    Compound: Doxorubicin
    Cytotoxicity against human LNCAP cells assessed as reduction in cell viability after 72 hrs by CellTiter96 AQueous one solution cell proliferation assay
    Cytotoxicity against human LNCAP cells assessed as reduction in cell viability after 72 hrs by CellTiter96 AQueous one solution cell proliferation assay
    		[PMID: 28617598]
    LNCaP IC50
    0.02 μM
    Compound: Doxorubicin
    Antiproliferative activity against human LNCaP cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay
    Antiproliferative activity against human LNCaP cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay
    		[PMID: 34851111]
    LNCaP IC50
    0.1 μM
    Compound: Doxorubicin
    Cytotoxicity against human LNCaP cells assessed as reduction in cell proliferation by MTT assay
    Cytotoxicity against human LNCaP cells assessed as reduction in cell proliferation by MTT assay
    		[PMID: 38414352]
    LNCaP IC50
    0.154 μM
    Compound: Doxorubicin
    Antiproliferative activity against human LNCAP cells assessed as inhibition of cell proliferation after 3 days by MTS assay
    Antiproliferative activity against human LNCAP cells assessed as inhibition of cell proliferation after 3 days by MTS assay
    		10.1039/C1MD00155H
    LNCaP IC50
    0.2 μM
    Compound: DOX, Doxorubicin
    Antiproliferative activity against human LNCAP cells after 72 hrs by MTT assay
    Antiproliferative activity against human LNCAP cells after 72 hrs by MTT assay
    		[PMID: 24095089]
    LNCaP IC50
    0.2 μM
    Compound: Doxorubicin
    Antiproliferative activity against human LNCAP cells assessed as reduction in cell growth after 24 hrs by MTS assay
    Antiproliferative activity against human LNCAP cells assessed as reduction in cell growth after 24 hrs by MTS assay
    		[PMID: 25300820]
    LNCaP IC50
    1.07 μM
    Compound: Doxorubicin
    Cytotoxicity against human LNCaP cells assessed as cell death measured by MTT assay
    Cytotoxicity against human LNCaP cells assessed as cell death measured by MTT assay
    		[PMID: 39137365]
    LNCaP IC50
    1.4 μM
    Compound: Doxorubicin
    Cytotoxicity against human LNCAP cells by Alamar Blue assay
    Cytotoxicity against human LNCAP cells by Alamar Blue assay
    		[PMID: 27536968]
    LNCaP IC50
    1.66 μM
    Compound: Doxo
    Cytotoxicity against androgen receptor-positive human LNCAP cells after 48 hrs by MTT assay
    Cytotoxicity against androgen receptor-positive human LNCAP cells after 48 hrs by MTT assay
    		[PMID: 21885273]
    LNCaP IC50
    13.52 nM
    Compound: Doxorubicin
    Cytotoxicity against human LNCAP cells after 72 hrs by Alamar Blue assay
    Cytotoxicity against human LNCAP cells after 72 hrs by Alamar Blue assay
    		[PMID: 24973030]
    LNCaP IC50
    16.02 μM
    Compound: Adriamycin
    Cytotoxicity against human LNCAP cells after 24 hrs by MTT assay
    Cytotoxicity against human LNCAP cells after 24 hrs by MTT assay
    		[PMID: 22276650]
    LNCaP IC50
    2.76 μM
    Compound: Doxorubicin
    Cytotoxicity against human LNCAP cells after 48 hrs by MTT assay
    Cytotoxicity against human LNCAP cells after 48 hrs by MTT assay
    		[PMID: 22818039]
    LNCaP IC50
    4.6 μM
    Compound: adriamycin
    Cytotoxicity against human LnCap cells after 4 days by MTT assay
    Cytotoxicity against human LnCap cells after 4 days by MTT assay
    		[PMID: 17194586]
    LNCaP IC50
    5.23 μM
    Compound: Doxorubicin
    Cytotoxicity against human LNCAP cells
    Cytotoxicity against human LNCAP cells
    		[PMID: 22123320]
    LNCaP IC50
    5.28 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human LNCAP cells assessed as cell viability after 72 hrs by MTT assay
    Cytotoxicity against human LNCAP cells assessed as cell viability after 72 hrs by MTT assay
    		[PMID: 28171832]
    LNCaP IC50
    6.3 μM
    Compound: Doxorubicin
    Cytotoxicity against human LNCAP cells after 48 hrs by MTT assay
    Cytotoxicity against human LNCAP cells after 48 hrs by MTT assay
    		[PMID: 21429743]
    LNCaP IC50
    6.46 μM
    Compound: Doxorubicin
    Cytotoxicity against human LNCAP cells after 48 hrs by MTT assay in absence of 10% FBS
    Cytotoxicity against human LNCAP cells after 48 hrs by MTT assay in absence of 10% FBS
    		[PMID: 26298501]
    LNCaP IC50
    7.4 μM
    Compound: Doxorubicin
    Cytotoxicity against human LNCAP cells after 48 hrs by MTT assay in presence of 10% FBS
    Cytotoxicity against human LNCAP cells after 48 hrs by MTT assay in presence of 10% FBS
    		[PMID: 26298501]
    LNCaP IC50
    7.42 μM
    Compound: Doxo
    Cytotoxicity against androgen receptor-positive human LNCAP cells after 24 hrs by MTT assay
    Cytotoxicity against androgen receptor-positive human LNCAP cells after 24 hrs by MTT assay
    		[PMID: 21885273]
    LNCaP IC50
    77.6 nM
    Compound: Dox
    Cytotoxicity against human LNCAP cells
    Cytotoxicity against human LNCAP cells
    		[PMID: 20936874]
    LNCaP C4-2 IC50
    0.57 μM
    Compound: Doxorubicin
    Cytotoxicity against human castration-resistant C4-2 cells after 48 hrs by MTT assay in presence of 10% FBS
    Cytotoxicity against human castration-resistant C4-2 cells after 48 hrs by MTT assay in presence of 10% FBS
    		[PMID: 26298501]
    LNCaP C4-2 IC50
    1.02 μM
    Compound: Doxorubicin
    Cytotoxicity against human castration-resistant C4-2 cells after 48 hrs by MTT assay in absence of 10% FBS
    Cytotoxicity against human castration-resistant C4-2 cells after 48 hrs by MTT assay in absence of 10% FBS
    		[PMID: 26298501]
    LNCaP C4-2 IC50
    1.85 μM
    Compound: Doxorubicin
    Cytotoxicity against human C4-2 cells after 48 hrs by MTT assay
    Cytotoxicity against human C4-2 cells after 48 hrs by MTT assay
    		[PMID: 27173802]
    LNCaP C4-2 IC50
    2.5 μM
    Compound: Doxorubicin
    Cytotoxicity against human C4-2 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Cytotoxicity against human C4-2 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    		[PMID: 28254167]
    LNCaP C4-2 IC50
    3.2 μM
    Compound: Doxorubicin
    Cytotoxicity against human C4-2 cells after 48 hrs by MTT assay
    Cytotoxicity against human C4-2 cells after 48 hrs by MTT assay
    		[PMID: 29573910]
    LNCaP C4-2 IC50
    3.25 μM
    Compound: Doxorubicin
    Growth inhibition of human C4-2 cells after 48 hrs by MTT assay
    Growth inhibition of human C4-2 cells after 48 hrs by MTT assay
    		[PMID: 30072225]
    LNCaP C4-2 IC50
    > 32 nM
    Compound: Dox
    Cytotoxicity against PSMA-positive human C4-2 cells by cellTiter 96 aqueous cell proliferation assay
    Cytotoxicity against PSMA-positive human C4-2 cells by cellTiter 96 aqueous cell proliferation assay
    		[PMID: 30904185]
    LOX IMVI ED50
    0.001 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human LOXIMVI cells by sulforhodamine B method
    Cytotoxicity against human LOXIMVI cells by sulforhodamine B method
    		[PMID: 12193011]
    LOX IMVI ED50
    0.13 μg/mL
    Compound: adriamycin
    Cytotoxicity against human LOXIMVI cells after 48 hrs by SRB assay
    Cytotoxicity against human LOXIMVI cells after 48 hrs by SRB assay
    		10.1021/np50124a024
    LOX IMVI GI50
    0.07 μM
    Compound: Doxorubicin
    Growth inhibition of human LOXIMVI cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human LOXIMVI cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28329730]
    LOX IMVI GI50
    0.07 μM
    Compound: Doxorubicin
    Growth inhibition of human LOXIMVI cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human LOXIMVI cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 29102177]
    LOX IMVI GI50
    0.07 μM
    Compound: Doxorubicin hydrochloride, NSC 123127
    Cytotoxicity against human LOXIMVI cells after 48 hrs by SRB assay
    Cytotoxicity against human LOXIMVI cells after 48 hrs by SRB assay
    		[PMID: 23871905]
    LOX IMVI IC50
    0.11 μg/mL
    Compound: Adriamycin
    Inhibitory concentration required against LOX-IMVI melanoma cell line
    Inhibitory concentration required against LOX-IMVI melanoma cell line
    		[PMID: 11354370]
    LOX IMVI IC50
    42 nM
    Compound: Doxorubicin
    Cytotoxicity was determined in vitro in LOX cells (melanoma) of human tumor cell lines by using MTT assay
    Cytotoxicity was determined in vitro in LOX cells (melanoma) of human tumor cell lines by using MTT assay
    		[PMID: 7853331]
    LS174T GI50
    248 nM
    Compound: DOX
    Antiproliferative activity against human LS174T cells assessed as growth inhibition incubated for 3 days
    Antiproliferative activity against human LS174T cells assessed as growth inhibition incubated for 3 days
    		[PMID: 38599298]
    LS180 IC50
    0.04 μM
    Compound: Doxorubicin
    Cytotoxicity against human LS180 cells after 72 hrs by MTT assay
    Cytotoxicity against human LS180 cells after 72 hrs by MTT assay
    		[PMID: 23827179]
    LS180 IC50
    0.09 μM
    Compound: doxorubicin
    Antiproliferative activity against human LS180 cells assessed as growth inhibition after 72 hrs by SRB method
    Antiproliferative activity against human LS180 cells assessed as growth inhibition after 72 hrs by SRB method
    		[PMID: 25644674]
    LS180 IC50
    0.13 μM
    Compound: Doxorubicin
    Cytotoxicity against Homo sapiens (human) LS180 cells after 96 hr by MTT assay
    Cytotoxicity against Homo sapiens (human) LS180 cells after 96 hr by MTT assay
    		10.1007/s00044-010-9340-3
    LS180 IC50
    0.18 μM
    Compound: Doxorubicin
    Cytotoxicity against human LS180 cells at 50 uM by MTT reduction assay
    Cytotoxicity against human LS180 cells at 50 uM by MTT reduction assay
    		[PMID: 33276991]
    LS180 IC50
    0.7 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human LS180 cells assessed as cell growth inhibition
    Cytotoxicity against human LS180 cells assessed as cell growth inhibition
    		[PMID: 35526504]
    LS180 IC50
    0.84 μM
    Compound: Doxorubicin
    Cytotoxicity against human LS180 cells assessed as cell growth inhibition after 48 hrs by MTT assay
    Cytotoxicity against human LS180 cells assessed as cell growth inhibition after 48 hrs by MTT assay
    		[PMID: 27371926]
    LX-2 IC50
    0.21 μM
    Compound: DOX
    Antiproliferative activity against human LX2 cells assessed as inhibition of cell growth incubated for 48 hrs by CellTiter 96 Aqueous One Solution Cell Proliferation Assay
    Antiproliferative activity against human LX2 cells assessed as inhibition of cell growth incubated for 48 hrs by CellTiter 96 Aqueous One Solution Cell Proliferation Assay
    		[PMID: 38626522]
    LXFL 529 IC50
    0.03 μM
    Compound: Adriamycin
    Tested for induction of cellular death in Human lung LXF 529L tumor cell line in Propidium Iodide Monolayer Assay
    Tested for induction of cellular death in Human lung LXF 529L tumor cell line in Propidium Iodide Monolayer Assay
    		[PMID: 12852768]
    LXFL 529 IC50
    0.04 μM
    Compound: Doxorubicin
    Antiproliferative activity assessed in the LXFL529 human lung carcinoma using the BrdU
    Antiproliferative activity assessed in the LXFL529 human lung carcinoma using the BrdU
    		[PMID: 12459020]
    LXFL 529 IC50
    < 0.052 μM
    Compound: adriamycin
    Cytotoxicity against human LXFL529 cells after 24 hrs by CellTiter-BlueCell viability assay
    Cytotoxicity against human LXFL529 cells after 24 hrs by CellTiter-BlueCell viability assay
    		[PMID: 20545334]
    LoVo GI50
    0.01 μM
    Compound: Adriamycin
    In vitro antiproliferative activity against human LOVO colon cell line
    In vitro antiproliferative activity against human LOVO colon cell line
    		[PMID: 14971893]
    LoVo GI50
    0.12 μM
    Compound: Doxorubicin
    Cytotoxicity against human LoVo cells assessed as growth inhibition after 72 hrs by MTT assay
    Cytotoxicity against human LoVo cells assessed as growth inhibition after 72 hrs by MTT assay
    		[PMID: 25317694]
    LoVo GI50
    2.4 μM
    Compound: Adriamycin
    In vitro antiproliferative activity against human LOVO-DOX colon cell line
    In vitro antiproliferative activity against human LOVO-DOX colon cell line
    		[PMID: 14971893]
    LoVo GI50
    5.48 mM
    Compound: Doxorubicin
    Photocytotoxicity against human LoVo cells irradiated with 2.5 J cm^-2 ultraviolet radiation after 72 hrs by MTT assay
    Photocytotoxicity against human LoVo cells irradiated with 2.5 J cm^-2 ultraviolet radiation after 72 hrs by MTT assay
    		[PMID: 18023182]
    LoVo GI50
    8.54 mM
    Compound: Doxorubicin
    Photocytotoxicity against human LoVo cells irradiated with 1.25 J cm^-2 ultraviolet radiation after 72 hrs by MTT assay
    Photocytotoxicity against human LoVo cells irradiated with 1.25 J cm^-2 ultraviolet radiation after 72 hrs by MTT assay
    		[PMID: 18023182]
    LoVo IC50
    0.024 μM
    Compound: Doxorubicin (Dx)
    Cytotoxicity activity on LoVo human adenocarcinoma cell line after 144 hr of drug exposure
    Cytotoxicity activity on LoVo human adenocarcinoma cell line after 144 hr of drug exposure
    		[PMID: 11806721]
    LoVo IC50
    0.033 μM
    Compound: Doxorubicin
    Inhibitory concentration against LoVo colon carcinoma cell line
    Inhibitory concentration against LoVo colon carcinoma cell line
    		[PMID: 15715481]
    LoVo IC50
    0.033 μM
    Compound: doxorubicin
    Cytotoxicity against human LoVo cells
    Cytotoxicity against human LoVo cells
    		[PMID: 17375902]
    LoVo IC50
    0.03 μg/mL
    Compound: Dx
    Tested in vitro for cytotoxic activity against Human colon Adenocarcinoma sensitive cell line (LoVo)
    Tested in vitro for cytotoxic activity against Human colon Adenocarcinoma sensitive cell line (LoVo)
    		[PMID: 8145234]
    LoVo IC50
    0.04 μM
    Compound: Doxorubicin
    Antiproliferative activity against human LoVo cells after 72 hrs by SRB assay
    Antiproliferative activity against human LoVo cells after 72 hrs by SRB assay
    		[PMID: 22944121]
    LoVo IC50
    0.057 μM
    Compound: doxorubicin
    Tested in vitro for inhibition after 144 hr exposure against human colon carcinoma LoVo cell line
    Tested in vitro for inhibition after 144 hr exposure against human colon carcinoma LoVo cell line
    		[PMID: 7996544]
    LoVo IC50
    0.09 μM
    Compound: Doxorubicin
    Cytotoxicity against human LoVo cells assessed as growth inhibition after 72 hrs by MTT assay
    Cytotoxicity against human LoVo cells assessed as growth inhibition after 72 hrs by MTT assay
    		[PMID: 24858544]
    LoVo IC50
    0.09 μM
    Compound: Doxorubicin
    Antiproliferative activity against human LoVo cells after 72 hrs
    Antiproliferative activity against human LoVo cells after 72 hrs
    		[PMID: 26163197]
    LoVo IC50
    0.092 μM
    Compound: Doxorubicin
    Antiproliferative activity against human LoVo cells incubated for 72 hrs by sulforhodamine B assay
    Antiproliferative activity against human LoVo cells incubated for 72 hrs by sulforhodamine B assay
    		[PMID: 32432867]
    LoVo IC50
    0.11 μM
    Compound: Doxorubicin
    Antiproliferative activity against human LoVo cells after 72 hrs by sulforhodamine B assay
    Antiproliferative activity against human LoVo cells after 72 hrs by sulforhodamine B assay
    		[PMID: 26496013]
    LoVo IC50
    0.12 μM
    Compound: Doxorubicin
    Antiproliferative activity against human LoVo cells after 72 hrs by MTT assay
    Antiproliferative activity against human LoVo cells after 72 hrs by MTT assay
    		[PMID: 22027100]
    LoVo IC50
    0.15 μM
    Compound: Doxorubicin
    Antiproliferative activity against human LoVo cells assessed as reduction in cell viability after 72 hrs by SRB assay
    Antiproliferative activity against human LoVo cells assessed as reduction in cell viability after 72 hrs by SRB assay
    		[PMID: 26639764]
    LoVo IC50
    0.15 μM
    Compound: doxorubicin
    Antiproliferative activity against human LoVo cells assessed as growth inhibition after 72 hrs by SRB method
    Antiproliferative activity against human LoVo cells assessed as growth inhibition after 72 hrs by SRB method
    		[PMID: 25644674]
    LoVo IC50
    0.17 μM
    Compound: Doxorubicin
    Antiproliferative activity against human LoVo cells
    Antiproliferative activity against human LoVo cells
    		[PMID: 24631190]
    LoVo IC50
    0.24 μM
    Compound: DX
    Antiproliferative activity against human LoVo cells after 72 hrs by SRB assay
    Antiproliferative activity against human LoVo cells after 72 hrs by SRB assay
    		[PMID: 30025346]
    LoVo IC50
    0.28 μM
    Compound: Doxorubicin
    Antiproliferative activity against human LoVo cells
    Antiproliferative activity against human LoVo cells
    		[PMID: 26338363]
    LoVo IC50
    0.3 μM
    Compound: DOXO
    Cytotoxicity against human LoVo cells after 72 hrs by sulforhodamine B assay
    Cytotoxicity against human LoVo cells after 72 hrs by sulforhodamine B assay
    		[PMID: 28342398]
    LoVo IC50
    0.3 μM
    Compound: Doxo
    Antiproliferative activity against human LoVo cells after 72 hrs by SRB assay
    Antiproliferative activity against human LoVo cells after 72 hrs by SRB assay
    		[PMID: 29945793]
    LoVo IC50
    0.31 μM
    Compound: Doxorubicin
    Cytostatic activity against human LoVo cells after 72 hrs by SRB assay
    Cytostatic activity against human LoVo cells after 72 hrs by SRB assay
    		[PMID: 21704523]
    LoVo IC50
    0.38 μM
    Compound: Doxorubicin
    Cytotoxicity against human LoVo cells incubated for 72 hrs by MTT assay
    Cytotoxicity against human LoVo cells incubated for 72 hrs by MTT assay
    		[PMID: 23079523]
    LoVo IC50
    0.52 μg/mL
    Compound: doxorubicin
    In vitro cytotoxic activity against human colon adenocarcinoma (LoVo) cells
    In vitro cytotoxic activity against human colon adenocarcinoma (LoVo) cells
    		[PMID: 10698460]
    LoVo IC50
    0.55 μg/mL
    Compound: Doxorubicin
    Antiproliferative activity against human LoVo cells
    Antiproliferative activity against human LoVo cells
    		[PMID: 20022253]
    LoVo IC50
    0.58 μg/mL
    Compound: doxorubicin
    In vitro cytotoxicity on human colon adenocarcinoma (LoVo ) tumor cell line.
    In vitro cytotoxicity on human colon adenocarcinoma (LoVo ) tumor cell line.
    		[PMID: 9876113]
    LoVo IC50
    0.86 μM
    Compound: Doxorubicin (Dx)
    Cytotoxicity activity on LoVo human adenocarcinoma cell line after 1 hr of drug exposure
    Cytotoxicity activity on LoVo human adenocarcinoma cell line after 1 hr of drug exposure
    		[PMID: 11806721]
    LoVo IC50
    1 μM
    Compound: Doxorubicin
    In vitro cytotoxicity was tested against human colon adenocarcinoma LoVo cell line
    In vitro cytotoxicity was tested against human colon adenocarcinoma LoVo cell line
    		[PMID: 10411474]
    LoVo IC50
    1.46 μM
    Compound: doxorubicin
    Cytotoxicity against human LoVo cells after 48 hrs by MTT assay
    Cytotoxicity against human LoVo cells after 48 hrs by MTT assay
    		[PMID: 18251492]
    LoVo IC50
    12.2 μM
    Compound: Doxorubicin
    Cytostatic activity against doxorubicin-resistant human LoVo cells after 72 hrs by SRB assay
    Cytostatic activity against doxorubicin-resistant human LoVo cells after 72 hrs by SRB assay
    		[PMID: 21704523]
    LoVo IC50
    120 nM
    Compound: Doxorubicin
    Antiproliferative activity against human LoVo cells after 72 hrs by MTT assay
    Antiproliferative activity against human LoVo cells after 72 hrs by MTT assay
    		[PMID: 23117171]
    LoVo IC50
    120 nM
    Compound: doxorubicin
    Antiproliferative activity against human LoVo cells assessed as growth inhibition after 72 hrs by MTT assay
    Antiproliferative activity against human LoVo cells assessed as growth inhibition after 72 hrs by MTT assay
    		[PMID: 21663319]
    LoVo IC50
    13.1 μM
    Compound: Doxorubicin
    Antiproliferative activity against doxorubicin-resistant human LoVo cells after 72 hrs by MTT assay
    Antiproliferative activity against doxorubicin-resistant human LoVo cells after 72 hrs by MTT assay
    		[PMID: 22027100]
    LoVo IC50
    13150 nM
    Compound: doxorubicin
    Antiproliferative activity against human doxorubicin-resistant LoVo cells overexpressing P-gp assessed as growth inhibition after 72 hrs by MTT assay
    Antiproliferative activity against human doxorubicin-resistant LoVo cells overexpressing P-gp assessed as growth inhibition after 72 hrs by MTT assay
    		[PMID: 21663319]
    LoVo IC50
    160 nM
    Compound: DX
    Antiproliferative activity against human LoVo cells assessed as inhibition of proliferation after 72 hrs by SRB assay
    Antiproliferative activity against human LoVo cells assessed as inhibition of proliferation after 72 hrs by SRB assay
    		[PMID: 34116158]
    LoVo IC50
    2.4 μM
    Compound: Doxorubicin (Dx)
    Cytotoxicity activity on LoVo/Dx human adenocarcinoma cell line after 144 hr of drug exposure
    Cytotoxicity activity on LoVo/Dx human adenocarcinoma cell line after 144 hr of drug exposure
    		[PMID: 11806721]
    LoVo IC50
    2.7 μM
    Compound: Adriamycin
    Cytotoxicity against human LoVo cells by MTT colorimetric method
    Cytotoxicity against human LoVo cells by MTT colorimetric method
    		[PMID: 23043498]
    LoVo IC50
    22 nM
    Compound: DX
    Cytotoxicity against human LoVo cancer cell line was determined after 1 hr
    Cytotoxicity against human LoVo cancer cell line was determined after 1 hr
    		[PMID: 15456268]
    LoVo IC50
    2300 nM
    Compound: DX
    Cytotoxicity against doxorubicin resistant LoVo cell line was determined against 144 hrs
    Cytotoxicity against doxorubicin resistant LoVo cell line was determined against 144 hrs
    		[PMID: 15456268]
    LoVo IC50
    24.33 μM
    Compound: Doxorubicin
    Anticancer activity against human LoVo cells after 48 hrs by SRB assay
    Anticancer activity against human LoVo cells after 48 hrs by SRB assay
    		[PMID: 24077528]
    LoVo IC50
    30.74 μM
    Compound: doxorubicin
    Resistant factor, ratio of IC50 for human multi drug resistant LoVo cells to IC50 for human LoVo cells
    Resistant factor, ratio of IC50 for human multi drug resistant LoVo cells to IC50 for human LoVo cells
    		[PMID: 18251492]
    LoVo IC50
    44.89 μM
    Compound: doxorubicin
    Cytotoxicity against human multidrug resistant LoVo cells after 48 hrs by MTT assay
    Cytotoxicity against human multidrug resistant LoVo cells after 48 hrs by MTT assay
    		[PMID: 18251492]
    LoVo IC50
    48.9 μg/mL
    Compound: doxorubicin
    In vitro cytotoxic activity against human colon adenocarcinoma resistant to doxorubicin (LoVo Dx) cells
    In vitro cytotoxic activity against human colon adenocarcinoma resistant to doxorubicin (LoVo Dx) cells
    		[PMID: 10698460]
    LoVo IC50
    4 μg/mL
    Compound: Dx
    Tested in vitro for cytotoxic activity against Doxorubicin resistant Human colon Adenocarcinoma sensitive cell line
    Tested in vitro for cytotoxic activity against Doxorubicin resistant Human colon Adenocarcinoma sensitive cell line
    		[PMID: 8145234]
    LoVo IC50
    520.2 nM
    Compound: Doxorubicin
    Antiproliferative activity against human LoVo cells assessed as reduction in cell viability
    Antiproliferative activity against human LoVo cells assessed as reduction in cell viability
    		[PMID: 31655432]
    LoVo IC50
    53 μg/mL
    Compound: doxorubicin
    In vitro cytotoxicity on human colon adenocarcinoma resistant to doxorubicin (LoVo/Dx ) tumor cell line.
    In vitro cytotoxicity on human colon adenocarcinoma resistant to doxorubicin (LoVo/Dx ) tumor cell line.
    		[PMID: 9876113]
    LoVo IC50
    7.6 μM
    Compound: doxorubicin
    Tested in vitro for inhibition after 144 hr against human colon carcinoma LoVo/DX cell line resistant to Doxorubicin (DX)
    Tested in vitro for inhibition after 144 hr against human colon carcinoma LoVo/DX cell line resistant to Doxorubicin (DX)
    		[PMID: 7996544]
    LoVo IC50
    71 nM
    Compound: DX
    Antiproliferative activity against human LoVo cells assessed as inhibition of cell proliferation incubated for 72 hrs by SRB assay
    Antiproliferative activity against human LoVo cells assessed as inhibition of cell proliferation incubated for 72 hrs by SRB assay
    		[PMID: 34592435]
    LoVo IC50
    78.3 nM
    Compound: Doxorubicin
    Cytotoxicity against human LoVo cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
    Cytotoxicity against human LoVo cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
    		[PMID: 30429975]
    LoVo IC50
    8 nM
    Compound: Doxorubicin
    In vitro cytotoxicity expressed as concentration that inhibits 50% of LoVo (colon) sensitive variant cell proliferation
    In vitro cytotoxicity expressed as concentration that inhibits 50% of LoVo (colon) sensitive variant cell proliferation
    		[PMID: 11606141]
    LoVo IC50
    80 nM
    Compound: Doxorubicin
    In vitro cytotoxicity expressed as concentration that inhibits 50% of LoVo (colon) resistant cell proliferation
    In vitro cytotoxicity expressed as concentration that inhibits 50% of LoVo (colon) resistant cell proliferation
    		[PMID: 11606141]
    LoVo IC50
    83.2 nM
    Compound: DX
    Antiproliferative activity against human LoVo cells assessed as inhibition of cell growth measured after 72 hrs by SRB assay
    Antiproliferative activity against human LoVo cells assessed as inhibition of cell growth measured after 72 hrs by SRB assay
    		[PMID: 33611191]
    LoVo IC50
    9.7 μM
    Compound: Doxorubicin (Dx)
    Cytotoxicity activity on LoVo/Dx human adenocarcinoma cell line after 1 hr of drug exposure
    Cytotoxicity activity on LoVo/Dx human adenocarcinoma cell line after 1 hr of drug exposure
    		[PMID: 11806721]
    LoVo IC50
    91 μM
    Compound: Doxorubicin
    In vitro cytotoxicity was tested against human colon adenocarcinoma LoVo/Dx resistant cell line
    In vitro cytotoxicity was tested against human colon adenocarcinoma LoVo/Dx resistant cell line
    		[PMID: 10411474]
    LoVo IC50
    9100 nM
    Compound: DX
    Cytotoxicity against doxorubicin resistant LoVo cell line was determined against 1 hour
    Cytotoxicity against doxorubicin resistant LoVo cell line was determined against 1 hour
    		[PMID: 15456268]
    LoVo IC50
    92 nM
    Compound: DOX; DX
    Antiproliferative activity against human LoVo cells assessed as reduction in cell viability incubated for 120 hrs by MTT assay
    Antiproliferative activity against human LoVo cells assessed as reduction in cell viability incubated for 120 hrs by MTT assay
    		[PMID: 31653441]
    LoVo IC50
    92 nM
    Compound: Doxorubicin
    Antiproliferative activity against human LoVo cells incubated for 72 hrs by SRB assay
    Antiproliferative activity against human LoVo cells incubated for 72 hrs by SRB assay
    		[PMID: 33465696]
    LoVo IC50
    95.6 nM
    Compound: Doxorubicin
    Growth inhibition of human LoVo cells after 72 hrs by MTT assay
    Growth inhibition of human LoVo cells after 72 hrs by MTT assay
    		[PMID: 25025853]
    LoVo IC50
    95.6 nM
    Compound: doxorubicin
    Cytotoxicity against human LoVo cells after 72 hrs by MTT assay
    Cytotoxicity against human LoVo cells after 72 hrs by MTT assay
    		[PMID: 23445496]
    LoVo IC50
    > 400 μM
    Compound: Adriamycin
    Cytotoxicity against human LoVo cells by SRB method
    Cytotoxicity against human LoVo cells by SRB method
    		[PMID: 18181575]
    LoVo IC50
    4.3 x 10-8 M
    Compound: Doxorubicin
    Inhibitory activity against human colon adenocarcinoma cell line LoVo.
    Inhibitory activity against human colon adenocarcinoma cell line LoVo.
    		[PMID: 7853345]
    LoVo IC50
    6.0 x 10-6 M
    Compound: Doxorubicin
    Inhibitory activity against human colon adenocarcinoma cell line LoVo/Dx.
    Inhibitory activity against human colon adenocarcinoma cell line LoVo/Dx.
    		[PMID: 7853345]
    Lymphoblastoid cell CC50
    0.02 μM
    Compound: doxorubicin
    Cytotoxicity for lymphoblastoid cell lines
    Cytotoxicity for lymphoblastoid cell lines
    		[PMID: 12431048]
    Lymphoblastoid cell CC50
    0.06 μM
    Compound: Doxorubicin
    Cytotoxicity was evaluated against lymphoblastoid cell line.
    Cytotoxicity was evaluated against lymphoblastoid cell line.
    		[PMID: 10411476]
    Lymphocyte GI50
    0.5 μM
    Compound: Dox
    Cytotoxicity against mitogen activated human peripheral blood lymphocytes assessed as cell growth inhibition incubated for 48 hrs by MTT assay
    Cytotoxicity against mitogen activated human peripheral blood lymphocytes assessed as cell growth inhibition incubated for 48 hrs by MTT assay
    		[PMID: 35533562]
    Lymphocyte GI50
    2.9 μM
    Compound: Dox
    Cytotoxicity against mitogen activated human peripheral blood lymphocytes assessed as cell growth inhibition incubated for 24 hrs by MTT assay
    Cytotoxicity against mitogen activated human peripheral blood lymphocytes assessed as cell growth inhibition incubated for 24 hrs by MTT assay
    		[PMID: 35533562]
    Lymphocyte IC50
    0.7 μM
    Compound: Doxorubicin
    Cytotoxicity against human lymphocytes by colorimetric method
    Cytotoxicity against human lymphocytes by colorimetric method
    		[PMID: 24387625]
    Lymphocyte IC50
    10 μM
    Compound: Dox
    Cytotoxicity against human Lymphocyte cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    Cytotoxicity against human Lymphocyte cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    		[PMID: 37001390]
    Lymphocyte IC50
    4.36 μM
    Compound: Dox
    Cytotoxicity against human lymphocytes after 24 to 48 hrs by MTT assay
    Cytotoxicity against human lymphocytes after 24 to 48 hrs by MTT assay
    		[PMID: 29398445]
    Lymphocyte IC50
    9 μM
    Compound: Dox
    Cytotoxicity against human lymphocytes after 72 hrs by MTT assay
    Cytotoxicity against human lymphocytes after 72 hrs by MTT assay
    		[PMID: 30659997]
    M-HeLa IC50
    2.1 μM
    Compound: Doxorubicin
    Cytotoxicity against human HelaM cells assessed as number of viable cells measured after 48 hrs by MTT based colorimetric assay
    Cytotoxicity against human HelaM cells assessed as number of viable cells measured after 48 hrs by MTT based colorimetric assay
    		[PMID: 36970146]
    M-HeLa IC50
    3 μM
    Compound: Doxorubicin
    Antiproliferative activity against human M-HeLa cells by fluorescence based viable cell counting method
    Antiproliferative activity against human M-HeLa cells by fluorescence based viable cell counting method
    		[PMID: 31610378]
    M-HeLa IC50
    3 μM
    Compound: Doxorubicin
    Cytotoxicity against human M-HeLa cells
    Cytotoxicity against human M-HeLa cells
    		[PMID: 32386856]
    M-HeLa IC50
    3 μM
    Compound: Doxorubicin
    Cytotoxicity against human HelaM cells assessed as reduction in cell viability after 24 hrs by DAPI staining-based fluorescence assay
    Cytotoxicity against human HelaM cells assessed as reduction in cell viability after 24 hrs by DAPI staining-based fluorescence assay
    		[PMID: 32786882]
    M059J IC50
    6.9 μM
    Compound: DXR
    Cytotoxicity against human M059J cells assessed as cell growth inhibition after 24 hrs by XTT assay
    Cytotoxicity against human M059J cells assessed as cell growth inhibition after 24 hrs by XTT assay
    		[PMID: 26649907]
    M14 GI50
    0.18 μM
    Compound: Doxorubicin
    Growth inhibition of human M14 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human M14 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28329730]
    M14 GI50
    0.18 μM
    Compound: Doxorubicin
    Growth inhibition of human M14 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human M14 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 29102177]
    M14 GI50
    0.18 μM
    Compound: Doxorubicin hydrochloride, NSC 123127
    Cytotoxicity against human M14 cells after 48 hrs by SRB assay
    Cytotoxicity against human M14 cells after 48 hrs by SRB assay
    		[PMID: 23871905]
    M14 IC50
    0.09 μM
    Compound: Doxorubicin
    Cytotoxicity against human M14 cells assessed as reduction in cell viability after 72 hrs by CellTiter96 AQueous one solution cell proliferation assay
    Cytotoxicity against human M14 cells assessed as reduction in cell viability after 72 hrs by CellTiter96 AQueous one solution cell proliferation assay
    		[PMID: 28617598]
    M14 IC50
    0.09 μM
    Compound: Doxorubicin
    Antiproliferative activity against human M14 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay
    Antiproliferative activity against human M14 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay
    		[PMID: 34851111]
    M14 IC50
    0.82 μM
    Compound: Doxorubicin
    Cytotoxicity against human M14 cells after 24 hrs by SRB method
    Cytotoxicity against human M14 cells after 24 hrs by SRB method
    		[PMID: 18429610]
    M14 IC50
    1 μM
    Compound: doxorubicin
    Cytotoxicity against human M14 cells after 24 to 48 hrs by MTT assay
    Cytotoxicity against human M14 cells after 24 to 48 hrs by MTT assay
    		[PMID: 21058726]
    M14 IC50
    2.13 μM
    Compound: Dox
    Cytotoxicity against human M14 cells assessed as inhibition of cell growth preincubated for 2 hrs followed by administration of single dose of 8 Gy gamma irradiation for 21.4 mins and measured 24 hrs after irradiation by MTT assay
    Cytotoxicity against human M14 cells assessed as inhibition of cell growth preincubated for 2 hrs followed by administration of single dose of 8 Gy gamma irradiation for 21.4 mins and measured 24 hrs after irradiation by MTT assay
    		[PMID: 36395650]
    M14 IC50
    3.4 μM
    Compound: DOX
    Antiproliferative activity against human M14 cells after 72 hrs by MTT assay
    Antiproliferative activity against human M14 cells after 72 hrs by MTT assay
    		[PMID: 30429098]
    M14 IC50
    5.11 μM
    Compound: Dox
    Cytotoxicity against human M14 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay
    Cytotoxicity against human M14 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay
    		[PMID: 36395650]
    MC-38 IC50
    10 nM
    Compound: adriamycin
    Tested for cytotoxicity against C38 cell lines measured by MAT assay
    Tested for cytotoxicity against C38 cell lines measured by MAT assay
    		[PMID: 8057291]
    MCF-10A CC50
    0.5 μM
    Compound: Dox
    Cytotoxicity against human MCF-10A cells incubated for 72 hrs by MTT assay
    Cytotoxicity against human MCF-10A cells incubated for 72 hrs by MTT assay
    		[PMID: 39079310]
    MCF-10A CC50
    13.9 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF10A cells assessed as reduction in cell viability by MTT assay
    Cytotoxicity against human MCF10A cells assessed as reduction in cell viability by MTT assay
    		[PMID: 33784602]
    MCF-10A GI50
    > 5 μM
    Compound: Doxorubicin
    Growth inhibition of human MCF10A cells after 72 hrs by celltiter-blue viability assay
    Growth inhibition of human MCF10A cells after 72 hrs by celltiter-blue viability assay
    		[PMID: 21348461]
    MCF-10A IC50
    0.033 μM
    Compound: Dox
    Cytotoxicity against human MCF-10A cells assessed as reduction in cell viability incubated for 96 hrs by MTT method
    Cytotoxicity against human MCF-10A cells assessed as reduction in cell viability incubated for 96 hrs by MTT method
    		[PMID: 34236840]
    MCF-10A IC50
    0.047 μM
    Compound: Dox
    Cytotoxicity against human MCF-10A assessed as cell viability under normoxia conditions measured after 72 hrs by MTT assay
    Cytotoxicity against human MCF-10A assessed as cell viability under normoxia conditions measured after 72 hrs by MTT assay
    		[PMID: 34902732]
    MCF-10A IC50
    0.051 μM
    Compound: Dox
    Cytotoxicity against human MCF-10A assessed as cell viability under hypoxia conditions measured after 72 hrs by MTT assay
    Cytotoxicity against human MCF-10A assessed as cell viability under hypoxia conditions measured after 72 hrs by MTT assay
    		[PMID: 34902732]
    MCF-10A IC50
    0.06 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF10A cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Cytotoxicity against human MCF10A cells assessed as reduction in cell viability after 48 hrs by MTT assay
    		[PMID: 28327308]
    MCF-10A IC50
    0.15 μM
    Compound: DOX
    Antiproliferative activity against human MCF10A cells after 72 hrs by CellTiter-Glo assay
    Antiproliferative activity against human MCF10A cells after 72 hrs by CellTiter-Glo assay
    		[PMID: 27769032]
    MCF-10A IC50
    0.18 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF10A cells after 48 hrs by MTT assay
    Cytotoxicity against human MCF10A cells after 48 hrs by MTT assay
    		[PMID: 20064676]
    MCF-10A IC50
    0.31 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF-10A cells after 3 days by microplate reader analysis
    Cytotoxicity against human MCF-10A cells after 3 days by microplate reader analysis
    		[PMID: 32705864]
    MCF-10A IC50
    0.4 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF10A cells after 24 hrs by XTT assay
    Cytotoxicity against human MCF10A cells after 24 hrs by XTT assay
    		[PMID: 27227682]
    MCF-10A IC50
    0.49 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF-10A cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
    Cytotoxicity against human MCF-10A cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
    		[PMID: 34315044]
    MCF-10A IC50
    0.58 μM
    Compound: DX
    Antiproliferative activity against human MCF10A cells after 72 hrs by SRB assay
    Antiproliferative activity against human MCF10A cells after 72 hrs by SRB assay
    		[PMID: 30025346]
    MCF-10A IC50
    0.58 μM
    Compound: Dox
    Cytotoxicity against human MCF-10A cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
    Cytotoxicity against human MCF-10A cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
    		[PMID: 37956506]
    MCF-10A IC50
    0.74 μM
    Compound: DOX
    Cytotoxicity against human MCF-10A cells assessed as inhibition in cell growth measured after 48 hrs by MTT assay
    Cytotoxicity against human MCF-10A cells assessed as inhibition in cell growth measured after 48 hrs by MTT assay
    		[PMID: 37602711]
    MCF-10A IC50
    0.75 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF10A cells after 24 hrs by MTT assay
    Cytotoxicity against human MCF10A cells after 24 hrs by MTT assay
    		[PMID: 20064676]
    MCF-10A IC50
    0.93 μM
    Compound: Dox
    Cytotoxicity against human MCF10A cells after 2 days
    Cytotoxicity against human MCF10A cells after 2 days
    		[PMID: 24904965]
    MCF-10A IC50
    1.2 μM
    Compound: Dox
    Cytotoxicity against human MCF10A cells after 48 hrs by MTT assay
    Cytotoxicity against human MCF10A cells after 48 hrs by MTT assay
    		[PMID: 24028446]
    MCF-10A IC50
    1.2 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF10A cells assessed as inhibition of metabolic activity after 48 hrs by MTT assay
    Cytotoxicity against human MCF10A cells assessed as inhibition of metabolic activity after 48 hrs by MTT assay
    		[PMID: 27187858]
    MCF-10A IC50
    1.23 μM
    Compound: Adriamycin
    Cytotoxicity against human MCF10A cells after 2 days by CCK8 assay
    Cytotoxicity against human MCF10A cells after 2 days by CCK8 assay
    		[PMID: 26361737]
    MCF-10A IC50
    1.37 μM
    Compound: Dox
    Cytotoxicity against human MCF-10A cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
    Cytotoxicity against human MCF-10A cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
    		[PMID: 33852973]
    MCF-10A IC50
    1.54 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF10A cells after 72 hrs by sulforhodamine B assay
    Cytotoxicity against human MCF10A cells after 72 hrs by sulforhodamine B assay
    		[PMID: 30081238]
    MCF-10A IC50
    12.51 μM
    Compound: Dox
    Cytotoxicity against human MCF10A after 72 hrs by MTT assay
    Cytotoxicity against human MCF10A after 72 hrs by MTT assay
    		[PMID: 28549734]
    MCF-10A IC50
    13.437 μM
    Compound: Dox
    Cytotoxicity against human MCF-10A cells assessed as inhibition of cell viability by MTT assay
    Cytotoxicity against human MCF-10A cells assessed as inhibition of cell viability by MTT assay
    		[PMID: 37922829]
    MCF-10A IC50
    19 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF10A cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    Cytotoxicity against human MCF10A cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    		[PMID: 34791873]
    MCF-10A IC50
    2.64 μM
    Compound: Dox
    Cytotoxicity against human MCF-10A cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay
    Cytotoxicity against human MCF-10A cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay
    		[PMID: 33713977]
    MCF-10A IC50
    2.8 μM
    Compound: DOX
    Cytotoxicity against human MCF-10A cells assessed as cell viability incubated for 72 hrs by MTT assay
    Cytotoxicity against human MCF-10A cells assessed as cell viability incubated for 72 hrs by MTT assay
    		[PMID: 39153333]
    MCF-10A IC50
    2.8 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF10A cells assessed as growth inhibition after 72 hrs by MTT assay
    Cytotoxicity against human MCF10A cells assessed as growth inhibition after 72 hrs by MTT assay
    		[PMID: 24044895]
    MCF-10A IC50
    24 μM
    Compound: Doxo
    Cytotoxicity against human MCF10A cells after 48 hrs by MTT assay
    Cytotoxicity against human MCF10A cells after 48 hrs by MTT assay
    		[PMID: 25563891]
    MCF-10A IC50
    3.52 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF-10A cells assessed as reduction in cell viability
    Cytotoxicity against human MCF-10A cells assessed as reduction in cell viability
    		[PMID: 33352388]
    MCF-10A IC50
    31 μM
    Compound: Doxo
    Cytotoxicity against human MCF10A cells assessed as cell viability after 48 hrs by MTT assay
    Cytotoxicity against human MCF10A cells assessed as cell viability after 48 hrs by MTT assay
    		10.1039/C2MD20302B
    MCF10 IC50
    0.16 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF10 cells assessed as reduction in cell growth after 72 hrs by cell titer glo assay
    Cytotoxicity against human MCF10 cells assessed as reduction in cell growth after 72 hrs by cell titer glo assay
    		[PMID: 27080175]
    MCF7 CC50
    0.37 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
    Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
    		[PMID: 30103191]
    MCF7 CC50
    0.4 μM
    Compound: Dox
    Cytotoxicity against human MCF7 cells incubated for 72 hrs by MTT assay
    Cytotoxicity against human MCF7 cells incubated for 72 hrs by MTT assay
    		[PMID: 39079310]
    MCF7 CC50
    0.9 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured for 48 hrs by MTT assay
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured for 48 hrs by MTT assay
    		[PMID: 38056297]
    MCF7 CC50
    7 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
    Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
    		[PMID: 29792325]
    MCF7 EC50
    0.2 μM
    Compound: doxorubicin
    Cytotoxicity against human MCF7 cells after 72 hrs
    Cytotoxicity against human MCF7 cells after 72 hrs
    		[PMID: 17378530]
    MCF7 EC50
    0.3 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells after 96 hrs by MTT assay
    Cytotoxicity against human MCF7 cells after 96 hrs by MTT assay
    		[PMID: 26320088]
    MCF7 EC50
    1.1 μM
    Compound: DR
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
    		[PMID: 32956968]
    MCF7 EC50
    1.1 μM
    Compound: Dox
    Cytotoxicity against human MCF7 cells incubated for 72 hrs by SRB assay
    Cytotoxicity against human MCF7 cells incubated for 72 hrs by SRB assay
    		[PMID: 36780832]
    MCF7 EC50
    1.1 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 72 hrs by SRB assay
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 72 hrs by SRB assay
    		[PMID: 33049606]
    MCF7 EC50
    15.3 μM
    Compound: 12
    Dark toxicity in human MCF7 cells assessed as decrease in cell viability after 24 hrs by MTT assay
    Dark toxicity in human MCF7 cells assessed as decrease in cell viability after 24 hrs by MTT assay
    		[PMID: 29172528]
    MCF7 EC50
    153 nM
    Compound: Doxorubicin
    Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 5 days by celltiter-glo assay
    Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 5 days by celltiter-glo assay
    		[PMID: 30996949]
    MCF7 ED50
    0.0058 μg/mL
    Compound: Adriamycin
    In vitro cytotoxic activity against MCF-7 (human breast carcinoma) cell line
    In vitro cytotoxic activity against MCF-7 (human breast carcinoma) cell line
    		[PMID: 11551759]
    MCF7 ED50
    0.0138 μg/mL
    Compound: ADRIAMYCIN
    Compound was tested for cytotoxic activity against human breast carcinoma (MCF-7)
    Compound was tested for cytotoxic activity against human breast carcinoma (MCF-7)
    		10.1016/0960-894X(94)80019-7
    MCF7 ED50
    0.0176 μg/mL
    Compound: Adriamycin
    Tested in vitro for cytotoxicity against MCF-7 breast cancer cells
    Tested in vitro for cytotoxicity against MCF-7 breast cancer cells
    		[PMID: 8027979]
    MCF7 ED50
    0.031 μM
    Compound: Adriamycin
    Cytotoxic concentration required to inhibit 50% cell growth in MCF-7 breast carcinoma cell lines
    Cytotoxic concentration required to inhibit 50% cell growth in MCF-7 breast carcinoma cell lines
    		[PMID: 1875350]
    MCF7 ED50
    0.03 μg/mL
    Compound: Adriamycin
    Cytotoxicity against human MCF7 cells after 24 hrs by SRB assay
    Cytotoxicity against human MCF7 cells after 24 hrs by SRB assay
    		[PMID: 20850305]
    MCF7 ED50
    0.129 μg/mL
    Compound: adriamycin
    Cytotoxicity against human MCF7 cells after 7 days by MTT assay
    Cytotoxicity against human MCF7 cells after 7 days by MTT assay
    		[PMID: 10514307]
    MCF7 ED50
    0.12 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells by MTT assay
    Cytotoxicity against human MCF7 cells by MTT assay
    		[PMID: 17315955]
    MCF7 ED50
    0.194 μg/mL
    Compound: Adriamycin
    Cytotoxicity concentration against human breast carcinoma MCF-7 cell line
    Cytotoxicity concentration against human breast carcinoma MCF-7 cell line
    		[PMID: 8627602]
    MCF7 ED50
    0.1 μg/mL
    Compound: Adriamycin
    Cytotoxicity against human MCF7 cells
    Cytotoxicity against human MCF7 cells
    		[PMID: 10346965]
    MCF7 ED50
    0.1 μg/mL
    Compound: doxorubicin
    Cytotoxicity against human MCF7 cells after 3 days by MTT assay
    Cytotoxicity against human MCF7 cells after 3 days by MTT assay
    		[PMID: 16252910]
    MCF7 ED50
    0.42 μg/mL
    Compound: Adriamycin
    Cytotoxicity against human breast carcinoma MCF-7 cell lines
    Cytotoxicity against human breast carcinoma MCF-7 cell lines
    		10.1016/0960-894X(95)00182-S
    MCF7 ED50
    0.43 μg/mL
    Compound: Adriamycin
    Cytotoxic activity was tested against human MCF-7 (breast carcinoma) cell line
    Cytotoxic activity was tested against human MCF-7 (breast carcinoma) cell line
    		10.1016/0960-894X(95)00309-H
    MCF7 ED50
    0.953 μg/mL
    Compound: adriamycin
    Cytotoxicity against human MCF7 cells after 7 days by MTT assay
    Cytotoxicity against human MCF7 cells after 7 days by MTT assay
    		[PMID: 11087592]
    MCF7 ED50
    1.03 x 10-2 μg/mL
    Compound: adriamycin
    Cytotoxicity against human MCF7 cells after 7 days by MTT assay
    Cytotoxicity against human MCF7 cells after 7 days by MTT assay
    		[PMID: 8676130]
    MCF7 ED50
    1.05 x 10-4 μg/mL
    Compound: adriamycin
    Cytotoxicity against human MCF7 cells
    Cytotoxicity against human MCF7 cells
    		[PMID: 1294696]
    MCF7 ED50
    1.06 x 10-1 μg/mL
    Compound: Adriamycin
    Cytotoxicity against human MCF7 cells after 7 days by MTT assay
    Cytotoxicity against human MCF7 cells after 7 days by MTT assay
    		[PMID: 7673936]
    MCF7 ED50
    1.08 x 10-2 μg/mL
    Compound: Adriamycin
    Cytotoxicity against human MCF7 cells
    Cytotoxicity against human MCF7 cells
    		[PMID: 1479382]
    MCF7 ED50
    1.15 x 10-1 μg/mL
    Compound: adriamycin
    Cytotoxicity against human MCF7 cells
    Cytotoxicity against human MCF7 cells
    		[PMID: 1665173]
    MCF7 ED50
    1.24 x 10-1 μg/mL
    Compound: adriamycin
    Cytotoxicity against human MCF7 cells after 7 days by MTT assay
    Cytotoxicity against human MCF7 cells after 7 days by MTT assay
    		[PMID: 9584396]
    MCF7 ED50
    1.26 x 10-1 μg/mL
    Compound: Adriamycin
    Cytotoxicity against human MCF7 cells after 7 days by MTT assay
    Cytotoxicity against human MCF7 cells after 7 days by MTT assay
    		[PMID: 7673926]
    MCF7 ED50
    1.42 x 10-1 μg/mL
    Compound: Adriamycin
    Cytotoxicity against human MCF7 cells after 7 days by MTT assay
    Cytotoxicity against human MCF7 cells after 7 days by MTT assay
    		[PMID: 7494150]
    MCF7 ED50
    1.42 x 10-1 μg/mL
    Compound: Adriamycin
    Cytotoxicity against human MCF7 cells after 7 days by MTT assay
    Cytotoxicity against human MCF7 cells after 7 days by MTT assay
    		[PMID: 7673935]
    MCF7 ED50
    1.47 x 10-1 μg/mL
    Compound: adriamycin
    Cytotoxicity against human MCF7 cells after 7 days
    Cytotoxicity against human MCF7 cells after 7 days
    		[PMID: 1593281]
    MCF7 ED50
    1.47 x 10-1 μg/mL
    Compound: adriamycin
    Cytotoxicity against human MCF7 cells after 7 days
    Cytotoxicity against human MCF7 cells after 7 days
    		[PMID: 8201311]
    MCF7 ED50
    1.52 x 10-1 μg/mL
    Compound: adriamycin
    Cytotoxicity against human MCF7 cells after 7 days by MTT assay
    Cytotoxicity against human MCF7 cells after 7 days by MTT assay
    		[PMID: 8882434]
    MCF7 ED50
    1.7 x 10-1 μg/mL
    Compound: Adriamycin
    Cytotoxicity against human MCF7 cells after 7 days by MTT assay
    Cytotoxicity against human MCF7 cells after 7 days by MTT assay
    		[PMID: 8946743]
    MCF7 ED50
    1.77 x 10-2 μg/mL
    Compound: adriamycin
    Cytotoxicity against human MCF7 cells
    Cytotoxicity against human MCF7 cells
    		[PMID: 1791471]
    MCF7 ED50
    1.79 x 10-1 μg/mL
    Compound: adriamycin
    Cytotoxicity against human MCF7 cells after 7 days by MTT assay
    Cytotoxicity against human MCF7 cells after 7 days by MTT assay
    		[PMID: 9599260]
    MCF7 ED50
    1.8 x 10-3 μg/mL
    Compound: adriamycin
    Cytotoxicity against human MCF7 cells after 6 days by BCA assay
    Cytotoxicity against human MCF7 cells after 6 days by BCA assay
    		[PMID: 8984151]
    MCF7 ED50
    1.82 x 10-2 μg/mL
    Compound: adriamycin
    Cytotoxicity against human MCF7 cells after 7 days by MTT assay
    Cytotoxicity against human MCF7 cells after 7 days by MTT assay
    		[PMID: 11325235]
    MCF7 ED50
    1.89 x 10-1 μg/mL
    Compound: adriamycin
    Cytotoxicity against human MCF7 cells after 7 days by MTT assay
    Cytotoxicity against human MCF7 cells after 7 days by MTT assay
    		[PMID: 9014350]
    MCF7 ED50
    2.02 x 10-3 μg/mL
    Compound: Adriamycin
    Cytotoxicity against human MCF7 cells
    Cytotoxicity against human MCF7 cells
    		[PMID: 8350089]
    MCF7 ED50
    2.09 x 10-1 μg/mL
    Compound: adriamycin
    Cytotoxicity against human MCF7 cells after 7 days by MTT assay
    Cytotoxicity against human MCF7 cells after 7 days by MTT assay
    		[PMID: 8904848]
    MCF7 ED50
    2.1 x 10-1 μg/mL
    Compound: adriamycin
    Cytotoxicity against human MCF7 cells by MTT assay
    Cytotoxicity against human MCF7 cells by MTT assay
    		[PMID: 9917277]
    MCF7 ED50
    2.1 x 10-3 μg/mL
    Compound: adriamycin
    Cytotoxicity against human MCF7 cells after 6 days by coulter counted assay
    Cytotoxicity against human MCF7 cells after 6 days by coulter counted assay
    		[PMID: 8984151]
    MCF7 ED50
    2.12 x 10-1 μg/mL
    Compound: adriamycin
    Cytotoxicity against human MCF7 cells after 7 days by MTT assay
    Cytotoxicity against human MCF7 cells after 7 days by MTT assay
    		[PMID: 9599253]
    MCF7 ED50
    2.28 x 10-2 μg/mL
    Compound: Adriamycin
    Cytotoxicity against human MCF7 cells after 7 days by MTT assay
    Cytotoxicity against human MCF7 cells after 7 days by MTT assay
    		[PMID: 7714532]
    MCF7 ED50
    2.28 x 10-2 μg/mL
    Compound: adriamycin
    Cytotoxicity against human MCF7 cells after 7 days
    Cytotoxicity against human MCF7 cells after 7 days
    		[PMID: 8021648]
    MCF7 ED50
    2.3 x 10-1 μg/mL
    Compound: adriamycin
    Cytotoxicity against human MCF7 cells after 7 hrs by MTT assay
    Cytotoxicity against human MCF7 cells after 7 hrs by MTT assay
    		[PMID: 7623031]
    MCF7 ED50
    2.31 x 10-1 μg/mL
    Compound: Adriamycin
    Cytotoxicity against human MCF7 cells after 7 days
    Cytotoxicity against human MCF7 cells after 7 days
    		[PMID: 1453182]
    MCF7 ED50
    2.53 x 10-1 μg/mL
    Compound: adr
    Cytotoxicity against human MCF7 cells after 7 days by MTT assay
    Cytotoxicity against human MCF7 cells after 7 days by MTT assay
    		[PMID: 9461654]
    MCF7 ED50
    2.9 x 10-2 μg/mL
    Compound: Adriamycin
    Cytotoxicity against human MCF7 cells
    Cytotoxicity against human MCF7 cells
    		[PMID: 2348205]
    MCF7 ED50
    2 x 10-1 μg/mL
    Compound: Adriamycin
    Cytotoxicity against human MCF7 cells after 7 days by MTT assay
    Cytotoxicity against human MCF7 cells after 7 days by MTT assay
    		[PMID: 9214729]
    MCF7 ED50
    2 x 10-2 μg/mL
    Compound: Adriamycin
    Cytotoxicity against human MCF7 cells by MTT assay
    Cytotoxicity against human MCF7 cells by MTT assay
    		[PMID: 7714533]
    MCF7 ED50
    2 x 10-2 μg/mL
    Compound: adriamycin
    Cytotoxicity against human MCF7 cells after 7 days by MTT assay
    Cytotoxicity against human MCF7 cells after 7 days by MTT assay
    		[PMID: 8882437]
    MCF7 ED50
    3.1 μM
    Compound: Adriamycin
    Cytotoxicity against human MCF-7 breast cancer cell line.
    Cytotoxicity against human MCF-7 breast cancer cell line.
    		[PMID: 1613753]
    MCF7 ED50
    3.29 x 10-1 μg/mL
    Compound: Adriamycin
    Cytotoxicity against human MCF7 cells after 7 days by MTT assay
    Cytotoxicity against human MCF7 cells after 7 days by MTT assay
    		[PMID: 7494147]
    MCF7 ED50
    3.47 x 10-1 μg/mL
    Compound: adriamycin
    Cytotoxicity against human MCF7 cells
    Cytotoxicity against human MCF7 cells
    		[PMID: 8991957]
    MCF7 ED50
    3.69 x 10-1 μg/mL
    Compound: Adriamycin
    Cytotoxicity against human MCF7 cells after 7 days by MTT assay
    Cytotoxicity against human MCF7 cells after 7 days by MTT assay
    		[PMID: 9322367]
    MCF7 ED50
    3.6 μg/mL
    Compound: Adriamycin
    Cytotoxicity against human MCF7 cells
    Cytotoxicity against human MCF7 cells
    		[PMID: 10479316]
    MCF7 ED50
    3.76 μg/mL
    Compound: Adriamycin
    Cytotoxicity on breast carcinoma (MCF-7) cell line
    Cytotoxicity on breast carcinoma (MCF-7) cell line
    		[PMID: 8632402]
    MCF7 ED50
    3 x 10-1 μg/mL
    Compound: adriyamicin
    Cytotoxicity against human MCF7 cells
    Cytotoxicity against human MCF7 cells
    		[PMID: 8991955]
    MCF7 ED50
    4.95 x 10-1 μg/mL
    Compound: Adriamycin
    Cytotoxicity against human MCF7 cells
    Cytotoxicity against human MCF7 cells
    		[PMID: 8946744]
    MCF7 ED50
    5.1 x 10-2 μg/mL
    Compound: Adriamycin
    Cytotoxicity against human MCF7 cells
    Cytotoxicity against human MCF7 cells
    		[PMID: 1602301]
    MCF7 ED50
    8 μM
    Compound: doxorubicin
    Antitumor activity against human MCF7 cells after 24 hrs by MTT assay
    Antitumor activity against human MCF7 cells after 24 hrs by MTT assay
    		[PMID: 17482824]
    MCF7 ED50
    8.97 x 10-2 μg/mL
    Compound: adriamycin
    Cytotoxicity against human MCF7 cells after 7 days by MTT assay
    Cytotoxicity against human MCF7 cells after 7 days by MTT assay
    		10.1021/np970510f
    MCF7 ED50
    9.13 x 10-2 μg/mL
    Compound: adriamycin
    Cytotoxicity against human MCF7 cells
    Cytotoxicity against human MCF7 cells
    		[PMID: 8377016]
    MCF7 ED50
    9.53 x 10-1 μg/mL
    Compound: adriamycin
    Cytotoxicity against human MCF7 cells after 7 days by MTT assay
    Cytotoxicity against human MCF7 cells after 7 days by MTT assay
    		[PMID: 15730242]
    MCF7 ED50
    9.68 x 10-2 μg/mL
    Compound: Adr
    Cytotoxicity against human MCF7 cells
    Cytotoxicity against human MCF7 cells
    		[PMID: 8778247]
    MCF7 ED50
    9 x 10-2 μg/mL
    Compound: adriamycin
    Cytotoxicity against human MCF7 cells after 7 days by MTT assay
    Cytotoxicity against human MCF7 cells after 7 days by MTT assay
    		[PMID: 10395501]
    MCF7 GI50
    0.013 μM
    Compound: Doxorubicin
    Tested for in vitro concentration required to inhibit growth by 50% against MCF-7 human breast cancer cell line cell line
    Tested for in vitro concentration required to inhibit growth by 50% against MCF-7 human breast cancer cell line cell line
    		[PMID: 11755363]
    MCF7 GI50
    0.02 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay
    Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay
    		[PMID: 20675130]
    MCF7 GI50
    0.02 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
    Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
    		[PMID: 21115210]
    MCF7 GI50
    0.02 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
    Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
    		[PMID: 23831811]
    MCF7 GI50
    0.02 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
    Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
    		[PMID: 27889456]
    MCF7 GI50
    0.02 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth
    Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth
    		[PMID: 33148490]
    MCF7 GI50
    0.03 μM
    Compound: Doxorubicin hydrochloride, NSC 123127
    Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay
    Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay
    		[PMID: 23871905]
    MCF7 GI50
    0.038 μg/mL
    Compound: DOX
    Antiproliferative activity against human MCF7 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    Antiproliferative activity against human MCF7 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    		[PMID: 25062010]
    MCF7 GI50
    0.03 μg/mL
    Compound: DOX
    Growth inhibition of human MCF7 cells after 48 hrs by sulforhodamine B assay
    Growth inhibition of human MCF7 cells after 48 hrs by sulforhodamine B assay
    		[PMID: 21041092]
    MCF7 GI50
    0.04 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells by sulforhodamine B assay
    Cytotoxicity against human MCF7 cells by sulforhodamine B assay
    		[PMID: 20413188]
    MCF7 GI50
    0.04 μM
    Compound: Doxorubicin
    Growth inhibition of human MCF7 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human MCF7 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28329730]
    MCF7 GI50
    0.04 μM
    Compound: Doxorubicin
    Growth inhibition of human MCF7 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human MCF7 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 29102177]
    MCF7 GI50
    0.04 μM
    Compound: Doxorubicin
    Growth inhibition of human MCF7 cells
    Growth inhibition of human MCF7 cells
    		[PMID: 31404864]
    MCF7 GI50
    0.04 μM
    Compound: doxorubicin
    Growth inhibition of Homo sapiens (human) MCF7 cells after 48 hr by SRB assay
    Growth inhibition of Homo sapiens (human) MCF7 cells after 48 hr by SRB assay
    		10.1007/s00044-012-0213-9
    MCF7 GI50
    0.0428 μM
    Compound: Doxorubicin
    Growth inhibition of human MCF7 cells after 48 hrs by sulforhodamine B assay
    Growth inhibition of human MCF7 cells after 48 hrs by sulforhodamine B assay
    		[PMID: 21435889]
    MCF7 GI50
    0.043 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay
    Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay
    		[PMID: 15620248]
    MCF7 GI50
    0.07 μM
    Compound: Dox
    Growth inhibition of human MCF7 cells after 48 hrs by sulforhodamine B dye-based spectrophotometric assay
    Growth inhibition of human MCF7 cells after 48 hrs by sulforhodamine B dye-based spectrophotometric assay
    		[PMID: 28505535]
    MCF7 GI50
    0.073 μM
    Compound: DOXO
    Antiproliferative activity against human MCF7 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    Antiproliferative activity against human MCF7 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    		[PMID: 31247374]
    MCF7 GI50
    0.07 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    Cytotoxicity against human MCF7 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    		[PMID: 26561866]
    MCF7 GI50
    0.1 μM
    Compound: Adriamycin
    Cytotoxicity against human MCF7 cells by MTT assay
    Cytotoxicity against human MCF7 cells by MTT assay
    		[PMID: 19405508]
    MCF7 GI50
    0.13 μM
    Compound: ADR
    Cytotoxicity against human MCF7 cells after 48 hrs by sulforhodamine B assay
    Cytotoxicity against human MCF7 cells after 48 hrs by sulforhodamine B assay
    		[PMID: 21737288]
    MCF7 GI50
    0.15 μM
    Compound: DOX
    Cytotoxicity against human MCF7 cells assessed as growth inhibition after 72 hrs by MTT assay
    Cytotoxicity against human MCF7 cells assessed as growth inhibition after 72 hrs by MTT assay
    		[PMID: 29705710]
    MCF7 GI50
    0.15 μM
    Compound: DOX
    Growth inhibition of human MCF7 cells after 72 hrs by MTT assay
    Growth inhibition of human MCF7 cells after 72 hrs by MTT assay
    		[PMID: 30336023]
    MCF7 GI50
    0.15 μM
    Compound: DOX
    Growth inhibition of human MCF7 cells incubated for 72 hrs by MTT assay
    Growth inhibition of human MCF7 cells incubated for 72 hrs by MTT assay
    		[PMID: 31176097]
    MCF7 GI50
    0.17 μM
    Compound: ADR
    Growth inhibition of human MCF7 cells
    Growth inhibition of human MCF7 cells
    		10.1039/C1MD00072A
    MCF7 GI50
    0.17 μM
    Compound: ADR
    Cytotoxicity against human MCF7 cells after 48 hrs by sulforhodamine B assay
    Cytotoxicity against human MCF7 cells after 48 hrs by sulforhodamine B assay
    		[PMID: 18657979]
    MCF7 GI50
    0.17 μM
    Compound: ADR
    Growth inhibition of human MCF7 cells after 48 hrs by SRB assay
    Growth inhibition of human MCF7 cells after 48 hrs by SRB assay
    		[PMID: 20031423]
    MCF7 GI50
    0.17 μM
    Compound: ADR
    Cytotoxicity against human MCF7 cells after 24 hrs by WST-1 assay
    Cytotoxicity against human MCF7 cells after 24 hrs by WST-1 assay
    		[PMID: 20732817]
    MCF7 GI50
    0.17 μM
    Compound: ADR
    Anticancer activity against human MCF7 cells by SRB method
    Anticancer activity against human MCF7 cells by SRB method
    		[PMID: 21676506]
    MCF7 GI50
    0.17 μM
    Compound: ADR
    Growth inhibition of human MCF7 cells by SRB assay
    Growth inhibition of human MCF7 cells by SRB assay
    		[PMID: 22361684]
    MCF7 GI50
    0.17 μM
    Compound: ADR
    Growth inhibition of human MCF7 cells after 48 hrs by sulforhodamine B assay
    Growth inhibition of human MCF7 cells after 48 hrs by sulforhodamine B assay
    		[PMID: 22364746]
    MCF7 GI50
    0.17 μM
    Compound: ADR
    Growth inhibition of human MCF7 cells after 48 hrs by sulforhodamine B assay
    Growth inhibition of human MCF7 cells after 48 hrs by sulforhodamine B assay
    		[PMID: 23849207]
    MCF7 GI50
    0.18 μM
    Compound: ADR, Adriamycin
    Growth inhibition of human MCF7 cells by SRB method
    Growth inhibition of human MCF7 cells by SRB method
    		[PMID: 18207392]
    MCF7 GI50
    0.18 μM
    Compound: adriamycin
    Cytotoxicity against human MCF7 cells after 24 hrs by SRB method
    Cytotoxicity against human MCF7 cells after 24 hrs by SRB method
    		[PMID: 18262426]
    MCF7 GI50
    0.25 μM
    Compound: Doxorubicin
    Growth inhibition of human MCF7 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human MCF7 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 33477019]
    MCF7 GI50
    0.2 μg/mL
    Compound: adriamycin
    Cytotoxicity against human MCF7 cells by MTT assay
    Cytotoxicity against human MCF7 cells by MTT assay
    		[PMID: 11000028]
    MCF7 GI50
    0.31 μM
    Compound: Doxorubicin
    Antiproliferative activity against human MCF7 cells after 2 days by sulforhodamine B assay
    Antiproliferative activity against human MCF7 cells after 2 days by sulforhodamine B assay
    		[PMID: 24184076]
    MCF7 GI50
    0.38 μg/mL
    Compound: adriamycin
    Cytotoxicity against human MCF7 cells
    Cytotoxicity against human MCF7 cells
    		[PMID: 16562847]
    MCF7 GI50
    0.4 μM
    Compound: Dox
    Cytotoxicity against human MCF7 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
    Cytotoxicity against human MCF7 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
    		[PMID: 34634616]
    MCF7 GI50
    0.75 μM
    Compound: Dox
    Anticancer activity against human MCF7 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    Anticancer activity against human MCF7 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    		[PMID: 35533562]
    MCF7 GI50
    0.82 μM
    Compound: Dox
    Antiproliferative activity against human MCF7 cells incubated for 72 hrs and measured by MTT assay
    Antiproliferative activity against human MCF7 cells incubated for 72 hrs and measured by MTT assay
    		[PMID: 35973342]
    MCF7 GI50
    0.9 μM
    Compound: Doxorubicin
    Antiproliferative activity against human MCF7 cells assessed as growth inhibition incubated for 48 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells assessed as growth inhibition incubated for 48 hrs by MTT assay
    		[PMID: 31128433]
    MCF7 GI50
    1.15 μM
    Compound: Doxorubicin
    Antiproliferative activity against human MCF7 cells assessed as growth inhibition by MTT assay
    Antiproliferative activity against human MCF7 cells assessed as growth inhibition by MTT assay
    		[PMID: 39026636]
    MCF7 GI50
    1.6 μM
    Compound: Doxorubicin
    Anti-proliferative activity against human MCF7 cells incubated for 48 hrs by SRB assay
    Anti-proliferative activity against human MCF7 cells incubated for 48 hrs by SRB assay
    		[PMID: 26163220]
    MCF7 GI50
    2 x 10-3 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells assessed as growth inhibition after 72 hrs by MTT assay
    Cytotoxicity against human MCF7 cells assessed as growth inhibition after 72 hrs by MTT assay
    		[PMID: 29670691]
    MCF7 GI50
    2 x 10-3 μM
    Compound: Doxorubicin
    Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay
    		[PMID: 30071406]
    MCF7 GI50
    42.8 nM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay
    Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay
    		[PMID: 15270581]
    MCF7 GI50
    42.8 nM
    Compound: Doxorubicin
    Growth inhibition of human MCF7 cells
    Growth inhibition of human MCF7 cells
    		[PMID: 17614292]
    MCF7 GI50
    42.8 nM
    Compound: Doxorubicin
    Antitumor activity against human MCF7 cells expressing estrogen receptor assessed as inhibition of growth after 48 hrs using sulforhodamine B dye
    Antitumor activity against human MCF7 cells expressing estrogen receptor assessed as inhibition of growth after 48 hrs using sulforhodamine B dye
    		[PMID: 19428155]
    MCF7 GI50
    42.8 nM
    Compound: doxorubicin
    Growth inhibition of human MCF7 cells after 48 hrs
    Growth inhibition of human MCF7 cells after 48 hrs
    		[PMID: 17692432]
    MCF7 GI50
    42.8 nM
    Compound: doxorubicin
    Cytotoxicity against human MCF7 cells after 48 hrs
    Cytotoxicity against human MCF7 cells after 48 hrs
    		[PMID: 17964791]
    MCF7 GI50
    42.8 nM
    Compound: doxorubicin
    Antitumor activity against human MCF7 cells after 48 hrs
    Antitumor activity against human MCF7 cells after 48 hrs
    		[PMID: 18439831]
    MCF7 GI50
    42.8 μM
    Compound: Doxorubicin
    Growth inhibition of human MCF7 cells after 48 hrs by SRB assay
    Growth inhibition of human MCF7 cells after 48 hrs by SRB assay
    		[PMID: 15165162]
    MCF7 GI50
    42.8 μM
    Compound: Doxorubicin
    Growth inhibition of human MCF7 cells after 48 hrs by sulforhodamine B assay
    Growth inhibition of human MCF7 cells after 48 hrs by sulforhodamine B assay
    		[PMID: 21504224]
    MCF7 GI50
    42.8 μM
    Compound: doxorubicin
    Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay
    Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay
    		[PMID: 19070942]
    MCF7 GI50
    43.3 nM
    Compound: Doxorubucin
    Growth inhibition of human MCF7 cells after 48 hrs by SRB assay
    Growth inhibition of human MCF7 cells after 48 hrs by SRB assay
    		[PMID: 21138784]
    MCF7 GI50
    43.3 nM
    Compound: doxorubicin
    Growth inhibition of human MCF7 cells after 48 hrs by sulforhodamine B assay
    Growth inhibition of human MCF7 cells after 48 hrs by sulforhodamine B assay
    		[PMID: 20934235]
    MCF7 GI50
    5.5 x 10-2 μM
    Compound: doxorubicin
    Cytotoxicity against human MCF7 cells by SRB assay
    Cytotoxicity against human MCF7 cells by SRB assay
    		[PMID: 11678649]
    MCF7 GI50
    5.7 μM
    Compound: ADR
    Cytotoxicity in human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay
    Cytotoxicity in human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay
    		[PMID: 28754470]
    MCF7 GI50
    59.77 nM
    Compound: Doxorubicin
    Growth inhibition of human MCF7 cells after 48 hrs by SRB assay
    Growth inhibition of human MCF7 cells after 48 hrs by SRB assay
    		[PMID: 24411197]
    MCF7 GI50
    6.2 x 10-7 μg/mL
    Compound: adriamycin
    Cytotoxicity against human MCF7 cells
    Cytotoxicity against human MCF7 cells
    		[PMID: 12828475]
    MCF7 GI50
    6.5 x 10-7 μg/mL
    Compound: adriamycin
    Cytotoxicity against human MCF7 cells
    Cytotoxicity against human MCF7 cells
    		[PMID: 15043429]
    MCF7 GI50
    6.5 x 10-7 μg/mL
    Compound: adriamycin
    Cytotoxicity against human MCF7 cells
    Cytotoxicity against human MCF7 cells
    		[PMID: 15787438]
    MCF7 GI50
    65.4 nM
    Compound: Doxorubicin
    Growth inhibition of human MCF7 cells after 48 hrs by sulforhodamine B assay
    Growth inhibition of human MCF7 cells after 48 hrs by sulforhodamine B assay
    		[PMID: 23623253]
    MCF7 GI50
    65.4 nM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay
    Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay
    		[PMID: 24113365]
    MCF7 GI50
    68.8 nM
    Compound: Doxorubicin
    Growth inhibition of human MCF7 cells after 48 hrs by SRB assay
    Growth inhibition of human MCF7 cells after 48 hrs by SRB assay
    		[PMID: 22177409]
    MCF7 GI50
    8 x 10-7 μM
    Compound: adriamycin
    Cytotoxicity against human MCF7 cells
    Cytotoxicity against human MCF7 cells
    		[PMID: 14640532]
    MCF7 GI50
    8.4 μM
    Compound: DOX
    Growth inhibition of human MCF7 cells after 48 hrs by SRB assay
    Growth inhibition of human MCF7 cells after 48 hrs by SRB assay
    		[PMID: 28433679]
    MCF7 GI50
    8.4 μM
    Compound: DOX
    Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay
    Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay
    		[PMID: 29316526]
    MCF7 GI50
    8.4 μM
    Compound: Dox
    Cytotoxicity against human MCF7 cells assessed as growth inhibition after 48 hrs by SRB assay
    Cytotoxicity against human MCF7 cells assessed as growth inhibition after 48 hrs by SRB assay
    		[PMID: 29407991]
    MCF7 GI50
    < 0.025 μg/mL
    Compound: DOX; Doxo
    Antiproliferative activity against human MCF7 cells after 48 hrs by SRB assay
    Antiproliferative activity against human MCF7 cells after 48 hrs by SRB assay
    		[PMID: 26859070]
    MCF7 GI50
    < 0.046 μM
    Compound: Dox
    Antiproliferative activity against human MCF7 cells assessed as growth inhibition after 48 hrs by SRB assay
    Antiproliferative activity against human MCF7 cells assessed as growth inhibition after 48 hrs by SRB assay
    		[PMID: 26454648]
    MCF7 GI50
    < 0.046 μM
    Compound: Doxorubicin
    Anticancer activity against human MCF7 cells assessed as cell growth inhibition measured after 48 hrs by sulforhodamine B assay
    Anticancer activity against human MCF7 cells assessed as cell growth inhibition measured after 48 hrs by sulforhodamine B assay
    		[PMID: 33214037]
    MCF7 GI50
    < 0.1 μM
    Compound: ADR
    Cytotoxicity against human MCF7 cells by SRB assay
    Cytotoxicity against human MCF7 cells by SRB assay
    		10.1007/s00044-013-0855-2
    MCF7 GI50
    < 0.1 μM
    Compound: ADR
    Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay
    Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay
    		[PMID: 20673627]
    MCF7 GI50
    < 0.1 μM
    Compound: ADR
    Anticancer activity against human MCF7 cells by SRB method
    Anticancer activity against human MCF7 cells by SRB method
    		[PMID: 22104151]
    MCF7 GI50
    < 0.1 μM
    Compound: Doxorubicin
    Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition
    Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition
    		[PMID: 32961322]
    MCF7 GI50
    < 10 μM
    Compound: Doxorubicin
    Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition by SRB assay
    Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition by SRB assay
    		[PMID: 37875056]
    MCF7 GI50
    > 5 μM
    Compound: Doxorubicin
    Growth inhibition of human MCF7 cells after 72 hrs by celltiter-blue viability assay
    Growth inhibition of human MCF7 cells after 72 hrs by celltiter-blue viability assay
    		[PMID: 21348461]
    MCF7 GI50
    6.2 x 10-7 μg/mL
    Compound: adriamycin
    Cytotoxicity against human MCF7 cell
    Cytotoxicity against human MCF7 cell
    		[PMID: 15730249]
    MCF7 IC50
    0.0007 μM
    Compound: Doxorubicin
    Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay
    		[PMID: 17949859]
    MCF7 IC50
    0.0039 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells after 24 hrs by MTS assay
    Cytotoxicity against human MCF7 cells after 24 hrs by MTS assay
    		[PMID: 30289713]
    MCF7 IC50
    0.005 μg
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells assessed as decrease in cell viability after 48 hrs by SRB assay
    Cytotoxicity against human MCF7 cells assessed as decrease in cell viability after 48 hrs by SRB assay
    		[PMID: 27393950]
    MCF7 IC50
    0.0071 μM
    Compound: Doxorubicin
    Inhibition of serum-induced proliferation of human MCF7 cells
    Inhibition of serum-induced proliferation of human MCF7 cells
    		[PMID: 17601739]
    MCF7 IC50
    0.009 mM
    Compound: DOX
    Cytotoxicity against human MCF7 cells after 3 days by MTT assay
    Cytotoxicity against human MCF7 cells after 3 days by MTT assay
    		[PMID: 22520152]
    MCF7 IC50
    0.009 μM
    Compound: ADR
    Cytotoxicity against human MCF7 cells assessed as growth inhibition after 96 hrs by SRB assay
    Cytotoxicity against human MCF7 cells assessed as growth inhibition after 96 hrs by SRB assay
    		[PMID: 25817774]
    MCF7 IC50
    0.0093 μM
    Compound: Doxorubicin
    Anticancer activity against human MCF7 cells assessed as inhibition of cell growth incubated for 48 hrs by SRB assay
    Anticancer activity against human MCF7 cells assessed as inhibition of cell growth incubated for 48 hrs by SRB assay
    		[PMID: 33940466]
    MCF7 IC50
    0.01 μM
    Compound: DOX
    Antiproliferative activity against human MCF7 cells measured after 72 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells measured after 72 hrs by MTT assay
    		[PMID: 31431364]
    MCF7 IC50
    0.01 μM
    Compound: DOX
    Cytotoxicity against human MCF7 cells incubated for 48 hrs by MTT assay
    Cytotoxicity against human MCF7 cells incubated for 48 hrs by MTT assay
    		[PMID: 38185054]
    MCF7 IC50
    0.01 μM
    Compound: Doxorubicin
    Inhibitory activity against MCF-7 wt cell line using MTT assay (ER+,pgR+,wildtype p53)
    Inhibitory activity against MCF-7 wt cell line using MTT assay (ER+,pgR+,wildtype p53)
    		[PMID: 10780913]
    MCF7 IC50
    0.015 μM
    Compound: Adriamycin
    Antitumor activity against breast carcinoma cell line (MCF-7M)
    Antitumor activity against breast carcinoma cell line (MCF-7M)
    		[PMID: 2547068]
    MCF7 IC50
    0.015 μM
    Compound: Doxorubicin
    Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 31546197]
    MCF7 IC50
    0.018 μM
    Compound: Doxorubicin
    Antiproliferative activity against human MCF7 cells after 24 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells after 24 hrs by MTT assay
    		[PMID: 17949859]
    MCF7 IC50
    0.02 μM
    Compound: Dox
    Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay
    Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay
    		[PMID: 23802716]
    MCF7 IC50
    0.02 μM
    Compound: Doxorubicin
    Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay
    		[PMID: 24780599]
    MCF7 IC50
    0.02 μM
    Compound: Doxorubicin
    Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay
    		[PMID: 27448912]
    MCF7 IC50
    0.022 μM
    Compound: Doxorubicin
    Inhibitory concentration against MCF-7 human breast carcinoma cell line
    Inhibitory concentration against MCF-7 human breast carcinoma cell line
    		[PMID: 15715481]
    MCF7 IC50
    0.022 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells after 24 hrs by SRB method
    Cytotoxicity against human MCF7 cells after 24 hrs by SRB method
    		[PMID: 18429610]
    MCF7 IC50
    0.022 μM
    Compound: doxorubicin
    Cytotoxicity against human MCF7 cells
    Cytotoxicity against human MCF7 cells
    		[PMID: 17375902]
    MCF7 IC50
    0.0234 μM
    Compound: DOX
    Cytotoxicity against human MCF7 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    Cytotoxicity against human MCF7 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    		[PMID: 30826510]
    MCF7 IC50
    0.031 μM
    Compound: DOX
    Antitumor activity against human MCF7 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    Antitumor activity against human MCF7 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    		[PMID: 34319100]
    MCF7 IC50
    0.033 μM
    Compound: DOX
    Cytotoxicity against human MCF7 cells incubated for 72 hrs by SRB assay
    Cytotoxicity against human MCF7 cells incubated for 72 hrs by SRB assay
    		[PMID: 38996651]
    MCF7 IC50
    0.035 μM
    Compound: DOX
    Cytotoxicity against human MCF-7 assessed as reduction in cell viability by SRB assay
    Cytotoxicity against human MCF-7 assessed as reduction in cell viability by SRB assay
    		[PMID: 33130288]
    MCF7 IC50
    0.038 μM
    Compound: Dox
    Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay
    Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay
    		[PMID: 34116381]
    MCF7 IC50
    0.04 μM
    Compound: DOX
    Antitumor activity against human MCF7 cells after 72 hrs by MTT assay
    Antitumor activity against human MCF7 cells after 72 hrs by MTT assay
    		[PMID: 17935309]
    MCF7 IC50
    0.04 μM
    Compound: DOX
    Antiproliferative activity against human MCF7 cells after 72 hrs by Sulforhodamine B-stain assay
    Antiproliferative activity against human MCF7 cells after 72 hrs by Sulforhodamine B-stain assay
    		[PMID: 27484508]
    MCF7 IC50
    0.04 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    Cytotoxicity against human MCF7 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    		10.1007/s00044-013-0712-3
    MCF7 IC50
    0.04 μM
    Compound: Doxorubicin
    Antiproliferative activity assessed in the MCF-7 human mamma carcinoma using the BrdU
    Antiproliferative activity assessed in the MCF-7 human mamma carcinoma using the BrdU
    		[PMID: 12459020]
    MCF7 IC50
    0.04 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
    Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
    		[PMID: 20207049]
    MCF7 IC50
    0.042 μg/mL
    Compound: Doxorubicin
    Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay
    Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay
    		[PMID: 34973507]
    MCF7 IC50
    0.04 μg/L
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells assessed as inhibition of cell viability after 72 hrs by SRB assay
    Cytotoxicity against human MCF7 cells assessed as inhibition of cell viability after 72 hrs by SRB assay
    		[PMID: 26420384]
    MCF7 IC50
    0.05 μM
    Compound: Adriamycin
    Tested for induction of cellular death in Human breast MCF-7 tumor cell line in Propidium Iodide Monolayer Assay
    Tested for induction of cellular death in Human breast MCF-7 tumor cell line in Propidium Iodide Monolayer Assay
    		[PMID: 12852768]
    MCF7 IC50
    0.05 μM
    Compound: Doxo
    Antiproliferative activity against human MCF7 cells assessed as cell viability measured after 4 days by MTT assay
    Antiproliferative activity against human MCF7 cells assessed as cell viability measured after 4 days by MTT assay
    		[PMID: 31869654]
    MCF7 IC50
    0.05 μM
    Compound: Doxorubicin
    Antitumor activity against human breast adenocarcinoma MCF-7 cells.
    Antitumor activity against human breast adenocarcinoma MCF-7 cells.
    		[PMID: 12431049]
    MCF7 IC50
    0.05 μM
    Compound: Doxorubicin
    Antiproliferative activity against human MCF7 cells after 96 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells after 96 hrs by MTT assay
    		[PMID: 19053767]
    MCF7 IC50
    0.05 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells after 48 hrs by neutral red dye based assay
    Cytotoxicity against human MCF7 cells after 48 hrs by neutral red dye based assay
    		[PMID: 29317147]
    MCF7 IC50
    0.05 μM
    Compound: doxorubicin
    Antitumor activity against human breast adenocarcinoma MCF-7 cells
    Antitumor activity against human breast adenocarcinoma MCF-7 cells
    		[PMID: 12431048]
    MCF7 IC50
    0.053 μM
    Compound: DOX
    Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 48 hrs by CellTiter 96 Aqueous One Solution Cell Proliferation Assay
    Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 48 hrs by CellTiter 96 Aqueous One Solution Cell Proliferation Assay
    		[PMID: 38626522]
    MCF7 IC50
    0.06 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
    Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
    		[PMID: 22414612]
    MCF7 IC50
    0.06 μM
    Compound: Doxorubicin
    Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay
    		[PMID: 22555152]
    MCF7 IC50
    0.06 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells assessed as growth inhibition incubated for 72 hrs by MTT assay
    Cytotoxicity against human MCF7 cells assessed as growth inhibition incubated for 72 hrs by MTT assay
    		[PMID: 26280922]
    MCF7 IC50
    0.06 μM
    Compound: Doxorubicin
    Cytotoxicity activity against human MCF7 cells incubated for 48 hrs by SRB assay
    Cytotoxicity activity against human MCF7 cells incubated for 48 hrs by SRB assay
    		[PMID: 34119830]
    MCF7 IC50
    0.06 μM
    Compound: doxorubicin
    Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
    Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
    		[PMID: 18164206]
    MCF7 IC50
    0.063 mM
    Compound: Doxorubicin
    Cytotoxicity against Homo sapiens (human) MCF7 cells after 48 hr by neutral red assay
    Cytotoxicity against Homo sapiens (human) MCF7 cells after 48 hr by neutral red assay
    		10.1007/s00044-011-9761-7
    MCF7 IC50
    0.063 μM
    Compound: ADR
    In vitro inhibition of tumor cell growth in the human mammary tumor MCF-7 system
    In vitro inhibition of tumor cell growth in the human mammary tumor MCF-7 system
    		[PMID: 1447730]
    MCF7 IC50
    0.065 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells after 48 hrs by CCK8 assay
    Cytotoxicity against human MCF7 cells after 48 hrs by CCK8 assay
    		[PMID: 23777898]
    MCF7 IC50
    0.07 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay
    Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay
    		[PMID: 17190470]
    MCF7 IC50
    0.07 μM
    Compound: Doxorubicin
    Antiproliferative activity against human MCF7 cells assessed as cell viability after 48 hrs by SRB assay
    Antiproliferative activity against human MCF7 cells assessed as cell viability after 48 hrs by SRB assay
    		[PMID: 26947606]
    MCF7 IC50
    0.07 μM
    Compound: Doxorubicine
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by Hoechst-33342 staining based cell counting method (Rvb > 25 microM)
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by Hoechst-33342 staining based cell counting method (Rvb > 25 microM)
    		[PMID: 33422908]
    MCF7 IC50
    0.07 μM
    Compound: doxorubicin
    Cytotoxicity against human MCF7 cells by MTT assay
    Cytotoxicity against human MCF7 cells by MTT assay
    		[PMID: 15620238]
    MCF7 IC50
    0.07 μM
    Compound: doxorubicin
    Cytotoxicity against human MCF7 cells by MTT assay
    Cytotoxicity against human MCF7 cells by MTT assay
    		[PMID: 15921417]
    MCF7 IC50
    0.07 μM
    Compound: doxorubicin
    Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
    Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
    		[PMID: 17286429]
    MCF7 IC50
    0.07 μM
    Compound: doxorubicin
    Antiproliferative activity against human MCF7 cells by MTT assay
    Antiproliferative activity against human MCF7 cells by MTT assay
    		[PMID: 18052326]
    MCF7 IC50
    0.07 μM
    Compound: doxorubicin
    Antiproliferative activity against human MCF7 cells by MTT assay
    Antiproliferative activity against human MCF7 cells by MTT assay
    		[PMID: 18247573]
    MCF7 IC50
    0.077 μM
    Compound: Adriamycin
    Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
    Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
    		[PMID: 24684844]
    MCF7 IC50
    0.0795 μM
    Compound: Dox
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 96 hrs by MTT method
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 96 hrs by MTT method
    		[PMID: 34236840]
    MCF7 IC50
    0.07 μg/mL
    Compound: dox, doxorubicin
    Cytotoxicity against human MCF7 cells
    Cytotoxicity against human MCF7 cells
    		[PMID: 17618015]
    MCF7 IC50
    0.088 μM
    Compound: 21
    Antitumor activity against human MCF7 cells assessed as inhibition of cell proliferation in the presence of 1mM of eugenol
    Antitumor activity against human MCF7 cells assessed as inhibition of cell proliferation in the presence of 1mM of eugenol
    		[PMID: 36858050]
    MCF7 IC50
    0.09 μM
    Compound: Doxorubicin
    Antiproliferative activity against human MCF-7 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Antiproliferative activity against human MCF-7 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    		[PMID: 33477020]
    MCF7 IC50
    0.092 μM
    Compound: Doxorubicin
    Antiproliferative activity against human MCF7 cells incubated for 72 hrs by sulforhodamine B assay
    Antiproliferative activity against human MCF7 cells incubated for 72 hrs by sulforhodamine B assay
    		[PMID: 32432867]
    MCF7 IC50
    0.097 μM
    Compound: DOX
    Cytotoxicity against human MCF7 cells measured after 72 hrs by Celltiter-Glo assay
    Cytotoxicity against human MCF7 cells measured after 72 hrs by Celltiter-Glo assay
    		[PMID: 31820976]
    MCF7 IC50
    0.1 μM
    Compound: Adriblastine
    Cytotoxicity against human MCF7 cells
    Cytotoxicity against human MCF7 cells
    		[PMID: 15974615]
    MCF7 IC50
    0.1 μM
    Compound: Dox
    Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
    Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
    		[PMID: 30659997]
    MCF7 IC50
    0.1 μM
    Compound: Doxo
    Cytotoxicity against human MCF7 cells assessed as cell viability after 48 hrs by MTT assay
    Cytotoxicity against human MCF7 cells assessed as cell viability after 48 hrs by MTT assay
    		10.1039/C2MD20302B
    MCF7 IC50
    0.1 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells assessed as intracellular ATP level after 72 hrs by luminometry
    Cytotoxicity against human MCF7 cells assessed as intracellular ATP level after 72 hrs by luminometry
    		[PMID: 21354800]
    MCF7 IC50
    0.1 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs
    		[PMID: 34601029]
    MCF7 IC50
    0.112 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
    Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
    		[PMID: 26840362]
    MCF7 IC50
    0.12 μM
    Compound: Adriamycin
    Cytotoxicity against human MCF7 cells by SRB assay
    Cytotoxicity against human MCF7 cells by SRB assay
    		[PMID: 19341288]
    MCF7 IC50
    0.12 μM
    Compound: DOX
    Antiproliferative activity against ER positive human MCF7 cells assessed as inhibition of cell growth after 48 hrs by MTT assay
    Antiproliferative activity against ER positive human MCF7 cells assessed as inhibition of cell growth after 48 hrs by MTT assay
    		[PMID: 25737400]
    MCF7 IC50
    0.12 μM
    Compound: Doxo
    Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
    Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
    		[PMID: 25563891]
    MCF7 IC50
    0.12 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells after 24 hrs by XTT assay
    Cytotoxicity against human MCF7 cells after 24 hrs by XTT assay
    		[PMID: 27227682]
    MCF7 IC50
    0.12 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability by CellTiter Glo luminescent assay
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability by CellTiter Glo luminescent assay
    		[PMID: 32755677]
    MCF7 IC50
    0.12 μg/mL
    Compound: (20) adriamycin
    In vitro cytotoxicity of compound against MCF7, human breast cancer was defined by microculture tetrazolium assay
    In vitro cytotoxicity of compound against MCF7, human breast cancer was defined by microculture tetrazolium assay
    		[PMID: 12620075]
    MCF7 IC50
    0.13 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells assessed as cell viability after 72 hrs by MTT assay
    Cytotoxicity against human MCF7 cells assessed as cell viability after 72 hrs by MTT assay
    		[PMID: 24530030]
    MCF7 IC50
    0.13 μM
    Compound: Doxorubicin
    Antiproliferative activity against human MCF7 cells assessed as growth inhibition incubated for 48 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells assessed as growth inhibition incubated for 48 hrs by MTT assay
    		[PMID: 26253231]
    MCF7 IC50
    0.13 μM
    Compound: Doxorubicin
    Growth inhibition of human MCF7 cells incubated for 48 hrs by MTT assay
    Growth inhibition of human MCF7 cells incubated for 48 hrs by MTT assay
    		[PMID: 27080187]
    MCF7 IC50
    0.13 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells assessed as decrease in cell viability after 24 hrs by MTT assay
    Cytotoxicity against human MCF7 cells assessed as decrease in cell viability after 24 hrs by MTT assay
    		[PMID: 27496212]
    MCF7 IC50
    0.13 μM
    Compound: doxorubicin
    Cytotoxicity against human MCF7 cells after 96 hrs by MTT assay
    Cytotoxicity against human MCF7 cells after 96 hrs by MTT assay
    		[PMID: 18513976]
    MCF7 IC50
    0.137 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells at 50 uM by MTT reduction assay
    Cytotoxicity against human MCF7 cells at 50 uM by MTT reduction assay
    		[PMID: 33276991]
    MCF7 IC50
    0.13 μg/mL
    Compound: Adriamycin
    Inhibitory concentration required against MCF-7 breast cancer cell line
    Inhibitory concentration required against MCF-7 breast cancer cell line
    		[PMID: 11354370]
    MCF7 IC50
    0.14 μM
    Compound: DOX
    Cytotoxicity against against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 30340899]
    MCF7 IC50
    0.14 μM
    Compound: Dox
    Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay
    		[PMID: 27423028]
    MCF7 IC50
    0.14 μM
    Compound: Doxorubicine
    Inhibitory activity against MCF-7 breast cell line using sulforhodamine B (SRB) protein assay
    Inhibitory activity against MCF-7 breast cell line using sulforhodamine B (SRB) protein assay
    		[PMID: 12039588]
    MCF7 IC50
    0.14 μM
    Compound: doxorubicin
    Cytotoxicity against human MCF7 cells
    Cytotoxicity against human MCF7 cells
    		[PMID: 12608854]
    MCF7 IC50
    0.142 μM
    Compound: DOX
    Cytotoxicity against human MCF7 cells after 24 to 72 hrs by MTT assay
    Cytotoxicity against human MCF7 cells after 24 to 72 hrs by MTT assay
    		[PMID: 29032034]
    MCF7 IC50
    0.15 μM
    Compound: ADM
    Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay
    		[PMID: 30344912]
    MCF7 IC50
    0.15 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 28782948]
    MCF7 IC50
    0.15 μg/mL
    Compound: Doxorubicin
    In vitro cytotoxic activity against human breast cancer cells (MCF-7) by using SRB assay after 72 hr of drug exposure
    In vitro cytotoxic activity against human breast cancer cells (MCF-7) by using SRB assay after 72 hr of drug exposure
    		10.1016/0960-894X(96)00156-4
    MCF7 IC50
    0.16 μM
    Compound: DOX
    Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
    Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
    		[PMID: 26386603]
    MCF7 IC50
    0.16 μM
    Compound: DOX
    Antiproliferative activity against human MCF7 cells after 48 hrs by CellTiter-Glo assay
    Antiproliferative activity against human MCF7 cells after 48 hrs by CellTiter-Glo assay
    		[PMID: 27769032]
    MCF7 IC50
    0.16 μM
    Compound: Doxorubicin
    Toxicity in human MCF7 cells assessed as reduction in cell number after 48 hrs by Hoechst 33342 staining based assay
    Toxicity in human MCF7 cells assessed as reduction in cell number after 48 hrs by Hoechst 33342 staining based assay
    		[PMID: 31753515]
    MCF7 IC50
    0.16 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth after 48 hrs by SRB assay
    Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth after 48 hrs by SRB assay
    		[PMID: 34077833]
    MCF7 IC50
    0.16 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
    Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
    		[PMID: 21708464]
    MCF7 IC50
    0.16 μg/mL
    Compound: adriamycin
    Cytotoxicity against human MCF7 cells by SRB assay
    Cytotoxicity against human MCF7 cells by SRB assay
    		[PMID: 17981473]
    MCF7 IC50
    0.17 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
    		[PMID: 31836446]
    MCF7 IC50
    0.17 μM
    Compound: doxorubicin
    Cytotoxicity against doxorubicin-sensitive human MCF7 cells
    Cytotoxicity against doxorubicin-sensitive human MCF7 cells
    		[PMID: 15921419]
    MCF7 IC50
    0.18 μM
    Compound: ADM; DOX
    Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    		[PMID: 31491611]
    MCF7 IC50
    0.18 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by resazurin dye-based fluorescence assay
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by resazurin dye-based fluorescence assay
    		[PMID: 32663024]
    MCF7 IC50
    0.18 μg/mL
    Compound: DOX
    Antiproliferative activity against human MCF7 cells assessed as growth inhibition after 24 to 48 hrs by SRB assay
    Antiproliferative activity against human MCF7 cells assessed as growth inhibition after 24 to 48 hrs by SRB assay
    		[PMID: 24012683]
    MCF7 IC50
    0.19 μM
    Compound: DOX
    Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay
    		[PMID: 21496972]
    MCF7 IC50
    0.19 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells after 44 hrs by SRB assay
    Cytotoxicity against human MCF7 cells after 44 hrs by SRB assay
    		10.1007/s00044-013-0788-9
    MCF7 IC50
    0.2 μM
    Compound: DOX
    Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
    Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
    		[PMID: 25259516]
    MCF7 IC50
    0.2 μM
    Compound: DOX
    Cytotoxicity against human MCF7 cells assessed as cell growth inhibition after 72 hrs by MTT assay
    Cytotoxicity against human MCF7 cells assessed as cell growth inhibition after 72 hrs by MTT assay
    		[PMID: 26720155]
    MCF7 IC50
    0.2 μM
    Compound: DOX
    Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay
    		[PMID: 28135634]
    MCF7 IC50
    0.2 μM
    Compound: DOX
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 28427016]
    MCF7 IC50
    0.2 μM
    Compound: DOX
    Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth after 72 hrs by MTT assay
    Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth after 72 hrs by MTT assay
    		[PMID: 30746062]
    MCF7 IC50
    0.2 μM
    Compound: DOX
    Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability measured after 6 days by MTT assay
    Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability measured after 6 days by MTT assay
    		[PMID: 32653698]
    MCF7 IC50
    0.2 μM
    Compound: DOX
    Antiproliferative activity against human MCF7 cells by MTT colorimetric assay
    Antiproliferative activity against human MCF7 cells by MTT colorimetric assay
    		[PMID: 38527380]
    MCF7 IC50
    0.2 μM
    Compound: DOX
    Antiproliferative activity against estrogen receptor positive human MCF7 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    Antiproliferative activity against estrogen receptor positive human MCF7 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    		[PMID: 39067378]
    MCF7 IC50
    0.2 μM
    Compound: Dox
    Cytotoxicity against human MCF7 cells assessed as cell growth inhibition after 72 hrs by MTT assay
    Cytotoxicity against human MCF7 cells assessed as cell growth inhibition after 72 hrs by MTT assay
    		[PMID: 27231128]
    MCF7 IC50
    0.2 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
    Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
    		[PMID: 23827179]
    MCF7 IC50
    0.2 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
    Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
    		[PMID: 26963142]
    MCF7 IC50
    0.2 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells assessed as cell growth inhibition after 48 hrs by SRB assay
    Cytotoxicity against human MCF7 cells assessed as cell growth inhibition after 48 hrs by SRB assay
    		[PMID: 28641156]
    MCF7 IC50
    0.2 μM
    Compound: Doxorubicin
    Cytotoxicity activity against human MCF7 assessed as inhibition of cell growth measured after 72 hrs by MTT assay
    Cytotoxicity activity against human MCF7 assessed as inhibition of cell growth measured after 72 hrs by MTT assay
    		[PMID: 33340938]
    MCF7 IC50
    0.2 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells by MTT assay
    Cytotoxicity against human MCF7 cells by MTT assay
    		[PMID: 34332400]
    MCF7 IC50
    0.211 μM
    Compound: Doxorubicin
    Cytotoxicity against Homo sapiens (human) MCF7 cells after 96 hr by MTT assay
    Cytotoxicity against Homo sapiens (human) MCF7 cells after 96 hr by MTT assay
    		10.1007/s00044-010-9340-3
    MCF7 IC50
    0.22 μM
    Compound: DOX
    Antiproliferative activity against human MCF7 cells after 72 hrs by SRB assay
    Antiproliferative activity against human MCF7 cells after 72 hrs by SRB assay
    		[PMID: 30106296]
    MCF7 IC50
    0.22 μM
    Compound: Doxorubicin
    Antiproliferative activity against human MCF7 cells after 72 hrs by MTT reduction assay
    Antiproliferative activity against human MCF7 cells after 72 hrs by MTT reduction assay
    		[PMID: 28551177]
    MCF7 IC50
    0.23 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 4 hrs by MTT assay
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 4 hrs by MTT assay
    		[PMID: 30773423]
    MCF7 IC50
    0.23 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells
    Cytotoxicity against human MCF7 cells
    		[PMID: 34332400]
    MCF7 IC50
    0.24 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells after 72 hrs by resazurin/resorufin-based fluorescence assay
    Cytotoxicity against human MCF7 cells after 72 hrs by resazurin/resorufin-based fluorescence assay
    		[PMID: 23600925]
    MCF7 IC50
    0.242 μM
    Compound: DOX
    Antiproliferative activity against human MCF7 cells transfected with empty vector assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells transfected with empty vector assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    		[PMID: 37409679]
    MCF7 IC50
    0.25 μM
    Compound: 1, Dox
    Tumor killing activity in MCF7 breast cancer cells by MTT assay
    Tumor killing activity in MCF7 breast cancer cells by MTT assay
    		[PMID: 16168650]
    MCF7 IC50
    0.25 μM
    Compound: ADR, ADM
    Cytotoxicity against human MCF7 cells after 72 hrs by SRB assay
    Cytotoxicity against human MCF7 cells after 72 hrs by SRB assay
    		[PMID: 21761866]
    MCF7 IC50
    0.25 μM
    Compound: Doxorubicin
    Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    		[PMID: 36242992]
    MCF7 IC50
    0.25 μM
    Compound: adriamycin
    Inhibition of 10e-2 uM estradiol induced estrogen receptor positive MCF-7 human breast cancer cell proliferation
    Inhibition of 10e-2 uM estradiol induced estrogen receptor positive MCF-7 human breast cancer cell proliferation
    		[PMID: 8784443]
    MCF7 IC50
    0.259 μM
    Compound: Doxorubicin
    Anticancer activity against human MCF7 cell assessed as cell growth inhibition measured after 24 to 72 hrs by MTT assay
    Anticancer activity against human MCF7 cell assessed as cell growth inhibition measured after 24 to 72 hrs by MTT assay
    		[PMID: 36577217]
    MCF7 IC50
    0.26 μM
    Compound: DX
    Antiproliferative activity against human MCF7 cells after 72 hrs by SRB assay
    Antiproliferative activity against human MCF7 cells after 72 hrs by SRB assay
    		[PMID: 30025346]
    MCF7 IC50
    0.27 μM
    Compound: Doxorubicin
    Antiproliferative activity against human MCF7 cells
    Antiproliferative activity against human MCF7 cells
    		[PMID: 34655985]
    MCF7 IC50
    0.27 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 6 hrs by SRB assay
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 6 hrs by SRB assay
    		[PMID: 36691388]
    MCF7 IC50
    0.28 μM
    Compound: Doxorubicin
    Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    		[PMID: 39026643]
    MCF7 IC50
    0.29 μM
    Compound: Dox
    Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay
    		[PMID: 26494582]
    MCF7 IC50
    0.294 nM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells assessed as cell viability after 5 days by cell viability analyzer
    Cytotoxicity against human MCF7 cells assessed as cell viability after 5 days by cell viability analyzer
    		[PMID: 26291039]
    MCF7 IC50
    0.29 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells
    Cytotoxicity against human MCF7 cells
    		[PMID: 23511021]
    MCF7 IC50
    0.2 μg/mL
    Compound: doxorubicin
    Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
    Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
    		[PMID: 15787450]
    MCF7 IC50
    0.2 μg/mL
    Compound: doxorubicin
    Cytotoxicity against human MCF7 cells by MTT assay
    Cytotoxicity against human MCF7 cells by MTT assay
    		[PMID: 18973388]
    MCF7 IC50
    0.3 μM
    Compound: DOX
    Antiproliferative activity against wild type human MCF7 cells after 72 hrs by MTT assay
    Antiproliferative activity against wild type human MCF7 cells after 72 hrs by MTT assay
    		[PMID: 17964170]
    MCF7 IC50
    0.3 μM
    Compound: DOX
    Antiproliferative activity against human MCF7 cells after 24 hrs by CellTiter-Glo assay
    Antiproliferative activity against human MCF7 cells after 24 hrs by CellTiter-Glo assay
    		[PMID: 27769032]
    MCF7 IC50
    0.3 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells assessed as cell growth inhibition measured after 24 to 72 hrs by MTT assay
    Cytotoxicity against human MCF7 cells assessed as cell growth inhibition measured after 24 to 72 hrs by MTT assay
    		[PMID: 33586438]
    MCF7 IC50
    0.3 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells assessed as inhibition of cell proliferation measured after 72 hrs by resazurin dye based AlamarBlue assay
    Cytotoxicity against human MCF7 cells assessed as inhibition of cell proliferation measured after 72 hrs by resazurin dye based AlamarBlue assay
    		[PMID: 34495663]
    MCF7 IC50
    0.31 μM
    Compound: Dox
    Antiproliferative activity against human MCF7 cells assessed as growth inhibition measured after 72 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells assessed as growth inhibition measured after 72 hrs by MTT assay
    		[PMID: 34902732]
    MCF7 IC50
    0.31 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
    Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
    		[PMID: 18692939]
    MCF7 IC50
    0.31 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
    Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
    		[PMID: 22677031]
    MCF7 IC50
    0.32 μM
    Compound: Doxorubicin
    Antiproliferative activity against human MCF7 cells after 72 hrs
    Antiproliferative activity against human MCF7 cells after 72 hrs
    		[PMID: 25127463]
    MCF7 IC50
    0.32 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells after 72 hrs by resazurin-based colorimetric assay
    Cytotoxicity against human MCF7 cells after 72 hrs by resazurin-based colorimetric assay
    		[PMID: 27071003]
    MCF7 IC50
    0.32 μM
    Compound: doxorubicin
    Cytotoxicity against human MCF7 cells assessed as inhibition of cell proliferation/survival after 72 hrs by resazurin dye reduction assay
    Cytotoxicity against human MCF7 cells assessed as inhibition of cell proliferation/survival after 72 hrs by resazurin dye reduction assay
    		[PMID: 26305181]
    MCF7 IC50
    0.32 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells by MTT assay
    Cytotoxicity against human MCF7 cells by MTT assay
    		[PMID: 18590313]
    MCF7 IC50
    0.34 μg/mL
    Compound: DOX
    Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
    Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
    		[PMID: 24589485]
    MCF7 IC50
    0.34 μg/mL
    Compound: doxo
    Cytotoxicity against human MCF7 cells by MTT method
    Cytotoxicity against human MCF7 cells by MTT method
    		[PMID: 17417907]
    MCF7 IC50
    0.35 μM
    Compound: DOX
    Antiproliferative activity against human MCF7 cells after 48 hrs by SRB assay
    Antiproliferative activity against human MCF7 cells after 48 hrs by SRB assay
    		[PMID: 30106296]
    MCF7 IC50
    0.35 μM
    Compound: Doxorubicin
    Antiproliferative activity against human MCF7 cells after 24 and 72 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells after 24 and 72 hrs by MTT assay
    		[PMID: 24941130]
    MCF7 IC50
    0.35 μM
    Compound: doxorubicin
    Cytotoxicity against human MCF7 cells after 72 hrs by Alamar Blue assay
    Cytotoxicity against human MCF7 cells after 72 hrs by Alamar Blue assay
    		[PMID: 24251417]
    MCF7 IC50
    0.35 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells by MTT assay
    Cytotoxicity against human MCF7 cells by MTT assay
    		[PMID: 21106454]
    MCF7 IC50
    0.36 μM
    Compound: ADM
    Anticancer activity against human MCF7 cells after 48 hrs by MTT assay
    Anticancer activity against human MCF7 cells after 48 hrs by MTT assay
    		[PMID: 25462264]
    MCF7 IC50
    0.36 μM
    Compound: Dox
    Anticancer activity against human MCF7 cells
    Anticancer activity against human MCF7 cells
    		[PMID: 31306817]
    MCF7 IC50
    0.36 μg/mL
    Compound: Doxorubicin
    Antiproliferative activity against human MCF7 cells after 48 hrs by CCK-8 assay
    Antiproliferative activity against human MCF7 cells after 48 hrs by CCK-8 assay
    		[PMID: 22658083]
    MCF7 IC50
    0.37 μM
    Compound: DOX
    Cytotoxicity against human MCF7 cells expressing high level of topoisomerase I/II measured after 72 hrs by MTT assay
    Cytotoxicity against human MCF7 cells expressing high level of topoisomerase I/II measured after 72 hrs by MTT assay
    		[PMID: 35612499]
    MCF7 IC50
    0.37 μM
    Compound: Dox
    Antiproliferative activity against human MCF7 cells assessed as growth inhibition under hypoxia conditions measured after 72 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells assessed as growth inhibition under hypoxia conditions measured after 72 hrs by MTT assay
    		[PMID: 34902732]
    MCF7 IC50
    0.37 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells under hypoxic condition by MTT assay
    Cytotoxicity against human MCF7 cells under hypoxic condition by MTT assay
    		[PMID: 29684705]
    MCF7 IC50
    0.37 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
    Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
    		[PMID: 30170925]
    MCF7 IC50
    0.38 μM
    Compound: DOX
    Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay
    Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay
    		[PMID: 35341920]
    MCF7 IC50
    0.38 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay
    Cytotoxicity against human MCF7 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay
    		[PMID: 27080182]
    MCF7 IC50
    0.38 μM
    Compound: Doxorubicin
    Cytotoxicity against ER-positive human MCF7 cells assessed as redution in cell viability incubated for 72 hrs by SRB assay
    Cytotoxicity against ER-positive human MCF7 cells assessed as redution in cell viability incubated for 72 hrs by SRB assay
    		[PMID: 31810778]
    MCF7 IC50
    0.38 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells
    Cytotoxicity against human MCF7 cells
    		[PMID: 17970595]
    MCF7 IC50
    0.39 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells assessed as reduction in cell survival after 48 hrs by MTT assay
    Cytotoxicity against human MCF7 cells assessed as reduction in cell survival after 48 hrs by MTT assay
    		[PMID: 28494255]
    MCF7 IC50
    0.3 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells by MTT colorimetric method
    Cytotoxicity against human MCF7 cells by MTT colorimetric method
    		[PMID: 17125220]
    MCF7 IC50
    0.4 μM
    Compound: Adriamycin
    Cytotoxicity against human MCF7 cells after 2 days by CCK-8 assay
    Cytotoxicity against human MCF7 cells after 2 days by CCK-8 assay
    		[PMID: 25481396]
    MCF7 IC50
    0.4 μM
    Compound: DOX
    Antiproliferative activity against human MCF7 cells assessed as inhibition of cell viability incubated for 72 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells assessed as inhibition of cell viability incubated for 72 hrs by MTT assay
    		[PMID: 35818137]
    MCF7 IC50
    0.4 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells after 72 hrs by Alamar blue assay
    Cytotoxicity against human MCF7 cells after 72 hrs by Alamar blue assay
    		[PMID: 21999655]
    MCF7 IC50
    0.4 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells by resazurin dye based Alamar blue assay
    Cytotoxicity against human MCF7 cells by resazurin dye based Alamar blue assay
    		[PMID: 29373790]
    MCF7 IC50
    0.4 μM
    Compound: Doxorubicin
    Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
    		[PMID: 30179747]
    MCF7 IC50
    0.4 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 24 hrs by CCK8 assay
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 24 hrs by CCK8 assay
    		[PMID: 32324401]
    MCF7 IC50
    0.4 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells assessed as number of viable cells measured after 48 hrs by MTT based colorimetric assay
    Cytotoxicity against human MCF7 cells assessed as number of viable cells measured after 48 hrs by MTT based colorimetric assay
    		[PMID: 36970146]
    MCF7 IC50
    0.405 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 72 hrs by MTS assay
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 72 hrs by MTS assay
    		[PMID: 33261897]
    MCF7 IC50
    0.41 μM
    Compound: DOX
    Cytotoxicity against human MCF7 cells after 48 hrs by [3H]hypoxanthine incorporation assay
    Cytotoxicity against human MCF7 cells after 48 hrs by [3H]hypoxanthine incorporation assay
    		[PMID: 20362359]
    MCF7 IC50
    0.41 μM
    Compound: Doxorubicin
    Anticancer activity against human MCF7 cells incubated for 24 hrs by MTT assay
    Anticancer activity against human MCF7 cells incubated for 24 hrs by MTT assay
    		[PMID: 28579122]
    MCF7 IC50
    0.41 μM
    Compound: Doxorubicin
    Antiproliferative activity against human MCF-7 cells assessed as reduction in cell viability measured after 72 hrs by MTS assay
    Antiproliferative activity against human MCF-7 cells assessed as reduction in cell viability measured after 72 hrs by MTS assay
    		[PMID: 31962262]
    MCF7 IC50
    0.42 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells after 72 hrs by resazurin/AlamarBlue dye-based fluorescence assay
    Cytotoxicity against human MCF7 cells after 72 hrs by resazurin/AlamarBlue dye-based fluorescence assay
    		[PMID: 28139929]
    MCF7 IC50
    0.42 μM
    Compound: Doxorubicin
    Growth inhibition of human MCF7 cells after 72 hrs by MTT assay
    Growth inhibition of human MCF7 cells after 72 hrs by MTT assay
    		[PMID: 30471828]
    MCF7 IC50
    0.42 μM
    Compound: doxorubicin
    Cytotoxicity against human MCF7 cells after 72 hrs by Alamar blue assay
    Cytotoxicity against human MCF7 cells after 72 hrs by Alamar blue assay
    		[PMID: 22264149]
    MCF7 IC50
    0.42 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells
    Cytotoxicity against human MCF7 cells
    		[PMID: 20036537]
    MCF7 IC50
    0.43 μM
    Compound: DX
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by CCK-8 method
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by CCK-8 method
    		[PMID: 38039788]
    MCF7 IC50
    0.43 μM
    Compound: Doxorubicin
    Antiproliferative activity against human MCF7 cells incubated for 48 hrs by CCK-8 assay
    Antiproliferative activity against human MCF7 cells incubated for 48 hrs by CCK-8 assay
    		[PMID: 33725657]
    MCF7 IC50
    0.43 μM
    Compound: adriamycin
    Cytotoxicity against human MCF7 cells by MTT assay
    Cytotoxicity against human MCF7 cells by MTT assay
    		[PMID: 17125240]
    MCF7 IC50
    0.43 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells after 3 days by MTT assay
    Cytotoxicity against human MCF7 cells after 3 days by MTT assay
    		[PMID: 19691312]
    MCF7 IC50
    0.44 μM
    Compound: Doxorubicin
    Cytotoxicity against estrogen receptor-positive human MCF7 cells after 24 hrs by MTT assay
    Cytotoxicity against estrogen receptor-positive human MCF7 cells after 24 hrs by MTT assay
    		[PMID: 24513041]
    MCF7 IC50
    0.44 μM
    Compound: Doxorubicin
    Antiproliferative activity against human MCF7 cells after 72 hrs by sulforhodamine B assay
    Antiproliferative activity against human MCF7 cells after 72 hrs by sulforhodamine B assay
    		[PMID: 26496013]
    MCF7 IC50
    0.44 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    		[PMID: 38056297]
    MCF7 IC50
    0.45 μM
    Compound: Doxorubicin
    Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition measured after 72 to 96 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition measured after 72 to 96 hrs by MTT assay
    		[PMID: 36566714]
    MCF7 IC50
    0.45 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay
    Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay
    		[PMID: 20732814]
    MCF7 IC50
    0.46 μM
    Compound: doxorubicin
    Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
    Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
    		[PMID: 25314138]
    MCF7 IC50
    0.467 μM
    Compound: Doxorubicin
    Anticancer activity against human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs by MTT colorimetric assay
    Anticancer activity against human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs by MTT colorimetric assay
    		[PMID: 35694689]
    MCF7 IC50
    0.47 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    		[PMID: 37216812]
    MCF7 IC50
    0.48 μM
    Compound: DOX
    Antiproliferative activity against human MCF7 cells after 72 hrs by CCK-8 assay
    Antiproliferative activity against human MCF7 cells after 72 hrs by CCK-8 assay
    		[PMID: 29614418]
    MCF7 IC50
    0.49 μM
    Compound: ADR
    Cytotoxicity in human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    Cytotoxicity in human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    		[PMID: 28754470]
    MCF7 IC50
    0.49 μM
    Compound: Doxorubicin
    Cytotoxicity in human MCF7 cells incubated for 72 hrs by MTT assay
    Cytotoxicity in human MCF7 cells incubated for 72 hrs by MTT assay
    		[PMID: 30978023]
    MCF7 IC50
    0.4 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells by MTT assay
    Cytotoxicity against human MCF7 cells by MTT assay
    		[PMID: 16724859]
    MCF7 IC50
    0.4 μg/mL
    Compound: adriamycin
    Compound was evaluated for the growth inhibition of MCF-7 breast cell line.
    Compound was evaluated for the growth inhibition of MCF-7 breast cell line.
    		[PMID: 9873640]
    MCF7 IC50
    0.5 μM
    Compound: 21
    Antitumor activity against human MCF7 cells assessed as inhibition of cell proliferation
    Antitumor activity against human MCF7 cells assessed as inhibition of cell proliferation
    		[PMID: 36858050]
    MCF7 IC50
    0.5 μM
    Compound: ADR
    Cytotoxicity against human MCF7 cells by sulforhodamine B assay
    Cytotoxicity against human MCF7 cells by sulforhodamine B assay
    		[PMID: 17822905]
    MCF7 IC50
    0.5 μM
    Compound: ADR
    Cytotoxicity against human MCF7 cells by SRB assay
    Cytotoxicity against human MCF7 cells by SRB assay
    		[PMID: 18656370]
    MCF7 IC50
    0.5 μM
    Compound: Adriamycin
    Antiproliferative activity against human MCF7 cells after 48 hrs by sulforhodamine B assay
    Antiproliferative activity against human MCF7 cells after 48 hrs by sulforhodamine B assay
    		[PMID: 23501113]
    MCF7 IC50
    0.5 μM
    Compound: Adriamycin
    Cytotoxicity against human MCF7 cells after 48 hrs by sulforhodamine B assay
    Cytotoxicity against human MCF7 cells after 48 hrs by sulforhodamine B assay
    		[PMID: 24910974]
    MCF7 IC50
    0.5 μM
    Compound: Dox
    Cytotoxicity against human MCF7 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay
    Cytotoxicity against human MCF7 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay
    		[PMID: 30599418]
    MCF7 IC50
    0.5 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
    Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
    		[PMID: 19394829]
    MCF7 IC50
    0.5 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay
    Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay
    		[PMID: 21215623]
    MCF7 IC50
    0.5 μM
    Compound: Doxorubicin
    Antiproliferative activity against human MCF7 cells assessed as cell viability after 72 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells assessed as cell viability after 72 hrs by MTT assay
    		[PMID: 24012378]
    MCF7 IC50
    0.5 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay
    Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay
    		[PMID: 36044031]
    MCF7 IC50
    0.51 μM
    Compound: Doxorubicin
    Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay
    		[PMID: 34315044]
    MCF7 IC50
    0.53 μM
    Compound: ADR
    Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
    Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
    		[PMID: 19523827]
    MCF7 IC50
    0.54 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
    Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
    		[PMID: 22537362]
    MCF7 IC50
    0.54 μM
    Compound: doxorubicin
    Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
    Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
    		[PMID: 21087017]
    MCF7 IC50
    0.55 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
    Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
    		[PMID: 27116711]
    MCF7 IC50
    0.56 μM
    Compound: Doxorubicin
    Cytotoxicity in human MCF7 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    Cytotoxicity in human MCF7 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    		[PMID: 28923382]
    MCF7 IC50
    0.56 μg/mL
    Compound: doxorubicin
    Cytotoxicity against human MCF7 cells after 3 days by MTT assay
    Cytotoxicity against human MCF7 cells after 3 days by MTT assay
    		[PMID: 16252914]
    MCF7 IC50
    0.57 μg/mL
    Compound: doxorubicin
    Cytotoxicity against human MCF7 cells by resazurin microplate assay
    Cytotoxicity against human MCF7 cells by resazurin microplate assay
    		[PMID: 20329738]
    MCF7 IC50
    0.59 μM
    Compound: Doxorubucin
    Cytotoxicity against human MCF7 cells by MTT assay
    Cytotoxicity against human MCF7 cells by MTT assay
    		[PMID: 20718475]
    MCF7 IC50
    0.6 μM
    Compound: ADM
    Cytotoxicity against human MCF7 cells by SRB method
    Cytotoxicity against human MCF7 cells by SRB method
    		[PMID: 29144133]
    MCF7 IC50
    0.6 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells by MTT assay
    Cytotoxicity against human MCF7 cells by MTT assay
    		[PMID: 25172418]
    MCF7 IC50
    0.6 μM
    Compound: Doxorubicin
    Growth inhibition of human MCF7 cells after 72 hrs by MTT assay
    Growth inhibition of human MCF7 cells after 72 hrs by MTT assay
    		[PMID: 28189083]
    MCF7 IC50
    0.6 μM
    Compound: Doxorubicin
    Anticancer activity against human MCF7 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay
    Anticancer activity against human MCF7 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay
    		[PMID: 32438251]
    MCF7 IC50
    0.61 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells after 48 hrs by sulforhodamine B assay
    Cytotoxicity against human MCF7 cells after 48 hrs by sulforhodamine B assay
    		[PMID: 21071221]
    MCF7 IC50
    0.61 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells by MTT assay
    Cytotoxicity against human MCF7 cells by MTT assay
    		[PMID: 30719909]
    MCF7 IC50
    0.62 μM
    Compound: DOX
    Antiproliferative activity against human MCF7 cells after 3 days by MTT assay
    Antiproliferative activity against human MCF7 cells after 3 days by MTT assay
    		[PMID: 28291685]
    MCF7 IC50
    0.62 μM
    Compound: DOX
    Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay
    Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay
    		[PMID: 31820976]
    MCF7 IC50
    0.62 μM
    Compound: Dox
    Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
    		[PMID: 26494582]
    MCF7 IC50
    0.62 μM
    Compound: Dox
    Cytotoxicity against human MCF7 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    Cytotoxicity against human MCF7 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    		[PMID: 37001390]
    MCF7 IC50
    0.629 μM
    Compound: DOX
    Cytotoxicity against human MCF7 cells after 48 hrs by sulforhodamine B assay
    Cytotoxicity against human MCF7 cells after 48 hrs by sulforhodamine B assay
    		[PMID: 23123017]
    MCF7 IC50
    0.63 μM
    Compound: Doxorubicin
    Anticancer activity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Anticancer activity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    		[PMID: 26330077]
    MCF7 IC50
    0.63 μM
    Compound: Doxorubicin
    Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay
    		[PMID: 28886509]
    MCF7 IC50
    0.64 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells after 96 hrs by MTT assay
    Cytotoxicity against human MCF7 cells after 96 hrs by MTT assay
    		[PMID: 24852278]
    MCF7 IC50
    0.65 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells after 3 days by MTT assay
    Cytotoxicity against human MCF7 cells after 3 days by MTT assay
    		[PMID: 18547115]
    MCF7 IC50
    0.66 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells assessed as cell survival after 24 hrs by XTT assay
    Cytotoxicity against human MCF7 cells assessed as cell survival after 24 hrs by XTT assay
    		[PMID: 25059501]
    MCF7 IC50
    0.66 μM
    Compound: Doxorubicin
    Antiproliferative activity against human MCF7 cells incubated for 48 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells incubated for 48 hrs by MTT assay
    		[PMID: 32035399]
    MCF7 IC50
    0.67 μM
    Compound: Doxorubicin
    Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
    		[PMID: 28554092]
    MCF7 IC50
    0.68 μM
    Compound: Dox
    Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    		[PMID: 37956506]
    MCF7 IC50
    0.7 μM
    Compound: DOX
    Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
    		[PMID: 28756264]
    MCF7 IC50
    0.7 μM
    Compound: DOX
    Cytotoxicity in human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Cytotoxicity in human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    		[PMID: 30860373]
    MCF7 IC50
    0.7 μM
    Compound: Doxo
    Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
    Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
    		[PMID: 20334960]
    MCF7 IC50
    0.7 μM
    Compound: Doxorubicin
    Cytotoxicity against Homo sapiens (human) MCF7 cells after 48 hr by SRB assay
    Cytotoxicity against Homo sapiens (human) MCF7 cells after 48 hr by SRB assay
    		10.1007/s00044-012-0272-y
    MCF7 IC50
    0.7 μM
    Compound: Doxorubicin
    Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay
    		[PMID: 19632833]
    MCF7 IC50
    0.7 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells assessed as growth inhibition after 72 hrs by MTT assay
    Cytotoxicity against human MCF7 cells assessed as growth inhibition after 72 hrs by MTT assay
    		[PMID: 24044895]
    MCF7 IC50
    0.7 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells by MTT assay
    Cytotoxicity against human MCF7 cells by MTT assay
    		[PMID: 25241926]
    MCF7 IC50
    0.7 μM
    Compound: Doxorubicin
    Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
    		[PMID: 30679134]
    MCF7 IC50
    0.707 μM
    Compound: DOXO
    Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
    		[PMID: 29685681]
    MCF7 IC50
    0.72 μM
    Compound: DOX
    Antiproliferative activity against human MCF7 cells after 24 hrs by SRB assay
    Antiproliferative activity against human MCF7 cells after 24 hrs by SRB assay
    		[PMID: 30106296]
    MCF7 IC50
    0.72 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 29275232]
    MCF7 IC50
    0.72 μg/mL
    Compound: Dox
    Cytotoxicity against human MCF7 cells after 48 hrs by sulforhodamine B assay
    Cytotoxicity against human MCF7 cells after 48 hrs by sulforhodamine B assay
    		[PMID: 20399544]
    MCF7 IC50
    0.74 μM
    Compound: DOX
    Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay
    		[PMID: 37602711]
    MCF7 IC50
    0.74 μM
    Compound: doxorubicin
    Cytotoxicity against human MCF7 cells after 72 hrs by MTT colorimetric method
    Cytotoxicity against human MCF7 cells after 72 hrs by MTT colorimetric method
    		[PMID: 17622129]
    MCF7 IC50
    0.75 μM
    Compound: DOX
    Cytotoxicity against ER-positive human MCF7 cells assessed as growth inhibition after 48 hrs by MTT assay
    Cytotoxicity against ER-positive human MCF7 cells assessed as growth inhibition after 48 hrs by MTT assay
    		[PMID: 24148837]
    MCF7 IC50
    0.75 μM
    Compound: DOX
    Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
    		[PMID: 25619894]
    MCF7 IC50
    0.75 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells expressing estrogen receptor after 48 hrs by MTT assay
    Cytotoxicity against human MCF7 cells expressing estrogen receptor after 48 hrs by MTT assay
    		10.1039/C2MD20327H
    MCF7 IC50
    0.75 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
    Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
    		[PMID: 20846862]
    MCF7 IC50
    0.75 μM
    Compound: Doxorubicin
    Cytotoxicity against ER-positive human MCF7 cells after 1 hr by SRB assay
    Cytotoxicity against ER-positive human MCF7 cells after 1 hr by SRB assay
    		[PMID: 22770744]
    MCF7 IC50
    0.75 μM
    Compound: Doxorubicin
    Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
    		[PMID: 30108986]
    MCF7 IC50
    0.77 μM
    Compound: Doxo
    Cytotoxicity against human MCF7 cells after 3 days by MTT assay
    Cytotoxicity against human MCF7 cells after 3 days by MTT assay
    		[PMID: 21800859]
    MCF7 IC50
    0.7 μg/mL
    Compound: Dox
    Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay
    Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay
    		[PMID: 19540022]
    MCF7 IC50
    0.8 μM
    Compound: Dox
    Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability by MTT assay
    Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability by MTT assay
    		[PMID: 31765156]
    MCF7 IC50
    0.8 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells assessed as cell viability after 48 hrs by MTT assay
    Cytotoxicity against human MCF7 cells assessed as cell viability after 48 hrs by MTT assay
    		[PMID: 25655719]
    MCF7 IC50
    0.8 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells assessed as cell growth inhibition by MTT assay
    Cytotoxicity against human MCF7 cells assessed as cell growth inhibition by MTT assay
    		[PMID: 27187861]
    MCF7 IC50
    0.8 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    		[PMID: 29702447]
    MCF7 IC50
    0.81 μM
    Compound: Doxorubicin
    Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
    		[PMID: 27060757]
    MCF7 IC50
    0.812 μM
    Compound: DOX
    Growth inhibition of human MCF7 cells after 24 hrs by MTT assay
    Growth inhibition of human MCF7 cells after 24 hrs by MTT assay
    		[PMID: 28094220]
    MCF7 IC50
    0.82 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability by MTT assay
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability by MTT assay
    		[PMID: 31404864]
    MCF7 IC50
    0.83 μM
    Compound: Dox
    Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth after 48 hrs by MTT assay
    Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth after 48 hrs by MTT assay
    		[PMID: 27397495]
    MCF7 IC50
    0.83 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
    Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
    		[PMID: 26398312]
    MCF7 IC50
    0.85 μM
    Compound: DOXO
    Cytotoxicity against human MCF7 cells assessed as cell viability after 48 hrs by alamar blue assay
    Cytotoxicity against human MCF7 cells assessed as cell viability after 48 hrs by alamar blue assay
    		[PMID: 21797280]
    MCF7 IC50
    0.85 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells after 48 hrs by Alamar blue assay
    Cytotoxicity against human MCF7 cells after 48 hrs by Alamar blue assay
    		[PMID: 20931970]
    MCF7 IC50
    0.87 μg/mL
    Compound: Doxorubicine
    Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay
    Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay
    		[PMID: 24177357]
    MCF7 IC50
    0.89 μM
    Compound: Dox
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
    		[PMID: 33852973]
    MCF7 IC50
    0.89 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells assessed as inhibition of metabolic activity after 48 hrs by MTT assay
    Cytotoxicity against human MCF7 cells assessed as inhibition of metabolic activity after 48 hrs by MTT assay
    		[PMID: 27187858]
    MCF7 IC50
    0.899 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells by resazurin microplate assay
    Cytotoxicity against human MCF7 cells by resazurin microplate assay
    		[PMID: 19456117]
    MCF7 IC50
    0.8 μg/mL
    Compound: doxorubicin
    Cytotoxicity against human MCF7 cells by MTT assay
    Cytotoxicity against human MCF7 cells by MTT assay
    		[PMID: 22413887]
    MCF7 IC50
    0.9 μM
    Compound: DXR
    Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay
    Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay
    		[PMID: 34808062]
    MCF7 IC50
    0.9 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability by MTT assay
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability by MTT assay
    		[PMID: 26646219]
    MCF7 IC50
    0.9 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability by MTT assay
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability by MTT assay
    		[PMID: 26774921]
    MCF7 IC50
    0.9 μM
    Compound: Doxorubicin
    Antiproliferative activity against human MCF7 cells after 72 hrs by CellTiter-Glo luminescent cell viability assay
    Antiproliferative activity against human MCF7 cells after 72 hrs by CellTiter-Glo luminescent cell viability assay
    		[PMID: 28273560]
    MCF7 IC50
    0.9 μM
    Compound: Doxorubicin
    Antiproliferative activity against human MCF7 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay
    		[PMID: 31108261]
    MCF7 IC50
    0.9 μM
    Compound: doxorubicin
    Cytotoxicity against human MCF7 cells after 3 days by MTT assay
    Cytotoxicity against human MCF7 cells after 3 days by MTT assay
    		[PMID: 18419154]
    MCF7 IC50
    0.92 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay
    Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay
    		[PMID: 19795842]
    MCF7 IC50
    0.92 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells assessed as growth inhibition after 48 hrs by MTT assay
    Cytotoxicity against human MCF7 cells assessed as growth inhibition after 48 hrs by MTT assay
    		[PMID: 26381063]
    MCF7 IC50
    0.92 μM
    Compound: Doxorubicin
    Antiproliferative activity against human MCF7 cells assessed as reduction in cell growth incubated for 24 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells assessed as reduction in cell growth incubated for 24 hrs by MTT assay
    		[PMID: 33744686]
    MCF7 IC50
    0.924 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells assessed as growth inhibition after 48 hrs by MTT assay
    Cytotoxicity against human MCF7 cells assessed as growth inhibition after 48 hrs by MTT assay
    		[PMID: 26972921]
    MCF7 IC50
    0.93 μM
    Compound: Doxorubicin
    Antiproliferative activity against human MCF7 cells assessed as cell viability after 48 hrs MTT assay
    Antiproliferative activity against human MCF7 cells assessed as cell viability after 48 hrs MTT assay
    		[PMID: 33039723]
    MCF7 IC50
    0.94 μM
    Compound: doxorubicin
    Cytotoxicity against human MCF7 cells assessed as growth inhibition after 48 hrs by MTT assay
    Cytotoxicity against human MCF7 cells assessed as growth inhibition after 48 hrs by MTT assay
    		[PMID: 23806110]
    MCF7 IC50
    0.96 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
    Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
    		[PMID: 26264845]
    MCF7 IC50
    0.97 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by CCK-8 assay
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by CCK-8 assay
    		[PMID: 36693198]
    MCF7 IC50
    0.99 μM
    Compound: Doxorubicin
    Anticancer activity against human MCF7 cells after 48 hrs by MTT assay
    Anticancer activity against human MCF7 cells after 48 hrs by MTT assay
    		[PMID: 25615796]
    MCF7 IC50
    1 μM
    Compound: Doxorubicin
    Cytotoxicity against Homo sapiens (human) MCF7 cells by tetrazolium-reduction assay
    Cytotoxicity against Homo sapiens (human) MCF7 cells by tetrazolium-reduction assay
    		10.1007/s00044-012-0450-y
    MCF7 IC50
    1 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay
    Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay
    		10.1039/C3MD00013C
    MCF7 IC50
    1 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells by MTT assay
    Cytotoxicity against human MCF7 cells by MTT assay
    		[PMID: 21996519]
    MCF7 IC50
    1 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells by MTT assay
    Cytotoxicity against human MCF7 cells by MTT assay
    		[PMID: 23079527]
    MCF7 IC50
    1 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
    Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
    		[PMID: 27797185]
    MCF7 IC50
    1 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 29789258]
    MCF7 IC50
    1 μM
    Compound: Doxorubicin
    Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    		[PMID: 31546197]
    MCF7 IC50
    1 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    		[PMID: 33743356]
    MCF7 IC50
    1.02 μM
    Compound: DOX
    Cytotoxicity against human MCF7 cells assessed as cell viability after 48 hrs by MTT assay
    Cytotoxicity against human MCF7 cells assessed as cell viability after 48 hrs by MTT assay
    		[PMID: 27149641]
    MCF7 IC50
    1.02 μM
    Compound: Dox
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 28704759]
    MCF7 IC50
    1.03 μM
    Compound: doxorubicin
    Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
    Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
    		[PMID: 19819703]
    MCF7 IC50
    1.05 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells by MTT assay
    Cytotoxicity against human MCF7 cells by MTT assay
    		[PMID: 23764302]
    MCF7 IC50
    1.05 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells by MTT assay
    Cytotoxicity against human MCF7 cells by MTT assay
    		[PMID: 23911578]
    MCF7 IC50
    1.05 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells by MTT assay
    Cytotoxicity against human MCF7 cells by MTT assay
    		[PMID: 24113366]
    MCF7 IC50
    1.05 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells by MTT assay
    Cytotoxicity against human MCF7 cells by MTT assay
    		[PMID: 25172420]
    MCF7 IC50
    1.05 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells by resazurin microplate assay
    Cytotoxicity against human MCF7 cells by resazurin microplate assay
    		[PMID: 32193929]
    MCF7 IC50
    1.054 μM
    Compound: Doxorubicin
    Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
    		[PMID: 26301558]
    MCF7 IC50
    1.07 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells by MTT assay
    Cytotoxicity against human MCF7 cells by MTT assay
    		[PMID: 24287557]
    MCF7 IC50
    1.07 μM
    Compound: Doxorubicin
    In vitro cytotoxicity against human MCF7 cells assessed as growth inhibition by MTT assay
    In vitro cytotoxicity against human MCF7 cells assessed as growth inhibition by MTT assay
    		[PMID: 24742385]
    MCF7 IC50
    1.08 μM
    Compound: Dox
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 30615450]
    MCF7 IC50
    1.08 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells assessed as growth inhibition after 48 hrs by MTT assay
    Cytotoxicity against human MCF7 cells assessed as growth inhibition after 48 hrs by MTT assay
    		[PMID: 26433616]
    MCF7 IC50
    1.08 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    		[PMID: 31404864]
    MCF7 IC50
    1.08 μM
    Compound: Doxorubicin
    Growth inhibition of human MCF7 cells by MTT assay
    Growth inhibition of human MCF7 cells by MTT assay
    		[PMID: 33901643]
    MCF7 IC50
    1.08 μM
    Compound: Doxorubicin
    Antitumor activity against human MCF7 cells incubated for 48 hrs by CCK8 assay
    Antitumor activity against human MCF7 cells incubated for 48 hrs by CCK8 assay
    		[PMID: 37229830]
    MCF7 IC50
    1.096 μM
    Compound: DOX
    Antiproliferative activity against human MCF7 cells transfected with AKR1C3 assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells transfected with AKR1C3 assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    		[PMID: 37409679]
    MCF7 IC50
    1.09 μg/mL
    Compound: Doxorubicin
    Anticancer activity against human cells MCF7 cells assessed as growth inhibition after 48 hrs by MTT assay
    Anticancer activity against human cells MCF7 cells assessed as growth inhibition after 48 hrs by MTT assay
    		[PMID: 25042338]
    MCF7 IC50
    1.1 μM
    Compound: DX
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
    		[PMID: 32422522]
    MCF7 IC50
    1.1 μM
    Compound: Doxorubicin
    Cytotoxicity against human tamoxifen-resistant MCF7 cells by WST-1 assay
    Cytotoxicity against human tamoxifen-resistant MCF7 cells by WST-1 assay
    		[PMID: 22197145]
    MCF7 IC50
    1.1 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells assessed as cell growth inhibition
    Cytotoxicity against human MCF7 cells assessed as cell growth inhibition
    		[PMID: 36092140]
    MCF7 IC50
    1.1 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    		[PMID: 38452407]
    MCF7 IC50
    1.117 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    		[PMID: 28482219]
    MCF7 IC50
    1.12 μM
    Compound: Dox
    Antiproliferative activity against human MCF7 cells after 24 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells after 24 hrs by MTT assay
    		[PMID: 26494582]
    MCF7 IC50
    1.13 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells assessed as cell viability after 48 hrs by MTT assay
    Cytotoxicity against human MCF7 cells assessed as cell viability after 48 hrs by MTT assay
    		[PMID: 27015609]
    MCF7 IC50
    1.13 μM
    Compound: Doxorubicin
    Anticancer activity against human MCF7 cells assessed as inhibition of cell growth incubated for 3 days by MTT assay
    Anticancer activity against human MCF7 cells assessed as inhibition of cell growth incubated for 3 days by MTT assay
    		[PMID: 35007724]
    MCF7 IC50
    1.17 μM
    Compound: Doxorubicin
    Antiproliferative activity against human MCF7 cells after 72 hrs by SRB assay
    Antiproliferative activity against human MCF7 cells after 72 hrs by SRB assay
    		[PMID: 25462265]
    MCF7 IC50
    1.17 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells assessed as reduction in cell growth after 72 hrs by cell titer glo assay
    Cytotoxicity against human MCF7 cells assessed as reduction in cell growth after 72 hrs by cell titer glo assay
    		[PMID: 27080175]
    MCF7 IC50
    1.17 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells assessed as cell growth inhibition and measured after 72 hrs by SRB assay
    Cytotoxicity against human MCF7 cells assessed as cell growth inhibition and measured after 72 hrs by SRB assay
    		[PMID: 34000484]
    MCF7 IC50
    1.172 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells after 72 hrs by SRB assay
    Cytotoxicity against human MCF7 cells after 72 hrs by SRB assay
    		10.1039/C5MD00127G
    MCF7 IC50
    1.172 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells after 72 hrs by SRB assay
    Cytotoxicity against human MCF7 cells after 72 hrs by SRB assay
    		[PMID: 24231309]
    MCF7 IC50
    1.172 μM
    Compound: Doxorubicin
    Anticancer against human MCF7 cells assessed as tumor growth inhibition after 72 hrs by SRB assay
    Anticancer against human MCF7 cells assessed as tumor growth inhibition after 72 hrs by SRB assay
    		[PMID: 26256032]
    MCF7 IC50
    1.18 μM
    Compound: Doxorubicin
    Antiproliferative activity against human cells MCF-7 assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Antiproliferative activity against human cells MCF-7 assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    		[PMID: 33477020]
    MCF7 IC50
    1.2 nM
    Compound: Doxorubicin
    Cytotoxicity against human breast carcinoma cell lines MCF-7
    Cytotoxicity against human breast carcinoma cell lines MCF-7
    		[PMID: 12392727]
    MCF7 IC50
    1.2 μM
    Compound: Dox
    Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
    Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
    		[PMID: 24028446]
    MCF7 IC50
    1.2 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells by MTT assay
    Cytotoxicity against human MCF7 cells by MTT assay
    		[PMID: 21425785]
    MCF7 IC50
    1.21 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells after 3 days by MTT assay
    Cytotoxicity against human MCF7 cells after 3 days by MTT assay
    		[PMID: 15387653]
    MCF7 IC50
    1.227 μM
    Compound: DOX
    Cytotoxicity against human MCF7 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay
    Cytotoxicity against human MCF7 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay
    		[PMID: 34700239]
    MCF7 IC50
    1.28 μM
    Compound: Dox
    Anticancer activity against Homo sapiens (human) MCF7 cells assessed as growth inhibition after 48 hr by SRB assay
    Anticancer activity against Homo sapiens (human) MCF7 cells assessed as growth inhibition after 48 hr by SRB assay
    		10.1007/s00044-012-0057-3
    MCF7 IC50
    1.29 μM
    Compound: Doxorubicin
    Cytotoxicity activity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity activity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 32627543]
    MCF7 IC50
    1.32 μM
    Compound: Doxorubicin
    Anticancer activity against human MCF7 cells after 72 hrs by sulforhodamine B assay
    Anticancer activity against human MCF7 cells after 72 hrs by sulforhodamine B assay
    		[PMID: 30081238]
    MCF7 IC50
    1.33 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
    Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
    		[PMID: 26948541]
    MCF7 IC50
    1.35 μM
    Compound: ADM
    Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
    Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
    		[PMID: 25874331]
    MCF7 IC50
    1.35 μM
    Compound: ADM
    Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
    Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
    		[PMID: 26280921]
    MCF7 IC50
    1.37 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay
    Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay
    		[PMID: 22687747]
    MCF7 IC50
    1.4 μM
    Compound: DOX
    Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay
    		[PMID: 30429098]
    MCF7 IC50
    1.4 μM
    Compound: DOX
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability by MTT assay
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability by MTT assay
    		[PMID: 34323485]
    MCF7 IC50
    1.4 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    		[PMID: 28277681]
    MCF7 IC50
    1.4 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells incubated for 48 hrs by MTT assay
    Cytotoxicity against human MCF7 cells incubated for 48 hrs by MTT assay
    		[PMID: 33421712]
    MCF7 IC50
    1.43 μM
    Compound: DOX
    Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay
    Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay
    		[PMID: 32435420]
    MCF7 IC50
    1.48 μM
    Compound: DOX
    Anticancer activity against human MCF7 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay
    Anticancer activity against human MCF7 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay
    		[PMID: 38784465]
    MCF7 IC50
    1.5 μM
    Compound: DOX
    Inhibition of topoisomerase 2 in human MCF7 cells assessed as reduction in cell growth measured after 72 hrs by MTT assay
    Inhibition of topoisomerase 2 in human MCF7 cells assessed as reduction in cell growth measured after 72 hrs by MTT assay
    		[PMID: 30846253]
    MCF7 IC50
    1.5 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells by resazurin microplate assay
    Cytotoxicity against human MCF7 cells by resazurin microplate assay
    		[PMID: 19739600]
    MCF7 IC50
    1.51 μM
    Compound: Doxo
    Cytotoxicity against estrogen receptor-positive human MCF7 cells after 48 hrs by MTT assay
    Cytotoxicity against estrogen receptor-positive human MCF7 cells after 48 hrs by MTT assay
    		[PMID: 21885273]
    MCF7 IC50
    1.51 μM
    Compound: Doxorubicin
    Cytotoxicity activity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Cytotoxicity activity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    		[PMID: 32531682]
    MCF7 IC50
    1.52 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability
    		[PMID: 32005414]
    MCF7 IC50
    1.54 μM
    Compound: doxorubicin
    Cytotoxicity against human MCF7 cells after 72 hrs by CellTiter-Glo assay
    Cytotoxicity against human MCF7 cells after 72 hrs by CellTiter-Glo assay
    		[PMID: 22316168]
    MCF7 IC50
    1.6 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells assessed as cell growth inhibition after 72 hrs by alamar blue assay
    Cytotoxicity against human MCF7 cells assessed as cell growth inhibition after 72 hrs by alamar blue assay
    		[PMID: 31403289]
    MCF7 IC50
    1.6 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells
    Cytotoxicity against human MCF7 cells
    		[PMID: 33421712]
    MCF7 IC50
    1.65 μM
    Compound: Adriamycin
    Cytotoxicity against human MCF7 cells by MTT assay
    Cytotoxicity against human MCF7 cells by MTT assay
    		[PMID: 23434227]
    MCF7 IC50
    1.659 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    		[PMID: 28462842]
    MCF7 IC50
    1.69 μM
    Compound: Adriamycin
    Cytotoxicity against human MCF7 cells by MTT assay
    Cytotoxicity against human MCF7 cells by MTT assay
    		[PMID: 21115246]
    MCF7 IC50
    1.7 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells by WST-1 assay
    Cytotoxicity against human MCF7 cells by WST-1 assay
    		[PMID: 22197145]
    MCF7 IC50
    1.7 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    		[PMID: 32975117]
    MCF7 IC50
    1.738 μM
    Compound: Doxorubicin
    Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
    		[PMID: 29501940]
    MCF7 IC50
    1.74 μM
    Compound: Doxorubicin
    Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay
    		[PMID: 30500683]
    MCF7 IC50
    1.77 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay
    		[PMID: 33352388]
    MCF7 IC50
    1.819 μM
    Compound: Doxorubicin
    Anti-proliferative activity against human MCF7 cells measured after 48 hrs by MTT assay
    Anti-proliferative activity against human MCF7 cells measured after 48 hrs by MTT assay
    		[PMID: 27744185]
    MCF7 IC50
    1.83 μM
    Compound: DOX
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs
    		[PMID: 32736079]
    MCF7 IC50
    1.88 μM
    Compound: Doxorubicin
    Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth after 48 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth after 48 hrs by MTT assay
    		[PMID: 33784602]
    MCF7 IC50
    1.9 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
    		[PMID: 33668008]
    MCF7 IC50
    1.9 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells assessed as cell growth inhibition incubated for 24 to 72 hrs by MTT assay
    Cytotoxicity against human MCF7 cells assessed as cell growth inhibition incubated for 24 to 72 hrs by MTT assay
    		[PMID: 37989057]
    MCF7 IC50
    1.93 μM
    Compound: Doxorubicin
    Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    		[PMID: 34791873]
    MCF7 IC50
    1.94 μM
    Compound: Doxo
    Cytotoxicity against human MCF7 cells assessed as inhibition of cell proliferation after 24 hrs by MTT assay
    Cytotoxicity against human MCF7 cells assessed as inhibition of cell proliferation after 24 hrs by MTT assay
    		[PMID: 27036521]
    MCF7 IC50
    1.98 μM
    Compound: Doxorubicin
    Antiproliferative activity against human MCF7 cells
    Antiproliferative activity against human MCF7 cells
    		[PMID: 34655985]
    MCF7 IC50
    10.6 μM
    Compound: Doxorubicin
    Antiproliferative activity against human MCF7 cells after 48 hrs by sulforhodamine B assay
    Antiproliferative activity against human MCF7 cells after 48 hrs by sulforhodamine B assay
    		[PMID: 29133058]
    MCF7 IC50
    10.9 μM
    Compound: DOX
    Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
    Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
    		[PMID: 24487188]
    MCF7 IC50
    10.9 μM
    Compound: Dox
    Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay
    Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay
    		10.1007/s00044-013-0584-6
    MCF7 IC50
    10.9 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells assessed as inhibition of cell viability after 48 hrs by MTT assay
    Cytotoxicity against human MCF7 cells assessed as inhibition of cell viability after 48 hrs by MTT assay
    		[PMID: 24953027]
    MCF7 IC50
    107.11 μM
    Compound: Doxorubicin
    Antiproliferative activity against drug-resistant human MCF7 cells incubated for 48 hrs by MTT assay
    Antiproliferative activity against drug-resistant human MCF7 cells incubated for 48 hrs by MTT assay
    		[PMID: 32035399]
    MCF7 IC50
    11.1 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay
    Cytotoxicity against human MCF7 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay
    		[PMID: 35526504]
    MCF7 IC50
    11.52 μM
    Compound: doxorubicin
    Antiproliferative activity against human MCF7 cells assessed as reduction in cell growth incubated at 37 degC for 3 days by resazurin microplate assay
    Antiproliferative activity against human MCF7 cells assessed as reduction in cell growth incubated at 37 degC for 3 days by resazurin microplate assay
    		[PMID: 25734623]
    MCF7 IC50
    11.6 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    		[PMID: 37484570]
    MCF7 IC50
    11.67 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells
    Cytotoxicity against human MCF7 cells
    		[PMID: 22123320]
    MCF7 IC50
    1172 nM
    Compound: Doxorubicin
    Tested against MXF7 breast carcinoma (doxorubicin resistant) cell line in the sulforhodamine B assay.
    Tested against MXF7 breast carcinoma (doxorubicin resistant) cell line in the sulforhodamine B assay.
    		[PMID: 8648600]
    MCF7 IC50
    1172 nM
    Compound: dixorubicin
    Antitumor activity against human mammary carcinoma doxorubicin-resistant MXF7 breast cell line.
    Antitumor activity against human mammary carcinoma doxorubicin-resistant MXF7 breast cell line.
    		[PMID: 8960558]
    MCF7 IC50
    1172 nM
    Compound: doxorubicin
    Tested for inhibitory activity against human tumor cell line D40, a strain resistant to doxorubicin of breast carcinoma using sulforhodamine B assay.
    Tested for inhibitory activity against human tumor cell line D40, a strain resistant to doxorubicin of breast carcinoma using sulforhodamine B assay.
    		[PMID: 10956214]
    MCF7 IC50
    12 nM
    Compound: doxorubicin
    Cytotoxicity against human MCF7 cells after 72 hrs by MTS assay
    Cytotoxicity against human MCF7 cells after 72 hrs by MTS assay
    		[PMID: 19655762]
    MCF7 IC50
    12.34 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells assessed as cell viability by SRB assay
    Cytotoxicity against human MCF7 cells assessed as cell viability by SRB assay
    		[PMID: 26022842]
    MCF7 IC50
    12.8 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells measured after 24 to 72 hrs by MTT assay
    Cytotoxicity against human MCF7 cells measured after 24 to 72 hrs by MTT assay
    		[PMID: 37482018]
    MCF7 IC50
    1210.1 nM
    Compound: Doxorubicin
    Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability
    Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability
    		[PMID: 31655432]
    MCF7 IC50
    13.4 μg/mL
    Compound: Adriamycin
    Antiproliferative activity against PLCgamma1 expressing human MCF7 cells
    Antiproliferative activity against PLCgamma1 expressing human MCF7 cells
    		[PMID: 10869194]
    MCF7 IC50
    13.51 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells after 2 days by MTT assay
    Cytotoxicity against human MCF7 cells after 2 days by MTT assay
    		[PMID: 23932340]
    MCF7 IC50
    13.97 μM
    Compound: doxo
    Antiproliferative activity against human MCF7 cells assessed as decrease in cell viability measured after 72 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells assessed as decrease in cell viability measured after 72 hrs by MTT assay
    		[PMID: 30763817]
    MCF7 IC50
    130 μM
    Compound: Dox
    Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
    		[PMID: 35339100]
    MCF7 IC50
    131.5 nM
    Compound: DX
    Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth measured after 72 hrs by SRB assay
    Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth measured after 72 hrs by SRB assay
    		[PMID: 33611191]
    MCF7 IC50
    135000 nM
    Compound: ADR
    Antiproliferative activity measured against MCF-7-mdr cells.
    Antiproliferative activity measured against MCF-7-mdr cells.
    		[PMID: 9876111]
    MCF7 IC50
    139 nM
    Compound: Dox
    Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth measured after 72 hrs by Celltiter-glo proliferation assay
    Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth measured after 72 hrs by Celltiter-glo proliferation assay
    		[PMID: 36001933]
    MCF7 IC50
    14 μM
    Compound: DOX
    Antineoplastic activity against human MCF7 cells measured after 36 hrs by MTT assay
    Antineoplastic activity against human MCF7 cells measured after 36 hrs by MTT assay
    		[PMID: 30746067]
    MCF7 IC50
    14.1 μg/mL
    Compound: DOX
    Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay
    Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay
    		[PMID: 24090920]
    MCF7 IC50
    146 nM
    Compound: DX
    Antiproliferative activity against human MCF7 cells assessed as inhibition of cell proliferation incubated for 72 hrs by SRB assay
    Antiproliferative activity against human MCF7 cells assessed as inhibition of cell proliferation incubated for 72 hrs by SRB assay
    		[PMID: 34592435]
    MCF7 IC50
    15 μM
    Compound: DOX
    Antiproliferative activity against doxorubicin-resistant human MCF7 cells after 48 hrs by SRB method
    Antiproliferative activity against doxorubicin-resistant human MCF7 cells after 48 hrs by SRB method
    		[PMID: 25061803]
    MCF7 IC50
    15.12 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells assessed as decrease in cell viability after 48 hrs by MTT assay
    Cytotoxicity against human MCF7 cells assessed as decrease in cell viability after 48 hrs by MTT assay
    		[PMID: 28262524]
    MCF7 IC50
    15.2 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability by resazurin based fluorescence assay
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability by resazurin based fluorescence assay
    		[PMID: 33852304]
    MCF7 IC50
    15.69 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability by resazurin microplate assay
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability by resazurin microplate assay
    		[PMID: 27311894]
    MCF7 IC50
    15.88 μM
    Compound: doxorubicin
    Cytotoxicity against human MCF7 cells by colorimetric method
    Cytotoxicity against human MCF7 cells by colorimetric method
    		[PMID: 23795891]
    MCF7 IC50
    16 μM
    Compound: Doxorubicin
    Anticancer activity against human MCF7 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
    Anticancer activity against human MCF7 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
    		[PMID: 34838335]
    MCF7 IC50
    16.8 μM
    Compound: Dox
    Cytotoxicity against human MCF7 cells after 24 hrs by MTS assay
    Cytotoxicity against human MCF7 cells after 24 hrs by MTS assay
    		[PMID: 21094049]
    MCF7 IC50
    16.8 μM
    Compound: doxorubicin
    Cytotoxicity against human MCF7 cells by resazurin reduction assay
    Cytotoxicity against human MCF7 cells by resazurin reduction assay
    		[PMID: 22482432]
    MCF7 IC50
    16.9 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 24 hrs by MTT assay
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 24 hrs by MTT assay
    		[PMID: 24681979]
    MCF7 IC50
    17 μM
    Compound: Doxorubicin
    Inhibition of serum-induced proliferation of human adriamycin-resistant MCF7 cells
    Inhibition of serum-induced proliferation of human adriamycin-resistant MCF7 cells
    		[PMID: 17601739]
    MCF7 IC50
    17.67 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
    Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
    		[PMID: 22647723]
    MCF7 IC50
    17.9 nM
    Compound: Doxorubicin
    Antiproliferative activity against human MCF7 cells after 96 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells after 96 hrs by MTT assay
    		[PMID: 21296467]
    MCF7 IC50
    17.9 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells after 3 days by resazurin microplate assay
    Cytotoxicity against human MCF7 cells after 3 days by resazurin microplate assay
    		[PMID: 22280818]
    MCF7 IC50
    18.5 μM
    Compound: 21
    Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
    Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
    		[PMID: 29289880]
    MCF7 IC50
    18.6 mM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    		[PMID: 32631569]
    MCF7 IC50
    18 μg/mL
    Compound: DOX
    Anticancer activity against Homo sapiens (human) MCF-7 cells assessed as inhibition of cell survival after 24 hr by MTT assay
    Anticancer activity against Homo sapiens (human) MCF-7 cells assessed as inhibition of cell survival after 24 hr by MTT assay
    		10.1007/s00044-012-0071-5
    MCF7 IC50
    19 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells after 96 hrs by MTT assay
    Cytotoxicity against human MCF7 cells after 96 hrs by MTT assay
    		10.1007/s00044-013-0586-4
    MCF7 IC50
    2 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay
    Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay
    		[PMID: 30654238]
    MCF7 IC50
    2.02 μM
    Compound: Doxorubicin
    Anticancer activity against human MCF7 cells after 48 hrs by MTT assay
    Anticancer activity against human MCF7 cells after 48 hrs by MTT assay
    		[PMID: 22136907]
    MCF7 IC50
    2.02 μM
    Compound: Doxorubicin
    Anticancer activity against human MCF-7 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
    Anticancer activity against human MCF-7 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
    		[PMID: 34124677]
    MCF7 IC50
    2.08 μM
    Compound: Doxorubicin
    Growth inhibition of human MCF7 cells by MTT assay
    Growth inhibition of human MCF7 cells by MTT assay
    		[PMID: 28462836]
    MCF7 IC50
    2.09 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells assessed as inhibition in cell growth incubated for 72 hrs by MTT assay
    Cytotoxicity against human MCF7 cells assessed as inhibition in cell growth incubated for 72 hrs by MTT assay
    		[PMID: 37567059]
    MCF7 IC50
    2.1 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    		[PMID: 33823396]
    MCF7 IC50
    2.1 μM
    Compound: Doxorubicin
    Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition by MTT assay
    Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition by MTT assay
    		[PMID: 34838335]
    MCF7 IC50
    2.18 μM
    Compound: Doxo
    Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
    		[PMID: 29129513]
    MCF7 IC50
    2.18 μM
    Compound: doxorubicin
    Cytotoxicity against human MCF7 cells
    Cytotoxicity against human MCF7 cells
    		[PMID: 20815366]
    MCF7 IC50
    2.24 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells assessed as cell viability after 48 hrs by MTT assay
    Cytotoxicity against human MCF7 cells assessed as cell viability after 48 hrs by MTT assay
    		[PMID: 25594739]
    MCF7 IC50
    2.29 μM
    Compound: doxorubicin
    Cytotoxicity against human MCF7 cells by SRB assay
    Cytotoxicity against human MCF7 cells by SRB assay
    		[PMID: 22004007]
    MCF7 IC50
    2.2 μg/mL
    Compound: doxorubicin
    Cytotoxicity against human MCF7 cells by SRB assay
    Cytotoxicity against human MCF7 cells by SRB assay
    		[PMID: 19778068]
    MCF7 IC50
    2.3 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells by resazurin microplate assay
    Cytotoxicity against human MCF7 cells by resazurin microplate assay
    		[PMID: 21090800]
    MCF7 IC50
    2.3 μM
    Compound: Doxorubicin
    Growth inhibition of human MCF7 cells by MTT assay
    Growth inhibition of human MCF7 cells by MTT assay
    		[PMID: 28916158]
    MCF7 IC50
    2.31 μM
    Compound: DOX
    Cytotoxicity against human MCF7 cells after 48 hrs by SRB method
    Cytotoxicity against human MCF7 cells after 48 hrs by SRB method
    		[PMID: 25933593]
    MCF7 IC50
    2.36 μM
    Compound: Dox
    Antiproliferative activity against human MCF7 cells measured after 48 hrs under normoxia condition by MTT assay
    Antiproliferative activity against human MCF7 cells measured after 48 hrs under normoxia condition by MTT assay
    		[PMID: 31276899]
    MCF7 IC50
    2.37 μM
    Compound: Dox
    Antiproliferative activity against human MCF7 cells by MTT assay
    Antiproliferative activity against human MCF7 cells by MTT assay
    		[PMID: 28802125]
    MCF7 IC50
    2.4 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
    Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
    		[PMID: 20832916]
    MCF7 IC50
    2.44 μM
    Compound: Doxorubicin
    Antiproliferative activity against human MCF7 cells
    Antiproliferative activity against human MCF7 cells
    		[PMID: 34655985]
    MCF7 IC50
    2.44 μM
    Compound: doxorubicin
    Cytotoxicity against human MCF7 cells after 96 hrs by MTT assay
    Cytotoxicity against human MCF7 cells after 96 hrs by MTT assay
    		10.1007/s00044-013-0795-x
    MCF7 IC50
    2.46 μM
    Compound: DOX
    Antiproliferative activity against human MCF7 cells assessed as inhibition of cell proliferation incubated for 48 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells assessed as inhibition of cell proliferation incubated for 48 hrs by MTT assay
    		[PMID: 38215590]
    MCF7 IC50
    2.5 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells after 48 hrs by alamar blue assay
    Cytotoxicity against human MCF7 cells after 48 hrs by alamar blue assay
    		[PMID: 22272829]
    MCF7 IC50
    2.57 μM
    Compound: Dox
    Cytotoxicity against human MCF7 cells assessed as cell viability after 24 hrs by crystal violet staining assay
    Cytotoxicity against human MCF7 cells assessed as cell viability after 24 hrs by crystal violet staining assay
    		[PMID: 26706352]
    MCF7 IC50
    2.57 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells after 48 hrs
    Cytotoxicity against human MCF7 cells after 48 hrs
    		[PMID: 20873721]
    MCF7 IC50
    2.58 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells incubated for 72 hrs by Sulphorhodamine assay
    Cytotoxicity against human MCF7 cells incubated for 72 hrs by Sulphorhodamine assay
    		[PMID: 37146520]
    MCF7 IC50
    2.6 μM
    Compound: Doxorubicin
    Antiproliferative activity against human MCF7 cells after 48 hrs by SRB assay
    Antiproliferative activity against human MCF7 cells after 48 hrs by SRB assay
    		[PMID: 30503942]
    MCF7 IC50
    2.62 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 after 24 hrs by MTT assay
    Cytotoxicity against human MCF7 after 24 hrs by MTT assay
    		[PMID: 20056520]
    MCF7 IC50
    2.63 μM
    Compound: Doxorubicin
    Anticancer activity against human MCF7 cells by MTT assay
    Anticancer activity against human MCF7 cells by MTT assay
    		[PMID: 25743216]
    MCF7 IC50
    2.67 μM
    Compound: Dox
    Cytotoxicity against Homo sapiens (human) MCF7 cells assessed as reduction of cell survival after 48 hr by MTT assay
    Cytotoxicity against Homo sapiens (human) MCF7 cells assessed as reduction of cell survival after 48 hr by MTT assay
    		10.1007/s00044-012-0150-7
    MCF7 IC50
    2.71 μM
    Compound: DOX
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 28531811]
    MCF7 IC50
    2.7 x 10-2 μg/mL
    Compound: adriamycin
    Cytotoxicity against human MCF7 cells
    Cytotoxicity against human MCF7 cells
    		[PMID: 8991944]
    MCF7 IC50
    2.78 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
    Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
    		[PMID: 25462233]
    MCF7 IC50
    2.78 μM
    Compound: Doxorubicin
    Antiproliferative activity against human MCF7 cells assessed as cell viability after 24 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells assessed as cell viability after 24 hrs by MTT assay
    		[PMID: 26874744]
    MCF7 IC50
    2.8 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells by MTT assay
    Cytotoxicity against human MCF7 cells by MTT assay
    		[PMID: 19583252]
    MCF7 IC50
    2.82 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay
    Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay
    		[PMID: 22542958]
    MCF7 IC50
    2.8 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay
    Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay
    		[PMID: 24095746]
    MCF7 IC50
    2.9 μM
    Compound: Dox
    Cytotoxicity against human MCF7 cells assessed as growth inhibition after 72 hrs by SRB assay
    Cytotoxicity against human MCF7 cells assessed as growth inhibition after 72 hrs by SRB assay
    		[PMID: 22000946]
    MCF7 IC50
    2.9 μM
    Compound: Doxorubicin
    Anticancer activity against Homo sapiens (human) MCF-7 cells assessed as inhibition of cell viability after 72 hr by SRB assay
    Anticancer activity against Homo sapiens (human) MCF-7 cells assessed as inhibition of cell viability after 72 hr by SRB assay
    		10.1007/s00044-012-0098-7
    MCF7 IC50
    2.9 μM
    Compound: Doxorubicin
    Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition incubated for 4 hrs under normoxia condition by MTT colorimetric assay
    Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition incubated for 4 hrs under normoxia condition by MTT colorimetric assay
    		[PMID: 35551035]
    MCF7 IC50
    2.96 μM
    Compound: Doxorubicin
    Antiproliferative activity against human MCF7 cells after 24 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells after 24 hrs by MTT assay
    		10.1039/C5MD00581G
    MCF7 IC50
    2.97 μM
    Compound: Doxorubicin
    Antiproliferative activity against Homo sapiens (human) MCF7 cells after 72 hr by SRB assay
    Antiproliferative activity against Homo sapiens (human) MCF7 cells after 72 hr by SRB assay
    		10.1007/s00044-011-9874-z
    MCF7 IC50
    2.97 μg/mL
    Compound: DOX
    Cytotoxicity against Homo sapiens (human) MCF7 cells after 48 hr by SRB assay
    Cytotoxicity against Homo sapiens (human) MCF7 cells after 48 hr by SRB assay
    		10.1007/s00044-011-9636-y
    MCF7 IC50
    2.97 μg/mL
    Compound: DOX
    Cytotoxicity against human MCF7 cells after 72 hrs by sulforhodamine B assay
    Cytotoxicity against human MCF7 cells after 72 hrs by sulforhodamine B assay
    		[PMID: 22370339]
    MCF7 IC50
    2.97 μg/mL
    Compound: Doxorubicin
    Antitumor activity against human MCF7 cells
    Antitumor activity against human MCF7 cells
    		[PMID: 20739102]
    MCF7 IC50
    2.97 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells assessed as inhibition of cell viability after 48 hrs by Sulforhodamine B assay
    Cytotoxicity against human MCF7 cells assessed as inhibition of cell viability after 48 hrs by Sulforhodamine B assay
    		[PMID: 21429629]
    MCF7 IC50
    2.97 μg/mL
    Compound: Doxorubicin
    Anticancer activity against human MCF7 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay
    Anticancer activity against human MCF7 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay
    		[PMID: 38669910]
    MCF7 IC50
    2.97 μg/mL
    Compound: Doxorubicin
    Anticancer activity against human MCF7 cells assessed as inhibition of cell growth incubated for 48 hrs by SRB assay
    Anticancer activity against human MCF7 cells assessed as inhibition of cell growth incubated for 48 hrs by SRB assay
    		[PMID: 38669910]
    MCF7 IC50
    2.99 μM
    Compound: Dox
    Cytotoxicity against human MCF-7 assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Cytotoxicity against human MCF-7 assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    		[PMID: 33065435]
    MCF7 IC50
    20.2 μM
    Compound: 12
    Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
    		[PMID: 29852328]
    MCF7 IC50
    200 nM
    Compound: 1, DOX
    Growth inhibition of MCF7 cells expressing ER and antiestrogen binding sites
    Growth inhibition of MCF7 cells expressing ER and antiestrogen binding sites
    		[PMID: 15588086]
    MCF7 IC50
    200 nM
    Compound: DOX
    Inhibition of estrogen receptor positive MCF-7 breast cancer cell proliferation
    Inhibition of estrogen receptor positive MCF-7 breast cancer cell proliferation
    		[PMID: 14971899]
    MCF7 IC50
    22 nM
    Compound: Doxorubicin
    Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
    		[PMID: 25937236]
    MCF7 IC50
    22.6 μM
    Compound: Doxorubicin
    Antiproliferative activity against human MCF7 cells assessed as cell viability incubated for 48 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells assessed as cell viability incubated for 48 hrs by MTT assay
    		[PMID: 32771798]
    MCF7 IC50
    23.4 nM
    Compound: Dox
    Anticancer activity against human MCF7 cells assessed as reduction in cell viability by MTT assay
    Anticancer activity against human MCF7 cells assessed as reduction in cell viability by MTT assay
    		[PMID: 31740054]
    MCF7 IC50
    240 nM
    Compound: DX
    Antiproliferative activity against human MCF-7 cells assessed as inhibition of proliferation after 72 hrs by SRB assay
    Antiproliferative activity against human MCF-7 cells assessed as inhibition of proliferation after 72 hrs by SRB assay
    		[PMID: 34116158]
    MCF7 IC50
    26.1 μg/mL
    Compound: Doxorubicin
    Growth inhibition of human MCF7 cells after 48 hrs by MTT assay
    Growth inhibition of human MCF7 cells after 48 hrs by MTT assay
    		[PMID: 29793751]
    MCF7 IC50
    26.7 μM
    Compound: Doxorubicine
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability by resazurin microplate assay
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability by resazurin microplate assay
    		[PMID: 34748348]
    MCF7 IC50
    26.9 μM
    Compound: Doxorubicin
    Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    		[PMID: 31323616]
    MCF7 IC50
    27 μM
    Compound: Doxorubicin
    Anticancer activity against human MCF7 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay
    Anticancer activity against human MCF7 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay
    		[PMID: 37060756]
    MCF7 IC50
    28 nM
    Compound: Doxorubicin
    Tested against MXF7 breast carcinoma (mitoxantrone resistant)cell line in the sulforhodamine B assay.
    Tested against MXF7 breast carcinoma (mitoxantrone resistant)cell line in the sulforhodamine B assay.
    		[PMID: 8648600]
    MCF7 IC50
    28 nM
    Compound: Doxorubicin
    Tested against MXF7 breast carcinoma (sensitive) cell line in the sulforhodamine B assay.
    Tested against MXF7 breast carcinoma (sensitive) cell line in the sulforhodamine B assay.
    		[PMID: 8648600]
    MCF7 IC50
    28 nM
    Compound: dixorubicin
    Antitumor activity against human mammary carcinoma mitoxantrone-resistant MXF7 breast cell line.
    Antitumor activity against human mammary carcinoma mitoxantrone-resistant MXF7 breast cell line.
    		[PMID: 8960558]
    MCF7 IC50
    28 nM
    Compound: dixorubicin
    Antitumor activity against human mammary carcinoma sensitive MXF7 breast cell line.
    Antitumor activity against human mammary carcinoma sensitive MXF7 breast cell line.
    		[PMID: 8960558]
    MCF7 IC50
    28 nM
    Compound: doxorubicin
    Tested for inhibitory activity against human tumor cell line MCF7, a strain resistant to mitoxantrone of breast carcinoma using sulforhodamine B assay.
    Tested for inhibitory activity against human tumor cell line MCF7, a strain resistant to mitoxantrone of breast carcinoma using sulforhodamine B assay.
    		[PMID: 10956214]
    MCF7 IC50
    28 nM
    Compound: doxorubicin
    Tested for inhibitory activity against human tumor cell line MCF7, a strain sensitive to doxorubicin of breast carcinoma using sulforhodamine B assay.
    Tested for inhibitory activity against human tumor cell line MCF7, a strain sensitive to doxorubicin of breast carcinoma using sulforhodamine B assay.
    		[PMID: 10956214]
    MCF7 IC50
    3 μM
    Compound: Doxorubicin
    Anticancer activity against human MCF7 cells assessed as cell viability after 48 hrs by MTT microcultured tetrazolium assay
    Anticancer activity against human MCF7 cells assessed as cell viability after 48 hrs by MTT microcultured tetrazolium assay
    		[PMID: 25096298]
    MCF7 IC50
    3 μM
    Compound: Doxorubicin
    Antiproliferative activity against human MCF7 cells by fluorescence based viable cell counting method
    Antiproliferative activity against human MCF7 cells by fluorescence based viable cell counting method
    		[PMID: 31610378]
    MCF7 IC50
    3 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells
    Cytotoxicity against human MCF7 cells
    		[PMID: 32386856]
    MCF7 IC50
    3 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 24 hrs by DAPI staining-based fluorescence assay
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 24 hrs by DAPI staining-based fluorescence assay
    		[PMID: 32786882]
    MCF7 IC50
    3 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability by DAPI staining based assay
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability by DAPI staining based assay
    		[PMID: 33461146]
    MCF7 IC50
    3.04 μM
    Compound: Doxorubicin
    Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition incubated for 4 hrs under hypoxia condition by MTT colorimetric assay
    Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition incubated for 4 hrs under hypoxia condition by MTT colorimetric assay
    		[PMID: 35551035]
    MCF7 IC50
    3.05 μM
    Compound: Doxorubicin
    Antiproliferative activity against human cells MCF-7 assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    Antiproliferative activity against human cells MCF-7 assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    		[PMID: 33477020]
    MCF7 IC50
    3.09 μM
    Compound: Doxorubicin
    Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay
    Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay
    		[PMID: 33744443]
    MCF7 IC50
    3.1 μM
    Compound: ADR
    In vitro inhibition of tumor cell growth in the human mammary carcinoma MCF-7/ADR system.
    In vitro inhibition of tumor cell growth in the human mammary carcinoma MCF-7/ADR system.
    		[PMID: 1447730]
    MCF7 IC50
    3.12 μM
    Compound: Doxo (I)
    Antiproliferative activity against human MCF7 cells by MTT assay
    Antiproliferative activity against human MCF7 cells by MTT assay
    		10.1039/C4MD00228H
    MCF7 IC50
    3.14 μM
    Compound: DOX
    Cytotoxicity against human MCF7 cells assessed as inhibition of cell viability incubated for 48 hrs by MTT assay
    Cytotoxicity against human MCF7 cells assessed as inhibition of cell viability incubated for 48 hrs by MTT assay
    		[PMID: 38169372]
    MCF7 IC50
    3.15 μM
    Compound: Doxorubicin
    Antiproliferative activity against human MCF7 cells assessed as inhibition of cell proliferation measured after 72 hrs by CCK-8 assay
    Antiproliferative activity against human MCF7 cells assessed as inhibition of cell proliferation measured after 72 hrs by CCK-8 assay
    		[PMID: 34365102]
    MCF7 IC50
    3.18 μM
    Compound: Doxorubicin
    Anticancer activity against human MCF7 cells assessed as cell viability after 48 hrs by MTT assay
    Anticancer activity against human MCF7 cells assessed as cell viability after 48 hrs by MTT assay
    		[PMID: 26542964]
    MCF7 IC50
    3.19 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells by CCK8 assay
    Cytotoxicity against human MCF7 cells by CCK8 assay
    		[PMID: 29452840]
    MCF7 IC50
    3.2 nM
    Compound: Doxorubicin
    Inhibition of TRK in human MCF7 cells after 48 hrs by ELISA
    Inhibition of TRK in human MCF7 cells after 48 hrs by ELISA
    		[PMID: 24013411]
    MCF7 IC50
    3.22 μM
    Compound: Doxorubicin
    Anticancer activity against Homo sapiens (human) MCF7 cells after 48 hr by SRB assay
    Anticancer activity against Homo sapiens (human) MCF7 cells after 48 hr by SRB assay
    		10.1007/s00044-011-9653-x
    MCF7 IC50
    3.22 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells assessed as inhibition of cell proliferation after 24 hrs by SRB assay
    Cytotoxicity against human MCF7 cells assessed as inhibition of cell proliferation after 24 hrs by SRB assay
    		[PMID: 20850308]
    MCF7 IC50
    3.24 x 10-7 M
    Compound: Doxorubucin
    Cytotoxicity against human MCF7 cells after 72 hrs by XTT assay
    Cytotoxicity against human MCF7 cells after 72 hrs by XTT assay
    		[PMID: 20538470]
    MCF7 IC50
    3.28 μM
    Compound: DOX
    Antiproliferative activity against human MCF7 cells after 72 hrs by CCK8 assay
    Antiproliferative activity against human MCF7 cells after 72 hrs by CCK8 assay
    		[PMID: 30071408]
    MCF7 IC50
    3.28 μM
    Compound: DOX
    Antiproliferative activity against human MCF7 cells after 72 hrs by CCK-8 assay
    Antiproliferative activity against human MCF7 cells after 72 hrs by CCK-8 assay
    		[PMID: 30245395]
    MCF7 IC50
    3.28 μM
    Compound: DOX
    Antiproliferative activity against human MCF-7 cells measured by MTT assay
    Antiproliferative activity against human MCF-7 cells measured by MTT assay
    		[PMID: 33860662]
    MCF7 IC50
    3.28 μM
    Compound: DOX
    Cytotoxicity against human MCF-7 cells measured by MTT assay
    Cytotoxicity against human MCF-7 cells measured by MTT assay
    		[PMID: 33860662]
    MCF7 IC50
    3.3 μM
    Compound: Doxorubicin
    Anticancer activity against human MCF7 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay
    Anticancer activity against human MCF7 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay
    		[PMID: 34838335]
    MCF7 IC50
    3.41 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
    		[PMID: 39026656]
    MCF7 IC50
    3.51 μM
    Compound: Doxorubicin
    Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
    		[PMID: 24418772]
    MCF7 IC50
    3.62 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells treated for 72 hrs by MTT assay
    Cytotoxicity against human MCF7 cells treated for 72 hrs by MTT assay
    		[PMID: 35344904]
    MCF7 IC50
    3.69 μM
    Compound: Adriamycin
    Cytotoxicity against human MCF7 cells after 2 days
    Cytotoxicity against human MCF7 cells after 2 days
    		[PMID: 22318164]
    MCF7 IC50
    3.7 μM
    Compound: DOX
    Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition by MTT assay
    Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition by MTT assay
    		[PMID: 32631524]
    MCF7 IC50
    3.76 μg/mL
    Compound: DOX
    Antitumor activity against human MCF7 cells after 48 hrs by MTT assay
    Antitumor activity against human MCF7 cells after 48 hrs by MTT assay
    		[PMID: 20599299]
    MCF7 IC50
    3.83 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay
    Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay
    		[PMID: 27769619]
    MCF7 IC50
    3.84 μM
    Compound: Doxorubicin
    Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth under normoxia condition by MTT colorimetric assay
    Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth under normoxia condition by MTT colorimetric assay
    		[PMID: 38653067]
    MCF7 IC50
    3.89 μM
    Compound: Doxorubicin
    Antiproliferative activity against human MCF-7 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay
    Antiproliferative activity against human MCF-7 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay
    		[PMID: 31884407]
    MCF7 IC50
    3.9 μM
    Compound: Doxorubicin
    Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth measured after 24 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth measured after 24 hrs by MTT assay
    		[PMID: 37098901]
    MCF7 IC50
    3.97 μM
    Compound: Doxorubicin
    Antitumor activity against human MCF7 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay
    Antitumor activity against human MCF7 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay
    		[PMID: 30138804]
    MCF7 IC50
    3.97 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 24 hrs by MTT assay
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 24 hrs by MTT assay
    		[PMID: 31404864]
    MCF7 IC50
    3.97 μM
    Compound: Doxorubicin
    Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay
    		[PMID: 35367708]
    MCF7 IC50
    300 nmol equiv/L
    Compound: Doxorubicin
    Compound was tested for its toxicity against human breast cancer cells(MCF-7)
    Compound was tested for its toxicity against human breast cancer cells(MCF-7)
    		[PMID: 9548820]
    MCF7 IC50
    300 nmol equiv/L
    Compound: doxorubicin
    compound was tested in vitro for inhibition activity against a sensitive human breast carcinoma line cells.
    compound was tested in vitro for inhibition activity against a sensitive human breast carcinoma line cells.
    		[PMID: 9258351]
    MCF7 IC50
    32 μM
    Compound: DOX
    Cytotoxicity against human MCF7 cells after 48 hrs by sulforhodamine B assay
    Cytotoxicity against human MCF7 cells after 48 hrs by sulforhodamine B assay
    		[PMID: 22583778]
    MCF7 IC50
    32.02 μM
    Compound: DOX
    Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay
    Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay
    		[PMID: 21093116]
    MCF7 IC50
    33.13 μM
    Compound: DOX
    Cytotoxicity against human MCF7 cells after 72 hrs by sulforhodamine B assay
    Cytotoxicity against human MCF7 cells after 72 hrs by sulforhodamine B assay
    		[PMID: 25912674]
    MCF7 IC50
    33.48 μM
    Compound: Dox
    Antiproliferative activity against human MCF7 cells assessed as inhibition of cell proliferation incubated for 72 hrs by CellTiter-Glo assay
    Antiproliferative activity against human MCF7 cells assessed as inhibition of cell proliferation incubated for 72 hrs by CellTiter-Glo assay
    		[PMID: 27687968]
    MCF7 IC50
    34.2 nM
    Compound: Dox
    Cytotoxicity against human MCF7 cells incubated for 72 hrs by SRB assay
    Cytotoxicity against human MCF7 cells incubated for 72 hrs by SRB assay
    		[PMID: 37480713]
    MCF7 IC50
    34.52 μM
    Compound: doxorubicin
    Cytotoxicity against human MCF7 cells assessed as inhibition of cell viability after 24 hrs by MTT assay
    Cytotoxicity against human MCF7 cells assessed as inhibition of cell viability after 24 hrs by MTT assay
    		[PMID: 26200396]
    MCF7 IC50
    37.57 μg/mL
    Compound: Doxorubicin
    In vitro cytotoxic activity against subline resistant to doxorubicin (MCF-7/R) by using SRB assay after 72 hr of drug exposure
    In vitro cytotoxic activity against subline resistant to doxorubicin (MCF-7/R) by using SRB assay after 72 hr of drug exposure
    		10.1016/0960-894X(96)00156-4
    MCF7 IC50
    38.12 μg/mL
    Compound: DOX
    Cytotoxicity against human MCF7 assessed as reduction in cell viability
    Cytotoxicity against human MCF7 assessed as reduction in cell viability
    		[PMID: 34438013]
    MCF7 IC50
    386 nM
    Compound: DOX; DX
    Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 120 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 120 hrs by MTT assay
    		[PMID: 31653441]
    MCF7 IC50
    386 nM
    Compound: Doxorubicin
    Antiproliferative activity against human MCF-7 cells incubated for 72 hrs by SRB assay
    Antiproliferative activity against human MCF-7 cells incubated for 72 hrs by SRB assay
    		[PMID: 33465696]
    MCF7 IC50
    4.12 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against Homo sapiens (human) MCF7 cells assessed as cell viability after 48 hr by MTT assay
    Cytotoxicity against Homo sapiens (human) MCF7 cells assessed as cell viability after 48 hr by MTT assay
    		10.1007/s00044-012-0168-x
    MCF7 IC50
    4.17 μM
    Compound: DOX
    Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay
    Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay
    		[PMID: 30015070]
    MCF7 IC50
    4.17 μM
    Compound: DOX
    Antiproliferative activity against human MCF7 cells by MTT assay
    Antiproliferative activity against human MCF7 cells by MTT assay
    		[PMID: 30216848]
    MCF7 IC50
    4.17 μM
    Compound: DOX
    Anticancer activity against human MCF7 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay
    Anticancer activity against human MCF7 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay
    		[PMID: 32085964]
    MCF7 IC50
    4.17 μM
    Compound: DOX
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 24 hrs by MTT assay
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 24 hrs by MTT assay
    		[PMID: 32307260]
    MCF7 IC50
    4.17 μM
    Compound: DOX
    Antiproliferative activity against human MCF7 cells assessed as reduction in cell growth
    Antiproliferative activity against human MCF7 cells assessed as reduction in cell growth
    		[PMID: 33388654]
    MCF7 IC50
    4.17 μM
    Compound: DOX
    Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay
    		[PMID: 35964425]
    MCF7 IC50
    4.17 μM
    Compound: DOX
    Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay
    Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay
    		[PMID: 36242988]
    MCF7 IC50
    4.17 μM
    Compound: DOX
    Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay
    		[PMID: 37054758]
    MCF7 IC50
    4.17 μM
    Compound: DOX
    Cytotoxicity against human MCF7 cells under hypoxia condition by MTT assay
    Cytotoxicity against human MCF7 cells under hypoxia condition by MTT assay
    		[PMID: 38642371]
    MCF7 IC50
    4.17 μM
    Compound: Dox
    Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    		[PMID: 32527460]
    MCF7 IC50
    4.17 μM
    Compound: Dox
    Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    		[PMID: 34126285]
    MCF7 IC50
    4.17 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells assessed as decrease in cell viability after 48 hrs by MTT assay
    Cytotoxicity against human MCF7 cells assessed as decrease in cell viability after 48 hrs by MTT assay
    		[PMID: 29702448]
    MCF7 IC50
    4.17 μM
    Compound: Doxorubicin
    Antitumor activity against human MCF7 cells assessed as inhibition of cell viability by MTT assay
    Antitumor activity against human MCF7 cells assessed as inhibition of cell viability by MTT assay
    		[PMID: 33065442]
    MCF7 IC50
    4.17 μM
    Compound: Doxorubicin
    Antiproliferative activity against human MCF7 cells measured after 24 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells measured after 24 hrs by MTT assay
    		[PMID: 37875056]
    MCF7 IC50
    4.2 μM
    Compound: Doxorubicin
    Antiproliferative activity against human MCF7
    Antiproliferative activity against human MCF7
    		[PMID: 33421712]
    MCF7 IC50
    4.24 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells assessed as cell viability after 72 hrs by MTT assay
    Cytotoxicity against human MCF7 cells assessed as cell viability after 72 hrs by MTT assay
    		[PMID: 28171832]
    MCF7 IC50
    4.302 μg/mL
    Compound: Doxo
    Cytotoxicity against human MCF7 cells after 48 hrs by alamar blue assay
    Cytotoxicity against human MCF7 cells after 48 hrs by alamar blue assay
    		[PMID: 25468043]
    MCF7 IC50
    4.33 μM
    Compound: DOX
    Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    		[PMID: 36252396]
    MCF7 IC50
    4.39 μM
    Compound: Dox
    Cytotoxicity against human MCF7 cells assessed as decrease in cell viability treated for 2 hrs measured after 48 hrs by MTT assay
    Cytotoxicity against human MCF7 cells assessed as decrease in cell viability treated for 2 hrs measured after 48 hrs by MTT assay
    		[PMID: 28129977]
    MCF7 IC50
    4.39 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells by MTT assay
    Cytotoxicity against human MCF7 cells by MTT assay
    		[PMID: 33148490]
    MCF7 IC50
    4.4 μM
    Compound: Doxorubicin
    Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
    		[PMID: 28919340]
    MCF7 IC50
    4.4 μg/mL
    Compound: DOX
    Cytotoxicity against human MCF7 cells by SRB assay
    Cytotoxicity against human MCF7 cells by SRB assay
    		[PMID: 23831694]
    MCF7 IC50
    4.5 μM
    Compound: Dox
    Cytotoxicity against human MCF7 cells assessed as growth inhibition after 48 hrs by SRB assay
    Cytotoxicity against human MCF7 cells assessed as growth inhibition after 48 hrs by SRB assay
    		[PMID: 22000946]
    MCF7 IC50
    4.5 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay
    Cytotoxicity against human MCF7 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay
    		[PMID: 35696863]
    MCF7 IC50
    4.5 μM
    Compound: adriamycin
    Cytotoxicity against human MCF7 cells after 4 days by MTT assay
    Cytotoxicity against human MCF7 cells after 4 days by MTT assay
    		[PMID: 17194586]
    MCF7 IC50
    4.56 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells after 24 hrs by SRB assay
    Cytotoxicity against human MCF7 cells after 24 hrs by SRB assay
    		[PMID: 30096580]
    MCF7 IC50
    4.56 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability by SRB assay
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability by SRB assay
    		[PMID: 32361329]
    MCF7 IC50
    4.5 μg/mL
    Compound: doxorubicin
    Cytotoxicity against human MCF7 cells assessed as [3H]hypoxanthin incorporation after 24 to 72 hrs
    Cytotoxicity against human MCF7 cells assessed as [3H]hypoxanthin incorporation after 24 to 72 hrs
    		[PMID: 19296616]
    MCF7 IC50
    4.6 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells by MTT assay
    Cytotoxicity against human MCF7 cells by MTT assay
    		[PMID: 33766771]
    MCF7 IC50
    4.63 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
    Cytotoxicity against human MCF7 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
    		[PMID: 34838335]
    MCF7 IC50
    4.6 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
    Cytotoxicity against human MCF7 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
    		[PMID: 35526504]
    MCF7 IC50
    4.78 μM
    Compound: Dox
    Antiproliferative activity against human MCF7 cells assessed as inhibition of cell viability by MTT assay
    Antiproliferative activity against human MCF7 cells assessed as inhibition of cell viability by MTT assay
    		[PMID: 37922829]
    MCF7 IC50
    4.7 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
    Cytotoxicity against human MCF7 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
    		[PMID: 27894044]
    MCF7 IC50
    4.89 μM
    Compound: Doxorubicin
    Anticancer activity against human MCF7 cells assessed as cell growth inhibition measured after 24 hrs by SRB assay
    Anticancer activity against human MCF7 cells assessed as cell growth inhibition measured after 24 hrs by SRB assay
    		[PMID: 36481599]
    MCF7 IC50
    4.9 x 10-2 μM
    Compound: adriamycin
    Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
    Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
    		[PMID: 19285863]
    MCF7 IC50
    41.9 nM
    Compound: Doxorubicin
    Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs by SRB assay
    Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs by SRB assay
    		[PMID: 31655432]
    MCF7 IC50
    42.52 μM
    Compound: Dox
    Cytotoxicity against human MCF7 cells after 3 days by MTT assay
    Cytotoxicity against human MCF7 cells after 3 days by MTT assay
    		[PMID: 21741833]
    MCF7 IC50
    43.44 μM
    Compound: ADR, ADM
    Cytotoxicity against adriyamycin-resistant human MCF7 cells over expressing P-glycoprotein after 72 hrs by SRB assay
    Cytotoxicity against adriyamycin-resistant human MCF7 cells over expressing P-glycoprotein after 72 hrs by SRB assay
    		[PMID: 21761866]
    MCF7 IC50
    44 μM
    Compound: 21
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 24 hrs by MTT assay
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 24 hrs by MTT assay
    		[PMID: 32435401]
    MCF7 IC50
    47.8 μM
    Compound: DOX
    Antiproliferative activity against adriamycin resistant human MCF7 cells after 72 hrs by MTT assay
    Antiproliferative activity against adriamycin resistant human MCF7 cells after 72 hrs by MTT assay
    		[PMID: 17964170]
    MCF7 IC50
    4 μg/mL
    Compound: Doxorubicin
    Antiproliferative activity against human MCF7 cells after 48 hrs by SRB assay
    Antiproliferative activity against human MCF7 cells after 48 hrs by SRB assay
    		[PMID: 27688190]
    MCF7 IC50
    5 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 72 hrs under hypoxic condition by MTT assay
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 72 hrs under hypoxic condition by MTT assay
    		[PMID: 31972093]
    MCF7 IC50
    5.17 μM
    Compound: Dox
    Cytotoxicity against human MCF7 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay
    Cytotoxicity against human MCF7 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay
    		[PMID: 35635947]
    MCF7 IC50
    5.2 μM
    Compound: DOX
    Cytotoxicity against human MCF7 cells assessed as cell viability incubated for 72 hrs by MTT assay
    Cytotoxicity against human MCF7 cells assessed as cell viability incubated for 72 hrs by MTT assay
    		[PMID: 39153333]
    MCF7 IC50
    5.3 μM
    Compound: DXR
    Cytotoxicity against human MCF7 cells assessed as cell growth inhibition after 24 hrs by XTT assay
    Cytotoxicity against human MCF7 cells assessed as cell growth inhibition after 24 hrs by XTT assay
    		[PMID: 26649907]
    MCF7 IC50
    5.3 μM
    Compound: Doxorubicin
    Inhibitory concentration against MCF-7 human breast carcinoma resistant to doxorubicin
    Inhibitory concentration against MCF-7 human breast carcinoma resistant to doxorubicin
    		[PMID: 15715481]
    MCF7 IC50
    5.3 μM
    Compound: doxorubicin
    Cytotoxicity against doxorubicin-resistant human MCF7 cells
    Cytotoxicity against doxorubicin-resistant human MCF7 cells
    		[PMID: 17375902]
    MCF7 IC50
    5.4 nM
    Compound: Dox
    Cytotoxicity against human MCF7 cells assessed as inhibition of cell viability after 48 hrs by SRB assay
    Cytotoxicity against human MCF7 cells assessed as inhibition of cell viability after 48 hrs by SRB assay
    		[PMID: 23085106]
    MCF7 IC50
    5.46 μM
    Compound: Doxorubicin
    Antitumor activity against Homo sapiens (human) MCF7 cells assessed as cell growth inhibition after 48 hr by MTT assay
    Antitumor activity against Homo sapiens (human) MCF7 cells assessed as cell growth inhibition after 48 hr by MTT assay
    		10.1007/s00044-013-0497-4
    MCF7 IC50
    5.46 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells after 48 hrs by sulforhodamine B assay
    Cytotoxicity against human MCF7 cells after 48 hrs by sulforhodamine B assay
    		[PMID: 22119131]
    MCF7 IC50
    5.46 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells after 48 hrs by sulforhodamine B assay
    Cytotoxicity against human MCF7 cells after 48 hrs by sulforhodamine B assay
    		[PMID: 22119132]
    MCF7 IC50
    5.46 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells assessed as cell survival after 48 hrs by SRB assay
    Cytotoxicity against human MCF7 cells assessed as cell survival after 48 hrs by SRB assay
    		[PMID: 23708013]
    MCF7 IC50
    5.49 mM
    Compound: doxorubicin
    Antiproliferative activity against human MCF7 cells after 48 hrs by SRB assay
    Antiproliferative activity against human MCF7 cells after 48 hrs by SRB assay
    		[PMID: 24583357]
    MCF7 IC50
    5.5 μM
    Compound: Doxorubicin
    Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth after overnight incubation by MTT assay
    Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth after overnight incubation by MTT assay
    		[PMID: 32165076]
    MCF7 IC50
    5.51 μM
    Compound: Dox
    Cytotoxicity against human MCF7 cells assessed as cell viability measured after 24 hrs by MTT assay
    Cytotoxicity against human MCF7 cells assessed as cell viability measured after 24 hrs by MTT assay
    		[PMID: 33183865]
    MCF7 IC50
    5.73 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells by MTT assay
    Cytotoxicity against human MCF7 cells by MTT assay
    		[PMID: 26873414]
    MCF7 IC50
    5.9 μM
    Compound: Doxorubicin
    Anticancer activity against human MCF7 cells assessed as inhibition of cell proliferation measured after 24 hrs by MTT based microplate ELISA reader analysis
    Anticancer activity against human MCF7 cells assessed as inhibition of cell proliferation measured after 24 hrs by MTT based microplate ELISA reader analysis
    		[PMID: 34438126]
    MCF7 IC50
    50 μM
    Compound: doxorubicin
    Cytotoxicity against doxorubicin-resistant human MCF7 cells
    Cytotoxicity against doxorubicin-resistant human MCF7 cells
    		[PMID: 15921419]
    MCF7 IC50
    5300 nM
    Compound: Doxorubicin
    Antiproliferative activity against human doxorubicin-resistant MCF7 cells after 48 hrs by MTT assay
    Antiproliferative activity against human doxorubicin-resistant MCF7 cells after 48 hrs by MTT assay
    		[PMID: 25937236]
    MCF7 IC50
    58 nM
    Compound: doxorubicin
    Cytotoxicity against human MCF7 cells expressing P-glycoprotein after 72 hrs by MTS assay
    Cytotoxicity against human MCF7 cells expressing P-glycoprotein after 72 hrs by MTS assay
    		[PMID: 19655762]
    MCF7 IC50
    580 nM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
    Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
    		[PMID: 30172625]
    MCF7 IC50
    5 μg
    Compound: Doxorubicin
    Anticancer activity against human MCF7 cells after 48 hrs by MTT assay
    Anticancer activity against human MCF7 cells after 48 hrs by MTT assay
    		[PMID: 28372908]
    MCF7 IC50
    5 μg/mL
    Compound: adriamycin
    Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
    Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
    		[PMID: 19700322]
    MCF7 IC50
    6.1 μM
    Compound: DX
    Cytotoxicity against human MCF7 cells after 48 hrs by sulforhodamine B assay
    Cytotoxicity against human MCF7 cells after 48 hrs by sulforhodamine B assay
    		10.1039/C5MD00513B
    MCF7 IC50
    6.1 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells assessed as surviving fraction after 48 hrs by SRB assay
    Cytotoxicity against human MCF7 cells assessed as surviving fraction after 48 hrs by SRB assay
    		[PMID: 24686014]
    MCF7 IC50
    6.2 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    Cytotoxicity against human MCF7 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    		[PMID: 26317881]
    MCF7 IC50
    6.3 μM
    Compound: Doxorubicin
    Antiproliferative activity against human MCF7 cells by MTT reduction assay
    Antiproliferative activity against human MCF7 cells by MTT reduction assay
    		[PMID: 33421712]
    MCF7 IC50
    6.31 μM
    Compound: Doxorubicin
    Antiproliferative activity against human MCF7 cells
    Antiproliferative activity against human MCF7 cells
    		[PMID: 32688198]
    MCF7 IC50
    6.32 μM
    Compound: Dox
    Antiproliferative activity against human MCF7 cells after 48 hrs under hypoxic condition by MTT assay
    Antiproliferative activity against human MCF7 cells after 48 hrs under hypoxic condition by MTT assay
    		[PMID: 30445264]
    MCF7 IC50
    6.37 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability
    		[PMID: 31404864]
    MCF7 IC50
    6.521 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells incubated for 72 hrs by MTT assay
    Cytotoxicity against human MCF7 cells incubated for 72 hrs by MTT assay
    		[PMID: 38894896]
    MCF7 IC50
    6.71 μg/mL
    Compound: DOX
    Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay
    Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay
    		[PMID: 19932530]
    MCF7 IC50
    6.75 μM
    Compound: DOX
    Anticancer activity against human MCF7 cells assessed as inhibition of tumor cell proliferation after 48 hrs by MTT assay
    Anticancer activity against human MCF7 cells assessed as inhibition of tumor cell proliferation after 48 hrs by MTT assay
    		[PMID: 25064350]
    MCF7 IC50
    6.75 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells by resazurin microplate assay
    Cytotoxicity against human MCF7 cells by resazurin microplate assay
    		[PMID: 27228159]
    MCF7 IC50
    6.75 μg/mL
    Compound: Doxorubicin
    Antiproliferative activity against human MCF7 cells assessed as reduction in cell growth measured after 24 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells assessed as reduction in cell growth measured after 24 hrs by MTT assay
    		[PMID: 37453330]
    MCF7 IC50
    6.9 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
    Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
    		[PMID: 22304344]
    MCF7 IC50
    65.6 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells by MTT assay
    Cytotoxicity against human MCF7 cells by MTT assay
    		[PMID: 36325400]
    MCF7 IC50
    65.6 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells by SRB assay
    Cytotoxicity against human MCF7 cells by SRB assay
    		[PMID: 36325400]
    MCF7 IC50
    65.6 μg/mL
    Compound: Doxorubicin
    Antitumor activity against human MCF7 xenografted BALB/c mouse assessed as reduction in tumor growth at 30 mg/kg, ip administered for once every 3 days measured after 15 days
    Antitumor activity against human MCF7 xenografted BALB/c mouse assessed as reduction in tumor growth at 30 mg/kg, ip administered for once every 3 days measured after 15 days
    		[PMID: 34147747]
    MCF7 IC50
    66.2 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
    Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
    		[PMID: 21429743]
    MCF7 IC50
    7 μM
    Compound: ADM
    Cytotoxicity against human MCF7 cells
    Cytotoxicity against human MCF7 cells
    		[PMID: 22283451]
    MCF7 IC50
    7.2 μM
    Compound: Dox
    Growth inhibition of Homo sapiens (human) MCF7 cells after 48 hr by MTT assay
    Growth inhibition of Homo sapiens (human) MCF7 cells after 48 hr by MTT assay
    		10.1007/s00044-013-0534-3
    MCF7 IC50
    7.66 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells by SRB assay
    Cytotoxicity against human MCF7 cells by SRB assay
    		[PMID: 23806014]
    MCF7 IC50
    7.67 μM
    Compound: Doxorubicin
    Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    		[PMID: 33214036]
    MCF7 IC50
    7.86 μM
    Compound: Doxorubicin
    Antiproliferative activity against human MCF7 cells incubated for 24 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells incubated for 24 hrs by MTT assay
    		[PMID: 29409753]
    MCF7 IC50
    71.8 μM
    Compound: Doxorubicin
    Cytotoxicity against Homo sapiens (human) MCF-7 cells after 48 hr by SRB assay relative to control
    Cytotoxicity against Homo sapiens (human) MCF-7 cells after 48 hr by SRB assay relative to control
    		10.1007/s00044-010-9332-3
    MCF7 IC50
    71.8 μM
    Compound: Doxorubicin
    Anticancer activity against human MCF7 cells assessed as survival fraction after 48 hrs by SRB assay
    Anticancer activity against human MCF7 cells assessed as survival fraction after 48 hrs by SRB assay
    		[PMID: 20684857]
    MCF7 IC50
    71.8 μM
    Compound: Doxorubicin
    Anticancer activity against human MCF7 cells assessed as viable cells after 48 hrs by SRB assay
    Anticancer activity against human MCF7 cells assessed as viable cells after 48 hrs by SRB assay
    		[PMID: 21890248]
    MCF7 IC50
    75.6 nM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells assessed as growth inhibition after 72 hrs by MTT assay
    Cytotoxicity against human MCF7 cells assessed as growth inhibition after 72 hrs by MTT assay
    		[PMID: 29886322]
    MCF7 IC50
    792 nM
    Compound: Doxorubicin
    Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition measured after 48 hrs by MTS assay
    Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition measured after 48 hrs by MTS assay
    		[PMID: 35737669]
    MCF7 IC50
    8.02 nM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells after 48 hrs by sulforhodamine-B assay
    Cytotoxicity against human MCF7 cells after 48 hrs by sulforhodamine-B assay
    		[PMID: 25255434]
    MCF7 IC50
    8.02 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells assessed as reduction in cell survival after 48 hrs by MTT assay
    Cytotoxicity against human MCF7 cells assessed as reduction in cell survival after 48 hrs by MTT assay
    		[PMID: 24878360]
    MCF7 IC50
    8.02 μM
    Compound: Doxorubicin
    Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
    		[PMID: 26907155]
    MCF7 IC50
    8.09 μM
    Compound: DOX
    Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay
    Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay
    		[PMID: 22444025]
    MCF7 IC50
    8.1 x 10-2 μg/mL
    Compound: Adriamycin
    Cytotoxicity against human MCF7 cells by MTT assay
    Cytotoxicity against human MCF7 cells by MTT assay
    		[PMID: 9644064]
    MCF7 IC50
    8.3 μM
    Compound: DOX
    Cytotoxicity against human MCF7 cells by MTT assay
    Cytotoxicity against human MCF7 cells by MTT assay
    		[PMID: 19329312]
    MCF7 IC50
    8.39 μM
    Compound: Dox
    Antiproliferative activity against human MCF7 cells measured after 48 hrs under hypoxia condition by MTT assay
    Antiproliferative activity against human MCF7 cells measured after 48 hrs under hypoxia condition by MTT assay
    		[PMID: 31276899]
    MCF7 IC50
    8.4 nM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability by SRB assay
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability by SRB assay
    		[PMID: 30660827]
    MCF7 IC50
    8.4 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
    Cytotoxicity against human MCF7 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
    		[PMID: 35526504]
    MCF7 IC50
    8.62 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
    Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
    		[PMID: 22818039]
    MCF7 IC50
    8.62 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells
    Cytotoxicity against human MCF7 cells
    		[PMID: 24793880]
    MCF7 IC50
    8.81 μM
    Compound: Doxo
    Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
    		[PMID: 27597408]
    MCF7 IC50
    8.94 μM
    Compound: Doxo
    Cytotoxicity against estrogen receptor-positive human MCF7 cells after 24 hrs by MTT assay
    Cytotoxicity against estrogen receptor-positive human MCF7 cells after 24 hrs by MTT assay
    		[PMID: 21885273]
    MCF7 IC50
    8.98 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells after 72 hrs by resazurin based fluorescence assay
    Cytotoxicity against human MCF7 cells after 72 hrs by resazurin based fluorescence assay
    		[PMID: 28927795]
    MCF7 IC50
    879 nM
    Compound: Doxorubicin
    Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
    		[PMID: 29795767]
    MCF7 IC50
    9.11 μM
    Compound: Dox
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 28549734]
    MCF7 IC50
    9.29 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    		[PMID: 38665840]
    MCF7 IC50
    9.34 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells measured after 24 hrs by MTT assay
    Cytotoxicity against human MCF7 cells measured after 24 hrs by MTT assay
    		[PMID: 34363937]
    MCF7 IC50
    9.43 μM
    Compound: Doxorubicin
    Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth under hypoxia condition by MTT colorimetric assay
    Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth under hypoxia condition by MTT colorimetric assay
    		[PMID: 38653067]
    MCF7 IC50
    9.84 nM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
    Cytotoxicity against human MCF7 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
    		[PMID: 30429975]
    MCF7 IC50
    9.86 μM
    Compound: Doxo
    Cytotoxicity against human MCF7 cells measured after 24 hrs by MTT assay
    Cytotoxicity against human MCF7 cells measured after 24 hrs by MTT assay
    		[PMID: 31104996]
    MCF7 IC50
    < 0.26 μM
    Compound: Doxorubicin
    Antiproliferative activity against human MCF7 cells assessed as inhibition of cell proliferation measured after 96 hrs by SRB assay
    Antiproliferative activity against human MCF7 cells assessed as inhibition of cell proliferation measured after 96 hrs by SRB assay
    		[PMID: 33276991]
    MCF7 IC50
    < 1 μM
    Compound: doxorubicin
    Cytotoxicity against human MCF7 cells by SRB assay
    Cytotoxicity against human MCF7 cells by SRB assay
    		[PMID: 33847126]
    MCF7 IC50
    > 10 μM
    Compound: Doxorubicin
    Antiproliferative activity against human MCF7 cells assessed as reduction in cell growth after 24 hrs by MTS assay
    Antiproliferative activity against human MCF7 cells assessed as reduction in cell growth after 24 hrs by MTS assay
    		[PMID: 25300820]
    MCF7 IC50
    > 100 μM
    Compound: Doxorubicin
    Cytotoxicity against Homo sapiens (human) MCF7 cells assessed as inhibition of cell proliferation after 24 hr by MTT assay
    Cytotoxicity against Homo sapiens (human) MCF7 cells assessed as inhibition of cell proliferation after 24 hr by MTT assay
    		10.1007/s00044-012-0436-9
    MCF7 IC50
    > 20 μM
    Compound: DOX
    Cytotoxicity against human MCF7 cells after 24 hrs by XTT assay
    Cytotoxicity against human MCF7 cells after 24 hrs by XTT assay
    		[PMID: 24900344]
    MCF7 IC50
    > 60 μM
    Compound: DOX
    Cytotoxicity against human MCF7 cells after 24 hrs by XTT assay
    Cytotoxicity against human MCF7 cells after 24 hrs by XTT assay
    		[PMID: 24900668]
    MCF7-DOX IC50
    3.8 μM
    Compound: Dox
    Cytotoxicity against human MCF7/Dox cells after 72 hrs by MTT assay
    Cytotoxicity against human MCF7/Dox cells after 72 hrs by MTT assay
    		[PMID: 30659997]
    MCF7-DOX IC50
    33.66 μM
    Compound: Doxorubicin
    Antiproliferative activity against human MCF7-DOX cells assessed as cell growth inhibition measured after 72 to 96 hrs by MTT assay
    Antiproliferative activity against human MCF7-DOX cells assessed as cell growth inhibition measured after 72 to 96 hrs by MTT assay
    		[PMID: 36566714]
    MCF9 ED50
    0.0673 μg/mL
    Compound: Adriamycin
    Compound was tested for its cytotoxic activity in MTT assay against MCF-9 cell line (human breast carcinoma)
    Compound was tested for its cytotoxic activity in MTT assay against MCF-9 cell line (human breast carcinoma)
    		10.1016/0960-894X(95)00004-D
    MDA-MB-231 CC50
    0.34 μM
    Compound: Dox
    Cytotoxicity against human MDA-MB-231 cells incubated for 72 hrs by MTT assay
    Cytotoxicity against human MDA-MB-231 cells incubated for 72 hrs by MTT assay
    		[PMID: 39079310]
    MDA-MB-231 GI50
    0.01 μM
    Compound: Doxorubicin
    Growth inhibition of human MDA-MB-231 cells after 48 hrs by SRB assay
    Growth inhibition of human MDA-MB-231 cells after 48 hrs by SRB assay
    		[PMID: 26067381]
    MDA-MB-231 GI50
    0.02 μM
    Compound: Doxorubicin
    Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by SRB assay
    Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by SRB assay
    		[PMID: 25827522]
    MDA-MB-231 GI50
    0.023 μM
    Compound: Doxorubicin
    Antiproliferative activity against human MDA-MB-231 cells by SRB assay
    Antiproliferative activity against human MDA-MB-231 cells by SRB assay
    		[PMID: 31546197]
    MDA-MB-231 GI50
    0.038 μM
    Compound: Doxorubicin
    Cytotoxicity against human MDA-MB-231 cells after 72 hrs by SRB assay
    Cytotoxicity against human MDA-MB-231 cells after 72 hrs by SRB assay
    		[PMID: 20014800]
    MDA-MB-231 GI50
    0.046 μM
    Compound: Doxorubicin
    Antiproliferative activity against human MDA-MB-231 cells assessed as growth inhibition after 72 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells assessed as growth inhibition after 72 hrs by MTT assay
    		[PMID: 30360625]
    MDA-MB-231 GI50
    0.068 μM
    Compound: ADR
    Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay
    Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay
    		[PMID: 28870801]
    MDA-MB-231 GI50
    0.068 μM
    Compound: ADR
    Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 72 hrs by SRB assay
    Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 72 hrs by SRB assay
    		[PMID: 30253887]
    MDA-MB-231 GI50
    0.073 μM
    Compound: Doxorubicin
    Growth inhibition of human MDA-MB-231 cells after 48 hrs by SRB assay
    Growth inhibition of human MDA-MB-231 cells after 48 hrs by SRB assay
    		[PMID: 27964883]
    MDA-MB-231 GI50
    0.085 μM
    Compound: Doxorubicin
    Growth inhibition of human MDA-MB-231 cells after 48 hrs by SRB assay
    Growth inhibition of human MDA-MB-231 cells after 48 hrs by SRB assay
    		[PMID: 25264072]
    MDA-MB-231 GI50
    0.085 μM
    Compound: Doxorubicin
    Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in net protein increase after 48 hrs by SRB assay
    Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in net protein increase after 48 hrs by SRB assay
    		[PMID: 25462234]
    MDA-MB-231 GI50
    0.085 μM
    Compound: Doxorubicin
    Antiproliferative activity against human MDA-MB-231 cells assessed as growth inhibition after 48 hrs by SRB assay
    Antiproliferative activity against human MDA-MB-231 cells assessed as growth inhibition after 48 hrs by SRB assay
    		[PMID: 27209232]
    MDA-MB-231 GI50
    0.086 μM
    Compound: ADR
    Anticancer activity against human MDA-MB-231 cells assessed as growth inhibition incubated for 48 hrs by sulforhodamine B method
    Anticancer activity against human MDA-MB-231 cells assessed as growth inhibition incubated for 48 hrs by sulforhodamine B method
    		[PMID: 34500188]
    MDA-MB-231 GI50
    0.09 μM
    Compound: Doxorubicin
    Cytotoxicity against human MDA-MB-231 cells after 48 hrs by sulforhodamine B assay
    Cytotoxicity against human MDA-MB-231 cells after 48 hrs by sulforhodamine B assay
    		[PMID: 24158013]
    MDA-MB-231 GI50
    0.1 μM
    Compound: doxorubicin
    Cytotoxicity against human MDA-MB-231 cells by SRB assay
    Cytotoxicity against human MDA-MB-231 cells by SRB assay
    		[PMID: 17512741]
    MDA-MB-231 GI50
    0.1 μM
    Compound: doxorubicin
    Cytotoxicity against human MDA-MB-231 cells by SRB assay
    Cytotoxicity against human MDA-MB-231 cells by SRB assay
    		[PMID: 19007287]
    MDA-MB-231 GI50
    0.112 μM
    Compound: ADR
    Cytotoxicity against human MDA-MB-231 cells after 72 hrs by sulforhodamine B assay
    Cytotoxicity against human MDA-MB-231 cells after 72 hrs by sulforhodamine B assay
    		[PMID: 27096046]
    MDA-MB-231 GI50
    0.15 μM
    Compound: Dox
    Growth inhibition of human MDA-MB-231 cells after 72 hrs by MTT assay
    Growth inhibition of human MDA-MB-231 cells after 72 hrs by MTT assay
    		[PMID: 24163729]
    MDA-MB-231 GI50
    0.18 μM
    Compound: Doxorubicin
    Anticancer activity against human MDA-MB-231 cells by SRB assay
    Anticancer activity against human MDA-MB-231 cells by SRB assay
    		[PMID: 20732810]
    MDA-MB-231 GI50
    0.194 μM
    Compound: doxorubicin
    Cytotoxicity against human MDA-MB-231 cells
    Cytotoxicity against human MDA-MB-231 cells
    		[PMID: 20579876]
    MDA-MB-231 GI50
    0.2 μM
    Compound: Doxorubicin
    Cytotoxic activity against human MDA-MB-231 cells
    Cytotoxic activity against human MDA-MB-231 cells
    		[PMID: 28256841]
    MDA-MB-231 GI50
    0.2 μM
    Compound: Doxorubicin
    Cytotoxicity against human MDA-MB-231 cells after 48 hrs by sulforhodamine B assay
    Cytotoxicity against human MDA-MB-231 cells after 48 hrs by sulforhodamine B assay
    		[PMID: 29112820]
    MDA-MB-231 GI50
    0.39 μg/mL
    Compound: Adriamycin
    Antiproliferative activity against human MDA-MB-231 cells by SRB assay
    Antiproliferative activity against human MDA-MB-231 cells by SRB assay
    		[PMID: 18023932]
    MDA-MB-231 GI50
    0.49 μM
    Compound: Doxorubicin
    Cytotoxicity against human MDA-MB-231 cells after 72 hrs by SRB assay
    Cytotoxicity against human MDA-MB-231 cells after 72 hrs by SRB assay
    		[PMID: 21885166]
    MDA-MB-231 GI50
    0.51 μM
    Compound: Doxorubicin
    Growth inhibition of human MDA-MB-231 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human MDA-MB-231 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28329730]
    MDA-MB-231 GI50
    0.51 μM
    Compound: Doxorubicin
    Growth inhibition of human MDA-MB-231 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human MDA-MB-231 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 29102177]
    MDA-MB-231 GI50
    0.51 μM
    Compound: Doxorubicin hydrochloride, NSC 123127
    Cytotoxicity against human MDA-MB-231 cells after 48 hrs by SRB assay
    Cytotoxicity against human MDA-MB-231 cells after 48 hrs by SRB assay
    		[PMID: 23871905]
    MDA-MB-231 GI50
    0.56 μM
    Compound: ADR
    Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 72 hrs by sulforhodamine B assay
    Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 72 hrs by sulforhodamine B assay
    		[PMID: 25953156]
    MDA-MB-231 GI50
    0.61 μM
    Compound: Doxorubicin
    Cytotoxicity against human MDA-MB-231 cells by SRB assay
    Cytotoxicity against human MDA-MB-231 cells by SRB assay
    		[PMID: 19596579]
    MDA-MB-231 GI50
    0.76 μM
    Compound: Dox
    Antiproliferative activity against human MDA-MB-231 cells incubated for 72 hrs and measured by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells incubated for 72 hrs and measured by MTT assay
    		[PMID: 35973342]
    MDA-MB-231 GI50
    1 μM
    Compound: Doxorubicin
    Anticancer activity against human MDA-MB-231 cells assessed as growth inhibition
    Anticancer activity against human MDA-MB-231 cells assessed as growth inhibition
    		[PMID: 31830636]
    MDA-MB-231 GI50
    1.79 μM
    Compound: ADR
    Antiproliferative activity against human MDA-MB-231 cells by SRB assay
    Antiproliferative activity against human MDA-MB-231 cells by SRB assay
    		[PMID: 22738641]
    MDA-MB-231 GI50
    1.79 μM
    Compound: ADR
    Antiproliferative activity against human MDA-MB-231 cells by SRB method
    Antiproliferative activity against human MDA-MB-231 cells by SRB method
    		[PMID: 24835787]
    MDA-MB-231 GI50
    1.8 μM
    Compound: Doxorubicin
    Cytotoxicity against human MDA-MB-231 cells after 48 hrs by sulforhodamine B assay
    Cytotoxicity against human MDA-MB-231 cells after 48 hrs by sulforhodamine B assay
    		[PMID: 23964644]
    MDA-MB-231 GI50
    1.84 μM
    Compound: Doxorubicin
    Growth inhibition of human MDA-MB-231 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human MDA-MB-231 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 33477019]
    MDA-MB-231 GI50
    10.7 μM
    Compound: Doxorubicin
    Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by MTS-PMS assay
    Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by MTS-PMS assay
    		[PMID: 27614919]
    MDA-MB-231 GI50
    10.86 nM
    Compound: Doxorubicin
    Antitumor activity against human estrogen receptor deficient MDA-MB-231 cells assessed as inhibition of growth after 48 hrs using sulforhodamine B dye
    Antitumor activity against human estrogen receptor deficient MDA-MB-231 cells assessed as inhibition of growth after 48 hrs using sulforhodamine B dye
    		[PMID: 19428155]
    MDA-MB-231 GI50
    18 μg/mL
    Compound: doxorubicin
    Growth inhibition of human MDA-MB-231 cells cultured as 2D cells by tryphan blue based analysis
    Growth inhibition of human MDA-MB-231 cells cultured as 2D cells by tryphan blue based analysis
    		[PMID: 37104545]
    MDA-MB-231 GI50
    38 μg/mL
    Compound: doxorubicin
    Growth inhibition of human MDA-MB-231 cells cultured as 3D cells by tryphan blue based analysis
    Growth inhibition of human MDA-MB-231 cells cultured as 3D cells by tryphan blue based analysis
    		[PMID: 37104545]
    MDA-MB-231 GI50
    4.1 μM
    Compound: ADR
    Cytotoxicity in human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay
    Cytotoxicity in human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay
    		[PMID: 28754470]
    MDA-MB-231 GI50
    45 μg/mL
    Compound: doxorubicin
    Growth inhibition of human MDA-MB-231 cells cultured as 2.5D cells by tryphan blue based analysis
    Growth inhibition of human MDA-MB-231 cells cultured as 2.5D cells by tryphan blue based analysis
    		[PMID: 37104545]
    MDA-MB-231 GI50
    5.95 μM
    Compound: Dox
    Anticancer activity against human MDA-MB-231 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    Anticancer activity against human MDA-MB-231 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    		[PMID: 35533562]
    MDA-MB-231 GI50
    < 0.01 μM
    Compound: Doxorubicin
    Growth inhibition of human MDA-MB-231 cells after 48 hrs by SRB assay
    Growth inhibition of human MDA-MB-231 cells after 48 hrs by SRB assay
    		10.1039/C6MD00097E
    MDA-MB-231 GI50
    < 0.01 μM
    Compound: Doxorubicin
    Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by SRB assay
    Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by SRB assay
    		[PMID: 26994690]
    MDA-MB-231 GI50
    < 0.01 μM
    Compound: Doxorubicin
    Growth inhibition in human MDA-MB-231 cells after 48 hrs by SRB assay
    Growth inhibition in human MDA-MB-231 cells after 48 hrs by SRB assay
    		[PMID: 31546197]
    MDA-MB-231 IC50
    0.006 μM
    Compound: Doxorubicin
    Inhibitory activity against MDA-231 cell line using MTT assay (ER-,EGFR+,mutant p53)
    Inhibitory activity against MDA-231 cell line using MTT assay (ER-,EGFR+,mutant p53)
    		[PMID: 10780913]
    MDA-MB-231 IC50
    0.0069 μM
    Compound: Doxorubicin
    Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay
    		[PMID: 31264855]
    MDA-MB-231 IC50
    0.01 μM
    Compound: Doxorubicine
    Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs by Hoechst-33342 staining based cell counting method (Rvb > 25 microM)
    Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs by Hoechst-33342 staining based cell counting method (Rvb > 25 microM)
    		[PMID: 33422908]
    MDA-MB-231 IC50
    0.012 μM
    Compound: Doxorubicin
    Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by Hoechst 33342 staining-based assay
    Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by Hoechst 33342 staining-based assay
    		[PMID: 30655216]
    MDA-MB-231 IC50
    0.02 μM
    Compound: Doxorubicin
    Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell proliferation incubated for 72 hrs by conventional ATP quantification method
    Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell proliferation incubated for 72 hrs by conventional ATP quantification method
    		[PMID: 25937235]
    MDA-MB-231 IC50
    0.02 μM
    Compound: Doxorubicin
    Toxicity in human MDA-MB-231 cells assessed as reduction in cell number after 48 hrs by Hoechst 33342 staining based assay
    Toxicity in human MDA-MB-231 cells assessed as reduction in cell number after 48 hrs by Hoechst 33342 staining based assay
    		[PMID: 31753515]
    MDA-MB-231 IC50
    0.03 μM
    Compound: Doxorubicin
    Cytotoxicity against Homo sapiens (human) MDA-MB-231 cells assessed as growth inhibition after 72 hr by MTT assay
    Cytotoxicity against Homo sapiens (human) MDA-MB-231 cells assessed as growth inhibition after 72 hr by MTT assay
    		10.1007/s00044-012-0428-9
    MDA-MB-231 IC50
    0.03 μM
    Compound: Doxorubicin
    Cytotoxicity against human MDA-MB-231 cells assessed as cell growth inhibition
    Cytotoxicity against human MDA-MB-231 cells assessed as cell growth inhibition
    		[PMID: 26934105]
    MDA-MB-231 IC50
    0.03 μM
    Compound: doxorubicin
    Cytotoxicity against human MDA-MB-231 cells by MTT assay
    Cytotoxicity against human MDA-MB-231 cells by MTT assay
    		[PMID: 17141923]
    MDA-MB-231 IC50
    0.034 μM
    Compound: Doxorubicin
    Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    		[PMID: 31883489]
    MDA-MB-231 IC50
    0.04 μM
    Compound: Doxorubicin
    Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTS assay
    Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTS assay
    		[PMID: 23148652]
    MDA-MB-231 IC50
    0.04 μM
    Compound: Doxorubicin
    Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 48 hrs
    Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 48 hrs
    		[PMID: 34601029]
    MDA-MB-231 IC50
    0.047 nM
    Compound: Doxorubicine
    Cytotoxicity against human MDA231 cells after 72 hrs by MTS assay
    Cytotoxicity against human MDA231 cells after 72 hrs by MTS assay
    		[PMID: 21142180]
    MDA-MB-231 IC50
    0.05 μM
    Compound: Doxorubicin
    Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability
    Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability
    		[PMID: 31945642]
    MDA-MB-231 IC50
    0.06 μM
    Compound: Doxorubicin
    Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    		[PMID: 33743356]
    MDA-MB-231 IC50
    0.07 μM
    Compound: Doxorubicin
    Cytotoxicity against human MDA-MB-231 cells after 3 days by MTT assay
    Cytotoxicity against human MDA-MB-231 cells after 3 days by MTT assay
    		[PMID: 18547115]
    MDA-MB-231 IC50
    0.07 μM
    Compound: Doxorubicin
    Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay
    Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay
    		[PMID: 28257197]
    MDA-MB-231 IC50
    0.07 μM
    Compound: Doxorubicin
    Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    		[PMID: 28327308]
    MDA-MB-231 IC50
    0.07 μM
    Compound: doxorubicin
    Cytotoxicity against human MDA-MB-231cells after 6 days by MTT method
    Cytotoxicity against human MDA-MB-231cells after 6 days by MTT method
    		[PMID: 16309317]
    MDA-MB-231 IC50
    0.08 μM
    Compound: Doxorubicin
    Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 72 hrs by SRB assay
    Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 72 hrs by SRB assay
    		[PMID: 30457333]
    MDA-MB-231 IC50
    0.08 μM
    Compound: Doxorubicin
    Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 31546197]
    MDA-MB-231 IC50
    0.0805 μM
    Compound: Dox
    Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 96 hrs by MTT method
    Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 96 hrs by MTT method
    		[PMID: 34236840]
    MDA-MB-231 IC50
    0.09 μM
    Compound: DOX
    Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay
    Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay
    		[PMID: 25259516]
    MDA-MB-231 IC50
    0.09 μM
    Compound: DOX
    Cytotoxicity against human MDA-MB-231 cells assessed as cell growth inhibition after 72 hrs by MTT assay
    Cytotoxicity against human MDA-MB-231 cells assessed as cell growth inhibition after 72 hrs by MTT assay
    		[PMID: 26720155]
    MDA-MB-231 IC50
    0.09 μM
    Compound: DOX
    Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 28427016]
    MDA-MB-231 IC50
    0.09 μM
    Compound: DOX
    Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell growth after 72 hrs by MTT assay
    Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell growth after 72 hrs by MTT assay
    		[PMID: 30746062]
    MDA-MB-231 IC50
    0.09 μM
    Compound: DOX
    Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability measured after 6 days by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability measured after 6 days by MTT assay
    		[PMID: 32653698]
    MDA-MB-231 IC50
    0.09 μM
    Compound: DOX
    Antiproliferative activity against human MDA-MB-231 cells by MTT colorimetric assay
    Antiproliferative activity against human MDA-MB-231 cells by MTT colorimetric assay
    		[PMID: 38527380]
    MDA-MB-231 IC50
    0.09 μM
    Compound: DOX
    Antiproliferative activity against estrogen receptor negative human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    Antiproliferative activity against estrogen receptor negative human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    		[PMID: 39067378]
    MDA-MB-231 IC50
    0.09 μM
    Compound: Dox
    Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay
    		[PMID: 26494582]
    MDA-MB-231 IC50
    0.09 μM
    Compound: Dox
    Cytotoxicity against human MDA-MB-231 cells assessed as cell growth inhibition after 72 hrs by MTT assay
    Cytotoxicity against human MDA-MB-231 cells assessed as cell growth inhibition after 72 hrs by MTT assay
    		[PMID: 27231128]
    MDA-MB-231 IC50
    0.09 μM
    Compound: Doxorubicin
    Cytotoxicity against human MDA-MB-231 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
    Cytotoxicity against human MDA-MB-231 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
    		[PMID: 33340938]
    MDA-MB-231 IC50
    0.1 μM
    Compound: Doxo
    Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay
    Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay
    		[PMID: 20334960]
    MDA-MB-231 IC50
    0.1 μM
    Compound: Doxorubicin
    Cytotoxicity against Homo sapiens (human) MDA-MB-231 cells after 72 hr by MTT assay
    Cytotoxicity against Homo sapiens (human) MDA-MB-231 cells after 72 hr by MTT assay
    		10.1007/s00044-010-9517-9
    MDA-MB-231 IC50
    0.1 μM
    Compound: Doxorubicin
    Antiproliferative activity against human MDA-MB-231 cells assessed as cell viability after 24 hrs
    Antiproliferative activity against human MDA-MB-231 cells assessed as cell viability after 24 hrs
    		[PMID: 33139111]
    MDA-MB-231 IC50
    0.1 μM
    Compound: adriamycin
    Antitumor activity against human MDA-MB-231 cells by methylene blue staining method
    Antitumor activity against human MDA-MB-231 cells by methylene blue staining method
    		[PMID: 17656091]
    MDA-MB-231 IC50
    0.12 μM
    Compound: DOX
    Cytotoxicity against ER-negative human MDA-MB-231 cells assessed as growth inhibition after 48 hrs by MTT assay
    Cytotoxicity against ER-negative human MDA-MB-231 cells assessed as growth inhibition after 48 hrs by MTT assay
    		[PMID: 24148837]
    MDA-MB-231 IC50
    0.12 μM
    Compound: DOX
    Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay
    		[PMID: 25619894]
    MDA-MB-231 IC50
    0.12 μM
    Compound: Doxorubicin
    Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell proliferation after 3 days by MTS assay
    Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell proliferation after 3 days by MTS assay
    		10.1039/C1MD00155H
    MDA-MB-231 IC50
    0.12 μM
    Compound: Doxorubicin
    Cytotoxicity against estrogen receptor-deficient human MDA-MB-231 cells after 48 hrs by MTT assay
    Cytotoxicity against estrogen receptor-deficient human MDA-MB-231 cells after 48 hrs by MTT assay
    		10.1039/C2MD20327H
    MDA-MB-231 IC50
    0.12 μM
    Compound: Doxorubicin
    Cytotoxicity against ER-negative human MDA-MB-231 cells after 1 hr by SRB assay
    Cytotoxicity against ER-negative human MDA-MB-231 cells after 1 hr by SRB assay
    		[PMID: 22770744]
    MDA-MB-231 IC50
    0.12 μM
    Compound: Doxorubicin
    Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay
    		[PMID: 30108986]
    MDA-MB-231 IC50
    0.12 μM
    Compound: Doxorubicin
    Cytotoxicity against human MDA-MB-231 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
    Cytotoxicity against human MDA-MB-231 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
    		[PMID: 37951135]
    MDA-MB-231 IC50
    0.13 μM
    Compound: DOX
    Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 27668963]
    MDA-MB-231 IC50
    0.13 μM
    Compound: Doxorubicin
    Cytotoxicity against human MDA-MB-231 pcDNA cells assessed as reduction in cell viability after 72 hrs by RRA assay
    Cytotoxicity against human MDA-MB-231 pcDNA cells assessed as reduction in cell viability after 72 hrs by RRA assay
    		[PMID: 33508467]
    MDA-MB-231 IC50
    0.14 μM
    Compound: doxorubicin
    Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT colorimetric method
    Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT colorimetric method
    		[PMID: 17622129]
    MDA-MB-231 IC50
    0.15 μM
    Compound: Adriamycin
    In vitro antitumor activity against MB231 (breast) human tumor cell lines.
    In vitro antitumor activity against MB231 (breast) human tumor cell lines.
    		10.1016/0960-894X(96)00167-9
    MDA-MB-231 IC50
    0.153 μM
    Compound: Dox
    Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    		[PMID: 37837671]
    MDA-MB-231 IC50
    0.15 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human MDA-MB-231 cells by MTT assay
    Cytotoxicity against human MDA-MB-231 cells by MTT assay
    		[PMID: 18590313]
    MDA-MB-231 IC50
    0.16 μM
    Compound: Doxo
    Cytotoxicity against human MDA-MB-231 cells assessed as cell viability after 48 hrs by MTT assay
    Cytotoxicity against human MDA-MB-231 cells assessed as cell viability after 48 hrs by MTT assay
    		10.1039/C2MD20302B
    MDA-MB-231 IC50
    0.16 μM
    Compound: Doxorubicin
    Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell growth after 72 hrs by cell titer glo assay
    Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell growth after 72 hrs by cell titer glo assay
    		[PMID: 27080175]
    MDA-MB-231 IC50
    0.16 μM
    Compound: Doxorubicin
    Antiproliferative activity against 2D culture of human MDA-MB-231 cells after 72 hrs MTS assay
    Antiproliferative activity against 2D culture of human MDA-MB-231 cells after 72 hrs MTS assay
    		[PMID: 27721156]
    MDA-MB-231 IC50
    0.17 μM
    Compound: Dox
    Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay
    		[PMID: 26494582]
    MDA-MB-231 IC50
    0.17 μM
    Compound: Doxorubicin
    Cytotoxicity against human MDA-MB-231 cells after 72 hrs by resazurin/resorufin-based fluorescence assay
    Cytotoxicity against human MDA-MB-231 cells after 72 hrs by resazurin/resorufin-based fluorescence assay
    		[PMID: 23600925]
    MDA-MB-231 IC50
    0.18 μM
    Compound: DOX
    Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by SRB assay
    Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by SRB assay
    		[PMID: 30106296]
    MDA-MB-231 IC50
    0.18 μM
    Compound: DOX
    Cytotoxicity against human MDA-MB-231 cells measured after 72 hrs by Celltiter-Glo assay
    Cytotoxicity against human MDA-MB-231 cells measured after 72 hrs by Celltiter-Glo assay
    		[PMID: 31820976]
    MDA-MB-231 IC50
    0.18 μM
    Compound: doxorubicin
    Cytotoxicity against human MDA-MB-231 cells after 3 days by MTT assay
    Cytotoxicity against human MDA-MB-231 cells after 3 days by MTT assay
    		[PMID: 18419154]
    MDA-MB-231 IC50
    0.19 μg/mL
    Compound: doxo
    Cytotoxicity against human MDA-MB-231 cells by MTT method
    Cytotoxicity against human MDA-MB-231 cells by MTT method
    		[PMID: 17417907]
    MDA-MB-231 IC50
    0.1 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human MDA-MB-231 cells by MTT colorimetric method
    Cytotoxicity against human MDA-MB-231 cells by MTT colorimetric method
    		[PMID: 17125220]
    MDA-MB-231 IC50
    0.2 μM
    Compound: Doxorubicin
    Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by SRB assay
    Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by SRB assay
    		[PMID: 18063366]
    MDA-MB-231 IC50
    0.2 μM
    Compound: Doxorubicin
    Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay
    Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay
    		[PMID: 19394829]
    MDA-MB-231 IC50
    0.2 μM
    Compound: Doxorubicin
    Antiproliferative activity against human MDA-MB-231 cells assessed as cell viability after 72 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells assessed as cell viability after 72 hrs by MTT assay
    		[PMID: 24012378]
    MDA-MB-231 IC50
    0.21 μM
    Compound: DOX
    Anti-proliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    Anti-proliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    		[PMID: 38776807]
    MDA-MB-231 IC50
    0.23 μM
    Compound: DOX
    Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by SRB assay
    Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by SRB assay
    		[PMID: 30106296]
    MDA-MB-231 IC50
    0.23 μM
    Compound: Doxorubicin
    Antiproliferative activity against 3D culture of human MDA-MB-231 cells after 72 hrs MTS assay
    Antiproliferative activity against 3D culture of human MDA-MB-231 cells after 72 hrs MTS assay
    		[PMID: 27721156]
    MDA-MB-231 IC50
    0.24 μM
    Compound: Doxorubucin
    Cytotoxicity against human MDA-MB-231 cells by MTT assay
    Cytotoxicity against human MDA-MB-231 cells by MTT assay
    		[PMID: 20718475]
    MDA-MB-231 IC50
    0.24 μg/mL
    Compound: Adriamycin
    Inhibitory concentration required against MDA-MB-231 breast cancer cell line
    Inhibitory concentration required against MDA-MB-231 breast cancer cell line
    		[PMID: 11354370]
    MDA-MB-231 IC50
    0.25 μM
    Compound: Dox
    Antiproliferative activity against human MDA-MB-231 cells assessed as growth inhibition under hypoxia conditions measured after 72 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells assessed as growth inhibition under hypoxia conditions measured after 72 hrs by MTT assay
    		[PMID: 34902732]
    MDA-MB-231 IC50
    0.25 μM
    Compound: Doxorubicin
    Growth inhibition of human MDA-MB-231 cells after 72 hrs by MTT assay
    Growth inhibition of human MDA-MB-231 cells after 72 hrs by MTT assay
    		[PMID: 30471828]
    MDA-MB-231 IC50
    0.26 μM
    Compound: Dox
    Antiproliferative activity against human MDA-MB-231 cells after 24 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells after 24 hrs by MTT assay
    		[PMID: 26494582]
    MDA-MB-231 IC50
    0.27 μM
    Compound: Doxorubicin
    Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    		[PMID: 39026643]
    MDA-MB-231 IC50
    0.2 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human MDA-MB-231 cells by MTT assay
    Cytotoxicity against human MDA-MB-231 cells by MTT assay
    		[PMID: 16724859]
    MDA-MB-231 IC50
    0.2 μg/mL
    Compound: Doxorubicin
    Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by CCK-8 assay
    Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by CCK-8 assay
    		[PMID: 22658083]
    MDA-MB-231 IC50
    0.2 μg/mL
    Compound: doxorubicin
    Cytotoxicity against human MDA-MB-231 cells by MTT assay
    Cytotoxicity against human MDA-MB-231 cells by MTT assay
    		[PMID: 18973388]
    MDA-MB-231 IC50
    0.3 μM
    Compound: DOX
    Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay
    		[PMID: 30429098]
    MDA-MB-231 IC50
    0.3 μM
    Compound: Doxorubicin
    Anticancer activity against human MDA-MB-231 cells assessed as inhibition of cell growth measured after 72 hrs by SRB assay
    Anticancer activity against human MDA-MB-231 cells assessed as inhibition of cell growth measured after 72 hrs by SRB assay
    		[PMID: 33940466]
    MDA-MB-231 IC50
    0.31 μM
    Compound: Doxorubicin
    Antiproliferative activity against human MDA-MB-231 cells after 72 hrs
    Antiproliferative activity against human MDA-MB-231 cells after 72 hrs
    		[PMID: 25127463]
    MDA-MB-231 IC50
    0.32 μM
    Compound: ADM
    Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
    		[PMID: 36332551]
    MDA-MB-231 IC50
    0.33 μM
    Compound: Dox
    Antiproliferative activity against human MDA-MB-231 cells assessed as growth inhibition under normoxia conditions measured after 72 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells assessed as growth inhibition under normoxia conditions measured after 72 hrs by MTT assay
    		[PMID: 34902732]
    MDA-MB-231 IC50
    0.36 μM
    Compound: Doxorubicin
    Cytotoxic activity in human MDA-MB-231 cells assessed as reduction in cell viability incubated for 3 days by MTT assay
    Cytotoxic activity in human MDA-MB-231 cells assessed as reduction in cell viability incubated for 3 days by MTT assay
    		[PMID: 28395220]
    MDA-MB-231 IC50
    0.369 μM
    Compound: Doxorubicin
    Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay
    		[PMID: 28406643]
    MDA-MB-231 IC50
    0.37 μg/mL
    Compound: Doxorubicin
    Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay
    Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay
    		[PMID: 34973507]
    MDA-MB-231 IC50
    0.38 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human MDA-MB-231 cells
    Cytotoxicity against human MDA-MB-231 cells
    		[PMID: 23511021]
    MDA-MB-231 IC50
    0.39 μM
    Compound: Adriamycin
    Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay
    Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay
    		[PMID: 21721528]
    MDA-MB-231 IC50
    0.41 μM
    Compound: Doxorubicin
    Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    		[PMID: 37216812]
    MDA-MB-231 IC50
    0.414 nM
    Compound: Doxorubicin
    Cytotoxicity against human MDA-MB-231 cells assessed as cell viability after 5 days by cell viability analyzer
    Cytotoxicity against human MDA-MB-231 cells assessed as cell viability after 5 days by cell viability analyzer
    		[PMID: 26291039]
    MDA-MB-231 IC50
    0.42 μM
    Compound: Dox
    Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay
    		[PMID: 35339100]
    MDA-MB-231 IC50
    0.44 μM
    Compound: DOX
    Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition after 72 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition after 72 hrs by MTT assay
    		[PMID: 33276990]
    MDA-MB-231 IC50
    0.44 μM
    Compound: Doxorubicin
    Cytotoxicity against human MDA-MB-231 cells under hypoxic condition by MTT assay
    Cytotoxicity against human MDA-MB-231 cells under hypoxic condition by MTT assay
    		[PMID: 29684705]
    MDA-MB-231 IC50
    0.45 μM
    Compound: DOX
    Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 72 hrs by MTT assay
    Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 72 hrs by MTT assay
    		[PMID: 27016707]
    MDA-MB-231 IC50
    0.45 μM
    Compound: DOX
    Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell growth measured after 72 hrs by CCK8 assay
    Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell growth measured after 72 hrs by CCK8 assay
    		[PMID: 31784322]
    MDA-MB-231 IC50
    0.45 μM
    Compound: Doxorubicin
    Cytotoxicity against human MDA-MB-231 cells assessed as effect on cell viability measured after 48 hrs by MTT assay
    Cytotoxicity against human MDA-MB-231 cells assessed as effect on cell viability measured after 48 hrs by MTT assay
    		[PMID: 27521588]
    MDA-MB-231 IC50
    0.45 μg/mL
    Compound: Doxorubicin
    Anticancer activity against human MDA-MB-231 cells by MTT assay
    Anticancer activity against human MDA-MB-231 cells by MTT assay
    		[PMID: 31404864]
    MDA-MB-231 IC50
    0.46 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human MDA-MB-231 cells after 3 days by MTT assay
    Cytotoxicity against human MDA-MB-231 cells after 3 days by MTT assay
    		[PMID: 19691312]
    MDA-MB-231 IC50
    0.47 μM
    Compound: DOX
    Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell viability incubated for 72 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell viability incubated for 72 hrs by MTT assay
    		[PMID: 35818137]
    MDA-MB-231 IC50
    0.4817 μM
    Compound: Doxorubicin
    Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
    		[PMID: 34325324]
    MDA-MB-231 IC50
    0.49 μM
    Compound: Doxorubicin
    Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay
    		[PMID: 28554092]
    MDA-MB-231 IC50
    0.5 μM
    Compound: Doxorubicin
    Cytotoxicity against human MDA-MB-231 cells after 72 hrs by Alamar blue assay
    Cytotoxicity against human MDA-MB-231 cells after 72 hrs by Alamar blue assay
    		[PMID: 21999655]
    MDA-MB-231 IC50
    0.5 μM
    Compound: Doxorubicin
    Cytotoxicity against human MDA-MB-231 cells by MTT assay
    Cytotoxicity against human MDA-MB-231 cells by MTT assay
    		[PMID: 23911578]
    MDA-MB-231 IC50
    0.5 μM
    Compound: Doxorubicin
    Cytotoxicity against human MDA-MB-231 cells by MTT assay
    Cytotoxicity against human MDA-MB-231 cells by MTT assay
    		[PMID: 25172420]
    MDA-MB-231 IC50
    0.501 μM
    Compound: Doxorubicin
    Cytotoxicity against human MDA-MB-231 cells by MTT assay
    Cytotoxicity against human MDA-MB-231 cells by MTT assay
    		[PMID: 23764302]
    MDA-MB-231 IC50
    0.501 μM
    Compound: Doxorubicin
    Cytotoxicity against human MDA-MB-231 cells by MTT assay
    Cytotoxicity against human MDA-MB-231 cells by MTT assay
    		[PMID: 24113366]
    MDA-MB-231 IC50
    0.53 μM
    Compound: ADR
    Cytotoxicity in human MDA-MB-231 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    Cytotoxicity in human MDA-MB-231 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    		[PMID: 28754470]
    MDA-MB-231 IC50
    0.53 μM
    Compound: DOX
    Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay
    		[PMID: 37602711]
    MDA-MB-231 IC50
    0.53 μM
    Compound: Dox
    Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay
    Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay
    		[PMID: 33713977]
    MDA-MB-231 IC50
    0.53 μM
    Compound: Dox
    Cytotoxicity against human MDA-MB-231 cells by MTT assay
    Cytotoxicity against human MDA-MB-231 cells by MTT assay
    		[PMID: 36057236]
    MDA-MB-231 IC50
    0.53 μM
    Compound: Dox
    Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell growth by MTT assay
    Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell growth by MTT assay
    		[PMID: 36336315]
    MDA-MB-231 IC50
    0.55 μM
    Compound: Doxorubicin
    Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell survival after 48 hrs by MTT assay
    Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell survival after 48 hrs by MTT assay
    		[PMID: 28494255]
    MDA-MB-231 IC50
    0.55 μM
    Compound: Doxorubicin
    Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    		[PMID: 31546197]
    MDA-MB-231 IC50
    0.55 μM
    Compound: Doxorubicin
    Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay
    		[PMID: 34315044]
    MDA-MB-231 IC50
    0.57 μM
    Compound: Doxorubicin
    Cytotoxicity against human MDA-MB-231 cells incubated for 72 hrs by Sulphorhodamine assay
    Cytotoxicity against human MDA-MB-231 cells incubated for 72 hrs by Sulphorhodamine assay
    		[PMID: 37146520]
    MDA-MB-231 IC50
    0.58 μM
    Compound: Doxorubicin
    Cytotoxicity against human MDA-MB-231 cells after 72 hrs by resazurin/AlamarBlue dye-based fluorescence assay
    Cytotoxicity against human MDA-MB-231 cells after 72 hrs by resazurin/AlamarBlue dye-based fluorescence assay
    		[PMID: 28139929]
    MDA-MB-231 IC50
    0.58 μM
    Compound: doxorubicin
    Cytotoxicity against human MDA-MB-231 cells after 72 hrs by Alamar blue assay
    Cytotoxicity against human MDA-MB-231 cells after 72 hrs by Alamar blue assay
    		[PMID: 22264149]
    MDA-MB-231 IC50
    0.6 μM
    Compound: DOX
    Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability measured after 72 hrs under hypoxia condition by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability measured after 72 hrs under hypoxia condition by MTT assay
    		[PMID: 38283214]
    MDA-MB-231 IC50
    0.6 μM
    Compound: Doxorubicin
    Cytotoxicity against human MDA-MB-231 cells by MTT assay
    Cytotoxicity against human MDA-MB-231 cells by MTT assay
    		[PMID: 24300737]
    MDA-MB-231 IC50
    0.6 μM
    Compound: Doxorubicin
    Cytotoxicity against human MDA-MB-231 cells after 24 hrs by MTT assay
    Cytotoxicity against human MDA-MB-231 cells after 24 hrs by MTT assay
    		[PMID: 26252628]
    MDA-MB-231 IC50
    0.6 μM
    Compound: Doxorubicin
    Anticancer activity against human MDA-MB-231 cells incubated for 24 hrs by MTT assay
    Anticancer activity against human MDA-MB-231 cells incubated for 24 hrs by MTT assay
    		[PMID: 28579122]
    MDA-MB-231 IC50
    0.6 μM
    Compound: Doxorubicin
    Cytotoxicity against human MDA-MB-231 cells by resazurin dye based Alamar blue assay
    Cytotoxicity against human MDA-MB-231 cells by resazurin dye based Alamar blue assay
    		[PMID: 29373790]
    MDA-MB-231 IC50
    0.6 μM
    Compound: Doxorubicin
    Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 24 hrs in hypoxic condition by MTT assay
    Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 24 hrs in hypoxic condition by MTT assay
    		[PMID: 31404864]
    MDA-MB-231 IC50
    0.6 μM
    Compound: Doxorubicin
    Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 24 hrs in normoxic condition by MTT assay
    Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 24 hrs in normoxic condition by MTT assay
    		[PMID: 31404864]
    MDA-MB-231 IC50
    0.6 μM
    Compound: Doxorubicin
    Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 96 hrs under normaxic condition by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 96 hrs under normaxic condition by MTT assay
    		[PMID: 31546197]
    MDA-MB-231 IC50
    0.6 μM
    Compound: Doxorubicin
    Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability preincubated for 24 hrs under hypoxia condition further incubated for 72 hrs under normaxic condition by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability preincubated for 24 hrs under hypoxia condition further incubated for 72 hrs under normaxic condition by MTT assay
    		[PMID: 31546197]
    MDA-MB-231 IC50
    0.6 μM
    Compound: Doxorubicin
    Antiproliferative activity against human MDA-MB-231 cells incubated for 96 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells incubated for 96 hrs by MTT assay
    		[PMID: 38340509]
    MDA-MB-231 IC50
    0.65 μM
    Compound: Doxorubicin
    Cytotoxicity against estrogen receptor-negative human MDA-MB-231 cells after 24 hrs by MTT assay
    Cytotoxicity against estrogen receptor-negative human MDA-MB-231 cells after 24 hrs by MTT assay
    		[PMID: 24513041]
    MDA-MB-231 IC50
    0.65 μg/mL
    Compound: doxorubicin
    Cytotoxicity against human MDA-MB-231 cells after 3 days by MTT assay
    Cytotoxicity against human MDA-MB-231 cells after 3 days by MTT assay
    		[PMID: 16252914]
    MDA-MB-231 IC50
    0.68 μM
    Compound: doxorubicin
    Cytotoxicity against human MDA-MB-231 cells after 72 hrs by Alamar Blue assay
    Cytotoxicity against human MDA-MB-231 cells after 72 hrs by Alamar Blue assay
    		[PMID: 24251417]
    MDA-MB-231 IC50
    0.6 μg/mL
    Compound: Doxorubicin
    Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell viability by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell viability by MTT assay
    		[PMID: 32223924]
    MDA-MB-231 IC50
    0.7 μM
    Compound: Doxorubicin
    Cytotoxicity against human MDA-MB-231 cells by MTT assay
    Cytotoxicity against human MDA-MB-231 cells by MTT assay
    		[PMID: 26586599]
    MDA-MB-231 IC50
    0.7 μM
    Compound: Doxorubicin
    Cytotoxicity against human MDA-MB-231 cells incubated for 24 hrs by MTT asasy
    Cytotoxicity against human MDA-MB-231 cells incubated for 24 hrs by MTT asasy
    		[PMID: 28615134]
    MDA-MB-231 IC50
    0.7 μM
    Compound: Doxorubicin
    Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell proliferation measured after 72 hrs by resazurin dye based AlamarBlue assay
    Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell proliferation measured after 72 hrs by resazurin dye based AlamarBlue assay
    		[PMID: 34495663]
    MDA-MB-231 IC50
    0.72 μM
    Compound: Doxorubicin
    Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay
    		[PMID: 27886545]
    MDA-MB-231 IC50
    0.73 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human MDA-MB-231 cells after 3 days by MTT assay
    Cytotoxicity against human MDA-MB-231 cells after 3 days by MTT assay
    		[PMID: 15387653]
    MDA-MB-231 IC50
    0.75 μM
    Compound: DOX
    Antiproliferative activity against ER negative human MDA-MB-231 cells assessed as inhibition of cell growth after 48 hrs by MTT assay
    Antiproliferative activity against ER negative human MDA-MB-231 cells assessed as inhibition of cell growth after 48 hrs by MTT assay
    		[PMID: 25737400]
    MDA-MB-231 IC50
    0.75 μM
    Compound: Doxorubicin
    Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay
    		[PMID: 28886509]
    MDA-MB-231 IC50
    0.78 μM
    Compound: DOX
    Antiproliferative activity against human MDA-MB-231 cells after 24 hrs by SRB assay
    Antiproliferative activity against human MDA-MB-231 cells after 24 hrs by SRB assay
    		[PMID: 30106296]
    MDA-MB-231 IC50
    0.79 μM
    Compound: Dox
    Antiproliferative activity against human MDA-MB-231 cells by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells by MTT assay
    		[PMID: 38387333]
    MDA-MB-231 IC50
    0.8 μM
    Compound: Dox
    Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 24 hrs by MTT assay
    Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 24 hrs by MTT assay
    		[PMID: 24507927]
    MDA-MB-231 IC50
    0.8 μM
    Compound: Dox
    Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth after 48 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth after 48 hrs by MTT assay
    		[PMID: 33479622]
    MDA-MB-231 IC50
    0.8 μM
    Compound: Doxorubicin
    Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 24 hrs by MTT assay
    Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 24 hrs by MTT assay
    		[PMID: 24780595]
    MDA-MB-231 IC50
    0.81 μM
    Compound: DOX
    Cytotoxicity against human MDA-MB-231 cells expressing high level of topoisomerase I/II measured after 72 hrs by MTT assay
    Cytotoxicity against human MDA-MB-231 cells expressing high level of topoisomerase I/II measured after 72 hrs by MTT assay
    		[PMID: 35612499]
    MDA-MB-231 IC50
    0.85 μM
    Compound: Doxorubicin
    Cytotoxicity against human MDA-MB-231 cells assessed as cell viability at 0.1 to 100 uM after 48 hrs by MTT assay
    Cytotoxicity against human MDA-MB-231 cells assessed as cell viability at 0.1 to 100 uM after 48 hrs by MTT assay
    		[PMID: 26263187]
    MDA-MB-231 IC50
    0.88 μM
    Compound: Doxorubicin
    Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay
    Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay
    		[PMID: 25419616]
    MDA-MB-231 IC50
    0.89 μM
    Compound: DX
    Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs by CCK-8 method
    Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs by CCK-8 method
    		[PMID: 38039788]
    MDA-MB-231 IC50
    0.9 μM
    Compound: Doxorubicin
    Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 72 hrs by MTT assay
    Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 72 hrs by MTT assay
    		[PMID: 24044895]
    MDA-MB-231 IC50
    0.9 μM
    Compound: Doxorubicin
    Cytotoxicity against human MDA-MB-231 cells assessed as cell death after 24 hrs by MTS assay
    Cytotoxicity against human MDA-MB-231 cells assessed as cell death after 24 hrs by MTS assay
    		[PMID: 29757646]
    MDA-MB-231 IC50
    0.91 μM
    Compound: Adriamycin
    Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 48 hrs by MTT assay
    Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 48 hrs by MTT assay
    		[PMID: 26356746]
    MDA-MB-231 IC50
    0.91 μM
    Compound: Doxorubicin
    Cytotoxicity against human MDA-MB-231 cells after 2 days by MTT assay
    Cytotoxicity against human MDA-MB-231 cells after 2 days by MTT assay
    		[PMID: 23932340]
    MDA-MB-231 IC50
    0.91 μM
    Compound: Doxorubicin
    Cytotoxicity against human MDA-MB-231 cells by MTT assay
    Cytotoxicity against human MDA-MB-231 cells by MTT assay
    		[PMID: 24287557]
    MDA-MB-231 IC50
    0.91 μM
    Compound: Doxorubicin
    In vitro cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition by MTT assay
    In vitro cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition by MTT assay
    		[PMID: 24742385]
    MDA-MB-231 IC50
    0.91 μM
    Compound: Doxorubicin
    Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 48 hrs by MTT assay
    Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 48 hrs by MTT assay
    		[PMID: 26433616]
    MDA-MB-231 IC50
    0.98 μM
    Compound: Adriamycin
    Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell proliferation after 48 hrs by XTT assay
    Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell proliferation after 48 hrs by XTT assay
    		[PMID: 24717154]
    MDA-MB-231 IC50
    1 μM
    Compound: Doxorubicin
    Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition by MTT assay
    Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition by MTT assay
    		[PMID: 25765907]
    MDA-MB-231 IC50
    1.05 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human MDA-MB-231 cells
    Cytotoxicity against human MDA-MB-231 cells
    		[PMID: 20036537]
    MDA-MB-231 IC50
    1.07 μM
    Compound: DOX
    Cytotoxicity against human MDA-MB-231 cells after 96 hrs under normoxic condition by MTT assay
    Cytotoxicity against human MDA-MB-231 cells after 96 hrs under normoxic condition by MTT assay
    		[PMID: 29649740]
    MDA-MB-231 IC50
    1.07 μM
    Compound: DOX
    Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability measured after 72 hrs under normoxia condition by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability measured after 72 hrs under normoxia condition by MTT assay
    		[PMID: 38283214]
    MDA-MB-231 IC50
    1.13 μM
    Compound: Doxorubicin
    Antitumor activity against human MDA231 cells after 24 to 48 hrs by MTT assay
    Antitumor activity against human MDA231 cells after 24 to 48 hrs by MTT assay
    		[PMID: 21553829]
    MDA-MB-231 IC50
    1.151 μM
    Compound: DOX
    Cytotoxicity against human MDA-MB-231 cells incubated for 48 hrs by MTT assay
    Cytotoxicity against human MDA-MB-231 cells incubated for 48 hrs by MTT assay
    		[PMID: 38185054]
    MDA-MB-231 IC50
    1.2 μM
    Compound: Doxorubicin
    Cytotoxicity against human MDA-MB-231 cells by MTT assay
    Cytotoxicity against human MDA-MB-231 cells by MTT assay
    		[PMID: 29975532]
    MDA-MB-231 IC50
    1.23 μM
    Compound: Doxorubicin
    Cytotoxicity against triple-negative human MDA-MB-231 cells assessed as redution in cell viability incubated for 72 hrs by SRB assay
    Cytotoxicity against triple-negative human MDA-MB-231 cells assessed as redution in cell viability incubated for 72 hrs by SRB assay
    		[PMID: 31810778]
    MDA-MB-231 IC50
    1.246 μM
    Compound: Doxorubicin
    Cytotoxicity activity against human MDA-MB-231 cells assessed as cell growth inhibition after 48 hrs by MTT assay
    Cytotoxicity activity against human MDA-MB-231 cells assessed as cell growth inhibition after 48 hrs by MTT assay
    		[PMID: 30433783]
    MDA-MB-231 IC50
    1.27 μM
    Compound: Doxorubicin
    Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    		[PMID: 30389295]
    MDA-MB-231 IC50
    1.3 μM
    Compound: Doxorubicin
    Growth inhibition of human MDA-MB-231 cells by MTT assay
    Growth inhibition of human MDA-MB-231 cells by MTT assay
    		[PMID: 33901643]
    MDA-MB-231 IC50
    1.32 μM
    Compound: II
    Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay
    Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay
    		[PMID: 29289881]
    MDA-MB-231 IC50
    1.32 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human MDA-MB-231 cells by MTT assay
    Cytotoxicity against human MDA-MB-231 cells by MTT assay
    		[PMID: 21106454]
    MDA-MB-231 IC50
    1.36 μM
    Compound: Doxorubicin
    Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay
    		[PMID: 24941129]
    MDA-MB-231 IC50
    1.39 μM
    Compound: adriamycin
    Cytotoxicity against human MDA-MB-231 cells
    Cytotoxicity against human MDA-MB-231 cells
    		[PMID: 18178085]
    MDA-MB-231 IC50
    1.39 μg/mL
    Compound: doxorubicin
    Cytotoxicity against human MDA-MB-231 cells by MTT assay
    Cytotoxicity against human MDA-MB-231 cells by MTT assay
    		[PMID: 22413887]
    MDA-MB-231 IC50
    1.4 μM
    Compound: Adriamycin
    Cytotoxicity against human MDA-MB-231 cells after 4 days by MTT assay
    Cytotoxicity against human MDA-MB-231 cells after 4 days by MTT assay
    		[PMID: 21704436]
    MDA-MB-231 IC50
    1.43 μM
    Compound: Doxorubicin
    Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability after 24 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability after 24 hrs by MTT assay
    		[PMID: 31546197]
    MDA-MB-231 IC50
    1.43 μM
    Compound: Doxorubicin
    Antiproliferative activity against human MDA-MB-231 cells
    Antiproliferative activity against human MDA-MB-231 cells
    		[PMID: 31945642]
    MDA-MB-231 IC50
    1.47 μM
    Compound: Dox
    Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay
    Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay
    		[PMID: 25247771]
    MDA-MB-231 IC50
    1.5 μM
    Compound: DOX
    Cytotoxicity against human MDA-MB-231 cells (Rvb = 3.0 uM)
    Cytotoxicity against human MDA-MB-231 cells (Rvb = 3.0 uM)
    		[PMID: 34303870]
    MDA-MB-231 IC50
    1.546 μM
    Compound: Doxorubicin
    Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 72 hrs by MTT assay
    Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 72 hrs by MTT assay
    		[PMID: 25703298]
    MDA-MB-231 IC50
    1.6 μM
    Compound: Doxorubicin
    Cytotoxicity against human MDA-MB-231 cells assessed as decrease in cell viability after 24 hrs by MTT assay
    Cytotoxicity against human MDA-MB-231 cells assessed as decrease in cell viability after 24 hrs by MTT assay
    		[PMID: 27496212]
    MDA-MB-231 IC50
    1.6 μM
    Compound: Doxorubicin
    Anticancer activity against human MDA-MB-231 cells assessed as growth inhibition incubated for 48 hrs by MTT assay
    Anticancer activity against human MDA-MB-231 cells assessed as growth inhibition incubated for 48 hrs by MTT assay
    		[PMID: 34363936]
    MDA-MB-231 IC50
    1.67 μM
    Compound: Doxorubicin
    Cytotoxicity against human MDA-MB-231 cells assessed as cell growth inhibition after 48 hrs by MTT assay
    Cytotoxicity against human MDA-MB-231 cells assessed as cell growth inhibition after 48 hrs by MTT assay
    		[PMID: 26708114]
    MDA-MB-231 IC50
    1.69 μM
    Compound: DOX
    Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay
    Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay
    		[PMID: 24487188]
    MDA-MB-231 IC50
    1.69 μM
    Compound: Doxorubicin
    Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell viability after 48 hrs by MTT assay
    Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell viability after 48 hrs by MTT assay
    		[PMID: 24953027]
    MDA-MB-231 IC50
    1.8 μM
    Compound: Doxorubicin
    Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by SRB assay
    Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by SRB assay
    		[PMID: 28419927]
    MDA-MB-231 IC50
    1.8 μM
    Compound: Doxorubicin
    Antiproliferative activity against human MDA-MB-231 cells measured after 48 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells measured after 48 hrs by MTT assay
    		[PMID: 33316752]
    MDA-MB-231 IC50
    1.81 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against Homo sapiens (human) MDA-MB-231 cells assessed as cell viability after 48 hr by MTT assay
    Cytotoxicity against Homo sapiens (human) MDA-MB-231 cells assessed as cell viability after 48 hr by MTT assay
    		10.1007/s00044-012-0168-x
    MDA-MB-231 IC50
    1.93 μM
    Compound: Doxo
    Cytotoxicity against human MDA-MB-231 cells after 3 days by MTT assay
    Cytotoxicity against human MDA-MB-231 cells after 3 days by MTT assay
    		[PMID: 21800859]
    MDA-MB-231 IC50
    10 μM
    Compound: Doxorubicin
    Growth inhibition of human MDA-MB-231 cells
    Growth inhibition of human MDA-MB-231 cells
    		[PMID: 22464458]
    MDA-MB-231 IC50
    10.02 μM
    Compound: Dox
    Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 28549734]
    MDA-MB-231 IC50
    10.2 μM
    Compound: DOX
    Cytotoxicity against human MDA-MB-231 cells MTT assay
    Cytotoxicity against human MDA-MB-231 cells MTT assay
    		[PMID: 19329312]
    MDA-MB-231 IC50
    106 nM
    Compound: DOX
    Anticancer activity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Anticancer activity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 33901898]
    MDA-MB-231 IC50
    1240 nM
    Compound: Doxorubicin
    Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
    Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
    		[PMID: 30429975]
    MDA-MB-231 IC50
    14.35 μM
    Compound: Doxorubicin
    Cytotoxicity against human MDA-MB-231 cells after 24 hrs by MTT assay
    Cytotoxicity against human MDA-MB-231 cells after 24 hrs by MTT assay
    		[PMID: 20064676]
    MDA-MB-231 IC50
    14.66 μM
    Compound: Dox
    Cytotoxicity against human MDA-MB-231 cells assessed as decrease in cell viability treated for 2 hrs measured after 48 hrs by MTT assay
    Cytotoxicity against human MDA-MB-231 cells assessed as decrease in cell viability treated for 2 hrs measured after 48 hrs by MTT assay
    		[PMID: 28129977]
    MDA-MB-231 IC50
    17.6 μM
    Compound: adriamycin
    Cytotoxicity against human MDA-MB-231 cells after 4 days by MTT assay
    Cytotoxicity against human MDA-MB-231 cells after 4 days by MTT assay
    		[PMID: 17194586]
    MDA-MB-231 IC50
    19.01 μM
    Compound: Doxorubicin
    Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay
    Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay
    		[PMID: 22818039]
    MDA-MB-231 IC50
    2 μM
    Compound: Doxorubicin
    Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay
    		[PMID: 25453802]
    MDA-MB-231 IC50
    2 μM
    Compound: doxorubicin
    Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay
    Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay
    		[PMID: 20405844]
    MDA-MB-231 IC50
    2.01 μM
    Compound: ADM
    Cytotoxicity against human MDA-MB-231 cells after 38 hrs by MTT assay
    Cytotoxicity against human MDA-MB-231 cells after 38 hrs by MTT assay
    		[PMID: 25965778]
    MDA-MB-231 IC50
    2.1 μM
    Compound: Doxorubicin
    Cytotoxicity against human MDA-MB-231 cells by WST-1 assay
    Cytotoxicity against human MDA-MB-231 cells by WST-1 assay
    		[PMID: 22197145]
    MDA-MB-231 IC50
    2.1 μM
    Compound: Doxorubicin
    Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay
    Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay
    		[PMID: 22749279]
    MDA-MB-231 IC50
    2.1 μM
    Compound: Doxorubicin
    Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability measured after 48 hrs by SRB assay
    Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability measured after 48 hrs by SRB assay
    		[PMID: 28818768]
    MDA-MB-231 IC50
    2.2 μM
    Compound: DOX
    Antiproliferative activity against human MDA-MB-231 cells measured by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells measured by MTT assay
    		[PMID: 33860662]
    MDA-MB-231 IC50
    2.2 μM
    Compound: DOX
    Cytotoxicity against human MDA-MB-231 cells measured by MTT assay
    Cytotoxicity against human MDA-MB-231 cells measured by MTT assay
    		[PMID: 33860662]
    MDA-MB-231 IC50
    2.2 μM
    Compound: Doxorubicin
    Cytotoxicity against human MDA-MB-231 cells by MTT assay
    Cytotoxicity against human MDA-MB-231 cells by MTT assay
    		[PMID: 21425785]
    MDA-MB-231 IC50
    2.25 μM
    Compound: Doxorubicin
    Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay
    Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay
    		[PMID: 28390228]
    MDA-MB-231 IC50
    2.3 μM
    Compound: Doxorubicin
    Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay
    Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay
    		[PMID: 20832916]
    MDA-MB-231 IC50
    2.36 μM
    Compound: DOX
    Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay
    Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay
    		[PMID: 32435420]
    MDA-MB-231 IC50
    2.56 μM
    Compound: Doxorubicin
    Anticancer activity against human MDA-MB-231 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
    Anticancer activity against human MDA-MB-231 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
    		[PMID: 34124677]
    MDA-MB-231 IC50
    2.76 μM
    Compound: Doxorubicin
    Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell proliferation measured after 72 hrs by CCK-8 assay
    Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell proliferation measured after 72 hrs by CCK-8 assay
    		[PMID: 34365102]
    MDA-MB-231 IC50
    2.8 μM
    Compound: Doxorubicin
    Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 29789258]
    MDA-MB-231 IC50
    2.86 μM
    Compound: Doxorubicin
    Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay
    Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay
    		[PMID: 33744443]
    MDA-MB-231 IC50
    2.9 μM
    Compound: Doxorubicin
    Antiproliferative activity against human MDA-MB-231 cells after 4 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells after 4 hrs by MTT assay
    		[PMID: 25453798]
    MDA-MB-231 IC50
    22.2 nM
    Compound: Dox
    Inhibition of human MDA-MB-231 cell spheroids incubated for 7 days by luciferase based assay
    Inhibition of human MDA-MB-231 cell spheroids incubated for 7 days by luciferase based assay
    		[PMID: 36780832]
    MDA-MB-231 IC50
    25.8 μM
    Compound: Doxorubicin
    Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Blue cell viability assay
    Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Blue cell viability assay
    		[PMID: 35271771]
    MDA-MB-231 IC50
    3.06 μM
    Compound: Adriamycin
    Cytotoxicity against human MDA-MB-231 cells selected at 100 ug/ml vinblastine after 72 hrs by MTT assay
    Cytotoxicity against human MDA-MB-231 cells selected at 100 ug/ml vinblastine after 72 hrs by MTT assay
    		[PMID: 21721528]
    MDA-MB-231 IC50
    3.07 μM
    Compound: Doxorubicin
    Cytotoxicity against human MDA-MB-231 cells
    Cytotoxicity against human MDA-MB-231 cells
    		[PMID: 22123320]
    MDA-MB-231 IC50
    3.1 μM
    Compound: Doxorubicin
    Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 4 hrs by MTT assay
    Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 4 hrs by MTT assay
    		[PMID: 30773423]
    MDA-MB-231 IC50
    3.18 μM
    Compound: DOX
    Antiproliferative activity against human MDA231 cells by MTT assay
    Antiproliferative activity against human MDA231 cells by MTT assay
    		[PMID: 30216848]
    MDA-MB-231 IC50
    3.41 μM
    Compound: DOX
    Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs
    Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs
    		[PMID: 32736079]
    MDA-MB-231 IC50
    3.41 μM
    Compound: Doxo (I)
    Antiproliferative activity against human MDA-MB-231 cells by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells by MTT assay
    		10.1039/C4MD00228H
    MDA-MB-231 IC50
    3.61 μM
    Compound: Doxorubicin
    Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay
    Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay
    		[PMID: 20064676]
    MDA-MB-231 IC50
    3.68 μM
    Compound: DOX
    Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 48 hrs by sulphorhodamine-B assay
    Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 48 hrs by sulphorhodamine-B assay
    		[PMID: 38810335]
    MDA-MB-231 IC50
    3.8 μM
    Compound: DOX
    Inhibition of topoisomerase 2 in human MDA-MB-231 cells assessed as reduction in cell growth measured after 72 hrs by MTT assay
    Inhibition of topoisomerase 2 in human MDA-MB-231 cells assessed as reduction in cell growth measured after 72 hrs by MTT assay
    		[PMID: 30846253]
    MDA-MB-231 IC50
    3.97 μM
    Compound: Doxorubicin
    Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 24 hrs by MTT assay
    Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 24 hrs by MTT assay
    		[PMID: 31404864]
    MDA-MB-231 IC50
    300 nM
    Compound: 1, DOX
    Growth inhibition of MDA-MB-231 cells containing antiestrogen binding sites
    Growth inhibition of MDA-MB-231 cells containing antiestrogen binding sites
    		[PMID: 15588086]
    MDA-MB-231 IC50
    300 nM
    Compound: DOX
    Inhibition of estrogen receptor negative MDA-MB-231 breast cancer cell proliferation
    Inhibition of estrogen receptor negative MDA-MB-231 breast cancer cell proliferation
    		[PMID: 14971899]
    MDA-MB-231 IC50
    33.98 μM
    Compound: Doxorubicin
    Anticancer activity against human MDA-MB-231 cells after 48 hrs by SRB assay
    Anticancer activity against human MDA-MB-231 cells after 48 hrs by SRB assay
    		[PMID: 24077528]
    MDA-MB-231 IC50
    340 nM
    Compound: doxorubicin
    Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by XTT assay
    Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by XTT assay
    		[PMID: 22515366]
    MDA-MB-231 IC50
    4 μM
    Compound: ADM
    Cytotoxicity against human MDA-MB-231 cells
    Cytotoxicity against human MDA-MB-231 cells
    		[PMID: 22283451]
    MDA-MB-231 IC50
    4.21 μM
    Compound: Doxorubicin
    Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay
    		[PMID: 35367708]
    MDA-MB-231 IC50
    4.4 μM
    Compound: Doxorubicin
    Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell viability incubated for 48 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell viability incubated for 48 hrs by MTT assay
    		[PMID: 31753800]
    MDA-MB-231 IC50
    4.8 μM
    Compound: DOX
    Cytotoxicity against human MDA-MB-231 cells assessed as cell viability incubated for 72 hrs by MTT assay
    Cytotoxicity against human MDA-MB-231 cells assessed as cell viability incubated for 72 hrs by MTT assay
    		[PMID: 39153333]
    MDA-MB-231 IC50
    46.5 μM
    Compound: Doxorubicin
    Cytotoxicity against human MDA-MB-231 cells assessed as cell death measured by MTT assay
    Cytotoxicity against human MDA-MB-231 cells assessed as cell death measured by MTT assay
    		[PMID: 39137365]
    MDA-MB-231 IC50
    5.12 μM
    Compound: Doxorubicin
    Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay
    Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay
    		[PMID: 31884407]
    MDA-MB-231 IC50
    5.8 μM
    Compound: Doxorubicin
    Cytotoxicity against human MDA-MB-231 cells incubated for 24 hrs by MTT assay
    Cytotoxicity against human MDA-MB-231 cells incubated for 24 hrs by MTT assay
    		[PMID: 36621136]
    MDA-MB-231 IC50
    5.96 μM
    Compound: Doxorubicin
    Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 48 hrs by MTT assay
    Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 48 hrs by MTT assay
    		[PMID: 25140752]
    MDA-MB-231 IC50
    5.98 μM
    Compound: DOX
    Cytotoxicity against human MDA-MB-231 cells after 96 hrs under hypoxic condition by MTT assay
    Cytotoxicity against human MDA-MB-231 cells after 96 hrs under hypoxic condition by MTT assay
    		[PMID: 29649740]
    MDA-MB-231 IC50
    6.03 μM
    Compound: Doxorubicin
    Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay in absence of 10% FBS
    Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay in absence of 10% FBS
    		[PMID: 26298501]
    MDA-MB-231 IC50
    6.25 μM
    Compound: Doxorubicin
    Growth inhibition of human MDA-MB-231 cells after 48 hrs by MTT assay
    Growth inhibition of human MDA-MB-231 cells after 48 hrs by MTT assay
    		[PMID: 30072225]
    MDA-MB-231 IC50
    6.29 μM
    Compound: Doxorubicin
    Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay in presence of 10% FBS
    Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay in presence of 10% FBS
    		[PMID: 26298501]
    MDA-MB-231 IC50
    6.75 μM
    Compound: Doxorubicin
    Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay
    Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay
    		[PMID: 27173802]
    MDA-MB-231 IC50
    6.8 μM
    Compound: Doxorubicin
    Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay
    Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay
    		[PMID: 21429743]
    MDA-MB-231 IC50
    7.46 μM
    Compound: Doxorubicin
    Anticancer activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 3 days by MTT assay
    Anticancer activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 3 days by MTT assay
    		[PMID: 35007724]
    MDA-MB-231 IC50
    7.68 μM
    Compound: Doxorubicin
    Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    		[PMID: 38665840]
    MDA-MB-231 IC50
    7.85 μM
    Compound: Doxorubicin
    Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay
    Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay
    		[PMID: 29573910]
    MDA-MB-231 IC50
    8.14 μM
    Compound: Doxorubicin
    Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay
    		10.1039/C2MD20023F
    MDA-MB-231 IC50
    8.14 μM
    Compound: Doxorubicin
    Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay
    Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay
    		[PMID: 22386528]
    MDA-MB-231 IC50
    8.5 μM
    Compound: Dox
    Antiproliferative activity against human MDA-MB-231 cells after 48 hrs under hypoxic condition by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells after 48 hrs under hypoxic condition by MTT assay
    		[PMID: 30445264]
    MDA-MB-231 IC50
    8.53 μM
    Compound: DOX
    Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay
    		[PMID: 30398868]
    MDA-MB-231 IC50
    8.6 μg/mL
    Compound: 1; Dox
    Growth inhibition of human MDA-MB-231 cell line assessed as reduction in cell viability by SRB colorimetric assay
    Growth inhibition of human MDA-MB-231 cell line assessed as reduction in cell viability by SRB colorimetric assay
    		[PMID: 37482023]
    MDA-MB-231 IC50
    86.5 μM
    Compound: Doxorubicin
    Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    		[PMID: 39038494]
    MDA-MB-231 IC50
    935.5 nM
    Compound: Doxorubicin
    Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability
    Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability
    		[PMID: 31655432]
    MDA-MB-231 IC50
    < 1 μM
    Compound: ADM
    Cytotoxicity against human MDA-MB-231 cells by SRB method
    Cytotoxicity against human MDA-MB-231 cells by SRB method
    		[PMID: 37807846]
    MDA-MB-231 IC50
    < 1 μM
    Compound: Doxorubicin
    Cytotoxicity against Homo sapiens (human) MDA231 cells after 48 hr by MTT assay
    Cytotoxicity against Homo sapiens (human) MDA231 cells after 48 hr by MTT assay
    		10.1007/s00044-011-9884-x
    MDA-MB-231 IC50
    < 1 μM
    Compound: Doxorubicin
    Cytotoxicity against Homo sapiens (human) MDA-MB-231 cells by tetrazolium-reduction assay
    Cytotoxicity against Homo sapiens (human) MDA-MB-231 cells by tetrazolium-reduction assay
    		10.1007/s00044-012-0450-y
    MDA-MB-231 IC50
    < 1 μM
    Compound: Doxorubicin
    Cytotoxicity against human MDA231 cells by MTT assay
    Cytotoxicity against human MDA231 cells by MTT assay
    		[PMID: 21996519]
    MDA-MB-231 IC50
    < 1 μM
    Compound: Doxorubicin
    Cytotoxicity against human MDA-MB-231 cells by MTT assay
    Cytotoxicity against human MDA-MB-231 cells by MTT assay
    		[PMID: 23079527]
    MDA-MB-231 IC50
    < 1 μM
    Compound: Doxorubicin
    Cytotoxicity against human MDA-MB-231 cells by SRB assay
    Cytotoxicity against human MDA-MB-231 cells by SRB assay
    		[PMID: 33371684]
    MDA-MB-231 IC50
    < 1 μM
    Compound: Doxorubicin
    Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell growth by MTT assay
    Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell growth by MTT assay
    		[PMID: 36734533]
    MDA-MB-231 IC50
    < 1 μM
    Compound: Doxorubicin
    Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell growth by SRB assay
    Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell growth by SRB assay
    		[PMID: 38064664]
    MDA-MB-231 IC50
    < 1 μM
    Compound: doxorubicin
    Cytotoxicity against human MDA-MB-231 cells by SRB assay
    Cytotoxicity against human MDA-MB-231 cells by SRB assay
    		[PMID: 33847126]
    MDA-MB-361 IC50
    12 nM
    Compound: Doxo
    The compound was tested for intracellular cytotoxicity against MDA MB 361(mammary carcinoma cell line) expressing LacZ (beta-galactosidase).
    The compound was tested for intracellular cytotoxicity against MDA MB 361(mammary carcinoma cell line) expressing LacZ (beta-galactosidase).
    		[PMID: 10395490]
    MDA-MB-361 IC50
    18 nM
    Compound: Doxo
    The compound was tested for extracellular cytotoxicity against MDA MB 361(mammary carcinoma cell line) expressing carboxypeptidase stCPG2.
    The compound was tested for extracellular cytotoxicity against MDA MB 361(mammary carcinoma cell line) expressing carboxypeptidase stCPG2.
    		[PMID: 10395490]
    MDA-MB-361 IC50
    2.03 μM
    Compound: Doxorubicin
    Cytotoxicity against human MDA-MB-361 cells after 94 hrs by MTT assay
    Cytotoxicity against human MDA-MB-361 cells after 94 hrs by MTT assay
    		[PMID: 21868138]
    MDA-MB-361 IC50
    33 nM
    Compound: Doxo
    The compound was tested for intracellular cytotoxicity against MDA MB 361(mammary carcinoma cell line) expressing carboxypeptidase G2(CPG2).
    The compound was tested for intracellular cytotoxicity against MDA MB 361(mammary carcinoma cell line) expressing carboxypeptidase G2(CPG2).
    		[PMID: 10395490]
    MDA-MB-435 GI50
    0.2 μM
    Compound: adriamycin
    Antitumor activity against human MDA-MB435 cells after 48 hrs by sulforhodamine B protein assay
    Antitumor activity against human MDA-MB435 cells after 48 hrs by sulforhodamine B protein assay
    		[PMID: 17448574]
    MDA-MB-435 GI50
    0.25 μM
    Compound: Doxorubicin
    Growth inhibition of human MDA-MB-435 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human MDA-MB-435 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28329730]
    MDA-MB-435 GI50
    0.25 μM
    Compound: Doxorubicin
    Growth inhibition of human MDA-MB-435 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human MDA-MB-435 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 29102177]
    MDA-MB-435 GI50
    0.25 μM
    Compound: Doxorubicin hydrochloride, NSC 123127
    Cytotoxicity against human MDA-MB-435 cells after 48 hrs by SRB assay
    Cytotoxicity against human MDA-MB-435 cells after 48 hrs by SRB assay
    		[PMID: 23871905]
    MDA-MB-435 IC50
    0.02 μM
    Compound: Doxorubicin
    Cytotoxicity activity against human MDA435 cells
    Cytotoxicity activity against human MDA435 cells
    		[PMID: 25478997]
    MDA-MB-435 IC50
    0.03 μM
    Compound: Dox
    Cytotoxicity against human MDA-MB-435 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human MDA-MB-435 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 31306817]
    MDA-MB-435 IC50
    0.03 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human MDA-MB-435 cells after 72 hrs by MTT assay
    Cytotoxicity against human MDA-MB-435 cells after 72 hrs by MTT assay
    		[PMID: 20537433]
    MDA-MB-435 IC50
    0.09 μM
    Compound: Doxorubicin
    Antiproliferative activity against human MDA-MB-435 cells
    Antiproliferative activity against human MDA-MB-435 cells
    		[PMID: 33421712]
    MDA-MB-435 IC50
    0.15 μM
    Compound: Dox
    Cytotoxicity against human MDA-MB-435 cells after 48 hrs by MTT assay in presence of verapamil
    Cytotoxicity against human MDA-MB-435 cells after 48 hrs by MTT assay in presence of verapamil
    		[PMID: 24028446]
    MDA-MB-435 IC50
    0.24 μg/mL
    Compound: Dox
    Anticancer activity against Homo sapiens (human) MDA-MB-435 cells assessed as inhibition of cell survival after 72 hr by MTT assay
    Anticancer activity against Homo sapiens (human) MDA-MB-435 cells assessed as inhibition of cell survival after 72 hr by MTT assay
    		10.1007/s00044-012-0236-2
    MDA-MB-435 IC50
    0.4 μM
    Compound: doxorubicin
    Antiproliferative activity against MDA-MB-435 human breast carcinoma cells in vivo using MDA-MB-435 monolayer growth assay.
    Antiproliferative activity against MDA-MB-435 human breast carcinoma cells in vivo using MDA-MB-435 monolayer growth assay.
    		[PMID: 11606134]
    MDA-MB-435 IC50
    0.47 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human MDA-MB-435 cells after 72 hrs by MTT assay
    Cytotoxicity against human MDA-MB-435 cells after 72 hrs by MTT assay
    		[PMID: 18586355]
    MDA-MB-435 IC50
    0.47 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human MDA-MB-435 cells after 3 days by MTT assay
    Cytotoxicity against human MDA-MB-435 cells after 3 days by MTT assay
    		[PMID: 19159272]
    MDA-MB-435 IC50
    0.47 μg/mL
    Compound: doxorubicin
    Cytotoxicity against human MDA-MB-435 cells after 72 hrs by MTT assay
    Cytotoxicity against human MDA-MB-435 cells after 72 hrs by MTT assay
    		[PMID: 17827021]
    MDA-MB-435 IC50
    0.48 μg/mL
    Compound: Dox
    Cytotoxicity against Homo sapiens (human) MDA-MB-435 cells after 72 hr by MTT assay
    Cytotoxicity against Homo sapiens (human) MDA-MB-435 cells after 72 hr by MTT assay
    		10.1007/s00044-011-9894-8
    MDA-MB-435 IC50
    0.48 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human MDA-MB-435 cells by MTT assay
    Cytotoxicity against human MDA-MB-435 cells by MTT assay
    		[PMID: 17764956]
    MDA-MB-435 IC50
    0.6 μM
    Compound: Dox
    Cytotoxicity against human MDA-MB-435 cells after 48 hrs by MTT assay
    Cytotoxicity against human MDA-MB-435 cells after 48 hrs by MTT assay
    		[PMID: 24028446]
    MDA-MB-435 IC50
    0.69 μg/mL
    Compound: Doxo
    Cytotoxicity against human MDA-MB-435 cells for 72 hrs by MTT assay
    Cytotoxicity against human MDA-MB-435 cells for 72 hrs by MTT assay
    		[PMID: 21334795]
    MDA-MB-435 IC50
    0.83 μM
    Compound: Doxorubicin
    Cytotoxicity against MDA-MB-435 cells
    Cytotoxicity against MDA-MB-435 cells
    		[PMID: 17175071]
    MDA-MB-435 IC50
    0.83 μM
    Compound: Doxorubicin
    Cytotoxicity against human MDA-MB-435 cells assessed as cell viability after 72 hrs by MTT assay
    Cytotoxicity against human MDA-MB-435 cells assessed as cell viability after 72 hrs by MTT assay
    		[PMID: 24530030]
    MDA-MB-435 IC50
    0.83 μM
    Compound: Doxorubicin
    Cytotoxicity against human MDA-MB-435 cells after 72 hrs by MTT assay
    Cytotoxicity against human MDA-MB-435 cells after 72 hrs by MTT assay
    		[PMID: 27363939]
    MDA-MB-435 IC50
    0.83 μM
    Compound: doxorubicin
    Cytotoxicity against human MDA-MB-435 cells after 72 hrs by MTT assay
    Cytotoxicity against human MDA-MB-435 cells after 72 hrs by MTT assay
    		[PMID: 21381705]
    MDA-MB-435 IC50
    0.86 μM
    Compound: Doxorubicin
    Cytotoxicity against human MDA-MB-435 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Cytotoxicity against human MDA-MB-435 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    		[PMID: 33158575]
    MDA-MB-435 IC50
    0.88 μM
    Compound: DOXO
    Cytotoxicity against human MDA-MB-435 cells after 72 hrs by MTT assay
    Cytotoxicity against human MDA-MB-435 cells after 72 hrs by MTT assay
    		[PMID: 19947600]
    MDA-MB-435 IC50
    0.88 μM
    Compound: Dox
    Cytotoxicity against human MDA-MB-435 cells after 72 hrs by MTT assay
    Cytotoxicity against human MDA-MB-435 cells after 72 hrs by MTT assay
    		[PMID: 25147145]
    MDA-MB-435 IC50
    0.88 μM
    Compound: Doxorubicin
    Cytotoxicity against human MDA-MB-435 cells after 72 hrs by MTT assay
    Cytotoxicity against human MDA-MB-435 cells after 72 hrs by MTT assay
    		[PMID: 21115213]
    MDA-MB-435 IC50
    0.94 μM
    Compound: DOXO
    Antiproliferative activity against human MDA-MB-435 cells after 72 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-435 cells after 72 hrs by MTT assay
    		[PMID: 28818447]
    MDA-MB-435 IC50
    0.96 μM
    Compound: D
    Antineoplastic activity against human MDA-MB-435 cells after 72 hrs by MTT assay
    Antineoplastic activity against human MDA-MB-435 cells after 72 hrs by MTT assay
    		[PMID: 22000949]
    MDA-MB-435 IC50
    0.96 μM
    Compound: DOXO
    Cytotoxicity against human MDA-MB-435 cells assessed as cell viability after 72 hrs by MTT assay
    Cytotoxicity against human MDA-MB-435 cells assessed as cell viability after 72 hrs by MTT assay
    		[PMID: 26142490]
    MDA-MB-435 IC50
    0.96 μM
    Compound: Doxorubicin
    Cytotoxicity against human MDA-MB-435 cells after 72 hrs by MTT assay
    Cytotoxicity against human MDA-MB-435 cells after 72 hrs by MTT assay
    		[PMID: 19406535]
    MDA-MB-435 IC50
    0.96 μM
    Compound: Doxorubicin
    Cytotoxicity against human MDA-MB-435 cells after 72 hrs by MTT assay
    Cytotoxicity against human MDA-MB-435 cells after 72 hrs by MTT assay
    		[PMID: 20971532]
    MDA-MB-435 IC50
    0.96 μM
    Compound: Doxorubicin
    Cytotoxicity against human MDA-MB-435 cells overexpressing NQO1 assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human MDA-MB-435 cells overexpressing NQO1 assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 27341379]
    MDA-MB-435 IC50
    1.3 μM
    Compound: DOX
    Antiproliferative activity against human MDA-MB-435 cells after 72 hrs by Sulforhodamine B-stain assay
    Antiproliferative activity against human MDA-MB-435 cells after 72 hrs by Sulforhodamine B-stain assay
    		[PMID: 27484508]
    MDA-MB-435 IC50
    1.3 μM
    Compound: Doxorubicin
    Antitumor activity against human MDA-MB-435 cells after 24 to 48 hrs by MTT assay
    Antitumor activity against human MDA-MB-435 cells after 24 to 48 hrs by MTT assay
    		[PMID: 21553829]
    MDA-MB-435 IC50
    1.51 μM
    Compound: Doxorubicin
    Cytotoxicity against human MDA-MB-435 cells by colorimetric method
    Cytotoxicity against human MDA-MB-435 cells by colorimetric method
    		[PMID: 24387625]
    MDA-MB-435 IC50
    1.56 μM
    Compound: Dox
    Cytotoxicity against doxorubicin-resistant multidrug-resistant human MDA-MB-435 cells after 48 hrs by MTT assay in presence of verapamil
    Cytotoxicity against doxorubicin-resistant multidrug-resistant human MDA-MB-435 cells after 48 hrs by MTT assay in presence of verapamil
    		[PMID: 24028446]
    MDA-MB-435 IC50
    1.67 μM
    Compound: Doxorubicin
    Cytotoxicity against human MDA-MB-435 cells after 69 hrs by MTT assay
    Cytotoxicity against human MDA-MB-435 cells after 69 hrs by MTT assay
    		[PMID: 19780590]
    MDA-MB-435 IC50
    150 nM
    Compound: 1, DOX
    Growth inhibition of MDA-MB-435 cells containing antiestrogen binding sites
    Growth inhibition of MDA-MB-435 cells containing antiestrogen binding sites
    		[PMID: 15588086]
    MDA-MB-435 IC50
    150 nM
    Compound: DOX
    Inhibition of MDA-MB-435 breast cancer cell proliferation
    Inhibition of MDA-MB-435 breast cancer cell proliferation
    		[PMID: 14971899]
    MDA-MB-435 IC50
    21.9 μM
    Compound: Dox
    Cytotoxicity against doxorubicin-resistant multidrug-resistant human MDA-MB-435 cells after 48 hrs by MTT assay
    Cytotoxicity against doxorubicin-resistant multidrug-resistant human MDA-MB-435 cells after 48 hrs by MTT assay
    		[PMID: 24028446]
    MDA-MB-435 IC50
    3.5 nM
    Compound: Doxorubicine
    Cytotoxicity against human MDA435 cells after 72 hrs by MTS assay
    Cytotoxicity against human MDA435 cells after 72 hrs by MTS assay
    		[PMID: 21142180]
    MDA-MB-435 IC50
    300 nM
    Compound: doxorubicin
    Antiproliferative activity against MDA435/LCC6 cells by ELISA
    Antiproliferative activity against MDA435/LCC6 cells by ELISA
    		[PMID: 17154505]
    MDA-MB-435 IC50
    300 nM
    Compound: doxorubicin
    Antiproliferative activity against multidrug resistant MDA435/LCC6 cells in presence of 5 uM verapamil by ELISA
    Antiproliferative activity against multidrug resistant MDA435/LCC6 cells in presence of 5 uM verapamil by ELISA
    		[PMID: 17154505]
    MDA-MB-435 IC50
    4690 nM
    Compound: doxorubicin
    Antiproliferative activity against multidrug resistant MDA435/LCC6 cells by ELISA
    Antiproliferative activity against multidrug resistant MDA435/LCC6 cells by ELISA
    		[PMID: 17154505]
    MDA-MB-435 IC50
    550 nM
    Compound: doxorubicin
    Antiproliferative activity against multidrug resistant MDA435/LCC6 cells in presence of 5 uM 1,13-bis[4'-((5,7-dihydroxy)-4H-chromen-4-on-2-yl)phenyl]-1,4,7,10,13-pentaoxatridecane by ELISA
    Antiproliferative activity against multidrug resistant MDA435/LCC6 cells in presence of 5 uM 1,13-bis[4'-((5,7-dihydroxy)-4H-chromen-4-on-2-yl)phenyl]-1,4,7,10,13-pentaoxatridecane by ELISA
    		[PMID: 17154505]
    MDA-MB-436 IC50
    0.1 μM
    Compound: Doxorubicin
    Cytotoxicity against human MDA-MB-436 cells after 72 hrs by resazurin/resorufin-based fluorescence assay
    Cytotoxicity against human MDA-MB-436 cells after 72 hrs by resazurin/resorufin-based fluorescence assay
    		[PMID: 23600925]
    MDA-MB-453 CC50
    0.04 μM
    Compound: Dox
    Cytotoxicity against human MDA-MB-453 cells incubated for 72 hrs by MTT assay
    Cytotoxicity against human MDA-MB-453 cells incubated for 72 hrs by MTT assay
    		[PMID: 39079310]
    MDA-MB-453 IC50
    0.12 μM
    Compound: doxorubicine
    Cytotoxic activity against human MDA-MB-453 cells after 69 hrs by MTT assay
    Cytotoxic activity against human MDA-MB-453 cells after 69 hrs by MTT assay
    		[PMID: 19788290]
    MDA-MB-453 IC50
    1.99 μM
    Compound: DOX
    Cytotoxicity against human MDA-MB-453 cells after 48 hrs by MTT assay
    Cytotoxicity against human MDA-MB-453 cells after 48 hrs by MTT assay
    		[PMID: 24487188]
    MDA-MB-453 IC50
    1.99 μM
    Compound: Doxorubicin
    Cytotoxicity against human MDA-MB-453 cells assessed as inhibition of cell viability after 48 hrs by MTT assay
    Cytotoxicity against human MDA-MB-453 cells assessed as inhibition of cell viability after 48 hrs by MTT assay
    		[PMID: 24953027]
    MDA-MB-453 IC50
    1.99 μM
    Compound: Doxorubicin
    Cytotoxicity in human MDA-MB-453 cells incubated for 48 hrs by MTT assay
    Cytotoxicity in human MDA-MB-453 cells incubated for 48 hrs by MTT assay
    		[PMID: 28923381]
    MDA-MB-468 GI50
    0.05 μM
    Compound: Doxorubicin
    Growth inhibition of human MDA-MB-468 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human MDA-MB-468 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28329730]
    MDA-MB-468 GI50
    0.05 μM
    Compound: Doxorubicin
    Growth inhibition of human MDA-MB-468 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human MDA-MB-468 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 29102177]
    MDA-MB-468 GI50
    0.05 μM
    Compound: Doxorubicin hydrochloride, NSC 123127
    Cytotoxicity against human MDA-MB-468 cells after 48 hrs by SRB assay
    Cytotoxicity against human MDA-MB-468 cells after 48 hrs by SRB assay
    		[PMID: 23871905]
    MDA-MB-468 GI50
    0.085 μM
    Compound: Dox
    Growth inhibition of human MDA-MB-468 cells after 72 hrs by MTT assay
    Growth inhibition of human MDA-MB-468 cells after 72 hrs by MTT assay
    		[PMID: 24163729]
    MDA-MB-468 IC50
    0.005 μM
    Compound: Doxorubicin
    Inhibitory activity against MDA-468 cell line using MTT assay (ER-, amplified EGFR, mutant p53)
    Inhibitory activity against MDA-468 cell line using MTT assay (ER-, amplified EGFR, mutant p53)
    		[PMID: 10780913]
    MDA-MB-468 IC50
    0.007 μM
    Compound: 1 (Doxorubicin)
    In vitro cytotoxic activity against human breast cancer cell line MD-MB-468 after 72 hr of drug exposure determined by the SRB assay
    In vitro cytotoxic activity against human breast cancer cell line MD-MB-468 after 72 hr of drug exposure determined by the SRB assay
    		[PMID: 14980672]
    MDA-MB-468 IC50
    0.0521 μM
    Compound: Dox
    Cytotoxicity against human MDA-MB-468 cells assessed as reduction in cell viability incubated for 96 hrs by MTT method
    Cytotoxicity against human MDA-MB-468 cells assessed as reduction in cell viability incubated for 96 hrs by MTT method
    		[PMID: 34236840]
    MDA-MB-468 IC50
    0.06 μM
    Compound: Doxorubicin
    Cytotoxicity against human MDA-MB-468 cells assessed as reduction in cell viability after 48 hrs
    Cytotoxicity against human MDA-MB-468 cells assessed as reduction in cell viability after 48 hrs
    		[PMID: 34601029]
    MDA-MB-468 IC50
    0.07 μM
    Compound: Doxorubicin
    Cytotoxicity against human MDA-MB-468 cells assessed as growth inhibition after 72 hrs by SRB assay
    Cytotoxicity against human MDA-MB-468 cells assessed as growth inhibition after 72 hrs by SRB assay
    		[PMID: 30457333]
    MDA-MB-468 IC50
    2.81 μM
    Compound: Doxorubicin
    Antiproliferative activity against human MDA-MB-468 cells after 48 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-468 cells after 48 hrs by MTT assay
    		[PMID: 29547830]
    MDA-MB-468 IC50
    6.8 μM
    Compound: Dox
    Cytotoxicity against human MDA-MB-468 cells by SRB assay
    Cytotoxicity against human MDA-MB-468 cells by SRB assay
    		[PMID: 38516606]
    MDA-MB-468 IC50
    > 100 μM
    Compound: DOX
    Cytotoxicity against human MDA-MB-468 cells measured after 72 hrs by Celltiter-Glo assay
    Cytotoxicity against human MDA-MB-468 cells measured after 72 hrs by Celltiter-Glo assay
    		[PMID: 31820976]
    MDCK IC50
    0.43 μM
    Compound: DOXO
    Cytotoxicity against MDCK cells assessed as cell viability after 72 hrs by MTT assay
    Cytotoxicity against MDCK cells assessed as cell viability after 72 hrs by MTT assay
    		[PMID: 26142490]
    ME-180 IC50
    0.39 μM
    Compound: DOX
    Cytotoxicity against human ME180 cells after 48 hrs by MTT assay
    Cytotoxicity against human ME180 cells after 48 hrs by MTT assay
    		[PMID: 24487188]
    ME-180 IC50
    0.39 μM
    Compound: Doxorubicin
    Cytotoxicity against human ME180 cells assessed as inhibition of cell viability after 48 hrs by MTT assay
    Cytotoxicity against human ME180 cells assessed as inhibition of cell viability after 48 hrs by MTT assay
    		[PMID: 24953027]
    ME-180 IC50
    0.39 μM
    Compound: Doxorubicin
    Cytotoxicity against human ME180 cells after 72 hrs by MTT assay
    Cytotoxicity against human ME180 cells after 72 hrs by MTT assay
    		[PMID: 25453799]
    ME-180 IC50
    0.5 μM
    Compound: Doxorubicin
    Anticancer activity against human ME180 cells by MTT assay
    Anticancer activity against human ME180 cells by MTT assay
    		10.1039/C4MD00219A
    MEF IC50
    3.4 μM
    Compound: Doxorubicin
    Cytotoxicity against mouse wild type MEF cells after 72 hrs by SRB assay
    Cytotoxicity against mouse wild type MEF cells after 72 hrs by SRB assay
    		[PMID: 19186946]
    MEL-JUSO IC50
    0.237 μM
    Compound: 1
    Cytotoxicity in human MEL-JUSO cells assessed as reduction in cell viability incubated for 2 hrs by Cell-titer-blue assay
    Cytotoxicity in human MEL-JUSO cells assessed as reduction in cell viability incubated for 2 hrs by Cell-titer-blue assay
    		[PMID: 33064004]
    MEL-JUSO IC50
    0.523 μM
    Compound: 1
    Cytotoxicity against human MEL-JUSO cells incubated for 2 hrs by cell titre blue viability assay
    Cytotoxicity against human MEL-JUSO cells incubated for 2 hrs by cell titre blue viability assay
    		[PMID: 37561481]
    MES-SA ED50
    173 μM
    Compound: doxorubicin
    Antitumor activity against human MES-SA cells after 24 hrs by MTT assay
    Antitumor activity against human MES-SA cells after 24 hrs by MTT assay
    		[PMID: 17482824]
    MES-SA GI50
    0.0051 μM
    Compound: Doxorubicin
    Antiproliferative activity against human MESSA cells by SRB assay
    Antiproliferative activity against human MESSA cells by SRB assay
    		[PMID: 19394218]
    MES-SA IC50
    0.0097 μM
    Compound: Dx
    Antiproliferative activity against MES-SA cells by MTT assay after 72 hrs
    Antiproliferative activity against MES-SA cells by MTT assay after 72 hrs
    		[PMID: 16824751]
    MES-SA IC50
    0.01 μM
    Compound: Doxorubicin
    Antiproliferative activity against human MESSA cells after 72 hrs by SRB assay
    Antiproliferative activity against human MESSA cells after 72 hrs by SRB assay
    		[PMID: 22944121]
    MES-SA IC50
    0.016 μM
    Compound: Doxorubicin (Dx)
    In vitro cytotoxicity against uterine sarcoma MES-SA cells
    In vitro cytotoxicity against uterine sarcoma MES-SA cells
    		[PMID: 16169719]
    MES-SA IC50
    0.03 μM
    Compound: Adriamycin
    Cytotoxicity against human MES-SA cells after 72 hrs by MTT assay
    Cytotoxicity against human MES-SA cells after 72 hrs by MTT assay
    		[PMID: 21721528]
    MES-SA IC50
    0.03 μM
    Compound: Dx
    Cytotoxicity against human MES-SA cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
    Cytotoxicity against human MES-SA cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
    		[PMID: 21444205]
    MES-SA IC50
    0.035 μM
    Compound: Dox
    Antiproliferative activity against human MES-SA cells after 72 hrs by MTT assay
    Antiproliferative activity against human MES-SA cells after 72 hrs by MTT assay
    		[PMID: 25998504]
    MES-SA IC50
    0.038 μM
    Compound: doxorubicin
    Cytotoxicity against human MES-SA cells after 72 hrs by Presto Blue assay
    Cytotoxicity against human MES-SA cells after 72 hrs by Presto Blue assay
    		[PMID: 23360284]
    MES-SA IC50
    0.04 μM
    Compound: doxorubicin
    Ability to inhibit growth of doxorubicin-sensitive (MES-SA) uterine sarcoma cell line was determined in an in vitro MTT assay.
    Ability to inhibit growth of doxorubicin-sensitive (MES-SA) uterine sarcoma cell line was determined in an in vitro MTT assay.
    		[PMID: 1995877]
    MES-SA IC50
    0.1 μM
    Compound: DOXO
    Cytotoxicity against human MESSA cells after 72 hrs by sulforhodamine B assay
    Cytotoxicity against human MESSA cells after 72 hrs by sulforhodamine B assay
    		[PMID: 28342398]
    MES-SA IC50
    0.16 μM
    Compound: Doxo
    Antiproliferative activity against human MES-SA cells after 72 hrs by SRB assay
    Antiproliferative activity against human MES-SA cells after 72 hrs by SRB assay
    		[PMID: 29945793]
    MES-SA IC50
    0.17 μM
    Compound: Doxorubicin
    Antiproliferative activity against human MES-SA cells after 96 hrs by SRB assay
    Antiproliferative activity against human MES-SA cells after 96 hrs by SRB assay
    		[PMID: 20151639]
    MES-SA IC50
    0.25 μM
    Compound: Adriamycin (ADR)
    In vitro cytotoxic activity was evaluated using the human uterine sarcoma cell line MES-SA
    In vitro cytotoxic activity was evaluated using the human uterine sarcoma cell line MES-SA
    		[PMID: 12443763]
    MES-SA IC50
    0.347 μM
    Compound: doxorubicin
    Growth inhibition of doxorubicin-sensitive human MES-SA cells after 48 hrs by MTT assay
    Growth inhibition of doxorubicin-sensitive human MES-SA cells after 48 hrs by MTT assay
    		[PMID: 17888666]
    MES-SA IC50
    0.87 μM
    Compound: Adriamycin
    Cytotoxicity against adriamycin-selected human MES-SA cells after 72 hrs by MTT assay
    Cytotoxicity against adriamycin-selected human MES-SA cells after 72 hrs by MTT assay
    		[PMID: 21721528]
    MES-SA IC50
    1.56 μM
    Compound: Doxorubicin (Dx)
    In vitro cytotoxicity variant MES-SA/Dx5 multidrug resistant cells
    In vitro cytotoxicity variant MES-SA/Dx5 multidrug resistant cells
    		[PMID: 16169719]
    MES-SA IC50
    12 μM
    Compound: Adriamycin (ADR)
    In vitro cytotoxic activity was evaluated using the MES-SA multidrug-resistant subline MES-SA/Dx5
    In vitro cytotoxic activity was evaluated using the MES-SA multidrug-resistant subline MES-SA/Dx5
    		[PMID: 12443763]
    MES-SA IC50
    26.4 nM
    Compound: Doxoruibicin
    Cytotoxicity against human MES-SA cells
    Cytotoxicity against human MES-SA cells
    		[PMID: 21324692]
    MES-SA IC50
    26.4 nM
    Compound: doxorubicin
    Antiproliferative activity against human MES-SA cells assessed as growth inhibition
    Antiproliferative activity against human MES-SA cells assessed as growth inhibition
    		[PMID: 21324686]
    MES-SA IC50
    4.2 μM
    Compound: doxorubicin
    Ability to inhibit growth of doxorubicin-resistant (MES-SA/DOX) uterine sarcoma cell line was determined in an in vitro MTT assay.
    Ability to inhibit growth of doxorubicin-resistant (MES-SA/DOX) uterine sarcoma cell line was determined in an in vitro MTT assay.
    		[PMID: 1995877]
    MES-SA/Dx5 ED50
    > 500 μM
    Compound: doxorubicin
    Antitumor activity against doxorubucin-resistant human MES-SA/Dx5 cells by MTT assay after 24 hrs
    Antitumor activity against doxorubucin-resistant human MES-SA/Dx5 cells by MTT assay after 24 hrs
    		[PMID: 17482824]
    MES-SA/Dx5 GI50
    0.93 μM
    Compound: Doxorubicin
    Antiproliferative activity against multidrug resistant human MES-SA/Dx5 cells by SRB assay
    Antiproliferative activity against multidrug resistant human MES-SA/Dx5 cells by SRB assay
    		[PMID: 19394218]
    MES-SA/Dx5 IC50
    0.25 μM
    Compound: Doxorubicin
    Antiproliferative activity against human MESSA/DX5 cells after 72 hrs by SRB assay
    Antiproliferative activity against human MESSA/DX5 cells after 72 hrs by SRB assay
    		[PMID: 22944121]
    MES-SA/Dx5 IC50
    0.704 μM
    Compound: Dx
    Antiproliferative activity against doxorubicin-resistant MES-SA/Dx5 cells by MTT assay after 72 hrs
    Antiproliferative activity against doxorubicin-resistant MES-SA/Dx5 cells by MTT assay after 72 hrs
    		[PMID: 16824751]
    MES-SA/Dx5 IC50
    1.55 μM
    Compound: doxorubicin
    Growth inhibition of doxorubicin-resistant human MES-SA/Dx5 cells after 48 hrs by MTT assay
    Growth inhibition of doxorubicin-resistant human MES-SA/Dx5 cells after 48 hrs by MTT assay
    		[PMID: 17888666]
    MES-SA/Dx5 IC50
    13.9 μM
    Compound: DOXO
    Cytotoxicity against human MESSA/DX5 cells after 72 hrs by sulforhodamine B assay
    Cytotoxicity against human MESSA/DX5 cells after 72 hrs by sulforhodamine B assay
    		[PMID: 28342398]
    MES-SA/Dx5 IC50
    16.2 μM
    Compound: Doxo
    Antiproliferative activity against human MES-SA/Dx5 cells after 72 hrs by SRB assay
    Antiproliferative activity against human MES-SA/Dx5 cells after 72 hrs by SRB assay
    		[PMID: 29945793]
    MES-SA/Dx5 IC50
    2.3 μM
    Compound: doxorubicin
    Cytotoxicity against human MES-SA/Dx5 cells after 72 hrs by Presto Blue assay
    Cytotoxicity against human MES-SA/Dx5 cells after 72 hrs by Presto Blue assay
    		[PMID: 23360284]
    MES-SA/Dx5 IC50
    2.398 μM
    Compound: Dx
    Cytotoxicity against human MES-SA/Dx5 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
    Cytotoxicity against human MES-SA/Dx5 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
    		[PMID: 21444205]
    MES-SA/Dx5 IC50
    2.807 μM
    Compound: Dox
    Antiproliferative activity against human MES-SA/Dx5 cells after 72 hrs by MTT assay
    Antiproliferative activity against human MES-SA/Dx5 cells after 72 hrs by MTT assay
    		[PMID: 25998504]
    MES-SA/Dx5 IC50
    3.1 μM
    Compound: Doxorubicin
    Antiproliferative activity against human MES-SA/Dx5 cells after 96 hrs by SRB assay
    Antiproliferative activity against human MES-SA/Dx5 cells after 96 hrs by SRB assay
    		[PMID: 20151639]
    MG-22A IC50
    0.73 μg/mL
    Compound: 1 (doxorubicin)
    In vitro cytotoxic concentration against mouse hepatoma cell line (MG-22A) using MTT coloration
    In vitro cytotoxic concentration against mouse hepatoma cell line (MG-22A) using MTT coloration
    		[PMID: 15013011]
    MG-22A IC50
    < 0.001 μg/mL
    Compound: 1 (doxorubicin)
    In vitro inhibitory activity against mouse hepatoma cell line (MG-22A) using CV coloration
    In vitro inhibitory activity against mouse hepatoma cell line (MG-22A) using CV coloration
    		[PMID: 15013011]
    MG-63 IC50
    0.74 μM
    Compound: doxorubicin
    Cytotoxicity against human MG63 cells after 48 hrs by MTT assay
    Cytotoxicity against human MG63 cells after 48 hrs by MTT assay
    		[PMID: 25314138]
    MG-63 IC50
    2.7 μM
    Compound: Adriamycin
    Cytotoxicity against human MG63 cells by MTT colorimetric method
    Cytotoxicity against human MG63 cells by MTT colorimetric method
    		[PMID: 23043498]
    MG-63 IC50
    2.8 μM
    Compound: Adriamycin
    Growth inhibition of human MG63 cells by MTT assay
    Growth inhibition of human MG63 cells by MTT assay
    		[PMID: 21721519]
    MG-63 IC50
    3.17 μM
    Compound: Dox
    Cytotoxicity against Homo sapiens (human) MG63 cells assessed as reduction of cell survival after 48 hr by MTT assay
    Cytotoxicity against Homo sapiens (human) MG63 cells assessed as reduction of cell survival after 48 hr by MTT assay
    		10.1007/s00044-012-0150-7
    MG-63 IC50
    3.17 μM
    Compound: Doxorubicin
    Cytotoxicity against human MG63 cells after 48 hrs by MTT assay
    Cytotoxicity against human MG63 cells after 48 hrs by MTT assay
    		[PMID: 23792352]
    MG-63 IC50
    3.2 μM
    Compound: Adriamycin
    Cytotoxicity against human MG63 cells by MTT assay
    Cytotoxicity against human MG63 cells by MTT assay
    		[PMID: 22647719]
    MGC-803 IC50
    0.1 μM
    Compound: doxorubicin
    Cytotoxicity against human MGC803 cells after 72 hrs by MTS assay
    Cytotoxicity against human MGC803 cells after 72 hrs by MTS assay
    		[PMID: 25490132]
    MGC-803 IC50
    0.17 μM
    Compound: Adriamycin
    Cytotoxicity against human MGC803 cells after 24 hrs by SRB assay
    Cytotoxicity against human MGC803 cells after 24 hrs by SRB assay
    		[PMID: 24370114]
    MGC-803 IC50
    0.4 μM
    Compound: ADM
    Antiproliferative activity against human MGC803 cells after 48 hrs by MTT assay
    Antiproliferative activity against human MGC803 cells after 48 hrs by MTT assay
    		[PMID: 30025345]
    MGC-803 IC50
    0.48 μM
    Compound: Doxorubicin
    Anticancer activity against human MGC-803 cells incubated for 48 hrs by MTT assay
    Anticancer activity against human MGC-803 cells incubated for 48 hrs by MTT assay
    		[PMID: 35367708]
    MGC-803 IC50
    0.51 μg/mL
    Compound: Doxorubicin
    Antiproliferative activity against human MGC-803 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay
    Antiproliferative activity against human MGC-803 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay
    		[PMID: 34973507]
    MGC-803 IC50
    0.7 μM
    Compound: ADM
    Antiproliferative activity against human MGC803 cells after 72 hrs by MTT assay
    Antiproliferative activity against human MGC803 cells after 72 hrs by MTT assay
    		[PMID: 23124210]
    MGC-803 IC50
    0.7 μM
    Compound: ADM
    Cytotoxicity against human MGC803 cells after 72 hrs by MTT assay
    Cytotoxicity against human MGC803 cells after 72 hrs by MTT assay
    		[PMID: 25874331]
    MGC-803 IC50
    0.7 μM
    Compound: ADM
    Cytotoxicity against human MGC803 cells after 72 hrs by MTT assay
    Cytotoxicity against human MGC803 cells after 72 hrs by MTT assay
    		[PMID: 26280921]
    MGC-803 IC50
    0.74 μM
    Compound: ADM
    Cytotoxicity against human MGC803 cells after 72 hrs by MTT assay
    Cytotoxicity against human MGC803 cells after 72 hrs by MTT assay
    		10.1007/s00044-013-0854-3
    MGC-803 IC50
    1.01 μM
    Compound: AMD
    Antiproliferative activity against human MGC803 cells after 48 hrs by MTT assay
    Antiproliferative activity against human MGC803 cells after 48 hrs by MTT assay
    		[PMID: 26807545]
    MGC-803 IC50
    1.01 μM
    Compound: AMD
    Cytotoxicity against human MGC803 cells after 48 hrs by MTT assay
    Cytotoxicity against human MGC803 cells after 48 hrs by MTT assay
    		[PMID: 26900656]
    MGC-803 IC50
    1.19 μM
    Compound: AMD
    Anticancer activity against human MGC803 cells assessed as cell survival after 48 hrs by MTT assay
    Anticancer activity against human MGC803 cells assessed as cell survival after 48 hrs by MTT assay
    		[PMID: 25812966]
    MGC-803 IC50
    3.22 μM
    Compound: ADM
    Cytotoxicity against human MGC803 cells after 38 hrs by MTT assay
    Cytotoxicity against human MGC803 cells after 38 hrs by MTT assay
    		[PMID: 25965778]
    MGC-803 IC50
    3.6 μM
    Compound: Dox
    Antiproliferative activity against human MGC803 cells assessed as reduction in cell viability by MTT assay
    Antiproliferative activity against human MGC803 cells assessed as reduction in cell viability by MTT assay
    		[PMID: 31765156]
    MIA PaCa-2 CC50
    2.97 μM
    Compound: Doxorubicin
    Cytotoxicity against human MIAPaCa2 cells after 72 hrs by MTT assay
    Cytotoxicity against human MIAPaCa2 cells after 72 hrs by MTT assay
    		[PMID: 29792325]
    MIA PaCa-2 EC50
    130 nM
    Compound: Dox
    Antiproliferative activity against human MIA PaCa-2 cells assessed as inhibition of cell growth incubated for 72 hrs by MTS assay
    Antiproliferative activity against human MIA PaCa-2 cells assessed as inhibition of cell growth incubated for 72 hrs by MTS assay
    		[PMID: 37982711]
    MIA PaCa-2 ED50
    0.00018 μg/mL
    Compound: Adriamycin
    In vitro cytotoxic activity against PACA-2 (human pancreatic carcinoma) cell line
    In vitro cytotoxic activity against PACA-2 (human pancreatic carcinoma) cell line
    		[PMID: 11551759]
    MIA PaCa-2 ED50
    0.00101 μg/mL
    Compound: adriamycin
    Cytotoxicity against human MIA PaCa2 cells after 7 days by MTT assay
    Cytotoxicity against human MIA PaCa2 cells after 7 days by MTT assay
    		[PMID: 10514307]
    MIA PaCa-2 ED50
    0.00136 μg/mL
    Compound: Adriamycin
    Cytotoxicity against human pancreatic carcinoma MIA PaCa-2 cell lines
    Cytotoxicity against human pancreatic carcinoma MIA PaCa-2 cell lines
    		10.1016/0960-894X(95)00182-S
    MIA PaCa-2 ED50
    0.0061 μg/mL
    Compound: adriamycin
    Cytotoxicity against human MiaPaCa2 cells after 7 days by MTT assay
    Cytotoxicity against human MiaPaCa2 cells after 7 days by MTT assay
    		[PMID: 11087592]
    MIA PaCa-2 ED50
    0.031 μg/mL
    Compound: Adriamycin
    Cytotoxic activity was tested against human PAC-2 (pancreatici carcinoma) cell line
    Cytotoxic activity was tested against human PAC-2 (pancreatici carcinoma) cell line
    		10.1016/0960-894X(95)00309-H
    MIA PaCa-2 ED50
    0.034 μg/mL
    Compound: Adriamycin
    Cytotoxicity concentration against human pancreatic carcinoma PaCa-2 cell line
    Cytotoxicity concentration against human pancreatic carcinoma PaCa-2 cell line
    		[PMID: 8627602]
    MIA PaCa-2 ED50
    1.1 x 10-3 μg/mL
    Compound: Adriamycin
    Cytotoxicity against human PaCa2 cells
    Cytotoxicity against human PaCa2 cells
    		[PMID: 10479316]
    MIA PaCa-2 ED50
    1.32 x 10-3 μg/mL
    Compound: adriamycin
    Cytotoxicity against human MIAPaCa2 cells after 7 days by MTT assay
    Cytotoxicity against human MIAPaCa2 cells after 7 days by MTT assay
    		[PMID: 8676130]
    MIA PaCa-2 ED50
    1.33 x 10-2 μg/mL
    Compound: adr
    Cytotoxicity against human MIAPaCa2 cells after 7 days by MTT assay
    Cytotoxicity against human MIAPaCa2 cells after 7 days by MTT assay
    		[PMID: 9461654]
    MIA PaCa-2 ED50
    1.42 x 10-3 μg/mL
    Compound: Adriamycin
    Cytotoxicity against human MIAPaCa2 cells after 7 days by MTT assay
    Cytotoxicity against human MIAPaCa2 cells after 7 days by MTT assay
    		[PMID: 9322367]
    MIA PaCa-2 ED50
    1.45 x 10-3 μg/mL
    Compound: adriamycin
    Cytotoxicity against human MIAPaCa2 cells after 7 days by MTT assay
    Cytotoxicity against human MIAPaCa2 cells after 7 days by MTT assay
    		[PMID: 9599253]
    MIA PaCa-2 ED50
    1.53 x 10-2 μg/mL
    Compound: adriamycin
    Cytotoxicity against human MIAPaCa2 cells after 7 days by MTT assay
    Cytotoxicity against human MIAPaCa2 cells after 7 days by MTT assay
    		[PMID: 9599260]
    MIA PaCa-2 ED50
    1.63 μg/mL
    Compound: Adriamycin
    Cytotoxicity on pancreatic carcinoma (PACA-2) cell line
    Cytotoxicity on pancreatic carcinoma (PACA-2) cell line
    		[PMID: 8632402]
    MIA PaCa-2 ED50
    1.8 x 10-2 μg/mL
    Compound: Adriamycin
    Cytotoxicity against human MIAPaCa2 cells after 7 days by MTT assay
    Cytotoxicity against human MIAPaCa2 cells after 7 days by MTT assay
    		[PMID: 9214729]
    MIA PaCa-2 ED50
    1.95 x 10-3 μg/mL
    Compound: Adriamycin
    Cytotoxicity against human MIAPaCa2 cells after 7 days by MTT assay
    Cytotoxicity against human MIAPaCa2 cells after 7 days by MTT assay
    		[PMID: 7494147]
    MIA PaCa-2 ED50
    2.24 x 10-2 μg/mL
    Compound: Adr
    Cytotoxicity against human MIAPaCa2 cells
    Cytotoxicity against human MIAPaCa2 cells
    		[PMID: 8778247]
    MIA PaCa-2 ED50
    2.3 x 10-2 μg/mL
    Compound: adriamycin
    Cytotoxicity against human PaCa2 cells by MTT assay
    Cytotoxicity against human PaCa2 cells by MTT assay
    		[PMID: 9917277]
    MIA PaCa-2 ED50
    2.43 x 10-3 μg/mL
    Compound: Adriamycin
    Cytotoxicity against human MIAPaCa2 cells after 7 days by MTT assay
    Cytotoxicity against human MIAPaCa2 cells after 7 days by MTT assay
    		[PMID: 8946743]
    MIA PaCa-2 ED50
    2.62 x 10-3 μg/mL
    Compound: adriamycin
    Cytotoxicity against human MIAPaCa2 cells after 7 days by MTT assay
    Cytotoxicity against human MIAPaCa2 cells after 7 days by MTT assay
    		[PMID: 11325235]
    MIA PaCa-2 ED50
    2.88 x 10-3 μg/mL
    Compound: adriamycin
    Cytotoxicity against human MIAPaCa2 cells after 7 days by MTT assay
    Cytotoxicity against human MIAPaCa2 cells after 7 days by MTT assay
    		10.1021/np970510f
    MIA PaCa-2 ED50
    3.17 x 10-3 μg/mL
    Compound: adriamycin
    Cytotoxicity against human MIAPaCa2 cells
    Cytotoxicity against human MIAPaCa2 cells
    		[PMID: 8991957]
    MIA PaCa-2 ED50
    3.79 x 10-3 μg/mL
    Compound: adriamycin
    Cytotoxicity against human MIAPaCa2 cells after 7 days by MTT assay
    Cytotoxicity against human MIAPaCa2 cells after 7 days by MTT assay
    		[PMID: 8882434]
    MIA PaCa-2 ED50
    3.92 x 10-2 μg/mL
    Compound: adriamycin
    Cytotoxicity against human MIAPaCa2 cells after 7 days by MTT assay
    Cytotoxicity against human MIAPaCa2 cells after 7 days by MTT assay
    		[PMID: 9134750]
    MIA PaCa-2 ED50
    4.23 x 10-3 μg/mL
    Compound: Adriamycin
    Cytotoxicity against human MIAPaCa2 cells
    Cytotoxicity against human MIAPaCa2 cells
    		[PMID: 8946744]
    MIA PaCa-2 ED50
    4.3 x 10-3 μg/mL
    Compound: adriamycin
    Cytotoxicity against human PACA2 cells after 7 days by MTT assay
    Cytotoxicity against human PACA2 cells after 7 days by MTT assay
    		[PMID: 10395501]
    MIA PaCa-2 ED50
    4.56 x 10-3 μg/mL
    Compound: adriamycin
    Cytotoxicity against human MIAPaCa2 cells after 7 days by MTT assay
    Cytotoxicity against human MIAPaCa2 cells after 7 days by MTT assay
    		[PMID: 9584396]
    MIA PaCa-2 ED50
    6.1 x 10-3 μg/mL
    Compound: adriamycin
    Cytotoxicity against human MIA PaCa2 cells after 7 days by MTT assay
    Cytotoxicity against human MIA PaCa2 cells after 7 days by MTT assay
    		[PMID: 15730242]
    MIA PaCa-2 ED50
    6.3 nM
    Compound: Adriamycin
    In vitro cytotoxicity against Bladder PACA-2 human tumors following a 6 day exposure
    In vitro cytotoxicity against Bladder PACA-2 human tumors following a 6 day exposure
    		[PMID: 10498214]
    MIA PaCa-2 ED50
    7.9 x 10-3 μg/mL
    Compound: adriamycin
    Cytotoxicity against human MIAPaCa2 cells after 7 days by MTT assay
    Cytotoxicity against human MIAPaCa2 cells after 7 days by MTT assay
    		[PMID: 8904848]
    MIA PaCa-2 IC50
    0.01 μM
    Compound: Doxorubicin
    Cytotoxicity against human MIAPaCa2 cells after 72 hrs by MTT assay
    Cytotoxicity against human MIAPaCa2 cells after 72 hrs by MTT assay
    		[PMID: 20207049]
    MIA PaCa-2 IC50
    0.02 μM
    Compound: DOX
    Antitumor activity against human MiaPaCa2 cells after 72 hrs by MTT assay
    Antitumor activity against human MiaPaCa2 cells after 72 hrs by MTT assay
    		[PMID: 17935309]
    MIA PaCa-2 IC50
    0.02 μM
    Compound: Doxorubicin
    Cytotoxicity against human MIAPaCa2 cells assessed as reduction in cell growth after 72 hrs by cell titer glo assay
    Cytotoxicity against human MIAPaCa2 cells assessed as reduction in cell growth after 72 hrs by cell titer glo assay
    		[PMID: 27080175]
    MIA PaCa-2 IC50
    0.03 μM
    Compound: Doxorubicin
    Antiproliferative activity against human MIAPaCa2 cells after 72 hrs by MTT assay
    Antiproliferative activity against human MIAPaCa2 cells after 72 hrs by MTT assay
    		[PMID: 22555152]
    MIA PaCa-2 IC50
    0.04 μM
    Compound: Doxorubicin
    Cytotoxicity against human MIAPaCa2 cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay
    Cytotoxicity against human MIAPaCa2 cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay
    		[PMID: 28257197]
    MIA PaCa-2 IC50
    0.049 μM
    Compound: Doxorubicin
    Cytotoxicity against human MIAPaCa2 cells assessed as reduction in cell proliferation measured after 48 hrs by SRB assay
    Cytotoxicity against human MIAPaCa2 cells assessed as reduction in cell proliferation measured after 48 hrs by SRB assay
    		[PMID: 27856237]
    MIA PaCa-2 IC50
    0.05 μM
    Compound: Doxorubicin
    Cytotoxicity against human MIA PaCa2 cells after 24 hrs by MTT assay
    Cytotoxicity against human MIA PaCa2 cells after 24 hrs by MTT assay
    		[PMID: 17190470]
    MIA PaCa-2 IC50
    0.05 μM
    Compound: doxorubicin
    Cytotoxicity against human MIAPaCa2 cells by MTT assay
    Cytotoxicity against human MIAPaCa2 cells by MTT assay
    		[PMID: 15620238]
    MIA PaCa-2 IC50
    0.05 μM
    Compound: doxorubicin
    Cytotoxicity against human MIAPaCa2 cells
    Cytotoxicity against human MIAPaCa2 cells
    		[PMID: 15921417]
    MIA PaCa-2 IC50
    0.05 μM
    Compound: doxorubicin
    Cytotoxicity against human MIAPaCa2 cells after 72 hrs by MTT assay
    Cytotoxicity against human MIAPaCa2 cells after 72 hrs by MTT assay
    		[PMID: 17286429]
    MIA PaCa-2 IC50
    0.05 μg/mL
    Compound: dox, doxorubicin
    Cytotoxicity against human MIA-PaCa2 cells
    Cytotoxicity against human MIA-PaCa2 cells
    		[PMID: 17618015]
    MIA PaCa-2 IC50
    0.14 μM
    Compound: Doxo
    Cytotoxicity against human MIAPaCa2 cells assessed as cell viability after 48 hrs by MTT assay
    Cytotoxicity against human MIAPaCa2 cells assessed as cell viability after 48 hrs by MTT assay
    		10.1039/C2MD20302B
    MIA PaCa-2 IC50
    0.15 μM
    Compound: Doxorubicin
    Cytotoxicity against human MIAPaCa2 cells after 72 hrs by MTT assay
    Cytotoxicity against human MIAPaCa2 cells after 72 hrs by MTT assay
    		[PMID: 19361894]
    MIA PaCa-2 IC50
    0.2 μM
    Compound: 27
    Cytotoxicity against human MIA PaCa-2 cells assessed as inhibition of cell growth measured after 72 hrs by MTS assay
    Cytotoxicity against human MIA PaCa-2 cells assessed as inhibition of cell growth measured after 72 hrs by MTS assay
    		[PMID: 32858470]
    MIA PaCa-2 IC50
    0.3 μM
    Compound: Doxorubicin
    Cytotoxicity against human MIAPaCa2 cells after 72 hrs by Alamar blue assay
    Cytotoxicity against human MIAPaCa2 cells after 72 hrs by Alamar blue assay
    		[PMID: 21999655]
    MIA PaCa-2 IC50
    0.43 μM
    Compound: Doxorubicin
    Cytotoxicity against human MIA PaCa-2 cells assessed as reduction in cell viability by MTT assay
    Cytotoxicity against human MIA PaCa-2 cells assessed as reduction in cell viability by MTT assay
    		[PMID: 32915576]
    MIA PaCa-2 IC50
    1.02 μM
    Compound: Doxorubicin
    Cytotoxicity against human MIAPaCa2 cells assessed as reduction in cell viability
    Cytotoxicity against human MIAPaCa2 cells assessed as reduction in cell viability
    		[PMID: 32005414]
    MIA PaCa-2 IC50
    1.75 μM
    Compound: Doxorubicin
    Cytotoxicity against human MIAPaCa2 cells assessed as cell growth inhibition after 48 hrs by MTT assay
    Cytotoxicity against human MIAPaCa2 cells assessed as cell growth inhibition after 48 hrs by MTT assay
    		[PMID: 27371926]
    MIA PaCa-2 IC50
    1.9 μM
    Compound: Doxorubicin
    Cytotoxicity against human MIAPaCa2 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    Cytotoxicity against human MIAPaCa2 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    		[PMID: 28277681]
    MIA PaCa-2 IC50
    18.23 μM
    Compound: Doxorubicin
    Cytotoxicity against human MIAPaCa2 cells
    Cytotoxicity against human MIAPaCa2 cells
    		[PMID: 22123320]
    MIA PaCa-2 IC50
    2.4 x 10-3 μg/mL
    Compound: Adriamycin
    Cytotoxicity against human MIAPaCa2 cells by MTT assay
    Cytotoxicity against human MIAPaCa2 cells by MTT assay
    		[PMID: 9644064]
    MIA PaCa-2 IC50
    25.3 μM
    Compound: Doxorubicin
    Cytotoxicity against human MIAPaCa2 cells after 48 hrs by MTT assay
    Cytotoxicity against human MIAPaCa2 cells after 48 hrs by MTT assay
    		[PMID: 21429743]
    MIA PaCa-2 IC50
    3.1 μM
    Compound: Doxorubicin
    Cytotoxicity against human MIAPaCa2 cells assessed as reduction in cell viability after 70 hrs by alamar blue assay
    Cytotoxicity against human MIAPaCa2 cells assessed as reduction in cell viability after 70 hrs by alamar blue assay
    		[PMID: 29471119]
    MIA PaCa-2 IC50
    4 μM
    Compound: 1; dox
    Cytotoxicity against doxorubicin-sensitive human MIA PaCa-2 cells assessed as inhibition of cell growth incubated for 30 mins by crystal violet staining assay
    Cytotoxicity against doxorubicin-sensitive human MIA PaCa-2 cells assessed as inhibition of cell growth incubated for 30 mins by crystal violet staining assay
    		[PMID: 26881291]
    MIA PaCa-2 IC50
    4.8 μM
    Compound: Doxo
    Cytotoxicity against human MIAPaCa2 cells assessed as cell viability after 24 hrs by MTT assay
    Cytotoxicity against human MIAPaCa2 cells assessed as cell viability after 24 hrs by MTT assay
    		[PMID: 24484281]
    MIA PaCa-2 IC50
    66 μM
    Compound: 1; dox
    Cytotoxicity against doxorubicin-sensitive human MIA PaCa-2 cells assessed as inhibition of cell growth incubated for 90 mins by crystal violet staining assay
    Cytotoxicity against doxorubicin-sensitive human MIA PaCa-2 cells assessed as inhibition of cell growth incubated for 90 mins by crystal violet staining assay
    		[PMID: 26881291]
    MIA PaCa-2 IC50
    < 0.1 μM
    Compound: DOX, Doxorubicin
    Antiproliferative activity against human MIAPaCa2 cells after 72 hrs by MTT assay
    Antiproliferative activity against human MIAPaCa2 cells after 72 hrs by MTT assay
    		[PMID: 24095089]
    MKN-1 IC50
    0.64 μM
    Compound: doxorubicin
    Growth inhibitory concentration of compound was measured against human gastric adenocarcinoma cell line (MKN-1)
    Growth inhibitory concentration of compound was measured against human gastric adenocarcinoma cell line (MKN-1)
    		[PMID: 10698436]
    MKN-28 GI50
    0.24 μM
    Compound: Doxorubicin
    Antiproliferative activity against human MKN28 cells after 2 days by sulforhodamine B assay
    Antiproliferative activity against human MKN28 cells after 2 days by sulforhodamine B assay
    		[PMID: 24184076]
    MKN-28 IC50
    0.22 μM
    Compound: Doxorubicin
    Cytotoxicity against human MKN28 cells after 44 hrs by SRB assay
    Cytotoxicity against human MKN28 cells after 44 hrs by SRB assay
    		10.1007/s00044-013-0788-9
    MKN-45 IC50
    0.127 μM
    Compound: ADR
    Antiproliferative activity against human MKN45 cells after 72 hrs by sulforhodamine B assay
    Antiproliferative activity against human MKN45 cells after 72 hrs by sulforhodamine B assay
    		[PMID: 30241010]
    MKN-45 IC50
    0.168 μM
    Compound: Doxorubicin
    Cytotoxicity against human MKN45 cells after 48 hrs by MTT assay
    Cytotoxicity against human MKN45 cells after 48 hrs by MTT assay
    		[PMID: 22647723]
    MKN-45 IC50
    0.19 nM
    Compound: Doxorubicin
    Antiproliferative activity against human MKN45 cells after 72 hrs by methylene blue staining
    Antiproliferative activity against human MKN45 cells after 72 hrs by methylene blue staining
    		[PMID: 21067930]
    MKN-45 IC50
    0.19 μM
    Compound: DOX
    Cytotoxicity against human MKN45 cells measured after 72 hrs by Celltiter-Glo assay
    Cytotoxicity against human MKN45 cells measured after 72 hrs by Celltiter-Glo assay
    		[PMID: 31820976]
    MKN-45 IC50
    3.13 μM
    Compound: Adriamycin
    Cytotoxicity of compound against human gastric adenocarcinoma cell line (MKN 45)
    Cytotoxicity of compound against human gastric adenocarcinoma cell line (MKN 45)
    		[PMID: 9822542]
    MKN-74 IC50
    0.204 μM
    Compound: ADR
    Antiproliferative activity against human MKN74 cells after 72 hrs by sulforhodamine B assay
    Antiproliferative activity against human MKN74 cells after 72 hrs by sulforhodamine B assay
    		[PMID: 30241010]
    MLM ED50
    0.13 μM
    Compound: Adriamycin
    Cytotoxic concentration required to inhibit 50% cell growth in MLM melanoma cell lines
    Cytotoxic concentration required to inhibit 50% cell growth in MLM melanoma cell lines
    		[PMID: 1875350]
    MLM ED50
    1.3 μM
    Compound: Adriamycin
    Compound was evaluated for cytotoxicity against human MLM melanoma cell line.
    Compound was evaluated for cytotoxicity against human MLM melanoma cell line.
    		[PMID: 1613753]
    MOLT-3 IC50
    0.04 μM
    Compound: doxorubicin
    Cytotoxicity against human MOLT3 cells by XTT assay
    Cytotoxicity against human MOLT3 cells by XTT assay
    		[PMID: 19824618]
    MOLT-3 IC50
    0.051 μM
    Compound: Doxorubicin
    Antiproliferative activity against human MOLT3 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Antiproliferative activity against human MOLT3 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    		[PMID: 31704206]
    MOLT-4 GI50
    0.03 μM
    Compound: Doxorubicin
    Growth inhibition of human MOLT4 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human MOLT4 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28329730]
    MOLT-4 GI50
    0.03 μM
    Compound: Doxorubicin
    Growth inhibition of human MOLT4 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human MOLT4 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 29102177]
    MOLT-4 GI50
    0.03 μM
    Compound: Doxorubicin hydrochloride, NSC 123127
    Cytotoxicity against human MOLT4 cells after 48 hrs by SRB assay
    Cytotoxicity against human MOLT4 cells after 48 hrs by SRB assay
    		[PMID: 23871905]
    MOLT-4 IC50
    0.002 μM
    Compound: Doxorubicin
    Antiproliferative activity against human MOLT4 cells after 72 hrs by MTT assay
    Antiproliferative activity against human MOLT4 cells after 72 hrs by MTT assay
    		[PMID: 19632833]
    MOLT-4 IC50
    0.01 μM
    Compound: Doxorubicin
    Antiproliferative activity against human MOLT4 cells after 72 hrs by MTT assay
    Antiproliferative activity against human MOLT4 cells after 72 hrs by MTT assay
    		[PMID: 27808511]
    MOLT-4 IC50
    0.015 μM
    Compound: Doxorubicin
    Antiproliferative activity against human MOLT4 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Antiproliferative activity against human MOLT4 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 31546197]
    MOLT-4 IC50
    0.02 μM
    Compound: DOX
    Cytotoxicity against human MOLT4 cells after 48 hrs by MTT assay
    Cytotoxicity against human MOLT4 cells after 48 hrs by MTT assay
    		[PMID: 23218718]
    MOLT-4 IC50
    0.02 μM
    Compound: DOXO
    Cytotoxicity against human MOLT4 cells assessed as cell viability after 72 hrs by MTT assay
    Cytotoxicity against human MOLT4 cells assessed as cell viability after 72 hrs by MTT assay
    		[PMID: 26142490]
    MOLT-4 IC50
    0.02 μM
    Compound: Doxorubicin
    Antitumor activity against human acute T-lymphoblastic MOLT-4 leukemia cells.
    Antitumor activity against human acute T-lymphoblastic MOLT-4 leukemia cells.
    		[PMID: 12431049]
    MOLT-4 IC50
    0.02 μM
    Compound: Doxorubicin
    Cytotoxicity against human MOLT4 cells assessed as growth inhibition after 72 hrs by MTT assay
    Cytotoxicity against human MOLT4 cells assessed as growth inhibition after 72 hrs by MTT assay
    		[PMID: 27623548]
    MOLT-4 IC50
    0.02 μM
    Compound: adriamycin
    Cytotoxicity against MOLT4 cells after 72 hrs by MTT assay
    Cytotoxicity against MOLT4 cells after 72 hrs by MTT assay
    		[PMID: 17107806]
    MOLT-4 IC50
    0.02 μM
    Compound: doxo
    Antiproliferative activity against human MOLT4 cell line by MTT assay
    Antiproliferative activity against human MOLT4 cell line by MTT assay
    		[PMID: 16913700]
    MOLT-4 IC50
    0.02 μM
    Compound: doxorubicin
    Antitumor activity against human acute T-lymphoblastic leukemia MOLT-4 cells
    Antitumor activity against human acute T-lymphoblastic leukemia MOLT-4 cells
    		[PMID: 12431048]
    MOLT-4 IC50
    0.03 μM
    Compound: Doxorubicin
    Antitumor activity was evaluated against leukemia cell line MOLT-4(human acute T lymphoblastic leukemia)
    Antitumor activity was evaluated against leukemia cell line MOLT-4(human acute T lymphoblastic leukemia)
    		[PMID: 10411476]
    MOLT-4 IC50
    0.05 μM
    Compound: Doxorubicin
    Compound was tested for its effect on the proliferation of MOLT-4 human lymphoblastic T-leukemia cell line.
    Compound was tested for its effect on the proliferation of MOLT-4 human lymphoblastic T-leukemia cell line.
    		10.1016/0960-894X(96)00216-8
    MOLT-4 IC50
    0.2 μM
    Compound: 1, DOX
    Antiproliferative activity against human Molt4/C8 cells after 72 hrs by MTT assay
    Antiproliferative activity against human Molt4/C8 cells after 72 hrs by MTT assay
    		[PMID: 25244612]
    MOLT-4 IC50
    0.2 μM
    Compound: DOX
    Cytotoxicity against human MOLT4 cells after 24 hrs by XTT assay
    Cytotoxicity against human MOLT4 cells after 24 hrs by XTT assay
    		[PMID: 24900344]
    MOLT-4 IC50
    0.2 μM
    Compound: Dox
    Cytotoxicity against human Molt4/C8 cells after 72 hrs by MTT assay
    Cytotoxicity against human Molt4/C8 cells after 72 hrs by MTT assay
    		[PMID: 21144624]
    MOLT-4 IC50
    0.46 μg/mL
    Compound: DOX
    Cytotoxicity against human MOLT4 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Cytotoxicity against human MOLT4 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    		[PMID: 29274817]
    MOLT-4 IC50
    35 nM
    Compound: ADRIAMYCIN
    Compound was tested for its anticancer activity against human T-lymphocytic leukemia MOLT-4 cells.
    Compound was tested for its anticancer activity against human T-lymphocytic leukemia MOLT-4 cells.
    		10.1016/S0960-894X(96)00486-6
    MOLT-4F ED50
    0.02 μg/mL
    Compound: adriamycin
    Cytotoxicity against human MOLT4F cells after 48 hrs by SRB assay
    Cytotoxicity against human MOLT4F cells after 48 hrs by SRB assay
    		10.1021/np50124a024
    MRC5 CC50
    15.7 μM
    Compound: Doxorubicin
    Cytotoxicity against human MRC5 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
    Cytotoxicity against human MRC5 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
    		[PMID: 37944413]
    MRC5 EC50
    0.3 μM
    Compound: Doxorubicin
    Cytotoxicity against human MRC5 cells after 96 hrs by MTT assay
    Cytotoxicity against human MRC5 cells after 96 hrs by MTT assay
    		[PMID: 26320088]
    MRC5 GI50
    12.47 μM
    Compound: Doxorubicin
    Cytotoxicity against human MRC5 cells assessed as cell growth inhibition
    Cytotoxicity against human MRC5 cells assessed as cell growth inhibition
    		[PMID: 36584305]
    MRC5 IC50
    0.039 μM
    Compound: Doxorubicin
    Cytotoxicity against human MRC5 cells assessed as reduction in cell viability by CellTiter Glo luminescent assay
    Cytotoxicity against human MRC5 cells assessed as reduction in cell viability by CellTiter Glo luminescent assay
    		[PMID: 32755677]
    MRC5 IC50
    0.04 μM
    Compound: Doxorubicin
    Cytotoxicity against human MRC5 cells assessed as reduction in cell viability after 72 hrs by CellTiter Glo assay
    Cytotoxicity against human MRC5 cells assessed as reduction in cell viability after 72 hrs by CellTiter Glo assay
    		[PMID: 33021377]
    MRC5 IC50
    0.05 μM
    Compound: Doxorubicin
    Antiproliferative activity against human MRC5 cells assessed as reduction in cell viability
    Antiproliferative activity against human MRC5 cells assessed as reduction in cell viability
    		[PMID: 31945642]
    MRC5 IC50
    0.1 μM
    Compound: DOX
    Cytotoxicity against human MRC5 cells after 72 hrs by MTT assay
    Cytotoxicity against human MRC5 cells after 72 hrs by MTT assay
    		[PMID: 18783950]
    MRC5 IC50
    0.1 μM
    Compound: DOX
    Antiproliferative activity against human MRC5 cells after 72 hrs by MTT assay
    Antiproliferative activity against human MRC5 cells after 72 hrs by MTT assay
    		[PMID: 20359789]
    MRC5 IC50
    0.1 μM
    Compound: DOX
    Antiproliferative activity against human MRC5 cells after 72 hrs by MTT assay
    Antiproliferative activity against human MRC5 cells after 72 hrs by MTT assay
    		[PMID: 24021462]
    MRC5 IC50
    0.1 μM
    Compound: DOX
    Cytotoxicity against human MRC5 cells after 72 hrs by MTT assay
    Cytotoxicity against human MRC5 cells after 72 hrs by MTT assay
    		[PMID: 25259516]
    MRC5 IC50
    0.1 μM
    Compound: DOX
    Cytotoxicity against human MRC5 cells assessed as cell growth inhibition after 72 hrs by MTT assay
    Cytotoxicity against human MRC5 cells assessed as cell growth inhibition after 72 hrs by MTT assay
    		[PMID: 26720155]
    MRC5 IC50
    0.1 μM
    Compound: DOX
    Antiproliferative activity against human MRC5 cells after 72 hrs by MTT assay
    Antiproliferative activity against human MRC5 cells after 72 hrs by MTT assay
    		[PMID: 28135634]
    MRC5 IC50
    0.1 μM
    Compound: DOX
    Cytotoxicity against human MRC5 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human MRC5 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 28427016]
    MRC5 IC50
    0.1 μM
    Compound: DOX
    Cytotoxicity against human MRC5 cells assessed as inhibition of cell growth after 72 hrs by MTT assay
    Cytotoxicity against human MRC5 cells assessed as inhibition of cell growth after 72 hrs by MTT assay
    		[PMID: 30746062]
    MRC5 IC50
    0.1 μM
    Compound: DOX
    Cytotoxicity against human MRC5 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Cytotoxicity against human MRC5 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    		[PMID: 31557614]
    MRC5 IC50
    0.1 μM
    Compound: DOX
    Cytotoxicity against human MRC5 cells assessed as reduction in cell viability measured after 6 days by MTT assay
    Cytotoxicity against human MRC5 cells assessed as reduction in cell viability measured after 6 days by MTT assay
    		[PMID: 32653698]
    MRC5 IC50
    0.1 μM
    Compound: DOX
    Antiproliferative activity against human MRC5 cells by MTT colorimetric assay
    Antiproliferative activity against human MRC5 cells by MTT colorimetric assay
    		[PMID: 38527380]
    MRC5 IC50
    0.1 μM
    Compound: DOX
    Cytotoxicity against human MRC5 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    Cytotoxicity against human MRC5 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    		[PMID: 39067378]
    MRC5 IC50
    0.1 μM
    Compound: Dox
    Cytotoxicity against human MRC5 cells assessed as cell growth inhibition after 72 hrs by MTT assay
    Cytotoxicity against human MRC5 cells assessed as cell growth inhibition after 72 hrs by MTT assay
    		[PMID: 27231128]
    MRC5 IC50
    0.11 μM
    Compound: Dox
    Cytotoxicity against human MRC5 cells after 48 hrs by MTT assay
    Cytotoxicity against human MRC5 cells after 48 hrs by MTT assay
    		[PMID: 26494582]
    MRC5 IC50
    0.12 μM
    Compound: DOX
    Cytotoxicity against human MRC5 cells assessed as growth inhibition after 48 hrs by MTT assay
    Cytotoxicity against human MRC5 cells assessed as growth inhibition after 48 hrs by MTT assay
    		[PMID: 24148837]
    MRC5 IC50
    0.12 μM
    Compound: DOX
    Antiproliferative activity against human MRC5 cells after 48 hrs by MTT assay
    Antiproliferative activity against human MRC5 cells after 48 hrs by MTT assay
    		[PMID: 25619894]
    MRC5 IC50
    0.12 μM
    Compound: DOX
    Antiproliferative activity against human MRC5 cells assessed as inhibition of cell growth after 48 hrs by MTT assay
    Antiproliferative activity against human MRC5 cells assessed as inhibition of cell growth after 48 hrs by MTT assay
    		[PMID: 25737400]
    MRC5 IC50
    0.12 μM
    Compound: Doxorubicin
    Cytotoxicity against human MRC5 cells expressing estrogen receptor after 48 hrs by MTT assay
    Cytotoxicity against human MRC5 cells expressing estrogen receptor after 48 hrs by MTT assay
    		10.1039/C2MD20327H
    MRC5 IC50
    0.12 μM
    Compound: Doxorubicin
    Cytotoxicity against human MRC5 cells after 1 hr by SRB assay
    Cytotoxicity against human MRC5 cells after 1 hr by SRB assay
    		[PMID: 22770744]
    MRC5 IC50
    0.12 μM
    Compound: Doxorubicin
    Antiproliferative activity against human MRC5 cells after 48 hrs by MTT assay
    Antiproliferative activity against human MRC5 cells after 48 hrs by MTT assay
    		[PMID: 30108986]
    MRC5 IC50
    0.24 μM
    Compound: Doxorubicin
    Cytotoxicity against human MRC5 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
    Cytotoxicity against human MRC5 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
    		[PMID: 33340938]
    MRC5 IC50
    0.29 μM
    Compound: DOX
    Cytotoxicity against human MRC5 cells after 72 hrs by MTT assay
    Cytotoxicity against human MRC5 cells after 72 hrs by MTT assay
    		[PMID: 29970309]
    MRC5 IC50
    0.3 μM
    Compound: Doxorubicin
    Antiproliferative activity against human MRC5 cells after 96 hrs by MTT assay
    Antiproliferative activity against human MRC5 cells after 96 hrs by MTT assay
    		[PMID: 19053767]
    MRC5 IC50
    0.39 μg/mL
    Compound: DOX
    Cytotoxicity against human MRC5 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    Cytotoxicity against human MRC5 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    		[PMID: 36958177]
    MRC5 IC50
    0.77 μg/mL
    Compound: doxo
    Cytotoxicity against human MRC5 cells by MTT method
    Cytotoxicity against human MRC5 cells by MTT method
    		[PMID: 17417907]
    MRC5 IC50
    1.4 μM
    Compound: Doxorubicin
    Cytotoxicity against human MRC5 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Cytotoxicity against human MRC5 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    		[PMID: 33823396]
    MRC5 IC50
    14.76 μM
    Compound: DOX
    Cytotoxicity against human MRC5 cells
    Cytotoxicity against human MRC5 cells
    		[PMID: 30015070]
    MRC5 IC50
    14.84 μM
    Compound: Doxorubicin
    Antiproliferative activity against human MRC5 cells after 48 hrs by MTT assay
    Antiproliferative activity against human MRC5 cells after 48 hrs by MTT assay
    		10.1039/C2MD20023F
    MRC5 IC50
    14.84 μM
    Compound: Doxorubicin
    Cytotoxicity against human MRC5 cells after 48 hrs by MTT assay
    Cytotoxicity against human MRC5 cells after 48 hrs by MTT assay
    		[PMID: 22386528]
    MRC5 IC50
    148 nM
    Compound: 5; Dox
    Cytotoxicity against human MRC5 cells assessed as reduction in cell viability incubated for 72 hrs by AlamarBlue cell viability assay
    Cytotoxicity against human MRC5 cells assessed as reduction in cell viability incubated for 72 hrs by AlamarBlue cell viability assay
    		[PMID: 31347843]
    MRC5 IC50
    2.19 μM
    Compound: Doxorubicin
    Cytotoxicity against human MRC5 cells assessed as reduction in cell growth measured after 48 hrs by MTT assay
    Cytotoxicity against human MRC5 cells assessed as reduction in cell growth measured after 48 hrs by MTT assay
    		[PMID: 31416738]
    MRC5 IC50
    2.4 μM
    Compound: Doxorubicin
    Cytotoxicity against human MRC5 cells assessed as cell growth inhibition after 72 hrs by alamar blue assay
    Cytotoxicity against human MRC5 cells assessed as cell growth inhibition after 72 hrs by alamar blue assay
    		[PMID: 31403289]
    MRC5 IC50
    2.5 μM
    Compound: Doxorubicin
    Cytotoxicity against human MRC5 cells assessed as inhibition in cell growth incubated for 72 hrs by MTT assay
    Cytotoxicity against human MRC5 cells assessed as inhibition in cell growth incubated for 72 hrs by MTT assay
    		[PMID: 37567059]
    MRC5 IC50
    2.91 μM
    Compound: Doxorubicin
    Cytotoxicity against human MRC5 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Cytotoxicity against human MRC5 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    		[PMID: 31704206]
    MRC5 IC50
    3.5 μM
    Compound: Doxorubicin
    Cytotoxicity against human MRC5 cells assessed as cell growth inhibition
    Cytotoxicity against human MRC5 cells assessed as cell growth inhibition
    		[PMID: 38630559]
    MRC5 IC50
    3.88 μM
    Compound: Doxorubicin
    Cytotoxicity against human MRC5 cells assessed as reduction in cell viability
    Cytotoxicity against human MRC5 cells assessed as reduction in cell viability
    		[PMID: 33352388]
    MRC5 IC50
    70.6 μM
    Compound: Doxorubicin
    Cytotoxicity against human MRC5 cells after 24 hrs by MTT assay
    Cytotoxicity against human MRC5 cells after 24 hrs by MTT assay
    		[PMID: 27769619]
    MRC5 IC50
    89.68 μM
    Compound: Doxo
    Cytotoxicity against human MRC5 cells assessed as cell viability after 24 hrs by MTT assay
    Cytotoxicity against human MRC5 cells assessed as cell viability after 24 hrs by MTT assay
    		[PMID: 27036521]
    MRC5 IC50
    > 20 μM
    Compound: Doxorubicin
    Cytotoxicity against human MRC5 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay
    Cytotoxicity against human MRC5 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay
    		[PMID: 35293752]
    MRC5 IC50
    > 50 μM
    Compound: DOX
    Cytotoxicity against human MRC5 cells assessed as reduction in cell viability after 48 hrs by CCK8 assay
    Cytotoxicity against human MRC5 cells assessed as reduction in cell viability after 48 hrs by CCK8 assay
    		[PMID: 30576904]
    MRC5 IC50
    > 50 μM
    Compound: DOX
    Cytotoxicity against human MRC5 cells assessed as reduction in cell growth incubated for 48 hrs by CCK8 assay
    Cytotoxicity against human MRC5 cells assessed as reduction in cell growth incubated for 48 hrs by CCK8 assay
    		[PMID: 31671309]
    MRC5 IC50
    > 91.99 μM
    Compound: Doxorubicin
    Cytotoxicity against human MRC5 cells by MTT assay
    Cytotoxicity against human MRC5 cells by MTT assay
    		[PMID: 25747499]
    MT4 EC50
    0.03 μM
    Compound: Doxorubicin
    Antiproliferative activity against human MT4 cells after 96 hrs by MTT assay
    Antiproliferative activity against human MT4 cells after 96 hrs by MTT assay
    		[PMID: 26320088]
    MT4 IC50
    0.003 μM
    Compound: Doxorubicin
    Antiproliferative activity against human MT4 cells after 96 hrs by MTT assay
    Antiproliferative activity against human MT4 cells after 96 hrs by MTT assay
    		[PMID: 19053767]
    MT4 IC50
    0.01 μM
    Compound: Doxo
    Antiproliferative activity against human MT-4 cells assessed as cell viability measured after 4 days by MTT assay
    Antiproliferative activity against human MT-4 cells assessed as cell viability measured after 4 days by MTT assay
    		[PMID: 31869654]
    MT4 IC50
    0.01 μM
    Compound: Doxorubicin
    Antitumor activity against CD4+ human acute T-lymphoblastic MT-4 leukemia cells.
    Antitumor activity against CD4+ human acute T-lymphoblastic MT-4 leukemia cells.
    		[PMID: 12431049]
    MT4 IC50
    0.01 μM
    Compound: doxo
    Antiproliferative activity against human MT4 cell line by MTT assay
    Antiproliferative activity against human MT4 cell line by MTT assay
    		[PMID: 16913700]
    MT4 IC50
    0.01 μM
    Compound: doxorubicin
    Antitumor activity against CD+ human acute T-lymphoblastic leukemia MT-4 cells
    Antitumor activity against CD+ human acute T-lymphoblastic leukemia MT-4 cells
    		[PMID: 12431048]
    MT4 IC50
    0.01 μM
    Compound: doxorubicin
    Antitumor activity against human CD4+T cells expressing the TAT gene of HTLV-1 MT-4 cells
    Antitumor activity against human CD4+T cells expressing the TAT gene of HTLV-1 MT-4 cells
    		[PMID: 12431048]
    MT4 IC50
    0.02 μM
    Compound: Doxorubicin
    Antitumor activity was evaluated against leukemia cell line MT-4(human CD4+ T cells expressing the TAT gene of HTLV-1).
    Antitumor activity was evaluated against leukemia cell line MT-4(human CD4+ T cells expressing the TAT gene of HTLV-1).
    		[PMID: 10411476]
    MT4 IC50
    0.05 μM
    Compound: Doxorubicin
    Compound was tested for its effect on the proliferation of MT-4 cells expressing the TAT gene of HTLV-1.
    Compound was tested for its effect on the proliferation of MT-4 cells expressing the TAT gene of HTLV-1.
    		10.1016/0960-894X(96)00216-8
    MV4-11 IC50
    0.05 μM
    Compound: Doxorubicin
    Antiproliferative activity against human MV4-11 cells after 72 hrs
    Antiproliferative activity against human MV4-11 cells after 72 hrs
    		[PMID: 26163197]
    MV4-11 IC50
    0.05 μM
    Compound: Doxorubicin
    Antiproliferative activity against human MV4-11 cells
    Antiproliferative activity against human MV4-11 cells
    		[PMID: 26338363]
    MV4-11 IC50
    0.16 μM
    Compound: DOX
    Cytotoxicity against human MV4-11 cells measured after 72 hrs by Celltiter-Glo assay
    Cytotoxicity against human MV4-11 cells measured after 72 hrs by Celltiter-Glo assay
    		[PMID: 31820976]
    MX1 IC50
    0.42 μM
    Compound: DOX
    Cytotoxicity against human MX1 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human MX1 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 29660689]
    MX1 IC50
    0.5 μM
    Compound: Doxorubicin
    Cytotoxicity against human MX1 cells assessed as cell viability after 72 hrs by MTT assay
    Cytotoxicity against human MX1 cells assessed as cell viability after 72 hrs by MTT assay
    		[PMID: 24530030]
    Malme-3M GI50
    0.12 μM
    Compound: Doxorubicin
    Growth inhibition of human MALME-3M cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human MALME-3M cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28329730]
    Malme-3M GI50
    0.12 μM
    Compound: Doxorubicin
    Growth inhibition of human MALME-3M cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human MALME-3M cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 29102177]
    Malme-3M GI50
    0.12 μM
    Compound: Doxorubicin hydrochloride, NSC 123127
    Cytotoxicity against human MALME-3M cells after 48 hrs by SRB assay
    Cytotoxicity against human MALME-3M cells after 48 hrs by SRB assay
    		[PMID: 23871905]
    Malme-3M GI50
    0.1 μg/mL
    Compound: adriamycin
    Cytotoxicity against human MALME-3M cells by MTT assay
    Cytotoxicity against human MALME-3M cells by MTT assay
    		[PMID: 11000028]
    Malme-3M IC50
    0.5 μM
    Compound: Doxorubicin
    Cytotoxicity against human MALME-3M cells after 72 hrs by MTT assay
    Cytotoxicity against human MALME-3M cells after 72 hrs by MTT assay
    		[PMID: 30783501]
    Melanoma cell IC50
    > 5 μg/mL
    Compound: DOX
    Tested for anticancer activity against human melanoma
    Tested for anticancer activity against human melanoma
    		[PMID: 11514168]
    Melanoma cell line IC50
    0.28 μM
    Compound: doxorubicin
    Growth inhibitory concentration of compound was measured against human melanoma cell line (HMV-1)
    Growth inhibitory concentration of compound was measured against human melanoma cell line (HMV-1)
    		[PMID: 10698436]
    N2a EC50
    127 μM
    Compound: Doxorubicin
    Cytotoxicity against mouse Neuro-2a cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Cytotoxicity against mouse Neuro-2a cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    		[PMID: 32816476]
    N2a IC50
    0.004 μg/mL
    Compound: 1 (doxorubicin)
    In vitro inhibitory activity against mouse neuroblastoma (neuro 2A) using CV coloration
    In vitro inhibitory activity against mouse neuroblastoma (neuro 2A) using CV coloration
    		[PMID: 15013011]
    N2a IC50
    1.2 μM
    Compound: Doxorubicin
    Cytotoxicity against mouse Neuro2a cells by MTT assay
    Cytotoxicity against mouse Neuro2a cells by MTT assay
    		[PMID: 21996519]
    N2a IC50
    < 0.001 μg/mL
    Compound: 1 (doxorubicin)
    In vitro cytotoxic concentration against mouse neuroblastoma (neuro 2A) using MTT coloration
    In vitro cytotoxic concentration against mouse neuroblastoma (neuro 2A) using MTT coloration
    		[PMID: 15013011]
    N592 IC50
    0.04 μM
    Compound: Adriamycin
    Cytotoxicity against human small-cell lung cancer (SCLC)
    Cytotoxicity against human small-cell lung cancer (SCLC)
    		[PMID: 8258835]
    NAMALVA IC50
    0.05 μM
    Compound: Doxorubicin
    Antiproliferative activity against human NAMALWA cells assessed as inhibition of cell proliferation incubated for 72 hrs by conventional ATP quantification method
    Antiproliferative activity against human NAMALWA cells assessed as inhibition of cell proliferation incubated for 72 hrs by conventional ATP quantification method
    		[PMID: 25937235]
    NAMALVA IC50
    0.09 μM
    Compound: Doxorubicin
    Cytotoxicity against human NAMALVA cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
    Cytotoxicity against human NAMALVA cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
    		[PMID: 33668008]
    NAMALVA IC50
    0.09 μM
    Compound: Doxorubicin
    Cytotoxicity against human NAMALVA cells assessed as cell growth inhibition incubated for 24 to 72 hrs by MTT assay
    Cytotoxicity against human NAMALVA cells assessed as cell growth inhibition incubated for 24 to 72 hrs by MTT assay
    		[PMID: 37989057]
    NB1 IC50
    5.15 x 10-3 μM
    Compound: Doxorubicin
    Cytotoxicity against human NB-1 cells by MTT assay
    Cytotoxicity against human NB-1 cells by MTT assay
    		[PMID: 19345581]
    NB1 IC50
    5.15 x 10-3 μM
    Compound: Doxorubicin
    Cytotoxicity against human NB-1 cells after 3 days by MTT assay
    Cytotoxicity against human NB-1 cells after 3 days by MTT assay
    		[PMID: 20356655]
    NCI-H1299 IC50
    0.5 μM
    Compound: DOX
    Cytotoxicity against human H1299 cells measured after 72 hrs by Celltiter-Glo assay
    Cytotoxicity against human H1299 cells measured after 72 hrs by Celltiter-Glo assay
    		[PMID: 31820976]
    NCI-H1299 IC50
    1.299 μM
    Compound: DOX
    Cytotoxicity against human NCI-H1299 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay
    Cytotoxicity against human NCI-H1299 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay
    		[PMID: 34700239]
    NCI-H1299 IC50
    1.4 μM
    Compound: Doxorubicin
    Cytotoxicity against human NCI-H1299 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Cytotoxicity against human NCI-H1299 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    		[PMID: 37672645]
    NCI-H157 IC50
    0.61 μM
    Compound: Doxorubicin
    Antiproliferative activity against human NCI-H157 cells after 48 hrs by MTT assay
    Antiproliferative activity against human NCI-H157 cells after 48 hrs by MTT assay
    		[PMID: 28919340]
    NCI-H187 IC50
    0.03 μM
    Compound: Dox
    Cytotoxicity against human NCI-H187 cells after 3 days by MTT assay
    Cytotoxicity against human NCI-H187 cells after 3 days by MTT assay
    		[PMID: 21741833]
    NCI-H187 IC50
    0.042 μg/mL
    Compound: doxorubicin
    Cytotoxicity against human NCI-H187 cells by sulforhodamine B assay
    Cytotoxicity against human NCI-H187 cells by sulforhodamine B assay
    		[PMID: 19555123]
    NCI-H187 IC50
    0.048 μg/mL
    Compound: doxorubicin
    Cytotoxicity against human NCI-H187 cells
    Cytotoxicity against human NCI-H187 cells
    		[PMID: 17567069]
    NCI-H187 IC50
    0.04 μg/mL
    Compound: doxorubicin
    Cytotoxicity against human NCI-H187 cells by SRB assay
    Cytotoxicity against human NCI-H187 cells by SRB assay
    		[PMID: 19778068]
    NCI-H187 IC50
    0.04 μg/mL
    Compound: doxorubicin
    Cytotoxicity against human NCI-H187 cells by resazurin microplate assay
    Cytotoxicity against human NCI-H187 cells by resazurin microplate assay
    		[PMID: 20329738]
    NCI-H187 IC50
    0.058 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human NCI-H187 cells by resazurin microplate assay
    Cytotoxicity against human NCI-H187 cells by resazurin microplate assay
    		[PMID: 19456117]
    NCI-H187 IC50
    0.06 μM
    Compound: Doxorubicin
    Cytotoxicity against human NCI-H187 cells after 72 hrs by resazurin based fluorescence assay
    Cytotoxicity against human NCI-H187 cells after 72 hrs by resazurin based fluorescence assay
    		[PMID: 28927795]
    NCI-H187 IC50
    0.08 μM
    Compound: Doxorubicin
    Cytotoxicity against human NCI-H187 cells by SRB assay
    Cytotoxicity against human NCI-H187 cells by SRB assay
    		[PMID: 20038128]
    NCI-H187 IC50
    0.098 μM
    Compound: Doxorubicin
    Cytotoxicity against human NCI-H187 cells by resazurin microplate assay
    Cytotoxicity against human NCI-H187 cells by resazurin microplate assay
    		[PMID: 21090800]
    NCI-H187 IC50
    0.1 μM
    Compound: doxorubicin
    Cytotoxicity against human NCI-H187 cells
    Cytotoxicity against human NCI-H187 cells
    		[PMID: 16919455]
    NCI-H187 IC50
    0.1 μM
    Compound: doxorubicin
    Cytotoxicity against human NCI-H187 cells by resazurin reduction assay
    Cytotoxicity against human NCI-H187 cells by resazurin reduction assay
    		[PMID: 22482432]
    NCI-H187 IC50
    0.11 μM
    Compound: doxorubicin
    Cytotoxicity against human NCI-H187 cells by SRB assay
    Cytotoxicity against human NCI-H187 cells by SRB assay
    		[PMID: 22004007]
    NCI-H187 IC50
    0.12 μM
    Compound: doxorubicin
    Cytotoxicity against human NCI-H187 cells by colorimetric method
    Cytotoxicity against human NCI-H187 cells by colorimetric method
    		[PMID: 23795891]
    NCI-H187 IC50
    0.14 μM
    Compound: Doxorubicin
    Cytotoxicity against human NCI-H187 cells by SRB assay
    Cytotoxicity against human NCI-H187 cells by SRB assay
    		[PMID: 23806014]
    NCI-H187 IC50
    0.16 μM
    Compound: Doxorubicin
    Cytotoxicity against human NCI-H187 cells after 5 days by resazurin microplate assay
    Cytotoxicity against human NCI-H187 cells after 5 days by resazurin microplate assay
    		[PMID: 22280818]
    NCI-H187 IC50
    0.2 μM
    Compound: Doxorubicin
    Cytotoxicity against human NCI-H187 cells assessed as reduction in cell viability by resazurin based fluorescence assay
    Cytotoxicity against human NCI-H187 cells assessed as reduction in cell viability by resazurin based fluorescence assay
    		[PMID: 33852304]
    NCI-H187 IC50
    0.2 μM
    Compound: Doxorubicine
    Cytotoxicity against human NCI-H187 cells assessed as reduction in cell viability by resazurin microplate assay
    Cytotoxicity against human NCI-H187 cells assessed as reduction in cell viability by resazurin microplate assay
    		[PMID: 34748348]
    NCI-H187 IC50
    0.23 μM
    Compound: Doxorubicin
    Cytotoxicity against human NCI-H187 cells by resazurin microplate assay
    Cytotoxicity against human NCI-H187 cells by resazurin microplate assay
    		[PMID: 32193929]
    NCI-H187 IC50
    0.25 μM
    Compound: Doxorubicin
    Cytotoxicity against human NCI-H187 cells by resazurin microplate assay
    Cytotoxicity against human NCI-H187 cells by resazurin microplate assay
    		[PMID: 19739600]
    NCI-H187 IC50
    4.05 x 10-5 M
    Compound: doxorubicin
    Cytotoxicity against human NCI-H187 cells by SRB assay
    Cytotoxicity against human NCI-H187 cells by SRB assay
    		[PMID: 16933890]
    NCI-H1975 IC50
    0.03 μM
    Compound: Doxorubicin
    Cytotoxicity against human NCI-H1975 cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay
    Cytotoxicity against human NCI-H1975 cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay
    		[PMID: 28257197]
    NCI-H1975 IC50
    0.087 μM
    Compound: DOX
    Cytotoxicity against human NCI-H1975 cells harboring EGFR double L858R/T790M mutant measured after 72 hrs by Celltiter-Glo assay
    Cytotoxicity against human NCI-H1975 cells harboring EGFR double L858R/T790M mutant measured after 72 hrs by Celltiter-Glo assay
    		[PMID: 31820976]
    NCI-H1975 IC50
    0.12 μM
    Compound: Doxorubicin
    Cytotoxicity against human NCI-H1975 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Cytotoxicity against human NCI-H1975 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    		[PMID: 37672645]
    NCI-H1975 IC50
    0.62 μM
    Compound: Dox
    Antiproliferative activity against human NCI-H1975 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    Antiproliferative activity against human NCI-H1975 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    		[PMID: 38176358]
    NCI-H1975 IC50
    2.64 μM
    Compound: DOX
    Cytotoxicity against human NCI-H1975 cells assessed as inhibition of cell viability incubated for 48 hrs by MTT assay
    Cytotoxicity against human NCI-H1975 cells assessed as inhibition of cell viability incubated for 48 hrs by MTT assay
    		[PMID: 38169372]
    NCI-H1975 IC50
    2.676 μM
    Compound: DOX
    Cytotoxicity against human NCI-H1975 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay
    Cytotoxicity against human NCI-H1975 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay
    		[PMID: 34700239]
    NCI-H2228 IC50
    0.097 μM
    Compound: DOX
    Cytotoxicity against human NCI-H2228 cells measured after 72 hrs by Celltiter-Glo assay
    Cytotoxicity against human NCI-H2228 cells measured after 72 hrs by Celltiter-Glo assay
    		[PMID: 31820976]
    NCI-H226 GI50
    0.05 μM
    Compound: Doxorubicin
    Growth inhibition of human NCI-H226 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human NCI-H226 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28329730]
    NCI-H226 GI50
    0.05 μM
    Compound: Doxorubicin
    Growth inhibition of human NCI-H226 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human NCI-H226 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 29102177]
    NCI-H226 GI50
    0.05 μM
    Compound: Doxorubicin hydrochloride, NSC 123127
    Cytotoxicity against human NCI-H226 cells after 48 hrs by SRB assay
    Cytotoxicity against human NCI-H226 cells after 48 hrs by SRB assay
    		[PMID: 23871905]
    NCI-H226 GI50
    < 10 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human NCI-H226 cells after 48 hrs by SRB assay
    Cytotoxicity against human NCI-H226 cells after 48 hrs by SRB assay
    		10.1039/C5MD00224A
    NCI-H226 IC50
    0.008 μM
    Compound: Doxorubicin
    Inhibitory activity against NCI-H226 cell line using MTT assay(mutant p53)
    Inhibitory activity against NCI-H226 cell line using MTT assay(mutant p53)
    		[PMID: 10780913]
    NCI-H226 IC50
    5.07 μM
    Compound: Doxorubicin
    Antiproliferative activity against human NCI-H226 cells after 48 hrs by MTT assay
    Antiproliferative activity against human NCI-H226 cells after 48 hrs by MTT assay
    		[PMID: 29547830]
    NCI-H23 ED50
    0.1 μg/mL
    Compound: Adriamycin
    Cytotoxicity against human NCI-H23 cells
    Cytotoxicity against human NCI-H23 cells
    		[PMID: 10346965]
    NCI-H23 GI50
    0.005 μM
    Compound: Doxorubicin
    Cytostatic activity against human NCI-H23 cells after 5 days by SRB assay
    Cytostatic activity against human NCI-H23 cells after 5 days by SRB assay
    		[PMID: 21711054]
    NCI-H23 GI50
    0.072 μM
    Compound: ADR
    Anticancer activity against human NCI-H23 cells assessed as growth inhibition incubated for 48 hrs by sulforhodamine B method
    Anticancer activity against human NCI-H23 cells assessed as growth inhibition incubated for 48 hrs by sulforhodamine B method
    		[PMID: 34500188]
    NCI-H23 GI50
    0.0726 μM
    Compound: ADR
    Cytotoxicity against human NCI-H23 cells after 72 hrs by sulforhodamine B assay
    Cytotoxicity against human NCI-H23 cells after 72 hrs by sulforhodamine B assay
    		[PMID: 27096046]
    NCI-H23 GI50
    0.09 μM
    Compound: ADR
    Cytotoxicity against human NCI-H23 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay
    Cytotoxicity against human NCI-H23 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay
    		[PMID: 28870801]
    NCI-H23 GI50
    0.09 μM
    Compound: ADR
    Cytotoxicity against human NCI-H23 cells assessed as growth inhibition after 72 hrs by SRB assay
    Cytotoxicity against human NCI-H23 cells assessed as growth inhibition after 72 hrs by SRB assay
    		[PMID: 30253887]
    NCI-H23 GI50
    0.15 μM
    Compound: Doxorubicin
    Growth inhibition of human NCI-H23 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human NCI-H23 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28329730]
    NCI-H23 GI50
    0.15 μM
    Compound: Doxorubicin
    Growth inhibition of human NCI-H23 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human NCI-H23 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 29102177]
    NCI-H23 GI50
    0.15 μM
    Compound: Doxorubicin hydrochloride, NSC 123127
    Cytotoxicity against human NCI-H23 cells after 48 hrs by SRB assay
    Cytotoxicity against human NCI-H23 cells after 48 hrs by SRB assay
    		[PMID: 23871905]
    NCI-H23 GI50
    0.178 μM
    Compound: ADR
    Cytotoxicity against human NCI-H23 cells assessed as growth inhibition after 72 hrs by SRB assay
    Cytotoxicity against human NCI-H23 cells assessed as growth inhibition after 72 hrs by SRB assay
    		[PMID: 24792464]
    NCI-H23 GI50
    0.178 μM
    Compound: doxorubicin
    Cytotoxicity against human NCI-H23 cells
    Cytotoxicity against human NCI-H23 cells
    		[PMID: 20579876]
    NCI-H23 GI50
    0.4 μM
    Compound: ADR
    Cytotoxicity against human NCI-H23 cells assessed as growth inhibition after 72 hrs by sulforhodamine B assay
    Cytotoxicity against human NCI-H23 cells assessed as growth inhibition after 72 hrs by sulforhodamine B assay
    		[PMID: 25953156]
    NCI-H23 GI50
    0.51 μM
    Compound: Doxorubicin
    Cytotoxicity against human NCI-H23 cells by SRB assay
    Cytotoxicity against human NCI-H23 cells by SRB assay
    		[PMID: 19596579]
    NCI-H23 GI50
    1.66 μM
    Compound: ADR
    Antiproliferative activity against human NCI-H23 cells by SRB assay
    Antiproliferative activity against human NCI-H23 cells by SRB assay
    		[PMID: 22738641]
    NCI-H23 GI50
    1.66 μM
    Compound: ADR
    Antiproliferative activity against human NCI-H23 cells by SRB method
    Antiproliferative activity against human NCI-H23 cells by SRB method
    		[PMID: 24835787]
    NCI-H23 GI50
    1.9 μM
    Compound: Doxorubicin
    Cytotoxicity against human NCI-H23 cells after 48 hrs by sulforhodamine B assay
    Cytotoxicity against human NCI-H23 cells after 48 hrs by sulforhodamine B assay
    		[PMID: 23964644]
    NCI-H23 IC50
    0.1 μg/mL
    Compound: Adriamycin
    Inhibitory concentration required against NCI-H23 lung cancer cell line
    Inhibitory concentration required against NCI-H23 lung cancer cell line
    		[PMID: 11354370]
    NCI-H292 IC50
    0.02 μg/mL
    Compound: DOX
    Cytotoxicity against human NCI-H292 cells after 72 hrs by MTT assay
    Cytotoxicity against human NCI-H292 cells after 72 hrs by MTT assay
    		[PMID: 24589485]
    NCI-H292 IC50
    0.19 μM
    Compound: Doxorubicin
    Cytotoxicity against human NCI-H292 cells assessed as inhibition of cell viability after 72 hrs by MTT assay
    Cytotoxicity against human NCI-H292 cells assessed as inhibition of cell viability after 72 hrs by MTT assay
    		[PMID: 29329071]
    NCI-H292 IC50
    0.37 μM
    Compound: Doxorubicin
    Cytotoxicity against human NCI-H292 cells after 72 hrs by MTT assay
    Cytotoxicity against human NCI-H292 cells after 72 hrs by MTT assay
    		[PMID: 27116711]
    NCI-H292 IC50
    0.6 μM
    Compound: Doxorubicin
    Growth inhibition of human NCI-H292 cells after 72 hrs by MTT assay
    Growth inhibition of human NCI-H292 cells after 72 hrs by MTT assay
    		[PMID: 28189083]
    NCI-H292 IC50
    351 nM
    Compound: Doxorubicin
    Cytotoxicity against human NCI-H292 cells after 72 hrs by MTT assay
    Cytotoxicity against human NCI-H292 cells after 72 hrs by MTT assay
    		[PMID: 28459574]
    NCI-H322M GI50
    0.54 μM
    Compound: Doxorubicin
    Growth inhibition of human NCI-H322M cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human NCI-H322M cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28329730]
    NCI-H322M GI50
    0.54 μM
    Compound: Doxorubicin
    Growth inhibition of human NCI-H322M cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human NCI-H322M cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 29102177]
    NCI-H322M GI50
    0.54 μM
    Compound: Doxorubicin hydrochloride, NSC 123127
    Cytotoxicity against human NCI-H322M cells after 48 hrs by SRB assay
    Cytotoxicity against human NCI-H322M cells after 48 hrs by SRB assay
    		[PMID: 23871905]
    NCI-H322M IC50
    0.03 μM
    Compound: Doxorubicin
    Inhibitory activity against NCI-H322 cell line using MTT assay(mutant p53)
    Inhibitory activity against NCI-H322 cell line using MTT assay(mutant p53)
    		[PMID: 10780913]
    NCI-H322M IC50
    29 μM
    Compound: DOX
    Antiproliferative activity against human NCI-H322M cells after 72 hrs by MTT assay
    Antiproliferative activity against human NCI-H322M cells after 72 hrs by MTT assay
    		[PMID: 30429098]
    NCI-H358 IC50
    0.13 μM
    Compound: Doxorubicin
    Inhibitory activity against NCI-H358 cell line using MTT assay(mutant p53)
    Inhibitory activity against NCI-H358 cell line using MTT assay(mutant p53)
    		[PMID: 10780913]
    NCI-H358 IC50
    0.62 μM
    Compound: adriamycin
    Compound was evaluated for inhibitory activity against H 358 human lung cancer cell line
    Compound was evaluated for inhibitory activity against H 358 human lung cancer cell line
    		[PMID: 1479585]
    NCI-H358 IC50
    0.9 μM
    Compound: Dox
    Cytotoxicity against human NCI-H358 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human NCI-H358 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 31306817]
    NCI-H417 IC50
    0.23 μM
    Compound: adriamycin
    Compound was evaluated for inhibitory activity against N 417 human lung cancer cell line
    Compound was evaluated for inhibitory activity against N 417 human lung cancer cell line
    		[PMID: 1479585]
    NCI-H446 IC50
    0.0248 μg/mL
    Compound: DOX
    Cytotoxicity against human NCI-H446 cells after 72 hrs by MTT assay
    Cytotoxicity against human NCI-H446 cells after 72 hrs by MTT assay
    		[PMID: 20722446]
    NCI-H446 IC50
    0.39 nM
    Compound: Doxorubicin
    Antiproliferative activity against human NCI-H446 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay
    Antiproliferative activity against human NCI-H446 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay
    		[PMID: 35932565]
    NCI-H446 IC50
    5.71 nM
    Compound: Doxorubicin
    Antiproliferative activity against Irinotecan-resistant human NCI-H446 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay
    Antiproliferative activity against Irinotecan-resistant human NCI-H446 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay
    		[PMID: 35932565]
    NCI-H446 IC50
    5.71 nM
    Compound: Doxorubicin
    Antiproliferative activity against etoposide/cisplatin combination-resistant human NCI-H446 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay
    Antiproliferative activity against etoposide/cisplatin combination-resistant human NCI-H446 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay
    		[PMID: 35932565]
    NCI-H460 EC50
    0.04 μM
    Compound: Doxorubicin
    Cytotoxicity against human NCI-H460 cells after 48 hrs by resazurin dye assay
    Cytotoxicity against human NCI-H460 cells after 48 hrs by resazurin dye assay
    		[PMID: 23988351]
    NCI-H460 GI50
    0.02 μM
    Compound: Doxorubicin
    Growth inhibition of human NCI-H460 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human NCI-H460 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28329730]
    NCI-H460 GI50
    0.02 μM
    Compound: Doxorubicin
    Growth inhibition of human NCI-H460 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human NCI-H460 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 29102177]
    NCI-H460 GI50
    0.02 μM
    Compound: Doxorubicin hydrochloride, NSC 123127
    Cytotoxicity against human NCI-H460 cells after 48 hrs by SRB assay
    Cytotoxicity against human NCI-H460 cells after 48 hrs by SRB assay
    		[PMID: 23871905]
    NCI-H460 GI50
    0.03 μM
    Compound: Doxo
    Inhibition of cell growth in human NCI-H460 cells incubated for 48 hrs by SRB method
    Inhibition of cell growth in human NCI-H460 cells incubated for 48 hrs by SRB method
    		[PMID: 39093920]
    NCI-H460 GI50
    0.04 μM
    Compound: Doxorubicin
    Growth inhibition of human NCI-H460 cells
    Growth inhibition of human NCI-H460 cells
    		[PMID: 31404864]
    NCI-H460 GI50
    0.05 μM
    Compound: Doxorubicin
    Cytotoxicity against human NCI-H460 cells by sulforhodamine B assay
    Cytotoxicity against human NCI-H460 cells by sulforhodamine B assay
    		[PMID: 20413188]
    NCI-H460 GI50
    0.0547 μM
    Compound: Doxorubicin
    Cytotoxicity against human NCI-H460 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay
    Cytotoxicity against human NCI-H460 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay
    		[PMID: 31534659]
    NCI-H460 GI50
    0.09 μM
    Compound: Dox
    Growth inhibition of human NCI-H460 cells after 48 hrs by sulforhodamine B dye-based spectrophotometric assay
    Growth inhibition of human NCI-H460 cells after 48 hrs by sulforhodamine B dye-based spectrophotometric assay
    		[PMID: 28505535]
    NCI-H460 GI50
    0.09 μM
    Compound: Dox
    Growth inhibition of human NCI-H460 cells by MTT assay
    Growth inhibition of human NCI-H460 cells by MTT assay
    		[PMID: 31330449]
    NCI-H460 GI50
    0.09 μM
    Compound: doxorubicin
    Growth inhibition of Homo sapiens (human) NCI-H460 cells after 48 hr by SRB assay
    Growth inhibition of Homo sapiens (human) NCI-H460 cells after 48 hr by SRB assay
    		10.1007/s00044-012-0213-9
    NCI-H460 GI50
    0.094 μM
    Compound: Doxorubicin
    Cytotoxicity against human NCI-H460 cells after 48 hrs by SRB assay
    Cytotoxicity against human NCI-H460 cells after 48 hrs by SRB assay
    		[PMID: 15620248]
    NCI-H460 GI50
    0.094 μM
    Compound: Doxorubicin
    Growth inhibition of human NCI-H460 cells after 48 hrs by sulforhodamine B assay
    Growth inhibition of human NCI-H460 cells after 48 hrs by sulforhodamine B assay
    		[PMID: 21435889]
    NCI-H460 GI50
    0.11 μM
    Compound: Doxorubicin
    Growth inhibition of Homo sapiens (human) H460 cells after 48 hr by MTT assay
    Growth inhibition of Homo sapiens (human) H460 cells after 48 hr by MTT assay
    		10.1007/s00044-012-0232-6
    NCI-H460 GI50
    0.123 μM
    Compound: Doxorubicin
    Cytotoxicity against human NCI-H460 cells assessed as growth inhibition measured after 48 hrs by SRB assay
    Cytotoxicity against human NCI-H460 cells assessed as growth inhibition measured after 48 hrs by SRB assay
    		[PMID: 31059248]
    NCI-H460 GI50
    0.37 μM
    Compound: DOXO
    Antiproliferative activity against human NCI-H460 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    Antiproliferative activity against human NCI-H460 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    		[PMID: 31247374]
    NCI-H460 GI50
    0.42 μg/mL
    Compound: adriamycin
    Cytotoxicity against human H460 cells
    Cytotoxicity against human H460 cells
    		[PMID: 16562847]
    NCI-H460 GI50
    0.81 x 10-2 μM
    Compound: doxorubicin
    Cytotoxicity against human NCI-H460 cells by SRB assay
    Cytotoxicity against human NCI-H460 cells by SRB assay
    		[PMID: 11678649]
    NCI-H460 GI50
    20 nM
    Compound: Doxorubicin
    Antiproliferative activity against human NCI-H460 cells measured after 48 hrs by sulforhodamine B assay
    Antiproliferative activity against human NCI-H460 cells measured after 48 hrs by sulforhodamine B assay
    		[PMID: 27908756]
    NCI-H460 GI50
    3 x 10-7 μM
    Compound: adriamycin
    Cytotoxicity against human H460 cells
    Cytotoxicity against human H460 cells
    		[PMID: 14640532]
    NCI-H460 GI50
    3.6 x 10-7 μg/mL
    Compound: adriamycin
    Cytotoxicity against human H460 cells
    Cytotoxicity against human H460 cells
    		[PMID: 12828475]
    NCI-H460 GI50
    34.07 nM
    Compound: Doxorubicin
    Growth inhibition of human NCI-H460 cells after 48 hrs by SRB assay
    Growth inhibition of human NCI-H460 cells after 48 hrs by SRB assay
    		[PMID: 24411197]
    NCI-H460 GI50
    35.6 nM
    Compound: Doxorubucin
    Growth inhibition of human NCI-H460 cells after 48 hrs by SRB assay
    Growth inhibition of human NCI-H460 cells after 48 hrs by SRB assay
    		[PMID: 21138784]
    NCI-H460 GI50
    35.6 nM
    Compound: doxorubicin
    Growth inhibition of human NCI-H460 cells after 48 hrs by sulforhodamine B assay
    Growth inhibition of human NCI-H460 cells after 48 hrs by sulforhodamine B assay
    		[PMID: 20934235]
    NCI-H460 GI50
    64.1 nM
    Compound: Doxorubicin
    Growth inhibition of human NCI-H460 cells after 48 hrs by sulforhodamine B assay
    Growth inhibition of human NCI-H460 cells after 48 hrs by sulforhodamine B assay
    		[PMID: 23623253]
    NCI-H460 GI50
    64.1 nM
    Compound: Doxorubicin
    Cytotoxicity against human NCI-H460 cells after 48 hrs by SRB assay
    Cytotoxicity against human NCI-H460 cells after 48 hrs by SRB assay
    		[PMID: 24113365]
    NCI-H460 GI50
    7.2 x 10-7 μg/mL
    Compound: adriamycin
    Cytotoxicity against human H460 cells
    Cytotoxicity against human H460 cells
    		[PMID: 15043429]
    NCI-H460 GI50
    7.2 x 10-7 μg/mL
    Compound: adriamycin
    Cytotoxicity against human H460 cells
    Cytotoxicity against human H460 cells
    		[PMID: 15787438]
    NCI-H460 GI50
    86 nM
    Compound: Doxorubicin
    Growth inhibition of human NCI-H460 cells after 48 hrs by SRB assay
    Growth inhibition of human NCI-H460 cells after 48 hrs by SRB assay
    		[PMID: 22177409]
    NCI-H460 GI50
    94 nM
    Compound: Doxorubicin
    Cytotoxicity against human NCI-H460 cells after 48 hrs by SRB assay
    Cytotoxicity against human NCI-H460 cells after 48 hrs by SRB assay
    		[PMID: 15270581]
    NCI-H460 GI50
    94 nM
    Compound: Doxorubicin
    Growth inhibition of human NCI-H460 cells
    Growth inhibition of human NCI-H460 cells
    		[PMID: 17614292]
    NCI-H460 GI50
    94 nM
    Compound: Doxorubicin
    Antitumor activity against human NCI-H460 cells assessed as inhibition of growth after 48 hrs using sulforhodamine B dye
    Antitumor activity against human NCI-H460 cells assessed as inhibition of growth after 48 hrs using sulforhodamine B dye
    		[PMID: 19428155]
    NCI-H460 GI50
    94 nM
    Compound: doxorubicin
    Growth inhibition of human NCI-H460 cells after 48 hrs
    Growth inhibition of human NCI-H460 cells after 48 hrs
    		[PMID: 17692432]
    NCI-H460 GI50
    94 nM
    Compound: doxorubicin
    Cytotoxicity against human NCI-H460 cells after 48 hrs
    Cytotoxicity against human NCI-H460 cells after 48 hrs
    		[PMID: 17964791]
    NCI-H460 GI50
    94 nM
    Compound: doxorubicin
    Antitumor activity against human NCI-H460 cells after 48 hrs
    Antitumor activity against human NCI-H460 cells after 48 hrs
    		[PMID: 18439831]
    NCI-H460 GI50
    94 μM
    Compound: Doxorubicin
    Growth inhibition of human NCI-H460 cells after 48 hrs by SRB assay
    Growth inhibition of human NCI-H460 cells after 48 hrs by SRB assay
    		[PMID: 15165162]
    NCI-H460 GI50
    94 μM
    Compound: Doxorubicin
    Growth inhibition of human NCI-H460 cells after 48 hrs by sulforhodamine B assay
    Growth inhibition of human NCI-H460 cells after 48 hrs by sulforhodamine B assay
    		[PMID: 21504224]
    NCI-H460 GI50
    94 μM
    Compound: doxorubicin
    Cytotoxicity against human NCI-H460 cells after 48 hrs by SRB assay
    Cytotoxicity against human NCI-H460 cells after 48 hrs by SRB assay
    		[PMID: 19070942]
    NCI-H460 GI50
    < 0.025 μg/mL
    Compound: DOX
    Antiproliferative activity against human NCI-H460 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    Antiproliferative activity against human NCI-H460 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    		[PMID: 25062010]
    NCI-H460 GI50
    < 0.025 μg/mL
    Compound: DOX; Doxo
    Antiproliferative activity against human NCI-H460 cells after 48 hrs by SRB assay
    Antiproliferative activity against human NCI-H460 cells after 48 hrs by SRB assay
    		[PMID: 26859070]
    NCI-H460 GI50
    < 0.025 μg/mL
    Compound: Doxorubicin
    Growth inhibition of human NCI-H460 cells after 48 hrs by sulforhodamine B assay
    Growth inhibition of human NCI-H460 cells after 48 hrs by sulforhodamine B assay
    		[PMID: 22410248]
    NCI-H460 GI50
    < 0.03 μg/mL
    Compound: DOX
    Growth inhibition of human NCI-H460 cells after 48 hrs by sulforhodamine B assay
    Growth inhibition of human NCI-H460 cells after 48 hrs by sulforhodamine B assay
    		[PMID: 21041092]
    NCI-H460 GI50
    < 0.046 μM
    Compound: Dox
    Antiproliferative activity against human NCI-H460 cells assessed as growth inhibition after 48 hrs by SRB assay
    Antiproliferative activity against human NCI-H460 cells assessed as growth inhibition after 48 hrs by SRB assay
    		[PMID: 26454648]
    NCI-H460 GI50
    < 0.046 μM
    Compound: Doxorubicin
    Anticancer activity against human NCI-H460 cells assessed as cell growth inhibition measured after 48 hrs by sulforhodamine B assay
    Anticancer activity against human NCI-H460 cells assessed as cell growth inhibition measured after 48 hrs by sulforhodamine B assay
    		[PMID: 33214037]
    NCI-H460 GI50
    3.6 x 10-7 μg/mL
    Compound: adriamycin
    Cytotoxicity against human H460 cells
    Cytotoxicity against human H460 cells
    		[PMID: 15730249]
    NCI-H460 IC50
    0.003 μM
    Compound: DOX
    Antiproliferative activity against human H460 cells measured after 72 hrs by MTT assay
    Antiproliferative activity against human H460 cells measured after 72 hrs by MTT assay
    		[PMID: 31431364]
    NCI-H460 IC50
    0.0037 μM
    Compound: adriamycin
    Antitumor activity against human NCI-H460 cells by methylene blue staining method
    Antitumor activity against human NCI-H460 cells by methylene blue staining method
    		[PMID: 17656091]
    NCI-H460 IC50
    0.004 μM
    Compound: Doxorubicin
    Inhibitory activity against H460pv8 cell line using MTT assay
    Inhibitory activity against H460pv8 cell line using MTT assay
    		[PMID: 10780913]
    NCI-H460 IC50
    0.01 μM
    Compound: Doxorubicin
    Inhibitory activity against NCI-H460 cell line using MTT assay
    Inhibitory activity against NCI-H460 cell line using MTT assay
    		[PMID: 10780913]
    NCI-H460 IC50
    0.01 μM
    Compound: Doxorubicin
    Inhibitory activity against NCI-H460 cell line using MTT assay(Wild type p53)
    Inhibitory activity against NCI-H460 cell line using MTT assay(Wild type p53)
    		[PMID: 10780913]
    NCI-H460 IC50
    0.01 μM
    Compound: Doxorubicin
    Inhibitory concentration against NCI-H460 lung carcinoma cell line
    Inhibitory concentration against NCI-H460 lung carcinoma cell line
    		[PMID: 15715481]
    NCI-H460 IC50
    0.01 μM
    Compound: Doxorubicin
    Cytotoxicity against human NCI-H460 cells after 24 hrs by MTT assay
    Cytotoxicity against human NCI-H460 cells after 24 hrs by MTT assay
    		[PMID: 17190470]
    NCI-H460 IC50
    0.01 μM
    Compound: Doxorubicin
    Cytotoxicity against human NCI-H460 cells assessed as reduction in cell viability incubated for 6 hrs by SRB assay
    Cytotoxicity against human NCI-H460 cells assessed as reduction in cell viability incubated for 6 hrs by SRB assay
    		[PMID: 36691388]
    NCI-H460 IC50
    0.01 μM
    Compound: doxorubicin
    Cytotoxicity against human NCI-H460 cells by MTT assay
    Cytotoxicity against human NCI-H460 cells by MTT assay
    		[PMID: 15620238]
    NCI-H460 IC50
    0.01 μM
    Compound: doxorubicin
    Cytotoxicity against human NCI-H460 cells by MTT assay
    Cytotoxicity against human NCI-H460 cells by MTT assay
    		[PMID: 15921417]
    NCI-H460 IC50
    0.01 μM
    Compound: doxorubicin
    Cytotoxicity against human NCI-H460 cells after 72 hrs by MTT assay
    Cytotoxicity against human NCI-H460 cells after 72 hrs by MTT assay
    		[PMID: 17286429]
    NCI-H460 IC50
    0.01 μM
    Compound: doxorubicin
    Cytotoxicity against human NCI-H460 cells
    Cytotoxicity against human NCI-H460 cells
    		[PMID: 17375902]
    NCI-H460 IC50
    0.01 μM
    Compound: doxorubicin
    Antiproliferative activity against human NCI-H460 cells by MTT assay
    Antiproliferative activity against human NCI-H460 cells by MTT assay
    		[PMID: 18052326]
    NCI-H460 IC50
    0.01 μM
    Compound: doxorubicin
    Antiproliferative activity against human NCI-H460 cells by MTT assay
    Antiproliferative activity against human NCI-H460 cells by MTT assay
    		[PMID: 18247573]
    NCI-H460 IC50
    0.01 μg/mL
    Compound: dox, doxorubicin
    Cytotoxicity against human NCI-H460 cells
    Cytotoxicity against human NCI-H460 cells
    		[PMID: 17618015]
    NCI-H460 IC50
    0.02 μM
    Compound: Doxorubicin
    Antiproliferative activity against human NCI-H460 cells assessed as inhibition of cell proliferation incubated for 72 hrs by conventional ATP quantification method
    Antiproliferative activity against human NCI-H460 cells assessed as inhibition of cell proliferation incubated for 72 hrs by conventional ATP quantification method
    		[PMID: 25937235]
    NCI-H460 IC50
    0.028 μM
    Compound: doxorubicin
    Antiproliferative activity against human NCI-H460 cells after 72 hrs by trypan blue test
    Antiproliferative activity against human NCI-H460 cells after 72 hrs by trypan blue test
    		[PMID: 18077173]
    NCI-H460 IC50
    0.03 μM
    Compound: Doxorubicin
    Antiproliferative activity against human H460 cells after 72 hrs by MTT assay
    Antiproliferative activity against human H460 cells after 72 hrs by MTT assay
    		[PMID: 24780599]
    NCI-H460 IC50
    0.03 μM
    Compound: Doxorubicin
    Antiproliferative activity against human H460 cells after 72 hrs by MTT assay
    Antiproliferative activity against human H460 cells after 72 hrs by MTT assay
    		[PMID: 27448912]
    NCI-H460 IC50
    0.04 μM
    Compound: Dox
    Cytotoxicity against human NCI-H460 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human NCI-H460 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 30615450]
    NCI-H460 IC50
    0.05 μM
    Compound: Doxorubicin
    Cytotoxicity against human NCI-H460 cells after 72 hrs by resazurin-based colorimetric assay
    Cytotoxicity against human NCI-H460 cells after 72 hrs by resazurin-based colorimetric assay
    		[PMID: 27071003]
    NCI-H460 IC50
    0.05 μM
    Compound: Doxorubicin
    Cytotoxicity against human NCI-H460 cells assessed as cell growth inhibition measured after 24 to 72 hrs by MTT assay
    Cytotoxicity against human NCI-H460 cells assessed as cell growth inhibition measured after 24 to 72 hrs by MTT assay
    		[PMID: 33586438]
    NCI-H460 IC50
    0.05 μM
    Compound: doxorubicin
    Cytotoxicity against human NCI-H460 cells after 72 hrs by Alamar Blue assay
    Cytotoxicity against human NCI-H460 cells after 72 hrs by Alamar Blue assay
    		[PMID: 24251417]
    NCI-H460 IC50
    0.05 μM
    Compound: doxorubicin
    Cytotoxicity against human NCI-H460 cells assessed as inhibition of cell proliferation/survival after 72 hrs by resazurin dye reduction assay
    Cytotoxicity against human NCI-H460 cells assessed as inhibition of cell proliferation/survival after 72 hrs by resazurin dye reduction assay
    		[PMID: 26305181]
    NCI-H460 IC50
    0.05 μg/mL
    Compound: Adriamycin
    Inhibitory concentration against human lung carcinoma cell line H460 after 48 hr in MTT assay
    Inhibitory concentration against human lung carcinoma cell line H460 after 48 hr in MTT assay
    		[PMID: 15715467]
    NCI-H460 IC50
    0.08 μM
    Compound: Adriamycin
    Cytotoxicity against human NCI-H460 cells assessed as inhibition of cell proliferation after 48 hrs by XTT assay
    Cytotoxicity against human NCI-H460 cells assessed as inhibition of cell proliferation after 48 hrs by XTT assay
    		[PMID: 24717154]
    NCI-H460 IC50
    0.08 μg/mL
    Compound: Doxorubicin
    Antiproliferative activity against human NCI-H460 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    Antiproliferative activity against human NCI-H460 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    		[PMID: 33940463]
    NCI-H460 IC50
    0.09 μM
    Compound: Doxorubicin
    Cytotoxicity against human NCI-H460 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    Cytotoxicity against human NCI-H460 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    		10.1007/s00044-013-0712-3
    NCI-H460 IC50
    0.09 μg/L
    Compound: Doxorubicin
    Cytotoxicity against human NCI-H460 cells assessed as inhibition of cell viability after 72 hrs by SRB assay
    Cytotoxicity against human NCI-H460 cells assessed as inhibition of cell viability after 72 hrs by SRB assay
    		[PMID: 26420384]
    NCI-H460 IC50
    0.1 μM
    Compound: Doxorubicin
    Cytotoxicity against human NCI-H460 cells assessed as inhibition of cell proliferation measured after 72 hrs by resazurin dye based AlamarBlue assay
    Cytotoxicity against human NCI-H460 cells assessed as inhibition of cell proliferation measured after 72 hrs by resazurin dye based AlamarBlue assay
    		[PMID: 34495663]
    NCI-H460 IC50
    0.15 μM
    Compound: DOX
    Cytotoxicity against human NCI-H460 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human NCI-H460 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 29660689]
    NCI-H460 IC50
    0.15 μM
    Compound: Dox
    Cytotoxicity against human NCI-H460 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human NCI-H460 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 33479619]
    NCI-H460 IC50
    0.15 μM
    Compound: Doxorubicin
    Cytotoxicity against human H460 cells assessed as growth inhibition after 48 hrs by MTT assay
    Cytotoxicity against human H460 cells assessed as growth inhibition after 48 hrs by MTT assay
    		[PMID: 26972921]
    NCI-H460 IC50
    0.17 μM
    Compound: DOX
    Antiproliferative activity against human H460 cells after 72 hrs by Sulforhodamine B-stain assay
    Antiproliferative activity against human H460 cells after 72 hrs by Sulforhodamine B-stain assay
    		[PMID: 27484508]
    NCI-H460 IC50
    0.18 μg/mL
    Compound: adriamycin
    Cytotoxicity against human H460 cells by SRB assay
    Cytotoxicity against human H460 cells by SRB assay
    		[PMID: 17981473]
    NCI-H460 IC50
    0.2 μM
    Compound: Doxorubicin
    Cytotoxic activity against human H460 cells incubated for 48 hrs by MTT assay
    Cytotoxic activity against human H460 cells incubated for 48 hrs by MTT assay
    		[PMID: 28055219]
    NCI-H460 IC50
    0.23 μM
    Compound: adriamycin
    Compound was evaluated for inhibitory activity against H 460 human lung cancer cell line
    Compound was evaluated for inhibitory activity against H 460 human lung cancer cell line
    		[PMID: 1479585]
    NCI-H460 IC50
    0.252 μM
    Compound: Dox
    Cytotoxicity against human NCI-H460 cells incubated for 72 hrs by MTT assay
    Cytotoxicity against human NCI-H460 cells incubated for 72 hrs by MTT assay
    		[PMID: 39149093]
    NCI-H460 IC50
    0.3 μM
    Compound: Doxorubicin
    Cytotoxicity against human NCI-H460 cells after 72 hrs by Alamar blue assay
    Cytotoxicity against human NCI-H460 cells after 72 hrs by Alamar blue assay
    		[PMID: 21999655]
    NCI-H460 IC50
    0.38 nM
    Compound: Doxorubicin
    Antiproliferative activity against human H460 cells after 72 hrs by methylene blue staining
    Antiproliferative activity against human H460 cells after 72 hrs by methylene blue staining
    		[PMID: 21067930]
    NCI-H460 IC50
    0.4 μM
    Compound: Dox
    Antiproliferative activity against human NCI-H460 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay
    Antiproliferative activity against human NCI-H460 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay
    		[PMID: 32428792]
    NCI-H460 IC50
    0.4 μM
    Compound: Doxorubicin
    Cytotoxicity against human NCI-H460 cells by resazurin dye based Alamar blue assay
    Cytotoxicity against human NCI-H460 cells by resazurin dye based Alamar blue assay
    		[PMID: 29373790]
    NCI-H460 IC50
    0.4 μM
    Compound: Doxorubicin
    Cytotoxicity in human NCI-H460 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Cytotoxicity in human NCI-H460 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    		[PMID: 34082225]
    NCI-H460 IC50
    0.42 μM
    Compound: Doxorubicin
    Cytotoxicity against human NCI-H460 cells after 72 hrs by resazurin/AlamarBlue dye-based fluorescence assay
    Cytotoxicity against human NCI-H460 cells after 72 hrs by resazurin/AlamarBlue dye-based fluorescence assay
    		[PMID: 28139929]
    NCI-H460 IC50
    0.42 μM
    Compound: doxorubicin
    Cytotoxicity against human NCI-H460 cells after 72 hrs by Alamar blue assay
    Cytotoxicity against human NCI-H460 cells after 72 hrs by Alamar blue assay
    		[PMID: 22264149]
    NCI-H460 IC50
    0.456 μM
    Compound: Dox
    Cytotoxicity against human NCI-H460 cells by MTT assay
    Cytotoxicity against human NCI-H460 cells by MTT assay
    		[PMID: 21983438]
    NCI-H460 IC50
    0.456 μM
    Compound: Doxorubicin
    Cytotoxicity against human NCI-H460 cells after 48 hrs by sulforhodamine B assay
    Cytotoxicity against human NCI-H460 cells after 48 hrs by sulforhodamine B assay
    		10.1039/C0MD00219D
    NCI-H460 IC50
    0.581 μM
    Compound: DOX
    Cytotoxicity against human NCI-H460 cells assessed as inhibition of cell viability incubated for 48 hrs by MTT assay
    Cytotoxicity against human NCI-H460 cells assessed as inhibition of cell viability incubated for 48 hrs by MTT assay
    		[PMID: 38169372]
    NCI-H460 IC50
    0.66 μM
    Compound: adriamycin
    Cytotoxicity against human NCI-H460 cells by MTT assay
    Cytotoxicity against human NCI-H460 cells by MTT assay
    		[PMID: 17125240]
    NCI-H460 IC50
    0.8 μM
    Compound: DOX
    Cytotoxicity against human NCI-H460 cells after 48 hrs by MTT assay
    Cytotoxicity against human NCI-H460 cells after 48 hrs by MTT assay
    		[PMID: 31057738]
    NCI-H460 IC50
    0.98 μM
    Compound: Adriamycin
    Cytotoxicity against human H460 cells by MTT assay
    Cytotoxicity against human H460 cells by MTT assay
    		[PMID: 24182355]
    NCI-H460 IC50
    0.98 μM
    Compound: Doxorubicin
    Cytotoxicity against human H460 cells assessed as growth inhibition after 72 hrs by MTT assay
    Cytotoxicity against human H460 cells assessed as growth inhibition after 72 hrs by MTT assay
    		[PMID: 26874404]
    NCI-H460 IC50
    1.62 μM
    Compound: DOX
    Anticancer activity against against human multi-drug resistant NCI-H460/R cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
    Anticancer activity against against human multi-drug resistant NCI-H460/R cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
    		[PMID: 35450348]
    NCI-H460 IC50
    1.72 μM
    Compound: Adriamycin
    Tested for induction of cellular death in Human lung H-460 tumor cell line in Propidium Iodide Monolayer Assay
    Tested for induction of cellular death in Human lung H-460 tumor cell line in Propidium Iodide Monolayer Assay
    		[PMID: 12852768]
    NCI-H460 IC50
    11 nM
    Compound: Doxorubicin
    Cytotoxicity against human NCI-H460 cells after 48 hrs by [3H]thymidine incorporation assay
    Cytotoxicity against human NCI-H460 cells after 48 hrs by [3H]thymidine incorporation assay
    		[PMID: 20210346]
    NCI-H460 IC50
    11 μM
    Compound: ADM
    Cytotoxicity against human NCI-H460 cells
    Cytotoxicity against human NCI-H460 cells
    		[PMID: 22283451]
    NCI-H460 IC50
    11 μM
    Compound: Doxorubicin
    Cytotoxicity against human NCI-H460 cells after 48 hrs by MTT assay
    Cytotoxicity against human NCI-H460 cells after 48 hrs by MTT assay
    		[PMID: 22304344]
    NCI-H460 IC50
    180 nM
    Compound: Doxorubicin
    Cytotoxicity against human NCI-H460 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Cytotoxicity against human NCI-H460 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    		[PMID: 31468974]
    NCI-H460 IC50
    2.5 μM
    Compound: DOX
    Antiproliferative activity against human NCI-H460 cells after 48 hrs by MTT assay
    Antiproliferative activity against human NCI-H460 cells after 48 hrs by MTT assay
    		[PMID: 28756264]
    NCI-H460 IC50
    2.64 x 10-7 M
    Compound: Doxorubucin
    Cytotoxicity against human NCI-H460 cells after 72 hrs by XTT assay
    Cytotoxicity against human NCI-H460 cells after 72 hrs by XTT assay
    		[PMID: 20538470]
    NCI-H460 IC50
    34 nM
    Compound: Doxorubicin
    Cytotoxicity against human NCI-H460 cells after 72 hrs by MTT assay
    Cytotoxicity against human NCI-H460 cells after 72 hrs by MTT assay
    		[PMID: 28459574]
    NCI-H460 IC50
    4.29 nM
    Compound: Doxorubicin
    Antiproliferative activity against human NCI-H460 cells assessed as cell growth inhibition measured after 72 hrs by crystal violet staining based assay
    Antiproliferative activity against human NCI-H460 cells assessed as cell growth inhibition measured after 72 hrs by crystal violet staining based assay
    		[PMID: 34795858]
    NCI-H460 IC50
    5.18 μM
    Compound: DOX
    Cytotoxicity against human NCI-H460 cells after 48 hrs by MTT assay
    Cytotoxicity against human NCI-H460 cells after 48 hrs by MTT assay
    		[PMID: 27889629]
    NCI-H460 IC50
    5.18 μM
    Compound: DOX
    Cytotoxicity against human NCI-H460 cells after 48 hrs by MTT assay
    Cytotoxicity against human NCI-H460 cells after 48 hrs by MTT assay
    		[PMID: 30108853]
    NCI-H460 IC50
    5.6 μM
    Compound: Doxorubicin
    Anticancer activity against human NCI-H460 cells after 48 hrs by MTT assay
    Anticancer activity against human NCI-H460 cells after 48 hrs by MTT assay
    		[PMID: 22668451]
    NCI-H460 IC50
    6.06 μM
    Compound: Doxorubicin
    Cytotoxicity against human NCI-H460 cells after 48 hrs
    Cytotoxicity against human NCI-H460 cells after 48 hrs
    		[PMID: 20873721]
    NCI-H460 IC50
    6.06 μM
    Compound: Doxorubicin
    Cytotoxicity against human NCI-H460 cells after 48 hrs by alamar blue assay
    Cytotoxicity against human NCI-H460 cells after 48 hrs by alamar blue assay
    		[PMID: 22272829]
    NCI-H460 IC50
    > 50 μM
    Compound: DOX
    Cytotoxicity against human doxorubicin-resistant NCI-H460 cells after 48 hrs by MTT assay
    Cytotoxicity against human doxorubicin-resistant NCI-H460 cells after 48 hrs by MTT assay
    		[PMID: 27889629]
    NCI-H522 GI50
    0.03 μM
    Compound: Doxorubicin
    Growth inhibition of human NCI-H522 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human NCI-H522 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28329730]
    NCI-H522 GI50
    0.03 μM
    Compound: Doxorubicin
    Growth inhibition of human NCI-H522 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human NCI-H522 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 29102177]
    NCI-H522 GI50
    0.03 μM
    Compound: Doxorubicin hydrochloride, NSC 123127
    Cytotoxicity against human NCI-H522 cells after 48 hrs by SRB assay
    Cytotoxicity against human NCI-H522 cells after 48 hrs by SRB assay
    		[PMID: 23871905]
    NCI-H596 IC50
    1.08 μM
    Compound: Doxorubicin
    Antiproliferative activity against human NCI-H596 cells measured after 48 hrs by MTT assay
    Antiproliferative activity against human NCI-H596 cells measured after 48 hrs by MTT assay
    		[PMID: 32682198]
    NCI-H596 IC50
    1.52 μM
    Compound: ADM
    Antiproliferative activity against NQO1-deficient human NCI-H596 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    Antiproliferative activity against NQO1-deficient human NCI-H596 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    		[PMID: 35803175]
    NCI-H647 IC50
    < 0.001 μM
    Compound: Doxorubicin
    Inhibitory activity against NCI-H647 cell line using MTT assay(mutant p53)
    Inhibitory activity against NCI-H647 cell line using MTT assay(mutant p53)
    		[PMID: 10780913]
    NCI-H661 ED50
    0.29 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human NCI-H661 cells by MTT assay
    Cytotoxicity against human NCI-H661 cells by MTT assay
    		[PMID: 15104488]
    NCI-H661 IC50
    0.35 μM
    Compound: Dox
    Cytotoxicity against human NCI-H661 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human NCI-H661 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 30615450]
    NCI-H661 IC50
    250 nM
    Compound: Dox
    Antiproliferative activity against human NCI-H661 cells assessed as inhibition of cell viability after 3 days by XTT assay in presence of beta-glucuronidase
    Antiproliferative activity against human NCI-H661 cells assessed as inhibition of cell viability after 3 days by XTT assay in presence of beta-glucuronidase
    		10.1039/C1MD00193K
    NCI-H69 IC50
    0.87 μM
    Compound: adriamycin
    Compound was evaluated for inhibitory activity against H69 human lung cancer cell line
    Compound was evaluated for inhibitory activity against H69 human lung cancer cell line
    		[PMID: 1479585]
    NCI-H69 IC50
    11.3 nM
    Compound: Doxorubicin
    Inhibitory concentration againstHuman cell lung carcinoma cell line NCI-H69; n=3
    Inhibitory concentration againstHuman cell lung carcinoma cell line NCI-H69; n=3
    		[PMID: 15743178]
    NCI-H69 IC50
    137 nM
    Compound: Doxorubicin
    Inhibitory activity against drug resistant H69/LX4 line overexpressing P-glycoprotein
    Inhibitory activity against drug resistant H69/LX4 line overexpressing P-glycoprotein
    		[PMID: 11806725]
    NCI-H69 IC50
    27 nM
    Compound: Doxorubicin
    Inhibitory activity against parental human small cell lung carcinoma cell line (H69P)
    Inhibitory activity against parental human small cell lung carcinoma cell line (H69P)
    		[PMID: 11806725]
    NCI-H69 IC50
    27.3 nM
    Compound: Doxorubicin
    Cytotoxicity measured using the H69 parental (H69/P) human small cell lung carcinoma cell line
    Cytotoxicity measured using the H69 parental (H69/P) human small cell lung carcinoma cell line
    		[PMID: 11806724]
    NCI-H69 IC50
    3 μM
    Compound: adriamycin
    Cytotoxicity against human H69 cells under deem light after 96 hrs by MTT assay
    Cytotoxicity against human H69 cells under deem light after 96 hrs by MTT assay
    		[PMID: 17993275]
    NCI-H69 IC50
    3874 nM
    Compound: Doxorubicin
    Cytotoxicity measured using the drug resistant, P-glycoprotein (Pgp) expressing human small cell lung carcinoma cell line H69/LX4
    Cytotoxicity measured using the drug resistant, P-glycoprotein (Pgp) expressing human small cell lung carcinoma cell line H69/LX4
    		[PMID: 11806724]
    NCI-H727 IC50
    0.03 μM
    Compound: Doxorubicin
    Antiproliferative activity against human NCI-H727 cells after 48 hrs by Hoechst 33342 staining-based assay
    Antiproliferative activity against human NCI-H727 cells after 48 hrs by Hoechst 33342 staining-based assay
    		[PMID: 30655216]
    NCI-H727 IC50
    0.66 μM
    Compound: Doxorubicin
    Toxicity in human NCI-H727 cells assessed as reduction in cell number after 48 hrs by Hoechst 33342 staining based assay
    Toxicity in human NCI-H727 cells assessed as reduction in cell number after 48 hrs by Hoechst 33342 staining based assay
    		[PMID: 31753515]
    NCI-H929 IC50
    0.065 μM
    Compound: Doxorubicin
    Cytotoxicity against human NCI-H929 cells after 72 hrs by resazurin/resorufin-based fluorescence assay
    Cytotoxicity against human NCI-H929 cells after 72 hrs by resazurin/resorufin-based fluorescence assay
    		[PMID: 23600925]
    NCI-H929 IC50
    0.2 μM
    Compound: Dox
    Cytotoxicity against human NCI-H929 cells after 72 hrs by MTT assay
    Cytotoxicity against human NCI-H929 cells after 72 hrs by MTT assay
    		[PMID: 30659997]
    NCI-N87 IC50
    0.047 μM
    Compound: DOX
    Cytotoxicity against human NCI-N87 cells measured after 72 hrs by Celltiter-Glo assay
    Cytotoxicity against human NCI-N87 cells measured after 72 hrs by Celltiter-Glo assay
    		[PMID: 31820976]
    NCI-N87 IC50
    1.6 μM
    Compound: Doxorubicin
    Cytotoxicity against human NCI-N87 cells after 72 hrs by MTT assay
    Cytotoxicity against human NCI-N87 cells after 72 hrs by MTT assay
    		[PMID: 27797185]
    NCI-N87 IC50
    419.8 nM
    Compound: Doxorubicin
    Antiproliferative activity against human NCI-N87 cells after 96 hrs by MTT assay
    Antiproliferative activity against human NCI-N87 cells after 96 hrs by MTT assay
    		[PMID: 21296467]
    NCI/ADR-RES ED50
    2.7 μg/mL
    Compound: adriamycin
    Cytotoxicity against human MCF7/ADR cells after 6 days by coulter counted assay
    Cytotoxicity against human MCF7/ADR cells after 6 days by coulter counted assay
    		[PMID: 8984151]
    NCI/ADR-RES ED50
    4.7 x 10-1 μg/mL
    Compound: adriamycin
    Cytotoxicity against human MCF7/ADR cells after 6 days by BCA assay
    Cytotoxicity against human MCF7/ADR cells after 6 days by BCA assay
    		[PMID: 8984151]
    NCI/ADR-RES GI50
    0.14 μg/mL
    Compound: DOX; Doxo
    Antiproliferative activity against human NCI-ADR-RES cells after 48 hrs by SRB assay
    Antiproliferative activity against human NCI-ADR-RES cells after 48 hrs by SRB assay
    		[PMID: 26859070]
    NCI/ADR-RES GI50
    0.14 μg/mL
    Compound: Doxorubicin
    Growth inhibition of human NCI-ADR-RES cells after 48 hrs by sulforhodamine B assay
    Growth inhibition of human NCI-ADR-RES cells after 48 hrs by sulforhodamine B assay
    		[PMID: 22410248]
    NCI/ADR-RES GI50
    0.21 μM
    Compound: Dox
    Antiproliferative activity against human NCI-ADR-RES cells assessed as growth inhibition after 48 hrs by SRB assay
    Antiproliferative activity against human NCI-ADR-RES cells assessed as growth inhibition after 48 hrs by SRB assay
    		[PMID: 26454648]
    NCI/ADR-RES GI50
    0.33 μg/mL
    Compound: DOX
    Growth inhibition of human NCI-ADR-RES cells after 48 hrs by sulforhodamine B assay
    Growth inhibition of human NCI-ADR-RES cells after 48 hrs by sulforhodamine B assay
    		[PMID: 21041092]
    NCI/ADR-RES GI50
    0.54 μg/mL
    Compound: DOX
    Antiproliferative activity against human NCI/ADR-RES cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    Antiproliferative activity against human NCI/ADR-RES cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    		[PMID: 25062010]
    NCI/ADR-RES GI50
    0.77 μM
    Compound: Dox
    Growth inhibition of human NCI-ADR-RES cells after 48 hrs by sulforhodamine B dye-based spectrophotometric assay
    Growth inhibition of human NCI-ADR-RES cells after 48 hrs by sulforhodamine B dye-based spectrophotometric assay
    		[PMID: 28505535]
    NCI/ADR-RES GI50
    1.44 μM
    Compound: DOXO
    Antiproliferative activity against human NCI-ADR-RES cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    Antiproliferative activity against human NCI-ADR-RES cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    		[PMID: 31247374]
    NCI/ADR-RES GI50
    11.67 μM
    Compound: DOX
    Cytotoxicity against human MCF7/ADR cells assessed as growth inhibition after 72 hrs by MTT assay
    Cytotoxicity against human MCF7/ADR cells assessed as growth inhibition after 72 hrs by MTT assay
    		[PMID: 29705710]
    NCI/ADR-RES GI50
    11.67 μM
    Compound: DOX
    Growth inhibition of human MCF7/ADR cells after 72 hrs by MTT assay
    Growth inhibition of human MCF7/ADR cells after 72 hrs by MTT assay
    		[PMID: 30336023]
    NCI/ADR-RES GI50
    11.67 μM
    Compound: DOX
    Growth inhibition of human MCF7/ADR cells incubated for 72 hrs by MTT assay
    Growth inhibition of human MCF7/ADR cells incubated for 72 hrs by MTT assay
    		[PMID: 31176097]
    NCI/ADR-RES GI50
    16.7 μM
    Compound: Doxorubicin
    Tested for in vitro concentration required to inhibit growth by 50% against MCF-7/ADR human breast cancer cell line cell line
    Tested for in vitro concentration required to inhibit growth by 50% against MCF-7/ADR human breast cancer cell line cell line
    		[PMID: 11755363]
    NCI/ADR-RES GI50
    5.1 μM
    Compound: Doxorubicin
    Cytotoxicity against human NCI-ADR-RES cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    Cytotoxicity against human NCI-ADR-RES cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    		[PMID: 26561866]
    NCI/ADR-RES GI50
    7.16 μM
    Compound: Doxorubicin
    Growth inhibition of human NCI/ADR-RES cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human NCI/ADR-RES cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28329730]
    NCI/ADR-RES GI50
    7.16 μM
    Compound: Doxorubicin
    Growth inhibition of human NCI/ADR-RES cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human NCI/ADR-RES cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 29102177]
    NCI/ADR-RES GI50
    7.16 μM
    Compound: Doxorubicin hydrochloride, NSC 123127
    Cytotoxicity against human NCI/ADR-RES cells after 48 hrs by SRB assay
    Cytotoxicity against human NCI/ADR-RES cells after 48 hrs by SRB assay
    		[PMID: 23871905]
    NCI/ADR-RES IC50
    0.206 μM
    Compound: Doxorubicin
    Anticancer activity against Multi drug resistant human NCI-ADR-RES cells assessed as inhibition of cell growth
    Anticancer activity against Multi drug resistant human NCI-ADR-RES cells assessed as inhibition of cell growth
    		[PMID: 33328099]
    NCI/ADR-RES IC50
    10000 nM
    Compound: 1, DOX
    Growth inhibition of multidrug resistant MCF7/Adr cells containing antiestrogen binding sites
    Growth inhibition of multidrug resistant MCF7/Adr cells containing antiestrogen binding sites
    		[PMID: 15588086]
    NCI/ADR-RES IC50
    10000 nM
    Compound: DOX
    Inhibition of MCF-7/Adr breast cancer cell proliferation
    Inhibition of MCF-7/Adr breast cancer cell proliferation
    		[PMID: 14971899]
    NCI/ADR-RES IC50
    10000 nmol equiv/L
    Compound: Doxorubicin
    Compound was tested for its toxicity against doxorubicin resistant human breast cancer cells (MCF-7/ADR).
    Compound was tested for its toxicity against doxorubicin resistant human breast cancer cells (MCF-7/ADR).
    		[PMID: 9548820]
    NCI/ADR-RES IC50
    10000 nmol equiv/L
    Compound: doxorubicin
    compound was tested in vitro for inhibition activity against doxorubicin resistant counterpart of human breast carcinoma line cells.
    compound was tested in vitro for inhibition activity against doxorubicin resistant counterpart of human breast carcinoma line cells.
    		[PMID: 9258351]
    NCI/ADR-RES IC50
    112.06 μM
    Compound: Dox
    Antiproliferative activity against human MCF7/ADR cells after 48 hrs by MTT assay
    Antiproliferative activity against human MCF7/ADR cells after 48 hrs by MTT assay
    		[PMID: 35339100]
    NCI/ADR-RES IC50
    13.6 μM
    Compound: Doxo
    Cytotoxicity against human MCF7/ADR cells after 48 hrs by MTT assay
    Cytotoxicity against human MCF7/ADR cells after 48 hrs by MTT assay
    		[PMID: 21885273]
    NCI/ADR-RES IC50
    1574.2 μM
    Compound: doxorubicin
    Cytotoxicity against human MCF7/ADR cells after 48 hrs by MTT assay
    Cytotoxicity against human MCF7/ADR cells after 48 hrs by MTT assay
    		[PMID: 25314138]
    NCI/ADR-RES IC50
    18.22 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7/ADR cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Cytotoxicity against human MCF7/ADR cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    		[PMID: 33823396]
    NCI/ADR-RES IC50
    189 nM
    Compound: Doxorubicin
    Antiproliferative activity against human MCF7/ADR cells assessed as cell growth inhibition measured after 48 hrs by MTS assay
    Antiproliferative activity against human MCF7/ADR cells assessed as cell growth inhibition measured after 48 hrs by MTS assay
    		[PMID: 35737669]
    NCI/ADR-RES IC50
    2.94 μM
    Compound: Dox
    Antiproliferative activity against human MCF7/ADR cells after 72 hrs by MTT assay
    Antiproliferative activity against human MCF7/ADR cells after 72 hrs by MTT assay
    		[PMID: 27423028]
    NCI/ADR-RES IC50
    220 μM
    Compound: 1; dox
    Cytotoxicity against doxorubicin-resistant human NCI/ADR-RES cells assessed as inhibition of cell growth incubated for 30 mins by crystal violet staining assay
    Cytotoxicity against doxorubicin-resistant human NCI/ADR-RES cells assessed as inhibition of cell growth incubated for 30 mins by crystal violet staining assay
    		[PMID: 26881291]
    NCI/ADR-RES IC50
    24.4 μg/mL
    Compound: DOX
    Antiproliferative activity against human MCF7/ADR cells assessed as growth inhibition after 24 to 48 hrs by SRB assay
    Antiproliferative activity against human MCF7/ADR cells assessed as growth inhibition after 24 to 48 hrs by SRB assay
    		[PMID: 24012683]
    NCI/ADR-RES IC50
    25.28 μM
    Compound: ADR
    Cytotoxicity against human MCF7/ADR cells after 72 hrs by MTT assay
    Cytotoxicity against human MCF7/ADR cells after 72 hrs by MTT assay
    		[PMID: 19523827]
    NCI/ADR-RES IC50
    37.214 μM
    Compound: Doxorubicin
    Cytotoxicity against DOX-resistant human MCF7/ADR cells assessed as doxorubicin IC50 incubated for 48 hrs in presence of doxorubicin by CCK8 assay
    Cytotoxicity against DOX-resistant human MCF7/ADR cells assessed as doxorubicin IC50 incubated for 48 hrs in presence of doxorubicin by CCK8 assay
    		[PMID: 36645980]
    NCI/ADR-RES IC50
    45.2 μM
    Compound: 1, Dox
    Tumor killing activity in MCF7/ADR drug-resistant cell line by MTT assay
    Tumor killing activity in MCF7/ADR drug-resistant cell line by MTT assay
    		[PMID: 16168650]
    NCI/ADR-RES IC50
    5.37 mg/mL
    Compound: Adriamycin
    Cytotoxicity against MCF-7/Adr cells.
    Cytotoxicity against MCF-7/Adr cells.
    		[PMID: 9207950]
    NCI/ADR-RES IC50
    50.85 μM
    Compound: Doxorubicin
    Antiproliferative activity against human MCF7/ADR cells incubated for 48 hrs by CCK-8 assay
    Antiproliferative activity against human MCF7/ADR cells incubated for 48 hrs by CCK-8 assay
    		[PMID: 33725657]
    NCI/ADR-RES IC50
    50.85 μM
    Compound: Doxorubicin
    Antitumor activity against human MCF7ADR cells incubated for 48 hrs by CCK8 assay
    Antitumor activity against human MCF7ADR cells incubated for 48 hrs by CCK8 assay
    		[PMID: 37229830]
    NCI/ADR-RES IC50
    50.85 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7ADR cells incubated for 48 hrs by CCK8 assay
    Cytotoxicity against human MCF7ADR cells incubated for 48 hrs by CCK8 assay
    		[PMID: 37229830]
    NCI/ADR-RES IC50
    52.5 μM
    Compound: ADM
    Anticancer activity against human MCF7/ADR cells after 48 hrs by MTT assay
    Anticancer activity against human MCF7/ADR cells after 48 hrs by MTT assay
    		[PMID: 25462264]
    NCI/ADR-RES IC50
    58.47 μM
    Compound: Dox
    Antiproliferative activity against human MCF7ADR cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay
    Antiproliferative activity against human MCF7ADR cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay
    		[PMID: 37956506]
    NCI/ADR-RES IC50
    58.47 μM
    Compound: Doxorubicin
    Antiproliferative activity against human multidrug resistant NCI-ADR-RES cells overexpressing P-gp assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Antiproliferative activity against human multidrug resistant NCI-ADR-RES cells overexpressing P-gp assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    		[PMID: 36242992]
    NCI/ADR-RES IC50
    6.7 μM
    Compound: 1, Dox
    Tumor killing activity in MCF7/ADR drug-resistant cell line with 10 uM verapamil (P-gp inhibitor)
    Tumor killing activity in MCF7/ADR drug-resistant cell line with 10 uM verapamil (P-gp inhibitor)
    		[PMID: 16168650]
    NCI/ADR-RES IC50
    620 nM
    Compound: 1; dox
    Cytotoxicity against doxorubicin-resistant human NCI/ADR-RES cells assessed as inhibition of cell growth incubated for 90 mins by crystal violet staining assay
    Cytotoxicity against doxorubicin-resistant human NCI/ADR-RES cells assessed as inhibition of cell growth incubated for 90 mins by crystal violet staining assay
    		[PMID: 26881291]
    NCI/ADR-RES IC50
    64.8 μM
    Compound: DOX
    Cytotoxicity in doxorubicin-resistant human MCF7/ADR cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Cytotoxicity in doxorubicin-resistant human MCF7/ADR cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    		[PMID: 30860373]
    NCI/ADR-RES IC50
    68.434 μM
    Compound: Adriamycin
    Cytotoxicity against human MCF7/ADR cells after 48 hrs by MTT assay
    Cytotoxicity against human MCF7/ADR cells after 48 hrs by MTT assay
    		[PMID: 24684844]
    NCI/ADR-RES IC50
    83.2 μM
    Compound: Doxorubicin
    Cytotoxicity against human MCF7/ADR cells by WST-1 assay
    Cytotoxicity against human MCF7/ADR cells by WST-1 assay
    		[PMID: 22197145]
    NCI/ADR-RES IC50
    9.26 μM
    Compound: ADR
    Cytotoxicity against human MCF7/ADR cells assessed as growth inhibition after 96 hrs by SRB assay
    Cytotoxicity against human MCF7/ADR cells assessed as growth inhibition after 96 hrs by SRB assay
    		[PMID: 25817774]
    NCI/ADR-RES IC50
    9.3 μM
    Compound: Adriamycin
    Cytotoxicity against adriamycin-selected human NCI/ADR-RES cells after 72 hrs by MTT assay
    Cytotoxicity against adriamycin-selected human NCI/ADR-RES cells after 72 hrs by MTT assay
    		[PMID: 21721528]
    NCI/ADR-RES IC50
    > 10 μM
    Compound: doxorubicin
    Cytotoxicity against human MCF7/ADR cells after 48 hrs by MTT assay
    Cytotoxicity against human MCF7/ADR cells after 48 hrs by MTT assay
    		[PMID: 21087017]
    NCI/ADR-RES IC50
    > 100000 nM
    Compound: Doxorubicin
    Antiproliferative activity against human MCF7/ADR cells after 48 hrs by MTT assay
    Antiproliferative activity against human MCF7/ADR cells after 48 hrs by MTT assay
    		[PMID: 29795767]
    NCI/ADR-RES IC50
    > 20 μM
    Compound: DOX, Doxorubicin
    Antiproliferative activity against human NCI/ADR-RES cells after 72 hrs by MTT assay
    Antiproliferative activity against human NCI/ADR-RES cells after 72 hrs by MTT assay
    		[PMID: 24095089]
    NCI/ADR-RES IC50
    > 20 μM
    Compound: Doxo
    Cytotoxicity against human MCF7/ADR cells after 24 hrs by MTT assay
    Cytotoxicity against human MCF7/ADR cells after 24 hrs by MTT assay
    		[PMID: 21885273]
    NCI/ADR-RES IC50
    > 50 μM
    Compound: Doxorubicin
    Cytotoxicity against multidrug-resistant human MCF7/ADR cells after 48 hrs by MTT assay
    Cytotoxicity against multidrug-resistant human MCF7/ADR cells after 48 hrs by MTT assay
    		[PMID: 22537362]
    NCTC-2544 EC50
    32.5 μM
    Compound: 12
    Dark toxicity in human NCTC-2544 cells assessed as decrease in cell viability after 24 hrs by MTT assay
    Dark toxicity in human NCTC-2544 cells assessed as decrease in cell viability after 24 hrs by MTT assay
    		[PMID: 29172528]
    NCTC-2544 GI50
    1.32 mM
    Compound: Doxorubicin
    Photocytotoxicity against human NCTC 2544 cells irradiated with 2.5 J cm^-2 ultraviolet radiation after 72 hrs by MTT assay
    Photocytotoxicity against human NCTC 2544 cells irradiated with 2.5 J cm^-2 ultraviolet radiation after 72 hrs by MTT assay
    		[PMID: 18023182]
    NCTC-2544 GI50
    3.04 mM
    Compound: Doxorubicin
    Photocytotoxicity against human NCTC 2544 cells irradiated with 1.25 J cm^-2 ultraviolet radiation after 72 hrs by MTT assay
    Photocytotoxicity against human NCTC 2544 cells irradiated with 1.25 J cm^-2 ultraviolet radiation after 72 hrs by MTT assay
    		[PMID: 18023182]
    NFF IC50
    125.6 nM
    Compound: Doxorubicin
    Cytotoxicity against human NFF cells after 72 hrs by Alamar Blue assay
    Cytotoxicity against human NFF cells after 72 hrs by Alamar Blue assay
    		[PMID: 24973030]
    NFS-60 IC50
    0.013 μM
    Compound: DOX
    Cytotoxicity against mouse NFS60 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    Cytotoxicity against mouse NFS60 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    		[PMID: 30826510]
    NFS-60 IC50
    13 nM
    Compound: Dox
    Anticancer activity against human NFS-60 cells assessed as reduction in cell viability by MTT assay
    Anticancer activity against human NFS-60 cells assessed as reduction in cell viability by MTT assay
    		[PMID: 31740054]
    NHDF GI50
    30 μg/mL
    Compound: doxorubicin
    Growth inhibition of human dermal fibroblast cultured as 2D cells by tryphan blue based analysis
    Growth inhibition of human dermal fibroblast cultured as 2D cells by tryphan blue based analysis
    		[PMID: 37104545]
    NHDF GI50
    462 nM
    Compound: Doxorubicin
    Antiproliferative activity against NHDF assessed as growth inhibition after 24 to 72 hrs by MTS assay
    Antiproliferative activity against NHDF assessed as growth inhibition after 24 to 72 hrs by MTS assay
    		10.1039/C0MD00179A
    NHDF IC50
    0.011 μM
    Compound: Doxorubicin
    Cytotoxicity against human HDF cells assessed as reduction in cell viability incubated for 7 days by CellTiter 96 aqueous one solution assay
    Cytotoxicity against human HDF cells assessed as reduction in cell viability incubated for 7 days by CellTiter 96 aqueous one solution assay
    		[PMID: 31596585]
    NHDF IC50
    0.137 μM
    Compound: Doxorubicin
    Cytotoxicity against NHDF cells assessed as reduction in cell viability measured after 72 hrs by MTS assay
    Cytotoxicity against NHDF cells assessed as reduction in cell viability measured after 72 hrs by MTS assay
    		[PMID: 33261897]
    NHDF IC50
    0.14 μM
    Compound: Doxorubicin
    Cytotoxicity against human NHDF cells incubated for 72 hrs by MTS assay
    Cytotoxicity against human NHDF cells incubated for 72 hrs by MTS assay
    		[PMID: 31158748]
    NHDF IC50
    0.14 μM
    Compound: Doxorubicin
    Cytotoxicity against human NHDF cells assessed as reduction in cell viability measured after 72 hrs by MTS assay
    Cytotoxicity against human NHDF cells assessed as reduction in cell viability measured after 72 hrs by MTS assay
    		[PMID: 31962262]
    NHDF IC50
    2.72 μM
    Compound: Doxorubicin
    Cytotoxicity against HDF cells
    Cytotoxicity against HDF cells
    		[PMID: 32932211]
    NHDF IC50
    3.38 μM
    Compound: DOXO
    Cytotoxicity against human NHDF cells after 96 hrs by MTS assay
    Cytotoxicity against human NHDF cells after 96 hrs by MTS assay
    		[PMID: 26890119]
    NIH3T3 EC50
    0.4 μM
    Compound: Doxorubicin
    Cytotoxicity against mouse NIH3T3 cells assessed as reduction in cell viability measured after 72 hrs by SRB assay
    Cytotoxicity against mouse NIH3T3 cells assessed as reduction in cell viability measured after 72 hrs by SRB assay
    		[PMID: 33049606]
    NIH3T3 EC50
    1.3 μM
    Compound: DR
    Cytotoxicity against mouse NIH3T3 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
    Cytotoxicity against mouse NIH3T3 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
    		[PMID: 32956968]
    NIH3T3 EC50
    1.7 μM
    Compound: Dox
    Cytotoxicity against mouse NIH/3T3 cells incubated for 72 hrs by SRB assay
    Cytotoxicity against mouse NIH/3T3 cells incubated for 72 hrs by SRB assay
    		[PMID: 36780832]
    NIH3T3 GI50
    0.28 μM
    Compound: Doxorubicin
    Cytotoxicity against mouse NIH/3T3 cells assessed as growth inhibition after 48 hrs by SRB assay
    Cytotoxicity against mouse NIH/3T3 cells assessed as growth inhibition after 48 hrs by SRB assay
    		[PMID: 33477019]
    NIH3T3 GI50
    4 μM
    Compound: Doxorubicin
    Cytotoxicity against mouse NIH/3T3 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    Cytotoxicity against mouse NIH/3T3 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    		[PMID: 26561866]
    NIH3T3 IC50
    0.05 μM
    Compound: Adriamycin
    Cytotoxicity against mouse NIH/3T3 cells after 72 hrs by MTT assay
    Cytotoxicity against mouse NIH/3T3 cells after 72 hrs by MTT assay
    		[PMID: 21721528]
    NIH3T3 IC50
    0.08 μM
    Compound: Adriamycin
    Cytotoxicity against mouse NIH/3T3 cells selected at 30 ug/ml vincristine after 72 hrs by MTT assay
    Cytotoxicity against mouse NIH/3T3 cells selected at 30 ug/ml vincristine after 72 hrs by MTT assay
    		[PMID: 21721528]
    NIH3T3 IC50
    0.38 μM
    Compound: Adriamycin
    Cytotoxicity against mouse NIH/3T3 cells transfected with wild-type P-gp G185 after 72 hrs by MTT assay
    Cytotoxicity against mouse NIH/3T3 cells transfected with wild-type P-gp G185 after 72 hrs by MTT assay
    		[PMID: 21721528]
    NIH3T3 IC50
    0.39 μM
    Compound: Doxorubicin
    Cytotoxicity against mouse NIH/3T3 cells after 72 hrs by MTT assay
    Cytotoxicity against mouse NIH/3T3 cells after 72 hrs by MTT assay
    		[PMID: 19361894]
    NIH3T3 IC50
    0.4 μM
    Compound: DX
    Cytotoxicity against mouse NIH3T3 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
    Cytotoxicity against mouse NIH3T3 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
    		[PMID: 32422522]
    NIH3T3 IC50
    0.53 μM
    Compound: Adriamycin
    Cytotoxicity against mouse NIH/3T3 cells transfected with PO4 mutant harboring Ser to Asp mutation selected at 2400 ug/ml vincristine after 72 hrs by MTT assay
    Cytotoxicity against mouse NIH/3T3 cells transfected with PO4 mutant harboring Ser to Asp mutation selected at 2400 ug/ml vincristine after 72 hrs by MTT assay
    		[PMID: 21721528]
    NIH3T3 IC50
    0.69 μM
    Compound: Adriamycin
    Cytotoxicity against mouse NIH/3T3 cells transfected with wild type p-glycoprotein ABCB1 selected at 600 ug/ml vincristine after 72 hrs by MTT assay
    Cytotoxicity against mouse NIH/3T3 cells transfected with wild type p-glycoprotein ABCB1 selected at 600 ug/ml vincristine after 72 hrs by MTT assay
    		[PMID: 21721528]
    NIH3T3 IC50
    0.72 μM
    Compound: Dox
    Cytotoxicity against mouse NIH3T3 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    Cytotoxicity against mouse NIH3T3 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    		[PMID: 37001390]
    NIH3T3 IC50
    0.79 μM
    Compound: Dox
    Antiproliferative activity against NIH3T3 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay
    Antiproliferative activity against NIH3T3 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay
    		[PMID: 36809707]
    NIH3T3 IC50
    1.58 μM
    Compound: Adriamycin
    Cytotoxicity against mouse NIH/3T3 cells selected at 1 ug/mL colchicine after 72 hrs by MTT assay
    Cytotoxicity against mouse NIH/3T3 cells selected at 1 ug/mL colchicine after 72 hrs by MTT assay
    		[PMID: 21721528]
    NIH3T3 IC50
    10.1 μM
    Compound: DX
    Cytotoxicity against human NIH/3T3 cells after 48 hrs by sulforhodamine B assay
    Cytotoxicity against human NIH/3T3 cells after 48 hrs by sulforhodamine B assay
    		10.1039/C5MD00513B
    NIH3T3 IC50
    1180.32 μM
    Compound: Dox
    Cytotoxicity against mouse NIH3T3 cells assessed as cell viability measured after 24 hrs by MTT assay
    Cytotoxicity against mouse NIH3T3 cells assessed as cell viability measured after 24 hrs by MTT assay
    		[PMID: 33183865]
    NIH3T3 IC50
    17.48 μM
    Compound: Adriamycin
    Cytotoxicity against 2.4 ug/mL vincristine selected mouse NIH/3T3 cells transfected with P-gp Ser to Asp phosphorylation mutant after 72 hrs by MTT assay
    Cytotoxicity against 2.4 ug/mL vincristine selected mouse NIH/3T3 cells transfected with P-gp Ser to Asp phosphorylation mutant after 72 hrs by MTT assay
    		[PMID: 21721528]
    NIH3T3 IC50
    1720 nM
    Compound: Doxorubicin
    Cytotoxicity against mouse NIH/3T3 cells after 48 hrs by MTT assay
    Cytotoxicity against mouse NIH/3T3 cells after 48 hrs by MTT assay
    		[PMID: 30172625]
    NIH3T3 IC50
    2.7 μM
    Compound: Adriamycin
    Cytotoxicity against mouse NIH/3T3 cells transfected with PO4 mutant harboring four Ser to Arg mutation selected at 2400 ug/ml vincristine after 72 hrs by MTT assay
    Cytotoxicity against mouse NIH/3T3 cells transfected with PO4 mutant harboring four Ser to Arg mutation selected at 2400 ug/ml vincristine after 72 hrs by MTT assay
    		[PMID: 21721528]
    NIH3T3 IC50
    21.32 μM
    Compound: Doxorubicin
    Cytotoxicity against mouse NIH/3T3 cells after 48 hrs by MTT assay
    Cytotoxicity against mouse NIH/3T3 cells after 48 hrs by MTT assay
    		[PMID: 29573910]
    NIH3T3 IC50
    3.24 μM
    Compound: Doxorubicin
    Cytotoxicity against Balb-c mouse 3T3 cells by MTT assay
    Cytotoxicity against Balb-c mouse 3T3 cells by MTT assay
    		[PMID: 23850203]
    NIH3T3 IC50
    3.5 μM
    Compound: Dox
    Cytotoxicity against mouse NIH/3T3 cells after 3 days by MTS assay
    Cytotoxicity against mouse NIH/3T3 cells after 3 days by MTS assay
    		[PMID: 21094049]
    NIH3T3 IC50
    3.7 μM
    Compound: doxorubicin
    Cytotoxicity against mouse 3T3 cells after 48 hrs by MTT assay
    Cytotoxicity against mouse 3T3 cells after 48 hrs by MTT assay
    		[PMID: 20405844]
    NIH3T3 IC50
    5.91 μM
    Compound: DOX
    Cytotoxicity against mouse NIH/3T3 cells after 48 hrs by SRB method
    Cytotoxicity against mouse NIH/3T3 cells after 48 hrs by SRB method
    		[PMID: 25933593]
    NIH3T3 IC50
    7.211 μM
    Compound: Dox
    Cytotoxicity against mouse NIH/3T3 cells assessed as cell killing effect after 72 hrs by MTT assay
    Cytotoxicity against mouse NIH/3T3 cells assessed as cell killing effect after 72 hrs by MTT assay
    		[PMID: 26005543]
    NIH3T3 IC50
    > 200 μM
    Compound: Doxorubicin
    Inhibition topoisomerase 1 in mouse NIH/3T3 cells assessed as conversion of supercoiled pBR322 DNA to relaxed form
    Inhibition topoisomerase 1 in mouse NIH/3T3 cells assessed as conversion of supercoiled pBR322 DNA to relaxed form
    		[PMID: 11430001]
    NRK-49F IC50
    24.22 μM
    Compound: Doxo
    Cytotoxicity against rat NRK-49F cells measured after 24 hrs by MTT assay
    Cytotoxicity against rat NRK-49F cells measured after 24 hrs by MTT assay
    		[PMID: 31104996]
    NUGC-3 GI50
    0.086 μM
    Compound: ADR
    Cytotoxicity against human NUGC3 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay
    Cytotoxicity against human NUGC3 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay
    		[PMID: 28870801]
    NUGC-3 GI50
    0.086 μM
    Compound: ADR
    Cytotoxicity against human NUGC3 cells assessed as growth inhibition after 72 hrs by SRB assay
    Cytotoxicity against human NUGC3 cells assessed as growth inhibition after 72 hrs by SRB assay
    		[PMID: 30253887]
    NUGC-3 GI50
    0.11 μg/mL
    Compound: Adriamycin
    Antiproliferative activity against human NUGC3 cells by SRB assay
    Antiproliferative activity against human NUGC3 cells by SRB assay
    		[PMID: 18023932]
    NUGC-3 GI50
    0.125 μM
    Compound: ADR
    Cytotoxicity against human NUGC3 cells after 72 hrs by sulforhodamine B assay
    Cytotoxicity against human NUGC3 cells after 72 hrs by sulforhodamine B assay
    		[PMID: 27096046]
    NUGC-3 GI50
    0.19 μM
    Compound: ADR
    Cytotoxicity against human NUGC3 cells assessed as growth inhibition after 72 hrs by sulforhodamine B assay
    Cytotoxicity against human NUGC3 cells assessed as growth inhibition after 72 hrs by sulforhodamine B assay
    		[PMID: 25953156]
    NUGC-3 GI50
    0.202 μM
    Compound: doxorubicin
    Cytotoxicity against human NUGC3 cells
    Cytotoxicity against human NUGC3 cells
    		[PMID: 20579876]
    NUGC-3 GI50
    0.25 μM
    Compound: Doxorubicin
    Cytotoxicity against human NUGC3 cells by SRB assay
    Cytotoxicity against human NUGC3 cells by SRB assay
    		[PMID: 19596579]
    NUGC-3 GI50
    0.51 μM
    Compound: Doxorubicin
    Cytotoxicity against human NUGC3 cells after 48 hrs by sulforhodamine B assay
    Cytotoxicity against human NUGC3 cells after 48 hrs by sulforhodamine B assay
    		[PMID: 23964644]
    NUGC-3 GI50
    1 μM
    Compound: ADR
    Antiproliferative activity against human NUGC3 cells by SRB assay
    Antiproliferative activity against human NUGC3 cells by SRB assay
    		[PMID: 22738641]
    NUGC-3 GI50
    1 μM
    Compound: ADR
    Antiproliferative activity against human NUGC3 cells by SRB method
    Antiproliferative activity against human NUGC3 cells by SRB method
    		[PMID: 24835787]
    OS-RC-2 IC50
    5.4 μM
    Compound: Doxorubicin
    Antiproliferative activity against human OS-RC2 cells after 72 hrs by MTT assay
    Antiproliferative activity against human OS-RC2 cells after 72 hrs by MTT assay
    		[PMID: 19632833]
    OVCAR GI50
    0.95 μM
    Compound: Doxorubicin
    Growth inhibition of Homo sapiens (human) OVCAR cells after 48 hr by MTT assay
    Growth inhibition of Homo sapiens (human) OVCAR cells after 48 hr by MTT assay
    		10.1007/s00044-012-0232-6
    OVCAR-3 GI50
    0.0087 μM
    Compound: DOXO
    Antiproliferative activity against human OVCAR3 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    Antiproliferative activity against human OVCAR3 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    		[PMID: 31247374]
    OVCAR-3 GI50
    0.07 μM
    Compound: Doxorubicin
    Cytotoxicity against human OVCAR-3 cells by sulforhodamine B assay
    Cytotoxicity against human OVCAR-3 cells by sulforhodamine B assay
    		[PMID: 20413188]
    OVCAR-3 GI50
    0.08 μg/mL
    Compound: DOX
    Growth inhibition of human OVCAR-3 cells after 48 hrs by sulforhodamine B assay
    Growth inhibition of human OVCAR-3 cells after 48 hrs by sulforhodamine B assay
    		[PMID: 21041092]
    OVCAR-3 GI50
    0.09 μM
    Compound: Doxorubicin
    Anticancer activity against human OVCAR-3 cells assessed as cell growth inhibition measured after 48 hrs by sulforhodamine B assay
    Anticancer activity against human OVCAR-3 cells assessed as cell growth inhibition measured after 48 hrs by sulforhodamine B assay
    		[PMID: 33214037]
    OVCAR-3 GI50
    0.22 μM
    Compound: Dox
    Growth inhibition of human OVCAR3 cells after 48 hrs by sulforhodamine B dye-based spectrophotometric assay
    Growth inhibition of human OVCAR3 cells after 48 hrs by sulforhodamine B dye-based spectrophotometric assay
    		[PMID: 28505535]
    OVCAR-3 GI50
    0.27 μg/mL
    Compound: Doxorubicin
    Growth inhibition of human OVCAR3 cells after 48 hrs by sulforhodamine B assay
    Growth inhibition of human OVCAR3 cells after 48 hrs by sulforhodamine B assay
    		[PMID: 22410248]
    OVCAR-3 GI50
    0.39 μM
    Compound: Doxorubicin
    Growth inhibition of human OVCAR3 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human OVCAR3 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28329730]
    OVCAR-3 GI50
    0.39 μM
    Compound: Doxorubicin
    Growth inhibition of human OVCAR3 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human OVCAR3 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 29102177]
    OVCAR-3 GI50
    0.39 μM
    Compound: Doxorubicin hydrochloride, NSC 123127
    Cytotoxicity against human OVCAR3 cells after 48 hrs by SRB assay
    Cytotoxicity against human OVCAR3 cells after 48 hrs by SRB assay
    		[PMID: 23871905]
    OVCAR-3 GI50
    0.43 μg/mL
    Compound: DOX
    Antiproliferative activity against human OVCAR3 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    Antiproliferative activity against human OVCAR3 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    		[PMID: 25062010]
    OVCAR-3 IC50
    0.02 μM
    Compound: Doxorubicin
    Antiproliferative activity against human OVCAR3 cells assessed as inhibition of cell proliferation incubated for 72 hrs by conventional ATP quantification method
    Antiproliferative activity against human OVCAR3 cells assessed as inhibition of cell proliferation incubated for 72 hrs by conventional ATP quantification method
    		[PMID: 25937235]
    OVCAR-3 IC50
    0.32 μM
    Compound: DOXO
    Cytotoxicity against human OVCAR3 cells assessed as cell viability after 72 hrs by MTT assay
    Cytotoxicity against human OVCAR3 cells assessed as cell viability after 72 hrs by MTT assay
    		[PMID: 26142490]
    OVCAR-3 IC50
    0.47 μM
    Compound: DOX
    Antiproliferative activity against human OVCAR3 cells after 72 hrs by Sulforhodamine B-stain assay
    Antiproliferative activity against human OVCAR3 cells after 72 hrs by Sulforhodamine B-stain assay
    		[PMID: 27484508]
    OVCAR-3 IC50
    10.53 μM
    Compound: Doxorubicin
    Cytotoxicity against human OVCAR3 cells after 48 hrs by MTT assay
    Cytotoxicity against human OVCAR3 cells after 48 hrs by MTT assay
    		[PMID: 22818039]
    OVCAR-3 IC50
    35 nM
    Compound: Doxorubicin
    Anti-tumor activity against human OVCAR-3 ovarian cancer cell lines by using MTT assay
    Anti-tumor activity against human OVCAR-3 ovarian cancer cell lines by using MTT assay
    		[PMID: 7699715]
    OVCAR-3 IC50
    35 nM
    Compound: Doxorubicin
    Inhibitory activity against OVCAR-3 cell line
    Inhibitory activity against OVCAR-3 cell line
    		[PMID: 8648600]
    OVCAR-3 IC50
    35 nM
    Compound: dixorubicin
    Antitumor activity against human ovarian OVCAR-3 cell lines.
    Antitumor activity against human ovarian OVCAR-3 cell lines.
    		[PMID: 8960558]
    OVCAR-3 IC50
    35 nM
    Compound: doxorubicin
    Tested for inhibitory activity against human tumor cell line OVCAR-3, a resistant ovarian carcinoma using sulforhodamine B assay.
    Tested for inhibitory activity against human tumor cell line OVCAR-3, a resistant ovarian carcinoma using sulforhodamine B assay.
    		[PMID: 10956214]
    OVCAR-3 IC50
    > 20 μM
    Compound: DOX
    Cytotoxicity against human OVCAR3 cells after 24 hrs by XTT assay
    Cytotoxicity against human OVCAR3 cells after 24 hrs by XTT assay
    		[PMID: 24900344]
    OVCAR-4 GI50
    0.37 μM
    Compound: Doxorubicin
    Growth inhibition of human OVCAR4 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human OVCAR4 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28329730]
    OVCAR-4 GI50
    0.37 μM
    Compound: Doxorubicin
    Growth inhibition of human OVCAR4 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human OVCAR4 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 29102177]
    OVCAR-4 GI50
    0.37 μM
    Compound: Doxorubicin hydrochloride, NSC 123127
    Cytotoxicity against human OVCAR4 cells after 48 hrs by SRB assay
    Cytotoxicity against human OVCAR4 cells after 48 hrs by SRB assay
    		[PMID: 23871905]
    OVCAR-4 IC50
    0.15 μM
    Compound: DOX
    Antiproliferative activity against human OVCAR4 cells after 72 hrs by MTT assay
    Antiproliferative activity against human OVCAR4 cells after 72 hrs by MTT assay
    		[PMID: 30429098]
    OVCAR-5 GI50
    0.41 μM
    Compound: Doxorubicin
    Growth inhibition of human OVCAR5 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human OVCAR5 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28329730]
    OVCAR-5 GI50
    0.41 μM
    Compound: Doxorubicin
    Growth inhibition of human OVCAR5 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human OVCAR5 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 29102177]
    OVCAR-5 GI50
    0.41 μM
    Compound: Doxorubicin hydrochloride, NSC 123127
    Cytotoxicity against human OVCAR5 cells after 48 hrs by SRB assay
    Cytotoxicity against human OVCAR5 cells after 48 hrs by SRB assay
    		[PMID: 23871905]
    OVCAR-8 GI50
    0.1 μM
    Compound: Doxorubicin
    Growth inhibition of human OVCAR8 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human OVCAR8 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28329730]
    OVCAR-8 GI50
    0.1 μM
    Compound: Doxorubicin
    Growth inhibition of human OVCAR8 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human OVCAR8 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 29102177]
    OVCAR-8 GI50
    0.1 μM
    Compound: Doxorubicin hydrochloride, NSC 123127
    Cytotoxicity against human OVCAR8 cells after 48 hrs by SRB assay
    Cytotoxicity against human OVCAR8 cells after 48 hrs by SRB assay
    		[PMID: 23871905]
    OVCAR-8 IC50
    0.09 μM
    Compound: Doxorubicin
    Cytotoxicity against human OVCAR8 cells after 72 hrs by MTT assay
    Cytotoxicity against human OVCAR8 cells after 72 hrs by MTT assay
    		10.1039/C4MD00371C
    OVCAR-8 IC50
    0.14 μM
    Compound: Adriamycin
    Cytotoxicity against human OVCAR8 cells after 72 hrs by MTT assay
    Cytotoxicity against human OVCAR8 cells after 72 hrs by MTT assay
    		[PMID: 21721528]
    OVCAR-8 IC50
    0.35 μM
    Compound: Doxorubicin
    Cytotoxicity against human OVCAR8 cells assessed as cell viability after 72 hrs by MTT assay
    Cytotoxicity against human OVCAR8 cells assessed as cell viability after 72 hrs by MTT assay
    		[PMID: 24530030]
    OVCAR-8 IC50
    0.41 μM
    Compound: DOXO
    Cytotoxicity against human OVCAR8 cells assessed as cell viability after 72 hrs by MTT assay
    Cytotoxicity against human OVCAR8 cells assessed as cell viability after 72 hrs by MTT assay
    		[PMID: 26142490]
    OVCAR-8 IC50
    0.41 μM
    Compound: Doxorubicin
    Cytotoxicity against human OVCAR8 cells overexpressing NQO1 assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human OVCAR8 cells overexpressing NQO1 assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 27341379]
    OVCAR-8 IC50
    0.45 μM
    Compound: DOX
    Cytotoxicity against human OVCAR8 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human OVCAR8 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 29660689]
    OVCAR-8 IC50
    0.488 μM
    Compound: Doxorubicin
    Cytotoxicity against human OVCAR8 cells assessed as growth inhibition by MTT assay
    Cytotoxicity against human OVCAR8 cells assessed as growth inhibition by MTT assay
    		[PMID: 24398294]
    OVCAR-8 IC50
    0.51 μM
    Compound: Doxorubicin
    Cytotoxicity against human OVCAR8 cells after 72 hrs by MTT assay
    Cytotoxicity against human OVCAR8 cells after 72 hrs by MTT assay
    		[PMID: 19406535]
    OVCAR-8 IC50
    0.6 μM
    Compound: DOX, Doxorubicin
    Antiproliferative activity against human OVCAR8 cells after 72 hrs by MTT assay
    Antiproliferative activity against human OVCAR8 cells after 72 hrs by MTT assay
    		[PMID: 24095089]
    OVCAR-8 IC50
    0.62 μM
    Compound: Dox
    Cytotoxicity against human OVCAR8 cells assessed as decrease in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human OVCAR8 cells assessed as decrease in cell viability after 72 hrs by MTT assay
    		[PMID: 30108718]
    OVCAR-8 IC50
    0.62 μM
    Compound: Dox
    Cytotoxicity against human OVCAR8 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Cytotoxicity against human OVCAR8 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    		[PMID: 32551011]
    P388 GI50
    12 nM
    Compound: adriamycin
    Cytotoxicity against mouse P388 cells by MTT assay
    Cytotoxicity against mouse P388 cells by MTT assay
    		[PMID: 10691710]
    P388 IC50
    0.0031 μg/mL
    Compound: Doxorubicin
    In vitro inhibitory activity against P-388 tumor cells
    In vitro inhibitory activity against P-388 tumor cells
    		10.1016/S0960-894X(97)00191-1
    P388 IC50
    0.003 μg/mL
    Compound: Adriamycin (ADM)
    Tested for the cytostatic activity as inhibitory concentration against P-388 mouse leukemia cells
    Tested for the cytostatic activity as inhibitory concentration against P-388 mouse leukemia cells
    		10.1016/S0960-894X(97)00071-1
    P388 IC50
    0.004 μg/mL
    Compound: Doxorubicin
    Cytotoxic activity against murine P388 leukemia cells
    Cytotoxic activity against murine P388 leukemia cells
    		[PMID: 15056007]
    P388 IC50
    0.004 μg/mL
    Compound: doxorubicin
    Cytotoxic activity of compound against Murine P388 Leukemia
    Cytotoxic activity of compound against Murine P388 Leukemia
    		[PMID: 12459024]
    P388 IC50
    0.005 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against mouse P388 cells
    Cytotoxicity against mouse P388 cells
    		[PMID: 8759170]
    P388 IC50
    0.0096 μg/mL
    Compound: Adriamycin
    In vitro cytotoxicity against P388 tumor cell lines.
    In vitro cytotoxicity against P388 tumor cell lines.
    		[PMID: 9871531]
    P388 IC50
    0.017 μg/mL
    Compound: adriamycin
    Growth inhibition of P388-D1 (murine leukemia) cell line.
    Growth inhibition of P388-D1 (murine leukemia) cell line.
    		[PMID: 2002477]
    P388 IC50
    0.02 μM
    Compound: 2
    Compound was evaluated for the cytotoxicity against P-388 tumor cell line after 3 days of incubation
    Compound was evaluated for the cytotoxicity against P-388 tumor cell line after 3 days of incubation
    		10.1016/S0960-894X(97)10122-6
    P388 IC50
    0.02 μM
    Compound: doxorubicin
    Growth inhibitory concentration of compound was measured against murine leukemia cell line (P388)
    Growth inhibitory concentration of compound was measured against murine leukemia cell line (P388)
    		[PMID: 10698436]
    P388 IC50
    0.02 μg/mL
    Compound: dox, doxorubicin
    Cytotoxicity against mouse P388 cells
    Cytotoxicity against mouse P388 cells
    		[PMID: 17618015]
    P388 IC50
    0.04 μg/mL
    Compound: adriamycin
    Cytotoxicity against mouse P388 cells
    Cytotoxicity against mouse P388 cells
    		[PMID: 12762806]
    P388 IC50
    0.068 μM
    Compound: 1
    Compound was evaluated for the growth inhibition of P388/S, cells.
    Compound was evaluated for the growth inhibition of P388/S, cells.
    		[PMID: 3761328]
    P388 IC50
    0.08 μM
    Compound: Doxorubicin
    Cytotoxicity against mouse P388 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
    Cytotoxicity against mouse P388 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
    		[PMID: 35802519]
    P388 IC50
    0.09 μg/mL
    Compound: Adriamycin
    In vitro cytotoxicity of compound was measured on murine lymphocytic leukemia (P-388) cells.
    In vitro cytotoxicity of compound was measured on murine lymphocytic leukemia (P-388) cells.
    		[PMID: 9873721]
    P388 IC50
    0.09 μg/mL
    Compound: adriamycin
    Cytotoxicity against mouse P388 cells
    Cytotoxicity against mouse P388 cells
    		[PMID: 9249977]
    P388 IC50
    0.2 μM
    Compound: doxorubicin
    Cytotoxicity against mouse P388 cells by MTT method
    Cytotoxicity against mouse P388 cells by MTT method
    		[PMID: 25781655]
    P388 IC50
    0.39 μg/mL
    Compound: (20) adriamycin
    In vitro cytotoxicity of compound against P388, mouse fibroblast leukemia was defined by microculture tetrazolium assay
    In vitro cytotoxicity of compound against P388, mouse fibroblast leukemia was defined by microculture tetrazolium assay
    		[PMID: 12620075]
    P388 IC50
    0.55 μg/mL
    Compound: adriamycin
    Cytotoxicity against mouse Adriamycin-resistant P388 cells
    Cytotoxicity against mouse Adriamycin-resistant P388 cells
    		[PMID: 9249977]
    P388 IC50
    0.83 μM
    Compound: Adriamycin
    In Vitro Cytotoxicity was measured by quantifying clonogenic survival in soft agar following a 1 hr transient exposure of P388 mouse leukemia cells to compound
    In Vitro Cytotoxicity was measured by quantifying clonogenic survival in soft agar following a 1 hr transient exposure of P388 mouse leukemia cells to compound
    		10.1016/0960-894X(96)00230-2
    P388 IC50
    0.83 μM
    Compound: adriamycin
    In vitro cytotoxicity measured by quantifying clonogenic survival in soft agar following a 1-hour transient exposure of p388 mouse leukemia cells.
    In vitro cytotoxicity measured by quantifying clonogenic survival in soft agar following a 1-hour transient exposure of p388 mouse leukemia cells.
    		[PMID: 9733489]
    P388 IC50
    0.8 μg/mL
    Compound: adriamycin
    Compound was evaluated for the growth inhibition of p388/0 leukemia cell line.
    Compound was evaluated for the growth inhibition of p388/0 leukemia cell line.
    		[PMID: 9873640]
    P388 IC50
    0.9 μM
    Compound: Doxorubicin
    Cytotoxicity against mouse P388 cells by Alamar blue assay
    Cytotoxicity against mouse P388 cells by Alamar blue assay
    		[PMID: 27256910]
    P388 IC50
    0.9 μM
    Compound: Doxorubicin
    Cytotoxicity against mouse P388 cells after 72 hrs by alamar blue assay
    Cytotoxicity against mouse P388 cells after 72 hrs by alamar blue assay
    		[PMID: 28159416]
    P388 IC50
    1.22 μM
    Compound: doxorubicin
    Ability to inhibit growth of P388 leukemic cell line was determined in an in vitro MTT assay.
    Ability to inhibit growth of P388 leukemic cell line was determined in an in vitro MTT assay.
    		[PMID: 1995877]
    P388 IC50
    15 nM
    Compound: Doxorubicin
    Inhibitory activity against murine P388 leukemia (P388) cells.
    Inhibitory activity against murine P388 leukemia (P388) cells.
    		[PMID: 11806725]
    P388 IC50
    15 nM
    Compound: Doxorubicin
    Growth inhibitory activity against murine P388 leukemia cells
    Growth inhibitory activity against murine P388 leukemia cells
    		[PMID: 12620081]
    P388 IC50
    15 nM
    Compound: doxorubicin
    Inhibitory concentration required to reduce murine p388 leukemia cell number to 50% of control cultures
    Inhibitory concentration required to reduce murine p388 leukemia cell number to 50% of control cultures
    		[PMID: 9191970]
    P388 IC50
    210 nM
    Compound: Doxorubicin
    Cytotoxicity against mouse P388 cells after 3 days by MTT assay
    Cytotoxicity against mouse P388 cells after 3 days by MTT assay
    		[PMID: 23848233]
    P388 IC50
    22 nM
    Compound: doxorubicin
    Antiproliferative activity against P388 cells by ELISA
    Antiproliferative activity against P388 cells by ELISA
    		[PMID: 17154505]
    P388 IC50
    31 nM
    Compound: Doxorubicin
    Inhibitory activity against Murine p38 leukemia
    Inhibitory activity against Murine p38 leukemia
    		[PMID: 10395479]
    P388 IC50
    74 nM
    Compound: Adriamycin
    Antiproliferative activity against mouse P388 cells after 48 hrs by MTT assay
    Antiproliferative activity against mouse P388 cells after 48 hrs by MTT assay
    		[PMID: 2778449]
    P388 IC50
    > 0.9 μM
    Compound: doxorubicin
    Growth inhibitory concentration of compound was measured against DOX resistant P388 cell line (P388 /DOX)
    Growth inhibitory concentration of compound was measured against DOX resistant P388 cell line (P388 /DOX)
    		[PMID: 10698436]
    P388/ADR GI50
    3.73 μM
    Compound: Doxorubicin
    Antiproliferative activity against mouse P388/ADR cells assessed as reduction in cell viability measured after 72 hrs
    Antiproliferative activity against mouse P388/ADR cells assessed as reduction in cell viability measured after 72 hrs
    		[PMID: 31945642]
    P388/ADR IC50
    123 nM
    Compound: doxorubicin
    Antiproliferative activity against adriamycin resistant P388 cells in presence of 5 uM 1,13-bis[4'-((5,7-dihydroxy)-4H-chromen-4-on-2-yl)phenyl]-1,4,7,10,13-pentaoxatridecane by ELISA
    Antiproliferative activity against adriamycin resistant P388 cells in presence of 5 uM 1,13-bis[4'-((5,7-dihydroxy)-4H-chromen-4-on-2-yl)phenyl]-1,4,7,10,13-pentaoxatridecane by ELISA
    		[PMID: 17154505]
    P388/ADR IC50
    1738 nM
    Compound: doxorubicin
    Antiproliferative activity against adriamycin resistant P388 cells by ELISA
    Antiproliferative activity against adriamycin resistant P388 cells by ELISA
    		[PMID: 17154505]
    P388/ADR IC50
    360 nM
    Compound: Adriamycin
    Evaluation of inhibitory activity against multidrug resistant P388 cells (P388/ADR) cells
    Evaluation of inhibitory activity against multidrug resistant P388 cells (P388/ADR) cells
    		[PMID: 8544183]
    P388/ADR IC50
    8.2 μM
    Compound: 1
    Compound was evaluated for the growth inhibition of P388/ADR cells.
    Compound was evaluated for the growth inhibition of P388/ADR cells.
    		[PMID: 3761328]
    P388/ADR IC50
    8.2 μM
    Compound: 2
    Compound was evaluated for the growth inhibition of P388/ADR cells.
    Compound was evaluated for the growth inhibition of P388/ADR cells.
    		[PMID: 3761325]
    P388/S IC50
    0.068 μM
    Compound: 2
    Compound was evaluated for the growth inhibition of P388/s cells.
    Compound was evaluated for the growth inhibition of P388/s cells.
    		[PMID: 3761325]
    P388/S IC50
    19 nM
    Compound: Adriamycin
    Evaluation of inhibitory activity against drug sensitive P388 cells (P388/S) cells
    Evaluation of inhibitory activity against drug sensitive P388 cells (P388/S) cells
    		[PMID: 8544183]
    P388D1 IC50
    0.338 μM
    Compound: Doxorubicin
    Anticancer activity against mouse P388D1 cells by MTT assay
    Anticancer activity against mouse P388D1 cells by MTT assay
    		[PMID: 21570750]
    PA-1 IC50
    0.63 μM
    Compound: Doxorubicin
    Cytotoxicity against human PA1 cells after 72 hrs by MTT assay
    Cytotoxicity against human PA1 cells after 72 hrs by MTT assay
    		[PMID: 19361894]
    PA-1 IC50
    0.64 μM
    Compound: Dox
    Cytotoxicity against human PA1 cells after 24 hrs by MTT assay
    Cytotoxicity against human PA1 cells after 24 hrs by MTT assay
    		10.1007/s00044-013-0584-6
    PAM IC50
    150 μM
    Compound: Adriamycin
    Inhibitory activity against PAM cell line
    Inhibitory activity against PAM cell line
    		[PMID: 9554873]
    PANC-1 GI50
    0.01 μM
    Compound: Doxorubicin
    Growth inhibition of human PANC1 cells after 48 hrs by SRB assay
    Growth inhibition of human PANC1 cells after 48 hrs by SRB assay
    		[PMID: 26067381]
    PANC-1 GI50
    1.15 μM
    Compound: Doxorubicin
    Antiproliferative activity against human PANC-1 cells assessed as growth inhibition by MTT assay
    Antiproliferative activity against human PANC-1 cells assessed as growth inhibition by MTT assay
    		[PMID: 39026636]
    PANC-1 GI50
    1.41 μM
    Compound: Doxorubicin
    Antiproliferative activity against human PANC1 cells assessed as growth inhibition incubated for 48 hrs by MTT assay
    Antiproliferative activity against human PANC1 cells assessed as growth inhibition incubated for 48 hrs by MTT assay
    		[PMID: 31128433]
    PANC-1 GI50
    3.5 μM
    Compound: Adriamycin
    In vitro antiproliferative activity against human PANC-1 pancreas cell line
    In vitro antiproliferative activity against human PANC-1 pancreas cell line
    		[PMID: 14971893]
    PANC-1 GI50
    < 0.01 μM
    Compound: Doxorubicin
    Growth inhibition of human PANC1 cells after 48 hrs by SRB assay
    Growth inhibition of human PANC1 cells after 48 hrs by SRB assay
    		10.1039/C6MD00097E
    PANC-1 GI50
    < 0.01 μM
    Compound: Doxorubicin
    Antiproliferative activity against human PANC1 cells after 48 hrs by SRB assay
    Antiproliferative activity against human PANC1 cells after 48 hrs by SRB assay
    		[PMID: 25827522]
    PANC-1 GI50
    < 0.01 μM
    Compound: Doxorubicin
    Growth inhibition in human PANC1 cells after 48 hrs by SRB assay
    Growth inhibition in human PANC1 cells after 48 hrs by SRB assay
    		[PMID: 31546197]
    PANC-1 IC50
    0.086 μM
    Compound: DOX
    Cytotoxicity against human PANC-1 cells incubated for 48 hrs by MTT assay
    Cytotoxicity against human PANC-1 cells incubated for 48 hrs by MTT assay
    		[PMID: 38185054]
    PANC-1 IC50
    0.41 μM
    Compound: Doxorubicin
    Antiproliferative activity against human PANC1 cells after 48 hrs by MTT assay
    Antiproliferative activity against human PANC1 cells after 48 hrs by MTT assay
    		[PMID: 28554092]
    PANC-1 IC50
    0.73 μM
    Compound: Doxorubicin
    Cytotoxicity against human PANC1 cells harboring mutant TP53 gene incubated for 72 hrs by MTS assay
    Cytotoxicity against human PANC1 cells harboring mutant TP53 gene incubated for 72 hrs by MTS assay
    		[PMID: 31158748]
    PANC-1 IC50
    0.73 μM
    Compound: Doxorubicin
    Antiproliferative activity against human PANC-1 cells assessed as reduction in cell viability measured after 72 hrs by MTS assay
    Antiproliferative activity against human PANC-1 cells assessed as reduction in cell viability measured after 72 hrs by MTS assay
    		[PMID: 31962262]
    PANC-1 IC50
    0.73 μM
    Compound: Doxorubicin
    Cytotoxicity against human PANC-1 cells assessed as reduction in cell viability measured after 72 hrs by MTS assay
    Cytotoxicity against human PANC-1 cells assessed as reduction in cell viability measured after 72 hrs by MTS assay
    		[PMID: 33261897]
    PANC-1 IC50
    0.9 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human PANC-1 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
    Cytotoxicity against human PANC-1 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
    		[PMID: 35526504]
    PANC-1 IC50
    1.026 μM
    Compound: Dox
    Cytotoxicity against human PANC1 cells assessed as cell killing effect after 72 hrs by MTT assay
    Cytotoxicity against human PANC1 cells assessed as cell killing effect after 72 hrs by MTT assay
    		[PMID: 26005543]
    PANC-1 IC50
    1.1 μM
    Compound: Dox
    Cytotoxicity against human PANC1 cells under normoxic condition after 24 hrs by crystal violet method
    Cytotoxicity against human PANC1 cells under normoxic condition after 24 hrs by crystal violet method
    		[PMID: 25375258]
    PANC-1 IC50
    1.41 μM
    Compound: Doxorubicin
    Antiproliferative activity against human PANC1 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay
    Antiproliferative activity against human PANC1 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay
    		[PMID: 31108261]
    PANC-1 IC50
    1.664 μM
    Compound: Doxorubicin
    Cytotoxicity activity against human PANC1 cells assessed as cell growth inhibition after 48 hrs by MTT assay
    Cytotoxicity activity against human PANC1 cells assessed as cell growth inhibition after 48 hrs by MTT assay
    		[PMID: 30433783]
    PANC-1 IC50
    1.73 μM
    Compound: DOX
    Antiproliferative activity against human PANC1 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Antiproliferative activity against human PANC1 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    		[PMID: 32996316]
    PANC-1 IC50
    1.9 μM
    Compound: Doxorubicin
    Cytotoxicity against human PANC1 cells assessed as reduction in cell viability measured after 48 hrs by SRB assay
    Cytotoxicity against human PANC1 cells assessed as reduction in cell viability measured after 48 hrs by SRB assay
    		[PMID: 28818768]
    PANC-1 IC50
    2.2 μM
    Compound: Doxorubicin
    Cytotoxicity against human PANC-1 cells assessed as number of viable cells measured after 48 hrs by MTT based colorimetric assay
    Cytotoxicity against human PANC-1 cells assessed as number of viable cells measured after 48 hrs by MTT based colorimetric assay
    		[PMID: 36970146]
    PANC-1 IC50
    3.1 μM
    Compound: DOX
    Cytotoxicity against human PANC-1 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay
    Cytotoxicity against human PANC-1 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay
    		[PMID: 34700239]
    PANC-1 IC50
    3.2 μM
    Compound: Doxorubicin
    Antiproliferative activity against human PANC1 cells after 48 hrs by SRB assay
    Antiproliferative activity against human PANC1 cells after 48 hrs by SRB assay
    		[PMID: 28419927]
    PANC-1 IC50
    3.2 μM
    Compound: Doxorubicin
    Cytotoxicity against human PANC1 cells
    Cytotoxicity against human PANC1 cells
    		[PMID: 32386856]
    PANC-1 IC50
    5.4 μM
    Compound: Dox
    Cytotoxicity against human PANC1 cells under hypoxic condition after 24 hrs by crystal violet method
    Cytotoxicity against human PANC1 cells under hypoxic condition after 24 hrs by crystal violet method
    		[PMID: 25375258]
    PANC-1 IC50
    6.9 μM
    Compound: DOX
    Antiproliferative activity against human PANC1 cells after 48 hrs by resazurin dye-based fluorescence assay
    Antiproliferative activity against human PANC1 cells after 48 hrs by resazurin dye-based fluorescence assay
    		[PMID: 29665526]
    PANC-1 IC50
    6.9 μM
    Compound: DOX
    Cytotoxicity against human PANC-1 cells under hypoxia condition by MTT assay
    Cytotoxicity against human PANC-1 cells under hypoxia condition by MTT assay
    		[PMID: 38642371]
    PANC-1 IC50
    6.9 μM
    Compound: Dox
    Cytotoxicity against human PANC1 cells after 48 hrs by resazurin assay
    Cytotoxicity against human PANC1 cells after 48 hrs by resazurin assay
    		[PMID: 29107422]
    PBL IC50
    0.97 μg/mL
    Compound: doxorubicin
    Cytotoxicity against human PBL cells after 72 hrs by alamar blue assay
    Cytotoxicity against human PBL cells after 72 hrs by alamar blue assay
    		[PMID: 18053728]
    PBMC IC50
    0.37 μM
    Compound: Doxorubicin
    Cytotoxicity against human PBMC cells after 72 hrs by MTT assay
    Cytotoxicity against human PBMC cells after 72 hrs by MTT assay
    		10.1039/C4MD00371C
    PBMC IC50
    0.38 μM
    Compound: Doxorubicin
    Cytotoxicity against human PBMC cells assessed as inhibition of cell viability after 72 hrs by alamar blue assay
    Cytotoxicity against human PBMC cells assessed as inhibition of cell viability after 72 hrs by alamar blue assay
    		[PMID: 29329071]
    PBMC IC50
    0.42 μM
    Compound: DOXO
    Cytotoxicity against human PBMC after 72 hrs by alamar blue assay
    Cytotoxicity against human PBMC after 72 hrs by alamar blue assay
    		[PMID: 19947600]
    PBMC IC50
    0.42 μM
    Compound: Doxorubicin
    Cytotoxicity against human PBMC cells after 72 hrs by Alamar Blue assay
    Cytotoxicity against human PBMC cells after 72 hrs by Alamar Blue assay
    		[PMID: 21115213]
    PBMC IC50
    0.42 μM
    Compound: Doxorubicin
    Cytotoxicity against human PBMC assessed as cell viability after 72 hrs by MTT assay
    Cytotoxicity against human PBMC assessed as cell viability after 72 hrs by MTT assay
    		[PMID: 24530030]
    PBMC IC50
    0.5 μM
    Compound: Doxorubicin
    Cytotoxicity against human PBMC after 72 hrs by alamar blue assay
    Cytotoxicity against human PBMC after 72 hrs by alamar blue assay
    		[PMID: 19780590]
    PBMC IC50
    0.55 μM
    Compound: DOX
    Cytotoxicity against human PBMC cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human PBMC cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 29660689]
    PBMC IC50
    0.55 μM
    Compound: DOXO
    Cytotoxicity against human PBMC assessed as cell viability after 72 hrs by MTT assay
    Cytotoxicity against human PBMC assessed as cell viability after 72 hrs by MTT assay
    		[PMID: 26142490]
    PBMC IC50
    0.55 μM
    Compound: Doxorubicin
    Cytotoxicity against NQO1-deficient human PBMC assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against NQO1-deficient human PBMC assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 27341379]
    PBMC IC50
    0.96 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human PBMC after 72 hrs by Alamar blue assay
    Cytotoxicity against human PBMC after 72 hrs by Alamar blue assay
    		[PMID: 20537433]
    PBMC IC50
    1.66 μM
    Compound: Doxorubicin
    Cytotoxicity against human PBMC after 72 hrs by Alamar Blue assay
    Cytotoxicity against human PBMC after 72 hrs by Alamar Blue assay
    		[PMID: 20971532]
    PBMC IC50
    1.7 μM
    Compound: Dox
    Cytotoxicity against human PBMC assessed as decrease in cell viability after 72 hrs by Alamar blue assay
    Cytotoxicity against human PBMC assessed as decrease in cell viability after 72 hrs by Alamar blue assay
    		[PMID: 30108718]
    PBMC IC50
    1.7 μM
    Compound: Doxorubicin
    Cytotoxicity against human PBMC assessed as cell viability after 72 hrs by MTT assay
    Cytotoxicity against human PBMC assessed as cell viability after 72 hrs by MTT assay
    		[PMID: 24485783]
    PBMC IC50
    1.77 μM
    Compound: Doxorubicin
    Cytotoxicity against human PBMC cells after 72 hrs by alamar blue assay
    Cytotoxicity against human PBMC cells after 72 hrs by alamar blue assay
    		[PMID: 19406535]
    PBMC IC50
    15.51 μM
    Compound: doxorubicin
    Cytotoxicity against human PBMCs after 24 hrs by MTT assay
    Cytotoxicity against human PBMCs after 24 hrs by MTT assay
    		[PMID: 17400463]
    PBMC IC50
    15.51 μM
    Compound: doxorubicin
    Cytotoxicity against human PBMC cells after 24 hrs by MTT assay
    Cytotoxicity against human PBMC cells after 24 hrs by MTT assay
    		[PMID: 18281125]
    PBMC IC50
    271 nM
    Compound: Doxorubicn
    Cytotoxicity against PHA-stimulated human PBMC cells after 48 hrs by Alamar Blue assay
    Cytotoxicity against PHA-stimulated human PBMC cells after 48 hrs by Alamar Blue assay
    		[PMID: 23673218]
    PBMC IC50
    9.36 μM
    Compound: Doxorubicin
    Cytotoxicity against concanavalin-A stimulated human PBMC after 72 hrs by alamar blue assay
    Cytotoxicity against concanavalin-A stimulated human PBMC after 72 hrs by alamar blue assay
    		[PMID: 24969014]
    PBMC IC50
    > 10 μM
    Compound: Doxo
    Cytotoxicity against human PBMC assessed as cell viability after 24 hrs by MTT assay
    Cytotoxicity against human PBMC assessed as cell viability after 24 hrs by MTT assay
    		[PMID: 24484281]
    PC-12 IC50
    0.52 μM
    Compound: DOX
    Antiproliferative activity against rat PC12 cells after 72 hrs by CCK-8 assay
    Antiproliferative activity against rat PC12 cells after 72 hrs by CCK-8 assay
    		[PMID: 29597166]
    PC-12 IC50
    5.71 μM
    Compound: Doxorubicin
    Cytotoxicity against rat PC12 cells by MTT assay
    Cytotoxicity against rat PC12 cells by MTT assay
    		[PMID: 30015071]
    PC-14 IC50
    0.29 μM
    Compound: Adriamycin
    Cytotoxicity of compound against human lung adenocarcinoma cell line (PC14)
    Cytotoxicity of compound against human lung adenocarcinoma cell line (PC14)
    		[PMID: 9822542]
    PC-14 IC50
    1.9 μM
    Compound: doxorubicin
    Growth inhibitory concentration of compound was measured against human lung carcinoma cell line (PC-14)
    Growth inhibitory concentration of compound was measured against human lung carcinoma cell line (PC-14)
    		[PMID: 10698436]
    PC-3 CC50
    12.6 μM
    Compound: Dox
    Cytotoxicity against human PC-3 cells incubated for 72 hrs by MTT assay
    Cytotoxicity against human PC-3 cells incubated for 72 hrs by MTT assay
    		[PMID: 39079310]
    PC-3 CC50
    < 500 nM
    Compound: Dox
    Cytotoxicity against PSMA-negative human PC3 cells by MTT assay
    Cytotoxicity against PSMA-negative human PC3 cells by MTT assay
    		[PMID: 30904185]
    PC-3 EC50
    2 μM
    Compound: doxorubicin
    Cytotoxicity against human PC3 cells after 72 hrs
    Cytotoxicity against human PC3 cells after 72 hrs
    		[PMID: 17378530]
    PC-3 EC50
    340 nM
    Compound: Doxorubicin
    Antiproliferative activity against androgen-insensitive human PC-3 cells assessed as reduction in cell viability measured after 72 hrs by MTS assay
    Antiproliferative activity against androgen-insensitive human PC-3 cells assessed as reduction in cell viability measured after 72 hrs by MTS assay
    		[PMID: 36577036]
    PC-3 ED50
    0.00024 μg/mL
    Compound: Adriamycin
    In vitro cytotoxic activity against PC-3 (human prostate adenocarcinoma) cell line
    In vitro cytotoxic activity against PC-3 (human prostate adenocarcinoma) cell line
    		[PMID: 11551759]
    PC-3 ED50
    0.0349 μg/mL
    Compound: Adriamycin
    Cytotoxicity against human prostate adenocarcinoma PC-3 cell lines
    Cytotoxicity against human prostate adenocarcinoma PC-3 cell lines
    		10.1016/0960-894X(95)00182-S
    PC-3 ED50
    0.0499 μg/mL
    Compound: adriamycin
    Cytotoxicity against human PC-3 cells after 7 days by MTT assay
    Cytotoxicity against human PC-3 cells after 7 days by MTT assay
    		[PMID: 10514307]
    PC-3 ED50
    0.0577 μg/mL
    Compound: adriamycin
    Cytotoxicity against human PC3 cells after 7 days by MTT assay
    Cytotoxicity against human PC3 cells after 7 days by MTT assay
    		[PMID: 11087592]
    PC-3 ED50
    0.26 μM
    Compound: DOX
    Cytotoxicity against human PC3 cells
    Cytotoxicity against human PC3 cells
    		[PMID: 17591444]
    PC-3 ED50
    0.287 μg/mL
    Compound: Adriamycin
    Cytotoxicity concentration against human prostate adrenocarcinoma PC-3 cell line
    Cytotoxicity concentration against human prostate adrenocarcinoma PC-3 cell line
    		[PMID: 8627602]
    PC-3 ED50
    0.33 μg/mL
    Compound: Adriamycin
    Cytotoxic activity was tested against human PC-3 (prostate adenocarcinoma) cell line
    Cytotoxic activity was tested against human PC-3 (prostate adenocarcinoma) cell line
    		10.1016/0960-894X(95)00309-H
    PC-3 ED50
    0.4 μg/mL
    Compound: Adriamycin
    Cytotoxicity against human PC-3 cells
    Cytotoxicity against human PC-3 cells
    		[PMID: 10346965]
    PC-3 ED50
    1.19 x 10-2 μg/mL
    Compound: adriamycin
    Cytotoxicity against human PC3 cells after 7 days by MTT assay
    Cytotoxicity against human PC3 cells after 7 days by MTT assay
    		[PMID: 9134750]
    PC-3 ED50
    1.46 x 10-2 μg/mL
    Compound: Adriamycin
    Cytotoxicity against human PC3 cells after 7 days by MTT assay
    Cytotoxicity against human PC3 cells after 7 days by MTT assay
    		[PMID: 9322367]
    PC-3 ED50
    1.89 x 10-2 μg/mL
    Compound: Adriamycin
    Cytotoxicity against human PC3 cells after 7 days by MTT assay
    Cytotoxicity against human PC3 cells after 7 days by MTT assay
    		[PMID: 8946743]
    PC-3 ED50
    1.96 x 10-2 μg/mL
    Compound: adriamycin
    Cytotoxicity against human PC3 cells after 7 days by MTT assay
    Cytotoxicity against human PC3 cells after 7 days by MTT assay
    		[PMID: 8676130]
    PC-3 ED50
    1 x 10-2 μg/mL
    Compound: Adriamycin
    Cytotoxicity against human PC3 cells by MTT assay
    Cytotoxicity against human PC3 cells by MTT assay
    		[PMID: 7714533]
    PC-3 ED50
    2.13 x 10-2 μg/mL
    Compound: adriamycin
    Cytotoxicity against human PC3 cells after 7 days by MTT assay
    Cytotoxicity against human PC3 cells after 7 days by MTT assay
    		10.1021/np970510f
    PC-3 ED50
    2.23 x 10-2 μg/mL
    Compound: adriamycin
    Cytotoxicity against human PC3 cells after 7 days by MTT assay
    Cytotoxicity against human PC3 cells after 7 days by MTT assay
    		[PMID: 8882434]
    PC-3 ED50
    2.27 x 10-2 μg/mL
    Compound: adriamycin
    Cytotoxicity against human PC3 cells after 7 days by MTT assay
    Cytotoxicity against human PC3 cells after 7 days by MTT assay
    		[PMID: 9599253]
    PC-3 ED50
    2.62 x 10-2 μg/mL
    Compound: adriamycin
    Cytotoxicity against human PC3 cells after 7 days by MTT assay
    Cytotoxicity against human PC3 cells after 7 days by MTT assay
    		[PMID: 8904848]
    PC-3 ED50
    2.76 x 10-2 μg/mL
    Compound: adr
    Cytotoxicity against human PC3 cells after 7 days by MTT assay
    Cytotoxicity against human PC3 cells after 7 days by MTT assay
    		[PMID: 9461654]
    PC-3 ED50
    2.81 x 10-2 μg/mL
    Compound: Adr
    Cytotoxicity against human PC3 cells
    Cytotoxicity against human PC3 cells
    		[PMID: 8778247]
    PC-3 ED50
    2 x 10-2 μg/mL
    Compound: adriamycin
    Cytotoxicity against human PC-3 cells after 7 days by MTT assay
    Cytotoxicity against human PC-3 cells after 7 days by MTT assay
    		[PMID: 10395501]
    PC-3 ED50
    3.2 x 10-2 μg/mL
    Compound: Adriamycin
    Cytotoxicity against human PC3 cells after 7 days by MTT assay
    Cytotoxicity against human PC3 cells after 7 days by MTT assay
    		[PMID: 9214729]
    PC-3 ED50
    3.42 x 10-1 μg/mL
    Compound: adriamycin
    Cytotoxicity against human PC3 cells
    Cytotoxicity against human PC3 cells
    		[PMID: 8991957]
    PC-3 ED50
    3.55 x 10-2 μg/mL
    Compound: adriamycin
    Cytotoxicity against human PC3 cells after 7 days by MTT assay
    Cytotoxicity against human PC3 cells after 7 days by MTT assay
    		[PMID: 9584396]
    PC-3 ED50
    4.6 x 10-2 μg/mL
    Compound: adriamycin
    Cytotoxicity against human PC3 cells after 7 days by MTT assay
    Cytotoxicity against human PC3 cells after 7 days by MTT assay
    		[PMID: 9599260]
    PC-3 ED50
    5.02 x 10-2 μg/mL
    Compound: adriamycin
    Cytotoxicity against human PC3 cells after 7 days by MTT assay
    Cytotoxicity against human PC3 cells after 7 days by MTT assay
    		[PMID: 11325235]
    PC-3 ED50
    5.6 x 10-3 μg/mL
    Compound: Adriamycin
    Cytotoxicity against human PC-3 cells
    Cytotoxicity against human PC-3 cells
    		[PMID: 10479316]
    PC-3 ED50
    5.77 x 10-2 μg/mL
    Compound: adriamycin
    Cytotoxicity against human PC-3 cells after 7 days by MTT assay
    Cytotoxicity against human PC-3 cells after 7 days by MTT assay
    		[PMID: 15730242]
    PC-3 ED50
    5.83 x 10-2 μg/mL
    Compound: Adriamycin
    Cytotoxicity against human PC3 cells
    Cytotoxicity against human PC3 cells
    		[PMID: 8946744]
    PC-3 ED50
    57 nM
    Compound: Adriamycin
    In vitro cytotoxicity against prostate PC-3 human tumors following a 6 day exposure
    In vitro cytotoxicity against prostate PC-3 human tumors following a 6 day exposure
    		[PMID: 10498214]
    PC-3 ED50
    6.2 x 10-2 μg/mL
    Compound: adriamycin
    Cytotoxicity against human PC-3 cells by MTT assay
    Cytotoxicity against human PC-3 cells by MTT assay
    		[PMID: 9917277]
    PC-3 ED50
    6.24 x 10-2 μg/mL
    Compound: Adriamycin
    Cytotoxicity against human PC3 cells after 7 days by MTT assay
    Cytotoxicity against human PC3 cells after 7 days by MTT assay
    		[PMID: 7494147]
    PC-3 ED50
    6.37 μg/mL
    Compound: Adriamycin
    Cytotoxicity on prostate adenocarcinoma (PC-3) cell line
    Cytotoxicity on prostate adenocarcinoma (PC-3) cell line
    		[PMID: 8632402]
    PC-3 GI50
    0.021 μM
    Compound: Doxorubicin
    Cytostatic activity against human PC3 cells after 5 days by SRB assay
    Cytostatic activity against human PC3 cells after 5 days by SRB assay
    		[PMID: 21711054]
    PC-3 GI50
    0.029 μg/mL
    Compound: Doxorubicin
    Antitumor cytotoxic activity against PC-3 cell line was determined
    Antitumor cytotoxic activity against PC-3 cell line was determined
    		[PMID: 11551772]
    PC-3 GI50
    0.076 μM
    Compound: ADR
    Cytotoxicity against human PC3 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay
    Cytotoxicity against human PC3 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay
    		[PMID: 28870801]
    PC-3 GI50
    0.076 μM
    Compound: ADR
    Cytotoxicity against human PC3 cells assessed as growth inhibition after 72 hrs by SRB assay
    Cytotoxicity against human PC3 cells assessed as growth inhibition after 72 hrs by SRB assay
    		[PMID: 30253887]
    PC-3 GI50
    0.085 μg/mL
    Compound: DOX; Doxo
    Antiproliferative activity against human PC3 cells after 48 hrs by SRB assay
    Antiproliferative activity against human PC3 cells after 48 hrs by SRB assay
    		[PMID: 26859070]
    PC-3 GI50
    0.09 μM
    Compound: ADR
    Anticancer activity against human PC-3 cells assessed as growth inhibition incubated for 48 hrs by sulforhodamine B method
    Anticancer activity against human PC-3 cells assessed as growth inhibition incubated for 48 hrs by sulforhodamine B method
    		[PMID: 34500188]
    PC-3 GI50
    0.09 μM
    Compound: Doxorubicin
    Antiproliferative activity against human PC3 assessed as growth inhibition after 48 hrs by SRB assay
    Antiproliferative activity against human PC3 assessed as growth inhibition after 48 hrs by SRB assay
    		[PMID: 21875046]
    PC-3 GI50
    0.0923 μM
    Compound: ADR
    Cytotoxicity against human PC3 cells after 72 hrs by sulforhodamine B assay
    Cytotoxicity against human PC3 cells after 72 hrs by sulforhodamine B assay
    		[PMID: 27096046]
    PC-3 GI50
    0.13 μM
    Compound: Dox
    Antiproliferative activity against human PC3 cells assessed as growth inhibition after 48 hrs by SRB assay
    Antiproliferative activity against human PC3 cells assessed as growth inhibition after 48 hrs by SRB assay
    		[PMID: 26454648]
    PC-3 GI50
    0.17 μM
    Compound: ADR
    Cytotoxicity against human PC3 cells after 48 hrs by SRB assay
    Cytotoxicity against human PC3 cells after 48 hrs by SRB assay
    		[PMID: 20673627]
    PC-3 GI50
    0.22 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human PC3 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    Cytotoxicity against human PC3 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    		[PMID: 26561866]
    PC-3 GI50
    0.24 μM
    Compound: Doxorubicin
    Growth inhibition of human PC3 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human PC3 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 33477019]
    PC-3 GI50
    0.24 μg/mL
    Compound: Doxorubicin
    Growth inhibition of human PC3 cells after 48 hrs by sulforhodamine B assay
    Growth inhibition of human PC3 cells after 48 hrs by sulforhodamine B assay
    		[PMID: 22410248]
    PC-3 GI50
    0.25 μM
    Compound: Doxorubicin
    Cytotoxicity against human PC3 cells after 72 hrs by MTT assay
    Cytotoxicity against human PC3 cells after 72 hrs by MTT assay
    		[PMID: 21115210]
    PC-3 GI50
    0.28 μM
    Compound: Doxorubicin
    Anticancer activity against human PC3 cells by SRB assay
    Anticancer activity against human PC3 cells by SRB assay
    		[PMID: 20732810]
    PC-3 GI50
    0.28 μg/mL
    Compound: DOX
    Growth inhibition of human PC3 cells after 48 hrs by sulforhodamine B assay
    Growth inhibition of human PC3 cells after 48 hrs by sulforhodamine B assay
    		[PMID: 21041092]
    PC-3 GI50
    0.317 μM
    Compound: doxorubicin
    Cytotoxicity against human PC3 cells
    Cytotoxicity against human PC3 cells
    		[PMID: 20579876]
    PC-3 GI50
    0.32 μM
    Compound: Doxorubicin
    Growth inhibition of human PC3 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human PC3 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28329730]
    PC-3 GI50
    0.32 μM
    Compound: Doxorubicin
    Growth inhibition of human PC3 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human PC3 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 29102177]
    PC-3 GI50
    0.32 μM
    Compound: Doxorubicin hydrochloride, NSC 123127
    Cytotoxicity against human PC3 cells after 48 hrs by SRB assay
    Cytotoxicity against human PC3 cells after 48 hrs by SRB assay
    		[PMID: 23871905]
    PC-3 GI50
    0.35 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human PC3 cells by sulforhodamine B assay
    Cytotoxicity against human PC3 cells by sulforhodamine B assay
    		[PMID: 26913941]
    PC-3 GI50
    0.42 μM
    Compound: Doxorubicin
    Anticancer activity against human PC-3 cells assessed as cell growth inhibition measured after 48 hrs by sulforhodamine B assay
    Anticancer activity against human PC-3 cells assessed as cell growth inhibition measured after 48 hrs by sulforhodamine B assay
    		[PMID: 33214037]
    PC-3 GI50
    0.52 μM
    Compound: Doxorubicin
    Cytotoxicity against human PC3 cells after 48 hrs by sulforhodamine B assay
    Cytotoxicity against human PC3 cells after 48 hrs by sulforhodamine B assay
    		[PMID: 23964644]
    PC-3 GI50
    0.73 μM
    Compound: Doxorubicin
    Cytotoxicity against human PC3 cells by SRB assay
    Cytotoxicity against human PC3 cells by SRB assay
    		[PMID: 19596579]
    PC-3 GI50
    0.74 μM
    Compound: DOXO
    Antiproliferative activity against human PC3 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    Antiproliferative activity against human PC3 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    		[PMID: 31247374]
    PC-3 GI50
    0.91 μM
    Compound: ADR
    Cytotoxicity against human PC3 cells assessed as growth inhibition after 72 hrs by sulforhodamine B assay
    Cytotoxicity against human PC3 cells assessed as growth inhibition after 72 hrs by sulforhodamine B assay
    		[PMID: 25953156]
    PC-3 GI50
    1 x 10-2 μM
    Compound: Doxorubicin
    Cytotoxicity against human PC3 cells assessed as growth inhibition after 72 hrs by MTT assay
    Cytotoxicity against human PC3 cells assessed as growth inhibition after 72 hrs by MTT assay
    		[PMID: 29670691]
    PC-3 GI50
    1 x 10-2 μM
    Compound: Doxorubicin
    Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay
    Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay
    		[PMID: 30071406]
    PC-3 GI50
    1.65 μM
    Compound: ADR
    Antiproliferative activity against human PC3 cells by SRB assay
    Antiproliferative activity against human PC3 cells by SRB assay
    		[PMID: 22738641]
    PC-3 GI50
    1.65 μM
    Compound: ADR
    Antiproliferative activity against human PC3 cells by SRB method
    Antiproliferative activity against human PC3 cells by SRB method
    		[PMID: 24835787]
    PC-3 GI50
    1.76 μM
    Compound: Doxorubicin
    Growth inhibition of Homo sapiens (human) PC3 cells after 48 hr by MTT assay
    Growth inhibition of Homo sapiens (human) PC3 cells after 48 hr by MTT assay
    		10.1007/s00044-012-0232-6
    PC-3 GI50
    1.81 μM
    Compound: ADR
    Cytotoxicity against human PC3 cells after 48 hrs by sulforhodamine B assay
    Cytotoxicity against human PC3 cells after 48 hrs by sulforhodamine B assay
    		[PMID: 18657979]
    PC-3 GI50
    1.81 μM
    Compound: ADR
    Growth inhibition of human PC3 cells after 48 hrs by SRB assay
    Growth inhibition of human PC3 cells after 48 hrs by SRB assay
    		[PMID: 20031423]
    PC-3 GI50
    1.81 μM
    Compound: ADR
    Cytotoxicity against human PC3 cells after 24 hrs by WST-1 assay
    Cytotoxicity against human PC3 cells after 24 hrs by WST-1 assay
    		[PMID: 20732817]
    PC-3 GI50
    1.81 μM
    Compound: ADR
    Anticancer activity against human PC3 cells by SRB method
    Anticancer activity against human PC3 cells by SRB method
    		[PMID: 21676506]
    PC-3 GI50
    1.81 μM
    Compound: ADR
    Growth inhibition of human PC3 cells by SRB assay
    Growth inhibition of human PC3 cells by SRB assay
    		[PMID: 22361684]
    PC-3 GI50
    1.81 μM
    Compound: ADR, Adriamycin
    Growth inhibition of human PC3 cells by SRB method
    Growth inhibition of human PC3 cells by SRB method
    		[PMID: 18207392]
    PC-3 GI50
    1.81 μM
    Compound: adriamycin
    Cytotoxicity against human PC3 cells after 24 hrs by SRB method
    Cytotoxicity against human PC3 cells after 24 hrs by SRB method
    		[PMID: 18262426]
    PC-3 GI50
    1.83 μM
    Compound: ADR
    Growth inhibition of human PC3 cells
    Growth inhibition of human PC3 cells
    		10.1039/C1MD00072A
    PC-3 GI50
    3.8 μg/mL
    Compound: DOX
    Antiproliferative activity against human PC3 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    Antiproliferative activity against human PC3 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    		[PMID: 25062010]
    PC-3 GI50
    < 0.1 μM
    Compound: Doxorubicin
    Antiproliferative activity against human PC-3 cells assessed as cell growth inhibition
    Antiproliferative activity against human PC-3 cells assessed as cell growth inhibition
    		[PMID: 32961322]
    PC-3 IC50
    0.002 μM
    Compound: Doxorubicin
    Cytotoxicity against human PC-3 cells assessed as reduction in cell viability by CellTiter Glo luminescent assay
    Cytotoxicity against human PC-3 cells assessed as reduction in cell viability by CellTiter Glo luminescent assay
    		[PMID: 32755677]
    PC-3 IC50
    0.008 μg
    Compound: Doxorubicin
    Cytotoxicity against human PC3 cells assessed as decrease in cell viability after 48 hrs by SRB assay
    Cytotoxicity against human PC3 cells assessed as decrease in cell viability after 48 hrs by SRB assay
    		[PMID: 27393950]
    PC-3 IC50
    0.01 μM
    Compound: Doxorubicin
    Cytotoxicity against human PC-3 cells assessed as inhibition of cell growth and measured after 72 hrs resazurin reduction assay
    Cytotoxicity against human PC-3 cells assessed as inhibition of cell growth and measured after 72 hrs resazurin reduction assay
    		[PMID: 36126331]
    PC-3 IC50
    0.02 μM
    Compound: DOXO
    Cytotoxicity against human PC3 cells assessed as cell viability after 72 hrs by MTT assay
    Cytotoxicity against human PC3 cells assessed as cell viability after 72 hrs by MTT assay
    		[PMID: 26142490]
    PC-3 IC50
    0.02 μM
    Compound: Doxorubicin
    Cytotoxicity against human PC3 cells overexpressing NQO1 assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human PC3 cells overexpressing NQO1 assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 27341379]
    PC-3 IC50
    0.05 μM
    Compound: DOXO
    Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay
    Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay
    		[PMID: 28818447]
    PC-3 IC50
    0.06 μM
    Compound: Doxorubicine
    Cytotoxicity against human PC-3 cells assessed as reduction in cell viability incubated for 48 hrs by Hoechst-33342 staining based cell counting method (Rvb > 25 microM)
    Cytotoxicity against human PC-3 cells assessed as reduction in cell viability incubated for 48 hrs by Hoechst-33342 staining based cell counting method (Rvb > 25 microM)
    		[PMID: 33422908]
    PC-3 IC50
    0.08 μM
    Compound: Doxorubicin
    Antiproliferative activity against human PC3 cells after 48 hrs by Hoechst 33342 staining-based assay
    Antiproliferative activity against human PC3 cells after 48 hrs by Hoechst 33342 staining-based assay
    		[PMID: 30655216]
    PC-3 IC50
    0.08 μM
    Compound: Doxorubicin
    Cytotoxicity against human PC-3 cells assessed as reduction in cell viability after 48 hrs
    Cytotoxicity against human PC-3 cells assessed as reduction in cell viability after 48 hrs
    		[PMID: 34601029]
    PC-3 IC50
    0.09 μM
    Compound: Doxorubicin
    Cytotoxicity against human PC3 cells assessed as cell growth inhibition
    Cytotoxicity against human PC3 cells assessed as cell growth inhibition
    		[PMID: 26934105]
    PC-3 IC50
    0.12 μM
    Compound: Doxorubicin
    Toxicity in human PC-3 cells assessed as reduction in cell number after 48 hrs by Hoechst 33342 staining based assay
    Toxicity in human PC-3 cells assessed as reduction in cell number after 48 hrs by Hoechst 33342 staining based assay
    		[PMID: 31753515]
    PC-3 IC50
    0.19 μM
    Compound: DOX
    Cytotoxicity against human PC3 cells after 48 hrs by MTT assay
    Cytotoxicity against human PC3 cells after 48 hrs by MTT assay
    		[PMID: 24487188]
    PC-3 IC50
    0.19 μM
    Compound: Doxorubicin
    Cytotoxicity against human PC3 cells assessed as inhibition of cell viability after 48 hrs by MTT assay
    Cytotoxicity against human PC3 cells assessed as inhibition of cell viability after 48 hrs by MTT assay
    		[PMID: 24953027]
    PC-3 IC50
    0.19 μM
    Compound: Doxorubicin
    Cytotoxicity in human PC3 cells incubated for 48 hrs by MTT assay
    Cytotoxicity in human PC3 cells incubated for 48 hrs by MTT assay
    		[PMID: 28923381]
    PC-3 IC50
    0.2 μM
    Compound: DOX
    Cytotoxicity against human PC3 cells after 48 hrs by MTT assay
    Cytotoxicity against human PC3 cells after 48 hrs by MTT assay
    		[PMID: 23218718]
    PC-3 IC50
    0.2 μM
    Compound: adriamycin
    Antitumor activity against human PC3 cells by methylene blue staining method
    Antitumor activity against human PC3 cells by methylene blue staining method
    		[PMID: 17656091]
    PC-3 IC50
    0.23 μM
    Compound: DOX
    Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay
    Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay
    		[PMID: 30429098]
    PC-3 IC50
    0.24 μg/mL
    Compound: doxorubicin
    Cytotoxicity against human PC3 cells after 72 hrs by MTT assay
    Cytotoxicity against human PC3 cells after 72 hrs by MTT assay
    		[PMID: 17827021]
    PC-3 IC50
    0.25 μM
    Compound: Doxorubicin
    Cytotoxicity against human PC3 cells after 48 hrs by SRB assay
    Cytotoxicity against human PC3 cells after 48 hrs by SRB assay
    		[PMID: 22100139]
    PC-3 IC50
    0.25 μM
    Compound: doxorubicin
    Cytotoxicity against human PC3 cells assessed as inhibition of cell proliferation/survival after 72 hrs by resazurin dye reduction assay
    Cytotoxicity against human PC3 cells assessed as inhibition of cell proliferation/survival after 72 hrs by resazurin dye reduction assay
    		[PMID: 26305181]
    PC-3 IC50
    0.3 μM
    Compound: Doxorubicin
    Cytotoxicity against human PC3 cells after 72 hrs by Alamar blue assay
    Cytotoxicity against human PC3 cells after 72 hrs by Alamar blue assay
    		[PMID: 21999655]
    PC-3 IC50
    0.3 μM
    Compound: Doxorubicin
    Cytotoxic activity in human PC3 cells assessed as reduction in cell viability incubated for 3 days by MTT assay
    Cytotoxic activity in human PC3 cells assessed as reduction in cell viability incubated for 3 days by MTT assay
    		[PMID: 28395220]
    PC-3 IC50
    0.3 μM
    Compound: Doxorubicin
    Cytotoxicity against human PC-3 cells assessed as cell growth inhibition measured after 24 to 72 hrs by MTT assay
    Cytotoxicity against human PC-3 cells assessed as cell growth inhibition measured after 24 to 72 hrs by MTT assay
    		[PMID: 33586438]
    PC-3 IC50
    0.31 μM
    Compound: DOX
    Antiproliferative activity against human PC3 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Antiproliferative activity against human PC3 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    		[PMID: 31678743]
    PC-3 IC50
    0.31 μM
    Compound: Doxorubicin
    Cytotoxicity against human PC-3 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
    Cytotoxicity against human PC-3 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
    		[PMID: 37951135]
    PC-3 IC50
    0.32 μM
    Compound: doxorubicin
    Cytotoxicity against human PC3 cells
    Cytotoxicity against human PC3 cells
    		[PMID: 12608854]
    PC-3 IC50
    0.336 μM
    Compound: Doxorubicin
    Cytotoxicity against human PC-3 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Cytotoxicity against human PC-3 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    		[PMID: 38056297]
    PC-3 IC50
    0.36 μM
    Compound: Doxorubicin
    Cytotoxicity against human PC3 cells assessed as growth inhibition after 72 hrs by Alamar blue assay
    Cytotoxicity against human PC3 cells assessed as growth inhibition after 72 hrs by Alamar blue assay
    		[PMID: 26904921]
    PC-3 IC50
    0.36 μM
    Compound: doxorubicin
    Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay
    Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay
    		[PMID: 27214307]
    PC-3 IC50
    0.3 μg/mL
    Compound: Adriamycin
    Inhibitory concentration required against PC-3 prostate cancer cell line
    Inhibitory concentration required against PC-3 prostate cancer cell line
    		[PMID: 11354370]
    PC-3 IC50
    0.4 μM
    Compound: Doxorubicin
    Cytotoxicity against human PC3 cells assessed as cell growth inhibition after 48 hrs by SRB assay
    Cytotoxicity against human PC3 cells assessed as cell growth inhibition after 48 hrs by SRB assay
    		[PMID: 28641156]
    PC-3 IC50
    0.41 μM
    Compound: Doxorubicin
    Cytotoxicity against human PC3 cells by colorimetric method
    Cytotoxicity against human PC3 cells by colorimetric method
    		[PMID: 24387625]
    PC-3 IC50
    0.44 μM
    Compound: Doxorubicin
    Cytotoxicity against human PC3 cells assessed as cell viability after 72 hrs by MTT assay
    Cytotoxicity against human PC3 cells assessed as cell viability after 72 hrs by MTT assay
    		[PMID: 24530030]
    PC-3 IC50
    0.442 μM
    Compound: Dox
    Cytotoxicity against human PC3 cells assessed as decrease in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human PC3 cells assessed as decrease in cell viability after 72 hrs by MTT assay
    		[PMID: 30108718]
    PC-3 IC50
    0.45 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human PC3 cells after 72 hrs by MTT assay
    Cytotoxicity against human PC3 cells after 72 hrs by MTT assay
    		[PMID: 18586355]
    PC-3 IC50
    0.467 μg/mL
    Compound: Doxorubicin
    Anticancer activity against human PC-3 cells assessed as reduction in cell viability
    Anticancer activity against human PC-3 cells assessed as reduction in cell viability
    		[PMID: 35694689]
    PC-3 IC50
    0.4 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human PC3 cells assessed as reduction in cell viability after 48 hrs by SRB assay
    Cytotoxicity against human PC3 cells assessed as reduction in cell viability after 48 hrs by SRB assay
    		[PMID: 30660827]
    PC-3 IC50
    0.5 μM
    Compound: ADR
    Cytotoxicity against human PC3 cells by sulforhodamine B assay
    Cytotoxicity against human PC3 cells by sulforhodamine B assay
    		[PMID: 17822905]
    PC-3 IC50
    0.5 μM
    Compound: ADR
    Cytotoxicity against human PC3 cells by SRB assay
    Cytotoxicity against human PC3 cells by SRB assay
    		[PMID: 18656370]
    PC-3 IC50
    0.5 μM
    Compound: Doxorubicin
    Cytotoxicity against human PC3 cells after 96 hrs by MTT assay
    Cytotoxicity against human PC3 cells after 96 hrs by MTT assay
    		[PMID: 24852278]
    PC-3 IC50
    0.5 μM
    Compound: Doxorubicin
    Antiproliferative activity against human PC3 cells measured after 48 hrs by MTT assay
    Antiproliferative activity against human PC3 cells measured after 48 hrs by MTT assay
    		[PMID: 31148449]
    PC-3 IC50
    0.539 μM
    Compound: DOX
    Cytotoxicity against human PC-3 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay
    Cytotoxicity against human PC-3 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay
    		[PMID: 34700239]
    PC-3 IC50
    0.54 μM
    Compound: Doxorubicin
    Antiproliferative activity against human PC3 cells after 72 hrs
    Antiproliferative activity against human PC3 cells after 72 hrs
    		[PMID: 25127463]
    PC-3 IC50
    0.567 μM
    Compound: DOX
    Cytotoxicity against human PC-3 cells incubated for 48 hrs by MTT assay
    Cytotoxicity against human PC-3 cells incubated for 48 hrs by MTT assay
    		[PMID: 38185054]
    PC-3 IC50
    0.59 μM
    Compound: Doxorubicin
    Cytotoxicity against human PC3 cells assessed as growth inhibition measured after 72 hrs by MTT assay
    Cytotoxicity against human PC3 cells assessed as growth inhibition measured after 72 hrs by MTT assay
    		[PMID: 31383628]
    PC-3 IC50
    0.6 μM
    Compound: ADM
    Cytotoxicity against human PC3 cells after 72 hrs by MTT assay
    Cytotoxicity against human PC3 cells after 72 hrs by MTT assay
    		[PMID: 25874331]
    PC-3 IC50
    0.6 μM
    Compound: ADM
    Cytotoxicity against human PC3 cells after 72 hrs by MTT assay
    Cytotoxicity against human PC3 cells after 72 hrs by MTT assay
    		[PMID: 26280921]
    PC-3 IC50
    0.6 μM
    Compound: Dox
    Cytotoxicity against human PC3 cells assessed as growth inhibition after 24 hrs by MTT assay
    Cytotoxicity against human PC3 cells assessed as growth inhibition after 24 hrs by MTT assay
    		[PMID: 24507927]
    PC-3 IC50
    0.6 μM
    Compound: Doxorubicin
    Cytotoxicity against human PC3 cells after 48 hrs by MTT assay
    Cytotoxicity against human PC3 cells after 48 hrs by MTT assay
    		[PMID: 20846862]
    PC-3 IC50
    0.6 μM
    Compound: Doxorubicin
    Cytotoxicity against human PC3 cells assessed as growth inhibition after 24 hrs by MTT assay
    Cytotoxicity against human PC3 cells assessed as growth inhibition after 24 hrs by MTT assay
    		[PMID: 24780595]
    PC-3 IC50
    0.6 μM
    Compound: Doxorubicin
    Cytotoxicity against human PC3 cells assessed as cell growth inhibition after 48 hrs by MTT assay
    Cytotoxicity against human PC3 cells assessed as cell growth inhibition after 48 hrs by MTT assay
    		[PMID: 27371926]
    PC-3 IC50
    0.6 μM
    Compound: Doxorubicin
    Cytotoxicity against human PC-3 cells assessed as reduction in cell viability measured for 48 hrs by resazurin dye based assay
    Cytotoxicity against human PC-3 cells assessed as reduction in cell viability measured for 48 hrs by resazurin dye based assay
    		[PMID: 36795859]
    PC-3 IC50
    0.6 μM
    Compound: Doxorubicin
    Cytotoxicity against human hormone nonresponsive PC-3 cells assessed as reduction in cell proliferation by MTT assay
    Cytotoxicity against human hormone nonresponsive PC-3 cells assessed as reduction in cell proliferation by MTT assay
    		[PMID: 38414352]
    PC-3 IC50
    0.63 μM
    Compound: DOX
    Cytotoxicity against human PC3 cells after 48 hrs by sulforhodamine B assay
    Cytotoxicity against human PC3 cells after 48 hrs by sulforhodamine B assay
    		[PMID: 23810282]
    PC-3 IC50
    0.63 μM
    Compound: Doxorubicin
    Antiproliferative activity against human PC3 cells assessed as cell viability incubated for 72 hrs by MTT assay
    Antiproliferative activity against human PC3 cells assessed as cell viability incubated for 72 hrs by MTT assay
    		[PMID: 25799376]
    PC-3 IC50
    0.64 μM
    Compound: Dox
    Cytotoxicity against human PC3 cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay
    Cytotoxicity against human PC3 cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay
    		[PMID: 33713977]
    PC-3 IC50
    0.64 μM
    Compound: Dox
    Cytotoxicity against human PC-3 cells by MTT assay
    Cytotoxicity against human PC-3 cells by MTT assay
    		[PMID: 36057236]
    PC-3 IC50
    0.64 μM
    Compound: Dox
    Cytotoxicity against human PC-3 cells assessed as inhibition of cell growth by MTT assay
    Cytotoxicity against human PC-3 cells assessed as inhibition of cell growth by MTT assay
    		[PMID: 36336315]
    PC-3 IC50
    0.68 μM
    Compound: Adriamycin
    Cytotoxicity against human PC3 cells by MTT assay
    Cytotoxicity against human PC3 cells by MTT assay
    		[PMID: 23434227]
    PC-3 IC50
    0.75 μM
    Compound: Dox
    Cytotoxicity against human PC3 cells after 24 hrs by MTT assay
    Cytotoxicity against human PC3 cells after 24 hrs by MTT assay
    		[PMID: 23802716]
    PC-3 IC50
    0.76 μM
    Compound: DOX
    Cytotoxicity against human PC3 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human PC3 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 29660689]
    PC-3 IC50
    0.76 μM
    Compound: Dox
    Cytotoxicity against human PC-3 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human PC-3 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 33479619]
    PC-3 IC50
    0.76 μM
    Compound: Doxorubicin
    Cytotoxicity against human PC-3 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    Cytotoxicity against human PC-3 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    		[PMID: 34778772]
    PC-3 IC50
    0.77 μM
    Compound: Doxorubicin
    Cytotoxicity against human PC-3 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay
    Cytotoxicity against human PC-3 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay
    		[PMID: 32736078]
    PC-3 IC50
    0.8 μM
    Compound: Dox
    Cytotoxicity against human PC3 cells after 72 hrs by sulforhodamine B assay
    Cytotoxicity against human PC3 cells after 72 hrs by sulforhodamine B assay
    		[PMID: 30132670]
    PC-3 IC50
    0.82 μM
    Compound: Doxorubicin
    Cytotoxicity against human PC3 cells assessed as reduction in cell viability by MTT assay
    Cytotoxicity against human PC3 cells assessed as reduction in cell viability by MTT assay
    		[PMID: 31404864]
    PC-3 IC50
    0.87 μM
    Compound: AMD
    Cytotoxicity against human PC3 cells after 48 hrs by MTT assay
    Cytotoxicity against human PC3 cells after 48 hrs by MTT assay
    		[PMID: 26900656]
    PC-3 IC50
    0.9 μM
    Compound: Doxorubicin
    Cytotoxicity against human PC3 cells after 3 days by MTT assay
    Cytotoxicity against human PC3 cells after 3 days by MTT assay
    		[PMID: 26711890]
    PC-3 IC50
    0.912 μM
    Compound: Doxorubicin
    Cytotoxicity against human PC3 cells after 72 hrs by MTT assay
    Cytotoxicity against human PC3 cells after 72 hrs by MTT assay
    		[PMID: 24844756]
    PC-3 IC50
    0.912 μM
    Compound: Doxorubicin
    Anticancer activity against human PC-3 cells
    Anticancer activity against human PC-3 cells
    		[PMID: 31926469]
    PC-3 IC50
    0.912 μM
    Compound: SD-1
    Cytotoxic activity against human PC3 cells after 48 hrs by MTT assay
    Cytotoxic activity against human PC3 cells after 48 hrs by MTT assay
    		[PMID: 25245672]
    PC-3 IC50
    0.912 μM
    Compound: doxorubicin
    Cytotoxicity against human PC3 cells after 72 hrs by MTT assay
    Cytotoxicity against human PC3 cells after 72 hrs by MTT assay
    		[PMID: 20356064]
    PC-3 IC50
    0.93 μM
    Compound: DOX
    Antiproliferative activity against human PC-3 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Antiproliferative activity against human PC-3 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    		[PMID: 32996316]
    PC-3 IC50
    1 μM
    Compound: DOX, Doxorubicin
    Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay
    Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay
    		[PMID: 24095089]
    PC-3 IC50
    1.01 μM
    Compound: ADM
    Cytotoxicity against human PC3 cells after 72 hrs by MTT assay
    Cytotoxicity against human PC3 cells after 72 hrs by MTT assay
    		10.1007/s00044-013-0854-3
    PC-3 IC50
    1.03 μM
    Compound: DXR
    Anticancer activity against human PC3 cells after 24 hrs by MTT assay
    Anticancer activity against human PC3 cells after 24 hrs by MTT assay
    		[PMID: 21600678]
    PC-3 IC50
    1.05 μM
    Compound: DXR
    Cytotoxicity against human androgen-independent PC3 cells by MTT assay
    Cytotoxicity against human androgen-independent PC3 cells by MTT assay
    		[PMID: 22326399]
    PC-3 IC50
    1.07 μM
    Compound: doxo
    Antiproliferative activity against human PC3 cells assessed as decrease in cell viability measured after 72 hrs by MTT assay
    Antiproliferative activity against human PC3 cells assessed as decrease in cell viability measured after 72 hrs by MTT assay
    		[PMID: 30763817]
    PC-3 IC50
    1.1 x 10-2 μg/mL
    Compound: Adriamycin
    Cytotoxicity against human PC3 cells by MTT assay
    Cytotoxicity against human PC3 cells by MTT assay
    		[PMID: 9644064]
    PC-3 IC50
    1.145 μM
    Compound: 1
    Cytotoxicity in human PC-3 cells assessed as reduction in cell viability incubated for 2 hrs by Cell-titer-blue assay
    Cytotoxicity in human PC-3 cells assessed as reduction in cell viability incubated for 2 hrs by Cell-titer-blue assay
    		[PMID: 33064004]
    PC-3 IC50
    1.22 μM
    Compound: Doxo
    Cytotoxicity against androgen receptor-negative human PC3 cells after 48 hrs by MTT assay
    Cytotoxicity against androgen receptor-negative human PC3 cells after 48 hrs by MTT assay
    		[PMID: 21885273]
    PC-3 IC50
    1.24 μM
    Compound: Doxorubicin
    Cytotoxicity against human PC-3 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    Cytotoxicity against human PC-3 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    		[PMID: 35339645]
    PC-3 IC50
    1.32 μM
    Compound: Doxorubicin
    Cytotoxicity against human PC3 cells after 72 hrs by MTT assay
    Cytotoxicity against human PC3 cells after 72 hrs by MTT assay
    		[PMID: 19406535]
    PC-3 IC50
    1.4 μM
    Compound: ADM
    Antiproliferative against human PC3 cells assessed as growth inhibition after 72 hrs by MTT assay
    Antiproliferative against human PC3 cells assessed as growth inhibition after 72 hrs by MTT assay
    		10.1039/C1MD00038A
    PC-3 IC50
    1.4 μM
    Compound: Doxorubicin
    Cytotoxicity against human PC3 cells assessed as decrease in cell viability after 24 hrs by MTT assay
    Cytotoxicity against human PC3 cells assessed as decrease in cell viability after 24 hrs by MTT assay
    		[PMID: 27496212]
    PC-3 IC50
    1.4 μM
    Compound: Doxorubicin
    Cytotoxicity against human PC-3 cells assessed as number of viable cells measured after 48 hrs by MTT based colorimetric assay
    Cytotoxicity against human PC-3 cells assessed as number of viable cells measured after 48 hrs by MTT based colorimetric assay
    		[PMID: 36970146]
    PC-3 IC50
    1.43 μM
    Compound: Doxorubicin
    Antiproliferative activity against human PC3 cells assessed as reduction in cell viability after 24 hrs by MTT assay
    Antiproliferative activity against human PC3 cells assessed as reduction in cell viability after 24 hrs by MTT assay
    		[PMID: 31546197]
    PC-3 IC50
    1.43 μM
    Compound: Doxorubicin
    Antiproliferative activity against human PC-3 cells
    Antiproliferative activity against human PC-3 cells
    		[PMID: 31945642]
    PC-3 IC50
    1.49 μM
    Compound: AMD
    Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay
    Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay
    		[PMID: 26807545]
    PC-3 IC50
    1.63 μM
    Compound: DOXO
    Cytotoxicity against human PC3 cells assessed as cell viability after 48 hrs by alamar blue assay
    Cytotoxicity against human PC3 cells assessed as cell viability after 48 hrs by alamar blue assay
    		[PMID: 21797280]
    PC-3 IC50
    1.63 μM
    Compound: Doxorubicin
    Cytotoxicity against human PC3 cells after 48 hrs by Alamar blue assay
    Cytotoxicity against human PC3 cells after 48 hrs by Alamar blue assay
    		[PMID: 20931970]
    PC-3 IC50
    1.66 μM
    Compound: Doxorubicin
    Cytotoxicity against human PC-3 cells treated for 72 hrs by MTT assay
    Cytotoxicity against human PC-3 cells treated for 72 hrs by MTT assay
    		[PMID: 35344904]
    PC-3 IC50
    1.69 μM
    Compound: Doxorubicin
    Cytotoxicity against human PC3 cells assessed as growth inhibition after 48 hrs by MTT assay
    Cytotoxicity against human PC3 cells assessed as growth inhibition after 48 hrs by MTT assay
    		[PMID: 26381063]
    PC-3 IC50
    1.7 μM
    Compound: DOX
    Antiproliferative activity against human PC3 cells assessed as growth inhibition after 48 hrs by MTT assay
    Antiproliferative activity against human PC3 cells assessed as growth inhibition after 48 hrs by MTT assay
    		[PMID: 22044164]
    PC-3 IC50
    1.76 μM
    Compound: DOX
    Antiproliferative activity against human PC3 cells by MTT assay
    Antiproliferative activity against human PC3 cells by MTT assay
    		[PMID: 20171108]
    PC-3 IC50
    10.2 μM
    Compound: Doxorubicin
    Cytotoxicity against human PC3 cells after 48 hrs by MTT assay
    Cytotoxicity against human PC3 cells after 48 hrs by MTT assay
    		[PMID: 29573910]
    PC-3 IC50
    102.8 nM
    Compound: Doxorubicin
    In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line PC3
    In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line PC3
    		[PMID: 10479282]
    PC-3 IC50
    114 nM
    Compound: doxorubicin
    Cytotoxicity against human PC3 cells assessed as viability after 96 hrs
    Cytotoxicity against human PC3 cells assessed as viability after 96 hrs
    		[PMID: 24900437]
    PC-3 IC50
    124 μM
    Compound: Doxorubicin
    Cytotoxicity against human PC3 cells after 48 hrs by MTT assay
    Cytotoxicity against human PC3 cells after 48 hrs by MTT assay
    		[PMID: 21429743]
    PC-3 IC50
    15.82 μM
    Compound: Doxorubicin
    Anticancer activity against human PC-3 cells assessed as cell growth inhibition
    Anticancer activity against human PC-3 cells assessed as cell growth inhibition
    		[PMID: 32771798]
    PC-3 IC50
    16.86 μM
    Compound: Doxorubicin
    Cytotoxicity against human PC-3 cells assessed as inhibition of cell growth after 48 hrs by SRB assay
    Cytotoxicity against human PC-3 cells assessed as inhibition of cell growth after 48 hrs by SRB assay
    		[PMID: 34077833]
    PC-3 IC50
    17 μM
    Compound: Doxo
    Cytotoxicity against human PC3 cells after 48 hrs by alamar blue assay
    Cytotoxicity against human PC3 cells after 48 hrs by alamar blue assay
    		[PMID: 25468043]
    PC-3 IC50
    17.5 μM
    Compound: Doxorubicin
    Cytotoxicity against human PC-3 cells assessed as cell death measured by MTT assay
    Cytotoxicity against human PC-3 cells assessed as cell death measured by MTT assay
    		[PMID: 39137365]
    PC-3 IC50
    186 nM
    Compound: Doxorubicine
    Cytotoxicity against human PC3 cells after 72 hrs by MTS assay
    Cytotoxicity against human PC3 cells after 72 hrs by MTS assay
    		[PMID: 21142180]
    PC-3 IC50
    19.51 μM
    Compound: Adriamycin
    Cytotoxicity against human PC3 cells after 24 hrs by MTT assay
    Cytotoxicity against human PC3 cells after 24 hrs by MTT assay
    		[PMID: 22276650]
    PC-3 IC50
    2 μM
    Compound: doxorubicin
    Cytotoxicity against human PC3 cells by MTT method
    Cytotoxicity against human PC3 cells by MTT method
    		[PMID: 26287401]
    PC-3 IC50
    2.1 μM
    Compound: Dox
    Cytotoxicity against human PC3 cells assessed as inhibition of cell viability after 48 hrs by MTT assay
    Cytotoxicity against human PC3 cells assessed as inhibition of cell viability after 48 hrs by MTT assay
    		[PMID: 27055942]
    PC-3 IC50
    2.26 μM
    Compound: ADR
    Cytotoxicity against human PC3 cells
    Cytotoxicity against human PC3 cells
    		[PMID: 17723301]
    PC-3 IC50
    2.31 μM
    Compound: Doxorubicin
    Cytotoxicity against human PC-3 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
    Cytotoxicity against human PC-3 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
    		[PMID: 39026656]
    PC-3 IC50
    2.3 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human PC3 cells after 48 hrs by MTT assay
    Cytotoxicity against human PC3 cells after 48 hrs by MTT assay
    		[PMID: 21708464]
    PC-3 IC50
    2.51 μM
    Compound: Dox
    Anticancer activity against human PC3 cells after 48 hrs by MTT assay
    Anticancer activity against human PC3 cells after 48 hrs by MTT assay
    		[PMID: 22209733]
    PC-3 IC50
    2.6 μM
    Compound: Dox
    Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay
    Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay
    		[PMID: 29249562]
    PC-3 IC50
    2.6 μM
    Compound: Doxorubicin
    Antiproliferative activity against human PC-3 cells incubated for 48 hrs by MTT assay
    Antiproliferative activity against human PC-3 cells incubated for 48 hrs by MTT assay
    		[PMID: 38442524]
    PC-3 IC50
    2.63 μM
    Compound: Doxorubicin
    Cytotoxicity against human PC3 cells after 48 hrs by MTT assay
    Cytotoxicity against human PC3 cells after 48 hrs by MTT assay
    		[PMID: 28390228]
    PC-3 IC50
    275 ng/mL
    Compound: ADR
    Cytotoxicity against human cancer cell lines PC-3 of lung
    Cytotoxicity against human cancer cell lines PC-3 of lung
    		[PMID: 11311062]
    PC-3 IC50
    3 μM
    Compound: Doxorubicin
    Cytotoxicity against human PC-3 cells assessed as reduction in cell viability by DAPI staining based assay
    Cytotoxicity against human PC-3 cells assessed as reduction in cell viability by DAPI staining based assay
    		[PMID: 33461146]
    PC-3 IC50
    3.16 μM
    Compound: doxorubicin
    Cytotoxicity against human PC3 cells after 48 hrs by MTT assay
    Cytotoxicity against human PC3 cells after 48 hrs by MTT assay
    		[PMID: 20405844]
    PC-3 IC50
    3.18 μM
    Compound: Doxorubicin
    Cytotoxic activity against human PC3 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Cytotoxic activity against human PC3 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    		[PMID: 25966052]
    PC-3 IC50
    3.3 μM
    Compound: ADM
    Cytotoxicity against human PC3 cells after 72 hrs by MTT assay
    Cytotoxicity against human PC3 cells after 72 hrs by MTT assay
    		[PMID: 20817326]
    PC-3 IC50
    3.86 μM
    Compound: Doxorubicin
    Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay
    Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay
    		[PMID: 31200236]
    PC-3 IC50
    32 μM
    Compound: Doxorubicine
    Inhibitory activity against PC-3 prostate cell line using sulforhodamine B (SRB) protein assay
    Inhibitory activity against PC-3 prostate cell line using sulforhodamine B (SRB) protein assay
    		[PMID: 12039588]
    PC-3 IC50
    38.02 μM
    Compound: Doxorubicin
    Antiproliferative activity against human PC3 cells assessed as inhibition of cell growth after 72 hrs by MTT assay
    Antiproliferative activity against human PC3 cells assessed as inhibition of cell growth after 72 hrs by MTT assay
    		[PMID: 32311607]
    PC-3 IC50
    390 nM
    Compound: ADR
    Antiproliferative activity measured against PC-3 human prostate adenocarcinoma
    Antiproliferative activity measured against PC-3 human prostate adenocarcinoma
    		[PMID: 9876111]
    PC-3 IC50
    4.1 μM
    Compound: Doxo
    Cytotoxicity against androgen receptor-negative human PC3 cells after 24 hrs by MTT assay
    Cytotoxicity against androgen receptor-negative human PC3 cells after 24 hrs by MTT assay
    		[PMID: 21885273]
    PC-3 IC50
    49.8 nM
    Compound: Doxorubicin
    Cytotoxicity against prostate cancer cell lines PC-3 was determined
    Cytotoxicity against prostate cancer cell lines PC-3 was determined
    		[PMID: 12392727]
    PC-3 IC50
    5.05 μM
    Compound: Doxorubicin
    Antiproliferative activity against human PC3 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Antiproliferative activity against human PC3 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    		[PMID: 31883489]
    PC-3 IC50
    5.9 μM
    Compound: Doxorubicin
    Anticancer activity against human PC3 cells after 48 hrs by MTT assay
    Anticancer activity against human PC3 cells after 48 hrs by MTT assay
    		[PMID: 22668451]
    PC-3 IC50
    6 μM
    Compound: Adriamycin
    Antiproliferative activity against human PC3 cells after 48 hrs by sulforhodamine B assay
    Antiproliferative activity against human PC3 cells after 48 hrs by sulforhodamine B assay
    		[PMID: 23501113]
    PC-3 IC50
    6 μM
    Compound: Adriamycin
    Cytotoxicity against human PC3 cells after 48 hrs by sulforhodamine B assay
    Cytotoxicity against human PC3 cells after 48 hrs by sulforhodamine B assay
    		[PMID: 24910974]
    PC-3 IC50
    6 μM
    Compound: Adriamycin
    Cytotoxicity against human PC3 cells assessed as growth inhibition after 48 hrs by sulphorhodamine B assay
    Cytotoxicity against human PC3 cells assessed as growth inhibition after 48 hrs by sulphorhodamine B assay
    		[PMID: 26222449]
    PC-3 IC50
    60 nM
    Compound: Adriamycin
    Cytotoxicity against human PC3 cells after 48 hrs by SRB assay
    Cytotoxicity against human PC3 cells after 48 hrs by SRB assay
    		[PMID: 22858298]
    PC-3 IC50
    62.26 μM
    Compound: Doxorubicin
    Cytotoxicity against human PC3 cells
    Cytotoxicity against human PC3 cells
    		[PMID: 22123320]
    PC-3 IC50
    7.65 μM
    Compound: Doxorubicin
    Cytotoxicity against human PC3 cells after 48 hrs by MTT assay in absence of 10% FBS
    Cytotoxicity against human PC3 cells after 48 hrs by MTT assay in absence of 10% FBS
    		[PMID: 26298501]
    PC-3 IC50
    8.46 μM
    Compound: Doxorubicin
    Cytotoxicity against human PC3 cells after 24 hrs by MTT assay
    Cytotoxicity against human PC3 cells after 24 hrs by MTT assay
    		[PMID: 22687747]
    PC-3 IC50
    8.54 μM
    Compound: DOX
    Antiproliferative activity against human PC-3 cells after 72 hrs by MTT assay
    Antiproliferative activity against human PC-3 cells after 72 hrs by MTT assay
    		[PMID: 35964425]
    PC-3 IC50
    8.83 μM
    Compound: Doxorubicin
    Cytotoxicity against human PC3 cells after 48 hrs by SRB assay
    Cytotoxicity against human PC3 cells after 48 hrs by SRB assay
    		[PMID: 23994327]
    PC-3 IC50
    8.87 μM
    Compound: DOX
    Cytotoxicity against human PC3 cells after 24 hrs by MTT assay
    Cytotoxicity against human PC3 cells after 24 hrs by MTT assay
    		[PMID: 30015070]
    PC-3 IC50
    8.87 μM
    Compound: DOX
    Anticancer activity against human PC3 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay
    Anticancer activity against human PC3 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay
    		[PMID: 32085964]
    PC-3 IC50
    8.87 μM
    Compound: DOX
    Antiproliferative activity against human PC3 cells assessed as reduction in cell growth
    Antiproliferative activity against human PC3 cells assessed as reduction in cell growth
    		[PMID: 33388654]
    PC-3 IC50
    8.87 μM
    Compound: DOX
    Cytotoxicity against human PC-3 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay
    Cytotoxicity against human PC-3 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay
    		[PMID: 36242988]
    PC-3 IC50
    8.87 μM
    Compound: DOX
    Antiproliferative activity against human PC-3 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay
    Antiproliferative activity against human PC-3 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay
    		[PMID: 37054758]
    PC-3 IC50
    8.87 μM
    Compound: DOX
    Cytotoxicity against human PC-3 cells under hypoxia condition by MTT assay
    Cytotoxicity against human PC-3 cells under hypoxia condition by MTT assay
    		[PMID: 38642371]
    PC-3 IC50
    8.87 μM
    Compound: Dox
    Antiproliferative activity against human PC-3 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Antiproliferative activity against human PC-3 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    		[PMID: 34126285]
    PC-3 IC50
    8.87 μM
    Compound: Doxorubicin
    Antiproliferative activity against human PC3 after 24 hrs by MTT assay
    Antiproliferative activity against human PC3 after 24 hrs by MTT assay
    		[PMID: 30826188]
    PC-3 IC50
    8.87 μg/mL
    Compound: Doxorubicin
    Antiproliferative activity against human PC-3 cells assessed as reduction in cell growth measured after 24 hrs by MTT assay
    Antiproliferative activity against human PC-3 cells assessed as reduction in cell growth measured after 24 hrs by MTT assay
    		[PMID: 37453330]
    PC-3 IC50
    84.23 μM
    Compound: Doxorubicin
    Cytotoxicity against human PC-3 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
    Cytotoxicity against human PC-3 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
    		[PMID: 33340938]
    PC-3 IC50
    89.9 μM
    Compound: Dox
    Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay
    Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay
    		[PMID: 26494582]
    PC-3 IC50
    9.5 μM
    Compound: Doxorubicin
    Cytotoxicity against human PC3 cells after 48 hrs by MTT assay
    Cytotoxicity against human PC3 cells after 48 hrs by MTT assay
    		[PMID: 27173802]
    PC-3 IC50
    9.58 μM
    Compound: Doxorubicin
    Growth inhibition of human PC3 cells after 48 hrs by MTT assay
    Growth inhibition of human PC3 cells after 48 hrs by MTT assay
    		[PMID: 30072225]
    PC-3 IC50
    9.8 μM
    Compound: Doxorubicin
    Cytotoxicity against human PC3 cells after 48 hrs by MTT assay in presence of 10% FBS
    Cytotoxicity against human PC3 cells after 48 hrs by MTT assay in presence of 10% FBS
    		[PMID: 26298501]
    PC-3 IC50
    95.61 μM
    Compound: DOX
    Cytotoxicity against human PC3 cells assessed as growth inhibition after 48 hrs by MTT assay
    Cytotoxicity against human PC3 cells assessed as growth inhibition after 48 hrs by MTT assay
    		[PMID: 24148837]
    PC-3 IC50
    95.61 μM
    Compound: DOX
    Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay
    Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay
    		[PMID: 25619894]
    PC-3 IC50
    95.61 μM
    Compound: DOX
    Antiproliferative activity against human PC3 cells assessed as inhibition of cell growth after 48 hrs by MTT assay
    Antiproliferative activity against human PC3 cells assessed as inhibition of cell growth after 48 hrs by MTT assay
    		[PMID: 25737400]
    PC-3 IC50
    95.61 μM
    Compound: Doxorubicin
    Cytotoxicity against human PC3 cells expressing estrogen receptor after 48 hrs by MTT assay
    Cytotoxicity against human PC3 cells expressing estrogen receptor after 48 hrs by MTT assay
    		10.1039/C2MD20327H
    PC-3 IC50
    95.61 μM
    Compound: Doxorubicin
    Cytotoxicity against AR-negative human PC3 cells after 1 hr by SRB assay
    Cytotoxicity against AR-negative human PC3 cells after 1 hr by SRB assay
    		[PMID: 22770744]
    PC-3 IC50
    95.61 μM
    Compound: Doxorubicin
    Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay
    Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay
    		[PMID: 30108986]
    PC-3 IC50
    > 32 nM
    Compound: Dox
    Cytotoxicity against PSMA-negative human PC3 cells by cellTiter 96 aqueous cell proliferation assay
    Cytotoxicity against PSMA-negative human PC3 cells by cellTiter 96 aqueous cell proliferation assay
    		[PMID: 30904185]
    PC-3M IC50
    0.04 μM
    Compound: DOXO
    Cytotoxicity against human PC3M cells assessed as cell viability after 72 hrs by MTT assay
    Cytotoxicity against human PC3M cells assessed as cell viability after 72 hrs by MTT assay
    		[PMID: 26142490]
    PC-3M IC50
    0.2 μM
    Compound: Doxorubicin
    Cytotoxicity against human PC3M cells by resazurin dye based Alamar blue assay
    Cytotoxicity against human PC3M cells by resazurin dye based Alamar blue assay
    		[PMID: 29373790]
    PC-3M IC50
    0.24 μM
    Compound: Doxorubicin
    Cytotoxicity against human PC3M cells after 72 hrs by resazurin/AlamarBlue dye-based fluorescence assay
    Cytotoxicity against human PC3M cells after 72 hrs by resazurin/AlamarBlue dye-based fluorescence assay
    		[PMID: 28139929]
    PC-3M IC50
    0.24 μM
    Compound: doxorubicin
    Cytotoxicity against human PC3M cells after 72 hrs by Alamar blue assay
    Cytotoxicity against human PC3M cells after 72 hrs by Alamar blue assay
    		[PMID: 22264149]
    PC-3M IC50
    0.25 μM
    Compound: Doxorubicin
    Cytotoxicity against human PC3M cells after 72 hrs by resazurin-based colorimetric assay
    Cytotoxicity against human PC3M cells after 72 hrs by resazurin-based colorimetric assay
    		[PMID: 27071003]
    PC-3M IC50
    0.27 μM
    Compound: doxorubicin
    Cytotoxicity against human PC3M cells after 72 hrs by Alamar Blue assay
    Cytotoxicity against human PC3M cells after 72 hrs by Alamar Blue assay
    		[PMID: 24251417]
    PC-3M IC50
    0.3 μM
    Compound: Doxorubicin
    Cytotoxicity against human PC3M cells after 72 hrs by Alamar blue assay
    Cytotoxicity against human PC3M cells after 72 hrs by Alamar blue assay
    		[PMID: 21999655]
    PC-3M IC50
    0.3 μM
    Compound: Doxorubicin
    Cytotoxicity against human PC-3M cells assessed as inhibition of cell proliferation measured after 72 hrs by resazurin dye based AlamarBlue assay
    Cytotoxicity against human PC-3M cells assessed as inhibition of cell proliferation measured after 72 hrs by resazurin dye based AlamarBlue assay
    		[PMID: 34495663]
    PC-3M IC50
    0.368 μM
    Compound: Dox
    Cytotoxicity against human PC3M cells assessed as decrease in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human PC3M cells assessed as decrease in cell viability after 72 hrs by MTT assay
    		[PMID: 30108718]
    PC-3M IC50
    0.66 μM
    Compound: Doxorubicin
    Cytotoxicity against human PC-3M cells expressing PTB/GFP fusion protein assessed as reduction in ATP level and measured after 24 to 48 hrs by ATPlite luminescence assay
    Cytotoxicity against human PC-3M cells expressing PTB/GFP fusion protein assessed as reduction in ATP level and measured after 24 to 48 hrs by ATPlite luminescence assay
    		[PMID: 35696646]
    PC-3M IC50
    0.86 μM
    Compound: Doxorubicin
    Anticancer activity in human PC-3M cells expressing PTB/GFP fusion protein assessed as perinucleolar compartment disassembly and measured after 24 hrs by Hoechst 33342 staining based microscopic method
    Anticancer activity in human PC-3M cells expressing PTB/GFP fusion protein assessed as perinucleolar compartment disassembly and measured after 24 hrs by Hoechst 33342 staining based microscopic method
    		[PMID: 35696646]
    PC-3M IC50
    1.11 μM
    Compound: doxorubicin
    Antiproliferative activity against human PC3M cells by MTT assay
    Antiproliferative activity against human PC3M cells by MTT assay
    		[PMID: 18247573]
    PC-3M IC50
    1.26 μM
    Compound: doxorubicin
    Cytotoxicity against human PC3M cells by MTT assay
    Cytotoxicity against human PC3M cells by MTT assay
    		[PMID: 18052324]
    PC-3M IC50
    < 0.001 μg/mL
    Compound: DOX
    Cytotoxicity against human PC3M cells after 72 hrs by MTT assay
    Cytotoxicity against human PC3M cells after 72 hrs by MTT assay
    		[PMID: 20722446]
    PC-9 IC50
    0.22 μM
    Compound: Doxorubicin
    Cytotoxicity against human PC-9 cells incubated for 48 hrs by MTT assay
    Cytotoxicity against human PC-9 cells incubated for 48 hrs by MTT assay
    		[PMID: 36496202]
    PLC-PRF-5 EC50
    > 10 μM
    Compound: doxorubicin
    Cytotoxicity against human PLC/PRF/5 cells expressing mutant p53 gene (codon 249) by MTT assay
    Cytotoxicity against human PLC/PRF/5 cells expressing mutant p53 gene (codon 249) by MTT assay
    		[PMID: 20455578]
    PLC-PRF-5 IC50
    1.03 μM
    Compound: Doxorubicin
    Cytotoxicity against human PLC-PRF-5 cells by SRB assay
    Cytotoxicity against human PLC-PRF-5 cells by SRB assay
    		[PMID: 34128674]
    PSN1 GI50
    0.2 μM
    Compound: Doxorubicin
    Cytotoxicity against human PSN1 cells after 48 hrs by sulforhodamine B assay
    Cytotoxicity against human PSN1 cells after 48 hrs by sulforhodamine B assay
    		[PMID: 29112820]
    Panel NCI-60 (60 carcinoma cell lines) GI50
    0.15 μM
    Compound: DOX
    Growth inhibition of human NCI60 cells
    Growth inhibition of human NCI60 cells
    		[PMID: 33068712]
    Panel NCI-60 (60 carcinoma cell lines) GI50
    97 μM
    Compound: Doxorubicin
    Growth inhibition of human Panel NCI-60 (60 carcinoma cell lines) incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human Panel NCI-60 (60 carcinoma cell lines) incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 33766762]
    Peritoneal macrophage IC50
    1.9 μM
    Compound: Doxorubicin
    Cytotoxicity against rat peritoneal macrophages assessed as reduction in cell viability after 46 hrs by MTT assay
    Cytotoxicity against rat peritoneal macrophages assessed as reduction in cell viability after 46 hrs by MTT assay
    		[PMID: 29138027]
    QG-56 IC50
    2.5 mM
    Compound: Adriamycin
    Cytotoxicity against human QG56 cells after 48 hrs by MTT assay
    Cytotoxicity against human QG56 cells after 48 hrs by MTT assay
    		[PMID: 22440624]
    QG-56 IC50
    2.5 mM
    Compound: Adriamycin
    Cytotoxicity against human QG56 cells after 24 hrs by MTT assay
    Cytotoxicity against human QG56 cells after 24 hrs by MTT assay
    		[PMID: 23685942]
    QGY-7703 IC50
    0.42 μg/mL
    Compound: Doxorubicin
    Antiproliferative activity against human QGY7703 cells
    Antiproliferative activity against human QGY7703 cells
    		[PMID: 20022253]
    QGY-7703 IC50
    1.37 μM
    Compound: DOX
    Cytotoxicity against human QGY7703 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    Cytotoxicity against human QGY7703 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    		[PMID: 30771605]
    QGY-7703 IC50
    1.44 μM
    Compound: DOX
    Cytotoxicity against human QGY7703 cells assessed as reduction in cell viability after 24 hrs by MTT assay
    Cytotoxicity against human QGY7703 cells assessed as reduction in cell viability after 24 hrs by MTT assay
    		[PMID: 29909338]
    QGY-7703 IC50
    1.9 μM
    Compound: DOX
    Cytotoxicity against human QGY-7703 cells assessed as reduction in cell viability measured after 24 hrs by CCK8 assay
    Cytotoxicity against human QGY-7703 cells assessed as reduction in cell viability measured after 24 hrs by CCK8 assay
    		[PMID: 34450496]
    RAW264.7 CC50
    0.8 μM
    Compound: Doxorubicin
    Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    		[PMID: 31800248]
    RAW264.7 IC50
    0.63 μM
    Compound: Doxorubicin
    Cytotoxic activity against mouse RAW264.7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Cytotoxic activity against mouse RAW264.7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    		[PMID: 25966052]
    RD CC50
    1.3 μM
    Compound: Dox
    Cytotoxicity against human RD cells incubated for 72 hrs by MTT assay
    Cytotoxicity against human RD cells incubated for 72 hrs by MTT assay
    		[PMID: 39079310]
    RD IC50
    0.53 μM
    Compound: Doxorubicin
    Cytotoxicity in human RD cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    Cytotoxicity in human RD cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    		[PMID: 28923382]
    RD IC50
    1.27 μM
    Compound: DOX
    Cytotoxicity against against human RD cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against against human RD cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 30340899]
    RD IC50
    170 nM
    Compound: Dox
    Antiproliferative activity against human RD cells assessed as inhibition of cell growth measured after 72 hrs by Celltiter-glo proliferation assay
    Antiproliferative activity against human RD cells assessed as inhibition of cell growth measured after 72 hrs by Celltiter-glo proliferation assay
    		[PMID: 36001933]
    RD IC50
    2 μM
    Compound: Adriamycin
    Cytotoxicity against human RD cells by neutral red method
    Cytotoxicity against human RD cells by neutral red method
    		[PMID: 26291474]
    REH IC50
    0.285 μM
    Compound: Doxorubicin
    Cytotoxicity against human REH cells assessed as reduction in cell viability after 48 hrs by Alamar Blue assay
    Cytotoxicity against human REH cells assessed as reduction in cell viability after 48 hrs by Alamar Blue assay
    		[PMID: 30774864]
    RKO IC50
    0.3 μM
    Compound: Doxorubicin
    Cytotoxicity against human RKO cells assessed as reduction in cell viability after 24 hrs by CCK8 assay
    Cytotoxicity against human RKO cells assessed as reduction in cell viability after 24 hrs by CCK8 assay
    		[PMID: 32324401]
    RKO IC50
    1.5 μM
    Compound: Dox
    Antiproliferative activity against human RKO cells assessed as reduction in cell viability by MTT assay
    Antiproliferative activity against human RKO cells assessed as reduction in cell viability by MTT assay
    		[PMID: 31765156]
    RPMI ED50
    0.02 μg/mL
    Compound: Adriamycin
    Cytotoxicity against human RPMI cells after 24 hrs by SRB assay
    Cytotoxicity against human RPMI cells after 24 hrs by SRB assay
    		[PMID: 20850305]
    RPMI-8226 GI50
    0.08 μM
    Compound: Doxorubicin
    Growth inhibition of human RPMI8226 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human RPMI8226 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28329730]
    RPMI-8226 GI50
    0.08 μM
    Compound: Doxorubicin
    Growth inhibition of human RPMI8226 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human RPMI8226 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 29102177]
    RPMI-8226 GI50
    0.08 μM
    Compound: Doxorubicin hydrochloride, NSC 123127
    Cytotoxicity against human RPMI8226 cells after 48 hrs by SRB assay
    Cytotoxicity against human RPMI8226 cells after 48 hrs by SRB assay
    		[PMID: 23871905]
    RPMI-8226 IC50
    0.033 μM
    Compound: ADR
    In vitro inhibition of tumor cell growth in the human myeloma 8226 system.
    In vitro inhibition of tumor cell growth in the human myeloma 8226 system.
    		[PMID: 1447730]
    RPMI-8226 IC50
    0.41 μM
    Compound: Doxorubicin
    Cytotoxicity against human RPMI-8226 cells
    Cytotoxicity against human RPMI-8226 cells
    		[PMID: 34655985]
    RPMI-8226 IC50
    0.56 μM
    Compound: ADR
    In vitro inhibition of tumor cell growth in the human myeloma 8226/ADR system.
    In vitro inhibition of tumor cell growth in the human myeloma 8226/ADR system.
    		[PMID: 1447730]
    RPTEC GI50
    0.072 μg/mL
    Compound: Doxorubicin
    Antitumor cytotoxic activity against RPTEC cell line was determined
    Antitumor cytotoxic activity against RPTEC cell line was determined
    		[PMID: 11551772]
    RPTEC IC50
    12.53 μM
    Compound: Dox
    Cytotoxicity against human RPTEC cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay
    Cytotoxicity against human RPTEC cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay
    		[PMID: 36395650]
    RXF 393 GI50
    0.1 μM
    Compound: Doxorubicin
    Growth inhibition of human RXF393 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human RXF393 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28329730]
    RXF 393 GI50
    0.1 μM
    Compound: Doxorubicin
    Growth inhibition of human RXF393 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human RXF393 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 29102177]
    RXF 393 GI50
    0.1 μM
    Compound: Doxorubicin hydrochloride, NSC 123127
    Cytotoxicity against human RXF393 cells after 48 hrs by SRB assay
    Cytotoxicity against human RXF393 cells after 48 hrs by SRB assay
    		[PMID: 23871905]
    RXF 944 IC50
    0.06 μM
    Compound: Adriamycin
    Tested for induction of cellular death in Human renal RXF 944L tumor cell line in Propidium Iodide Monolayer Assay
    Tested for induction of cellular death in Human renal RXF 944L tumor cell line in Propidium Iodide Monolayer Assay
    		[PMID: 12852768]
    Raji IC50
    0.03 μM
    Compound: Doxorubicin
    Antitumor activity against human Burkitt lymphoma Raji cells.
    Antitumor activity against human Burkitt lymphoma Raji cells.
    		[PMID: 12431049]
    Raji IC50
    0.03 μM
    Compound: doxorubicin
    Antitumor activity against human Burkitt lym phoma Raji cells
    Antitumor activity against human Burkitt lym phoma Raji cells
    		[PMID: 12431048]
    Raji IC50
    0.039 μM
    Compound: Doxorubicin
    Cytotoxicity against Homo sapiens (human) Raji cells after 96 hr by MTT assay
    Cytotoxicity against Homo sapiens (human) Raji cells after 96 hr by MTT assay
    		10.1007/s00044-010-9340-3
    Raji IC50
    0.1 μM
    Compound: Doxorubicin
    Compound was tested for its effect on the proliferation of RAJI burkitt lymphoma cell line.
    Compound was tested for its effect on the proliferation of RAJI burkitt lymphoma cell line.
    		10.1016/0960-894X(96)00216-8
    Raji IC50
    0.17 μM
    Compound: Doxorubicin
    Cytotoxicity against human Raji cells assessed as reduction in cell viability after 48 hrs by CCK-8 assay
    Cytotoxicity against human Raji cells assessed as reduction in cell viability after 48 hrs by CCK-8 assay
    		[PMID: 29288944]
    Raji IC50
    2 μM
    Compound: adriamycin
    Cytotoxicity against human Raji cells under deem light after 96 hrs by MTT assay
    Cytotoxicity against human Raji cells under deem light after 96 hrs by MTT assay
    		[PMID: 17993275]
    Raji IC50
    2.98 μM
    Compound: DOX
    Cytotoxicity against human Raji cells after 72 hrs by MTT assay
    Cytotoxicity against human Raji cells after 72 hrs by MTT assay
    		[PMID: 18783950]
    Raji IC50
    2.98 μM
    Compound: DOX
    Antiproliferative activity against human Raji cells after 72 hrs by MTT assay
    Antiproliferative activity against human Raji cells after 72 hrs by MTT assay
    		[PMID: 20359789]
    Raji IC50
    2.98 μM
    Compound: DOX
    Antiproliferative activity against human Raji cells after 72 hrs by MTT assay
    Antiproliferative activity against human Raji cells after 72 hrs by MTT assay
    		[PMID: 24021462]
    Raji IC50
    2.98 μM
    Compound: DOX
    Cytotoxicity against human Raji cells after 72 hrs by MTT assay
    Cytotoxicity against human Raji cells after 72 hrs by MTT assay
    		[PMID: 25259516]
    Raji IC50
    2.98 μM
    Compound: DOX
    Cytotoxicity against human Raji cells assessed as cell growth inhibition after 72 hrs by MTT assay
    Cytotoxicity against human Raji cells assessed as cell growth inhibition after 72 hrs by MTT assay
    		[PMID: 26720155]
    Raji IC50
    2.98 μM
    Compound: DOX
    Antiproliferative activity against human Raji cells after 72 hrs by MTT assay
    Antiproliferative activity against human Raji cells after 72 hrs by MTT assay
    		[PMID: 28135634]
    Raji IC50
    2.98 μM
    Compound: DOX
    Cytotoxicity against human Raji cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human Raji cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 28427016]
    Raji IC50
    2.98 μM
    Compound: DOX
    Cytotoxicity against human Raji cells assessed as inhibition of cell growth after 72 hrs by MTT assay
    Cytotoxicity against human Raji cells assessed as inhibition of cell growth after 72 hrs by MTT assay
    		[PMID: 30746062]
    Raji IC50
    2.98 μM
    Compound: DOX
    Antiproliferative activity against human Raji cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay
    Antiproliferative activity against human Raji cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay
    		[PMID: 31557614]
    Raji IC50
    2.98 μM
    Compound: DOX
    Antiproliferative activity against human Raji cells assessed as reduction in cell viability measured after 6 days by MTT assay
    Antiproliferative activity against human Raji cells assessed as reduction in cell viability measured after 6 days by MTT assay
    		[PMID: 32653698]
    Raji IC50
    2.98 μM
    Compound: DOX
    Antiproliferative activity against human Raji cells by MTT colorimetric assay
    Antiproliferative activity against human Raji cells by MTT colorimetric assay
    		[PMID: 38527380]
    Raji IC50
    2.98 μM
    Compound: DOX
    Antiproliferative activity against human Raji cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    Antiproliferative activity against human Raji cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    		[PMID: 39067378]
    Raji IC50
    2.98 μM
    Compound: Dox
    Cytotoxicity against human Raji cells assessed as cell growth inhibition after 72 hrs by MTT assay
    Cytotoxicity against human Raji cells assessed as cell growth inhibition after 72 hrs by MTT assay
    		[PMID: 27231128]
    SAOS-2 IC50
    0.144 μM
    Compound: DOX
    Cytotoxicity against human SAOS-2 cells incubated for 48 hrs by MTT assay
    Cytotoxicity against human SAOS-2 cells incubated for 48 hrs by MTT assay
    		[PMID: 38185054]
    SAOS-2 IC50
    0.33 μM
    Compound: Doxorubicin
    Antiproliferative activity against human Saos2 cells after 24 and 72 hrs by MTT assay
    Antiproliferative activity against human Saos2 cells after 24 and 72 hrs by MTT assay
    		[PMID: 24941130]
    SBC-3 IC50
    11.2 ng/mL
    Compound: ADR
    Cytotoxicity against human cancer cell lines SBC-3 of lung
    Cytotoxicity against human cancer cell lines SBC-3 of lung
    		[PMID: 11311062]
    SCC-25 IC50
    2.24 μM
    Compound: Doxorubicin
    Cytotoxicity against human SCC25 cells assessed as reduction in cell viability after 4 hrs by MTT assay
    Cytotoxicity against human SCC25 cells assessed as reduction in cell viability after 4 hrs by MTT assay
    		[PMID: 30773423]
    SCC-9 IC50
    0.39 μM
    Compound: Doxorubicin
    Cytotoxicity against human SCC-9 cells assessed as cell growth inhibition
    Cytotoxicity against human SCC-9 cells assessed as cell growth inhibition
    		[PMID: 36092140]
    SCLC IC50
    0.03 μM
    Compound: Adriamycin
    Cytotoxicity against human SCLC cells resistant to cisplatin (SCLC/CDDP)
    Cytotoxicity against human SCLC cells resistant to cisplatin (SCLC/CDDP)
    		[PMID: 8258835]
    SF-268 GI50
    0.04 μM
    Compound: Doxorubicin
    Growth inhibition of human SF268 cells
    Growth inhibition of human SF268 cells
    		[PMID: 31404864]
    SF-268 GI50
    0.09 μM
    Compound: doxorubicin
    Growth inhibition of Homo sapiens (human) SF268 cells after 48 hr by SRB assay
    Growth inhibition of Homo sapiens (human) SF268 cells after 48 hr by SRB assay
    		10.1007/s00044-012-0213-9
    SF-268 GI50
    0.093 μM
    Compound: Doxorubicin
    Cytotoxicity against human SF268 cells after 48 hrs by SRB assay
    Cytotoxicity against human SF268 cells after 48 hrs by SRB assay
    		[PMID: 15620248]
    SF-268 GI50
    0.094 μM
    Compound: Doxorubicin
    Growth inhibition of human SF268 cells after 48 hrs by sulforhodamine B assay
    Growth inhibition of human SF268 cells after 48 hrs by sulforhodamine B assay
    		[PMID: 21435889]
    SF-268 GI50
    0.1 μM
    Compound: Doxorubicin
    Growth inhibition of human SF268 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human SF268 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28329730]
    SF-268 GI50
    0.1 μM
    Compound: Doxorubicin
    Growth inhibition of human SF268 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human SF268 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 29102177]
    SF-268 GI50
    0.1 μM
    Compound: Doxorubicin hydrochloride, NSC 123127
    Cytotoxicity against human SF268 cells after 48 hrs by SRB assay
    Cytotoxicity against human SF268 cells after 48 hrs by SRB assay
    		[PMID: 23871905]
    SF-268 GI50
    0.5 μg/mL
    Compound: adriamycin
    Cytotoxicity against human SF268 cells
    Cytotoxicity against human SF268 cells
    		[PMID: 16562847]
    SF-268 GI50
    5.3 x 10-7 μg/mL
    Compound: adriamycin
    Cytotoxicity against human SF268 cells
    Cytotoxicity against human SF268 cells
    		[PMID: 12828475]
    SF-268 GI50
    8.5 x 10-7 μM
    Compound: adriamycin
    Cytotoxicity against human SF268 cells
    Cytotoxicity against human SF268 cells
    		[PMID: 14640532]
    SF-268 GI50
    8.6 x 10-7 μg/mL
    Compound: adriamycin
    Cytotoxicity against human SF268 cells
    Cytotoxicity against human SF268 cells
    		[PMID: 15043429]
    SF-268 GI50
    8.6 x 10-7 μg/mL
    Compound: adriamycin
    Cytotoxicity against human SF268 cells
    Cytotoxicity against human SF268 cells
    		[PMID: 15787438]
    SF-268 GI50
    9.3 x 10-2 μM
    Compound: doxorubicin
    Cytotoxicity against human SF268 cells by SRB assay
    Cytotoxicity against human SF268 cells by SRB assay
    		[PMID: 11678649]
    SF-268 GI50
    93 nM
    Compound: Doxorubicin
    Growth inhibition of human SF268 cells
    Growth inhibition of human SF268 cells
    		[PMID: 17614292]
    SF-268 GI50
    93 nM
    Compound: doxorubicin
    Growth inhibition of human SF268 cells after 48 hrs
    Growth inhibition of human SF268 cells after 48 hrs
    		[PMID: 17692432]
    SF-268 GI50
    93 nM
    Compound: doxorubicin
    Cytotoxicity against human SF268 cells after 48 hrs
    Cytotoxicity against human SF268 cells after 48 hrs
    		[PMID: 17964791]
    SF-268 GI50
    93 μM
    Compound: Doxorubicin
    Growth inhibition of human SF268 cells after 48 hrs by SRB assay
    Growth inhibition of human SF268 cells after 48 hrs by SRB assay
    		[PMID: 15165162]
    SF-268 GI50
    94 nM
    Compound: Doxorubicin
    Cytotoxicity against human SF268 cells after 48 hrs by SRB assay
    Cytotoxicity against human SF268 cells after 48 hrs by SRB assay
    		[PMID: 15270581]
    SF-268 GI50
    94 nM
    Compound: Doxorubicin
    Antitumor activity against human SF268 cells assessed as inhibition of growth after 48 hrs using sulforhodamine B dye
    Antitumor activity against human SF268 cells assessed as inhibition of growth after 48 hrs using sulforhodamine B dye
    		[PMID: 19428155]
    SF-268 GI50
    94 nM
    Compound: doxorubicin
    Antitumor activity against human SF268 cells after 48 hrs
    Antitumor activity against human SF268 cells after 48 hrs
    		[PMID: 18439831]
    SF-268 GI50
    94 μM
    Compound: Doxorubicin
    Growth inhibition of human SF268 cells after 48 hrs by sulforhodamine B assay
    Growth inhibition of human SF268 cells after 48 hrs by sulforhodamine B assay
    		[PMID: 21504224]
    SF-268 GI50
    5.3 x 10-7 μg/mL
    Compound: adriamycin
    Cytotoxicity against human SF-268 cells
    Cytotoxicity against human SF-268 cells
    		[PMID: 15730249]
    SF-268 IC50
    0.04 μM
    Compound: Doxorubicin
    Cytotoxicity against human SF-268 cells after 24 hrs by MTT assay
    Cytotoxicity against human SF-268 cells after 24 hrs by MTT assay
    		[PMID: 17190470]
    SF-268 IC50
    0.04 μM
    Compound: doxorubicin
    Cytotoxicity against human SF268 cells by MTT assay
    Cytotoxicity against human SF268 cells by MTT assay
    		[PMID: 15620238]
    SF-268 IC50
    0.04 μM
    Compound: doxorubicin
    Cytotoxicity against human SF268 cells
    Cytotoxicity against human SF268 cells
    		[PMID: 15921417]
    SF-268 IC50
    0.04 μM
    Compound: doxorubicin
    Cytotoxicity against human SF268 cells after 72 hrs by MTT assay
    Cytotoxicity against human SF268 cells after 72 hrs by MTT assay
    		[PMID: 17286429]
    SF-268 IC50
    0.04 μM
    Compound: doxorubicin
    Antiproliferative activity against human SF268 cells by MTT assay
    Antiproliferative activity against human SF268 cells by MTT assay
    		[PMID: 18052326]
    SF-268 IC50
    0.04 μM
    Compound: doxorubicin
    Antiproliferative activity against human SF268 cells by MTT assay
    Antiproliferative activity against human SF268 cells by MTT assay
    		[PMID: 18247573]
    SF-268 IC50
    0.04 μg/mL
    Compound: dox, doxorubicin
    Cytotoxicity against human SF268 cells
    Cytotoxicity against human SF268 cells
    		[PMID: 17618015]
    SF-268 IC50
    0.09 μM
    Compound: DOX
    Antiproliferative activity against human SF268 cells after 72 hrs by Sulforhodamine B-stain assay
    Antiproliferative activity against human SF268 cells after 72 hrs by Sulforhodamine B-stain assay
    		[PMID: 27484508]
    SF-268 IC50
    0.09 μM
    Compound: Doxorubicin
    Cytotoxicity against human SF268 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    Cytotoxicity against human SF268 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    		10.1007/s00044-013-0712-3
    SF-268 IC50
    0.09 μg/L
    Compound: Doxorubicin
    Cytotoxicity against human SF268 cells assessed as inhibition of cell viability after 72 hrs by SRB assay
    Cytotoxicity against human SF268 cells assessed as inhibition of cell viability after 72 hrs by SRB assay
    		[PMID: 26420384]
    SF-268 IC50
    0.14 μg/mL
    Compound: adriamycin
    Cytotoxicity against human SF268 cells by SRB assay
    Cytotoxicity against human SF268 cells by SRB assay
    		[PMID: 17981473]
    SF-268 IC50
    0.2 μM
    Compound: Doxorubicin
    Antiproliferative activity against human SF-268 cells after 96 hrs by MTT assay
    Antiproliferative activity against human SF-268 cells after 96 hrs by MTT assay
    		[PMID: 19053767]
    SF-268 IC50
    0.31 μM
    Compound: doxorubicin
    Cytotoxicity against human SF268 cells after 72 hrs by Alamar Blue assay
    Cytotoxicity against human SF268 cells after 72 hrs by Alamar Blue assay
    		[PMID: 24251417]
    SF-268 IC50
    0.45 μM
    Compound: Doxorubicin
    Cytotoxicity against human SF268 cells after 72 hrs by resazurin-based colorimetric assay
    Cytotoxicity against human SF268 cells after 72 hrs by resazurin-based colorimetric assay
    		[PMID: 27071003]
    SF-268 IC50
    0.45 μM
    Compound: doxorubicin
    Cytotoxicity against human SF268 cells assessed as inhibition of cell proliferation/survival after 72 hrs by resazurin dye reduction assay
    Cytotoxicity against human SF268 cells assessed as inhibition of cell proliferation/survival after 72 hrs by resazurin dye reduction assay
    		[PMID: 26305181]
    SF-268 IC50
    0.5 μM
    Compound: Doxorubicin
    Cytotoxicity against human SF-268 cells assessed as cell growth inhibition measured after 24 to 72 hrs by MTT assay
    Cytotoxicity against human SF-268 cells assessed as cell growth inhibition measured after 24 to 72 hrs by MTT assay
    		[PMID: 33586438]
    SF-268 IC50
    0.5 μM
    Compound: Doxorubicin
    Cytotoxicity against human SF-268 cells assessed as inhibition of cell proliferation measured after 72 hrs by resazurin dye based AlamarBlue assay
    Cytotoxicity against human SF-268 cells assessed as inhibition of cell proliferation measured after 72 hrs by resazurin dye based AlamarBlue assay
    		[PMID: 34495663]
    SF-268 IC50
    0.6 μM
    Compound: Doxorubicin
    Cytotoxicity against human SF268 cells after 72 hrs by Alamar blue assay
    Cytotoxicity against human SF268 cells after 72 hrs by Alamar blue assay
    		[PMID: 21999655]
    SF-268 IC50
    0.6 μM
    Compound: Doxorubicin
    Cytotoxicity against human SF268 cells by resazurin dye based Alamar blue assay
    Cytotoxicity against human SF268 cells by resazurin dye based Alamar blue assay
    		[PMID: 29373790]
    SF-268 IC50
    0.62 μM
    Compound: Doxorubicin
    Cytotoxicity against human SF268 cells after 72 hrs by resazurin/AlamarBlue dye-based fluorescence assay
    Cytotoxicity against human SF268 cells after 72 hrs by resazurin/AlamarBlue dye-based fluorescence assay
    		[PMID: 28139929]
    SF-268 IC50
    0.62 μM
    Compound: doxorubicin
    Cytotoxicity against human SF268 cells after 72 hrs by Alamar blue assay
    Cytotoxicity against human SF268 cells after 72 hrs by Alamar blue assay
    		[PMID: 22264149]
    SF-268 IC50
    1.55 μM
    Compound: adriamycin
    Cytotoxicity against human SF-268 cells by MTT assay
    Cytotoxicity against human SF-268 cells by MTT assay
    		[PMID: 17125240]
    SF-268 IC50
    2.2 x 10-7 M
    Compound: Doxorubucin
    Cytotoxicity against human SF268 cells after 72 hrs by XTT assay
    Cytotoxicity against human SF268 cells after 72 hrs by XTT assay
    		[PMID: 20538470]
    SF-295 GI50
    0.1 μM
    Compound: Doxorubicin
    Growth inhibition of human SF295 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human SF295 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28329730]
    SF-295 GI50
    0.1 μM
    Compound: Doxorubicin
    Growth inhibition of human SF295 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human SF295 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 29102177]
    SF-295 GI50
    0.1 μM
    Compound: Doxorubicin hydrochloride, NSC 123127
    Cytotoxicity against human SF295 cells after 48 hrs by SRB assay
    Cytotoxicity against human SF295 cells after 48 hrs by SRB assay
    		[PMID: 23871905]
    SF-295 IC50
    0.03 μM
    Compound: Dox
    Cytotoxicity against human SF295 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human SF295 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 31306817]
    SF-295 IC50
    0.035 μM
    Compound: Doxorubicin
    In vitro cytotoxic activity against SF-295 (CNS carcinoma) cell lines by using SRB assay
    In vitro cytotoxic activity against SF-295 (CNS carcinoma) cell lines by using SRB assay
    		[PMID: 9873661]
    SF-295 IC50
    0.04 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human SF295 cells after 72 hrs by MTT assay
    Cytotoxicity against human SF295 cells after 72 hrs by MTT assay
    		[PMID: 20537433]
    SF-295 IC50
    0.08 μM
    Compound: Dox
    Cytotoxicity against human SF295 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Cytotoxicity against human SF295 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    		[PMID: 32551011]
    SF-295 IC50
    0.23 μM
    Compound: DOX
    Antiproliferative activity against human SF295 cells after 72 hrs by Sulforhodamine B-stain assay
    Antiproliferative activity against human SF295 cells after 72 hrs by Sulforhodamine B-stain assay
    		[PMID: 27484508]
    SF-295 IC50
    0.23 μg/mL
    Compound: Dox
    Cytotoxicity against Homo sapiens (human) SF295 cells after 72 hr by MTT assay
    Cytotoxicity against Homo sapiens (human) SF295 cells after 72 hr by MTT assay
    		10.1007/s00044-011-9894-8
    SF-295 IC50
    0.25 μM
    Compound: Doxorubicin
    Cytotoxicity against human SF295 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
    Cytotoxicity against human SF295 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
    		[PMID: 31836446]
    SF-295 IC50
    0.25 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human SF295 cells after 72 hrs by MTT assay
    Cytotoxicity against human SF295 cells after 72 hrs by MTT assay
    		[PMID: 19084293]
    SF-295 IC50
    0.25 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human SF295 cells after 3 days by MTT assay
    Cytotoxicity against human SF295 cells after 3 days by MTT assay
    		[PMID: 19159272]
    SF-295 IC50
    0.25 μg/mL
    Compound: doxorubicin
    Cytotoxicity against human SF295 cells after 72 hrs by MTT assay
    Cytotoxicity against human SF295 cells after 72 hrs by MTT assay
    		[PMID: 17827021]
    SF-295 IC50
    0.37 μM
    Compound: Doxorubicin
    Cytotoxicity against human SF295 cells after 69 hrs by MTT assay
    Cytotoxicity against human SF295 cells after 69 hrs by MTT assay
    		[PMID: 19780590]
    SF-295 IC50
    0.39 μM
    Compound: Doxorubicin
    Cytotoxicity against human SF295 cells after 72 hrs by MTT assay
    Cytotoxicity against human SF295 cells after 72 hrs by MTT assay
    		[PMID: 27363939]
    SF-295 IC50
    0.399 μM
    Compound: Dox
    Cytotoxicity against human SF295 cells assessed as decrease in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human SF295 cells assessed as decrease in cell viability after 72 hrs by MTT assay
    		[PMID: 30108718]
    SF-295 IC50
    0.4 μM
    Compound: Doxorubicin
    Cytotoxicity against human SF295 cells assessed as cell viability after 72 hrs by MTT assay
    Cytotoxicity against human SF295 cells assessed as cell viability after 72 hrs by MTT assay
    		[PMID: 24530030]
    SF-295 IC50
    0.4 μM
    Compound: doxorubicin
    Cytotoxicity against human SF295 cells after 72 hrs by MTT assay
    Cytotoxicity against human SF295 cells after 72 hrs by MTT assay
    		[PMID: 21381705]
    SF-295 IC50
    0.41 μM
    Compound: DOX
    Cytotoxicity against human SF295 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human SF295 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 29660689]
    SF-295 IC50
    0.41 μM
    Compound: DOXO
    Cytotoxicity against human SF295 cells after 72 hrs by MTT assay
    Cytotoxicity against human SF295 cells after 72 hrs by MTT assay
    		[PMID: 19947600]
    SF-295 IC50
    0.41 μM
    Compound: Doxorubicin
    Cytotoxicity against human SF295 cells after 72 hrs by MTT assay
    Cytotoxicity against human SF295 cells after 72 hrs by MTT assay
    		[PMID: 21115213]
    SF-295 IC50
    0.41 μg/mL
    Compound: Doxo
    Cytotoxicity against human SF295 cells for 72 hrs by MTT assay
    Cytotoxicity against human SF295 cells for 72 hrs by MTT assay
    		[PMID: 21334795]
    SF-295 IC50
    0.42 μM
    Compound: Doxorubicin
    Cytotoxicity against SF295 cells
    Cytotoxicity against SF295 cells
    		[PMID: 17175071]
    SF-295 IC50
    0.423 μM
    Compound: Doxorubicin
    Cytotoxicity against human SF295 cells assessed as growth inhibition by MTT assay
    Cytotoxicity against human SF295 cells assessed as growth inhibition by MTT assay
    		[PMID: 24398294]
    SF-295 IC50
    0.45 μM
    Compound: DOXO
    Antiproliferative activity against human SF295 cells after 72 hrs by MTT assay
    Antiproliferative activity against human SF295 cells after 72 hrs by MTT assay
    		[PMID: 28818447]
    SF-295 IC50
    0.48 μM
    Compound: Doxorubicin
    Cytotoxicity against human SF295 cells after 72 hrs by MTT assay
    Cytotoxicity against human SF295 cells after 72 hrs by MTT assay
    		10.1039/C4MD00371C
    SF-295 IC50
    0.48 μM
    Compound: Doxorubicin
    Cytotoxicity against human SF295 cells after 72 hrs by MTT assay
    Cytotoxicity against human SF295 cells after 72 hrs by MTT assay
    		[PMID: 19406535]
    SF-295 IC50
    0.48 μM
    Compound: Doxorubicin
    Cytotoxicity against human SF295 cells after 72 hrs by MTT assay
    Cytotoxicity against human SF295 cells after 72 hrs by MTT assay
    		[PMID: 20971532]
    SF-295 IC50
    0.48 μg/mL
    Compound: Dox
    Anticancer activity against Homo sapiens (human) SF295 cells assessed as inhibition of cell survival after 72 hr by MTT assay
    Anticancer activity against Homo sapiens (human) SF295 cells assessed as inhibition of cell survival after 72 hr by MTT assay
    		10.1007/s00044-012-0236-2
    SF-295 IC50
    0.51 μM
    Compound: DOXO
    Cytotoxicity against human SF295 cells assessed as cell viability after 72 hrs by MTT assay
    Cytotoxicity against human SF295 cells assessed as cell viability after 72 hrs by MTT assay
    		[PMID: 26142490]
    SF-295 IC50
    0.51 μM
    Compound: Doxorubicin
    Cytotoxicity against human SF295 cells overexpressing NQO1 assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human SF295 cells overexpressing NQO1 assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 27341379]
    SF-295 IC50
    0.7 μM
    Compound: Doxorubicin
    Cytotoxicity against human SF295 cells by colorimetric method
    Cytotoxicity against human SF295 cells by colorimetric method
    		[PMID: 24387625]
    SF-295 IC50
    0.75 μM
    Compound: doxorubicine
    Cytotoxic activity against human SF295 cells after 69 hrs by MTT assay
    Cytotoxic activity against human SF295 cells after 69 hrs by MTT assay
    		[PMID: 19788290]
    SF-295 IC50
    4.4 μM
    Compound: Doxorubicin
    Antitumor activity against human SF295 cells after 24 to 48 hrs by MTT assay
    Antitumor activity against human SF295 cells after 24 to 48 hrs by MTT assay
    		[PMID: 21553829]
    SF-539 ED50
    0.2 μg/mL
    Compound: Adriamycin
    Cytotoxicity against human SF-539 cells
    Cytotoxicity against human SF-539 cells
    		[PMID: 10346965]
    SF-539 GI50
    0.12 μM
    Compound: Doxorubicin
    Growth inhibition of human SF539 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human SF539 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28329730]
    SF-539 GI50
    0.12 μM
    Compound: Doxorubicin
    Growth inhibition of human SF539 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human SF539 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 29102177]
    SF-539 GI50
    0.12 μM
    Compound: Doxorubicin hydrochloride, NSC 123127
    Cytotoxicity against human SF539 cells after 48 hrs by SRB assay
    Cytotoxicity against human SF539 cells after 48 hrs by SRB assay
    		[PMID: 23871905]
    SGC-7901 GI50
    0.55 μM
    Compound: Adriamycin
    Growth inhibition of human SGC7901 cells by sulforhodamine B assay
    Growth inhibition of human SGC7901 cells by sulforhodamine B assay
    		[PMID: 24650643]
    SGC-7901 GI50
    0.55 μM
    Compound: Adriamycin
    Antiproliferative activity against human SGC7901 cells assessed as growth inhibition after 72 hrs by MTT assay
    Antiproliferative activity against human SGC7901 cells assessed as growth inhibition after 72 hrs by MTT assay
    		[PMID: 24686011]
    SGC-7901 IC50
    0.011 μM
    Compound: Doxorubicin
    Cytotoxic activity against human SGC7901 cells
    Cytotoxic activity against human SGC7901 cells
    		[PMID: 24195466]
    SGC-7901 IC50
    0.13 μM
    Compound: ADR
    Antiproliferative activity against human SGC7901 cells after 72 hrs by sulforhodamine B assay
    Antiproliferative activity against human SGC7901 cells after 72 hrs by sulforhodamine B assay
    		[PMID: 30241010]
    SGC-7901 IC50
    0.2 μM
    Compound: Doxorubicin
    Cytotoxicity against human SGC7901 cells assessed as reduction in cell viability incubated for 72 hrs by MTT method
    Cytotoxicity against human SGC7901 cells assessed as reduction in cell viability incubated for 72 hrs by MTT method
    		[PMID: 25932671]
    SGC-7901 IC50
    0.72 μM
    Compound: Doxorubicin
    Anticancer activity against human SGC-7901 cells incubated for 48 hrs by MTT assay
    Anticancer activity against human SGC-7901 cells incubated for 48 hrs by MTT assay
    		[PMID: 35367708]
    SGC-7901 IC50
    0.8 μM
    Compound: AMD
    Antiproliferative activity against human SGC7901 cells after 48 hrs by MTT assay
    Antiproliferative activity against human SGC7901 cells after 48 hrs by MTT assay
    		[PMID: 26807545]
    SGC-7901 IC50
    0.87 μM
    Compound: ADM
    Antiproliferative activity against human SGC7901 cells after 48 hrs by MTT assay
    Antiproliferative activity against human SGC7901 cells after 48 hrs by MTT assay
    		[PMID: 30025345]
    SGC-7901 IC50
    0.9 μM
    Compound: Doxorubicin
    Antiproliferative activity against human SGC7901 cells after 72 hrs by MTT assay
    Antiproliferative activity against human SGC7901 cells after 72 hrs by MTT assay
    		[PMID: 19632833]
    SGC-7901 IC50
    1.2 μM
    Compound: Dox
    Cytotoxicity against human SGC7901 cells assessed as inhibition of cell growth after 48 hrs by MTT assay
    Cytotoxicity against human SGC7901 cells assessed as inhibition of cell growth after 48 hrs by MTT assay
    		[PMID: 27397495]
    SGC-7901 IC50
    1.3 x 10-2 μM
    Compound: adriamycin
    Cytotoxicity against human SGC7901 cells after 72 hrs by MTT assay
    Cytotoxicity against human SGC7901 cells after 72 hrs by MTT assay
    		[PMID: 19285863]
    SGC-7901 IC50
    1.359 μg/mL
    Compound: ADM
    Cytotoxicity against human SGC7901 cells by MTT assay
    Cytotoxicity against human SGC7901 cells by MTT assay
    		[PMID: 25862199]
    SGC-7901 IC50
    1.45 μM
    Compound: AMD
    Anticancer activity against human SGC7901 cells assessed as cell survival after 48 hrs by MTT assay
    Anticancer activity against human SGC7901 cells assessed as cell survival after 48 hrs by MTT assay
    		[PMID: 25812966]
    SGC-7901 IC50
    1.53 μM
    Compound: Doxorubicin
    Cytotoxicity against human SGC-7901 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Cytotoxicity against human SGC-7901 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    		[PMID: 32866757]
    SGC-7901 IC50
    2.59 μM
    Compound: Doxorubicin
    Antiproliferative activity against human SGC7901 cells after 24 hrs by MTT assay
    Antiproliferative activity against human SGC7901 cells after 24 hrs by MTT assay
    		10.1039/C5MD00581G
    SGC-7901 IC50
    2.9 μM
    Compound: Doxorubicin
    Cytotoxicity against human SGC7901 cells assessed as reduction in cell viability
    Cytotoxicity against human SGC7901 cells assessed as reduction in cell viability
    		[PMID: 25105722]
    SGC-7901 IC50
    3.41 μM
    Compound: AMD
    Antiproliferative activity against human SGC-7901 cells measured after 48 hrs by MTT assay
    Antiproliferative activity against human SGC-7901 cells measured after 48 hrs by MTT assay
    		[PMID: 27639364]
    SGC-7901 IC50
    3.5 μM
    Compound: ADM
    Cytotoxicity against human SGC7901 cells after 38 hrs by MTT assay
    Cytotoxicity against human SGC7901 cells after 38 hrs by MTT assay
    		[PMID: 25965778]
    SGC-7901 IC50
    36.9 μM
    Compound: 21
    Antitumor activity against human SGC-7901 cells assessed as cell growth inhibition
    Antitumor activity against human SGC-7901 cells assessed as cell growth inhibition
    		[PMID: 36858050]
    SGC-7901 IC50
    5.72 μM
    Compound: Doxorubicin
    Cytotoxicity against human SGC7901 cells after 48 hrs by MTT assay
    Cytotoxicity against human SGC7901 cells after 48 hrs by MTT assay
    		[PMID: 23871222]
    SH-SY5Y CC50
    0.7 μM
    Compound: Doxorubicin
    Cytotoxicity against human SH-SY5Y cells after 72 hrs by MTT assay
    Cytotoxicity against human SH-SY5Y cells after 72 hrs by MTT assay
    		[PMID: 29792325]
    SH-SY5Y IC50
    0.04 μM
    Compound: Doxorubicin
    Cytotoxicity against human SH-SY5Y cells assessed as inhibition of cell growth and measured after 72 hrs resazurin reduction assay
    Cytotoxicity against human SH-SY5Y cells assessed as inhibition of cell growth and measured after 72 hrs resazurin reduction assay
    		[PMID: 36126331]
    SH-SY5Y IC50
    0.14 μM
    Compound: D
    Antiproliferative activity against human SH-SY5Y cells after 72 hrs by MTT assay
    Antiproliferative activity against human SH-SY5Y cells after 72 hrs by MTT assay
    		10.1039/C6MD00431H
    SH-SY5Y IC50
    0.35 μM
    Compound: DOX
    Antiproliferative activity against human SH-SY5Y cells after 72 hrs by CCK-8 assay
    Antiproliferative activity against human SH-SY5Y cells after 72 hrs by CCK-8 assay
    		[PMID: 29597166]
    SH-SY5Y IC50
    0.5 μM
    Compound: DOXO
    Cytotoxicity against human SH-SY5Y cells assessed as cell viability after 48 hrs by alamar blue assay
    Cytotoxicity against human SH-SY5Y cells assessed as cell viability after 48 hrs by alamar blue assay
    		[PMID: 21797280]
    SH-SY5Y IC50
    0.8 μM
    Compound: DOX
    Cytotoxicity against human SH-SY5Y cells expressing low level of topoisomerase I/II measured after 72 hrs by MTT assay
    Cytotoxicity against human SH-SY5Y cells expressing low level of topoisomerase I/II measured after 72 hrs by MTT assay
    		[PMID: 35612499]
    SH-SY5Y IC50
    0.89 μM
    Compound: DOX
    Antiproliferative activity against human SH-SY5Y cells after 72 hrs by CCK-8 assay
    Antiproliferative activity against human SH-SY5Y cells after 72 hrs by CCK-8 assay
    		[PMID: 29614418]
    SH-SY5Y IC50
    1.543 μM
    Compound: Dox
    Antiproliferative activity against human SH-SY5Y cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    Antiproliferative activity against human SH-SY5Y cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    		[PMID: 36240546]
    SH-SY5Y IC50
    2.3 μM
    Compound: Doxorubicin
    Neurotoxicity in human SH-SY5Y cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    Neurotoxicity in human SH-SY5Y cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    		[PMID: 33439019]
    SJSA-1 IC50
    6.2 nM
    Compound: doxorubicin
    Cytotoxicity against human SJSA1 cells expressing GRP78 after 6 hrs by MTT assay
    Cytotoxicity against human SJSA1 cells expressing GRP78 after 6 hrs by MTT assay
    		[PMID: 18243696]
    SK-BR-3 GI50
    1.1 μM
    Compound: Adriamycin
    In vitro antiproliferative activity against human SK-BR-3 breast cell line
    In vitro antiproliferative activity against human SK-BR-3 breast cell line
    		[PMID: 14971893]
    SK-BR-3 IC50
    0.02 μM
    Compound: Doxorubicin
    Inhibitory activity against SKBR-3 cell line using MTT assay (ER-amplified erB2,mutant p53)
    Inhibitory activity against SKBR-3 cell line using MTT assay (ER-amplified erB2,mutant p53)
    		[PMID: 10780913]
    SK-BR-3 IC50
    0.034 μM
    Compound: DOX
    Antiproliferative activity against human SKBR3 cells after 24 hrs by CellTiter-Glo assay
    Antiproliferative activity against human SKBR3 cells after 24 hrs by CellTiter-Glo assay
    		[PMID: 27769032]
    SK-BR-3 IC50
    0.05 μM
    Compound: DOX
    Antiproliferative activity against human SKBR3 cells after 48 hrs by CellTiter-Glo assay
    Antiproliferative activity against human SKBR3 cells after 48 hrs by CellTiter-Glo assay
    		[PMID: 27769032]
    SK-BR-3 IC50
    0.09 μM
    Compound: Doxorubicin
    Cytotoxicity against human SK-BR-3 cells after 72 hrs by resazurin/resorufin-based fluorescence assay
    Cytotoxicity against human SK-BR-3 cells after 72 hrs by resazurin/resorufin-based fluorescence assay
    		[PMID: 23600925]
    SK-BR-3 IC50
    0.1 μM
    Compound: Doxorubicin
    Antiproliferative activity against 2D culture of human SK-BR-3 cells after 72 hrs MTS assay
    Antiproliferative activity against 2D culture of human SK-BR-3 cells after 72 hrs MTS assay
    		[PMID: 27721156]
    SK-BR-3 IC50
    0.202 μM
    Compound: Doxorubicin
    Antiproliferative activity against human SKBR3 cells after 72 hrs by MTT reduction assay
    Antiproliferative activity against human SKBR3 cells after 72 hrs by MTT reduction assay
    		[PMID: 28551177]
    SK-BR-3 IC50
    0.21 μM
    Compound: doxorubicin
    Cytotoxicity against human SK-BR-3 cells after 72 hrs by CellTiter-Glo assay
    Cytotoxicity against human SK-BR-3 cells after 72 hrs by CellTiter-Glo assay
    		[PMID: 22316168]
    SK-BR-3 IC50
    0.28 μM
    Compound: DOX
    Cytotoxicity against human SKBr3 assessed as reduction in cell viability by SRB assay
    Cytotoxicity against human SKBr3 assessed as reduction in cell viability by SRB assay
    		[PMID: 33130288]
    SK-BR-3 IC50
    0.28 μM
    Compound: Doxorubicin
    Cytotoxicity against HER2-positive human SKBR3 cells assessed as redution in cell viability incubated for 72 hrs by SRB assay
    Cytotoxicity against HER2-positive human SKBR3 cells assessed as redution in cell viability incubated for 72 hrs by SRB assay
    		[PMID: 31810778]
    SK-BR-3 IC50
    0.29 μM
    Compound: adriamycin
    Cytotoxicity against SKBR3 cells after 72 hrs by MTT assay
    Cytotoxicity against SKBR3 cells after 72 hrs by MTT assay
    		[PMID: 17107806]
    SK-BR-3 IC50
    0.37 μM
    Compound: DX
    Antiproliferative activity against human SK-BR-3 cells after 72 hrs by SRB assay
    Antiproliferative activity against human SK-BR-3 cells after 72 hrs by SRB assay
    		[PMID: 30025346]
    SK-BR-3 IC50
    1.29 μM
    Compound: Doxorubicin
    Antiproliferative activity against 3D culture of human SK-BR-3 cells after 72 hrs MTS assay
    Antiproliferative activity against 3D culture of human SK-BR-3 cells after 72 hrs MTS assay
    		[PMID: 27721156]
    SK-BR-3 IC50
    2.36 μM
    Compound: Doxorubicin
    Cytotoxicity against human SK-BR-3 cells treated for 72 hrs by MTT assay
    Cytotoxicity against human SK-BR-3 cells treated for 72 hrs by MTT assay
    		[PMID: 35344904]
    SK-BR-3 IC50
    8.48 μM
    Compound: Dox
    Cytotoxicity against human SKBR3 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human SKBR3 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 28549734]
    SK-ES1 IC50
    0.042 μM
    Compound: Doxorubicin
    Cytotoxicity against human SK-ES-1 cells after 72 hrs by resazurin/resorufin-based fluorescence assay
    Cytotoxicity against human SK-ES-1 cells after 72 hrs by resazurin/resorufin-based fluorescence assay
    		[PMID: 23600925]
    SK-HEP1 GI50
    0.07 μg/mL
    Compound: Adriamycin
    Antiproliferative activity against human SKHEP1 cells by SRB assay
    Antiproliferative activity against human SKHEP1 cells by SRB assay
    		[PMID: 18023932]
    SK-HEP1 IC50
    0.1 μM
    Compound: Doxorubicin
    Antiproliferative activity against human SK-HEP1 cells after 72 hrs by SRB assay
    Antiproliferative activity against human SK-HEP1 cells after 72 hrs by SRB assay
    		[PMID: 18063366]
    SK-HEP1 IC50
    10 nM
    Compound: Doxorubicin
    Cytotoxicity against human SKHEP1 cells after 48 hrs by [3H]thymidine incorporation assay
    Cytotoxicity against human SKHEP1 cells after 48 hrs by [3H]thymidine incorporation assay
    		[PMID: 20210346]
    SK-LU-1 IC50
    6.7 nM
    Compound: Adriamycin
    Cytotoxicity against human SKLU1 cells after 48 hrs by SRB assay
    Cytotoxicity against human SKLU1 cells after 48 hrs by SRB assay
    		[PMID: 22858298]
    SK-MEL IC50
    0.009 μM
    Compound: Doxorubicin
    Antiproliferative activity against human SK-MEL cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Antiproliferative activity against human SK-MEL cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    		[PMID: 27010926]
    SK-MEL IC50
    0.14 μM
    Compound: Doxorubicin
    Cytotoxicity against human SK-MEL cells after 48 hrs by neutral red assay relative to control
    Cytotoxicity against human SK-MEL cells after 48 hrs by neutral red assay relative to control
    		[PMID: 25975638]
    SK-MEL IC50
    0.159 μM
    Compound: Doxorubicin
    Cytotoxicity against human SK-MEL cells after 48 hrs by neutral red dye based assay
    Cytotoxicity against human SK-MEL cells after 48 hrs by neutral red dye based assay
    		[PMID: 29317147]
    SK-MEL IC50
    0.17 μM
    Compound: Doxorubicin
    Antiproliferative activity against human SK-MEL cells assessed as reduction in cell growth inhibition
    Antiproliferative activity against human SK-MEL cells assessed as reduction in cell growth inhibition
    		[PMID: 27010926]
    SK-MEL IC50
    0.55 μM
    Compound: Doxorubicin
    Cytotoxicity against Homo sapiens (human) SK-MEL cells by neutral red staining
    Cytotoxicity against Homo sapiens (human) SK-MEL cells by neutral red staining
    		10.1007/s00044-011-9587-3
    SK-MEL IC50
    0.6 μg/mL
    Compound: doxorubicin
    Cytotoxicity against human SKMEL cells by neutral red assay
    Cytotoxicity against human SKMEL cells by neutral red assay
    		[PMID: 17976995]
    SK-MEL IC50
    0.6 μg/mL
    Compound: doxorubicin
    Cytotoxicity against human SK-MEL cells after 48 hrs by neutral red dye staining
    Cytotoxicity against human SK-MEL cells after 48 hrs by neutral red dye staining
    		[PMID: 19928902]
    SK-MEL IC50
    0.6 μg/mL
    Compound: doxorubicin
    Cytotoxicity against human SK-MEL cells after 48 hrs by Neutral Red dye
    Cytotoxicity against human SK-MEL cells after 48 hrs by Neutral Red dye
    		[PMID: 20550123]
    SK-MEL IC50
    1.1 μM
    Compound: Doxorubicin
    Cytotoxicity against human SK-MEL cells assessed as cell growth inhibition after 48 hrs by neutral red assay
    Cytotoxicity against human SK-MEL cells assessed as cell growth inhibition after 48 hrs by neutral red assay
    		[PMID: 26005918]
    SK-MEL IC50
    1.11 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human SK-MEL cells assessed as cell growth inhibition after 48 hrs by neutral red dye based assay
    Cytotoxicity against human SK-MEL cells assessed as cell growth inhibition after 48 hrs by neutral red dye based assay
    		[PMID: 27769668]
    SK-MEL IC50
    1.2 μM
    Compound: Doxorubicin
    Cytotoxicity against human SK-MEL cells after 48 hrs by Neutral red assay
    Cytotoxicity against human SK-MEL cells after 48 hrs by Neutral red assay
    		[PMID: 19658408]
    SK-MEL IC50
    1.5 μM
    Compound: Doxorubicin
    Cytotoxicity against human SK-MEL cells assessed as reduction in cell viability after 48 hrs by neutral red dye-based assay
    Cytotoxicity against human SK-MEL cells assessed as reduction in cell viability after 48 hrs by neutral red dye-based assay
    		[PMID: 27618204]
    SK-MEL IC50
    1.5 μM
    Compound: doxorubicin
    Cytotoxicity against human SK-MEL cells assessed as growth inhibition measured after 48 hrs by XTT assay
    Cytotoxicity against human SK-MEL cells assessed as growth inhibition measured after 48 hrs by XTT assay
    		[PMID: 23547843]
    SK-MEL IC50
    1.57 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human SK-MEL cells after 48 hrs by neutral red staining
    Cytotoxicity against human SK-MEL cells after 48 hrs by neutral red staining
    		[PMID: 15165136]
    SK-MEL IC50
    1.57 μg/mL
    Compound: doxorubicin
    Cytotoxicity against human SK-MEL cells
    Cytotoxicity against human SK-MEL cells
    		[PMID: 12880315]
    SK-MEL IC50
    1.6 μM
    Compound: doxorubicin
    Cytotoxicity against human SK-MEL cells assessed as viable cells by neutral red dye method
    Cytotoxicity against human SK-MEL cells assessed as viable cells by neutral red dye method
    		[PMID: 22530813]
    SK-MEL IC50
    1.73 μM
    Compound: doxorubicin
    Cytotoxicity against human SK-MEL cells after 48 hrs by neutral red assay
    Cytotoxicity against human SK-MEL cells after 48 hrs by neutral red assay
    		[PMID: 19879765]
    SK-MEL IC50
    < 0.55 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human SK-MEL cells after 48 hrs by neutral red assay
    Cytotoxicity against human SK-MEL cells after 48 hrs by neutral red assay
    		[PMID: 19105653]
    SK-MEL IC50
    < 1.1 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human SK-MEL cells after 2 to 7 days by neutral red assay
    Cytotoxicity against human SK-MEL cells after 2 to 7 days by neutral red assay
    		[PMID: 11374943]
    SK-MEL-1 IC50
    3.092 μM
    Compound: Doxorubicin
    Cytotoxicity against human SK-MEL-1 cells after 94 hrs by MTT assay
    Cytotoxicity against human SK-MEL-1 cells after 94 hrs by MTT assay
    		[PMID: 21868138]
    SK-MEL-2 EC50
    0.01 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human SK-MEL-2 cells
    Cytotoxicity against human SK-MEL-2 cells
    		[PMID: 18990572]
    SK-MEL-2 ED50
    0.001 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human SK-MEL-2 cells after 48 hrs by sulforhodamine B assay
    Cytotoxicity against human SK-MEL-2 cells after 48 hrs by sulforhodamine B assay
    		[PMID: 19783438]
    SK-MEL-2 ED50
    0.002 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human SK-MEL-2 cells by sulforhodamine B method
    Cytotoxicity against human SK-MEL-2 cells by sulforhodamine B method
    		[PMID: 12193011]
    SK-MEL-2 ED50
    0.003 μg/mL
    Compound: doxorubicin
    Cytotoxicity against human SK-MEL-2 cells by SRB method
    Cytotoxicity against human SK-MEL-2 cells by SRB method
    		[PMID: 16252909]
    SK-MEL-2 ED50
    0.01 μg/mL
    Compound: doxorubicin
    Cytotoxicity against human SK-MEL-2 cells after 48 hrs by SRB assay
    Cytotoxicity against human SK-MEL-2 cells after 48 hrs by SRB assay
    		[PMID: 15921415]
    SK-MEL-2 ED50
    0.01 μg/mL
    Compound: doxorubicin
    Cytotoxicity against human SK-MEL-2 cells
    Cytotoxicity against human SK-MEL-2 cells
    		[PMID: 16441084]
    SK-MEL-2 ED50
    0.01 μg/mL
    Compound: doxorubicin
    Cytotoxicity against human SK-MEL-2 cell line
    Cytotoxicity against human SK-MEL-2 cell line
    		[PMID: 17253840]
    SK-MEL-2 ED50
    0.02 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human SK-MEL-2 cells
    Cytotoxicity against human SK-MEL-2 cells
    		[PMID: 12350153]
    SK-MEL-2 ED50
    0.02 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human SK-MEL-2 cells
    Cytotoxicity against human SK-MEL-2 cells
    		[PMID: 12662097]
    SK-MEL-2 ED50
    0.02 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human SK-MEL-2 cells
    Cytotoxicity against human SK-MEL-2 cells
    		[PMID: 15104487]
    SK-MEL-2 ED50
    0.02 μg/mL
    Compound: doxorubicin
    Cytotoxicity against human SK-MEL-2 cells
    Cytotoxicity against human SK-MEL-2 cells
    		[PMID: 11678655]
    SK-MEL-2 ED50
    0.03 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human SK-MEL-2 cells
    Cytotoxicity against human SK-MEL-2 cells
    		[PMID: 11520227]
    SK-MEL-2 ED50
    0.03 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human SK-MEL-2 cells
    Cytotoxicity against human SK-MEL-2 cells
    		[PMID: 12662102]
    SK-MEL-2 ED50
    0.03 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human SK-MEL-2 cells
    Cytotoxicity against human SK-MEL-2 cells
    		[PMID: 14640526]
    SK-MEL-2 ED50
    0.04 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human SK-MEL-2 cells
    Cytotoxicity against human SK-MEL-2 cells
    		[PMID: 14640527]
    SK-MEL-2 ED50
    0.04 μg/mL
    Compound: doxorubicin
    Cytotoxicity against human SK-MEL-2 cells
    Cytotoxicity against human SK-MEL-2 cells
    		[PMID: 15787431]
    SK-MEL-2 ED50
    0.04 μg/mL
    Compound: doxorubicin
    Cytotoxicity against human SK-MEL-2 cells
    Cytotoxicity against human SK-MEL-2 cells
    		[PMID: 16643027]
    SK-MEL-2 ED50
    0.05 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human SK-MEL-2 cells
    Cytotoxicity against human SK-MEL-2 cells
    		[PMID: 15270579]
    SK-MEL-2 ED50
    0.05 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human SK-MEL-2 cells
    Cytotoxicity against human SK-MEL-2 cells
    		[PMID: 15497935]
    SK-MEL-2 ED50
    0.05 μg/mL
    Compound: adriamycin
    Cytotoxicity against human SK-MEL-2 cells by SRB assay
    Cytotoxicity against human SK-MEL-2 cells by SRB assay
    		10.1021/np960188t
    SK-MEL-2 ED50
    0.06 μg/mL
    Compound: doxorubicin
    Cytotoxicity against human SK-MEL-2 cells
    Cytotoxicity against human SK-MEL-2 cells
    		[PMID: 12762820]
    SK-MEL-2 ED50
    0.06 μg/mL
    Compound: doxorubicin
    Cytotoxicity against human SK-MEL-2 cells
    Cytotoxicity against human SK-MEL-2 cells
    		[PMID: 14640517]
    SK-MEL-2 ED50
    0.08 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human SK-MEL-2 cells
    Cytotoxicity against human SK-MEL-2 cells
    		[PMID: 17190456]
    SK-MEL-2 ED50
    0.117 μM
    Compound: doxorubicin
    Cytotoxicity against human SK-MEL-2 cells by SRB assay
    Cytotoxicity against human SK-MEL-2 cells by SRB assay
    		[PMID: 18314958]
    SK-MEL-2 ED50
    0.11 μg/mL
    Compound: doxorubicin
    Cytotoxicity against human SK-MEL-2 cells by SRB assay
    Cytotoxicity against human SK-MEL-2 cells by SRB assay
    		[PMID: 9392887]
    SK-MEL-2 ED50
    0.12 μg/mL
    Compound: doxorubicin
    Cytotoxicity against human SK-MEL-2 cells
    Cytotoxicity against human SK-MEL-2 cells
    		[PMID: 15104515]
    SK-MEL-2 ED50
    0.2 μg/mL
    Compound: doxorubicin
    Cytotoxicity against human SK-MEL-2 cells
    Cytotoxicity against human SK-MEL-2 cells
    		[PMID: 10217707]
    SK-MEL-2 GI50
    0.059 μg/mL
    Compound: Doxorubicin
    Antitumor cytotoxic activity against SK-MEL-2 cell line was determined
    Antitumor cytotoxic activity against SK-MEL-2 cell line was determined
    		[PMID: 11551772]
    SK-MEL-2 GI50
    0.11 μM
    Compound: Doxorubicin
    Growth inhibition of human SK-MEL-2 cells after 72 hrs by SRB assay
    Growth inhibition of human SK-MEL-2 cells after 72 hrs by SRB assay
    		[PMID: 18585035]
    SK-MEL-2 GI50
    0.17 μM
    Compound: Doxorubicin hydrochloride, NSC 123127
    Cytotoxicity against human SK-MEL-2 cells after 48 hrs by SRB assay
    Cytotoxicity against human SK-MEL-2 cells after 48 hrs by SRB assay
    		[PMID: 23871905]
    SK-MEL-2 GI50
    0.21 μM
    Compound: Doxorubicin
    Growth inhibition of human SK-MEL-2 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human SK-MEL-2 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 29102177]
    SK-MEL-2 IC50
    0.001 μM
    Compound: Doxorubicin
    Cytotoxicity against human SK-MEL-2 cells assessed as cell growth inhibition after 48 hrs by SRB assay
    Cytotoxicity against human SK-MEL-2 cells assessed as cell growth inhibition after 48 hrs by SRB assay
    		[PMID: 25466198]
    SK-MEL-2 IC50
    0.001 μM
    Compound: Doxorubicin
    Cytotoxicity against human SK-MEL-2 cells assessed as inhibition of cell growth incubated for 48 hrs by SRB assay
    Cytotoxicity against human SK-MEL-2 cells assessed as inhibition of cell growth incubated for 48 hrs by SRB assay
    		[PMID: 25981688]
    SK-MEL-2 IC50
    0.001 μM
    Compound: Doxorubicin
    Cytotoxicity against human SK-MEL-2 cells assessed as reduction in cell proliferation measured after 48 hrs by SRB assay
    Cytotoxicity against human SK-MEL-2 cells assessed as reduction in cell proliferation measured after 48 hrs by SRB assay
    		[PMID: 27856237]
    SK-MEL-2 IC50
    0.002 μM
    Compound: Doxorubicin
    Cytotoxicity against human SK-MEL-2 cells by SRB assay
    Cytotoxicity against human SK-MEL-2 cells by SRB assay
    		[PMID: 20719504]
    SK-MEL-2 IC50
    0.002 μM
    Compound: Doxorubicin
    Cytotoxicity against human SK-MEL-2 cells after 48 hrs by SRB assay
    Cytotoxicity against human SK-MEL-2 cells after 48 hrs by SRB assay
    		[PMID: 22483395]
    SK-MEL-2 IC50
    0.0025 μM
    Compound: Doxorubicin
    Cytotoxicity against human SK-MEL-2 cells by sulforhodamine B bioassay
    Cytotoxicity against human SK-MEL-2 cells by sulforhodamine B bioassay
    		[PMID: 25098650]
    SK-MEL-2 IC50
    0.004 μM
    Compound: Doxorubicin
    Cytotoxicity against human SK-MEL-2 cells by SRB assay
    Cytotoxicity against human SK-MEL-2 cells by SRB assay
    		[PMID: 22951040]
    SK-MEL-2 IC50
    0.009 μM
    Compound: Doxorubicin
    Antiproliferative activity against human SK-MEL-2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Antiproliferative activity against human SK-MEL-2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    		[PMID: 27010926]
    SK-MEL-2 IC50
    0.01 μM
    Compound: Doxorubicin
    Cytotoxicity against human SK-MEL-2 cells assessed as growth inhibition by SRB assay
    Cytotoxicity against human SK-MEL-2 cells assessed as growth inhibition by SRB assay
    		[PMID: 23634786]
    SK-MEL-2 IC50
    0.01 μM
    Compound: Doxorubicin
    Cytotoxicity against human SK-MEL-2 cells by sulforhodamine B assay
    Cytotoxicity against human SK-MEL-2 cells by sulforhodamine B assay
    		[PMID: 23815260]
    SK-MEL-2 IC50
    0.012 μM
    Compound: Doxorubicin
    Cytotoxicity against human SK-MEL-2 cells by SRB assay
    Cytotoxicity against human SK-MEL-2 cells by SRB assay
    		[PMID: 20594848]
    SK-MEL-2 IC50
    0.015 μg/mL
    Compound: doxorubicin
    Anticancer activity against human SK-MEL-2 cells after 72 hrs by sulforhodamine B assay
    Anticancer activity against human SK-MEL-2 cells after 72 hrs by sulforhodamine B assay
    		[PMID: 19342127]
    SK-MEL-2 IC50
    0.019 μM
    Compound: doxorubicin
    Cytotoxicity against human SK-MEL-2 cells after 3 days by SRB assay
    Cytotoxicity against human SK-MEL-2 cells after 3 days by SRB assay
    		[PMID: 18321715]
    SK-MEL-2 IC50
    0.028 μM
    Compound: Doxorubicin
    Anticancer activity against human SK-MEL-2 cells by sulforhodamine B assay
    Anticancer activity against human SK-MEL-2 cells by sulforhodamine B assay
    		[PMID: 19819696]
    SK-MEL-2 IC50
    0.03 μg/mL
    Compound: adriamycin
    Cytotoxicity against human SK-MEL-2 cells by SRB assay
    Cytotoxicity against human SK-MEL-2 cells by SRB assay
    		[PMID: 15921426]
    SK-MEL-2 IC50
    0.04 μM
    Compound: Doxorubicin
    Cytotoxicity against human SK-MEL-2 cells by SRB assay
    Cytotoxicity against human SK-MEL-2 cells by SRB assay
    		[PMID: 20176479]
    SK-MEL-2 IC50
    0.07 μM
    Compound: doxorubicin
    Cytotoxicity against human SK-MEL-2 cells by SRB assay
    Cytotoxicity against human SK-MEL-2 cells by SRB assay
    		[PMID: 17194596]
    SK-MEL-2 IC50
    0.07 μg/mL
    Compound: Doxorubicin
    Cytotoxic activity against SKMEL-2 cell line
    Cytotoxic activity against SKMEL-2 cell line
    		[PMID: 15922597]
    SK-MEL-2 IC50
    0.097 μM
    Compound: Doxorubicin
    Anticancer activity against human SK-MEL-2 cells after 48 hrs by SRB assay
    Anticancer activity against human SK-MEL-2 cells after 48 hrs by SRB assay
    		[PMID: 17070967]
    SK-MEL-2 IC50
    0.09 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human SK-MEL-2 cells by sulforhodamine B assay
    Cytotoxicity against human SK-MEL-2 cells by sulforhodamine B assay
    		[PMID: 21684168]
    SK-MEL-2 IC50
    0.117 μM
    Compound: doxorubicin
    Cytotoxicity against human SK-MEL-2 cells by SRB assay
    Cytotoxicity against human SK-MEL-2 cells by SRB assay
    		[PMID: 19435339]
    SK-MEL-2 IC50
    0.16 μM
    Compound: doxorubicin
    Cytotoxicity against human SK-MEL-2 cells after 48 hrs
    Cytotoxicity against human SK-MEL-2 cells after 48 hrs
    		[PMID: 17673337]
    SK-MEL-2 IC50
    0.1 μg/mL
    Compound: adriamycin
    Compound was evaluated for the growth inhibition of SKm12 melanoma cell line.
    Compound was evaluated for the growth inhibition of SKm12 melanoma cell line.
    		[PMID: 9873640]
    SK-MEL-2 IC50
    11.7 nM
    Compound: Doxorubicin
    Antiproliferative activity against human SK-MEL-2 cells assessed as reduction in cell viability incubated for 24 hrs by SRB assay
    Antiproliferative activity against human SK-MEL-2 cells assessed as reduction in cell viability incubated for 24 hrs by SRB assay
    		[PMID: 31655432]
    SK-MEL-2 IC50
    4.78 μM
    Compound: Doxorubicin
    Cytotoxic activity against SK-MEL-2 human melanoma cell line, using sulforhodamine B (SRB) assay.
    Cytotoxic activity against SK-MEL-2 human melanoma cell line, using sulforhodamine B (SRB) assay.
    		[PMID: 14643344]
    SK-MEL-2 IC50
    4.78 μM
    Compound: Doxorubicin
    Cytotoxicity against human SK-MEL-2 cells
    Cytotoxicity against human SK-MEL-2 cells
    		[PMID: 21095131]
    SK-MEL-2 IC50
    4.78 μM
    Compound: doxorubicin
    Cytotoxicity against human SK-MEL-2 cells by SRB assay
    Cytotoxicity against human SK-MEL-2 cells by SRB assay
    		[PMID: 17827007]
    SK-MEL-28 EC50
    0.7 μM
    Compound: Doxorubicin
    Cytotoxicity against human SK-MEL-28 cells after 96 hrs by MTT assay
    Cytotoxicity against human SK-MEL-28 cells after 96 hrs by MTT assay
    		[PMID: 26320088]
    SK-MEL-28 GI50
    0.08 μM
    Compound: Doxorubicin
    Growth inhibition of human SK-MEL-28 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human SK-MEL-28 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 29102177]
    SK-MEL-28 GI50
    0.21 μM
    Compound: Doxorubicin
    Growth inhibition of human SK-MEL-28 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human SK-MEL-28 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28329730]
    SK-MEL-28 GI50
    0.21 μM
    Compound: Doxorubicin hydrochloride, NSC 123127
    Cytotoxicity against human SK-MEL-28 cells after 48 hrs by SRB assay
    Cytotoxicity against human SK-MEL-28 cells after 48 hrs by SRB assay
    		[PMID: 23871905]
    SK-MEL-28 GI50
    3.1 μM
    Compound: Adriamycin
    In vitro antiproliferative activity against human MEL-28 melanoma cell line
    In vitro antiproliferative activity against human MEL-28 melanoma cell line
    		[PMID: 14971893]
    SK-MEL-28 IC50
    0.02 μM
    Compound: 2
    Compound was evaluated for the cytotoxicity against MEL-28 tumor cell line after 3 days of incubation
    Compound was evaluated for the cytotoxicity against MEL-28 tumor cell line after 3 days of incubation
    		10.1016/S0960-894X(97)10122-6
    SK-MEL-28 IC50
    0.06 μM
    Compound: Doxo
    Antiproliferative activity against human SKMEL-28 cells assessed as cell viability measured after 4 days by MTT assay
    Antiproliferative activity against human SKMEL-28 cells assessed as cell viability measured after 4 days by MTT assay
    		[PMID: 31869654]
    SK-MEL-28 IC50
    0.06 μM
    Compound: doxorubicin
    Antitumor activity against human skin melanoma SKMEK-28 cells
    Antitumor activity against human skin melanoma SKMEK-28 cells
    		[PMID: 12431048]
    SK-MEL-28 IC50
    0.25 μM
    Compound: Doxorubicin
    Cytotoxicity against human SK-MEL-28 cells assessed as reduction in cell viability after 72 hrs by CellTiter96 AQueous one solution cell proliferation assay
    Cytotoxicity against human SK-MEL-28 cells assessed as reduction in cell viability after 72 hrs by CellTiter96 AQueous one solution cell proliferation assay
    		[PMID: 28617598]
    SK-MEL-28 IC50
    0.25 μM
    Compound: Doxorubicin
    Antiproliferative activity against human SK-MEL-28 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay
    Antiproliferative activity against human SK-MEL-28 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay
    		[PMID: 34851111]
    SK-MEL-28 IC50
    0.6 μM
    Compound: Doxorubicin
    Antitumor activity against human SK-MEL-28 cells after 24 to 48 hrs by MTT assay
    Antitumor activity against human SK-MEL-28 cells after 24 to 48 hrs by MTT assay
    		[PMID: 21553829]
    SK-MEL-28 IC50
    1.64 μM
    Compound: Dox
    Cytotoxicity against human SK-MEL-28 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay
    Cytotoxicity against human SK-MEL-28 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay
    		[PMID: 35635947]
    SK-MEL-28 IC50
    1.8 μM
    Compound: Doxorubicin
    Anticancer activity against human SK-MEL-28 cells assessed as growth inhibition incubated for 48 hrs by MTT assay
    Anticancer activity against human SK-MEL-28 cells assessed as growth inhibition incubated for 48 hrs by MTT assay
    		[PMID: 34363936]
    SK-MEL-28 IC50
    3 μM
    Compound: Doxorubicin
    Cytotoxicity against human SK-MEL-28 cells after 72 hrs by MTT assay
    Cytotoxicity against human SK-MEL-28 cells after 72 hrs by MTT assay
    		[PMID: 30783501]
    SK-MEL-5 ED50
    0.032 μM
    Compound: Adriamycin
    Cytotoxic concentration required to inhibit 50% cell growth in SKMEL-5 melanoma cell lines
    Cytotoxic concentration required to inhibit 50% cell growth in SKMEL-5 melanoma cell lines
    		[PMID: 1875350]
    SK-MEL-5 ED50
    2.8 x 10-4 μg/mL
    Compound: Adriamycin
    Cytotoxicity against human SK-MEL-5 cells by MTT assay
    Cytotoxicity against human SK-MEL-5 cells by MTT assay
    		[PMID: 7714533]
    SK-MEL-5 ED50
    3.2 μM
    Compound: Adriamycin
    Compound was evaluated for cytotoxicity against human SKMEL-5 melanoma cell line.
    Compound was evaluated for cytotoxicity against human SKMEL-5 melanoma cell line.
    		[PMID: 1613753]
    SK-MEL-5 GI50
    0.03 μg/mL
    Compound: adriamycin
    Cytotoxicity against human SK-MEL-5 cells by MTT assay
    Cytotoxicity against human SK-MEL-5 cells by MTT assay
    		[PMID: 11000028]
    SK-MEL-5 GI50
    0.08 μM
    Compound: Doxorubicin
    Growth inhibition of human SK-MEL-5 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human SK-MEL-5 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28329730]
    SK-MEL-5 GI50
    0.08 μM
    Compound: Doxorubicin hydrochloride, NSC 123127
    Cytotoxicity against human SK-MEL-5 cells after 48 hrs by SRB assay
    Cytotoxicity against human SK-MEL-5 cells after 48 hrs by SRB assay
    		[PMID: 23871905]
    SK-MEL-5 GI50
    0.14 μM
    Compound: Doxorubicin
    Growth inhibition of human SK-MEL-5 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human SK-MEL-5 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 29102177]
    SK-MEL3 ED50
    0.02 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human SK-MEL-3 cells after 48 hrs by SRB assay
    Cytotoxicity against human SK-MEL-3 cells after 48 hrs by SRB assay
    		[PMID: 11325244]
    SK-MES-1 EC50
    0.1 μM
    Compound: Doxorubicin
    Cytotoxicity against human SKMES1 cells after 96 hrs by MTT assay
    Cytotoxicity against human SKMES1 cells after 96 hrs by MTT assay
    		[PMID: 26320088]
    SK-MES-1 IC50
    0.03 μM
    Compound: doxorubicin
    Antitumor activity against human lung squamous carcinoma SK-MES-1 cells
    Antitumor activity against human lung squamous carcinoma SK-MES-1 cells
    		[PMID: 12431048]
    SK-N-MC IC50
    0.12 μM
    Compound: Doxorubicin
    Cytotoxicity against human SK-N-MC cells after 72 hrs by MTT assay
    Cytotoxicity against human SK-N-MC cells after 72 hrs by MTT assay
    		[PMID: 20303768]
    SK-N-SH IC50
    0.97 μM
    Compound: Doxorubicin
    Antiproliferative activity against human SK-N-SH cells after 48 hrs by MTT assay
    Antiproliferative activity against human SK-N-SH cells after 48 hrs by MTT assay
    		10.1039/C2MD20023F
    SK-N-SH IC50
    0.97 μM
    Compound: Doxorubicin
    Cytotoxicity against human SK-N-SH cells after 48 hrs by MTT assay
    Cytotoxicity against human SK-N-SH cells after 48 hrs by MTT assay
    		[PMID: 22386528]
    SK-N-SH IC50
    1.1 μM
    Compound: Doxorubicin
    Cytotoxicity against human SK-N-SH cells after 48 hrs by MTT assay
    Cytotoxicity against human SK-N-SH cells after 48 hrs by MTT assay
    		[PMID: 20832916]
    SK-N-SH IC50
    10.88 μM
    Compound: Doxorubicin
    Cytotoxicity against human SK-N-SH cells after 24 hrs by MTT assay
    Cytotoxicity against human SK-N-SH cells after 24 hrs by MTT assay
    		10.1039/C3MD00013C
    SK-N-SH IC50
    19.9 μM
    Compound: DOX
    Cytotoxicity against Homo sapiens (human) SK-N-SH cells assessed as growth inhibition after 48 hr by MTT assay
    Cytotoxicity against Homo sapiens (human) SK-N-SH cells assessed as growth inhibition after 48 hr by MTT assay
    		10.1007/s00044-012-0018-x
    SK-N-SH IC50
    19.9 μM
    Compound: DOX
    Cytotoxicity against human SK-N-SH cells assessed as inhibition of cell growth after 48 hrs by MTT assay
    Cytotoxicity against human SK-N-SH cells assessed as inhibition of cell growth after 48 hrs by MTT assay
    		[PMID: 21440337]
    SK-N-SH IC50
    2.42 μM
    Compound: Doxorubicin
    Antiproliferative activity against human SK-N-SH cells incubated for 24 hrs by MTT assay
    Antiproliferative activity against human SK-N-SH cells incubated for 24 hrs by MTT assay
    		[PMID: 29409753]
    SK-N-SH IC50
    2.85 μM
    Compound: DOX
    Antiproliferative activity against human SK-N-SH cells assessed as cell growth inhibition by MTT assay
    Antiproliferative activity against human SK-N-SH cells assessed as cell growth inhibition by MTT assay
    		[PMID: 32631524]
    SK-N-SH IC50
    6.3 μM
    Compound: Doxorubicin
    Antiproliferative activity against human SK-N-SH cells by MTT reduction assay
    Antiproliferative activity against human SK-N-SH cells by MTT reduction assay
    		[PMID: 33421712]
    SK-N-SH IC50
    6.42 μM
    Compound: Doxo
    Cytotoxicity against human SK-N-SH cells measured after 24 hrs by MTT assay
    Cytotoxicity against human SK-N-SH cells measured after 24 hrs by MTT assay
    		[PMID: 31104996]
    SK-N-SH IC50
    7.36 μM
    Compound: Doxorubicin
    Cytotoxicity against human SK-N-SH cells assessed as cell viability by SRB assay
    Cytotoxicity against human SK-N-SH cells assessed as cell viability by SRB assay
    		[PMID: 26022842]
    SK-N-SH IC50
    8.5 μM
    Compound: Doxorubicin
    Cytotoxicity against human SK-N-SH cells assessed as growth inhibition after 48 hrs by MTT assay
    Cytotoxicity against human SK-N-SH cells assessed as growth inhibition after 48 hrs by MTT assay
    		[PMID: 25140752]
    SK-OV-3 EC50
    0.01 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human SKOV3 cells
    Cytotoxicity against human SKOV3 cells
    		[PMID: 18990572]
    SK-OV-3 EC50
    0.29 μM
    Compound: Doxorubicin
    Cytotoxicity against human SKOV3 cells after 48 hrs by resazurin dye assay
    Cytotoxicity against human SKOV3 cells after 48 hrs by resazurin dye assay
    		[PMID: 23988351]
    SK-OV-3 ED50
    0.003 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human SKOV3 cells after 48 hrs by sulforhodamine B assay
    Cytotoxicity against human SKOV3 cells after 48 hrs by sulforhodamine B assay
    		[PMID: 19783438]
    SK-OV-3 ED50
    0.01 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human SKOV3 cells by sulforhodamine B method
    Cytotoxicity against human SKOV3 cells by sulforhodamine B method
    		[PMID: 12193011]
    SK-OV-3 ED50
    0.03 μg/mL
    Compound: doxorubicin
    Cytotoxicity against human SKOV3 cells after 48 hrs by SRB assay
    Cytotoxicity against human SKOV3 cells after 48 hrs by SRB assay
    		[PMID: 15921415]
    SK-OV-3 ED50
    0.03 μg/mL
    Compound: doxorubicin
    Cytotoxicity against human SKOV3 cells
    Cytotoxicity against human SKOV3 cells
    		[PMID: 16441084]
    SK-OV-3 ED50
    0.03 μg/mL
    Compound: doxorubicin
    Cytotoxicity against human SK-OV-3 cell line
    Cytotoxicity against human SK-OV-3 cell line
    		[PMID: 17253840]
    SK-OV-3 ED50
    0.056 μM
    Compound: doxorubicin
    Cytotoxicity against human SKOV3 cells by SRB assay
    Cytotoxicity against human SKOV3 cells by SRB assay
    		[PMID: 18314958]
    SK-OV-3 ED50
    0.08 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human SKOV3 cells
    Cytotoxicity against human SKOV3 cells
    		[PMID: 15104487]
    SK-OV-3 ED50
    0.09 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human SKOV3 cells
    Cytotoxicity against human SKOV3 cells
    		[PMID: 14640527]
    SK-OV-3 ED50
    0.09 μg/mL
    Compound: doxorubicin
    Cytotoxicity against human SKOV3 cells
    Cytotoxicity against human SKOV3 cells
    		[PMID: 15787431]
    SK-OV-3 ED50
    0.11 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human SKOV3 cells after 48 hrs by SRB assay
    Cytotoxicity against human SKOV3 cells after 48 hrs by SRB assay
    		[PMID: 11325244]
    SK-OV-3 ED50
    0.11 μg/mL
    Compound: adriamycin
    Cytotoxicity against human SKOV3 cells by SRB assay
    Cytotoxicity against human SKOV3 cells by SRB assay
    		10.1021/np960188t
    SK-OV-3 ED50
    0.11 μg/mL
    Compound: doxorubicin
    Cytotoxicity against human SKOV3 cells
    Cytotoxicity against human SKOV3 cells
    		[PMID: 11678655]
    SK-OV-3 ED50
    0.12 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human SKOV3 cells
    Cytotoxicity against human SKOV3 cells
    		[PMID: 15497935]
    SK-OV-3 ED50
    0.12 μg/mL
    Compound: doxorubicin
    Cytotoxicity against human SKOV3 cells by SRB method
    Cytotoxicity against human SKOV3 cells by SRB method
    		[PMID: 16252909]
    SK-OV-3 ED50
    0.13 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human SKOV3 cells
    Cytotoxicity against human SKOV3 cells
    		[PMID: 11520227]
    SK-OV-3 ED50
    0.13 μg/mL
    Compound: doxorubicin
    Cytotoxicity against human SKOV3 cells
    Cytotoxicity against human SKOV3 cells
    		[PMID: 12762820]
    SK-OV-3 ED50
    0.13 μg/mL
    Compound: doxorubicin
    Cytotoxicity against human SK-OV-3 cells
    Cytotoxicity against human SK-OV-3 cells
    		[PMID: 16643027]
    SK-OV-3 ED50
    0.13 μg/mL
    Compound: doxorubicin
    Cytotoxicity against human SKOV3 cells by SRB assay
    Cytotoxicity against human SKOV3 cells by SRB assay
    		[PMID: 9392887]
    SK-OV-3 ED50
    0.15 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human SKOV3 cells
    Cytotoxicity against human SKOV3 cells
    		[PMID: 12662102]
    SK-OV-3 ED50
    0.15 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human SKOV3 cells
    Cytotoxicity against human SKOV3 cells
    		[PMID: 14640526]
    SK-OV-3 ED50
    0.15 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human SKOV3 cells
    Cytotoxicity against human SKOV3 cells
    		[PMID: 15270579]
    SK-OV-3 ED50
    0.15 μg/mL
    Compound: doxorubicin
    Cytotoxicity against human SKOV3 cells
    Cytotoxicity against human SKOV3 cells
    		[PMID: 14640517]
    SK-OV-3 ED50
    0.16 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human SKOV3 cells
    Cytotoxicity against human SKOV3 cells
    		[PMID: 12350153]
    SK-OV-3 ED50
    0.17 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human SKOV3 cells
    Cytotoxicity against human SKOV3 cells
    		[PMID: 12662097]
    SK-OV-3 ED50
    0.19 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human SKOV3 cells
    Cytotoxicity against human SKOV3 cells
    		[PMID: 17190456]
    SK-OV-3 ED50
    0.24 μg/mL
    Compound: doxorubicin
    Cytotoxicity against human SKOV3 cells
    Cytotoxicity against human SKOV3 cells
    		[PMID: 15104515]
    SK-OV-3 ED50
    0.2 μg/mL
    Compound: doxorubicin
    Cytotoxicity against human SKOV3 cells
    Cytotoxicity against human SKOV3 cells
    		[PMID: 10217707]
    SK-OV-3 ED50
    2.5 x 10-3 μg/mL
    Compound: Adriamycin
    Cytotoxicity against human SKOV3 cells by MTT assay
    Cytotoxicity against human SKOV3 cells by MTT assay
    		[PMID: 7714533]
    SK-OV-3 GI50
    0.021 μM
    Compound: Doxorubicin
    Antiproliferative activity against human SKOV3 cells by SRB assay
    Antiproliferative activity against human SKOV3 cells by SRB assay
    		[PMID: 19394218]
    SK-OV-3 GI50
    0.073 μg/mL
    Compound: Doxorubicin
    Antitumor cytotoxic activity against SK-OV-3 cell line was determined
    Antitumor cytotoxic activity against SK-OV-3 cell line was determined
    		[PMID: 11551772]
    SK-OV-3 GI50
    0.0789 μM
    Compound: Doxorubicin
    Cytotoxicity against human SKOV3 cells assessed as growth inhibition measured after 48 hrs by SRB assay
    Cytotoxicity against human SKOV3 cells assessed as growth inhibition measured after 48 hrs by SRB assay
    		[PMID: 31059248]
    SK-OV-3 GI50
    0.0875 μM
    Compound: Doxorubicin
    Cytotoxicity against human SKOV3 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay
    Cytotoxicity against human SKOV3 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay
    		[PMID: 31534659]
    SK-OV-3 GI50
    0.12 μM
    Compound: Doxorubicin
    Growth inhibition of human SKOV3 cells after 72 hrs by SRB assay
    Growth inhibition of human SKOV3 cells after 72 hrs by SRB assay
    		[PMID: 18585035]
    SK-OV-3 GI50
    0.22 μM
    Compound: Doxorubicin
    Growth inhibition of human SKOV3 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human SKOV3 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28329730]
    SK-OV-3 GI50
    0.22 μM
    Compound: Doxorubicin
    Growth inhibition of human SKOV3 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human SKOV3 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 29102177]
    SK-OV-3 GI50
    0.22 μM
    Compound: Doxorubicin hydrochloride, NSC 123127
    Cytotoxicity against human SKOV3 cells after 48 hrs by SRB assay
    Cytotoxicity against human SKOV3 cells after 48 hrs by SRB assay
    		[PMID: 23871905]
    SK-OV-3 GI50
    8.8 μM
    Compound: Dox
    Antiproliferative activity against human SK-OV-3 cells incubated for 72 hrs and measured by MTT assay
    Antiproliferative activity against human SK-OV-3 cells incubated for 72 hrs and measured by MTT assay
    		[PMID: 35973342]
    SK-OV-3 GI50
    9.1 μM
    Compound: Dox
    Anticancer activity against human SK-OV-3 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    Anticancer activity against human SK-OV-3 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    		[PMID: 35533562]
    SK-OV-3 IC50
    0.001 μM
    Compound: Doxorubicin
    Cytotoxicity against human SKOV3 cells by SRB assay
    Cytotoxicity against human SKOV3 cells by SRB assay
    		[PMID: 20719504]
    SK-OV-3 IC50
    0.00184 μM
    Compound: Doxorubicin
    Antiproliferative activity against human SKOV3 cells after 48 hrs by CCK-8 assay
    Antiproliferative activity against human SKOV3 cells after 48 hrs by CCK-8 assay
    		[PMID: 30253344]
    SK-OV-3 IC50
    0.002 μM
    Compound: Doxorubicin
    Cytotoxicity against human SKOV3 cells after 48 hrs by SRB assay
    Cytotoxicity against human SKOV3 cells after 48 hrs by SRB assay
    		[PMID: 22483395]
    SK-OV-3 IC50
    0.003 μM
    Compound: Doxorubicin
    Cytotoxicity against human SKOV3 cells by SRB assay
    Cytotoxicity against human SKOV3 cells by SRB assay
    		[PMID: 20594848]
    SK-OV-3 IC50
    0.004 μM
    Compound: Doxorubicin
    Cytotoxicity against human SKOV3 cells by SRB assay
    Cytotoxicity against human SKOV3 cells by SRB assay
    		[PMID: 22951040]
    SK-OV-3 IC50
    0.008 μM
    Compound: Adriamycin
    Cytotoxicity against human SKOV3 cells
    Cytotoxicity against human SKOV3 cells
    		[PMID: 11754602]
    SK-OV-3 IC50
    0.009 μM
    Compound: Doxorubicin
    Antiproliferative activity against human SK-OV-3 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Antiproliferative activity against human SK-OV-3 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    		[PMID: 27010926]
    SK-OV-3 IC50
    0.01 μM
    Compound: Doxorubicin
    Cytotoxicity against human SKOV3 cells assessed as growth inhibition by SRB assay
    Cytotoxicity against human SKOV3 cells assessed as growth inhibition by SRB assay
    		[PMID: 23634786]
    SK-OV-3 IC50
    0.01 μM
    Compound: Doxorubicin
    Cytotoxicity against human SKOV3 cells by sulforhodamine B assay
    Cytotoxicity against human SKOV3 cells by sulforhodamine B assay
    		[PMID: 23815260]
    SK-OV-3 IC50
    0.012 μM
    Compound: Doxorubicin
    Cytotoxicity against human SKOV3 cells assessed as cell growth inhibition after 48 hrs by SRB assay
    Cytotoxicity against human SKOV3 cells assessed as cell growth inhibition after 48 hrs by SRB assay
    		[PMID: 25466198]
    SK-OV-3 IC50
    0.012 μM
    Compound: Doxorubicin
    Cytotoxicity against human SKOV3 cells assessed as inhibition of cell growth incubated for 48 hrs by SRB assay
    Cytotoxicity against human SKOV3 cells assessed as inhibition of cell growth incubated for 48 hrs by SRB assay
    		[PMID: 25981688]
    SK-OV-3 IC50
    0.01 μg/mL
    Compound: doxorubicin
    Cytotoxicity against human SKOV3 cells after 2 to 7 days by neutral red assay
    Cytotoxicity against human SKOV3 cells after 2 to 7 days by neutral red assay
    		[PMID: 8984156]
    SK-OV-3 IC50
    0.02 μM
    Compound: 1 (Doxorubicin)
    In vitro cytotoxic activity against human ovarian carcinoma cell line SK-OV-3 after 72 hr of drug exposure determined by the SRB assay
    In vitro cytotoxic activity against human ovarian carcinoma cell line SK-OV-3 after 72 hr of drug exposure determined by the SRB assay
    		[PMID: 14980672]
    SK-OV-3 IC50
    0.02 μM
    Compound: Doxorubicin
    Antiproliferative activity against human SKOV3 cells assessed as inhibition of cell proliferation incubated for 72 hrs by conventional ATP quantification method
    Antiproliferative activity against human SKOV3 cells assessed as inhibition of cell proliferation incubated for 72 hrs by conventional ATP quantification method
    		[PMID: 25937235]
    SK-OV-3 IC50
    0.02 μM
    Compound: Doxorubicin
    Compound was tested for its antitumor activity against SKOV3 human ovarian cancer cell line
    Compound was tested for its antitumor activity against SKOV3 human ovarian cancer cell line
    		[PMID: 9873394]
    SK-OV-3 IC50
    0.02 μM
    Compound: Doxorubicin
    In vitro cytotoxic activity against SK-OV-3 (ovarian carcinoma) cell lines by using SRB assay
    In vitro cytotoxic activity against SK-OV-3 (ovarian carcinoma) cell lines by using SRB assay
    		[PMID: 9873661]
    SK-OV-3 IC50
    0.0217 μM
    Compound: Doxorubicin
    Cytotoxicity against human SKOV3 cells by sulforhodamine B bioassay
    Cytotoxicity against human SKOV3 cells by sulforhodamine B bioassay
    		[PMID: 25098650]
    SK-OV-3 IC50
    0.024 μg/mL
    Compound: doxorubicin
    Anticancer activity against human SKOV3 cells after 72 hrs by sulforhodamine B assay
    Anticancer activity against human SKOV3 cells after 72 hrs by sulforhodamine B assay
    		[PMID: 19342127]
    SK-OV-3 IC50
    0.0251 μM
    Compound: Doxorubicin
    Inhibitory concentration the viability of SKOV 3 cell population by 50%.
    Inhibitory concentration the viability of SKOV 3 cell population by 50%.
    		[PMID: 9003520]
    SK-OV-3 IC50
    0.03 μM
    Compound: Adriamycin
    Cytotoxicity against human SKOV3 cells after 72 hrs by WST8 assay
    Cytotoxicity against human SKOV3 cells after 72 hrs by WST8 assay
    		[PMID: 23039861]
    SK-OV-3 IC50
    0.032 μM
    Compound: Doxorubicin
    Antiproliferative activity against human SKOV3 cells after 72 hrs by MTT assay
    Antiproliferative activity against human SKOV3 cells after 72 hrs by MTT assay
    		[PMID: 31264855]
    SK-OV-3 IC50
    0.033 μM
    Compound: DOX
    Cytotoxicity against human SK-OV-3 cells incubated for 48 hrs by MTT assay
    Cytotoxicity against human SK-OV-3 cells incubated for 48 hrs by MTT assay
    		[PMID: 38185054]
    SK-OV-3 IC50
    0.041 μM
    Compound: doxorubicin
    Cytotoxicity against human SKOV3 cells after 3 days by SRB assay
    Cytotoxicity against human SKOV3 cells after 3 days by SRB assay
    		[PMID: 18321715]
    SK-OV-3 IC50
    0.043 μM
    Compound: doxorubicin
    Compound was tested for cytotoxicity against ovarian adenocarcinoma, multidrug resistant
    Compound was tested for cytotoxicity against ovarian adenocarcinoma, multidrug resistant
    		[PMID: 8182705]
    SK-OV-3 IC50
    0.046 μM
    Compound: Doxorubicin
    Anticancer activity against human SKOV3 cells by sulforhodamine B assay
    Anticancer activity against human SKOV3 cells by sulforhodamine B assay
    		[PMID: 19819696]
    SK-OV-3 IC50
    0.05 μM
    Compound: DOX
    Antiproliferative activity against human SKOV3 cells after 72 hrs by Sulforhodamine B-stain assay
    Antiproliferative activity against human SKOV3 cells after 72 hrs by Sulforhodamine B-stain assay
    		[PMID: 27484508]
    SK-OV-3 IC50
    0.056 μM
    Compound: doxorubicin
    Cytotoxicity against human SKOV3 cells by SRB assay
    Cytotoxicity against human SKOV3 cells by SRB assay
    		[PMID: 19435339]
    SK-OV-3 IC50
    0.073 μM
    Compound: Dox
    Antiproliferative activity against human SKOV3 cells after 72 hrs by MTT assay
    Antiproliferative activity against human SKOV3 cells after 72 hrs by MTT assay
    		[PMID: 27089210]
    SK-OV-3 IC50
    0.074 μM
    Compound: Doxorubicin
    Cytotoxicity against human SKOV3 cells assessed as reduction in cell proliferation measured after 48 hrs by SRB assay
    Cytotoxicity against human SKOV3 cells assessed as reduction in cell proliferation measured after 48 hrs by SRB assay
    		[PMID: 27856237]
    SK-OV-3 IC50
    0.078 μM
    Compound: Doxirubicin
    Concentration required to inhibit SKOV-3-cell growth by 50%
    Concentration required to inhibit SKOV-3-cell growth by 50%
    		[PMID: 9703471]
    SK-OV-3 IC50
    0.078 μM
    Compound: Doxorubicin
    In vitro cytotoxicity was tested against human Ovarian carcinoma SKOV-3 cell line
    In vitro cytotoxicity was tested against human Ovarian carcinoma SKOV-3 cell line
    		[PMID: 10411474]
    SK-OV-3 IC50
    0.078 μM
    Compound: Dx
    The compound was tested for cytotoxic activity against SKOV-3 cell line(human ovarian carcinoma )
    The compound was tested for cytotoxic activity against SKOV-3 cell line(human ovarian carcinoma )
    		[PMID: 11123989]
    SK-OV-3 IC50
    0.08 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human SKOV3 cells by sulforhodamine B assay
    Cytotoxicity against human SKOV3 cells by sulforhodamine B assay
    		[PMID: 21684168]
    SK-OV-3 IC50
    0.09 μg/mL
    Compound: Doxorubicin
    Cytotoxic activity against SKOV-3 cell line (human solid ovarian tumor cell line)
    Cytotoxic activity against SKOV-3 cell line (human solid ovarian tumor cell line)
    		[PMID: 15922597]
    SK-OV-3 IC50
    0.16 μM
    Compound: DOX
    Cytotoxicity against human SKOV3 cells assessed as cell growth inhibition after 48 hrs by MTT assay
    Cytotoxicity against human SKOV3 cells assessed as cell growth inhibition after 48 hrs by MTT assay
    		[PMID: 31999451]
    SK-OV-3 IC50
    0.17 μM
    Compound: ADR
    Cytotoxicity against human SKOV3 cells after 72 hrs by sulforhodamine B assay
    Cytotoxicity against human SKOV3 cells after 72 hrs by sulforhodamine B assay
    		[PMID: 20949916]
    SK-OV-3 IC50
    0.181 μM
    Compound: Doxorubicin
    Anticancer activity against human SKOV3 cells after 48 hrs by SRB assay
    Anticancer activity against human SKOV3 cells after 48 hrs by SRB assay
    		[PMID: 17070967]
    SK-OV-3 IC50
    0.18 μg/mL
    Compound: adriamycin
    Cytotoxicity against human SKOV3 cells by SRB assay
    Cytotoxicity against human SKOV3 cells by SRB assay
    		[PMID: 15921426]
    SK-OV-3 IC50
    0.19 μM
    Compound: ADM
    Antiproliferative activity against human SK-OV-3 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
    Antiproliferative activity against human SK-OV-3 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
    		[PMID: 36332551]
    SK-OV-3 IC50
    0.2 μM
    Compound: Doxorubicin
    Cytotoxicity against human SKOV3 cells after 48 hrs by neutral red assay relative to control
    Cytotoxicity against human SKOV3 cells after 48 hrs by neutral red assay relative to control
    		[PMID: 25975638]
    SK-OV-3 IC50
    0.23 μM
    Compound: doxorubicin
    Cytotoxicity against human SK-OV3 cells after 48 hrs
    Cytotoxicity against human SK-OV3 cells after 48 hrs
    		[PMID: 17673337]
    SK-OV-3 IC50
    0.29 μM
    Compound: doxorubicin
    Cytotoxicity against human SK-OV-3 cells by SRB assay
    Cytotoxicity against human SK-OV-3 cells by SRB assay
    		[PMID: 17194596]
    SK-OV-3 IC50
    0.321 μM
    Compound: Doxorubicin
    Cytotoxicity against human SKOV3 cells after 48 hrs by neutral red dye based assay
    Cytotoxicity against human SKOV3 cells after 48 hrs by neutral red dye based assay
    		[PMID: 29317147]
    SK-OV-3 IC50
    0.38 μM
    Compound: Doxorubicin
    Cytotoxicity against human SKOV3 cells by SRB assay
    Cytotoxicity against human SKOV3 cells by SRB assay
    		[PMID: 20176479]
    SK-OV-3 IC50
    0.42 μM
    Compound: Doxorubicin
    Cytotoxicity against human SKOV3 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Cytotoxicity against human SKOV3 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    		[PMID: 28327308]
    SK-OV-3 IC50
    0.6 μg/mL
    Compound: doxorubicin
    Cytotoxicity against human SKOV3 cells after 48 hrs by neutral red dye staining
    Cytotoxicity against human SKOV3 cells after 48 hrs by neutral red dye staining
    		[PMID: 19928902]
    SK-OV-3 IC50
    0.7 μM
    Compound: Doxorubicin
    Cytotoxicity against human SKOV3 cells assessed as reduction in cell viability by MTT assay
    Cytotoxicity against human SKOV3 cells assessed as reduction in cell viability by MTT assay
    		[PMID: 26646219]
    SK-OV-3 IC50
    0.7 μM
    Compound: Doxorubicin
    Cytotoxicity against human SKOV3 cells assessed as reduction in cell viability by MTT assay
    Cytotoxicity against human SKOV3 cells assessed as reduction in cell viability by MTT assay
    		[PMID: 26774921]
    SK-OV-3 IC50
    0.7 μM
    Compound: Doxorubicin
    Cytotoxicity against human SKOV3 cells assessed as cell growth inhibition by MTT assay
    Cytotoxicity against human SKOV3 cells assessed as cell growth inhibition by MTT assay
    		[PMID: 27187861]
    SK-OV-3 IC50
    0.7 μM
    Compound: Doxorubicin
    Cytotoxicity against human SKOV3 cells incubated for 24 hrs by MTT asasy
    Cytotoxicity against human SKOV3 cells incubated for 24 hrs by MTT asasy
    		[PMID: 28615134]
    SK-OV-3 IC50
    0.75 μg/mL
    Compound: doxorubicin
    Cytotoxicity against human SK-OV3 cells by neutral red assay
    Cytotoxicity against human SK-OV3 cells by neutral red assay
    		[PMID: 17976995]
    SK-OV-3 IC50
    0.8 μM
    Compound: Doxorubicin
    Cytotoxicity against Homo sapiens (human) SKOV3 cells by neutral red staining
    Cytotoxicity against Homo sapiens (human) SKOV3 cells by neutral red staining
    		10.1007/s00044-011-9587-3
    SK-OV-3 IC50
    0.8 μM
    Compound: Doxorubicin
    Cytotoxicity against human SKOV3 cells after 48 hrs by Neutral red assay
    Cytotoxicity against human SKOV3 cells after 48 hrs by Neutral red assay
    		[PMID: 19658408]
    SK-OV-3 IC50
    0.8 μM
    Compound: Doxorubicin
    Cytotoxicity against human SKOV3 cells by MTT assay
    Cytotoxicity against human SKOV3 cells by MTT assay
    		[PMID: 26586599]
    SK-OV-3 IC50
    1.1 μM
    Compound: Doxorubicin
    Cytotoxicity against human SKOV3 cells assessed as cell growth inhibition after 48 hrs by neutral red assay
    Cytotoxicity against human SKOV3 cells assessed as cell growth inhibition after 48 hrs by neutral red assay
    		[PMID: 26005918]
    SK-OV-3 IC50
    1.17 μM
    Compound: Doxorubicin
    Cytotoxic activity against SKOV-3 human ovarian tumor cell line, using sulforhodamine B (SRB) assay.
    Cytotoxic activity against SKOV-3 human ovarian tumor cell line, using sulforhodamine B (SRB) assay.
    		[PMID: 14643344]
    SK-OV-3 IC50
    1.17 μM
    Compound: Doxorubicin
    Cytotoxicity against human SKOV3 cells
    Cytotoxicity against human SKOV3 cells
    		[PMID: 21095131]
    SK-OV-3 IC50
    1.2 μg/mL
    Compound: doxorubicin
    Cytotoxicity against human SKOV3 cells after 48 hrs by Neutral Red dye
    Cytotoxicity against human SKOV3 cells after 48 hrs by Neutral Red dye
    		[PMID: 20550123]
    SK-OV-3 IC50
    1.3 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human SKOV3 cells assessed as cell growth inhibition after 48 hrs by neutral red dye based assay
    Cytotoxicity against human SKOV3 cells assessed as cell growth inhibition after 48 hrs by neutral red dye based assay
    		[PMID: 27769668]
    SK-OV-3 IC50
    1.5 μM
    Compound: doxorubicin
    Cytotoxicity against human SKOV3 cells assessed as viable cells by neutral red dye method
    Cytotoxicity against human SKOV3 cells assessed as viable cells by neutral red dye method
    		[PMID: 22530813]
    SK-OV-3 IC50
    1.53 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human SKOV3 cells after 48 hrs by neutral red staining
    Cytotoxicity against human SKOV3 cells after 48 hrs by neutral red staining
    		[PMID: 15165136]
    SK-OV-3 IC50
    1.53 μg/mL
    Compound: doxorubicin
    Cytotoxicity against human SKOV3 cells
    Cytotoxicity against human SKOV3 cells
    		[PMID: 12880315]
    SK-OV-3 IC50
    1.7 μM
    Compound: DOX
    Antiproliferative activity against human SKOV3 cells after 48 hrs by MTT assay
    Antiproliferative activity against human SKOV3 cells after 48 hrs by MTT assay
    		[PMID: 28756264]
    SK-OV-3 IC50
    128 nM
    Compound: Doxorubicin
    Cytotoxicity against arrested non-proliferative human SKOV3 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
    Cytotoxicity against arrested non-proliferative human SKOV3 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
    		[PMID: 30429975]
    SK-OV-3 IC50
    16.37 μM
    Compound: Doxorubicin
    Cytotoxicity against human SKOV3 cells by MTT assay
    Cytotoxicity against human SKOV3 cells by MTT assay
    		[PMID: 26873414]
    SK-OV-3 IC50
    2.04 μM
    Compound: doxorubicin
    Cytotoxicity against human SKOV3 cells after 48 hrs by neutral red assay
    Cytotoxicity against human SKOV3 cells after 48 hrs by neutral red assay
    		[PMID: 19879765]
    SK-OV-3 IC50
    2.6 μM
    Compound: Doxorubicin
    Cytotoxicity against human SKOV3 cells assessed as reduction in cell viability after 48 hrs by neutral red dye-based assay
    Cytotoxicity against human SKOV3 cells assessed as reduction in cell viability after 48 hrs by neutral red dye-based assay
    		[PMID: 27618204]
    SK-OV-3 IC50
    2.6 μM
    Compound: doxorubicin
    Cytotoxicity against human SKOV3 cells assessed as growth inhibition measured after 48 hrs by XTT assay
    Cytotoxicity against human SKOV3 cells assessed as growth inhibition measured after 48 hrs by XTT assay
    		[PMID: 23547843]
    SK-OV-3 IC50
    2.947 μM
    Compound: Doxorubicin
    Anticancer activity against human SKOV3 cells by MTT assay
    Anticancer activity against human SKOV3 cells by MTT assay
    		[PMID: 21570750]
    SK-OV-3 IC50
    25.04 μM
    Compound: Doxo
    Cytotoxicity against human SKOV3 cells assessed as inhibition of cell proliferation after 24 hrs by MTT assay
    Cytotoxicity against human SKOV3 cells assessed as inhibition of cell proliferation after 24 hrs by MTT assay
    		[PMID: 27036521]
    SK-OV-3 IC50
    25.83 nM
    Compound: Doxorubicin
    Antiproliferative activity against human SK-OV-3 cells assessed as cell growth inhibition measured after 72 hrs by crystal violet staining based assay
    Antiproliferative activity against human SK-OV-3 cells assessed as cell growth inhibition measured after 72 hrs by crystal violet staining based assay
    		[PMID: 34795858]
    SK-OV-3 IC50
    3 μM
    Compound: DOX
    Cytotoxicity against human SKOV3 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay
    Cytotoxicity against human SKOV3 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay
    		[PMID: 31589431]
    SK-OV-3 IC50
    3.12 μM
    Compound: DOX
    Antiproliferative activity against human SK-OV-3 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Antiproliferative activity against human SK-OV-3 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    		[PMID: 36252396]
    SK-OV-3 IC50
    32.6 nM
    Compound: Doxorubicin
    Cytotoxicity against human SKOV3 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
    Cytotoxicity against human SKOV3 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
    		[PMID: 30429975]
    SK-OV-3 IC50
    34.2 nM
    Compound: Doxorubicin
    Antiproliferative activity against human SKOV3 cells assessed as reduction in cell viability incubated for 24 hrs by SRB assay
    Antiproliferative activity against human SKOV3 cells assessed as reduction in cell viability incubated for 24 hrs by SRB assay
    		[PMID: 31655432]
    SK-OV-3 IC50
    36 nM
    Compound: Doxorubicin
    Cytotoxicity was determined in vitro in SK-OV-3 cells (ovarian) of human tumor cell lines by using MTT assay
    Cytotoxicity was determined in vitro in SK-OV-3 cells (ovarian) of human tumor cell lines by using MTT assay
    		[PMID: 7853331]
    SK-OV-3 IC50
    36 nM
    Compound: Doxorubicin
    Human tumor cell cytotoxicity assay was performed using MTT (SK-OV3 cell line )
    Human tumor cell cytotoxicity assay was performed using MTT (SK-OV3 cell line )
    		[PMID: 8576914]
    SK-OV-3 IC50
    4.15 μM
    Compound: Doxorubicin
    Cytotoxicity against human ovarian adenocarcinoma (SK-OV-3) cell line using MTT assay
    Cytotoxicity against human ovarian adenocarcinoma (SK-OV-3) cell line using MTT assay
    		[PMID: 9873387]
    SK-OV-3 IC50
    4.16 x 10-3 μM
    Compound: Doxorubicin
    Cytotoxicity against human SKOV3 cells by MTT assay
    Cytotoxicity against human SKOV3 cells by MTT assay
    		[PMID: 19345581]
    SK-OV-3 IC50
    4.16 μM
    Compound: Doxorubicin
    Cytotoxicity against human SKOV3 cells after 3 days by MTT assay
    Cytotoxicity against human SKOV3 cells after 3 days by MTT assay
    		[PMID: 20356655]
    SK-OV-3 IC50
    41 nM
    Compound: Doxorubicine
    Cytotoxicity against human SKOV3 cells after 72 hrs by MTS assay
    Cytotoxicity against human SKOV3 cells after 72 hrs by MTS assay
    		[PMID: 21142180]
    SK-OV-3 IC50
    5 μM
    Compound: Dox
    Cytotoxicity against human SKOV3 cells after 48 hrs
    Cytotoxicity against human SKOV3 cells after 48 hrs
    		[PMID: 22276998]
    SK-OV-3 IC50
    55.7 μM
    Compound: DOX
    Cytotoxicity against human SKOV3 cells after 24 hrs by XTT assay
    Cytotoxicity against human SKOV3 cells after 24 hrs by XTT assay
    		[PMID: 24900668]
    SK-OV-3 IC50
    6.7 μM
    Compound: Doxorubicin
    Cytotoxicity against human SK-OV-3 cells assessed as number of viable cells measured after 48 hrs by MTT based colorimetric assay
    Cytotoxicity against human SK-OV-3 cells assessed as number of viable cells measured after 48 hrs by MTT based colorimetric assay
    		[PMID: 36970146]
    SK-OV-3 IC50
    88.4 μM
    Compound: Doxorubicin
    Antiproliferative activity against human SK-OV-3 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    Antiproliferative activity against human SK-OV-3 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    		[PMID: 39038494]
    SK-OV-3 IC50
    < 0.55 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human SKOV3 cells after 48 hrs by neutral red assay
    Cytotoxicity against human SKOV3 cells after 48 hrs by neutral red assay
    		[PMID: 19105653]
    SK-OV-3 IC50
    < 1.1 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human SKOV3 cells after 2 to 7 days by neutral red assay
    Cytotoxicity against human SKOV3 cells after 2 to 7 days by neutral red assay
    		[PMID: 11374943]
    SK-OV-3 IC50
    > 20 μM
    Compound: DOX
    Cytotoxicity against human SKOV3 cells after 24 hrs by XTT assay
    Cytotoxicity against human SKOV3 cells after 24 hrs by XTT assay
    		[PMID: 24900344]
    SK-UT-1 IC50
    0.076 μM
    Compound: Doxorubicin
    Cytotoxicity against human SK-UT-1 cells after 72 hrs by resazurin/resorufin-based fluorescence assay
    Cytotoxicity against human SK-UT-1 cells after 72 hrs by resazurin/resorufin-based fluorescence assay
    		[PMID: 23600925]
    SK-VLB IC50
    0.009 μM
    Compound: Doxorubicin
    Antiproliferative activity against human SK-VLB cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Antiproliferative activity against human SK-VLB cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    		[PMID: 27010926]
    SK-VLB IC50
    5600 nM
    Compound: Doxorubicin
    Human tumor cell cytotoxicity assay was performed using MTT (SKVLB cell line )
    Human tumor cell cytotoxicity assay was performed using MTT (SKVLB cell line )
    		[PMID: 8576914]
    SK-VLB IC50
    5650 nM
    Compound: Doxorubicin
    Cytotoxicity was determined in vitro in SKVLB cells(ovarian with upregulated MDRp-glycoprotein) of human tumor cell lines by using MTT assay
    Cytotoxicity was determined in vitro in SKVLB cells(ovarian with upregulated MDRp-glycoprotein) of human tumor cell lines by using MTT assay
    		[PMID: 7853331]
    SK-VLB IC50
    6.54 μM
    Compound: Doxorubicin
    Inhibitory concentration that reduced the viability of SKVLB cell population by 50%.
    Inhibitory concentration that reduced the viability of SKVLB cell population by 50%.
    		[PMID: 9003520]
    SK-VLB IC50
    > 10 μM
    Compound: doxorubicin
    Compound was tested for cytotoxicity against colon adenocarcinoma
    Compound was tested for cytotoxicity against colon adenocarcinoma
    		[PMID: 8182705]
    SMMC-7721 IC50
    0.23 μM
    Compound: Doxorubicin
    Cytotoxicity against human SMMC-7721 cells
    Cytotoxicity against human SMMC-7721 cells
    		[PMID: 31926469]
    SMMC-7721 IC50
    0.3 μM
    Compound: Doxorubicin
    Cytotoxicity against human SMMC7721 cells after 24 hrs by MTT assay
    Cytotoxicity against human SMMC7721 cells after 24 hrs by MTT assay
    		[PMID: 25554367]
    SMMC-7721 IC50
    0.37 μM
    Compound: Doxorubicin
    Cytotoxicity against human SMMC7721 cells after 48 hrs by MTT assay
    Cytotoxicity against human SMMC7721 cells after 48 hrs by MTT assay
    		[PMID: 22537362]
    SMMC-7721 IC50
    0.37 μM
    Compound: doxorubicin
    Cytotoxicity against human SMMC7721 cells after 48 hrs by MTT assay
    Cytotoxicity against human SMMC7721 cells after 48 hrs by MTT assay
    		[PMID: 21087017]
    SMMC-7721 IC50
    0.46 μM
    Compound: Doxorubicin
    Anticancer activity against human SMMC-7721 cells incubated for 48 hrs by MTT assay
    Anticancer activity against human SMMC-7721 cells incubated for 48 hrs by MTT assay
    		[PMID: 35367708]
    SMMC-7721 IC50
    0.57 μM
    Compound: Doxorubicin
    Cytotoxicity against human SMMC7721 cells assessed as growth inhibition incubated for 72 hrs by MTT assay
    Cytotoxicity against human SMMC7721 cells assessed as growth inhibition incubated for 72 hrs by MTT assay
    		[PMID: 26280922]
    SMMC-7721 IC50
    0.706 μM
    Compound: Doxorubicin
    Cytotoxicity against human SMMC-7721 cells by SRB assay
    Cytotoxicity against human SMMC-7721 cells by SRB assay
    		[PMID: 34128674]
    SMMC-7721 IC50
    0.73 μM
    Compound: ADM
    Antiproliferative activity against human SMMC7721 cells after 48 hrs by MTT assay
    Antiproliferative activity against human SMMC7721 cells after 48 hrs by MTT assay
    		[PMID: 30025345]
    SMMC-7721 IC50
    1.02 μM
    Compound: Doxorubicin
    Cytotoxicity against human SMMC-7721 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
    Cytotoxicity against human SMMC-7721 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
    		[PMID: 34838335]
    SMMC-7721 IC50
    1.06 μM
    Compound: Doxorubicin
    Cytotoxicity against human SMMC7721 cells after 48 hrs by MTT assay
    Cytotoxicity against human SMMC7721 cells after 48 hrs by MTT assay
    		[PMID: 20846862]
    SMMC-7721 IC50
    1.1 μM
    Compound: doxorubicin
    Cytotoxicity against human SMMC7721 cells after 48 hrs by MTT assay
    Cytotoxicity against human SMMC7721 cells after 48 hrs by MTT assay
    		[PMID: 25314138]
    SMMC-7721 IC50
    1.2 μM
    Compound: Doxorubicin
    Cytotoxicity against human SMMC7721 cells assessed as reduction in cell viability by MTT assay
    Cytotoxicity against human SMMC7721 cells assessed as reduction in cell viability by MTT assay
    		[PMID: 30660827]
    SMMC-7721 IC50
    1.22 μM
    Compound: AMD
    Anticancer activity against human SMMC7721 cells assessed as cell survival after 48 hrs by MTT assay
    Anticancer activity against human SMMC7721 cells assessed as cell survival after 48 hrs by MTT assay
    		[PMID: 25812966]
    SMMC-7721 IC50
    1.39 μM
    Compound: Dox
    Cytotoxicity against human SMMC7721 cells assessed as inhibition of cell growth after 48 hrs by MTT assay
    Cytotoxicity against human SMMC7721 cells assessed as inhibition of cell growth after 48 hrs by MTT assay
    		[PMID: 27397495]
    SMMC-7721 IC50
    1.4 μM
    Compound: DOX
    Cytotoxicity against human SMMC-7721 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    Cytotoxicity against human SMMC-7721 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    		[PMID: 32371335]
    SMMC-7721 IC50
    1.47 μM
    Compound: DOX
    Cytotoxicity against human SMMC7721 cells assessed as reduction in cell viability after 24 hrs by MTT assay
    Cytotoxicity against human SMMC7721 cells assessed as reduction in cell viability after 24 hrs by MTT assay
    		[PMID: 29909338]
    SMMC-7721 IC50
    1.59 μM
    Compound: Doxorubicin
    Antiproliferative activity against human SMMC7721 cells after 72 hrs by MTT assay
    Antiproliferative activity against human SMMC7721 cells after 72 hrs by MTT assay
    		[PMID: 29172084]
    SMMC-7721 IC50
    1.6 μM
    Compound: Doxorubicin
    Cytotoxicity against human SMMC7721 cells assessed as reduction in cell viability
    Cytotoxicity against human SMMC7721 cells assessed as reduction in cell viability
    		[PMID: 30660827]
    SMMC-7721 IC50
    1.8 μM
    Compound: DOX
    Cytotoxicity against human SMMC-7721 cells assessed as reduction in cell viability measured after 24 hrs by CCK8 assay
    Cytotoxicity against human SMMC-7721 cells assessed as reduction in cell viability measured after 24 hrs by CCK8 assay
    		[PMID: 34450496]
    SMMC-7721 IC50
    1.95 μM
    Compound: AMD
    Antiproliferative activity against human SMMC-7721 cells measured after 48 hrs by MTT assay
    Antiproliferative activity against human SMMC-7721 cells measured after 48 hrs by MTT assay
    		[PMID: 27639364]
    SMMC-7721 IC50
    172 μM
    Compound: ADM
    Cytotoxicity against human SMMC7721 cells
    Cytotoxicity against human SMMC7721 cells
    		[PMID: 22283451]
    SMMC-7721 IC50
    2.3 μM
    Compound: Doxorubicin
    Antiproliferative activity against human SMMC7721 cells by MTT assay
    Antiproliferative activity against human SMMC7721 cells by MTT assay
    		[PMID: 30660827]
    SMMC-7721 IC50
    2.5 μM
    Compound: Doxorubicin
    Antiproliferative activity against human SMMC7721 cells after 24 to 72 hrs by MTT assay
    Antiproliferative activity against human SMMC7721 cells after 24 to 72 hrs by MTT assay
    		[PMID: 30660827]
    SMMC-7721 IC50
    2.75 μM
    Compound: DOX
    Cytotoxicity against human SMMC7721 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    Cytotoxicity against human SMMC7721 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    		[PMID: 30771605]
    SN12C GI50
    0.07 μM
    Compound: Doxorubicin
    Growth inhibition of human SN12C cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human SN12C cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28329730]
    SN12C GI50
    0.07 μM
    Compound: Doxorubicin
    Growth inhibition of human SN12C cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human SN12C cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 29102177]
    SN12C GI50
    0.07 μM
    Compound: Doxorubicin hydrochloride, NSC 123127
    Cytotoxicity against human SN12C cells after 48 hrs by SRB assay
    Cytotoxicity against human SN12C cells after 48 hrs by SRB assay
    		[PMID: 23871905]
    SNB-19 ED50
    0.002 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human SNB19 cells by sulforhodamine B method
    Cytotoxicity against human SNB19 cells by sulforhodamine B method
    		[PMID: 12193011]
    SNB-19 GI50
    0.04 μM
    Compound: Doxorubicin
    Growth inhibition of human SNB19 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human SNB19 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28329730]
    SNB-19 GI50
    0.04 μM
    Compound: Doxorubicin
    Growth inhibition of human SNB19 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human SNB19 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 29102177]
    SNB-19 GI50
    0.04 μM
    Compound: Doxorubicin hydrochloride, NSC 123127
    Cytotoxicity against human SNB19 cells after 48 hrs by SRB assay
    Cytotoxicity against human SNB19 cells after 48 hrs by SRB assay
    		[PMID: 23871905]
    SNB-19 IC50
    0.15 μM
    Compound: DOX
    Antiproliferative activity against human SNB19 cells after 72 hrs by MTT assay
    Antiproliferative activity against human SNB19 cells after 72 hrs by MTT assay
    		[PMID: 30429098]
    SNB-19 IC50
    0.29 μg/mL
    Compound: Adriamycin
    Inhibitory concentration required against SNB19 CNS cancer cell line
    Inhibitory concentration required against SNB19 CNS cancer cell line
    		[PMID: 11354370]
    SNB-19 IC50
    0.76 μM
    Compound: Doxorubicin
    Antiproliferative activity against human SNB-19 cells assessed as reduction in cell viability by MTT assay
    Antiproliferative activity against human SNB-19 cells assessed as reduction in cell viability by MTT assay
    		[PMID: 34715305]
    SNB-19 IC50
    0.8 μM
    Compound: Doxorubicin
    Antitumor activity against human SNB19 cells after 24 to 48 hrs by MTT assay
    Antitumor activity against human SNB19 cells after 24 to 48 hrs by MTT assay
    		[PMID: 21553829]
    SNB-19 IC50
    1.2 μM
    Compound: Doxorubicin
    Cytotoxicity against human SNB-19 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    Cytotoxicity against human SNB-19 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    		[PMID: 34778772]
    SNB-75 GI50
    0.07 μM
    Compound: Doxorubicin
    Growth inhibition of human SNB75 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human SNB75 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28329730]
    SNB-75 GI50
    0.07 μM
    Compound: Doxorubicin
    Growth inhibition of human SNB75 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human SNB75 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 29102177]
    SNB-75 GI50
    0.07 μM
    Compound: Doxorubicin hydrochloride, NSC 123127
    Cytotoxicity against human SNB75 cells after 48 hrs by SRB assay
    Cytotoxicity against human SNB75 cells after 48 hrs by SRB assay
    		[PMID: 23871905]
    SNB-75 IC50
    5.82 μM
    Compound: Dox
    Cytotoxicity against human SNB-75 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay
    Cytotoxicity against human SNB-75 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay
    		[PMID: 36395650]
    SNU-16 IC50
    0.16 μg/mL
    Compound: Adriamycin
    In vitro cytotoxicity against SNU16 tumor cell lines.
    In vitro cytotoxicity against SNU16 tumor cell lines.
    		[PMID: 9871531]
    SNU-354 IC50
    0.54 μg/mL
    Compound: Doxorubicin
    In vitro cytotoxic activity against SNU-354(liver cancer cell) by using SRB assay after 72 hr of drug exposure
    In vitro cytotoxic activity against SNU-354(liver cancer cell) by using SRB assay after 72 hr of drug exposure
    		10.1016/0960-894X(96)00156-4
    SNU-354 IC50
    < 0.5 μg/mL
    Compound: Doxorubicin
    In vitro cytotoxic activity against human tumor SNU 354 (liver) cell line
    In vitro cytotoxic activity against human tumor SNU 354 (liver) cell line
    		10.1016/0960-894X(95)00338-T
    SNU-398 GI50
    0.39 μM
    Compound: Doxorubicin
    Induction of apoptosis in human SNU398 cells assessed as caspase activation after 48 hrs
    Induction of apoptosis in human SNU398 cells assessed as caspase activation after 48 hrs
    		[PMID: 19282188]
    SNU-449 IC50
    71.4 μM
    Compound: Doxorubicin
    Antiproliferative activity against human SNU-449 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    Antiproliferative activity against human SNU-449 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    		[PMID: 39038494]
    SNU-5 IC50
    0.237 μM
    Compound: ADR
    Antiproliferative activity against human SNU5 cells after 72 hrs by CCK8 assay
    Antiproliferative activity against human SNU5 cells after 72 hrs by CCK8 assay
    		[PMID: 30241010]
    SNU-638 GI50
    0.13 μM
    Compound: Doxorubicin
    Growth inhibition of human HCT116 cells after 2 days by SRB assay
    Growth inhibition of human HCT116 cells after 2 days by SRB assay
    		[PMID: 22000924]
    SNU-638 IC50
    0.052 μM
    Compound: doxorubicin
    Cytotoxicity against human SNU638 cells after 3 days by SRB assay
    Cytotoxicity against human SNU638 cells after 3 days by SRB assay
    		[PMID: 18321715]
    SNU-638 IC50
    0.06 μM
    Compound: doxorubicin
    Cytotoxicity against human SNU638 cells by SRB assay
    Cytotoxicity against human SNU638 cells by SRB assay
    		[PMID: 17194596]
    SNU-638 IC50
    0.07 μM
    Compound: Doxorubicin
    Antiproliferative activity against human SNU638 cells after 72 hrs by SRB assay
    Antiproliferative activity against human SNU638 cells after 72 hrs by SRB assay
    		[PMID: 18063366]
    SNU-638 IC50
    0.69 μM
    Compound: Doxorubicin
    In vitro cytotoxicity against human SNU-638 (stomach cancer) cell line.
    In vitro cytotoxicity against human SNU-638 (stomach cancer) cell line.
    		[PMID: 15177438]
    SNU-638 IC50
    0.84 μM
    Compound: Adriamycin
    Cytotoxicity against human SNU638 cells by MTT assay
    Cytotoxicity against human SNU638 cells by MTT assay
    		[PMID: 23608763]
    SNU-C4 IC50
    < 0.5 μg/mL
    Compound: Doxorubicin
    In vitro cytotoxic activity against human tumor SNU C-4(colon) cell line
    In vitro cytotoxic activity against human tumor SNU C-4(colon) cell line
    		10.1016/0960-894X(95)00338-T
    SNU1 IC50
    0.27 μg/mL
    Compound: Doxorubicin
    In vitro cytotoxic activity against SNU-1(stomach cancer cell) by using SRB assay after 72 hr of drug exposure
    In vitro cytotoxic activity against SNU-1(stomach cancer cell) by using SRB assay after 72 hr of drug exposure
    		10.1016/0960-894X(96)00156-4
    SNU1 IC50
    2.15 μg/mL
    Compound: Adriamycin
    In vitro cytotoxicity of compound was measured on human gastric adenocarcinoma (SNU-1) cells.
    In vitro cytotoxicity of compound was measured on human gastric adenocarcinoma (SNU-1) cells.
    		[PMID: 9873721]
    SNU1 IC50
    4 μM
    Compound: adriamycin
    Cytotoxicity against human SNU1 cells by rapid colorimetric assay
    Cytotoxicity against human SNU1 cells by rapid colorimetric assay
    		[PMID: 19585998]
    SNU1 IC50
    < 0.5 μg/mL
    Compound: Doxorubicin
    In vitro cytotoxic activity against human tumor SNU 1 (stomach) cell line
    In vitro cytotoxic activity against human tumor SNU 1 (stomach) cell line
    		10.1016/0960-894X(95)00338-T
    SR GI50
    0.03 μM
    Compound: Doxorubicin
    Growth inhibition of human SR cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human SR cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28329730]
    SR GI50
    0.03 μM
    Compound: Doxorubicin
    Growth inhibition of human SR cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human SR cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 29102177]
    SR GI50
    0.03 μM
    Compound: Doxorubicin hydrochloride, NSC 123127
    Cytotoxicity against human SR cells after 48 hrs by SRB assay
    Cytotoxicity against human SR cells after 48 hrs by SRB assay
    		[PMID: 23871905]
    SR IC50
    0.59 μM
    Compound: Doxorubicin
    Antiproliferative activity against human SR cells assessed as inhibition of cell growth incubated for 2 to 4 hrs by MTT assay
    Antiproliferative activity against human SR cells assessed as inhibition of cell growth incubated for 2 to 4 hrs by MTT assay
    		[PMID: 38389871]
    SUM149PT IC50
    0.36 μM
    Compound: Doxorubicin
    Antiproliferative activity against human SUM149PT cells after 48 hrs by SRB assay
    Antiproliferative activity against human SUM149PT cells after 48 hrs by SRB assay
    		[PMID: 29407962]
    SUP-T1 IC50
    0.04 μM
    Compound: Doxorubicin
    Cytotoxicity against human SupT1 cells assessed as growth inhibition after 72 hrs by MTT assay
    Cytotoxicity against human SupT1 cells assessed as growth inhibition after 72 hrs by MTT assay
    		[PMID: 27623548]
    SW 1116 IC50
    6.9 μM
    Compound: Doxorubicin
    Antiproliferative activity against human SW1116 cells assessed as inhibition of cell growth after overnight incubation by MTT assay
    Antiproliferative activity against human SW1116 cells assessed as inhibition of cell growth after overnight incubation by MTT assay
    		[PMID: 32165076]
    SW-620 ED50
    0.003 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human SW620 cells by sulforhodamine B method
    Cytotoxicity against human SW620 cells by sulforhodamine B method
    		[PMID: 12193011]
    SW-620 ED50
    0.1 μg/mL
    Compound: Adriamycin
    Cytotoxicity against human SW620 cells
    Cytotoxicity against human SW620 cells
    		[PMID: 10346965]
    SW-620 GI50
    0.03 μM
    Compound: Doxorubicin
    Growth inhibition of Homo sapiens (human) SW620 cells after 48 hr by MTT assay
    Growth inhibition of Homo sapiens (human) SW620 cells after 48 hr by MTT assay
    		10.1007/s00044-012-0232-6
    SW-620 GI50
    0.09 μM
    Compound: Doxorubicin
    Growth inhibition of human SW620 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human SW620 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28329730]
    SW-620 GI50
    0.09 μM
    Compound: Doxorubicin
    Growth inhibition of human SW620 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human SW620 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 29102177]
    SW-620 GI50
    0.09 μM
    Compound: Doxorubicin hydrochloride, NSC 123127
    Cytotoxicity against human SW620 cells after 48 hrs by SRB assay
    Cytotoxicity against human SW620 cells after 48 hrs by SRB assay
    		[PMID: 23871905]
    SW-620 IC50
    0.01 μM
    Compound: Adriamycin
    Cytotoxicity against human SW620 cells after 72 hrs by MTT assay
    Cytotoxicity against human SW620 cells after 72 hrs by MTT assay
    		[PMID: 21721528]
    SW-620 IC50
    0.02 μM
    Compound: DOX
    Antitumor activity against human SW620 cells after 72 hrs by MTT assay
    Antitumor activity against human SW620 cells after 72 hrs by MTT assay
    		[PMID: 17935309]
    SW-620 IC50
    0.02 μM
    Compound: Doxorubicin
    Cytotoxicity against human SW620 cells after 72 hrs by MTT assay
    Cytotoxicity against human SW620 cells after 72 hrs by MTT assay
    		[PMID: 20207049]
    SW-620 IC50
    0.04 μM
    Compound: Doxorubicin
    Antiproliferative activity against human SW620 cells after 72 hrs by MTT assay
    Antiproliferative activity against human SW620 cells after 72 hrs by MTT assay
    		[PMID: 22555152]
    SW-620 IC50
    0.08 μM
    Compound: Doxorubicin
    Cytotoxicity against human SW620 cells after 72 hrs by MTT assay
    Cytotoxicity against human SW620 cells after 72 hrs by MTT assay
    		[PMID: 19361894]
    SW-620 IC50
    0.11 μM
    Compound: Doxorubicin
    Antiproliferative activity against human SW620 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Antiproliferative activity against human SW620 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    		[PMID: 31975579]
    SW-620 IC50
    0.12 μM
    Compound: Adriamycin
    Cytotoxicity against human SW620 cells assessed as inhibition of cell proliferation after 48 hrs by XTT assay
    Cytotoxicity against human SW620 cells assessed as inhibition of cell proliferation after 48 hrs by XTT assay
    		[PMID: 24717154]
    SW-620 IC50
    0.12 μM
    Compound: Doxorubicin
    Antitumor activity against human SW620 cells after 24 to 48 hrs by MTT assay
    Antitumor activity against human SW620 cells after 24 to 48 hrs by MTT assay
    		[PMID: 21553829]
    SW-620 IC50
    0.17 μM
    Compound: Doxorubicin
    Growth inhibition of human SW620 cells after 72 hrs by SRB assay
    Growth inhibition of human SW620 cells after 72 hrs by SRB assay
    		[PMID: 25215856]
    SW-620 IC50
    0.178 μM
    Compound: Doxorubicin
    Inhibitory concentration against SW 620 human colon carcinoma cell line
    Inhibitory concentration against SW 620 human colon carcinoma cell line
    		[PMID: 15715481]
    SW-620 IC50
    0.178 μM
    Compound: Doxorubicin
    Cytotoxicity against human SW620 cells after 24 hrs by SRB method
    Cytotoxicity against human SW620 cells after 24 hrs by SRB method
    		[PMID: 18429610]
    SW-620 IC50
    0.178 μM
    Compound: doxorubicin
    Cytotoxicity against human SW620 cells
    Cytotoxicity against human SW620 cells
    		[PMID: 17375902]
    SW-620 IC50
    0.17 μg/mL
    Compound: Adriamycin
    Inhibitory concentration required against SW620 colon cancer cell line
    Inhibitory concentration required against SW620 colon cancer cell line
    		[PMID: 11354370]
    SW-620 IC50
    0.21 μM
    Compound: Doxorubicin
    Cytotoxicity against human SW620 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human SW620 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 29501942]
    SW-620 IC50
    0.23 μM
    Compound: Dox
    Cytotoxicity against human SW620 cells after 3 days by MTT assay
    Cytotoxicity against human SW620 cells after 3 days by MTT assay
    		[PMID: 21741833]
    SW-620 IC50
    0.24 μM
    Compound: Adriamycin
    Cytotoxicity against human SW620 cells selected at 20 ng/mL adriamycin after 72 hrs by MTT assay
    Cytotoxicity against human SW620 cells selected at 20 ng/mL adriamycin after 72 hrs by MTT assay
    		[PMID: 21721528]
    SW-620 IC50
    0.256 μM
    Compound: DOX
    Reversal of doxorubicin-induced multidrug resistance in human SW620 cells measured after 48 hrs by CCK-8 method
    Reversal of doxorubicin-induced multidrug resistance in human SW620 cells measured after 48 hrs by CCK-8 method
    		[PMID: 38389882]
    SW-620 IC50
    0.26 μM
    Compound: DOX
    Antiproliferative activity against human SW620 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Antiproliferative activity against human SW620 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    		[PMID: 31678743]
    SW-620 IC50
    0.26 μM
    Compound: Doxorubicin
    Cytotoxicity against human SW620 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
    Cytotoxicity against human SW620 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
    		[PMID: 37951135]
    SW-620 IC50
    0.29 μM
    Compound: DOXO
    Antiproliferative activity against human SW620 cells after 72 hrs by MTT assay
    Antiproliferative activity against human SW620 cells after 72 hrs by MTT assay
    		[PMID: 28818447]
    SW-620 IC50
    0.75 μM
    Compound: Doxorubicin
    Antiproliferative activity tested as 50% inhibition of DNA synthesis in human SW620 colon carcinoma cell line
    Antiproliferative activity tested as 50% inhibition of DNA synthesis in human SW620 colon carcinoma cell line
    		[PMID: 11720862]
    SW-620 IC50
    0.77 μM
    Compound: Dox
    Cytotoxicity against human SW620 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human SW620 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 31306817]
    SW-620 IC50
    1.33 μM
    Compound: DOX
    Antiproliferative activity against human SW620 cells after 72 hrs by sulforhodamine B assay
    Antiproliferative activity against human SW620 cells after 72 hrs by sulforhodamine B assay
    		[PMID: 25981689]
    SW-620 IC50
    2.3 μM
    Compound: Doxorubicin
    Antiproliferative activity against human SW-620 cells assessed as reduction in cell viability incubated for 48 hrs by CCK-8 assay
    Antiproliferative activity against human SW-620 cells assessed as reduction in cell viability incubated for 48 hrs by CCK-8 assay
    		[PMID: 38856635]
    SW-620 IC50
    > 10 μg/mL
    Compound: doxorubicin
    Cytotoxicity against human SW620 cells after 3 days by MTT assay
    Cytotoxicity against human SW620 cells after 3 days by MTT assay
    		[PMID: 19456120]
    SW1990 IC50
    > 100 μM
    Compound: Doxorubicin
    Cytotoxicity against human SW1990 cells after 48 hrs by MTT assay
    Cytotoxicity against human SW1990 cells after 48 hrs by MTT assay
    		[PMID: 22304344]
    SW480 IC50
    0.06 μM
    Compound: Adriamycin
    In vitro antitumor activity against SW480 (colon) human tumor cell lines.
    In vitro antitumor activity against SW480 (colon) human tumor cell lines.
    		10.1016/0960-894X(96)00167-9
    SW480 IC50
    0.06 μM
    Compound: Doxorubicin
    Anticancer activity against human SW480 cells after 48 hrs by MTT assay
    Anticancer activity against human SW480 cells after 48 hrs by MTT assay
    		[PMID: 21641694]
    SW480 IC50
    0.29 μM
    Compound: Doxorubicin
    Cytotoxicity against human SW480 cells assessed as growth inhibition measured after 72 hrs by MTT assay
    Cytotoxicity against human SW480 cells assessed as growth inhibition measured after 72 hrs by MTT assay
    		[PMID: 31383628]
    SW480 IC50
    0.406 μM
    Compound: Doxorubicin
    Antiproliferative activity against human SW480 cells after 48 hrs by MTT assay
    Antiproliferative activity against human SW480 cells after 48 hrs by MTT assay
    		[PMID: 28406643]
    SW480 IC50
    0.53 μM
    Compound: Doxorubicin
    Antiproliferative activity against human SW480 cells after 48 hrs by MTT assay
    Antiproliferative activity against human SW480 cells after 48 hrs by MTT assay
    		10.1039/C5MD00163C
    SW480 IC50
    0.75 μM
    Compound: DOX
    Antiproliferative activity against human SW480 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Antiproliferative activity against human SW480 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    		[PMID: 31678743]
    SW480 IC50
    0.75 μM
    Compound: Doxorubicin
    Cytotoxicity against human SW480 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
    Cytotoxicity against human SW480 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
    		[PMID: 37951135]
    SW480 IC50
    12.4 μM
    Compound: Doxorubicin
    Cytotoxicity against human SW480 cells measured after 24 to 72 hrs by MTT assay
    Cytotoxicity against human SW480 cells measured after 24 to 72 hrs by MTT assay
    		[PMID: 37482018]
    SW480 IC50
    2.43 μM
    Compound: Doxorubicin
    Antiproliferative activity against human SW480 cells after 48 hrs by MTT assay
    Antiproliferative activity against human SW480 cells after 48 hrs by MTT assay
    		[PMID: 24418772]
    SW480 IC50
    65.25 μM
    Compound: Doxorubicin
    Cytotoxicity against human SW480 cells after 24 hrs by MTT assay
    Cytotoxicity against human SW480 cells after 24 hrs by MTT assay
    		[PMID: 22182926]
    SW620/AD300 IC50
    10.52 μM
    Compound: DOX
    Reversal of doxorubicin-induced multidrug resistance in human SW620/AD300 cells measured after 48 hrs by CCK-8 method
    Reversal of doxorubicin-induced multidrug resistance in human SW620/AD300 cells measured after 48 hrs by CCK-8 method
    		[PMID: 38389882]
    SW620/AD300 IC50
    15.24 μM
    Compound: Doxorubicin
    Cytotoxicity against human SW620/AD300 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human SW620/AD300 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 29501942]
    SW620/AD300 IC50
    28.2 μM
    Compound: Doxorubicin
    Growth inhibition of human SW620/AD300 cells after 72 hrs by SRB assay
    Growth inhibition of human SW620/AD300 cells after 72 hrs by SRB assay
    		[PMID: 25215856]
    SW620/AD300 IC50
    4.9 μM
    Compound: Doxorubicin
    Antiproliferative activity against human SW620/AD300 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Antiproliferative activity against human SW620/AD300 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    		[PMID: 31975579]
    SW872 IC50
    0.14 μM
    Compound: Doxorubicin
    Cytotoxicity against human SW872 cells after 72 hrs by resazurin/resorufin-based fluorescence assay
    Cytotoxicity against human SW872 cells after 72 hrs by resazurin/resorufin-based fluorescence assay
    		[PMID: 23600925]
    SiHa GI50
    0.14 μM
    Compound: ADR
    Growth inhibition of human SiHa cells by SRB assay
    Growth inhibition of human SiHa cells by SRB assay
    		[PMID: 22361684]
    SiHa GI50
    0.17 μM
    Compound: ADR
    Growth inhibition of human SiHa cells
    Growth inhibition of human SiHa cells
    		10.1039/C1MD00072A
    SiHa GI50
    0.17 μM
    Compound: ADR
    Growth inhibition of human SiHa cells after 48 hrs by SRB assay
    Growth inhibition of human SiHa cells after 48 hrs by SRB assay
    		[PMID: 20031423]
    SiHa GI50
    0.17 μM
    Compound: ADR
    Cytotoxicity against human SiHa cells after 24 hrs by WST-1 assay
    Cytotoxicity against human SiHa cells after 24 hrs by WST-1 assay
    		[PMID: 20732817]
    SiHa GI50
    0.17 μM
    Compound: ADR
    Anticancer activity against human SiHa cells by SRB method
    Anticancer activity against human SiHa cells by SRB method
    		[PMID: 21676506]
    SiHa GI50
    0.17 μM
    Compound: ADR
    Growth inhibition of human SiHa cells after 48 hrs by sulforhodamine B assay
    Growth inhibition of human SiHa cells after 48 hrs by sulforhodamine B assay
    		[PMID: 23849207]
    SiHa GI50
    0.18 μM
    Compound: ADR
    Cytotoxicity against human SiHa cells after 48 hrs by sulforhodamine B assay
    Cytotoxicity against human SiHa cells after 48 hrs by sulforhodamine B assay
    		[PMID: 18657979]
    SiHa GI50
    0.18 μM
    Compound: ADR, Adriamycin
    Growth inhibition of human SiHa cells by SRB method
    Growth inhibition of human SiHa cells by SRB method
    		[PMID: 18207392]
    SiHa GI50
    0.18 μM
    Compound: adriamycin
    Cytotoxicity against human SiHa cells after 24 hrs by SRB method
    Cytotoxicity against human SiHa cells after 24 hrs by SRB method
    		[PMID: 18262426]
    SiHa GI50
    1.9 μM
    Compound: ADR
    Anticancer activity against human SiHa cells by SRB method
    Anticancer activity against human SiHa cells by SRB method
    		[PMID: 22104151]
    SiHa GI50
    2.1 μM
    Compound: ADR
    Cytotoxicity against human SiHa cells after 48 hrs by SRB assay
    Cytotoxicity against human SiHa cells after 48 hrs by SRB assay
    		[PMID: 20673627]
    SiHa GI50
    < 0.01 μM
    Compound: Doxorubicin
    Growth inhibition of human SiHa cells after 48 hrs by SRB assay
    Growth inhibition of human SiHa cells after 48 hrs by SRB assay
    		10.1039/C6MD00097E
    SiHa GI50
    < 0.01 μM
    Compound: Doxorubicin
    Growth inhibition in human SiHa cells after 48 hrs by SRB assay
    Growth inhibition in human SiHa cells after 48 hrs by SRB assay
    		[PMID: 31546197]
    SiHa IC50
    0.311 μM
    Compound: Doxorubicin
    Antiproliferative activity against human SiHa cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Antiproliferative activity against human SiHa cells assessed as reduction in cell viability after 48 hrs by MTT assay
    		[PMID: 31883489]
    SiHa IC50
    0.45 μM
    Compound: Doxorubicin
    Anticancer activity against human SiHa cells after 48 hrs by MTT assay
    Anticancer activity against human SiHa cells after 48 hrs by MTT assay
    		[PMID: 21641694]
    SiHa IC50
    0.5 μM
    Compound: adriamycin
    Cytotoxicity against human SIHA cells under deem light after 96 hrs by MTT assay
    Cytotoxicity against human SIHA cells under deem light after 96 hrs by MTT assay
    		[PMID: 17993275]
    SiHa IC50
    0.76 μM
    Compound: Dox
    Cytotoxicity against human SiHa cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human SiHa cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 30615450]
    SiHa IC50
    1.5 μM
    Compound: ADR
    Cytotoxicity against human SiHa cells by sulforhodamine B assay
    Cytotoxicity against human SiHa cells by sulforhodamine B assay
    		[PMID: 17822905]
    SiHa IC50
    1.5 μM
    Compound: ADR
    Cytotoxicity against human SiHa cells by SRB assay
    Cytotoxicity against human SiHa cells by SRB assay
    		[PMID: 18656370]
    SiHa IC50
    1.5 μM
    Compound: Doxorubicin
    Cytotoxicity against human SiHa cells assessed as reduction in cell viability measured after 48 hrs by SRB assay
    Cytotoxicity against human SiHa cells assessed as reduction in cell viability measured after 48 hrs by SRB assay
    		[PMID: 28818768]
    SiHa IC50
    1.9 μM
    Compound: Doxorubicin
    Antiproliferative activity against human SiHa cells after 48 hrs by SRB assay
    Antiproliferative activity against human SiHa cells after 48 hrs by SRB assay
    		[PMID: 28419927]
    SiHa IC50
    2.04 μM
    Compound: Doxorubicin
    Antitumor activity against human SiHa cells assessed as inhibition of cell growth by MTT assay
    Antitumor activity against human SiHa cells assessed as inhibition of cell growth by MTT assay
    		[PMID: 25160837]
    T-24 CC50
    5.2 μM
    Compound: Doxorubicin
    Antiproliferative activity against human T24 cells assessed as cell growth inhibition by MTT assay
    Antiproliferative activity against human T24 cells assessed as cell growth inhibition by MTT assay
    		[PMID: 37944413]
    T-24 IC50
    0.64 μM
    Compound: doxorubicin
    Growth inhibitory concentration of compound was measured against human bladder carcinoma cell line (T24)
    Growth inhibitory concentration of compound was measured against human bladder carcinoma cell line (T24)
    		[PMID: 10698436]
    T-24 IC50
    0.96 μM
    Compound: DOX
    Cytotoxicity against human T24 cells after 48 hrs by MTT assay
    Cytotoxicity against human T24 cells after 48 hrs by MTT assay
    		[PMID: 31057738]
    T-24 IC50
    20 nM
    Compound: Doxorubicin
    In vitro cytotoxicity expressed as concentration that inhibits 50% of T24 (bladder) sensitive variant cell proliferation
    In vitro cytotoxicity expressed as concentration that inhibits 50% of T24 (bladder) sensitive variant cell proliferation
    		[PMID: 11606141]
    T-24 IC50
    > 10000 nM
    Compound: Doxorubicin
    In vitro cytotoxicity expressed as concentration that inhibits 50% of T24 (bladder) resistant variant cell proliferation
    In vitro cytotoxicity expressed as concentration that inhibits 50% of T24 (bladder) resistant variant cell proliferation
    		[PMID: 11606141]
    T47D EC50
    0.57 μM
    Compound: Doxorubicin
    Induction of apoptosis in human T47D cells assessed as caspase activation after 48 hrs
    Induction of apoptosis in human T47D cells assessed as caspase activation after 48 hrs
    		[PMID: 19282188]
    T47D EC50
    127 nM
    Compound: Doxorubicin
    Antiproliferative activity against human T47D cells assessed as reduction in cell viability incubated for 5 days by celltiter-glo assay
    Antiproliferative activity against human T47D cells assessed as reduction in cell viability incubated for 5 days by celltiter-glo assay
    		[PMID: 30996949]
    T47D GI50
    0.06 μM
    Compound: Doxorubicin
    Growth inhibition of human T47D cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human T47D cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28329730]
    T47D GI50
    0.06 μM
    Compound: Doxorubicin
    Growth inhibition of human T47D cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human T47D cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 29102177]
    T47D GI50
    0.06 μM
    Compound: Doxorubicin hydrochloride, NSC 123127
    Cytotoxicity against human T47D cells after 48 hrs by SRB assay
    Cytotoxicity against human T47D cells after 48 hrs by SRB assay
    		[PMID: 23871905]
    T47D IC50
    0.007 μM
    Compound: 1 (Doxorubicin)
    In vitro cytotoxic activity against human breast cancer cell line T-47D after 72 hr of drug exposure determined by the SRB assay
    In vitro cytotoxic activity against human breast cancer cell line T-47D after 72 hr of drug exposure determined by the SRB assay
    		[PMID: 14980672]
    T47D IC50
    0.007 μM
    Compound: Doxorubicin
    Inhibitory activity against T47D cell line using MTT assay (ER+,mutant p53)
    Inhibitory activity against T47D cell line using MTT assay (ER+,mutant p53)
    		[PMID: 10780913]
    T47D IC50
    0.02 μM
    Compound: Doxorubicin
    Antiproliferative activity against human T47D cells assessed as inhibition of cell proliferation incubated for 72 hrs by conventional ATP quantification method
    Antiproliferative activity against human T47D cells assessed as inhibition of cell proliferation incubated for 72 hrs by conventional ATP quantification method
    		[PMID: 25937235]
    T47D IC50
    0.027 μM
    Compound: adriamycin
    Antitumor activity against human T47D cells by methylene blue staining method
    Antitumor activity against human T47D cells by methylene blue staining method
    		[PMID: 17656091]
    T47D IC50
    0.08 μM
    Compound: Doxorubicin
    Antiproliferative activity against 2D culture of human T47D cells after 72 hrs MTS assay
    Antiproliferative activity against 2D culture of human T47D cells after 72 hrs MTS assay
    		[PMID: 27721156]
    T47D IC50
    0.1 μM
    Compound: Doxorubicin
    Antiproliferative activity against human T47D cells after 72 hrs by SRB assay
    Antiproliferative activity against human T47D cells after 72 hrs by SRB assay
    		[PMID: 18063366]
    T47D IC50
    0.1 μM
    Compound: Doxorubicin
    Cytotoxicity against human T47D cells after 72 hrs by resazurin/resorufin-based fluorescence assay
    Cytotoxicity against human T47D cells after 72 hrs by resazurin/resorufin-based fluorescence assay
    		[PMID: 23600925]
    T47D IC50
    0.16 μM
    Compound: Dox
    Antiproliferative activity against human T47D cells assessed as growth inhibition under normoxia conditions measured after 72 hrs by MTT assay
    Antiproliferative activity against human T47D cells assessed as growth inhibition under normoxia conditions measured after 72 hrs by MTT assay
    		[PMID: 34902732]
    T47D IC50
    0.18 μM
    Compound: Dox
    Antiproliferative activity against human T47D cells assessed as growth inhibition under hypoxia conditions measured after 72 hrs by MTT assay
    Antiproliferative activity against human T47D cells assessed as growth inhibition under hypoxia conditions measured after 72 hrs by MTT assay
    		[PMID: 34902732]
    T47D IC50
    0.25 μM
    Compound: Doxorubicin
    Cytotoxicity against human T47D cells after 2 days by MTT assay
    Cytotoxicity against human T47D cells after 2 days by MTT assay
    		[PMID: 20800481]
    T47D IC50
    0.33 μM
    Compound: Doxorubicin
    Cytotoxicity against human T47D cells after 72 hrs by MTT assay
    Cytotoxicity against human T47D cells after 72 hrs by MTT assay
    		[PMID: 22677031]
    T47D IC50
    0.41 μM
    Compound: Adriamycin
    Cytotoxicity against human T47D cells after 2 days by CCK-8 assay
    Cytotoxicity against human T47D cells after 2 days by CCK-8 assay
    		[PMID: 24013413]
    T47D IC50
    0.7 μM
    Compound: Doxorubicin
    Antiproliferative activity against human T47D cells assessed as reduction in cell growth after 24 hrs by MTS assay
    Antiproliferative activity against human T47D cells assessed as reduction in cell growth after 24 hrs by MTS assay
    		[PMID: 25300820]
    T47D IC50
    0.84 μM
    Compound: Dox
    Cytotoxicity against human T47D cells after 2 days
    Cytotoxicity against human T47D cells after 2 days
    		[PMID: 24904965]
    T47D IC50
    0.88 μM
    Compound: Doxorubicin
    Cytotoxicity against human T47D cells assessed as reduction in cell growth measured after 48 hrs by MTT assay
    Cytotoxicity against human T47D cells assessed as reduction in cell growth measured after 48 hrs by MTT assay
    		[PMID: 31416738]
    T47D IC50
    1 μM
    Compound: Doxorubicin
    Antiproliferative activity against human T47D cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Antiproliferative activity against human T47D cells assessed as reduction in cell viability after 48 hrs by MTT assay
    		[PMID: 31546197]
    T47D IC50
    1.01 μM
    Compound: Doxorubicin
    Antiproliferative activity against 3D culture of human T47D cells after 72 hrs MTS assay
    Antiproliferative activity against 3D culture of human T47D cells after 72 hrs MTS assay
    		[PMID: 27721156]
    T47D IC50
    1.05 μM
    Compound: Adriamycin
    Cytotoxicity against human T47D cells after 2 days by cell counting kit-8 analysis
    Cytotoxicity against human T47D cells after 2 days by cell counting kit-8 analysis
    		[PMID: 22503656]
    T47D IC50
    1.34 μM
    Compound: adriamycin
    Cytotoxicity against human T47D cells measured on day 4 by CCK8 assay
    Cytotoxicity against human T47D cells measured on day 4 by CCK8 assay
    		[PMID: 25936262]
    T47D IC50
    1.82 μM
    Compound: ADR
    Cytotoxicity against human T47D cells after 72 hrs by MTT assay
    Cytotoxicity against human T47D cells after 72 hrs by MTT assay
    		[PMID: 22819942]
    T47D IC50
    1.88 μM
    Compound: Adriamycin
    Cytotoxicity against human T47D cells after 2 days by CCK8 assay
    Cytotoxicity against human T47D cells after 2 days by CCK8 assay
    		[PMID: 26361737]
    T47D IC50
    1.9 μM
    Compound: DOX
    Cytotoxicity against human T47D cells measured after 2 days by MTT assay
    Cytotoxicity against human T47D cells measured after 2 days by MTT assay
    		[PMID: 26334499]
    T47D IC50
    1.9 μM
    Compound: doxorubicin
    Cytotoxicity against human T47D cells after 72 hrs by CellTiter-Glo assay
    Cytotoxicity against human T47D cells after 72 hrs by CellTiter-Glo assay
    		[PMID: 22316168]
    T47D IC50
    15.53 μM
    Compound: DOX
    Anticancer activity against human T47D cells assessed as inhibition of tumor cell proliferation after 48 hrs by MTT assay
    Anticancer activity against human T47D cells assessed as inhibition of tumor cell proliferation after 48 hrs by MTT assay
    		[PMID: 25064350]
    T47D IC50
    2.53 μM
    Compound: Doxorubicin
    Antiproliferative activity against human T47D cells incubated for 72 hrs by microplate reader analysis
    Antiproliferative activity against human T47D cells incubated for 72 hrs by microplate reader analysis
    		[PMID: 37418826]
    T47D IC50
    2.91 μM
    Compound: Adriamycin
    Cytotoxicity against human T47D cells by MTT assay
    Cytotoxicity against human T47D cells by MTT assay
    		[PMID: 23608763]
    T47D IC50
    264 nM
    Compound: Doxorubicin
    Cytotoxicity against human T47D cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay
    Cytotoxicity against human T47D cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay
    		[PMID: 23468529]
    T47D IC50
    3.2 μM
    Compound: Doxorubicin
    Antiproliferative activity against human T47D cells assessed as cell growth inhibition incubated for 4 hrs under normoxia condition by MTT colorimetric assay
    Antiproliferative activity against human T47D cells assessed as cell growth inhibition incubated for 4 hrs under normoxia condition by MTT colorimetric assay
    		[PMID: 35551035]
    T47D IC50
    3.8 μM
    Compound: Doxorubicin
    Antiproliferative activity against human T47D cells assessed as cell growth inhibition incubated for 4 hrs under hypoxia condition by MTT colorimetric assay
    Antiproliferative activity against human T47D cells assessed as cell growth inhibition incubated for 4 hrs under hypoxia condition by MTT colorimetric assay
    		[PMID: 35551035]
    T47D IC50
    4.61 μM
    Compound: DOX
    Cytotoxicity against human T47D cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human T47D cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 28531811]
    T47D IC50
    72 nM
    Compound: Doxorubicin
    Cytotoxicity was determined in vitro in T47D cells(breast) of human tumor cell lines by using MTT assay
    Cytotoxicity was determined in vitro in T47D cells(breast) of human tumor cell lines by using MTT assay
    		[PMID: 7853331]
    T47D IC50
    9.8 μM
    Compound: Doxorubicin
    Cytotoxicity against human T47D cells after 48 hrs by sulforhodamine B assay
    Cytotoxicity against human T47D cells after 48 hrs by sulforhodamine B assay
    		[PMID: 27770735]
    T47D IC50
    9.8 μM
    Compound: Doxorubicin
    Antiproliferative activity against human T47D cells after 48 hrs by SRB assay
    Antiproliferative activity against human T47D cells after 48 hrs by SRB assay
    		[PMID: 28427017]
    T98G IC50
    0.1 μM
    Compound: Doxorubicin
    Cytotoxicity against p53 mutated human T98G cells asessed as reduction in cell viability incubated for 24 hrs by MTT assay
    Cytotoxicity against p53 mutated human T98G cells asessed as reduction in cell viability incubated for 24 hrs by MTT assay
    		[PMID: 31324563]
    T98G IC50
    0.5 μM
    Compound: doxorubicin
    Antiproliferative activity against human T98G cells after 24 hrs by EZ-Tox assay
    Antiproliferative activity against human T98G cells after 24 hrs by EZ-Tox assay
    		[PMID: 26631318]
    T98G IC50
    1 μM
    Compound: Doxorubicin
    Cytotoxicity against human T98G cells assessed as number of viable cells measured after 48 hrs by MTT based colorimetric assay
    Cytotoxicity against human T98G cells assessed as number of viable cells measured after 48 hrs by MTT based colorimetric assay
    		[PMID: 36970146]
    T98G IC50
    7 μM
    Compound: Doxorubicin
    Cytotoxicity against human T98G cells assessed as reduction in cell viability by DAPI staining based assay
    Cytotoxicity against human T98G cells assessed as reduction in cell viability by DAPI staining based assay
    		[PMID: 33461146]
    TE-1 IC50
    1.74 μM
    Compound: DOX
    Antiproliferative activity against human TE-1 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay
    Antiproliferative activity against human TE-1 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay
    		[PMID: 38079530]
    TERT-RPE1 IC50
    1 μM
    Compound: Dox
    Cytotoxicity against human TERT-RPE1 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay
    Cytotoxicity against human TERT-RPE1 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay
    		[PMID: 32428792]
    TERT-RPE1 IC50
    13.965 μM
    Compound: Dox
    Cytotoxicity against human RPE1 cells after 48 hrs by resazurin assay
    Cytotoxicity against human RPE1 cells after 48 hrs by resazurin assay
    		[PMID: 29107422]
    TERT-RPE1 IC50
    2.76 μM
    Compound: ADR
    Cytotoxicity in human hTERT-RPE1 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    Cytotoxicity in human hTERT-RPE1 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    		[PMID: 28754470]
    TERT-RPE1 IC50
    < 6.25 μM
    Compound: DOX
    Cytotoxicity against hTERT-RPE1 cells after 48 hrs by resazurin dye-based fluorescence assay
    Cytotoxicity against hTERT-RPE1 cells after 48 hrs by resazurin dye-based fluorescence assay
    		[PMID: 29665526]
    THLE-2 CC50
    12.7 μM
    Compound: Doxorubicin
    Cytotoxicity against human THLE2 cells assessed as reduction in cell viability by MTT assay
    Cytotoxicity against human THLE2 cells assessed as reduction in cell viability by MTT assay
    		[PMID: 33784602]
    THLE-2 GI50
    17.1 μM
    Compound: Doxorubicin
    Cytotoxicity against human THLE-2 cells assessed as cell growth inhibition
    Cytotoxicity against human THLE-2 cells assessed as cell growth inhibition
    		[PMID: 36584305]
    THP-1 CC50
    0.008 μM
    Compound: Doxorubicin
    Cytotoxicity against human THP1 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Cytotoxicity against human THP1 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    		[PMID: 25559208]
    THP-1 CC50
    0.58 μM
    Compound: Doxorubicin
    Cytotoxicity against human THP1 cells assessed as growth inhibition after 120 hrs by Alamar blue dye based fluorometric analysis
    Cytotoxicity against human THP1 cells assessed as growth inhibition after 120 hrs by Alamar blue dye based fluorometric analysis
    		[PMID: 33493972]
    THP-1 CC50
    0.7 μM
    Compound: Doxorubicin
    Cytotoxicity against human THP-1 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human THP-1 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 32652409]
    THP-1 CC50
    1.4 μM
    Compound: Doxorubicin
    Cytotoxicity against human THP1 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human THP1 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 30092366]
    THP-1 GI50
    0.6 μM
    Compound: Dox
    Cytotoxicity against human THP-1 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
    Cytotoxicity against human THP-1 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
    		[PMID: 34634616]
    THP-1 GI50
    23.1 μM
    Compound: Dox
    Antiproliferative activity against human THP-1 cells incubated for 72 hrs and measured by MTT assay
    Antiproliferative activity against human THP-1 cells incubated for 72 hrs and measured by MTT assay
    		[PMID: 35973342]
    THP-1 IC50
    0.008 μM
    Compound: Doxorubicin
    Cytotoxicity against human THP1 cells after 72 hrs by flow cytometry
    Cytotoxicity against human THP1 cells after 72 hrs by flow cytometry
    		[PMID: 20833057]
    THP-1 IC50
    0.008 μM
    Compound: Doxorubicin
    Cytotoxicity against human THP1 cells after 72 hrs by MTT assay
    Cytotoxicity against human THP1 cells after 72 hrs by MTT assay
    		[PMID: 25846065]
    THP-1 IC50
    0.02 μM
    Compound: Doxorubicin
    Cytotoxicity against human THP-1 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Cytotoxicity against human THP-1 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    		[PMID: 34782182]
    THP-1 IC50
    0.045 μM
    Compound: Doxorubicin
    Cytotoxicity against human THP-1 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    Cytotoxicity against human THP-1 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    		[PMID: 39026643]
    THP-1 IC50
    0.05 μM
    Compound: Doxorubicin
    Cytotoxicity against human THP1 cells assessed as cell viability after 72 hrs by Alamar blue assay
    Cytotoxicity against human THP1 cells assessed as cell viability after 72 hrs by Alamar blue assay
    		[PMID: 19914747]
    THP-1 IC50
    0.05 μM
    Compound: Doxorubicin
    Cytotoxicity against human THP1 cells assessed as cell viability after 72 hrs by MTT assay
    Cytotoxicity against human THP1 cells assessed as cell viability after 72 hrs by MTT assay
    		[PMID: 24650715]
    THP-1 IC50
    0.05 μM
    Compound: Doxorubicine
    Cytotoxicity against human THP1 cells after 72 hrs by propidium iodide staining-based flow cytometry
    Cytotoxicity against human THP1 cells after 72 hrs by propidium iodide staining-based flow cytometry
    		[PMID: 19748781]
    THP-1 IC50
    0.05 μM
    Compound: doxorubicin
    Cytotoxicity against human THP1 cells by MTT assay
    Cytotoxicity against human THP1 cells by MTT assay
    		[PMID: 17981462]
    THP-1 IC50
    0.07 μM
    Compound: Doxorubicin
    Cytotoxicity against human THP1 cells using propidium iodide staining after 72 hrs by flow cytometry
    Cytotoxicity against human THP1 cells using propidium iodide staining after 72 hrs by flow cytometry
    		[PMID: 20638854]
    THP-1 IC50
    0.11 μM
    Compound: Doxorubicin
    Antiproliferative activity against human THP1 cells after 72 hrs by XTT assay
    Antiproliferative activity against human THP1 cells after 72 hrs by XTT assay
    		10.1039/C1MD00234A
    THP-1 IC50
    0.3 μM
    Compound: Dox
    Cytotoxicity against human THP1 Cells
    Cytotoxicity against human THP1 Cells
    		[PMID: 31129455]
    THP-1 IC50
    0.67 μM
    Compound: DOX
    Cytotoxicity against human THP1 cells assessed as reduction in cell viability after 24 hrs by MTT assay
    Cytotoxicity against human THP1 cells assessed as reduction in cell viability after 24 hrs by MTT assay
    		[PMID: 29421568]
    THP-1 IC50
    1.8 μM
    Compound: Doxorubicin
    Cytotoxicity against human THP1 cells assessed as reduction in cell viability after 120 hrs by alamar blue assay
    Cytotoxicity against human THP1 cells assessed as reduction in cell viability after 120 hrs by alamar blue assay
    		[PMID: 32073851]
    THP-1 IC50
    15.7 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human THP-1 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay
    Cytotoxicity against human THP-1 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay
    		[PMID: 35526504]
    THP-1 IC50
    3.5 μM
    Compound: Doxorubicin
    Antiproliferative activity against human THP1 cells after 48 hrs by MTT assay
    Antiproliferative activity against human THP1 cells after 48 hrs by MTT assay
    		[PMID: 25453802]
    THP-1 IC50
    3 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human THP-1 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
    Cytotoxicity against human THP-1 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
    		[PMID: 35526504]
    THP-1 IC50
    6.5 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human THP-1 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
    Cytotoxicity against human THP-1 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
    		[PMID: 35526504]
    THP-1 IC50
    7.19 μM
    Compound: DOX
    Antiproliferative activity against human THP1 cells after 48 hrs by MTT assay
    Antiproliferative activity against human THP1 cells after 48 hrs by MTT assay
    		[PMID: 27108400]
    TK-10 GI50
    0.18 μM
    Compound: Doxorubicin hydrochloride, NSC 123127
    Cytotoxicity against human TK10 cells after 48 hrs by SRB assay
    Cytotoxicity against human TK10 cells after 48 hrs by SRB assay
    		[PMID: 23871905]
    TK-10 GI50
    0.38 μM
    Compound: Doxorubicin
    Growth inhibition of human TK10 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human TK10 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28329730]
    TK-10 GI50
    0.38 μM
    Compound: Doxorubicin
    Growth inhibition of human TK10 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human TK10 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 29102177]
    TK-10 GI50
    57 x 10-2 μM
    Compound: doxorubicin
    Cytotoxicity against human TK10 cells by SRB assay
    Cytotoxicity against human TK10 cells by SRB assay
    		[PMID: 11678649]
    TK-10 IC50
    0.02 μM
    Compound: Doxorubicin
    Antiproliferative activity against human TK10 cells assessed as inhibition of cell proliferation incubated for 72 hrs by conventional ATP quantification method
    Antiproliferative activity against human TK10 cells assessed as inhibition of cell proliferation incubated for 72 hrs by conventional ATP quantification method
    		[PMID: 25937235]
    TOV21G CC50
    4.1 μM
    Compound: Doxorubicin
    Antiproliferative activity against human TOV-21G cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
    Antiproliferative activity against human TOV-21G cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
    		[PMID: 37944413]
    TOV21G IC50
    0.373 μM
    Compound: Doxorubicin
    Anticancer activity against human TOV-21G-RT cells assessed as inhibition of cell growth
    Anticancer activity against human TOV-21G-RT cells assessed as inhibition of cell growth
    		[PMID: 33328099]
    TRAMP-C1A GI50
    20.4 nM
    Compound: DOX
    Growth inhibition of mouse C1A cells after 72 hrs by MTT assay
    Growth inhibition of mouse C1A cells after 72 hrs by MTT assay
    		[PMID: 17181166]
    TRAMP-C1A GI50
    20.4 nM
    Compound: Doxorubicin
    Cytotoxicity against mouse TRAMP-C1A cells assessed as inhibition of cell growth measured for 72 hrs by MTT assay
    Cytotoxicity against mouse TRAMP-C1A cells assessed as inhibition of cell growth measured for 72 hrs by MTT assay
    		[PMID: 31945642]
    TRAMP-C1A IC50
    75.9 nM
    Compound: Doxorubicin
    Inhibitory concentration to inhibit growth of C1A prostate cancer cell line by using MTT assay
    Inhibitory concentration to inhibit growth of C1A prostate cancer cell line by using MTT assay
    		[PMID: 14971910]
    TRAMP-C2H GI50
    15.8 nM
    Compound: DOX
    Growth inhibition of mouse C2H cells after 72 hrs by MTT assay
    Growth inhibition of mouse C2H cells after 72 hrs by MTT assay
    		[PMID: 17181166]
    TRAMP-C2H GI50
    15.8 nM
    Compound: Doxorubicin
    Cytotoxicity against mouse TRAMP-C2H cells assessed as inhibition of cell growth measured for 72 hrs by MTT assay
    Cytotoxicity against mouse TRAMP-C2H cells assessed as inhibition of cell growth measured for 72 hrs by MTT assay
    		[PMID: 31945642]
    TRAMP-C2H IC50
    30.3 nM
    Compound: Doxorubicin
    Inhibitory concentration to inhibit growth of C2H prostate cancer cell line by using MTT assay
    Inhibitory concentration to inhibit growth of C2H prostate cancer cell line by using MTT assay
    		[PMID: 14971910]
    U-251 EC50
    0.07 μM
    Compound: Doxorubicin
    Antiproliferative activity against human U-251 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay
    Antiproliferative activity against human U-251 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay
    		[PMID: 35567964]
    U-251 EC50
    0.12 μM
    Compound: Adriamycin
    Inhibition of HIF1 activation in human U251 cells stably transfected in pGL2-TK-HRE plasmid under hypoxic condition after 16 to 24 hrs by luciferase reporter gene assay
    Inhibition of HIF1 activation in human U251 cells stably transfected in pGL2-TK-HRE plasmid under hypoxic condition after 16 to 24 hrs by luciferase reporter gene assay
    		[PMID: 19405508]
    U-251 ED50
    0.001 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human U251 cells by sulforhodamine B method
    Cytotoxicity against human U251 cells by sulforhodamine B method
    		[PMID: 12193011]
    U-251 ED50
    0.02 μg/mL
    Compound: Adriamycin
    Cytotoxicity against human U251 cells after 24 hrs by SRB assay
    Cytotoxicity against human U251 cells after 24 hrs by SRB assay
    		[PMID: 20850305]
    U-251 GI50
    0.039 μg/mL
    Compound: DOX
    Antiproliferative activity against human U251 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    Antiproliferative activity against human U251 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    		[PMID: 25062010]
    U-251 GI50
    0.04 μM
    Compound: Doxorubicin
    Growth inhibition of human U251 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human U251 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28329730]
    U-251 GI50
    0.04 μM
    Compound: Doxorubicin
    Growth inhibition of human U251 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human U251 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 29102177]
    U-251 GI50
    0.04 μM
    Compound: Doxorubicin hydrochloride, NSC 123127
    Cytotoxicity against human U251 cells after 48 hrs by SRB assay
    Cytotoxicity against human U251 cells after 48 hrs by SRB assay
    		[PMID: 23871905]
    U-251 GI50
    0.068 μg/mL
    Compound: Doxorubicin
    Growth inhibition of human U251 cells after 48 hrs by sulforhodamine B assay
    Growth inhibition of human U251 cells after 48 hrs by sulforhodamine B assay
    		[PMID: 22410248]
    U-251 GI50
    0.14 μM
    Compound: Dox
    Growth inhibition of human U251 cells after 48 hrs by sulforhodamine B dye-based spectrophotometric assay
    Growth inhibition of human U251 cells after 48 hrs by sulforhodamine B dye-based spectrophotometric assay
    		[PMID: 28505535]
    U-251 GI50
    0.21 μM
    Compound: DOXO
    Antiproliferative activity against human U251 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    Antiproliferative activity against human U251 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    		[PMID: 31247374]
    U-251 GI50
    0.89 μM
    Compound: Dox
    Anticancer activity against human U-251 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    Anticancer activity against human U-251 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    		[PMID: 35533562]
    U-251 GI50
    < 0.025 μg/mL
    Compound: DOX; Doxo
    Antiproliferative activity against human U251 cells after 48 hrs by SRB assay
    Antiproliferative activity against human U251 cells after 48 hrs by SRB assay
    		[PMID: 26859070]
    U-251 GI50
    < 0.046 μM
    Compound: Dox
    Antiproliferative activity against human U251 cells assessed as growth inhibition after 48 hrs by SRB assay
    Antiproliferative activity against human U251 cells assessed as growth inhibition after 48 hrs by SRB assay
    		[PMID: 26454648]
    U-251 GI50
    < 0.046 μM
    Compound: Doxorubicin
    Anticancer activity against human U-251 cells assessed as cell growth inhibition measured after 48 hrs by sulforhodamine B assay
    Anticancer activity against human U-251 cells assessed as cell growth inhibition measured after 48 hrs by sulforhodamine B assay
    		[PMID: 33214037]
    U-251 IC50
    0.05 μM
    Compound: Doxorubicin
    Cytotoxicity against human U251 cells harboring mutant TP53 gene incubated for 72 hrs by MTS assay
    Cytotoxicity against human U251 cells harboring mutant TP53 gene incubated for 72 hrs by MTS assay
    		[PMID: 31158748]
    U-251 IC50
    0.05 μM
    Compound: Doxorubicin
    Antiproliferative activity against human U251 cells assessed as reduction in cell viability measured after 72 hrs by MTS assay
    Antiproliferative activity against human U251 cells assessed as reduction in cell viability measured after 72 hrs by MTS assay
    		[PMID: 31962262]
    U-251 IC50
    0.052 μM
    Compound: Doxorubicin
    Cytotoxicity against human U-251 cells assessed as reduction in cell viability measured after 72 hrs by MTS assay
    Cytotoxicity against human U-251 cells assessed as reduction in cell viability measured after 72 hrs by MTS assay
    		[PMID: 33261897]
    U-251 IC50
    0.09 μM
    Compound: Doxorubicine
    Inhibitory activity against U251 CNS cell line using sulforhodamine B (SRB) protein assay
    Inhibitory activity against U251 CNS cell line using sulforhodamine B (SRB) protein assay
    		[PMID: 12039588]
    U-251 IC50
    0.09 μM
    Compound: doxorubicin
    Cytotoxicity against human U251 cells
    Cytotoxicity against human U251 cells
    		[PMID: 12608854]
    U-251 IC50
    0.106 μM
    Compound: Doxorubicin
    Antiproliferative activity against human U-251 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
    Antiproliferative activity against human U-251 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
    		[PMID: 34325324]
    U-251 IC50
    0.17 μM
    Compound: DOX
    Cytotoxicity against human U251 cells measured after 72 hrs by Celltiter-Glo assay
    Cytotoxicity against human U251 cells measured after 72 hrs by Celltiter-Glo assay
    		[PMID: 31820976]
    U-251 IC50
    0.32 μM
    Compound: Adriamycin
    Cytotoxicity against human U251 cells after 48 hrs by SRB assay
    Cytotoxicity against human U251 cells after 48 hrs by SRB assay
    		[PMID: 17125233]
    U-251 IC50
    0.45 μM
    Compound: ADM
    Cytotoxicity against human U251 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay
    Cytotoxicity against human U251 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay
    		[PMID: 36332551]
    U-251 IC50
    0.6 μM
    Compound: Doxorubicin
    Antiproliferative activity against human U251 cells after 72 hrs by MTT assay
    Antiproliferative activity against human U251 cells after 72 hrs by MTT assay
    		[PMID: 19632833]
    U-251 IC50
    0.61 μM
    Compound: DOX
    Antiproliferative activity against human U-251 cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay
    Antiproliferative activity against human U-251 cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay
    		[PMID: 34968902]
    U-251 IC50
    2.2 μM
    Compound: DOX
    Antiproliferative activity against human U251 cells after 72 hrs by sulforhodamine B assay
    Antiproliferative activity against human U251 cells after 72 hrs by sulforhodamine B assay
    		[PMID: 25981689]
    U-251 IC50
    3.3 μM
    Compound: Dox
    Cytotoxicity against human U251 cells after 72 hrs by sulforhodamine B assay
    Cytotoxicity against human U251 cells after 72 hrs by sulforhodamine B assay
    		[PMID: 28504888]
    U-251 IC50
    3.9 μM
    Compound: DOX
    Antiproliferative activities against human U-251 cells by SRB assay
    Antiproliferative activities against human U-251 cells by SRB assay
    		[PMID: 32864967]
    U-251 IC50
    6.8 μM
    Compound: Dox
    Antiproliferative activity against human U251 cells assessed as reduction in cell viability after 72 hrs by SRB assay
    Antiproliferative activity against human U251 cells assessed as reduction in cell viability after 72 hrs by SRB assay
    		[PMID: 31584271]
    U-266 IC50
    0.67 μM
    Compound: Doxorubicin
    Cytotoxicity against human U266 cells after 72 hrs by resazurin/resorufin-based fluorescence assay
    Cytotoxicity against human U266 cells after 72 hrs by resazurin/resorufin-based fluorescence assay
    		[PMID: 23600925]
    U-373MG ATCC IC50
    10 nM
    Compound: Doxorubicin
    In vitro cytotoxicity expressed as concentration that inhibits 50% of U373 (glioblastoma) sensitive variant cell proliferation
    In vitro cytotoxicity expressed as concentration that inhibits 50% of U373 (glioblastoma) sensitive variant cell proliferation
    		[PMID: 11606141]
    U-373MG ATCC IC50
    130 nM
    Compound: Doxorubicin
    In vitro cytotoxicity expressed as concentration that inhibits 50% of U373 (glioblastoma) resistant variant cell proliferation
    In vitro cytotoxicity expressed as concentration that inhibits 50% of U373 (glioblastoma) resistant variant cell proliferation
    		[PMID: 11606141]
    U-87MG ATCC GI50
    2.6 μM
    Compound: Doxorubicin
    Anticancer activity against human U-87 MG cells assessed as growth inhibition
    Anticancer activity against human U-87 MG cells assessed as growth inhibition
    		[PMID: 31830636]
    U-87MG ATCC IC50
    0.08 μM
    Compound: Doxorubicin
    Antiproliferative activity against human U87 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Antiproliferative activity against human U87 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 31546197]
    U-87MG ATCC IC50
    0.09 μM
    Compound: Doxorubicin
    Cytotoxicity against human U-87 MG cells assessed as reduction in cell viability by CellTiter Glo luminescent assay
    Cytotoxicity against human U-87 MG cells assessed as reduction in cell viability by CellTiter Glo luminescent assay
    		[PMID: 32755677]
    U-87MG ATCC IC50
    0.11 μM
    Compound: DOX
    Cytotoxicity against human U87 cells measured after 72 hrs by Celltiter-Glo assay
    Cytotoxicity against human U87 cells measured after 72 hrs by Celltiter-Glo assay
    		[PMID: 31820976]
    U-87MG ATCC IC50
    0.14 μM
    Compound: DOX
    Antiproliferative activity against human U87 cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay
    Antiproliferative activity against human U87 cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay
    		[PMID: 34968902]
    U-87MG ATCC IC50
    0.1864 μM
    Compound: Doxorubicin
    Antiproliferative activity against human U87 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
    Antiproliferative activity against human U87 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
    		[PMID: 34325324]
    U-87MG ATCC IC50
    0.25 μM
    Compound: ADM
    Antiproliferative activity against human U87 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    Antiproliferative activity against human U87 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    		[PMID: 36332551]
    U-87MG ATCC IC50
    0.26 μM
    Compound: Doxorubicin
    Cytotoxicity against human U87 cells assessed as reduction in cell viability after 72 hrs by RRA assay
    Cytotoxicity against human U87 cells assessed as reduction in cell viability after 72 hrs by RRA assay
    		[PMID: 33508467]
    U-87MG ATCC IC50
    0.3 μM
    Compound: Doxorubicin
    Cytotoxicity against human U87MG cells assessed as reduction in cell survival after 96 hrs by MTT assay
    Cytotoxicity against human U87MG cells assessed as reduction in cell survival after 96 hrs by MTT assay
    		[PMID: 28471664]
    U-87MG ATCC IC50
    0.381 μM
    Compound: 1
    Cytotoxicity in human U87 cells assessed as reduction in cell viability incubated for 2 hrs by Cell-titer-blue assay
    Cytotoxicity in human U87 cells assessed as reduction in cell viability incubated for 2 hrs by Cell-titer-blue assay
    		[PMID: 33064004]
    U-87MG ATCC IC50
    0.4 μM
    Compound: Dox
    Cytotoxicity against human U87MG cells after 72 hrs by sulforhodamine B assay
    Cytotoxicity against human U87MG cells after 72 hrs by sulforhodamine B assay
    		[PMID: 28504888]
    U-87MG ATCC IC50
    0.48 μM
    Compound: ADM
    Antiproliferative activity against human U87 cells after 48 hrs by MTT assay
    Antiproliferative activity against human U87 cells after 48 hrs by MTT assay
    		[PMID: 30025345]
    U-87MG ATCC IC50
    0.57 μM
    Compound: Doxorubicin
    Anticancer activity against human U87 cells incubated for 48 hrs by MTT assay
    Anticancer activity against human U87 cells incubated for 48 hrs by MTT assay
    		[PMID: 35367708]
    U-87MG ATCC IC50
    0.6 μM
    Compound: DOX
    Antiproliferative activities against human U-87 MG cells by SRB assay
    Antiproliferative activities against human U-87 MG cells by SRB assay
    		[PMID: 32864967]
    U-87MG ATCC IC50
    0.93 μM
    Compound: DOX
    Antiproliferative activity against human U87MG cells after 72 hrs by sulforhodamine B assay
    Antiproliferative activity against human U87MG cells after 72 hrs by sulforhodamine B assay
    		[PMID: 25981689]
    U-87MG ATCC IC50
    1 μM
    Compound: Doxorubicin
    Cytotoxicity against human U87MG cells assessed as reduction in cell viability after 46 hrs by MTT assay
    Cytotoxicity against human U87MG cells assessed as reduction in cell viability after 46 hrs by MTT assay
    		[PMID: 29138027]
    U-87MG ATCC IC50
    1.6 μM
    Compound: Dox
    Antiproliferative activity against human U87MG cells assessed as reduction in cell viability after 72 hrs by SRB assay
    Antiproliferative activity against human U87MG cells assessed as reduction in cell viability after 72 hrs by SRB assay
    		[PMID: 31584271]
    U-87MG ATCC IC50
    1.7 μM
    Compound: Doxorubicin
    Anticancer activity against human U-87 MG cells assessed as growth inhibition incubated for 48 hrs by MTT assay
    Anticancer activity against human U-87 MG cells assessed as growth inhibition incubated for 48 hrs by MTT assay
    		[PMID: 34363936]
    U-87MG ATCC IC50
    140 nM
    Compound: Doxorubicin
    In vitro cytotoxicity expressed as concentration that inhibits 50% of U87 (glioblastoma) resistant variant cell proliferation
    In vitro cytotoxicity expressed as concentration that inhibits 50% of U87 (glioblastoma) resistant variant cell proliferation
    		[PMID: 11606141]
    U-87MG ATCC IC50
    18 nM
    Compound: Doxorubicin
    Cytotoxicity against human U87MG cells after 48 hrs by [3H]thymidine incorporation assay
    Cytotoxicity against human U87MG cells after 48 hrs by [3H]thymidine incorporation assay
    		[PMID: 20210346]
    U-87MG ATCC IC50
    450 nM
    Compound: Doxorubicin
    Cytotoxicity against human U87MG cells assessed as reduction in cell viability after 48 hrs under normoxia condition by MTT assay
    Cytotoxicity against human U87MG cells assessed as reduction in cell viability after 48 hrs under normoxia condition by MTT assay
    		[PMID: 32186874]
    U-87MG ATCC IC50
    5.939 μM
    Compound: Doxorubicin
    Antiproliferative activity against human U87 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Antiproliferative activity against human U87 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    		[PMID: 31883489]
    U-87MG ATCC IC50
    60 nM
    Compound: Doxorubicin
    In vitro cytotoxicity expressed as concentration that inhibits 50% of U87 (glioblastoma) sensitive variant cell proliferation
    In vitro cytotoxicity expressed as concentration that inhibits 50% of U87 (glioblastoma) sensitive variant cell proliferation
    		[PMID: 11606141]
    U-87MG ATCC IC50
    790 nM
    Compound: doxorubicin
    Antiproliferative activity against human U87MG cells after 48 hrs by XTT assay
    Antiproliferative activity against human U87MG cells after 48 hrs by XTT assay
    		[PMID: 22515366]
    U-87MG ATCC IC50
    980 nM
    Compound: Doxorubicin
    Cytotoxicity against human U87MG cells assessed as reduction in cell viability after 48 hrs under hypoxia condition by MTT assay
    Cytotoxicity against human U87MG cells assessed as reduction in cell viability after 48 hrs under hypoxia condition by MTT assay
    		[PMID: 32186874]
    U-87MG ATCC IC50
    99.6 μM
    Compound: Doxorubicin
    Antiproliferative activity against human U87 cells assessed as reduction in cell viability after 72 hrs by CellTiter Glo assay
    Antiproliferative activity against human U87 cells assessed as reduction in cell viability after 72 hrs by CellTiter Glo assay
    		[PMID: 33016067]
    U-937 IC50
    0.05 μM
    Compound: Doxorubicin
    Cytotoxicity against human U-937 cells incubated for 48 hrs by MTT assay
    Cytotoxicity against human U-937 cells incubated for 48 hrs by MTT assay
    		[PMID: 36496202]
    U-937 IC50
    0.077 μM
    Compound: DOX
    Cytotoxicity against human U937 cells assessed as cell growth inhibition after 48 hrs by MTT assay
    Cytotoxicity against human U937 cells assessed as cell growth inhibition after 48 hrs by MTT assay
    		[PMID: 26638041]
    U-937 IC50
    0.1 μM
    Compound: Dox
    Cytotoxicity against human U937 cells after 72 hrs by MTT assay
    Cytotoxicity against human U937 cells after 72 hrs by MTT assay
    		[PMID: 30659997]
    U-937 IC50
    0.1 μM
    Compound: Doxorubicin
    Cytotoxicity against human U937 cells assessed as reduction in cell viability incubated for 72 hrs by MTT method
    Cytotoxicity against human U937 cells assessed as reduction in cell viability incubated for 72 hrs by MTT method
    		[PMID: 25932671]
    U-937 IC50
    0.1 μM
    Compound: Doxorubicin
    Cytotoxicity against human U937 cells after 72 hrs by CCK8 assay
    Cytotoxicity against human U937 cells after 72 hrs by CCK8 assay
    		[PMID: 28398051]
    U-937 IC50
    0.1 μM
    Compound: Doxorubicin
    Cytotoxicity in human U-937 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Cytotoxicity in human U-937 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    		[PMID: 34082225]
    U-937 IC50
    0.12 μM
    Compound: Dox
    Cytotoxicity against human U937 cells after 24 hrs by MTT assay
    Cytotoxicity against human U937 cells after 24 hrs by MTT assay
    		[PMID: 23802716]
    U-937 IC50
    0.28 μM
    Compound: Doxorubicin
    Cytotoxicity activity against human U937 cells assessed as reduction in cell viability after 48 hrs by CCK-8 assay
    Cytotoxicity activity against human U937 cells assessed as reduction in cell viability after 48 hrs by CCK-8 assay
    		[PMID: 29288944]
    U-937 IC50
    0.42 μM
    Compound: Doxorubicin
    Cytotoxicity against human U937 cells assessed as growth inhibition after 72 hrs by MTT assay
    Cytotoxicity against human U937 cells assessed as growth inhibition after 72 hrs by MTT assay
    		[PMID: 27623548]
    U-937 IC50
    0.8 μM
    Compound: doxorubicin
    Cytotoxicity against human U937 cells after 24 to 48 hrs by MTT assay
    Cytotoxicity against human U937 cells after 24 to 48 hrs by MTT assay
    		[PMID: 21058726]
    U-937 IC50
    0.93 μM
    Compound: Doxorubicin
    Antitumor activity against human U937 cells after 24 to 48 hrs by MTT assay
    Antitumor activity against human U937 cells after 24 to 48 hrs by MTT assay
    		[PMID: 21553829]
    U-937 IC50
    1.1 μM
    Compound: doxorubicin
    Cytotoxicity against human U937 cells
    Cytotoxicity against human U937 cells
    		[PMID: 20035557]
    U-937 IC50
    4.45 x 10-3 μM
    Compound: Doxorubicin
    Cytotoxicity against human U937 cells by MTT assay
    Cytotoxicity against human U937 cells by MTT assay
    		[PMID: 19345581]
    U-937 IC50
    4.45 x 10-3 μM
    Compound: Doxorubicin
    Cytotoxicity against human U937 cells after 3 days by MTT assay
    Cytotoxicity against human U937 cells after 3 days by MTT assay
    		[PMID: 20356655]
    U-937 IC50
    > 100 μM
    Compound: Dox
    Cytotoxicity against human U937 assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Cytotoxicity against human U937 assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    		[PMID: 33065435]
    U-937/GTB IC50
    0.1 μM
    Compound: Doxorubicin
    Cytotoxicity against human U937/GTB cells after 72 hrs by trypan blue exclusion method
    Cytotoxicity against human U937/GTB cells after 72 hrs by trypan blue exclusion method
    		[PMID: 14987049]
    U-937/GTB IC50
    0.11 μM
    Compound: doxorubicin
    Cytotoxicity against human U937 GTB cells after 72 hrs by fluorometric microculture cytotoxicity assay
    Cytotoxicity against human U937 GTB cells after 72 hrs by fluorometric microculture cytotoxicity assay
    		[PMID: 16562840]
    U-937/GTB IC50
    0.11 μM
    Compound: doxorubicin
    Cytotoxicity against U937 GTB cells
    Cytotoxicity against U937 GTB cells
    		[PMID: 17442577]
    U-937/GTB IC50
    0.16 μM
    Compound: Doxorubicin
    Cytotoxicity against human U937/GTB cells after 72 hrs by fluorometric microculture cytotoxicity assay
    Cytotoxicity against human U937/GTB cells after 72 hrs by fluorometric microculture cytotoxicity assay
    		[PMID: 21434649]
    U2OS IC50
    0.3 μM
    Compound: DOX, Doxorubicin
    Antiproliferative activity against human U2OS cells after 72 hrs by MTT assay
    Antiproliferative activity against human U2OS cells after 72 hrs by MTT assay
    		[PMID: 24095089]
    U2OS IC50
    0.339 μM
    Compound: 1
    Cytotoxicity against human U2OS cells incubated for 2 hrs by cell titre blue viability assay
    Cytotoxicity against human U2OS cells incubated for 2 hrs by cell titre blue viability assay
    		[PMID: 37561481]
    U2OS IC50
    0.563 μM
    Compound: Doxorubicin
    Antiproliferative activity against human U2OS cells after 48 hrs by MTT assay
    Antiproliferative activity against human U2OS cells after 48 hrs by MTT assay
    		[PMID: 28406643]
    U2OS IC50
    0.65 μM
    Compound: doxorubicin
    Cytotoxicity against human U2OS cells after 48 hrs by MTT assay
    Cytotoxicity against human U2OS cells after 48 hrs by MTT assay
    		[PMID: 25314138]
    U2OS IC50
    3.4 μM
    Compound: Doxorubicin
    Cytotoxicity against human U2OS cells after 72 hrs by MTT assay
    Cytotoxicity against human U2OS cells after 72 hrs by MTT assay
    		[PMID: 22749279]
    UACC-257 GI50
    0.12 μM
    Compound: Doxorubicin
    Growth inhibition of human UACC257 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human UACC257 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 29102177]
    UACC-257 GI50
    0.14 μM
    Compound: Doxorubicin
    Growth inhibition of human UACC257 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human UACC257 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28329730]
    UACC-257 GI50
    0.14 μM
    Compound: Doxorubicin hydrochloride, NSC 123127
    Cytotoxicity against human UACC257 cells after 48 hrs by SRB assay
    Cytotoxicity against human UACC257 cells after 48 hrs by SRB assay
    		[PMID: 23871905]
    UACC-257 IC50
    0.6 μM
    Compound: Doxorubicin
    Cytotoxicity against human UACC257 cells after 72 hrs by MTT assay
    Cytotoxicity against human UACC257 cells after 72 hrs by MTT assay
    		[PMID: 19406535]
    UACC-375 IC50
    112 nM
    Compound: Doxorubicin
    Anti-tumor activity against human UACC375 melanoma cell lines by using MTT assay
    Anti-tumor activity against human UACC375 melanoma cell lines by using MTT assay
    		[PMID: 7699715]
    UACC-375 IC50
    112 nM
    Compound: Doxorubicin
    Inhibitory activity against AUC375 cell line
    Inhibitory activity against AUC375 cell line
    		[PMID: 8648600]
    UACC-375 IC50
    112 nM
    Compound: dixorubicin
    Antitumor activity against human melanoma UACC375 cell line.
    Antitumor activity against human melanoma UACC375 cell line.
    		[PMID: 8960558]
    UACC-375 IC50
    112 nM
    Compound: doxorubicin
    Tested for inhibitory activity against human tumor cell line UA375 of melanoma using sulforhodamine B assay.
    Tested for inhibitory activity against human tumor cell line UA375 of melanoma using sulforhodamine B assay.
    		[PMID: 10956214]
    UACC-62 ED50
    0.2 μg/mL
    Compound: Adriamycin
    Cytotoxicity against human UACC-62 cells
    Cytotoxicity against human UACC-62 cells
    		[PMID: 10346965]
    UACC-62 GI50
    0.05 μM
    Compound: Dox
    Antiproliferative activity against human UACC62 cells assessed as growth inhibition after 48 hrs by SRB assay
    Antiproliferative activity against human UACC62 cells assessed as growth inhibition after 48 hrs by SRB assay
    		[PMID: 26454648]
    UACC-62 GI50
    0.09 μg/mL
    Compound: DOX
    Growth inhibition of human UACC62 cells after 48 hrs by sulforhodamine B assay
    Growth inhibition of human UACC62 cells after 48 hrs by sulforhodamine B assay
    		[PMID: 21041092]
    UACC-62 GI50
    0.12 μM
    Compound: Doxorubicin hydrochloride, NSC 123127
    Cytotoxicity against human UACC62 cells after 48 hrs by SRB assay
    Cytotoxicity against human UACC62 cells after 48 hrs by SRB assay
    		[PMID: 23871905]
    UACC-62 GI50
    0.14 μM
    Compound: Doxorubicin
    Growth inhibition of human UACC62 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human UACC62 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28329730]
    UACC-62 GI50
    0.18 μM
    Compound: Doxorubicin
    Cytotoxicity against human UACC62 cells by sulforhodamine B assay
    Cytotoxicity against human UACC62 cells by sulforhodamine B assay
    		[PMID: 20413188]
    UACC-62 GI50
    9.4 x 10-2 μM
    Compound: doxorubicin
    Cytotoxicity against human UACC62 cells by SRB assay
    Cytotoxicity against human UACC62 cells by SRB assay
    		[PMID: 11678649]
    UACC-62 GI50
    94 nM
    Compound: Doxorubicin
    Growth inhibition of human UACC62 cells
    Growth inhibition of human UACC62 cells
    		[PMID: 17614292]
    UACC-62 GI50
    94 μM
    Compound: Doxorubicin
    Growth inhibition of human UACC62 cells after 48 hrs by sulforhodamine B assay
    Growth inhibition of human UACC62 cells after 48 hrs by sulforhodamine B assay
    		[PMID: 21504224]
    UACC-62 IC50
    0.06 μg/mL
    Compound: Adriamycin
    Inhibitory concentration required against UACC62 melanoma cell line
    Inhibitory concentration required against UACC62 melanoma cell line
    		[PMID: 11354370]
    UMUC3 IC50
    9.2 nM
    Compound: Doxorubicin
    Cytotoxicity against bladder cancer cell lines UMUC3 was determined
    Cytotoxicity against bladder cancer cell lines UMUC3 was determined
    		[PMID: 12392727]
    UO-31 ED50
    0.3 μg/mL
    Compound: adriamycin
    Cytotoxicity against human UO31 cells after 48 hrs by SRB assay
    Cytotoxicity against human UO31 cells after 48 hrs by SRB assay
    		10.1021/np50124a024
    UO-31 GI50
    0.49 μM
    Compound: Doxorubicin
    Growth inhibition of human UO31 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human UO31 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28329730]
    UO-31 GI50
    0.49 μM
    Compound: Doxorubicin
    Growth inhibition of human UO31 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human UO31 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 29102177]
    UO-31 GI50
    0.49 μM
    Compound: Doxorubicin hydrochloride, NSC 123127
    Cytotoxicity against human UO31 cells after 48 hrs by SRB assay
    Cytotoxicity against human UO31 cells after 48 hrs by SRB assay
    		[PMID: 23871905]
    UO-31 IC50
    0.1 μM
    Compound: adriamycin
    Antitumor activity against human UO31 cells by methylene blue staining method
    Antitumor activity against human UO31 cells by methylene blue staining method
    		[PMID: 17656091]
    UO-31 IC50
    0.36 μM
    Compound: DOX
    Antiproliferative activity against human UO31 cells after 72 hrs by Sulforhodamine B-stain assay
    Antiproliferative activity against human UO31 cells after 72 hrs by Sulforhodamine B-stain assay
    		[PMID: 27484508]
    UO-31 IC50
    3.01 μM
    Compound: Dox
    Cytotoxicity against human UO-31 cells assessed as inhibition of cell growth preincubated for 2 hrs followed by administration of single dose of 8 Gy gamma irradiation for 21.4 mins and measured 24 hrs after irradiation by MTT assay
    Cytotoxicity against human UO-31 cells assessed as inhibition of cell growth preincubated for 2 hrs followed by administration of single dose of 8 Gy gamma irradiation for 21.4 mins and measured 24 hrs after irradiation by MTT assay
    		[PMID: 36395650]
    UO-31 IC50
    3.61 μM
    Compound: Dox
    Cytotoxicity against human UO-31 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay
    Cytotoxicity against human UO-31 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay
    		[PMID: 36395650]
    UO-31 IC50
    6.44 μM
    Compound: Doxorubicin
    Antiproliferative activity against human UO31 cells after 48 hrs by MTT assay
    Antiproliferative activity against human UO31 cells after 48 hrs by MTT assay
    		[PMID: 29547830]
    UO-31 IC50
    7.453 nM
    Compound: Dox
    Antiproliferative against human UO31 cells incubated for 24 hrs by MTT assay
    Antiproliferative against human UO31 cells incubated for 24 hrs by MTT assay
    		[PMID: 31539778]
    V79 IC50
    0.24 μM
    Compound: Doxorubicin
    Cytotoxicity against chinese hamster V79 cells assessed as cell viability after 72 hrs by MTT assay
    Cytotoxicity against chinese hamster V79 cells assessed as cell viability after 72 hrs by MTT assay
    		[PMID: 24530030]
    V79 IC50
    0.25 μM
    Compound: DOXO
    Antiproliferative activity against chinese hamster V79 cells after 72 hrs by MTT assay
    Antiproliferative activity against chinese hamster V79 cells after 72 hrs by MTT assay
    		[PMID: 28818447]
    V79 IC50
    0.28 μM
    Compound: DOXO
    Cytotoxicity against chinese hamster V79 cells assessed as cell viability after 72 hrs by MTT assay
    Cytotoxicity against chinese hamster V79 cells assessed as cell viability after 72 hrs by MTT assay
    		[PMID: 26142490]
    V79 IC50
    0.28 μM
    Compound: Doxorubicin
    Cytotoxicity against NQO1-deficient chinese hamster V79 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against NQO1-deficient chinese hamster V79 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 27341379]
    V79 IC50
    2.21 μM
    Compound: Doxorubicin
    Cytotoxicity against Chinese Hamster V79 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
    Cytotoxicity against Chinese Hamster V79 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
    		[PMID: 31753514]
    VCaP EC50
    670 nM
    Compound: Doxorubicin
    Antiproliferative activity against AR-positive human VCaP cells assessed as reduction in cell viability measured after 72 hrs by MTS assay
    Antiproliferative activity against AR-positive human VCaP cells assessed as reduction in cell viability measured after 72 hrs by MTS assay
    		[PMID: 36577036]
    Vero CC50
    10 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against african green monkey Vero cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Cytotoxicity against african green monkey Vero cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    		[PMID: 37731699]
    Vero IC50
    0.92 μM
    Compound: Doxorubicin
    Cytotoxicity against African green monkey Vero cells after 48 hrs by neutral red assay relative to control
    Cytotoxicity against African green monkey Vero cells after 48 hrs by neutral red assay relative to control
    		[PMID: 25975638]
    Vero IC50
    1.3 μM
    Compound: Doxorubicin
    Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability by MTT assay
    Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability by MTT assay
    		[PMID: 31820973]
    Vero IC50
    1.4 μM
    Compound: Doxorubicin
    Cytotoxicity against African green monkey Vero cells after 72 hrs by MTT assay
    Cytotoxicity against African green monkey Vero cells after 72 hrs by MTT assay
    		[PMID: 28927795]
    Vero IC50
    1.5 μg/mL
    Compound: doxorubicin
    Cytotoxicity against african green monkey Vero cells after 2 to 7 days by neutral red assay
    Cytotoxicity against african green monkey Vero cells after 2 to 7 days by neutral red assay
    		[PMID: 8984156]
    Vero IC50
    1.87 μM
    Compound: Doxorubicin
    Cytotoxicity against african green monkey Vero cells incubated for 72 hrs by Sulphorhodamine assay
    Cytotoxicity against african green monkey Vero cells incubated for 72 hrs by Sulphorhodamine assay
    		[PMID: 37146520]
    Vero IC50
    1.93 μM
    Compound: DOX
    Cytotoxicity against African green monkey Vero cells assessed as cell growth inhibition after 48 hrs by MTT assay
    Cytotoxicity against African green monkey Vero cells assessed as cell growth inhibition after 48 hrs by MTT assay
    		[PMID: 26638041]
    Vero IC50
    10.4 μM
    Compound: Dox
    Cytotoxicity against african green monkey Vero cells after 3 days by MTS assay
    Cytotoxicity against african green monkey Vero cells after 3 days by MTS assay
    		[PMID: 21094049]
    Vero IC50
    14 μM
    Compound: Doxorubicin
    Cytotoxicity against African green monkey Vero cells measured after 48 hrs by neutral red assay
    Cytotoxicity against African green monkey Vero cells measured after 48 hrs by neutral red assay
    		[PMID: 27750201]
    Vero IC50
    20 μM
    Compound: Doxorubicin
    Cytotoxicity against african green monkey Vero cells
    Cytotoxicity against african green monkey Vero cells
    		[PMID: 19910192]
    Vero IC50
    23.94 μM
    Compound: Adriamycin
    Concentration required to inhibit growth of african green monkey kidney cell line
    Concentration required to inhibit growth of african green monkey kidney cell line
    		[PMID: 15317455]
    Vero IC50
    23.94 μM
    Compound: Doxorubicin
    Cytotoxicity against african geen monkey Vero cells after 4 days by GFP reporter assay
    Cytotoxicity against african geen monkey Vero cells after 4 days by GFP reporter assay
    		[PMID: 23313636]
    Vero IC50
    28.81 μM
    Compound: Doxorubicin
    Cytotoxicity against african green monkey Vero cells expressing GFP after 4 days by fluorescence assay
    Cytotoxicity against african green monkey Vero cells expressing GFP after 4 days by fluorescence assay
    		[PMID: 22280818]
    Vero IC50
    3.2 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against african green monkey Vero cells after 48 hrs by neutral red assay
    Cytotoxicity against african green monkey Vero cells after 48 hrs by neutral red assay
    		[PMID: 19105653]
    Vero IC50
    3.6 μM
    Compound: DOX
    Cytotoxicity against african green monkey Vero cells assessed as cell growth after 48 hrs by hemocytometry
    Cytotoxicity against african green monkey Vero cells assessed as cell growth after 48 hrs by hemocytometry
    		[PMID: 20961671]
    Vero IC50
    5.12 μM
    Compound: Doxorubicin
    Cytotoxicity against african green monkey Vero cells assessed as inhibition of [3H]hypoxanthine incorporation after 48 hrs
    Cytotoxicity against african green monkey Vero cells assessed as inhibition of [3H]hypoxanthine incorporation after 48 hrs
    		[PMID: 20634081]
    Vero IC50
    5.12 μM
    Compound: Doxorubicin
    Cytotoxicity against african green monkey Vero cells assessed as inhibition of [3H]hypoxanthine incorporation after 48 hrs
    Cytotoxicity against african green monkey Vero cells assessed as inhibition of [3H]hypoxanthine incorporation after 48 hrs
    		[PMID: 21256013]
    Vero IC50
    5.4 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against african green monkey Vero cells assessed as reduction in cell viability incubated for 48 hrs by neutral red based assay
    Cytotoxicity against african green monkey Vero cells assessed as reduction in cell viability incubated for 48 hrs by neutral red based assay
    		[PMID: 26371504]
    Vero IC50
    5.4 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against African green monkey Vero cells assessed as cell viability after 48 hrs by neutral red-based assay
    Cytotoxicity against African green monkey Vero cells assessed as cell viability after 48 hrs by neutral red-based assay
    		[PMID: 26469557]
    Vero IC50
    5000 nM
    Compound: Doxorubicin
    In vitro cytotoxicity expressed as conc. that inhibits 50% of VERO(monkey kidney) cell proliferation
    In vitro cytotoxicity expressed as conc. that inhibits 50% of VERO(monkey kidney) cell proliferation
    		[PMID: 11606141]
    Vero IC50
    6.3 μM
    Compound: Doxorubicin
    Cytotoxicity against african green monkey Vero cells after 48 hrs by Neutral red assay
    Cytotoxicity against african green monkey Vero cells after 48 hrs by Neutral red assay
    		[PMID: 19658408]
    Vero IC50
    6.6 μM
    Compound: Doxorubicin
    Antiproliferative activity against African green monkey Vero cells by MTT assay
    Antiproliferative activity against African green monkey Vero cells by MTT assay
    		[PMID: 29072457]
    Vero IC50
    6400 nM
    Compound: Doxorubicin
    Cytotoxicity against african green monkey Vero cells
    Cytotoxicity against african green monkey Vero cells
    		[PMID: 22766218]
    Vero IC50
    7 μM
    Compound: Doxorubicin
    Cytotoxicity against african green monkey Vero cells after 48 hrs by Neutral Red assay
    Cytotoxicity against african green monkey Vero cells after 48 hrs by Neutral Red assay
    		10.1039/C3MD00097D
    Vero IC50
    7.4 μM
    Compound: DOX
    Cytotoxicity against african green monkey Vero cells after 48 hrs by [3H]hypoxanthine incorporation assay
    Cytotoxicity against african green monkey Vero cells after 48 hrs by [3H]hypoxanthine incorporation assay
    		[PMID: 20362359]
    Vero IC50
    7.5 μg/mL
    Compound: DOX
    Cytotoxicity against Vero cells by neutral red method
    Cytotoxicity against Vero cells by neutral red method
    		[PMID: 17181171]
    Vero IC50
    7.5 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against Chlorocebus aethiops (African green monkey) Vero cells after 48 hr by neutral red assay
    Cytotoxicity against Chlorocebus aethiops (African green monkey) Vero cells after 48 hr by neutral red assay
    		[PMID: 23024574]
    Vero IC50
    7.5 μg/mL
    Compound: doxorubicin
    Cytotoxicity against Vero cells by neutral red assay
    Cytotoxicity against Vero cells by neutral red assay
    		[PMID: 17070063]
    Vero IC50
    7.5 μg/mL
    Compound: doxorubicin
    Cytotoxicity against african green monkey Vero cells by neutral red assay
    Cytotoxicity against african green monkey Vero cells by neutral red assay
    		[PMID: 17976995]
    Vero IC50
    8.6 μM
    Compound: doxorubicin
    Cytotoxicity against african green monkey Vero cells after 48 hrs by neutral red assay
    Cytotoxicity against african green monkey Vero cells after 48 hrs by neutral red assay
    		[PMID: 24900509]
    Vero IC50
    8.7 μM
    Compound: DOX
    Cytotoxicity against African green monkey Vero cells under hypoxic condition by MTT assay
    Cytotoxicity against African green monkey Vero cells under hypoxic condition by MTT assay
    		[PMID: 38642371]
    Vero IC50
    > 10 μM
    Compound: Doxorubicin
    Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability after 48 hrs by neutral red dye-based assay
    Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability after 48 hrs by neutral red dye-based assay
    		[PMID: 27618204]
    Vero IC50
    > 100 μM
    Compound: Doxorubicin
    Cytotoxicity against African green monkey Vero cells assessed as growth inhibition after 48 hrs by MTT assay
    Cytotoxicity against African green monkey Vero cells assessed as growth inhibition after 48 hrs by MTT assay
    		[PMID: 26433616]
    Vero IC50
    > 10 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against African green monkey Vero cells assessed as reduction in viable cells measured after 48 hrs by neutral red dye-based method
    Cytotoxicity against African green monkey Vero cells assessed as reduction in viable cells measured after 48 hrs by neutral red dye-based method
    		[PMID: 27584935]
    Vero IC50
    > 10 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against African green monkey Vero cells assessed as cell growth inhibition after 48 hrs by neutral red dye based assay
    Cytotoxicity against African green monkey Vero cells assessed as cell growth inhibition after 48 hrs by neutral red dye based assay
    		[PMID: 27769668]
    Vero IC50
    > 200 μM
    Compound: Doxorubicin
    Inhibition topoisomerase 1 in african green monkey Vero cells assessed as conversion of supercoiled pBR322 DNA to relaxed form
    Inhibition topoisomerase 1 in african green monkey Vero cells assessed as conversion of supercoiled pBR322 DNA to relaxed form
    		[PMID: 11430001]
    Vero IC50
    > 5 μM
    Compound: Doxorubicin
    Cytotoxicity against Chlorocebus aethiops (African green monkey) Vero cells by neutral red staining
    Cytotoxicity against Chlorocebus aethiops (African green monkey) Vero cells by neutral red staining
    		10.1007/s00044-011-9587-3
    Vero IC50
    > 5 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against african green monkey Vero cells after 48 hrs by neutral red
    Cytotoxicity against african green monkey Vero cells after 48 hrs by neutral red
    		[PMID: 23891181]
    Vero IC50
    > 5 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability after 48 hrs by neutral red assay
    Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability after 48 hrs by neutral red assay
    		[PMID: 25686593]
    Vero IC50
    > 5 μg/mL
    Compound: doxorubicin
    Cytotoxicity against african green monkey Vero cell after 48 hrs by Neutral Red dye
    Cytotoxicity against african green monkey Vero cell after 48 hrs by Neutral Red dye
    		[PMID: 20550123]
    Vero IC50
    > 9 μM
    Compound: Doxorubicin
    Cytotoxicity against African green monkey Vero cells assessed as cell growth inhibition after 48 hrs by neutral red assay
    Cytotoxicity against African green monkey Vero cells assessed as cell growth inhibition after 48 hrs by neutral red assay
    		[PMID: 26005918]
    Vero IC50
    > 9.2 μM
    Compound: doxorubicin
    Cytotoxicity against african green monkey Vero cells assessed as growth inhibition measured after 48 hrs by XTT assay
    Cytotoxicity against african green monkey Vero cells assessed as growth inhibition measured after 48 hrs by XTT assay
    		[PMID: 23547843]
    WI-38 EC50
    800 nM
    Compound: Doxorubicin
    Cytotoxicity against human WI-38 cells assessed as reduction in cell viability measured after 72 hrs by MTS assay
    Cytotoxicity against human WI-38 cells assessed as reduction in cell viability measured after 72 hrs by MTS assay
    		[PMID: 36577036]
    WI-38 IC50
    0.0266 μM
    Compound: DOX
    Cytotoxicity against human WI38 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    Cytotoxicity against human WI38 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    		[PMID: 30826510]
    WI-38 IC50
    0.04 μM
    Compound: Doxorubicin
    Antiproliferative activity against human WI38 cells after 72 hrs by MTT assay
    Antiproliferative activity against human WI38 cells after 72 hrs by MTT assay
    		[PMID: 22555152]
    WI-38 IC50
    0.079 μg/mL
    Compound: E; DOX
    Antiproliferative activity against human WI-38 cells measured after 48 hrs by MTT assay
    Antiproliferative activity against human WI-38 cells measured after 48 hrs by MTT assay
    		[PMID: 35963130]
    WI-38 IC50
    0.129 μM
    Compound: Dox
    Cytotoxicity against human WI-38 cells incubated for 72 hrs by MTT assay
    Cytotoxicity against human WI-38 cells incubated for 72 hrs by MTT assay
    		[PMID: 39149093]
    WI-38 IC50
    0.3 μM
    Compound: Doxorubicin
    Cytotoxicity against human WI38 cells after 24 hrs by MTT assay
    Cytotoxicity against human WI38 cells after 24 hrs by MTT assay
    		[PMID: 17190470]
    WI-38 IC50
    0.3 μM
    Compound: doxorubicin
    Cytotoxicity against human WI38 cells by MTT assay
    Cytotoxicity against human WI38 cells by MTT assay
    		[PMID: 15620238]
    WI-38 IC50
    0.3 μM
    Compound: doxorubicin
    Cytotoxicity against human WI38 cells
    Cytotoxicity against human WI38 cells
    		[PMID: 15921417]
    WI-38 IC50
    0.35 μM
    Compound: Doxorubicin
    Cytotoxicity against human WI38 cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay
    Cytotoxicity against human WI38 cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay
    		[PMID: 28257197]
    WI-38 IC50
    0.38 μM
    Compound: ADM
    Growth inhibition of human WI38 cells after 48 hrs by WST8 assay
    Growth inhibition of human WI38 cells after 48 hrs by WST8 assay
    		[PMID: 16499322]
    WI-38 IC50
    0.4 μM
    Compound: Doxorubicin
    Cytotoxicity against human WI-38 cells assessed as number of viable cells measured after 48 hrs by MTT based colorimetric assay
    Cytotoxicity against human WI-38 cells assessed as number of viable cells measured after 48 hrs by MTT based colorimetric assay
    		[PMID: 36970146]
    WI-38 IC50
    0.59 μM
    Compound: Doxorubicin
    Cytotoxicity against human WI38 cells after 72 hrs by MTT assay
    Cytotoxicity against human WI38 cells after 72 hrs by MTT assay
    		[PMID: 31264855]
    WI-38 IC50
    0.66 μM
    Compound: ADM
    Cytotoxicity against human WI 38 cells after 48 hrs by WST-8 assay
    Cytotoxicity against human WI 38 cells after 48 hrs by WST-8 assay
    		[PMID: 15730243]
    WI-38 IC50
    0.66 μM
    Compound: ADM
    Cytotoxicity against human WI38 cells by WST-8 assay
    Cytotoxicity against human WI38 cells by WST-8 assay
    		[PMID: 16933868]
    WI-38 IC50
    0.66 μM
    Compound: Adriamycin
    Growth inhibition of human WI38 cells
    Growth inhibition of human WI38 cells
    		[PMID: 17490878]
    WI-38 IC50
    0.7 mM
    Compound: ADM
    Growth inhibition of human WI38 cells
    Growth inhibition of human WI38 cells
    		[PMID: 17595134]
    WI-38 IC50
    0.71 μg/mL
    Compound: adriamycin
    Growth inhibition of WI38 cells
    Growth inhibition of WI38 cells
    		[PMID: 17547458]
    WI-38 IC50
    0.76 μg/mL
    Compound: adriamycin
    Growth inhibition of human WI38 cells
    Growth inhibition of human WI38 cells
    		[PMID: 17358082]
    WI-38 IC50
    0.8 μM
    Compound: Doxorubicin
    Cytotoxicity against human WI38 cells after 72 hrs by Alamar blue assay
    Cytotoxicity against human WI38 cells after 72 hrs by Alamar blue assay
    		[PMID: 21999655]
    WI-38 IC50
    0.8 μM
    Compound: Doxorubicin
    Cytotoxicity against human WI-38 cells assessed as cell growth inhibition measured after 24 to 72 hrs by MTT assay
    Cytotoxicity against human WI-38 cells assessed as cell growth inhibition measured after 24 to 72 hrs by MTT assay
    		[PMID: 33586438]
    WI-38 IC50
    0.8 μM
    Compound: Doxorubicin
    Cytotoxicity against human WI-38 cells assessed as inhibition of cell proliferation measured after 72 hrs by resazurin dye based AlamarBlue assay
    Cytotoxicity against human WI-38 cells assessed as inhibition of cell proliferation measured after 72 hrs by resazurin dye based AlamarBlue assay
    		[PMID: 34495663]
    WI-38 IC50
    1.21 μM
    Compound: ADM
    Cytotoxicity against human WI38 cells
    Cytotoxicity against human WI38 cells
    		[PMID: 16724842]
    WI-38 IC50
    1.3 μM
    Compound: Doxorubicin
    Cytotoxicity against human WI-38 cells assessed as reduction in cell viability after 24 hrs by DAPI staining-based fluorescence assay
    Cytotoxicity against human WI-38 cells assessed as reduction in cell viability after 24 hrs by DAPI staining-based fluorescence assay
    		[PMID: 32786882]
    WI-38 IC50
    1.3 μM
    Compound: Doxorubicin
    Cytotoxicity against human WI-38 cells assessed as reduction in cell viability by DAPI staining based assay
    Cytotoxicity against human WI-38 cells assessed as reduction in cell viability by DAPI staining based assay
    		[PMID: 33461146]
    WI-38 IC50
    1.96 μM
    Compound: Doxorubicin
    Cytotoxicity against human WI-38 cells assessed as reduction in cell growth incubated for 24 hrs by MTT assay
    Cytotoxicity against human WI-38 cells assessed as reduction in cell growth incubated for 24 hrs by MTT assay
    		[PMID: 33744686]
    WI-38 IC50
    12.3 μM
    Compound: Doxorubicin
    Antiproliferative activity against human WI38 cells after 24 hrs by BrdU incorporation assay
    Antiproliferative activity against human WI38 cells after 24 hrs by BrdU incorporation assay
    		[PMID: 27555286]
    WI-38 IC50
    26.6 nM
    Compound: Dox
    Cytotoxicity against human WI-38 cells assessed as reduction in cell viability by MTT assay
    Cytotoxicity against human WI-38 cells assessed as reduction in cell viability by MTT assay
    		[PMID: 31740054]
    WI-38 IC50
    34.1 nM
    Compound: DOX
    Cytotoxicity against human WI-38 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human WI-38 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 33901898]
    WI-38 IC50
    6.68 μM
    Compound: Doxorubicin
    Cytotoxicity against human W138 cells assessed as decrease in cell viability after 48 hrs by MTT assay
    Cytotoxicity against human W138 cells assessed as decrease in cell viability after 48 hrs by MTT assay
    		[PMID: 29702448]
    WI-38 IC50
    6.68 μM
    Compound: Doxorubicin
    Cytotoxicity against human W138 cells after 48 hrs by MTT assay
    Cytotoxicity against human W138 cells after 48 hrs by MTT assay
    		[PMID: 30138804]
    WI-38 IC50
    6.7 μM
    Compound: Doxorubicin
    Antiproliferative activity against human WI-38
    Antiproliferative activity against human WI-38
    		[PMID: 33421712]
    WI-38 IC50
    6.72 μM
    Compound: DOX
    Cytotoxicity against human WI38 cells by MTT assay
    Cytotoxicity against human WI38 cells by MTT assay
    		[PMID: 33388654]
    WI-38 IC50
    6.72 μM
    Compound: DOX
    Cytotoxicity against human WI-38 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay
    Cytotoxicity against human WI-38 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay
    		[PMID: 36242988]
    WI-38 IC50
    6.72 μM
    Compound: DOX
    Cytotoxicity against human WI-38 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay
    Cytotoxicity against human WI-38 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay
    		[PMID: 37054758]
    WI-38 IC50
    6.72 μM
    Compound: Dox
    Cytotoxicity against human WI-38 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Cytotoxicity against human WI-38 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    		[PMID: 32527460]
    WI-38 IC50
    6.72 μM
    Compound: Doxorubicin
    Cytotoxicity against human WI38 cells assessed as reduction in cell viability by MTT assay
    Cytotoxicity against human WI38 cells assessed as reduction in cell viability by MTT assay
    		[PMID: 33065442]
    WI-38 IC50
    6.72 μM
    Compound: Doxorubicin
    Cytotoxicity against human WI-38 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    Cytotoxicity against human WI-38 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    		[PMID: 37871406]
    WI-38 IC50
    71 nM
    Compound: Doxorubicin
    Cytotoxicity against human WI38 cells assessed as reduction in cell viability after 96 hrs by MTT assay
    Cytotoxicity against human WI38 cells assessed as reduction in cell viability after 96 hrs by MTT assay
    		[PMID: 28600080]
    WI-38 IC50
    79.7 μM
    Compound: Doxorubicin
    Cytotoxicity against human WI-38 cells assessed as inhibition of cell growth incubated for 3 days by MTT assay
    Cytotoxicity against human WI-38 cells assessed as inhibition of cell growth incubated for 3 days by MTT assay
    		[PMID: 35007724]
    WI-38 IC50
    9 μM
    Compound: Doxorubicin
    Cytotoxicity against human WI38 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Cytotoxicity against human WI38 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    		[PMID: 28327308]
    WI-38 IC50
    > 10 μM
    Compound: adriamycin
    Cytotoxicity against human WI38 cells after 72 hrs by SRB assay
    Cytotoxicity against human WI38 cells after 72 hrs by SRB assay
    		[PMID: 19028425]
    WI-38 VA13 IC50
    0.08 μg/mL
    Compound: adriamycin
    Growth inhibition of human VA13 cells
    Growth inhibition of human VA13 cells
    		[PMID: 17358082]
    WI-38 VA13 IC50
    0.22 μM
    Compound: ADM
    Growth inhibition of human VA13 cells after 48 hrs by WST8 assay
    Growth inhibition of human VA13 cells after 48 hrs by WST8 assay
    		[PMID: 16499322]
    WI-38 VA13 IC50
    0.38 μM
    Compound: ADM
    Cytotoxicity against human VA13 cells after 48 hrs by WST-8 assay
    Cytotoxicity against human VA13 cells after 48 hrs by WST-8 assay
    		[PMID: 15730243]
    WI-38 VA13 IC50
    0.38 μM
    Compound: ADM
    Cytotoxicity against human VA-13 cells by by WST-8 assay
    Cytotoxicity against human VA-13 cells by by WST-8 assay
    		[PMID: 16933868]
    WI-38 VA13 IC50
    0.38 μM
    Compound: Adriamycin
    Growth inhibition of human VA13 cells
    Growth inhibition of human VA13 cells
    		[PMID: 17490878]
    WI-38 VA13 IC50
    0.39 μg/mL
    Compound: adriamycin
    Growth inhibition of VA13 cells
    Growth inhibition of VA13 cells
    		[PMID: 17547458]
    WI-38 VA13 IC50
    0.4 mM
    Compound: ADM
    Growth inhibition of human VA13 cells
    Growth inhibition of human VA13 cells
    		[PMID: 17595134]
    WI-38 VA13 IC50
    0.699 μM
    Compound: ADM
    Cytotoxicity against human VA13 cells
    Cytotoxicity against human VA13 cells
    		[PMID: 16724842]
    WIL2-NS CC50
    0.02 μM
    Compound: Doxorubicin
    Cytotoxicity against human WIL2-NS cells after 96 hrs by MTT assay
    Cytotoxicity against human WIL2-NS cells after 96 hrs by MTT assay
    		[PMID: 26119992]
    WIL2-NS EC50
    0.04 μM
    Compound: Doxorubicin
    Cytotoxicity against human WIL2-NS cells after 96 hrs by MTT assay
    Cytotoxicity against human WIL2-NS cells after 96 hrs by MTT assay
    		[PMID: 26320088]
    WIL2-NS IC50
    0.02 μM
    Compound: Doxorubicin
    Antitumor activity was evaluated against lymphoma cell line Wil2-NS (human splenic B lymphoblastoid cells).
    Antitumor activity was evaluated against lymphoma cell line Wil2-NS (human splenic B lymphoblastoid cells).
    		[PMID: 10411476]
    WIL2-NS IC50
    0.02 μM
    Compound: doxo
    Antiproliferative activity against human Wil2-NS cells by MTT assay
    Antiproliferative activity against human Wil2-NS cells by MTT assay
    		[PMID: 16913700]
    WIL2-NS IC50
    0.02 μM
    Compound: doxorubicin
    Antitumor activity against human splenic B-lympho blastoid Wil2-NS cells
    Antitumor activity against human splenic B-lympho blastoid Wil2-NS cells
    		[PMID: 12431048]
    WIL2-NS IC50
    0.2 μM
    Compound: Doxorubicin
    Compound was tested for its effect on the proliferation of WIL-2-NS cell line.
    Compound was tested for its effect on the proliferation of WIL-2-NS cell line.
    		10.1016/0960-894X(96)00216-8
    WISH IC50
    3.18 μM
    Compound: Doxorubicin
    Cytotoxicity against human WISH cells assessed as reduction in cell viability by MTT assay
    Cytotoxicity against human WISH cells assessed as reduction in cell viability by MTT assay
    		[PMID: 33065442]
    WISH IC50
    8.14 μM
    Compound: Doxorubicin
    Cytotoxicity against human WISH cells assessed as decrease in cell viability after 48 hrs by MTT assay
    Cytotoxicity against human WISH cells assessed as decrease in cell viability after 48 hrs by MTT assay
    		[PMID: 29702448]
    WISH IC50
    8.14 μM
    Compound: Doxorubicin
    Cytotoxicity against human WISH cells after 48 hrs by MTT assay
    Cytotoxicity against human WISH cells after 48 hrs by MTT assay
    		[PMID: 30138804]
    WM 266-4 IC50
    0.15 μM
    Compound: Doxorubicin
    Antiproliferative activity against human WM266.4 cells assessed as inhibition of cell proliferation incubated for 72 hrs by conventional ATP quantification method
    Antiproliferative activity against human WM266.4 cells assessed as inhibition of cell proliferation incubated for 72 hrs by conventional ATP quantification method
    		[PMID: 25937235]
    WM793 GI50
    0.6 μM
    Compound: Dox
    Cytotoxicity against human WM793 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
    Cytotoxicity against human WM793 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
    		[PMID: 34634616]
    WM793 GI50
    0.9 μM
    Compound: Dox
    Antiproliferative activity against human WM793 cells incubated for 72 hrs and measured by MTT assay
    Antiproliferative activity against human WM793 cells incubated for 72 hrs and measured by MTT assay
    		[PMID: 35973342]
    WRL68 IC50
    0.259 μM
    Compound: Doxorubicin
    Anticancer activity against human WRL68 cell assessed as cell growth inhibition measured after 24 to 72 hrs by MTT assay
    Anticancer activity against human WRL68 cell assessed as cell growth inhibition measured after 24 to 72 hrs by MTT assay
    		[PMID: 36577217]
    WiDr ED50
    0.12 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human WiDr cells by MTT assay
    Cytotoxicity against human WiDr cells by MTT assay
    		[PMID: 17315955]
    WiDr IC50
    0.62 μM
    Compound: adriamycin
    Inhibition of WiDr human cancer cell proliferation with 10e-2 uM estradiol
    Inhibition of WiDr human cancer cell proliferation with 10e-2 uM estradiol
    		[PMID: 8784443]
    WiDr IC50
    130 nM
    Compound: Doxorubicin
    Compound was tested against WiDr colon carcinoma (resistant) in the sulforhodamine B assay.
    Compound was tested against WiDr colon carcinoma (resistant) in the sulforhodamine B assay.
    		[PMID: 8648600]
    WiDr IC50
    130 nM
    Compound: dixorubicin
    Activity against human colon carcinoma multi drug resistant (MDR)-WiDr cell line.
    Activity against human colon carcinoma multi drug resistant (MDR)-WiDr cell line.
    		[PMID: 8960558]
    WiDr IC50
    130 nM
    Compound: doxorubicin
    Tested for inhibitory activity against a multi drug resistant (MDR) strain of human colon carcinoma WiDr using sulforhodamine B assay (it is MRP positive but non-P-glycoprotein).
    Tested for inhibitory activity against a multi drug resistant (MDR) strain of human colon carcinoma WiDr using sulforhodamine B assay (it is MRP positive but non-P-glycoprotein).
    		[PMID: 10956214]
    WiDr IC50
    53 nM
    Compound: Doxorubicin
    Tested against WiDr colon (sensitive) in the sulforhodamine B assay.
    Tested against WiDr colon (sensitive) in the sulforhodamine B assay.
    		[PMID: 8648600]
    WiDr IC50
    53 nM
    Compound: dixorubicin
    Activity against human colon carcinoma sensitive WiDr cell line.
    Activity against human colon carcinoma sensitive WiDr cell line.
    		[PMID: 8960558]
    WiDr IC50
    53 nM
    Compound: doxorubicin
    Tested for inhibitory activity against a sensitive strain of human colon carcinoma WiDr using sulforhodamine B assay (it is MRP positive but non-P-glycoprotein).
    Tested for inhibitory activity against a sensitive strain of human colon carcinoma WiDr using sulforhodamine B assay (it is MRP positive but non-P-glycoprotein).
    		[PMID: 10956214]
    XF498 EC50
    0.03 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human XF498 cells
    Cytotoxicity against human XF498 cells
    		[PMID: 18990572]
    XF498 ED50
    0.01 μg/mL
    Compound: doxorubicin
    Cytotoxicity against human XF498 cells after 48 hrs by SRB assay
    Cytotoxicity against human XF498 cells after 48 hrs by SRB assay
    		[PMID: 15921415]
    XF498 ED50
    0.01 μg/mL
    Compound: doxorubicin
    Cytotoxicity against human XF498 cells by SRB method
    Cytotoxicity against human XF498 cells by SRB method
    		[PMID: 16252909]
    XF498 ED50
    0.01 μg/mL
    Compound: doxorubicin
    Cytotoxicity against human XF498 cells
    Cytotoxicity against human XF498 cells
    		[PMID: 16441084]
    XF498 ED50
    0.01 μg/mL
    Compound: doxorubicin
    Cytotoxicity against human XF498 cell line
    Cytotoxicity against human XF498 cell line
    		[PMID: 17253840]
    XF498 ED50
    0.029 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human XF498 cells after 48 hrs by sulforhodamine B assay
    Cytotoxicity against human XF498 cells after 48 hrs by sulforhodamine B assay
    		[PMID: 19783438]
    XF498 ED50
    0.02 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human XF498 cells
    Cytotoxicity against human XF498 cells
    		[PMID: 14640527]
    XF498 ED50
    0.06 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human XF498 cells
    Cytotoxicity against human XF498 cells
    		[PMID: 12662097]
    XF498 ED50
    0.06 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human XF498 cells
    Cytotoxicity against human XF498 cells
    		[PMID: 15104487]
    XF498 ED50
    0.06 μg/mL
    Compound: doxorubicin
    Cytotoxicity against human XF498 cells
    Cytotoxicity against human XF498 cells
    		[PMID: 16643027]
    XF498 ED50
    0.07 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human XF498 cells
    Cytotoxicity against human XF498 cells
    		[PMID: 17190456]
    XF498 ED50
    0.07 μg/mL
    Compound: doxorubicin
    Cytotoxicity against human XF498 cells
    Cytotoxicity against human XF498 cells
    		[PMID: 15787431]
    XF498 ED50
    0.08 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human XF498 cells after 48 hrs by SRB assay
    Cytotoxicity against human XF498 cells after 48 hrs by SRB assay
    		[PMID: 11325244]
    XF498 ED50
    0.08 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human XF498 cells
    Cytotoxicity against human XF498 cells
    		[PMID: 11520227]
    XF498 ED50
    0.08 μg/mL
    Compound: doxorubicin
    Cytotoxicity against human XF498 cells
    Cytotoxicity against human XF498 cells
    		[PMID: 11678655]
    XF498 ED50
    0.12 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human XF498 cells
    Cytotoxicity against human XF498 cells
    		[PMID: 15497935]
    XF498 ED50
    0.12 μg/mL
    Compound: doxorubicin
    Cytotoxicity against human XF498 cells
    Cytotoxicity against human XF498 cells
    		[PMID: 15104515]
    XF498 ED50
    0.13 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human XF498 cells
    Cytotoxicity against human XF498 cells
    		[PMID: 12350153]
    XF498 ED50
    0.15 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human XF498 cells
    Cytotoxicity against human XF498 cells
    		[PMID: 12662102]
    XF498 ED50
    0.15 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human XF498 cells
    Cytotoxicity against human XF498 cells
    		[PMID: 15270579]
    XF498 ED50
    0.19 μg/mL
    Compound: doxorubicin
    Cytotoxicity against human XF498 cells
    Cytotoxicity against human XF498 cells
    		[PMID: 12762820]
    XF498 ED50
    0.19 μg/mL
    Compound: doxorubicin
    Cytotoxicity against human XF498 cells
    Cytotoxicity against human XF498 cells
    		[PMID: 14640517]
    XF498 ED50
    0.1 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human XF498 cells
    Cytotoxicity against human XF498 cells
    		[PMID: 14640526]
    XF498 ED50
    0.1 μg/mL
    Compound: adriamycin
    Cytotoxicity against human XF498 cells by SRB assay
    Cytotoxicity against human XF498 cells by SRB assay
    		10.1021/np960188t
    XF498 ED50
    0.23 μg/mL
    Compound: doxorubicin
    Cytotoxicity against human XF498 cells by SRB assay
    Cytotoxicity against human XF498 cells by SRB assay
    		[PMID: 9392887]
    XF498 ED50
    0.2 μg/mL
    Compound: doxorubicin
    Cytotoxicity against human XF498 cells
    Cytotoxicity against human XF498 cells
    		[PMID: 10217707]
    XF498 IC50
    0.009 μM
    Compound: Doxorubicin
    Antiproliferative activity against human XF498 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Antiproliferative activity against human XF498 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    		[PMID: 27010926]
    XF498 IC50
    0.015 μM
    Compound: Doxorubicin
    Cytotoxicity against human XF498 cells after 48 hrs by SRB assay
    Cytotoxicity against human XF498 cells after 48 hrs by SRB assay
    		[PMID: 22483395]
    XF498 IC50
    0.04 μM
    Compound: doxorubicin
    Cytotoxicity against human XF498 cells by SRB assay
    Cytotoxicity against human XF498 cells by SRB assay
    		[PMID: 17194596]
    XF498 IC50
    0.044 μM
    Compound: doxorubicin
    Cytotoxicity against human XF498 cells after 3 days by SRB assay
    Cytotoxicity against human XF498 cells after 3 days by SRB assay
    		[PMID: 18321715]
    XF498 IC50
    0.09 μg/mL
    Compound: Doxorubicin
    Cytotoxic activity against XF498 cell line (human CNS solid tumor)
    Cytotoxic activity against XF498 cell line (human CNS solid tumor)
    		[PMID: 15922597]
    XF498 IC50
    0.112 μM
    Compound: Doxorubicin
    Anticancer activity against human XF498 cells after 48 hrs by SRB assay
    Anticancer activity against human XF498 cells after 48 hrs by SRB assay
    		[PMID: 17070967]
    XF498 IC50
    0.12 μg/mL
    Compound: adriamycin
    Cytotoxicity against human XF498 cells by SRB assay
    Cytotoxicity against human XF498 cells by SRB assay
    		[PMID: 15921426]
    XF498 IC50
    0.16 μM
    Compound: Doxorubicin
    Antiproliferative activity against human XF498 cells after 96 hrs by MTT assay
    Antiproliferative activity against human XF498 cells after 96 hrs by MTT assay
    		[PMID: 19053767]
    XF498 IC50
    0.19 μg/mL
    Compound: doxorubicin
    Anticancer activity against human XF498 cells after 72 hrs by sulforhodamine B assay
    Anticancer activity against human XF498 cells after 72 hrs by sulforhodamine B assay
    		[PMID: 19342127]
    XF498 IC50
    0.35 μM
    Compound: Doxorubicin
    Anticancer activity against human XF498 cells by sulforhodamine B assay
    Anticancer activity against human XF498 cells by sulforhodamine B assay
    		[PMID: 19819696]
    YOSHIDA IC50
    < 0.02 μM
    Compound: Adriamycin
    Concentration inhibiting [3H]TdR incorporation in Yoshida sarcoma tumor cells in vitro in rats
    Concentration inhibiting [3H]TdR incorporation in Yoshida sarcoma tumor cells in vitro in rats
    		[PMID: 1322986]
    Z-138 IC50
    1.59 μM
    Compound: Dox
    Antiproliferative activity against human Z138 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    Antiproliferative activity against human Z138 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    		[PMID: 38176358]
    ZR-75-1 EC50
    100 nM
    Compound: Doxorubicin
    Antiproliferative activity against human ZR-75-1 cells assessed as reduction in cell viability incubated for 5 days by celltiter-glo assay
    Antiproliferative activity against human ZR-75-1 cells assessed as reduction in cell viability incubated for 5 days by celltiter-glo assay
    		[PMID: 30996949]
    ZR-75-1 ED50
    0.04 μM
    Compound: DOX
    Cytotoxicity against human ZR751 cells
    Cytotoxicity against human ZR751 cells
    		[PMID: 17591444]
    ZR-75-1 GI50
    0.11 μM
    Compound: ADR
    Cytotoxicity against human ZR-75-1 cells after 48 hrs by sulforhodamine B assay
    Cytotoxicity against human ZR-75-1 cells after 48 hrs by sulforhodamine B assay
    		[PMID: 21737288]
    ZR-75-1 GI50
    0.13 μM
    Compound: ADR
    Cytotoxicity against human ZR-75-1 cells after 48 hrs by SRB assay
    Cytotoxicity against human ZR-75-1 cells after 48 hrs by SRB assay
    		[PMID: 20673627]
    ZR-75-1 GI50
    1.79 μM
    Compound: ADR
    Growth inhibition of human ZR-75-1 cells
    Growth inhibition of human ZR-75-1 cells
    		10.1039/C1MD00072A
    ZR-75-1 GI50
    1.79 μM
    Compound: ADR
    Cytotoxicity against human Zr-75-1 cells after 48 hrs by sulforhodamine B assay
    Cytotoxicity against human Zr-75-1 cells after 48 hrs by sulforhodamine B assay
    		[PMID: 18657979]
    ZR-75-1 GI50
    1.79 μM
    Compound: ADR
    Growth inhibition of human ZR-75-1 cells after 48 hrs by SRB assay
    Growth inhibition of human ZR-75-1 cells after 48 hrs by SRB assay
    		[PMID: 20031423]
    ZR-75-1 GI50
    1.79 μM
    Compound: ADR
    Cytotoxicity against human ZR-75-1 cells after 24 hrs by WST-1 assay
    Cytotoxicity against human ZR-75-1 cells after 24 hrs by WST-1 assay
    		[PMID: 20732817]
    ZR-75-1 GI50
    1.79 μM
    Compound: ADR
    Anticancer activity against human ZR-75-1 cells by SRB method
    Anticancer activity against human ZR-75-1 cells by SRB method
    		[PMID: 21676506]
    ZR-75-1 GI50
    1.79 μM
    Compound: ADR
    Growth inhibition of human ZR-75-1 cells by SRB assay
    Growth inhibition of human ZR-75-1 cells by SRB assay
    		[PMID: 22361684]
    ZR-75-1 GI50
    1.79 μM
    Compound: ADR
    Growth inhibition of human ZR-75-1 cells after 48 hrs by sulforhodamine B assay
    Growth inhibition of human ZR-75-1 cells after 48 hrs by sulforhodamine B assay
    		[PMID: 22364746]
    ZR-75-1 GI50
    1.79 μM
    Compound: ADR
    Growth inhibition of human ZR-75-1 cells after 48 hrs by sulforhodamine B assay
    Growth inhibition of human ZR-75-1 cells after 48 hrs by sulforhodamine B assay
    		[PMID: 23849207]
    ZR-75-1 GI50
    1.79 μM
    Compound: ADR, Adriamycin
    Growth inhibition of human Zr-75-1 cells by SRB method
    Growth inhibition of human Zr-75-1 cells by SRB method
    		[PMID: 18207392]
    ZR-75-1 GI50
    < 0.1 μM
    Compound: ADR
    Anticancer activity against human ZR-75-1 cells by SRB method
    Anticancer activity against human ZR-75-1 cells by SRB method
    		[PMID: 22104151]
    ZR-75-1 IC50
    0.009 μM
    Compound: Doxorubicin
    Inhibitory activity against ZR-75-1 cell line using MTT assay (ER+,pgr+,mutant p53)
    Inhibitory activity against ZR-75-1 cell line using MTT assay (ER+,pgr+,mutant p53)
    		[PMID: 10780913]
    ZR-75-1 IC50
    0.04 μM
    Compound: doxorubicin
    Cytotoxicity against human ZR751cells by SRB microtiter plate assay
    Cytotoxicity against human ZR751cells by SRB microtiter plate assay
    		[PMID: 17585747]
    ZR-75-1 IC50
    0.6 μM
    Compound: ADR
    Cytotoxicity against human ZR-75-1 cells by sulforhodamine B assay
    Cytotoxicity against human ZR-75-1 cells by sulforhodamine B assay
    		[PMID: 17822905]
    ZR-75-1 IC50
    0.6 μM
    Compound: ADR
    Cytotoxicity against human ZR751 cells by SRB assay
    Cytotoxicity against human ZR751 cells by SRB assay
    		[PMID: 18656370]
    ZR-75-1 IC50
    2.32 μM
    Compound: ADR
    Cytotoxicity against human Zr75-1 cells
    Cytotoxicity against human Zr75-1 cells
    		[PMID: 17723301]
    ZR-75-1 IC50
    453 nM
    Compound: Doxorubicin
    Cytotoxicity against human ZR-75-1 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay
    Cytotoxicity against human ZR-75-1 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay
    		[PMID: 23468529]
    ZR-75-1 IC50
    6.39 ng/mL
    Compound: ADR
    Cytotoxicity against human cancer cell lines ZR-75-1 of breast.
    Cytotoxicity against human cancer cell lines ZR-75-1 of breast.
    		[PMID: 11311062]
    carcinoma cell line IC50
    1800 nM
    Compound: Doxorubicin
    Inhibitory concentration againstHuman cell lung carcinoma cell line NCI-H69/LX4; n=3
    Inhibitory concentration againstHuman cell lung carcinoma cell line NCI-H69/LX4; n=3
    		[PMID: 15743178]
    carcinoma cell line IC50
    < 0.01 μM
    Compound: doxorubicin
    Inhibitory effect against murine renal cell carcinoma cell line (RENCA cells) using a BrdU-incorporation assay
    Inhibitory effect against murine renal cell carcinoma cell line (RENCA cells) using a BrdU-incorporation assay
    		[PMID: 11454467]
    hTERT-BJ IC50
    < 6.25 μM
    Compound: DOX
    Cytotoxicity against hTERT-BJ cells after 48 hrs by resazurin dye-based fluorescence assay
    Cytotoxicity against hTERT-BJ cells after 48 hrs by resazurin dye-based fluorescence assay
    		[PMID: 29665526]
    In Vitro

    Doxorubicin (1-8 μM; 24 and 48 hours) decreases the viability of MCF-10F, MCF-7 and MDA-MB-231 cells in a time- and dose-dependent manner[4].
    Doxorubicin (1 μM; 3 and 24 hours) results in Hct-116 human colon carcinoma cells reduction in G0/G1 phase and accumulation in G2 phase[5].
    Doxorubicin (1 μM for MCF-10F and MDA-MB-231 cells, 4 μM for MCF-7 cells; 48 hours) induces apoptosis by upregulating Bax, caspase-8 and caspase-3 and downregulation of Bcl-2 protein expression[4].
    Doxorubicin (5 μM; 10-30 min) can be accumulated in B16-F10 melanoma cell line CRL-6475 in a time-dependent manner, and can be detected by green or red fluorescence (green fluorescence has higher detection sensitivity) with a maximum excitation wavelength (λex) and a maximum emission wavelength (λem) of 470 nm and 560 nm, respectively[8].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Doxorubicin Related Antibodies

    Cell Viability Assay[4]

    Cell Line: Breast cancer cell lines MCF-10F, MCF-7 and MDA-MB-231
    Concentration: 0, 1, 2, 4 and 8 μM
    Incubation Time: 24 and 48 hours
    Result: IC50 was 1 μM for both MCF-10F and MDA-MB-231 cell lines.
    IC50 was 4 μM for MCF-7 cell line.

    Cell Cycle Analysis[5]

    Cell Line: Hct-116 human colon carcinoma cells
    Concentration: 1 μM
    Incubation Time: 3 hours and 24 hours
    Result: Both, bolus (3 h) and continuous (24 h) incubation led to a significant reduction of cells in G0/G1 and accumulation in G2 phase.

    Western Blot Analysis[4]

    Cell Line: Breast cancer cell lines MCF-10F, MCF-7 and MDA-MB-231
    Concentration: 1 μM for MCF-10F and MDA-MB-231 cells, 4 μM for MCF-7 cells
    Incubation Time: 48 hours
    Result: Bax protein expression was upregulated in MCF-10F and MDA-MB-231 cell lines but MCF-7 cells did not show any significant increase.
    Caspase-8 gene expression was upregulated in MCF-10F, but it was downregulated in MCF-7 and MDA-MB-231 cells.
    In Vivo

    Doxorubicin (2 mg/kg; i.v.; once a week; 6 weeks) inhibits MDA-G8 breast tumor growth in mice[6].
    Doxorubicin (4%-20%; Intrastriatal injection; Single dose) is neurotoxic in Sprague-Dawley rats[7].

    Note:
    Please do not refer to only one article to determine the experimental conditions. It is recommended to determine the optimal experimental conditions (animal strain, age, dosage, frequency and cycle, detection time and indicators, etc.) through preliminary experiments before the formal experiment.

    Doxorubicin hydrochloride can be used to induce models of cardiotoxicity and heart failure.

    1. Inducing cardiotoxicity[10]
    Background
    The mechanism of short-term induction of cardiotoxicity: promoting extracellular remodeling of myocardium to induce heart failure, and also works at the molecular level. Including: interacting with iron, changing the activity of oxidases in cells or mitochondria, and binding to topoisomerases.
    Specific Modeling Methods
    Mice: Female C57BL/6j mice • 20-22 g • 6 weeks old
    Administration: 2 mg/kg, 10 mg/kg • ip • once every the other day for 2 or 3 times
    Note
    Mice were sacrificed 3 days after the first injection.
    Modeling Indicators
    molecular level: (1) Pro-inflammatory cytokines (such as TNF-α and IL-6) increase significantly, while anti-inflammatory cytokine IL-10 decreases; (2) Inducible - Nitric oxide synthase (iNOS) was overexpressed and serum nitrite levels were elevated; nitrotyrosine expression was significantly increased.
    2. Induction of heart failure[11]
    Background
    The long-term mechanisms inducing heart failure remain to be carefully elucidated.
    Specific Modeling Methods
    Rat: Male Wistar rats • 180-200 g
    Administration: 2.5 mg/kg • ip • once every week, for 6 weeks • treated at 4 weeks later.
    Modeling Indicators
    Cellular/tissue level: Myocardial sarcomeres are destroyed, mitochondria are swollen and damaged, Myocardial cells showed inflammation and apoptosis (transmission electron microscopy results); myocardial fibrosis, and left ventricular collagen I and II levels were downregulated (immunohistochemistry results).
    Changes in macroscopic indicators: Hemodynamic parameters and echocardiography show cardiac insufficiency and impaired left ventricular function; such as increases in LVIDd, LVIDs and LVEDP.
    Opposite Product(s): Captopril (HY-B0368)

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Model: Athymic male nude mice model of xenografts of PC3 prostate carcinoma cells[5]
    Dosage: 2 mg/kg, 4 mg/kg, 8 mg/kg
    Administration: ntraperitoneal injection (i.p.); Single dose .After injected PC3 cells (4 × 106) subcutaneously into the flank of mice.
    Result: A dose of 2 mg/ kg did not affect tumor growth while higher dosages (4 mg/kg, 8 mg/kg) delayed tumor growth initially.
    Animal Model: Male Sprague-Dawley rats model[6]
    Dosage: 10 mg/kg (schedule 1), 1 mg/kg (schedule 2), 2 mg/kg (schedule 3)
    Administration: Intraperitoneal injection (i.p.) ; Single dose (schedule 1). Intraperitoneal injection (i.p.); Once daily for 10 days (schedule 2). Intraperitoneal injection (i.p.); Once per week, for 5 weeks(schedule 3).
    Result: In schedule 1, caused 30% of the rats to die at the end of week 2 and 80% by day 28.
    In schedule 2 , caused 55% of the rats to die at the end of week 13 and 80% by day 107.
    In schedule 3, caused 42% of the rats to die at the end of week 13 and 80% by day 98.
    Animal Model: Male Sprague-Dawley rats[8]
    Dosage: 1%, 2%, 4%, 5%, 6%, 10%, 20%
    Administration: Intrastriatal injection; Single dose
    Result: In doses of 4, 5, 6, 10 or 20% caused obvious loss of ipsilateral SNc and VTA neuronsz and doses of 1 or 2% failed to produce obvious neuron loss.
    Molecular Weight

    543.52

    Formula

    C27H29NO11
    CAS No.
    Appearance

    Solid

    Color

    Orange to red

    SMILES

    COC1=C2C(C(C(C(O)=C(C[C@](C(CO)=O)(O)C[C@@H]3O[C@@]4([H])C[C@H](N)[C@H](O)[C@H](C)O4)C3=C5O)=C5C2=O)=O)=CC=C1
    Structure Classification
    Initial Source

    Streptomyces peucetius.
    Shipping

    Room temperature in continental US; may vary elsewhere.
    Storage

    4°C, sealed storage, away from moisture and light

    *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

    Solvent & Solubility

    • Molarity Calculator

    • Dilution Calculator

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start)

    C1

    ×
    Volume (start)

    V1

    =
    Concentration (final)

    C2

    ×
    Volume (final)

    V2

    In Vivo:

    The following protocol is derived from the literature and is for reference only. It is recommended to first try a small sample.

    • Protocol 1

      Doxorubicin (dissolved with distilled water) is incorporated into 0.035% CaCl2 solution[5].

    • Protocol 2

      Doxorubicin (Adriamycin) is prepared in vehicle (PBS)[6].

    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Calculation results:
    Working solution concentration: mg/mL
    Purity & Documentation
    References
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    Doxorubicin Related Classifications

    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Keywords:

    Doxorubicin23214-92-8HydroxydaunorubicinADC PayloadAntibioticBacterialTopoisomeraseAMPKHIVAutophagyMitophagyApoptosisHBVFluorescent DyeADC CytotoxinAMP-activated protein kinaseHuman immunodeficiency virusMitochondrial AutophagyHepatitis B virusCardiotoxicityNeurotoxicityfluorescenceHelaCRL-6475fluorescence detectionantibioticstumorapoptosisautophagyInhibitorinhibitorinhibit

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Requested Quantity *

    Applicant Name *

    		 

    Salutation

    Email Address *

    		 

    Phone Number *

    Department

    		 

    Organization Name *

    City

    State

    Country or Region *

    		      

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    Doxorubicin
    Cat. No.:
    HY-15142A
    Quantity:
    MCE Japan Authorized Agent:

    Customer Review

    Thank You for Your Feedback!

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Lot #

    Applicant Name *

    		 

    Email Address *

    Phone Number

    		 

    Department *

    Organization Name *

    		 

    Country or Region *

    Remarks

    SAFETY DATA SHEET (SDS)

    English - EN (394 KB) Français - FR (394 KB) Deutsch - DE (394 KB) Norwegian - NO (394 KB) Español - ES (394 KB) Swedish - SV (394 KB) Italian - IT (394 KB) Korean - KR (394 KB) Portuguese - PT (394 KB)

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.